<SEC-DOCUMENT>0001439222-24-000035.txt : 20240215
<SEC-HEADER>0001439222-24-000035.hdr.sgml : 20240215
<ACCEPTANCE-DATETIME>20240215103302
ACCESSION NUMBER:		0001439222-24-000035
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		107
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240215
DATE AS OF CHANGE:		20240215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGIOS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001439222
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36014
		FILM NUMBER:		24642625

	BUSINESS ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-649-8600

	MAIL ADDRESS:	
		STREET 1:		88 SIDNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AGIOS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20080703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>agio-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:agio="http://agios.com/20231231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>agio-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-32">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-33">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-34">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0001439222</ix:nonNumeric><ix:nonNumeric contextRef="c-60" name="agio:AvailableForSaleSecuritiesCurrentMaturityPeriod" id="f-407">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-60" name="agio:AvailableForSaleSecuritiesNonCurrentMaturityPeriod" id="f-409">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-113" name="agio:LesseeOperatingLeaseOptionToExtendExtensionPeriod" id="f-596">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-113" name="agio:LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo" id="f-597">P22M</ix:nonNumeric><ix:nonNumeric contextRef="c-14" name="us-gaap:DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-967">http://fasb.org/us-gaap/2023#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="agio-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agio:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:VorasidenibMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agio:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agio:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agio:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agio:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>agio:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>agio:security</xbrli:measure></xbrli:unit><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:EightyEightSidneyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="leaseterm"><xbrli:measure>agio:leaseTerm</xbrli:measure></xbrli:unit><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:EightyEightSidneyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="extension"><xbrli:measure>agio:extension</xbrli:measure></xbrli:unit><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">agio:FederalOrphanDrugTaxCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="audit"><xbrli:measure>agio:audit</xbrli:measure></xbrli:unit><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agio:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agio:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>agio:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-05</xbrli:startDate><xbrli:endDate>2021-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramRule10b51RepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramRule10b51RepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-02</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439222</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>agio:lawsuit</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-36014</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">AGIOS PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:48.532%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.534%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">26-0662915</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">88 Sidney Street</ix:nonNumeric>,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">02139</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">617</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">649-8600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.333%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of Exchange on Which Registered</span></td></tr><tr><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">AGIO</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">None</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#9745;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;&#9745;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;&#9745;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;&#9745;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.283%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric>&#160;&#160;&#9745;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated&#160;filer&#160;&#160;&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#160;&#9744;</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller reporting company&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9745;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes &#160;&#160;&#9744; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No &#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9745;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting Common Stock held by non-affiliates of the registrant computed by reference to the price of the registrant&#8217;s Common Stock as of June&#160;30, 2023 (based on the last reported sale price on the Nasdaq Global Select Market as of such date) was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-29">1,557,785,326</ix:nonFraction>.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of February&#160;9, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">56,194,847</ix:nonFraction> shares of Common Stock, $0.001 par value per share, outstanding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true">Portions of the registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2023 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</ix:nonNumeric> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.014%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_10">PART I</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_16">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_19">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_802">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_802">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_22">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_22">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_25">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_25">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_28">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_28">65</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_31">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_34">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_34">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_37">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_37">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_40">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_40">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_43">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_43">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_46">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_46">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_49">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_49">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_52">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_52">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_55">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_55">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_58">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_58">83</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_61">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_64">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_64">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_67">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_67">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_70">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_70">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_73">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_73">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_76">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_76">84</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_79">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_82">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_82">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_94">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_94">88</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">References to Agios</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Annual Report on Form 10-K, &#8220;the Company,&#8221; &#8220;Agios,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#8220;our board of directors&#8221; refers to the board of directors of Agios Pharmaceuticals, Inc. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-looking Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;vision,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negatives of these words and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements regarding:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our commercialization efforts and plans to commercialize PYRUKYND&#174; (mitapivat);</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the initiation, timing, progress and results of current, planned and future preclinical studies and clinical trials, and our research and development programs;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential of the isoforms of pyruvate kinase, including pyruvate kinase-R, or PKR, as therapeutic targets;</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.68pt">the potential benefits of our products and product candidates targeting PKR, including PYRUKYND&#174; (mitapivat) and AG-946, and of our product candidate in our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%">phenylalanine hydroxylase, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or PAH, stabilizer program, AG-181;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our plans to develop and commercialize any additional product candidates for which we may receive approval, either alone or with partners; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish and maintain collaborations or to obtain additional funding, if needed;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing or likelihood of regulatory filings and approvals;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our strategic vision;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing, likelihood and amount of contingent consideration we may receive from Servier Pharmaceuticals LLC, or Servier, in connection with the sale of our oncology business to Servier that we consummated in March 2021; </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">the amount and timing of future milestone and royalty payments potentially payable to Alnylam Pharmaceuticals, Inc. pursuant to the license agreement entered into in July 2023;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the implementation of our business model and strategic plans for our business, product candidates and technology;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our commercialization, sales, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our competitive position;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our intellectual property position;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">developments and projections relating to our competitors and our industry; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;padding-right:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our estimates regarding our expenses, future revenue, capital requirements and needs for additional financing; and</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">the potential impact of public health epidemics or pandemics, including the COVID-19 pandemic, and of global economic developments on our business, operations, strategy and goals.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in this Annual Report on Form 10-K, particularly in the &#8220;Summary Risk Factors&#8221; and &#8220;Risk Factors&#8221; sections, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, in-licensing arrangements, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">opportunities. All of the market data used in this Annual Report on Form 10-K involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. We believe that the information from these industry publications, research, surveys and studies is reliable. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, including those described in the sections titled &#8220;Summary Risk Factors&#8221; and &#8220;Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary Risk Factors </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is subject to a number of risks that if realized could materially affect our business, financial condition, results of operations, cash flows and access to liquidity. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. Our principal risks include the following: </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we do not successfully commercialize PYRUKYND&#174; for the treatment of adults with PK deficiency in the approved jurisdictions and other products for which we receive approval, our prospects may be substantially harmed. Our ability to generate product revenue from PYRUKYND&#174; depends heavily on our successful development and commercialization of the product. </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We depend heavily on the success of our clinical-stage product candidates, including the potential approval of PYRUKYND&#174; for use in indications other than PK deficiency and in other jurisdictions. Clinical trials of our product candidates may not be successful for a number of important reasons. If we or our collaborators are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may engage in in-licensing transactions or acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim or topline results of clinical trials do not necessarily predict success in future clinical trials. The results of clinical trials of PYRUKYND&#174; for the treatment of PK deficiency do not predict that PYRUKYND&#174; will be efficacious in our  clinical trials in other indications.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">PYRUKYND&#174;, or any of our product candidates that may receive marketing approval in the future, may be less effective than previously believed or cause undesirable side effects that were not previously identified in clinical trials or may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success, which could compromise our ability, or that of any collaborators, to market the product.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we are unable to establish and maintain sales and marketing capabilities or enter into agreements with third parties to sell and market our products, we may not be successful in commercializing PYRUKYND&#174; or our product candidates if they are approved.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We provide certain development estimates related to the development of PYRUKYND&#174; and our product candidates. If we do not achieve our projected development estimates in the timeframes we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the indications for which we are developing PYRUKYND&#174; or our product candidates. Our competitors may develop products that are more effective, safer, more convenient or less costly than PYRUKYND&#174; or any product candidates that we are developing or that would render PYRUKYND&#174; or our product candidates obsolete or non-competitive. </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We are singularly focused on products and product candidates for the treatment of rare diseases. As a result, we may be more susceptible to changing market conditions, including fluctuations and risks particular to the markets for patients with rare diseases, than a more diversified company, which could adversely affect our business, financial condition and results of operations. </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If our existing capital is insufficient to fund our operating expenses and capital expenditures, we will need to raise capital, and if we are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We have historically incurred operating losses. We expect to incur losses in the future and may never achieve or maintain profitability. Our net loss for the year ended December 31, 2023 was $352.1 million, our net loss for the year ended December 31, 2022 was $231.8 million and our net income for the year ended December 31, 2021 was $1.6 billion. The net income we generated in the year ended December 31, 2021 was due to the sale of our oncology business to Servier in March 2021. As of December&#160;31, 2023, we had an accumulated deficit of $822.6 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We currently rely and expect to continue to rely on third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercial supply of PYRUKYND&#174; and any product candidate for which we may obtain marketing approval. Any performance failure on the part of our existing or future third-party manufacturers could delay clinical development, marketing approval or our commercialization efforts.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We rely and expect to continue to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">We may depend on collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">If we are unable to obtain and maintain patent or trade secret protection for our medicines and technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize medicines and technology similar or identical to ours, and our ability to successfully commercialize our medicines and technology may be adversely affected. If we do not, or are unable to, obtain or maintain any issued patents for any of our most advanced product candidates, it could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_13"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Business</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through leadership in the field of cellular metabolism, with the goal of creating differentiated medicines for rare diseases, with a focus on classical hematology. With a history of focused study on cellular metabolism, we have a deep and mature understanding of this biology, which is involved in the healthy functioning of nearly every system in the body. Building on this expertise, these learnings can be rapidly applied to our clinical trials with the goal of developing medicines that can have a significant impact for patients. We accelerate the impact of our portfolio by cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for rare diseases.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Business Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rare diseases</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead product candidate in our portfolio, PYRUKYND&#174; (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. In February 2022, the U.S. Food and Drug Administration, or FDA, approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In November 2022, we received marketing authorization from the European Commission for PYRUKYND&#174; for the treatment of PK deficiency in adult patients in the European Union, or EU. In December 2022, we received marketing authorization in Great Britain for PYRUKYND&#174; for the treatment of PK deficiency in adult patients under the European Commission Decision Reliance Procedure. In addition, we are currently evaluating PYRUKYND&#174; in clinical trials for the treatment of thalassemia, sickle cell disease, or SCD, and in pediatric patients with PK deficiency. We are also developing (i) AG-946, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndrome, or LR MDS, and hemolytic anemias, and (ii) AG-181, our phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, in July 2023 we entered into a license agreement with Alnylam Pharmaceuticals, Inc., or Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the transmembrane serine protease 6, or TMPRSS6, gene and we intend to pursue development of a licensed product for the potential disease-modifying treatment of patients with polycythemia vera, or PV, a rare blood disorder. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Alnylam License Agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the license agreement with Alnylam, in the year ended December 31, 2023, we made an up-front payment to Alnylam and recognized in-process research and development of $17.5&#160;million. We will also pay Alnylam for certain expenses associated with the development of the TMPRSS6 gene. Additionally, we are responsible to pay up to $130.0&#160;million in potential development and regulatory milestones, in addition to sales milestones as well as tiered royalties on annual net sales, if any, of licensed products, which may be subject to specified reductions and offsets. Because the acquired assets under the license agreement with Alnylam do not meet the definition of a business in accordance with ASC 805, Business Combinations, we accounted for the agreement as an asset acquisition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sale of Oncology Business to Servier and Sale of Contingent Payments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business, including TIBSOVO&#174;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs, to Servier, for a payment of approximately $1.8&#160;billion in cash at the closing, subject to certain adjustments, and a payment of $200.0&#160;million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application approval from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through loss of exclusivity, and a royalty of 15% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity, with these royalties referred to as contingent payments and recognized as income when realizable. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#8217;s IDHIFA&#174; and the right to receive a $25.0&#160;million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and Servier is responsible for conducting certain clinical development activities within the IDHIFA&#174; development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we sold our rights to future contingent payments associated with the royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through the loss of exclusivity to entities affiliated with Sagard Healthcare Partners, or Sagard, and recognized income of $127.9&#160;million within the gain on sale of contingent payments line item in our consolidated statements of operations for the year ended December 31, 2022. We retain our rights to the potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, Servier announced that it was planning to submit a new drug application, or NDA, for vorasidenib for the treatment of IDH-mutant diffuse glioma to the FDA by the end of 2023 and to the European Medicines Agency, or EMA, in early 2024.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy and Long-term Goals</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our long-term strategy, we have developed and articulated a strategic vision that delineates our expected evolution in light of our focus on rare diseases. We aim to build a sustainable, value-creating company, based on our expertise in cellular metabolism and classical hematology, that develops and delivers differentiated medicines for patients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By 2026, our vision is to: establish a classical hematology franchise with PYRUKYND&#174; approvals across PK deficiency, thalassemia and SCD; and expand our portfolio by advancing AG-946, AG-181 and our preclinical pipeline as well as through disciplined business development aligned with our core therapeutic focus areas and capabilities.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Core Values</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our values cultivate an environment that promotes collaboration, contribution, engagement and high regard for others&#8217; points of view. This foundation helps our people push the boundaries of our science and create transformative medicines, which we believe will provide long-term benefits for all our stakeholders. Our connections &#8211; with each other and with external parties &#8211; fuel the development of new therapies for the people who need them. Our core values include:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Aim High: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We set the bar high for ourselves, and we keep working to raise it. At our core, we&#8217;re guided by a deep respect for the science and a commitment always to act with the utmost integrity.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Come Together:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We grow supportive relationships with patients and caregivers. We build trusting connections with collaborators. Together, we make a bigger impact than we ever could alone.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Embrace Differences:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Because opportunities and insights come from anywhere and anyone, we honor all voices and encourage honest dialogue. We learn equally from success and failure, bringing an open mind and a flexible approach to everything we do.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Bring Your Whole Self:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We know we make the biggest impact when each of us can contribute and lead in our own way.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:31.5pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Blaze New Trails: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ask the tough questions that can lead to groundbreaking scientific advances. We nurture a creative mindset and resourceful approach that spark life-changing innovations for patients. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cellular Metabolism</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cellular metabolism is involved in the healthy functioning of nearly every system in the body and refers to the set of life-sustaining chemical transformations within the cells of living organisms. The conversion of nutrients into energy via enzyme-catalyzed reactions allows organisms to grow and reproduce, maintain their structures, and respond to their environments. Additionally, metabolites serve as key regulators of diverse aspects of cellular biology, and pharmacologic targeting of metabolism can therefore have disease-modifying effects in a wide variety of pathologies. The chemical reactions of metabolism are organized into metabolic pathways, in which one chemical is transformed through a series of steps into another </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chemical, by a sequence of enzymes. Enzymes catalyze quick and efficient reactions, serve as key regulators of metabolic pathways, and respond to changes in the cell&#8217;s environment or signals from other cells.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rare diseases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diseases are typically considered rare if they affect fewer than 200,000 people in the United States, or fewer than five per 10,000 people in France, Germany, Italy, Spain, United Kingdom, or the EU5. Many rare diseases are likely to be under-diagnosed given the lack of available therapies or diagnostics, the rarity of the condition, or limited understanding of how the disease genetics relate to the disease phenotype. It has been shown that small molecule therapies able to specifically correct genetic deficiencies and their associated organ dysfunction may have application in conditions that arise independent of patient genetics but for which identical organ dysfunction occurs. For example, a treatment for a hereditary hemolytic anemia may find direct application in the treatment of a secondarily acquired hemolytic anemia. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many rare diseases carry severe or life-threatening features. In many of these disorders, the defect of single or multiple genes leads to a deficient expression or function in one or several gene products which collectively manifest in organ dysfunction. As these conditions are by nature congenital and frequently hereditary, they are often detected either by genetic testing or phenotypic diagnosis in newborns or in early childhood. A typical course of many such diseases is inexorable deterioration until death or significant irreversible life-long disability and/or suffering.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current treatment options for these disorders are generally limited. Severe and sustained diet modification or nutrient supplementation can be beneficial in certain rare diseases. Several of these disorders, from a group known as lysosomal storage diseases, have been treated successfully with enzyme replacement therapy, or ERT, the therapeutic administration of a functional version of the defective enzyme. Examples of ERTs for lysosomal storage disorders include Fabrazyme&#174; for Fabry disease, Myozome&#174; for Pompe disease, Cerezyme&#174; for Gaucher disease, and Elaprase&#174; for Hunter syndrome. In addition, treatment of polygenic conditions such as achondroplasia by Vosoritide&#174; and the monogenic condition, spinal muscular atrophy by gene therapy with Zolgensma&#174; and Spinraza&#174; represent novel technologic approaches to addressing rare diseases.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most mutations driving rare diseases are intracellular and not amenable to corrective treatment with ERTs. Novel technologic approaches such as gene therapy are also being tested in a minority of conditions and are technologies with limited application based on cost, complexity and patient selection factors. Despite the promising progress made for patients with a small group of rare diseases, the majority of patients with these diseases have few therapeutic options, and the standard of care for many such conditions is palliative, meaning treatment of symptoms with no effect on underlying disease mechanisms. Our goal is to develop mechanistically specific, small molecule approaches with the potential to have disease modifying and long-term effects, rather than palliative effects. We are taking a novel small molecule approach to correct the defects within diseased cells with a goal of developing transformative medicines for patients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classical hematology</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classical hematology refers to the study and treatment of blood disorders that are not cancerous, including thrombotic and hemorrhagic disorders, anemia, thrombocytopenia, disorders of iron metabolism and hemoglobin disorders. Many of these diseases are debilitating, have a negative impact on patients&#8217; quality of life and are associated with severe complications and/or shortened life expectancy. Despite the significant need for novel therapies and improved patient care, there is a shortage of research and trained specialists in the field of classical hematology, and patients with these disorders are often underserved and experience health disparities and inequity. In addition, even in diseases in which some progress has been made, large subsets of the disease may remain underserved. Our goal is to develop transformative oral treatments for patients with various classical hematological disorders through broad clinical development programs in order to address the unmet needs of a large range of patients.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Development Programs</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that leveraging our core capabilities in cellular metabolism combined with our singular focus on rare diseases and our differentiated expertise in classical hematology has significantly enhanced our ability to advance new therapeutic candidates and bring innovative medicines to patients in need. We have a proven track record of developing new therapeutic approaches and multiple proprietary first-in-class orally available small molecules.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our approved product and most advanced clinical product candidates, each of which is described in further detail below. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><img src="agio-20231231_g1.jpg" alt="Agios-2023Pipeline-v3a-1.jpg" style="height:564px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PK Activator Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PK is an enzyme involved in glycolysis &#8212; the conversion of glucose into lactic acid. This enzyme has several tissue-specific isoforms (PKR, PKL, PKM1 and PKM2). Pyruvate kinase-R, or PKR, is the isoform of PK that is present in red blood cells, or RBCs. Mutations in PKR cause defects in RBC glycolysis and lead to a hematological rare disease known as PK deficiency. Glycolysis is the only pathway available for RBCs to maintain the production of adenosine triphosphate, or ATP, which is a form of chemical energy within cells. Accordingly, we believe that activation of mutant forms of PKR can restore glycolytic pathway activity and increase RBC health in patients with PK deficiency, and activation of wild-type (non-mutated) PKR can increase ATP which can then meet the increased energy demands resulting from metabolic stress in RBCs of patients with hemolytic anemias such as thalassemia and SCD. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PK Deficiency</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PK deficiency is a rare genetic disorder and disease understanding is still evolving. We estimate that the prevalence of PK deficiency is between approximately 3,000 and 8,000 individuals in the United States and EU5, and believe that the disease is likely under-diagnosed. PK deficiency leads to a shortened life span for RBCs and is the most common form of non-spherocytic hemolytic anemia in humans. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is currently no known unique ethnic or geographic representation of the disease. The disease manifests by mild to severe forms of anemia caused by the excessive premature destruction of RBCs. The chronic hemolysis can lead to long-term complications and comorbidities, regardless of the degree of the anemia, often resulting in jaundice and lifelong conditions </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with chronic anemia and secondary complications. The precise mechanism for the hemolysis is not well understood but is thought to result from membrane instability secondary to the metabolic defect caused by the low level of PKR enzyme. The hemolysis is &#8220;extra-vascular&#8221; in that the RBCs are destroyed in small capillaries or organs and do not spontaneously break open in the circulation. PK deficiency is an autosomal recessive disease whereby all patients inherit two mutations, one from each parent. Children with the disease produce PKR enzyme that has only a fraction of the normal level of activity (generally &lt;50%). Current management strategies for PK deficiency, including blood transfusion and splenectomy, are associated with both short- and long-term risks. More than 350 different mutations have been identified to date. As a result, there are many different possible mutant combinations and no one clear mutational profile. The mutations observed in PK deficiency patients are classified in two main categories. A missense mutation causes a single amino acid change in the protein, generally resulting in some functional protein in the RBCs.&#160;A non-missense mutation is any mutation other than a missense mutation, generally resulting in little functional protein in the RBCs. It is estimated that 58&#160;percent of patients with PK deficiency have two missense mutations, 27&#160;percent have one missense and one non-missense mutation, and 15&#160;percent have two non-missense mutations. Boston Children&#8217;s Hospital, in collaboration with us, is conducting a Natural History Study to better understand the symptoms and complications of PK deficiency, identify patients and treatment centers, and capture other clinical data, including genetic information. We maintain a global registry, called Peak, for up to 500 adult and pediatric patients with PK deficiency to increase understanding of the long-term disease burden of this chronic hemolytic anemia. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Thalassemia</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thalassemia is a hereditary blood disorder in which mutations in the &#945;- or &#946;-globin chains of hemoglobin lead to globin chain precipitates and aggregates that disturb the RBC membrane and induce oxidative stress, leading to decreased survival of RBC precursors, ineffective erythropoiesis, hemolysis of mature RBCs, and anemia. We estimate that the prevalence of thalassemia is between 18,000 and 23,000 individuals in the United States and EU5; approximately 70,000 individuals in Saudi Arabia, United Arab Emirates, Kuwait, Bahrain, Qatar and Oman, also known as the Gulf Council Countries, or GCC; and greater than one million individuals worldwide. In addition to anemia, patients with thalassemia can experience enlarged spleen, bone deformities, iron overload, fatigue, and infection. Current treatment strategies for thalassemia include blood transfusion and bone marrow transplantation, as well as newer therapies such as Reblozyl&#174; (luspatercept-aamt) for the treatment of beta-thalassemia or Casgevy&#174; for the treatment of transfusion-dependent beta-thalassemia. We believe that the activation of wild-type PKR may increase ATP production and improve red cell fitness and survival of thalassemic RBCs, by increasing the clearance globin chain aggregates through ATP-dependent proteolytic mechanisms.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sickle Cell Disease (SCD)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SCD is an inherited blood disorder caused by mutations in hemoglobin that enable the hemoglobin to form long polymeric chains under certain conditions such as low oxygenation, or deoxygenation. Polymerization of this irregular hemoglobin results in RBCs taking on a sickle shape, causing them to aggregate and obstruct small blood vessels, restricting blood flow to organs resulting in pain, cell death and organ damage. We estimate that the prevalence of SCD is between 120,000 and 135,000 individuals in the United States and EU5 and greater than three million individuals worldwide. RBC deoxygenation is modulated by several factors, including the levels of 2,3-diphosphoglycerate, or 2,3-DPG, which is found to be elevated in sickle cell patient RBCs. Current treatment strategies focus on managing and preventing acute RBC sickling, and include hydroxyurea, L-glutamine and blood transfusions, as well as recently approved therapies such as Adakveo&#174; and Oxbryta&#174;. We believe that activation of wild-type PKR in patients with SCD may reduce hemoglobin polymerization and the sickling process by at least two mechanisms. Reducing the level of 2,3-DPG in RBCs would increase the oxygenation state of hemoglobin to reduce sickling, while increasing the levels of ATP may improve RBC hydration status which may also inhibit the sickling process.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lower Risk MDS (LR MDS)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MDS is a heterogeneous group of rare hematological malignancies characterized by dysfunctional hematopoiesis (or formation of blood cells), progressive cytopenia (or lower-than-normal number of blood cells) and an increased risk of progression to acute myeloid leukemia, or AML. The most common type of MDS is LR MDS, but many existing therapies and therapies under development focus on high risk MDS. Among patients with LR MDS, which is less likely to progress to AML, the primary concern is symptomatic anemia. We estimate that the prevalence of LR MDS in the United States and EU5 is between 75,000 and 80,000 individuals. We believe that activation of wild-type PK in LR MDS patients may improve deficient PK activity in MDS erythrocytes. Current treatment options for LR MDS often require in-office visits and transfusions, and erythropoiesis stimulating agents and Reblozyl&#174; are the only approved therapies to treat anemia in a subset of patients. Despite approved therapies in subsets of patients, LR MDS associated anemia remains a disease with a high unmet medical need.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phenylketonuria (PKU)</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PKU, is a rare, genetic disease caused by deficiency of the PAH enzyme. Lack of PAH activity leads to the accumulation of phenylalanine and downstream neurocognitive deficits.  Patients with PKU are therefore often advised to consume a highly restricted diet to in order to minimize phenylalanine intake, which can further reduce patient quality of life. We estimate that the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevalence of PKU in the United States and EU5 is between 35,000 and 40,000 individuals. To directly address the underlying cause of PKU, we are developing AG-181, a PAH stabilizer with a goal of reducing phenylalanine levels.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Polycythemia Vera (PV)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PV is a rare blood disorder with no disease-modifying treatments that affects approximately 100,000 individuals in the United States. PV is characterized by excessive production of RBCs, which leads to increased blood volume and viscosity, and can result in thrombosis, cardiovascular events, and death. Phlebotomy, which is the procedure of withdrawing blood, is the current standard of care for patients with PV.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PYRUKYND&#174; (mitapivat): First-in-Class PK Activator</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing PYRUKYND&#174; for the treatment of PK deficiency and other hemolytic anemias such as thalassemia and SCD. PYRUKYND&#174; is an orally available small molecule and a potent activator of the wild-type and mutated PK enzymes.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the FDA approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In November 2022, we received marketing authorization from the European Commission for PYRUKYND&#174; for the treatment of PK deficiency in adult patients in the EU. In December 2022, we received marketing authorization in Great Britain for PYRUKYND&#174; for the treatment of PK deficiency in adult patients under the European Commission Decision Reliance Procedure. In addition, we are currently evaluating PYRUKYND&#174; in clinical trials for the treatment of thalassemia, SCD, and in pediatric patients with PK deficiency. We have worldwide development and commercial rights to PYRUKYND&#174; and expect to fund the future development and commercialization costs related to this program. PYRUKYND&#174; has been granted orphan drug designation for the treatment of PK deficiency by the FDA and the EMA. Additionally, PYRUKYND&#174; has received orphan drug designation from the FDA for the treatment of thalassemia and SCD.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built our commercial infrastructure to support the commercial launch of PYRUKYND&#174; in adult PK deficiency in the United States. In connection with our regulatory approvals in the EU and Great Britain, we are currently providing access to PYRUKYND&#174; free of charge for eligible patients in those jurisdictions through a global managed access program. We may provide access to PYRUKYND&#174; for adult patients with PK deficiency in other jurisdictions upon request through the global managed access program, on either a free of charge or for charge basis. Beyond the global managed access program, we continue to evaluate options for the commercialization of PYRUKYND&#174; outside of the United States, including through exploring potential partnership opportunities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating PYRUKYND&#174; in the following clinical trials:</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">An extension study evaluating the long-term safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from ENERGIZE, our completed phase 3, double-blind, randomized, placebo-controlled multicenter study pivotal trial of PYRUKYND&#174; in adults with non-transfusion-dependent alpha- or beta-thalassemia. We announced topline data for ENERGIZE in January 2024. A total of 194 patients were enrolled in the study, with 130 randomized to PYRUKYND&#174; 100 mg twice-daily, and 64 randomized to matched placebo. 122 patients (93.8%) in the PYRUKYND&#174; arm and 62 patients (96.9%) in the placebo arm completed the 24-week double-blind period of the study.  The study met the primary endpoint of hemoglobin response, where treatment with PYRUKYND&#174; demonstrated a statistically significant increase in hemoglobin response compared to placebo, as 42.3% of patients in the PYRUKYND&#174; arm achieved a hemoglobin response, compared to 1.6% of patients in the placebo arm (2-sided p&lt;0.0001). Treatment with PYRUKYND&#174; also demonstrated statistically significant improvements compared to placebo for both key secondary endpoints: (i) change from baseline in average Functional Assessment of Chronic Illness Therapy-Fatigue, or FACIT-Fatigue, subscale score from week 12 to week 24 and (ii) change from baseline in average emoglobin concentration from week 12 to week 24.  During the 24-week double-blind period, four (3.1%) subjects in the PYRUKYND&#174; arm experienced adverse events, or AEs, leading to discontinuation, and there were no AEs in the placebo arm leading to discontinuation. We plan to provide a more detailed analysis of the data from this trial at an upcoming medical meeting and we aim to submit an NDA for PYRUKYND&#174; in thalassemia to the FDA by the end of 2024.     </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ENERGIZE-T, a phase 3, double-blind, randomized, placebo-controlled multicenter study evaluating the efficacy and safety of PYRUKYND&#174; as a potential treatment for adults with transfusion-dependent alpha- or beta-thalassemia, defined as 6 to 20 RBC units transfused and &#8804; six-week transfusion-free period during the 24-week period before randomization. The primary endpoint of the trial is percentage of patients with transfusion reduction response, defined as a &#8805;50% reduction in transfused RBC units with a reduction of &#8805;2 units of transfused RBCs in any consecutive 12-week period through week 48 compared with baseline. Secondary endpoints include additional transfusion reduction measures and percentage of participants with transfusion-independence. This trial has completed enrollment and we plan to announce topline data from this trial in mid-2024.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">RISE UP, a phase 2/3 study evaluating the efficacy and safety of PYRUKYND&#174; in SCD patients who are 16 years of age or older, have had between two and 10 sickle cell pain crises in the past 12 months, and have hemoglobin within the range of 5.5 to 10.5 g/dL during screening. We enrolled 79 patients in the phase 2 portion of the trial, with 26 patients in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the 50 mg twice daily mitapivat arm, 26 patients in the 100 mg twice daily mitapivat arm and 27 patients in the placebo arm. The primary endpoints of the phase 2 portion of the trial were hemoglobin response, defined as defined as &#8805; 1 g/dL increase in average hemoglobin concentration from week 10 to week 12 compared to baseline, and safety.  In June 2023, we announced the phase 2 portion of this trial had achieved its primary endpoint of hemoglobin response in patients in both 50 mg and 100 mg twice daily mitapivat arms. 46.2% of patients (n=12) in the 50 mg twice daily mitapivat arm and 50.0% of patients (n=13) in the 100 mg twice daily mitapivat arm achieved a hemoglobin response, compared to 3.7% of patients (n=1) in the placebo arm (2-sided p=0.0003 and 0.0001, respectively). In December 2023, we announced the following additional results of the phase 2 portion of the trial: (i) the least-squares mean (95% confidence interval) for average change from baseline in hemoglobin levels, from week 10 through week 12, for patients in the 50 mg twice daily mitapivat, 100 mg twice daily mitapivat, and placebo arms, respectively, was 1.11 (0.77, 1.45) g/dL, 1.13 (0.79, 1.47) g/dL, and 0.05 (&#8722;0.28, 0.39) g/dL; (ii) we observed improvements in annualized rates of sickle cell pain crises as the annualized rate of sickle cell pain crises (95% confidence interval) for patients in the 50 mg twice daily and 100 mg twice daily mitapivat arms, respectively, was 0.83 (0.34, 1.99) and 0.51 (0.16, 1.59), compared to 1.71 (0.95, 3.08) for patients in the placebo arm; (iii) we observed improvement in patient-reported fatigue scores in the 50 mg twice daily mitapivat arm compared to the placebo arm, and the least-squares mean (95% confidence interval) for average changes from baseline in patient-reported fatigue score, from week 10 through week 12, for patients in the 50 mg twice daily mitapivat, 100 mg twice daily mitapivat, and placebo arms, respectively, was &#8722;3.80 (&#8722;7.16, &#8722;0.45), &#8722;0.10 (&#8722;3.27, 3.08), and &#8722;0.17 (&#8722;3.40, 3.07). The safety profile for mitapivat observed in the phase 2 portion of the trial was generally consistent with previously reported data in other studies of SCD and other hemolytic anemias. The most common treatment-emergent AEs in the 50 mg BID, 100 mg BID, and placebo arms, respectively, were: headache (n=6, 6, 7), arthralgia (n=3, 5, 9), dysmenorrhea (n=0, 3, 0), pain (n=3, 3, 2), pain in extremity (n=1, 3, 6), back pain (n=4, 2, 3), nausea (n=1, 2, 4), fatigue (n=4, 1, 5), and influenza-like illness (n=1, 1, 3). There were no serious treatment-emergent adverse events, or TEAEs, attributed to mitapivat and there were no adverse events leading to drug reduction, discontinuation, interruption or death in either the mitapivat or the placebo arms. Of the 79 patients enrolled in the study, 73 continued into the Phase 2 open-label extension period. In October 2023, we enrolled the first patient in the phase 3 portion of this trial. The phase 3 portion includes a 52-week randomized, placebo-controlled period in which participants will be randomized in a 2:1 ratio to receive the recommended (100 mg twice daily) PYRUKYND&#174; dose level or the placebo. The primary endpoints are hemoglobin response, defined as &#8805;1 g/dL increase in average hemoglobin from baseline to week 52, and annualized rate of sickle cell pain crises. Participants who complete either the phase 2 or phase 3 portion will have the option to move into a 216-week open-label extension period to continue to receive PYRUKYND&#174;. We anticipate completing enrollment by the end of 2024 and announcing topline data for this trial in 2025.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ACTIVATE-kids and ACTIVATE-kidsT, double-blind phase 3 studies evaluating the efficacy and safety of PYRUKYND&#174; as a potential treatment for PK deficiency in not regularly transfused and regularly transfused patients between one and 18 years old, respectively.  The primary endpoint of ACTIVATE-kids is percentage of patients with hemoglobin response, defined as &#8805;1.5 g/dL increase in hemoglobin concentration from baseline that is sustained at two or more scheduled assessments at weeks 12, 16, and 20 during the double-blind period.  The primary endpoint of ACTIVATE-kidsT is transfusion reduction response, defined as &#8805;33% reduction in total RBC transfusion volume from week 9 through week 32 of the double-blind period. ACTIVATE-kidsT has completed enrollment and we expect to announce topline data for this trial by the end of 2024. ACTIVATE-kids is currently enrolling patients, we expect to complete enrollment for this trial by mid-2024, and we anticipate announcing topline data for this trial in 2025.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">An extension study evaluating the long-term safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from ACTIVATE and ACTIVATE-T, our completed pivotal trials of PYRUKYND&#174; in not regularly transfused and regularly transfused adult patients with PK deficiency. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">An extension study evaluating the long-term safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from DRIVE PK, our completed global phase 2, first-in-patient, open-label safety and efficacy clinical trial of PYRUKYND&#174; in adult, not regularly transfused patients with PK deficiency.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">An extension study evaluating the safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from our completed phase 2, open-label safety and efficacy clinical trial of PYRUKYND&#174; in adults with non-transfusion-dependent alpha- and beta-thalassemia. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In collaboration with the Company, the National Institutes of Health, or NIH, is evaluating PYRUKYND&#174; in a phase 1 trial in patients with SCD pursuant to a cooperative research and development agreement. The core trial period has completed, and the long-term extension study is ongoing. In June 2020, clinical proof of concept was established based on a preliminary analysis of the data from this trial.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In collaboration with the Company, University Medical Center Utrecht, or UMC Utrecht, is evaluating PYRUKYND&#174; in patients with SCD pursuant to an investigator sponsored trial agreement. The trial has completed enrollment and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patient follow-up is ongoing, and a 2-year extension study has been initiated for patients who complete the follow-up period.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AG-946: Novel PK Activator</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing AG-946, a novel PK activator, for the potential treatment of LR MDS and hemolytic anemias. We are evaluating AG-946 in a phase 1 trial of AG-946 in healthy volunteers and in patients with SCD. We have presented data from the healthy volunteer cohorts, and we have initiated the SCD patient cohort of this phase 1 trial. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a phase 2a clinical trial of AG-946 in adults with LR MDS in the third quarter of 2022, and the trial has completed enrollment with 22 patients, including 12 patients classified as non-transfused and 10 patients classified as low transfusion burden. Patients received 5 mg of AG-946 once daily for up to 16 weeks. The two primary endpoints of the trial were transfusion independence (for patients classified as low transfusion burden), defined as transfusion-free for &#8805; eight consecutive weeks during the 16-week treatment period, and hemoglobin response, defined as a &#8805; 1.5 g/dL increase from baseline in the average hemoglobin concentration measured from week 8 through week 16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we announced that we achieved clinical proof-of-concept in the phase 2a portion of the trial. We observed that four of the 10 patients with low transfusion burden achieved the transfusion independence endpoint, and one of the 22 patients achieved the hemoglobin response endpoint in the 16-week treatment period. The safety profile observed was consistent with data reported in the healthy volunteer study of AG-946. 19 patients elected to enroll in the extension period for up to 156 weeks. We intend to complete a full evaluation of the phase 2a trial results and assess the impact on the phase 2b portion of the protocol in 2024. We anticipate initiating a phase 2b trial of AG-946 in adults with LR MDS in mid-2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, we are developing AG-181, a PAH stabilizer for the potential treatment of PKU, for which we filed an investigational new drug, or IND, application in December 2023, and plan to initiate a phase 1 study in healthy volunteers in the first half of 2024. Also, in July 2023, we entered into a license agreement with Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the TMPRSS6 gene, and we intend to pursue development of a licensed product for the potential treatment of patients with PV.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates and our core technologies, including novel biomarker and diagnostic discoveries, and other know-how, to operate without infringing on the proprietary rights of others and to prevent others from infringing on our proprietary or intellectual property rights. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing United States and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We also rely on confidential information, know-how, in-licensing opportunities and continuing technological innovation to develop and maintain our proprietary and intellectual property position. We may also choose to rely on trade secrets to protect certain aspects of our business that are not suitable or appropriate for patent protection. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file, or may collaborate with third parties to file, patent applications directed to our key products and product candidates, including PYRUKYND&#174;, AG-946 and AG-181, in addition to related compounds and potential back-up compounds, in an effort to establish intellectual property positions to protect these new chemical entities as well as methods of using these compounds in the treatment of diseases, formulations, solid state forms, and manufacturing processes. We may also seek patent protection for certain biomarkers that may be useful in identifying the appropriate patient population for therapies with our product candidates. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PK activator program </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent portfolio for our PK activator program contains issued patents and pending patent applications directed to compositions of matter for PYRUKYND&#174;, as well as to related compounds, various solid state forms of PYRUKYND&#174;, compositions of matter for additional PKR activators, such as AG-946, as well as various solid state forms, methods of use and methods of manufacture for AG-946 and other novel compounds. As of February 1, 2024, we owned 16 issued United States patents and 401 issued foreign patents, and have pending patent applications in the United States and in various foreign jurisdictions. The patents that have issued or will issue for PYRUKYND&#174; will have a statutory expiration date of at least 2030 to 2042, and the patents that have issued or will issue for AG-946 will have a statutory expiration date of at least 2038 to 2044. Patent term adjustments or patent term extensions could result in later expiration dates. In some cases, the term of a United States patent can be shortened by the filing of a terminal disclaimer which operates to reduce the term of a patent to that of an earlier expiring patent. The foreign issued patents and pending patent applications are in a number of jurisdictions, including </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Argentina, Australia, Austria, Belgium, Brazil, Canada, China, the Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Lebanon, Lithuania, Mexico, the Netherlands, Norway, Poland, Portugal, Romania, Russia, Saudi Arabia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Turkey, and the United Kingdom. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination can be significantly narrowed by the time they issue, if they issue at all. We expect this could be the case with respect to some of our pending patent applications referred to above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PAH stabilizer program </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent portfolio for our PAH stabilizer program contains an issued patent and pending patent applications directed to compositions of matter and methods of use for AG-181 and other novel PAH stabilizers. As of February 1, 2024, we owned one issued foreign patent and have pending patent applications in the United States and in various foreign jurisdictions. We expect to file national stage patent applications in additional foreign jurisdictions in accordance with Patent Cooperation Treaty timelines.  The patents that have been issued or will issue for our PAH stabilizer program will have a statutory expiration date of at least 2043. Patent term adjustments or patent term extensions could result in later expiration dates. In some cases, the term of a United States patent can be shortened by the filing of a terminal disclaimer which operates to reduce the term of a patent to that of an earlier expiring patent. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination can be significantly narrowed by the time they issue, if they issue at all. We expect this could be the case with respect to some of our pending patent applications referred to above.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non-provisional patent application, although term extensions may be available. In the United States, a patent&#8217;s term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office, or USPTO, in examining and granting a patent or may be shortened if a patent is terminally disclaimed over an earlier filed patent. The term of a patent that covers a drug or biological product may also be eligible for patent term extension when FDA approval is granted, provided statutory and regulatory requirements are met. The extension of the term of foreign patents varies, in accordance with local law. Although certain of the patents granted by the regulatory authorities of the EU may expire at specific dates, the terms of patents granted in certain European countries may extend beyond such EU patent expiration date if we were to obtain a supplementary protection certificate. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, if and when our product candidates receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical trials for each product candidate and other factors. There can be no assurance that any of our pending patent applications will be issued or that we will benefit from any patent term extension or favorable adjustment to the term of any of our patents. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Considerations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our product, product candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, patent applications that we may file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may receive in the future may be challenged, invalidated or circumvented. For example, a third party can challenge the patentability of one or more of the claims of an issued patent in a post-grant proceeding before the USPTO or a foreign patent office such as the European Patent Office, which can result in the loss of certain claims or the loss of an entire patent. In addition, it is possible that a third party has filed a patent application in the United States, or abroad, that claims the same technology or chemical structures that are claimed in our own patent applications or patents. In such cases, we may have to participate in legal proceedings or enter into a licensing arrangement, which could result in substantial costs to us, even if the eventual outcome is favorable to us. In addition to patent protection, we also rely upon unpatented confidential information, including confidential technical information, know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality agreements with our collaborators, third-party service providers, scientific advisors, employees and consultants, and by invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors and collaborators. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses requiring invention assignment, to grant us ownership of technologies that are developed through a relationship with a third party. Nevertheless, confidential information and know-how can be difficult to protect. In particular, we anticipate that at least some of our technical information and know-how will, over time, become </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">known within the industry through independent development, the publication of journal articles, and the movement of personnel skilled in the art from academic to industry scientific positions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. PYRUKYND&#174; and any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in pharmaceutical, biotechnology and other related markets that address rare diseases, particularly hemolytic anemias, PKU and PV. There are other companies working to develop rare disease therapies, including divisions of large pharmaceutical companies and biotechnology companies of various sizes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors include but are not limited to: Bristol-Myers Squibb Company, or BMS; BioMarin Pharmaceutical, Inc., or BioMarin; bluebird bio, Inc., or bluebird; Merck &amp; Co., Inc., or Merck; Novartis International AG, or Novartis; Novo Nordisk A/S, or Novo; Pfizer, Inc., or Pfizer; Rocket Pharmaceuticals, Inc., or Rocket Pharma; Vertex Pharmaceuticals Incorporated, or Vertex; CRISPR Therapeutics AG, or CRISPR; Emmaus Life Sciences, Inc., or Emmaus; Fulcrum Therapeutics, Inc., or Fulcrum; Geron Corporation, or Geron; Keros Therapeutics, Inc., or Keros; PTC Therapeutics, Inc., or PTC; Jnana Therapeutics Inc., or Jnana; Homology Medicines Inc., or Homology; Silence Therapeutics plc, or Silence; Protagonist Therapeutics, Inc., or Protagonist; Ionis Pharmaceuticals, Inc., or Ionis; PharmaEssentia USA Corporation, or PharmaEssentia; and Incyte Corporation, or Incyte.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most common methods for treating patients with rare diseases include dietary restriction, dietary supplementation or replacement, treatment of symptoms and complications, gene therapy, blood transfusions, phlebotomies, stem cell transplant and ERTs and there are several marketed therapies available for treating patients with hemolytic anemias, PKU and PV. For example, recently approved treatments for thalassemia, SCD, LR MDS, PKU and PV include Reblozyl&#174; from Merck/BMS (formerly Acceleron/BMS); Revlimid&#174; from BMS; Zynteglo&#174; and Lyfgenia&#174; from bluebird; Adakveo&#174; from Novartis; Oxbryta&#174; from Pfizer; Casgevy&#174; from Vertex/CRISPR; Kuvan&#174; and Palynziq&#174; from BioMarin; Endari&#174; from Emmaus; Besremi&#174; from PharmaEssentia; and Jakafi&#174; from Incyte. While our product and product candidates may compete with existing medicines and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product or product candidates may not be competitive with them. In addition to currently marketed therapies, there are also several products that are either small molecules, biologics, ERTs or gene therapies in various stages of development to treat hemolytic anemias, PKU and PV. For example, Rocket Pharma is conducting a clinical trial of a gene therapy targeting PK deficiency; Novo is developing etavopivat (a PKR activator) for the treatment of hemolytic anemias, including alpha and beta thalassemia, SCD and MDS; Pfizer is developing inclacumab and GBT-601 for the treatment of SCD; Geron is developing imetelstat for the treatment of LR MDS (for which they have a Prescription Drug User Fee Act, or PDUFA, goal date of June 16, 2024 for their new drug application); Fulcrum is developing pociredir (FTX-6058) in SCD;  Keros is developing KER-050 for the treatment of anemia in LR MDS; a number of companies, including PTC, Jnana and Homology are developing therapies to treat PKU; and a number of companies, including Silence, Protagonist and Ionis are developing therapies to treat PV. These products may provide efficacy, safety, convenience and other benefits not provided by current marketed therapies or the current standards of care. As a result, they may provide competition for any of our product or product candidates for which we obtain market approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors may have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and globally marketing approved medicines than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring or in-licensing technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of PYRUKYND&#174; and any of our product candidates that we develop, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics where appropriate, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any medicines that we may develop. Our competitors also may obtain FDA or other regulatory approval for their medicines more rapidly than we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic or other branded medicines. There are generic medicines currently on the market for indications that we are pursuing, and additional medicines are expected to become available on a generic basis over the coming years. We expect that PYRUKYND&#174; and any of our product candidates that may receive marketing approval in the future will be priced at a significant premium over competitive generic medicines.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply Chain</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PYRUKYND&#174;, AG-946, and AG-181 are organic compounds of low molecular weight, generally called small molecules. Our siRNA program targeting the TMPRSS6 gene is an oligonucleotide intended for use as a sterile parenteral administration. Each can be manufactured in reliable and reproducible synthetic processes from readily available starting materials. The chemistry is amenable to scale-up and does not require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing or supply chain related facilities. We currently, and expect to continue to, rely on third parties for the manufacture and supply of our clinical and preclinical product candidates, as well as for commercial manufacture of PYRUKYND&#174; and any product for which we may receive marketing approval in the future. We conduct extensive prequalification programs to ensure the compliance, quality and reliability of third-party manufacturing and supply operations.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have obtained materials for PYRUKYND&#174;, AG-946, AG-181 and our siRNA program for our ongoing and planned clinical testing and ongoing preclinical testing from third-party manufacturers. We have long-term commercial manufacture and supply agreements in place for PYRUKYND&#174;, and we obtain our supplies from these manufacturers on a purchase order basis.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the volatility of the supply networks globally, we have gained regulatory approval for redundant supply of raw materials and active pharmaceutical ingredient, or API, for PYRUKYND&#174;, and have an ongoing program to ensure this risk mitigation remains effective, including establishing safety stocks. We do not currently have arrangements in place for redundant supply for drug product, but maintain a broad safety stock program. As we have done for PYRUKYND&#174;, we intend to identify and qualify additional manufacturing and supply related services for our other product candidates.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approvals</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the EU, extensively regulate, among other things, the research, development, testing, manufacture, pricing, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of biopharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approval and Regulation of Drugs in the United States</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, drug products are regulated under the Federal Food, Drug and Cosmetic Act, or FDCA, and applicable implementing regulations and guidance. A company, institution, or organization responsible for initiating and managing a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor seeking approval to market and distribute a new drug in the United States generally must satisfactorily complete each of the following steps before the product candidate will be approved by the FDA:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">preclinical testing including laboratory tests, animal studies and formulation studies which must be performed in accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations and standards;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">design of a clinical protocol and submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication, in accordance with current good clinical practices, or GCP;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">preparation and submission to the FDA of an NDA for a drug product which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling for one or more proposed indication(s);</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">satisfactory completion of FDA inspection of the manufacturing facility or facilities, including those of third parties, at which the product candidate or components thereof are manufactured to assess compliance with current good manufacturing practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">satisfactory completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with GCP and the integrity of clinical data in support of the NDA;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">payment of user fees and securing FDA approval of the NDA to allow marketing of the new drug product; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">compliance with any post-approval requirements, including the potential requirement to implement risk evaluation and mitigation strategies, or REMS, and the potential requirement to conduct any post-approval studies required by the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Studies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a sponsor begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability and other studies to evaluate, among other things, the toxicity of the product candidate. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards, and the United States Department of Agriculture&#8217;s Animal Welfare Act, if applicable. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND and are typically referred to as IND-enabling studies. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The IND and IRB Processes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved NDA. In addition to reviewing an IND to assure the safety and rights of patients, the FDA also focuses on the quality of the investigation and whether it will be adequate to permit an evaluation of the drug's safety and efficacy. In support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, or thereafter, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical or partial clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following commencement of a clinical trial under an IND, the FDA may also place a clinical or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements, including GCP requirements, of the FDA to use the study as support for an IND or application for marketing approval. The GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made based on evolving business objectives and/or competitive climate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reporting Clinical Trial Results</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Public Health Service Act, sponsors of certain clinical trials of certain FDA-regulated products, including prescription drugs and biologics, are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the NIH. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. With the issuance of pre-notices for voluntary corrective action and several notices of non-compliance during the past two years, the FDA has signaled the government&#8217;s willingness to enforce these requirements against non-compliant clinical trial sponsors. While these notices of non-compliance did not result in civil monetary penalties, the failure to submit clinical trial information to clinicaltrials.gov is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. Violations may also result in injunctions and/or criminal prosecution or disqualification from federal grants. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expanded Access to an Investigational Drug for Treatment Use </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational new drug products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational drugs for patients who may benefit from investigational therapies. FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the drug under a treatment protocol or Treatment IND Application. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there is no obligation to make investigational products available for expanded access, sponsors are required to make policies for evaluating and responding to requests for expanded access publicly available upon the earlier of initiation of a Phase 2 or Phase 3 clinical trial, or 15 days after the drug or biologic receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Right to Try Act, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act, but the manufacturer must develop an internal policy and respond to patient requests according to that policy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human Clinical Trials in Support of an NDA</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including AEs, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the investigational drug product&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are generally conducted to identify possible AEs and safety risks, evaluate the efficacy of the product candidate for specific targeted indications, and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are well controlled, closely monitored and conducted in a limited patient population.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. The FDA may require more than one Phase 3 clinical trial to support approval of a product candidate. A well-controlled, statistically robust Phase 3 clinical trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a drug; such Phase 3 clinical trials are referred to as &#8220;pivotal.&#8221; A Phase 2 clinical trial can be a &#8220;pivotal&#8221; trial if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need. A company&#8217;s designation of the phase of a trial is not necessarily indicative that the trial will be sufficient to satisfy the FDA requirements of that phase.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, with the passage of the Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product.  These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products.  Specifically, action plans must include the sponsor&#8217;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them.  In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, the FDA issued draft guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The draft guidance is adopted from the International Council for Harmonisation&#8217;s recently updated E6(R3) draft guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise. In addition, the FDA issued draft guidance outlining recommendations for the implementation of decentralized clinical trials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may approve an NDA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These trials are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group and to further document a clinical benefit in the case of drugs approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of clinical trials must be submitted at least annually to the FDA and more frequently if serious AEs occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interactions with the FDA During the Clinical Development Program</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the clearance of an IND and the commencement of clinical trials, a sponsor will continue to have interactions with the FDA and the sponsor may meet with the FDA at certain points in the clinical development program. Specifically, sponsors may meet with the FDA prior to the submission of an IND, or a pre-IND meeting, at the end of Phase 2 clinical trial, or a EOP2 meeting, and before an NDA is submitted, or a pre-NDA meeting. Meetings at other times may also be requested. These meetings provide an opportunity for the sponsor to share information about the data gathered to date with the FDA and for the FDA to provide advice on the next phase of development.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are five types of meetings that occur between sponsors and the FDA. Type A meetings are those necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND and pre-NDA meetings as well as end of phase meetings, such as EOP2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product, including, for example, meetings to facilitate early consultations on the use of a biomarker as a new surrogate endpoint that has never been previously used as the primary basis for product approval in the proposed context of use.  A Type D meeting is focused on a narrow set of issues (typically limited to no more than two focused topics) and should not require input from more than three disciplines or divisions.  Finally, INitial Targeted Engagement for Regulatory Advice on CBER producTs, or INTERACT, meetings are intended for novel products and development programs that present unique challenges in the early development of an investigational product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such meetings may be conducted in person, via teleconference/videoconference, or written response only with minutes reflecting the questions that the sponsor posed to the FDA and the FDA&#8217;s responses. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure.  In September 2023, the FDA issued draft guidance outlining the terms of such meetings in more detail.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of an NDA </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain approval to market a drug product in the United States, a marketing application must be submitted to the FDA that provides sufficient data establishing the safety and efficacy of the proposed drug product for its intended indication. The application must include all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a product use, or from alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the drug product to the satisfaction of the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NDA is a vehicle through which sponsors formally propose that the FDA approve a new product for marketing and sale in the United States for one or more indications. Every new drug product candidate must be the subject of an approved NDA before it may be commercialized in the United States. Under federal law, the submission of most NDAs is subject to an application user fee, which for federal fiscal year 2024 is approximately $4.05 million. The sponsor of an approved NDA is also subject to an annual program fee, which for fiscal year 2024 is $416,734 per product. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation and a waiver for certain small businesses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following submission of an NDA, the FDA conducts a preliminary review of the application generally within 60 calendar days of its receipt and must inform the sponsor at that time or before whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. Under the goals and policies agreed to by the FDA under the PDUFA, applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which the FDA accepts the application for filing. The review process and the PDUFA goal date may be extended by the FDA for three additional months to consider new information or clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an application, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including component manufacturing, finished product manufacturing and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP requirements and are adequate to assure consistent production of the product within required specifications. Under the FDA Reauthorization Act of 2017, the FDA must implement a protocol to expedite review of responses to inspection reports pertaining to certain applications, including applications for products in shortage or those for which approval is dependent on remediation of conditions identified in the inspection report. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a condition of approval, the FDA may require a sponsor to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. REMS could include medication guides, communication plans for health care professionals, and elements to assure safe use, including special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patent registries. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events and whether the product is an NME.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel product which presents difficult questions of safety or efficacy to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations when making decisions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track, Breakthrough Therapy, Priority Review and Regenerative Advanced Therapy Designations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are called Fast Track designation, Breakthrough Therapy designation, priority review designation and regenerative advanced therapy designation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Fast Track Designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA may designate a product for Fast Track review if it is intended, either alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review process may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. However, the FDA&#8217;s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Breakthrough Therapy Designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. The FDA may take certain actions with respect to Breakthrough Therapies, including: holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Priority Review</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for review of a marketing application from ten months to six months.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Regenerative Advanced Therapy Designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A product is eligible for regenerative advanced therapies designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated Approval Pathway</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to: (i) require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, (ii) require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six months (until the study is completed); and (iii) use expedited procedures to withdraw accelerated approval of an NDA or biologics license application after the confirmatory trial fails to verify the product&#8217;s clinical benefit. Further, FDORA requires the FDA to publish on its website the rationale for why a post-approval study is not appropriate or necessary, whenever it decides not to require such a study upon granting accelerated approval. In March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA&#8217;s Decision on an NDA</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its evaluation of the application and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for the approved indications. A complete response letter generally indicates that the review cycle is complete and outlines the deficiencies in the submission, and may require substantial additional testing or information in order for the FDA to reconsider the application. A sponsor has one year to respond to the deficiencies identified in the complete response letter. The FDA has committed to reviewing such resubmissions </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a new product, it may limit the approved indications for use of the product. The FDA may also require contraindications, warnings or precautions be included in the product labeling, require post-approval trials, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Ensuring Innovation Act, signed into law in 2021, the FDA must publish action packages summarizing its decisions to approve new drugs within 30 days of approval of such drugs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA may have imposed as part of the approval process. The sponsor will be required to report, among other things, certain adverse reactions and manufacturing problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP and other regulatory requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, with manufacturing processes, or failure to comply with regulatory requirements, may result in: revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information, although it may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. In the United States, health care professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of off-label uses. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the FDA published final regulations that describe the types of evidence that the agency will consider in determining the intended use of a drug or biologic. In addition, in October 2023, the FDA published draft guidance outlining the agency&#8217;s non-binding policies governing the distribution of scientific information on unapproved uses to healthcare providers.  This draft guidance calls for such communications to be truthful, non-misleading, factual and unbiased and include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the DOJ, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines, and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, and its implementing regulations, as well as the Drug Supply Chain Security Act, or DSCSA, which regulate the distribution and tracing of prescription drug samples at the federal level, and set minimum standards for the regulation of drug distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section&#160;505(b)(2) NDAs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NDAs for most new drug products are based on two full clinical trials which must contain substantial evidence of the safety and efficacy of the proposed new product for the proposed use. These applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section 505(b)(2) of the FDCA. This type of application allows the applicant to rely, in part, on the FDA&#8217;s previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section 505(b)(2) applies to NDAs for a drug for which the investigations made to show whether or not the drug is safe for use and effective in use and relied upon by the sponsor for approval of the application &#8220;were not conducted by or for the sponsor and for which the sponsor has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 505(b)(2) authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the sponsor. NDAs filed under Section 505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the 505(b)(2) sponsor can establish that reliance on the FDA&#8217;s previous approval is scientifically appropriate, the sponsor may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) sponsor.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Generic Drugs and Regulatory Exclusivity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. Such previously approved drugs are known as the reference listed drugs, or RLDs. Abbreviated new drug applications, or ANDAs, for generic drugs generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, the sponsor may rely on the preclinical and clinical testing previously conducted for the RLD. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hatch-Waxman Act, the FDA may not approve an ANDA or 505(b)(2) application until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity, or NCE. For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, a generic or follow-on drug application may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the sponsor may submit its application four years following the original product approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the sponsor and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product, such as new indications, dosage forms, route of administration, combination of ingredients. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs or 505(b)(2) NDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product; rather, this three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving follow-on applications for drugs containing the original active ingredient.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon submission of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the sponsor&#8217;s product or an approved method of using the product. Upon approval of a new drug, each of the patents listed by the NDA sponsor is published in the FDA's publication "Approved Drug Products with Therapeutic Equivalence Evaluations," also referred to as the Orange Book. When an ANDA sponsor files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book. Specifically, the sponsor must certify: (i) the required patent information has not been filed, (ii) the listed patent has expired, (iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration or (iv) the listed patent is invalid, unenforceable or will not be infringed by the new product. To the extent that the Section 505(b)(2) sponsor is relying on studies conducted for an already approved product, the sponsor is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA sponsor would.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the sponsor does not challenge the listed patents, the ANDA or 505(b)(2) NDA will not be approved until all the listed patents claiming the referenced product have expired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the ANDA sponsor or the 505(b)(2) sponsor has provided a Paragraph IV certification to the FDA, the sponsor must also send notice of the Paragraph IV certification to the NDA owner and patent holders once the ANDA or 505(b)(2) NDA has been accepted for filing by the FDA. The NDA owner and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) sponsor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Studies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, or PREA, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by regulation. The sponsor, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For drugs intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of a sponsor, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss pediatric study plans with sponsors, and the FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than ninety (90) days after the FDA&#8217;s receipt of the study plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The law requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has recently taken steps to limit what it considers abuse of this statutory exemption in PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA maintains a list of diseases that are exempt from the requirements of the PREA. In May 2023, the FDA issued new draft guidance that further describes the pediatric study requirements under PREA.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Exclusivity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months to the term of any existing patent or regulatory exclusivity for drug products. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but effectively extends the regulatory period during which the FDA cannot approve another application. With regard to patents, the six-month pediatric exclusivity period will not attach to any patents for which a generic (ANDA or 505(b)(2) NDA) sponsor submitted a Paragraph IV certification, unless the NDA sponsor or patent owner first obtains a court determination that the patent is valid and infringed by a proposed generic product. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition, generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a product available in the United States for treatment of the disease or condition will be recovered from sales of the product. A company must seek orphan drug designation before submitting an NDA for the candidate product. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not shorten the PDUFA goal dates for the regulatory review and approval process, although it does convey certain advantages such as tax benefits and exemption from the PDUFA application fee.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation, or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same drug for the same condition for seven years, except in certain limited circumstances. Orphan exclusivity does not block the approval of a different product for the same rare disease or condition, nor does it block the approval of the same product for different conditions. If a drug designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug exclusivity will also not bar approval of another product under certain circumstances, including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan exclusivity regardless of a showing of clinical superiority.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of market exclusivity, the term &#8220;same disease or condition&#8221; in the statute means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Thus, the court concluded that orphan drug exclusivity applies to the entire designated disease or condition rather than the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. In January 2023, the FDA announced that, in matters beyond the scope of that court&#8217;s order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Restoration and Extension</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent claiming a new drug product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of when a clinical investigation involving human beings has begun and the submission date of an application for approval, plus the time between the submission date of an application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining patent term past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Care Law and Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">broadly applicable fraud and abuse, anti-kickback, false claims laws, patient privacy laws and regulations and other health care laws and regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state health care laws and regulations, include the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or making false statements relating to health care matters;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items or services;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within the United States Department of Health and Human Services, or HHS, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to health care items or services that are reimbursed by non-government third-party payors, including private insurers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, such as Medicare and Medicaid. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Insurance Coverage and Health Care Reform</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products on an approved list, also known as a formulary, which might not include all the approved products for a particular indication.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of health care costs also has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs, biologics and other medical products, government control and other changes to the health care system in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for drug products under government health care programs. Among the provisions of the ACA of importance to our potential product candidates are: </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program, or MDRP, by increasing the minimum rebate for both branded and generic drugs, and revising the definition of &#8220;average manufacturer price,&#8221; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">addressed a new methodology by which rebates owed by manufacturers under the MDRP are calculated for drugs that are inhaled, infused, instilled, implanted or injected; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expanded the types of entities eligible for the 340B drug discount program; </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide a 50% (and 70% starting January 1, 2019) point-of-sale-discount off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D; and </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which will now remain in effect for six months into 2032. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010, or PAYGO, sequester for two years, through the end of 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Appropriations Act&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into 2032 and lowers the payment reduction percentages in years 2030 and 2031.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017 on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On November 10, 2020, the Supreme Court heard oral arguments as to whether the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act of 2017, the remaining provisions of the ACA are invalid as well. On June 17, 2021, the Supreme Court dismissed this action after finding that the plaintiffs did not have standing to challenge the ACA&#8217;s minimum essential coverage provision at issue in the case. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden rescinded those orders and issued a new executive order which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access. Under this executive order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the ACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and under the ACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Prices</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of drugs under Medicare and Medicaid. To those ends, the Trump Administration issued several executive orders intended to lower the costs of prescription drug products. Certain of these orders are reflected in recently promulgated regulations, including an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021, but such rule has been subject to a nationwide preliminary injunction. In December 2021, the CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nine states (Colorado, Florida, Maine, New Hampshire, New Mexico, North Dakota, Texas, Vermont and Wisconsin) have passed laws allowing for the importation of drugs from Canada.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these states have submitted Section 804 Importation Program proposals and are awaiting FDA approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would also eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the Inflation Reduction Act of 2022, or IRA, has been delayed by Congress to January 1, 2032.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Medicare Part D drugs in 2027, 15 Medicare Part B or Part D drugs in 2028, and 20 Medicare Part B or Part D drugs in 2029 and beyond.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA includes a provision exempting orphan drugs from Medicare price negotiation but this exclusion has been interpreted by CMS in final guidance issued in July 2023 to apply only to those orphan drugs with an approved indication (or indications) for a single rare disease or condition. The final guidance clarifies that CMS will consider only active designations/approvals when evaluating a drug for the exclusion, such that designations/indications withdrawn before the selected drug publication date will not be considered. CMS also clarified that, if a drug loses its orphan drug exclusion status, the agency will use the earliest date of approval/licensure to determine whether the product is a qualifying single source drug subject to price negotiations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, Merck filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, several other parties, including the U.S. Chamber of Commerce and pharmaceutical companies, also filed lawsuits in various courts with similar constitutional claims against HHS and CMS. Litigation involving these and other provisions of the IRA will continue with unpredictable and uncertain results.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Many states have required drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers and wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Review and Approval of Medicinal Products in the European Union</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, a sponsor must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy, and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, a sponsor will need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial Approval</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the Clinical Trials Regulation (EU) No 536/2014, or the Clinical Trials Regulation, became effective in the EU and replaced the prior Clinical Trials Directive 2001/20/EC. The Clinical Trials Regulation aims to simplify and streamline the authorization, conduct and transparency of clinical trials in the EU. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one Member State of the EU, or EU Member State, will only be required to submit a single application for approval. The submission will be made through the Clinical Trials Information System, a new clinical trials portal overseen by the EMA, and available to clinical trial sponsors, competent authorities of the EU Member States and the public. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond streamlining the process, the Clinical Trials Regulation includes a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted, or EU Member States </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">concerned. Part II is assessed separately by each EU Member State concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the EU Member State concerned. However, overall related timelines will be defined by the Clinical Trials Regulation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Clinical Trials Regulation did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific clinical site after the applicable ethics committee has issued a favorable opinion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the EU at the EudraCT website.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Priority Medicines (PRIME) Designation in the EU</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The priority medicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated MAA assessment once a dossier has been submitted. Importantly, a dedicated agency contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketing Authorization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain a marketing authorization for a product under EU regulatory systems, a sponsor must submit an MAA either under a centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the EU Member States, decentralized procedure; national procedure; or mutual recognition procedure. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single marketing authorization by the EMA that is valid in all EU Member States, as well as Iceland, Liechtenstein and Norway. The centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products, and products with a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The centralized procedure may at the request of the sponsor also be used in certain other cases. The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the sponsor in response to questions of the CHMP. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and from the viewpoint of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is 150 days, excluding stop clocks. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Decentralized procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Using the decentralized procedure, a sponsor may apply for simultaneous authorization in more than one EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized procedure. The sponsor may choose a member state as the reference member state to lead the scientific evaluation of the application.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.5pt">Mutual recognition procedure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the mutual recognition procedure, a medicine is first authorized in one EU Member State (which acts as the reference member state), in accordance with the national procedures of that country. Following this, further marketing authorizations can be progressively sought from other EU countries in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization produced by the reference member state.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the Member States of the European Economic Area, or EEA, make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conditional Approval </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may also grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i) the product candidate is intended for the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases, (ii) the risk-benefit balance of the product candidate is positive; (iii) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data; (iv) the product fulfills an unmet medical need; and (v) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new clinical studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization, but applicants can also request the  EMA to conduct an accelerated assessment, for instance in cases of unmet medical needs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Data Protection in the EU</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, innovative medicinal products approved based on a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance with the centralized authorization procedure. Data exclusivity prevents sponsors for authorization of generics of these innovative products from referencing the innovator&#8217;s data to assess a generic (abridged) application for a period of eight years. During an additional two-year period of market exclusivity, a generic MAA can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be an NCE so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical, preclinical and clinical trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Periods of Authorization and Renewals</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years based on a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Studies and Exclusivity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining a marketing authorization in the EU, sponsors must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the so-called Pediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or not appropriate, such as for diseases that only affect the adult population. Before an MAA can be filed or an existing marketing authorization can be amended, the EMA requests that companies comply with the agreed studies and measures listed in each relevant PIP. If a sponsor obtains a marketing authorization in all EU Member States, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate, or SPC, or alternatively a one year extension of the regulatory market exclusivity from ten to eleven years, as selected by the marketing authorization holder.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation (EC) No. 141/2000, as implemented by Regulation (EC) No. 847/2000 provides that a drug can be designated as an orphan drug by the European Commission if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of: (1) a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU when the application is made; or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the sponsor must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once authorized, orphan medicinal products are entitled to 10 years of market exclusivity in all EU Member States and a range of other benefits during the development and regulatory review process, including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure covering all member countries, and a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the 10-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extensions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU also provides for patent term extension through SPCs. The rules and requirements for obtaining an SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of 15 years of marketing exclusivity for a drug. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained. Although SPCs are available throughout the EU, sponsors must apply on a country by country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the EU.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements after a Marketing Authorization has been Obtained</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The EU&#8217;s pharmacovigilance or safety reporting rules, which can impose post-authorization studies and additional monitoring obligations.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and API, including the manufacture of API outside of the EU with the intention to import the API into the EU.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC, as amended, and EU Member State laws. Direct-to-consumer advertising of prescription medicines is prohibited across the EU.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Data Protection Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries outside of the United States maintain rigorous laws governing the privacy and security of personal information. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is subject to the European Union General Data Protection Regulation, or GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield framework, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. This CJEU decision may lead to increased scrutiny on data transfers from the EU to the United States generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The EU initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022 and the European Commission adopted the adequacy decision on July 10, 2023. The adequacy decision permits U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the United States. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As with other issues related to withdrawal of the United Kingdom from the EU, there are open questions about how personal data will be protected in the United Kingdom and whether personal information can transfer from the EU to the United Kingdom. Following the withdrawal of the United Kingdom from the EU, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the Data Protection Act 2018 in the United Kingdom that &#8220;implements&#8221; and complements the GDPR has achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under GDPR. The UK government has already determined that it considers all EU and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the EU/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the United Kingdom as being &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to the United Kingdom, although this decision may be re-evaluated in the future.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Brexit and the Regulatory Framework in the United Kingdom</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom&#8217;s withdrawal from the EU took place on January 31, 2020. The EU and the United Kingdom reached an agreement on their new partnership in the Trade and Cooperation Agreement, which was applied provisionally beginning on January 1, 2021, and which entered into force on May 1, 2021. The Trade and Cooperation Agreement focuses primarily on free trade by ensuring no tariffs or quotas on trade in goods, including healthcare products such as medicinal products. The EU and the United Kingdom will form two separate markets governed by two distinct regulatory and legal regimes, except that Northern Ireland will continue to broadly follow EU laws as further described below. As such, the Trade and Cooperation Agreement seeks to minimize barriers to trade in goods while accepting that border checks will become inevitable as a consequence that the United Kingdom is no longer part of the single market. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland, and Wales under domestic law whereas Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 27, 2023, the United Kingdom government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the &#8220;Windsor Framework&#8221;. This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the United Kingdom. In particular, the MHRA will be responsible for approving all </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medicinal products destined for the United Kingdom market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single United Kingdom-wide marketing authorization will be granted by the MHRA for all medicinal products to be sold in the United Kingdom, enabling products to be sold in a single pack and under a single authorization throughout the United Kingdom. The Windsor Framework was approved by the EU-United Kingdom Joint Committee on March 24, 2023. The United Kingdom government and the EU will enact legislative measures to bring it into law. On June 9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from January 1, 2025. The Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or HMR, is the primary legal instrument for the regulation of medicines in the United Kingdom. The HMR has incorporated into the domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the United Kingdom&#8217;s withdrawal from the EU.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EU laws which have been transposed into United Kingdom law through secondary legislation continue to be applicable as &#8220;retained EU law&#8221;. However, new legislation such as the Clinical Trials Regulation will not be applicable in Great Britain. Since a significant proportion of the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorizations, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit may have a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval, and commercialization of our product candidates in the United Kingdom. For example, the United Kingdom is no longer covered by the centralized procedures for obtaining EU-wide marketing authorizations from the EMA, and a separate marketing authorization will be required to market our product candidates in the United Kingdom. A new international recognition framework has been in place since January 1, 2024, whereby the MHRA will have regard to decisions on the approval of marketing authorizations made by the EMA and certain other regulators when determining an application for a new Great Britain marketing authorization.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pricing Decisions for Approved Products</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU provides options for its Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals, and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and negotiations may continue after reimbursement has been obtained. Reference pricing used by various Member States, and parallel trade (i.e., arbitrage between low-priced and high-priced Member States), can further reduce prices. There can be no assurance that any country with price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting and Geographical Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged solely in the discovery and development of medicines in the field of cellular metabolism. Accordingly, we have determined that we operate in one operating segment.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had 383 full-time employees and 3 part-time employees, all based in the United States and of which 100 held Ph.D., Pharm.D. or M.D. degrees. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We also retain independent contractors to support the goals of our organization. We prioritize our employee experience and we are proud of our strong employee and contractor relations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We understand that attracting, retaining, engaging and supporting our talented team and maintaining a diverse and inclusive organization is critical to our success and our ability to increase the value we can provide for patients, shareholders and all stakeholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to cultivate a positive, respectful and fair work environment guided by the following three pillars:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Flexibility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We provide flexible work arrangements which result in happier, more engaged and more productive employees. We encourage a culture that promotes different perspectives, different work styles, health and wellness, care of families and productivity.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Psychological safety</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We aim to ensure our teams experience psychological safety &#8211; the belief that risk-taking and failure will not be punished, which leads to higher performing teams, more creativity, candor and better results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Deliberate development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We emphasize providing ongoing opportunities for employees to grow professionally, whether through bringing in external speakers, offering preceptorships in different departments, and providing tuition reimbursement and leadership skills training.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To incentivize and reward strong performance, we have adopted a pay for performance philosophy and we provide competitive and balanced compensation and benefits package, including short-term and long-term incentives, discretionary paid time off policy, generous parental and family leave plans and premium medical benefits.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to fostering a welcoming and diverse workplace in which individuals from a variety of backgrounds can thrive. Our diversity and inclusion program focuses on valuing three types of differences: </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Representative differences (demographic diversity, such as gender, race, ethnicity, sexual orientation)</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Experiential differences (identities based on life experiences that may change over time)</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cognitive differences (unique ways of understanding and interpreting the world)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We set goals and track our progress to ensure that we continue to incorporate different voices across the business. We have an active cross-functional diversity council that furthers our commitment to building a diverse and inclusive organization by:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Representing and reflecting the different voices in the Agios community</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Furthering the work of diversity, equity and inclusion at Agios and in our communities</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Working in partnership with our leadership, human resources and employee resource groups to share, drive and lead our diversity, equity and inclusion efforts</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a majority female organization and maintain significant representation at all levels, including the Board of Directors. As of December&#160;31, 2023, 59% of our workforce were women. Racial and ethnic diversity continues to be an area of focus at the Company. As of December&#160;31, 2023, 33% of our workforce were ethnically diverse and 47% of all new hires that joined the Company in 2023 were ethnically diverse. We recognize that there is still important progress to be made, particularly as it relates to Black and Latino representation at our company, and this remains an area of continued emphasis for us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly evaluate the effectiveness of our human capital management practices through employee surveys and fostering a culture of ongoing feedback and two-way dialogue. We received feedback from employees that helped to inform how we approach programs and opportunities to improve the employee experience heading into 2024. In addition, we track important human capital metrics such as turnover rate. Voluntary and involuntary turnover rates across all levels (executives/ senior managers, mid-level managers and professionals) are in alignment with the industry average. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to providing employees with an opportunity to choose the right working arrangement for them based on their role: whether remote, hybrid, or onsite in our Cambridge office, and we continue to evaluate how we can enhance these arrangements for an optimal employee experience. The opportunity to work remotely has enabled us to hire a more diverse team including individuals from different locations and backgrounds and with a variety of responsibilities in their personal lives. In 2023, 84% of our new hires chose to work remotely and our overall organization now has a majority population of remote workers representing 59% of all employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ability to evolve with the ever-changing environment, coupled with our long-standing culture and values around flexibility and connection, continue to help us deliver for patients.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Corporate Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive offices are located at 88 Sidney Street, Cambridge, Massachusetts 02139, and our telephone number is (617)&#160;649-8600. Our website address is www.agios.com. References to our website are inactive textual references only and the content of our website should not be deemed incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to these reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available free of charge on our website located at www.agios.com as soon as reasonably practicable after they are filed with or furnished to the Securities and Exchange Commission, or SEC. These reports are also available at the SEC&#8217;s website at www.sec.gov.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of our Corporate Governance Guidelines, Code of Business Conduct and Ethics and the charters of the Audit Committee, Compensation and People Committee, Nominating and Corporate Governance Committee, and Science and Technology Committee are posted on our website, www.agios.com, under the heading &#8220;Corporate Governance&#8221; and are available in print to any person who requests copies by contacting us by calling (617)&#160;649-8600 or by writing to Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A. Risk Factors</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following risk factors and other information included in this Annual Report on Form 10-K should be carefully considered. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see page <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_10">1</a> of this Annual Report on Form 10-K for a discussion of some of the forward-looking statements that are qualified by these risk factors. If any of the following risks occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery, Development, and Commercialization of our Products and Product Candidates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we do not successfully commercialize PYRUKYND&#174; and other products for which we receive approval, our prospects may be substantially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we obtained marketing approval from the FDA for PYRUKYND&#174; (mitapivat) for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In November 2022, we received marketing authorization from the European Commission for PYRUKYND&#174; for the treatment of PK deficiency in adult patients in the EU and in December 2022 we received marketing authorization in Great Britain for PYRUKYND&#174; for the treatment of PK deficiency in adult patients under the European Commission Decision Reliance Procedure. PYRUKYND&#174; is the first product in our rare disease portfolio that has received marketing approval and is our first product following the sale of our oncology business to Servier in March 2021. Our ability to generate meaningful revenue from PYRUKYND&#174; will depend heavily on our successful development and commercialization of the product. In connection with our regulatory approvals in the EU and Great Britain, we are currently providing access to PYRUKYND&#174; free of charge for eligible patients in those jurisdictions through a global managed access program.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of PYRUKYND&#174; could be unsuccessful if:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the medical community and third-party payors do not accept PYRUKYND&#174; as safe, efficacious and cost-effective for the treatment of adults with PK deficiency in the approved jurisdictions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to maintain the necessary financial resources and expertise to manufacture, market and sell PYRUKYND&#174;;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to develop, implement and maintain effective marketing, sales and distribution strategies and operations for the development and commercialization of PYRUKYND&#174;; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to continue to develop, validate and maintain a commercially viable manufacturing process for PYRUKYND&#174; that is compliant with current good manufacturing practices, or cGMP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to successfully obtain third party reimbursement and generate commercial demand that results in expected sales of PYRUKYND&#174;;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PYRUKYND&#174; may become subject to unfavorable pricing regulations and third-party reimbursement practices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we encounter any third-party patent interference, derivation, inter partes review, post-grant review, reexamination or patent infringement claims with respect to PYRUKYND&#174;;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we fail to comply with regulatory and legal requirements applicable to the sale of PYRUKYND&#174;; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing drug products are approved for the same indications as PYRUKYND&#174;;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant safety, manufacturing and/or quality risks are identified; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PYRUKYND&#174; fails to gain and/or maintain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a significant number of eligible patients with PK deficiency are not prescribed PYRUKYND&#174; and, if they are, such patients do not stay on treatment; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PYRUKYND&#174; does not demonstrate acceptable safety and efficacy in current or future clinical trials, or otherwise does not meet applicable regulatory standards for approval in other indications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience significant delays or an inability to successfully develop and commercialize PYRUKYND&#174; our business would be materially harmed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of our clinical-stage product candidates, including the potential approval of PYRUKYND&#174; for use in indications other than PK deficiency and in other jurisdictions. Clinical trials of our product candidates may not be successful for a number of important reasons. If we or our collaborators are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested a significant portion of our efforts and financial resources in the identification of our product candidates and the development of our most advanced clinical programs, including PYRUKYND&#174;. Our ability to generate meaningful product revenue will depend heavily on the successful clinical development and eventual commercialization of our current and any future product candidates, including PYRUKYND&#174;. While we obtained marketing approval of PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States and marketing authorization of PYRUKYND&#174; for the treatment of adults with PK deficiency in the EU and Great Britain, we cannot be certain that we will obtain marketing approval of PYRUKYND&#174; in indications other than PK deficiency or in other jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and any collaborators, are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements in foreign jurisdictions. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of product development. Moreover, we, or any collaborators, may experience any of a number of possible unforeseen adverse events in connection with clinical trials, many of which are beyond our control, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our collaborators, may fail to demonstrate efficacy in a clinical trial or across a broad population of patients;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. For example, many compounds that initially showed promise in earlier stage testing for treating specific indications have later been found to cause side effects that prevented further development of the compound;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics or otherwise expose participants to unacceptable health risks, causing us, our collaborators or our investigators, regulators or institutional review boards or the data safety monitoring board for such trial to halt, delay, interrupt, suspend or terminate the trials or cause us, or any collaborators, to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if our product candidates have undesirable side effects, it could result in a more restrictive label, or it could result in the delay or denial of marketing approval by the FDA or comparable foreign regulatory authorities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we, or our collaborators, may decide, or regulators may require us, to conduct additional clinical trials, including testing in more subjects, or abandon product development programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards may not authorize us, our collaborators or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our collaborators may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate; enrollment in these clinical trials, which may be particularly challenging for some of the orphan diseases we target in our rare disease programs, may be slower than we anticipate; or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors used by us or our collaborators may fail to comply with regulatory requirements or meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant preclinical study or clinical trial delays could shorten any periods during which we, or any collaborators, may have the exclusive right to commercialize our product candidates or allow our competitors, or the competitors of any collaborators, to bring products to market before we, or any collaborators, do;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than anticipated; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we withdrew our IND for AG-519, our second PK activator, following verbal notification of a clinical hold from the FDA relating to a previously disclosed case of drug-induced cholestatic hepatitis which occurred in our phase 1 clinical trial of AG-519 in healthy volunteers. Although these decisions and this hepatic adverse event finding do not affect our ongoing clinical trials for PYRUKYND&#174;, our first PK activator, we cannot provide any assurances that there will not be other treatment-related severe adverse events in our other clinical trials, or that our other trials will not be placed on clinical hold in the future. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully begin and complete clinical trials of our product candidates and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market any of our product candidates could result in additional costs to us, or any collaborators, would impair our ability to generate revenue from product sales, regulatory and commercialization milestones and royalties and would significantly harm our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in in-licensing transactions or acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have and may in the future enter into additional transactions to in-license products, technologies or assets or to acquire other products, technologies, assets or businesses. As part of the evolution of our research organization, we plan to prioritize in-licensing or acquiring assets for future pipeline growth. For example, in July 2023, we entered into a license agreement with Alnylam for the development and commercialization of products containing or comprised of an siRNA development candidate discovered by Alnylam and targeting the TMPRSS6 gene, and we intend to pursue development of a licensed product for the potential treatment of PV. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to successfully in-license or acquire assets and develop product candidates following such transactions is unproven. If we do identify additional suitable candidates or assets for in-licensing transactions or acquisitions, we may not be able to make such transactions on favorable terms, or at all. Such transactions may require us to relinquish rights to develop product candidates in certain indications, limit our ability to pursue certain targets or require us to make significant milestone or royalty payments to third parties upon achievement of certain events. For example, we are responsible to pay up to $130.0 million in potential development and regulatory milestones, in addition to sales milestones as well as tiered royalties on annual net sales, if any, of any licensed products, under the license agreement with Alnylam. Further, any in-licensing transaction or acquisitions we undertake may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or an in-licensing transaction or issue our common stock or other equity securities to the stockholders of the counterparty, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business, product or technology that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Such transactions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot ensure that following any transaction we would achieve the expected synergies to justify the transactions. We cannot predict the number, timing or size of future transactions or the effect that any such transactions might have on our operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health epidemics or pandemics may affect our ability to initiate or continue our planned, ongoing and future preclinical studies and clinical trials, disrupt regulatory activities, disrupt our ability to maintain a commercial infrastructure for our product or have other adverse effects on our business and operations.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health emergencies or pandemics could adversely affect our business, financial condition, results of operations, and prospects. We may face delays, disruptions or shortages as a result of such pandemics that may affect our ability to initiate and complete preclinical studies and clinical trials or impact our commercialization efforts. We have experienced disruptions to certain clinical and research activities at our contract research organizations, or CROs, due to the recent COVID-19 pandemic. Any future pandemic or public health emergency could result in site initiation, participant recruitment and enrollment, participant dosing, distribution of clinical trial materials, study monitoring and data analysis being paused or delayed due to changes in hospital or university policies, federal, state or local regulations, diversion of hospital resources or other reasons related to a public health emergency. If a pandemic or public health emergency arises in the future, we may face difficulties recruiting or retaining patients in our ongoing clinical trials, and patients enrolled in our clinical trials may be unable or unwilling to visit clinical trial sites which may impact the collection of important clinical trial data and may necessitate remote data verification. In addition, limitations on the ability to visit sites may affect our enrollment timelines for our clinical trials, and may adversely affect the timing of completion of our clinical trials or our ability to complete clinical trials in a fully compliant manner. Additionally, the potential suspension of clinical trial activity at clinical trial sites or reduced availability of CRO personnel may have an adverse impact on our clinical trial plans and timelines.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The public health emergency declarations related to COVID-19 ended on May 11, 2023. The FDA ended a number of COVID-19 related policies and retained a number of COVID-19 related policies. It is unclear how, if at all, these developments will impact our efforts to develop and commercialize our product candidates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain what the overall impact of future health emergencies or pandemics will be on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators may not be able to initiate, continue or complete clinical trials for our product candidates if we or they are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or analogous regulatory authorities outside the United States. Furthermore, enrollment had previously been particularly challenging in light of the recent COVID-19 pandemic. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment is also affected by other factors including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevalence and severity of the disease under investigation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability and efficacy of approved medications for the disease under investigation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eligibility criteria for the study in question;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient referral practices of physicians;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilizing our precision medicine approach, we generally focus our development activities on genetically or biomarker defined patients most likely to respond to our therapies. As a result, the potential patient populations for our clinical trials are narrowed, and we may experience difficulties in identifying and enrolling a sufficient number of patients in our clinical trials. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, with the passage of the Food and Drug Omnibus Reform Act, Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other "pivotal study" of a new drug product. These plans are meant to encourage enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. If we are not able to adhere to these new requirements, our ability to conduct clinical trials may be delayed or halted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some of our competitors may have ongoing or planned clinical trials for product candidates that would treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. For example, Rocket Pharma is developing a gene therapy targeting PK deficiency; Novo Nordisk is developing molecules for the treatment of alpha and beta thalassemia, SCD and LR MDS; Pfizer is developing molecules for the treatment of SCD; Fulcrum Therapeutics Inc., or Fulcrum, is developing a treatment for SCD; Geron Corporation, or Geron, is developing imetelstat for the treatment of LR MDS (for which they have a Prescription Drug User Fee Act goal date of June 16, 2024 for their new drug application); Keros Therapeutics, or Keros, is developing KER-050 for the treatment of anemia in LR MDS; PTC Therapeutics, Inc., or PTC, and Jnana Therapeutics, Inc., or Jnana, and Homology Medicines Inc., or Homology, are developing therapies to treat PKU; and Protagonist Therapeutics, or Protagonist, Ionis Pharmaceuticals, Inc., or Ionis, Silence Therapeutics, or Silence, and Merck are developing therapies to treat PV. Competition for eligible patients may make it particularly difficult for us to enroll a sufficient number of patients to complete our clinical trials for our product candidates in a timely and cost-effective manner.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have a small number of clinical trial sites for certain clinical trials in the Middle East, including in Lebanon and Israel, that could be affected by the current armed conflict in Israel and the Gaza Strip.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. Our or our collaborators&#8217; inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether, or result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of preclinical studies and early clinical trials may not be predictive of results of later-stage clinical trials.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and interim results of clinical trials do not necessarily predict success in future clinical trials. Many companies in the pharmaceutical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier stages of development, and we could face similar setbacks. The design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we, or any collaborators, believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. While we obtained marketing approval of PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States and marketing authorization of PYRUKYND&#174; for the treatment of adults with PK deficiency in the EU and Great Britain, we cannot be certain that we will obtain marketing approval of PYRUKYND&#174; in other indications. The results of clinical trials of PYRUKYND&#174; for the treatment of PK deficiency do not predict that PYRUKYND&#174; will be efficacious in our ongoing clinical trials in other indications, such as thalassemia or SCD. If we fail to receive positive results in clinical trials of our product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. We have decided to evolve our approach to exploratory research and drug discovery to prioritize investment in advancing our late lead-optimization research, while continuing to progress our registration-enabling clinical programs in thalassemia, SCD and pediatric PK deficiency, our phase 2a trial in LR MDS, our IND-enabling studies for AG-181, our PAH stabilizer for the potential treatment of PKU, and our development of a licensed siRNA development candidate under our license agreement with Alnylam. Our resource allocation decisions may cause us to fail to capitalize on viable commercial medicines or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or others may later discover that PYRUKYND&#174;, or any of our product candidates that may receive marketing approval in the future, is less effective than previously believed or causes undesirable side effects that were not previously identified, which could compromise our ability, or that of any collaborators, to market the product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that our clinical trials, or those of any collaborators, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, including PYRUKYND&#174;, we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or any collaborators, may be required to recall the product, change the way the product is administered or conduct additional clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the particular product;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or any collaborators, may be required to create a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or any collaborators, could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PYRUKYND&#174;, or any of our product candidates that may receive marketing approval in the future, may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PYRUKYND&#174;, or any of our product candidates that may receive marketing approval in the future, may fail to gain and/or maintain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. If PYRUKYND&#174; or any of our product candidates that may receive marketing approval do not achieve an adequate level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market acceptance of PYRUKYND&#174; and any of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efficacy and potential advantages compared to alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our medicines for sale at competitive prices;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensuring uninterrupted product supply;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient third-party coverage or reimbursement; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing PYRUKYND&#174; or any of our product candidates if they are approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in the sale, marketing or distribution of pharmaceutical products. To achieve commercial success for approved medicines for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to other third parties. We have established sales and marketing capabilities to support our commercial launch of PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In addition, in connection with our regulatory approvals in the EU and Great Britain, we are currently providing access to PYRUKYND&#174; free of charge for eligible patients in those jurisdictions through a global managed access program. We may provide access to PYRUKYND&#174; for adult patients with PK deficiency in other jurisdictions upon request through the global managed access program, on either a free of charge or for charge basis. We may need to further build our sales and marketing infrastructure, either directly or with third-party partners, to maintain our ongoing commercialization efforts and to commercialize PYRUKYND&#174; in other indications or outside of the United States or to commercialize any of our other product candidates for which we obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our medicines on our own include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future medicines;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the lack of complementary medicines to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of product revenue to us are likely to be lower than if we were to market and sell any medicines that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and any of them may fail to devote the necessary resources and attention to sell and market our medicines effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing PYRUKYND&#174; or any of our product candidates for which we obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We provide certain development estimates related to the development of PYRUKYND&#174; and our product candidates. If we do not achieve our projected development estimates in the timeframes we announce and expect, the commercialization of our products may be delayed and, as a result, our stock price may decline.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we provide estimates related to the development of PYRUKYND&#174; and our product candidates . We also estimate the timing of the anticipated accomplishment of various scientific, preclinical, clinical, regulatory and other product development goals. These estimates may include the commencement or completion of clinical trials and the submission of regulatory filings. From time to time, we may publicly announce our estimates, including the timing of certain milestones related to our product candidates. All of these estimates are and will be based on numerous assumptions. The actual results and timing of our preclinical and clinical trials can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If our estimates change or we do not meet the timing of our estimates as publicly announced, or at all, the commercialization of our products may be delayed or never achieved and, as a result, our stock price may decline.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition with respect to PYRUKYND&#174; and our current product candidates, and we will face competition with respect to any product candidates that we may seek to develop or commercialize in the future. Potential competitors may include major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the indications for which we are developing our product or our product candidates, such as PK deficiency, thalassemia, SCD, LR MDS, PKU, and PV. For example, Merck and Bristol-Myers Squibb Company, or BMS, are marketing a therapy to treat beta thalassemia and LR MDS and are conducting clinical trials for alpha thalassemia and LR MDS patients that are ESA na&#239;ve and non-transfusion dependent; Novartis International AG, or Novartis, Emmaus Life Sciences, and Pfizer are each marketing therapies to treat SCD, with Pfizer continuing to conduct clinical trials for therapies in SCD; BioMarin is marketing and conducting clinical trials for therapies to treat PKU; Novo is conducting clinical trials for the treatment of alpha and beta thalassemia, SCD and LR MDS; bluebird is marketing a gene therapy to treat transfusion-dependent beta-thalassemia and SCD; Vertex, with CRISPR, is marketing a gene therapy targeting SCD and transfusion-dependent beta-thalassemia; Fulcrum is conducting clinical trials for a potential treatment for SCD; Geron and Keros are conducting clinical trials for potential treatments for LR MDS (for which Geron has a Prescription Drug User Fee Act goal date of June 16, 2024 for their new drug application); PTC, Jnana and Homology are conducting clinical trials for potential treatments for PKU; PharmaEssentia Corp, or PharmaEssentia, and Incyte Corporation, or Incyte, are marketing therapies to treat PV, with Protagonist, Ionis, and Silence are developing therapies to treat PV; and a number of other biotechnology companies have product candidates in clinical development in similar indications as ours.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a variety of treatment options available, including a number of marketed ERTs, for treating patients with rare diseases. In addition to currently marketed therapies, there are also a number of products that are either ERTs, gene therapies or PK activators in various stages of clinical development to treat rare diseases. These products in development may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies or for which there are no approved treatments. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also a number of product candidates in preclinical or clinical development by third parties to treat rare diseases by targeting similar mechanisms of action or target indications as our product candidates. These companies include large pharmaceutical companies, such as Novartis, Novo Nordisk, Pfizer, BMS, Merck and Vertex as well as biotechnology companies of various sizes, such as BioMarin, bluebird, PTC and Rocket Pharma.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may develop products that are more effective, safer, more convenient or less costly than PYRUKYND&#174; or any product candidates that we are developing or that would render PYRUKYND&#174; or our product candidates obsolete or non-competitive. In addition, our competitors may discover biomarkers that more efficiently measure metabolic pathways than our methods, which may give them a competitive advantage in developing potential products. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and globally marketing approved </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and clinical stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring or in-licensing technologies complementary to, or necessary for, our programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA does not grant our products, if and when approved, appropriate periods of data exclusivity before approving generic or follow-on versions of our products, the sales of our products could be adversely affected. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With FDA approval of an NDA, the product covered by the application is specified as a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; or the Orange Book. Manufacturers may seek approval of generic versions of reference-listed drugs through submission of abbreviated new drug applications, or ANDAs, in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the sponsor generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any reference-listed drug may be typically lost to the generic product. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A manufacturer may also submit an NDA under section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, or FDCA, that references the FDA&#8217;s prior approval of the innovator product or preclinical studies and/or clinical trials that were not conducted by, or for, the sponsor and for which the sponsor has not obtained a right of reference. A 505(b)(2) NDA product, or follow-product, may be for a new or improved version of the original reference listed drug. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not approve an ANDA or 505(b)(2) NDA until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The FDCA provides a period of five years of new chemical entity exclusivity for a new drug containing a new active moiety. Specifically, in cases where such exclusivity has been granted, an ANDA or a 505(b)(2) NDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference-listed drug is either invalid or will not be infringed by the generic product, in which case the sponsor may submit its application four years following approval of the reference-listed drug. The FDCA also provides a period of three years of new clinical investigation data exclusivity in connection with the approval of a supplemental indication for the product for which a clinical trial is deemed by the FDA as essential for approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a generic or follow-on manufacturer is somehow able to obtain FDA approval without adherence to these periods of data exclusivity, the competition that our approved products may face from generic and follow-on versions could negatively impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on our investments in those product candidates.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if there are patents listed for our drug products in the Orange Book, ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the sponsor intends to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic or follow-on competitor would address such patents, whether we would sue on any such patents or the outcome of any such suit. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us or any collaborators could cause us or our collaborators to incur substantial liabilities and could limit commercialization of any medicines that we or they may develop.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and any collaborators face a risk of product liability exposure related to our product candidates in human clinical trials and face an even greater risk as we or they commercially sell any medicines, including PYRUKYND&#174;. If we or any collaborators cannot successfully defend ourselves or themselves against claims that our product candidates or medicines caused injuries, we or they could incur substantial costs and liabilities. Regardless of merit or eventual outcome, liability claims may also result in, among other things, decreased demand for any product candidates or medicines that we may develop, reputational harm and lost revenue.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our internal information technology systems, or those of any third parties with which we contract, may fail or suffer security breaches, loss of data or other disruptions which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, trigger legal obligations, potentially exposing us to liability, competitive or reputational harm or otherwise adversely affecting our business and financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal information technology systems and those of third parties with which we contract are vulnerable to damage from computer viruses, worms and other destructive or disruptive software, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or business partners, or from cyber incidents by malicious third parties. Cybersecurity incidents are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cybersecurity incidents could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cybersecurity incidents also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. Attackers may use artificial intelligence and machine learning to launch more automated, targeted and coordinated attacks against targets. We could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information systems and networks of our company, including personal information of our employees. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">System failures, accidents, cybersecurity incidents or security breaches could cause interruptions in our operations, and could result in a material disruption of our clinical and commercialization activities and business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions, in addition to possibly requiring substantial expenditures of resources to remedy. For example, the loss of clinical trial data from completed or future trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and our product research, development and commercialization efforts could be delayed. In addition, we may not have adequate insurance coverage to provide compensation for any losses associated with such events.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a material breach of our security or that of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed, and, as a result, we could lose business and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or replace information systems or networks. Although we develop and maintain processes, systems and controls designed to prevent these events from occurring, and we have a process to assess, identify and manage threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become more sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. We cannot guarantee that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent any cyber-attacks or security breaches.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, EU and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. Enforcement activity by the U.S. Department of Health &amp; Human Services, or HHS, can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to potential enforcement by HHS, we are also potentially subject to privacy enforcement from the Federal Trade Commission, or FTC. The FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section 5 of the FTC Act, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). The agency is also in the process of developing rules related to commercial surveillance and data security that may impact our business. We will need to account for the FTC&#8217;s evolving rules and guidance for proper privacy and data security practices in order to mitigate our risk for a potential enforcement action, which may be costly. If we are subject to a potential FTC enforcement action, we may be subject to a settlement order that requires us to adhere to very specific privacy and data security practices, which may impact our business. We may also be required to pay fines as part of a settlement (depending on the nature of the alleged violations). If we violate any consent order that we reach with the FTC, we may be subject to additional fines and compliance requirements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States are also active in creating specific rules relating to the processing of personal information. In 2018, California passed into law the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#8217;s requirements are similar to those found in the General Data Protection Regulation, or GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#8220;sales&#8221; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or CPRA, which went into effect on January 1, 2023 and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to California, eleven other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026.  Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data (which includes health data in some cases). Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering or are in the process of enacting privacy laws that will go into effect in 2024 and beyond, including New Hampshire and New Jersey. Other states will be considering these laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, Washington state passed a health privacy law that will regulate the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation in 2024. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.   </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is regulated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the GDPR, which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR places restrictions on the cross-border transfer of personal data from the EU to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the U.S. This CJEU decision has resulted in increased scrutiny on data transfers generally and may increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022, and the European Commission adopted the adequacy decision on July 10, 2023. The adequacy decision will permit U.S. companies who self-certify to the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the EU to the U.S. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework. If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business internationally.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Brexit, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the United Kingdom and the EU have determined, through separate &#8220;adequacy&#8221; decisions, that data transfers between the two jurisdictions are in compliance with the UK Data Protection Act and the GDPR, respectively. The United Kingdom and the U.S. are also in discussions to develop a US-UK &#8220;data bridge&#8221;, which would function similarly to the EU-U.S. Data Privacy Framework and provide an additional legal mechanism for companies to transfer data from the United Kingdom to the U.S. In addition to the United Kingdom, Switzerland is also in the process of approving an adequacy decision in relation to the Swiss-U.S. Data Privacy Framework (which would function similarly to the EU-U.S. Data Privacy Framework and the U.S.-UK &#8220;data bridge&#8221; in relation to data transfers from Switzerland to the United States). Any changes or updates to these developments have the potential to impact our business.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and the sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">        </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face new challenges as a smaller, less diversified company following the sale of our oncology business to Servier.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We developed most of our initial products and product candidates for the treatment of various types of cancer. The sale of our oncology business to Servier in 2021, including our approved products at the time of sale, TIBSOVO&#174; and IDHIFA&#174;, has resulted in us being a smaller, less diversified company with a more limited business concentrated on products and product candidates for the treatment of rare diseases. The success of the rare disease business is subject to various risks and uncertainties, including the possibility that we may not be able to successfully commercialize PYRUKYND&#174;, the possibility of adverse clinical and other developments in respect of PYRUKYND&#174; or our other product candidates of the rare disease business, and unanticipated changes in applicable laws and regulations that may adversely affect the rare disease business. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be more susceptible to changing market conditions, including fluctuations and risks particular to the markets for patients with rare diseases, than a more diversified company, which could adversely affect our business, financial condition and results of operations. In addition, even with the FDA approval of PYRUKYND&#174;, the diversification of our revenues, costs and cash flows has diminished following the sale of our oncology business. Our results of operations, cash flows, working capital and financing requirements may be subject to increased volatility and our ability to fund capital expenditures and investments or satisfy other financial commitments may be diminished.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may restrict our operations, require us to relinquish rights to our technologies or product candidates or cause dilution to our stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, including from sales of PYRUKYND&#174;, we expect to finance our cash needs primarily through cash on hand, a potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA with a label that permits vorasidenib's use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation, and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. In addition, we may pursue opportunistic debt offerings, and equity or equity-linked offerings. We do not have any committed external source of funds other than the potential milestone and royalty payments that we are eligible to receive with respect to vorasidenib under our purchase agreement with Servier. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may require us to enter into agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures or declaring dividends. In addition, securing financing could require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from day-to-day activities, which may adversely affect our management&#8217;s ability to oversee the development of our product candidates.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our existing capital is insufficient to fund our operating expenses and capital expenditures, we will need to raise capital, and if we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">are unable to raise capital when needed, we would be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur significant expenses as we continue to advance our ongoing activities. Our estimate as to how long we expect our existing cash, cash equivalents, and marketable securities to be available to fund our operating expenses and capital expenditures is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount and timing of future revenue received from commercial sales of PYRUKYND&#174; and any of our other product candidates for which we may receive marketing approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amount of contingent consideration we ultimately receive from Servier;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of our ongoing commercialization activities, including product manufacturing, sales, marketing and distribution, for PYRUKYND&#174; for the treatment of adults with PK deficiency in the approved jurisdictions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated cost-savings associated with the evolution of our research organization;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with in-licensing or acquiring assets for pipeline growth, including the amount and timing of future milestone and royalty payments payable to Alnylam pursuant to the license agreement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval;  </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully execute on our strategic plans;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operational delays due to public health epidemics, including the recent COVID-19 pandemic; and</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operational delays, disruptions and/or increased costs associated with global economic developments, rising global energy prices or energy shortages or rationing.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically incurred operating losses. We expect to incur losses in the future and may never achieve or maintain profitability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a history of incurring operating losses. Our net losses for the twelve months ended December 31, 2023 and 2022 were $352.1 million and $231.8 million, respectively. As of December&#160;31, 2023, we had an accumulated deficit of $822.6 million. Prior to the sale of our oncology business to Servier in March 2021, we had generated only modest revenue from sales of TIBSOVO&#174; and, prior to our sale to Royalty Pharma of our royalty rights to IDHIFA&#174;, from royalties on sales of IDHIFA&#174;. Following receipt of marketing approval in February 2022, we have begun to commercialize PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. We are currently providing access to PYRUKYND&#174; free of charge for eligible patients in the EU and Great Britain through a global managed access program, and we may provide access to PYRUKYND&#174; for adult patients with PK deficiency in other jurisdictions through the global managed access program on either a free of charge or for charge basis. PYRUKYND&#174; is the first product we have received marketing approval for following the sale of our oncology business. We have neither obtained marketing approval for PYRUKYND&#174; in any other indications nor have we obtained marketing approval for any of our other product candidates, all of which are in preclinical or clinical development stages.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the sale of our oncology business, we have financed and expect to continue to finance our operations primarily through cash on hand, royalty payments from Servier with respect to U.S. net sales of TIBSOVO&#174; prior to the sale of these royalty rights to Sagard, proceeds from the sale of our rights to the royalty on U.S. net sales of TIBSOVO&#174; to Sagard, a potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA with a label that permits vorasidenib's use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation, the actual and potential future sales of PYRUKYND&#174; and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. In addition, we may pursue opportunistic debt offerings, and equity or equity-linked offerings. We expect to continue to incur significant expenses and net losses until such time as we are able to report profitable results. The net losses we incur may fluctuate significantly from quarter to quarter. We anticipate that we will incur significant expenses if and as we:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercially launch PYRUKYND&#174; for approved indications in approved jurisdictions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to establish and maintain a sales, marketing and distribution infrastructure to commercialize PYRUKYND&#174; and other product candidates for which we may obtain marketing approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiate and continue clinical trials for our products and product candidates, including PYRUKYND&#174; in other indications; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our research and preclinical development of our product candidates and seek to identify additional product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for our product candidates that successfully complete clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the manufacture of larger quantities of product candidates for clinical development and commercialization;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add additional personnel to support our product research and development and planned future commercialization efforts and our operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add equipment and physical infrastructure to support our research and development; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire or in-license other product candidates, medicines and technologies.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and successfully commercialize medicines with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical testing and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those medicines for which we may obtain marketing approval and satisfying any post-marketing requirements. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The amount of contingent consideration we will receive from the sale of our oncology business to Servier is subject to various risks and uncertainties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing of the sale of our oncology business to Servier, Servier assumed certain liabilities with respect to the oncology business and paid to us: approximately $1.8 billion in cash, net of certain adjustments for the working capital of the oncology business at the time of closing of the transaction and amounts for a representation and warranty insurance policy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Servier agreed to pay to us:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$200.0 million in cash if, prior to January 1, 2027, vorasidenib is granted approval for an NDA from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an IDH1 or IDH2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval);</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a royalty payment of 5% of the U.S. net sales (as defined in the purchase agreement with Servier) of TIBSOVO&#174; from the completion of the transaction through loss of exclusivity of TIBSOVO&#174;, which we sold to Sagard in October 2022; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a royalty payment of 15% of the U.S. net sales (as defined in the purchase agreement with Servier) of vorasidenib from its first commercial sale through loss of exclusivity of vorasidenib.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent consideration described above is subject to various risks and uncertainties. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale to Sagard, we have received royalties from Servier on U.S. net sales of TIBSOVO&#174;. We cannot however predict what success, if any, Servier may have in the United States with respect to future sales of vorasidenib, if approved, and, therefore, we cannot predict the amount of royalty payments that we can expect to receive from Servier prior to the loss of exclusivity of vorasidenib. The potential royalty payments with respect to vorasidenib are also subject to deductions and other adjustments under the terms of the purchase agreement, the amounts of which are uncertain as of the date of this report. In addition, there is no guarantee that vorasidenib will be approved by the FDA, and that, as such we will receive the $200.0 million regulatory milestone payment. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax law may adversely affect our business or financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act, or the Tax Act, which significantly reformed the U.S. Internal Revenue Code of 1986, as amended, or the Code. The Tax Act, among other things, contained significant changes to corporate taxation. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of Congress&#8217; response to the recent COVID-19 pandemic, economic relief legislation was enacted in 2020 and 2021. Such legislation contains numerous tax provisions. In addition, the Inflation Reduction Act of 2022, or IRA, was signed into law in August 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA introduced new tax provisions, including a 1% excise tax imposed on certain stock repurchases by publicly traded corporations. The 1% excise tax generally applies to any acquisition by the publicly traded corporation (or certain of its affiliates) of stock of the publicly traded corporation in exchange for money or other property (other than stock of the corporation itself), subject to a de minimis exception. Thus, the excise tax could apply to certain transactions that are not traditional stock repurchases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory guidance under the IRA, the Tax Act, and such additional legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen impact of these laws on our business and financial condition. In addition, it is uncertain if and to what extent various states will conform to the IRA, the Tax Act, and additional tax legislation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties to conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not independently conduct clinical trials of any of our product candidates. We rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials. In addition, we currently rely and expect to continue to rely on third parties to conduct some aspects of our research and preclinical testing. Any of these third parties may terminate their engagements with us, some in the event of an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uncured material breach and some at any time. If any of our relationships with these third parties terminate, we may not be able to enter into similar arrangements with alternative third-parties or to do so on commercially reasonable terms. Switching or adding additional third parties involves additional cost and requires management time and focus. As a result, delays may occur in our product development activities. Although we seek to carefully manage our relationships with our CROs, we could encounter such challenges or delays that could have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our responsibility to comply with any such standards. We and these third parties are required to comply with current good clinical practices, or cGCP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the EEA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the EMA, or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you a given regulatory authority will determine that any of our clinical trials comply with cGCP regulations. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. We are exposed to risk of fraud or other misconduct by such third parties. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, third parties on whom we rely may also have relationships with other entities, some of which may be our competitors. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical, and preclinical programs. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to successfully commercialize our medicines.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If either we or any third parties on which we rely are adversely impacted by rising global energy costs or energy shortages or rationing, delays may occur in our product development activities, which delays could have a material adverse impact on our business, financial condition and prospects.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely and expect to continue to rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our medicines, producing additional losses and depriving us of potential product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and for commercialization. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any manufacturing or supply chain related facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the materials and manufacture of our product candidates for preclinical and clinical testing and for commercial supply of PYRUKYND&#174; and any product candidate for which we obtain marketing approval. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have entered into long-term supply agreements for commercial supply of PYRUKYND&#174; with third-party manufacturers, we may be unable to establish similar long-term supply agreements with third-party manufacturers with respect to our other product candidates or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reliance on the third party for regulatory compliance, quality assurance, environmental and safety and pharmacovigilance reporting;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the possible breach of the manufacturing agreement by the third party; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with cGMPs, regulations or similar regulatory requirements on a global basis. Our failure, or the failure of our third-party manufacturers, to comply with currently applicable regulations, or regulations or specifications to which we become subject in the future, could result in sanctions being imposed on us, including fines, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If either we or any third parties on which we rely are adversely impacted by restrictions resulting from the recent COVID-19 pandemic, the emergence of another public health epidemic, by rising global energy costs or energy shortages or rationing and/or the impacts of the Russia-Ukraine war, our supply chain may be disrupted, limiting our ability to manufacture our product candidates for our clinical trials and research and development operations and our product for commercialization.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay preclinical development, clinical development, marketing approval or our commercialization efforts. Due to the volatility of the supply networks globally, we have obtained regulatory approval for redundant supply of raw materials and active pharmaceutical ingredient for PYRUKYND&#174;, and have an ongoing program to monitor supply, including establishing safety stocks. While we maintain a broad safety stock of drug product, we do not currently have arrangements in place for redundant supply for drug product. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product or our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may depend on collaborations with third parties for the development and commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek collaborations for the development and commercialization of our product candidates with large and mid-size pharmaceutical companies and biotechnology companies. We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. Collaborators may have rights that restrict us from entering into future agreements on certain terms with potential collaborators.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we enter into any such arrangements with collaborators, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates competing priorities. Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing, which may result in a need for additional capital to pursue further development or commercialization of the applicable product candidate. Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation. Disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our medicines or product candidates or that result in costly litigation or arbitration that diverts management attention and resources. In addition, our ability to enter into arrangements with collaborators in specific regions, such as the Middle East, may be affected by localized geopolitical unrest or military conflict, such as the current armed conflict in Israel and the Gaza Strip.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent or trade secret protection for our medicines and technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize medicines and technology similar or identical to ours, and our ability to successfully commercialize our medicines and technology may be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary medicines and technology. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and medicines that are important to our business. We do not yet have issued patents for all our most advanced product candidates in all markets in which we intend to commercialize but we continue to actively pursue patent protection for our assets around the world.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is costly and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify and/or file patent applications on every aspect of our research and development output that is or may be eligible for patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who may have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. There is also the possibility that loss or theft of data or records may jeopardize the ability to seek patent protection or impede the progress or drafting of patent applications.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed patent rights, and in the future may license additional patent rights, from third parties. Such licenses may be accompanied by milestone and/or royalty payment obligations. These licensed patent rights may be valuable to our business, and we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology or medicines underlying such licenses. We cannot be certain that these patents and applications will be prosecuted and enforced in a manner consistent with the best interests of our business. If any such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated and our right to develop and commercialize any of our products that are the subject of such licensed rights could be adversely affected. In addition to the foregoing, the risks associated with patent rights that we license from third parties also apply to patent rights we own.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or medicines or that effectively prevent others from commercializing competitive technologies and medicines. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming the other requirements for patentability are met, prior to March 2013, in the United States, the first to make the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. Beginning in March 2013, the United States transitioned to a first inventor to file system in which, assuming the other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent. We may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant and inter partes review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize medicines without infringing third-party patent rights.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of the patent or in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one or more patent claims being narrowed or invalidated, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and medicines. Given the significant amount of time required for the discovery, development, preclinical and clinical testing and regulatory review and approval of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In such circumstances we would be relying primarily on regulatory or marketing exclusivity to exclude others from commercializing a generic version of our products. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents and other intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we or our collaborators are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product and product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We have in the past and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our medicines and technology, including opposition, derivation, revocation, reexamination, post-grant and inter partes review or interference proceedings before the USPTO or other patent offices around the world. We are not aware of any legal proceedings having been filed against us following the sale of our oncology business to Servier. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we or one of our collaborators are found to infringe a third party&#8217;s intellectual property rights, we or they could be required to obtain a license from such third party to continue developing and marketing our medicines and technology. However, we or our collaborators may not be able to obtain any required license on commercially reasonable terms or at all. Even if we or our collaborators were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us. We or our collaborators could be forced, including by court order, to cease developing and commercializing the infringing technology or medicine. In addition, we or our collaborators could be found liable for monetary damages. A finding of infringement could prevent us or our collaborators from commercializing our product and product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we or our collaborators have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants or advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our organization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our confidential information related to our proprietary platforms and technology, our business and competitive position could be harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and medicines, we also rely on maintaining the confidentiality of unpatented know-how, technology and other proprietary information, to maintain our competitive position. For example, we consider the confidential information and know-how related to our cellular metabolism technology platform to be our primary intellectual property assets in this space. Unpatented proprietary technical information and know-how can be difficult to protect. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect this proprietary technical information and know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated proprietary information is difficult, expensive and time-consuming, and the outcome is unpredictable. If any of our proprietary technical information and know-how were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. Moreover, we anticipate that with respect to this platform, at least some of this technical information and know-how will, over time, be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel skilled in the art from academic to industry scientific positions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. If we or our collaborators are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we or they will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, record keeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import, are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and comparable regulatory authorities in other countries.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we or our collaborators ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved medicine not commercially viable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, EMA and other foreign regulatory authorities have substantial discretion in the approval process. Accordingly, it is possible that the FDA or EMA may refuse to accept for substantive review any NDA, sNDA or MAA that we submit for our product candidates, or may conclude after review of our data that our marketing application is insufficient to obtain marketing approval of our product candidates. If the FDA or EMA does not accept or approve our applications for any of our product candidates, the applicable regulator may require that we conduct additional clinical trials, preclinical studies or manufacturing validation studies and submit that data before reconsidering our applications. Depending on the extent of these or any other FDA- or EMA-required trials or studies, approval of any marketing applications that we submit may be delayed by several years, or may require us to expend more resources than we planned. It is also possible that additional trials or studies, if performed and completed, may not be considered sufficient by the FDA or EMA to approve any marketing applications. We may not be successful in obtaining FDA or EMA approval of our product candidates on a timely basis, or ever. We have limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party contract research organizations to assist us in this process, and failure to obtain marketing approval for our product candidates will prevent us from commercializing the product candidate in the applicable jurisdictions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may prolong the time necessary for regulatory submissions to be reviewed and/or new drugs to be approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown were to occur, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. For example, should the FDA determine that an inspection is necessary for approval of a regulatory submission and an inspection cannot be completed during the review cycle, and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue a complete response letter or defer action on the regulatory submission until an inspection can be completed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, our ability to develop and market new drug products may be threatened by the results of ongoing litigation challenging the FDA&#8217;s approval of another company&#8217;s drug. Specifically, in April 2023, the U.S. District Court for the Northern District of Texas invalidated the approval by the FDA of mifepristone, a drug product which was originally approved in 2000 and whose distribution is governed by various measures adopted under a REMS. In reaching that decision, the district court made a number of findings that may negatively impact the development, approval and distribution of new drug products in the United States.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Court of Appeals for the Fifth Circuit declined to order the removal of mifepristone from the market, finding that a challenge to the FDA&#8217;s initial approval in 2000 is barred by the statute of limitations. But the Court of Appeals for the Fifth Circuit did hold that plaintiffs were likely to prevail in their claim that changes allowing for expanded access of mifepristone that the FDA authorized in 2016 and 2021 were arbitrary and capricious. In December 2023, the Supreme Court announced that it will review the appeals court decision. Depending on the outcome of this litigation and the regulatory uncertainty it has engendered, our ability to develop new drug product candidates and to maintain approval of existing drug products and measures adopted under a REMS is at risk and our efforts to develop and market new drug products could be delayed, undermined or subject to protracted litigation. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators experience delays in obtaining approval or if we or they fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our medicines from being marketed in such jurisdictions and any of our medicines that are approved for marketing in such jurisdiction will be subject to risk associated with foreign operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our medicines in the EU and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, a product must be approved for reimbursement before the product can be approved for sale in that country. We or our collaborators may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Moreover, approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. Although we have received marketing authorization for PYRUKYND&#174; for the treatment of adults with PK deficiency in the EU and Great Britain, we may not be able to file for additional marketing approvals and may not receive necessary approvals to commercialize our medicines in any other foreign market.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could face heightened risks with respect to seeking marketing approval in the United Kingdom as a result of the withdrawal of the United Kingdom from the EU on December 31, 2020, commonly referred to as Brexit. Since the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, the consequences of Brexit and the impact on the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom remains unclear. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to EU rules under the Northern Ireland Protocol. The United Kingdom and the EU have however agreed to the Windsor Framework which fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the United Kingdom. Once implemented, the changes introduced by the Windsor Framework will result in the MHRA being responsible for approving all medicinal products destined for the United Kingdom market (Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may prevent us from commercializing any product candidates in the United Kingdom and/or the EU and may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom, which could significantly and materially harm our business.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the European Union pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (including potentially reducing the duration of regulatory data protection and revising the eligibility for expedited pathways) was published on April 26, 2023. The proposed revisions remain to be agreed and adopted by the European Parliament and European Council and the proposals may therefore be substantially revised before adoption, which is not anticipated before early 2026. The revisions may however have a significant impact on the pharmaceutical industry and our business in the long term.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States. In addition, we do not have experience commercializing products outside of the United States and such efforts may depend on our ability to find a suitable collaborator.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast track designation and/or priority review designation by the FDA or PRIME designation in the EU may not actually lead to a faster development or regulatory review or approval process, nor does it assure approval of the product candidate by the FDA or the EMA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek fast track designation, priority review designation and/or PRIME designation for our product candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product candidate is intended for the treatment of a serious or life-threatening disease or condition and the product candidate demonstrates the potential to address unmet medical needs for this disease or condition, the drug sponsor may apply for FDA fast track designation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or thereafter.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad discretion on whether to grant fast track designation and/or priority review designation to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Even if our product candidates receive fast track designation and/or priority review designation, we may not experience a faster development process, review or approval, if at all, compared to conventional FDA procedures. The FDA </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the EU, the PRIME designation program focuses on product candidates that target conditions for which there exists no satisfactory method of treatment in the EU or product candidates that may offer a major therapeutic advantage over existing treatments. The benefits of a PRIME designation include, among other things, the potential to qualify product for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME designation enables a sponsor to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if our product candidates receive PRIME designation, we may not experience a faster development process, review or approval compared to conventional EMA procedures and it does not assure or increase the likelihood of the EMA&#8217;s grant of a marketing authorization.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, or any collaborators, may not be able to obtain orphan drug designation or orphan drug exclusivity for our drug candidates and, even if we do, that exclusivity may not prevent the FDA or the EMA from approving competing drugs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs and biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another marketing application for the same product for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. Moreover, even after an orphan drug is approved, the FDA can subsequently approve a different product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even after an orphan drug is approved, the FDA can subsequently approve a different product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and could not be interpreted by the FDA to mean the &#8220;indication or use.&#8221; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. We do not know if, when, or how the FDA or Congress may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any product or product candidate for which we or our collaborators obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our medicines, when and if any of them are approved.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product or product candidate for which we or our collaborators obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such medicine, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and record keeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the medicine may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine, including the requirement to implement a risk evaluation and mitigation strategy.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other agencies, including the DOJ, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our medicines for uses other than their respective approved indications, we may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to enforcement actions for off-label marketing. Violations of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws, which violations may result in the imposition of significant administrative, civil and criminal penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, physicians and third-party payors are subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which, in the event of a violation, could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of PYRUKYND&#174; and any product candidates for which we obtain marketing approval. Our future arrangements with healthcare providers, physicians and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute PYRUKYND&#174; and any other medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs to report payments and other transfers of value to physicians and teaching hospitals and other covered recipients; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws and transparency statutes, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States, such as the U.K. Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PYRUKYND&#174; or any product candidate that we commercialize may become subject to unfavorable pricing regulations and third-party reimbursement practices, which would harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built our commercial infrastructure to support the commercial launch of PYRUKYND&#174; in adult PK deficiency in the United States. We are providing access to PYRUKYND&#174; free of charge for eligible patients in the EU and Great Britain through a global managed access program, and we may provide access to PYRUKYND&#174; for adult patients with PK deficiency in other jurisdictions through the global managed access program on either a free of charge or for charge basis. The commercial success of PYRUKYND&#174; or of any of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by third-party payors, including government health administration authorities and private health coverage insurers. If coverage and reimbursement is not available, or reimbursement is available only to limited levels, we, or any collaborators, may not be able to successfully commercialize PYRUKYND&#174; or our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us, or any future collaborators, to establish or maintain pricing sufficient to realize a sufficient return on our or their investments. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved drugs. Marketing approvals, pricing and reimbursement for new drug products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of our product candidates to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our ability to generate revenues and become profitable could be impaired.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we, or any collaborators, might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, which may negatively impact the revenue we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability or the ability of any collaborators to recoup our or their investment in one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, our ability, and the ability of any collaborators, to commercialize PYRUKYND&#174; or any of our product candidates will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from third-party payors. Third-party payors decide which medications they will cover and establish reimbursement levels. The healthcare industry is acutely focused on cost containment, both in the United States and elsewhere. Government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability or that of any collaborators to sell PYRUKYND&#174; or our product candidates profitably. These payors may not view our products, if any, as cost-effective, and coverage and reimbursement may not be available to our customers, or those of any collaborators, or may not be sufficient to allow our products, if any, to be marketed on a competitive basis. Cost-control initiatives could cause us, or any collaborators, to decrease the price we, or they, might establish for products, which could result in lower than anticipated product revenue. If the prices for our products, if any, decrease or if governmental and other third-party payors do not provide coverage or adequate reimbursement, our prospects for revenue and profitability will suffer.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, increasingly, third-party payors are requiring higher levels of evidence of the benefits and clinical outcomes of new technologies and are challenging the prices charged. We cannot be sure that coverage will be available for PYRUKYND&#174; or any product candidate that we, or any collaborator, may commercialize and, if available, that the reimbursement rates will be adequate. Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. An inability to promptly obtain coverage and adequate payment rates from both government-funded and private payors for PYRUKYND&#174; or any of our product candidates for which we, or any collaborator, may obtain marketing approval could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly harm our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future healthcare reform legislation may increase the difficulty and cost for us and any collaborators to obtain reimbursement and commercialize our drug candidates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell PYRUKYND&#174; or any other product for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products. If reimbursement of our products is unavailable or limited in scope, our business could be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively, the ACA. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. This legislation resulted in aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which will remain in effect for six months into fiscal year 2032. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indeed, under current legislation, the actual reductions in Medicare payments may vary up to 4%. The Consolidated Appropriations Act, which was signed into law by President Biden in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010, or PAYGO, sequester for two years, through the end of calendar year 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Consolidated Appropriations Act&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal year 2032 and lowers the payment reduction percentages in fiscal years 2030 and 2031.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, in 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On November 10, 2020, the Supreme Court heard oral arguments as to whether the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On February 10, 2021, the Biden Administration withdrew the federal government&#8217;s support for overturning the ACA. On June 17, 2021, the Supreme Court struck down the lower court rulings, finding that the plaintiffs did not have standing to challenge the ACA&#8217;s minimum essential coverage provision at issue in the case.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Trump Administration also took executive actions to undermine or delay implementation of the ACA, including directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden revoked these Orders and issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#8217; access to health care, and consider actions that will protect and strengthen that access. This Executive Order also directs the U.S. Department of Health and Human Services to create a special enrollment period for the Health Insurance Marketplace in response to the recent COVID-19 pandemic. We cannot predict how federal agencies will respond to such Executive Orders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our drug products, if and when approved, and/or the sustainability of those prices.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, there have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and Medicaid. To those ends, President Trump issued several executive orders intended to lower the costs of prescription products. Certain provisions of these orders </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been reflected in promulgated regulations, including an interim final rule implementing a most favored nation model for prices, which would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries. Such final rule has been subject to a nationwide preliminary injunction, and, on December 29, 2021, Centers for Medicare &amp; Medicaid Services, or CMS, issued a final rule to rescind it. With the issuance of this rule, CMS stated it will explore all options to incorporate value into payments for Medicare Part B drugs and improve beneficiaries&#8217; access to evidence-based care.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Nine states (Colorado, Florida, Maine, New Hampshire, New Mexico, North Dakota, Texas, Vermont and Wisconsin) have passed laws allowing for the importation of drugs from Canada.  Certain of these states have submitted Section 804 Importation Program proposals and are awaiting FDA approval.  On January 5, 2023, the FDA approved Florida&#8217;s plan for Canadian drug importation. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the IRA, has been delayed by Congress to January 1, 2032.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D.  CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Medicare Part D drugs in 2027, 15 Medicare Part B or Part D drugs in 2028, and 20 Medicare Part B or Part D drugs in 2029 and beyond.  This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition.  Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations.  Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.  In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#8220;catastrophic period&#8221; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, Merck filed a lawsuit against the HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the Constitution. Subsequently, a number of other parties, including the U.S. Chamber of Commerce and pharmaceutical companies, also filed lawsuits in various courts with similar constitutional claims against HHS and CMS. We expect that litigation involving these and other provisions of the IRA will continue, with unpredictable and uncertain results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product or product candidates or additional pricing pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In many countries, including those of the EU, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our collaborators may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our product is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and foreign export control, import, sanctions, anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Control, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We may have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. In addition, we may engage third party intermediaries to promote our clinical research activities abroad and/or to obtain necessary permits, licenses, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncompliance with such laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">With the passage of the CREATES Act, we are exposed to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, former President Trump signed legislation intended to facilitate the development of generic and biosimilar products. The bill, previously known as the CREATES Act, authorizes sponsors of ANDAs and 505(b)(2) applications to file lawsuits against companies holding NDAs that decline to provide sufficient quantities of an approved reference drug on commercially reasonable, market-based terms. Drug products on FDA&#8217;s drug shortage list are exempt from these new provisions unless the product has been on the list for more than six continuous months or the FDA determines that the supply of the product will help alleviate or prevent a shortage. For the purposes of the statute, the term &#8220;commercially reasonable, market-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based terms&#8221; is defined as (1) the nondiscriminatory price at or below the most recent wholesale acquisition cost for the product, (2) a delivery schedule that meets the statutorily defined timetable, and (3) no additional conditions on the sale.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To bring an action under the statute, an ANDA or 505(b)(2) sponsor must take certain steps to request the reference product, which, in the case of products covered by a Risk Evaluation and Mitigation Strategy with elements to assure safe use, include obtaining authorization from the FDA for the acquisition of the reference product. If the sponsor does bring an action for failure to provide a reference product, there are certain affirmative defenses available to the NDA holder, which must be shown by a preponderance of evidence. If the sponsor prevails in litigation, it is entitled to a court order directing the NDA holder to provide, without delay, sufficient quantities of the applicable product on commercially reasonable, market-based terms, plus reasonable attorney fees and costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the statutory provisions authorize a federal court to award the product developer an amount &#8220;sufficient to deter&#8221; the NDA holder from refusing to provide sufficient product quantities on commercially reasonable, market-based terms if the court finds, by a preponderance of the evidence, that the NDA holder did not have a legitimate business justification to delay providing the product or failed to comply with the court&#8217;s order. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to comply fully with the terms of these new statutory provisions, we are still exposed to potential litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of ANDAs and 505(b)(2) applications. Such litigation would subject us to additional costs, damages and reputational harm, which could lead to lower revenues. The CREATES Act may enable generic competition with PYRUKYND&#174; and any of our product candidates, if approved, which could impact our ability to maximize product revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our key executives and scientific leadership and to attract, retain and motivate qualified personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the principal members of our management and scientific teams, each of whom is employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. We cannot predict the likelihood, timing or effect of future transitions among our executive leadership. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, regulatory and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and universities and research institutions for similar personnel. Our consultants and advisors, including our scientific co-founders, who assist us in formulating our research and development and commercialization strategy may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Furthermore, the recent COVID-19 pandemic and our flexible workplace policy allowing employees to work from home may make it difficult for us to maintain our corporate culture.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future we may experience growth in the number of our development, regulatory and sales and marketing personnel. To manage any anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations or regulations in other jurisdictions, provide accurate information to the FDA or other regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately, disclose unauthorized activities to us, or comply with securities laws. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, including for illegal insider trading activities, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock and Other Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board of Directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Among other things, these provisions:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a classified board of directors such that not all members of the board are elected at one time;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our Board of Directors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from our Board of Directors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board of Directors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a shareholder rights plan, or so-called &#8220;poison pill,&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock is likely to be volatile, which could result in substantial losses for purchasers of our common stock.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been, and may continue to be, volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. For example, since January 1, 2015 the closing price of our common stock on the Nasdaq Global Select Market has ranged from $17.06 per share to $135.01 per share. The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. While the full extent of the economic impact of the recent COVID-19 pandemic or recent increases in inflation rates (particularly as it relates to clinical- or manufacturing-related costs) may be difficult to assess or predict, such impacts have already caused, and are likely to result in further, significant disruption of global financial markets, which may reduce our ability to access capital either at all or on favorable terms. If we are unable to raise additional funds through equity or debt financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price for our common stock may be influenced by many factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our success in launching and commercializing PYRUKYND&#174;; </span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the decision to focus our efforts on our rare disease business following the sale of our oncology business to Servier;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the evolution of our research organization;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, in-licensing arrangements, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and results of clinical trials of product candidates, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory actions with respect to our product or product candidates or our competitors&#8217; products and product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commencement or termination of collaborations for our development programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure or discontinuation of any of our development programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our products, product candidates or development programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to develop additional product candidates and products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results or development timelines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement or expectation of additional financing efforts;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, our insiders or other stockholders, including shares issuable upon exercise of outstanding stock options and upon vesting of stock units under our stock incentive plans;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or results of companies that are perceived to be similar to us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates, evaluations or recommendations by securities analysts, that cover our stock or the failure by one or more securities analysts to continue to cover our stock;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the societal and economic impact of public health epidemics or pandemics, such as the recent COVID-19 pandemic and any recession, depression or sustained market event resulting from such epidemics or pandemics;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company's securities, securities class-action litigation often has been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs to defend such claims and divert managements' attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot guarantee that an active trading market for our shares will be sustained. An inactive trading market for our common stock may impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our shares as consideration. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition and operating results also may fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders maintain the ability to significantly influence all matters submitted to stockholders for approval.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our executive officers, directors and principal stockholders, in the aggregate, beneficially owned shares representing a significant percentage of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other stockholders may desire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 of the Code and corresponding provisions of state law, if a company undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership by certain stockholders over a three-year period, the company&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change taxable income may be limited. Our prior equity offerings and other changes in our stock ownership, some of which are outside of our control, may have resulted or could in the future result in an ownership change. We completed a review of our changes in ownership through December&#160;31, 2023, and determined that we did not have a qualified ownership change since our last review as of December&#160;31, 2022. Future ownership changes under Section 382 may limit the amount of net operating loss and tax credit carryforwards that we could potentially utilize to reduce future tax liabilities.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that due to regulatory changes, such as suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities. The Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act includes changes to U.S. federal tax rates and the rules governing net operating loss carryforwards that may significantly impact our ability to utilize our net operating losses to offset taxable income in the future. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons we may be unable to use a material portion of our net operating losses and other tax attributes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different from previous periods or our current expectations due to numerous factors, including as a result of changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.</span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and will continue to incur significant legal, accounting and other expenses as a public company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations. Our management and other personnel devote, and will need to continue to devote, a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders for the foreseeable future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B. Unresolved Staff Comments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_802"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1C. Cybersecurity</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain processes for assessing, identifying and managing cybersecurity risks, which are built into our overall information technology function and are designed to help protect our information assets and operations from internal and external cyber threats, and protect employee, collaborator and patient information from unauthorized access or attack, as well as secure our networks and systems. Such processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine review of our policies and procedures to identify risks and refine our practices.  We engage certain external parties, including consultants, computer security firms and risk management advisors, peer companies, industry groups and governance experts, to enhance our cybersecurity oversight including by gaining valuable insights into the ever-evolving cybersecurity landscape. We consider the internal risk oversight programs of third-party service providers before engaging them in order to help protect us from any related vulnerabilities. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that there are currently any known risks from cybersecurity threats that are reasonably likely to materially affect us or our business strategy, results of operations or financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee of our Board of Directors provides direct oversight over cybersecurity risk, and provides updates to the Board of Directors regarding such oversight. The Audit Committee receives periodic updates from management regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity threats or incidents. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vice President, Information Technology and Facilities, or the VP of IT, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks. Our VP of IT has worked in the information technology field for over 20 years at both biotechnology companies and management consulting firms, and holds a Bachelor of Science in Management and a Masters of Business Administration. We also maintain a team of experienced senior level engineers who design, implement and operate our information technology ecosystem, helping to implement cybersecurity best practices throughout our information technology infrastructure and governance processes. We periodically assess our processes against cybersecurity frameworks, such as the National Institute of Standards and Technology, or NIST, Cybersecurity Framework, Center for Internet Security, or CIS, Controls, and International Organization for Standardization, or ISO, 27001.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to deter and detect cyber threats, we annually provide all employees, including part-time and temporary employees, with a data protection, cybersecurity and incident response and prevention training and compliance program, which covers timely and relevant topics, including social engineering, phishing, password protection, confidential data protection, asset use and mobile security, and educates employees on the importance of reporting all incidents immediately. We also use technology-based tools that are designed to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_22"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Properties</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease approximately 146,000 square feet at 88 Sidney Street, 43,000 square feet at 64 Sidney Street, and 13,000 square feet at 38 Sidney Street, Cambridge, Massachusetts. All leases, as amended, expire on February 29, 2028. At the end of the initial lease period, we have the option to extend the leases at all facilities for two consecutive five-year periods at the fair market rent at the time of the extension. In August 2021, we entered into a long-term sublease agreement for the 13,000 square feet at 38 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through December 2024. In April 2022, we entered into a long-term sublease agreement for 27,000 square feet of office space at 64 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through April 2025. In May 2023, we entered into a long-term sublease agreement for 7,407 square feet of office space on the first floor of 64 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through April 2025. We believe our existing facilities are adequate for our current needs.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_25"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Legal Proceedings</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we were not a party to any material legal or arbitration proceedings. No governmental proceedings are pending or, to our knowledge, contemplated against us. We are not a party to any material proceedings in which any director, member of senior management or affiliate of ours is either a party adverse to us or our subsidiaries or has a material interest adverse to us or our subsidiaries.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_28"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_34"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#8220;AGIO&#8221; since July&#160;24, 2013. Prior to that time, there was no public market for our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;9, 2024, there were approximately nine holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends to holders of common stock in the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about our equity compensation plans is incorporated herein by reference to <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_70">Item&#160;12, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_70">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Annual Report on Form 10-K.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, nor shall such information be incorporated by reference into any future filing under the Exchange Act or the Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the performance of our common stock to the NASDAQ Composite Index and the NASDAQ Biotechnology Index from December&#160;31, 2018 through December&#160;31, 2023. The comparison assumes $100 was invested after the market closed on December&#160;31, 2018 in our common stock and in each of the foregoing indices, and it assumes reinvestment of dividends, if any. The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><img src="agio-20231231_g2.jpg" alt="Stock Performance Graph 2023.jpg" style="height:374px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer or Affiliated Purchasers</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review "<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_16">Item 1A, Risk Factors</a>" of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through leadership in the field of cellular metabolism, with the goal of creating differentiated medicines for rare diseases, with a focus on classical hematology. With a history of focused study on cellular metabolism, we have a deep and mature understanding of this biology, which is involved in the healthy functioning of nearly every system in the body. Building on this expertise, these learnings can be rapidly applied to our clinical trials with the goal of developing medicines that can have a significant impact for patients. We accelerate the impact of our portfolio by cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for rare diseases.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead product candidate in our portfolio, PYRUKYND&#174; (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. In February 2022, the U.S. Food and Drug Administration, or FDA, approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In November 2022, we received marketing authorization from the European Commission for PYRUKYND&#174; for the treatment of PK deficiency in adult patients in the European Union, or EU. In December 2022, we received marketing authorization in Great Britain for PYRUKYND&#174; for the treatment of PK deficiency in adult patients under the European Commission Decision Reliance Procedure. In addition, we are currently evaluating PYRUKYND&#174; in clinical trials for the treatment of thalassemia, sickle cell disease, or SCD, and in pediatric patients with PK deficiency. We are also developing (i) AG-946, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndrome, or LR MDS, and hemolytic anemias, and (ii) AG-181, our phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, in July 2023 we entered into a license agreement with Alnylam Pharmaceuticals, Inc., or Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the transmembrane serine protease 6, or TMPRSS6, gene and we intend to pursue development of a licensed product for the potential disease-modifying treatment of patients with polycythemia vera, or PV, a rare blood disorder. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Alnylam License Agreement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the license agreement with Alnylam, in the year ended December 31, 2023, we made an up-front payment to Alnylam and recognized in-process research and development of $17.5&#160;million which was recorded in research and development expense within our Consolidated Statements of Operations and classified as investing activities within our Consolidated Statements of Cash Flows. We will also pay Alnylam for certain expenses associated with the development of the TMPRSS6 gene and these will be recorded in our Consolidated Statements of Operations as incurred. Additionally, we are responsible to pay up to $130.0&#160;million in potential development and regulatory milestones, in addition to sales milestones as well as tiered royalties on annual net sales, if any, of licensed products, which may be subject to specified reductions and offsets. Because the acquired assets under the license agreement with Alnylam do not meet the definition of a business in accordance with ASC 805, Business Combinations, we accounted for the agreement as an asset acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Oncology Business to Servier Pharmaceuticals, LLC (Servier) and Sale of Contingent Payments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO&#174;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $1.8&#160;billion in cash at the closing, subject to certain adjustments, and a payment of $200.0&#160;million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application approval from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through loss of exclusivity, and a royalty of 15% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity, with these royalties referred to as contingent payments and recognized as income when </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">realizable. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#8217;s IDHIFA&#174; and the right to receive a $25.0&#160;million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and Servier is responsible for conducting certain clinical development activities within the IDHIFA&#174; development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we sold our rights to future contingent payments associated with the royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through the loss of exclusivity to entities affiliated with Sagard Healthcare Partners, or Sagard, and recognized income of $127.9&#160;million within the gain on sale of contingent payments line item in our consolidated statements of operations for the year ended December 31, 2022. We retain our rights to the potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, Servier announced that it was planning to submit a new drug application, or NDA, for vorasidenib for the treatment of IDH-mutant diffuse glioma to the FDA by the end of 2023 and to the European Medicines Agency, or EMA, in early 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The oncology business met the criteria within Accounting Standards Codification 205-20 to be reported as discontinued operations because the transaction was a strategic shift in business that had a major effect on our operations and financial results. Therefore, we have reported the historical results of the oncology business including the results of operations and cash flows as discontinued operations, and related assets and liabilities were retrospectively reclassified as assets and liabilities of discontinued operations for all periods presented herein. Refer to <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_166">Note 15, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_166">Discontinued Operations</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our consolidated financial statements included in this Annual Report on Form 10-K for additional information. A more complete description of our business prior to the consummation of the transaction is included in Item 1. &#8220;Business&#8221;, in Part I of our Annual Report on Form 10-K for the year ended December 31, 2020 that was previously filed with the Securities and Exchange Commission, or SEC, on February 25, 2021.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Financial Operations Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">General</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, our operations have primarily focused on organizing and staffing our company, business planning, raising capital, assembling our core capabilities in cellular metabolism and classical hematology, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, establishing a commercial infrastructure, preparing for and executing on the commercial launch of PYRUKYND&#174; and, prior to the sale of our oncology business to Servier on March 31, 2021, marketing TIBSOVO&#174; and IDHIFA&#174;. Through March 31, 2021, we financed our operations primarily through proceeds from the sale of our royalty rights, commercial sales of TIBSOVO&#174;, funding received from our collaboration agreements, private placements of our preferred stock, our initial public offering of our common stock and concurrent private placement of common stock to an affiliate of Celgene, and our follow-on public offerings. Following the sale of our oncology business to Servier on March 31, 2021, we have financed and expect to continue to finance our operations primarily through cash on hand, royalty payments from Servier with respect to U.S. net sales of TIBSOVO&#174; prior to the sale of these contingent payments to Sagard, proceeds from the sale of contingent payments to Sagard, a potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA with a label that permits vorasidenib's use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation, the actual and potential future sales of PYRUKYND&#174; and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. In addition, we may pursue opportunistic debt offerings, and equity or equity-linked offerings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, since inception, we have incurred significant operating losses. Our net loss for the year ended December 31, 2023 was $352.1 million, our net loss for the year ended December 31, 2022 was $231.8 million and our net income for the year ended December 31, 2021 was $1.6 billion. As of December&#160;31, 2023, we had an accumulated deficit of $822.6 million. The net income we generated in the year ended December 31, 2021 was due to the sale of our oncology business to Servier. We expect to incur significant expenses and net losses until such time we are able to report profitable results. Our net losses may fluctuate significantly from year to year. We expect that we will continue to incur significant expenses as we continue to advance and expand clinical development and commercialization activities for PYRUKYND&#174;; advance and expand clinical development of AG-946; continue to prioritize advancement of AG-181, our PAH stabilizer; initiate preclinical development of a licensed siRNA development candidate pursuant to our license agreement with Alnylam; expand and protect our intellectual property portfolio, including by in-licensing or acquiring assets for pipeline growth; and hire additional commercial and development personnel.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Revenues</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wholly owned product, PYRUKYND&#174;, received approval from the FDA on February 17, 2022, for the treatment of hemolytic anemia in adults with PK deficiency in the United States. Upon FDA approval of PYRUKYND&#174; in the United States, we began generating product revenue from sales of PYRUKYND&#174;. We sell PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense PYRUKYND&#174; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;. For further discussion of our revenue recognition policy, see <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_127">Note 2, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_127">Summary of Significant Accounting Polices</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_145">Note 8, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_145">Product Revenue</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements in this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the future, we expect to continue to generate revenue from a combination of product sales, and we may potentially generate revenue from royalties on product sales, milestone payments, and upfront payments under existing arrangements or future collaborations or licensing agreements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of manufacturing costs for sales of PYRUKYND&#174;. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#174; recorded during the years ended December&#160;31, 2023 and December&#160;31, 2022 were expensed prior to February 17, 2022, and, therefore, are not included in costs of sales during the years ended December&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs related to our portfolio to increase as our product candidate development programs progress. However, the successful development of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the remainder of the development and to commercialize these product candidates. We are unable to predict the amount of net cash inflows from PYRUKYND&#174; or any of our product candidates. This is due to the numerous risks and uncertainties associated with developing medicines, including the uncertainty of:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing an appropriate safety profile with an investigational new drug application, or IND, and/or new drug application, or NDA, enabling toxicology and clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the successful enrollment in, and completion of, clinical trials;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing compliant commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">launching commercial sales of the products, if and when approved, whether alone or in collaboration with others; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintaining an acceptable safety profile of the products following approval.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">employee-related expenses, including salaries, benefits and stock-based compensation expense;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">expenses incurred under agreements with third parties, including CROs, that conduct research and development and both preclinical and clinical activities on our behalf, and the cost of consultants;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the cost of lab supplies and acquiring, developing and manufacturing preclinical and clinical study materials; and</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">facilities, depreciation, and other expenses, which include direct and allocated expenses for rent and the maintenance of facilities, insurance and other operating costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we announced our determination to evolve our approach to exploratory research and drug discovery to focus on our existing late-lead optimization programs and to prioritize in-licensing or acquiring assets for pipeline growth. We reduced approximately 45 roles focused on exploratory research in connection with this evolution of our research organization, and retained an internal research team focused on roles critical to advancing our current and future late-stage research and early clinical programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our most advanced programs:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PYRUKYND&#174; (mitapivat): First-in-Class PK Activator</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing PYRUKYND&#174; for the treatment of PK deficiency and other hemolytic anemias such as thalassemia and SCD. PYRUKYND&#174; is an orally available small molecule and a potent activator of the wild-type and mutated PK enzymes.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the FDA approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In November 2022, we received marketing authorization from the European Commission for PYRUKYND&#174; for the treatment of PK deficiency in adult patients in the EU. In December 2022, we received marketing authorization in Great Britain for PYRUKYND&#174; for the treatment of PK deficiency in adult patients under the European Commission Decision Reliance Procedure. In addition, we are currently evaluating PYRUKYND&#174; in clinical trials for the treatment of thalassemia, SCD, and in pediatric patients with PK deficiency. We have worldwide development and commercial rights to PYRUKYND&#174; and expect to fund the future development and commercialization costs related to this program. PYRUKYND&#174; has been granted orphan drug designation for the treatment of PK deficiency by the FDA and the EMA. Additionally, PYRUKYND&#174; has received orphan drug designation from the FDA for the treatment of thalassemia and SCD.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have built our commercial infrastructure to support the commercial launch of PYRUKYND&#174; in adult PK deficiency in the United States. In connection with our regulatory approvals in the EU and Great Britain, we are currently providing access to PYRUKYND&#174; free of charge for eligible patients in those jurisdictions through a global managed access program. We may provide access to PYRUKYND&#174; for adult patients with PK deficiency in other jurisdictions upon request through the global managed access program, on either a free of charge or for charge basis. Beyond the global managed access program, we continue to evaluate options for the commercialization of PYRUKYND&#174; outside of the United States, including through exploring potential partnership opportunities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating PYRUKYND&#174; in the following clinical trials:</span></div><div style="padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.8pt">An extension study evaluating the long-term safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from ENERGIZE, our completed phase 3, double-blind, randomized, placebo-controlled multicenter study pivotal trial of PYRUKYND&#174; in adults with non-transfusion-dependent alpha- or beta-thalassemia. We announced topline data for ENERGIZE in January 2024. A total of 194 patients were enrolled in the study, with 130 randomized to PYRUKYND&#174; 100 mg twice-daily, and 64 randomized to matched placebo. 122 patients (93.8%) in the PYRUKYND&#174; arm and 62 patients (96.9%) in the placebo arm completed the 24-week double-blind period of the study.  The study met the primary endpoint of hemoglobin response, where treatment with PYRUKYND&#174; demonstrated a statistically significant increase in hemoglobin response compared to placebo, as 42.3% of patients in the PYRUKYND&#174; arm achieved a hemoglobin response, compared to 1.6% of patients in the placebo arm (2-sided p&lt;0.0001). Treatment with PYRUKYND&#174; also demonstrated statistically significant improvements compared to placebo for both key secondary endpoints: (i) change from baseline in average Functional Assessment of Chronic Illness Therapy-Fatigue, or FACIT-Fatigue, subscale score from week 12 to week 24 and (ii) change from baseline in average emoglobin concentration from week 12 to week 24.  During the 24-week double-blind period, four (3.1%) subjects in the PYRUKYND&#174; arm experienced adverse events, or AEs, leading to discontinuation, and there were no AEs in the placebo arm leading to discontinuation. We plan to provide a more detailed analysis of the data from this trial at an upcoming medical meeting and we aim to submit an NDA for PYRUKYND&#174; in thalassemia to the FDA by the end of 2024.     </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ENERGIZE-T, a phase 3, double-blind, randomized, placebo-controlled multicenter study evaluating the efficacy and safety of PYRUKYND&#174; as a potential treatment for adults with transfusion-dependent alpha- or beta-thalassemia, defined as 6 to 20 RBC units transfused and &#8804; six-week transfusion-free period during the 24-week period before randomization. The primary endpoint of the trial is percentage of patients with transfusion reduction response, defined as a &#8805;50% reduction in transfused RBC units with a reduction of &#8805;2 units of transfused RBCs in any consecutive 12-week period through week 48 compared with baseline. Secondary endpoints include additional transfusion reduction measures and percentage of participants with transfusion-independence. This trial has completed enrollment and we plan to announce topline data from this trial in mid-2024.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">RISE UP, a phase 2/3 study evaluating the efficacy and safety of PYRUKYND&#174; in SCD patients who are 16 years of age or older, have had between two and 10 sickle cell pain crises in the past 12 months, and have hemoglobin within the range of 5.5 to 10.5 g/dL during screening. We enrolled 79 patients in the phase 2 portion of the trial, with 26 patients in the 50 mg twice daily mitapivat arm, 26 patients in the 100 mg twice daily mitapivat arm and 27 patients in the placebo arm. The primary endpoints of the phase 2 portion of the trial were hemoglobin response, defined as defined as &#8805; 1 g/dL </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in average hemoglobin concentration from week 10 to week 12 compared to baseline, and safety.  In June 2023, we announced the phase 2 portion of this trial had achieved its primary endpoint of hemoglobin response in patients in both 50 mg and 100 mg twice daily mitapivat arms. 46.2% of patients (n=12) in the 50 mg twice daily mitapivat arm and 50.0% of patients (n=13) in the 100 mg twice daily mitapivat arm achieved a hemoglobin response, compared to 3.7% of patients (n=1) in the placebo arm (2-sided p=0.0003 and 0.0001, respectively). In December 2023, we announced the following additional results of the phase 2 portion of the trial: (i) the least-squares mean (95% confidence interval) for average change from baseline in hemoglobin levels, from week 10 through week 12, for patients in the 50 mg twice daily mitapivat, 100 mg twice daily mitapivat, and placebo arms, respectively, was 1.11 (0.77, 1.45) g/dL, 1.13 (0.79, 1.47) g/dL, and 0.05 (&#8722;0.28, 0.39) g/dL; (ii) we observed improvements in annualized rates of sickle cell pain crises as the annualized rate of sickle cell pain crises (95% confidence interval) for patients in the 50 mg twice daily and 100 mg twice daily mitapivat arms, respectively, was 0.83 (0.34, 1.99) and 0.51 (0.16, 1.59), compared to 1.71 (0.95, 3.08) for patients in the placebo arm; (iii) we observed improvement in patient-reported fatigue scores in the 50 mg twice daily mitapivat arm compared to the placebo arm, and the least-squares mean (95% confidence interval) for average changes from baseline in patient-reported fatigue score, from week 10 through week 12, for patients in the 50 mg twice daily mitapivat, 100 mg twice daily mitapivat, and placebo arms, respectively, was &#8722;3.80 (&#8722;7.16, &#8722;0.45), &#8722;0.10 (&#8722;3.27, 3.08), and &#8722;0.17 (&#8722;3.40, 3.07). The safety profile for mitapivat observed in the phase 2 portion of the trial was generally consistent with previously reported data in other studies of SCD and other hemolytic anemias. The most common treatment-emergent AEs in the 50 mg BID, 100 mg BID, and placebo arms, respectively, were: headache (n=6, 6, 7), arthralgia (n=3, 5, 9), dysmenorrhea (n=0, 3, 0), pain (n=3, 3, 2), pain in extremity (n=1, 3, 6), back pain (n=4, 2, 3), nausea (n=1, 2, 4), fatigue (n=4, 1, 5), and influenza-like illness (n=1, 1, 3). There were no serious treatment-emergent adverse events, or TEAEs, attributed to mitapivat and there were no adverse events leading to drug reduction, discontinuation, interruption or death in either the mitapivat or the placebo arms. Of the 79 patients enrolled in the study, 73 continued into the Phase 2 open-label extension period. In October 2023, we enrolled the first patient in the phase 3 portion of this trial. The phase 3 portion includes a 52-week randomized, placebo-controlled period in which participants will be randomized in a 2:1 ratio to receive the recommended (100 mg twice daily) PYRUKYND&#174; dose level or the placebo. The primary endpoints are hemoglobin response, defined as &#8805;1 g/dL increase in average hemoglobin from baseline to week 52, and annualized rate of sickle cell pain crises. Participants who complete either the phase 2 or phase 3 portion will have the option to move into a 216-week open-label extension period to continue to receive PYRUKYND&#174;. We anticipate completing enrollment by the end of 2024 and announcing topline data for this trial in 2025.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ACTIVATE-kids and ACTIVATE-kidsT, double-blind phase 3 studies evaluating the efficacy and safety of PYRUKYND&#174; as a potential treatment for PK deficiency in not regularly transfused and regularly transfused patients between one and 18 years old, respectively.  The primary endpoint of ACTIVATE-kids is percentage of patients with hemoglobin response, defined as &#8805;1.5 g/dL increase in hemoglobin concentration from baseline that is sustained at two or more scheduled assessments at weeks 12, 16, and 20 during the double-blind period.  The primary endpoint of ACTIVATE-kidsT is transfusion reduction response, defined as &#8805;33% reduction in total RBC transfusion volume from week 9 through week 32 of the double-blind period. ACTIVATE-kidsT has completed enrollment and we expect to announce topline data for this trial by the end of 2024. ACTIVATE-kids is currently enrolling patients, we expect to complete enrollment for this trial by mid-2024, and we anticipate announcing topline data for this trial in 2025.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">An extension study evaluating the long-term safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from ACTIVATE and ACTIVATE-T, our completed pivotal trials of PYRUKYND&#174; in not regularly transfused and regularly transfused adult patients with PK deficiency. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">An extension study evaluating the long-term safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from DRIVE PK, our completed global phase 2, first-in-patient, open-label safety and efficacy clinical trial of PYRUKYND&#174; in adult, not regularly transfused patients with PK deficiency.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">An extension study evaluating the safety, tolerability and efficacy of treatment with PYRUKYND&#174; in patients from our completed phase 2, open-label safety and efficacy clinical trial of PYRUKYND&#174; in adults with non-transfusion-dependent alpha- and beta-thalassemia. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In collaboration with the Company, the National Institutes of Health, or NIH, is evaluating PYRUKYND&#174; in a phase 1 trial in patients with SCD pursuant to a cooperative research and development agreement. The core trial period has completed, and the long-term extension study is ongoing. In June 2020, clinical proof of concept was established based on a preliminary analysis of the data from this trial.</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In collaboration with the Company, University Medical Center Utrecht, or UMC Utrecht, is evaluating PYRUKYND&#174; in patients with SCD pursuant to an investigator sponsored trial agreement. The trial has completed enrollment and patient follow-up is ongoing, and a 2-year extension study has been initiated for patients who complete the follow-up period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AG-946: Novel PK Activator</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing AG-946, a novel PK activator, for the potential treatment of LR MDS and hemolytic anemias. We are evaluating AG-946 in a phase 1 trial of AG-946 in healthy volunteers and in patients with SCD. We have presented data from the healthy volunteer cohorts, and we have initiated the SCD patient cohort of this phase 1 trial. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a phase 2a clinical trial of AG-946 in adults with LR MDS in the third quarter of 2022, and the trial has completed enrollment with 22 patients, including 12 patients classified as non-transfused and 10 patients classified as low transfusion burden. Patients received 5 mg of AG-946 once daily for up to 16 weeks. The two primary endpoints of the trial were transfusion independence (for patients classified as low transfusion burden), defined as transfusion-free for &#8805; eight consecutive weeks during the 16-week treatment period, and hemoglobin response, defined as a &#8805; 1.5 g/dL increase from baseline in the average hemoglobin concentration measured from week 8 through week 16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we announced that we achieved clinical proof-of-concept in the phase 2a portion of the trial. We observed that four of the 10 patients with low transfusion burden achieved the transfusion independence endpoint, and one of the 22 patients achieved the hemoglobin response endpoint in the 16-week treatment period. The safety profile observed was consistent with data reported in the healthy volunteer study of AG-946. 19 patients elected to enroll in the extension period for up to 156 weeks. We intend to complete a full evaluation of the phase 2a trial results and assess the impact on the phase 2b portion of the protocol in 2024. We anticipate initiating a phase 2b trial of AG-946 in adults with LR MDS in mid-2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, we are developing AG-181, a PAH stabilizer for the potential treatment of PKU, for which we filed an investigational new drug, or IND, application in December 2023, and plan to initiate a phase 1 study in healthy volunteers in the first half of 2024. Also, in July 2023, we entered into a license agreement with Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the TMPRSS6 gene, and we intend to pursue development of a licensed product for the potential treatment of patients with PV.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, business development, commercial, legal, information technology and human resources functions. Other significant costs include facility-related costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that our selling, general and administrative expenses will increase in the future to support continued research and development activities and ongoing and future commercialization activities related to our portfolio, including the ongoing commercialization of PYRUKYND&#174; and any of our other product candidates, which may include the hiring of additional personnel. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 on our Business</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we have not experienced a significant financial or supply chain impact directly related to the recent COVID-19 pandemic, but have experienced some disruptions to clinical operations and certain clinical and research activities at our contract research organizations, or CROs. Although the public health emergency declaration related to COVID-19 ended on May 11, 2023, the extent of the effect of any future pandemics or public health emergencies on our operational and financial performance will depend in large part on future developments, which cannot be predicted and are out of our control.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements included in this Annual Report on Form 10-K, we believe that the following accounting policies are the most critical in fully understanding and evaluating our financial condition and results of operations and are policies that require a significant level of judgment and estimates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense PYRUKYND&#174; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contractual Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Government Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Research and Development Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. Certain service providers invoice us in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to: (i) CROs and other third parties in connection with clinical studies and preclinical development activities; (ii) investigative sites in connection with clinical studies; and (iii) third parties related to product manufacturing, development and distribution of clinical supplies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base our expenses related to CROs on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs that conduct research and development on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation awards in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#160;&#8211;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 718. For stock-based awards granted to employees, non-employees and members of the board of directors for their services and for participation in our employee stock purchase plan, we estimate the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires us to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the &#8220;simplified method&#8221; as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to estimate the expected term of stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the stock options, taking into consideration multiple vesting tranches. We utilize this method due to the plain-vanilla nature of our share-based awards. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility has been determined using Agios' historical volatilities for a period equal to the expected term of the option grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free rate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term of the options being valued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid, and do not anticipate paying, any cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the option-pricing model. </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forfeitures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for forfeitures as they occur and, therefore, do not estimate forfeitures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For awards subject to service-based vesting conditions, we recognize stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. For awards subject to performance-based vesting conditions, we recognize stock-based compensation expense if the performance condition is considered probable of achievement using management&#8217;s best estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the sale of our oncology business in the first quarter of 2021 in accordance with ASC 205, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Accounting Standards Update, or ASU, No. 2014-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We followed the held-for-sale criteria as defined in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 205. ASC 205 requires that a component of an entity that has been disposed of or is classified as held for sale and has operations and cash flows that can be clearly distinguished from the rest of the entity be reported as assets held for sale and discontinued operations. In the period a component of an entity has been disposed of or classified as held for sale, the results of operations for the periods presented are reclassified into separate line items in the consolidated statements of operations. Assets and liabilities are also reclassified into separate line items on the related consolidated balance sheets for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented. The statements of cash flows for the periods presented are also reclassified to reflect the results of discontinued operations as separate line items. ASU 2014-08 requires that only a disposal of a component of an entity, or a group of components of an entity, that represents a strategic shift that has, or will have, a major effect on the reporting entity&#8217;s operations and financial results be reported in the financial statements as discontinued operations. ASU 2014-08 also provides guidance on the financial statement presentations and disclosures of discontinued operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the sale of our oncology business during the first quarter of 2021, in accordance with ASC 205, we have classified the results of the oncology business as discontinued operations in our consolidated statements of operations and cash flows for all periods presented, and refer to <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_166">Note 15, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_166">Discontinued Operations</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior-year amounts have been reclassified to conform with current presentation. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of years ended December&#160;31, 2023, 2022 and 2021</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,823&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,240&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Total Revenue &#8211; 2023 vs. 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; The increase in total revenue of $12.6&#160;million in 2023 compared to 2022 was due to increased product revenue associated with PYRUKYND&#174;, which was approved by the FDA in February 2022, partially offset by revenue recognized in 2022 associated with the licensing of intellectual property for our Friedreich's Ataxia preclinical program.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Total Revenue &#8211; 2022 vs. 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8211; The increase in total revenue of $14.2&#160;million in 2022 compared to 2021 was due to product revenue associated with PYRUKYND&#174;, which was approved in February 2022, and revenue recognized associated with the licensing of intellectual property for our Friedreich's Ataxia preclinical program.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Operating Expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Operating Expenses</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403,287&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Operating Expenses &#8211; 2023 vs. 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The increase in total operating expenses of $15.0&#160;million in 2023 compared to 2022 was primarily due to an increase of $15.6&#160;million in research and development expenses, which is described below under Research and Development Expenses.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Operating Expenses &#8211; 2022 vs 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The increase in total operating expenses of $24.9&#160;million in 2022 compared to 2021 was primarily due to an increase of $22.9&#160;million in research and development expenses, which is described below under Research and Development Expenses. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses, by major program, are outlined in the table below: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PK activator (PYRUKYND&#174;)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novel PK activator (AG-946)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and platform programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,581&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,855&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,616&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Facilities and IT related expenses &amp; other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Other expenses - transition services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total indirect research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,945&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,055&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,357&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,526&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,973&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Research and Development Expenses &#8211; 2023 vs. 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The increase in research and development expenses of $15.6&#160;million in 2023 compared to 2022 was due to a $22.7&#160;million increase in our direct expense offset by a $7.1&#160;million decrease in our indirect expenses. The increase in direct expenses was primarily due to a $18.1 million increase in PYRUKYND&#174; costs and in-process research and development from the $17.5 million up-front payment associated with the license agreement with Alnylam discussed above under Overview, offset by a $15.3 million decrease in other research and platform programs. The increase in PYRUKYND&#174; costs was primarily due to increased costs for the phase 3 trials of PYRUKYND&#174; in patients with thalassemia, ENERGIZE and ENERGIZE-T, and increased process development and medical affairs expenses. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in other research and platform programs was primarily due to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our decision to evolve our approach to exploratory research and drug discovery to focus on our existing late-lead optimization programs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in indirect expenses was primarily due to a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decrease in facilities and IT related expenses &amp; other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to a reduction in facility expenses associated with the evolution of our research organization, and the $1.5 million of reimbursable transition related services we provided to Servier in 2022 related to the sale of the oncology business for discovery, clinical development, technical operations, and related activities, which were completed during the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Research and Development Expenses &#8211; 2022 vs 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The increase in research and development expenses of $22.9&#160;million in 2022 compared to 2021 was due to an $18.2&#160;million increase in our direct expenses and a $4.7&#160;million increase in our indirect expenses. The increase in direct expenses was due to a $9.3 million increase in PYRUKYND&#174; costs, a $5.1 million increase in AG-946 costs, and a $3.9 million increase in other research and platform programs. The increase in PYRUKYND&#174; costs was primarily due to increased costs for the phase 3 trials of PYRUKYND&#174; in patients with thalassemia, ENERGIZE and ENERGIZE-T, the phase 3 trials of PYRUKYND&#174; in pediatric patients with PK deficiency, ACTIVATE-kids and ACTIVATE-kidsT, and the phase 2/3 trial of PYRUKYND&#174; in patients with SCD, RISE UP, offset by closeouts of the ACTIVATE and ACTIVATE-T studies. The increase in AG-946 costs was primarily due to start-up costs for the phase 2 trial of AG-946 in patients with LR MDS and increased spend for the phase 1 trial of AG-946 in h</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ealthy volunteers and in patients with SCD. The increase in other research and platform programs was primarily driven by increased activity associated with our preclinical PAH program as well as increased activity on various other exploratory activities.  The increase in indirect expenses was primarily due to a $14.1 million increase in compensation and related expenses primarily due to increased headcount, as well as certain workforce-related expenses associated with the evolution of our research organization. Th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is increase was partially offset by $7.9 million of additional reimbursable transition related services we provided to Servier in 2021 compared to 2022 related to the sale of the oncology business for discovery, clinical development, technical operations, and related activities, which were completed during the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income and Expense</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of contingent payments</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,853&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty income from gain on sale of oncology business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income and Expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 2023 vs. 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The decrease in gain on sale of contingent payments and royalty income from gain on sale of oncology business in 2023 compared to 2022 was due to the sale to Sagard in the fourth quarter of 2022 of our rights to future contingent payments associated with royalties on U.S. next sales of TIBSOVO&#174;. The $20.6&#160;million increase in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest income, net in 2023 compared to 2022 is primarily attributable to an increase in interest rates. The $0.7 million decrease in other income, net in 2023 compared to 2022 primarily related to approximately $2.6&#160;million of reimbursable transition related services and fees for the sale of the oncology business in 2022, partially offset by sublease income of $6.1 million in 2023 compared to $4.1 million in 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income and Expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 2022 vs 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The $127.9&#160;million gain on sale of contingent payments in 2022 was due to the October 27, 2022 sale of future contingent payments to entities affiliated with Sagard. The $12.0&#160;million increase in interest income, net in 2022 compared to 2021 was primarily attributable to an increase in interest rates. The $3.2&#160;million increase in royalty income from gain on sale of oncology business related to higher income from royalties on U.S. net sales of TIBSOVO&#174; by Servier in 2022 compared to 2021. The $7.7 million decrease in other income, net in 2022 compared to 2021 primarily related to approximately $13.8&#160;million of reimbursable transition related services and fees for the sale of the oncology business in 2021 compared to $2.6 million in 2022, partially offset by sublease income of $4.1 million in 2022 compared to $0.5 million in 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss from Operations and Net (Loss) Income</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352,088)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,801)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356,510)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,961,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352,088)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,801)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,604,715&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss from Operations and Net Loss &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> vs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The $120.3 million increase in net loss from continuing operations in 2023 compared to 2022 was primarily driven by the gain on sale of contingent payments in 2022 described above in Other Income and Expense, higher research and development expenses discussed above under Research and Development Expenses, which includes the $17.5 million up-front payment associated with the license agreement with Alnylam discussed above under Overview, and the decrease in royalty income from gain on sale of oncology business described above in Other Income and Expense. These were partially offset by the increase in interest income, net discussed above in Other Income and Expense and the increase in revenue discussed above under Revenues.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss from Operations and Net (Loss) Income &#8211; 2022 vs 2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; The $124.7 million decrease in net loss from continuing operations in 2022 compared to 2021 was primarily driven by the gain on sale of contingent payments in 2022 described above in Other Income and Expense, the increase in revenue in 2022 compared to 2021 discussed above under Revenues, and the increase in interest income, net and royalty income from gain on sale of oncology business discussed above under Other Income and Expense. These were partially offset by higher research and development expenses discussed above under Research and Development Expenses and a decrease in other income, net discussed above under Other Income and Expense. The change in net income from discontinued operations and net (loss) income in 2022 compared to 2021 was primarily driven by the sale of our oncology business to Servier for approximately $1.8&#160;billion in cash in the first quarter of 2021, which is included within net income from discontinued operations.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, and through March 31, 2021, we financed our operations primarily through proceeds from the sale of our royalty rights, commercial sales of TIBSOVO&#174;, funding received from our collaboration agreements, private placements of our preferred stock, our initial public offering of our common stock and concurrent private placement of common stock to an affiliate of Celgene, and our follow-on public offerings. Following the sale of our oncology business to Servier on March 31, 2021, we have financed and expect to continue to finance our operations primarily through cash on hand, royalty payments from Servier with respect to U.S. net sales of TIBSOVO&#174; prior to the sale of these contingent payments to Sagard, proceeds from the sale of contingent payments to Sagard, a potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA with a label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation, the actual and potential future sales of PYRUKYND&#174; and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. In addition, we may pursue opportunistic debt offerings, and equity or equity-linked offerings.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier. The transaction included the sale of our oncology business, including TIBSOVO&#174;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted NDA approval from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diagnostic test is granted an FDA premarket approval), as well as a royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through loss of exclusivity, and a royalty of 15% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. The milestone payment for approval of vorasidenib and royalty payments related to vorasidenib and TIBSOVO&#174; represent contingent consideration. Servier also acquired our co-commercialization rights for Bristol Myers Squibb's IDHIFA&#174; and the right to receive a $25.0 million potential milestone payment under our prior collaboration agreement with Celgene, and following the sale Servier is responsible for conducting certain clinical development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the IDHIFA&#174; development progra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">m. As discussed below in <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124">Note</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124"> 1, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124">Na</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124">t</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124">ure of </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124"> Business</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in October 2022, we sold our rights to the royalty on U.S. net sales of TIBSOVO&#174; to Sagard for $131.8&#160;million. We retained our rights to the potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA. In November 2023, Servier announced that it planned to submit a new drug application for vorasidenib for the treatment of IDH-mutant diffuse glioma to the FDA by the end of 2023 and to the European Medicines Agency, or EMA, in early 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and marketable securities balance was $806.4 million at December&#160;31, 2023. The $200.0&#160;million milestone payment and royalty payments discussed above are our only committed potential external sources of funds. Whether the regulatory approval milestone for vorasidenib will be achieved is subject to various risks and uncertainties, which are outside our control. Furthermore, we cannot predict what success, if any, Servier may have in the United States with respect to sales of vorasidenib, if approved, and consequently we cannot estimate the amount of royalty payments that we can expect to receive from Servier prior to the loss of exclusivity of vorasidenib.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands) </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,062)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309,478)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(407,320)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(765,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,054)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,867)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in operating activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities of $296.1&#160;million during the year ended December&#160;31, 2023, of which all was used by continuing operations, was primarily due to operating expenses driven by research and development costs described above under Research and Development Expenses, partially offset by cash received related to interest income of $31.2 million and cash received from revenues of $28.6 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities of $309.5&#160;million during the year ended December 31, 2022, of which all was used by continuing operations, was primarily due to operating expenses driven by research and development costs described above under Research and Development Expenses, partially offset by cash received from revenues of $13.3 million, cash received related to interest income of $11.6 million and cash received from royalties on U.S. net sales of TIBSOVO&#174; of $8.6 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities of $407.3&#160;million during the year ended December 31, 2021, of which $314.1&#160;million was used by continuing operations and $93.2&#160;million was used by discontinued operations, was primarily due to operating expenses driven by research and development costs described above in Research and Development Expenses, offset by cash received of $39.5 million from sales of TIBSOVO&#174;, and $1.2 million in cost reimbursements related to our collaboration agreements with Celgene.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by investing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash provided by investing activities for the year ended December&#160;31, 2023, of which all was provided by continuing operations, was primarily due to higher proceeds from maturities and sales of marketable securities than purchases of marketable securities, partially offset by the $17.5 million up-front payment associated with the Alnylam license agreement discussed above under Overview.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash provided by investing activities for the year ended December 31, 2022, of which all was provided by continuing operations, was primarily due to cash received of $131.8 million from the sale of future contingent payments described above in Other Income and Expense and higher proceeds from maturities and sales of marketable securities than purchases of marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash provided by investing activities for the year ended December 31, 2021, of which $1,802.9&#160;million was provided by discontinued operations and $554.2&#160;million was used by continuing operations was primarily due to the approximately $1.8 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">billion in cash proceeds received from the sale of our oncology business to Servier that was completed on March 31, 2021, and the result of higher purchases of marketable securities than proceeds from maturities and sales of marketable securities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash provided by financing activities for the year ended December&#160;31, 2023 was due to $5.4&#160;million of proceeds received from stock option exercises and purchases made pursuant to our employee stock purchase plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash provided by financing activities for the year ended December 31, 2022 was primarily due to $2.7&#160;million of proceeds received from stock option exercises and purchases made pursuant to our employee stock purchase plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash used in financing activities for the year ended December 31, 2021 was primarily the due to the repurchase of common stock under our Repurchase Program of $802.5&#160;million, partially offset by $37.3&#160;million of proceeds received from stock option exercises and purchases made pursuant to our employee stock purchase plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect our expenses to increase as we continue the research, development and clinical trials of, seek marketing approvals for, and commercialize our product candidates in our portfolio, including as we continue to commercialize PYRUKYND&#174;. If we obtain additional marketing approvals for PYRUKYND&#174; in other indications or outside of the United States or for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our existing cash, cash equivalents and marketable securities as of&#160;December&#160;31, 2023, together with anticipated product revenue, interest income and the potential vorasidenib milestone will enable us to fund our operating expenses and capital expenditures through several value-creating milestones and at least into 2026. This guidance does not include cash inflows from potential royalties or royalty monetization from vorasidenib, commercializing mitapivat outside of the United States through one or more partnerships, or other potential strategic business or financial agreements. Our future capital requirements will depend on many factors, including:</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount and timing of future revenue received from commercial sales of PYRUKYND&#174; or any of our product candidates for which we may receive marketing approval;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the amount of contingent consideration we ultimately receive from Servier;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs and timing of our ongoing commercialization activities, including product manufacturing, sales, marketing and distribution for PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in approved jurisdictions; </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs associated with in-licensing or acquiring assets for pipeline growth, including the amount and timing of future milestone and royalty payments potentially payable to Alnylam pursuant to the license agreement;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the costs and timing of future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our ability to successfully execute on our strategic plans; </span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">operational delays due to public health epidemics, including the recent COVID-19 pandemic; and</span></div><div style="margin-bottom:9pt;margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">operational delays, disruptions and/or increased costs associated with global economic developments, rising global energy prices or energy shortages or rationing.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs primarily through cash on hand, the potential milestone payment and royalties from Servier if vorasidenib is approved by the FDA, the actual and potential future sales of PYRUKYND&#174; and, potentially, collaborations, strategic alliances, licensing arrangements and other nondilutive strategic transactions. In addition, we may pursue opportunistic debt offerings, and equity or equity-linked offerings. We do not have any committed external source of funds other than the potential milestone and royalty payments that we are eligible to receive with respect to vorasidenib under our purchase agreement with Servier. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures or declaring dividends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC rules. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as of the payment due date by period at December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less<br/>than<br/>1 year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3<br/>years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5<br/>years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More<br/>than<br/>5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations (1)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,142&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,657&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,234&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing arrangements (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service arrangements (3)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Relates to payment obligations under lease agreements covering approximately 146,000 square feet at 88 Sidney Street, 43,000 square feet at 64 Sidney Street, and 13,000 square feet at 38 Sidney Street, Cambridge, Massachusetts. All leases, as amended, expire on February 29, 2028. At the end of the initial lease period, we have the option to extend the leases at all facilities for two consecutive five-year periods at the fair market rent at the time of the extension. </span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Relates to payment obligations under a packaging and supply agreement for drug product.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Relates to payment obligations under a development and manufacturing services agreement for drug product. Arrangement is for a contractual term of five years, however, the total funds can be allocated in any manner to meet the agreement terms. Amounts included assume equal payments each year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into agreements in the normal course of business with CROs for clinical trials and contract manufacturing organizations, or CMOs, for supply manufacturing and with vendors for preclinical research studies and other services and products for operating purposes. These contractual obligations are cancelable at any time by us, generally upon prior written notice to the vendor, and are thus not included in the contractual obligations table. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, we entered into a license agreement with Alnylam as discussed above under Overview and under <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124">Note 1, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124">Nature of Business</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements. Under the license agreement, we may be required to pay up to $130.0 million in potential development and regulatory milestones, in addition to sales milestones as well as tiered royalties on annual net sales, if any, of licensed products, which may be subject to specified reductions and offsets. Such payment obligations are contingent upon the occurrence of future events and the timing and likelihood of such potential obligations are not known.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_43"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk related to changes in interest rates. As of December&#160;31, 2023 and December&#160;31, 2022, we had cash, cash equivalents and marketable securities of $806.4&#160;million and $1.1&#160;billion, respectively, consisting primarily of investments in U.S. Treasuries, government securities and corporate debt securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are primarily in short-term marketable securities. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we do not believe an immediate and uniform 100 basis point change in interest rates would have a material effect on the fair market value of our investment portfolio. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also exposed to market risk related to changes in foreign currency exchange rates. We have contracts with CROs and CMOs that are located in Asia and Europe and are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these agreements. We do not currently hedge our foreign currency exchange rate risk. As of December&#160;31, 2023 and December&#160;31, 2022, we had minimal or no liabilities denominated in foreign currencies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements required to be filed pursuant to this Item&#160;8 are appended to this Annual Report on Form 10-K. An index of those financial statements is found in <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_82">Item&#160;15, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_82">Exhibits and Financial Statement Schedules</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Annual Report on Form 10-K.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_52"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Annual Report on Form 10-K, the effectiveness of our disclosure controls and procedures. Based on that evaluation of our disclosure controls and procedures as of December&#160;31, 2023, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</span></div><div style="margin-top:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control&#160;&#8211;&#160;Integrated Framework. Based on our assessment, our management has concluded that, as of December&#160;31, 2023, our internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of&#160;December&#160;31, 2023, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which is included herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B. Other Information</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Director and Officer Trading Arrangements</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers <ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-36"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-37">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-38"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-39">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the three months ended December 31, 2023.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;10 will be included in our definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_67"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11. Executive Compensation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;11 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and, other than the information required by Item 402(v) of Regulation S-K, is incorporated herein by reference.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_70"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;12 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_73"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;13 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_76"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14. Principal Accountant Fees and Services</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;14 will be included in our definitive proxy statement to be filed with the SEC with respect to our 2024 Annual Meeting of Stockholders and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_82"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. Exhibits and Financial Statement Schedules </span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_85"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)&#160;&#160; Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are included on pages F-1 through F-29 attached hereto and are filed as part of this Annual Report on Form 10-K.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.583%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_103">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID 238)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_103">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_106">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_106">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_109">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_109">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_112">Consolidated Statements of Comprehensive (Loss)</a> Income</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_112">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_115">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_115">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_118">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_118">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_121">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_121">9</a></span></div></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)&#160;&#160; Financial Statement Schedules</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules have been omitted since they are either not required or not applicable or the information is otherwise included herein.</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_91"></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)&#160;&#160; Exhibits</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.826%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Description of Exhibit</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Incorporated by Reference</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Herewith</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">File</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Date of Filing</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312520323482/d70467dex21.htm">Purchase and Sale Agreement, dated as of December 20, 2020, by and among the Registrant, Servier Pharmaceuticals, LLC, and, solely for purposes of guaranteeing certain obligations of the Purchaser, Servier S.A.S</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 22, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/exhibit22-123122.htm">Purchase and Sale Agreement, dated October 27, 2022, by and among the Registrant, </a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/exhibit22-123122.htm">Sagard Healthcare Royalty Partners, LP</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/exhibit22-123122.htm"> and S</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/exhibit22-123122.htm">agard Healthcare Partners Co-Invest Designated Activity Company</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 23, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312513307909/d574969dex31.htm">Restated Certificate of Incorp</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312513307909/d574969dex31.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312513307909/d574969dex31.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312513307909/d574969dex31.htm">ation of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">July 30, 2013</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/d638020dex31.htm">Third</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/d638020dex31.htm"> Amended and Restated By-Law</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">s</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 3, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513269075/d538215dex41.htm">Specimen Stock Certificate evidencing the shares of common stock</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-189216</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 24, 2013</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922220000014/exhibit43-descriptiono.htm">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 19, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513269075/d538215dex104.htm">2013 Stock Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-189216</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 24, 2013</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.2#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513269075/d538215dex105.htm">Form of Incentive Stock Option Agreement under 2013 Stock Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-189216</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 24, 2013</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.3#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513269075/d538215dex106.htm">Form of Nonstatutory Stock Option Agreement under 2013 Stock Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-189216</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 24, 2013</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.6</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.4#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513269075/d538215dex107.htm">2013 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-189216</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 24, 2013</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.7</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312513288239/d538215dex1012.htm">Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-189216</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">July 11, 2013</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.12</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312514347187/d791663dex101.htm">Lease, dated as of September&#160;15, 2014, between the Registrant and Forest City 88 Sidney, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 19, 2014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312514427159/d827911dex101.htm">First Amendment to Lease for 88 Sidney Street, dated as of November&#160;21, 2014, between the Registrant and Forest City 88 Sidney, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 26, 2014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.8#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312515181968/d917154dex101.htm">Summary Description of Annual Cash Incentive Program</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 11, 2015</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312515261146/d73570dex101.htm">Second Amendment to Lease for 88 Sidney Street, dated July&#160;20, 2015, by and between the Registrant and Forest City 88 Sidney Street, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">July 23, 2015</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.10#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312516481973/d113932dex1025.htm">Form of Performance Share Unit Agreement under 2013 Stock Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 26, 2016</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.25</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312517350678/d424503dex101.htm">Lease, dated as of November 17, 2017, between the Registrant and UP 64 Sidney Street, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 22, 2017</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312517350678/d424503dex102.htm">Third Amendment to Lease for 88 Sidney Street, dated November&#160;17, 2017, by and between the Registrant and Forest City 88 Sidney Street, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 22, 2017</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000119312518116870/d570104dex101.htm">First Amendment of Lease, dated April 11, 2018, by and between UP 64 Sidney Street, LLC and Agios Pharmaceuticals. Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">April 13, 2018</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.14#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000143922218000009/exhibit10-1x03x31x2018.htm">Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan (for employees)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May 4, 2018</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.15#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000143922219000004/agio-ex1032x123118.htm">Form of Restricted Stock Unit Agreement under 2013 Stock Incentive Plan (for directors)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 14, 2019</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.32</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000143922219000017/exhibit10-1x06x30x19.htm">Lease, dated as of April 11, 2019, by and between the Registrant and Thirty-Eight Sidney Street Limited LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 1, 2019</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000143922219000017/exhibit10-2x06x30x19.htm">Fourth Amendment to Lease, dated as of April 11, 2019, by and between the Registrant and Forest City 88 Sidney Street, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 1, 2019</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1439222/000143922219000017/exhibit10-3x06x30x19.htm">Third Amendment of Lease, dated as of April 11, 2019, by and between the Registrant and UP 64 Sidney Street, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 1, 2019</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922221000073/exhibit1029-30x2138sidneys.htm">Sublease Agreement, dated July 27, 2021, between the Registrant and Prime Medicine, Inc. (38 Sidney Street)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 3, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922222000024/ex1044-subleaseagreementda.htm">Sublease Agreement, dated July 27, 2021, between the Registrant and Prime Medicine, Inc. (64 Sidney Street)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 24, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.44</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit-1021x123123.htm">Sublease Agreement, dated April 14, 2023, between the Registrant and Watershed Informatics, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.22#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922222000070/exhibit102-063022.htm">Letter Agreement, dated July 8, 2022, between the Registrant and Brian Goff</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 4, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.23#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922222000070/exhibit103-063022.htm">Form of Inducement Stock Option Agreement for Brian Goff</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 4, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.24#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922222000070/exhibit104-063022.htm">Form of Inducement Restricted Stock Unit Agreement for Brian Goff</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 4, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.25#**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922222000070/exhibit105-063022.htm">Form of Inducement Performance Stock Unit Agreement for Brian Goff</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 4, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.26#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922222000099/exhibit105-093022.htm">Letter Agreement, dated as of September 16, 2022, between the Registrant and Cecilia Jones</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 3, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.27#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312522251376/d358037dex991.htm">Form of Inducement Stock Option Agreement for Cecilia Jones</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333- 267624</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 26, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.28#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312522251376/d358037dex992.htm">Form of Inducement Restricted Stock Unit Agreement for Cecilia Jones</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333- 267624</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 26, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.29#**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312522251376/d358037dex993.htm">Form of Inducement Performance Stock Unit Agreement for Cecilia Jones</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333- 267624</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">September 26, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.30#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312522259591/d363139dex101.htm">Amended and Restated Severance Benefits Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 7, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.31#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/exhibit1038-123122.htm">Letter Agreement, dated as of December 5, 2022, between the Registrant and Tsveta Milanova</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 23, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.38</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.32#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312523000881/d398924dex991.htm">Form of Inducement Stock Option Agreement for Tsveta Milanova</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333- 269018</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">January 3, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.33#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312523000881/d398924dex992.htm">Form of Inducement Restricted Stock Unit Agreement for Tsveta Milanova</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333- 269108</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">January 3, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.34#**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312523000881/d398924dex993.htm">Form of Inducement Performance Stock Unit Agreement for Tsveta Milanova</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333- 269108</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">January 3, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.35#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000119312523166035/d482039dex991.htm">2023 Stock Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">333-272615</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">June 13, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.36#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000119/exhibit102.htm">Form of Stock Option Agreement Under 2023 Stock Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 3, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.37#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000119/exhibit103.htm">Form of Restricted Stock Unit  Agreement Under 2023 Stock Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 3, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.38#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000119/exhibit104.htm">Form of Restricted Stock Unit  Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000119/exhibit104.htm"> (P</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000119/exhibit104.htm">erformance</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000119/exhibit104.htm">-Based)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1439222/000143922223000119/exhibit104.htm"> Under 2023 Stock Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">001-36014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">August 3, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="agio-ex211x123123.htm">Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="agio-ex231x123123.htm">Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">31.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit31-1x12x31x23.htm">Certification of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">31.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit31-2x12x31x23.htm">Certification of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit32-1x12x31x23.htm">Certification of principal executive officer pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">32.2*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit32-2x12x31x23.htm">Certification of principal financial officer pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">97.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit-971x123123.htm">Dodd-Frank Compensation Recovery Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XBRL Instance Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XBRL Taxonomy Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XBRL Taxonomy Label Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">XBRL Taxonomy Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">104</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">X</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicates management contract or compensatory plan or arrangement.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">**</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_94"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16. Form 10-K Summary</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:57.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.404%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.745%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AGIOS PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian Goff</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian Goff</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:47.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian Goff</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief&#160;Executive&#160;Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal executive officer)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian Goff</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Cecilia Jones</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal financial officer)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cecilia Jones</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ T.J. Washburn</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Controller</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal accounting officer)</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">T.J. Washburn</span></div><div><span><br/></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jacqualyn A. Fouse</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board of Directors</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jacqualyn A. Fouse, Ph.D.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rahul Ballal</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rahul Ballal, Ph.D.</span></div><div><span><br/></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey Capello</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey Capello</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kaye Foster</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kaye Foster</span></div><div><span><br/></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Maykin Ho</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maykin Ho, Ph.D.</span></div><div><span><br/></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Catherine Owen</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Catherine Owen</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Scadden</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Scadden, M.D.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David P. Schenkein</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David P. Schenkein, M.D.</span></div><div><span><br/></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Cynthia Smith</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cynthia Smith</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agios Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Index to Consolidated Financial Statements</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_103">Report of Independent Registered Public Accounting Firm </a>(PCAOB ID <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-40">238</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_103">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_106">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_106">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_109">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_109">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_112">Consolidated Statements of Comprehensive (Loss)</a> Income</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_112">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_115">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_115">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_118">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_118">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_121">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_121">9</a></span></div></td></tr></table></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Agios Pharmaceuticals, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Agios Pharmaceuticals, Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2023 and 2022, and the related consolidated statements of operations, of comprehensive (loss) income, of stockholders&#8217; equity and of cash flows for each of the three years in the period ended December&#160;31, 2023, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited the Company's internal control over financial reporting as of December&#160;31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013)</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2023 and 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the results of its</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operations and its</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash flows for each of the three years in the period ended December&#160;31, 2023 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013)</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued by the COSO.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management's Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements included performing procedures to assess the risks of material misstatement of the consolidated</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition - PYRUKYND&#174; Product Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 2 and 8 to the consolidated financial statements, the Company generates product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers.  These Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense directly to patients.  The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.  Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with the Customers, healthcare providers, payors and other indirect customers relating to the sale of its products.  For the year ended December 31, 2023, the Company recognized $26.8 million of net product revenue relating to the sale of PYRUKYND&#174;.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal consideration for our determination that performing procedures relating to PYRUKYND&#174; product revenue recognition is a critical audit matter is a high degree of auditor effort in performing procedures related to the Company&#8217;s product revenue recognition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the revenue recognition process, including controls over the recording of PYRUKYND&#174; product revenue at the transaction price once control passes to the customer.  These procedures also included, among others, (i) evaluating management&#8217;s revenue recognition policy and (ii) testing the completeness, accuracy, and occurrence of revenue recognized for a sample of product revenue transactions by obtaining and inspecting source documents, such as purchase orders, invoices, proof of delivery, and subsequent cash receipts. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-41">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-42">Boston, Massachusetts</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have served as the Company&#8217;s auditor since 2017.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agios Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands, except share and per share data) December 31:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-43">88,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-44">139,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-45">688,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">643,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-49">19,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-50">8,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">35,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">38,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">833,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">832,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">29,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">313,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-57">54,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-58">65,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-59">15,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-60">22,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">4,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">3,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-63">937,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-64">1,238,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">9,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">18,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">43,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">30,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">15,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">13,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">67,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">62,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">56,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">71,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">1,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-77">126,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-78">137,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingent liabilities (Note 16)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-79"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-80"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="f-81"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="f-82">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-84">25,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-85"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-86"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-87"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-88">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2023 and 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="f-91"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" format="ixt:num-dot-decimal" scale="0" id="f-92">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-93"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-94">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-95">72,161,489</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96">55,945,078</ix:nonFraction> outstanding at December 31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-97">71,256,118</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-98">55,039,707</ix:nonFraction> outstanding at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="f-99">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="f-100">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-101">2,436,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-102">2,386,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-103">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-104">12,535</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-105">822,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-106">470,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost (<ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-108">16,216,411</ix:nonFraction></ix:nonFraction> shares at December 31, 2023 and December 31, 2022)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="f-109">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="f-110">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">811,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-112">1,100,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-113">937,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-114">1,238,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agios Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands, except share and per share data) Years Ended December 31:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-115">26,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-116">11,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-117">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-119">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-120">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-121">26,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-122">14,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-124">2,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-125">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-127">295,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-128">279,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-129">256,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-130">119,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">121,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-132">121,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-133">418,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-134">403,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-135">378,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-136">391,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-137">389,047</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-138">378,418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of contingent payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:GainLossOnSaleOfContingentPayments" format="ixt:fixed-zero" scale="3" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:GainLossOnSaleOfContingentPayments" format="ixt:num-dot-decimal" scale="3" id="f-140">127,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="agio:GainLossOnSaleOfContingentPayments" format="ixt:fixed-zero" scale="3" id="f-141">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty income from gain on sale of oncology business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" format="ixt:fixed-zero" scale="3" id="f-142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-143">9,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-144">6,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-145">33,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-146">12,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-147">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-148">6,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-149">6,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-150">14,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-151">352,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-152">231,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-153">356,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-156">1,961,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-157">352,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-158">231,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-159">1,604,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from continuing operations per share - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-160"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-161">6.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-162"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-163">4.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-164"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-165">5.90</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations per share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-166"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-167">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-168"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-169">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-170"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="f-171">32.45</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income per share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-172"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-173">6.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-174"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-175">4.23</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-176"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-177">26.55</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share &#8211; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-178"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-179">55,651,487</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-180"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-181">54,789,435</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-182"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-183">60,447,346</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agios Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive (Loss) Income</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands) Years Ended December 31:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">352,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-185">231,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">1,604,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-187">12,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-188">11,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-189">1,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-190">339,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-191">243,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-192">1,603,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agios Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.437%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;<br/>Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(In thousands, except share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-193">69,293,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-194">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-195">2,242,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-196">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">1,843,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="0" id="f-198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-199">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-200">399,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" format="ixt:num-dot-decimal" scale="3" id="f-201">1,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" format="ixt:num-dot-decimal" scale="3" id="f-202">1,303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">1,604,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-204">1,604,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-205">53,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-206">53,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-207">1,256,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-208">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-209">37,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-210">37,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-211">16,216,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-212">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-213">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Disposition of oncology business</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="agio:StockholdersEquityDispositionOfBusiness" scale="3" id="f-214">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="agio:StockholdersEquityDispositionOfBusiness" scale="3" id="f-215">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-216">70,550,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-217">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-218">2,334,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-219">1,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-220">238,760</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-221">16,216,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-222">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-223">1,291,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" format="ixt:num-dot-decimal" scale="3" id="f-224">11,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" format="ixt:num-dot-decimal" scale="3" id="f-225">11,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-226">231,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-227">231,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-228">49,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-229">49,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-230">705,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-231">2,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-232">2,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-233">71,256,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-234">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-235">2,386,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">12,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-237">470,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-238">16,216,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-239">802,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-240">1,100,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" format="ixt:num-dot-decimal" scale="3" id="f-241">12,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" format="ixt:num-dot-decimal" scale="3" id="f-242">12,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-243">352,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-244">352,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-245">44,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-246">44,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under stock incentive plan and ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-247">905,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-248">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-249">5,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-250">5,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-251">72,161,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-252">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-253">2,436,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-254">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-255">822,649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-256">16,216,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-257">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-258">811,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agios Pharmaceuticals, Inc.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands) Years Ended December 31:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-259">352,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-260">231,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-261">1,604,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="f-263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-264">1,961,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-265">352,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-266">231,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-267">356,510</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-268">6,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-269">8,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-270">9,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-271">44,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-272">49,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-273">53,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (accretion of discount) amortization of premium on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-274">5,051</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-275">1,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-276">6,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of contingent payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:GainLossOnSaleOfContingentPayments" format="ixt:fixed-zero" scale="3" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:GainLossOnSaleOfContingentPayments" format="ixt:num-dot-decimal" scale="3" id="f-278">127,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="agio:GainLossOnSaleOfContingentPayments" format="ixt:fixed-zero" scale="3" id="f-279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-280">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-281">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="f-282">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-283">10,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-284">9,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-285">9,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expense associated with license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ExpenseAssociatedWithLicenseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-286">17,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ExpenseAssociatedWithLicenseAgreement" format="ixt:fixed-zero" scale="3" id="f-287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="agio:ExpenseAssociatedWithLicenseAgreement" format="ixt:fixed-zero" scale="3" id="f-288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Realized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:RealizedGainOnInvestments" scale="3" id="f-289">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:RealizedGainOnInvestments" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="agio:RealizedGainOnInvestments" format="ixt:fixed-zero" scale="3" id="f-291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="f-292">604</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-293">2,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-295">10,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-296">8,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="3" id="f-298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="f-299">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="f-300">4,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-301">3,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-302">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-303">26,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-304">8,733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-305">3,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-306">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-307">12,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-308">1,617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="f-309">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-310">13,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-311">10,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-312">7,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-313">2,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-314">3,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:fixed-zero" scale="3" id="f-315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities - continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-316">296,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-317">309,478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-318">314,086</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities - discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-321">93,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-322">296,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-323">309,478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-324">407,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-325">417,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-326">1,030,781</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-327">1,378,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-328">674,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-329">1,146,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-330">829,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of contingent payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ProceedsFromSaleOfContingentPayments" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ProceedsFromSaleOfContingentPayments" format="ixt:num-dot-decimal" scale="3" id="f-332">131,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="agio:ProceedsFromSaleOfContingentPayments" format="ixt:fixed-zero" scale="3" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments associated with license agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:PaymentsAssociatedWithLicenseAgreement" format="ixt:num-dot-decimal" scale="3" id="f-334">17,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:PaymentsAssociatedWithLicenseAgreement" format="ixt:fixed-zero" scale="3" id="f-335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="agio:PaymentsAssociatedWithLicenseAgreement" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-337">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-338">4,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-339">5,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-340">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" scale="3" id="f-341">964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" format="ixt:fixed-zero" scale="3" id="f-342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities - continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-343">239,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-344">243,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-345">554,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities - discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-348">1,802,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-349">239,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-350">243,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-351">1,248,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments on financing lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="f-352">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-353">331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-354">578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfEquity" format="ixt:fixed-zero" scale="3" id="f-355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfEquity" format="ixt:fixed-zero" scale="3" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-357">802,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net proceeds from stock option exercises and employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-358">5,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-359">2,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-360">37,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-361">5,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-362">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-363">765,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-364">51,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-365">63,867</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-366">75,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-367">139,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-368">203,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-369">127,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of the period</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-370">88,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-371">139,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-372">203,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosure of non-cash investing and financing transactions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to property and equipment in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-373">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-374">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-375">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-376">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-378">16,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing lease liabilities arising from obtaining financing lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="f-381">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_121"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agios Pharmaceuticals, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_124"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-382" continuedAt="f-382-1" escape="true">Nature of Business</ix:nonNumeric></span></div><ix:continuation id="f-382-1" continuedAt="f-382-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">References to Agios</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Annual Report on Form 10-K, &#8220;the Company,&#8221; &#8220;Agios,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#8220;our board of directors&#8221; refers to the board of directors of Agios Pharmaceuticals, Inc. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through leadership in the field of cellular metabolism, with the goal of creating differentiated medicines for rare diseases, with a focus on classical hematology. With a history of focused study on cellular metabolism, we have a deep and mature understanding of this biology, which is involved in the healthy functioning of nearly every system in the body. Building on this expertise, these learnings can be rapidly applied to our clinical trials with the goal of developing medicines that can have a significant impact for patients. We accelerate the impact of our portfolio by cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for rare diseases.&#160;We are located in Cambridge, Massachusetts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead product candidate in our portfolio, PYRUKYND&#174; (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. In February 2022, the U.S. Food and Drug Administration, or FDA, approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In November 2022, we received marketing authorization from the European Commission for PYRUKYND&#174; for the treatment of PK deficiency in adult patients in the European Union, or EU. In December 2022, we received marketing authorization in Great Britain for PYRUKYND&#174; for the treatment of PK deficiency in adult patients under the European Commission Decision Reliance Procedure. In addition, we are currently evaluating PYRUKYND&#174; in clinical trials for the treatment of thalassemia, sickle cell disease, or SCD, and in pediatric patients with PK deficiency. We are also developing (i) AG-946, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndrome, or LR MDS, and hemolytic anemias, and (ii) AG-181, our phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, in July 2023 we entered into a license agreement with Alnylam Pharmaceuticals, Inc., or Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the transmembrane serine protease 6, or TMPRSS6, gene and we intend to pursue development of a licensed product for the potential disease-modifying treatment of patients with polycythemia vera, or PV, a rare blood disorder.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks common to companies in our industry including, but not limited to, uncertainties relating to conducting preclinical and clinical research and development, the manufacture and supply of products for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for our products, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, potential litigation, potential product liability claims and potential government investigations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Alnylam License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2023, we entered into a license agreement with Alnylam under which we acquired the rights to develop and commercialize Alnylam&#8217;s novel preclinical siRNA targeting the TMPRSS6 gene, as a potential disease-modifying treatment for patients with PV. Because the acquired assets do not meet the definition of a business in accordance with ASC 805, Business Combinations, we will account for the agreement as an asset acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the license agreement, in the twelve months ended December 31, 2023, we made an up-front payment to Alnylam and recognized in-process research and development of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="agio:PaymentsForAssetAcquisition" format="ixt:num-dot-decimal" scale="6" id="f-383">17.5</ix:nonFraction>&#160;million which was recorded in research and development expense within our Consolidated Statements of Operations and classified as investing activities within our Consolidated Statements of Cash Flows. We will also pay Alnylam for certain expenses associated with the development of TMPRSS6 and these will be recorded in our Consolidated Statements of Operations as incurred. Additionally, we are responsible to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="agio:AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="f-384">130.0</ix:nonFraction>&#160;million in potential development and regulatory milestones, in addition to sales milestones as well as tiered royalties on annual net sales, if any, of licensed products, which may be subject to specified reductions and offsets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><ix:continuation id="f-382-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Sale of Oncology Business to Servier and Sale of Contingent Payments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO&#174;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="9" id="f-385">1.8</ix:nonFraction>&#160;billion in cash at the closing, subject to certain adjustments, and a payment of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:GainContingencyUnrecordedAmount" format="ixt:num-dot-decimal" scale="6" id="f-386">200.0</ix:nonFraction>&#160;million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of <ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="agio:GainContingencyRoyaltyPercentageOfNetSales" scale="-2" id="f-387">5</ix:nonFraction>% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through loss of exclusivity, and a royalty of <ix:nonFraction unitRef="number" contextRef="c-54" decimals="2" name="agio:GainContingencyRoyaltyPercentageOfNetSales" scale="-2" id="f-388">15</ix:nonFraction>% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#8217;s IDHIFA&#174; and the right to receive a $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" format="ixt:num-dot-decimal" scale="6" id="f-389">25.0</ix:nonFraction>&#160;million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier will conduct certain clinical development activities within the IDHIFA&#174; development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we sold our rights to future contingent payments associated with the royalty of <ix:nonFraction unitRef="number" contextRef="c-53" decimals="2" name="agio:GainContingencyRoyaltyPercentageOfNetSales" scale="-2" id="f-390">5</ix:nonFraction>% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through the loss of exclusivity to entities affiliated with Sagard Healthcare Partners, or Sagard, and recognized income of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="agio:GainLossOnSaleOfContingentPayments" format="ixt:num-dot-decimal" scale="6" id="f-391">127.9</ix:nonFraction>&#160;million within the gain on sale of contingent payments line item in our Consolidated Statements of Operations for the year ended December&#160;31, 2022. We retain our rights to the potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded income from royalties of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="agio:ContingentGainOnDispositionOfBusinessRecognized" format="ixt:num-dot-decimal" scale="6" id="f-392">9.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="agio:ContingentGainOnDispositionOfBusinessRecognized" format="ixt:num-dot-decimal" scale="6" id="f-393">6.6</ix:nonFraction>&#160;million on U.S. net sales of TIBSOVO&#174; by Servier in the royalty income from gain on sale of oncology business line item within the consolidated statements of operation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the years ended December&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, we had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-394">806.4</ix:nonFraction>&#160;million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities to be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. If we are unable to raise additional funds through equity or debt financings, we may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 30, 2020, we entered into an at-the-market sales agreement, or the 2020 sales agreement, with Cowen &amp; Company LLC, or Cowen, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="agio:SaleOfStockMaximumValueOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="f-395">250.0</ix:nonFraction>&#160;million through Cowen pursuant to a universal shelf registration statement on Form S-3 filed with the SEC on April 30, 2020. As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="agio:SaleOfStockCommonStockReservedForFutureIssuanceValue" format="ixt:num-dot-decimal" scale="6" id="f-396">250.0</ix:nonFraction>&#160;million in common stock remained available for future issuance under the 2020 sales agreement. On February 15, 2023, we delivered written notice to Cowen that we were terminating the 2020 sales agreement, effective on February 22, 2023. As of the termination of the 2020 sales agreement, we had not sold any shares of our common stock under the 2020 sales agreement.</span></div></ix:continuation><div id="i62bc41bff6df4446af4f8c46a1b0e260_127"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-397" continuedAt="f-397-1" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="f-397-1" continuedAt="f-397-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-398" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries, Agios Securities Corporation, Agios International Sarl (GmbH), Agios Germany GmbH, Agios Netherlands B.V., Agios Italy S.R.L., Agios France SARL, and Agios Limited. All intercompany transactions have been eliminated in consolidation. The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-399" continuedAt="f-399-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><ix:continuation id="f-397-2" continuedAt="f-397-3"><ix:continuation id="f-399-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the recent COVID-19 pandemic, or other pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-400" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-401" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-402" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, PYRUKYND&#174;, by the FDA on February 17, 2022 for the treatment of hemolytic anemia in adults with PK deficiency in the United States, we began to capitalize inventories of PYRUKYND&#174;.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-403" continuedAt="f-403-1" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense PYRUKYND&#174; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contractual Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><ix:continuation id="f-397-3" continuedAt="f-397-4"><ix:continuation id="f-403-1"><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Government Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CostOfSalesPolicyTextBlock" id="f-404" escape="true"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of manufacturing costs for sales of PYRUKYND&#174;. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#174; recorded during the twelve months ended December 31, 2023 and 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the twelve months ended December 31, 2023 and 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-405" escape="true"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at&#160;December&#160;31, 2023 and 2022 consisted of investments in U.S. Treasuries, government securities and corporate debt securities. We determine the appropriate classification of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date. We classify our marketable securities as available-for-sale pursuant to ASC 320,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Marketable securities are recorded at fair value. Unrealized gains and losses are included as a component of accumulated other comprehensive (loss) income in the consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive (loss) income in the consolidated statements of comprehensive (loss) income, until realized. Realized gains and losses are included in investment income on a specific-identification basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;December&#160;31, 2023 and 2022, we held both current and non-current investments. Investments classified as current are those that: (i) have a maturity of less than <ix:nonNumeric contextRef="c-1" name="agio:AvailableForSaleSecuritiesCurrentMaturityPeriod" format="ixt-sec:durwordsen" id="f-406">one year</ix:nonNumeric>, or (ii) have a maturity of <span style="-sec-ix-hidden:f-407">one</span> to <ix:nonNumeric contextRef="c-61" name="agio:AvailableForSaleSecuritiesCurrentMaturityPeriod" format="ixt-sec:durwordsen" id="f-408">two years</ix:nonNumeric> but we intend to liquidate within the next twelve months. Investments classified as non-current are those that: (i)&#160;have a maturity of&#160;<span style="-sec-ix-hidden:f-409">one</span> to <ix:nonNumeric contextRef="c-61" name="agio:AvailableForSaleSecuritiesNonCurrentMaturityPeriod" format="ixt-sec:durwordsen" id="f-410">two years</ix:nonNumeric>, and (ii)&#160;we do not intend to liquidate within the next&#160;<ix:nonNumeric contextRef="c-1" name="agio:AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod" format="ixt-sec:durwordsen" id="f-411">one year</ix:nonNumeric>, although these funds are available for use and therefore classified as available-for-sale.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review marketable securities for impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#8217;s carrying amount is not recoverable. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive (loss) income, net of taxes. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity of the impairment, collectability of the security, and any adverse conditions specifically related to the security, an industry, or geographic area.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-412" continuedAt="f-412-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and marketable securities at fair value. ASC&#160;820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1&#160;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><ix:continuation id="f-397-4" continuedAt="f-397-5"><ix:continuation id="f-412-1"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2023 or 2022. Fair value information for these assets, including their classification in the fair value hierarchy is included in <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_130">Note 3</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_130">, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_130">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the valuation methods during the years ended December&#160;31, 2023 and 2022. We evaluate transfers between levels at the end of each reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other receivables, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values due to their short-term maturities.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-413" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, and marketable securities. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-414" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of laboratory equipment, computer equipment and software, leasehold improvements, furniture and fixtures, and office equipment. Costs of major additions and betterment are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.</span></div><ix:nonNumeric contextRef="c-1" name="agio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="f-415" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, and depreciated using the straight-line method over the estimated useful lives of the respective assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.182%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-62" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-416">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-63" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-417">3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-64" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-418">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-65" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-419">5</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the lesser of the remaining lease term or the estimated useful life of the improvement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-420" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate our long-lived assets for potential impairment in accordance with ASC&#160;360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is assessed based on the undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. We did not recognize any impairment charges through December&#160;31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-421" continuedAt="f-421-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. An arrangement is determined to contain a lease if the contract conveys the right to control the use of an identified property or equipment for a period of time in exchange for consideration. If we can benefit from the various underlying assets of a lease on their own or together with other resources that are readily available, or if the various underlying assets are neither highly dependent on nor highly interrelated with other underlying assets in the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><ix:continuation id="f-397-5" continuedAt="f-397-6"><ix:continuation id="f-421-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangement, they are considered to be a separate lease component. In the event multiple underlying assets are identified, the lease consideration is allocated to the various components based on each of the component&#8217;s relative fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the leasing arrangement. Operating lease assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, in determining the operating lease liabilities we use an estimate of our incremental borrowing rate. The incremental borrowing rate is determined using two alternative credit scoring models to estimate our credit rating, adjusted for collateralization. The calculation of the operating lease assets includes any lease payments made and excludes any lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, we record operating lease assets and lease liabilities in our consolidated balance sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Short-term leases, or leases that have a lease term of 12 months or less at commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any material short-term leases or financing leases as of December&#160;31, 2023.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-422" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs, including those accrued as of each balance sheet date, are expensed as incurred. These costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, fees paid to contract research organizations, or CROs, and other third parties in connection with clinical trials and preclinical development activities, fees paid to investigative sites in connection with clinical studies, the costs associated with the product manufacturing, development, and distribution of clinical supplies, the costs of laboratory equipment and facilities, and other external costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. Additionally, there may be instances in which payments made to our vendors will exceed the level of services provided, and result in a prepayment of the research and development expense. The capitalized amounts are expensed as the related goods are delivered or the services are performed. We estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-423" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation awards in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#160;&#8211;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 718. For stock-based awards granted to employees, non-employees and members of the board of directors for their services and for participation in our employee stock purchase plan, we estimate the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires us to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, we recognize stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. For awards subject to performance-based vesting conditions, we recognize stock-based compensation expense if the performance condition is considered probable of achievement using management&#8217;s best estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-424" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 740, which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. We determine our deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also account for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><ix:continuation id="f-397-6" continuedAt="f-397-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-425" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive (loss) income</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances, and currently consists of net loss and unrealized gains and losses on available-for-sale securities. Accumulated other comprehensive (loss) income consists entirely of unrealized gains and losses from available-for-sale securities as of December&#160;31, 2023 and 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-426" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (loss) income per share</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated by dividing net (loss) income by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by adjusting weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the dilutive net (loss) income per share calculation, stock options, restricted stock units, or RSUs, performance-based stock units, or PSUs, and market-based stock units, or MSUs, for which the performance and market vesting conditions, respectively, have been deemed probable, and employee stock purchase plan shares are considered to be common stock equivalents but are excluded from the calculation of diluted net (loss) income per share as their effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss from continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income (loss) from discontinued operations per share or net (loss) income per share.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-427" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and geographic information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker or decision-making group in making decisions on how to allocate resources and assess performance. Our chief operating decision maker is the chief executive officer. Our chief operating decision maker and we view our operations and manage our business as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-428">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="f-429" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the sale of our oncology business in the first quarter of 2021 in accordance with ASC 205, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Accounting Standards Update, or ASU, No. 2014-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We followed the held-for-sale criteria as defined in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 205. ASC 205 requires that a component of an entity that has been disposed of or is classified as held for sale and has operations and cash flows that can be clearly distinguished from the rest of the entity be reported as assets held for sale and discontinued operations. In the period a component of an entity has been disposed of or classified as held for sale, the results of operations for the periods presented are reclassified into separate line items in the consolidated statements of operations. Assets and liabilities are also reclassified into separate line items on the related consolidated balance sheets for the periods presented. The statements of cash flows for the periods presented are also reclassified to reflect the results of discontinued operations as separate line items. ASU 2014-08 requires that only a disposal of a component of an entity, or a group of components of an entity, that represents a strategic shift that has, or will have, a major effect on the reporting entity&#8217;s operations and financial results be reported in the financial statements as discontinued operations. ASU 2014-08 also provides guidance on the financial statement presentations and disclosures of discontinued operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the sale of our oncology business during the first quarter of 2021, in accordance with ASC 205, we have classified the results of the oncology business as discontinued operations in our consolidated statements of operations and cash flows for all periods presented, and refer to <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_166">Note 15, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_166">Discontinued Operations</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-430" continuedAt="f-430-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury stock</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-430-1">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-431" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Content</a>s</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" id="f-432" escape="true"><ix:continuation id="f-397-7"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent events</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered events or transactions occurring after the balance sheet date, but prior to the issuance of the consolidated financial statements, for potential recognition or disclosure in our consolidated financial statements. All significant subsequent events have been properly disclosed in the consolidated financial statements.</span></div></ix:continuation></ix:nonNumeric><div id="i62bc41bff6df4446af4f8c46a1b0e260_130"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-433" continuedAt="f-433-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="f-433-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-434" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash equivalents and marketable securities measured at fair value and by level (as described in <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_127">Note</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_127"> </a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_127">2,</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_127"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_127">Su</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_127">mmary of Significant Accounting Policies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on a recurring basis as of December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-435">30,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-438">30,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-439">30,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-442">30,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-444">35,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-446">35,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-448">257,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-450">257,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-452">425,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-454">425,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-456">718,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-458">718,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="agio:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-459">30,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="agio:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-460">718,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="agio:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="agio:CashEquivalentsAndAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-462">748,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1 and Level 2 and we had <ix:nonFraction unitRef="usd" contextRef="c-72" decimals="INF" name="us-gaap:FairValueNetAssetLiability" format="ixt:fixed-zero" scale="0" id="f-463">no</ix:nonFraction> financial assets or liabilities that were classified as Level&#160;3 at any point during the year ended December&#160;31, 2023.</span></div></ix:continuation><div id="i62bc41bff6df4446af4f8c46a1b0e260_133"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-464" continuedAt="f-464-1" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-465" continuedAt="f-465-1" escape="true"><ix:continuation id="f-464-1" continuedAt="f-464-2"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2023 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-466">30,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-468">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-469">30,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-470">247,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-471">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-472">695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-473">246,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-474">411,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-475">874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-476">975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-477">410,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-478">689,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-479">1,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-480">1,726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-481">688,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-482">4,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-483">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-485">4,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-486">9,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-487">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-489">10,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-490">14,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-491">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-493">14,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-494">29,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-495">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-497">29,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-498">718,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-499">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-500">1,726</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-501">718,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:continuation id="f-464-2"><ix:continuation id="f-465-1"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2022 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:49.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.650%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-502">68,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-503">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-504">811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-505">67,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-506">220,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-507">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-508">5,289</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-509">215,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-510">363,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-511">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-512">2,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-513">360,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-514">652,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-515">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-516">8,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-517">643,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-518">17,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-519">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-520">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-521">17,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-522">117,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-523">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-524">1,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-525">115,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-526">183,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-527">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-528">2,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-529">180,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-530">317,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-531">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-532">4,143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-533">313,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-534">970,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-535">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-536">12,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-537">957,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-538"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="0" id="f-539">no</ix:nonFraction></ix:nonFraction> material realized gains or losses on marketable securities for the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;December&#160;31, 2023 and 2022, we held&#160;<ix:nonFraction unitRef="security" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-540">151</ix:nonFraction> and <ix:nonFraction unitRef="security" contextRef="c-6" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="f-541">259</ix:nonFraction> debt securities, respectively, that were in an unrealized loss position for less than one year. We did <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="f-542"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="f-543">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses as of December&#160;31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at&#160;December&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-544">513.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-545">868.2</ix:nonFraction> million, respectively. There were&#160;<ix:nonFraction unitRef="security" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:fixed-zero" scale="0" id="f-546"><ix:nonFraction unitRef="security" contextRef="c-6" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:fixed-zero" scale="0" id="f-547">no</ix:nonFraction></ix:nonFraction> individual securities that were in a significant unrealized loss position as of&#160;December&#160;31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of&#160;December&#160;31, 2023 and 2022.</span></div></ix:continuation><div id="i62bc41bff6df4446af4f8c46a1b0e260_136"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-548" continuedAt="f-548-1" escape="true">Inventory</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-549" escape="true"><ix:continuation id="f-548-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of commercial supply of PYRUKYND&#174;, consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="f-550">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:fixed-zero" scale="3" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-552">17,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-553">7,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-554">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="f-555">942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-556">19,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-557">8,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i62bc41bff6df4446af4f8c46a1b0e260_139"></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-558" continuedAt="f-558-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-558-1" continuedAt="f-558-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of <ix:nonNumeric contextRef="c-5" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-559">four years</ix:nonNumeric> and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease approximately <ix:nonFraction unitRef="sqft" contextRef="c-102" decimals="-3" name="agio:LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="f-560">146,000</ix:nonFraction> square feet at 88 Sidney Street, <ix:nonFraction unitRef="sqft" contextRef="c-103" decimals="-3" name="agio:LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="f-561">43,000</ix:nonFraction> square feet at 64 Sidney Street, and <ix:nonFraction unitRef="sqft" contextRef="c-104" decimals="-3" name="agio:LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="f-562">13,000</ix:nonFraction> square feet at 38 Sidney Street, Cambridge, Massachusetts. All leases, as amended, expire on February 29, 2028. At the end of the initial lease period, we have the option to extend the leases at all facilities for <ix:nonFraction unitRef="leaseterm" contextRef="c-102" decimals="INF" name="agio:LesseeOperatingLeaseNumberOfLeaseTerms" format="ixt-sec:numwordsen" scale="0" id="f-563"><ix:nonFraction unitRef="leaseterm" contextRef="c-103" decimals="INF" name="agio:LesseeOperatingLeaseNumberOfLeaseTerms" format="ixt-sec:numwordsen" scale="0" id="f-564"><ix:nonFraction unitRef="leaseterm" contextRef="c-104" decimals="INF" name="agio:LesseeOperatingLeaseNumberOfLeaseTerms" format="ixt-sec:numwordsen" scale="0" id="f-565">two</ix:nonFraction></ix:nonFraction></ix:nonFraction> consecutive <ix:nonNumeric contextRef="c-105" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-566"><ix:nonNumeric contextRef="c-106" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-567"><ix:nonNumeric contextRef="c-107" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-568">five-year</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> periods at the fair market rent at the time of the extension.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-569" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense and other information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-570">15,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-571">15,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-572">15,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-573">18,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-574">17,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-575">14,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any material short-term leases or financing leases as of December&#160;31, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:continuation id="f-558-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arriving at the operating lease liabilities as of December&#160;31, 2023, we applied the weighted-average incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" format="ixt:num-dot-decimal" scale="-2" id="f-576">5.7</ix:nonFraction>% from inception over a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-577">4.2</ix:nonNumeric> years. In arriving at the operating lease liabilities as of December&#160;31, 2022, we applied the weighted-average incremental borrowing rate of <ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" format="ixt:num-dot-decimal" scale="-2" id="f-578">5.7</ix:nonFraction>% over a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-579">5.2</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-580" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-581">17,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-582">19,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-583">20,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-584">20,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-585">3,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-587">81,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-588">9,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-589">71,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provided our landlord a security deposit of $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-590">2.9</ix:nonFraction> million as security for our leases, which is included within other non-current assets on our consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a long-term sublease agreement for <ix:nonFraction unitRef="sqft" contextRef="c-109" decimals="-3" name="agio:LesseeOperatingSubleaseAreaOfPremisesSubleased" format="ixt:num-dot-decimal" scale="0" id="f-591">13,000</ix:nonFraction> square feet of the office space at 38 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through December 2024. In April 2022, we entered into a long-term sublease agreement for <ix:nonFraction unitRef="sqft" contextRef="c-110" decimals="-3" name="agio:LesseeOperatingSubleaseAreaOfPremisesSubleased" format="ixt:num-dot-decimal" scale="0" id="f-592">27,000</ix:nonFraction> square feet of the office space at 64 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through April 2025. At the end of the initial sublease periods, the subtenant has the option to extend the leases for <ix:nonFraction unitRef="extension" contextRef="c-111" decimals="INF" name="agio:LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods" format="ixt-sec:numwordsen" scale="0" id="f-593">one</ix:nonFraction> additional <ix:nonNumeric contextRef="c-111" name="agio:LesseeOperatingLeaseOptionToExtendExtensionPeriod" format="ixt-sec:durmonth" id="f-594">6</ix:nonNumeric>-month period. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we entered into a long-term sublease agreement for <ix:nonFraction unitRef="sqft" contextRef="c-112" decimals="INF" name="agio:LesseeOperatingSubleaseAreaOfPremisesSubleased" format="ixt:num-dot-decimal" scale="0" id="f-595">7,407</ix:nonFraction> square feet of office space on the first floor of 64 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through April 2025. At the end of the initial sublease period, the subtenant has the option to extend the lease for <span style="-sec-ix-hidden:f-596">one</span> additional year, followed by a second extension option for <span style="-sec-ix-hidden:f-597">twenty-two</span> additional months. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded operating sublease income of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-598">6.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-599">4.1</ix:nonFraction>&#160;million for the years ended December&#160;31, 2023 and December&#160;31, 2022, respectively, in other income, net in the consolidated statements of operations. We received a security deposit from our sublessee of approximately $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:SecurityDepositLiability" format="ixt:num-dot-decimal" scale="6" id="f-600">1.2</ix:nonFraction>&#160;million which is recorded within other non-current assets on our consolidated balance sheet.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="f-601" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the future minimum lease payments to be received under the long-term sublease agreements were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-602">5,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="3" id="f-603">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="f-604">6,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i62bc41bff6df4446af4f8c46a1b0e260_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="f-605" continuedAt="f-605-1" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-606" escape="true"><ix:continuation id="f-605-1"><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following at December 31:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-607">23,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-608">18,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="agio:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-609">15,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:AccruedResearchAndDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-610">8,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-611">3,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-612">2,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-613">1,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-614">1,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-615">43,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-616">30,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_145"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-617" continuedAt="f-617-1" escape="true">Product Revenue</ix:nonNumeric></span></div><ix:continuation id="f-617-1" continuedAt="f-617-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense PYRUKYND&#174; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-618" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, was as follows for the years ended December 31: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-619">26,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-620">11,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-621">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-622" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize balances and activity in each of the product revenue allowance and reserve categories for the years ended December&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerContractualAdjustmentReserve" scale="3" id="f-623">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerRebateReserve" scale="3" id="f-624">573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductReserve" scale="3" id="f-625">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="f-626">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:CurrentYearProvisionForContractualAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-627">1,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:CurrentYearProvisionsForRebateReserve" format="ixt:num-dot-decimal" scale="3" id="f-628">2,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ProvisionForRightToRecoverProductInCurrentYear" format="ixt:num-dot-decimal" scale="3" id="f-629">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerCurrentYearReserveProvisions" format="ixt:num-dot-decimal" scale="3" id="f-630">5,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:PriorYearProvisionForContractualAdjustments" format="ixt:fixed-zero" scale="3" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="agio:PriorYearProvisionsForRebateReserve" scale="3" id="f-632">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="agio:ProvisionForRightToRecoverProductInPriorYears" scale="3" id="f-633">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="agio:ContractWithCustomerPriorYearsReserveProvisions" scale="3" id="f-634">314</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" scale="3" id="f-635">938</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear" format="ixt:num-dot-decimal" scale="3" id="f-636">1,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" format="ixt:num-dot-decimal" scale="3" id="f-637">1,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerCurrentYearReserveRecoveries" format="ixt:num-dot-decimal" scale="3" id="f-638">3,899</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear" scale="3" id="f-639">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears" scale="3" id="f-640">335</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries" scale="3" id="f-641">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerPriorYearsReserveRecoveries" scale="3" id="f-642">433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="agio:ContractWithCustomerContractualAdjustmentReserve" scale="3" id="f-643">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="agio:ContractWithCustomerRebateReserve" format="ixt:num-dot-decimal" scale="3" id="f-644">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductReserve" scale="3" id="f-645">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" format="ixt:num-dot-decimal" scale="3" id="f-646">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="agio:ContractWithCustomerContractualAdjustmentReserve" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="agio:ContractWithCustomerRebateReserve" format="ixt:fixed-zero" scale="3" id="f-648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductReserve" format="ixt:fixed-zero" scale="3" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" format="ixt:fixed-zero" scale="3" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:CurrentYearProvisionForContractualAdjustments" scale="3" id="f-651">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:CurrentYearProvisionsForRebateReserve" scale="3" id="f-652">912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ProvisionForRightToRecoverProductInCurrentYear" scale="3" id="f-653">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerCurrentYearReserveProvisions" format="ixt:num-dot-decimal" scale="3" id="f-654">1,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:PriorYearProvisionForContractualAdjustments" format="ixt:fixed-zero" scale="3" id="f-655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:PriorYearProvisionsForRebateReserve" format="ixt:fixed-zero" scale="3" id="f-656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ProvisionForRightToRecoverProductInPriorYears" format="ixt:fixed-zero" scale="3" id="f-657">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerPriorYearsReserveProvisions" format="ixt:fixed-zero" scale="3" id="f-658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" scale="3" id="f-659">432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear" scale="3" id="f-660">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" format="ixt:fixed-zero" scale="3" id="f-661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerCurrentYearReserveRecoveries" scale="3" id="f-662">771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear" format="ixt:fixed-zero" scale="3" id="f-663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears" format="ixt:fixed-zero" scale="3" id="f-664">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries" format="ixt:fixed-zero" scale="3" id="f-665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerPriorYearsReserveRecoveries" format="ixt:fixed-zero" scale="3" id="f-666">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerContractualAdjustmentReserve" scale="3" id="f-667">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerRebateReserve" scale="3" id="f-668">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerRightToRecoverProductReserve" scale="3" id="f-669">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="f-670">771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:continuation id="f-617-2" continuedAt="f-617-3"><ix:nonNumeric contextRef="c-1" name="agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" id="f-671" escape="true"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-672">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="3" id="f-673">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Component of accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="agio:ContractWithCustomerAllowanceAndReservesLiability" format="ixt:num-dot-decimal" scale="3" id="f-674">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerAllowanceAndReservesLiability" scale="3" id="f-675">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" format="ixt:num-dot-decimal" scale="3" id="f-676">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:ContractWithCustomerTotalAllowancesAndReserves" scale="3" id="f-677">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" id="f-678" continuedAt="f-678-1" escape="true"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets, which consisted of accounts receivable, net: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:74.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="f-679">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="3" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerAssetRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-681">31,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerAssetRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-682">13,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Deductions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" format="ixt:num-dot-decimal" scale="3" id="f-683">31,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables" format="ixt:num-dot-decimal" scale="3" id="f-684">11,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="f-685">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="3" id="f-686">2,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="f-678-1"><ix:continuation id="f-617-3">(1)  Additions to contract assets relate to amounts billed to Customers for product sales, and deductions to contract assets primarily relate to collection of receivables during the reporting period.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_148"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-687" continuedAt="f-687-1" escape="true">Share-Based Payments </ix:nonNumeric></span></div><ix:continuation id="f-687-1" continuedAt="f-687-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Stock Incentive Plan and Inducement Grants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, our stockholders approved the 2023 Stock Incentive Plan, or the 2023 Plan. The 2023 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based share units, or PSUs, and other stock-based awards to employees, advisors, consultants and non-employee directors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the adoption of the 2023 Plan, we ceased granting equity awards under the 2013 Stock Incentive Plan, or the 2013 Plan. Any outstanding equity awards that were previously granted under the 2013 Plan continue to be governed by their terms. Following adoption of the 2013 Plan, we ceased granting equity awards under the 2007 Stock Incentive Plan, or the 2007 Plan. There are no outstanding equity awards under the 2007 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the start of employment of our Chief Executive Officer and Chief Financial Officer in 2022, and our Chief Commercial Officer in 2023, our board of directors granted each of them equity awards in the form of stock options, RSUs and PSUs, which awards were made outside our equity incentive plans as inducements material to their respective entry into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was <ix:nonFraction unitRef="shares" contextRef="c-114" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-688">12,004,551</ix:nonFraction>, and we had <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-689">4,989,341</ix:nonFraction> shares available for future issuance under the 2023 Plan.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:continuation id="f-687-2" continuedAt="f-687-3"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-690" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity of all stock incentive plans for the year ended December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:49.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value (in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-691">5,772,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-692">48.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-693">6.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-694">5,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-695">886,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-696">25.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-697">235,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-698">12.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-699">1,160,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-700">56.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-701">5,263,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-702">44.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-703">6.36</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-704">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-705">3,344,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-706">53.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-707">5.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="f-708">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-709">5,263,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-710">44.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-711">6.36</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="f-712">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-713">14.32</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-714">15.64</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="0" id="f-715">31.20</ix:nonFraction> during the years ended December&#160;31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-716">2.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-717">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-718">8.5</ix:nonFraction> million during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the total unrecognized compensation expense related to unvested stock option awards was $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-719">27.8</ix:nonFraction> million, which we expect to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="c-116" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-720">2.40</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon vesting, each RSU entitles the holder to receive a specified number of shares of our common stock. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-721" continuedAt="f-721-1" escape="true">The following table presents RSU activity for the year ended December&#160;31, 2023:</ix:nonNumeric></span><ix:continuation id="f-721-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-722">1,117,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-119" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-723">38.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-724">914,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-725">25.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-726">464,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-727">41.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-120" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-728">221,282</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-120" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-729">33.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-730">1,346,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-121" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-731">29.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-732">22.6</ix:nonFraction> million of total unrecognized compensation expense related to RSUs, which we expect to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-120" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-733">1.75</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the achievement of the performance-based and service-based vesting criteria, each PSU entitles the holder to receive a specified number of shares of our common stock. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="f-734" continuedAt="f-734-1" escape="true">The following table presents PSU activity for the year ended December&#160;31, 2023:</ix:nonNumeric></span><ix:continuation id="f-734-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-735">430,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-122" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-736">35.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-737">125,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-738">25.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-739">92,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-740">30.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-741">101,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-742">46.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-743">362,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-744">30.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in unvested shares were <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="agio:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-745">145,023</ix:nonFraction> shares with performance-based vesting criteria that were considered probable of achievement at December&#160;31, 2023 and vested in January 2024. Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#8217;s best estimates. As of December&#160;31, 2023, there was <ix:nonFraction unitRef="usd" contextRef="c-124" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="0" id="f-746">no</ix:nonFraction> unrecognized compensation expense related to PSUs with performance-</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:continuation id="f-687-3" continuedAt="f-687-4"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based vesting criteria that are considered probable of achievement that we expect to recognize. There is $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="agio:ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" format="ixt:num-dot-decimal" scale="6" id="f-747">5.9</ix:nonFraction>&#160;million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market-based stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued certain equity awards that contain market based vesting conditions, in which shares of stock are earned at vesting based on stock price performance. The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="f-748" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents MSU activity for the year ended December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-749">42,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-750">41.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-751">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-752">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-753">42,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-754">41.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was <ix:nonFraction unitRef="usd" contextRef="c-127" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="0" id="f-755">no</ix:nonFraction> remaining unrecognized compensation expense related to MSUs.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional <ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-756">509,091</ix:nonFraction> shares authorized for issuance. We issued <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-757">112,832</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-758">104,867</ix:nonFraction> shares during the years ended December&#160;31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="f-759">2,363,636</ix:nonFraction> shares of our common stock. As of December&#160;31, 2023, we had <ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-760">1,686,039</ix:nonFraction> shares available for future issuance under the 2013 ESPP. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, 2022 and 2021, we recorded stock-based compensation expense for employee and non-employee stock options, RSUs, PSUs, and ESPP shares. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-761" continuedAt="f-761-1" escape="true">Stock-based compensation expense by award type included within the consolidated statements of operations is as follows:</ix:nonNumeric></span></div><ix:continuation id="f-761-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-762">17,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-763">23,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-764">30,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-765">19,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-766">21,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-767">21,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-768">7,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-769">2,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-771">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-772">976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-773">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-774">44,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-775">49,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-776">53,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-777" escape="true"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to equity-based awards were allocated as follows in the consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-778">17,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-779">20,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-780">24,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-781">27,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-782">28,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-783">28,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-784">44,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-785">49,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-786">53,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-787"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-788"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-789">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> related tax benefits were recognized for the years ended December&#160;31, 2023, 2022 and 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:continuation id="f-687-4"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted to employees and non-employees is estimated on the date of grant using the Black-Scholes option-pricing model. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-790" continuedAt="f-790-1" escape="true">The following table summarizes the weighted average assumptions used in calculating the grant date fair value of the awards:</ix:nonNumeric></span></div><ix:continuation id="f-790-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-791">4.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-792">2.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-793">0.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-795">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-796">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-797">5.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-798">6.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-14" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-799">6.05</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-800">54.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-801">55.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-802">61.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expected term</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the &#8220;simplified method&#8221; as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to estimate the expected term of stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-803">ten years</ix:nonNumeric> and the weighted-average vesting term of the stock options, taking into consideration multiple vesting tranches. We utilize this method due to the plain-vanilla nature of our share-based awards. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility has been determined using our historical volatilities for a period equal to the expected term of the option grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk-free rate</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term of the options being valued. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid, and do not anticipate paying, any cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-804">zero</ix:nonFraction> in the option-pricing model. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forfeitures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for forfeitures as they occur and, therefore, do not estimate forfeitures.</span></div></ix:continuation><div id="i62bc41bff6df4446af4f8c46a1b0e260_151"></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-805" continuedAt="f-805-1" escape="true">Net Income (Loss) per Share</ix:nonNumeric></span></div><ix:continuation id="f-805-1" continuedAt="f-805-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net income (loss) per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of December&#160;31, 2023 are not considered to be common stock equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is net loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss from continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income (loss) from discontinued operations per share or net income (loss) per share. Basic and diluted net income (loss) per share was the same for all periods presented.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-806" escape="true"><ix:continuation id="f-805-2"><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-148" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-807">5,263,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-808">5,772,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-150" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-809">4,798,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-151" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-810">1,346,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-152" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-811">1,117,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-153" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-812">1,002,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-154" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-813">145,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-155" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-156" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="f-815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-157" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-816">48,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-817">42,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-159" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-818">39,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-819">6,804,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-820">6,932,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-821">5,841,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i62bc41bff6df4446af4f8c46a1b0e260_154"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-822" continuedAt="f-822-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-822-1" continuedAt="f-822-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-823" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of loss from continuing operations before income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-824">352,085</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-825">231,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-826">356,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-827">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-828">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="f-829">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-830">352,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-831">231,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-832">356,510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any provision for income taxes for the years ended December&#160;31, 2023, 2022 and 2021.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-833" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the expected income tax benefit (expense) computed using the federal statutory income tax rate to our effective income tax rate is as follows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit computed at federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-834">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-835">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-836">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-837">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-838">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-839">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-840">23.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-841">25.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-842">24.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="agio:EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" scale="-2" id="f-843">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="agio:EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" scale="-2" id="f-844">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="agio:EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" scale="-2" id="f-845">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-846">2.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-847">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-848">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-849">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-850">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-851">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:continuation id="f-822-2" continuedAt="f-822-3"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-855" continuedAt="f-855-1" escape="true">Significant components of our deferred tax assets and liabilities for the years ended December&#160;31, 2023 and 2022 are as follows:</ix:nonNumeric></span></div><ix:continuation id="f-855-1"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-856">64,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-857">32,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-858">180,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-859">163,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-860">14,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-861">11,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-862">20,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-863">26,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="agio:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-864">16,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="agio:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-865">21,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible accruals and reserves, including inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" format="ixt:num-dot-decimal" scale="3" id="f-866">5,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" format="ixt:num-dot-decimal" scale="3" id="f-867">3,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 R&amp;D expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-868">93,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-869">56,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-870">395,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-871">316,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-872">1,986</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-873">3,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-874">13,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-875">16,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-876">379,660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-877">295,993</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (TCJA) requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. The Company capitalized research and experimental costs of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="f-880">232.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="6" id="f-881">261.4</ix:nonFraction> million for the years ended December&#160;31, 2023 and December&#160;31, 2022, respectively. We will amortize these costs for tax purposes over <ix:nonNumeric contextRef="c-160" name="agio:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" format="ixt-sec:duryear" id="f-882">5</ix:nonNumeric> years if the research and experimentation was performed in the U.S. and over <ix:nonNumeric contextRef="c-161" name="agio:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" format="ixt-sec:duryear" id="f-883">15</ix:nonNumeric> years if the research and experimentation was performed outside the U.S.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-884">131.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-885">502.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-886">65.2</ix:nonFraction> million, respectively. At December&#160;31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-887">25.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-888">28.1</ix:nonFraction> million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December&#160;31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="f-889">132.9</ix:nonFraction> million. If not utilized, the orphan drug credits begin to expire in 2035.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As provided by Section&#160;382 of the Internal Revenue Code of 1986, or Section&#160;382, and similar state provisions, utilization of NOLs and tax credit carryforwards may be subject to substantial annual limitations due to ownership change limitations that have previously occurred or that could occur in the future. Ownership changes may limit the amount of NOLs and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section&#160;382, results from transactions that increase the ownership of five percent stockholders in the stock of a corporation by more than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="agio:PercentageOfStockholdersOwnershipIncrease" scale="-2" id="f-890">50</ix:nonFraction> percent in the aggregate over a <ix:nonNumeric contextRef="c-1" name="agio:PeriodOfChangeInStockholdersOwnership" format="ixt-sec:durwordsen" id="f-891">three year</ix:nonNumeric> period. We completed a review of our changes in ownership through December&#160;31, 2023 and determined that transactions have resulted in no ownership changes during the year ended December&#160;31, 2023, as defined by Section&#160;382. The impact of the historical ownership changes has been reflected in our deferred tax assets in the table above. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-892">379.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-893">296.0</ix:nonFraction> million as of December&#160;31, 2023 and December&#160;31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-894">83.7</ix:nonFraction>&#160;million for the year ended December&#160;31, 2023 and by $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="f-895">59.5</ix:nonFraction>&#160;million for the year ended December&#160;31, 2022 primarily due to the Section 174 R&amp;D expense capitalization.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:continuation id="f-822-3" continuedAt="f-822-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-896" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our change in valuation allowance for the years ended December&#160;31, 2023 and, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-897">295,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-898">236,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) for the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-899">83,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-900">59,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-901">379,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-902">295,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the unremitted earnings of our foreign subsidiaries are not material. We have not provided for U.S. income taxes or foreign withholding taxes on these earnings as it is our current intention to permanently reinvest these earnings outside the U.S. The tax liability on these earnings is also not material. Events that could trigger a tax liability include, but are not limited to, distributions, reorganizations or restructurings and/or tax law changes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. Our reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by us in our tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-903" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our unrecognized tax benefits activity for the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-904">26,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-905">24,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-906">2,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-907">1,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-908">28,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-909">26,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will recognize interest and penalties related to uncertain tax positions above the line as an expense to continuing operations. As of December&#160;31, 2023 and 2022, we had <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-910"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-911">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized. If all of the Company&#8217;s unrecognized tax benefits as of December&#160;31, 2023 were to become recognizable in the future, we would record $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="f-912">28.6</ix:nonFraction>&#160;million of unrecognized tax benefits. The uncertain tax position does not impact our effective income tax rate due to the full valuation allowance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the United States, Switzerland, Netherlands, Germany, Italy and France. The statute of limitations for assessment by the IRS and state tax authorities is open for tax years ending December&#160;31, 2023, 2022, 2021, and 2020, although carryforward attributes that were generated for tax years prior to 2020 may still be adjusted upon examination by the IRS or state tax authorities if they either have been, or will be, used in a future period. The statute of limitations for assessment in Switzerland remains open for tax years ending December&#160;31, 2023, 2022, 2021, 2020 and 2019. The Company&#8217;s subsidiaries in the Netherlands and Germany were incorporated in 2019 and have statute of limitations for 5 and 4 years, respectively, for assessment. The tax years that remain open in these jurisdictions are for the tax years ending December&#160;31, 2023, 2022, 2021, 2020 and 2019. The Company&#8217;s subsidiaries in Italy and France were incorporated in 2020 and have statute of limitations for 5 and 3 years, respectively, for assessment. The tax years that remain open in these jurisdictions are for the tax years ending December&#160;31, 2023, 2022, 2021 and 2020. There are currently <ix:nonFraction unitRef="audit" contextRef="c-13" decimals="INF" name="agio:NumberOfStatesFederalOrForeignInAuditingProcess" format="ixt:fixed-zero" scale="6" id="f-913"><ix:nonFraction unitRef="audit" contextRef="c-14" decimals="INF" name="agio:NumberOfStatesFederalOrForeignInAuditingProcess" format="ixt:fixed-zero" scale="6" id="f-914"><ix:nonFraction unitRef="audit" contextRef="c-1" decimals="INF" name="agio:NumberOfStatesFederalOrForeignInAuditingProcess" format="ixt:fixed-zero" scale="6" id="f-915">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> federal, state or foreign audits in progress.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-822-4">As of December&#160;31, 2023 and 2022, we had an income tax receivable of $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="f-916">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:IncomeTaxReceivable" format="ixt:num-dot-decimal" scale="6" id="f-917">0.3</ix:nonFraction>&#160;million, respectively, recorded within prepaid expenses and other current assets.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_157"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-918" continuedAt="f-918-1" escape="true">Property and Equipment, net</ix:nonNumeric></span></div><ix:continuation id="f-918-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-919" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following at December 31:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-920">17,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-921">23,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-922">6,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-923">6,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-924">37,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-925">37,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-926">3,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-927">3,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-928">2,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-929">2,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-930">608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-931">657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-932">67,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-933">73,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-934">52,229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-935">50,070</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-936">15,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-937">22,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-938">6.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-939">8.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-940">8.8</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i62bc41bff6df4446af4f8c46a1b0e260_160"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-941" continuedAt="f-941-1" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="f-941-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-942"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-943">125,000,000</ix:nonFraction></ix:nonFraction> shares of our common stock. Holders of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-6" decimals="INF" name="agio:NumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="f-944"><ix:nonFraction unitRef="vote" contextRef="c-5" decimals="INF" name="agio:NumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="f-945">one</ix:nonFraction></ix:nonFraction> vote per share. Additionally, holders of common stock are entitled to receive dividends, if and when declared by our board of directors, and to share ratably in our assets legally available for distribution to our shareholders in the event of liquidation.</span></div></ix:continuation><div id="i62bc41bff6df4446af4f8c46a1b0e260_163"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. <ix:nonNumeric contextRef="c-1" name="us-gaap:TreasuryStockTextBlock" id="f-946" continuedAt="f-946-1" escape="true">Share Repurchase Program</ix:nonNumeric></span></div><ix:continuation id="f-946-1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-947">1.2</ix:nonFraction>&#160;billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-948">7.1</ix:nonFraction>&#160;million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-949">344.5</ix:nonFraction>&#160;million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-180" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:num-dot-decimal" scale="0" id="f-950">48.38</ix:nonFraction> per share. This repurchase was completed on April 5, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-951">600.0</ix:nonFraction>&#160;million of shares of our common stock. As of December&#160;31, 2023, we repurchased approximately <ix:nonFraction unitRef="shares" contextRef="c-182" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-952">9.1</ix:nonFraction>&#160;million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-953">458.0</ix:nonFraction> million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:num-dot-decimal" scale="0" id="f-954">50.35</ix:nonFraction> per share, under the Rule 10b5-1 repurchase plan. In total, as of December&#160;31, 2023, we repurchased <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-955">16.2</ix:nonFraction> million shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-956">802.5</ix:nonFraction> million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-183" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" format="ixt:num-dot-decimal" scale="0" id="f-957">49.49</ix:nonFraction> per share, under the Repurchase Program. <ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-958"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-959">No</ix:nonFraction></ix:nonFraction> common stock was purchased during the years ended December&#160;31, 2023 or December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2021, we terminated our Rule 10b5-1 share repurchase plan and on October 13, 2021, we entered into a Rule 10b-18 repurchase plan that allows us to conduct open market repurchases over time up to our remaining authorization under the Repurchase Program. We have paused our share repurchases for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchased shares are held as treasury stock until they are retired or re-issued. Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Repurchases of our common stock are accounted for as of the settlement date. There were no retirements or re-issuances of treasury stock during the year ended December&#160;31, 2023.</span></div></ix:continuation><div id="i62bc41bff6df4446af4f8c46a1b0e260_166"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-960" continuedAt="f-960-1" escape="true">Discontinued Operations</ix:nonNumeric></span></div><ix:continuation id="f-960-1" continuedAt="f-960-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier. We determined the sale of the oncology business represented a strategic shift that had a major effect on our business and therefore met the criteria for classification as discontinued operations at March 31, 2021. Accordingly, the oncology business was reported as discontinued operations in accordance with ASC 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The results of operations from the oncology business were classified as discontinued operations in the consolidated statements of operations. We recognized a gain on the sale of the oncology business upon closing.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i62bc41bff6df4446af4f8c46a1b0e260_7">Table of Contents</a></span></div></div><ix:continuation id="f-960-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-961" continuedAt="f-961-1" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gain on the sale for the year ended December 31, 2021: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="3" id="f-962">1,802,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: transaction and insurance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="agio:DiscontinuedOperationsTransactionAndInsuranceCosts" format="ixt:num-dot-decimal" scale="3" id="f-963">53,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: net liabilities distributed, including working capital adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="agio:DiscontinuedOperationsLiabilitiesDistributedNet" format="ixt:num-dot-decimal" scale="3" id="f-964">239,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale, pre-tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-965">1,989,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-966">12,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-967">Gain on sale, net of tax</span></span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-968">1,976,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and December 31, 2022, there were <ix:nonFraction unitRef="usd" contextRef="c-187" decimals="INF" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-969"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="INF" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-970"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="INF" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-971"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="INF" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:fixed-zero" scale="0" id="f-972">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> assets or liabilities classified as discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-961-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the financial results of the discontinued operations: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-973">36,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-974">1,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="f-975">491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-976">2,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-977">41,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="f-978">706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="agio:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-979">41,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-980">8,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-981">50,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-982">9,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense for the sale of future revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="agio:DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue" format="ixt:num-dot-decimal" scale="3" id="f-983">5,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on the sale of the oncology business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-984">1,989,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, pre-tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-985">1,974,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-986">12,799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-987">1,961,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 205-20, only expenses specifically identifiable and related to a business to be disposed may be presented in discontinued operations. As such, the research and development, marketing, selling and general and administrative expenses in discontinued operations include corporate costs incurred directly to solely support our oncology business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also entered into a Transition Services Agreement with Servier, through which we provided transitional services related to discovery, clinical development, technical operations, commercial and general and administrative related activities through March 31, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The milestone payment for approval of vorasidenib and royalty payments related to vorasidenib and TIBSOVO&#174; represent contingent consideration. Contingent consideration has been accounted for as a gain contingency in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and will be recognized in earnings in the period when realizable. As described in <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124">Note 1, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none" href="#i62bc41bff6df4446af4f8c46a1b0e260_124">Nature of Business</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on October 27, 2022, we sold our rights to future contingent payments related to TIBSOVO&#174; royalties to entities affiliated with Sagard and recognized income of $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="agio:GainLossOnSaleOfContingentPayments" format="ixt:num-dot-decimal" scale="6" id="f-988">127.9</ix:nonFraction>&#160;million within the gain on sale of contingent payments line item in our consolidated statements of operations for the year ended December 31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><div id="i62bc41bff6df4446af4f8c46a1b0e260_169"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-989" continuedAt="f-989-1" escape="true">Commitments and Contingent Liabilities </ix:nonNumeric></span></div><ix:continuation id="f-989-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Commitments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to various agreements with contract manufacturing organizations that we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Under such agreements, we are obligated to make certain minimum payments, with the exact amounts in the event of termination to be based on the timing of the termination and the exact terms of the agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes and legal proceedings in the ordinary course of business. These proceedings may include allegations of infringement of intellectual property, employment or other matters. We do <ix:nonFraction unitRef="lawsuit" contextRef="c-5" decimals="INF" name="agio:NumberOfLegalProceedingsThatHaveMaterialEffect" format="ixt:fixed-zero" scale="0" id="f-990">no</ix:nonFraction>t have any ongoing legal proceedings that, based on our estimates, could have a material effect on our consolidated financial statements.</span></div></ix:continuation><div id="i62bc41bff6df4446af4f8c46a1b0e260_172"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-991" continuedAt="f-991-1" escape="true">Defined Contribution Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="f-991-1"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a 401(k) retirement plan, in which substantially all of our full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. We will make matching contributions equal to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-992">100</ix:nonFraction>% of the employee&#8217;s contributions, subject to a maximum of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-993">4</ix:nonFraction>% of eligible compensation.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>2
<FILENAME>exhibit-1021x123123.htm
<DESCRIPTION>EX-10.21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9404c0ed81b14c3cab2a0147b4343aff_40"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ex. 10.21</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">SUBLEASE AGREEMENT</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;THIS SUBLEASE AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is made as of the 14th day of April,&#160;2023, by and between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agios Pharmaceuticals, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Sublandlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Watershed Informatics, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subtenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RECITALS&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BRE-BMR 64 SIDNEY LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), successor in interest to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Up 64 Sidney Street, LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, a Delaware limited liability company,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as landlord, and Sublandlord, as tenant, are parties to the Lease dated November 17, 2017 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Original Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as amended by the First Amendment of Lease dated April 11, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">First Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), as further amended by the Second Amendment to Lease dated as of December 14, 2018 (the&#160;&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Second Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and as further amended by the Third Amendment to Lease dated as of April 11, 2019 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Third Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, and collectively with the Original Lease, the First Amendment and the Second Amendment, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Prime Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), pursuant to which Landlord leased to Sublandlord certain premises including approximately </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7,407</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> rentable square feet of office space (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subleased</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) on the first (1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) floor of the building more commonly known as 64 Sidney Street, Cambridge, Massachusetts (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Building</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and as further described on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> attached hereto. A redacted copy of the Prime Lease is attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and is incorporated herein by reference&#59; and </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Sublandlord desires to sublease to Subtenant and Subtenant desires to sublease from Sublandlord the Subleased Premises in accordance with the provisions of this Sublease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW THEREFORE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the premises, the rents, and the mutual covenants herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Sublease of Subleased Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Sublandlord does hereby sublease to Subtenant, and Subtenant does hereby sublease from Sublandlord, for the Term (as hereinafter defined) and upon the conditions hereafter provided, the Subleased Premises.  The Subleased Premises being sublet to Subtenant by Sublandlord under this Sublease are part of the premises being leased by Sublandlord from Landlord under the Prime Lease.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;The Term of this Sublease shall commence on the later of, (i) the date of full execution of this Sublease and receipt of Landlord&#8217;s written consent to this Sublease as provided in Section 27 herein, and (ii) Sublandlord&#8217;s delivery to Subtenant of exclusive possession of the Subleased Premises in the condition required herein (such later date, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and shall expire, absolutely and without the need for notice from either party to the other, on that date which is two (2) years after the Commencement Date, unless the Commencement Date does not occur on the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> calendar day of a calendar month, in which case the Term shall end on the date which is two (2) years following the last day of the calendar month in which the Commencement Date occurs (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), unless otherwise terminated as hereinafter provided. Subtenant shall have early access to the Subleased Premises commencing on the date that is thirty (30) days prior to the Target Date, free of charge, for the purpose of setting up and installing its furniture, fixtures and equipment in the Subleased Premises.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;The parties have targeted May 1, 2023</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Target Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as the anticipated Commencement Date.  In the event the Commencement Date has not occurred by the date (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Outside Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that is thirty (30) days after the Target Date, then at any time thereafter so long as the Commencement Date has not occurred, Subtenant and Sublandlord shall each have the right to terminate this Sublease by written notice, in which event this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sublease shall thereupon terminate and Sublandlord shall refund to Subtenant any rent paid in advance hereunder together with Subtenant&#8217;s security deposit, unless Landlord&#8217;s consent shall have been obtained within ten (10) days after receipt of notice of termination, in which case this Sublease shall not terminate.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;Beginning on the Commencement Date (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Rent Commencement Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Subtenant shall pay to Sublandlord, in lawful money of the United States, base annual rent (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Base Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) during the first year of the Term in the amount of Six Hundred Seven Thousand Three Hundred Seventy Four and 00&#47;100 Dollars ($607,374.00), payable in equal monthly installments of Fifty Thousand Six Hundred Fourteen and 50&#47;100 ($50,614.50) which are payable on or before the first (1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) day of each calendar month during the Term, without notice or demand and without abatement, set-off or deduction (except that Subtenant shall pay the first monthly installment on the execution hereof), which Base Rent shall be adjusted on each anniversary of the Commencement Date (unless the Commencement Date is other than the first day of a month, in which event the Base Rent shall be adjusted on the anniversary of the first day of the calendar month following the Commencement Date) as follows&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Annual Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Base Monthly Rent</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Year 1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$ 607,374.00&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$ 50,614.50</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Year 2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$ 625,595.22&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;$ 52,132.94</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Subtenant shall also pay any and all charges, fees or expenses payable under the Prime Lease that are attributable or arises out of the Subtenant&#8217;s use or occupancy of the Subleased Premises as follows&#58; (i) Subtenant&#8217;s Proportionate Share (as hereinafter defined) of the increase in Real Estate Taxes (as such term is defined in Section 3.2(d) of the Prime Lease) incurred with respect to the current year over and above the amount of Real Estate Taxes incurred with respect to the Base Year (as hereinafter defined)&#59; (ii) Subtenant&#8217;s Proportionate Share of the increase in Operating Expenses (as such term is defined in Section 3.3(b) of the Prime Lease) incurred with respect to the current year over and above the amount of Operating Expenses incurred with respect to the Base Year&#59; (iii) any additional rent payable on account of Subtenant&#8217;s use of excess heating, ventilation and air conditioning and electricity, but in no event shall Subtenant use more electricity in the Subleased Premises than that which the feeders, risers, panels and other electricity supply equipment serving the Subleased Premises are capable of safely supplying&#59; (iv) amounts payable to Landlord or Sublandlord for separately sub-metered utilities and services pursuant to Section 3.4 of the Prime Lease&#59; and (v) any additional rent payable on account of any services provided by Landlord or Sublandlord to Subtenant or otherwise attributable to or arising out of the use or occupancy of the Subleased Premises (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Additional Rent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Subtenant agrees to pay the Additional Rent within thirty (30) days of invoice therefor. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subtenant&#8217;s Proportionate Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean forty-seven and 29&#47;100 (47.29%) percent of the Operating Expenses and Real Estate Taxes related to the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> floor portion of Sublandlord&#8217;s Premises, which is calculated by dividing the square footage of the Subleased Premises (7,407 sq. ft.) by the square footage of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> floor portion of Sublandlord&#8217;s Premises (15,663 sq. ft.) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Base Year</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean calendar year 2023 with respect to Operating Expenses, and fiscal year 2024 with respect to Real Estate Taxes.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.&#160;&#160;&#160;&#160;Sublandlord shall provide to Subtenant copies of any Operating Expenses budget for the Building, Premises and Subleased Premises that Sublandlord receives from Landlord within thirty (30) days of receipt.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Payments by the Subtenant for Subtenant&#8217;s Proportionate Share of the Operating Expenses and Real Estate Taxes for the Subleased Premises shall be made in monthly installments of one-twelfth (1&#47;12</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) of Subtenant&#8217;s Proportionate Share of the Operating Expenses and Real Estate Taxes as further described in Article 3 of the Prime Lease.  The amount so to be paid to the Sublandlord shall be an amount from time to time reasonably estimated by the Sublandlord to be sufficient to aggregate a sum equal to the Subtenant&#8217;s Proportionate Share of the Operating Expenses and Real Estate Taxes for the Subleased Premises for each calendar year.  Following the end of each calendar year, as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">soon as practically possible after receipt of a statement from Landlord in accordance with Article 3 of the Prime Lease, Sublandlord shall provide a statement to Subtenant for the previous calendar year.  If at the time such statement is rendered it is determined with respect to the previous calendar year, that the Subtenant has paid (i) less than the Subtenant&#8217;s Proportionate Share of the Operating Expenses and Real Estate Taxes, or (ii) more than the Subtenant&#8217;s Proportionate Share of the Operating Expenses and Real Estate Taxes, then, in the case of (i), the Subtenant shall pay to the Landlord, as Additional Rent, within thirty (30) days of such statement the amounts of such underpayment or, in the case of (ii), the Sublandlord shall credit the amount of such overpayment against the monthly installments of the Subtenant&#8217;s Proportionate Share of the Operating Expenses and Real Estate Taxes next thereafter coming due (or refund such overpayment within thirty (30) days if the Term has expired and the Subtenant has no further obligation to the Sublandlord). </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.&#160;&#160;&#160;&#160;During the Term, the Subtenant shall pay directly to the provider charges for all separately metered utilities serving the Subleased Premises (if any), and shall pay to Sublandlord as Additional Rent Subtenant&#8217;s Proportionate Share of water, sewer and other services and utilities.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary above, Subtenant shall reimburse Sublandlord for Subtenant&#8217;s Proportionate Share of any janitorial costs related to the Subleased Premises.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Extension Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  On the conditions (which conditions Sublandlord may waive in its sole discretion by notice to Tenant) that, both at the time Subtenant exercises an Extension Option (as defined below) or at any time thereafter until the commencement of the corresponding Extension Term (as defined below), (i) there exists no event of default (beyond applicable notice and cure periods) hereunder, both (1) as of the date of the Extension Notice (hereinafter defined), and (2) at the commencement of the applicable Extension Term (hereinafter defined), and (ii) this Sublease is still in full force and effect and Subtenant is in actual occupancy of the entire Subleased Premises and has not assigned its interest in this Sublease nor sublet more than thirty percent (30%) of the Subleased Premises to anyone other than an affiliated entity and&#47;or a successor of Subtenant, Subtenant may extend the term of the Sublease for one (1) initial extension term of one (1) year (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Extension Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), followed by one (1) additional extension term through the expiration of the Prime Lease, which date is February 28, 2028 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Second Extension Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, and collectively with the Initial Extension Option, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Extension Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), by delivering written notice of its exercise of the Extension Option no later than nine (9) months prior to the expiration of the applicable Term (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Extension Notice</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). The initial extension term along with the second extension term shall be collectively referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Extension Term</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;. The Base Rent for each year of such Extension Term shall continue to increase by three (3%) annually (on each anniversary of the Commencement Date) through the Extension Term.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Condition of Subleased Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Sublandlord shall deliver the Subleased Premises to Subtenant in its &#8220;as is, where is&#8221; broom-clean condition and &#8220;with all faults&#8221; provided that the Subleased Premises shall be demised and with all required base building systems, including, but not limited to, HVAC, electrical, life safety and plumbing systems in good working condition. Sublandlord shall be responsible for maintaining all base building systems, including, but not limited to, HVAC, electrical, life safety and plumbing systems. Subtenant&#8217;s taking possession of the Subleased Premises shall be conclusive evidence as against Subtenant that the Subleased Premises were in good order and satisfactory condition when Subtenant took possession.  No promise of Sublandlord to alter, remodel or improve the Subleased Premises and no representation respecting the condition of the Subleased Premises or the Building have been made to Subtenant.  Additionally, throughout the Term, Subtenant shall have the right to use, free of charge, the existing office furniture and IT and audiovisual equipment, as well as monitors and wiring and cabling in the Subleased Premises&#59; such existing furniture is listed herein in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subtenant shall have no obligations for the removal of the existing furniture and equipment at the end of the Term. Subtenant shall have the right to remove furniture and IT </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and audiovisual equipment during the Term but shall be obligated to replace such furniture and IT and audiovisual equipment that has been removed at the end of the Term.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Use</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subtenant will use and occupy the Subleased Premises solely for general business and administrative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">offices and customary accessory uses supporting the foregoing. Subtenant has inspected the Subleased Premises and will accept the Subleased Premises in its condition existing on the date Subtenant takes occupancy of the Subleased Premises.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Security Deposit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Simultaneously with the execution of this Sublease by Subtenant, Subtenant shall deliver to Sublandlord, and that Sublandlord shall hold the same throughout the Term of this Sublease as security for the performance by Subtenant of all obligations on the part of Subtenant hereunder, a security deposit in the amount of $101,229.00.  Sublandlord shall have the right from time to time, without prejudice to any other remedy Sublandlord may have on account thereof, to apply such deposit, or any part thereof, to Sublandlord damages arising from, or to cure, any default by Subtenant.  If Sublandlord shall so apply any or all of such deposit, Subtenant shall immediately upon demand deposit with Sublandlord the amount so applied to be held as security hereunder.  Sublandlord shall return the deposit, or so much thereof as shall not have theretofore been applied in accordance with the terms of this Section 7, to Subtenant on the expiration or earlier termination of the Term of this Sublease and surrender of possession of the Subleased Premises by Subtenant to Sublandlord at such time, provided that there is then existing no default of Subtenant (nor any circumstance which, with the passage of time or the giving of notice, or both, would constitute a default of Subtenant). While Sublandlord holds such deposit, Sublandlord shall have no obligation to pay interest on the same and shall have the right to commingle the same with Sublandlord&#8217;s other funds.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Default Under and&#47;or Termination of the Prime Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;If for any reason the term of the Prime Lease is terminated prior to the anticipated expiration date of this Sublease, this Sublease shall thereupon terminate without further notice and without further obligation or liability on the part of the parties&#59; provided, however, that if the Prime Lease terminates as a result of a default or breach by Sublandlord or Subtenant under this Sublease and&#47;or the Prime Lease, then the defaulting party shall be liable to the non-defaulting party for the actual and direct damage (specifically excluding consequential, punitive and other similar damages) suffered as a result of such termination or forfeiture, except that Sublandlord shall not be so liable to Subtenant for a default or breach by Sublandlord under the Prime Lease resulting from any act or omission of Subtenant, and Sublandlord shall return to Subtenant the security deposit as well as rent paid in advance by Subtenant, if any, prorated as of the date of the termination of the Prime Lease.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;From and after the date of any default by Sublandlord resulting in a termination, reentry or dispossession under the Prime Lease, until the date that this Sublease is terminated in accordance with this Section 8, Subtenant shall pay all Base Rent, Additional Rent and any other sums due by Subtenant under the Sublease directly to Landlord and Subtenant shall continue to perform all of its obligations hereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt;text-decoration:underline">Notice of Default</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Sublandlord hereby agrees to provide to Subtenant, within five (5) business days after receipt thereof, a copy of any notice of default under the Prime Lease which Sublandlord receives from Landlord.  Subtenant shall have the option, but not the obligation, of curing any monetary default which is not being contested by Sublandlord by forwarding to Sublandlord sufficient funds to cure such default.  Sublandlord hereby agrees to immediately remit such sums to Landlord.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Subordination to and Incorporation of Terms of Prime Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;This Sublease is in all respects subject and subordinate to any mortgage, deed, deed of trust, ground lease or other instrument now or hereafter encumbering the Building or the land on which it is located, to the terms and conditions of the Prime Lease and to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">matters to which the Prime Lease, including any amendments thereto, is or shall be subordinate.  The terms, provisions, covenants, stipulations, conditions, rights, obligations, remedies and agreements of the Prime Lease are incorporated into this Sublease by reference and made a part hereof as if herein set forth at length, and shall, as between Sublandlord and Subtenant (as if they were the landlord and the tenant, respectively, under the Prime Lease and as if the Subleased Premises were the Premises demised under the Prime Lease), constitute the terms of this Sublease, except to the extent that they do not relate to the Subleased Premises or are inapplicable to, or modified or eliminated by, the terms of this Sublease.  Sublandlord and Subtenant each agree to observe and be bound by each and every covenant, condition and provision of the Prime Lease insofar as any such covenant, condition or provision affects the Subleased Premises or Subtenant&#8217;s use thereof.  Notwithstanding the foregoing, or anything else to the contrary herein, the following provisions of the Prime Lease shall not be incorporated herein by reference and are expressly excluded from the terms of this Sublease&#58; Sections 2.3, 2.4, 2.5, 2.6, 2.7, 4.5, 12.8, 12.10, 12.13, 12.14 and 12.15 and Exhibits A and I of the Original Lease, the First Amendment, the Second Amendment and the Third Amendment&#59; provided, however, that notwithstanding such non-incorporation, this Sublease remains subject and subordinate to all of the foregoing provisions as provided above. Subtenant acknowledges that it has reviewed and is familiar with the Prime Lease (as redacted). In confirmation of the subordination provided for in this paragraph, Subtenant shall, at Sublandlord&#8217;s reasonable request, promptly execute any reasonably requested or appropriate certificate or other document in commercially reasonable form.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;To the extent that Sublandlord is entitled under the Prime Lease to any abatement of rent as a result of damage or casualty to the Subleased Premises, then Subtenant shall have the right to a corresponding abatement of rent hereunder.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;c.&#160;&#160;&#160;&#160; Subtenant hereby assumes and agrees to perform faithfully and be bound by, with respect to the Subleased Premises, all of Sublandlord&#8217;s obligations, covenants, agreements and liabilities under the Prime Lease and all terms, conditions, provisions and restrictions contained in the Prime Lease except the following provisions of the Prime Lease&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:62.24pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)Section 2.6 &#8211; Extension Options&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:59.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)Section 2.7 &#8211; Right of First Offer&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:57.36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)Section 3.1 &#8211; Annual Fixed Rent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The reference in this Sublease to any particular section or article of the Prime Lease shall not in any way be deemed or construed to derogate from the general incorporation by reference of the entire Prime Lease (except as aforesaid) into this Sublease.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;d.&#160;&#160;&#160;&#160;Neither Sublandlord nor Subtenant shall do anything which could result in a default under the Prime Lease or permit the Prime Lease to be cancelled or terminated.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;e.&#160;&#160;&#160;&#160;It is expressly understood and agreed that Sublandlord does not assume and shall not have any of the obligations or liabilities of Landlord under the Prime Lease and that Sublandlord is not making the representations or warranties, if any, made by Landlord in the Prime Lease.  With respect to work, services, repairs and restoration or the performance of other obligations required of Landlord under the Prime Lease, Sublandlord&#8217;s sole obligation with respect thereto shall be to request the same, upon written request from Subtenant, and to use reasonable efforts to obtain the same from Landlord, which efforts shall not require initiating any litigation.  Sublandlord shall not be liable in damages, nor shall rent abate hereunder, for or on account of any failure by Landlord to perform the obligations and duties imposed on it under the Prime Lease.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;f.&#160;&#160;&#160;&#160;Whenever Subtenant desires to do any act or thing that requires the consent or approval of the Landlord pursuant to the Prime Lease, (i) Subtenant shall not do such act or thing without first having obtained the consent or approval of both Landlord and Sublandlord (and Sublandlord&#8217;s right to withhold consent or approval shall be independent of Landlord&#8217;s right), which consent of Sublandlord shall not be unreasonably withheld, conditioned </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or delayed, and (ii) in no event shall Sublandlord be required to give its consent or approval prior to Landlord doing so, unless required by Landlord.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Signage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Sublandlord, at its sole cost and expense, shall request that Landlord provide to Subtenant Building standard signage on all tenant directories at the Building as well as at the entrance to the Subleased Premises. All signage to be installed at the Subleased Premises shall be subject to the approval of Landlord and subject to the terms of the Prime Lease. Subtenant shall not have any right to exterior Building signage.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Building Rules and Regulations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subtenant shall comply with all rules and regulations of the Building.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Alterations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary contained in the Prime Lease, Subtenant shall not make any improvements, alterations or changes to the Subleased Premises whatsoever, including without limitation, structural or non-structural changes, without the prior written consent of Sublandlord (which consent of Sublandlord shall not be unreasonably withheld, conditioned or delayed) and Landlord and in accordance with the terms of the Prime Lease.  Subtenant will not suffer or permit to attach nor will it do any act or make any contract that may create the foundation of any mechanic&#8217;s or other lien for work, labor, services or materials, or otherwise, and whenever any such lien shall be filed or shall attach Subtenant will, within ten (10) days thereafter, secure a cancellation thereof by paying the same or in such other manner prescribed by law.  Notwithstanding anything to the contrary herein, Subtenant shall have access to the existing tel&#47;data closet and card reader systems located within the Subleased Premises for the purpose of installing, maintaining and&#47;or repairing its own phone, IT, security and alarm systems at Subtenant&#8217;s sole expense, subject to written consent of Sublandlord (which consent of Sublandlord shall not be unreasonably withheld, conditioned or delayed) and Landlord and in accordance with the terms of the Prime Lease.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subtenant shall maintain insurance of the kinds and in the amounts required to be maintained by Sublandlord under the Prime Lease and in accordance with all other requirements therein.  All policies of liability insurance shall name as additional insureds the Landlord and Sublandlord and their respective officers, directors or partners, as the case may be, and the respective agents and employees of each of them.  Subtenant shall deliver certificates evidencing such insurance with delivery of the first month&#8217;s rent.  Before taking occupancy of the Subleased Premises, Subtenant shall provide Sublandlord with proof of such insurance.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Assignment and Further Sublease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Provided that both on the date on which Subtenant notifies Sublandlord of its desire to enter into an assignment and on the date on which such assignment is to take effect, Subtenant is not in default (beyond applicable notice and cure periods) of any of its obligations hereunder, during the term of the Sublease, Subtenant shall have the right to sub-sublease all or portion of the Subleased Premises subject to (i) Sublandlord&#8217;s written consent, which shall not be unreasonably withheld or delayed, (ii) Landlord&#8217;s written consent, which shall be subject to and in accordance with the Prime Lease (including the right to terminate the Lease, and, accordingly the Sublease), and (iii) payment of any fee which is required in accordance with the Prime Lease.  Subtenant will remain liable for all obligations under the Sublease.  Assignment rights shall be pursuant the Prime Lease.  Subtenant shall provide such financial and other information regarding the proposed assignee as reasonably requested by Sublandlord and&#47;or Landlord in accordance with the Prime Lease.  In the event that Sublandlord and Landlord consent to any assignment or sublease of the Subleased Premises, as a condition of such consent, Subtenant shall pay to Sublandlord fifty percent (50%) of any rent, sum or other consideration to be paid or given for such assignment or sublet (after first deducting Subtenant&#8217;s reasonable actual costs to sub sublet the Subleased Premises), either initially or over time, in excess of Base Rent and Additional Rent hereunder, as if such amount were originally called for by the terms of this Sublease as Additional Rent. Subtenant shall furnish Sublandlord with a sworn statement, certified by an officer of Subtenant, setting forth in detail the computation of any such excess rent (which computation shall be based upon generally accepted accounting principles, including an amortization of Subtenant&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">actual costs in such assignment or sublease (e.g., the cost of commissions, improvement allowance and any other reasonable actual out-of-pocket transaction cost)), and Sublandlord, or its representatives, shall have access to the books, records and papers of Subtenant in relation thereto, and to make copies thereof.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Access</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subtenant shall be afforded access to the Subleased Premises 24 hours a day, 7 days a week, and 365 days a year, and on all dates and at all times permitted by applicable government rules and regulations, and in accordance with the terms of the Prime Lease, excluding emergency events, which may cause the Building to limit access to tenants.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Surrender</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon expiration of the Term or other termination of this Sublease, Subtenant shall quit and surrender to Sublandlord the Subleased Premises and remove all of its furniture, furnishings, personal property and equipment in order to leave the Subleased Premises, broom clean and in as good order, repair and condition as they were on the date the Term of this Sublease commenced, ordinary wear and tear excepted.  The obligations of Subtenant to perform this covenant shall survive the expiration or other termination of this Sublease. Notwithstanding anything in the Prime Lease or this Sublease to the contrary&#58; (i)&#160;Subtenant shall not be responsible for the cost or performance of the removal of any alterations, additions or improvements in the Subleased Premises performed or installed by prior to the Commencement Date hereof (collectively, &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pre-Existing Improvements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Any removal of or restoration work related to the Pre-Existing Improvements shall be performed after the expiration of the Term of this Sublease.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Default&#59; Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a.&#160;&#160;&#160;&#160;Sublandlord reserves the right to terminate this Sublease and Subtenant&#8217;s occupancy of the Subleased Premises in the event that (i) Subtenant fails to make any Base Rent payment, Additional Rent or any other monetary amount due under this Sublease on or before the date on which the same become due and payable, if such condition continues for five (5) business days after written notice that the same are due&#59; provided, however if Subtenant shall fail to pay any of the foregoing (after receipt by Subtenant of written notice from Sublandlord) when due two (2) times in any period of twelve (12) consecutive months, then Sublandlord shall not be required to give notice to Subtenant of any future failure to pay during the remainder of the Term and any extension thereof, and such failure shall thereafter constitute an Event of Default if not cured within five (5) business days after the same are due, or (ii)&#160;Subtenant fails to observe and perform any of its obligations under this Sublease within twenty (20) days after written notice thereof from Sublandlord, except to the extent such default cannot be cured within said twenty (20) day period, in which event Subtenant shall have such additional time as may be necessary to cure such default so long as Subtenant has commenced cure within such twenty (20) day period and is diligently and continuously pursuing the remedies necessary to cure such default within thirty (30) days after notice thereof.  The acceptance of any late payments of Base Rent shall not be deemed a waiver of Sublandlord&#8217;s rights under this section.  In the event it becomes necessary for Sublandlord or Subtenant to enforce its rights against the other party hereunder by legal action the non-prevailing party shall pay all of the prevailing party&#8217;s reasonable legal costs and expenses in connection therewith including reasonable legal fees.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;b.&#160;&#160;&#160;&#160;In case of any such termination, Subtenant shall pay to and indemnify Sublandlord each month against all loss of rent and all costs, expenses, or obligations which Sublandlord may incur by reason of any such termination between the time of termination and the end of the Term, or, at such election of Sublandlord, exercised at the time of the termination or at any time thereafter, Subtenant shall pay to Sublandlord as damages, in a lump sum, the then present value of the aggregate amount of rent and other payments provided herein to be paid by Subtenant to Sublandlord through the time when the Term of this Sublease would have expired but for the default by Subtenant.  It is understood and agreed that at the time of the termination or at any time thereafter that Subtenant shall be liable for any expenses incurred by Sublandlord in connection with obtaining possession of the Subleased Premises, with removing from the Subleased Premises property of Subtenant and persons claiming under Subtenant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(including warehouse charges), with putting the Subleased Premises into condition for delivery to Landlord or reletting and with any reletting, including without limitation, attorneys&#8217; fees and brokers&#8217; fees, and that any monies collected from any reletting shall be applied first to the foregoing expenses and then to the payment of rent and all other payments due from Subtenant to Sublandlord.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subtenant shall indemnify and hold harmless Sublandlord from and against any and all losses, claims, damages, liabilities, actions, costs and expenses (including reasonable attorneys&#8217; fees) incurred by Sublandlord arising out of or related to this Sublease or Subtenant&#8217;s use and occupancy of the Subleased Premises, provided that the foregoing indemnity shall not include any cost or damage arising from any act, omission or negligence of the Sublandlord, or the Sublandlord&#8217;s contractors, licensees, invitees, agents, servants or employees.  This indemnification shall survive termination of this Sublease.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any notice required or permitted to be given hereunder shall be in writing and may be given by certified mail, return receipt requested, personal delivery, Federal Express or other delivery service.  If notice is given by certified mail, return receipt requested, notice shall be deemed given three (3) days after the notice is deposited with the U.S. Mail, postage prepaid, addressed to Subtenant or to Sublandlord at the address set forth below.  If notice is given by personal delivery, Federal Express or other delivery service, notice shall be deemed given on the date the notice is actually received by Sublandlord or Subtenant.  Either party may by notice to the other specify a different address for notice purposes.  </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If to Sublandlord&#58;&#160;&#160;&#160;&#160;Agios Pharmaceuticals, Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;88 Sidney Street</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cambridge, MA 02139</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attn&#58; James Burns&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;With a copy to&#58;&#160;&#160;&#160;&#160;Eckert, Seamans, Cherin &#38; Mellott, LLC</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Two International Place, 16</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Floor</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Boston, MA  02110</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attn&#58; Stuart A. Offner, Esq.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-right:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;If to Subtenant&#58;&#160;&#160;&#160;&#160;Watershed Informatics, Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;1 Broadway, 14</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Floor</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Cambridge, MA 02142&#93;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attn&#58; Jonathan Wang, CEO</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;With a copy to&#58;&#160;&#160;&#160;&#160;Langer &#38; McLaughlin, LLP</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;535 Boylston Street, 3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> Floor</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Boston, MA  02116</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Attn&#58; Watershed Informatics Matters&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If Sublandlord receives any notice from Landlord which affects Subtenant or the Subleased Premises, Sublandlord shall provide Subtenant with a copy thereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Hold Over</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Subtenant holds over after the expiration of the Term or earlier termination thereof, such tenancy shall be a tenancy at sufferance, and shall not constitute a renewal hereof or an extension for any further term, and in such case Base Rent shall be payable at a monthly rate equal to 150% of Base Rent and Additional Rent applicable during the last rental period of the Term for the first two (2) months following the expiration of the Term, then at a monthly rate equal to 200% of Base Rent and Additional Rent applicable during the last rental period of the Term during any further hold over period beyond two (2) months.  Such tenancy shall be subject to every other applicable term, covenant and agreement contained herein.  Nothing contained in this paragraph shall be construed as consent by Sublandlord to any holding over by Subtenant, and Sublandlord expressly reserves the right to require Subtenant to surrender possession of the Subleased Premises to Landlord as provided in the Sublease and Prime Lease upon the expiration or other termination of this Sublease.  If </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subtenant holds over without Sublandlord&#8217;s express written consent, and tenders payment of rent for any period beyond the expiration of the Term by way of check (whether directly to Sublandlord, its agents, or to a lock box) or wire transfer, Subtenant acknowledges and agrees that the cashing of such check or acceptance of such wire shall be considered inadvertent and not be construed as creating a month-to-month tenancy.  The provisions of this paragraph shall not be deemed to limit or constitute a waiver of any other rights or remedies of Sublandlord provided herein or at law.  If Subtenant fails to surrender the Subleased Premises upon the termination or expiration of this Sublease, in addition to any other liabilities to Sublandlord accruing therefrom, Subtenant shall protect, defend, indemnify and hold Sublandlord harmless from all loss, costs (including reasonable attorneys&#8217; fees) and liability resulting from such failure, including, without limiting the generality of the foregoing, any claims made by Landlord or any succeeding tenant founded upon such failure to surrender and any lost profits to Sublandlord resulting therefrom. </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Brokerage Commissions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party hereby represents and warrants to the other that it has had no dealings with any real estate broker or agent in connection with this Sublease, excepting only CBRE, which shall be paid in accordance with an existing agreement with Sublandlord, and that it knows of no other real estate broker or agent who is or might be entitled to a commission in connection with this Sublease.  Each party agrees to protect, defend, indemnify and hold the other harmless from and against any and all claims inconsistent with the foregoing representations and warranties for any brokerage, finder&#8217;s or similar fee or commission in connection with this Sublease, if such claims are based on or relate to any act of the indemnifying party which is contrary to the foregoing representations and warranties.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  THE PARTIES HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING INVOLVING THE SUBLEASED PREMISES, BUILDING OR ARISING OUT OF THIS SUBLEASE OR THE PRIME LEASE.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Modification</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Sublease may only be modified by written agreement signed by Sublandlord and Subtenant.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Sublease may be executed in counterparts, each of which shall be an original and all of which, when assembled, shall constitute but one document.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The terms and provisions of this Sublease shall be governed by the laws of the Commonwealth of Massachusetts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  It is expressly understood and agreed that this Sublease, and the parties&#8217; rights and obligations hereunder, are contingent upon the Landlord&#8217;s written consent of this Sublease, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Landlord&#8217;s consent shall not have been obtained within thirty (30) days after the date of this Sublease, Sublandlord and Subtenant shall each have the right to terminate this Sublease as set forth in Section 2(b) above.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Subtenant Improvements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.&#160;&#160;&#160;&#160;Subtenant shall have the right to hire a mutually approved architect, construction manager and project manager for any construction relative to the Subleased Premises (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Subtenant Improvements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Prior to the performance of any of the Subtenant Improvements, Subtenant shall submit to Sublandlord and Landlord for Sublandlord&#8217;s and Landlord&#8217;s prior written approval, not to be unreasonably withheld or delayed, Subtenant&#8217;s plans and specifications for the Subtenant Improvements on the Subleased Premises.  Subtenant may commence its work only after&#58; (a) receipt of Sublandlord&#8217;s and Landlord&#8217;s approval to perform the same&#59; (b) Subtenant&#8217;s receipt of any and all required licenses, permits and approvals from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any local authority or any other governmental agency or authority&#59; and (c) delivery to Sublandlord and Landlord certificates of insurance naming the Sublandlord and Landlord as additional insured, evidencing the maintenance, by each contractor or other worker to be employed in the performance of the Subtenant Improvements, of comprehensive general liability insurance with limits in the amount of $1,000,000.00 per occurrence, property damage insurance with limits in the amount of $500,000.00 per occurrence, and workers compensation insurance to statutory limits. All insurance policies shall be issued by responsible companies qualified to conduct business in the Commonwealth of Massachusetts and such insurance policy shall provide for notification to Sublandlord and Landlord at least thirty (30) days prior to the cancellation of any such policy. Subtenant hereby agrees and further does warrant and represent to Sublandlord that the cost of performing any such work on the Subleased Premises shall be the sole obligation of Subtenant.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Subject to Sublandlord&#8217;s review and approval of Subtenant&#8217;s final plans and specifications therefor, and further subject to the terms and conditions of the Prime Lease, including, without limitation, Landlord&#8217;s review and approval thereof, Sublandlord approves the conceptual design of Subtenant Improvements as set forth on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, and addition of one (1) HVAC vent in Subtenant&#8217;s IT Room.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Additional Access</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a. &#160;&#160;&#160;&#160;Subtenant shall have temporary access to the kitchen area located in the 5,388 sq. ft. area shown on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> on the first (1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) floor of the Building for the period commencing on the Commencement Date and expiring on the earlier of, (i)&#160;the date Subtenant has completed its Subtenant Improvements which shall include a caf&#233; space within its own dedicated Subleased Premises, and (ii)&#160;September 30, 2023 (subject to External Causes (as defined in the Prime Lease)).  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.&#160;&#160;&#160;&#160;Subtenant shall have access to the gym area located in the 2,868 sq. ft. area shown on </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> on the first (1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) floor of the Building for a fee of $50 per user per month. The number of gym passes will be determined and agreed to between the parties on a monthly basis, and Sublandlord shall invoice Subtenant directly for the cost of all gym passes on an annual or other periodic basis.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Sublandlord&#8217;s Representations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Sublandlord represents and warrants to Subtenant, and covenants and agrees with Subtenant, that&#58;  (i)&#160;Sublandlord is the holder of the interest of the &#8220;Tenant&#8221; under the Prime Lease with respect to the Subleased Premises and such interest has not previously been assigned, transferred or sublet, (ii)&#160;the Prime Lease is in full force and effect, (iii)&#160;Sublandlord has no actual knowledge of any default by it under the Prime Lease and Sublandlord has not received any notices of default from Landlord which have not been cured, (iv)&#160;to Sublandlord&#8217;s knowledge, Landlord is not in default under the Prime Lease, (v)&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit E</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> annexed hereto contains a true, correct and complete copy of the redacted Prime Lease, and (vi)&#160;Sublandlord shall not amend the Prime Lease in any manner that will result in a material increase of any obligation of Subtenant or material decrease of any rights of Subtenant without Subtenant&#8217;s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.73pt;text-decoration:underline">Parking</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subtenant shall have access to five (5) unreserved parking passes for the parking garage located at 80 Lansdowne Street, Cambridge, Massachusetts, upon the terms and conditions provided in the Prime Lease.  Subtenant shall pay to Sublandlord $400.00 per month for each parking pass, or whatever the then prevailing rate charged by Landlord to Sublandlord from time to time for such parking passes.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#91;SIGNATURES APPEAR ON FOLLOWING PAGE.&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> the Sublandlord and Subtenant have each executed this Sublease effective as of the date first above written.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SUBLANDLORD&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Agios Pharmaceuticals, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jim Burns</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Jim Burns</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Legal Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SUBTENANT&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Watershed Informatics, Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jonathan Wang</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Jonathan Wang</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Subleased Premises</font></div><div><font><br></font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:458px;margin-bottom:5pt;vertical-align:text-bottom;width:623px"></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">**Note&#58; The 7,407 SF area shown above represents the Subleased Premises.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit B</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Existing Furniture and Equipment</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">IT Equipment&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#4472c4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item Description</font></td><td colspan="3" style="background-color:#4472c4;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quantity</font></td><td colspan="3" style="background-color:#4472c4;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Comment</font></td><td colspan="3" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d9e1f2;border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ThinkPad USB 3.0 Ultra Dock</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Universal USB Dock (*w&#47;DisplayLink Drivers)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ThinkVision P24q-10 Monitor</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">122</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2 Monitors Mounted &#47;desk (including offices)</font></td><td colspan="3" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#d9e1f2;border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Logitech Wireless Keyboard&#47;Mouse Combo</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">61</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Logitech Combo w&#47;Unifying USB receiver on dock</font></td><td colspan="3" style="border-left:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:16pt"><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#4472c4;border-left:0.5pt solid #8ea9db;border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Conference&#47;Huddle Room</font></td><td colspan="3" style="background-color:#4472c4;border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quantity</font></td><td colspan="3" style="background-color:#4472c4;border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Comment</font></td><td colspan="3" style="background-color:#4472c4;border-right:0.5pt solid #000000;border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Serial#</font></td></tr><tr><td colspan="3" style="background-color:#d9e1f2;border-left:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cisco Webex Room Kit</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64-112 Huddle</font></td><td colspan="3" style="background-color:#d9e1f2;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FOC2330NS93</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cisco Webex Room Kit</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64-117 Huddle</font></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FOC2330NS6B</font></td></tr><tr><td colspan="3" style="background-color:#d9e1f2;border-left:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cisco Webex Room Kit Plus</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64-121 - Kallipolis</font></td><td colspan="3" style="background-color:#d9e1f2;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FOC2329P22R</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #8ea9db;border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cisco Webex Room Kit</font></td><td colspan="3" style="border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64-122 - Santorini</font></td><td colspan="3" style="border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FOC2330NS9T</font></td></tr><tr><td colspan="3" style="background-color:#4472c4;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TV Displays</font></td><td colspan="3" style="background-color:#4472c4;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quantity</font></td><td colspan="3" style="background-color:#4472c4;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Location</font></td><td colspan="3" style="background-color:#4472c4;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Serial #</font></td></tr><tr><td colspan="3" style="background-color:#d9e1f2;border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Samsung QB49R</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64-112 Huddle</font></td><td colspan="3" style="background-color:#d9e1f2;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">07YTHNFM800727Z</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Samsung QB49R</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64-117 Huddle</font></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">07YTHNFM800730F</font></td></tr><tr><td colspan="3" style="background-color:#d9e1f2;border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Samsung QB98R</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#d9e1f2;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64-121 - Kallipolis</font></td><td colspan="3" style="background-color:#d9e1f2;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">08GXHNIM600335Z</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Samsung QB65R</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">64-122 - Santorini</font></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">07YKHNGM900325B</font></td></tr><tr><td colspan="3" style="background-color:#d9e1f2;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Samsung QB55R</font></td><td colspan="3" style="background-color:#d9e1f2;border-bottom:0.5pt solid #000000;border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#d9e1f2;border-bottom:0.5pt solid #000000;border-top:0.5pt solid #8ea9db;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Door Near 64-1 lobby (Digital Signage</font></td><td colspan="3" style="background-color:#d9e1f2;border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LH55QBREBGCXZA</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Furniture&#58; </font></div><div><font><br></font></div><div style="padding-left:3.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"></td><td style="width:32.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Area</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Item</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Details</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Quantity</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Large conference room</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Table</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24&#34; X 60&#34;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Benches</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"></td><td style="width:32.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Small conference room</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Table</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42&#34; X 96&#34;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairs</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Black</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairs</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Green</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Huddle room</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Table</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">72&#34; Horn Shape</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairs</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Orange</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Common Area</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Table</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48&#34; X 96&#34;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Table</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36&#34; round glass</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairs</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">White</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Book case</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36&#34; X 105&#34;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Stools</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Blue</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Phone booths</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Phone booth</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Framery</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Single office</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Task Seating</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Desk</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Height adjustable</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Credenza</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dual monitor arms</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Table</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30&#34; Round</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Side chairs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Double office</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Task Seating</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Desk</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Height adjustable</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Credenza</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dual monitor arms</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Workstations</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Task Seating</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Desk</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Height adjustable</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Credenza</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Coat cubby</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Dual monitor arms</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:3.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.166%"><tr><td style="width:1.0%"></td><td style="width:32.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Coat racks</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Coat racks</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">portable</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Wellness room</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Table</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7&#34; round</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit C</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Subtenant Improvements</font></div><div style="text-align:center"><img alt="image_1a.jpg" src="image_1a.jpg" style="height:797px;margin-bottom:5pt;vertical-align:text-bottom;width:559px"></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit D</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Form of Consent to Sublease</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CONSENT TO SUBLEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This CONSENT TO SUBLEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into as of the 14th day of April, 2023, by and between BRE-BMR 64 SIDNEY LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> as successor-in-interest to UP 64 SIDNEY STREET, LLC, a Delaware limited liability company, AGIOS PHARMACEUTICALS, INC. a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and WATERSHED INFORMATICS, INC. a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subtenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of November 17, 2017, as amended by that certain First Amendment to Lease dated as of April&#160;11,&#160;2018, as amended by that certain Second Amendment to Lease dated as of December&#160;14, 2018, and as amended by that certain Third Amendment to Lease dated as of April&#160;11, 2019 (as the same may have been amended, amended and restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Master Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), whereby Tenant leases certain premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from Landlord at 64 Sidney Street, Cambridge, Massachusetts (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">WHEREAS, Tenant has applied to Landlord for its consent to that certain Sublease dated as of April 14, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sublease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), by and between Tenant and Subtenant, whereby Tenant subleases its interest in a portion of the Premises (such portion, the&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Subleased&#160;Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to Subtenant.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, Landlord hereby consents to the Sublease, subject to and upon the following terms and conditions, to each of which Tenant, Subtenant and Landlord expressly agree&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Nothing contained in this Consent shall either&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">operate as a consent to or approval by Landlord of any of the provisions of the Sublease or as a representation or warranty by Landlord, and Landlord shall not be bound or estopped in any way by the provisions of the Sublease&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">be construed to modify, waive or affect any of the provisions, covenants or conditions of, or any rights or remedies of Landlord under, the Master Lease.  In the case of any conflict between the provisions of this Consent and those of the Sublease, the provisions of this Consent shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Each of Tenant and Subtenant expressly assumes and agrees that during the term of the Sublease, it shall perform and comply with each and every obligation of Tenant under the Master Lease&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that, in the case of Subtenant, Subtenant shall not violate the Master Lease but shall only be obligated to perform the affirmative obligations of Tenant under the Master Lease to the extent of Subtenant&#8217;s obligations under the Sublease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">If Landlord is entitled to a share of any portion of the rent or other payments that Subtenant is obligated to pay to Tenant pursuant to the Sublease, Landlord hereby requests that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Tenant pay such portion to Landlord, and Tenant hereby acknowledges and agrees to pay such portion to Landlord on a timely basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Neither the Sublease nor this Consent shall release or discharge Tenant from any obligation or liability under the Master Lease, and Tenant shall remain liable and responsible for the full performance of all of the provisions, obligations, covenants and conditions set forth in the Master Lease.  The acceptance of rent by Landlord from Subtenant or from any other person shall not be deemed a waiver by Landlord of any provisions of the Master Lease.  Tenant and Subtenant understand and represent that by entering into the Sublease, Landlord&#8217;s rights, remedies and liabilities under the Master Lease have not in any way been modified, diminished or waived.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Tenant and Subtenant warrant that the copy of the Sublease attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> represents the entire agreement between them.  Subtenant further warrants that there was no compensation or consideration paid to either party as a condition of this Consent or the Sublease other than as stated herein or therein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">The Sublease shall be subject and subordinate at all times to the Master Lease and all of its provisions, covenants and conditions.  In case of a conflict, the provisions of the Master Lease shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">This Consent shall not constitute consent to any subsequent assignment of the Master Lease or the Sublease or subletting of the Premises.  Neither Tenant nor Subtenant shall voluntarily or by operation of law, directly or indirectly (whether by merger or otherwise), assign, pledge, hypothecate, or otherwise transfer this Consent or any of such party&#8217;s rights, interests or obligations under this Consent, in whole or in part, without the prior written consent of Landlord in its sole and absolute discretion, and any such purported assignment, pledge, hypothecation, or transfer without the prior written consent of Landlord shall be null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">In addition to and without limiting any indemnity obligations set forth in the Master Lease, Tenant agrees to reimburse, indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord) and hold harmless Landlord and its affiliates and their respective shareholders, partners, directors, officers, employees, lenders and ground lessors and their respective successors and assigns, and Landlord&#8217;s contractors and agents (collectively with Landlord, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Landlord Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for, from and against any and all demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages, suits or judgments, and all reasonable expenses (including reasonable attorneys&#8217; fees, charges and disbursements, regardless of whether the applicable demand, claim, action, cause of action or suit is voluntarily withdrawn or dismissed) incurred in investigating or resisting the same (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of any kind or nature arising from Subtenant&#8217;s failure to perform or comply with any of Tenant&#8217;s or Subtenant&#8217;s obligations under the Sublease or this Consent, except to the extent directly caused by Landlord&#8217;s negligence or willful misconduct.  Subtenant agrees to reimburse, indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord) and hold harmless the Landlord Indemnitees for, from and against any and all Claims of any kind or nature arising from Tenant&#8217;s or Subtenant&#8217;s obligations under the Sublease or this Consent, except to the extent directly caused by Landlord&#8217;s negligence or willful misconduct. Tenant&#8217;s and Subtenant&#8217;s obligations under this Section shall not be affected, reduced or limited by any limitation on the amount or type of damages, compensation or benefits payable by or for Tenant or Subtenant under workers&#8217; compensation acts, disability benefit acts, employee benefit acts or similar legislation. Tenant&#8217;s and Subtenant&#8217;s obligations under this Section shall survive the expiration or earlier termination of this Consent.    </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Subtenant shall reimburse, indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord) and hold harmless the Landlord Indemnitees for, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from and against any and all Claims imposed upon or incurred by or asserted against  a Landlord Indemnitee and directly or indirectly arising out of or in any way relating to Tenant&#8217;s or Subtenant&#8217;s obligations under the Sublease or this Consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">In the event of any default by Subtenant under the Master Lease, Landlord may proceed directly against any or all of Tenant, Subtenant, any guarantors or anyone else liable under the Master Lease without first exhausting Landlord&#8217;s remedies against any other person or entity liable therefor to Landlord.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">In the event that Tenant defaults in its obligations under the Master Lease or in the event that the Master Lease is otherwise terminated prior to its natural expiration, Landlord may, at its option and without being obligated to do so, require Subtenant to attorn to Landlord with respect to the Subleased Premises.  Upon Landlord&#8217;s notice to Subtenant, (a) Subtenant shall thereafter make all payments otherwise due Tenant directly to Landlord, which payments shall be received by Landlord without any liability being incurred by Landlord, except to credit such payment against amounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">due by Tenant under the Lease and (b) within ten (10) days after such notice, Subtenant shall deposit with Landlord the entire Security Deposit (as defined in the Sublease), and replenish such Security Deposit from time to time, as necessary to maintain the amount required under the Sublease.  If Landlord elects to require Subtenant to so attorn, then Landlord shall undertake the obligations of Tenant under the Sublease with respect to the Subleased Premises from the time of the exercise of Landlord&#8217;s option under this Section until termination of the Sublease&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Landlord shall not be liable for any prepaid rents or any security deposit paid by Subtenant to Tenant, nor shall Landlord be liable for any other defaults of Tenant under the Sublease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Except as otherwise expressly set forth in this Consent, each party shall pay its own costs and expenses incurred in connection with this Consent and such party&#8217;s performance under this Consent, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if any party commences a proceeding, demand, claim, action, cause of action or suit against another party(ies) arising out of or in connection with this Consent, then the substantially prevailing party(ies) shall be reimbursed by the other party(ies) for all reasonable costs and expenses, including reasonable attorneys&#8217; fees and expenses, incurred by the substantially prevailing party(ies) in such proceeding, demand, claim, action, cause of action or suit, and in any appeal in connection therewith (regardless of whether the applicable proceeding, demand, claim, action, cause of action, suit or appeal is voluntarily withdrawn or dismissed).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Each of Tenant and Subtenant represents and warrants that it has dealt with no broker, agent or other person in connection with this transaction and that no broker, agent or other person brought about this transaction, other than CBRE, and Tenant and Subtenant agree to reimburse, indemnify, save, defend (at Landlord&#8217;s option and with counsel reasonably acceptable to Landlord) and hold harmless the Landlord Indemnitees for, from and against any Claims by this or any other broker, agent or other person claiming a commission or other form of compensation by virtue of having dealt with Tenant or Subtenant with regard to the Sublease.  The provisions of this Section shall survive the expiration or earlier termination of this Consent or the Master Lease.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Except as otherwise stated in this Consent, any notice, consent, demand, invoice, statement or other communication required or permitted to be given under this Consent shall be in writing and shall be given by (a) personal delivery, (b) overnight delivery with a reputable international overnight delivery service, such as FedEx, or (c) facsimile or email transmission, so long as such transmission is followed within one (1) business day by delivery utilizing one of the methods described in (a) or (b).  Any such notice, consent, demand, invoice, statement or other communication shall be deemed delivered (x) upon receipt, if given in accordance with subsection (a)&#59; (y) one (1) business day after deposit with a reputable international overnight </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">delivery service, if given in accordance with subsection (b)&#59; or (z) upon transmission, if given in accordance with subsection (c).  Any notice, consent, demand, invoice, statement or other communication required or permitted to be given under this Consent shall be addressed to the parties at the following addresses&#58;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Landlord&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BRE-BMR 64 SIDNEY LLC </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4570 Executive Drive, Suite 400</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">San Diego, California  92121</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Legal Department</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Facsimile&#58;  (858) 485-9843</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">legalreview&#64;biomedrealty.com</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Tenant&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agios Pharmaceuticals, Inc.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">88 Sidney Street</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cambridge, MA 02139</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58;  James Burns</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subtenant&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Watershed Informatics, Inc.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1 Broadway, 14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Floor</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cambridge, Massachusetts  02412</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58; Jonathan Wang, CEO</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; jonathan&#64;watershed.ai</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Either party may, by notice to the other(s) given pursuant to this Section, specify additional or different addresses for notice purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Where applicable in this Consent, the singular includes the plural and the masculine or neuter includes the masculine, feminine and neuter.  The words &#8220;include,&#8221; &#8220;includes,&#8221; &#8220;included&#8221; and &#8220;including&#8221; mean &#8220;&#8216;include,&#8217; etc., without limitation.&#8221; The word &#8220;shall&#8221; is mandatory and the word &#8220;may&#8221; is permissive.  Landlord, Tenant and Subtenant have each participated in the drafting and negotiation of this Consent, and the language in all parts of this Consent shall be in all cases construed as a whole according to its fair meaning and not strictly for or against either Landlord, Tenant or Subtenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Time is of the essence with respect to the performance of every provision of this Consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">The terms of this Consent are intended by the parties as a final, complete and exclusive expression of their agreement with respect to the terms that are included in this Consent, and may not be contradicted or supplemented by evidence of any other prior or contemporaneous agreement. No provision of this Consent may be modified, amended or supplemented except by an agreement in writing signed by Landlord, Tenant and Subtenant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Notwithstanding anything to the contrary contained in this Consent, Tenant&#8217;s and Subtenant&#8217;s obligations under this Consent are independent and shall not be conditioned upon performance by Landlord.  Each provision of this Consent performable by Tenant or Subtenant shall be deemed both a covenant and a condition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Any provision of this Consent that shall prove to be invalid, void or illegal shall in no way affect, impair or invalidate any other provision hereof, and all other provisions of this Consent shall remain in full force and effect and shall be interpreted as if the invalid, void or illegal provision did not exist.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Each of the covenants, conditions and agreements contained in this Consent shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns.  Nothing in this section shall in any way alter the provisions of this Consent restricting assignment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">This Consent is for the sole benefit of the parties and their respective heirs, legatees, devisees, executors, administrators and permitted successors and assigns, and nothing in this Consent shall give or be construed to give any other person or entity any legal or equitable rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">This Consent shall be governed by and construed and enforced in accordance with the laws of the Massachusetts, without regard to Massachusetts&#8217;s conflict of law principles.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant and Subtenant guaranty, warrant and represent that the individual or individuals signing this Consent have the power, authority and legal capacity to sign this Consent on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Tenant and Subtenant shall take all such actions and execute all such documents as are reasonable and necessary to implement or evidence the transactions contemplated by this Consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">A facsimile, portable document format (PDF) signature or other electronic signature on this Consent shall be equivalent to, and have the same force and effect as, an original signature.  This Consent may be executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">No waiver of any term, covenant or condition of this Consent shall be binding unless executed in writing by the party entitled to the benefit of such term, covenant or condition.  The waiver of any breach or default of any term, covenant or condition contained in this Consent shall not be deemed to be a waiver of any preceding or subsequent breach or default of such term, covenant or condition or any other term, covenant or condition of this Consent.  Except as expressly provided in this Consent, the rights and remedies under this Consent are in addition to and not exclusive of any other rights, remedies, powers and privileges under this Consent or available at law, in equity or otherwise.  No failure to exercise or delay in exercising any right, remedy, power or privilege shall operate as a waiver thereof, and no single or partial exercise of any right, remedy, power or privilege shall preclude the exercise of any other right, remedy, power or privilege.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">To the extent permitted by applicable laws, the parties waive trial by jury in any action, proceeding or counterclaim brought by the other party(ies) hereto related to matters arising out of or in any way connected with this Consent or any claim of injury or damage related to this Consent.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><div id="i9404c0ed81b14c3cab2a0147b4343aff_43"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Tenant and Subtenant have affixed their respective signatures hereto as evidence of understanding of and agreement to the above, and Landlord has affixed its signature hereto to convey its consent to the Sublease.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">LANDLORD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BRE-BMR 64 SIDNEY LLC,</font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">AGIOS PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SUBTENANT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WATERSHED INFORMATICS, INC,</font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;Jonathan Wang</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;CEO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i9404c0ed81b14c3cab2a0147b4343aff_46"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SUBLEASE</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(See attached)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:87.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit E</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Prime Lease</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:87.12pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;25</font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109556800.13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>agio-ex211x123123.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i0be10b0d0c22423ca31c7ecca9b6fe87_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.296%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State or other Jurisdiction of Incorporation or Organization</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agios Securities Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agios Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Agios International Sarl (GmbH)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Agios Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Agios Germany GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Agios Italy S.R.L.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Agios France SARL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>agio-ex231x123123.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3aea5e5ec9b545228c5b9c26190c9f59_40"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 23.1</font></div></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We hereby consent to the incorporation by reference in the Registration Statements on Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8 (Nos. 333-272615, 333-269951, 333-262956, 333-266675, 333-267624, 333- 269108, 333-253498, 333-236523, 333-229669, 333-223031, 333-216106, 333-209755, 333-201796, 333-193802, and 333-190101) and Form S-3 (No. 333-269949) of Agios Pharmaceuticals, Inc. of our report dated February 15, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PricewaterhouseCoopers LLP<br>Boston, Massachusetts<br>February 15, 2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Georgia',serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exhibit31-1x12x31x23.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i283c404ba2a64b3b9e08639fec9fe0a0_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brian Goff, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Agios Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;15, 2024 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian Goff</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian Goff</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exhibit31-2x12x31x23.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8255034aa3d94a8da4a782b8d1cf4a77_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Cecilia Jones, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of Agios Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;15, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.634%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Cecilia Jones</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cecilia Jones</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exhibit32-1x12x31x23.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib376c9060f16440db2da09a9b52325a7_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Annual Report on Form 10-K of Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the fiscal year ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Brian Goff, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to his knowledge on the date hereof&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;15, 2024</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brian Goff</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian Goff</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>exhibit32-2x12x31x23.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia1b50a62495e4adb83fdd36db0ca06c7_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this Annual Report on Form 10-K of Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the fiscal year ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Cecilia Jones, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, that, to her knowledge on the date hereof&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:45pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;15, 2024</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.486%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.314%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Cecilia Jones</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cecilia Jones</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>9
<FILENAME>exhibit-971x123123.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i051080c5bdcf4e54ad93464d96bb3ef7_40"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ex. 97.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AGIOS PHARMACEUTICALS, INC. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Dodd-Frank Compensation Recovery Policy</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Compensation Recovery Policy (this &#8220;Policy&#8221;) is adopted by Agios Pharmaceuticals, Inc. (the &#8220;Company&#8221;) in accordance with Nasdaq Listing Rule 5608 (&#8220;Rule 5608&#8221;), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) (as promulgated pursuant to Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010). This Policy is effective as of October 2, 2023 (the &#8220;Effective Date&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Definitions</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">&#8220;Accounting Restatement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means a requirement that the Company prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the U.S. federal securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. Changes to the Company&#8217;s financial statements that do not represent error corrections are not an Accounting Restatement, including&#58; (A) retrospective application of a change in accounting principle&#59; (B) retrospective revision to reportable segment information due to a change in the structure of the Company&#8217;s internal organization&#59; (C) retrospective reclassification due to a discontinued operation&#59; (D) retrospective application of a change in reporting entity, such as from a reorganization of entities under common control&#59; and (E) retrospective revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">&#8220;Committee&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the Compensation &#38; People Committee of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">&#8220;Covered Person&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a person who served as an Executive Officer at any time during the performance period for the applicable Incentive-Based Compensation. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">&#8220;Erroneously Awarded Compensation&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the amount of Incentive-Based Compensation that was Received that exceeds the amount of Incentive-Based Compensation that otherwise would have been Received had the amount of Incentive-Based Compensation been determined based on the restated amounts, computed without regard to any taxes paid by the Covered Person or by the Company on the Covered Person&#8217;s behalf. For Incentive-Based Compensation based on stock price or total shareholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the amount of Erroneously Awarded Compensation will be based on a reasonable estimate by the Committee of the effect of the Accounting Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received. The Company will maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">&#8220;Executive Officer&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company&#8217;s officers as defined in Rule 16a-1(f) under the Exchange Act.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.03pt">&#8220;Financial Reporting Measures&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means (A) measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures (whether or not such measures are presented within the Company&#8217;s financial statements or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ex. 97.1</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">included in a filing made with the U.S. Securities and Exchange Commission), (B) stock price and (C) total shareholder return.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">&#8220;Incentive-Based Compensation&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Incentive-Based Compensation is deemed to be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Received&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the applicable Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period or is subject to additional time-based vesting requirements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:24.69pt">&#8220;Recovery Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the three completed fiscal years immediately preceding the earlier of&#58; (A) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement&#59; or (B) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement. In addition, if there is a change in the Company&#8217;s fiscal year end, the Recovery Period will also include any transition period to the extent required by Rule 5608.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Recovery of Erroneously Awarded Compensation</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Application of Prior Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the Company is required to prepare an Accounting Restatement and the provisions of Section 2(b) of this Policy are inapplicable, the Clawback Policy previously adopted by the Board effective April 22, 2016 (the &#8220;Prior Policy&#8221;) will apply in accordance with its terms. The Prior Policy will not apply when Section 2(b) of this Policy is applicable.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Application of this Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to the terms of this Policy and the requirements of Rule 5608, if, on or after the Effective Date, the Company is required to prepare an Accounting Restatement, the Company will attempt to recover, reasonably promptly from each Covered Person, any Erroneously Awarded Compensation that was Received by such Covered Person during the Recovery Period pursuant to Incentive-Based Compensation that is subject to this Policy. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Interpretation and Administration</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Role of the Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Policy will be interpreted by the Committee in a manner that is consistent with Rule 5608 and any other applicable law and will otherwise be interpreted in the business judgment of the Committee. All decisions and interpretations of the Committee that are consistent with Rule 5608 will be final and binding. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Compensation Not Subject to this Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Policy does not apply to Incentive-Based Compensation that was Received before the Effective Date. With respect to any Covered Person, this Policy does not apply to Incentive-Based Compensation that was Received by such Covered Person before beginning service as an Executive Officer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Determination of Means of Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the requirement that recovery be made reasonably promptly, the Committee will determine the appropriate means of recovery, which may vary between Covered Persons or based on the nature of the applicable Incentive-Based Compensation, and which may involve, without limitation, establishing a deferred repayment plan or setting off against current or future compensation otherwise payable to the Covered Person. Recovery of Erroneously Awarded Compensation will be made without regard </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ex. 97.1</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to income taxes paid by the Covered Person or by the Company on the Covered Person&#8217;s behalf in connection with such Erroneously Awarded Compensation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Determination That Recovery is Impracticable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company is not required to recover Erroneously Awarded Compensation if a determination is made by the Committee that either (A) after the Company has made and documented a reasonable attempt to recover such Erroneously Awarded Compensation, the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered or (B) recovery of such Erroneously Awarded Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the registrant, to fail to meet the requirements of Section 401(a)(13) or 411(a) of the Internal Revenue Code and regulations thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Indemnification or Company-Paid Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company will not indemnify any Covered Person against the loss of Erroneously Awarded Compensation and will not pay or reimburse any Covered Person for the purchase of a third-party insurance policy to fund potential recovery obligations.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Interaction with Other Clawback Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company will be deemed to have recovered Erroneously Awarded Compensation in accordance with this Policy to the extent the Company actually receives such amounts pursuant to any other Company policy, program or agreement (including the Prior Policy), pursuant to Section 304 of the Sarbanes-Oxley Act or otherwise.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">No Limitation on Other Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Nothing in this Policy will be deemed to limit the Company&#8217;s right to terminate employment of any Covered Person, to seek recovery of other compensation paid to a Covered Person, or to pursue other rights or remedies available to the Company under applicable law.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Adopted by the Board on September 21, 2023.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>agio-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:2870ab7b-aea5-4779-abd7-f438083a7088,g:ac8cf5ba-8c61-4750-87a9-db53e1eda885-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:agio="http://agios.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://agios.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="agio-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://agios.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://agios.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://agios.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://agios.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://agios.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossIncome" roleURI="http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://agios.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://agios.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusiness" roleURI="http://agios.com/role/NatureofBusiness">
        <link:definition>0000009 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://agios.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://agios.com/role/MarketableSecurities">
        <link:definition>0000012 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://agios.com/role/Inventory">
        <link:definition>0000013 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://agios.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://agios.com/role/AccruedExpenses">
        <link:definition>0000015 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenue" roleURI="http://agios.com/role/ProductRevenue">
        <link:definition>0000016 - Disclosure - Product Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://agios.com/role/ShareBasedPayments">
        <link:definition>0000017 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossperShare" roleURI="http://agios.com/role/NetIncomeLossperShare">
        <link:definition>0000018 - Disclosure - Net Income (Loss) per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://agios.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://agios.com/role/PropertyandEquipmentnet">
        <link:definition>0000020 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://agios.com/role/CommonStock">
        <link:definition>0000021 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchaseProgram" roleURI="http://agios.com/role/ShareRepurchaseProgram">
        <link:definition>0000022 - Disclosure - Share Repurchase Program</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://agios.com/role/DiscontinuedOperations">
        <link:definition>0000023 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingentLiabilities" roleURI="http://agios.com/role/CommitmentsandContingentLiabilities">
        <link:definition>0000024 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionBenefitPlan" roleURI="http://agios.com/role/DefinedContributionBenefitPlan">
        <link:definition>0000025 - Disclosure - Defined Contribution Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://agios.com/role/FairValueMeasurementsTables">
        <link:definition>9954473 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://agios.com/role/MarketableSecuritiesTables">
        <link:definition>9954474 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://agios.com/role/InventoryTables">
        <link:definition>9954475 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://agios.com/role/LeasesTables">
        <link:definition>9954476 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://agios.com/role/AccruedExpensesTables">
        <link:definition>9954477 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueTables" roleURI="http://agios.com/role/ProductRevenueTables">
        <link:definition>9954478 - Disclosure - Product Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://agios.com/role/ShareBasedPaymentsTables">
        <link:definition>9954479 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossperShareTables" roleURI="http://agios.com/role/NetIncomeLossperShareTables">
        <link:definition>9954480 - Disclosure - Net Income (Loss) per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://agios.com/role/IncomeTaxesTables">
        <link:definition>9954481 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://agios.com/role/PropertyandEquipmentnetTables">
        <link:definition>9954482 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://agios.com/role/DiscontinuedOperationsTables">
        <link:definition>9954483 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessDetails" roleURI="http://agios.com/role/NatureofBusinessDetails">
        <link:definition>9954484 - Disclosure - Nature of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954485 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails" roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails">
        <link:definition>9954486 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9954487 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>9954488 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofMarketableSecuritiesDetails" roleURI="http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails">
        <link:definition>9954489 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAdditionalInformationDetails" roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails">
        <link:definition>9954490 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://agios.com/role/InventoryDetails">
        <link:definition>9954491 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetails" roleURI="http://agios.com/role/LeasesAdditionalInformationDetails">
        <link:definition>9954492 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofLeaseExpenseandOtherInformationRelatedtoLeasesDetails" roleURI="http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationRelatedtoLeasesDetails">
        <link:definition>9954493 - Disclosure - Leases - Schedule of Lease Expense and Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails" roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails">
        <link:definition>9954494 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1" roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1">
        <link:definition>9954494 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails" roleURI="http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails">
        <link:definition>9954495 - Disclosure - Leases - Schedule of Future Minimum Lease Payments to be Received under the Long-term Sublease Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://agios.com/role/AccruedExpensesDetails">
        <link:definition>9954496 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofProductRevenueNetDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails">
        <link:definition>9954497 - Disclosure - Product Revenue - Schedule of Product Revenue, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails">
        <link:definition>9954498 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofRevenueRelatedReservesDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails">
        <link:definition>9954499 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueScheduleofChangesinContractAssetsDetails" roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsDetails">
        <link:definition>9954500 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueAdditionalInformationDetails" roleURI="http://agios.com/role/ProductRevenueAdditionalInformationDetails">
        <link:definition>9954501 - Disclosure - Product Revenue - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsAdditionalInformationDetails" roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails">
        <link:definition>9954502 - Disclosure - Share-Based Payments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails">
        <link:definition>9954503 - Disclosure - Share-Based Payments - Schedule of Company's Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails">
        <link:definition>9954504 - Disclosure - Share-Based Payments - Schedule of Unvested RSUs, Performance-Based Stock and Market-Based Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails">
        <link:definition>9954505 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included within the Condensed Consolidated Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails">
        <link:definition>9954506 - Disclosure - Share-Based Payments - Schedule of Expenses Related to Stock Options and Stock-based Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails" roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails">
        <link:definition>9954507 - Disclosure - Share-Based Payments - Schedule of Grant Date Fair Value Option Award Weighted Average Assumptions Used (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeLossperShareDetails" roleURI="http://agios.com/role/NetIncomeLossperShareDetails">
        <link:definition>9954508 - Disclosure - Net Income (Loss) per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" roleURI="http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails">
        <link:definition>9954509 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails" roleURI="http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails">
        <link:definition>9954510 - Disclosure - Income Taxes - Reconciliation of Expected Income Tax Benefit (Expense) Computed Using Federal Statutory Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954511 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://agios.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9954512 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesChangesinValuationAllowanceDetails" roleURI="http://agios.com/role/IncomeTaxesChangesinValuationAllowanceDetails">
        <link:definition>9954513 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails" roleURI="http://agios.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails">
        <link:definition>9954514 - Disclosure - Income Taxes - Unrecognized Tax Benefits Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails" roleURI="http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails">
        <link:definition>9954515 - Disclosure - Property and Equipment, net - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetAdditionalInformationDetails" roleURI="http://agios.com/role/PropertyandEquipmentnetAdditionalInformationDetails">
        <link:definition>9954516 - Disclosure - Property and Equipment, net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockDetails" roleURI="http://agios.com/role/CommonStockDetails">
        <link:definition>9954517 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchaseProgramDetails" roleURI="http://agios.com/role/ShareRepurchaseProgramDetails">
        <link:definition>9954518 - Disclosure - Share Repurchase Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails" roleURI="http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails">
        <link:definition>9954519 - Disclosure - Discontinued Operations - Summary of Gain on Sale of Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsAdditionalInformationDetails" roleURI="http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails">
        <link:definition>9954520 - Disclosure - Discontinued Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails" roleURI="http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails">
        <link:definition>9954521 - Disclosure - Discontinued Operations - Financial Results of Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingentLiabilitiesDetails" roleURI="http://agios.com/role/CommitmentsandContingentLiabilitiesDetails">
        <link:definition>9954522 - Disclosure - Commitments and Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DefinedContributionBenefitPlanDetails" roleURI="http://agios.com/role/DefinedContributionBenefitPlanDetails">
        <link:definition>9954523 - Disclosure - Defined Contribution Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductReserve" abstract="false" name="ContractWithCustomerRightToRecoverProductReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_EmployeePurchasePlanMember" abstract="true" name="EmployeePurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_ContractualAdjustmentsRollForward" abstract="true" name="ContractualAdjustmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" abstract="false" name="ContractWithCustomerRebateReserveRecoveriesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_NumberOfLegalProceedingsThatHaveMaterialEffect" abstract="false" name="NumberOfLegalProceedingsThatHaveMaterialEffect" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" abstract="false" name="LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="agio_ContractAssetsAndLiabilitiesHeadingRollForward" abstract="true" name="ContractAssetsAndLiabilitiesHeadingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ScheduleOfSignificantAccountingPoliciesLineItems" abstract="true" name="ScheduleOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" abstract="true" name="March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" abstract="false" name="LesseeOperatingSubleaseAreaOfPremisesSubleased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="agio_ProductReturnsRollForward" abstract="true" name="ProductReturnsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_DiscontinuedOperationsLiabilitiesDistributedNet" abstract="false" name="DiscontinuedOperationsLiabilitiesDistributedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_GainLossOnSaleOfContingentPayments" abstract="false" name="GainLossOnSaleOfContingentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAllowanceAndReservesLiability" abstract="false" name="ContractWithCustomerAllowanceAndReservesLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PaymentsAssociatedWithLicenseAgreement" abstract="false" name="PaymentsAssociatedWithLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_DiscontinuedOperationsTransactionAndInsuranceCosts" abstract="false" name="DiscontinuedOperationsTransactionAndInsuranceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_EmployeeStockPurchasePlan2013Member" abstract="true" name="EmployeeStockPurchasePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_March252021RepurchaseProgramRule10b51RepurchaseMember" abstract="true" name="March252021RepurchaseProgramRule10b51RepurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" abstract="false" name="PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods" abstract="false" name="LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" abstract="false" name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="agio_NonCurrentAssetsMember" abstract="true" name="NonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" abstract="false" name="ContractWithCustomerRightToRecoverProductPriorYearRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ProceedsFromSaleOfContingentPayments" abstract="false" name="ProceedsFromSaleOfContingentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PaymentsForAssetAcquisition" abstract="false" name="PaymentsForAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_IncomeTaxesDisclosureLineItems" abstract="true" name="IncomeTaxesDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_AgiosOncologyBusinessMember" abstract="true" name="AgiosOncologyBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_PercentageOfStockholdersOwnershipIncrease" abstract="false" name="PercentageOfStockholdersOwnershipIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="agio_GovernmentRebatesRollForward" abstract="true" name="GovernmentRebatesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ScheduleOfSignificantAccountingPoliciesTable" abstract="true" name="ScheduleOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerTotalAllowancesAndReserves" abstract="false" name="ContractWithCustomerTotalAllowancesAndReserves" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod" abstract="false" name="AvailableForSaleSecuritiesNonCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_CollaborationRevenueRelatedPartyMember" abstract="true" name="CollaborationRevenueRelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_RealizedGainOnInvestments" abstract="false" name="RealizedGainOnInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_LesseeOperatingLeaseNumberOfLeaseTerms" abstract="false" name="LesseeOperatingLeaseNumberOfLeaseTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agio_CollaborationRevenueOtherMember" abstract="true" name="CollaborationRevenueOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_IncomeTaxesDisclosureTable" abstract="true" name="IncomeTaxesDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="agio_ContractWithCustomerContractualAdjustmentReserve" abstract="false" name="ContractWithCustomerContractualAdjustmentReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_SixtyFourSidneyStreetLeaseMember" abstract="true" name="SixtyFourSidneyStreetLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_PriorYearProvisionForContractualAdjustments" abstract="false" name="PriorYearProvisionForContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserve" abstract="false" name="ContractWithCustomerRebateReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_TwoThousandAndThirteenStockIncentivePlanMember" abstract="true" name="TwoThousandAndThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_StockholdersEquityDispositionOfBusiness" abstract="false" name="StockholdersEquityDispositionOfBusiness" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_PriorYearProvisionsForRebateReserve" abstract="false" name="PriorYearProvisionsForRebateReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetRevenueRecognized" abstract="false" name="ContractWithCustomerAssetRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ExpenseAssociatedWithLicenseAgreement" abstract="false" name="ExpenseAssociatedWithLicenseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" abstract="false" name="ContractWithCustomerContractAdjustmentRecoveriesPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" abstract="false" name="ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction" abstract="false" name="SaleOfStockMaximumValueOfSharesIssuedInTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_Agreement2010Member" abstract="true" name="Agreement2010Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" abstract="false" name="ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_AlnylamPharmaceuticalsIncMember" abstract="true" name="AlnylamPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="agio_PerformanceStockUnitMember" abstract="true" name="PerformanceStockUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_FederalOrphanDrugTaxCreditMember" abstract="true" name="FederalOrphanDrugTaxCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_NumberOfStatesFederalOrForeignInAuditingProcess" abstract="false" name="NumberOfStatesFederalOrForeignInAuditingProcess" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agio_ContingentGainOnDispositionOfBusinessRecognized" abstract="false" name="ContingentGainOnDispositionOfBusinessRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerPriorYearsReserveProvisions" abstract="false" name="ContractWithCustomerPriorYearsReserveProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod" abstract="false" name="LesseeOperatingLeaseOptionToExtendExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod" abstract="false" name="AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember" abstract="true" name="ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" abstract="false" name="ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="agio_PeriodOfChangeInStockholdersOwnership" abstract="false" name="PeriodOfChangeInStockholdersOwnership" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_CurrentYearProvisionsForRebateReserve" abstract="false" name="CurrentYearProvisionsForRebateReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_SaleOfStockCommonStockReservedForFutureIssuanceValue" abstract="false" name="SaleOfStockCommonStockReservedForFutureIssuanceValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ProvisionForRightToRecoverProductInPriorYears" abstract="false" name="ProvisionForRightToRecoverProductInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo" abstract="false" name="LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment" abstract="false" name="AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" abstract="false" name="ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="agio_TIBSOVOMember" abstract="true" name="TIBSOVOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" abstract="false" name="ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerCurrentYearReserveProvisions" abstract="false" name="ContractWithCustomerCurrentYearReserveProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" abstract="false" name="DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_AvailableForSaleSecuritiesCurrentMaturityPeriod" abstract="false" name="AvailableForSaleSecuritiesCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_March252021RepurchaseProgramMember" abstract="true" name="March252021RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" abstract="false" name="EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="agio_NumberOfVotesPerShare" abstract="false" name="NumberOfVotesPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="agio_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" abstract="false" name="ContractWithCustomerAssetProceedsFromCollectionOfReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerPriorYearsReserveRecoveries" abstract="false" name="ContractWithCustomerPriorYearsReserveRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_DeferredTaxAssetsValuationAllowanceRollForward" abstract="true" name="DeferredTaxAssetsValuationAllowanceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="agio_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_CurrentAssetMember" abstract="true" name="CurrentAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" abstract="false" name="ContractWithCustomerRebateReserveRecoveriesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_EightyEightSidneyStreetLeaseMember" abstract="true" name="EightyEightSidneyStreetLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="agio_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_GainContingencyRoyaltyPercentageOfNetSales" abstract="false" name="GainContingencyRoyaltyPercentageOfNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="agio_ProvisionForRightToRecoverProductInCurrentYear" abstract="false" name="ProvisionForRightToRecoverProductInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" abstract="true" name="TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_CurrentYearProvisionForContractualAdjustments" abstract="false" name="CurrentYearProvisionForContractualAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_ContractWithCustomerCurrentYearReserveRecoveries" abstract="false" name="ContractWithCustomerCurrentYearReserveRecoveries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="agio_MarketBasedStockUnitsMember" abstract="true" name="MarketBasedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="agio_VorasidenibMember" abstract="true" name="VorasidenibMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>agio-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:2870ab7b-aea5-4779-abd7-f438083a7088,g:ac8cf5ba-8c61-4750-87a9-db53e1eda885-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://agios.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7560c019-347d-4cc3-8e1e-86e9223c7074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_28ab73b0-bee1-4b1d-b4e6-a5926b5b3e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7560c019-347d-4cc3-8e1e-86e9223c7074" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_28ab73b0-bee1-4b1d-b4e6-a5926b5b3e39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7247b7e7-0985-4166-8023-5e15c1fa4289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7560c019-347d-4cc3-8e1e-86e9223c7074" xlink:to="loc_us-gaap_AccountsPayableCurrent_7247b7e7-0985-4166-8023-5e15c1fa4289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f83e6251-506d-42bf-bf41-1316c2f0c208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7560c019-347d-4cc3-8e1e-86e9223c7074" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f83e6251-506d-42bf-bf41-1316c2f0c208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6ea848a-45aa-41b4-8d3d-a46f81e4754c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_71814280-5a5d-4044-a3a7-6dd1d89e360a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6ea848a-45aa-41b4-8d3d-a46f81e4754c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_71814280-5a5d-4044-a3a7-6dd1d89e360a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_06deb7bb-35f0-49bc-97b6-d49d5741ee08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6ea848a-45aa-41b4-8d3d-a46f81e4754c" xlink:to="loc_us-gaap_StockholdersEquity_06deb7bb-35f0-49bc-97b6-d49d5741ee08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_399ba785-6873-48a9-87b9-ad1eb6238aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f6ea848a-45aa-41b4-8d3d-a46f81e4754c" xlink:to="loc_us-gaap_Liabilities_399ba785-6873-48a9-87b9-ad1eb6238aa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9777449b-e8d6-463b-8107-eee9567cdb52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_dab79f91-031d-428b-bc8b-c01778a4db66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9777449b-e8d6-463b-8107-eee9567cdb52" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_dab79f91-031d-428b-bc8b-c01778a4db66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3b97244f-9894-4f17-86d1-264609f65546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9777449b-e8d6-463b-8107-eee9567cdb52" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3b97244f-9894-4f17-86d1-264609f65546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1981ddec-5e33-482c-b57a-f088a9088a43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9777449b-e8d6-463b-8107-eee9567cdb52" xlink:to="loc_us-gaap_AssetsCurrent_1981ddec-5e33-482c-b57a-f088a9088a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_08eb5a8f-0ff4-4be8-be37-953fb07d7bde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9777449b-e8d6-463b-8107-eee9567cdb52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_08eb5a8f-0ff4-4be8-be37-953fb07d7bde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_974b3592-9bd6-4bc9-8979-9d76dc15dd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9777449b-e8d6-463b-8107-eee9567cdb52" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_974b3592-9bd6-4bc9-8979-9d76dc15dd3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d460a860-178c-4088-be25-9d0d106a4c40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b95beb52-0e2f-4ffe-abe5-f73819cbd367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d460a860-178c-4088-be25-9d0d106a4c40" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b95beb52-0e2f-4ffe-abe5-f73819cbd367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a08a5a56-356b-4fad-bd51-ee98eacb27a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d460a860-178c-4088-be25-9d0d106a4c40" xlink:to="loc_us-gaap_LiabilitiesCurrent_a08a5a56-356b-4fad-bd51-ee98eacb27a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f6df54b6-83e6-4ae5-a10e-9ec2f1ed07b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d460a860-178c-4088-be25-9d0d106a4c40" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f6df54b6-83e6-4ae5-a10e-9ec2f1ed07b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1329ef11-e046-42e5-9756-2702f5685de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_00e9e405-ebc4-423d-abd8-869c159c9bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1329ef11-e046-42e5-9756-2702f5685de4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_00e9e405-ebc4-423d-abd8-869c159c9bb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f182435c-1fa4-45d2-8211-dee89566775c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1329ef11-e046-42e5-9756-2702f5685de4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f182435c-1fa4-45d2-8211-dee89566775c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3612dd59-b340-4f0c-ad66-bcf309c28d19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1329ef11-e046-42e5-9756-2702f5685de4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3612dd59-b340-4f0c-ad66-bcf309c28d19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d63c89a6-3054-41be-87b1-a647408a8dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1329ef11-e046-42e5-9756-2702f5685de4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d63c89a6-3054-41be-87b1-a647408a8dfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ac6fa7da-8731-45d1-8e29-23e432ba537c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1329ef11-e046-42e5-9756-2702f5685de4" xlink:to="loc_us-gaap_InventoryNet_ac6fa7da-8731-45d1-8e29-23e432ba537c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2600df2b-29ff-409d-88ae-ead759d6dc31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d8bc9c48-c71d-4bfb-be65-c498d7582366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2600df2b-29ff-409d-88ae-ead759d6dc31" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_d8bc9c48-c71d-4bfb-be65-c498d7582366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_b7fb9032-ce40-4476-ab9e-b63a989c52f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2600df2b-29ff-409d-88ae-ead759d6dc31" xlink:to="loc_us-gaap_CommonStockValueOutstanding_b7fb9032-ce40-4476-ab9e-b63a989c52f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_c795e6ca-2312-4f6b-99b6-46904965dde1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2600df2b-29ff-409d-88ae-ead759d6dc31" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_c795e6ca-2312-4f6b-99b6-46904965dde1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_4bf0cbcf-f8aa-4876-9492-44137b4f1b89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2600df2b-29ff-409d-88ae-ead759d6dc31" xlink:to="loc_us-gaap_TreasuryStockValue_4bf0cbcf-f8aa-4876-9492-44137b4f1b89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0aded871-a393-4553-b209-6edbf7fdc3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2600df2b-29ff-409d-88ae-ead759d6dc31" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_0aded871-a393-4553-b209-6edbf7fdc3ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_10312c72-e018-4870-add4-d93de1e85dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2600df2b-29ff-409d-88ae-ead759d6dc31" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_10312c72-e018-4870-add4-d93de1e85dd5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://agios.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_2a0352bf-56ee-4183-9783-35f619a2a68b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c28429a0-db98-4f11-ab3a-1c7ea74fbec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2a0352bf-56ee-4183-9783-35f619a2a68b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c28429a0-db98-4f11-ab3a-1c7ea74fbec4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_450a8e01-8330-4be8-98dd-7b1a81505832" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2a0352bf-56ee-4183-9783-35f619a2a68b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_450a8e01-8330-4be8-98dd-7b1a81505832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aa1b8365-1967-41d6-8e13-d026425a8471" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_2a0352bf-56ee-4183-9783-35f619a2a68b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_aa1b8365-1967-41d6-8e13-d026425a8471" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_13467fcc-ef24-4f08-98c1-28098f9a4427" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48368c48-1415-4965-a57b-10a185328243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_13467fcc-ef24-4f08-98c1-28098f9a4427" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48368c48-1415-4965-a57b-10a185328243" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_5d2f92db-79cc-449d-803b-40456f34136d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_13467fcc-ef24-4f08-98c1-28098f9a4427" xlink:to="loc_us-gaap_CostsAndExpenses_5d2f92db-79cc-449d-803b-40456f34136d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ad49724-6fe6-48e0-8856-c1e1b4e9c240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_64033a9b-8a9e-4281-bfc2-530bf71b6048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0ad49724-6fe6-48e0-8856-c1e1b4e9c240" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_64033a9b-8a9e-4281-bfc2-530bf71b6048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dc8a10b0-5b58-46c7-8e3e-4ebc7b7be8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0ad49724-6fe6-48e0-8856-c1e1b4e9c240" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_dc8a10b0-5b58-46c7-8e3e-4ebc7b7be8a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7785fd64-77d3-4cdc-ad60-129029822756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_abe636a0-aba5-4b8e-b826-8548cdf4f901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7785fd64-77d3-4cdc-ad60-129029822756" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_abe636a0-aba5-4b8e-b826-8548cdf4f901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments_b5bd0094-c754-4746-9403-65273eb7006e" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7785fd64-77d3-4cdc-ad60-129029822756" xlink:to="loc_agio_GainLossOnSaleOfContingentPayments_b5bd0094-c754-4746-9403-65273eb7006e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2874cf09-8cd8-4b90-b855-13f1bb09d901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7785fd64-77d3-4cdc-ad60-129029822756" xlink:to="loc_us-gaap_OperatingIncomeLoss_2874cf09-8cd8-4b90-b855-13f1bb09d901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_25268795-f31f-4e7e-85ef-02ac51a6e784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7785fd64-77d3-4cdc-ad60-129029822756" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_25268795-f31f-4e7e-85ef-02ac51a6e784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_01335fa1-ff75-484b-a1e8-05b942526c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7785fd64-77d3-4cdc-ad60-129029822756" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_01335fa1-ff75-484b-a1e8-05b942526c5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedStatementsofComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7b7a04ae-e817-4823-8691-a3054a51d503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc3000a9-19c1-4c97-971c-83067b74764c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7b7a04ae-e817-4823-8691-a3054a51d503" xlink:to="loc_us-gaap_NetIncomeLoss_dc3000a9-19c1-4c97-971c-83067b74764c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c108cc09-aa01-485e-ad00-f57e0717929f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7b7a04ae-e817-4823-8691-a3054a51d503" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c108cc09-aa01-485e-ad00-f57e0717929f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://agios.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a1f2fb6d-87f6-4338-94e6-6c3de7183499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_71d357a9-cedc-46e0-8a5f-fcbfa0420241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a1f2fb6d-87f6-4338-94e6-6c3de7183499" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_71d357a9-cedc-46e0-8a5f-fcbfa0420241" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_52964b66-2cf0-4eae-a10c-4fe3e45f0068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a1f2fb6d-87f6-4338-94e6-6c3de7183499" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_52964b66-2cf0-4eae-a10c-4fe3e45f0068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4cd758f5-ee7b-4603-bf31-11bbcfcb3a19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_4cd758f5-ee7b-4603-bf31-11bbcfcb3a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RealizedGainOnInvestments_ab890a7c-1999-42d5-a88f-09e0c9ae3969" xlink:href="agio-20231231.xsd#agio_RealizedGainOnInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_agio_RealizedGainOnInvestments_ab890a7c-1999-42d5-a88f-09e0c9ae3969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ExpenseAssociatedWithLicenseAgreement_99722a5c-ab04-44d9-93cd-413e9f123317" xlink:href="agio-20231231.xsd#agio_ExpenseAssociatedWithLicenseAgreement"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_agio_ExpenseAssociatedWithLicenseAgreement_99722a5c-ab04-44d9-93cd-413e9f123317" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8a93b7d4-8faf-4614-8ba4-d941fccf7083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8a93b7d4-8faf-4614-8ba4-d941fccf7083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7105542c-5517-430d-b4b8-e30f9680cabc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7105542c-5517-430d-b4b8-e30f9680cabc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6254377b-81f7-4c4b-aec5-6737f3c9a24e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6254377b-81f7-4c4b-aec5-6737f3c9a24e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_72462df5-2633-4055-953b-4b517dceb24a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_72462df5-2633-4055-953b-4b517dceb24a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_996d5199-e6ee-417b-9ae2-82e6d5748e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_996d5199-e6ee-417b-9ae2-82e6d5748e2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c485807c-5616-4a5c-9c20-8c16d5e32c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c485807c-5616-4a5c-9c20-8c16d5e32c60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_16c6c6cf-32ff-4611-9349-23d7bb9e4018" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_16c6c6cf-32ff-4611-9349-23d7bb9e4018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_abab350d-d00c-4b43-8321-28e220d00adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_ShareBasedCompensation_abab350d-d00c-4b43-8321-28e220d00adf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_983f2ae2-2758-4673-b23a-56aa49209d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_983f2ae2-2758-4673-b23a-56aa49209d1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_a663fe6b-7d33-447e-b892-b880e1006e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_a663fe6b-7d33-447e-b892-b880e1006e3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_48d4c6e3-ca23-4e84-8333-a10f7483d559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_48d4c6e3-ca23-4e84-8333-a10f7483d559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a0302325-0092-4480-a299-fb8b3cc448cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a0302325-0092-4480-a299-fb8b3cc448cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4c07d120-03f4-43ec-bc7c-8f04e6b8b674" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4c07d120-03f4-43ec-bc7c-8f04e6b8b674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments_61fc57e2-a4d6-49b9-af62-caa78560cfe0" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_e65dd2ad-ddcd-4e87-b583-2b1ba31f7fcf" xlink:to="loc_agio_GainLossOnSaleOfContingentPayments_61fc57e2-a4d6-49b9-af62-caa78560cfe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e502c04-273d-40c7-b271-f3d0963f94ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_333ebf32-d4be-4f31-a8c6-0f4d6522413a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e502c04-273d-40c7-b271-f3d0963f94ea" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_333ebf32-d4be-4f31-a8c6-0f4d6522413a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2a335900-4dbc-4fc5-af85-ee86e3ddf042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6e502c04-273d-40c7-b271-f3d0963f94ea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_2a335900-4dbc-4fc5-af85-ee86e3ddf042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa44e251-17e8-4286-ada8-a0f9f69cad5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_d4808584-129c-4f24-ad4f-c3418705722e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa44e251-17e8-4286-ada8-a0f9f69cad5b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_d4808584-129c-4f24-ad4f-c3418705722e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_96c4685c-6dde-4151-96c0-befc61d65640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa44e251-17e8-4286-ada8-a0f9f69cad5b" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_96c4685c-6dde-4151-96c0-befc61d65640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b6b81a0a-81c1-45c3-b34f-a4f3bf93139c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa44e251-17e8-4286-ada8-a0f9f69cad5b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_b6b81a0a-81c1-45c3-b34f-a4f3bf93139c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2867a9e1-1ee3-46ee-b49c-e7ba5dda265c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5756f749-db74-43c5-b267-4b689bd61cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2867a9e1-1ee3-46ee-b49c-e7ba5dda265c" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_5756f749-db74-43c5-b267-4b689bd61cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_97ee97de-14ba-41ad-9823-70b108dfd641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2867a9e1-1ee3-46ee-b49c-e7ba5dda265c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_97ee97de-14ba-41ad-9823-70b108dfd641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e0a481f-ca91-4750-adf3-807d3fa17621" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_788887b1-b438-44a1-9def-1b3d31164022" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e0a481f-ca91-4750-adf3-807d3fa17621" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_788887b1-b438-44a1-9def-1b3d31164022" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_252ebcd0-ade2-4097-8e08-e00984a969c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e0a481f-ca91-4750-adf3-807d3fa17621" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_252ebcd0-ade2-4097-8e08-e00984a969c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69723994-9a8c-4210-991a-c42676a36cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0e0a481f-ca91-4750-adf3-807d3fa17621" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_69723994-9a8c-4210-991a-c42676a36cbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_5de02788-7f0d-43ad-acb9-1082ce704d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ef7a2a00-c4d9-464c-8d9e-36c289eff86b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_5de02788-7f0d-43ad-acb9-1082ce704d6b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ef7a2a00-c4d9-464c-8d9e-36c289eff86b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PaymentsAssociatedWithLicenseAgreement_e58b51c0-d533-49b8-942d-fbd5e8907bfb" xlink:href="agio-20231231.xsd#agio_PaymentsAssociatedWithLicenseAgreement"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_5de02788-7f0d-43ad-acb9-1082ce704d6b" xlink:to="loc_agio_PaymentsAssociatedWithLicenseAgreement_e58b51c0-d533-49b8-942d-fbd5e8907bfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_5092fc77-6480-4364-9e03-63bb975ef558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_5de02788-7f0d-43ad-acb9-1082ce704d6b" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_5092fc77-6480-4364-9e03-63bb975ef558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5219e1a9-bf46-4873-9f7b-737f8ebed41e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_5de02788-7f0d-43ad-acb9-1082ce704d6b" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5219e1a9-bf46-4873-9f7b-737f8ebed41e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9cc9017a-059e-4e65-bb10-d3d99de43074" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_5de02788-7f0d-43ad-acb9-1082ce704d6b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9cc9017a-059e-4e65-bb10-d3d99de43074" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfContingentPayments_12c674d5-caf4-4f9f-8574-5353b35c5a2a" xlink:href="agio-20231231.xsd#agio_ProceedsFromSaleOfContingentPayments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_5de02788-7f0d-43ad-acb9-1082ce704d6b" xlink:to="loc_agio_ProceedsFromSaleOfContingentPayments_12c674d5-caf4-4f9f-8574-5353b35c5a2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_afa4988f-9de9-4aa7-b566-30f93f9eeafa" xlink:href="agio-20231231.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7ac74bee-3186-4d94-b294-1211a765e68a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_afa4988f-9de9-4aa7-b566-30f93f9eeafa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7ac74bee-3186-4d94-b294-1211a765e68a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b87f695d-0ff0-428d-ae74-ce9402322204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_afa4988f-9de9-4aa7-b566-30f93f9eeafa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b87f695d-0ff0-428d-ae74-ce9402322204" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#MarketableSecuritiesScheduleofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8c129e0e-8931-4cfe-ab80-a0877dc0abbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0c812cae-da00-4f56-8016-caa78d5c6983" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8c129e0e-8931-4cfe-ab80-a0877dc0abbe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0c812cae-da00-4f56-8016-caa78d5c6983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fbba79c-8f85-428e-8dac-d21205b18a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8c129e0e-8931-4cfe-ab80-a0877dc0abbe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7fbba79c-8f85-428e-8dac-d21205b18a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f4e66524-0b46-417e-a7c5-06df08474714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8c129e0e-8931-4cfe-ab80-a0877dc0abbe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f4e66524-0b46-417e-a7c5-06df08474714" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e7e571c8-708c-4f3a-86f6-3d1bb54d1f28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9df72c86-2168-44ca-a814-6381424fab57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e7e571c8-708c-4f3a-86f6-3d1bb54d1f28" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9df72c86-2168-44ca-a814-6381424fab57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_438b12c8-024f-4d3a-b2a8-c75f289621d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e7e571c8-708c-4f3a-86f6-3d1bb54d1f28" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_438b12c8-024f-4d3a-b2a8-c75f289621d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_aced65f1-7928-452b-b2e9-b0acbd69bc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e7e571c8-708c-4f3a-86f6-3d1bb54d1f28" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_aced65f1-7928-452b-b2e9-b0acbd69bc9b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e21893bd-b3b2-4f1f-8a29-98108453ef3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5545dd62-d950-4bb8-9fb3-71b02a72ea61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e21893bd-b3b2-4f1f-8a29-98108453ef3c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5545dd62-d950-4bb8-9fb3-71b02a72ea61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3ad24c71-1774-422c-8575-29f109e74605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e21893bd-b3b2-4f1f-8a29-98108453ef3c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3ad24c71-1774-422c-8575-29f109e74605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d506a5b0-2e43-43c7-970b-44abad0b288b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e21893bd-b3b2-4f1f-8a29-98108453ef3c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d506a5b0-2e43-43c7-970b-44abad0b288b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b26e14ef-f235-46aa-b5df-b9349afb9587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e21893bd-b3b2-4f1f-8a29-98108453ef3c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b26e14ef-f235-46aa-b5df-b9349afb9587" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2ff1e729-2274-49d8-a5f5-c3224a2149ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e21893bd-b3b2-4f1f-8a29-98108453ef3c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2ff1e729-2274-49d8-a5f5-c3224a2149ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6928ca26-ba71-4d41-95c8-c484b2fae3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e21893bd-b3b2-4f1f-8a29-98108453ef3c" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6928ca26-ba71-4d41-95c8-c484b2fae3fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_75f7e644-aab5-4cd9-88f8-d95b154d518d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_01ac80c2-ff63-400a-920a-dba69024142b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_75f7e644-aab5-4cd9-88f8-d95b154d518d" xlink:to="loc_us-gaap_OperatingLeaseLiability_01ac80c2-ff63-400a-920a-dba69024142b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d42ea731-02a3-4c1e-82b1-76716df9cadb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_75f7e644-aab5-4cd9-88f8-d95b154d518d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d42ea731-02a3-4c1e-82b1-76716df9cadb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c0e3b3f2-4566-452a-9d64-b0a548739a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_401922db-c3ea-4c1b-be82-92709308451e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c0e3b3f2-4566-452a-9d64-b0a548739a87" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_401922db-c3ea-4c1b-be82-92709308451e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_d467048b-fcc1-434b-8832-773c3bfc78fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_c0e3b3f2-4566-452a-9d64-b0a548739a87" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_d467048b-fcc1-434b-8832-773c3bfc78fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e4db3e70-d4c0-47fa-8d19-dfe9da735c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6d60fe3f-8793-4606-a2f0-4e85080fa07a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e4db3e70-d4c0-47fa-8d19-dfe9da735c77" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6d60fe3f-8793-4606-a2f0-4e85080fa07a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_d26ac119-1816-4544-99bc-0da6b3ae97fe" xlink:href="agio-20231231.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e4db3e70-d4c0-47fa-8d19-dfe9da735c77" xlink:to="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_d26ac119-1816-4544-99bc-0da6b3ae97fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17b29241-9e45-458a-9f3d-de7d42c6c7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e4db3e70-d4c0-47fa-8d19-dfe9da735c77" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_17b29241-9e45-458a-9f3d-de7d42c6c7ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b99ec3da-b9b3-481e-8b99-e05de838527c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e4db3e70-d4c0-47fa-8d19-dfe9da735c77" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b99ec3da-b9b3-481e-8b99-e05de838527c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_2bf2abbb-a613-453f-b938-3c269a819607" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_5efc5d45-55df-4410-a303-22b25e65487c" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_2bf2abbb-a613-453f-b938-3c269a819607" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_5efc5d45-55df-4410-a303-22b25e65487c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_c207f433-30e2-4e77-a3c9-b7246d320582" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_2bf2abbb-a613-453f-b938-3c269a819607" xlink:to="loc_agio_ContractWithCustomerRebateReserve_c207f433-30e2-4e77-a3c9-b7246d320582" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_887be4bd-bac7-4807-99c3-a1005a680f61" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_2bf2abbb-a613-453f-b938-3c269a819607" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_887be4bd-bac7-4807-99c3-a1005a680f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_3e8a3b15-f31b-49ff-a7c3-deee9a240b6a" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_a39dee02-0ac2-42b1-96a0-50c81ca8cb32" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_3e8a3b15-f31b-49ff-a7c3-deee9a240b6a" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_a39dee02-0ac2-42b1-96a0-50c81ca8cb32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_df495eae-2b99-45a9-86a2-6f39fe9c68de" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_3e8a3b15-f31b-49ff-a7c3-deee9a240b6a" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_df495eae-2b99-45a9-86a2-6f39fe9c68de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_0e0a9f3d-7989-4df6-87d8-84ee9ca37ced" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_3e8a3b15-f31b-49ff-a7c3-deee9a240b6a" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_0e0a9f3d-7989-4df6-87d8-84ee9ca37ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_29a57c7f-98d6-4932-a405-8abd38ffae9d" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_a2a26000-28b4-4a1e-88b1-9bb7308be4e1" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_29a57c7f-98d6-4932-a405-8abd38ffae9d" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_a2a26000-28b4-4a1e-88b1-9bb7308be4e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_e56d3994-7474-4449-a1ce-603f5e94985d" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_29a57c7f-98d6-4932-a405-8abd38ffae9d" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_e56d3994-7474-4449-a1ce-603f5e94985d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_704ac227-346e-4bb4-b8c1-81bb04267d7a" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_29a57c7f-98d6-4932-a405-8abd38ffae9d" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_704ac227-346e-4bb4-b8c1-81bb04267d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_cb61d572-d816-4ee4-a2ed-ea8141d13da4" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve_52ece22d-fd90-4d82-b677-6d87e4aefd78" xlink:href="agio-20231231.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_cb61d572-d816-4ee4-a2ed-ea8141d13da4" xlink:to="loc_agio_CurrentYearProvisionsForRebateReserve_52ece22d-fd90-4d82-b677-6d87e4aefd78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_5d0bc0be-6820-4d72-b1e4-d2f50d9d77b3" xlink:href="agio-20231231.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_cb61d572-d816-4ee4-a2ed-ea8141d13da4" xlink:to="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_5d0bc0be-6820-4d72-b1e4-d2f50d9d77b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments_f27efab0-4e20-4690-85ed-90f624532085" xlink:href="agio-20231231.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_cb61d572-d816-4ee4-a2ed-ea8141d13da4" xlink:to="loc_agio_CurrentYearProvisionForContractualAdjustments_f27efab0-4e20-4690-85ed-90f624532085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_0dc7e0e5-bffd-4cff-85b7-951743279769" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve_e3b93894-46b7-4f44-af32-b320498de1b0" xlink:href="agio-20231231.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_0dc7e0e5-bffd-4cff-85b7-951743279769" xlink:to="loc_agio_PriorYearProvisionsForRebateReserve_e3b93894-46b7-4f44-af32-b320498de1b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears_707e3cc4-6360-47e0-9ecc-705922d1b0ff" xlink:href="agio-20231231.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_0dc7e0e5-bffd-4cff-85b7-951743279769" xlink:to="loc_agio_ProvisionForRightToRecoverProductInPriorYears_707e3cc4-6360-47e0-9ecc-705922d1b0ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments_337af61a-a198-4e97-b359-47de9c488a44" xlink:href="agio-20231231.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_0dc7e0e5-bffd-4cff-85b7-951743279769" xlink:to="loc_agio_PriorYearProvisionForContractualAdjustments_337af61a-a198-4e97-b359-47de9c488a44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_98e6907d-9d49-4e5b-9f71-64cf690d62b6" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ffb3bfe0-d314-48f8-8af7-136b517ba291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_98e6907d-9d49-4e5b-9f71-64cf690d62b6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_ffb3bfe0-d314-48f8-8af7-136b517ba291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_f587e95f-ee64-4791-a526-2e9d98d02d4a" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_98e6907d-9d49-4e5b-9f71-64cf690d62b6" xlink:to="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_f587e95f-ee64-4791-a526-2e9d98d02d4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ae0c3dc3-fa3a-4fea-bb6a-511b67433a91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f28237b1-943c-46c2-9469-bbbefb0d50d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ae0c3dc3-fa3a-4fea-bb6a-511b67433a91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f28237b1-943c-46c2-9469-bbbefb0d50d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_aa8c0d99-a4c8-4507-b088-40ae852a6e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ae0c3dc3-fa3a-4fea-bb6a-511b67433a91" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_aa8c0d99-a4c8-4507-b088-40ae852a6e9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5e8efb7a-e143-41e1-bae4-7f069754c0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9892da5f-b215-4ff1-8df9-a4c543cc9273" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5e8efb7a-e143-41e1-bae4-7f069754c0bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9892da5f-b215-4ff1-8df9-a4c543cc9273" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f2a9e907-0690-47ab-9612-5cbf313fb1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5e8efb7a-e143-41e1-bae4-7f069754c0bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_f2a9e907-0690-47ab-9612-5cbf313fb1d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a920caf-8ad9-45df-b231-39bb244556f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5e8efb7a-e143-41e1-bae4-7f069754c0bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a920caf-8ad9-45df-b231-39bb244556f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments_236506a5-c7f6-4fa0-81bd-010f714e18f5" xlink:href="agio-20231231.xsd#agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5e8efb7a-e143-41e1-bae4-7f069754c0bf" xlink:to="loc_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments_236506a5-c7f6-4fa0-81bd-010f714e18f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_443e457d-dbac-4ad6-be67-ff3925b6f029" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5e8efb7a-e143-41e1-bae4-7f069754c0bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_443e457d-dbac-4ad6-be67-ff3925b6f029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_c52dd8d5-620c-4055-ad41-c7ac9105f61c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5e8efb7a-e143-41e1-bae4-7f069754c0bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_c52dd8d5-620c-4055-ad41-c7ac9105f61c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6198e19d-5e54-4f11-b108-539c8b34d796" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2baeefe9-4edf-4001-896a-868290463d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6198e19d-5e54-4f11-b108-539c8b34d796" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2baeefe9-4edf-4001-896a-868290463d5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c9019f86-1247-4959-8fb8-717ab03e3a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6198e19d-5e54-4f11-b108-539c8b34d796" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c9019f86-1247-4959-8fb8-717ab03e3a2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_347df976-2685-42ec-b439-b5ec1e808e36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6198e19d-5e54-4f11-b108-539c8b34d796" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_347df976-2685-42ec-b439-b5ec1e808e36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9bf83eb1-250c-4817-8677-87505cee6ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6198e19d-5e54-4f11-b108-539c8b34d796" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9bf83eb1-250c-4817-8677-87505cee6ce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_4a3c3a97-44ad-46ce-8498-af06b7a2bb37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6198e19d-5e54-4f11-b108-539c8b34d796" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_4a3c3a97-44ad-46ce-8498-af06b7a2bb37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredTaxAssetsOperatingLeaseLiability_9131a7d7-7558-4414-ba59-3da444424254" xlink:href="agio-20231231.xsd#agio_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6198e19d-5e54-4f11-b108-539c8b34d796" xlink:to="loc_agio_DeferredTaxAssetsOperatingLeaseLiability_9131a7d7-7558-4414-ba59-3da444424254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e28a2832-3e35-43ca-96ce-f468c7f2863b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_6198e19d-5e54-4f11-b108-539c8b34d796" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e28a2832-3e35-43ca-96ce-f468c7f2863b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c5024ac0-fa11-4fbf-a581-a455ab7b286b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c95ccd3f-9da3-4c8f-8729-e359e7e8d2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c5024ac0-fa11-4fbf-a581-a455ab7b286b" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c95ccd3f-9da3-4c8f-8729-e359e7e8d2f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2b26887f-27f4-4ba7-97e9-96c8d4072443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c5024ac0-fa11-4fbf-a581-a455ab7b286b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2b26887f-27f4-4ba7-97e9-96c8d4072443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c4b5c10f-b82f-48b6-a6ed-70b652da5117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c5024ac0-fa11-4fbf-a581-a455ab7b286b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c4b5c10f-b82f-48b6-a6ed-70b652da5117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6078571d-9abc-49fe-9a16-11815821b7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c5024ac0-fa11-4fbf-a581-a455ab7b286b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6078571d-9abc-49fe-9a16-11815821b7d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72252400-fb68-4118-a750-0b59174b744d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_253e58f5-62ff-4869-990f-4b622621a20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_72252400-fb68-4118-a750-0b59174b744d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_253e58f5-62ff-4869-990f-4b622621a20b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7a3777cf-28fd-4e99-b42a-d8b1722235a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_72252400-fb68-4118-a750-0b59174b744d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7a3777cf-28fd-4e99-b42a-d8b1722235a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_842abfaa-0b49-4a2d-9a3b-f62c738aa3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_846766ac-4f12-425b-91f4-77bab6fc1d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_842abfaa-0b49-4a2d-9a3b-f62c738aa3b5" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_846766ac-4f12-425b-91f4-77bab6fc1d74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0ac05ac3-5fb5-4cfb-bffb-61b4c0e839f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_842abfaa-0b49-4a2d-9a3b-f62c738aa3b5" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_0ac05ac3-5fb5-4cfb-bffb-61b4c0e839f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9d705a58-c7e9-4289-b268-7eef3656f1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6332b8d3-9902-4ab5-b7a4-1d30876fbb75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9d705a58-c7e9-4289-b268-7eef3656f1a7" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6332b8d3-9902-4ab5-b7a4-1d30876fbb75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c3709616-6c0f-46af-bb61-fc3b8cb87695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_9d705a58-c7e9-4289-b268-7eef3656f1a7" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_c3709616-6c0f-46af-bb61-fc3b8cb87695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_13e25def-e4dd-498c-8169-081277d82849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_5321b512-4db6-40f9-80c0-63fa9d342d75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_13e25def-e4dd-498c-8169-081277d82849" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_5321b512-4db6-40f9-80c0-63fa9d342d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue_b9ae74b6-da2a-4a43-a0d5-7f950c5033bb" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_13e25def-e4dd-498c-8169-081277d82849" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue_b9ae74b6-da2a-4a43-a0d5-7f950c5033bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_f05ca3e1-fb84-43ca-a8c9-f95b1bdef553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_13e25def-e4dd-498c-8169-081277d82849" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_f05ca3e1-fb84-43ca-a8c9-f95b1bdef553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a058fe61-cdf9-404f-87da-b7835fd68b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_b7eb5b58-c0c8-4481-86b4-ee0be277e4dd" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a058fe61-cdf9-404f-87da-b7835fd68b92" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_b7eb5b58-c0c8-4481-86b4-ee0be277e4dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_21043ae2-f766-4a08-809d-7d3ce15394b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a058fe61-cdf9-404f-87da-b7835fd68b92" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_21043ae2-f766-4a08-809d-7d3ce15394b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_599c08d0-0c11-4b41-9077-8eb547195013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a058fe61-cdf9-404f-87da-b7835fd68b92" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_599c08d0-0c11-4b41-9077-8eb547195013" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_5b05edd9-e567-40f0-b565-238777ca630d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_d43b80e2-f2c8-48c5-b2c8-449a6c0f6c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_5b05edd9-e567-40f0-b565-238777ca630d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_d43b80e2-f2c8-48c5-b2c8-449a6c0f6c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_236928c5-b8f8-48b4-9f53-e592f5466f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_5b05edd9-e567-40f0-b565-238777ca630d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_236928c5-b8f8-48b4-9f53-e592f5466f7e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>agio-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:2870ab7b-aea5-4779-abd7-f438083a7088,g:ac8cf5ba-8c61-4750-87a9-db53e1eda885-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://agios.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_32259d05-fdd8-44a0-835f-2145c5113794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_StatementTable_32259d05-fdd8-44a0-835f-2145c5113794" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab064c6c-50a1-4177-91df-6f53887e2172" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_32259d05-fdd8-44a0-835f-2145c5113794" xlink:to="loc_srt_ProductOrServiceAxis_ab064c6c-50a1-4177-91df-6f53887e2172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab064c6c-50a1-4177-91df-6f53887e2172_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ab064c6c-50a1-4177-91df-6f53887e2172" xlink:to="loc_srt_ProductsAndServicesDomain_ab064c6c-50a1-4177-91df-6f53887e2172_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0bac9821-b493-479b-87ea-06ad61b1b4e8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ab064c6c-50a1-4177-91df-6f53887e2172" xlink:to="loc_srt_ProductsAndServicesDomain_0bac9821-b493-479b-87ea-06ad61b1b4e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_24b0a3bd-0674-4fc9-9eff-43ea3e570869" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0bac9821-b493-479b-87ea-06ad61b1b4e8" xlink:to="loc_us-gaap_ProductMember_24b0a3bd-0674-4fc9-9eff-43ea3e570869" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b3bbd8b1-2ccc-40fb-82f0-9c745e8c8d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0bac9821-b493-479b-87ea-06ad61b1b4e8" xlink:to="loc_us-gaap_RoyaltyMember_b3bbd8b1-2ccc-40fb-82f0-9c745e8c8d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a0389f85-bf94-4717-bcb5-bc5d45aed0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a0389f85-bf94-4717-bcb5-bc5d45aed0a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_43d2aea2-5bdc-4f07-a33a-be24de791d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a0389f85-bf94-4717-bcb5-bc5d45aed0a9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_43d2aea2-5bdc-4f07-a33a-be24de791d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_76eb6e4b-0a8b-4a17-9606-8f51844ab500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_76eb6e4b-0a8b-4a17-9606-8f51844ab500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d8305ff5-4c35-4bc2-838a-f072fa5dd83a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d8305ff5-4c35-4bc2-838a-f072fa5dd83a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7ca5c63f-d433-457d-ae2d-1c48eab2e976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7ca5c63f-d433-457d-ae2d-1c48eab2e976" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0badfec4-4b0c-4c7c-933d-99392601be7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:to="loc_us-gaap_CostsAndExpenses_0badfec4-4b0c-4c7c-933d-99392601be7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_33fa38fb-cd35-4201-bb1c-5625864d5875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_OperatingIncomeLoss_33fa38fb-cd35-4201-bb1c-5625864d5875" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments_ef1bade2-fc70-4709-ac28-d911c75bf02f" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_agio_GainLossOnSaleOfContingentPayments_ef1bade2-fc70-4709-ac28-d911c75bf02f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_06f63ab3-a3d1-4778-aefb-20fe6b5f0439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_06f63ab3-a3d1-4778-aefb-20fe6b5f0439" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_464e95bc-9ab7-4762-9c99-3b98e7bedd43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_464e95bc-9ab7-4762-9c99-3b98e7bedd43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_61382c98-40f5-4ca0-8546-b0ef82967076" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_61382c98-40f5-4ca0-8546-b0ef82967076" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8517e764-07fa-49f4-a391-2989096dc85c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8517e764-07fa-49f4-a391-2989096dc85c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_cb39a936-d3fb-4f3c-99e3-de9d2f69140b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_cb39a936-d3fb-4f3c-99e3-de9d2f69140b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d1bc3833-92fd-4da8-9f0e-46b1949cb505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_NetIncomeLoss_d1bc3833-92fd-4da8-9f0e-46b1949cb505" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fa86f602-fd8f-4c6a-ac0c-55e8560b3aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fa86f602-fd8f-4c6a-ac0c-55e8560b3aef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0ca8e032-b57b-4dca-a9ab-38eec0ae5e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0ca8e032-b57b-4dca-a9ab-38eec0ae5e64" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_8d5afabe-f917-49d3-bd6a-f051df91eeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_8d5afabe-f917-49d3-bd6a-f051df91eeb3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e038c293-bf2b-4b96-9e87-ef18bc01cebd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e038c293-bf2b-4b96-9e87-ef18bc01cebd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5821b64d-d9f4-4b2d-aba5-7508bdcbead9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_EarningsPerShareBasic_5821b64d-d9f4-4b2d-aba5-7508bdcbead9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6bf24624-36aa-43a8-b9ba-557903de17d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6bf24624-36aa-43a8-b9ba-557903de17d7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_424d8c13-53f9-4196-87ea-f363f02f010f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_424d8c13-53f9-4196-87ea-f363f02f010f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb23a262-c019-4315-a9a8-64853c3313ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb23a262-c019-4315-a9a8-64853c3313ca" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://agios.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cdd41e9c-f25f-4127-b0c9-f574a9494da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54ae78ad-9b8e-458e-b56d-db416cd35752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cdd41e9c-f25f-4127-b0c9-f574a9494da6" xlink:to="loc_us-gaap_StatementTable_54ae78ad-9b8e-458e-b56d-db416cd35752" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0e687414-ca6f-4949-a28f-ac6825bafcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_54ae78ad-9b8e-458e-b56d-db416cd35752" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0e687414-ca6f-4949-a28f-ac6825bafcf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e687414-ca6f-4949-a28f-ac6825bafcf2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0e687414-ca6f-4949-a28f-ac6825bafcf2" xlink:to="loc_us-gaap_EquityComponentDomain_0e687414-ca6f-4949-a28f-ac6825bafcf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0e687414-ca6f-4949-a28f-ac6825bafcf2" xlink:to="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bcef508f-c477-4dde-aeaa-49090752a4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_CommonStockMember_bcef508f-c477-4dde-aeaa-49090752a4ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8bf5e0e2-42b8-4fd4-b10e-b2c8545b8e02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8bf5e0e2-42b8-4fd4-b10e-b2c8545b8e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_141364cc-05a1-4bec-ac74-518775f357dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_141364cc-05a1-4bec-ac74-518775f357dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3c55c2ea-bc42-4f19-bede-065bd0d8a772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_RetainedEarningsMember_3c55c2ea-bc42-4f19-bede-065bd0d8a772" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_db5d9bd6-59c1-4aad-8b1e-a090e228aa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_TreasuryStockCommonMember_db5d9bd6-59c1-4aad-8b1e-a090e228aa3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cdd41e9c-f25f-4127-b0c9-f574a9494da6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2e636d71-2b2a-4d6e-bd91-8e626f916dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2e636d71-2b2a-4d6e-bd91-8e626f916dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ffa2d8c9-6f90-4eae-83a8-2390ef856243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_StockholdersEquity_ffa2d8c9-6f90-4eae-83a8-2390ef856243" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_3b7ed1f3-d246-42ef-bc6e-4c4c896ae554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_TreasuryStockCommonShares_3b7ed1f3-d246-42ef-bc6e-4c4c896ae554" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax_d250b23a-7092-46c1-913a-8acf9e204885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax_d250b23a-7092-46c1-913a-8acf9e204885" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8341fd4c-ce1a-4431-8bbd-713e838bfc46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_NetIncomeLoss_8341fd4c-ce1a-4431-8bbd-713e838bfc46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a8ba4fd4-75aa-438b-b45f-11397bc35b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a8ba4fd4-75aa-438b-b45f-11397bc35b83" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_be84cf38-e71b-40d2-b1e1-6c2eac351a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_be84cf38-e71b-40d2-b1e1-6c2eac351a0a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5e51d5f6-2e18-4170-a728-9b4522001d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5e51d5f6-2e18-4170-a728-9b4522001d04" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_782b9904-5e83-44d4-8547-b68e9b50bfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_782b9904-5e83-44d4-8547-b68e9b50bfd1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_98edcfcd-8283-4885-8d5e-903b1f23fffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_98edcfcd-8283-4885-8d5e-903b1f23fffe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_StockholdersEquityDispositionOfBusiness_7f556caa-7aa8-4a1a-98b9-6d22e09fe659" xlink:href="agio-20231231.xsd#agio_StockholdersEquityDispositionOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_agio_StockholdersEquityDispositionOfBusiness_7f556caa-7aa8-4a1a-98b9-6d22e09fe659" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_803f79be-7768-4c94-b39d-be69a62943c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd3d5538-9856-48f2-ad95-40977cccd111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_458526ee-1c80-47fc-baef-28cdae4dd9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#NatureofBusinessDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_82ec6627-4e4d-4e8a-b777-79afcfa68ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_AssetAcquisitionAxis_82ec6627-4e4d-4e8a-b777-79afcfa68ca3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_82ec6627-4e4d-4e8a-b777-79afcfa68ca3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_82ec6627-4e4d-4e8a-b777-79afcfa68ca3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_82ec6627-4e4d-4e8a-b777-79afcfa68ca3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_0d7527b5-0715-42d8-893c-5868b6aa95a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_82ec6627-4e4d-4e8a-b777-79afcfa68ca3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_0d7527b5-0715-42d8-893c-5868b6aa95a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AlnylamPharmaceuticalsIncMember_030361e0-3378-45b7-a83a-0973f7bf2e1d" xlink:href="agio-20231231.xsd#agio_AlnylamPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_0d7527b5-0715-42d8-893c-5868b6aa95a8" xlink:to="loc_agio_AlnylamPharmaceuticalsIncMember_030361e0-3378-45b7-a83a-0973f7bf2e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_56937154-1336-4c1b-b2e4-0513833f2459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_56937154-1336-4c1b-b2e4-0513833f2459" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_56937154-1336-4c1b-b2e4-0513833f2459_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_56937154-1336-4c1b-b2e4-0513833f2459" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_56937154-1336-4c1b-b2e4-0513833f2459_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_82001e37-7920-4799-9046-206d44ea7142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_56937154-1336-4c1b-b2e4-0513833f2459" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_82001e37-7920-4799-9046-206d44ea7142" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_080a60c5-a82d-4b37-9f3e-b5412f67ba0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_82001e37-7920-4799-9046-206d44ea7142" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_080a60c5-a82d-4b37-9f3e-b5412f67ba0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_37bab1a4-d50b-4a67-b771-f8078c60f02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_37bab1a4-d50b-4a67-b771-f8078c60f02a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_37bab1a4-d50b-4a67-b771-f8078c60f02a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_37bab1a4-d50b-4a67-b771-f8078c60f02a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_37bab1a4-d50b-4a67-b771-f8078c60f02a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93845f15-f26f-4c91-9325-451add59e7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_37bab1a4-d50b-4a67-b771-f8078c60f02a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93845f15-f26f-4c91-9325-451add59e7f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_913c9942-5abc-405f-b574-ad6a2d7c5d82" xlink:href="agio-20231231.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93845f15-f26f-4c91-9325-451add59e7f5" xlink:to="loc_agio_AgiosOncologyBusinessMember_913c9942-5abc-405f-b574-ad6a2d7c5d82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75ab2a96-2603-4fe2-b102-5bcfedf994db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_srt_ProductOrServiceAxis_75ab2a96-2603-4fe2-b102-5bcfedf994db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_75ab2a96-2603-4fe2-b102-5bcfedf994db_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_75ab2a96-2603-4fe2-b102-5bcfedf994db" xlink:to="loc_srt_ProductsAndServicesDomain_75ab2a96-2603-4fe2-b102-5bcfedf994db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_72df4ef5-aa5c-4c29-8321-4fbac05cc445" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_75ab2a96-2603-4fe2-b102-5bcfedf994db" xlink:to="loc_srt_ProductsAndServicesDomain_72df4ef5-aa5c-4c29-8321-4fbac05cc445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TIBSOVOMember_3a3a5b86-4e21-48d5-874b-068f2e8d1fcb" xlink:href="agio-20231231.xsd#agio_TIBSOVOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72df4ef5-aa5c-4c29-8321-4fbac05cc445" xlink:to="loc_agio_TIBSOVOMember_3a3a5b86-4e21-48d5-874b-068f2e8d1fcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_VorasidenibMember_8699f1a9-dd50-475c-a07d-0b2a466545b7" xlink:href="agio-20231231.xsd#agio_VorasidenibMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_72df4ef5-aa5c-4c29-8321-4fbac05cc445" xlink:to="loc_agio_VorasidenibMember_8699f1a9-dd50-475c-a07d-0b2a466545b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9ff760d-6710-4e6f-975b-6e7a72435b12" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_srt_StatementGeographicalAxis_a9ff760d-6710-4e6f-975b-6e7a72435b12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a9ff760d-6710-4e6f-975b-6e7a72435b12_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a9ff760d-6710-4e6f-975b-6e7a72435b12" xlink:to="loc_srt_SegmentGeographicalDomain_a9ff760d-6710-4e6f-975b-6e7a72435b12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_64194d80-280a-484f-acc4-4e50f0de98a2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a9ff760d-6710-4e6f-975b-6e7a72435b12" xlink:to="loc_srt_SegmentGeographicalDomain_64194d80-280a-484f-acc4-4e50f0de98a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_69c81cc6-789b-4eee-ac15-bc96038bdf3f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_64194d80-280a-484f-acc4-4e50f0de98a2" xlink:to="loc_country_US_69c81cc6-789b-4eee-ac15-bc96038bdf3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7527ba52-5f24-4422-8af1-453428f4b112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7527ba52-5f24-4422-8af1-453428f4b112" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7527ba52-5f24-4422-8af1-453428f4b112_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7527ba52-5f24-4422-8af1-453428f4b112" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7527ba52-5f24-4422-8af1-453428f4b112_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_864481bd-f2d3-4374-b431-66d942b5b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7527ba52-5f24-4422-8af1-453428f4b112" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_864481bd-f2d3-4374-b431-66d942b5b7fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_37831c3e-e839-4a6e-9fb1-b42da27abc46" xlink:href="agio-20231231.xsd#agio_Agreement2010Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_864481bd-f2d3-4374-b431-66d942b5b7fd" xlink:to="loc_agio_Agreement2010Member_37831c3e-e839-4a6e-9fb1-b42da27abc46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fc58967d-9081-4cd9-b2d8-612085674ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fc58967d-9081-4cd9-b2d8-612085674ba4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc58967d-9081-4cd9-b2d8-612085674ba4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc58967d-9081-4cd9-b2d8-612085674ba4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc58967d-9081-4cd9-b2d8-612085674ba4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aaa5099b-9812-47ee-a830-c52f4ca654b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc58967d-9081-4cd9-b2d8-612085674ba4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aaa5099b-9812-47ee-a830-c52f4ca654b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AtTheMarketOfferingMember_6e23cb22-606e-48d8-8791-d5f3360001d7" xlink:href="agio-20231231.xsd#agio_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aaa5099b-9812-47ee-a830-c52f4ca654b1" xlink:to="loc_agio_AtTheMarketOfferingMember_6e23cb22-606e-48d8-8791-d5f3360001d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PaymentsForAssetAcquisition_79b5a535-5230-4fb9-ba09-f9978a0eecd2" xlink:href="agio-20231231.xsd#agio_PaymentsForAssetAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_PaymentsForAssetAcquisition_79b5a535-5230-4fb9-ba09-f9978a0eecd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment_68016737-b298-45e0-862d-926fbc4dbe80" xlink:href="agio-20231231.xsd#agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment_68016737-b298-45e0-862d-926fbc4dbe80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_b7df6394-0ebe-4681-b8a3-0b2988450d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_b7df6394-0ebe-4681-b8a3-0b2988450d59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_62ea2c94-0fad-4719-b847-81870c335235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_62ea2c94-0fad-4719-b847-81870c335235" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainContingencyRoyaltyPercentageOfNetSales_b1959e9b-ab5d-44b3-ae6c-9826444e85c4" xlink:href="agio-20231231.xsd#agio_GainContingencyRoyaltyPercentageOfNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_GainContingencyRoyaltyPercentageOfNetSales_b1959e9b-ab5d-44b3-ae6c-9826444e85c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_07de5edb-04ca-465e-8661-4cdb695091b7" xlink:href="agio-20231231.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_07de5edb-04ca-465e-8661-4cdb695091b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments_1aa53eb5-424a-4e6d-b450-d41d505e83b5" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_GainLossOnSaleOfContingentPayments_1aa53eb5-424a-4e6d-b450-d41d505e83b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContingentGainOnDispositionOfBusinessRecognized_317f5f64-e56e-439f-95df-962aec75f954" xlink:href="agio-20231231.xsd#agio_ContingentGainOnDispositionOfBusinessRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_ContingentGainOnDispositionOfBusinessRecognized_317f5f64-e56e-439f-95df-962aec75f954" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3eeeada0-1e8f-42ba-83c0-4a5f822f3370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3eeeada0-1e8f-42ba-83c0-4a5f822f3370" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction_0e067dc4-aabd-4d88-a4b0-354591d4c5a4" xlink:href="agio-20231231.xsd#agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction_0e067dc4-aabd-4d88-a4b0-354591d4c5a4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue_cf107ac4-99e1-4e43-b12d-b23d2506faee" xlink:href="agio-20231231.xsd#agio_SaleOfStockCommonStockReservedForFutureIssuanceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue_cf107ac4-99e1-4e43-b12d-b23d2506faee" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:href="agio-20231231.xsd#agio_ScheduleOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfSignificantAccountingPoliciesTable_3faf2ae8-17cd-4156-b3d8-3c2ca721dc3b" xlink:href="agio-20231231.xsd#agio_ScheduleOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:to="loc_agio_ScheduleOfSignificantAccountingPoliciesTable_3faf2ae8-17cd-4156-b3d8-3c2ca721dc3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1112b1eb-c33a-4c59-a00d-0b817b6f6ec4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesTable_3faf2ae8-17cd-4156-b3d8-3c2ca721dc3b" xlink:to="loc_srt_RangeAxis_1112b1eb-c33a-4c59-a00d-0b817b6f6ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1112b1eb-c33a-4c59-a00d-0b817b6f6ec4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1112b1eb-c33a-4c59-a00d-0b817b6f6ec4" xlink:to="loc_srt_RangeMember_1112b1eb-c33a-4c59-a00d-0b817b6f6ec4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68d300c4-e2cb-4ede-9af5-636e43430d7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1112b1eb-c33a-4c59-a00d-0b817b6f6ec4" xlink:to="loc_srt_RangeMember_68d300c4-e2cb-4ede-9af5-636e43430d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_00b4fe70-d8b1-4d94-84eb-094248379899" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68d300c4-e2cb-4ede-9af5-636e43430d7c" xlink:to="loc_srt_MinimumMember_00b4fe70-d8b1-4d94-84eb-094248379899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f8099cf-5f14-467f-b1cd-796ae96f2267" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_68d300c4-e2cb-4ede-9af5-636e43430d7c" xlink:to="loc_srt_MaximumMember_8f8099cf-5f14-467f-b1cd-796ae96f2267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod_97addbed-b673-422f-8989-bd444a54a5c2" xlink:href="agio-20231231.xsd#agio_AvailableForSaleSecuritiesCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:to="loc_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod_97addbed-b673-422f-8989-bd444a54a5c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod_0fa1bffc-0c45-4e7f-b028-3e39f46d1304" xlink:href="agio-20231231.xsd#agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:to="loc_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod_0fa1bffc-0c45-4e7f-b028-3e39f46d1304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod_b284eb1f-9314-48da-99db-8aef8fe3737d" xlink:href="agio-20231231.xsd#agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:to="loc_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod_b284eb1f-9314-48da-99db-8aef8fe3737d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_620000da-f8c7-4c7d-afa4-81af115794d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:to="loc_us-gaap_NumberOfOperatingSegments_620000da-f8c7-4c7d-afa4-81af115794d8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5554cfec-e9fe-491f-a785-cc71a66b567f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a7fc012-b764-459e-a515-0c7428b055cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5554cfec-e9fe-491f-a785-cc71a66b567f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a7fc012-b764-459e-a515-0c7428b055cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67dcfa94-cc5a-4f65-a950-7eb17c117196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a7fc012-b764-459e-a515-0c7428b055cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67dcfa94-cc5a-4f65-a950-7eb17c117196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67dcfa94-cc5a-4f65-a950-7eb17c117196_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67dcfa94-cc5a-4f65-a950-7eb17c117196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_67dcfa94-cc5a-4f65-a950-7eb17c117196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67dcfa94-cc5a-4f65-a950-7eb17c117196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LaboratoryEquipmentMember_e099db7c-3bca-4689-8fd0-5d0cb42818f4" xlink:href="agio-20231231.xsd#agio_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:to="loc_agio_LaboratoryEquipmentMember_e099db7c-3bca-4689-8fd0-5d0cb42818f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ComputerEquipmentAndSoftwareMember_8a86b8fc-bc77-4b58-9525-fd9f07258825" xlink:href="agio-20231231.xsd#agio_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:to="loc_agio_ComputerEquipmentAndSoftwareMember_8a86b8fc-bc77-4b58-9525-fd9f07258825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0f8af241-7ec6-4a7d-bd8e-e926c8f2513d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0f8af241-7ec6-4a7d-bd8e-e926c8f2513d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_6a1d7cac-34ea-41e5-bee6-81a641174132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:to="loc_us-gaap_OfficeEquipmentMember_6a1d7cac-34ea-41e5-bee6-81a641174132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9ec2493b-139c-4ab6-bff8-c593fd42bf01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5554cfec-e9fe-491f-a785-cc71a66b567f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9ec2493b-139c-4ab6-bff8-c593fd42bf01" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2ba822d2-2ab3-4539-bf27-397443a5b631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2ba822d2-2ab3-4539-bf27-397443a5b631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2ba822d2-2ab3-4539-bf27-397443a5b631_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2ba822d2-2ab3-4539-bf27-397443a5b631" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2ba822d2-2ab3-4539-bf27-397443a5b631_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_58feeb17-ca7a-44a8-a025-471077eb5eae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2ba822d2-2ab3-4539-bf27-397443a5b631" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_58feeb17-ca7a-44a8-a025-471077eb5eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0f6b008b-2ca4-4c71-8c65-88728bd2f7db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_58feeb17-ca7a-44a8-a025-471077eb5eae" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0f6b008b-2ca4-4c71-8c65-88728bd2f7db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e48ed332-796f-436b-befa-a27b917322d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e48ed332-796f-436b-befa-a27b917322d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e48ed332-796f-436b-befa-a27b917322d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e48ed332-796f-436b-befa-a27b917322d9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e48ed332-796f-436b-befa-a27b917322d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e48ed332-796f-436b-befa-a27b917322d9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f587dd79-c41c-48af-8a14-8d95b7ec5ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f587dd79-c41c-48af-8a14-8d95b7ec5ff8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_113bf585-81db-45ab-8e0f-805889ed7abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_113bf585-81db-45ab-8e0f-805889ed7abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8b6f48b8-1c9a-4622-9cbe-70557f1cf87c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8b6f48b8-1c9a-4622-9cbe-70557f1cf87c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9a3c6dfc-7384-4f50-abf6-58836d6b93df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:to="loc_us-gaap_InvestmentTypeAxis_9a3c6dfc-7384-4f50-abf6-58836d6b93df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9a3c6dfc-7384-4f50-abf6-58836d6b93df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_9a3c6dfc-7384-4f50-abf6-58836d6b93df" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9a3c6dfc-7384-4f50-abf6-58836d6b93df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a4828bca-6127-49e3-ba25-2080584a7dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_9a3c6dfc-7384-4f50-abf6-58836d6b93df" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a4828bca-6127-49e3-ba25-2080584a7dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_a724a780-1009-4c05-8399-92c5e91de4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a4828bca-6127-49e3-ba25-2080584a7dcb" xlink:to="loc_us-gaap_CashEquivalentsMember_a724a780-1009-4c05-8399-92c5e91de4b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c01e9438-b21e-4dc6-8160-fa4b03673373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c01e9438-b21e-4dc6-8160-fa4b03673373" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c01e9438-b21e-4dc6-8160-fa4b03673373_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c01e9438-b21e-4dc6-8160-fa4b03673373" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c01e9438-b21e-4dc6-8160-fa4b03673373_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c01e9438-b21e-4dc6-8160-fa4b03673373" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5aad080e-6e7d-4aae-a18f-c78618692e49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5aad080e-6e7d-4aae-a18f-c78618692e49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d7331e19-7b1a-46f3-bc33-052ac7f8b6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d7331e19-7b1a-46f3-bc33-052ac7f8b6eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_528d9d16-c0f5-4f21-a53e-1c0a405de15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_528d9d16-c0f5-4f21-a53e-1c0a405de15c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5ca66f27-9cb2-4be7-8971-ebabd9968ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5ca66f27-9cb2-4be7-8971-ebabd9968ec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f5ba90f-d2f2-4fa9-801c-e5ad664c2aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f5ba90f-d2f2-4fa9-801c-e5ad664c2aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_74b3112e-1745-4c53-99c9-5844d5551893" xlink:href="agio-20231231.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:to="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_74b3112e-1745-4c53-99c9-5844d5551893" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_db9781c1-2a1d-41a8-b8e0-bb15320070f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecedd640-5132-46da-b818-eb90fa509c71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_db9781c1-2a1d-41a8-b8e0-bb15320070f8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecedd640-5132-46da-b818-eb90fa509c71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6521c7b-0029-476e-b0a2-c769f2b31587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecedd640-5132-46da-b818-eb90fa509c71" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6521c7b-0029-476e-b0a2-c769f2b31587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6521c7b-0029-476e-b0a2-c769f2b31587_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6521c7b-0029-476e-b0a2-c769f2b31587" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f6521c7b-0029-476e-b0a2-c769f2b31587_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a9ddd88-6681-43d5-b71f-03ecf28d38cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6521c7b-0029-476e-b0a2-c769f2b31587" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a9ddd88-6681-43d5-b71f-03ecf28d38cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3e97d970-8308-499b-9884-c14f9f3599b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a9ddd88-6681-43d5-b71f-03ecf28d38cc" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3e97d970-8308-499b-9884-c14f9f3599b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d80fad98-fcc2-487e-a7d5-8548efc17083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecedd640-5132-46da-b818-eb90fa509c71" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d80fad98-fcc2-487e-a7d5-8548efc17083" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d80fad98-fcc2-487e-a7d5-8548efc17083_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d80fad98-fcc2-487e-a7d5-8548efc17083" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d80fad98-fcc2-487e-a7d5-8548efc17083_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bf909e6d-0e79-4bb7-975b-3876c98ace82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d80fad98-fcc2-487e-a7d5-8548efc17083" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bf909e6d-0e79-4bb7-975b-3876c98ace82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a4b69ffd-67cf-42df-8b31-720b8bb4b318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bf909e6d-0e79-4bb7-975b-3876c98ace82" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a4b69ffd-67cf-42df-8b31-720b8bb4b318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_bae6583d-3fb0-420a-86d6-8c69202dcb75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_db9781c1-2a1d-41a8-b8e0-bb15320070f8" xlink:to="loc_us-gaap_FairValueNetAssetLiability_bae6583d-3fb0-420a-86d6-8c69202dcb75" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#MarketableSecuritiesScheduleofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cfe14f4d-aab2-4eed-910f-9789c863c4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cfe14f4d-aab2-4eed-910f-9789c863c4f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_24436d22-74d8-4601-8f61-4911c93920e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cfe14f4d-aab2-4eed-910f-9789c863c4f6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_24436d22-74d8-4601-8f61-4911c93920e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24436d22-74d8-4601-8f61-4911c93920e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_24436d22-74d8-4601-8f61-4911c93920e9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24436d22-74d8-4601-8f61-4911c93920e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_514b924c-b67e-44f0-8765-87f57f75e5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_24436d22-74d8-4601-8f61-4911c93920e9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_514b924c-b67e-44f0-8765-87f57f75e5ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember_c79bc158-50e0-4f11-b348-343bf06d622a" xlink:href="agio-20231231.xsd#agio_CurrentAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_514b924c-b67e-44f0-8765-87f57f75e5ff" xlink:to="loc_agio_CurrentAssetMember_c79bc158-50e0-4f11-b348-343bf06d622a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember_e15fd518-9e11-452f-aee2-ed88f722de77" xlink:href="agio-20231231.xsd#agio_NonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_514b924c-b67e-44f0-8765-87f57f75e5ff" xlink:to="loc_agio_NonCurrentAssetsMember_e15fd518-9e11-452f-aee2-ed88f722de77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8a0545d1-a0c2-45e4-8384-1ed3053969e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cfe14f4d-aab2-4eed-910f-9789c863c4f6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8a0545d1-a0c2-45e4-8384-1ed3053969e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a0545d1-a0c2-45e4-8384-1ed3053969e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8a0545d1-a0c2-45e4-8384-1ed3053969e5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8a0545d1-a0c2-45e4-8384-1ed3053969e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8a0545d1-a0c2-45e4-8384-1ed3053969e5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_779ef352-91e4-40fc-9362-abbdb3712241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_779ef352-91e4-40fc-9362-abbdb3712241" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_391a5219-7994-47f7-8092-dbc13ae22c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_391a5219-7994-47f7-8092-dbc13ae22c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_54759812-260b-4924-ac89-a4477e1705ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_54759812-260b-4924-ac89-a4477e1705ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20ff7ba1-cfe2-46af-a09e-26c123185eec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20ff7ba1-cfe2-46af-a09e-26c123185eec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49e2fd4b-f608-4da5-b8d7-231fb4a6d86f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49e2fd4b-f608-4da5-b8d7-231fb4a6d86f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da8a255c-b33a-4186-a680-b4bd6bbffed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da8a255c-b33a-4186-a680-b4bd6bbffed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f0e5bb1-b380-401a-9ff8-cc78c6d07e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f0e5bb1-b380-401a-9ff8-cc78c6d07e0f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_23445c6b-d4b1-4262-b938-37ad4b0d4153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_23445c6b-d4b1-4262-b938-37ad4b0d4153" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LeaseArrangementsAxis_564f85f1-4606-4538-b995-460f9b670282" xlink:href="agio-20231231.xsd#agio_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_23445c6b-d4b1-4262-b938-37ad4b0d4153" xlink:to="loc_agio_LeaseArrangementsAxis_564f85f1-4606-4538-b995-460f9b670282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LeaseArrangementsDomain_564f85f1-4606-4538-b995-460f9b670282_default" xlink:href="agio-20231231.xsd#agio_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_agio_LeaseArrangementsAxis_564f85f1-4606-4538-b995-460f9b670282" xlink:to="loc_agio_LeaseArrangementsDomain_564f85f1-4606-4538-b995-460f9b670282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:href="agio-20231231.xsd#agio_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_agio_LeaseArrangementsAxis_564f85f1-4606-4538-b995-460f9b670282" xlink:to="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EightyEightSidneyStreetLeaseMember_ccf615e5-4b19-4daf-b158-b5d1e7038039" xlink:href="agio-20231231.xsd#agio_EightyEightSidneyStreetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:to="loc_agio_EightyEightSidneyStreetLeaseMember_ccf615e5-4b19-4daf-b158-b5d1e7038039" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SixtyFourSidneyStreetLeaseMember_9321e2bf-510f-41c7-b648-89c522576fc8" xlink:href="agio-20231231.xsd#agio_SixtyFourSidneyStreetLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:to="loc_agio_SixtyFourSidneyStreetLeaseMember_9321e2bf-510f-41c7-b648-89c522576fc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember_f5f7a892-f8d3-4ebf-a5dc-cdb5b5324b6f" xlink:href="agio-20231231.xsd#agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:to="loc_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember_f5f7a892-f8d3-4ebf-a5dc-cdb5b5324b6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ffd77b16-5e6f-4464-88c5-d9b7574d26b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_23445c6b-d4b1-4262-b938-37ad4b0d4153" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ffd77b16-5e6f-4464-88c5-d9b7574d26b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ffd77b16-5e6f-4464-88c5-d9b7574d26b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ffd77b16-5e6f-4464-88c5-d9b7574d26b2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ffd77b16-5e6f-4464-88c5-d9b7574d26b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e2399316-8264-4ab9-b225-a49d8f6a0f44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ffd77b16-5e6f-4464-88c5-d9b7574d26b2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e2399316-8264-4ab9-b225-a49d8f6a0f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_473db1df-0c93-4299-be36-b108811c7ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e2399316-8264-4ab9-b225-a49d8f6a0f44" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_473db1df-0c93-4299-be36-b108811c7ffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2f9291cb-9b6e-4387-b50e-bbe6e739d244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2f9291cb-9b6e-4387-b50e-bbe6e739d244" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace_6c76d36f-37f1-4dd4-9356-ceb97dc45d21" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace_6c76d36f-37f1-4dd4-9356-ceb97dc45d21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseNumberOfLeaseTerms_de16d1aa-ef3c-43ff-80e7-0a3611e19741" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseNumberOfLeaseTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseNumberOfLeaseTerms_de16d1aa-ef3c-43ff-80e7-0a3611e19741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_26053bf8-50b2-45b3-b09c-67d9ec6014b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_26053bf8-50b2-45b3-b09c-67d9ec6014b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d66cc1b6-fc68-43d7-9dd0-79c2d903b2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d66cc1b6-fc68-43d7-9dd0-79c2d903b2bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9b71fb00-6afb-495a-81d1-61384b3e08e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9b71fb00-6afb-495a-81d1-61384b3e08e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_79eece62-ffd5-406b-9f2c-027a984a6eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_79eece62-ffd5-406b-9f2c-027a984a6eaa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_7b2acabd-15e9-4125-9117-2c84bffeb79c" xlink:href="agio-20231231.xsd#agio_LesseeOperatingSubleaseAreaOfPremisesSubleased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_7b2acabd-15e9-4125-9117-2c84bffeb79c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods_bb4c1c5c-677d-4aa1-b97b-6fce07e07341" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods_bb4c1c5c-677d-4aa1-b97b-6fce07e07341" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod_c5e9cbdd-e868-48a3-ab88-0966fdb7d215" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod_c5e9cbdd-e868-48a3-ab88-0966fdb7d215" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo_fe63fb59-3317-4b94-8331-09739c878452" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo_fe63fb59-3317-4b94-8331-09739c878452" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_77ac6745-e007-4899-b748-c521a2fdd7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_SubleaseIncome_77ac6745-e007-4899-b748-c521a2fdd7b8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDepositLiability_d84751f7-4a3a-47fc-9278-0f9130a4a6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_SecurityDepositLiability_d84751f7-4a3a-47fc-9278-0f9130a4a6e4" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenueScheduleofProductRevenueNetDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6aac1e4f-0347-4e2f-8f28-41bdad75509b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5cdd55b3-a415-4976-9cc8-95e79f8e71d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6aac1e4f-0347-4e2f-8f28-41bdad75509b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5cdd55b3-a415-4976-9cc8-95e79f8e71d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d2c3ab4b-2d30-45b9-86a9-bad01e432920" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5cdd55b3-a415-4976-9cc8-95e79f8e71d2" xlink:to="loc_srt_ProductOrServiceAxis_d2c3ab4b-2d30-45b9-86a9-bad01e432920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d2c3ab4b-2d30-45b9-86a9-bad01e432920_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d2c3ab4b-2d30-45b9-86a9-bad01e432920" xlink:to="loc_srt_ProductsAndServicesDomain_d2c3ab4b-2d30-45b9-86a9-bad01e432920_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a606a75-2720-4c39-8c7a-5417865b2894" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d2c3ab4b-2d30-45b9-86a9-bad01e432920" xlink:to="loc_srt_ProductsAndServicesDomain_1a606a75-2720-4c39-8c7a-5417865b2894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_1d61cb89-242b-4e65-9a37-1d8aaadd0e81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1a606a75-2720-4c39-8c7a-5417865b2894" xlink:to="loc_us-gaap_ProductMember_1d61cb89-242b-4e65-9a37-1d8aaadd0e81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb92ad41-c0c9-47ef-abcf-d40e4e679bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6aac1e4f-0347-4e2f-8f28-41bdad75509b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb92ad41-c0c9-47ef-abcf-d40e4e679bcd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f3f1fef-5f83-4799-b1cd-5581c28bc2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f3f1fef-5f83-4799-b1cd-5581c28bc2de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ac75a65b-d275-44b7-9d7e-8b823c37724f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f3f1fef-5f83-4799-b1cd-5581c28bc2de" xlink:to="loc_us-gaap_PlanNameAxis_ac75a65b-d275-44b7-9d7e-8b823c37724f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ac75a65b-d275-44b7-9d7e-8b823c37724f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ac75a65b-d275-44b7-9d7e-8b823c37724f" xlink:to="loc_us-gaap_PlanNameDomain_ac75a65b-d275-44b7-9d7e-8b823c37724f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ac75a65b-d275-44b7-9d7e-8b823c37724f" xlink:to="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_fe25a248-cfe9-4e6a-b9ab-d64165d7507b" xlink:href="agio-20231231.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:to="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_fe25a248-cfe9-4e6a-b9ab-d64165d7507b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_066a68d6-a640-4616-8d2f-809f1c27a878" xlink:href="agio-20231231.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:to="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_066a68d6-a640-4616-8d2f-809f1c27a878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_2c0b8f2c-c43f-4d01-bb0c-f9c9be3dfa89" xlink:href="agio-20231231.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_2c0b8f2c-c43f-4d01-bb0c-f9c9be3dfa89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_183684d1-dbb7-46f0-b5f0-7d6d1e10f9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f3f1fef-5f83-4799-b1cd-5581c28bc2de" xlink:to="loc_us-gaap_AwardTypeAxis_183684d1-dbb7-46f0-b5f0-7d6d1e10f9ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183684d1-dbb7-46f0-b5f0-7d6d1e10f9ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_183684d1-dbb7-46f0-b5f0-7d6d1e10f9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_183684d1-dbb7-46f0-b5f0-7d6d1e10f9ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_183684d1-dbb7-46f0-b5f0-7d6d1e10f9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b6954ed5-affb-4457-9760-6ea7aca2a127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b6954ed5-affb-4457-9760-6ea7aca2a127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_5ec70d0c-ac7f-49a4-8567-ab4c2eb1eb5d" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:to="loc_agio_PerformanceStockUnitMember_5ec70d0c-ac7f-49a4-8567-ab4c2eb1eb5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_1496194b-9c3c-4d47-a333-1f5be885acab" xlink:href="agio-20231231.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:to="loc_agio_MarketBasedStockUnitsMember_1496194b-9c3c-4d47-a333-1f5be885acab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3bf9daca-a0c6-453b-a381-6eef2c935949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3bf9daca-a0c6-453b-a381-6eef2c935949" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9947f31e-04b5-44b7-895f-c818770f9673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9947f31e-04b5-44b7-895f-c818770f9673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1a33321b-804e-4738-9171-68a4c97aa5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1a33321b-804e-4738-9171-68a4c97aa5d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d7490cf-16d2-4a0e-a287-497fa67d5e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d7490cf-16d2-4a0e-a287-497fa67d5e69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a9d7b7d2-07dd-443f-8057-9f4563d4af66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a9d7b7d2-07dd-443f-8057-9f4563d4af66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2212f30a-9b64-47c6-a67f-3891cab28812" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2212f30a-9b64-47c6-a67f-3891cab28812" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70f29e84-0e84-4fbb-afd3-178ddb4aef21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70f29e84-0e84-4fbb-afd3-178ddb4aef21" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_58f2b9d7-6fda-46eb-973b-dd59d5f4967b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_58f2b9d7-6fda-46eb-973b-dd59d5f4967b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares_e985a394-9526-417e-8ece-7833ea846ed7" xlink:href="agio-20231231.xsd#agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares_e985a394-9526-417e-8ece-7833ea846ed7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_d6f9ff4c-53b7-4612-801f-74bea76a798a" xlink:href="agio-20231231.xsd#agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_d6f9ff4c-53b7-4612-801f-74bea76a798a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69ac946e-6379-44f0-8bba-d2ff56de39fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69ac946e-6379-44f0-8bba-d2ff56de39fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_8d09d657-42f9-4b20-9488-be1c49d1e7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_8d09d657-42f9-4b20-9488-be1c49d1e7a1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5faec2cd-ae58-465e-9e34-c65ae5cce10d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5faec2cd-ae58-465e-9e34-c65ae5cce10d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_09cc3d3a-38f0-490b-9cad-18efe298df8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_09cc3d3a-38f0-490b-9cad-18efe298df8c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0480fa23-66b0-435d-8c22-1517fad80d91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0480fa23-66b0-435d-8c22-1517fad80d91" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d19b620-9824-407e-9304-d48adf4b45c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64187545-1310-4ed8-9df6-1459b4ae7962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d19b620-9824-407e-9304-d48adf4b45c8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64187545-1310-4ed8-9df6-1459b4ae7962" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4b62da7-22e0-449f-b215-555335df7164" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64187545-1310-4ed8-9df6-1459b4ae7962" xlink:to="loc_us-gaap_AwardTypeAxis_f4b62da7-22e0-449f-b215-555335df7164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4b62da7-22e0-449f-b215-555335df7164_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f4b62da7-22e0-449f-b215-555335df7164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4b62da7-22e0-449f-b215-555335df7164_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f4b62da7-22e0-449f-b215-555335df7164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eea8e7e7-546b-4f6e-8590-37a76df819cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eea8e7e7-546b-4f6e-8590-37a76df819cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_98751ece-6bd0-4d64-a587-02516bdf2df8" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:to="loc_agio_PerformanceStockUnitMember_98751ece-6bd0-4d64-a587-02516bdf2df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_629f3951-9c0d-485d-9e68-d948d69a461c" xlink:href="agio-20231231.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:to="loc_agio_MarketBasedStockUnitsMember_629f3951-9c0d-485d-9e68-d948d69a461c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d19b620-9824-407e-9304-d48adf4b45c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bdda556-db6a-4362-98a1-5dbbd5a74bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bdda556-db6a-4362-98a1-5dbbd5a74bb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e31a302-11f2-4b7c-9541-e8c6ea316f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e31a302-11f2-4b7c-9541-e8c6ea316f07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fe8cb937-7beb-48c7-b1d5-37c29749b63e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fe8cb937-7beb-48c7-b1d5-37c29749b63e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b62a8fdb-7406-47b5-8a24-fa10eb47bc45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b62a8fdb-7406-47b5-8a24-fa10eb47bc45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b0e9b9cd-7d16-46e2-9818-a3dd2801ca85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d19b620-9824-407e-9304-d48adf4b45c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a7d8955a-bae7-4ad2-ae66-a77357263ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a7d8955a-bae7-4ad2-ae66-a77357263ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_902f9ef6-0a65-44df-b8e6-5af9c2bd8adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_902f9ef6-0a65-44df-b8e6-5af9c2bd8adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5fecbefa-feb6-4a06-83b8-b5b62325e2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5fecbefa-feb6-4a06-83b8-b5b62325e2b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8fa3c394-7838-4291-a7c5-0880d5841d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8fa3c394-7838-4291-a7c5-0880d5841d84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_030aaa17-1d4f-4795-9fbe-a82adfe6730d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adab3361-93a8-4535-b3bb-8f233b876e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06735e09-beb2-4b7e-b801-6c4e9edab202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adab3361-93a8-4535-b3bb-8f233b876e92" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06735e09-beb2-4b7e-b801-6c4e9edab202" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a48697f1-e76c-4d11-921f-d40da295ba81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06735e09-beb2-4b7e-b801-6c4e9edab202" xlink:to="loc_us-gaap_AwardTypeAxis_a48697f1-e76c-4d11-921f-d40da295ba81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a48697f1-e76c-4d11-921f-d40da295ba81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a48697f1-e76c-4d11-921f-d40da295ba81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a48697f1-e76c-4d11-921f-d40da295ba81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a48697f1-e76c-4d11-921f-d40da295ba81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_85c227ed-d7f0-4258-b016-1755753df513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_85c227ed-d7f0-4258-b016-1755753df513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dda4e763-6cee-49c9-9688-32be5084a97f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dda4e763-6cee-49c9-9688-32be5084a97f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_4caeb5c1-032d-4f99-a466-c1d814503ab2" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:to="loc_agio_PerformanceStockUnitMember_4caeb5c1-032d-4f99-a466-c1d814503ab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_ed0dffca-ce5a-47c3-8c2e-214fd59f38b6" xlink:href="agio-20231231.xsd#agio_EmployeePurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:to="loc_agio_EmployeePurchasePlanMember_ed0dffca-ce5a-47c3-8c2e-214fd59f38b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0da930a0-d2da-43df-a355-42b3ff58b68b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adab3361-93a8-4535-b3bb-8f233b876e92" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0da930a0-d2da-43df-a355-42b3ff58b68b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050d077e-d528-4362-bdaf-cea1e8f50024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68f64668-f0a7-4581-ab1d-37920c92e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050d077e-d528-4362-bdaf-cea1e8f50024" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68f64668-f0a7-4581-ab1d-37920c92e07c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_01cb6338-5e1f-403b-a658-9a8dbae260f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68f64668-f0a7-4581-ab1d-37920c92e07c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_01cb6338-5e1f-403b-a658-9a8dbae260f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_01cb6338-5e1f-403b-a658-9a8dbae260f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_01cb6338-5e1f-403b-a658-9a8dbae260f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_01cb6338-5e1f-403b-a658-9a8dbae260f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_175c0847-a531-4bb4-af69-c4a36bfc7bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_01cb6338-5e1f-403b-a658-9a8dbae260f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_175c0847-a531-4bb4-af69-c4a36bfc7bfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9dc257db-6683-44dc-9d98-e8b98eab5162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_175c0847-a531-4bb4-af69-c4a36bfc7bfe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9dc257db-6683-44dc-9d98-e8b98eab5162" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_216e55d3-ef74-4ede-a715-7dc582595cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_175c0847-a531-4bb4-af69-c4a36bfc7bfe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_216e55d3-ef74-4ede-a715-7dc582595cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bacd962a-5532-4ce7-a7c0-66ee6dbc53dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050d077e-d528-4362-bdaf-cea1e8f50024" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bacd962a-5532-4ce7-a7c0-66ee6dbc53dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/NetIncomeLossperShareDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#NetIncomeLossperShareDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/NetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a97c4f98-2499-42aa-b324-627faf2a211d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fde4da77-83eb-4c4b-bd64-8183e5df2843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a97c4f98-2499-42aa-b324-627faf2a211d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fde4da77-83eb-4c4b-bd64-8183e5df2843" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2f217416-cfa7-4300-ade8-44c8a89b92fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fde4da77-83eb-4c4b-bd64-8183e5df2843" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2f217416-cfa7-4300-ade8-44c8a89b92fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f217416-cfa7-4300-ade8-44c8a89b92fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2f217416-cfa7-4300-ade8-44c8a89b92fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2f217416-cfa7-4300-ade8-44c8a89b92fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2f217416-cfa7-4300-ade8-44c8a89b92fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2fe5d4ed-9b56-4f4f-bf74-6566baf3b005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2fe5d4ed-9b56-4f4f-bf74-6566baf3b005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6def8a3a-3546-4447-8129-f526672a0862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6def8a3a-3546-4447-8129-f526672a0862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_40f0b948-8376-4dea-b61c-1edd633994bb" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:to="loc_agio_PerformanceStockUnitMember_40f0b948-8376-4dea-b61c-1edd633994bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_022709ea-fae1-46b9-8f77-c0132c6b24f5" xlink:href="agio-20231231.xsd#agio_EmployeePurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:to="loc_agio_EmployeePurchasePlanMember_022709ea-fae1-46b9-8f77-c0132c6b24f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b6fcbe06-a39f-4416-b6d2-6a2d8eda1638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a97c4f98-2499-42aa-b324-627faf2a211d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b6fcbe06-a39f-4416-b6d2-6a2d8eda1638" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:href="agio-20231231.xsd#agio_IncomeTaxesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:href="agio-20231231.xsd#agio_IncomeTaxesDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c87f0d29-a8c9-4ef9-8c2c-849090d524fc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:to="loc_srt_StatementGeographicalAxis_c87f0d29-a8c9-4ef9-8c2c-849090d524fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c87f0d29-a8c9-4ef9-8c2c-849090d524fc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_c87f0d29-a8c9-4ef9-8c2c-849090d524fc" xlink:to="loc_srt_SegmentGeographicalDomain_c87f0d29-a8c9-4ef9-8c2c-849090d524fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ab1ea70e-9579-4ab3-b3ff-39f23698f178" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_c87f0d29-a8c9-4ef9-8c2c-849090d524fc" xlink:to="loc_srt_SegmentGeographicalDomain_ab1ea70e-9579-4ab3-b3ff-39f23698f178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b3d810d5-7873-4b30-856d-71a229c46c40" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ab1ea70e-9579-4ab3-b3ff-39f23698f178" xlink:to="loc_country_US_b3d810d5-7873-4b30-856d-71a229c46c40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2186fe05-dd80-4d50-a66a-23025e0721aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ab1ea70e-9579-4ab3-b3ff-39f23698f178" xlink:to="loc_us-gaap_NonUsMember_2186fe05-dd80-4d50-a66a-23025e0721aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_506998ea-95da-46eb-a392-3d90d0a5933f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_506998ea-95da-46eb-a392-3d90d0a5933f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_506998ea-95da-46eb-a392-3d90d0a5933f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_506998ea-95da-46eb-a392-3d90d0a5933f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_506998ea-95da-46eb-a392-3d90d0a5933f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_506998ea-95da-46eb-a392-3d90d0a5933f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_adbfa02e-d8fb-4bd1-ad6c-2b60b5db1cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:to="loc_us-gaap_DomesticCountryMember_adbfa02e-d8fb-4bd1-ad6c-2b60b5db1cfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a87e06e7-c008-438a-8943-efa1761a979b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a87e06e7-c008-438a-8943-efa1761a979b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_00839ae3-b1fc-4e65-b45c-af1f3c50a923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:to="loc_us-gaap_ForeignCountryMember_00839ae3-b1fc-4e65-b45c-af1f3c50a923" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2210320a-2c1f-4610-960f-4abe628c0be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2210320a-2c1f-4610-960f-4abe628c0be5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_2210320a-2c1f-4610-960f-4abe628c0be5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2210320a-2c1f-4610-960f-4abe628c0be5" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_2210320a-2c1f-4610-960f-4abe628c0be5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0c4749b2-1754-4acb-9a8e-26529bb6eaef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2210320a-2c1f-4610-960f-4abe628c0be5" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0c4749b2-1754-4acb-9a8e-26529bb6eaef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_aa2ec4fa-a070-4fa0-a18c-b8d97266e881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0c4749b2-1754-4acb-9a8e-26529bb6eaef" xlink:to="loc_us-gaap_ResearchMember_aa2ec4fa-a070-4fa0-a18c-b8d97266e881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_FederalOrphanDrugTaxCreditMember_538a5a98-7ca5-465f-9b10-a03b3d0e336d" xlink:href="agio-20231231.xsd#agio_FederalOrphanDrugTaxCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0c4749b2-1754-4acb-9a8e-26529bb6eaef" xlink:to="loc_agio_FederalOrphanDrugTaxCreditMember_538a5a98-7ca5-465f-9b10-a03b3d0e336d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_159113a1-6c92-48ec-b5e1-31031e752829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_159113a1-6c92-48ec-b5e1-31031e752829" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_159113a1-6c92-48ec-b5e1-31031e752829_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_159113a1-6c92-48ec-b5e1-31031e752829" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_159113a1-6c92-48ec-b5e1-31031e752829_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1d0c375a-89a8-4b2d-b9b8-ad4b43e4a8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_159113a1-6c92-48ec-b5e1-31031e752829" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1d0c375a-89a8-4b2d-b9b8-ad4b43e4a8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_504c9162-429d-4915-a8c0-83921375275e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1d0c375a-89a8-4b2d-b9b8-ad4b43e4a8c1" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_504c9162-429d-4915-a8c0-83921375275e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_11e2f8a8-4bdb-41a9-944d-2233314e0abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_11e2f8a8-4bdb-41a9-944d-2233314e0abf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod_8cc1c4ad-0951-437b-a1a4-81aa5d5208ff" xlink:href="agio-20231231.xsd#agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod_8cc1c4ad-0951-437b-a1a4-81aa5d5208ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_bfe65771-8d6a-4715-868d-d75ae8e84993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_bfe65771-8d6a-4715-868d-d75ae8e84993" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_afd08272-9f1b-47b9-a61f-4be5435cfd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_afd08272-9f1b-47b9-a61f-4be5435cfd0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PercentageOfStockholdersOwnershipIncrease_3c750255-25e6-4f07-998e-fd6f2070904a" xlink:href="agio-20231231.xsd#agio_PercentageOfStockholdersOwnershipIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_agio_PercentageOfStockholdersOwnershipIncrease_3c750255-25e6-4f07-998e-fd6f2070904a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PeriodOfChangeInStockholdersOwnership_b84ccd52-ab7a-45ed-9bfa-4ce451019505" xlink:href="agio-20231231.xsd#agio_PeriodOfChangeInStockholdersOwnership"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_agio_PeriodOfChangeInStockholdersOwnership_b84ccd52-ab7a-45ed-9bfa-4ce451019505" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a054fdaa-cb0e-4bfa-8c1a-7a90897deb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a054fdaa-cb0e-4bfa-8c1a-7a90897deb2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_bc02b054-746a-4ce2-8afa-58cf210e8e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_bc02b054-746a-4ce2-8afa-58cf210e8e8e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_00919ba3-4413-4e9f-b002-196b0d659a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_00919ba3-4413-4e9f-b002-196b0d659a3c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_422e82ce-6303-4cf0-826f-ba2bf6b1466a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_422e82ce-6303-4cf0-826f-ba2bf6b1466a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NumberOfStatesFederalOrForeignInAuditingProcess_11624336-c729-43c6-a07e-aa76b1e5e32c" xlink:href="agio-20231231.xsd#agio_NumberOfStatesFederalOrForeignInAuditingProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_agio_NumberOfStatesFederalOrForeignInAuditingProcess_11624336-c729-43c6-a07e-aa76b1e5e32c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_700ae47c-31df-4f3a-b514-59c46e053c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_IncomeTaxReceivable_700ae47c-31df-4f3a-b514-59c46e053c81" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_737206ee-aa0d-4f38-9446-db62edf44155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_737206ee-aa0d-4f38-9446-db62edf44155" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_14a6d382-2003-4bc6-9d1d-d7a840e17294" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_737206ee-aa0d-4f38-9446-db62edf44155" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_14a6d382-2003-4bc6-9d1d-d7a840e17294" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14a6d382-2003-4bc6-9d1d-d7a840e17294_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_14a6d382-2003-4bc6-9d1d-d7a840e17294" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_14a6d382-2003-4bc6-9d1d-d7a840e17294_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_14a6d382-2003-4bc6-9d1d-d7a840e17294" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LaboratoryEquipmentMember_fe72d5df-f0eb-4d99-ade3-318f346937e1" xlink:href="agio-20231231.xsd#agio_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_agio_LaboratoryEquipmentMember_fe72d5df-f0eb-4d99-ade3-318f346937e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ComputerEquipmentAndSoftwareMember_878c8b3b-914d-44e0-a883-da826c2b5867" xlink:href="agio-20231231.xsd#agio_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_agio_ComputerEquipmentAndSoftwareMember_878c8b3b-914d-44e0-a883-da826c2b5867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_79a01129-2b57-41b5-b859-b91da4e067d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_79a01129-2b57-41b5-b859-b91da4e067d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_37749154-cca9-4557-a3a9-9461c1d6a1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_37749154-cca9-4557-a3a9-9461c1d6a1c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_3f8fc54c-ab45-4a37-9270-a0bd5be07e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_us-gaap_OfficeEquipmentMember_3f8fc54c-ab45-4a37-9270-a0bd5be07e16" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_83ba791c-1e88-4a34-a718-3a8eeae47ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_us-gaap_ConstructionInProgressMember_83ba791c-1e88-4a34-a718-3a8eeae47ee7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5770fd70-5d93-4716-a3cb-c1a204a1f156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5770fd70-5d93-4716-a3cb-c1a204a1f156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d787ef5c-8690-4293-a400-7664b92a2da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d787ef5c-8690-4293-a400-7664b92a2da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_69cf48cb-e55d-4a8a-ae8b-e5221261848e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_69cf48cb-e55d-4a8a-ae8b-e5221261848e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/ShareRepurchaseProgramDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareRepurchaseProgramDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/ShareRepurchaseProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_82d90910-1646-4c02-9cbb-67ee8c16877c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_82d90910-1646-4c02-9cbb-67ee8c16877c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0a31361f-0c4f-465d-bc73-b32300db8785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_82d90910-1646-4c02-9cbb-67ee8c16877c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0a31361f-0c4f-465d-bc73-b32300db8785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0a31361f-0c4f-465d-bc73-b32300db8785_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0a31361f-0c4f-465d-bc73-b32300db8785" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0a31361f-0c4f-465d-bc73-b32300db8785_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0a31361f-0c4f-465d-bc73-b32300db8785" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramMember_95dcbd65-b01f-4bca-91e5-db81ef3bc7fc" xlink:href="agio-20231231.xsd#agio_March252021RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:to="loc_agio_March252021RepurchaseProgramMember_95dcbd65-b01f-4bca-91e5-db81ef3bc7fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_10d188ae-58e4-40e1-9ac8-2df0337a9334" xlink:href="agio-20231231.xsd#agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:to="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_10d188ae-58e4-40e1-9ac8-2df0337a9334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_c5aa2e64-3649-4460-b27a-3790dec22c32" xlink:href="agio-20231231.xsd#agio_March252021RepurchaseProgramRule10b51RepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:to="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_c5aa2e64-3649-4460-b27a-3790dec22c32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4629ebb9-8470-4a95-86da-634cb6ff714b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4629ebb9-8470-4a95-86da-634cb6ff714b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7febe540-60d3-4e6b-bb7d-433af1aa45ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7febe540-60d3-4e6b-bb7d-433af1aa45ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5ae40161-dee9-4f82-b194-de989f07e226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5ae40161-dee9-4f82-b194-de989f07e226" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_200b6fac-145f-4e37-b293-3d4c1330e1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_200b6fac-145f-4e37-b293-3d4c1330e1f5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3cfd4278-e7de-4443-97c0-3e7fca48aa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3cfd4278-e7de-4443-97c0-3e7fca48aa8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c9eb3e3f-159d-40a4-9167-985567fd8cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3cfd4278-e7de-4443-97c0-3e7fca48aa8d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c9eb3e3f-159d-40a4-9167-985567fd8cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c9eb3e3f-159d-40a4-9167-985567fd8cf4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c9eb3e3f-159d-40a4-9167-985567fd8cf4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_c9eb3e3f-159d-40a4-9167-985567fd8cf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7f7951e-376a-4b50-8f6c-8c250a3d8d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c9eb3e3f-159d-40a4-9167-985567fd8cf4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7f7951e-376a-4b50-8f6c-8c250a3d8d5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_524e5c9c-ee92-4e2f-9105-656cadc3480b" xlink:href="agio-20231231.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7f7951e-376a-4b50-8f6c-8c250a3d8d5d" xlink:to="loc_agio_AgiosOncologyBusinessMember_524e5c9c-ee92-4e2f-9105-656cadc3480b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d88318d9-b68e-4165-aabf-eae293634f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3cfd4278-e7de-4443-97c0-3e7fca48aa8d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d88318d9-b68e-4165-aabf-eae293634f4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d88318d9-b68e-4165-aabf-eae293634f4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d88318d9-b68e-4165-aabf-eae293634f4c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d88318d9-b68e-4165-aabf-eae293634f4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2eae1c6b-0b59-4dfe-b37b-ad7b02365795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d88318d9-b68e-4165-aabf-eae293634f4c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2eae1c6b-0b59-4dfe-b37b-ad7b02365795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5a637e20-c42b-4a05-ae26-08e9585d4964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2eae1c6b-0b59-4dfe-b37b-ad7b02365795" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5a637e20-c42b-4a05-ae26-08e9585d4964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_922d96ff-a06b-468a-9ed7-ebdbd5f4cc77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_922d96ff-a06b-468a-9ed7-ebdbd5f4cc77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DiscontinuedOperationsTransactionAndInsuranceCosts_92d5e112-ac38-4a4d-81dd-0013c2a9f851" xlink:href="agio-20231231.xsd#agio_DiscontinuedOperationsTransactionAndInsuranceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_agio_DiscontinuedOperationsTransactionAndInsuranceCosts_92d5e112-ac38-4a4d-81dd-0013c2a9f851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DiscontinuedOperationsLiabilitiesDistributedNet_1515328a-61b5-44fd-8427-c01a160ed8e3" xlink:href="agio-20231231.xsd#agio_DiscontinuedOperationsLiabilitiesDistributedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_agio_DiscontinuedOperationsLiabilitiesDistributedNet_1515328a-61b5-44fd-8427-c01a160ed8e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_4c3ed381-c0d3-4794-a615-f809b2bdca44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_4c3ed381-c0d3-4794-a615-f809b2bdca44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_3967e5ef-44ff-4462-8ba5-a62f59d119cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_3967e5ef-44ff-4462-8ba5-a62f59d119cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_cb49e9e0-acae-44f4-8066-bcacc296ac56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_cb49e9e0-acae-44f4-8066-bcacc296ac56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_98cdf167-9566-4bc0-8f6a-63f9e632cae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_98cdf167-9566-4bc0-8f6a-63f9e632cae8" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71a7278d-e9df-4f3e-b770-844a6cb28fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71a7278d-e9df-4f3e-b770-844a6cb28fc9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18d52fb0-caa2-471d-ab4b-97db1c64648c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71a7278d-e9df-4f3e-b770-844a6cb28fc9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18d52fb0-caa2-471d-ab4b-97db1c64648c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_18d52fb0-caa2-471d-ab4b-97db1c64648c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18d52fb0-caa2-471d-ab4b-97db1c64648c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_18d52fb0-caa2-471d-ab4b-97db1c64648c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671dbbd0-f7c3-462d-a960-c980f24b95b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18d52fb0-caa2-471d-ab4b-97db1c64648c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671dbbd0-f7c3-462d-a960-c980f24b95b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_1a7da678-5179-471a-b35a-16affeb76f4a" xlink:href="agio-20231231.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671dbbd0-f7c3-462d-a960-c980f24b95b3" xlink:to="loc_agio_AgiosOncologyBusinessMember_1a7da678-5179-471a-b35a-16affeb76f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b4e4fbb3-1314-44e8-bcc2-321f9d1c3816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71a7278d-e9df-4f3e-b770-844a6cb28fc9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b4e4fbb3-1314-44e8-bcc2-321f9d1c3816" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b4e4fbb3-1314-44e8-bcc2-321f9d1c3816_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b4e4fbb3-1314-44e8-bcc2-321f9d1c3816" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b4e4fbb3-1314-44e8-bcc2-321f9d1c3816_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8a5000a9-4ef2-434d-adb5-47682004a51e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b4e4fbb3-1314-44e8-bcc2-321f9d1c3816" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8a5000a9-4ef2-434d-adb5-47682004a51e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_eb643649-5fca-4ffd-9be7-b01666d368c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8a5000a9-4ef2-434d-adb5-47682004a51e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_eb643649-5fca-4ffd-9be7-b01666d368c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_cd4483cd-2b06-4393-9a48-8cd781082397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_cd4483cd-2b06-4393-9a48-8cd781082397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_e6a649dd-b3c4-4697-9eae-4b155f51026d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_e6a649dd-b3c4-4697-9eae-4b155f51026d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments_a7ceea9e-8d4a-4e30-a1c9-f05e1c8b9ace" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:to="loc_agio_GainLossOnSaleOfContingentPayments_a7ceea9e-8d4a-4e30-a1c9-f05e1c8b9ace" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_052bd266-2090-4197-92fb-c08e18a7c061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_052bd266-2090-4197-92fb-c08e18a7c061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_052bd266-2090-4197-92fb-c08e18a7c061_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_052bd266-2090-4197-92fb-c08e18a7c061" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_052bd266-2090-4197-92fb-c08e18a7c061_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8235a644-a98a-48d1-a64c-ebff89443316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_052bd266-2090-4197-92fb-c08e18a7c061" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8235a644-a98a-48d1-a64c-ebff89443316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_1c32e2e1-3faa-4aa2-9c4e-fc536a08bb69" xlink:href="agio-20231231.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8235a644-a98a-48d1-a64c-ebff89443316" xlink:to="loc_agio_AgiosOncologyBusinessMember_1c32e2e1-3faa-4aa2-9c4e-fc536a08bb69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_daa316c3-9929-4c29-b884-8a5fef14f02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_daa316c3-9929-4c29-b884-8a5fef14f02e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_daa316c3-9929-4c29-b884-8a5fef14f02e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_daa316c3-9929-4c29-b884-8a5fef14f02e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_daa316c3-9929-4c29-b884-8a5fef14f02e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a2d92bbf-33cf-4b7e-bbed-d144da696100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_daa316c3-9929-4c29-b884-8a5fef14f02e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a2d92bbf-33cf-4b7e-bbed-d144da696100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6476a407-140e-483a-a9af-b61a0df83e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a2d92bbf-33cf-4b7e-bbed-d144da696100" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6476a407-140e-483a-a9af-b61a0df83e13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_385ffb5b-93db-4ca7-aaf6-362956308bc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:to="loc_srt_ProductOrServiceAxis_385ffb5b-93db-4ca7-aaf6-362956308bc2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_385ffb5b-93db-4ca7-aaf6-362956308bc2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_385ffb5b-93db-4ca7-aaf6-362956308bc2" xlink:to="loc_srt_ProductsAndServicesDomain_385ffb5b-93db-4ca7-aaf6-362956308bc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_385ffb5b-93db-4ca7-aaf6-362956308bc2" xlink:to="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_df38e887-a2d5-4ca4-a298-23f337686798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:to="loc_us-gaap_ProductMember_df38e887-a2d5-4ca4-a298-23f337686798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_40878318-d75c-44c4-9cc9-7220737b35e6" xlink:href="agio-20231231.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_40878318-d75c-44c4-9cc9-7220737b35e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_99fe8dd6-2556-465f-8a50-4029f21e2944" xlink:href="agio-20231231.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:to="loc_agio_CollaborationRevenueOtherMember_99fe8dd6-2556-465f-8a50-4029f21e2944" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b816e094-05e0-42e7-95a7-c2ba8e47beda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:to="loc_us-gaap_RoyaltyMember_b816e094-05e0-42e7-95a7-c2ba8e47beda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract_fea0a43d-617e-457b-af25-be0035e44fad" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract_fea0a43d-617e-457b-af25-be0035e44fad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_64c0f3d8-0168-43b1-bdc8-cca4e6c28919" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract_fea0a43d-617e-457b-af25-be0035e44fad" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_64c0f3d8-0168-43b1-bdc8-cca4e6c28919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_0443f96b-ed82-4490-a1f1-cc90bf97234d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_0443f96b-ed82-4490-a1f1-cc90bf97234d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_e4b6e66a-b73a-43b3-976d-eeae60d6d3af" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_e4b6e66a-b73a-43b3-976d-eeae60d6d3af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_7c215bb1-05f3-490e-87a1-a78a2608b304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_7c215bb1-05f3-490e-87a1-a78a2608b304" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3b5a9b2a-1650-4e2d-a23b-3394b12519db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3b5a9b2a-1650-4e2d-a23b-3394b12519db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a01f4d56-c066-4b13-93c9-c0231d2cbcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a01f4d56-c066-4b13-93c9-c0231d2cbcb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue_e3bbffa7-880a-4282-8453-10308111eebd" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue_e3bbffa7-880a-4282-8453-10308111eebd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_7355865a-1c32-41cf-8392-a0c95e8289ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_7355865a-1c32-41cf-8392-a0c95e8289ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_71454d51-f14f-4eec-8013-26f7322142b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_71454d51-f14f-4eec-8013-26f7322142b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ed4a99ce-83d2-4f98-a384-96f836aef021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ed4a99ce-83d2-4f98-a384-96f836aef021" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6f4f66b9-01b9-4963-9d39-03058327acfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6f4f66b9-01b9-4963-9d39-03058327acfc" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_e34f1fff-a848-4c33-910f-583d9e77f428" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_agio_PerformanceStockUnitMember_e34f1fff-a848-4c33-910f-583d9e77f428" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_48648a3b-68c9-425c-adb0-e2c89759dfb0" xlink:href="agio-20231231.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_agio_MarketBasedStockUnitsMember_48648a3b-68c9-425c-adb0-e2c89759dfb0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_d16a73a8-63ed-45f0-8331-f5cbb0026b7c" xlink:href="agio-20231231.xsd#agio_EmployeePurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_agio_EmployeePurchasePlanMember_d16a73a8-63ed-45f0-8331-f5cbb0026b7c" xlink:type="arc" order="7"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>agio-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:2870ab7b-aea5-4779-abd7-f438083a7088,g:ac8cf5ba-8c61-4750-87a9-db53e1eda885-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_7579248f-3e92-41e2-965a-25a3e25eea6b_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_dd332f2b-a36c-4052-99e5-052b6c2e86a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8d1cb608-a328-4ca3-8120-685724536d39_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_899fe118-ff1b-4e18-87e9-c32ea7367ede_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_58b1fa95-db8c-454f-83fc-823a9f0c5e78_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations per share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d6b8f48e-e3b4-465b-9c8a-fcf08fc47ebf_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EightyEightSidneyStreetLeaseMember_54a04fa6-5171-4a74-a16c-226747344e8a_terseLabel_en-US" xlink:label="lab_agio_EightyEightSidneyStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">88 Sidney Street Lease</link:label>
    <link:label id="lab_agio_EightyEightSidneyStreetLeaseMember_label_en-US" xlink:label="lab_agio_EightyEightSidneyStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eighty Eight Sidney Street Lease [Member]</link:label>
    <link:label id="lab_agio_EightyEightSidneyStreetLeaseMember_documentation_en-US" xlink:label="lab_agio_EightyEightSidneyStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eighty Eight Sidney Street Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EightyEightSidneyStreetLeaseMember" xlink:href="agio-20231231.xsd#agio_EightyEightSidneyStreetLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EightyEightSidneyStreetLeaseMember" xlink:to="lab_agio_EightyEightSidneyStreetLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_94d02579-9d6c-490b-97b3-b4665235e637_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0c6f4f12-4e6f-428c-999b-e38caf281a8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5caf5b1f-5eb7-438f-b74a-7ffef95880f4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e949f190-1794-42ce-9137-52e44829a9f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_41e687e7-597c-4c60-89e5-3f473b6663f6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_697ebc5f-882d-4a4b-900a-afffeb289d1f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_323b8eb6-99b3-48ef-957a-fefc7f9fd897_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace_d642e7b4-1134-4312-b20e-c3bb14b20312_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet of office space (in square feet)</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace_label_en-US" xlink:label="lab_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Square Feet Of Office Space</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace_documentation_en-US" xlink:label="lab_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Square Feet Of Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" xlink:to="lab_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContingentGainOnDispositionOfBusinessRecognized_4193cbcd-ecfe-4fc7-9239-17882cab2b65_terseLabel_en-US" xlink:label="lab_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earn-out revenue for royalties</link:label>
    <link:label id="lab_agio_ContingentGainOnDispositionOfBusinessRecognized_label_en-US" xlink:label="lab_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Gain On Disposition Of Business Recognized</link:label>
    <link:label id="lab_agio_ContingentGainOnDispositionOfBusinessRecognized_documentation_en-US" xlink:label="lab_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Gain On Disposition Of Business Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:href="agio-20231231.xsd#agio_ContingentGainOnDispositionOfBusinessRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:to="lab_agio_ContingentGainOnDispositionOfBusinessRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_25602a41-c3ac-497d-8cc1-04fb8e1f395c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_532597f0-eef5-4345-a1a9-b1532d575607_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fe3a2fa4-3c21-454c-9f3c-2a3981a20b2f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_aef88415-8933-4abb-9d9a-8f30b9e4de3f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_NumberOfLegalProceedingsThatHaveMaterialEffect_17ed5f6a-0718-4e1f-80ce-510866354a2d_terseLabel_en-US" xlink:label="lab_agio_NumberOfLegalProceedingsThatHaveMaterialEffect" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ongoing legal proceedings</link:label>
    <link:label id="lab_agio_NumberOfLegalProceedingsThatHaveMaterialEffect_label_en-US" xlink:label="lab_agio_NumberOfLegalProceedingsThatHaveMaterialEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Legal Proceedings That Have Material Effect</link:label>
    <link:label id="lab_agio_NumberOfLegalProceedingsThatHaveMaterialEffect_documentation_en-US" xlink:label="lab_agio_NumberOfLegalProceedingsThatHaveMaterialEffect" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Legal Proceedings that Have Material Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NumberOfLegalProceedingsThatHaveMaterialEffect" xlink:href="agio-20231231.xsd#agio_NumberOfLegalProceedingsThatHaveMaterialEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_NumberOfLegalProceedingsThatHaveMaterialEffect" xlink:to="lab_agio_NumberOfLegalProceedingsThatHaveMaterialEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_273d43f9-99d6-4606-9d5e-d26f3ae275f5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LeaseArrangementsAxis_53c17422-89e0-41e9-9389-67bfabf56c7b_terseLabel_en-US" xlink:label="lab_agio_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_agio_LeaseArrangementsAxis_label_en-US" xlink:label="lab_agio_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_agio_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_agio_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LeaseArrangementsAxis" xlink:href="agio-20231231.xsd#agio_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LeaseArrangementsAxis" xlink:to="lab_agio_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ExpenseAssociatedWithLicenseAgreement_64212fc6-4757-4ad6-9e59-adc4ac4f3ed6_terseLabel_en-US" xlink:label="lab_agio_ExpenseAssociatedWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense associated with license agreement</link:label>
    <link:label id="lab_agio_ExpenseAssociatedWithLicenseAgreement_label_en-US" xlink:label="lab_agio_ExpenseAssociatedWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Associated With License Agreement</link:label>
    <link:label id="lab_agio_ExpenseAssociatedWithLicenseAgreement_documentation_en-US" xlink:label="lab_agio_ExpenseAssociatedWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Associated With License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ExpenseAssociatedWithLicenseAgreement" xlink:href="agio-20231231.xsd#agio_ExpenseAssociatedWithLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ExpenseAssociatedWithLicenseAgreement" xlink:to="lab_agio_ExpenseAssociatedWithLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_76336bc1-6a45-4a5f-9ab4-3ec3da366b93_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_bb004d1c-387a-4dae-b650-98c56ef72c15_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_046785f6-cd77-4cf2-b415-0009f6f42afa_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit computed at federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_0bcccf3a-93c9-4227-b91a-ba96160912d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingent liabilities (Note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a6a96d81-de2f-487c-be3b-b0e6837b9568_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_939f0d01-c3eb-48ac-9420-911ba78d56cc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6c8d007c-0a56-4b43-b484-c1ce7e161833_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PeriodOfChangeInStockholdersOwnership_a3a7ea69-f939-47ef-ab77-f0f8d2e6d56f_terseLabel_en-US" xlink:label="lab_agio_PeriodOfChangeInStockholdersOwnership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate period</link:label>
    <link:label id="lab_agio_PeriodOfChangeInStockholdersOwnership_label_en-US" xlink:label="lab_agio_PeriodOfChangeInStockholdersOwnership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Of Change In Stockholders Ownership</link:label>
    <link:label id="lab_agio_PeriodOfChangeInStockholdersOwnership_documentation_en-US" xlink:label="lab_agio_PeriodOfChangeInStockholdersOwnership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of change in stockholders ownership .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PeriodOfChangeInStockholdersOwnership" xlink:href="agio-20231231.xsd#agio_PeriodOfChangeInStockholdersOwnership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PeriodOfChangeInStockholdersOwnership" xlink:to="lab_agio_PeriodOfChangeInStockholdersOwnership" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_996a0844-121d-4da7-a9f9-89f162d7b1cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e5232aec-5e66-4fe7-beda-7bc6365cc660_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_e849077f-60e0-4517-b435-21e0e8bb0706_negatedTotalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Prior Years Reserve Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:to="lab_agio_ContractWithCustomerPriorYearsReserveRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_7558b631-dc73-4875-8b44-6328efb3403a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_17a53c5c-edce-4f98-aac6-f807fa890884_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f9872d32-e024-46bc-a85f-eecad06a65c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_Agreement2010Member_e757e040-6fed-4c1d-9d40-b6801be6508d_terseLabel_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Agreement</link:label>
    <link:label id="lab_agio_Agreement2010Member_label_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement 2010 [Member]</link:label>
    <link:label id="lab_agio_Agreement2010Member_documentation_en-US" xlink:label="lab_agio_Agreement2010Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement 2010 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member" xlink:href="agio-20231231.xsd#agio_Agreement2010Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_Agreement2010Member" xlink:to="lab_agio_Agreement2010Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_46dfb6da-2551-4f8c-ac94-77f5efc34559_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax_8437e3d8-0a5b-4de5-b9e9-048efc0f59b4_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_6832f44b-854c-4eb6-b53f-251df743bca3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_c5436ae5-275b-43ca-92c8-e0c524c7fca9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_b41c41a3-6576-4e67-af79-0c82069fc150_terseLabel_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Plan and 2013 Plan</link:label>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:href="agio-20231231.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:to="lab_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_2193553d-10b5-4833-ae09-2fbb76029bd7_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities - discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_92168519-c4a6-4eb8-a85b-95251702b2d6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_5a288c06-dbc4-452e-8b42-9b3f56296772_negatedTotalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Current Year Reserve Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:to="lab_agio_ContractWithCustomerCurrentYearReserveRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c79a8007-2cce-41f5-bdb2-12849a4da916_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_24816c42-7544-4a5e-a748-2cc3caf93707_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant&#160;Date Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_99382ad7-7e60-4fbd-9e31-3837bb5ed12c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_acb7f511-9177-4f65-b1d0-0861574f6b8a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_StockholdersEquityDispositionOfBusiness_9ac48580-dc48-4328-83c8-1ef24d4a5543_negatedTerseLabel_en-US" xlink:label="lab_agio_StockholdersEquityDispositionOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposition of oncology business</link:label>
    <link:label id="lab_agio_StockholdersEquityDispositionOfBusiness_label_en-US" xlink:label="lab_agio_StockholdersEquityDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Disposition Of Business</link:label>
    <link:label id="lab_agio_StockholdersEquityDispositionOfBusiness_documentation_en-US" xlink:label="lab_agio_StockholdersEquityDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Disposition Of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_StockholdersEquityDispositionOfBusiness" xlink:href="agio-20231231.xsd#agio_StockholdersEquityDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_StockholdersEquityDispositionOfBusiness" xlink:to="lab_agio_StockholdersEquityDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a4a62b69-bcc6-4c56-a42a-80f8fd203666_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share - diluted (in usd share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_07a8e01f-875c-4569-8169-0d998ac9b0d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_VorasidenibMember_5a0714a5-9f1b-45ea-9eea-bba6cd418feb_terseLabel_en-US" xlink:label="lab_agio_VorasidenibMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">vorasidenib</link:label>
    <link:label id="lab_agio_VorasidenibMember_label_en-US" xlink:label="lab_agio_VorasidenibMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vorasidenib [Member]</link:label>
    <link:label id="lab_agio_VorasidenibMember_documentation_en-US" xlink:label="lab_agio_VorasidenibMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vorasidenib</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_VorasidenibMember" xlink:href="agio-20231231.xsd#agio_VorasidenibMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_VorasidenibMember" xlink:to="lab_agio_VorasidenibMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_024fdaea-6a19-4da3-a23e-9dd1222501c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (16,216,411 shares at December 31, 2023 and December 31, 2022)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_March252021RepurchaseProgramMember_51674f7c-e0df-49ca-bdd2-ad07db026c6b_terseLabel_en-US" xlink:label="lab_agio_March252021RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Program</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramMember_label_en-US" xlink:label="lab_agio_March252021RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program [Member]</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramMember_documentation_en-US" xlink:label="lab_agio_March252021RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramMember" xlink:href="agio-20231231.xsd#agio_March252021RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_March252021RepurchaseProgramMember" xlink:to="lab_agio_March252021RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_52d7dae5-1efc-450c-bdae-d9ff10d765e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_8fe1f956-efc9-4760-bd37-59794f1b64ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_1c910442-08d2-497a-8980-0c4972f67e42_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_e9ec3367-1f1f-4331-851e-760be96e71a4_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_21209623-a798-40ff-a86e-794e50c84570_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_48b6b998-2d12-4c39-a093-2f7131ab38f9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_01a80e5f-5565-41ec-9c1d-8bb52043119c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_aee56cd4-8c5f-4b84-959b-5f644ea98827_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under stock incentive plan and ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cbb95541-8070-4491-8be2-2efe61a276e1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_84a3e5ab-ab9f-4d2e-acd8-0bcdc338fa26_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ce3f9ce8-e4cc-4cfa-a721-e20c805b2a64_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b31dc0f7-f544-4b37-9cac-392239a5e5fc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of options (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2929b825-5946-45ca-b0e0-75d4dc0d209a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2d4833dd-fc3c-4960-bb04-16d41f6af904_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment_71ae9504-c92d-4f10-a0e9-65f6a7faa2e1_terseLabel_en-US" xlink:label="lab_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, contingent consideration, potential developmental and regulatory milestone payment</link:label>
    <link:label id="lab_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment_label_en-US" xlink:label="lab_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Potential Developmental and Regulatory Milestone Payment</link:label>
    <link:label id="lab_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment_documentation_en-US" xlink:label="lab_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Potential Developmental and Regulatory Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment" xlink:href="agio-20231231.xsd#agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment" xlink:to="lab_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_554f4774-712c-4239-bace-d2b10f5077fc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SixtyFourSidneyStreetLeaseMember_215d05a7-521a-47b9-870c-7c5bcd51cb27_terseLabel_en-US" xlink:label="lab_agio_SixtyFourSidneyStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">64 Sidney Street Lease</link:label>
    <link:label id="lab_agio_SixtyFourSidneyStreetLeaseMember_label_en-US" xlink:label="lab_agio_SixtyFourSidneyStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sixty-Four Sidney Street Lease [Member]</link:label>
    <link:label id="lab_agio_SixtyFourSidneyStreetLeaseMember_documentation_en-US" xlink:label="lab_agio_SixtyFourSidneyStreetLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sixty-Four Sidney Street Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SixtyFourSidneyStreetLeaseMember" xlink:href="agio-20231231.xsd#agio_SixtyFourSidneyStreetLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SixtyFourSidneyStreetLeaseMember" xlink:to="lab_agio_SixtyFourSidneyStreetLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_d23dbb1f-6310-4a45-93ea-34a90ff803b7_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue-related reserves</link:label>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_label_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Total Allowances And Reserves</link:label>
    <link:label id="lab_agio_ContractWithCustomerTotalAllowancesAndReserves_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:to="lab_agio_ContractWithCustomerTotalAllowancesAndReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d4b70e05-5823-4066-91e3-e2f2f4d68485_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_95623ed7-9362-4be2-9d8c-fda1a551080c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_85d7aa37-ae43-430a-9dd1-6e3de5e57530_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_9df85895-ce01-4e58-9bc2-3488efcc69f3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c5fe2283-c333-4976-9a06-97f9e05dce64_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b999d732-3dd4-489e-84f4-fdde480e1afc_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_f8904f81-b1f0-4d10-b7a8-5d210c6c4e80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf20be24-92f3-4cab-8c03-3b3fc5438d1d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under stock incentive plan and ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aeb75dbe-0549-49f8-974c-eb16815c1160_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_bc6518f3-6b4f-4484-952d-032246fb8c2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_088633e4-42b8-49fa-ad79-45d7d5a1c244_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_09423d02-b9dd-4731-a887-0b2895d00c74_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3f8c6949-e71e-4696-a037-e2ba1d839194_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Stock&#160;Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_59ef1c60-63d6-4cfb-9a75-8629cb2af131_terseLabel_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_label_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Right To Recover Product In Current Year</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInCurrentYear_documentation_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:href="agio-20231231.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:to="lab_agio_ProvisionForRightToRecoverProductInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c09d90db-3394-4bdb-a445-6a52361d87eb_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4297d458-83ac-4aa4-aad9-445b7d536062_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_df123f56-ec2b-4aff-bd9d-db169a4ff43c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_FederalOrphanDrugTaxCreditMember_91eb4b37-e775-465e-9bcd-dcd221dc0975_terseLabel_en-US" xlink:label="lab_agio_FederalOrphanDrugTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Orphan Drug Tax Credit</link:label>
    <link:label id="lab_agio_FederalOrphanDrugTaxCreditMember_label_en-US" xlink:label="lab_agio_FederalOrphanDrugTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Orphan Drug Tax Credit [Member]</link:label>
    <link:label id="lab_agio_FederalOrphanDrugTaxCreditMember_documentation_en-US" xlink:label="lab_agio_FederalOrphanDrugTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Orphan Drug Tax Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_FederalOrphanDrugTaxCreditMember" xlink:href="agio-20231231.xsd#agio_FederalOrphanDrugTaxCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_FederalOrphanDrugTaxCreditMember" xlink:to="lab_agio_FederalOrphanDrugTaxCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_d52e4572-0556-4ea7-82c3-08b67f7c8680_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_228dfda4-414b-4111-91fb-009a9bd7dd7c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_2544abd7-a19c-49bf-bd34-efac1ea96dd5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1cb34eae-1f6f-47be-b1dc-099535391b6f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_8fce5d9f-92ab-4d05-bd42-497e0c70679e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_82f08d8f-b411-4204-b594-909ff90aa56d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based awards reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_05481383-dc70-4224-a0f1-e90ed64a4035_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_19d77d5e-3f8d-414a-9e24-7546c16bd4b6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_ad4552bc-8b17-4523-ae75-a2326d984197_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8280c155-0be8-4e41-a13e-a1559eabb946_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_6f98d3ee-be92-4fdd-aabb-846b7942551f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_f832b685-8942-40ee-9d4d-f5e271b7e972_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ff89c492-4cf4-4cb6-9d38-f3b2ae4d1043_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_131894ef-1932-46a2-b6d2-0b43f5341b93_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_95cf6884-fdb5-4f7e-a585-fcd5b583081a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_9055bc8d-1c87-4140-84a9-5b8411f90563_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6d7ef631-6efb-44a8-8fe0-1df56dd4d303_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_09179515-b7c3-406a-92c0-19208fd9f506_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_32d88025-460a-46e4-a790-a1d153020ff4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_3b401e0c-0c9a-4276-8085-32b8a9fea353_terseLabel_en-US" xlink:label="lab_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_label_en-US" xlink:label="lab_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment Estimated Useful Life [Table Text Block]</link:label>
    <link:label id="lab_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_documentation_en-US" xlink:label="lab_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property plant and equipment estimated useful life.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="agio-20231231.xsd#agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="lab_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7ed291f6-facc-42c7-9498-f60acf36f57a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_f2b5cd9f-7485-4e7d-9fb7-c79b69cb419f_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_d60fddbc-b4c1-4dbb-bdbd-8bc5bb17d2cb_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_GovernmentRebatesRollForward_62d44609-427f-40a8-a88f-d17948542368_terseLabel_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates</link:label>
    <link:label id="lab_agio_GovernmentRebatesRollForward_label_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates [Roll Forward]</link:label>
    <link:label id="lab_agio_GovernmentRebatesRollForward_documentation_en-US" xlink:label="lab_agio_GovernmentRebatesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GovernmentRebatesRollForward" xlink:href="agio-20231231.xsd#agio_GovernmentRebatesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_GovernmentRebatesRollForward" xlink:to="lab_agio_GovernmentRebatesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LaboratoryEquipmentMember_ac50291d-70be-474a-a00d-4c53690e8c1c_verboseLabel_en-US" xlink:label="lab_agio_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_agio_LaboratoryEquipmentMember_1b47c2cb-aca8-44c6-a01b-4d94f5bbeda6_terseLabel_en-US" xlink:label="lab_agio_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_agio_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_agio_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_agio_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_agio_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LaboratoryEquipmentMember" xlink:href="agio-20231231.xsd#agio_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LaboratoryEquipmentMember" xlink:to="lab_agio_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a15039bd-9885-4ff8-8fde-e1ea7e1ae532_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_62bc7484-1897-4ac8-a091-08300ce723ae_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b97d7228-9d0f-442f-94c2-1b6d0f3f97f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_50ca4686-3a20-47de-862e-83fcaf85dea3_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_b93134b0-adee-433a-a4e5-b8fbc016eb72_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_aa95f3b2-1116-4fc2-ae99-5f2335083e0f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Undiscounted Minimum Rental Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ComputerEquipmentAndSoftwareMember_9492ecaf-43af-4ace-ac9d-ebb5837ccc6b_verboseLabel_en-US" xlink:label="lab_agio_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_agio_ComputerEquipmentAndSoftwareMember_8cd92f59-93ea-4a8f-a778-d13bbf925cca_terseLabel_en-US" xlink:label="lab_agio_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_agio_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_agio_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_agio_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_agio_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ComputerEquipmentAndSoftwareMember" xlink:href="agio-20231231.xsd#agio_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ComputerEquipmentAndSoftwareMember" xlink:to="lab_agio_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ScheduleOfSignificantAccountingPoliciesTable_9b48d14e-92f3-4add-9699-3eabd557fb04_terseLabel_en-US" xlink:label="lab_agio_ScheduleOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_agio_ScheduleOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_agio_ScheduleOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_agio_ScheduleOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_agio_ScheduleOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfSignificantAccountingPoliciesTable" xlink:href="agio-20231231.xsd#agio_ScheduleOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesTable" xlink:to="lab_agio_ScheduleOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7fb6f8e3-0729-4882-b540-ae57a9ab6a38_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_6ebf929a-46a7-43fc-9d87-94e0f081489c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction_4ebde360-85c3-481c-8ef9-19d890e4c72f_terseLabel_en-US" xlink:label="lab_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum value of shares issued</link:label>
    <link:label id="lab_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Value of Shares Issued in Transaction</link:label>
    <link:label id="lab_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction_documentation_en-US" xlink:label="lab_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Value of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:href="agio-20231231.xsd#agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:to="lab_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_519051b1-9e42-4292-9e3e-3dd1553ba1ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Excluded from Calculation of Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ed106c46-8a21-44b8-adfe-3c65880ae063_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_478c055b-6ec1-429c-aa2a-b1ec4f574c84_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Cost and Other Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_6ca911bc-d8a6-4f08-9764-10daa41c8de1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods_8332ba13-21d0-4600-83a8-a26cc6bc3275_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of extension periods</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods_label_en-US" xlink:label="lab_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Number Of Extension Periods</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods_documentation_en-US" xlink:label="lab_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Number Of Extension Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods" xlink:to="lab_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_567a9f47-22e9-43d5-99a0-cf07be324a3c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_061d6bbf-da84-41a2-b541-0d50854a6eac_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_855e6859-b207-41bb-932f-c0a9f5923593_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyUnrecordedAmount_58843f2a-f341-451f-bb14-03f43ae9b44a_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent milestone payment</link:label>
    <link:label id="lab_us-gaap_GainContingencyUnrecordedAmount_label_en-US" xlink:label="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Unrecorded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyUnrecordedAmount" xlink:to="lab_us-gaap_GainContingencyUnrecordedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eaff1a8a-7d44-44a3-8686-2451d82e548e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3bb45488-b984-4d20-ab9b-4f6ae208209d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_83fe147f-1734-49a0-81dd-5922b9dcdb93_negatedTerseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Asset Proceeds From Collection Of Receivables</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:to="lab_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_43427ab3-126f-4c70-93b6-3a8c7b292eff_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6dba0f6a-73a8-4f98-9337-a3b61513f38d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1f39ac20-1582-4ae3-9984-3c4560e71e5b_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing transactions:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3d106010-3744-43dc-97b8-97b0db308c68_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4a0121ce-67ed-4e7c-8927-c2838f98100a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense excluding options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3d3de582-ec1b-43d1-9978-552815805ae3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f03bf49a-8c24-4188-9d21-99d11f10a80c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_30457df8-e239-4b76-bde0-90ebef3430cb_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_28bb5c7f-3ad1-45c1-8e6a-077d2461a9f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d0ac1348-dfcd-4a58-9a57-ccc6073d3a31_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_06996560-2ea0-40c7-aeb6-33bccc6d484f_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c91d0d94-0cc9-4152-a623-a4fc2acdee2f_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_10846e96-fd46-4086-b7c6-2ae89908a95e_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_02e56013-3c21-4193-86b1-08552427089d_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses</link:label>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_label_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Allowance And Reserves, Liability</link:label>
    <link:label id="lab_agio_ContractWithCustomerAllowanceAndReservesLiability_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:to="lab_agio_ContractWithCustomerAllowanceAndReservesLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ba93df64-7c54-4998-b5e3-ffa2fe31f313_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fc064b6e-3229-449a-9cb0-87b9cefb7635_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_6c36ed5d-f39c-4228-ac01-a85e6ac6f244_terseLabel_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_label_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2013 [Member]</link:label>
    <link:label id="lab_agio_EmployeeStockPurchasePlan2013Member_documentation_en-US" xlink:label="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member" xlink:href="agio-20231231.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EmployeeStockPurchasePlan2013Member" xlink:to="lab_agio_EmployeeStockPurchasePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c527eecd-1103-407e-87f1-3f94f15db5f3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_46b128d3-7d58-480c-8f93-9549e91c2ef8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_08f44d78-ea29-4cd2-bb75-2d519a67fdee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4c460582-9b40-4c82-bd17-f60521ad54ad_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under 2013 ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_12cd133c-9675-48a4-ac17-20c54c45ac90_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_22ff63d6-8588-4df4-aa9f-e9172022695d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_be13ed1c-84e5-484b-b294-7203fafae01c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_dbca0217-b5d8-4a96-8680-6e61e6c5ea3c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bb7390e0-24b6-41b7-a9b7-3074915bc272_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingLeaseNumberOfLeaseTerms_7a97d065-30fa-4406-b903-d2e3d344a1ab_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingLeaseNumberOfLeaseTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of optional terms available at end of current lease term (in lease terms)</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseNumberOfLeaseTerms_label_en-US" xlink:label="lab_agio_LesseeOperatingLeaseNumberOfLeaseTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Lease Terms</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseNumberOfLeaseTerms_documentation_en-US" xlink:label="lab_agio_LesseeOperatingLeaseNumberOfLeaseTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Lease Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseNumberOfLeaseTerms" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseNumberOfLeaseTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingLeaseNumberOfLeaseTerms" xlink:to="lab_agio_LesseeOperatingLeaseNumberOfLeaseTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1305f2e7-d173-41bb-8cc6-70768a6b0da2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_92d18f5f-75f3-445a-85dd-5d6b88e100cc_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_a625bf5e-e49e-4307-9b20-a2643a06e7ce_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset, Revenue Recognized</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetRevenueRecognized_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetRevenueRecognized" xlink:to="lab_agio_ContractWithCustomerAssetRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4fc0396a-169e-4eed-bcac-c3478515dd66_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_bab23427-2e5f-42df-8bee-b916a3ef9acc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increases - current period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ScheduleOfSignificantAccountingPoliciesLineItems_6c6389e2-aa1e-46db-885b-cfc89f198d3e_terseLabel_en-US" xlink:label="lab_agio_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_agio_ScheduleOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_agio_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_agio_ScheduleOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_agio_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Significant Accounting Policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:href="agio-20231231.xsd#agio_ScheduleOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:to="lab_agio_ScheduleOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e24b7441-8743-43b4-868a-a0feff252188_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod_e357e232-03da-4475-84ff-40ad3c08c517_terseLabel_en-US" xlink:label="lab_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment maturity period, non-current</link:label>
    <link:label id="lab_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod_label_en-US" xlink:label="lab_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Non Current Maturity Period</link:label>
    <link:label id="lab_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities non current maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod" xlink:href="agio-20231231.xsd#agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod" xlink:to="lab_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7688efa0-2959-419e-9ff0-7ec0207e3a16_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d20928ea-2bf1-49d5-bf4c-4b767c7c4a7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5d562295-e970-43c6-9630-a4a3dfd92e18_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_cab3af71-b6b9-443c-8812-e0e5399853be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Domestic and Foreign Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_a7713cb9-1ab3-4ea0-9eb8-297089af3b9d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8a2787d8-d218-4b1e-8fa3-1e9d4d5757c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e0d7fb3f-5ad1-484e-91b2-5a56a30c7382_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_4ad47004-8751-4818-a783-1c06611fca8a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4357e873-fb15-4d29-9c76-ca49cb7b13f1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_bb40a389-c84d-45a6-aa68-6dd8dcda44d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c810a921-3d15-47f3-baed-b6553e110519_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_09affc94-7b75-47fe-a848-d30b9f7327f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Grant Date Fair Value Option Award Weighted Average Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6634962a-c97e-4c98-a351-d3c895a8eb37_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_28acbab2-30c9-48fa-b9a2-ff50fe722d49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_RealizedGainOnInvestments_f4b17ae5-e916-4556-8e87-4cd3485c8c64_negatedTerseLabel_en-US" xlink:label="lab_agio_RealizedGainOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_agio_RealizedGainOnInvestments_label_en-US" xlink:label="lab_agio_RealizedGainOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain On Investments</link:label>
    <link:label id="lab_agio_RealizedGainOnInvestments_documentation_en-US" xlink:label="lab_agio_RealizedGainOnInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain On Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RealizedGainOnInvestments" xlink:href="agio-20231231.xsd#agio_RealizedGainOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_RealizedGainOnInvestments" xlink:to="lab_agio_RealizedGainOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_6e429347-00d2-41c7-b936-28973bb15c8c_terseLabel_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment for achievement of specified ex-U.S. commercial milestone event</link:label>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_label_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion Of Potential Milestone Payment Receivable For Filing Of New Drug Application</link:label>
    <link:label id="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_documentation_en-US" xlink:label="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of potential milestone payment receivable for filing of new drug application.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:href="agio-20231231.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:to="lab_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e7a98cfb-f02a-4eaa-afe8-af8551c585e8_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_d64735cf-659b-461a-99bd-09287c9000d3_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_label_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Prior Years Reserve Provisions</link:label>
    <link:label id="lab_agio_ContractWithCustomerPriorYearsReserveProvisions_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:to="lab_agio_ContractWithCustomerPriorYearsReserveProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5040a3ae-1bed-468c-96a7-50ebf7893a75_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3858a182-8e5e-43bc-95a9-0ccc7e2d8878_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod_9663a438-712d-4fba-9b8f-528e9b9cf896_terseLabel_en-US" xlink:label="lab_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment maturity period, current</link:label>
    <link:label id="lab_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod_label_en-US" xlink:label="lab_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Current Maturity Period</link:label>
    <link:label id="lab_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities current maturity period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod" xlink:href="agio-20231231.xsd#agio_AvailableForSaleSecuritiesCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod" xlink:to="lab_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_8e52da7c-a355-45d2-881c-5722b6b60e42_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer's matching contribution percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AuditorInformationAbstract_label_en-US" xlink:label="lab_agio_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_agio_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_agio_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AuditorInformationAbstract" xlink:href="agio-20231231.xsd#agio_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AuditorInformationAbstract" xlink:to="lab_agio_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_810137c7-e383-4dff-83b9-fa82ab841bae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period to recognize compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_cb6d2aae-9d04-4afa-8fb6-624654bb02cb_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_05cd38c4-debf-4b6c-9ae9-fc01e36cbd05_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_af8c89d6-09d4-4d42-8fac-6cdf190a5c6f_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5e6b400d-4c20-423d-8203-841b4191bbdf_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_8b2d2cc7-c23b-4fb3-ba66-3df960833488_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d085018a-60ff-4d5f-8edd-c8b5d3c50e65_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations per share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b402ffab-01f8-4301-abf3-c2f156ff258b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_adeeeae8-a710-4d47-b9fa-87a6ef5dad8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_e32ca427-c3e5-420b-8a98-3eceec31c8dc_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_0755e8bc-ecfa-41ea-96b6-a06cb220bb29_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_9d3c1bb5-9c69-45bf-8f5e-9c52236f8ab6_terseLabel_en-US" xlink:label="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost not expected to be recognized</link:label>
    <link:label id="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_label_en-US" xlink:label="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount</link:label>
    <link:label id="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_documentation_en-US" xlink:label="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:href="agio-20231231.xsd#agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:to="lab_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AccruedResearchAndDevelopmentCostsCurrent_c3a161f8-65e8-477e-8144-18eea8c55c2c_terseLabel_en-US" xlink:label="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs</link:label>
    <link:label id="lab_agio_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Costs Current</link:label>
    <link:label id="lab_agio_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development costs current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="agio-20231231.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_agio_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares_6fd99ab6-dd5d-4e66-91f0-18d5b6876704_terseLabel_en-US" xlink:label="lab_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, expected to vest, number of shares (in shares)</link:label>
    <link:label id="lab_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares_label_en-US" xlink:label="lab_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Expected To Vest, Number of Shares</link:label>
    <link:label id="lab_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares_documentation_en-US" xlink:label="lab_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Expected To Vest, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares" xlink:href="agio-20231231.xsd#agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares" xlink:to="lab_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ab734154-b034-4779-bb35-b91a7701de3d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_8603a7dd-f22b-4455-97fd-e1b3ca112add_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_c771b51a-ec45-4875-9174-87415805ceae_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Right To Recover Product, Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0cfa8874-28e0-43ac-b4a8-2eefb24849e0_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6b018b75-d391-4982-986b-bba0209a006f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6aad8bde-3721-4ee3-bf0b-3bce74ca192e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7f00ff4b-023c-49cb-9665-d9c9b4259268_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_992d1691-4d44-4656-870c-95e460535f19_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c93aedda-b7ff-40f5-a71a-e75f4c66720f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_a9539d08-19fe-4bf4-ae1f-8f993c1eec8b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PerformanceStockUnitMember_3c14a881-bedb-4cc9-913a-72d03424aa56_terseLabel_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock units</link:label>
    <link:label id="lab_agio_PerformanceStockUnitMember_ef8e23da-caa1-4f81-8d15-22bb9293de2d_verboseLabel_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based stock units</link:label>
    <link:label id="lab_agio_PerformanceStockUnitMember_label_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit [Member]</link:label>
    <link:label id="lab_agio_PerformanceStockUnitMember_documentation_en-US" xlink:label="lab_agio_PerformanceStockUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PerformanceStockUnitMember" xlink:to="lab_agio_PerformanceStockUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_39d57a24-d78d-4856-a0a4-4f943acbbe57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_328a07a0-53a3-4bf7-980e-e28e831cd2d5_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_19df1e8a-ed53-4d1f-b42b-1cfd73eb4f91_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_a50b5706-e4b0-4ebf-92ba-5a0352d3b965_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8a9671fb-4bf2-44e4-8c52-cad524de2ee5_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_512309a4-4040-4d54-8750-04b3e9d00421_terseLabel_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Stock Incentive Plan</link:label>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_label_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Thirteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and thirteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:href="agio-20231231.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:to="lab_agio_TwoThousandAndThirteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8c3cfe4f-3140-4de6-a70e-ab26cc238dda_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_527cbbe3-bd4e-481a-b80d-15e980b59221_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_c9229522-238a-4671-be8c-62385bc98b6e_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d62716f4-a5c4-4218-afb2-67a55541a1e0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_01001209-cd87-41d8-9869-2b5f3c26d3ce_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_3228fcd0-f459-4ad8-ab26-758018f59d6a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_0dade597-4b50-4d68-b88f-6b1005c4a322_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LeaseArrangementsDomain_ca5f4463-8463-4104-a7e7-f39ca54a18ec_terseLabel_en-US" xlink:label="lab_agio_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_agio_LeaseArrangementsDomain_label_en-US" xlink:label="lab_agio_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_agio_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_agio_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LeaseArrangementsDomain" xlink:href="agio-20231231.xsd#agio_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LeaseArrangementsDomain" xlink:to="lab_agio_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7dd7c689-9195-4fb9-804e-424dc04432f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c0afe110-1248-4aa3-8b3b-51c99d29ba9a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested shares end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_08d45a93-db2a-4fe2-989c-291aac9d2fb8_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contract Adjustment, Recoveries, Current Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:to="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8449eacd-b8fd-4637-94ba-b5d2aec15ee6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_42354c19-1d24-4e7e-aa76-68c25bbca0d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue Allowance and Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4ff8ee89-e6e7-483c-b990-a4dd9d7acf55_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2713441f-4111-4438-bbdf-b25435fbc2ac_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_39b50edc-fb2b-4b7b-8c5d-241f1384feb0_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_aa79266e-330a-4af1-b0a7-ef5ae994a51c_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d4f31dca-9f68-41d3-9adc-1ed5b14f6e2a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_60f83943-bb37-488d-a015-c34b37abd3f0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_e5d42979-26ec-4de2-b847-2ea2bdae59fd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_9c350da9-a860-4256-9877-373e3047f87e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fe2f8e26-cf5a-4bf8-9422-cecc358a3921_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_84b28742-344b-4419-976b-2b40db230af4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_c62ff95a-64b1-441a-b0b3-a829f825e148_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_34f510a6-5096-4a1c-b8c2-0f4bfb058c7d_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_1a7f7953-4e2a-4362-9ca0-c655d16e2bf8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7556627c-b328-4b49-8dda-08aa40403edd_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_0b168236-10cd-4530-9760-95a64a2ec742_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b778e536-5d3a-448e-ba3f-10d92e092375_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b6283caf-44b9-4662-bfb3-af45f88d0f37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_92707b36-642c-4399-8e19-34f379c69b8e_terseLabel_en-US" xlink:label="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Repurchase</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_label_en-US" xlink:label="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program , Rule 10b5-1 Repurchase [Member]</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_documentation_en-US" xlink:label="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program , Rule 10b5-1 Repurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:href="agio-20231231.xsd#agio_March252021RepurchaseProgramRule10b51RepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:to="lab_agio_March252021RepurchaseProgramRule10b51RepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_47592b68-1b7e-46ca-afb1-f8708c5b436b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e172a202-baec-4c8e-876d-0030d4efae5b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4c03202b-ec74-4c8c-93e7-e306ecf18139_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_18b8a19f-8476-4164-910c-3e775d06e391_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group. including discontinued operation, assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_493a36ad-d8a3-4fc3-a90b-665582598de7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_48002c7e-b2ab-47c0-8b39-1774abbc8829_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ed4babdd-70a7-49d3-b612-d421d2c14ebd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_fbfe0e64-1d99-4a3d-99a3-928e8a42ee32_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_20597a22-1f05-42c4-a209-37563f05a22d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations per share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_1cadaef0-a352-4f33-a03d-890b0ad54d09_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_61b1931f-2638-436b-9698-63adab229a3a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense by Award Type Included within the Condensed Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_32159a28-640c-4759-a8ce-d33937a08ab6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7df232ae-28a3-4dcd-b350-a2e1898aea36_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8d213582-1694-4137-bbff-1fe59c48345a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_fbda1398-d56b-4348-bd8e-1fcde474a861_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_313b419a-f912-4c97-becd-d5bb5fd50653_terseLabel_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contract Assets</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_label_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Asset And Liability, Product Revenue [Table Text Block]</link:label>
    <link:label id="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:to="lab_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_9fd13ee1-4b36-4ec0-ac0c-cbe981c1ef68_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments to be Received</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_bcdd4811-bdb8-42b8-9cb8-ae185776aae3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of credit risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_df7cd9fd-dbe8-49cb-a9c8-2d525692f564_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_e5b2ce19-48ae-4051-93e7-0b212219625c_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProceedsFromSaleOfContingentPayments_ca0070a4-9c98-4cab-aa21-d5a4e0c068ce_terseLabel_en-US" xlink:label="lab_agio_ProceedsFromSaleOfContingentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of contingent payments</link:label>
    <link:label id="lab_agio_ProceedsFromSaleOfContingentPayments_label_en-US" xlink:label="lab_agio_ProceedsFromSaleOfContingentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Contingent Payments</link:label>
    <link:label id="lab_agio_ProceedsFromSaleOfContingentPayments_documentation_en-US" xlink:label="lab_agio_ProceedsFromSaleOfContingentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Contingent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfContingentPayments" xlink:href="agio-20231231.xsd#agio_ProceedsFromSaleOfContingentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProceedsFromSaleOfContingentPayments" xlink:to="lab_agio_ProceedsFromSaleOfContingentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember_3b08e466-f590-4c07-8b5f-4475fc82627a_terseLabel_en-US" xlink:label="lab_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">38 Sidney Street Lease</link:label>
    <link:label id="lab_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember_label_en-US" xlink:label="lab_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty-Eight Sidney Street, Cambridge, Massachusetts Lease [Member]</link:label>
    <link:label id="lab_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember_documentation_en-US" xlink:label="lab_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thirty-Eight Sidney Street, Cambridge, Massachusetts Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember" xlink:href="agio-20231231.xsd#agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember" xlink:to="lab_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_84621c94-870f-4fe6-83cc-2ddf06bf5bbe_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_5d186d12-7d6e-4912-aba3-38cd5c36ba8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2bb4eb17-eefe-46db-a8dc-f1f3715a0701_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer's contribution percentage of eligible compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_bebee293-3c49-453e-8ed5-59f0a0f58850_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ce443e75-bf9a-4ec3-93c5-697aa2c51eda_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_050b181d-1502-4b70-afc3-bbdd3e6adf8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e6a462f5-85e2-41bc-ac45-87146350c67a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_fe825c61-9b3e-415e-b1c2-461c705c49d9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_079ccd32-ace6-410f-9417-81d3d0b06d21_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_0ed8b588-36e5-42fe-9ce4-459baceedb6d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal group. including discontinued operation, liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e5c05dd3-ef61-4a15-9852-b59058efef6b_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_97fb9f01-6a7b-4e94-b579-bed961c66fd2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5fea7d5c-090f-4049-9210-0e4728bacfe0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractAssetsAndLiabilitiesHeadingRollForward_bb812e79-3c72-45fd-9ce5-8c5d4ee47335_terseLabel_en-US" xlink:label="lab_agio_ContractAssetsAndLiabilitiesHeadingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Assets and Liabilities [Roll Forward]</link:label>
    <link:label id="lab_agio_ContractAssetsAndLiabilitiesHeadingRollForward_label_en-US" xlink:label="lab_agio_ContractAssetsAndLiabilitiesHeadingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Assets And Liabilities [Heading Roll Forward]</link:label>
    <link:label id="lab_agio_ContractAssetsAndLiabilitiesHeadingRollForward_documentation_en-US" xlink:label="lab_agio_ContractAssetsAndLiabilitiesHeadingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractAssetsAndLiabilitiesHeadingRollForward" xlink:href="agio-20231231.xsd#agio_ContractAssetsAndLiabilitiesHeadingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractAssetsAndLiabilitiesHeadingRollForward" xlink:to="lab_agio_ContractAssetsAndLiabilitiesHeadingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_128f278a-bf80-40a1-ae80-d93ae0372960_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_fe28b6d3-a93c-4c45-98ed-a06007568eb9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_99060a5b-c772-4cf3-a6b7-5dedf33ab005_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61c08e04-0a4e-4e44-83da-7cb5ca62a335_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_80328af7-9929-4161-9ed2-39db945ae6d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of debt securities in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_34a30a05-aa97-482c-95f2-4e9242ad08a2_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8084a059-624b-47bb-a044-b52992f38fb7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f7de6dd1-c743-4cec-adad-d9df3257d229_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2294c18d-b940-47e8-a244-367a61d5517e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_df46398a-aa40-4422-a3d9-ec3edd56602e_terseLabel_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-based stock units</link:label>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_label_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units [Member]</link:label>
    <link:label id="lab_agio_MarketBasedStockUnitsMember_documentation_en-US" xlink:label="lab_agio_MarketBasedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market-Based Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember" xlink:href="agio-20231231.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_MarketBasedStockUnitsMember" xlink:to="lab_agio_MarketBasedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_42ed241c-7058-48b4-abaf-3c760ecbd5f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e526b438-e180-4bda-abdf-41b5fdeb1af9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Section 174 R&amp;D expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_aac8b22b-9467-4958-9f94-715d5a3c0fd1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_eb95b979-5004-4a2e-91bb-d7c4ab3b1687_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_8f445676-30e2-441e-88ff-6cc5ba782d5c_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contractual Adjustment Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractualAdjustmentReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:to="lab_agio_ContractWithCustomerContractualAdjustmentReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b1b48448-a082-4b63-ae3e-79ad5a16d161_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_8b349e5d-12cd-4183-acc5-e0d8bd282c07_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits related to stock based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_GainLossOnSaleOfContingentPayments_ffdf0b8a-202d-4653-b4a1-75b501c03b85_terseLabel_en-US" xlink:label="lab_agio_GainLossOnSaleOfContingentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of contingent payments</link:label>
    <link:label id="lab_agio_GainLossOnSaleOfContingentPayments_10b371a7-37c4-4be8-872e-6578f667a696_negatedTerseLabel_en-US" xlink:label="lab_agio_GainLossOnSaleOfContingentPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of contingent payments</link:label>
    <link:label id="lab_agio_GainLossOnSaleOfContingentPayments_label_en-US" xlink:label="lab_agio_GainLossOnSaleOfContingentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Sale Of Contingent Payments</link:label>
    <link:label id="lab_agio_GainLossOnSaleOfContingentPayments_documentation_en-US" xlink:label="lab_agio_GainLossOnSaleOfContingentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Sale Of Contingent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_GainLossOnSaleOfContingentPayments" xlink:to="lab_agio_GainLossOnSaleOfContingentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_a703f244-f8f8-42bd-a4c1-2bf1dc9a6ef1_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DiscontinuedOperationsLiabilitiesDistributedNet_e7058d99-9285-490e-873a-3ce02120d137_terseLabel_en-US" xlink:label="lab_agio_DiscontinuedOperationsLiabilitiesDistributedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus: net liabilities distributed, including working capital adjustment</link:label>
    <link:label id="lab_agio_DiscontinuedOperationsLiabilitiesDistributedNet_label_en-US" xlink:label="lab_agio_DiscontinuedOperationsLiabilitiesDistributedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Liabilities Distributed, Net</link:label>
    <link:label id="lab_agio_DiscontinuedOperationsLiabilitiesDistributedNet_documentation_en-US" xlink:label="lab_agio_DiscontinuedOperationsLiabilitiesDistributedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Liabilities Distributed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DiscontinuedOperationsLiabilitiesDistributedNet" xlink:href="agio-20231231.xsd#agio_DiscontinuedOperationsLiabilitiesDistributedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DiscontinuedOperationsLiabilitiesDistributedNet" xlink:to="lab_agio_DiscontinuedOperationsLiabilitiesDistributedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod_716a2ad6-38b7-4a8c-bdd2-2c8a93c35152_terseLabel_en-US" xlink:label="lab_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum period to liquidate</link:label>
    <link:label id="lab_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod_label_en-US" xlink:label="lab_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Non Current Minimum Liquidating Period</link:label>
    <link:label id="lab_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod_documentation_en-US" xlink:label="lab_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for sale securities non current minimum liquidating period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod" xlink:href="agio-20231231.xsd#agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod" xlink:to="lab_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_11a61798-7666-4127-8453-bf8531f83684_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_75eb5d0e-2f37-482e-a5bb-06ae4987583e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_d0e4c1e0-c327-4f48-95a2-f623e438c3ed_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment and geographic information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6961a5dd-a6e9-4136-b8ef-ac214b2aa356_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DeferredTaxAssetsValuationAllowanceRollForward_613d1cca-113b-4c3c-9f74-22daf195b971_terseLabel_en-US" xlink:label="lab_agio_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_agio_DeferredTaxAssetsValuationAllowanceRollForward_label_en-US" xlink:label="lab_agio_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance [Roll Forward]</link:label>
    <link:label id="lab_agio_DeferredTaxAssetsValuationAllowanceRollForward_documentation_en-US" xlink:label="lab_agio_DeferredTaxAssetsValuationAllowanceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredTaxAssetsValuationAllowanceRollForward" xlink:href="agio-20231231.xsd#agio_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DeferredTaxAssetsValuationAllowanceRollForward" xlink:to="lab_agio_DeferredTaxAssetsValuationAllowanceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncomeTaxesDisclosureLineItems_bdc04f63-a4c9-4cec-ab80-0979647fffdd_terseLabel_en-US" xlink:label="lab_agio_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_agio_IncomeTaxesDisclosureLineItems_label_en-US" xlink:label="lab_agio_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:label id="lab_agio_IncomeTaxesDisclosureLineItems_documentation_en-US" xlink:label="lab_agio_IncomeTaxesDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncomeTaxesDisclosureLineItems" xlink:href="agio-20231231.xsd#agio_IncomeTaxesDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems" xlink:to="lab_agio_IncomeTaxesDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_80361c04-5a81-41e5-85d2-22495b70f68b_terseLabel_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_label_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Roll Forward]</link:label>
    <link:label id="lab_agio_ContractualAdjustmentsRollForward_documentation_en-US" xlink:label="lab_agio_ContractualAdjustmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractualAdjustmentsRollForward" xlink:href="agio-20231231.xsd#agio_ContractualAdjustmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractualAdjustmentsRollForward" xlink:to="lab_agio_ContractualAdjustmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_a88d807c-120c-46ff-b786-e69d6a779f5e_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on financing lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_c11bd893-36c9-4233-9031-dd6a635b4ce8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract_3a2cc52a-2e7f-434d-8681-f2dc6048af00_terseLabel_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract_label_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenues [Abstract]</link:label>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract_documentation_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract" xlink:to="lab_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue_40243bd7-0c7b-4bd3-8da7-14e1618248d9_negatedLabel_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense for the sale of future revenue</link:label>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue_label_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense, Non-Cash, Sale Of Future Revenue</link:label>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue_documentation_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense, Non-Cash, Sale Of Future Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue" xlink:to="lab_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_46751cd6-dfaf-4f7d-9b33-cca2101676bf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7f1c9de3-00ec-4cb3-bd06-5897e71e6f0e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_71f0f765-768e-47db-b876-6b8783d5f7da_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_453d77f1-e430-4716-b079-af5358e24cdb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_4a44516c-ebf8-4003-8da8-ab41eb09ceb2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d0d27f34-76ee-4290-98fe-4dc57e60d4b8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1e08cd34-db25-4c21-8296-4932cfa8519e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Expected Income Tax Benefit (Expense) Computed Using Federal Statutory Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7dcafa3a-12a3-4c38-b8ba-49be91ec084d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_69eb1d7c-82bd-48b3-bd6c-9100e383ed7f_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0bafc127-2c6f-48e2-8d41-1809f9c0050c_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits at the end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9bf5ff47-31c3-400b-ad24-c9fc22e36ecb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_17730e78-5ce5-4b10-9369-d5eb6e3c7e49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_eabc996b-5042-4ff4-96ca-1ba4fb64b21e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_88bff2a6-fee9-4a94-9b34-6382d65601f4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a850e88b-034e-4e15-b56b-79c904e3ea9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_20fa676f-e178-4d06-8daa-032f51b968be_terseLabel_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_label_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Provision For Contractual Adjustments</link:label>
    <link:label id="lab_agio_PriorYearProvisionForContractualAdjustments_documentation_en-US" xlink:label="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments" xlink:href="agio-20231231.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PriorYearProvisionForContractualAdjustments" xlink:to="lab_agio_PriorYearProvisionForContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo_289e11ae-35ba-40cb-9a7b-fb49a27af36c_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second extension period</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo_label_en-US" xlink:label="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Extension Period Two</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo_documentation_en-US" xlink:label="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Extension Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo" xlink:to="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_4a75fdcb-074b-48fd-950d-81ecc5ebdc07_terseLabel_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research And Development Expenses</link:label>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research And Development Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:to="lab_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3d43b74d-ba96-4508-a0a1-cc57135e8b15_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_2d29c593-32d3-481e-aef5-1f7602376add_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_a5da2112-4422-4e56-91ea-523bf8ef3d40_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_47aafc57-4691-4140-889e-ee476dc14f41_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c40a4f1a-8354-4f2c-bab3-fe644525b6a0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6df30d0c-0b92-4fdf-8451-5e2b6736ecfb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_917d9677-736c-4129-948b-6c7102a11d6c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationRevenueOtherMember_81834c90-7007-4d12-9f8f-6723fd9f1ceb_verboseLabel_en-US" xlink:label="lab_agio_CollaborationRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue &#8211; other</link:label>
    <link:label id="lab_agio_CollaborationRevenueOtherMember_label_en-US" xlink:label="lab_agio_CollaborationRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue, Other [Member]</link:label>
    <link:label id="lab_agio_CollaborationRevenueOtherMember_documentation_en-US" xlink:label="lab_agio_CollaborationRevenueOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember" xlink:href="agio-20231231.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationRevenueOtherMember" xlink:to="lab_agio_CollaborationRevenueOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_17870cce-99fb-4d6d-b3ed-c2cdcca26dc4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_dcf13837-705a-4598-a890-9b11e9b15078_totalLabel_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_agio_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="agio-20231231.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_agio_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_3212e5e3-b0ab-4fe3-a2bb-9c5d4277ab4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_44912b3b-7a53-4f96-9fc7-1eff93d4912d_terseLabel_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_label_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs And Expenses [Abstract]</link:label>
    <link:label id="lab_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_documentation_en-US" xlink:label="lab_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs And Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:to="lab_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments_d5fa3206-6e99-48d6-adf8-8b27988fe9ba_terseLabel_en-US" xlink:label="lab_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General business credits and other credits</link:label>
    <link:label id="lab_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments_label_en-US" xlink:label="lab_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Tax Credits Adjustments</link:label>
    <link:label id="lab_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments_documentation_en-US" xlink:label="lab_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation tax credits adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" xlink:href="agio-20231231.xsd#agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" xlink:to="lab_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_7323cd3f-9191-4569-a953-38ff58322e4f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_87e92ff7-e743-4049-a2b3-cac5004e706d_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AtTheMarketOfferingMember_0ab6a129-979a-40c1-9768-649d39d35987_terseLabel_en-US" xlink:label="lab_agio_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering</link:label>
    <link:label id="lab_agio_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_agio_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:label id="lab_agio_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_agio_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AtTheMarketOfferingMember" xlink:href="agio-20231231.xsd#agio_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AtTheMarketOfferingMember" xlink:to="lab_agio_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_93df72ec-b7a7-40fd-a85d-9290857f71c7_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_565e751a-f75a-4807-98c5-c4b7b81793f5_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_8e31e5e3-0b34-44e0-b862-8557c7deb435_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_aa563328-fc1a-4ffd-a6dd-f750db51b79d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_23cc93c8-adf9-4193-92f5-4f56341995a9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_443ea9dd-5933-44b1-899c-98b227ff1c26_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ff28fdc8-d8e5-4560-b992-1114b73c49d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1da96f54-8e66-4e6e-93ac-8cf39fbddad6_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b14c4702-5b2a-430f-ab9e-734e1a5d44bd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_361c386e-7c93-44aa-b0c7-412f89ed07f7_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at the beginning of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_e393eb54-9e4d-4899-a98e-5dbdac205bdd_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance at the end of the year</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17e3101d-4546-4893-b74a-410963a2ffb0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_12b29b48-f78f-402b-8f76-2397be6562fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiability_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiability" xlink:to="lab_us-gaap_FairValueNetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_424403b8-a6aa-4b5a-a47d-c509d8d4a863_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_45ec638d-37d2-4556-9658-37b282ea3605_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4ebf476f-6dfa-4c17-82df-b6b5c5b4c9da_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_92fb32a8-6b8d-4edc-9597-ab91f624e332_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d456e240-5159-4fe3-9c18-08b7d9b56fd1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5643a7d4-220f-4527-ae14-151bb17ed3e2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_4a2887d3-7e4d-4940-848a-49e86b2745c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DeferredTaxAssetsOperatingLeaseLiability_73276e3c-1e29-4981-bfac-ae00dc679b39_terseLabel_en-US" xlink:label="lab_agio_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_agio_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_agio_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:label id="lab_agio_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_agio_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="agio-20231231.xsd#agio_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_agio_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2bee0287-db9e-41c3-a68c-99885d4bd52e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_26378d96-e313-4e41-8882-b30200d4c030_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty income from gain on sale of oncology business</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_b58723d5-114f-4a4a-b533-6841dbd74053_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_ca4eb17f-f5db-4f04-8214-c3a5ebb967af_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_6e1ba48e-a612-40f8-b818-952903409451_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_798d59c0-7ad9-4aeb-8f9f-562657bcc283_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_79629356-9f5a-432b-a137-e728f6a96910_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f951e70f-0bb6-4bd2-b874-4edb958d7268_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_f340fcdc-4f8b-45a6-8cce-2b996f91c397_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_af13f35a-ea82-462d-be92-d2cf8384a2e3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bd659dc5-76b3-4e00-b2b4-ba2f2040564b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0019d015-b7d9-4926-9be6-6ec82d902fbd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_174a49be-f1bb-4074-9cfc-f477c71fc191_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_95568172-fab6-4969-ae2f-d2a7d4953ebd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_be236085-a27f-452d-902d-c570de9870a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160; Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_893c24c2-a100-425f-8497-fb98cd3902a6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CollaborationRevenueRelatedPartyMember_62f998fa-8d9d-4111-bf06-d90656301e6c_verboseLabel_en-US" xlink:label="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue &#8211; related party</link:label>
    <link:label id="lab_agio_CollaborationRevenueRelatedPartyMember_label_en-US" xlink:label="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue, Related Party [Member]</link:label>
    <link:label id="lab_agio_CollaborationRevenueRelatedPartyMember_documentation_en-US" xlink:label="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember" xlink:href="agio-20231231.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CollaborationRevenueRelatedPartyMember" xlink:to="lab_agio_CollaborationRevenueRelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_843c3a0c-971e-4762-964b-9159fe7de479_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_5a0345bd-0e24-430f-b7b2-2c6d3aca9b19_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d8bfae18-bfb9-44cd-92d6-d3f3a15dc7db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_09eb6d1d-84a8-4592-a320-7450c5d4c6bf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_c83cf468-8301-4515-8d6d-c3ad97e157ce_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_7a926371-ec38-4f4c-b4c2-2a276cacb5ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_2a7d823e-999f-4535-bb8d-3b853a856bb5_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_c2b1e6e8-b176-448b-9598-fcec457491fb_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue &#8211; related party</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_ceea8485-b667-44b1-8971-7121f67aa0e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Market-based Stock Unit or MSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_96548368-c1a1-472d-8b43-6325a2407588_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_b3768427-e4ee-40bb-a072-a4c2ee1f7f7e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_ba2c00a2-ab4f-4bc0-b4d5-3e15b0057e20_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_9f079383-083a-446e-afe6-622a47bc2362_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible accruals and reserves, including inventory</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_85afa873-7cb8-4052-b4c8-79f7126b533e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0098cecb-6f63-4c7e-8c00-f9ddca9e321a_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_5e0b393c-081a-4231-8b5b-be2af13c97d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_IncomeTaxesDisclosureTable_ca1665f5-9dbf-4331-ab80-2894ad89d133_terseLabel_en-US" xlink:label="lab_agio_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_agio_IncomeTaxesDisclosureTable_label_en-US" xlink:label="lab_agio_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:label id="lab_agio_IncomeTaxesDisclosureTable_documentation_en-US" xlink:label="lab_agio_IncomeTaxesDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncomeTaxesDisclosureTable" xlink:href="agio-20231231.xsd#agio_IncomeTaxesDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_IncomeTaxesDisclosureTable" xlink:to="lab_agio_IncomeTaxesDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ed745a71-aa80-4ab8-9893-c0fb61dd64e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_f460233d-c80b-4570-beb0-d554630eed82_terseLabel_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_label_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Provisions For Rebate Reserve</link:label>
    <link:label id="lab_agio_CurrentYearProvisionsForRebateReserve_documentation_en-US" xlink:label="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve" xlink:href="agio-20231231.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentYearProvisionsForRebateReserve" xlink:to="lab_agio_CurrentYearProvisionsForRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_eb8d2a30-d168-48c3-aa89-16d1f41018da_terseLabel_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_label_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Provisions For Rebate Reserve</link:label>
    <link:label id="lab_agio_PriorYearProvisionsForRebateReserve_documentation_en-US" xlink:label="lab_agio_PriorYearProvisionsForRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve" xlink:href="agio-20231231.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PriorYearProvisionsForRebateReserve" xlink:to="lab_agio_PriorYearProvisionsForRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_5767ccda-bdcd-4f65-8d55-4570b49c8a51_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_be56df78-4c6e-4b7d-b1bc-6d9f52435438_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_5a60ed55-c24b-486e-8be6-ac754f51d55e_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_179bd977-6a43-4559-96c3-5cbb36e264a8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_03bd0bcd-8f97-4ade-9684-6bb268fab183_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_3eebd873-2bda-4377-8329-c47cdf565a3f_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Rebate Reserve, Recoveries In Current Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:to="lab_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_b2b13599-1458-4633-8adb-40d0a3a4ec90_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_295996fd-8701-4329-8a0c-e3f547ff9ae9_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fcc21f7-cc1c-4dc9-9b45-a2a33751eaf5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_ac700293-042a-4401-af32-8034b21e1394_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9980ee2a-071a-4262-afb1-6341fba75816_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_384cf8e2-d45d-433b-928a-1d835cf9d0f7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingent Liabilities</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a0177328-175f-4ed0-b366-d35eb7fe4605_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from continuing operations per share - diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_10e906be-8734-46a2-8844-8af344f49364_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_59e8b6d4-de0b-41a8-bf00-73080395e817_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of debt securities in an unrealized loss position for less than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d7b21c3e-cc08-4583-910d-6b200bad15ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expenses Related to Stock Options and Stock-based Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_b433110c-0fb3-45e8-979c-184eeb94e76d_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (accretion of discount) amortization of premium on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7ec21662-024b-42a6-934b-7ecce3f46d3f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1e9a47c0-c2e9-4f1d-a79f-b63f31cd93cb_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a6941349-570e-4bcb-b8f6-cd920a95dc90_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d212a376-1b23-4cac-8213-6e05af902b2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c11e08c8-2588-42d8-b2b5-c51863000e8e_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income per share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_8e8675d6-c27f-40d8-b358-7f0adefa6a26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_d45484e5-9723-46a5-aa21-348a688677f0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_fd56a40a-309a-4b30-bd4d-053bc144e3d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_8bf41b8e-0390-4c61-82d0-f55f4ef64165_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7e9c2b5f-1ad4-450a-a295-ae6374a29a92_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_97d59545-5472-4d49-9755-a5ca514950c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_a6f4f5c7-ebb7-4dcd-ad99-a2b54fc3cd65_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_912fcec3-32bb-4a32-849b-e66181a954b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_8d3e96e7-b182-479b-97c9-f912d1c4db11_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, pre-tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_26e2a828-3799-4b07-8246-424c55d1b5ad_terseLabel_en-US" xlink:label="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BMS Repurchase</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_label_en-US" xlink:label="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program, Bristol-Myers Squibb Company Repurchase [Member]</link:label>
    <link:label id="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_documentation_en-US" xlink:label="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">March 25 2021 Repurchase Program, Bristol-Myers Squibb Company Repurchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:href="agio-20231231.xsd#agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:to="lab_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_41287b01-3087-4ee6-ba26-aff34e8709db_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale, pre-tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_dbbaf64d-d01b-4b99-8cdc-b9f9aec01d0f_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on the sale of the oncology business</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_87593672-f70c-4c0b-9580-7a581400d002_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_GainContingencyRoyaltyPercentageOfNetSales_e171d89a-448b-405d-8409-c5422f853034_terseLabel_en-US" xlink:label="lab_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent royalty payment</link:label>
    <link:label id="lab_agio_GainContingencyRoyaltyPercentageOfNetSales_label_en-US" xlink:label="lab_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency Royalty Percentage Of Net Sales</link:label>
    <link:label id="lab_agio_GainContingencyRoyaltyPercentageOfNetSales_documentation_en-US" xlink:label="lab_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency Royalty Percentage Of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:href="agio-20231231.xsd#agio_GainContingencyRoyaltyPercentageOfNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:to="lab_agio_GainContingencyRoyaltyPercentageOfNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue_63ede789-4e98-47cf-b5c4-07029f103eab_terseLabel_en-US" xlink:label="lab_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of common stock reserved for future issuance</link:label>
    <link:label id="lab_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue_label_en-US" xlink:label="lab_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Common Stock Reserved For Future Issuance, Value</link:label>
    <link:label id="lab_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue_documentation_en-US" xlink:label="lab_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Common Stock Reserved For Future Issuance, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue" xlink:href="agio-20231231.xsd#agio_SaleOfStockCommonStockReservedForFutureIssuanceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue" xlink:to="lab_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_730cc881-efef-4d9a-847c-2f0df57828c7_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16587a08-44a4-4156-8be9-7b6fca0c6694_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term, vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_cc895f64-074f-45c3-95b3-fb49d739e26b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_05a946ea-a756-4ab7-9ced-08f8868a88df_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2abe8100-dcd0-4e46-a021-9703f100828d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_fae1ca8e-ca8a-45fb-a003-2129c132dbfd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a58e8915-1ae5-4775-8b2b-578c8bff324a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_cbe4ff19-998f-46a6-b04b-657e75b5ba5c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_ed4f3472-307a-4b37-9424-a2449c7d041b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fe52276c-9c7d-4f42-84b8-6bd903aaa234_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e4711b35-b805-404d-9b33-a5997cbfcad1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_6e636104-3dc2-46a8-8127-de573377400f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_897c632b-f385-4c01-9a46-465da003a275_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f1b3c3a5-91e9-4d66-83fd-3a10f982d675_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f52353be-1f9d-4f68-b9cf-7182a208bb62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_d31921ce-2b04-46f3-a26f-79909b152e87_terseLabel_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Related Reserves</link:label>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_label_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Notes Loans And Financing Receivable1 [Table Text Block]</link:label>
    <link:label id="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_documentation_en-US" xlink:label="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:href="agio-20231231.xsd#agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:to="lab_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_e0c8b3bc-a1f1-4f73-b539-80ad5a87a73e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PaymentsForAssetAcquisition_f27eea02-7581-44f6-a5e6-727c88836ebe_terseLabel_en-US" xlink:label="lab_agio_PaymentsForAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for asset acquisition</link:label>
    <link:label id="lab_agio_PaymentsForAssetAcquisition_label_en-US" xlink:label="lab_agio_PaymentsForAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisition</link:label>
    <link:label id="lab_agio_PaymentsForAssetAcquisition_documentation_en-US" xlink:label="lab_agio_PaymentsForAssetAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PaymentsForAssetAcquisition" xlink:href="agio-20231231.xsd#agio_PaymentsForAssetAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PaymentsForAssetAcquisition" xlink:to="lab_agio_PaymentsForAssetAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfEquity_3c536133-64bf-4564-895b-9af95bef924b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfEquity_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DiscontinuedOperationsTransactionAndInsuranceCosts_53fcb90d-5510-4a70-9de0-70a05614fcc5_negatedTerseLabel_en-US" xlink:label="lab_agio_DiscontinuedOperationsTransactionAndInsuranceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: transaction and insurance costs</link:label>
    <link:label id="lab_agio_DiscontinuedOperationsTransactionAndInsuranceCosts_label_en-US" xlink:label="lab_agio_DiscontinuedOperationsTransactionAndInsuranceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Transaction And Insurance Costs</link:label>
    <link:label id="lab_agio_DiscontinuedOperationsTransactionAndInsuranceCosts_documentation_en-US" xlink:label="lab_agio_DiscontinuedOperationsTransactionAndInsuranceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Transaction And Insurance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DiscontinuedOperationsTransactionAndInsuranceCosts" xlink:href="agio-20231231.xsd#agio_DiscontinuedOperationsTransactionAndInsuranceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DiscontinuedOperationsTransactionAndInsuranceCosts" xlink:to="lab_agio_DiscontinuedOperationsTransactionAndInsuranceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3b7f4a16-4d73-4be5-9581-72e9092d88e3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) for the current period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4dabb55b-46da-4664-809d-a2725c2c1a47_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDepositLiability_19fd66ef-dbd6-42c1-b444-d020fc49d980_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDepositLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit liability</link:label>
    <link:label id="lab_us-gaap_SecurityDepositLiability_label_en-US" xlink:label="lab_us-gaap_SecurityDepositLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDepositLiability" xlink:to="lab_us-gaap_SecurityDepositLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AgiosOncologyBusinessMember_85aadad0-80e5-466c-84f2-a176cdfd9ea0_terseLabel_en-US" xlink:label="lab_agio_AgiosOncologyBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agios Oncology Business</link:label>
    <link:label id="lab_agio_AgiosOncologyBusinessMember_label_en-US" xlink:label="lab_agio_AgiosOncologyBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agios Oncology Business [Member]</link:label>
    <link:label id="lab_agio_AgiosOncologyBusinessMember_documentation_en-US" xlink:label="lab_agio_AgiosOncologyBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agios Oncology Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember" xlink:href="agio-20231231.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AgiosOncologyBusinessMember" xlink:to="lab_agio_AgiosOncologyBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_a4fc5191-3503-4c49-8c37-c9ebcdf939cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 125,000,000 shares authorized; 72,161,489 shares issued and 55,945,078 outstanding at December 31, 2023 and 71,256,118 shares issued and 55,039,707 outstanding at December 31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fa161de5-8eae-4405-9619-11c321a56660_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_fb235fc9-41a5-44d9-a53b-3cd2bdfa4b2a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_44640ba6-4bc9-4051-b5ce-e054bb1b93b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_3bc08d05-45c7-484e-90b8-72b3fca397aa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities - continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_3a0614ca-3ab8-4653-8385-bf270eae1222_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities - continuing operations</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7e3571f9-ed3a-4192-a4eb-222a64c757e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited/expired (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_f121284c-e797-4025-a39c-091e328139ea_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_459829bc-1cb7-4b4c-80da-14a70d2db6ca_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_298b9a26-325a-49cc-9da2-0b2d954b7da1_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_NumberOfStatesFederalOrForeignInAuditingProcess_4531db09-11d6-4e08-b15a-27b24513b78e_terseLabel_en-US" xlink:label="lab_agio_NumberOfStatesFederalOrForeignInAuditingProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of federal, state or foreign audits in process</link:label>
    <link:label id="lab_agio_NumberOfStatesFederalOrForeignInAuditingProcess_label_en-US" xlink:label="lab_agio_NumberOfStatesFederalOrForeignInAuditingProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States Federal Or Foreign In Auditing Process</link:label>
    <link:label id="lab_agio_NumberOfStatesFederalOrForeignInAuditingProcess_documentation_en-US" xlink:label="lab_agio_NumberOfStatesFederalOrForeignInAuditingProcess" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states, federal or foreign in auditing process.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NumberOfStatesFederalOrForeignInAuditingProcess" xlink:href="agio-20231231.xsd#agio_NumberOfStatesFederalOrForeignInAuditingProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_NumberOfStatesFederalOrForeignInAuditingProcess" xlink:to="lab_agio_NumberOfStatesFederalOrForeignInAuditingProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_be06938d-6825-430f-8748-712d0b2791e2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_341c3868-b165-4e4e-be38-3e73879cab6e_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale, net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5ce993e8-07fe-4b35-9d80-9a4f53ff9bed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ea40f063-8a40-42e0-8ad1-c4d5830b9971_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_84cf8944-c4b6-43bb-ac9e-dc531ab321c6_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_4d411fc7-2884-4e31-8858-537a04ab850a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8834d135-ac24-4618-a37c-ba9be3034d65_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b0a7a062-d479-4ba3-b542-c51b6342e780_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_afa63784-d102-432a-825a-9fdd1f337a33_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_4a7b4993-e33e-46f8-b473-6c89d4129a09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, exercisable (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_545dc9fc-47db-46cf-ae36-fc7dc2df9fd0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d636f73d-3073-4ca5-a134-e1cfc8387eba_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_d810dcc0-fed5-4cab-a339-ad86712d8c81_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1221308d-6bcc-4298-be5e-db5f06c6439f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8710fa6f-c3a6-4af5-bf7b-5c5db30cf39a_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_efa392f7-73ff-4c72-8aa2-61a93183cd0a_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Right To Recover Product, Prior Year Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_0a9c4c03-8b0b-4962-ba28-af42e49345da_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_fcb67c77-bb61-4ff2-a9a9-363c02a585c2_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, payments/returns relating to sales in the prior years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Rebate Reserve, Recoveries In Prior Years</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:to="lab_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_839db600-1507-405e-bc6d-170d9079fdfe_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentAssetMember_985c9beb-2c6e-4af1-9535-b348fbf585b2_terseLabel_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_agio_CurrentAssetMember_label_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Asset [Member]</link:label>
    <link:label id="lab_agio_CurrentAssetMember_documentation_en-US" xlink:label="lab_agio_CurrentAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember" xlink:href="agio-20231231.xsd#agio_CurrentAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentAssetMember" xlink:to="lab_agio_CurrentAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dcdfcc53-7af0-4950-9b45-9ae7a7ce3295_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences and other adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_1871bc2a-1e94-4e5e-837e-7792bbce0f92_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_764f0c74-ca64-44d6-9c54-5fc844737bf5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f0442deb-4565-43c3-adca-28d199623670_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1cf493c0-e535-47ad-bfb7-633e0b9e31c8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_867de4f5-542c-4ced-8b84-9b2125e8e1eb_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities - discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_f37e7c48-b249-4515-ad09-c376ad5fc7e9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0f8da49b-777e-45e2-b241-b9aa81c0a655_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_17fd47b6-a452-470e-941f-768f6c74d3ef_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7cf294bb-20ca-48f3-a6eb-d770b1b16d1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_AlnylamPharmaceuticalsIncMember_799a78b6-3447-42d9-8fb7-850fae3ea4d7_terseLabel_en-US" xlink:label="lab_agio_AlnylamPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_agio_AlnylamPharmaceuticalsIncMember_label_en-US" xlink:label="lab_agio_AlnylamPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_agio_AlnylamPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_agio_AlnylamPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alnylam Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AlnylamPharmaceuticalsIncMember" xlink:href="agio-20231231.xsd#agio_AlnylamPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_AlnylamPharmaceuticalsIncMember" xlink:to="lab_agio_AlnylamPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a851c7a1-d806-40ec-94e1-b303b95223d8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f58bd225-2742-45fe-8518-c7622fb356bd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_cfc65491-7000-44d8-b530-abd72de11001_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b59c09b3-7dcc-4206-bb52-498dc7161ee2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_4fed0948-8eee-4929-ab19-26890c9a3df4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_305e3224-66a7-4918-97fd-fe1d8761311c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9ffdf652-7919-4174-8720-d25392c29490_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average incremental borrowing rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_6ae09aae-6829-4862-a474-310b20c94a1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opportunity to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_490bcf02-3718-48db-bee6-1676b2f92a0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_708b8f0d-2c5b-48ae-bcf4-0acd22f0c731_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod_bb923221-1395-4e31-bb06-7ae2e5413fc0_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod_label_en-US" xlink:label="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Extension Period</link:label>
    <link:label id="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod_documentation_en-US" xlink:label="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod" xlink:to="lab_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1c57e744-d6f9-4abe-9ed8-2cc6aefa9b95_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of property and equipment (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_dd19fae0-fb78-4dd1-b50d-40f9c790f4a3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f4afc013-bd17-42a7-8cdf-dc427058d4c9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5c82a7e3-831f-4b5c-82e0-86b8de472a74_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_TIBSOVOMember_287e12f3-51b3-48c0-9710-15f9660fd0ce_terseLabel_en-US" xlink:label="lab_agio_TIBSOVOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TIBSOVO</link:label>
    <link:label id="lab_agio_TIBSOVOMember_label_en-US" xlink:label="lab_agio_TIBSOVOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TIBSOVO [Member]</link:label>
    <link:label id="lab_agio_TIBSOVOMember_documentation_en-US" xlink:label="lab_agio_TIBSOVOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TIBSOVO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TIBSOVOMember" xlink:href="agio-20231231.xsd#agio_TIBSOVOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_TIBSOVOMember" xlink:to="lab_agio_TIBSOVOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PaymentsAssociatedWithLicenseAgreement_8de47d83-5ae1-4066-a2a2-f819babcd784_negatedLabel_en-US" xlink:label="lab_agio_PaymentsAssociatedWithLicenseAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments associated with license agreement</link:label>
    <link:label id="lab_agio_PaymentsAssociatedWithLicenseAgreement_label_en-US" xlink:label="lab_agio_PaymentsAssociatedWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Associated With License Agreement</link:label>
    <link:label id="lab_agio_PaymentsAssociatedWithLicenseAgreement_documentation_en-US" xlink:label="lab_agio_PaymentsAssociatedWithLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Associated With License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PaymentsAssociatedWithLicenseAgreement" xlink:href="agio-20231231.xsd#agio_PaymentsAssociatedWithLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PaymentsAssociatedWithLicenseAgreement" xlink:to="lab_agio_PaymentsAssociatedWithLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_d1d5ae93-b17c-408b-bedc-28a2a2a504c8_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_c223c8fd-0376-4834-8692-77621b0e8b2a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_fc285d2f-db9e-4921-bf9d-5263f1c821e7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing lease liabilities arising from obtaining financing lease assets</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1ee5475a-164a-4793-aaa1-b6315d096edf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_07666bf4-ff6a-420a-8807-0d6927eecdb3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7faa290e-1049-46e8-9eaf-c62053d1da44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_bf1c1852-fe84-49a2-b028-b82a64953d1e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5b55401d-003a-43d9-9866-f993cbccbfda_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1d4cc8f6-ee9b-4d45-b681-a258d42eba08_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_83d39db2-49fc-4a28-8667-b4efaea885a1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8b8e21e4-a7ad-417f-93e6-b7dcd225df72_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_f15fdd64-d271-4460-8a73-0a80b8bb9a30_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_EmployeePurchasePlanMember_4ca191d6-e9f2-426e-85fc-0ee07ab748c4_terseLabel_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_agio_EmployeePurchasePlanMember_2d4710ed-2e6f-4d45-a7ae-c608b730e576_verboseLabel_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan shares</link:label>
    <link:label id="lab_agio_EmployeePurchasePlanMember_label_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Purchase Plan [Member]</link:label>
    <link:label id="lab_agio_EmployeePurchasePlanMember_documentation_en-US" xlink:label="lab_agio_EmployeePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember" xlink:href="agio-20231231.xsd#agio_EmployeePurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_EmployeePurchasePlanMember" xlink:to="lab_agio_EmployeePurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_fe08d651-90bb-415d-a744-cc3cc7cb9504_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9b264a6f-7224-4f27-8c04-d35ad625cc75_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_b810a690-f0ab-406c-8311-7b72bbd7d8f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4944e7a8-5812-4073-b0c0-74203aa7f776_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_145bbd43-a576-48c1-af24-3177258773aa_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_35ffa028-ecc9-4567-b56a-f262e7325cec_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_29294411-a428-416e-ac73-a216771988c2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_6f6581a7-5f26-47c6-bbf3-6db3127f998e_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operation, gain (loss) on disposal, statement of income or comprehensive income [extensible enumeration]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0d890707-9b43-47dd-8db5-622bb7bb36d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_fea9a23d-aba5-4510-8ad2-4ab49b341590_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bf86f823-5027-4211-be21-141109026f61_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted minimum rental commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_57b279c4-1379-464b-b5f2-d5d20bdd11da_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_1f0ecc52-3ba2-4b44-a482-eb4969ec1333_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, payments/returns relating to sales in the prior year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_label_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Contract Adjustment, Recoveries, Prior Year</link:label>
    <link:label id="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:to="lab_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_7cf9e0c9-81f4-4848-ae38-7f0aed906a0b_totalLabel_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total allowances and reserves, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_label_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Current Year Reserve Provisions</link:label>
    <link:label id="lab_agio_ContractWithCustomerCurrentYearReserveProvisions_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:to="lab_agio_ContractWithCustomerCurrentYearReserveProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_82dae3fe-441e-4b91-ab02-9c39163c0c1d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_96414d01-333c-407d-b5c6-4b1f077063a6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_fd59eda8-b2c6-4c6c-a496-a27b488d2189_periodStartLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, beginning balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_afadaf14-0265-49c2-93bd-dc4847db57a1_periodEndLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government rebates, ending balance</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_label_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebate Reserve</link:label>
    <link:label id="lab_agio_ContractWithCustomerRebateReserve_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRebateReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRebateReserve" xlink:to="lab_agio_ContractWithCustomerRebateReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_93690852-59df-4f89-bc47-d00b4e80eefd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_042db634-f68e-4892-83ca-7fd26c8bcf14_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_3e6bc9d2-0a59-4fd8-bbed-0a8030a6c2c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for extension of operating lease (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_f932542e-3c39-482d-a2b6-72247488f959_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_464ec305-4da8-438c-bea3-901744a4e379_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_9a195aa4-923b-42c7-9add-33574309be24_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2e6f88bc-2954-4628-977d-75f03297a837_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_95ad58f8-d1b2-4413-b036-3afc8fa2ffa9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_758fef99-2dc8-4cdc-9b17-916e5bc77173_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_2d7623b9-b3c4-413f-a48f-f5db323ab070_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfbbe5ae-74c7-4ed0-af34-8490551eb9a9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d9dad9dd-0405-43b8-a014-b0ee46318f5e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_88f85ba8-178d-4ded-be05-1d7729d5c8f3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_caa3f653-540f-4c52-8645-ed2304a5b4f2_terseLabel_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, adjustments relating to prior years</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_label_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Right To Recover Product In Prior Years</link:label>
    <link:label id="lab_agio_ProvisionForRightToRecoverProductInPriorYears_documentation_en-US" xlink:label="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:href="agio-20231231.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:to="lab_agio_ProvisionForRightToRecoverProductInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5c82aad3-aacb-4b2c-b32f-b59cd8624308_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_NumberOfVotesPerShare_8014f8de-50c3-45af-9bd2-0c09529997ec_terseLabel_en-US" xlink:label="lab_agio_NumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per share</link:label>
    <link:label id="lab_agio_NumberOfVotesPerShare_label_en-US" xlink:label="lab_agio_NumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Share</link:label>
    <link:label id="lab_agio_NumberOfVotesPerShare_documentation_en-US" xlink:label="lab_agio_NumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NumberOfVotesPerShare" xlink:href="agio-20231231.xsd#agio_NumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_NumberOfVotesPerShare" xlink:to="lab_agio_NumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4ce6ed17-fcee-4582-839e-2f1801b2e860_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_02e939de-e57c-49f8-acde-2db4c4cc3caa_negatedLabel_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns, payments/returns relating to sales in the current year</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_label_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer Right To Recover Product, Current Year Recoveries</link:label>
    <link:label id="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_documentation_en-US" xlink:label="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:to="lab_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_PercentageOfStockholdersOwnershipIncrease_767d73f0-7e4a-46dd-9812-794134e21207_terseLabel_en-US" xlink:label="lab_agio_PercentageOfStockholdersOwnershipIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stock owned resulting in an ownership change</link:label>
    <link:label id="lab_agio_PercentageOfStockholdersOwnershipIncrease_label_en-US" xlink:label="lab_agio_PercentageOfStockholdersOwnershipIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Stockholders Ownership Increase</link:label>
    <link:label id="lab_agio_PercentageOfStockholdersOwnershipIncrease_documentation_en-US" xlink:label="lab_agio_PercentageOfStockholdersOwnershipIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stockholders ownership increase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PercentageOfStockholdersOwnershipIncrease" xlink:href="agio-20231231.xsd#agio_PercentageOfStockholdersOwnershipIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_PercentageOfStockholdersOwnershipIncrease" xlink:to="lab_agio_PercentageOfStockholdersOwnershipIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_9b6925ca-165b-4317-8fa7-2c2612603476_verboseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_03a2c3e1-c614-4cd6-a83a-29c94e652329_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_ProductReturnsRollForward_801c7ecb-c521-4a03-a112-edc15262d43b_terseLabel_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_agio_ProductReturnsRollForward_label_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Returns [Roll Forward]</link:label>
    <link:label id="lab_agio_ProductReturnsRollForward_documentation_en-US" xlink:label="lab_agio_ProductReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProductReturnsRollForward" xlink:href="agio-20231231.xsd#agio_ProductReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_ProductReturnsRollForward" xlink:to="lab_agio_ProductReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_cc20882e-4a9a-41fc-b7d5-2a502a3e6f17_terseLabel_en-US" xlink:label="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of premises subleased (in square feet)</link:label>
    <link:label id="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_label_en-US" xlink:label="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Area Of Premises Subleased</link:label>
    <link:label id="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_documentation_en-US" xlink:label="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Area Of Premises Subleased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:href="agio-20231231.xsd#agio_LesseeOperatingSubleaseAreaOfPremisesSubleased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:to="lab_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3a749bc2-44f2-49b0-9164-b20d3a490eef_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from stock option exercises and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_69e6d01b-b89e-44e2-8a83-5542266b1ad0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod_631f43c4-ff5b-402f-8544-25a4f83a6dda_terseLabel_en-US" xlink:label="lab_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development costs, amortization period</link:label>
    <link:label id="lab_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod_label_en-US" xlink:label="lab_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research And Development Costs, Amortization Period</link:label>
    <link:label id="lab_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod_documentation_en-US" xlink:label="lab_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research And Development Costs, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" xlink:href="agio-20231231.xsd#agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" xlink:to="lab_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d66d7ed7-56d6-45e5-b7eb-69c47e29170f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_62ea9aaa-b243-4505-90ca-1057cb3e5293_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_76424c7b-d562-4d18-a755-50ab5d5ba80c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_41dc3aea-3e34-418f-999c-6d873979ac5e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of PSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_cd38218e-54ec-49af-984d-3b35db039016_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_ef4cc639-e0cb-444a-a07d-55ac232e4f5a_terseLabel_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments, current provisions relating to sales in the current year</link:label>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_label_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Provision For Contractual Adjustments</link:label>
    <link:label id="lab_agio_CurrentYearProvisionForContractualAdjustments_documentation_en-US" xlink:label="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments" xlink:href="agio-20231231.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_CurrentYearProvisionForContractualAdjustments" xlink:to="lab_agio_CurrentYearProvisionForContractualAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_agio_NonCurrentAssetsMember_77a52799-e3e2-451b-9798-d8e101de5937_terseLabel_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current:</link:label>
    <link:label id="lab_agio_NonCurrentAssetsMember_label_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Assets [Member]</link:label>
    <link:label id="lab_agio_NonCurrentAssetsMember_documentation_en-US" xlink:label="lab_agio_NonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember" xlink:href="agio-20231231.xsd#agio_NonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_agio_NonCurrentAssetsMember" xlink:to="lab_agio_NonCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_2f077d4c-8e06-453d-aea8-74eb2d0bf7bc_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_7b1194c2-201d-4af4-9154-c7553514864d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_01b9ff8e-a8ef-4a0a-b4cc-1da01d0dc882_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_8d5e44d9-f6cc-4205-a6ca-ea89fb697e32_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>agio-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:2870ab7b-aea5-4779-abd7-f438083a7088,g:ac8cf5ba-8c61-4750-87a9-db53e1eda885-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://agios.com/role/CoverPage" xlink:type="simple" xlink:href="agio-20231231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://agios.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1cbc20e0-0a76-423d-b1d5-c8ab1847dc7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_DocumentType_1cbc20e0-0a76-423d-b1d5-c8ab1847dc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_de50e827-d47d-4990-9cc2-0a48181cf3b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_DocumentAnnualReport_de50e827-d47d-4990-9cc2-0a48181cf3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_412aa9d6-8f51-4771-b202-2fc5ba28d588" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_DocumentPeriodEndDate_412aa9d6-8f51-4771-b202-2fc5ba28d588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2c8ed39e-a26d-4ace-9e6d-64b502f5e61d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_CurrentFiscalYearEndDate_2c8ed39e-a26d-4ace-9e6d-64b502f5e61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c2033ff7-ae7c-4b64-8c07-85265442401f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_DocumentTransitionReport_c2033ff7-ae7c-4b64-8c07-85265442401f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_505b0b3b-ae78-4462-a671-0880067acca8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityFileNumber_505b0b3b-ae78-4462-a671-0880067acca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2a439f5e-d8cb-4f4f-9df2-cb2050d0f038" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityRegistrantName_2a439f5e-d8cb-4f4f-9df2-cb2050d0f038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e069dee6-17cb-4bb6-a246-7132b4eafb82" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e069dee6-17cb-4bb6-a246-7132b4eafb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c488d572-91b7-4566-af2f-b34dd45a7361" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityTaxIdentificationNumber_c488d572-91b7-4566-af2f-b34dd45a7361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_55722ed0-6b80-44f9-8d61-edd34597c6bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityAddressAddressLine1_55722ed0-6b80-44f9-8d61-edd34597c6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_11fa477b-971e-4a1b-b78a-6e2254200e20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityAddressCityOrTown_11fa477b-971e-4a1b-b78a-6e2254200e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6272e61c-1a09-4c4c-9041-a4c16002fe4f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityAddressStateOrProvince_6272e61c-1a09-4c4c-9041-a4c16002fe4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_45f74710-de71-4029-b2e6-b187edb31024" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityAddressPostalZipCode_45f74710-de71-4029-b2e6-b187edb31024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_89f81bec-42fd-4014-a43e-13cee9f3df5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_CityAreaCode_89f81bec-42fd-4014-a43e-13cee9f3df5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2f7660d0-2719-4a54-8d8b-755fe24613e9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_LocalPhoneNumber_2f7660d0-2719-4a54-8d8b-755fe24613e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_35af724b-0e5a-42d3-808f-2da841d2390a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_Security12bTitle_35af724b-0e5a-42d3-808f-2da841d2390a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_26ee78be-9732-4ac2-aeaf-55061fc84f26" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_TradingSymbol_26ee78be-9732-4ac2-aeaf-55061fc84f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8f6f7b77-0a68-4650-b3c4-7b1c32d7a372" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_SecurityExchangeName_8f6f7b77-0a68-4650-b3c4-7b1c32d7a372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_60a02996-8a5e-44b8-b08b-c5da66515d20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_60a02996-8a5e-44b8-b08b-c5da66515d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_eb90d9aa-e46d-495f-830e-ccd9cb1710b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityVoluntaryFilers_eb90d9aa-e46d-495f-830e-ccd9cb1710b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_66457a3c-ffbc-4829-9f9b-dcc58a29a3e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityCurrentReportingStatus_66457a3c-ffbc-4829-9f9b-dcc58a29a3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_38775aee-3e17-4fed-bb4e-6a2e61e2c655" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityInteractiveDataCurrent_38775aee-3e17-4fed-bb4e-6a2e61e2c655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0322680f-6837-49d6-852b-286496aa7fb4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityFilerCategory_0322680f-6837-49d6-852b-286496aa7fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ade7a57c-268f-4075-9a59-7270b19dfbe3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntitySmallBusiness_ade7a57c-268f-4075-9a59-7270b19dfbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_75707c64-a980-443c-a259-329fa0ebfa1d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityEmergingGrowthCompany_75707c64-a980-443c-a259-329fa0ebfa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_acb0255e-b02d-443f-b80a-79847798c826" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_IcfrAuditorAttestationFlag_acb0255e-b02d-443f-b80a-79847798c826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_8fca7653-aa13-424a-877f-3f07c492479c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_8fca7653-aa13-424a-877f-3f07c492479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e6d659e8-83c6-43ff-86d4-37aee7bbade3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityShellCompany_e6d659e8-83c6-43ff-86d4-37aee7bbade3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_112197f0-e681-4e4d-b95f-bc30f13a7d25" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityPublicFloat_112197f0-e681-4e4d-b95f-bc30f13a7d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_dd2240cb-28f8-436e-aa68-838fb1d5c45e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_dd2240cb-28f8-436e-aa68-838fb1d5c45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1d9bfd01-4f8b-4c5d-9367-5ba46c586dce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1d9bfd01-4f8b-4c5d-9367-5ba46c586dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2fe87e31-fd5d-4cdf-b55c-1a29cb8f4e0d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_DocumentFiscalYearFocus_2fe87e31-fd5d-4cdf-b55c-1a29cb8f4e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a433e4f1-16e2-4a69-9192-2582347831ad" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a433e4f1-16e2-4a69-9192-2582347831ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_798d44f2-08b1-4183-9065-50e5c7f799cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_AmendmentFlag_798d44f2-08b1-4183-9065-50e5c7f799cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cbda7a19-a745-4e11-b290-9cc0bf1e426e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_60eb298a-72df-419a-bd0e-5c6ace1fcd24" xlink:to="loc_dei_EntityCentralIndexKey_cbda7a19-a745-4e11-b290-9cc0bf1e426e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AuditInformation" xlink:type="simple" xlink:href="agio-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://agios.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_agio_AuditorInformationAbstract_d8150c55-d1c8-41f8-8de7-9d4cbd8bc110" xlink:href="agio-20231231.xsd#agio_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_69fcb038-baca-450f-a1b2-c6585ac4d2b8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_AuditorInformationAbstract_d8150c55-d1c8-41f8-8de7-9d4cbd8bc110" xlink:to="loc_dei_AuditorFirmId_69fcb038-baca-450f-a1b2-c6585ac4d2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_276e2cd1-ccc7-44d1-bcd7-d97cb583cd9f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_AuditorInformationAbstract_d8150c55-d1c8-41f8-8de7-9d4cbd8bc110" xlink:to="loc_dei_AuditorName_276e2cd1-ccc7-44d1-bcd7-d97cb583cd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_821d5e48-89e3-4f4d-b553-ff73aec57ae0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_AuditorInformationAbstract_d8150c55-d1c8-41f8-8de7-9d4cbd8bc110" xlink:to="loc_dei_AuditorLocation_821d5e48-89e3-4f4d-b553-ff73aec57ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://agios.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_92eaf35f-27ee-47b7-a37c-c9fbf0eca8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7d37ece9-0115-415a-bebb-54f7bcf092e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92eaf35f-27ee-47b7-a37c-c9fbf0eca8d6" xlink:to="loc_us-gaap_AssetsAbstract_7d37ece9-0115-415a-bebb-54f7bcf092e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6a4cbc46-7916-4304-8893-5d188ea38b47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d37ece9-0115-415a-bebb-54f7bcf092e1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6a4cbc46-7916-4304-8893-5d188ea38b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20248bd4-49f5-4fc0-960c-5904c6553e49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6a4cbc46-7916-4304-8893-5d188ea38b47" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_20248bd4-49f5-4fc0-960c-5904c6553e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_00dc9f82-069b-4513-939c-b4cef2f1e21a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6a4cbc46-7916-4304-8893-5d188ea38b47" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_00dc9f82-069b-4513-939c-b4cef2f1e21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_26cca045-4541-460c-ad9b-5b082828c5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6a4cbc46-7916-4304-8893-5d188ea38b47" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_26cca045-4541-460c-ad9b-5b082828c5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f03fdb51-04f0-4cb4-8683-bb03cfb0373c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6a4cbc46-7916-4304-8893-5d188ea38b47" xlink:to="loc_us-gaap_InventoryNet_f03fdb51-04f0-4cb4-8683-bb03cfb0373c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7756bc59-b256-4b69-be67-33e3d7d448f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6a4cbc46-7916-4304-8893-5d188ea38b47" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7756bc59-b256-4b69-be67-33e3d7d448f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_02be88c9-5f08-44d0-b3f1-ecd15125bed6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6a4cbc46-7916-4304-8893-5d188ea38b47" xlink:to="loc_us-gaap_AssetsCurrent_02be88c9-5f08-44d0-b3f1-ecd15125bed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c654dcd8-e6af-4e25-9ecf-fa76b12a170d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d37ece9-0115-415a-bebb-54f7bcf092e1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c654dcd8-e6af-4e25-9ecf-fa76b12a170d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5409606d-f45c-4eb5-860c-d7ce54fa9eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d37ece9-0115-415a-bebb-54f7bcf092e1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5409606d-f45c-4eb5-860c-d7ce54fa9eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e321097b-0043-4ed4-8d99-72df444a4c55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d37ece9-0115-415a-bebb-54f7bcf092e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e321097b-0043-4ed4-8d99-72df444a4c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4bb7dcd4-ec54-44ff-a4b0-1938c1760f44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d37ece9-0115-415a-bebb-54f7bcf092e1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4bb7dcd4-ec54-44ff-a4b0-1938c1760f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b928da2e-2d5f-4427-a270-38e5d87828e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7d37ece9-0115-415a-bebb-54f7bcf092e1" xlink:to="loc_us-gaap_Assets_b928da2e-2d5f-4427-a270-38e5d87828e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_473005a2-e76b-4fff-be79-c894fba8e326" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92eaf35f-27ee-47b7-a37c-c9fbf0eca8d6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_473005a2-e76b-4fff-be79-c894fba8e326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_e8324964-5084-4286-8b5b-3d9a74145be7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_473005a2-e76b-4fff-be79-c894fba8e326" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_e8324964-5084-4286-8b5b-3d9a74145be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2715244b-5cce-4b68-af5a-abf2f4724dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e8324964-5084-4286-8b5b-3d9a74145be7" xlink:to="loc_us-gaap_AccountsPayableCurrent_2715244b-5cce-4b68-af5a-abf2f4724dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_92f4292b-e973-4060-9e84-73d9befdcfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e8324964-5084-4286-8b5b-3d9a74145be7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_92f4292b-e973-4060-9e84-73d9befdcfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_75fbe1cf-53be-48ff-ace2-656b8bdd768a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e8324964-5084-4286-8b5b-3d9a74145be7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_75fbe1cf-53be-48ff-ace2-656b8bdd768a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7e55803c-ad3e-4445-ae19-1538efec21ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_e8324964-5084-4286-8b5b-3d9a74145be7" xlink:to="loc_us-gaap_LiabilitiesCurrent_7e55803c-ad3e-4445-ae19-1538efec21ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_77b3c38c-185a-470c-b2cf-24dc7572bbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_473005a2-e76b-4fff-be79-c894fba8e326" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_77b3c38c-185a-470c-b2cf-24dc7572bbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_578e60fb-0067-40ab-9b09-00433bffeb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_473005a2-e76b-4fff-be79-c894fba8e326" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_578e60fb-0067-40ab-9b09-00433bffeb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a2e844d3-997c-4ead-b304-be911c20349e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_473005a2-e76b-4fff-be79-c894fba8e326" xlink:to="loc_us-gaap_Liabilities_a2e844d3-997c-4ead-b304-be911c20349e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b4b5b84b-29e6-4657-a717-d5ee62721822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_473005a2-e76b-4fff-be79-c894fba8e326" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b4b5b84b-29e6-4657-a717-d5ee62721822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9e557e91-3e46-45cc-b2e9-ff10da87b542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_473005a2-e76b-4fff-be79-c894fba8e326" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9e557e91-3e46-45cc-b2e9-ff10da87b542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_5955b9ca-c1af-4c43-bc9e-cc052ca80b05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e557e91-3e46-45cc-b2e9-ff10da87b542" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_5955b9ca-c1af-4c43-bc9e-cc052ca80b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_c89b39f6-3e5c-473e-bcaa-125775bee305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e557e91-3e46-45cc-b2e9-ff10da87b542" xlink:to="loc_us-gaap_CommonStockValueOutstanding_c89b39f6-3e5c-473e-bcaa-125775bee305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4e8eef34-f78e-4777-bc7b-0b9b35218686" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e557e91-3e46-45cc-b2e9-ff10da87b542" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4e8eef34-f78e-4777-bc7b-0b9b35218686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dbc5832c-903f-4c8f-b107-32ddd30c5e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e557e91-3e46-45cc-b2e9-ff10da87b542" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_dbc5832c-903f-4c8f-b107-32ddd30c5e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92f6eb9f-90ff-4ca4-9eb9-60cc2f771753" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e557e91-3e46-45cc-b2e9-ff10da87b542" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92f6eb9f-90ff-4ca4-9eb9-60cc2f771753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_6bd3d0b3-995f-4c10-9f1d-357b9b808b86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e557e91-3e46-45cc-b2e9-ff10da87b542" xlink:to="loc_us-gaap_TreasuryStockValue_6bd3d0b3-995f-4c10-9f1d-357b9b808b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2078fce1-d672-4bce-9c58-60cec5200ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9e557e91-3e46-45cc-b2e9-ff10da87b542" xlink:to="loc_us-gaap_StockholdersEquity_2078fce1-d672-4bce-9c58-60cec5200ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c0f49659-906d-486f-950f-14f95b64075f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_473005a2-e76b-4fff-be79-c894fba8e326" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c0f49659-906d-486f-950f-14f95b64075f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://agios.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3f13e5a1-843e-4a1b-87b5-3bb1db40cb81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3f13e5a1-843e-4a1b-87b5-3bb1db40cb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5a8ee5ca-b16f-48b3-bafd-284a31b5ad7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5a8ee5ca-b16f-48b3-bafd-284a31b5ad7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_da1b7da7-4f30-4ed5-a556-661991522952" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_da1b7da7-4f30-4ed5-a556-661991522952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1a7c98d7-f9d4-40d2-8c43-86e33cf5b1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1a7c98d7-f9d4-40d2-8c43-86e33cf5b1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cb4f0b73-0993-4f97-8d65-0d34c06bff13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cb4f0b73-0993-4f97-8d65-0d34c06bff13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_de6b43d0-1c5c-4216-a78b-64955ae3772e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_de6b43d0-1c5c-4216-a78b-64955ae3772e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3767e2ed-b7ea-47f0-b280-d942ba9112f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:to="loc_us-gaap_CommonStockSharesIssued_3767e2ed-b7ea-47f0-b280-d942ba9112f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_938fd266-28d5-4c9e-a669-c414edaa97dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_938fd266-28d5-4c9e-a669-c414edaa97dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_dd5f8e7b-8a34-4c07-bba9-c60341b100b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2a669acc-3e3d-4188-81cd-5eed0c4d2b4d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_dd5f8e7b-8a34-4c07-bba9-c60341b100b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://agios.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_62ff7381-073a-4d1a-91d7-a5dbc59fd0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_32259d05-fdd8-44a0-835f-2145c5113794" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_62ff7381-073a-4d1a-91d7-a5dbc59fd0e7" xlink:to="loc_us-gaap_StatementTable_32259d05-fdd8-44a0-835f-2145c5113794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab064c6c-50a1-4177-91df-6f53887e2172" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_32259d05-fdd8-44a0-835f-2145c5113794" xlink:to="loc_srt_ProductOrServiceAxis_ab064c6c-50a1-4177-91df-6f53887e2172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0bac9821-b493-479b-87ea-06ad61b1b4e8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ab064c6c-50a1-4177-91df-6f53887e2172" xlink:to="loc_srt_ProductsAndServicesDomain_0bac9821-b493-479b-87ea-06ad61b1b4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_24b0a3bd-0674-4fc9-9eff-43ea3e570869" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0bac9821-b493-479b-87ea-06ad61b1b4e8" xlink:to="loc_us-gaap_ProductMember_24b0a3bd-0674-4fc9-9eff-43ea3e570869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b3bbd8b1-2ccc-40fb-82f0-9c745e8c8d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0bac9821-b493-479b-87ea-06ad61b1b4e8" xlink:to="loc_us-gaap_RoyaltyMember_b3bbd8b1-2ccc-40fb-82f0-9c745e8c8d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_32259d05-fdd8-44a0-835f-2145c5113794" xlink:to="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a0389f85-bf94-4717-bcb5-bc5d45aed0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a0389f85-bf94-4717-bcb5-bc5d45aed0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_43d2aea2-5bdc-4f07-a33a-be24de791d74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a0389f85-bf94-4717-bcb5-bc5d45aed0a9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_43d2aea2-5bdc-4f07-a33a-be24de791d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_76eb6e4b-0a8b-4a17-9606-8f51844ab500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_76eb6e4b-0a8b-4a17-9606-8f51844ab500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d8305ff5-4c35-4bc2-838a-f072fa5dd83a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d8305ff5-4c35-4bc2-838a-f072fa5dd83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7ca5c63f-d433-457d-ae2d-1c48eab2e976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7ca5c63f-d433-457d-ae2d-1c48eab2e976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0badfec4-4b0c-4c7c-933d-99392601be7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_29a5c9d5-0feb-4d83-ba35-8c492dbc6308" xlink:to="loc_us-gaap_CostsAndExpenses_0badfec4-4b0c-4c7c-933d-99392601be7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_33fa38fb-cd35-4201-bb1c-5625864d5875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_OperatingIncomeLoss_33fa38fb-cd35-4201-bb1c-5625864d5875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments_ef1bade2-fc70-4709-ac28-d911c75bf02f" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_agio_GainLossOnSaleOfContingentPayments_ef1bade2-fc70-4709-ac28-d911c75bf02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_06f63ab3-a3d1-4778-aefb-20fe6b5f0439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_06f63ab3-a3d1-4778-aefb-20fe6b5f0439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_464e95bc-9ab7-4762-9c99-3b98e7bedd43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_464e95bc-9ab7-4762-9c99-3b98e7bedd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_61382c98-40f5-4ca0-8546-b0ef82967076" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_61382c98-40f5-4ca0-8546-b0ef82967076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8517e764-07fa-49f4-a391-2989096dc85c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8517e764-07fa-49f4-a391-2989096dc85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_cb39a936-d3fb-4f3c-99e3-de9d2f69140b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_cb39a936-d3fb-4f3c-99e3-de9d2f69140b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d1bc3833-92fd-4da8-9f0e-46b1949cb505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_NetIncomeLoss_d1bc3833-92fd-4da8-9f0e-46b1949cb505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fa86f602-fd8f-4c6a-ac0c-55e8560b3aef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fa86f602-fd8f-4c6a-ac0c-55e8560b3aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0ca8e032-b57b-4dca-a9ab-38eec0ae5e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0ca8e032-b57b-4dca-a9ab-38eec0ae5e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_8d5afabe-f917-49d3-bd6a-f051df91eeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_8d5afabe-f917-49d3-bd6a-f051df91eeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e038c293-bf2b-4b96-9e87-ef18bc01cebd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e038c293-bf2b-4b96-9e87-ef18bc01cebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5821b64d-d9f4-4b2d-aba5-7508bdcbead9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_EarningsPerShareBasic_5821b64d-d9f4-4b2d-aba5-7508bdcbead9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6bf24624-36aa-43a8-b9ba-557903de17d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6bf24624-36aa-43a8-b9ba-557903de17d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_424d8c13-53f9-4196-87ea-f363f02f010f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_424d8c13-53f9-4196-87ea-f363f02f010f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb23a262-c019-4315-a9a8-64853c3313ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_69a4bcff-10dc-44fc-bbb1-7b035e66f047" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb23a262-c019-4315-a9a8-64853c3313ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedStatementsofComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d85ac453-3d7c-486a-b01f-2bd8f2303fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f94d9d74-7cf8-4d8c-ac6c-4f05ea2c1808" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d85ac453-3d7c-486a-b01f-2bd8f2303fc7" xlink:to="loc_us-gaap_NetIncomeLoss_f94d9d74-7cf8-4d8c-ac6c-4f05ea2c1808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_79c8277e-572f-481c-8415-50d38a08cae0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d85ac453-3d7c-486a-b01f-2bd8f2303fc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_79c8277e-572f-481c-8415-50d38a08cae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_12161946-0379-487a-a196-6ebd2d5151e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_79c8277e-572f-481c-8415-50d38a08cae0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_12161946-0379-487a-a196-6ebd2d5151e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_268ec90b-0447-4f7b-86e0-2c268b9503a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d85ac453-3d7c-486a-b01f-2bd8f2303fc7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_268ec90b-0447-4f7b-86e0-2c268b9503a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://agios.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e46a6e9a-9a0d-47d7-b64c-2f4c6835536e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54ae78ad-9b8e-458e-b56d-db416cd35752" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e46a6e9a-9a0d-47d7-b64c-2f4c6835536e" xlink:to="loc_us-gaap_StatementTable_54ae78ad-9b8e-458e-b56d-db416cd35752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0e687414-ca6f-4949-a28f-ac6825bafcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54ae78ad-9b8e-458e-b56d-db416cd35752" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0e687414-ca6f-4949-a28f-ac6825bafcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0e687414-ca6f-4949-a28f-ac6825bafcf2" xlink:to="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bcef508f-c477-4dde-aeaa-49090752a4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_CommonStockMember_bcef508f-c477-4dde-aeaa-49090752a4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8bf5e0e2-42b8-4fd4-b10e-b2c8545b8e02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8bf5e0e2-42b8-4fd4-b10e-b2c8545b8e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_141364cc-05a1-4bec-ac74-518775f357dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_141364cc-05a1-4bec-ac74-518775f357dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3c55c2ea-bc42-4f19-bede-065bd0d8a772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_RetainedEarningsMember_3c55c2ea-bc42-4f19-bede-065bd0d8a772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_db5d9bd6-59c1-4aad-8b1e-a090e228aa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a7a3d1fc-9f60-4afc-b4da-8de62413eaed" xlink:to="loc_us-gaap_TreasuryStockCommonMember_db5d9bd6-59c1-4aad-8b1e-a090e228aa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cdd41e9c-f25f-4127-b0c9-f574a9494da6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54ae78ad-9b8e-458e-b56d-db416cd35752" xlink:to="loc_us-gaap_StatementLineItems_cdd41e9c-f25f-4127-b0c9-f574a9494da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cdd41e9c-f25f-4127-b0c9-f574a9494da6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2e636d71-2b2a-4d6e-bd91-8e626f916dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2e636d71-2b2a-4d6e-bd91-8e626f916dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ffa2d8c9-6f90-4eae-83a8-2390ef856243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_StockholdersEquity_ffa2d8c9-6f90-4eae-83a8-2390ef856243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_3b7ed1f3-d246-42ef-bc6e-4c4c896ae554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_TreasuryStockCommonShares_3b7ed1f3-d246-42ef-bc6e-4c4c896ae554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax_d250b23a-7092-46c1-913a-8acf9e204885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax_d250b23a-7092-46c1-913a-8acf9e204885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8341fd4c-ce1a-4431-8bbd-713e838bfc46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_NetIncomeLoss_8341fd4c-ce1a-4431-8bbd-713e838bfc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a8ba4fd4-75aa-438b-b45f-11397bc35b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a8ba4fd4-75aa-438b-b45f-11397bc35b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_be84cf38-e71b-40d2-b1e1-6c2eac351a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_be84cf38-e71b-40d2-b1e1-6c2eac351a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5e51d5f6-2e18-4170-a728-9b4522001d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5e51d5f6-2e18-4170-a728-9b4522001d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_782b9904-5e83-44d4-8547-b68e9b50bfd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_782b9904-5e83-44d4-8547-b68e9b50bfd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_98edcfcd-8283-4885-8d5e-903b1f23fffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_98edcfcd-8283-4885-8d5e-903b1f23fffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_StockholdersEquityDispositionOfBusiness_7f556caa-7aa8-4a1a-98b9-6d22e09fe659" xlink:href="agio-20231231.xsd#agio_StockholdersEquityDispositionOfBusiness"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_agio_StockholdersEquityDispositionOfBusiness_7f556caa-7aa8-4a1a-98b9-6d22e09fe659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_803f79be-7768-4c94-b39d-be69a62943c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_803f79be-7768-4c94-b39d-be69a62943c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd3d5538-9856-48f2-ad95-40977cccd111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_StockholdersEquity_fd3d5538-9856-48f2-ad95-40977cccd111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_458526ee-1c80-47fc-baef-28cdae4dd9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de099df2-fd37-4388-8bc4-6c097e99d7d2" xlink:to="loc_us-gaap_TreasuryStockCommonShares_458526ee-1c80-47fc-baef-28cdae4dd9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="agio-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://agios.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3d2703e1-d0ba-44d5-a003-564893f16550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6297a20d-4c3b-4d04-91d6-a4e0c9647d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d2703e1-d0ba-44d5-a003-564893f16550" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6297a20d-4c3b-4d04-91d6-a4e0c9647d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_96f10d06-4137-41ea-8537-5eef39f5dee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6297a20d-4c3b-4d04-91d6-a4e0c9647d0c" xlink:to="loc_us-gaap_NetIncomeLoss_96f10d06-4137-41ea-8537-5eef39f5dee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_43e1b149-162d-48ff-ab32-0db1a625f8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6297a20d-4c3b-4d04-91d6-a4e0c9647d0c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_43e1b149-162d-48ff-ab32-0db1a625f8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_19821527-6a2d-4827-9498-2966a6d23dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6297a20d-4c3b-4d04-91d6-a4e0c9647d0c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_19821527-6a2d-4827-9498-2966a6d23dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6297a20d-4c3b-4d04-91d6-a4e0c9647d0c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_b49f1000-08b1-4f7c-a79f-bcaf568cc747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_b49f1000-08b1-4f7c-a79f-bcaf568cc747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9352b6ea-26c9-4737-835b-8ce5e271d013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:to="loc_us-gaap_ShareBasedCompensation_9352b6ea-26c9-4737-835b-8ce5e271d013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c9fd8664-9287-46fe-b903-ddb8e83a4b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c9fd8664-9287-46fe-b903-ddb8e83a4b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments_59c52911-6b9f-4827-973c-c102ead90b50" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:to="loc_agio_GainLossOnSaleOfContingentPayments_59c52911-6b9f-4827-973c-c102ead90b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_09771e62-7933-4855-aa98-eb5a0dadfdcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_09771e62-7933-4855-aa98-eb5a0dadfdcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3e5ea212-9b38-4a5d-a301-0503c31c0948" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3e5ea212-9b38-4a5d-a301-0503c31c0948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ExpenseAssociatedWithLicenseAgreement_7e6682a3-3618-437e-ba6f-1753199740ae" xlink:href="agio-20231231.xsd#agio_ExpenseAssociatedWithLicenseAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:to="loc_agio_ExpenseAssociatedWithLicenseAgreement_7e6682a3-3618-437e-ba6f-1753199740ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_RealizedGainOnInvestments_0fc0a0fe-9628-4c3b-add9-cf860c93a719" xlink:href="agio-20231231.xsd#agio_RealizedGainOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:to="loc_agio_RealizedGainOnInvestments_0fc0a0fe-9628-4c3b-add9-cf860c93a719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_88ab2212-8ac9-40bf-9389-74b2dd1cb594" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_28e35b77-b1fa-42cb-9f96-73e7f09ac65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_28e35b77-b1fa-42cb-9f96-73e7f09ac65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_980b8acb-d4db-43d2-8217-762daa3bf7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_980b8acb-d4db-43d2-8217-762daa3bf7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_686206af-db60-4d32-9ca3-03a53baf3ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_686206af-db60-4d32-9ca3-03a53baf3ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6c432238-fb84-49ef-a1b0-40dd598c9813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6c432238-fb84-49ef-a1b0-40dd598c9813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a5775015-5064-462e-b2ac-c01f38f64726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a5775015-5064-462e-b2ac-c01f38f64726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3b6b2e7a-d0e2-4ab2-8e96-d901d5da482c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3b6b2e7a-d0e2-4ab2-8e96-d901d5da482c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ec49fb6c-cc72-47d2-9ee9-3a517114a3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ec49fb6c-cc72-47d2-9ee9-3a517114a3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8eced8db-d6ea-49d8-bd8a-ff079f0268e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b286ac2b-e59b-40cc-a111-77b17fa8f7fb" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8eced8db-d6ea-49d8-bd8a-ff079f0268e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1ffd2a35-a9ee-40b2-9beb-843fe1185507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6297a20d-4c3b-4d04-91d6-a4e0c9647d0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1ffd2a35-a9ee-40b2-9beb-843fe1185507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_83ea7bdd-af73-4e93-ac99-43619021a665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6297a20d-4c3b-4d04-91d6-a4e0c9647d0c" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_83ea7bdd-af73-4e93-ac99-43619021a665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb98e507-1ce9-4c4c-a34c-40545eea0ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6297a20d-4c3b-4d04-91d6-a4e0c9647d0c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bb98e507-1ce9-4c4c-a34c-40545eea0ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d2703e1-d0ba-44d5-a003-564893f16550" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e000f968-b6e5-4915-9aba-b45d86c19eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e000f968-b6e5-4915-9aba-b45d86c19eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3466fc9c-ad58-4158-b31f-a58c833f655f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3466fc9c-ad58-4158-b31f-a58c833f655f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProceedsFromSaleOfContingentPayments_e8a5aa1f-6056-413d-ae43-5e96663d2aec" xlink:href="agio-20231231.xsd#agio_ProceedsFromSaleOfContingentPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:to="loc_agio_ProceedsFromSaleOfContingentPayments_e8a5aa1f-6056-413d-ae43-5e96663d2aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PaymentsAssociatedWithLicenseAgreement_1bc081fa-32f6-403a-a21b-d4bf873d849e" xlink:href="agio-20231231.xsd#agio_PaymentsAssociatedWithLicenseAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:to="loc_agio_PaymentsAssociatedWithLicenseAgreement_1bc081fa-32f6-403a-a21b-d4bf873d849e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_67af85ca-b95d-41da-a43d-0716c0147b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_67af85ca-b95d-41da-a43d-0716c0147b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_026573f4-4b56-4fe9-96bd-0e30f5da59fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:to="loc_us-gaap_ProceedsFromSaleOfMachineryAndEquipment_026573f4-4b56-4fe9-96bd-0e30f5da59fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_23b2b73d-4786-4782-9d66-1ec523107531" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_23b2b73d-4786-4782-9d66-1ec523107531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_62991aa8-1bd2-416a-a3e3-6a0b58dc8614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_62991aa8-1bd2-416a-a3e3-6a0b58dc8614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af0dbff7-b6bf-4bd7-ac17-ab00b73fcce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b420a0d1-902b-4d29-aa25-073650c0d7a8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af0dbff7-b6bf-4bd7-ac17-ab00b73fcce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce50489f-774a-4702-b4ad-2b50f55f1562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d2703e1-d0ba-44d5-a003-564893f16550" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce50489f-774a-4702-b4ad-2b50f55f1562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_02220a7f-12f5-483d-8e05-02646f433d07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce50489f-774a-4702-b4ad-2b50f55f1562" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_02220a7f-12f5-483d-8e05-02646f433d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_85524bbb-1c42-4f8c-974f-b2f6b9519be1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce50489f-774a-4702-b4ad-2b50f55f1562" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_85524bbb-1c42-4f8c-974f-b2f6b9519be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4fe60f67-6342-4dae-94d4-0bb083372800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce50489f-774a-4702-b4ad-2b50f55f1562" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4fe60f67-6342-4dae-94d4-0bb083372800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd4c105b-e93c-4d50-a5d8-1cbfe3d3f524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ce50489f-774a-4702-b4ad-2b50f55f1562" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cd4c105b-e93c-4d50-a5d8-1cbfe3d3f524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81f88b70-6f99-42f5-8794-847285433c08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d2703e1-d0ba-44d5-a003-564893f16550" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_81f88b70-6f99-42f5-8794-847285433c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_890daf77-a755-419f-af43-5397c465fb62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d2703e1-d0ba-44d5-a003-564893f16550" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_890daf77-a755-419f-af43-5397c465fb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e6ea8b4a-54d4-447d-a841-76940350b3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d2703e1-d0ba-44d5-a003-564893f16550" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e6ea8b4a-54d4-447d-a841-76940350b3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_488596e3-3f06-4ba0-8591-794d07ae2f77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d2703e1-d0ba-44d5-a003-564893f16550" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_488596e3-3f06-4ba0-8591-794d07ae2f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_281f7694-b109-425e-9043-0f21242b80da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_488596e3-3f06-4ba0-8591-794d07ae2f77" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_281f7694-b109-425e-9043-0f21242b80da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_0e257037-d465-4042-9997-ea06169cb8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_488596e3-3f06-4ba0-8591-794d07ae2f77" xlink:to="loc_us-gaap_IncomeTaxesPaid_0e257037-d465-4042-9997-ea06169cb8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_952579b5-4023-4f67-a942-3aaa1b9f80c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_488596e3-3f06-4ba0-8591-794d07ae2f77" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_952579b5-4023-4f67-a942-3aaa1b9f80c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/NatureofBusiness" xlink:type="simple" xlink:href="agio-20231231.xsd#NatureofBusiness"/>
  <link:presentationLink xlink:role="http://agios.com/role/NatureofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42637cc8-f2e1-48da-b099-bf0d03764b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_04868599-95e9-48eb-bf96-d17cd88599e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42637cc8-f2e1-48da-b099-bf0d03764b4f" xlink:to="loc_us-gaap_NatureOfOperations_04868599-95e9-48eb-bf96-d17cd88599e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="agio-20231231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4e35915e-a716-472f-a353-d71efec34142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2d2a12be-a988-406c-ba98-55de8be84eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e35915e-a716-472f-a353-d71efec34142" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2d2a12be-a988-406c-ba98-55de8be84eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="agio-20231231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_be17e474-8e63-4dbf-9138-fefde212b80c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_902878d5-c6ec-452b-817e-e7fefebe45ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_be17e474-8e63-4dbf-9138-fefde212b80c" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_902878d5-c6ec-452b-817e-e7fefebe45ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecurities" xlink:type="simple" xlink:href="agio-20231231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fee0792f-c9ce-40df-895c-513c10540ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_479da737-dc65-438a-a2ff-28faf610717e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_fee0792f-c9ce-40df-895c-513c10540ba4" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_479da737-dc65-438a-a2ff-28faf610717e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/Inventory" xlink:type="simple" xlink:href="agio-20231231.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://agios.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_911602f1-0f5d-4ed4-8cf2-cc83eed808ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_49674654-7e0f-4879-a84d-d18036e9244e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_911602f1-0f5d-4ed4-8cf2-cc83eed808ba" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_49674654-7e0f-4879-a84d-d18036e9244e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/Leases" xlink:type="simple" xlink:href="agio-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://agios.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_825144ea-d596-4d39-a436-6e9b29be741b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0bbe6d82-754e-4099-96dc-b25c47b7428c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_825144ea-d596-4d39-a436-6e9b29be741b" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0bbe6d82-754e-4099-96dc-b25c47b7428c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpenses" xlink:type="simple" xlink:href="agio-20231231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8270cd58-2b30-4145-975f-71f244aea16b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_5abbbe9d-4d86-4644-a4a2-f394c3113c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8270cd58-2b30-4145-975f-71f244aea16b" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_5abbbe9d-4d86-4644-a4a2-f394c3113c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenue" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenue"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e623f3d6-861c-4c00-b9cf-a2baf978a4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b4ef07f3-4c84-41f7-89e1-47ccca03e816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e623f3d6-861c-4c00-b9cf-a2baf978a4fa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b4ef07f3-4c84-41f7-89e1-47ccca03e816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd0eb1b5-ebde-4237-94a3-bffd0195b767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1e4c134b-6145-44f6-be72-6609a1d971cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd0eb1b5-ebde-4237-94a3-bffd0195b767" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1e4c134b-6145-44f6-be72-6609a1d971cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/NetIncomeLossperShare" xlink:type="simple" xlink:href="agio-20231231.xsd#NetIncomeLossperShare"/>
  <link:presentationLink xlink:role="http://agios.com/role/NetIncomeLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_38ea1902-b072-4468-8086-f79ad8bb2b67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f7a49220-9e59-4c9a-9a70-ca42542cdf43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_38ea1902-b072-4468-8086-f79ad8bb2b67" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f7a49220-9e59-4c9a-9a70-ca42542cdf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxes" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_16153ecc-27fb-4662-9b5d-8b448d8a91b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_50d3e0fc-040b-44b9-9bca-4b209b880086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16153ecc-27fb-4662-9b5d-8b448d8a91b3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_50d3e0fc-040b-44b9-9bca-4b209b880086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="agio-20231231.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://agios.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_67666bb0-a27e-4b1a-8988-8db137f368ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d28787e6-9f86-430c-9784-5c0c730bdfd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_67666bb0-a27e-4b1a-8988-8db137f368ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_d28787e6-9f86-430c-9784-5c0c730bdfd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CommonStock" xlink:type="simple" xlink:href="agio-20231231.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://agios.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0a1ebf9f-f2a1-4f2a-9f5e-922cf6546189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9bf83c43-1332-4d90-a247-883821af4717" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0a1ebf9f-f2a1-4f2a-9f5e-922cf6546189" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9bf83c43-1332-4d90-a247-883821af4717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareRepurchaseProgram" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareRepurchaseProgram"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareRepurchaseProgram" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_91b1157f-39ba-49c5-af12-651fef3afd53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_4ac6c711-a552-4476-8226-be6b3f79193f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_91b1157f-39ba-49c5-af12-651fef3afd53" xlink:to="loc_us-gaap_TreasuryStockTextBlock_4ac6c711-a552-4476-8226-be6b3f79193f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://agios.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_001cfbd8-dd26-4a2b-af88-86bcbf25ffcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_c11530ea-e7f6-4d01-8453-1e9f00976478" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_001cfbd8-dd26-4a2b-af88-86bcbf25ffcf" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_c11530ea-e7f6-4d01-8453-1e9f00976478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CommitmentsandContingentLiabilities" xlink:type="simple" xlink:href="agio-20231231.xsd#CommitmentsandContingentLiabilities"/>
  <link:presentationLink xlink:role="http://agios.com/role/CommitmentsandContingentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8814fb2-f36c-4029-b7b0-f5e4f492a18c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b0e928fe-893b-4071-8578-f923d6bd3bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c8814fb2-f36c-4029-b7b0-f5e4f492a18c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b0e928fe-893b-4071-8578-f923d6bd3bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/DefinedContributionBenefitPlan" xlink:type="simple" xlink:href="agio-20231231.xsd#DefinedContributionBenefitPlan"/>
  <link:presentationLink xlink:role="http://agios.com/role/DefinedContributionBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_028b9a15-4516-46ee-bb04-aa7c90d7a94b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7a051e71-3e67-4739-a692-f3625f347c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_028b9a15-4516-46ee-bb04-aa7c90d7a94b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7a051e71-3e67-4739-a692-f3625f347c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="agio-20231231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d9fbb82e-0d10-401b-9e07-ac9c25087f44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d9fbb82e-0d10-401b-9e07-ac9c25087f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2e4e0f69-d49b-42de-a67e-050bea4bd7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_UseOfEstimates_2e4e0f69-d49b-42de-a67e-050bea4bd7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e8b7eb3e-6bf3-405c-b26e-7cfdff8d300b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e8b7eb3e-6bf3-405c-b26e-7cfdff8d300b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_cfc0b8fb-8fce-42dd-8c90-91262d9e1a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_cfc0b8fb-8fce-42dd-8c90-91262d9e1a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_26580873-813f-46f9-963a-97f33c437a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_26580873-813f-46f9-963a-97f33c437a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b840e005-6ebb-44ea-90fa-9124a1cd0244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_b840e005-6ebb-44ea-90fa-9124a1cd0244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_fc0e2c54-3865-419e-9d63-1e9028726e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_fc0e2c54-3865-419e-9d63-1e9028726e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_40255f5e-14cd-47cb-9ed6-3828fce463f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_40255f5e-14cd-47cb-9ed6-3828fce463f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_261a1262-58e5-44d8-a94a-c9a6797a3b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_261a1262-58e5-44d8-a94a-c9a6797a3b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_ec2ae9d0-6a12-45f9-9873-1b5ed3e2d51e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_ec2ae9d0-6a12-45f9-9873-1b5ed3e2d51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17f965ce-1802-4c9f-a859-39b3f97660ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_17f965ce-1802-4c9f-a859-39b3f97660ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2afb6788-bc47-45e7-8523-51eebb02637c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2afb6788-bc47-45e7-8523-51eebb02637c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_beb38907-82a0-4ac0-bb34-5e3379ce54ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_beb38907-82a0-4ac0-bb34-5e3379ce54ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f3bf9f6d-c07e-4bc0-b769-e5b57e6c92bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f3bf9f6d-c07e-4bc0-b769-e5b57e6c92bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4bd684ca-3c02-442e-ba07-48472938f759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4bd684ca-3c02-442e-ba07-48472938f759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1084643d-be48-4c4c-8982-f5fa24cfb1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1084643d-be48-4c4c-8982-f5fa24cfb1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1d45bcc0-286a-46cd-a67b-cae2bbfe5e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1d45bcc0-286a-46cd-a67b-cae2bbfe5e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_ca8d3413-b012-4c13-ad76-5492dccbed5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_ca8d3413-b012-4c13-ad76-5492dccbed5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8ef130ec-c125-4550-b9ac-1f7a14a3c3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8ef130ec-c125-4550-b9ac-1f7a14a3c3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_5759c0de-6a11-4a16-98a3-93219357c2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_5759c0de-6a11-4a16-98a3-93219357c2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_7518f99f-de22-40c2-93a6-8682d6da83bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_7518f99f-de22-40c2-93a6-8682d6da83bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d993ae0d-bdc8-45a6-a87d-310cfcbb375c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d993ae0d-bdc8-45a6-a87d-310cfcbb375c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_43bad0ad-c3bf-4293-ba74-33afbe9a5610" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8491962-2aaf-45eb-9ac5-6528193d2efb" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_43bad0ad-c3bf-4293-ba74-33afbe9a5610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="agio-20231231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_507fad7c-cab9-4278-a277-63ace30b8e12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_dc195b27-d868-47f8-b1d5-62fa2b2b70ab" xlink:href="agio-20231231.xsd#agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_507fad7c-cab9-4278-a277-63ace30b8e12" xlink:to="loc_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_dc195b27-d868-47f8-b1d5-62fa2b2b70ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="agio-20231231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_63c5ae41-1d59-4475-854d-131566abfd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5c4b9b34-c101-41ae-bc51-2f25d95028ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_63c5ae41-1d59-4475-854d-131566abfd6f" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_5c4b9b34-c101-41ae-bc51-2f25d95028ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="agio-20231231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bcf5ff77-bd5f-43f2-830a-35e454a53ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_b04b4ce0-d5f0-4f3a-a99a-f889611b4e22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bcf5ff77-bd5f-43f2-830a-35e454a53ad4" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_b04b4ce0-d5f0-4f3a-a99a-f889611b4e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryTables" xlink:type="simple" xlink:href="agio-20231231.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ead2de05-d1f9-420a-ba45-36ff90308204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4079902e-f194-4c2b-860c-f8309ad162eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ead2de05-d1f9-420a-ba45-36ff90308204" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4079902e-f194-4c2b-860c-f8309ad162eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesTables" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_800bbc7b-8ed8-49ea-bb7d-50be72970da2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_cda7e137-df2c-4a57-922a-95888256b9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_800bbc7b-8ed8-49ea-bb7d-50be72970da2" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_cda7e137-df2c-4a57-922a-95888256b9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_33c0d6e9-a7f6-4736-a0a1-4522efedca4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_800bbc7b-8ed8-49ea-bb7d-50be72970da2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_33c0d6e9-a7f6-4736-a0a1-4522efedca4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_a75732a9-b2bb-44d6-bfb0-0cf3574b6a79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_800bbc7b-8ed8-49ea-bb7d-50be72970da2" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_a75732a9-b2bb-44d6-bfb0-0cf3574b6a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="agio-20231231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_156f4f5f-da6c-480a-acca-fa971010acb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cc0b439b-c2fa-43d5-95cf-8847690bb7b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_156f4f5f-da6c-480a-acca-fa971010acb3" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cc0b439b-c2fa-43d5-95cf-8847690bb7b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueTables" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenueTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1e7a1f98-d804-4ed5-9699-76c6f3ccc114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_30f51c9e-e3e8-48a6-8741-f9b7617afd33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1e7a1f98-d804-4ed5-9699-76c6f3ccc114" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_30f51c9e-e3e8-48a6-8741-f9b7617afd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_55cbfcdc-7e9d-47f9-bc96-159294793a58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1e7a1f98-d804-4ed5-9699-76c6f3ccc114" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_55cbfcdc-7e9d-47f9-bc96-159294793a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_08ee6f51-6c34-4b14-8386-21d14af38417" xlink:href="agio-20231231.xsd#agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1e7a1f98-d804-4ed5-9699-76c6f3ccc114" xlink:to="loc_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock_08ee6f51-6c34-4b14-8386-21d14af38417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_a0e36602-46be-445e-963f-73f5defae1a6" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_1e7a1f98-d804-4ed5-9699-76c6f3ccc114" xlink:to="loc_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock_a0e36602-46be-445e-963f-73f5defae1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14c5a1de-3f8a-4f01-9827-8a1d0f81aa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_99422c34-e9cc-4bc7-8292-0251cc7d8685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14c5a1de-3f8a-4f01-9827-8a1d0f81aa4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_99422c34-e9cc-4bc7-8292-0251cc7d8685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_df2bb5bb-effe-485d-a8b1-d99284b5c8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14c5a1de-3f8a-4f01-9827-8a1d0f81aa4a" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_df2bb5bb-effe-485d-a8b1-d99284b5c8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_0b37e43a-5c0f-49f0-95f7-fbf2b1a9e084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14c5a1de-3f8a-4f01-9827-8a1d0f81aa4a" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_0b37e43a-5c0f-49f0-95f7-fbf2b1a9e084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_95a6360e-12ae-47b3-a557-0e8b05bf7fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14c5a1de-3f8a-4f01-9827-8a1d0f81aa4a" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_95a6360e-12ae-47b3-a557-0e8b05bf7fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_24b3727f-f217-4838-9817-d896a246bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14c5a1de-3f8a-4f01-9827-8a1d0f81aa4a" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_24b3727f-f217-4838-9817-d896a246bc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_53a2f0b5-0130-4f7c-a398-600978c36217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14c5a1de-3f8a-4f01-9827-8a1d0f81aa4a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_53a2f0b5-0130-4f7c-a398-600978c36217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4e5a3c97-042c-4153-a8b0-e43d77a611ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14c5a1de-3f8a-4f01-9827-8a1d0f81aa4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4e5a3c97-042c-4153-a8b0-e43d77a611ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/NetIncomeLossperShareTables" xlink:type="simple" xlink:href="agio-20231231.xsd#NetIncomeLossperShareTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/NetIncomeLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c12abe82-4e17-4dca-ad77-409ad6644bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_12677ded-fc44-4989-a5f4-a1a54c2a901a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c12abe82-4e17-4dca-ad77-409ad6644bec" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_12677ded-fc44-4989-a5f4-a1a54c2a901a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2a28a82f-bc1d-452e-a85d-75a7a066bccb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_5bfe6ac7-7aca-4d68-9d21-7039ffeb1a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a28a82f-bc1d-452e-a85d-75a7a066bccb" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_5bfe6ac7-7aca-4d68-9d21-7039ffeb1a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_46609013-0582-40a7-a8df-e1a05caefcad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a28a82f-bc1d-452e-a85d-75a7a066bccb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_46609013-0582-40a7-a8df-e1a05caefcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9abbf563-0822-4e58-b270-e86fbd8437e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a28a82f-bc1d-452e-a85d-75a7a066bccb" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9abbf563-0822-4e58-b270-e86fbd8437e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_04e636a5-13e5-4c9e-bc4f-3782616529af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a28a82f-bc1d-452e-a85d-75a7a066bccb" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_04e636a5-13e5-4c9e-bc4f-3782616529af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4088a17b-51ce-4689-8627-32018861e9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a28a82f-bc1d-452e-a85d-75a7a066bccb" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4088a17b-51ce-4689-8627-32018861e9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="agio-20231231.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c30c621f-dcc2-4ac1-8fe7-9cff86d3fadb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_070449b4-3193-4b03-9837-40179b2d4447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c30c621f-dcc2-4ac1-8fe7-9cff86d3fadb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_070449b4-3193-4b03-9837-40179b2d4447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://agios.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a1c5a5b9-f7ed-4430-aa85-c58b196a84da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_58b0be20-6b3c-465a-a991-f58d8bdf8f30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a1c5a5b9-f7ed-4430-aa85-c58b196a84da" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_58b0be20-6b3c-465a-a991-f58d8bdf8f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/NatureofBusinessDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#NatureofBusinessDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/NatureofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_865c068f-c840-4b18-b7e3-95931d510406" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_865c068f-c840-4b18-b7e3-95931d510406" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_82ec6627-4e4d-4e8a-b777-79afcfa68ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_AssetAcquisitionAxis_82ec6627-4e4d-4e8a-b777-79afcfa68ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_0d7527b5-0715-42d8-893c-5868b6aa95a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_82ec6627-4e4d-4e8a-b777-79afcfa68ca3" xlink:to="loc_us-gaap_AssetAcquisitionDomain_0d7527b5-0715-42d8-893c-5868b6aa95a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AlnylamPharmaceuticalsIncMember_030361e0-3378-45b7-a83a-0973f7bf2e1d" xlink:href="agio-20231231.xsd#agio_AlnylamPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_0d7527b5-0715-42d8-893c-5868b6aa95a8" xlink:to="loc_agio_AlnylamPharmaceuticalsIncMember_030361e0-3378-45b7-a83a-0973f7bf2e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_56937154-1336-4c1b-b2e4-0513833f2459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_56937154-1336-4c1b-b2e4-0513833f2459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_82001e37-7920-4799-9046-206d44ea7142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_56937154-1336-4c1b-b2e4-0513833f2459" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_82001e37-7920-4799-9046-206d44ea7142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_080a60c5-a82d-4b37-9f3e-b5412f67ba0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_82001e37-7920-4799-9046-206d44ea7142" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_080a60c5-a82d-4b37-9f3e-b5412f67ba0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_37bab1a4-d50b-4a67-b771-f8078c60f02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_37bab1a4-d50b-4a67-b771-f8078c60f02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93845f15-f26f-4c91-9325-451add59e7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_37bab1a4-d50b-4a67-b771-f8078c60f02a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93845f15-f26f-4c91-9325-451add59e7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_913c9942-5abc-405f-b574-ad6a2d7c5d82" xlink:href="agio-20231231.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_93845f15-f26f-4c91-9325-451add59e7f5" xlink:to="loc_agio_AgiosOncologyBusinessMember_913c9942-5abc-405f-b574-ad6a2d7c5d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75ab2a96-2603-4fe2-b102-5bcfedf994db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_srt_ProductOrServiceAxis_75ab2a96-2603-4fe2-b102-5bcfedf994db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_72df4ef5-aa5c-4c29-8321-4fbac05cc445" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_75ab2a96-2603-4fe2-b102-5bcfedf994db" xlink:to="loc_srt_ProductsAndServicesDomain_72df4ef5-aa5c-4c29-8321-4fbac05cc445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TIBSOVOMember_3a3a5b86-4e21-48d5-874b-068f2e8d1fcb" xlink:href="agio-20231231.xsd#agio_TIBSOVOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72df4ef5-aa5c-4c29-8321-4fbac05cc445" xlink:to="loc_agio_TIBSOVOMember_3a3a5b86-4e21-48d5-874b-068f2e8d1fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_VorasidenibMember_8699f1a9-dd50-475c-a07d-0b2a466545b7" xlink:href="agio-20231231.xsd#agio_VorasidenibMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_72df4ef5-aa5c-4c29-8321-4fbac05cc445" xlink:to="loc_agio_VorasidenibMember_8699f1a9-dd50-475c-a07d-0b2a466545b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9ff760d-6710-4e6f-975b-6e7a72435b12" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_srt_StatementGeographicalAxis_a9ff760d-6710-4e6f-975b-6e7a72435b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_64194d80-280a-484f-acc4-4e50f0de98a2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a9ff760d-6710-4e6f-975b-6e7a72435b12" xlink:to="loc_srt_SegmentGeographicalDomain_64194d80-280a-484f-acc4-4e50f0de98a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_69c81cc6-789b-4eee-ac15-bc96038bdf3f" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_64194d80-280a-484f-acc4-4e50f0de98a2" xlink:to="loc_country_US_69c81cc6-789b-4eee-ac15-bc96038bdf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7527ba52-5f24-4422-8af1-453428f4b112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7527ba52-5f24-4422-8af1-453428f4b112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_864481bd-f2d3-4374-b431-66d942b5b7fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7527ba52-5f24-4422-8af1-453428f4b112" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_864481bd-f2d3-4374-b431-66d942b5b7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_Agreement2010Member_37831c3e-e839-4a6e-9fb1-b42da27abc46" xlink:href="agio-20231231.xsd#agio_Agreement2010Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_864481bd-f2d3-4374-b431-66d942b5b7fd" xlink:to="loc_agio_Agreement2010Member_37831c3e-e839-4a6e-9fb1-b42da27abc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fc58967d-9081-4cd9-b2d8-612085674ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fc58967d-9081-4cd9-b2d8-612085674ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aaa5099b-9812-47ee-a830-c52f4ca654b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fc58967d-9081-4cd9-b2d8-612085674ba4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aaa5099b-9812-47ee-a830-c52f4ca654b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AtTheMarketOfferingMember_6e23cb22-606e-48d8-8791-d5f3360001d7" xlink:href="agio-20231231.xsd#agio_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_aaa5099b-9812-47ee-a830-c52f4ca654b1" xlink:to="loc_agio_AtTheMarketOfferingMember_6e23cb22-606e-48d8-8791-d5f3360001d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6294ba7a-48cb-441e-96e3-f9d38fc15b29" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PaymentsForAssetAcquisition_79b5a535-5230-4fb9-ba09-f9978a0eecd2" xlink:href="agio-20231231.xsd#agio_PaymentsForAssetAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_PaymentsForAssetAcquisition_79b5a535-5230-4fb9-ba09-f9978a0eecd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment_68016737-b298-45e0-862d-926fbc4dbe80" xlink:href="agio-20231231.xsd#agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment_68016737-b298-45e0-862d-926fbc4dbe80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_b7df6394-0ebe-4681-b8a3-0b2988450d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_b7df6394-0ebe-4681-b8a3-0b2988450d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyUnrecordedAmount_62ea2c94-0fad-4719-b847-81870c335235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyUnrecordedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_us-gaap_GainContingencyUnrecordedAmount_62ea2c94-0fad-4719-b847-81870c335235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainContingencyRoyaltyPercentageOfNetSales_b1959e9b-ab5d-44b3-ae6c-9826444e85c4" xlink:href="agio-20231231.xsd#agio_GainContingencyRoyaltyPercentageOfNetSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_GainContingencyRoyaltyPercentageOfNetSales_b1959e9b-ab5d-44b3-ae6c-9826444e85c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_07de5edb-04ca-465e-8661-4cdb695091b7" xlink:href="agio-20231231.xsd#agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication_07de5edb-04ca-465e-8661-4cdb695091b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments_1aa53eb5-424a-4e6d-b450-d41d505e83b5" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_GainLossOnSaleOfContingentPayments_1aa53eb5-424a-4e6d-b450-d41d505e83b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContingentGainOnDispositionOfBusinessRecognized_317f5f64-e56e-439f-95df-962aec75f954" xlink:href="agio-20231231.xsd#agio_ContingentGainOnDispositionOfBusinessRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_ContingentGainOnDispositionOfBusinessRecognized_317f5f64-e56e-439f-95df-962aec75f954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3eeeada0-1e8f-42ba-83c0-4a5f822f3370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3eeeada0-1e8f-42ba-83c0-4a5f822f3370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction_0e067dc4-aabd-4d88-a4b0-354591d4c5a4" xlink:href="agio-20231231.xsd#agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction_0e067dc4-aabd-4d88-a4b0-354591d4c5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue_cf107ac4-99e1-4e43-b12d-b23d2506faee" xlink:href="agio-20231231.xsd#agio_SaleOfStockCommonStockReservedForFutureIssuanceValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_aa2da767-eea3-4af8-b372-386bba1be00a" xlink:to="loc_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue_cf107ac4-99e1-4e43-b12d-b23d2506faee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a44b3d49-2584-4257-9f6b-35ceeb3f8ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfSignificantAccountingPoliciesTable_3faf2ae8-17cd-4156-b3d8-3c2ca721dc3b" xlink:href="agio-20231231.xsd#agio_ScheduleOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a44b3d49-2584-4257-9f6b-35ceeb3f8ba7" xlink:to="loc_agio_ScheduleOfSignificantAccountingPoliciesTable_3faf2ae8-17cd-4156-b3d8-3c2ca721dc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1112b1eb-c33a-4c59-a00d-0b817b6f6ec4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesTable_3faf2ae8-17cd-4156-b3d8-3c2ca721dc3b" xlink:to="loc_srt_RangeAxis_1112b1eb-c33a-4c59-a00d-0b817b6f6ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_68d300c4-e2cb-4ede-9af5-636e43430d7c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1112b1eb-c33a-4c59-a00d-0b817b6f6ec4" xlink:to="loc_srt_RangeMember_68d300c4-e2cb-4ede-9af5-636e43430d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_00b4fe70-d8b1-4d94-84eb-094248379899" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_68d300c4-e2cb-4ede-9af5-636e43430d7c" xlink:to="loc_srt_MinimumMember_00b4fe70-d8b1-4d94-84eb-094248379899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f8099cf-5f14-467f-b1cd-796ae96f2267" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_68d300c4-e2cb-4ede-9af5-636e43430d7c" xlink:to="loc_srt_MaximumMember_8f8099cf-5f14-467f-b1cd-796ae96f2267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:href="agio-20231231.xsd#agio_ScheduleOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesTable_3faf2ae8-17cd-4156-b3d8-3c2ca721dc3b" xlink:to="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod_97addbed-b673-422f-8989-bd444a54a5c2" xlink:href="agio-20231231.xsd#agio_AvailableForSaleSecuritiesCurrentMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:to="loc_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod_97addbed-b673-422f-8989-bd444a54a5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod_0fa1bffc-0c45-4e7f-b028-3e39f46d1304" xlink:href="agio-20231231.xsd#agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:to="loc_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod_0fa1bffc-0c45-4e7f-b028-3e39f46d1304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod_b284eb1f-9314-48da-99db-8aef8fe3737d" xlink:href="agio-20231231.xsd#agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:to="loc_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod_b284eb1f-9314-48da-99db-8aef8fe3737d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_620000da-f8c7-4c7d-afa4-81af115794d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ScheduleOfSignificantAccountingPoliciesLineItems_bc3d4aff-b6d8-47be-888d-f0f646ea1787" xlink:to="loc_us-gaap_NumberOfOperatingSegments_620000da-f8c7-4c7d-afa4-81af115794d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fe8dbd0e-6ebb-442a-90a4-1b3044f67e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a7fc012-b764-459e-a515-0c7428b055cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fe8dbd0e-6ebb-442a-90a4-1b3044f67e4b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a7fc012-b764-459e-a515-0c7428b055cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67dcfa94-cc5a-4f65-a950-7eb17c117196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a7fc012-b764-459e-a515-0c7428b055cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67dcfa94-cc5a-4f65-a950-7eb17c117196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_67dcfa94-cc5a-4f65-a950-7eb17c117196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LaboratoryEquipmentMember_e099db7c-3bca-4689-8fd0-5d0cb42818f4" xlink:href="agio-20231231.xsd#agio_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:to="loc_agio_LaboratoryEquipmentMember_e099db7c-3bca-4689-8fd0-5d0cb42818f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ComputerEquipmentAndSoftwareMember_8a86b8fc-bc77-4b58-9525-fd9f07258825" xlink:href="agio-20231231.xsd#agio_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:to="loc_agio_ComputerEquipmentAndSoftwareMember_8a86b8fc-bc77-4b58-9525-fd9f07258825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0f8af241-7ec6-4a7d-bd8e-e926c8f2513d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0f8af241-7ec6-4a7d-bd8e-e926c8f2513d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_6a1d7cac-34ea-41e5-bee6-81a641174132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_386273da-29c4-46ad-be6d-10e900e390e8" xlink:to="loc_us-gaap_OfficeEquipmentMember_6a1d7cac-34ea-41e5-bee6-81a641174132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5554cfec-e9fe-491f-a785-cc71a66b567f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a7fc012-b764-459e-a515-0c7428b055cc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5554cfec-e9fe-491f-a785-cc71a66b567f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9ec2493b-139c-4ab6-bff8-c593fd42bf01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5554cfec-e9fe-491f-a785-cc71a66b567f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9ec2493b-139c-4ab6-bff8-c593fd42bf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6e96015c-1456-4590-94af-59a397d421f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6e96015c-1456-4590-94af-59a397d421f5" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2ba822d2-2ab3-4539-bf27-397443a5b631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2ba822d2-2ab3-4539-bf27-397443a5b631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_58feeb17-ca7a-44a8-a025-471077eb5eae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2ba822d2-2ab3-4539-bf27-397443a5b631" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_58feeb17-ca7a-44a8-a025-471077eb5eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0f6b008b-2ca4-4c71-8c65-88728bd2f7db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_58feeb17-ca7a-44a8-a025-471077eb5eae" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0f6b008b-2ca4-4c71-8c65-88728bd2f7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e48ed332-796f-436b-befa-a27b917322d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e48ed332-796f-436b-befa-a27b917322d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e48ed332-796f-436b-befa-a27b917322d9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f587dd79-c41c-48af-8a14-8d95b7ec5ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f587dd79-c41c-48af-8a14-8d95b7ec5ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_113bf585-81db-45ab-8e0f-805889ed7abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_113bf585-81db-45ab-8e0f-805889ed7abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8b6f48b8-1c9a-4622-9cbe-70557f1cf87c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0591c10c-a042-42b6-a84b-b61701e10ff4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8b6f48b8-1c9a-4622-9cbe-70557f1cf87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9a3c6dfc-7384-4f50-abf6-58836d6b93df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:to="loc_us-gaap_InvestmentTypeAxis_9a3c6dfc-7384-4f50-abf6-58836d6b93df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_a4828bca-6127-49e3-ba25-2080584a7dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_9a3c6dfc-7384-4f50-abf6-58836d6b93df" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_a4828bca-6127-49e3-ba25-2080584a7dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_a724a780-1009-4c05-8399-92c5e91de4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_a4828bca-6127-49e3-ba25-2080584a7dcb" xlink:to="loc_us-gaap_CashEquivalentsMember_a724a780-1009-4c05-8399-92c5e91de4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c01e9438-b21e-4dc6-8160-fa4b03673373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c01e9438-b21e-4dc6-8160-fa4b03673373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c01e9438-b21e-4dc6-8160-fa4b03673373" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_5aad080e-6e7d-4aae-a18f-c78618692e49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_5aad080e-6e7d-4aae-a18f-c78618692e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d7331e19-7b1a-46f3-bc33-052ac7f8b6eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d7331e19-7b1a-46f3-bc33-052ac7f8b6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_528d9d16-c0f5-4f21-a53e-1c0a405de15c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d21be03-02ad-4095-b49c-693b4c5d44a2" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_528d9d16-c0f5-4f21-a53e-1c0a405de15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_b426a913-0068-49fb-8895-5012d271ec3a" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5ca66f27-9cb2-4be7-8971-ebabd9968ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5ca66f27-9cb2-4be7-8971-ebabd9968ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f5ba90f-d2f2-4fa9-801c-e5ad664c2aaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7f5ba90f-d2f2-4fa9-801c-e5ad664c2aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_74b3112e-1745-4c53-99c9-5844d5551893" xlink:href="agio-20231231.xsd#agio_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_9bddc4f0-edea-40de-82aa-f471821a707a" xlink:to="loc_agio_CashEquivalentsAndAvailableForSaleSecurities_74b3112e-1745-4c53-99c9-5844d5551893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_092b95bd-a381-4cb3-8a5a-51088a0b97d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecedd640-5132-46da-b818-eb90fa509c71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_092b95bd-a381-4cb3-8a5a-51088a0b97d5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecedd640-5132-46da-b818-eb90fa509c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6521c7b-0029-476e-b0a2-c769f2b31587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecedd640-5132-46da-b818-eb90fa509c71" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6521c7b-0029-476e-b0a2-c769f2b31587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a9ddd88-6681-43d5-b71f-03ecf28d38cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f6521c7b-0029-476e-b0a2-c769f2b31587" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a9ddd88-6681-43d5-b71f-03ecf28d38cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3e97d970-8308-499b-9884-c14f9f3599b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_5a9ddd88-6681-43d5-b71f-03ecf28d38cc" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3e97d970-8308-499b-9884-c14f9f3599b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d80fad98-fcc2-487e-a7d5-8548efc17083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecedd640-5132-46da-b818-eb90fa509c71" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d80fad98-fcc2-487e-a7d5-8548efc17083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bf909e6d-0e79-4bb7-975b-3876c98ace82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d80fad98-fcc2-487e-a7d5-8548efc17083" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bf909e6d-0e79-4bb7-975b-3876c98ace82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a4b69ffd-67cf-42df-8b31-720b8bb4b318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bf909e6d-0e79-4bb7-975b-3876c98ace82" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a4b69ffd-67cf-42df-8b31-720b8bb4b318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_db9781c1-2a1d-41a8-b8e0-bb15320070f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ecedd640-5132-46da-b818-eb90fa509c71" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_db9781c1-2a1d-41a8-b8e0-bb15320070f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiability_bae6583d-3fb0-420a-86d6-8c69202dcb75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueNetAssetLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_db9781c1-2a1d-41a8-b8e0-bb15320070f8" xlink:to="loc_us-gaap_FairValueNetAssetLiability_bae6583d-3fb0-420a-86d6-8c69202dcb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#MarketableSecuritiesScheduleofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2e7af27-23e7-45f1-b80d-6638831c92df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cfe14f4d-aab2-4eed-910f-9789c863c4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2e7af27-23e7-45f1-b80d-6638831c92df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cfe14f4d-aab2-4eed-910f-9789c863c4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_24436d22-74d8-4601-8f61-4911c93920e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cfe14f4d-aab2-4eed-910f-9789c863c4f6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_24436d22-74d8-4601-8f61-4911c93920e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_514b924c-b67e-44f0-8765-87f57f75e5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_24436d22-74d8-4601-8f61-4911c93920e9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_514b924c-b67e-44f0-8765-87f57f75e5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentAssetMember_c79bc158-50e0-4f11-b348-343bf06d622a" xlink:href="agio-20231231.xsd#agio_CurrentAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_514b924c-b67e-44f0-8765-87f57f75e5ff" xlink:to="loc_agio_CurrentAssetMember_c79bc158-50e0-4f11-b348-343bf06d622a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NonCurrentAssetsMember_e15fd518-9e11-452f-aee2-ed88f722de77" xlink:href="agio-20231231.xsd#agio_NonCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_514b924c-b67e-44f0-8765-87f57f75e5ff" xlink:to="loc_agio_NonCurrentAssetsMember_e15fd518-9e11-452f-aee2-ed88f722de77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8a0545d1-a0c2-45e4-8384-1ed3053969e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cfe14f4d-aab2-4eed-910f-9789c863c4f6" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8a0545d1-a0c2-45e4-8384-1ed3053969e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8a0545d1-a0c2-45e4-8384-1ed3053969e5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_779ef352-91e4-40fc-9362-abbdb3712241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_779ef352-91e4-40fc-9362-abbdb3712241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_391a5219-7994-47f7-8092-dbc13ae22c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_391a5219-7994-47f7-8092-dbc13ae22c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_54759812-260b-4924-ac89-a4477e1705ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_842927b1-37b2-4de2-9c50-46f70305cb4c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_54759812-260b-4924-ac89-a4477e1705ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_cfe14f4d-aab2-4eed-910f-9789c863c4f6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20ff7ba1-cfe2-46af-a09e-26c123185eec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20ff7ba1-cfe2-46af-a09e-26c123185eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49e2fd4b-f608-4da5-b8d7-231fb4a6d86f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_49e2fd4b-f608-4da5-b8d7-231fb4a6d86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da8a255c-b33a-4186-a680-b4bd6bbffed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_da8a255c-b33a-4186-a680-b4bd6bbffed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f0e5bb1-b380-401a-9ff8-cc78c6d07e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ff94795-241b-4102-8859-2e7d52df9a98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f0e5bb1-b380-401a-9ff8-cc78c6d07e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#MarketableSecuritiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40697989-eb00-46ba-9200-18f0e54f8e59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_21acf1d1-cc24-4d61-8165-452f5e29a82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40697989-eb00-46ba-9200-18f0e54f8e59" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_21acf1d1-cc24-4d61-8165-452f5e29a82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_1b7cffba-a285-4ca0-829d-adac9e8af0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40697989-eb00-46ba-9200-18f0e54f8e59" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_1b7cffba-a285-4ca0-829d-adac9e8af0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_6c2ba1c6-82ea-4ae5-a166-bc33fd51abc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40697989-eb00-46ba-9200-18f0e54f8e59" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_6c2ba1c6-82ea-4ae5-a166-bc33fd51abc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_82638535-ccc5-4075-972f-4553bf007d23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40697989-eb00-46ba-9200-18f0e54f8e59" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_82638535-ccc5-4075-972f-4553bf007d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_5066934d-6686-438c-a806-52da7f9d2e28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_40697989-eb00-46ba-9200-18f0e54f8e59" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_5066934d-6686-438c-a806-52da7f9d2e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/InventoryDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bad5665d-263d-4d2e-9ffb-5ed8e18f3c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22be6eb9-ec45-44be-8d78-6b4e9d9b6c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bad5665d-263d-4d2e-9ffb-5ed8e18f3c4e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_22be6eb9-ec45-44be-8d78-6b4e9d9b6c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_684ff011-2545-4deb-a1eb-bea27df9380f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bad5665d-263d-4d2e-9ffb-5ed8e18f3c4e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_684ff011-2545-4deb-a1eb-bea27df9380f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7f648e54-9ef8-4c38-954c-fd07a71c6774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bad5665d-263d-4d2e-9ffb-5ed8e18f3c4e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_7f648e54-9ef8-4c38-954c-fd07a71c6774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_da1ae5d7-4539-44cf-88d3-9e8897493f08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bad5665d-263d-4d2e-9ffb-5ed8e18f3c4e" xlink:to="loc_us-gaap_InventoryNet_da1ae5d7-4539-44cf-88d3-9e8897493f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dd5aa0d1-6eaf-4ec4-ab8a-00026a80b0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_23445c6b-d4b1-4262-b938-37ad4b0d4153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dd5aa0d1-6eaf-4ec4-ab8a-00026a80b0ed" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_23445c6b-d4b1-4262-b938-37ad4b0d4153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LeaseArrangementsAxis_564f85f1-4606-4538-b995-460f9b670282" xlink:href="agio-20231231.xsd#agio_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_23445c6b-d4b1-4262-b938-37ad4b0d4153" xlink:to="loc_agio_LeaseArrangementsAxis_564f85f1-4606-4538-b995-460f9b670282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:href="agio-20231231.xsd#agio_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_LeaseArrangementsAxis_564f85f1-4606-4538-b995-460f9b670282" xlink:to="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EightyEightSidneyStreetLeaseMember_ccf615e5-4b19-4daf-b158-b5d1e7038039" xlink:href="agio-20231231.xsd#agio_EightyEightSidneyStreetLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:to="loc_agio_EightyEightSidneyStreetLeaseMember_ccf615e5-4b19-4daf-b158-b5d1e7038039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_SixtyFourSidneyStreetLeaseMember_9321e2bf-510f-41c7-b648-89c522576fc8" xlink:href="agio-20231231.xsd#agio_SixtyFourSidneyStreetLeaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:to="loc_agio_SixtyFourSidneyStreetLeaseMember_9321e2bf-510f-41c7-b648-89c522576fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember_f5f7a892-f8d3-4ebf-a5dc-cdb5b5324b6f" xlink:href="agio-20231231.xsd#agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_LeaseArrangementsDomain_7edf9d10-2da5-45af-81dd-0005e6772ff9" xlink:to="loc_agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember_f5f7a892-f8d3-4ebf-a5dc-cdb5b5324b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ffd77b16-5e6f-4464-88c5-d9b7574d26b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_23445c6b-d4b1-4262-b938-37ad4b0d4153" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ffd77b16-5e6f-4464-88c5-d9b7574d26b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e2399316-8264-4ab9-b225-a49d8f6a0f44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ffd77b16-5e6f-4464-88c5-d9b7574d26b2" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e2399316-8264-4ab9-b225-a49d8f6a0f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_473db1df-0c93-4299-be36-b108811c7ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_e2399316-8264-4ab9-b225-a49d8f6a0f44" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_473db1df-0c93-4299-be36-b108811c7ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_23445c6b-d4b1-4262-b938-37ad4b0d4153" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2f9291cb-9b6e-4387-b50e-bbe6e739d244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_2f9291cb-9b6e-4387-b50e-bbe6e739d244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace_6c76d36f-37f1-4dd4-9356-ceb97dc45d21" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace_6c76d36f-37f1-4dd4-9356-ceb97dc45d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseNumberOfLeaseTerms_de16d1aa-ef3c-43ff-80e7-0a3611e19741" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseNumberOfLeaseTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseNumberOfLeaseTerms_de16d1aa-ef3c-43ff-80e7-0a3611e19741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_26053bf8-50b2-45b3-b09c-67d9ec6014b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_26053bf8-50b2-45b3-b09c-67d9ec6014b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d66cc1b6-fc68-43d7-9dd0-79c2d903b2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d66cc1b6-fc68-43d7-9dd0-79c2d903b2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9b71fb00-6afb-495a-81d1-61384b3e08e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9b71fb00-6afb-495a-81d1-61384b3e08e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_79eece62-ffd5-406b-9f2c-027a984a6eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_79eece62-ffd5-406b-9f2c-027a984a6eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_7b2acabd-15e9-4125-9117-2c84bffeb79c" xlink:href="agio-20231231.xsd#agio_LesseeOperatingSubleaseAreaOfPremisesSubleased"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased_7b2acabd-15e9-4125-9117-2c84bffeb79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods_bb4c1c5c-677d-4aa1-b97b-6fce07e07341" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods_bb4c1c5c-677d-4aa1-b97b-6fce07e07341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod_c5e9cbdd-e868-48a3-ab88-0966fdb7d215" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod_c5e9cbdd-e868-48a3-ab88-0966fdb7d215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo_fe63fb59-3317-4b94-8331-09739c878452" xlink:href="agio-20231231.xsd#agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo_fe63fb59-3317-4b94-8331-09739c878452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_77ac6745-e007-4899-b748-c521a2fdd7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_SubleaseIncome_77ac6745-e007-4899-b748-c521a2fdd7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDepositLiability_d84751f7-4a3a-47fc-9278-0f9130a4a6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDepositLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6852f9f4-f564-4a43-96fb-7e13940bcb23" xlink:to="loc_us-gaap_SecurityDepositLiability_d84751f7-4a3a-47fc-9278-0f9130a4a6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesScheduleofLeaseExpenseandOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_41c60e57-9adb-450b-a1f6-c21201b39f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_0cff9351-ed9c-483e-8887-cc2ee394fe9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_41c60e57-9adb-450b-a1f6-c21201b39f24" xlink:to="loc_us-gaap_OperatingLeaseCost_0cff9351-ed9c-483e-8887-cc2ee394fe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_bf5f73cf-99a8-4ccf-b1ec-79a176a41ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_41c60e57-9adb-450b-a1f6-c21201b39f24" xlink:to="loc_us-gaap_OperatingLeasePayments_bf5f73cf-99a8-4ccf-b1ec-79a176a41ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85abacdd-ad1c-495e-a0af-710ca4159161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85abacdd-ad1c-495e-a0af-710ca4159161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_58dddb5e-a265-4d15-b21c-495a7e529e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_58dddb5e-a265-4d15-b21c-495a7e529e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4c12a8b0-8f53-4339-83aa-c63ef1c25706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4c12a8b0-8f53-4339-83aa-c63ef1c25706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e9e5576b-d804-4683-93dc-fce697f418fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e9e5576b-d804-4683-93dc-fce697f418fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bb15015b-e605-498c-9b88-a92e558d2215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bb15015b-e605-498c-9b88-a92e558d2215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5c80d63f-3c8e-4a7c-81da-885e3ff1d80b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5c80d63f-3c8e-4a7c-81da-885e3ff1d80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_611dbc96-acb4-418a-a14b-58f9b2c15494" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_611dbc96-acb4-418a-a14b-58f9b2c15494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_245d0869-beb0-4388-9593-78c64bac580b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_245d0869-beb0-4388-9593-78c64bac580b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9c8299a9-6830-465c-90a4-948dcab1e2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_556b5791-9fce-4af6-9249-d5b7ca1133e9" xlink:to="loc_us-gaap_OperatingLeaseLiability_9c8299a9-6830-465c-90a4-948dcab1e2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_832cf23c-4ac6-4aae-9d21-d0ddb89919e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_63e68662-3bbc-42a4-b145-d6b44bf5504f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_832cf23c-4ac6-4aae-9d21-d0ddb89919e1" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_63e68662-3bbc-42a4-b145-d6b44bf5504f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_6bb161ba-4bb2-4a06-81f0-ea173c81e993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_832cf23c-4ac6-4aae-9d21-d0ddb89919e1" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_6bb161ba-4bb2-4a06-81f0-ea173c81e993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_8659384c-2e95-44da-9f43-e3677bccaecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_832cf23c-4ac6-4aae-9d21-d0ddb89919e1" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_8659384c-2e95-44da-9f43-e3677bccaecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_58220454-1fc2-4e35-9be8-629eca676bea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_63a6978e-cd58-45f5-9ecc-bcd1cab375ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_58220454-1fc2-4e35-9be8-629eca676bea" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_63a6978e-cd58-45f5-9ecc-bcd1cab375ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_8b19500e-dfad-4734-b529-b439ebe74729" xlink:href="agio-20231231.xsd#agio_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_58220454-1fc2-4e35-9be8-629eca676bea" xlink:to="loc_agio_AccruedResearchAndDevelopmentCostsCurrent_8b19500e-dfad-4734-b529-b439ebe74729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_86825125-8bf8-4d48-982e-ca29623ec1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_58220454-1fc2-4e35-9be8-629eca676bea" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_86825125-8bf8-4d48-982e-ca29623ec1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f128276b-4b0b-4b16-b4ca-1ee5d3fc5f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_58220454-1fc2-4e35-9be8-629eca676bea" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_f128276b-4b0b-4b16-b4ca-1ee5d3fc5f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9ff06e10-b611-4f94-9495-22150ace0517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_58220454-1fc2-4e35-9be8-629eca676bea" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9ff06e10-b611-4f94-9495-22150ace0517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenueScheduleofProductRevenueNetDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_28c3d17e-e72a-4042-b9f2-edb44c207bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5cdd55b3-a415-4976-9cc8-95e79f8e71d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_28c3d17e-e72a-4042-b9f2-edb44c207bb2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5cdd55b3-a415-4976-9cc8-95e79f8e71d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d2c3ab4b-2d30-45b9-86a9-bad01e432920" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5cdd55b3-a415-4976-9cc8-95e79f8e71d2" xlink:to="loc_srt_ProductOrServiceAxis_d2c3ab4b-2d30-45b9-86a9-bad01e432920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1a606a75-2720-4c39-8c7a-5417865b2894" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d2c3ab4b-2d30-45b9-86a9-bad01e432920" xlink:to="loc_srt_ProductsAndServicesDomain_1a606a75-2720-4c39-8c7a-5417865b2894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_1d61cb89-242b-4e65-9a37-1d8aaadd0e81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1a606a75-2720-4c39-8c7a-5417865b2894" xlink:to="loc_us-gaap_ProductMember_1d61cb89-242b-4e65-9a37-1d8aaadd0e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_6aac1e4f-0347-4e2f-8f28-41bdad75509b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5cdd55b3-a415-4976-9cc8-95e79f8e71d2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_6aac1e4f-0347-4e2f-8f28-41bdad75509b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb92ad41-c0c9-47ef-abcf-d40e4e679bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_6aac1e4f-0347-4e2f-8f28-41bdad75509b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_eb92ad41-c0c9-47ef-abcf-d40e4e679bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eff3a9aa-30a1-43d9-9eb4-0828398be4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractualAdjustmentsRollForward_4c052c60-771e-4cdc-a76f-f7d8176290cc" xlink:href="agio-20231231.xsd#agio_ContractualAdjustmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eff3a9aa-30a1-43d9-9eb4-0828398be4c9" xlink:to="loc_agio_ContractualAdjustmentsRollForward_4c052c60-771e-4cdc-a76f-f7d8176290cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_ba9ee705-5228-475a-b91c-52ffacddf28f" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_4c052c60-771e-4cdc-a76f-f7d8176290cc" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_ba9ee705-5228-475a-b91c-52ffacddf28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionForContractualAdjustments_9e327113-ca4b-4bf6-a7ab-0117f9b738b5" xlink:href="agio-20231231.xsd#agio_CurrentYearProvisionForContractualAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_4c052c60-771e-4cdc-a76f-f7d8176290cc" xlink:to="loc_agio_CurrentYearProvisionForContractualAdjustments_9e327113-ca4b-4bf6-a7ab-0117f9b738b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionForContractualAdjustments_e60dc071-19ed-413d-bd30-bfcc290840b5" xlink:href="agio-20231231.xsd#agio_PriorYearProvisionForContractualAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_4c052c60-771e-4cdc-a76f-f7d8176290cc" xlink:to="loc_agio_PriorYearProvisionForContractualAdjustments_e60dc071-19ed-413d-bd30-bfcc290840b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_667c7027-5feb-458c-9936-be125f2979f9" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_4c052c60-771e-4cdc-a76f-f7d8176290cc" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear_667c7027-5feb-458c-9936-be125f2979f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_e34544cd-f569-47df-a3e1-c1198f48be4b" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_4c052c60-771e-4cdc-a76f-f7d8176290cc" xlink:to="loc_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear_e34544cd-f569-47df-a3e1-c1198f48be4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerContractualAdjustmentReserve_a8460f3d-5660-4001-badc-df6916865e3f" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerContractualAdjustmentReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractualAdjustmentsRollForward_4c052c60-771e-4cdc-a76f-f7d8176290cc" xlink:to="loc_agio_ContractWithCustomerContractualAdjustmentReserve_a8460f3d-5660-4001-badc-df6916865e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GovernmentRebatesRollForward_293b4675-a790-4c4d-9d9a-01ebdad7a119" xlink:href="agio-20231231.xsd#agio_GovernmentRebatesRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eff3a9aa-30a1-43d9-9eb4-0828398be4c9" xlink:to="loc_agio_GovernmentRebatesRollForward_293b4675-a790-4c4d-9d9a-01ebdad7a119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_717ae3b0-8213-457d-8142-6b49fb1c3060" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_293b4675-a790-4c4d-9d9a-01ebdad7a119" xlink:to="loc_agio_ContractWithCustomerRebateReserve_717ae3b0-8213-457d-8142-6b49fb1c3060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CurrentYearProvisionsForRebateReserve_17384b4a-eeb7-45a5-b0ea-19594b46204a" xlink:href="agio-20231231.xsd#agio_CurrentYearProvisionsForRebateReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_293b4675-a790-4c4d-9d9a-01ebdad7a119" xlink:to="loc_agio_CurrentYearProvisionsForRebateReserve_17384b4a-eeb7-45a5-b0ea-19594b46204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PriorYearProvisionsForRebateReserve_0a87188b-90bc-4abd-8266-a06a0498c72f" xlink:href="agio-20231231.xsd#agio_PriorYearProvisionsForRebateReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_293b4675-a790-4c4d-9d9a-01ebdad7a119" xlink:to="loc_agio_PriorYearProvisionsForRebateReserve_0a87188b-90bc-4abd-8266-a06a0498c72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_70b3e2d1-910a-403c-a309-7634a522bbdc" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_293b4675-a790-4c4d-9d9a-01ebdad7a119" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear_70b3e2d1-910a-403c-a309-7634a522bbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_27f26113-38ef-401f-a7d0-d44f433e81a9" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_293b4675-a790-4c4d-9d9a-01ebdad7a119" xlink:to="loc_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears_27f26113-38ef-401f-a7d0-d44f433e81a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRebateReserve_7d56cede-7191-4685-9452-d6f658dbe6d1" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRebateReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_GovernmentRebatesRollForward_293b4675-a790-4c4d-9d9a-01ebdad7a119" xlink:to="loc_agio_ContractWithCustomerRebateReserve_7d56cede-7191-4685-9452-d6f658dbe6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProductReturnsRollForward_190ec4e2-c922-4591-9bcd-c3ce72757f08" xlink:href="agio-20231231.xsd#agio_ProductReturnsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eff3a9aa-30a1-43d9-9eb4-0828398be4c9" xlink:to="loc_agio_ProductReturnsRollForward_190ec4e2-c922-4591-9bcd-c3ce72757f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_75afe027-6326-4dba-9d31-671716dfcc59" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_190ec4e2-c922-4591-9bcd-c3ce72757f08" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_75afe027-6326-4dba-9d31-671716dfcc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_c7fb132c-6959-45c3-a737-6e2b08241d15" xlink:href="agio-20231231.xsd#agio_ProvisionForRightToRecoverProductInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_190ec4e2-c922-4591-9bcd-c3ce72757f08" xlink:to="loc_agio_ProvisionForRightToRecoverProductInCurrentYear_c7fb132c-6959-45c3-a737-6e2b08241d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ProvisionForRightToRecoverProductInPriorYears_a8bdf4ec-0e27-45ea-ad79-350096f06bf8" xlink:href="agio-20231231.xsd#agio_ProvisionForRightToRecoverProductInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_190ec4e2-c922-4591-9bcd-c3ce72757f08" xlink:to="loc_agio_ProvisionForRightToRecoverProductInPriorYears_a8bdf4ec-0e27-45ea-ad79-350096f06bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_11bce449-3c33-45e6-b099-3bc17a289015" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_190ec4e2-c922-4591-9bcd-c3ce72757f08" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries_11bce449-3c33-45e6-b099-3bc17a289015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_454560d5-295a-4846-8c52-190e3ff6b6ed" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_190ec4e2-c922-4591-9bcd-c3ce72757f08" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries_454560d5-295a-4846-8c52-190e3ff6b6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerRightToRecoverProductReserve_e68197b2-81de-4886-9c49-87326cae3a5d" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerRightToRecoverProductReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ProductReturnsRollForward_190ec4e2-c922-4591-9bcd-c3ce72757f08" xlink:to="loc_agio_ContractWithCustomerRightToRecoverProductReserve_e68197b2-81de-4886-9c49-87326cae3a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9b8009d2-758e-4514-a021-2c14eb1f4f14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_eff3a9aa-30a1-43d9-9eb4-0828398be4c9" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9b8009d2-758e-4514-a021-2c14eb1f4f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_9344414e-d5d5-4b9c-8a3a-930c8a999f94" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9b8009d2-758e-4514-a021-2c14eb1f4f14" xlink:to="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_9344414e-d5d5-4b9c-8a3a-930c8a999f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_9097e803-50d4-443a-9562-d152b821b6db" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerCurrentYearReserveProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9b8009d2-758e-4514-a021-2c14eb1f4f14" xlink:to="loc_agio_ContractWithCustomerCurrentYearReserveProvisions_9097e803-50d4-443a-9562-d152b821b6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_a114d835-2952-4023-865b-5f7b2dba486c" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerPriorYearsReserveProvisions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9b8009d2-758e-4514-a021-2c14eb1f4f14" xlink:to="loc_agio_ContractWithCustomerPriorYearsReserveProvisions_a114d835-2952-4023-865b-5f7b2dba486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_77b6cd55-0e91-47c2-b4ed-cb45e7613d8c" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerCurrentYearReserveRecoveries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9b8009d2-758e-4514-a021-2c14eb1f4f14" xlink:to="loc_agio_ContractWithCustomerCurrentYearReserveRecoveries_77b6cd55-0e91-47c2-b4ed-cb45e7613d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_56400d30-fa01-4f92-be22-3ffbf5a35790" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerPriorYearsReserveRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_9b8009d2-758e-4514-a021-2c14eb1f4f14" xlink:to="loc_agio_ContractWithCustomerPriorYearsReserveRecoveries_56400d30-fa01-4f92-be22-3ffbf5a35790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenueScheduleofRevenueRelatedReservesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_436d6b6f-f43d-45b6-81e4-46a4798311da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8c937179-37bb-49b1-8271-c2d955974cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_436d6b6f-f43d-45b6-81e4-46a4798311da" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8c937179-37bb-49b1-8271-c2d955974cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_af5e1333-91d6-4a3b-9c7c-4d4a0e9f2e92" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerAllowanceAndReservesLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_436d6b6f-f43d-45b6-81e4-46a4798311da" xlink:to="loc_agio_ContractWithCustomerAllowanceAndReservesLiability_af5e1333-91d6-4a3b-9c7c-4d4a0e9f2e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_1f9fb1e7-4d50-45ce-8454-ce2dd460b671" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerTotalAllowancesAndReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_436d6b6f-f43d-45b6-81e4-46a4798311da" xlink:to="loc_agio_ContractWithCustomerTotalAllowancesAndReserves_1f9fb1e7-4d50-45ce-8454-ce2dd460b671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenueScheduleofChangesinContractAssetsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_310868c9-d57e-429c-b883-274952ef3d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractAssetsAndLiabilitiesHeadingRollForward_ca3372bc-ec5a-4429-a3f0-0fb439877902" xlink:href="agio-20231231.xsd#agio_ContractAssetsAndLiabilitiesHeadingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_310868c9-d57e-429c-b883-274952ef3d7e" xlink:to="loc_agio_ContractAssetsAndLiabilitiesHeadingRollForward_ca3372bc-ec5a-4429-a3f0-0fb439877902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_c03c1b87-7642-457e-930d-6511d89b88db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractAssetsAndLiabilitiesHeadingRollForward_ca3372bc-ec5a-4429-a3f0-0fb439877902" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_c03c1b87-7642-457e-930d-6511d89b88db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetRevenueRecognized_d56875ef-3b8e-4c87-9067-f5106af347fb" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerAssetRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractAssetsAndLiabilitiesHeadingRollForward_ca3372bc-ec5a-4429-a3f0-0fb439877902" xlink:to="loc_agio_ContractWithCustomerAssetRevenueRecognized_d56875ef-3b8e-4c87-9067-f5106af347fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_7d2f2494-3430-4ef4-9e57-84b5a16a08d1" xlink:href="agio-20231231.xsd#agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractAssetsAndLiabilitiesHeadingRollForward_ca3372bc-ec5a-4429-a3f0-0fb439877902" xlink:to="loc_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables_7d2f2494-3430-4ef4-9e57-84b5a16a08d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_9d2d089c-4f8f-41cd-817e-8b2dc8ef368e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_ContractAssetsAndLiabilitiesHeadingRollForward_ca3372bc-ec5a-4429-a3f0-0fb439877902" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_9d2d089c-4f8f-41cd-817e-8b2dc8ef368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ProductRevenueAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ProductRevenueAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ProductRevenueAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8a4fc05e-1160-4436-a5dc-4ed8f0948b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_b41a2f25-b013-40c2-a9de-c269a3e6aeea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8a4fc05e-1160-4436-a5dc-4ed8f0948b4d" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_b41a2f25-b013-40c2-a9de-c269a3e6aeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1581ad95-8480-4a4b-aa21-6bd5c8f4378a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f3f1fef-5f83-4799-b1cd-5581c28bc2de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1581ad95-8480-4a4b-aa21-6bd5c8f4378a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f3f1fef-5f83-4799-b1cd-5581c28bc2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ac75a65b-d275-44b7-9d7e-8b823c37724f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f3f1fef-5f83-4799-b1cd-5581c28bc2de" xlink:to="loc_us-gaap_PlanNameAxis_ac75a65b-d275-44b7-9d7e-8b823c37724f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ac75a65b-d275-44b7-9d7e-8b823c37724f" xlink:to="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_fe25a248-cfe9-4e6a-b9ab-d64165d7507b" xlink:href="agio-20231231.xsd#agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:to="loc_agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember_fe25a248-cfe9-4e6a-b9ab-d64165d7507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_066a68d6-a640-4616-8d2f-809f1c27a878" xlink:href="agio-20231231.xsd#agio_TwoThousandAndThirteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:to="loc_agio_TwoThousandAndThirteenStockIncentivePlanMember_066a68d6-a640-4616-8d2f-809f1c27a878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeeStockPurchasePlan2013Member_2c0b8f2c-c43f-4d01-bb0c-f9c9be3dfa89" xlink:href="agio-20231231.xsd#agio_EmployeeStockPurchasePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dabb7757-a9c3-4e08-a530-2acef2b10156" xlink:to="loc_agio_EmployeeStockPurchasePlan2013Member_2c0b8f2c-c43f-4d01-bb0c-f9c9be3dfa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_183684d1-dbb7-46f0-b5f0-7d6d1e10f9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f3f1fef-5f83-4799-b1cd-5581c28bc2de" xlink:to="loc_us-gaap_AwardTypeAxis_183684d1-dbb7-46f0-b5f0-7d6d1e10f9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_183684d1-dbb7-46f0-b5f0-7d6d1e10f9ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b6954ed5-affb-4457-9760-6ea7aca2a127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b6954ed5-affb-4457-9760-6ea7aca2a127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_5ec70d0c-ac7f-49a4-8567-ab4c2eb1eb5d" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:to="loc_agio_PerformanceStockUnitMember_5ec70d0c-ac7f-49a4-8567-ab4c2eb1eb5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_1496194b-9c3c-4d47-a333-1f5be885acab" xlink:href="agio-20231231.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d0db3a5-01f0-40e1-9dfa-3c933eb98dce" xlink:to="loc_agio_MarketBasedStockUnitsMember_1496194b-9c3c-4d47-a333-1f5be885acab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2f3f1fef-5f83-4799-b1cd-5581c28bc2de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3bf9daca-a0c6-453b-a381-6eef2c935949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3bf9daca-a0c6-453b-a381-6eef2c935949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9947f31e-04b5-44b7-895f-c818770f9673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9947f31e-04b5-44b7-895f-c818770f9673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1a33321b-804e-4738-9171-68a4c97aa5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1a33321b-804e-4738-9171-68a4c97aa5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d7490cf-16d2-4a0e-a287-497fa67d5e69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d7490cf-16d2-4a0e-a287-497fa67d5e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a9d7b7d2-07dd-443f-8057-9f4563d4af66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a9d7b7d2-07dd-443f-8057-9f4563d4af66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2212f30a-9b64-47c6-a67f-3891cab28812" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2212f30a-9b64-47c6-a67f-3891cab28812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70f29e84-0e84-4fbb-afd3-178ddb4aef21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70f29e84-0e84-4fbb-afd3-178ddb4aef21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_58f2b9d7-6fda-46eb-973b-dd59d5f4967b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_58f2b9d7-6fda-46eb-973b-dd59d5f4967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares_e985a394-9526-417e-8ece-7833ea846ed7" xlink:href="agio-20231231.xsd#agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares_e985a394-9526-417e-8ece-7833ea846ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_d6f9ff4c-53b7-4612-801f-74bea76a798a" xlink:href="agio-20231231.xsd#agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount_d6f9ff4c-53b7-4612-801f-74bea76a798a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69ac946e-6379-44f0-8bba-d2ff56de39fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_69ac946e-6379-44f0-8bba-d2ff56de39fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_8d09d657-42f9-4b20-9488-be1c49d1e7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_8d09d657-42f9-4b20-9488-be1c49d1e7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5faec2cd-ae58-465e-9e34-c65ae5cce10d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_5faec2cd-ae58-465e-9e34-c65ae5cce10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_09cc3d3a-38f0-490b-9cad-18efe298df8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_09cc3d3a-38f0-490b-9cad-18efe298df8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0480fa23-66b0-435d-8c22-1517fad80d91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_afca1ac1-881c-486c-a917-08583a7b44e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0480fa23-66b0-435d-8c22-1517fad80d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe28951-56cb-4da3-9464-a5d66b50971f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54692362-0da6-4d8a-95fa-1fa34157a167" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe28951-56cb-4da3-9464-a5d66b50971f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54692362-0da6-4d8a-95fa-1fa34157a167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5d335826-072d-4668-a61a-fb02ae96ec20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54692362-0da6-4d8a-95fa-1fa34157a167" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5d335826-072d-4668-a61a-fb02ae96ec20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_41a782c1-3220-4264-867b-2146f63f0742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54692362-0da6-4d8a-95fa-1fa34157a167" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_41a782c1-3220-4264-867b-2146f63f0742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_53265f20-9838-400a-bac3-8523789f5e07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54692362-0da6-4d8a-95fa-1fa34157a167" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_53265f20-9838-400a-bac3-8523789f5e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e9a83f4-27ed-4537-a47f-f9becdc61bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54692362-0da6-4d8a-95fa-1fa34157a167" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9e9a83f4-27ed-4537-a47f-f9becdc61bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa69aa57-a62e-4cfe-bc32-182f385650b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_54692362-0da6-4d8a-95fa-1fa34157a167" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_aa69aa57-a62e-4cfe-bc32-182f385650b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4e50ac3d-01ff-429d-ad8f-3ec773c307b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe28951-56cb-4da3-9464-a5d66b50971f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4e50ac3d-01ff-429d-ad8f-3ec773c307b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c6c1118e-9e15-4156-ac54-fa94a0b392f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe28951-56cb-4da3-9464-a5d66b50971f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c6c1118e-9e15-4156-ac54-fa94a0b392f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac7360d0-c226-4d13-907f-f934523bee50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe28951-56cb-4da3-9464-a5d66b50971f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac7360d0-c226-4d13-907f-f934523bee50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_09785b00-1ab9-455a-a949-19d6d6ac91fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac7360d0-c226-4d13-907f-f934523bee50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_09785b00-1ab9-455a-a949-19d6d6ac91fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e74f6849-3d4e-4d3c-9a81-2df0b4e01dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac7360d0-c226-4d13-907f-f934523bee50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e74f6849-3d4e-4d3c-9a81-2df0b4e01dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17bd523d-bf85-4849-9c4d-b1e4e85b868a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac7360d0-c226-4d13-907f-f934523bee50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_17bd523d-bf85-4849-9c4d-b1e4e85b868a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4decf92a-7184-485f-b025-60703c14f4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac7360d0-c226-4d13-907f-f934523bee50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_4decf92a-7184-485f-b025-60703c14f4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3310b97-fc8b-4e6e-9be4-ec40a3a2d162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ac7360d0-c226-4d13-907f-f934523bee50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c3310b97-fc8b-4e6e-9be4-ec40a3a2d162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2942d69c-d28a-4e52-a4d8-0193bc4d215a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe28951-56cb-4da3-9464-a5d66b50971f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2942d69c-d28a-4e52-a4d8-0193bc4d215a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cde37ebc-4cd9-4fd6-933f-c0085552660e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe28951-56cb-4da3-9464-a5d66b50971f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cde37ebc-4cd9-4fd6-933f-c0085552660e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a888073d-0feb-421b-bd70-10d949971536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0fe28951-56cb-4da3-9464-a5d66b50971f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a888073d-0feb-421b-bd70-10d949971536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8a65b86a-14d2-4e2e-ba33-e362b29665f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a888073d-0feb-421b-bd70-10d949971536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8a65b86a-14d2-4e2e-ba33-e362b29665f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5dde0abb-b662-4b03-b54b-336935258666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a888073d-0feb-421b-bd70-10d949971536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5dde0abb-b662-4b03-b54b-336935258666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b2e467cd-894d-4910-b947-5cae0b3b201a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a888073d-0feb-421b-bd70-10d949971536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_b2e467cd-894d-4910-b947-5cae0b3b201a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_34b1f733-fff8-4153-bd39-46411c6adac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a888073d-0feb-421b-bd70-10d949971536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_34b1f733-fff8-4153-bd39-46411c6adac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d99f0f43-5b1d-47a5-a95c-bd25c69804f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a888073d-0feb-421b-bd70-10d949971536" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d99f0f43-5b1d-47a5-a95c-bd25c69804f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b013acd4-1996-489d-adbc-be36239c0744" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a888073d-0feb-421b-bd70-10d949971536" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_b013acd4-1996-489d-adbc-be36239c0744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7407872d-695e-460b-8520-45353c1cdec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64187545-1310-4ed8-9df6-1459b4ae7962" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7407872d-695e-460b-8520-45353c1cdec1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64187545-1310-4ed8-9df6-1459b4ae7962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4b62da7-22e0-449f-b215-555335df7164" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64187545-1310-4ed8-9df6-1459b4ae7962" xlink:to="loc_us-gaap_AwardTypeAxis_f4b62da7-22e0-449f-b215-555335df7164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f4b62da7-22e0-449f-b215-555335df7164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eea8e7e7-546b-4f6e-8590-37a76df819cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eea8e7e7-546b-4f6e-8590-37a76df819cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_98751ece-6bd0-4d64-a587-02516bdf2df8" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:to="loc_agio_PerformanceStockUnitMember_98751ece-6bd0-4d64-a587-02516bdf2df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember_629f3951-9c0d-485d-9e68-d948d69a461c" xlink:href="agio-20231231.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f607a0fa-66d3-4631-909b-b34e0b24d859" xlink:to="loc_agio_MarketBasedStockUnitsMember_629f3951-9c0d-485d-9e68-d948d69a461c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d19b620-9824-407e-9304-d48adf4b45c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_64187545-1310-4ed8-9df6-1459b4ae7962" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d19b620-9824-407e-9304-d48adf4b45c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d19b620-9824-407e-9304-d48adf4b45c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bdda556-db6a-4362-98a1-5dbbd5a74bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1bdda556-db6a-4362-98a1-5dbbd5a74bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e31a302-11f2-4b7c-9541-e8c6ea316f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e31a302-11f2-4b7c-9541-e8c6ea316f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fe8cb937-7beb-48c7-b1d5-37c29749b63e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_fe8cb937-7beb-48c7-b1d5-37c29749b63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b62a8fdb-7406-47b5-8a24-fa10eb47bc45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b62a8fdb-7406-47b5-8a24-fa10eb47bc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b0e9b9cd-7d16-46e2-9818-a3dd2801ca85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_dee69588-8f0c-4d0a-8ddc-36636db05b3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b0e9b9cd-7d16-46e2-9818-a3dd2801ca85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4d19b620-9824-407e-9304-d48adf4b45c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a7d8955a-bae7-4ad2-ae66-a77357263ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a7d8955a-bae7-4ad2-ae66-a77357263ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_902f9ef6-0a65-44df-b8e6-5af9c2bd8adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_902f9ef6-0a65-44df-b8e6-5af9c2bd8adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5fecbefa-feb6-4a06-83b8-b5b62325e2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5fecbefa-feb6-4a06-83b8-b5b62325e2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8fa3c394-7838-4291-a7c5-0880d5841d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8fa3c394-7838-4291-a7c5-0880d5841d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_030aaa17-1d4f-4795-9fbe-a82adfe6730d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a0adbf59-6e90-499c-8a85-ac802634208c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_030aaa17-1d4f-4795-9fbe-a82adfe6730d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2746d598-9646-40fb-a5e7-8efabcfb4f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06735e09-beb2-4b7e-b801-6c4e9edab202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2746d598-9646-40fb-a5e7-8efabcfb4f38" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06735e09-beb2-4b7e-b801-6c4e9edab202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a48697f1-e76c-4d11-921f-d40da295ba81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06735e09-beb2-4b7e-b801-6c4e9edab202" xlink:to="loc_us-gaap_AwardTypeAxis_a48697f1-e76c-4d11-921f-d40da295ba81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a48697f1-e76c-4d11-921f-d40da295ba81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_85c227ed-d7f0-4258-b016-1755753df513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_85c227ed-d7f0-4258-b016-1755753df513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dda4e763-6cee-49c9-9688-32be5084a97f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dda4e763-6cee-49c9-9688-32be5084a97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_4caeb5c1-032d-4f99-a466-c1d814503ab2" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:to="loc_agio_PerformanceStockUnitMember_4caeb5c1-032d-4f99-a466-c1d814503ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_ed0dffca-ce5a-47c3-8c2e-214fd59f38b6" xlink:href="agio-20231231.xsd#agio_EmployeePurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_be70b78b-a119-430b-a03d-9fa9203d22f1" xlink:to="loc_agio_EmployeePurchasePlanMember_ed0dffca-ce5a-47c3-8c2e-214fd59f38b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adab3361-93a8-4535-b3bb-8f233b876e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06735e09-beb2-4b7e-b801-6c4e9edab202" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adab3361-93a8-4535-b3bb-8f233b876e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0da930a0-d2da-43df-a355-42b3ff58b68b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adab3361-93a8-4535-b3bb-8f233b876e92" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0da930a0-d2da-43df-a355-42b3ff58b68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52b58c11-ab78-445a-a800-ee6fb6579532" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68f64668-f0a7-4581-ab1d-37920c92e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52b58c11-ab78-445a-a800-ee6fb6579532" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68f64668-f0a7-4581-ab1d-37920c92e07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_01cb6338-5e1f-403b-a658-9a8dbae260f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68f64668-f0a7-4581-ab1d-37920c92e07c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_01cb6338-5e1f-403b-a658-9a8dbae260f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_175c0847-a531-4bb4-af69-c4a36bfc7bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_01cb6338-5e1f-403b-a658-9a8dbae260f9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_175c0847-a531-4bb4-af69-c4a36bfc7bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9dc257db-6683-44dc-9d98-e8b98eab5162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_175c0847-a531-4bb4-af69-c4a36bfc7bfe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9dc257db-6683-44dc-9d98-e8b98eab5162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_216e55d3-ef74-4ede-a715-7dc582595cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_175c0847-a531-4bb4-af69-c4a36bfc7bfe" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_216e55d3-ef74-4ede-a715-7dc582595cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050d077e-d528-4362-bdaf-cea1e8f50024" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_68f64668-f0a7-4581-ab1d-37920c92e07c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050d077e-d528-4362-bdaf-cea1e8f50024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bacd962a-5532-4ce7-a7c0-66ee6dbc53dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_050d077e-d528-4362-bdaf-cea1e8f50024" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bacd962a-5532-4ce7-a7c0-66ee6dbc53dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffb35e28-da58-45d4-8bbd-fd57f5aa4e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c783fdb8-b4d7-4d5e-aaab-1f499f6cd0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffb35e28-da58-45d4-8bbd-fd57f5aa4e3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c783fdb8-b4d7-4d5e-aaab-1f499f6cd0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ba5b0c2d-e8dd-49f5-93d9-a906a0ce4270" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffb35e28-da58-45d4-8bbd-fd57f5aa4e3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ba5b0c2d-e8dd-49f5-93d9-a906a0ce4270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0fd06bcd-a6e1-4e13-ad8f-c64e85522cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffb35e28-da58-45d4-8bbd-fd57f5aa4e3e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0fd06bcd-a6e1-4e13-ad8f-c64e85522cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f90c775b-20e6-4e69-93b6-a9b172e7ad96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ffb35e28-da58-45d4-8bbd-fd57f5aa4e3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f90c775b-20e6-4e69-93b6-a9b172e7ad96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/NetIncomeLossperShareDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#NetIncomeLossperShareDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/NetIncomeLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1146ca75-3375-4180-8fc1-c969e0657af9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fde4da77-83eb-4c4b-bd64-8183e5df2843" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1146ca75-3375-4180-8fc1-c969e0657af9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fde4da77-83eb-4c4b-bd64-8183e5df2843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2f217416-cfa7-4300-ade8-44c8a89b92fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fde4da77-83eb-4c4b-bd64-8183e5df2843" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2f217416-cfa7-4300-ade8-44c8a89b92fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2f217416-cfa7-4300-ade8-44c8a89b92fe" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2fe5d4ed-9b56-4f4f-bf74-6566baf3b005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2fe5d4ed-9b56-4f4f-bf74-6566baf3b005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6def8a3a-3546-4447-8129-f526672a0862" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6def8a3a-3546-4447-8129-f526672a0862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember_40f0b948-8376-4dea-b61c-1edd633994bb" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:to="loc_agio_PerformanceStockUnitMember_40f0b948-8376-4dea-b61c-1edd633994bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember_022709ea-fae1-46b9-8f77-c0132c6b24f5" xlink:href="agio-20231231.xsd#agio_EmployeePurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_984c4317-d593-4ea2-832b-20194190ec2f" xlink:to="loc_agio_EmployeePurchasePlanMember_022709ea-fae1-46b9-8f77-c0132c6b24f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a97c4f98-2499-42aa-b324-627faf2a211d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_fde4da77-83eb-4c4b-bd64-8183e5df2843" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a97c4f98-2499-42aa-b324-627faf2a211d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b6fcbe06-a39f-4416-b6d2-6a2d8eda1638" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a97c4f98-2499-42aa-b324-627faf2a211d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b6fcbe06-a39f-4416-b6d2-6a2d8eda1638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_25ab4b64-488e-416f-85ff-3abb9ca79ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e93201b8-dabb-4f33-bbe2-518db00bb874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25ab4b64-488e-416f-85ff-3abb9ca79ab2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e93201b8-dabb-4f33-bbe2-518db00bb874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_859b6485-08ca-47bd-8709-ce1bc692b20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25ab4b64-488e-416f-85ff-3abb9ca79ab2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_859b6485-08ca-47bd-8709-ce1bc692b20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_617cc6fa-1c27-4005-b8fa-647c62cb608b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25ab4b64-488e-416f-85ff-3abb9ca79ab2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_617cc6fa-1c27-4005-b8fa-647c62cb608b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2203fdd3-991f-4268-a4ba-263f9c581244" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6a4c2d60-f165-43b5-9cbe-feca06b8f76e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2203fdd3-991f-4268-a4ba-263f9c581244" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6a4c2d60-f165-43b5-9cbe-feca06b8f76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e6383610-35ad-4178-b0f2-8990351b8961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2203fdd3-991f-4268-a4ba-263f9c581244" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e6383610-35ad-4178-b0f2-8990351b8961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_80625cb5-c4af-4226-b27e-4a62878fb3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2203fdd3-991f-4268-a4ba-263f9c581244" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_80625cb5-c4af-4226-b27e-4a62878fb3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments_8287a156-9546-47ed-aeb4-2edbd072c761" xlink:href="agio-20231231.xsd#agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2203fdd3-991f-4268-a4ba-263f9c581244" xlink:to="loc_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments_8287a156-9546-47ed-aeb4-2edbd072c761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2c75e26f-04f5-4818-a63d-b5ac446020d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2203fdd3-991f-4268-a4ba-263f9c581244" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2c75e26f-04f5-4818-a63d-b5ac446020d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_6192d62e-2011-447f-84fd-c4430c067622" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2203fdd3-991f-4268-a4ba-263f9c581244" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_6192d62e-2011-447f-84fd-c4430c067622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5c667465-c74d-4c79-ae34-be35b2a7fd19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2203fdd3-991f-4268-a4ba-263f9c581244" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_5c667465-c74d-4c79-ae34-be35b2a7fd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0a0ef89f-28ec-4265-b57e-eab6c237025e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a0ef89f-28ec-4265-b57e-eab6c237025e" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c6865310-06fe-450c-aed9-51691663f22d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c6865310-06fe-450c-aed9-51691663f22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6da786d5-61e9-4c5d-85fd-443664a24f65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6da786d5-61e9-4c5d-85fd-443664a24f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_44f6c628-95ea-485a-ae9f-9a8ea7ced917" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_44f6c628-95ea-485a-ae9f-9a8ea7ced917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a09d2020-c9f8-470b-a256-89ee678b48b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a09d2020-c9f8-470b-a256-89ee678b48b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredTaxAssetsOperatingLeaseLiability_4863da76-a203-4cba-8d1d-e2044fc703fa" xlink:href="agio-20231231.xsd#agio_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:to="loc_agio_DeferredTaxAssetsOperatingLeaseLiability_4863da76-a203-4cba-8d1d-e2044fc703fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_0496219d-aa35-4731-8b11-21afab7cd956" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_0496219d-aa35-4731-8b11-21afab7cd956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c18058a7-6949-4589-ad6f-e84ec281eade" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c18058a7-6949-4589-ad6f-e84ec281eade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c718ded9-7ce1-44d4-a8d1-e428e6d4c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_f30114e2-cbc7-4a8d-9b4c-ffb8475d6ccc" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c718ded9-7ce1-44d4-a8d1-e428e6d4c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e726a818-b5a9-464e-bf25-856c42eb47fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a0ef89f-28ec-4265-b57e-eab6c237025e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e726a818-b5a9-464e-bf25-856c42eb47fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_5397c906-62a6-4e0a-861c-b57966170381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a0ef89f-28ec-4265-b57e-eab6c237025e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_5397c906-62a6-4e0a-861c-b57966170381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ce3f2333-7ec1-49b4-9c2a-fb37b09884d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a0ef89f-28ec-4265-b57e-eab6c237025e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_ce3f2333-7ec1-49b4-9c2a-fb37b09884d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d2488674-62c0-415c-8275-1ea35430217a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0a0ef89f-28ec-4265-b57e-eab6c237025e" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d2488674-62c0-415c-8275-1ea35430217a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e5bd4018-6c5b-409b-a0e2-9940484404f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:href="agio-20231231.xsd#agio_IncomeTaxesDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e5bd4018-6c5b-409b-a0e2-9940484404f8" xlink:to="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_c87f0d29-a8c9-4ef9-8c2c-849090d524fc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:to="loc_srt_StatementGeographicalAxis_c87f0d29-a8c9-4ef9-8c2c-849090d524fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ab1ea70e-9579-4ab3-b3ff-39f23698f178" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_c87f0d29-a8c9-4ef9-8c2c-849090d524fc" xlink:to="loc_srt_SegmentGeographicalDomain_ab1ea70e-9579-4ab3-b3ff-39f23698f178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b3d810d5-7873-4b30-856d-71a229c46c40" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ab1ea70e-9579-4ab3-b3ff-39f23698f178" xlink:to="loc_country_US_b3d810d5-7873-4b30-856d-71a229c46c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_2186fe05-dd80-4d50-a66a-23025e0721aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ab1ea70e-9579-4ab3-b3ff-39f23698f178" xlink:to="loc_us-gaap_NonUsMember_2186fe05-dd80-4d50-a66a-23025e0721aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_506998ea-95da-46eb-a392-3d90d0a5933f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_506998ea-95da-46eb-a392-3d90d0a5933f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_506998ea-95da-46eb-a392-3d90d0a5933f" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_adbfa02e-d8fb-4bd1-ad6c-2b60b5db1cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:to="loc_us-gaap_DomesticCountryMember_adbfa02e-d8fb-4bd1-ad6c-2b60b5db1cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_a87e06e7-c008-438a-8943-efa1761a979b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_a87e06e7-c008-438a-8943-efa1761a979b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_00839ae3-b1fc-4e65-b45c-af1f3c50a923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_67655b6e-3181-49c9-85c3-2e2c764d1f23" xlink:to="loc_us-gaap_ForeignCountryMember_00839ae3-b1fc-4e65-b45c-af1f3c50a923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2210320a-2c1f-4610-960f-4abe628c0be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2210320a-2c1f-4610-960f-4abe628c0be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0c4749b2-1754-4acb-9a8e-26529bb6eaef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2210320a-2c1f-4610-960f-4abe628c0be5" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0c4749b2-1754-4acb-9a8e-26529bb6eaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_aa2ec4fa-a070-4fa0-a18c-b8d97266e881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0c4749b2-1754-4acb-9a8e-26529bb6eaef" xlink:to="loc_us-gaap_ResearchMember_aa2ec4fa-a070-4fa0-a18c-b8d97266e881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_FederalOrphanDrugTaxCreditMember_538a5a98-7ca5-465f-9b10-a03b3d0e336d" xlink:href="agio-20231231.xsd#agio_FederalOrphanDrugTaxCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0c4749b2-1754-4acb-9a8e-26529bb6eaef" xlink:to="loc_agio_FederalOrphanDrugTaxCreditMember_538a5a98-7ca5-465f-9b10-a03b3d0e336d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_159113a1-6c92-48ec-b5e1-31031e752829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_159113a1-6c92-48ec-b5e1-31031e752829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1d0c375a-89a8-4b2d-b9b8-ad4b43e4a8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_159113a1-6c92-48ec-b5e1-31031e752829" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1d0c375a-89a8-4b2d-b9b8-ad4b43e4a8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_504c9162-429d-4915-a8c0-83921375275e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1d0c375a-89a8-4b2d-b9b8-ad4b43e4a8c1" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_504c9162-429d-4915-a8c0-83921375275e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:href="agio-20231231.xsd#agio_IncomeTaxesDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureTable_8a024e3e-1d3f-43a2-b78f-a0ed96c0928d" xlink:to="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_11e2f8a8-4bdb-41a9-944d-2233314e0abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_11e2f8a8-4bdb-41a9-944d-2233314e0abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod_8cc1c4ad-0951-437b-a1a4-81aa5d5208ff" xlink:href="agio-20231231.xsd#agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod_8cc1c4ad-0951-437b-a1a4-81aa5d5208ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_bfe65771-8d6a-4715-868d-d75ae8e84993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_bfe65771-8d6a-4715-868d-d75ae8e84993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_afd08272-9f1b-47b9-a61f-4be5435cfd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_afd08272-9f1b-47b9-a61f-4be5435cfd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PercentageOfStockholdersOwnershipIncrease_3c750255-25e6-4f07-998e-fd6f2070904a" xlink:href="agio-20231231.xsd#agio_PercentageOfStockholdersOwnershipIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_agio_PercentageOfStockholdersOwnershipIncrease_3c750255-25e6-4f07-998e-fd6f2070904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PeriodOfChangeInStockholdersOwnership_b84ccd52-ab7a-45ed-9bfa-4ce451019505" xlink:href="agio-20231231.xsd#agio_PeriodOfChangeInStockholdersOwnership"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_agio_PeriodOfChangeInStockholdersOwnership_b84ccd52-ab7a-45ed-9bfa-4ce451019505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a054fdaa-cb0e-4bfa-8c1a-7a90897deb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a054fdaa-cb0e-4bfa-8c1a-7a90897deb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_bc02b054-746a-4ce2-8afa-58cf210e8e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_bc02b054-746a-4ce2-8afa-58cf210e8e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_00919ba3-4413-4e9f-b002-196b0d659a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_00919ba3-4413-4e9f-b002-196b0d659a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_422e82ce-6303-4cf0-826f-ba2bf6b1466a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_422e82ce-6303-4cf0-826f-ba2bf6b1466a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NumberOfStatesFederalOrForeignInAuditingProcess_11624336-c729-43c6-a07e-aa76b1e5e32c" xlink:href="agio-20231231.xsd#agio_NumberOfStatesFederalOrForeignInAuditingProcess"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_agio_NumberOfStatesFederalOrForeignInAuditingProcess_11624336-c729-43c6-a07e-aa76b1e5e32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_700ae47c-31df-4f3a-b514-59c46e053c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_IncomeTaxesDisclosureLineItems_84debd68-9635-4ff1-be84-41203692506b" xlink:to="loc_us-gaap_IncomeTaxReceivable_700ae47c-31df-4f3a-b514-59c46e053c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesChangesinValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxesChangesinValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_88a48215-89cc-49ae-be9c-17d4a6b09653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DeferredTaxAssetsValuationAllowanceRollForward_9145db09-36ed-40ac-be2c-952e3cfb21aa" xlink:href="agio-20231231.xsd#agio_DeferredTaxAssetsValuationAllowanceRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88a48215-89cc-49ae-be9c-17d4a6b09653" xlink:to="loc_agio_DeferredTaxAssetsValuationAllowanceRollForward_9145db09-36ed-40ac-be2c-952e3cfb21aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b366f755-a26c-4096-86a2-8cff50f34cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_DeferredTaxAssetsValuationAllowanceRollForward_9145db09-36ed-40ac-be2c-952e3cfb21aa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b366f755-a26c-4096-86a2-8cff50f34cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4185715a-ff62-4095-b856-6009b3b40475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_DeferredTaxAssetsValuationAllowanceRollForward_9145db09-36ed-40ac-be2c-952e3cfb21aa" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_4185715a-ff62-4095-b856-6009b3b40475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f3506dbf-c39b-4e11-a65b-473934243baa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_DeferredTaxAssetsValuationAllowanceRollForward_9145db09-36ed-40ac-be2c-952e3cfb21aa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_f3506dbf-c39b-4e11-a65b-473934243baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0ff856a7-d7ab-4c0d-a453-3fadf8def727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_83d1e00a-eae9-49d9-b271-b7d0d0314322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0ff856a7-d7ab-4c0d-a453-3fadf8def727" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_83d1e00a-eae9-49d9-b271-b7d0d0314322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6f9a3c7a-f3f6-4440-b081-bced35703f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_83d1e00a-eae9-49d9-b271-b7d0d0314322" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6f9a3c7a-f3f6-4440-b081-bced35703f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_305ea40c-1a26-4fdf-b376-4d2df1c8e126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_83d1e00a-eae9-49d9-b271-b7d0d0314322" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_305ea40c-1a26-4fdf-b376-4d2df1c8e126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_18019a1f-ca78-4baa-8da1-dc3cc0fd0ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_83d1e00a-eae9-49d9-b271-b7d0d0314322" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_18019a1f-ca78-4baa-8da1-dc3cc0fd0ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9a100084-c46f-46c4-a403-7e68e4de10dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_737206ee-aa0d-4f38-9446-db62edf44155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9a100084-c46f-46c4-a403-7e68e4de10dd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_737206ee-aa0d-4f38-9446-db62edf44155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_14a6d382-2003-4bc6-9d1d-d7a840e17294" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_737206ee-aa0d-4f38-9446-db62edf44155" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_14a6d382-2003-4bc6-9d1d-d7a840e17294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_14a6d382-2003-4bc6-9d1d-d7a840e17294" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_LaboratoryEquipmentMember_fe72d5df-f0eb-4d99-ade3-318f346937e1" xlink:href="agio-20231231.xsd#agio_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_agio_LaboratoryEquipmentMember_fe72d5df-f0eb-4d99-ade3-318f346937e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_ComputerEquipmentAndSoftwareMember_878c8b3b-914d-44e0-a883-da826c2b5867" xlink:href="agio-20231231.xsd#agio_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_agio_ComputerEquipmentAndSoftwareMember_878c8b3b-914d-44e0-a883-da826c2b5867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_79a01129-2b57-41b5-b859-b91da4e067d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_79a01129-2b57-41b5-b859-b91da4e067d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_37749154-cca9-4557-a3a9-9461c1d6a1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_37749154-cca9-4557-a3a9-9461c1d6a1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_3f8fc54c-ab45-4a37-9270-a0bd5be07e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_us-gaap_OfficeEquipmentMember_3f8fc54c-ab45-4a37-9270-a0bd5be07e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_83ba791c-1e88-4a34-a718-3a8eeae47ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e2544697-c3f9-4958-9ad0-0d4f887694a6" xlink:to="loc_us-gaap_ConstructionInProgressMember_83ba791c-1e88-4a34-a718-3a8eeae47ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_737206ee-aa0d-4f38-9446-db62edf44155" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5770fd70-5d93-4716-a3cb-c1a204a1f156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5770fd70-5d93-4716-a3cb-c1a204a1f156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d787ef5c-8690-4293-a400-7664b92a2da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d787ef5c-8690-4293-a400-7664b92a2da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_69cf48cb-e55d-4a8a-ae8b-e5221261848e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_81b5560b-a484-4879-b15e-035d94f585de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_69cf48cb-e55d-4a8a-ae8b-e5221261848e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/PropertyandEquipmentnetAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#PropertyandEquipmentnetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/PropertyandEquipmentnetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d11ca982-0f83-4e49-9c7b-90f331599a30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d59e3608-3ab7-456d-bf65-4976c3cb40d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d11ca982-0f83-4e49-9c7b-90f331599a30" xlink:to="loc_us-gaap_Depreciation_d59e3608-3ab7-456d-bf65-4976c3cb40d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CommonStockDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#CommonStockDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f95053cc-d2a5-4960-ad91-3a5d85612fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_30554e9e-a7a9-4ac0-a86e-aba4e580f74e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f95053cc-d2a5-4960-ad91-3a5d85612fe1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_30554e9e-a7a9-4ac0-a86e-aba4e580f74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NumberOfVotesPerShare_c5f88711-32c3-4a91-adef-4f7cda118911" xlink:href="agio-20231231.xsd#agio_NumberOfVotesPerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f95053cc-d2a5-4960-ad91-3a5d85612fe1" xlink:to="loc_agio_NumberOfVotesPerShare_c5f88711-32c3-4a91-adef-4f7cda118911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/ShareRepurchaseProgramDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#ShareRepurchaseProgramDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/ShareRepurchaseProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2311c47f-ade5-4be6-bd97-767bac719e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_82d90910-1646-4c02-9cbb-67ee8c16877c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2311c47f-ade5-4be6-bd97-767bac719e2a" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_82d90910-1646-4c02-9cbb-67ee8c16877c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_0a31361f-0c4f-465d-bc73-b32300db8785" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_82d90910-1646-4c02-9cbb-67ee8c16877c" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_0a31361f-0c4f-465d-bc73-b32300db8785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_0a31361f-0c4f-465d-bc73-b32300db8785" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramMember_95dcbd65-b01f-4bca-91e5-db81ef3bc7fc" xlink:href="agio-20231231.xsd#agio_March252021RepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:to="loc_agio_March252021RepurchaseProgramMember_95dcbd65-b01f-4bca-91e5-db81ef3bc7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_10d188ae-58e4-40e1-9ac8-2df0337a9334" xlink:href="agio-20231231.xsd#agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:to="loc_agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember_10d188ae-58e4-40e1-9ac8-2df0337a9334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_c5aa2e64-3649-4460-b27a-3790dec22c32" xlink:href="agio-20231231.xsd#agio_March252021RepurchaseProgramRule10b51RepurchaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_f796f8d7-2ef9-4f05-804c-0c6a6e3d4742" xlink:to="loc_agio_March252021RepurchaseProgramRule10b51RepurchaseMember_c5aa2e64-3649-4460-b27a-3790dec22c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_82d90910-1646-4c02-9cbb-67ee8c16877c" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4629ebb9-8470-4a95-86da-634cb6ff714b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_4629ebb9-8470-4a95-86da-634cb6ff714b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7febe540-60d3-4e6b-bb7d-433af1aa45ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7febe540-60d3-4e6b-bb7d-433af1aa45ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5ae40161-dee9-4f82-b194-de989f07e226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_5ae40161-dee9-4f82-b194-de989f07e226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_200b6fac-145f-4e37-b293-3d4c1330e1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_e887c6ef-739f-418d-9e7f-3e2c1beea127" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_200b6fac-145f-4e37-b293-3d4c1330e1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_304ec580-04eb-487c-bddd-a4321ea6890d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3cfd4278-e7de-4443-97c0-3e7fca48aa8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_304ec580-04eb-487c-bddd-a4321ea6890d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3cfd4278-e7de-4443-97c0-3e7fca48aa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c9eb3e3f-159d-40a4-9167-985567fd8cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3cfd4278-e7de-4443-97c0-3e7fca48aa8d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c9eb3e3f-159d-40a4-9167-985567fd8cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7f7951e-376a-4b50-8f6c-8c250a3d8d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_c9eb3e3f-159d-40a4-9167-985567fd8cf4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7f7951e-376a-4b50-8f6c-8c250a3d8d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_524e5c9c-ee92-4e2f-9105-656cadc3480b" xlink:href="agio-20231231.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7f7951e-376a-4b50-8f6c-8c250a3d8d5d" xlink:to="loc_agio_AgiosOncologyBusinessMember_524e5c9c-ee92-4e2f-9105-656cadc3480b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d88318d9-b68e-4165-aabf-eae293634f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3cfd4278-e7de-4443-97c0-3e7fca48aa8d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d88318d9-b68e-4165-aabf-eae293634f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_2eae1c6b-0b59-4dfe-b37b-ad7b02365795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d88318d9-b68e-4165-aabf-eae293634f4c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_2eae1c6b-0b59-4dfe-b37b-ad7b02365795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5a637e20-c42b-4a05-ae26-08e9585d4964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_2eae1c6b-0b59-4dfe-b37b-ad7b02365795" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_5a637e20-c42b-4a05-ae26-08e9585d4964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_3cfd4278-e7de-4443-97c0-3e7fca48aa8d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_922d96ff-a06b-468a-9ed7-ebdbd5f4cc77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_922d96ff-a06b-468a-9ed7-ebdbd5f4cc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DiscontinuedOperationsTransactionAndInsuranceCosts_92d5e112-ac38-4a4d-81dd-0013c2a9f851" xlink:href="agio-20231231.xsd#agio_DiscontinuedOperationsTransactionAndInsuranceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_agio_DiscontinuedOperationsTransactionAndInsuranceCosts_92d5e112-ac38-4a4d-81dd-0013c2a9f851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DiscontinuedOperationsLiabilitiesDistributedNet_1515328a-61b5-44fd-8427-c01a160ed8e3" xlink:href="agio-20231231.xsd#agio_DiscontinuedOperationsLiabilitiesDistributedNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_agio_DiscontinuedOperationsLiabilitiesDistributedNet_1515328a-61b5-44fd-8427-c01a160ed8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_4c3ed381-c0d3-4794-a615-f809b2bdca44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_4c3ed381-c0d3-4794-a615-f809b2bdca44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_3967e5ef-44ff-4462-8ba5-a62f59d119cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_3967e5ef-44ff-4462-8ba5-a62f59d119cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_cb49e9e0-acae-44f4-8066-bcacc296ac56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_cb49e9e0-acae-44f4-8066-bcacc296ac56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_98cdf167-9566-4bc0-8f6a-63f9e632cae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_6683dc1e-dc0d-48ee-9fcd-da1a4358e562" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_98cdf167-9566-4bc0-8f6a-63f9e632cae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_13fe0760-07f3-4983-ac72-5f4d678dd4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71a7278d-e9df-4f3e-b770-844a6cb28fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_13fe0760-07f3-4983-ac72-5f4d678dd4e0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71a7278d-e9df-4f3e-b770-844a6cb28fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18d52fb0-caa2-471d-ab4b-97db1c64648c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71a7278d-e9df-4f3e-b770-844a6cb28fc9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18d52fb0-caa2-471d-ab4b-97db1c64648c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671dbbd0-f7c3-462d-a960-c980f24b95b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_18d52fb0-caa2-471d-ab4b-97db1c64648c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671dbbd0-f7c3-462d-a960-c980f24b95b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_1a7da678-5179-471a-b35a-16affeb76f4a" xlink:href="agio-20231231.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671dbbd0-f7c3-462d-a960-c980f24b95b3" xlink:to="loc_agio_AgiosOncologyBusinessMember_1a7da678-5179-471a-b35a-16affeb76f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_b4e4fbb3-1314-44e8-bcc2-321f9d1c3816" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71a7278d-e9df-4f3e-b770-844a6cb28fc9" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_b4e4fbb3-1314-44e8-bcc2-321f9d1c3816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8a5000a9-4ef2-434d-adb5-47682004a51e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_b4e4fbb3-1314-44e8-bcc2-321f9d1c3816" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8a5000a9-4ef2-434d-adb5-47682004a51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_eb643649-5fca-4ffd-9be7-b01666d368c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8a5000a9-4ef2-434d-adb5-47682004a51e" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_eb643649-5fca-4ffd-9be7-b01666d368c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71a7278d-e9df-4f3e-b770-844a6cb28fc9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_cd4483cd-2b06-4393-9a48-8cd781082397" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_cd4483cd-2b06-4393-9a48-8cd781082397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_e6a649dd-b3c4-4697-9eae-4b155f51026d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_e6a649dd-b3c4-4697-9eae-4b155f51026d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_GainLossOnSaleOfContingentPayments_a7ceea9e-8d4a-4e30-a1c9-f05e1c8b9ace" xlink:href="agio-20231231.xsd#agio_GainLossOnSaleOfContingentPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3539a860-8c71-43ce-a528-3a61c399a4c3" xlink:to="loc_agio_GainLossOnSaleOfContingentPayments_a7ceea9e-8d4a-4e30-a1c9-f05e1c8b9ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ce241be3-e082-4eac-8d5c-e26036368d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ce241be3-e082-4eac-8d5c-e26036368d96" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_052bd266-2090-4197-92fb-c08e18a7c061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_052bd266-2090-4197-92fb-c08e18a7c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8235a644-a98a-48d1-a64c-ebff89443316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_052bd266-2090-4197-92fb-c08e18a7c061" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8235a644-a98a-48d1-a64c-ebff89443316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_AgiosOncologyBusinessMember_1c32e2e1-3faa-4aa2-9c4e-fc536a08bb69" xlink:href="agio-20231231.xsd#agio_AgiosOncologyBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8235a644-a98a-48d1-a64c-ebff89443316" xlink:to="loc_agio_AgiosOncologyBusinessMember_1c32e2e1-3faa-4aa2-9c4e-fc536a08bb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_daa316c3-9929-4c29-b884-8a5fef14f02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_daa316c3-9929-4c29-b884-8a5fef14f02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a2d92bbf-33cf-4b7e-bbed-d144da696100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_daa316c3-9929-4c29-b884-8a5fef14f02e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a2d92bbf-33cf-4b7e-bbed-d144da696100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6476a407-140e-483a-a9af-b61a0df83e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a2d92bbf-33cf-4b7e-bbed-d144da696100" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_6476a407-140e-483a-a9af-b61a0df83e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_385ffb5b-93db-4ca7-aaf6-362956308bc2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:to="loc_srt_ProductOrServiceAxis_385ffb5b-93db-4ca7-aaf6-362956308bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_385ffb5b-93db-4ca7-aaf6-362956308bc2" xlink:to="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_df38e887-a2d5-4ca4-a298-23f337686798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:to="loc_us-gaap_ProductMember_df38e887-a2d5-4ca4-a298-23f337686798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueRelatedPartyMember_40878318-d75c-44c4-9cc9-7220737b35e6" xlink:href="agio-20231231.xsd#agio_CollaborationRevenueRelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:to="loc_agio_CollaborationRevenueRelatedPartyMember_40878318-d75c-44c4-9cc9-7220737b35e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_CollaborationRevenueOtherMember_99fe8dd6-2556-465f-8a50-4029f21e2944" xlink:href="agio-20231231.xsd#agio_CollaborationRevenueOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:to="loc_agio_CollaborationRevenueOtherMember_99fe8dd6-2556-465f-8a50-4029f21e2944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_b816e094-05e0-42e7-95a7-c2ba8e47beda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7baee5e-a5cd-4a79-a8ce-778a029bc4ca" xlink:to="loc_us-gaap_RoyaltyMember_b816e094-05e0-42e7-95a7-c2ba8e47beda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_7c9b5387-9e7a-48dd-81b9-728c9f426fe6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract_fea0a43d-617e-457b-af25-be0035e44fad" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract_fea0a43d-617e-457b-af25-be0035e44fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_64c0f3d8-0168-43b1-bdc8-cca4e6c28919" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract_fea0a43d-617e-457b-af25-be0035e44fad" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_64c0f3d8-0168-43b1-bdc8-cca4e6c28919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_0443f96b-ed82-4490-a1f1-cc90bf97234d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_0443f96b-ed82-4490-a1f1-cc90bf97234d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_e4b6e66a-b73a-43b3-976d-eeae60d6d3af" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses_e4b6e66a-b73a-43b3-976d-eeae60d6d3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_7c215bb1-05f3-490e-87a1-a78a2608b304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_7c215bb1-05f3-490e-87a1-a78a2608b304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3b5a9b2a-1650-4e2d-a23b-3394b12519db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract_ae137fda-5747-427e-93cb-d20510889fb1" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_3b5a9b2a-1650-4e2d-a23b-3394b12519db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a01f4d56-c066-4b13-93c9-c0231d2cbcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a01f4d56-c066-4b13-93c9-c0231d2cbcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue_e3bbffa7-880a-4282-8453-10308111eebd" xlink:href="agio-20231231.xsd#agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue_e3bbffa7-880a-4282-8453-10308111eebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_7355865a-1c32-41cf-8392-a0c95e8289ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_7355865a-1c32-41cf-8392-a0c95e8289ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_71454d51-f14f-4eec-8013-26f7322142b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_71454d51-f14f-4eec-8013-26f7322142b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ed4a99ce-83d2-4f98-a384-96f836aef021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ed4a99ce-83d2-4f98-a384-96f836aef021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6f4f66b9-01b9-4963-9d39-03058327acfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_738b929f-5c87-4156-b369-5b31c043daae" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6f4f66b9-01b9-4963-9d39-03058327acfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/CommitmentsandContingentLiabilitiesDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#CommitmentsandContingentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/CommitmentsandContingentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a203071-b679-42d3-a7ad-8a7011f12d44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_NumberOfLegalProceedingsThatHaveMaterialEffect_3aaa8520-6c7f-488d-a5d1-e5f7deec9e5e" xlink:href="agio-20231231.xsd#agio_NumberOfLegalProceedingsThatHaveMaterialEffect"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5a203071-b679-42d3-a7ad-8a7011f12d44" xlink:to="loc_agio_NumberOfLegalProceedingsThatHaveMaterialEffect_3aaa8520-6c7f-488d-a5d1-e5f7deec9e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://agios.com/role/DefinedContributionBenefitPlanDetails" xlink:type="simple" xlink:href="agio-20231231.xsd#DefinedContributionBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://agios.com/role/DefinedContributionBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01eba82b-a111-4eb2-a802-e6f65935a42d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_8462a639-0490-4d34-a921-e870ecbc620a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01eba82b-a111-4eb2-a802-e6f65935a42d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_8462a639-0490-4d34-a921-e870ecbc620a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_36c7835e-3497-4ccd-94a4-333b9210bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_01eba82b-a111-4eb2-a802-e6f65935a42d" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_36c7835e-3497-4ccd-94a4-333b9210bc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_PerformanceStockUnitMember" xlink:href="agio-20231231.xsd#agio_PerformanceStockUnitMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_agio_PerformanceStockUnitMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_MarketBasedStockUnitsMember" xlink:href="agio-20231231.xsd#agio_MarketBasedStockUnitsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_agio_MarketBasedStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_agio_EmployeePurchasePlanMember" xlink:href="agio-20231231.xsd#agio_EmployeePurchasePlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_agio_EmployeePurchasePlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>agio-20231231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 agio-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2'!7T# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTJ>@!:*@6X#2%?ER.,;N<]<8^G-3 G'(P?3- "T56>^6-E#@+N)5=S!2Q[
MXZ@'\C]:476Y057CW)&._/'''//TXH L456DO%C#_+E@<*N1\W^3D?@>W-6%
M;<H(H 6BBB@ HHJ)I65PNS(]0: ):*JK>>9M*)O4C.\'Y3]#[?\ ZLUR=A\:
M_ 6J^*I/#%EXST"\\2QR/"^BP:I ]\DB!BZ- &\Q2H5B05^4*2<8. #MJ*S8
M?$%A=75[!;W<$\MB_E7:1RAFMY-B2!) /N-Y<D;X;!PZ'H:T%;<H.,<9H =1
M69<>(+*TU.'3IKB%+^X1Y;>T\U?.FC0H'=4SDJK2(&(X7<N2,UHJQ*@D 'V.
M10 ZBBN*\8?&CP)\/=6@TOQ/XR\/^'M3GB$\-EJFJP6LTD98H'5)'4E=RD9'
M&1CD\4 =K12*P89%+0 4444 %%%% !114$EUY;8V%ACJN3^@'UH GHJO]JR,
MA"1NQGH!@=3Z?_JIRW&X@;&!R05/4=<''H<&@":BFJVY0<$9['K3J "BBN*\
M8?&CP)\/=6@TOQ/XR\/^'M3GB$\-EJFJP6LTD98H'5)'4E=RD9'&1CD\4 =K
M12*P89%5Y+HQ^9D)A6"CYCU(&,X'')'X'- %FBF;^!D<T^@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!NZOB?]O1OAUXX^*'P.^'?CN[
MT/2[&[U:ZUK4]7U.^CA-GI\$+9M7<LCQ1WC@1AA(HW0<+(R#;]?>)/%EEX5T
MNZO[V*_EAMP&:/3]/N+V=P?^><,$;R2'GD(K8[U\E_"7Q5;O^T+\4_BGXO\
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M73-9M4NH(M3MFM[A%8# 9#^.&!*L &5F5@QZ%M07[.TJ[<+S\S@>_P"''/\
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MKAN+I/(FN;B*WMT$$4<BRW4(:))C'$P8*7BSZ#X'T:^TO4U^#GPZO?\ A$O
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M %%%<]XW\?:'\.?"VI^(_$=_%I>B:;"9[J\FR5C0'&,*"S,3PJ@$LQ &20*
M,KQY\9O!_P ,]6\,Z9XEUN#3-1\2ZE'I.DV;*\D]W<.P4!8T4L%!9-TA 1=Z
M;F&X9ZY;S<VW80^2-I[X[CU'(_R#7Y_ZUJFE_M'>./A#XAL_B+X;U_Q1JOQ
ML-9TKPW#=0!O#FB6MO>7AA,2%YENY$2,W+$A3.(HLJD2L?6O'WC;XD)^V+HG
M@SP=XIN+C2+WPO+KU[H6J:59/I]JOF?94D:52ERZ;RTOE*26DC1/-2*9WMJ
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M4KY!.869VS]8)&%4*.F*8UG&QSL7[V[[O?&,_7''TXJ95VJ!G/&.:0#J***
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M%&.__P!?\<F@"6-=J*.N!C-/I%7: *6D 4444 %%%% !1110 4444 %%9?\
MPDEA_P ]OTH_X22P_P">WZ5/,AV9J45ER>([&*U>X,C,B=5CB=W/T15+'\ :
MQ?\ A:.A_P!S51]=&O!_[2HYD%F==17)?\+0T/\ NZK_ .":\_\ C5'_  M#
M0_[NJ_\ @FO/_C5',@LSK:*Y+_A:&A_W=5_\$UY_\:H_X6AH?]W5?_!->?\
MQJCF069UM%<E_P +0T/^[JO_ ()KS_XU1_PM#0_[NJ_^":\_^-4<R"S.MHKD
MO^%H:'_=U7_P37G_ ,:H_P"%H:'_ '=5_P#!->?_ !JCF069UM%<E_PM#0_[
MNJ_^":\_^-4?\+0T/^[JO_@FO/\ XU1S(+,ZVBN2_P"%H:'_ '=5_P#!->?_
M !JC_A:&A_W=5_\ !->?_&J.9!9G6T5R7_"T-#_NZK_X)KS_ .-4?\+0T/\
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M^%H:'_=U7_P37G_QJC_A:&A_W=5_\$UY_P#&J.9!9G6T5R7_  M#0_[NJ_\
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M-0%*ZJ#COH]YG]8J=_PM#0_[NJ_^":\_^-5[_,?%69UM%<E_PM#0_P"[JO\
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M+0T/^[JO_@FO/_C5',@LSK:*Y+_A:&A_W=5_\$UY_P#&J/\ A:&A_P!W5?\
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M0_[NJ_\ @FO/_C5'_"T-#_NZK_X)KS_XU1S(+,ZVBN2_X6AH?]W5?_!->?\
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M?/\ WOY_XT?/_>_G_C2T46 3Y_[W\_\ &CY_[W\_\:6BBP"?/_>_G_C1\_\
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MD=R@D=U9'&1O4;61I"+E32LKD\W4_4,,K.J@G>V2(SPX4=21VY[4DA,<<CD
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M1110 4444 %%%% !1110 4444 %%%% !1110.["BBB@04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 )_RS?\ W?ZFOQ+_ &5_B5\0
M_A5\1M1U?X:^&?\ A+M=FTN2VGT\V<UYLM3+"7?RH65A\RJ,Y[U^VBJS,(T
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M+<PQ!0PC$DE7_@D6\2+\4]SR'#:2N]DW%B?MF/NYYSG.<8 R,YKO/V _AO\
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M?^$5N!QUS]KM,\''?:/QK] ?VI]=LO#?[-GQ.O=1=X87T&\L1P9_](GC6"V
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M/18VATO2;5+:/<L:22XQNDEV*%:60[G<XPSN6QDUF,Z*-?+1.21C[VTKGWY
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MLN>#Z#&.,=!Q2N69]P8Y^[\W(V]QCIG/ITHHH :L8A 6)I%B#;O++<$XP<X
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MY?\ OFNP\K_;;\Z/*_VV_.M.4SYCC_L-S_S[R_\ ?-'V&Y_Y]Y?^^:[#RO\
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M[R_]\T?8;G_GWE_[YKL/*_VV_.CRO]MOSHY0YCC_ +#<_P#/O+_WS1]AN?\
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M/L-S_P ^\O\ WS78>5_MM^='E?[;?G1RAS''_8;G_GWE_P"^:/L-S_S[R_\
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MCE%S''_8;G_GWE_[YH^PW/\ S[R_]\UV'E?[;?G1Y7^VWYT<H<QQ_P!AN?\
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M_P#@';__ !%><\4<4?7,1_._O#^Q\O\ ^?$?N1Z-_P -$_$/_H8C_P" =O\
M_$4?\-$_$/\ Z&(_^ =O_P#$5YSQ1Q1]<Q'\[^\/['R__GQ'[D>C?\-$_$/_
M *&(_P#@';__ !%'_#1/Q#_Z&(_^ =O_ /$5YSQ1Q1]<Q'\[^\/['R__ )\1
M^Y'HW_#1/Q#_ .AB/_@';_\ Q%'_  T3\0_^AB/_ (!V_P#\17G/%'%'US$?
MSO[P_L?+_P#GQ'[D>C?\-$_$/_H8C_X!V_\ \11_PT3\0_\ H8C_ . =O_\
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M_P",UX[Q1Q7;]2PW\B^XOZ_B_P#GX_O/8O\ AKWXM_\ 0WM_X+K/_P",T?\
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M#'_G)HV?7\Z\C_5K =F:_6JAA_V'/_>7]:/[#G_O+^M;FSZ_G1L^OYU/^K6
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MU:P'9A]:J&'_ &'/_>7]:/[#G_O+^M;FSZ_G1L^OYT?ZM8#LP^M5##_L.?\
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M]+_\;KZ]\F+^XGY4>3%_<3\J/['PG8/]:LS_ )U]Q\A?\,F^,O\ G[TC_O\
M2_\ QNC_ (9-\9?\_>D?]_I?_C=?7ODQ?W$_*CR8O[B?E1_8^$[!_K5F?\Z^
MX^0O^&3?&7_/WI'_ '^E_P#C='_#)GC+_G[TC_O]+_\ &Z^O?)B_N)^5'DQ?
MW$_*C^Q\)V#_ %JS-Z<Z^X^._"OP-U_Q+#J:VUUIL;:7J$NES>=+(H+QJNYE
M_=\@EN/89K?7]F/Q0W_+]I6/^NLO_P ;KUWX*AE_X3I=_P#S-E^.G;"8%>E[
M>!AC^E>Y&$8I)(_,:V1X3$5959[R=WZGRO\ \,Q>*?\ G^TK_O[+_P#&Z/\
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M$/Q-:VFIZ'"^G"V$WG33C_60_+C]SS]WU[U,O[!?Q"906U3PVK'DA;JX(!]
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MO/\ <;]*-Y_N-^E !Y?T_*CR_I^5&\_W&_2C>?[C?I0 >7]/RH\OZ?E1O/\
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M/_!]??\ QZC_ (5[IG_/WKG_ (/K[_X]7344 <S_ ,*]TS_G[US_ ,'U]_\
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M/^?O7/\ P?7W_P >KIJ* .9_X5[IG_/WKG_@^OO_ (]1_P *]TS_ )^]<_\
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M_P#"O=,_Y^]<_P#!]??_ !ZC_A7NF?\ /WKG_@^OO_CU=-10!S/_  KW3/\
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MADM[+S&TZ8)]B1S()-KB8>7*L/S8GX;C>C ^I1>!F7"@HP^\&!YST]/UI[7
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M1=!_:N#_ .?A[5NHW5XK_P -3^&O^?+4O^_<7_QRC_AJ;PU_SY:E_P!^XO\
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M;Q*J11H$1%Z!0, #\*LUN?MU--02>XM%%%(T"BBB@#S/P/\ \EB^*'_<,_\
M2=J],KS/P/\ \EB^*'_<,_\ 2=J],H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,U_Y..;_L5O_;L5Z4GW
M5^E>:K_R<<W_ &*W_MV*]*3[J_2@!U%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5\Q?L3DM+\>R K#_ (6SKQ[;O^6 SUX'
MRE?PKZ=KYX\4?\$__@1XU\2:MK^M^!A?:MJE[-J%W<?VM?H))Y6+2/L6<*I)
M/\( '8"@#YT_:4\<:S/\:/C-XS^%[QZSJ'A+X91>%M6OK-Y"=+O)]6#R%6C8
M.)(K<7$K2QDB)H<N<H5/.?#CP;XM^'?Q6^$_C[0_A<W@--6U>VL=4\3:S\4+
M75XO$UM?!!*TB>:GGSL"]S'Y1VM(F?*?$>W[]\(_!7P3X"\'2>$] \,:7IOA
MF>+R;G34M5:.[4QK$QGW9\YF1%5FDW,W.XG-<5\,OV,_A#\'?%</B7PCX1BT
MO7+=)(K>\DN[BZ:!9-HD\L3R.$9PNTNH#;69=P#$&[H#Q#X!?!;P='^W=\?=
M;;3"NO:!<:7J&F2?;)U$,NHV,KWTH7< XD>1OO!@N %VUXY\)["W\<?LX_LI
M_#3Q']HL?AGXPUG6EUZ5)Y+9;B:WN+N6RL9)E(51<2ECY?#LT(\LJR5^BFA_
M#'P]X;\8^)O%.FV/V77?$IM3JUTLTA^T_9XO*@^0L53:G'R 9ZG)YKC;O]E'
MX7WWPDL?AA/X6MY? MC*)[;3'GG+PR"9IMZW'F><K;Y)3D.#B1EY4E2<P'S)
M<?#_ ,(_![2_VJ_!G@+Q1/-H\?@Z:\N/!ITR_,&@SMI9V2+J,LC0R-.K%RH!
M<JJKD+ 17!>-KCQ5XLA_9Q^'?_"$77CWP=<?#*RO5\+Q^*#X>BUR\$,'F)+(
MYVW0MDA@D$"!70R^8QV9S]M^"_V5_AE\//!_B?PMX?\ "]OIV@^)[>2VUFW6
M>X>6\C>(Q;&F>0R! CR84-PTCLNUF8EOCK]E7X9?$SP/X<\)>)_"]OJNA>'8
M%M=+@:>>.2TA6+R@B3)()<% F[+G<8T)R5!!= ?*'PNT;Q+X'_9M_:G\#:QX
M<M_"7AS2M!OK_2?"\WB:WUF[TH7>GW+SVTDD3[HH-R+)$'C0D3.VZ4DD9.F?
M!WP[\&/!G[*WQ/T&*_;X@^(O$WA[3=4U[4[N2ZGEM;RQEBEM?+D8QQJL3""/
M"AD1$&[(R?MKPO\ L\^ /!GPSU3X?Z-X=@L/">JPW-O?V,<DC-=K<*4E\R9F
M,KDH=FXN2%55!"JH%B^^!?@S4O#?@KP_<:1YFC^"[JRO=!M?M4X%E/:1F.V?
M<) S[%.,2%@<<@GFIN!\;ZM\(? W[0VM?M)^*_B[+>6'B+PKJ=[I.GNTETR>
M'-+M[/=::A'91R;W656:<[@8Y6C?8J[FSI?$<2>#O"O[/'[0">)H?$UAX-DC
MTGQ!XHU#1+FSGU'1KQA:"_DBFD:Y=H]Q,8_>>8]V95!1B&^B?BG^QG\'_C5X
MHE\1>,O!T.KZQ-$D,UTEY<VIG5>%,BP2HKL%PNX@MM1%)(10,3]ICX,^,?B5
MX!L/AQX 7P;X?\'7D/V+6&UC3I)7L;=9(3";"!%$1=524X8J5982C(P#J[H#
MD/V/]'/Q*^(7Q8^.TRV<MGXTU8V'A^Y@M54OI-B3:K,)"3)&9S%&7B8(=]LK
MXQA5Z#X2V)T']L3X^'4'A@.N:;X?U;2K4W$327-G';2VTLJ)NR%29&1LC S'
MV89]H^'/PWT?X6^!- \*>'H5M-,T>S2UA)BC61L#YI7V*J&1V+.[!1N=B2*Q
M/%?P-TSQ1\4O#'Q!AU?4] \2:%#-9^=HX@C34;.1D8VMV'B<RQ*4RJY&QG=E
M(8@B0/E[2V^+4O[9O[0S?"K_ (0UF7_A'EU)O&/VG(8Z;F'[-Y'48\S=NQUX
MKHYO@QXK^'OP-_:,\<^/]=T_5OB!XR\/WLNJQZ)$8]-M8K:QN([6"W+J)&"H
M^"SGT&"P=W^FM#^%OA[PWXR\5>+--LVMO$/BC[(-7O?/D8W(MD9(/E9BJ;48
MK\@&>I!K3\3>$]/\7^&]4T#58A<Z1JEK+8W=MRF^"2-D= RD%<JQ&0>E/F _
M+WX=:/\ $+]F'6?@Y\>?'C6?CKP7J_AVQT2]O5@EF_X1.RF$<=J4559H]D+K
MN=4(=Y+B,G?.LDOU=\9=;L=9_:W_ &5=1L+NWU.POX/$T]O-:R++%=0MIL;)
M)&P;8P.4P03D,,9'(^@5^%WAY?AY_P ((MBH\(C2!H::;YLF!9B+R?*W[]^/
M+ 7.<GDDD]/+=6_82^"^M^$=&\,7OA>ZN="T:6YGT^SDUS42MNUP8FF"G[1G
M:S0HQ7.-VYAAG8FN8#D_^"AVI6>I?L\ZAX#AO(?^$M\7ZAI]AH&EM<(DM_,M
M_;2-M)(4*HV[I'VJI=06RZ!M3]KG36\5>(/@3X?T^:WGU63XB:?J8L6N8E>2
MTLX;B6[E".V66./&[;DY>,$'.#VGPK_9!^$/P5UR36/!_@FQTS56*E;V>26\
MFAVAU_=/.\ABRLC!O+*[A@'(4 ;C? [2KKXU6OQ+U'5M4UC5-/T^73M*TN_^
MSO8:2LHC\Z6V41"1)I/+(:1I&9ED92=@15D#T2,;4 ))P.II]-CC$:*HZ*,"
MG4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?XG?\D]\4_\
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MHH#DCV(?LZ_W4_[YH^SK_=3_ +YJ:B@.2/8A^SK_ '4_[YH^SK_=3_OFIJ*
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MHH **** "BBB@ HHHH **** "BBB@ HHHH ****5@"H6MPS$D]?8?YZU-13
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M_P .Q>()==&A:6NMS3)<2:DEC&+F21(I(8W:3&XLL4TL8.<A9' P&(.#X>^
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M@%HG_@ZF_P#D2@#I:*YK^T/%_P#T M$_\'4W_P B4?VAXO\ ^@%HG_@ZF_\
MD2@#I:*YK^T/%_\ T M$_P#!U-_\B4?VAXO_ .@%HG_@ZF_^1* .EHKFO[0\
M7_\ 0"T3_P '4W_R)1_:'B__ * 6B?\ @ZF_^1* .EJ)OO'Z'^E<_P#VAXO_
M .@%HG_@ZF_^1*B.I>+EPTF@Z.$W8;R]8F8A>.0/LO/TH Y[]GO_ )(_H'UN
M/_1\M>EUXM\!M0\1?\*JT)+#2M+NK8"X/G3:E+"2WGR\;?LQ_/->AKJ/C!E!
M.@Z(#CD?VU-_\B4 =-17-?VAXO\ ^@%HG_@ZF_\ D2C^T/%__0"T3_P=3?\
MR)0!TM%<U_:'B_\ Z 6B?^#J;_Y$H_M#Q?\ ] +1/_!U-_\ (E '2T5S7]H>
M+_\ H!:)_P"#J;_Y$H_M#Q?_ - +1/\ P=3?_(E '2T5S7]H>+_^@%HG_@ZF
M_P#D2C^T/%__ $ M$_\ !U-_\B4 =+17-?VAXO\ ^@%HG_@ZF_\ D2C^T/%_
M_0"T3_P=3?\ R)0!TM%<U_:'B_\ Z 6B?^#J;_Y$H_M#Q?\ ] +1/_!U-_\
M(E '2T5S7]H>+_\ H!:)_P"#J;_Y$H_M#Q?_ - +1/\ P=3?_(E '2T5S7]H
M>+_^@%HG_@ZF_P#D2C^T/%__ $ M$_\ !U-_\B4 =+17-?VAXO\ ^@%HG_@Z
MF_\ D2C^T/%__0"T3_P=3?\ R)0!TM%<U_:'B_\ Z 6B?^#J;_Y$H_M#Q?\
M] +1/_!U-_\ (E '2T5S7]H>+_\ H!:)_P"#J;_Y$H_M#Q?_ - +1/\ P=3?
M_(E '2T5S7]H>+_^@%HG_@ZF_P#D2C^T/%__ $ M$_\ !U-_\B4 =+17-?VA
MXO\ ^@%HG_@ZF_\ D2C^T/%__0"T3_P=3?\ R)0!R_P7^_XZ_P"QLO\ ^25Z
M;7B_PEO/$4*^,VM-+TJ?=XHO6E\[4Y8@C83<%/V<[@#T/&1S@=*]"&I>+VP1
MH>AD?]AJ;_Y$H Z:BN:_M#Q?_P! +1/_  =3?_(E']H>+_\ H!:)_P"#J;_Y
M$H Z6BN:_M#Q?_T M$_\'4W_ ,B4?VAXO_Z 6B?^#J;_ .1* .EHKFO[0\7_
M /0"T3_P=3?_ ")1_:'B_P#Z 6B?^#J;_P"1* .EHKFO[0\7_P#0"T3_ ,'4
MW_R)1_:'B_\ Z 6B?^#J;_Y$H Z6BN:_M#Q?_P! +1/_  =3?_(E']H>+_\
MH!:)_P"#J;_Y$H Z6BN:_M#Q?_T M$_\'4W_ ,B4?VAXO_Z 6B?^#J;_ .1*
M .EHKFO[0\7_ /0"T3_P=3?_ ")1_:'B_P#Z 6B?^#J;_P"1* .EHKFO[0\7
M_P#0"T3_ ,'4W_R)1_:'B_\ Z 6B?^#J;_Y$H Z6BN:_M#Q?_P! +1/_  =3
M?_(E']H>+_\ H!:)_P"#J;_Y$H Z6BN:_M#Q?_T M$_\'4W_ ,B4?VAXO_Z
M6B?^#J;_ .1* .EHKFO[0\7_ /0"T3_P=3?_ ")1_:'B_P#Z 6B?^#J;_P"1
M* .EHKFO[0\7_P#0"T3_ ,'4W_R)1_:'B_\ Z 6B?^#J;_Y$H Z6BN:_M#Q?
M_P! +1/_  =3?_(E']H>+_\ H!:)_P"#J;_Y$H YCP/_ ,EB^*'_ '#/_2=J
M],KQ;P?J'B!/BQ\1/)TS2Y+QQIYN89-2E1(@('"E'^SG?GOPN/>O0EU+Q@R
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M/NK]*\7_ +0\1#X^;_[+TDZB?#@!MAJDOEB'[6<R>9]GZY&-NW\:]$6_\7@
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MJP8 @Y![TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH C\B/_ )YK_P!\BCR(_P#GFO\ WR*DHH C\B/_ )YK_P!\BCR(_P#GFO\
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MU_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\
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M^$5P8P?E/^E]<>O->E"&-N2BDGV%><+_ ,G'-_V*W_MV*]*3[J_2@!OD1_\
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M /<#_4K_ *B/_)?^"?I3]JC_ +R_G1]JC_O+^=?FMA?[J_E1A?[J_E1_;_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>9K_ ,G'-_V*W_MV*]*3[J_2O-5_Y..;_L5O_;L5Z4GW5^E #J*** "BBB@
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MYUN?\(_;>A_.C_A'[;T/YT?ZLX[R#ZS$P]A_V?SHV'_9_.MS_A'[;T/YT?\
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M</\ 6[+O[WW'R;Y,G_/)_P#ODT>3)_SR?_ODU]9?\,@^%/\ H*:O_P!_HO\
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M)_SR?_ODT>3)_P \G_[Y-?67_#(/A3_H*:O_ -_HO_C='_#(/A3_ *"FK_\
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M(O\ XW1_PRQX:_Y_=2_[^1?_ !NCD8?ZO8T^8./[WZ'_  HX_O?H?\*^G_\
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M%E^%/^AGT/\ \&47^-'_  LOPI_T,^A_^#*+_&NFQ1B@#F?^%E^%/^AGT/\
M\&47^-'_  LOPI_T,^A_^#*+_&NFQ1B@#F?^%E^%/^AGT/\ \&47^-'_  LO
MPI_T,^A_^#*+_&NFQ1B@#F?^%E^%/^AGT/\ \&47^-'_  LOPI_T,^A_^#*+
M_&NFQ1B@#F?^%E^%/^AGT/\ \&47^-'_  LOPI_T,^A_^#*+_&NFQ1B@#F?^
M%E^%/^AGT/\ \&47^-'_  LOPI_T,^A_^#*+_&NFQ1B@#F?^%E^%/^AGT/\
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M3_"3J&7Q3H14]#_:<7^-<UX'4_\ "Y/B><CY?[,P0HW?\>[=3W'L>E>EJN%
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M[83!KTO=TPIQ^% ]>H_)HR:9N/\ </Z4;O\ 8/Z4!J/R:,FF;O\ 8/Z4;O\
M8/Z4!J/R:,FF;O\ 8/Z4;O\ 8/Z4!J/R:,FF;O\ 8/Z4;O\ 8/Z4!J/R:,FF
M;O\ 8/Z4;O\ 8/Z4!J/R:,FF;O\ 8/Z4;O\ 8/Z4!J/R:,FF;O\ 8/Z4;O\
M8/Z4!J/R:,FF;O\ 8/Z4;O\ 8/Z4!J/R:,FF;O\ 8/Z4;O\ 8/Z4!J/R:,FF
M;O\ 8/Z4;O\ 8/Z4!J/R:,FF;O\ 8/Z4;O\ 8/Z4!J/R:,FF;O\ 8/Z4;O\
M8/Z4!J.W&C<:;G_8/Z4QKB-%RV5&<98$<U0:GG?@?_DL'Q0/_8,_])VKTRO,
M_ __ "6#XH#_ +!?_I.U>F5(PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \S7_DXYO\ L5O_ &[%>E)]U?I7
MFJ_\G'-_V*W_ +=BO2D^ZOTH =1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7+_$[_ ))[XI_[!%W_ .BFKJ*Y?XG?\D]\4_\ 8(N__134 /\ AI_R
M3GPK_P!@FU_]$I72US7PT_Y)SX5_[!-K_P"B4KI: (VD"J6/05E76M>6^U8]
MP]=W_P!:K>I,RV<FT9-<PI8JN[DU\'Q%FU;!.-*CI<[L/1C43<C3_MJ93P%Q
MVH_MR?\ NK^M9PHKX?\ MK'?\_&=WL:?8T?[<G_NK^M']N3_ -U?UK.HJ?[:
MQW_/QA[&GV-'^W)_[J_K1_;D_P#=7]:SJ*/[:QW_ #\8>QI]C1_MR?\ NK^M
M']N3_P!U?UK.HH_MK'?\_&'L:?8T?[<G_NK^M']N3_W5_6LZBC^VL=_S\8>Q
MI]C1_MR?^ZOZT?VY/_=7]:SJ*/[:QW_/QA[&GV-'^W)_[J_K1_;D_P#=7]:S
MJ*/[:QW_ #\8>QI]C1_MR?\ NK^M']N3_P!U?UK.HH_MK'?\_&'L:?8T?[<G
M_NK^M']N3_W5_6LZBC^VL=_S\8>QI]C1_MR?^ZOZT?VY/_=7]:SJ*/[:QW_/
MQA[&GV-'^W)_[J_K1_;D_P#=7]:SJ*/[:QW_ #\8>QI]C0_MJ?T7]:9+KDZ1
ML^%Z$8Q]*I5'<?\ 'J_X_P!*J&<XYS2=1C5&GS)6/E?P=^T-XC\$>';31K&V
MT^2VMQ)\TT<A9F:1GS]_CEOTK97]K+QDJC-KI!/KY,O_ ,=KQ<XS1Q7T<<SQ
M7*GSG[#2X?RV<(MTEJD>T_\ #67C+_GTTC_OS+_\<H_X:R\9?\^FD?\ ?F7_
M ..5XMQ1Q5?VGBOYS3_5W*_^?2_$]I_X:R\9?\^FD?\ ?F7_ ..4?\-9>,O^
M?32/^_,O_P <KQ;BCBC^T\5_.'^KN5_\^E^)[3_PUEXR_P"?32/^_,O_ ,<H
M_P"&LO&7_/II'_?F7_XY7BW%'%']IXK^</\ 5W*_^?2_$]I_X:R\9?\ /II'
M_?F7_P".4?\ #67C+_GTTC_OS+_\<KQ;BCBC^T\5_.'^KN5_\^E^)[3_ ,-9
M>,O^?32/^_,O_P <H_X:R\9?\^FD?]^9?_CE>+<4<4?VGBOYP_U=RO\ Y]+\
M3VG_ (:R\9?\^FD?]^9?_CE'_#67C+_GTTC_ +\R_P#QRO%N*.*/[3Q7\X?Z
MNY7_ ,^E^)[3_P -9>,O^?32/^_,O_QRC_AK+QE_SZ:1_P!^9?\ XY7BW%'%
M']IXK^</]7<K_P"?2_$]I_X:R\9?\^FD?]^9?_CE'_#67C+_ )]-(_[\R_\
MQRO%N*.*/[3Q7\X?ZNY7_P ^E^)[3_PUEXR_Y]-(_P"_,O\ \<H_X:R\9?\
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M8QO\YZ]_PT[XI_Y\=*_[]2__ !RC_AIWQ3_SXZ5_WZE_^.5Y#11S,/[8QO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKI-H]*-H]*/]5,'_ #2_ /K4CF_[+G_NT?V7/_=KI-H]*-H]*/\ 53!_S2_
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MDT?V#A^['_KCF'\L?N?^9\/?\,[?$/\ Z%T_^!EO_P#%T?\ #.WQ#_Z%T_\
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M\FC^P</W8?ZXYA_+'[G_ )GP]_PSM\0_^A=/_@9;_P#Q='_#.WQ#_P"A=/\
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M3[J_2@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?\C0 ;?>C;[T;Q[_ )&C>/?\C0 ;?>C;[T;Q[_D:-X]_R- !M]Z-OO1O'O\
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M-_<SQUKT-?"FIL 3XQUO\(K+_P"1JYI?^3CF_P"Q6_\ ;L5Z4GW5^E '.?\
M")ZG_P!#EKG_ 'ZLO_D:C_A$]3_Z'+7/^_5E_P#(U=+10!S7_")ZG_T.6N?]
M^K+_ .1J/^$3U/\ Z'+7/^_5E_\ (U=+10!S7_")ZG_T.6N?]^K+_P"1J/\
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M%%*R ****8!1110 4444 1" >O'?MWR/\]Z>B[5 ]!VIU% !1110 4444K(
MHHHI@%%%% !1110 4444 %%%%*P!1113 **** "BBB@ HHHH **** "BBB@
MHHHH *Y?XG?\D]\4_P#8(N__ $4U=17+_$[_ ))[XI_[!%W_ .BFH ?\-/\
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M /B*/KN'_P"?B#^S,=_SXE]S_P CU/=1NKRS_AICX=?]!UO_  $G_P#B*/\
MAICX=?\ 0=;_ ,!)_P#XBCZ[A_\ GX@_LS'?\^)?<_\ (]3W4;J\L_X:8^'7
M_0=;_P !)_\ XBC_ (:8^'7_ $'6_P# 2?\ ^(H^NX?_ )^(/[,QW_/B7W/_
M "/4]U&ZO+/^&F/AU_T'6_\  2?_ .(H_P"&F/AU_P!!UO\ P$G_ /B*/KN'
M_P"?B#^S,=_SXE]S_P CU/=1NKRS_AICX=?]!UO_  $G_P#B*/\ AICX=?\
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M+A_:&$_Y^Q^__@GI>[W_ $HW>_Z5YI_PT1X _P"@VW_@)/\ _$4?\-$> /\
MH-M_X"3_ /Q%%P_M#"?\_8_?_P $]+W>_P"E&[W_ $KS3_AHCP!_T&V_\!)_
M_B*/^&B/ '_0;;_P$G_^(HN']H83_G['[_\ @GI>[W_2C=[_ *5YI_PT1X _
MZ#;?^ D__P 11_PT1X _Z#;?^ D__P 11</[0PG_ #]C]_\ P3TS=Z4TR$5Y
MK_PT3X"'36F_\!)__B*Z+PK\2/#_ (W5VT;4([O8Q4KAD<8'4JP! SQG&,\9
MSQ5Z&D,90J/EIS39U8.12U%&XDC5AR",\'-2 U)V"T444 %%%% 'F?@?_DL7
MQ0_[AG_I.U>F5YGX'_Y+%\4/^X9_Z3M7IE !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YFO_)QS?]BM_P"W
M8KTI/NK]*\U7_DXYO^Q6_P#;L5Z4GW5^E #J*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[(-WO1N]Z-OM_P".M_A1M]O_ !UO\*+2_E"\.R#=[T;O>C;[?^.M_A1M]O\
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M '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R_P 3O^2>^*?^P1=_
M^BFKJ*Y?XG?\D]\4_P#8(N__ $4U #_AI_R3GPK_ -@FU_\ 1*5TM<U\-/\
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M/_"M/"O_ $+NE_\ @''_ /$T?\*T\*_]"[I?_@''_P#$UTU% OJ]'^1',_\
M"M/"O_0NZ7_X!Q__ !-'_"M/"O\ T+NE_P#@''_\37344!]7H_R(YG_A6GA7
M_H7=+_\  ./_ .)H_P"%:>%?^A=TO_P#C_\ B:Z:B@/J]'^1',_\*T\*_P#0
MNZ7_ . <?_Q-'_"M/"O_ $+NE_\ @''_ /$UTU% ?5Z/\B.9_P"%:>%?^A=T
MO_P#C_\ B:/^%:>%?^A=TO\ \ X__B:Z:B@/J]'^1',_\*T\*_\ 0NZ7_P"
M<?\ \31_PK3PK_T+NE_^ <?_ ,37344!]7H_R(YG_A6GA7_H7=+_ / ./_XF
MC_A6GA7_ *%W2_\ P#C_ /B:Z:B@/J]'^1',_P#"M/"O_0NZ7_X!Q_\ Q-'_
M  K3PK_T+NE_^ <?_P 37344!]7H_P B.9_X5IX5_P"A=TO_ , X_P#XFC_A
M6GA7_H7=+_\  ./_ .)KIJ* ^KT?Y$<S_P *U\*_]"[I?_@''_\ $UM6^F06
M<$<%O%'#;QJ$6)% 55'   [8XQ5RBF5&C3@[QBD,5"H )S[T[;2T4C8****
M"BBB@#S/P/\ \EB^*'_<,_\ 2=J],KS/P/\ \EB^*'_<,_\ 2=J],H ****
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M]G0!Z717FG_"[O\ J1/&G_@H_P#LZ/\ A=W_ %(GC3_P4?\ V= 'I=%>:?\
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M=W_4B>-/_!1_]G0!Z717FG_"[O\ J1/&G_@H_P#LZ/\ A=W_ %(GC3_P4?\
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M_4B>-/\ P4?_ &= 'I=%>:?\+N_ZD3QI_P""C_[.C_A=W_4B>-/_  4?_9T
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M=W_4B>-/_!1_]G0!Z717FG_"[O\ J1/&G_@H_P#LZ/\ A=W_ %(GC3_P4?\
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M)S_/\Z]0"[< ' ]*\V_9[_Y(_H'UN/\ T?+7I= "8]Z,>]+10 F/>C'O2T4
M)CWHQ[TM% "8]Z,>]+10 F/>C'O2T4 )CWHQ[TM% "8]Z,>]+10 F/>C'O2T
M4 )CWHQ[TM% "8]Z,>]+10 F/>C'O2T4 )CWHQ[TM% "8]Z,>]+10!YC\%U_
MY'L#[W_"5Z@-Q'/5#_6O3<>]>9_!?[_CK_L;+_\ DE>FT )CWHQ[TM% "8]Z
M,>]+10 F/>C'O2T4 )CWHQ[TM% "8]Z,>]+10 F/>C'O2T4 )CWHQ[TM% "8
M]Z,>]+10 F/>C'O2T4 )CWHQ[TM% "8]Z,>]+10 F/>C'O2T4 )CWHQ[TM%
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M.JLPC9J]C5]RAL8R,T@'4444 %%%% !1110 4444 %<O\3O^2>^*?^P1=_\
MHIJZBN7^)W_)/?%/_8(N_P#T4U #_AI_R3GPK_V";7_T2E=+7-?#3_DG/A7_
M +!-K_Z)2NEH :6QVI&DP,XJ.XE\F-FQTKG[C5)I2=IVBO!S+-Z.7:3W-:=*
M51Z'2[Q1O%<I]MN./WOZ4GV^X_YZ_I7SW^MM#^1G5]4EW.LWBC>*Y3[=<_\
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MSZY_X,Y?\:/]8*7\H?ZEXO\ GB?H/]I7_)%'VE?\D5^?'_"PO$__ $,^N?\
M@SE_QH_X6%XG_P"AGUS_ ,&<O^-'^L%+^4/]2\7_ #Q/T'^TK_DBC[0O^2*_
M/C_A87B?_H9]<_\ !G+_ (T?\+"\3_\ 0SZY_P"#.7_&C_6"E_*)\&8M*_/$
M^O/@O*5/CLL%'_%67^,-GCY!S7IGG#L0?QKX*TWQ=K]C;L;77M4@,[&>7;>2
M?/(2I9CSR3@Y^M7E^(7BH*!_PDFJ''_3T_\ C7T].HIQ4NZ/P_$\14<-7G1E
M'6+L?<_G#^\/SH\X?WA^=?#/_"PO%/\ T,>J?^!3_P"-'_"PO%/_ $,>J?\
M@4_^-:<T3G_UHH?RGW-YP_O#\Z/.']X?G7PS_P +"\4_]#'JG_@4_P#C1_PL
M+Q3_ -#'JG_@4_\ C1S1#_6BA_*?<WG#^\/SH\X?WA^=?#/_  L+Q3_T,>J?
M^!3_ .-'_"PO%/\ T,>J?^!3_P"-'-$/]:*'\I]S></[P_.CSA_>'YU\,_\
M"PO%/_0QZI_X%/\ XT?\+"\4_P#0QZI_X%/_ (T<T0_UHH?RGW-YP_O#\Z/.
M']X?G7PS_P +"\4_]#'JG_@4_P#C1_PL+Q3_ -#'JG_@4_\ C1S1#_6BA_*?
M<WG#^\/SH\X?WA^=?#/_  L+Q3_T,>J?^!3_ .-'_"PO%/\ T,>J?^!3_P"-
M'-$/]:*'\I]S></[P_.CSA_>'YU\,_\ "PO%/_0QZI_X%/\ XT?\+"\4_P#0
MQZI_X%/_ (T<T0_UHH?RGW-YP_O#\Z/.']X?G7PS_P +"\4_]#'JG_@4_P#C
M1_PL+Q3_ -#'JG_@4_\ C1S1#_6BA_*?<WG#^\/SH\X?WA^=?#/_  L+Q3_T
M,>J?^!3_ .-'_"PO%/\ T,>J?^!3_P"-'-$/]:*'\I]S&=>Q'YU$;W;UC<KS
MEE /3V')S["OAW_A87BG_H8]4_\  I_\:VO"?QF\3^%KYIY-5N=5M !)-:WT
MGF9&['#G)4=\#\<T<T2Z7$^'J3Y'&Q]GK)N7(Z4[=5/2KZ'4M-M;N%MT$\:R
M(WJI&0?R-6ZH^QC+F2DNHZBBBD4%%%% 'F?@?_DL7Q0_[AG_ *3M7IE>9^!_
M^2Q?%#_N&?\ I.U>F4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'F:_\G'-_P!BM_[=BO2D^ZOTKS5?^3CF
M_P"Q6_\ ;L5Z4GW5^E #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@"E."WW)#D$_= /.?Y_>]O6OBGX._##XZ_"CP\^E?!?
MQY\,O'7PE6XD;P_<>(5EEEMHS-*\RA[%%21_-DD1F\QQF,;4CR8Q]NM;ANAV
M_P"Z!U]?KU_.OG35/V%/",>I7<W@_P :_$#X8:=>3M=W&B>"O$#6-@]P^0\R
MQ%&\MBI5<1E458XPJKMY8'AOQ#^-M_K'["?Q8\0Z1HK?"WQ_I7B%-,\1'PU.
MMN?[8%]91W5Q%- ^YO,5U&XLSX;;N==K/Z%XHTW7/VD/VG/B)X5;XA^+_A[X
M5^'.GZ8D=OX/U%;.6^NKZ)[A[IY0A&Q454$3*_*E@RAI$?U76OV0?AYJ'P)U
M;X1Z382^$_"6IW$=U/\ V(X6Y:59XYRYEF$A=BT2+N?<0@51C:N&_%[]D_0/
MBYXXL/&2^+/&/@CQ3:Z<VDOJO@_5S8S7-H9?.$,I*O\ *K[F 4+]XYSM38[H
M#Y3^)'C?7=(_9S^!-_XB\2Z7\6];\-?%'2H9=1\#7S:W-J2Q+/)'"A"QYNO+
MQ&0Y8LV&+YD('JG[(_C#7OV@O'WB[XA^,/%5WINJZ3=R:3!\+;2ZG@AT%5)5
M)+V A/M$S#?B1E* AL$,BQV_K$/[(W@NS^'7PS\%6EQJEGHO@'6K7Q!IA2=9
M)I;R!Y'#2M(K95WFE9E4+]["[  !IZ#^S7X<\(?&/5OB)X<U#4] O=<1O[;T
M6Q>,:9JTIR?/FA*$B8,=V^-DY+DY,LI=W0'P?X(^,OB/P5^R#^SIX-T*;Q7!
M_P )7>Z\FH7O@NSCO-:-E;W-T98;6*5?EDD$H;SU*M"L+N ?N5[U^QSXH\:+
M\4/%?A:^L/BS?^!;BP@U?3=4^+-@8KNRNXF6*:U$^&6<2;XY5(=-OE. OWI&
M]4;]C'P:WP+\,_"Y=9\26^F^&]2_M?2M:L[];;4[6[\^682K)$BQY!GE7F/&
M&!QN56'0?"#]F?P]\(=2OM876_$?C3Q/=0K:?\)'XQU(ZCJ$%HIW"UAD*J(H
M=^7*H!N8@L3M0*M /-_A/M;]N;X\#6PIU/\ LO0SX=^W?Z_^S/LY^T_9-W/V
M?[7_ *SR_D\W9N_>5WGQD\9>#/A[?7OBEK2VU+Q_H6@WNJ6UC:W)AOY[.&VN
M'*SL@+"T+H4!F4PB9HFP91%4WQJ_9;\+?&O7M$\17&I:YX2\6:.&BM?$GA6\
M%EJ MV5U:W:7:V8\NS 8W*Q;:P$D@>U\)/V9O"'P?U:_UVPFU;7O%VI0+:ZA
MXI\1W[W^IW<*G*1M*_"JH"+MC5 PBCW!B@-&@'P1HGQ:^*=QH_A+XCV*?M">
M+?&V^SU+4;"3P^8O"NKV; ![>WAMU=8@T9(2X$3EF DVH7$D?U>S^3_P4@)*
M[53X3$CLN!JYY)QQ5CPW^P#X#\-W=O:_\)+XVU3P5;W9NX_ &IZX9_#XQ+YT
M<9M2F7C27$@5W;<R@N7YSZP/@KI'_"Z?^%G/>7DGB ^'_P#A&S;N8S:_9OM'
MV@L$V[O,WYYW8P0,<4[H#R+_ ()TC;^QS\/DD.W/]H8CDQDXU*YSW//08SQ^
ME0?\$Y]__#&OP\V&0Q>9?_<*L<_VE<=#]W;CKCWQ7L_P5^#>C_ GX9Z1X&T"
M[OKS2M*\[[//J<BR7#>;-),V]D5 ?GD;& ., Y/)\0\/_P#!/?2/".AQZ+H'
MQH^,.@Z1"&$%CIGBA+>&'<S,VU$@"C+,S$XR68DD\8@#P7XT>*-5\%Z+^VCJ
M_@G4[K1=-MM7\,FWOM!N#;VL>ILUNNI>5(C!%N"Q03\ASD"3J*],_:=;QM'\
M5;L:W+\81X#BLH#X:_X4JY,@?:6O/[4+9<R[_*$0.4"-QAC(1[AKW[(?P]U+
MX#ZM\(M)M;OPIX2U.19KAM'E7[69!-',7\V99"S$Q(N6#$*JJNT*H%7XC?LC
M:#X^\::EXMT_QCXV^'_B+55C75+SP;KTMD-1\J-(X?.C?S$_=JI"[ O$CYW;
MC5W0'A'QR_:&\0V_PV^!VA:#XOUWQJ_C9[MM2\5?#G181JNHV=K!B>*VLV9O
M(N6$@WNCJT+6\I5,CRQ;_9A^(WC7PUXJ^(6F7EC\2G\"6^A#7M/U;XU1OIC:
M?<P@+/;RWICD5H9 RR%Q@0+&VV%CN9O??&W[*/@;QA\*]!^']I'?>$=%\/W4
M%[HMQX:N#:W>G3Q$E9HY"&S(2\A+N&)+E_O@.*_@O]DOPEX7TWQ+;ZSJGB'Q
M]>^(K&32=0U;Q=J;WE\=/=65K..9=ABAR\CX3!+ON+$JN%H!\.>,OBQXF^#^
MAW/CW1/&7QX^(/B"UGAU2VU[5-!DM/!&J17$RLRFUDPT<)AE\I I0>8$:)ER
MA7U'XW:MXWT/XI>*-4\8ZW\7_#$%C=^?X<UKX;VHN_"&GZ4FUH;C4;<$M/(C
M^<]RCCYD3:GR&//I&I?\$W/!6O>%$\,:W\1/B7KWA^V2%=.TW4?$*R6^F-$0
M$DMXO*$:L(P\8#*RJLK[0I"%.O\ %'[$7@[Q)XDU74+?Q3XY\.Z3K=Y+J&N>
M&]#\13V^FZQ-,Y-PUQ&=SXE3;&RQN@V(H 6G= >-?M.?';Q#=_$[P3X!T?4O
M&NH>'KGPE_PDNK:E\&["&ZOM7\R9$MS;9=GM;<-"TGF)*^]9EB.=V^O0/V(/
M$GC6]T_QCH/BG3OB!)H^E7\<N@:U\1;)[;5+NSN%8FVG!4B1H)(W_>[V++,N
M!$NV.O2?BW^R[X8^+-KX/0:GK?@J\\)"6/1=1\&WG]FW%E#)&L3PQE5*JA1$
M! 4'"  A2RMK_!_X!Z#\&--U&/3;W4]=UK5)EFU/Q%XAN?M>I:B5R(O/FPN1
M&A*HJA54$G!8L66@'EOPCTF]F_;+^/U_J]G=$VVG>'K?1KF[C8E+.2WE>9+:
M1ONQ-<1ON"?*9(BQRZDCBM!^&'Q>\$_%3X@ZE\#_ (@> _$W@S6M9N[[5=#\
M4,TCZ=KDCHUTADM4\Q70(FU68;5<!HRP\Q_=O%WP(N=4^.GAGXGZ!KUOHFJV
M.F3:%K%O=Z<UXFJZ:\R3);C]\@@:-Q(RR*I8LZ[MR+L;G/&G[%_A'Q%XIU+Q
M%X=\2^,?AEJVK3FZU>;P-K;Z<NIR\8>=,,A(.]@553NEE8EBY-.Z ^:_BY\2
M/%?BO]G7]I30]6\'67AKXR>'&TQ/$NI^$(V^SZS8RRJT<ZR*S3E!8K,&25B%
MB)W$*7CC^W6/A%OAR=G]@MX$_LD\IY/]F_V9Y#;<?\LOL_E=/X-F[M6%\,OV
M:? GPK\-ZWH^FZ7_ &D/$ _XG]]K3F]N]:9E(D:[DDSYN\M*S+@)F:3"C<:\
MOL?^">'P^M89M'N/%/CW4/ $LLK_ /" 7'B.4:&J.[.(A"@60(DA$B_O,EE!
M8M1= <YXO_X1W_AIC]E+_A#\?\(]_P 53]DQN\O[/]D'E^3O^;R,;O)V?N?*
MV[/W>RNI_P""@&W_ (9JU/\ L_\ Y&?^U--_X1SR-_V_^T?MD>W[#M_>?:/*
M\[;Y7SXW_P .ZNO^,G[)OAOXP7/@NY3Q!XB\!W/@^&XM]'F\%7<>G/;1S)%&
MZJ?+8J D*HH7: K,""#@9_@K]B_PCX;\5:9XC\0>)/&'Q,UC1Y!-HUQXZUEM
M1.ER<[W@&U0&<E22P.#%&5VE<DN@,/XMZ3>1_ME_L^ZCI=G<1W%QI_B*'6;R
MPC(WV,=K&8DN64?-"MQ-&5#$JLCH0 6KZ95@R@CD>HZ5Y-X1^!MYI?QT\4_$
MWQ!XA@U[4=0TZ+1M'M;?3FLUTFQ2=YFAR)G$[.[1N7=0P9&V[48(OK*J%4 #
M ':H =1110 4444 %%%% !1110 5R_Q._P"2>^*?^P1=_P#HIJZBN7^)W_)/
M?%/_ &"+O_T4U #_ (:?\DY\*_\ 8)M?_1*5TM<U\-/^2<^%?^P3:_\ HE*Z
M6@"EJ"F:V<+UKF.%X8X(Z\5U?FCS&7;\N,YYYSG_  'YU0NK&*9L,GEY_B;
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M #[_ !0?68&/CWHQ[UL?\(^?^>W_ (Y_]>C_ (1\_P#/;_QS_P"O1_J]F?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX'_Y+%\4/^X9_P"D[5Z97F?@?_DL7Q0_[AG_ *3M7IE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YFO_)Q
MS?\ 8K?^W8KTI/NK]*\U7_DXYO\ L5O_ &[%>E)]U?I0 ZBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+_P"$DL/^>OZ4?\))8?\
M/7]*Y?'LOY48]E_*L>9FW*CJ/^$DL/\ GK^E'_"26'_/7]*Y?'LOY48]E_*C
MF8<J.H_X22P_YZ_I1_PDEA_SU_2N7Q[+^5&/9?RHYF'*CJ/^$DL/^>OZ4?\
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M&"<5V_\ PDEC_P ]?TKF-J[0I7*YRPSU]AZ<T$EB6;:6/).WOZT<S#E1T_\
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MF8<J.H_X22P_YZ_I1_PDEA_SU_2N7Q[+^5&/9?RHYF'*CJ/^$DL/^>OZ4?\
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M2BC\"/9AS15""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQQ\._B#\2OV@O ?B75?"MN-&T*QN;W1DO;NSDLM)U"9D2-KR GSYIDCC>XS
MWEB9K:))(Q%-<RZ-K\-_B-XO\;?&.^O+S4? "^))%T^UUN;5(+_9I]M$T=H+
M&,-OM_,>:>YE+,OEB55BQ)(\T?TBGR,6VJ9"N-^6R"3EB.>-P"YQR<9SGHB1
MQP[?*C!9#\OG$N ,YZ<>_P#G.3G#E1\[6?PV\9^)OA)X4^$U[H<OA[0=*LK'
M1_%.K:A?C?JMG;I$DL5B;>8R)'=&+9(\S0,L+G$;.Q1.K\!?#O59/CGXY^)7
MB.UNH+J1(_#?AZ&Z6'='ID(26:51 [*XEN6=U#KYBA,$+N"IZ[M"QQJ.3&P,
M98\KSG (P>YQSQUZYI)(PQQM38-I&00V5Z$LI!)!5,'MM..HP<S'8\N^+WB;
M6?%MG>?#WP-JENOBJY+07^J"9P?#EJ\)=KTE"K>>4*^5%N1F>0R!@D;X[+X<
M^!M*^&?@70_"FBP^1I>DVR6T2[(T>0#&YY-JA6D<[G8]&=BV,FK'A?P=I'@S
M39;+1M/M[%)IC<SRI&/-NYVV[Y[B3[TTSE%WR.2SX!8EOFK;8YSDLW/5\$_H
M!S]!4C&KD#DY?^)@,9-+110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:;_OFC[#<_\ /M-_WS1[P71!14_V&Y_Y]IO^^:/L-S_S[3?]\T>\%T045/\
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M?^?:;_OFCW@NB"BI_L-S_P ^TW_?-'V&Y_Y]IO\ OFCW@NCL?+_VF_.CR_\
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M +3?G1Y?^TWYT^BBR 9Y?^TWYT>7_M-^=/HHL@&>7_M-^='E_P"TWYT^BBR
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M,_9SU;XSZ3<'6?"=M9RW%E(T<]LUY,LI@2':T1DCW3[8M[)A<EC\HR:'P_\
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MV_\ W _U*_ZB/_)?^"?I3]JC_O+^='VJ/^\OYU^:V%_NK^5&%_NK^5']O_W
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M_P#?)KZR_P"&0?"G_04U?_O]%_\ &Z/^&0?"G_04U?\ [_1?_&Z/[#Q/</\
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M_P \G_[Y-'DR?\\G_P"^37UE_P ,@^%/^@IJ_P#W^B_^-T?\,@^%/^@IJ_\
MW^B_^-T?V'B>XO\ 6[+O[Q\^?!_0[CQ#\2-$AMD9OL]Y%=3R;2$18WC8ESZ'
M8J+_ +6T''?[W5=R*>AQ7&> ?A5H_P .=/:WTQ6#R%C+<2!6EE/.TLV.J@G&
M,#YF)&3FNU7.WYCD]_>OKLMP3P-+D;N?G&>9JLUQ7M8JR6P]>E+2+]VEKUCY
MP**** "BBB@#S+X+_?\ '7_8V7_\DKTVO,O@O]_QU_V-E_\ R2O3: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#S/P/_P EB^*'_<,_])VKTRO,_ __ "6+XH?]PS_TG:O3* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MS-?^3CF_[%;_ -NQ7I2?=7Z5YJO_ "<<W_8K?^W8KTI/NK]* '4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $+V^Y@VX@C./
MQQQ],BOEBS\6_M-_"\3>']4^'NF_&TQR320^+-,UVST.2XMV<^7'+:RH%691
MG.P>7AU&XNK,_P!6U7:V/F$A]JM]X;>2,<#/Y_G0!\-:]^R/X\T?]B[XH^!K
M>ST'5O&_C#Q!_;[:/X<46NEVOF7=KFVMGG:/Y%AMP1N*[0VP;MH+=_XR\/\
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M_P#KTKL"9?NC(QQ3J0#%+2 **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,O@O]_QU_P!C9?\ \DKTV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \S\#_P#)8OBA_P!PS_TG:O3*\S\#
M_P#)8OBA_P!PS_TG:O3* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#S-?\ DXYO^Q6_]NQ7I2?=7Z5YJO\
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MN?\ ^+H_X9O^'G_0!_\ )N?_ .+H ])W-_='Y_\ UJ-S?W1^?_UJ\V_X9O\
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M .+H_P"&;_AY_P! '_R;G_\ BZ8'I.YO[H_/_P"M1N;^Z/S_ /K5YM_PS?\
M#S_H _\ DW/_ /%T?\,W_#S_ * /_DW/_P#%T >D[F_NC\__ *U&YO[H_/\
M^M7FW_#-_P //^@#_P"3<_\ \71_PS?\//\ H _^3<__ ,70!Z3N;^Z/S_\
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M/_ZU&YO[H_/_ .M7FW_#-_P\_P"@#_Y-S_\ Q='_  S?\//^@#_Y-S__ !=
M'I.YO[H_/_ZU&YO[H_/_ .M7FW_#-_P\_P"@#_Y-S_\ Q='_  S?\//^@#_Y
M-S__ != 'I.YO[H_/_ZU1-)R3U&.3G@?YQ7G?_#-_P //^@#_P"3<_\ \73/
M^&<_A\DBL- Y5O,W?;;G.X=#_K/>@!?V>Y,?"#0<C'-QGMC,\G7.#WKTO<W8
M#'U_^M7S[\&O@GX.\5?#71M3U;2/M=[,L\<LGVNX3<JSR;0 ),#[HKN?^&</
MA[_T F_\#;C_ ..4 >D[F_NC\_\ ZU&YO[H_/_ZU>;?\,W_#S_H _P#DW/\
M_%T?\,W_  \_Z /_ )-S_P#Q= 'I.YO[H_/_ .M1N;^Z/S_^M7FW_#-_P\_Z
M /\ Y-S_ /Q='_#-_P //^@#_P"3<_\ \70!Z3N;^Z/S_P#K4;F_NC\__K5Y
MM_PS?\//^@#_ .3<_P#\71_PS?\ #S_H _\ DW/_ /%T >D[F_NC\_\ ZU&Y
MO[H_/_ZU>;?\,W_#S_H _P#DW/\ _%T?\,W_  \_Z /_ )-S_P#Q= 'I.YO[
MH_/_ .M1N;^Z/S_^M7FW_#-_P\_Z /\ Y-S_ /Q='_#-_P //^@#_P"3<_\
M\70!Z3N;^Z/S_P#K4;F_NC\__K5YM_PS?\//^@#_ .3<_P#\71_PS?\ #S_H
M _\ DW/_ /%T >D[F_NC\_\ ZU&YO[H_/_ZU>;?\,W_#S_H _P#DW/\ _%T?
M\,W_  \_Z /_ )-S_P#Q= 'I.YO[H_/_ .M1N;^Z/S_^M7FW_#-_P\_Z /\
MY-S_ /Q='_#-_P //^@#_P"3<_\ \70!Z3N;^Z/S_P#K4;F_NC\__K5YM_PS
M?\//^@#_ .3<_P#\71_PS?\ #S_H _\ DW/_ /%T >D[F_NC\_\ ZU&YO[H_
M/_ZU>;?\,W_#S_H _P#DW/\ _%T?\,W_  \_Z /_ )-S_P#Q= 'I.YO[H_/_
M .M1N;^Z/S_^M7FW_#-_P\_Z /\ Y-S_ /Q='_#-_P //^@#_P"3<_\ \70!
MZ3N;^Z/S_P#K4;F_NC\__K5YM_PS?\//^@#_ .3<_P#\71_PS?\ #S_H _\
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M/_ZU&YO[H_/_ .M7FW_#-_P\_P"@#_Y-S_\ Q='_  S?\//^@#_Y-S__ !=
M'I.YO[H_/_ZU&YO[H_/_ .M7FW_#-_P\_P"@#_Y-S_\ Q='_  S?\//^@#_Y
M-S__ != 'I.YO[H_/_ZU&YO[H_/_ .M7FW_#-_P\_P"@#_Y-S_\ Q='_  S?
M\//^@#_Y-S__ != 'I.YO[H_/_ZU&YO[H_/_ .M7FW_#-_P\_P"@#_Y-S_\
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M_#S_ * /_DW/_P#%T?\ #-_P\_Z /_DW/_\ %T >D[F_NC\__K4;F_NC\_\
MZU>;?\,W_#S_ * /_DW/_P#%T?\ #-_P\_Z /_DW/_\ %T >D[F_NC\__K4;
MF_NC\_\ ZU>;?\,W_#S_ * /_DW/_P#%T?\ #-_P\_Z /_DW/_\ %T >D[F_
MNC\__K4;F_NC\_\ ZU>;?\,W_#S_ * /_DW/_P#%T?\ #-_P\_Z /_DW/_\
M%T >D[F_NC\__K4;F_NC\_\ ZU>;?\,W_#S_ * /_DW/_P#%T?\ #-_P\_Z
M/_DW/_\ %T >D[F_NC\__K4;F_NC\_\ ZU>;?\,W_#S_ * /_DW/_P#%T?\
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MH_/_ .M1N;^Z/S_^M7FW_#-_P\_Z /\ Y-S_ /Q='_#-_P //^@#_P"3<_\
M\70!Z3N;^Z/S_P#K4;F_NC\__K5YM_PS?\//^@#_ .3<_P#\71_PS?\ #S_H
M _\ DW/_ /%T >D[F_NC\_\ ZU&YO[H_/_ZU>;?\,W_#S_H _P#DW/\ _%T?
M\,W_  \_Z /_ )-S_P#Q= 'I.YO[H_/_ .M1N;^Z/S_^M7FW_#-_P\_Z /\
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MBH/M2\C!RH)/!Z9^GM^/:F27N&V(JN_8%L XQD].G(''<U.H%JBJTEYL$>%
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MR_Y]-(_[\R__ !RO%N*.*/[3Q7\X?ZNY7_SZ7XGM/_#67C+_ )]-(_[\R_\
MQRC_ (:R\9?\^FD?]^9?_CE>+<4<4?VGBOYP_P!7<K_Y]+\3VG_AK+QE_P ^
MFD?]^9?_ (Y1_P -9>,O^?32/^_,O_QRO%N*.*/[3Q7\X?ZNY7_SZ7XGM/\
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M^VN-1A\/BRM_!FAZ7?K';SVL,:Q7-W]HB4-R9G4QD2,</("!P!5D3<^A;/\
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M'#]V'^N.8?RQ^Y_YGP]_PSM\0_\ H73_ .!EO_\ %T?\,[?$/_H73_X&6_\
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M0Q-N9&$J,'79\I!.1I?"GX1:#\&?AWH?@OPV+B/2-)@,,374GFRR[G9Y'D.
M"SN[N< *"YVJHP!VF[V-&[V-.[%8Y7_A5/A#_A#/^$//A?1/^$2Z?V"--A^P
MX,GFD>1MV8\SYNG7GKS4_C'X<^&OB)I,6F^*= TGQ-8QR"9;36;".\@\Q0P5
M_+D##<-QPW7EN>371[O8T;O8T#.4/PG\&_+CPMHHVZ4-!!&G0Y_LT?\ +E]W
MBW_Z9#Y!Q@<5MZ;X?LM&TVVT[3[6WL-.M88[:WM+6%8XH8D "1HBX5550 %
MP!P..*T-WL:-WL:+L1R6D_"?PCX?\2:CXATCPSHFDZ]J0<7VJ6.FPPW5WO8,
M_FS* \FYAD[F.2 >H!K5T_P?I&DZUJFL6.FV5IJVJF,W]]!;(D]YY:[(O-D
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MX+_?\=?]C9?_ ,DKTVO,/@RVW_A/7(PH\5WY!/ QA/7WS^5>F"3Y<E3^'(H
M?13=WL:-WL: '44W=[&C=[&@!U%-W>QHW>QH =13=WL:-WL: '44W=[&C=[&
M@!U%-W>QHW>QH =13=WL:-WL: '44W=[&C=[&@!U%-W>QHW>QH =13=WL:-W
ML: '44W=[&C=[&@!U%-W>QHW>QH =13=WL:-WL: /-? _P#R6+XH?]PS_P!)
MVKTRO,? ['_A<?Q0  )/]F8Y_P"G9CSZ5Z6LH901G!&>E #Z*;N]C1N]C0 Z
MBF[O8T;O8T .HIN[V-&[V- #J*;N]C1N]C0 ZBF[O8T;O8T .HIN[V-&[V-
M#J*;N]C1N]C0 ZBF[O8T;O8T .HIN[V-&[V- #J*;N]C1N]C0 ZBF[O8T;O8
MT .HIN[V-&[V- #J*;N]C1N]C0!YJO\ R<<W_8K?^W8KTI/NK]*\R60_\-'$
MX^7_ (18#KSDWA!X]MOZUZ6K%54$8..: )**;N]C1N]C0 ZBF[O8T;O8T .H
MIN[V-&[V- #J*;N]C1N]C0 ZBF[O8T;O8T .HIN[V-&[V- #J*;N]C1N]C0
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MV3_OW_\ 7H_MR_\ ^>R?]^__ *]4:*.9ARHO?VY?_P#/9/\ OW_]>C^W+_\
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MH_MR_P#^>R?]^_\ Z]4:*.9ARHO?VY?_ //9/^_?_P!>C^W+_P#Y[)_W[_\
MKU1HHYF'*B]_;E__ ,]D_P"_?_UZ/[<O_P#GLG_?O_Z]4:*.9ARHO?VY?_\
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MH_MR_P#^>R?]^_\ Z]4:*.9ARHO?VY?_ //9/^_?_P!>C^W+_P#Y[)_W[_\
MKU1HHYF'*B]_;E__ ,]D_P"_?_UZ/[<O_P#GLG_?O_Z]4:*.9ARHO?VY?_\
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M*B]_;E__ ,]D_P"_?_UZ/[<O_P#GLG_?O_Z]4:*.9ARHO?VY?_\ /9/^_?\
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MJ-%',PY47O[<O_\ GLG_ '[_ /KT?VY?_P#/9/\ OW_]>J-%',PY47O[<O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-\"-4N-7\>:'XZG\3^/->F@6UTWP_?6EWI\2P1V\,COY:EXU\I54*7R7<8#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRB\E0?4CN.>G3Z4YFRQQD#MDDX_.F,-Q;[QW'OR3_,G]:2BBD 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSZ>]'*',C$HJO\/;O_A//!]AKNS[#]J\S_1\^9MV2.GWN,YVYZ=ZZ7_A%_\
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M_P#D/_Z]'*'.C"HK=_X1?_IY_P#(?_UZ/^$7_P"GG_R'_P#7HY0YT85%;O\
MPB__ $\_^0__ *]'_"+_ /3S_P"0_P#Z]'*'.C"HK=_X1?\ Z>?_ "'_ /7H
M_P"$7_Z>?_(?_P!>CE#G1A45N_\ "+_]//\ Y#_^O1_PB_\ T\_^0_\ Z]'*
M'.C"HK=_X1?_ *>?_(?_ ->C_A%_^GG_ ,A__7HY0YT85%;O_"+_ /3S_P"0
M_P#Z]'_"+_\ 3S_Y#_\ KT<H<Z,*BJW@N\_X3!M=&S[)_9>K7&E]=_F^4%_>
M=L9STYQCJ:Z;_A%_^GG_ ,A__7HY0YD85%;O_"+_ /3S_P"0_P#Z]'_"+_\
M3S_Y#_\ KT<H<Z,*BMW_ (1?_IY_\A__ %Z/^$7_ .GG_P A_P#UZ.4.=&%1
M6[_PB_\ T\_^0_\ Z]'_  B__3S_ .0__KT<H<Z,*BMW_A%_^GG_ ,A__7H_
MX1?_ *>?_(?_ ->CE#G1A45N_P#"+_\ 3S_Y#_\ KT?\(O\ ]//_ )#_ /KT
M<H<Z,*BMW_A%_P#IY_\ (?\ ]>C_ (1?_IY_\A__ %Z.4.=&%16[_P (O_T\
M_P#D/_Z]'_"+_P#3S_Y#_P#KT<H<Z,*BMW_A%_\ IY_\A_\ UZ/^$7_Z>?\
MR'_]>CE#G1A45N_\(O\ ]//_ )#_ /KT?\(O_P!//_D/_P"O1RASHPJ*W?\
MA%_^GG_R'_\ 7H_X1?\ Z>?_ "'_ /7HY0YT85%;O_"+_P#3S_Y#_P#KT?\
M"+_]//\ Y#_^O1RASHPJ*W?^$7_Z>?\ R'_]>C_A%_\ IY_\A_\ UZ.4.=&%
M16[_ ,(O_P!//_D/_P"O1_PB_P#T\_\ D/\ ^O1RASHPJ*KZ'>?VUXQ\4:%L
M\G^Q/LO^D9W>=YT9?[O&W&,=3GVKI?\ A%_^GG_R'_\ 7HY0YD85%;O_  B_
M_3S_ .0__KT?\(O_ -//_D/_ .O1RASHPJ*W?^$7_P"GG_R'_P#7H_X1?_IY
M_P#(?_UZ.4.=&%16[_PB_P#T\_\ D/\ ^O1_PB__ $\_^0__ *]'*'.C"HK=
M_P"$7_Z>?_(?_P!>C_A%_P#IY_\ (?\ ]>CE#G1A45N_\(O_ -//_D/_ .O1
M_P (O_T\_P#D/_Z]'*'.C"HK=_X1?_IY_P#(?_UZ/^$7_P"GG_R'_P#7HY0Y
MT85%;O\ PB__ $\_^0__ *]'_"+_ /3S_P"0_P#Z]'*'.C"HK=_X1?\ Z>?_
M "'_ /7H_P"$7_Z>?_(?_P!>CE#G1A45N_\ "+_]//\ Y#_^O1_PB_\ T\_^
M0_\ Z]'*'.C"HK=_X1?_ *>?_(?_ ->C_A%_^GG_ ,A__7HY0YT85%;O_"+_
M /3S_P"0_P#Z]'_"+_\ 3S_Y#_\ KT<H<Z,*BMW_ (1?_IY_\A__ %Z/^$7_
M .GG_P A_P#UZ.4.=&%16[_PB_\ T\_^0_\ Z]'_  B__3S_ .0__KT<H<Z,
M*BJ_VS_BXY\*;.FE_P!I?:\_]-A'LV?KG/MBND7PSN /VG_R'_\ 7HY0YD8=
M%;O_  B__3S_ .0__KT?\(O_ -//_D/_ .O1RASHPJ*W?^$7_P"GG_R'_P#7
MH_X1?_IY_P#(?_UZ.4.=&%16[_PB_P#T\_\ D/\ ^O1_PB__ $\_^0__ *]'
M*'.C"HK=_P"$7_Z>?_(?_P!>C_A%_P#IY_\ (?\ ]>CE#G1A45N_\(O_ -//
M_D/_ .O1_P (O_T\_P#D/_Z]'*'.C"HK=_X1?_IY_P#(?_UZ/^$7_P"GG_R'
M_P#7HY0YT85%;O\ PB__ $\_^0__ *]'_"+_ /3S_P"0_P#Z]'*'.C"HK=_X
M1?\ Z>?_ "'_ /7H_P"$7_Z>?_(?_P!>CE#G1A45N_\ "+_]//\ Y#_^O1_P
MB_\ T\_^0_\ Z]'*'.C"HK=_X1?_ *>?_(?_ ->C_A%_^GG_ ,A__7HY0YT;
MU%%%;&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M],KS/P/_ ,EB^*'_ '#/_2=J],H **** "BBB@ HHHH **** "BBB@ HHHH
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M8E0N!UYYXYYJ+:O3"GC'(KUIY]RRMR'W&&X.GB*,:JK;_P!U_P"9^E/VJ/\
MO+^='VJ/^\OYU^:V%_NK^5&%_NK^53_K!_<-O]2O^HC_ ,E_^V/TI^U1_P!Y
M?SH^U1_WE_.OS6PO]U?RHPO]U?RH_M_^X'^I7_41_P"2_P#!/TCCU..60(OS
M'=M]^,Y/TXZ]^U3K,6Y"\8R*_.[PSXPUCP=<R7&CZA-I\DG#K$08GP" 6C8,
MK'!_B! [ 5]S_#GQPGCWPC8:U'#Y23H=ZLV=C*2K+G S@@C/%>Q@<RAC6XQ5
MFCYG.,AKY0E.3YH/J=<#D4M-C;Y1GKCL:=7L'RX4444 %%%% !1110 4444
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M 4444 %%%% !1110 5R_Q._Y)[XI_P"P1=_^BFKJ*Y?XG?\ )/?%/_8(N_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@!NW\:38?7Z4^B@!!Q2T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >9?!?[_CK_L;+_P#DE>FUYE\%_O\ CK_L;+_^25Z;0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >9^!_^2Q?%#_N&?\ I.U>F5YGX'_Y+%\4/^X9_P"D[5Z90 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M9K_R<<W_ &*W_MV*]*3[J_2O-5_Y..;_ +%;_P!NQ7I2?=7Z4 .HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P?\ A*/^G;_R)_\
M6H_X2C_IV_\ (G_UJPJ*QYF;<J-W_A*/^G;_ ,B?_6H_X2C_ *=O_(G_ -:L
M*BCF8<J-W_A*/^G;_P B?_6H_P"$H_Z=O_(G_P!:L*BCF8<J-W_A*/\ IV_\
MB?\ UJ/^$H_Z=O\ R)_]:L*BCF8<J-W_ (2C_IV_\B?_ %J/^$H_Z=O_ ")_
M]:L*BCF8<J-W_A*/^G;_ ,B?_6H_X2C_ *=O_(G_ -:L*BCF8<J-W_A*/^G;
M_P B?_6H_P"$H_Z=O_(G_P!:L*BCF8<J-W_A*/\ IV_\B?\ UJ/^$H_Z=O\
MR)_]:L*BCF8<J-W_ (2C_IV_\B?_ %J/^$H_Z=O_ ")_]:L*BCF8<J-W_A*/
M^G;_ ,B?_6H_X2C_ *=O_(G_ -:L*BCF8<J-W_A*/^G;_P B?_6H_P"$H_Z=
MO_(G_P!:L*BCF8<J-W_A*/\ IV_\B?\ UJ/^$H_Z=O\ R)_]:L*BCF8<J-W_
M (2C_IV_\B?_ %J/^$H_Z=O_ ")_]:L*BCF8<J-W_A*/^G;_ ,B?_6H_X2C_
M *=O_(G_ -:L*BCF8<J-W_A*/^G;_P B?_6H_P"$H_Z=O_(G_P!:L*BCF8<J
M-W_A*/\ IV_\B?\ UJ/^$H_Z=O\ R)_]:L*BCF8<J-W_ (2C_IV_\B?_ %J/
M^$H_Z=O_ ")_]:L*BCF8<J-W_A*/^G;_ ,B?_6H_X2C_ *=O_(G_ -:L*BCF
M8<J-W_A*/^G;_P B?_6H_P"$H_Z=O_(G_P!:L*BCF8<J-W_A*/\ IV_\B?\
MUJ/^$H_Z=O\ R)_]:L*BCF8<J-W_ (2C_IV_\B?_ %JS/$U[_P )'X=U72]G
MV?[=:36OFYW;-Z%=V.,XSTR*JT4<S#E1;\,W_P#PCOAS2M*V?:/L-I%:^=G;
MOV(%W8YQG&<9-:7_  E'_3M_Y$_^M6%11S,.5&[_ ,)1_P!.W_D3_P"M1_PE
M'_3M_P"1/_K5A44<S#E1N_\ "4?].W_D3_ZU'_"4?].W_D3_ .M6%11S,.5&
M[_PE'_3M_P"1/_K4?\)1_P!.W_D3_P"M6%11S,.5&[_PE'_3M_Y$_P#K4?\
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M *U85%',PY4;O_"4?].W_D3_ .M1_P )1_T[?^1/_K5A44<S#E1N_P#"4?\
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M *U85%',PY4;O_"4?].W_D3_ .M1_P )1_T[?^1/_K5A44<S#E1N_P#"4?\
M3M_Y$_\ K4?\)1_T[?\ D3_ZU85%',PY4;O_  E'_3M_Y$_^M1_PE'_3M_Y$
M_P#K5A44<S#E1N_\)1_T[?\ D3_ZU'_"4?\ 3M_Y$_\ K5A44<S#E1N_\)1_
MT[?^1/\ ZU'_  E'_3M_Y$_^M6%11S,.5&[_ ,)1_P!.W_D3_P"M1_PE'_3M
M_P"1/_K5A44<S#E17^Q_\7'/BO?UTO\ LW[)C_IL)-^_],8]\UTB^)MH ^S?
M^1/_ *U8=%',PY4;O_"4?].W_D3_ .M1_P )1_T[?^1/_K5A44<S#E1N_P#"
M4?\ 3M_Y$_\ K4?\)1_T[?\ D3_ZU85%',PY4;O_  E'_3M_Y$_^M1_PE'_3
MM_Y$_P#K5A44<S#E1N_\)1_T[?\ D3_ZU'_"4?\ 3M_Y$_\ K5A44<S#E1N_
M\)1_T[?^1/\ ZU'_  E'_3M_Y$_^M6%11S,.5&[_ ,)1_P!.W_D3_P"M1_PE
M'_3M_P"1/_K5A44<S#E1N_\ "4?].W_D3_ZU'_"4?].W_D3_ .M6%11S,.5&
M[_PE'_3M_P"1/_K4?\)1_P!.W_D3_P"M6%11S,.5&[_PE'_3M_Y$_P#K4?\
M"4?].W_D3_ZU85%',PY4;O\ PE'_ $[?^1/_ *U'_"4?].W_ )$_^M6%11S,
M.5!1114E!1110 445RUC\5O!.J>)CX:L?&7AZ]\2I</;2Z/;ZI"]W%(F3(C1
M!MP955R5QD%<''6I]X#J:*X74?CO\-M'N[JSU#Q_X7L;^TGDMKFTN=:M8I+>
M1"5=)%:0%6!&"I&0>M,T[X_?#'6M2M-.TWXC>$;_ %"\E2"VM(->M&DGD>18
MT1%$F69F8  9.[Y>M/7L/3N=[1575]4M/#]E+>ZE=06-A;Q2SW%W/*J11(BL
MS.SM@!0$8LS$*H&2<'-<]X4^+/@CQQ?M9>'_ !CX?UZZC0RRPZ3JUM=2)&"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&5 ;<D*"Q !)P.M<%_P4P\"Z1\+/!/P0\*:!$4T?2+/4K.%9AN>7:MGOED.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>9CL?(WP _9J^+?PY^!7Q#^%WB+5?#%_IFK:7?0Z3=VFHW4LUE<W$!C>)U>
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M<=U>,6O_  3M^+7Q&\16+_%SXHMJ^BV2F2,Q7MUJ]R-SQK)!&+E56(21@CS
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_6H_L.__ .>*?]_/_K4<H<R*-%7O[#O_ /GBG_?S_P"M1_8=_P#\\4_[^?\
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M]:C^P[__ )XI_P!_/_K4<H<R*-%7O[#O_P#GBG_?S_ZU']AW_P#SQ3_OY_\
M6HY0YD4:*O?V'?\ _/%/^_G_ -:C^P[_ /YXI_W\_P#K4<H<R*-%7O[#O_\
MGBG_ '\_^M1_8=__ ,\4_P"_G_UJ.4.9%&BKW]AW_P#SQ3_OY_\ 6H_L._\
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M\_\ K4?V'?\ _/%/^_G_ -:CE#F11HJ]_8=__P \4_[^?_6H_L.__P">*?\
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M_P#6H_L._P#^>*?]_/\ ZU'*',BC15[^P[__ )XI_P!_/_K4?V'?_P#/%/\
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M;C_T?+7I= #=ON:-ON:=10 W;[FC;[FG44 -V^YHV^YIU% #=ON:-ON:=10
MW;[FC;[FG44 -V^YHV^YIU% #=ON:-ON:=10 W;[FC;[FG44 -V^YHV^YIU%
M #=ON:-ON:=10 W;[FC;[FG44 -V^YHV^YIU% #=ON:-ON:=10!YA\&8RW_"
M>J6RI\5WX /( PGK[Y_.O2UAVKC=^0P*\V^"_P!_QU_V-E__ "2O3:!C?+'J
M?SHV^YIU% ANWW-&WW-.HH ;M]S1M]S3J* &[?<T;?<TZB@!NWW-&WW-.HH
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M9(W>/</FB?RV91)&VY' 8A65ADXIV ZJBOE'Q)^W]HUCH]UXHT3PE?:Q\/\
M1_%J>%==\4M=KY%J&<#[; ENDYG@"E6!8Q%O/M@FXRG9]5A^O&/K2 ?1110
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M?]C9?_R2O3:\R^"_W_'7_8V7_P#)*]-H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,_ __ "6+XH?]PS_T
MG:O3*\S\#_\ )8OBA_W#/_2=J],H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /,U_Y..;_L5O\ V[%>E)]U
M?I7FJ_\ )QS?]BM_[=BO2D^ZOTH =1110 4444 %%%% !1110 4444 %%%%
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MOU(7NH17&IP)&6DE<-&\<,H65(_*4$AU)._<N+\+_&WQ$T#XT_#_ %33-/\
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M+>*:.46BS^<AMT8H=S*I;[F"H#*_K"QD+@MD]R!CFH DHHHH **** "BBB@
MHHHH **** "N7^)W_)/?%/\ V"+O_P!%-745R_Q._P"2>^*?^P1=_P#HIJ '
M_#3_ ))SX5_[!-K_ .B4KI:YKX:?\DY\*_\ 8)M?_1*5TM %#4)&6UDVCG!K
MF?F\M3G#D<_6NOFB$BL">#6)<Z/(N6C._G[N,5^><29=BL5*-6E&Z1WX>I&&
MYF\]^315Q=+G(Y7!H_LN?^[7P?\ 9F-_Y]2.[VE/N4Z*N?V7/_=H_LN?^[3_
M ++QO_/J7X_Y"]I3[E.BKG]ES_W:/[+G_NT?V7C?^?4OQ_R#VE/N4Z*N?V7/
M_=H_LN?^[1_9>-_Y]2_'_(/:4^Y3HJY_9<_]VC^RY_[M']EXW_GU+\?\@]I3
M[E.BKG]ES_W:/[+G_NT?V7C?^?4OQ_R#VE/N4Z*N?V7/_=H_LN?^[1_9>-_Y
M]2_'_(/:4^Y3HJY_9<_]VC^RY_[M']EXW_GU+\?\@]I3[E.BKG]ES_W:/[+G
M_NT?V7C?^?4OQ_R#VE/N4Z*N?V7/_=H_LN?^[1_9>-_Y]2_'_(/:4^Y3HJY_
M9<_]VC^RY_[M']EXW_GU+\?\@]I3[E/--?;LW;O,Y*K&#E23V(J[_9<V?NU+
M:Z.XD/F(%0$,NT8Y!SG]?TKHPV48VO6Y53<?,4ZL+;E/X;VL-GX6$$&Q88[Z
M^V(@P%'VJ;"@>V<?A76 _+TKSGX S3W7PET66YF:XGE:Y9Y'[DSRDG\Z]'"X
MQ7[=1C*G3C![I'BRU=QU%%%= @HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#S+X+_?\=?]C9?_ ,DKTVO,O@O]_P =
M?]C9?_R2O3: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:\R^"_W_ !U_V-E__)*]-H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /,_ _P#R6+XH?]PS_P!)VKTRO,_
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M_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\
M^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!
M_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF
M_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N
M?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_A
MY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:
MO-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?
MW1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y
M_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H
M])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)
MN?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'
MG_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XN
MC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T
M?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^
M&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?
M_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#U
MJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-
M_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\
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M_P#Q='_#-_P\_P"@#_Y-S_\ Q= 'I.YO[H_/_P"M1N;^Z/S_ /K5YM_PS?\
M#S_H _\ DW/_ /%T?\,W_#S_ * /_DW/_P#%T >D[F_NC\__ *U&YO[H_/\
M^M7FW_#-_P //^@#_P"3<_\ \71_PS?\//\ H _^3<__ ,70!Z3N;^Z/S_\
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MS_\ K4;F_NC\_P#ZU>;?\,W_  \_Z /_ )-S_P#Q='_#-_P\_P"@#_Y-S_\
MQ= 'I.YO[H_/_P"M1N;^Z/S_ /K5YM_PS?\ #S_H _\ DW/_ /%T?\,W_#S_
M * /_DW/_P#%T >D[F_NC\__ *U&YO[H_/\ ^M7FW_#-_P //^@#_P"3<_\
M\71_PS?\//\ H _^3<__ ,70!Z3N;^Z/S_\ K5%YF=S$84 \@Y[_ /UOUKSO
M_AF_X>?] '_R;G_^+IZ_L[^ 8V5UT-@ZCC-[<D=?3S* (OV>6;_A3^@;HVC<
M-< H_!&;B3^AS7I:NS*#@<^__P!:O.$_9S^'Z1QQC0=B1DE%CO+A0,\]/,]:
M;_PS?\/>^@GI_P _MQ_\<H ])W-_='Y__6HW-_='Y_\ UJ\V_P"&;_AY_P!
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M+H ])W-_='Y__6HW-_='Y_\ UJ\V_P"&;_AY_P! '_R;G_\ BZ/^&;_AY_T
M?_)N?_XN@#TG<W]T?G_]:C<W]T?G_P#6KS;_ (9O^'G_ $ ?_)N?_P"+H_X9
MO^'G_0!_\FY__BZ /2=S?W1^?_UJ-S?W1^?_ -:O-O\ AF_X>?\ 0!_\FY__
M (NC_AF_X>?] '_R;G_^+H ])W-_='Y__6HW-_='Y_\ UJ\V_P"&;_AY_P!
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M-_P\_P"@#_Y-S_\ Q= 'I.YO[H_/_P"M1N;^Z/S_ /K5YM_PS?\ #S_H _\
MDW/_ /%T?\,W_#S_ * /_DW/_P#%T >D[F_NC\__ *U&YO[H_/\ ^M7FW_#-
M_P //^@#_P"3<_\ \71_PS?\//\ H _^3<__ ,70 G@C>OQC^)@*'$G]FD-@
MX($!!P<<]:])5W/\(''0M7G'_#./P]W;O[ YW!LB\N 20,#)\SFFK^S=\/54
M#^P3@= +VXQ_Z,H ]*W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XN
MC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T
M?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^
M&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?
M_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#U
MJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-
M_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\
M^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!
M_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF
M_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N
M?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:O-O^&;_A
MY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?W1^?_P!:
MO-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y_P#UJ-S?
MW1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H ])W-_='Y
M_P#UJ-S?W1^?_P!:O-O^&;_AY_T ?_)N?_XNC_AF_P"'G_0!_P#)N?\ ^+H
M:Q=?VB2^S ;PQM&[(!/VO.,XQG _6O2EW*H&T?B:\V;]F_X>M@?V"5'JMY<9
M(SG&?,SC-+_PS?\ #WMH)'_;Y/\ _%T >D[F_NC\_P#ZU&YO[H_/_P"M7FW_
M  S?\//^@#_Y-S__ !='_#-_P\_Z /\ Y-S_ /Q= 'I.YO[H_/\ ^M1N;^Z/
MS_\ K5YM_P ,W_#S_H _^3<__P 71_PS?\//^@#_ .3<_P#\70!Z3N;^Z/S_
M /K4;F_NC\__ *U>;?\ #-_P\_Z /_DW/_\ %T?\,W_#S_H _P#DW/\ _%T
M>D[F_NC\_P#ZU&YO[H_/_P"M7FW_  S?\//^@#_Y-S__ !='_#-_P\_Z /\
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M=][AI"#GZ4 =TKAE##D'O3J0+C'.?>EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
/ **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>agio-20231231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 agio-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 95"X\# 2(  A$! Q$!_\0
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC/B+_S#_P#MI_[+79UQGQ%_
MYA__ &T_]EH N_#_ /Y TW_7PW_H*UTU<S\/_P#D#3?]?#?^@K734 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %<9\1?^8?_ -M/_9:[.N,^(O\ S#_^VG_LM %WX?\ _(&F_P"O
MAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HKF_B'\0-&^%_A'4/$>O7!@T^S3)"C+R,3A8T'=
MF. !^)P 37YR?%O]L[Q_\1M0GCTS49O"FB9(BL],D,<I7L9)A\S''I@>U 'Z
M?T5^/5GIOQ&U:&/5K2T\47L17*7T,=S(I7G)#@=.O>O5OV?_ -JKX@>$/'6B
M:)JVKW6O:)=WL5E<6FJL9985=PA9)&^=2N?ND[>,8[@ _2^BH[BXBM+>6>>1
M888E+O)(P554#)))Z "O@/X_?MV:UK6J76C?#R?^R=&B;RSJ^P&YN2#R4SQ&
MGIQN/7(Z4 ?H!17Y 6J_$[XG-+=VJ^+/%9W9>: 7-YAAZD9YYIL/C/XD?"W5
M%A_M;Q)X9O4'_'M/+/;DC/1HVQD9[$8H _8&BOD#]EG]L^Y\=ZU:^$/'30+J
M]R=EAJT:B)+A^T4BC@.>Q7 )P, XS]?T %%?DS\5?CAX[USXA^(9G\6ZS;Q+
M?SQPVUM?2Q10QB0A41%8    =.<9.371? _]J3QKX!^(&D_V[XFU/5?#TEPE
MO?VNJW+W"QPD[69-Y)0H#NXQG;@\4 ?J)12*P900<@\@BEH **_-K]J3]IGQ
M9XD^*>L:/X;\1:AI/A[2YFL88M+N'@^T.ORR.[(07R^X 9QM"\9R3YM\._C?
MX^T/QMHEQ!XOUJ1?MD(D@N+^66*52X!5T9B&!!/44 ?K=117Y,_%7XW^.M<^
M(GB*=_%>L6T2W\\<-M:W\L44,8D8*BJK   8'OWH _6:BOR5M=:^-5K:_;[:
M_P#'L-LT7F?:HIKU4,9&=VX'&W&#GI71_#W]LSXF^!;^)KK6Y/$NGA@9;/5S
MYI=>X$OWU..^2/4&@#]1Z*XOX0_%72/C)X'LO$NC[XX9BT<UM*09+>9?O1MC
MOR"#W!![U8^*_CB+X:_#?Q%XFE*YTZS>6)6Z/*1MB7\7*C\: .LHK\<[SXP^
M.[ZZEN)_&>OO-*Q=F_M*8<GV#8'T%?9_[ ?QFU7QC8^(?"GB#5KK5;ZQV7UE
M+>S-+*83\DB;F).U6V8_ZZ&@#Z]HHKP_]LKQEK/@?X%ZE?Z%J$^EW\EU;VXN
M[5RDJ*S_ #;6'*D@8R.>30![A17X\Z3X^^(NO7R6>F>(_%&HWC@E;>TOKF61
M@!DD*K$G K;O/&WQG\'VJ7%[KGCG1[17^5[JZO(HMV>GS$*?I0!^M=%?GE\$
M?V[_ !3X?UJUT_QY.NOZ%,ZQO?&-4N;0$XW_ "*/,4=2"-WH>Q_0BUNH;VVB
MN+>5)X)D$D<D;!E=2,@@CJ"* ):*_+[]ISXI>,K3X[>+[.W\5ZU:V=K>&&"W
MM[^6..) JX"JK "ON[]E[7-1\2? 7PAJ6K7UQJ6H36\GFW5U(9)9,3.H+,>2
M< #)]* /4Z*^-?VO?VNM7\%>(I_!'@F=+.^MT7^T=5VAY(W89$40/ (4@EN3
MS@8()KY7T?1_BQ\7(YKZPC\4^*(8W.^Y$D\Z!N21N)QGD\#GGWH _7*BOR?T
M'XJ_%KX!ZY;Q37NNZ.8R&.DZTDOD2J",CRI.,$?Q+@\\&OU=AD\Z&.3&W<H;
M'ID4 /HKY\_:@_:LL_@= FC:1!%JGBZYC$BPRY,-I&>CRX())QP@(SU) QGX
M/U[XS?$_XJZQY<_B'7-4N9F+1V&GR2*G_ (8L#@>V: /USHK\?M0\/\ Q,\#
MPC4;[3?%GA^$=+NX@N;9>H(^<@=\=Z]-^#_[:_COX>ZE;PZ_?S^+=!+ 307[
M[[E5[M',?FR/1B0?;.: /TTHK'\(^+-+\=>&=.U[1KE;S3+^(30RKZ'J".S
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M-ZM>P8$UM:33)D9&Y4)'ZB@#3HK\=;SXQ>/M4O9+B?QGX@EN)FRQ&I3#)]
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M8:?)(J?\ ABP.![9JCJ'A_XF>!X1J-]IOBSP_".EW<07-LO4$?.0.^.] '[
MT5^9?P?_ &U_'?P]U*WAU^_G\6Z"6 F@OWWW*KW:.8_-D>C$@^V<U^CGA'Q9
MI?CKPSIVO:-<K>:9?Q":&5?0]01V8'(([$$4 ;%%?%__  4"^)_BCPEJGA?1
M=#UN]T:RNK::XN/L$S0O,P=54,RD'  /&<<G-?+O@O\ :+^(O@C7+34+7Q;J
M]Y'!('>QO[V6>VF&1N5XV8CD#&1R.Q!H _7*BN=^'OCC3OB3X+TCQ+I3[K+4
M8%F5<@F-NCQM_M*P*GW!KRG]M;Q-JWA7X$W]YHNI76E7CWEO";BSE:*386.5
M#*01G'.#TXH ]XHKX/\ ^"?_ (^\3>(_B9K^G:MX@U35;%=(:X6WOKN29%D$
MT2A@&)P<,1QZUQ/[36M?%&/XZ>+(K"\\4Q:?'<*MK'8RW"P+%Y:E=@0[<$'/
M'<GO0!^DU%?C]J7C/XF:/"LU_KOBRQB9MBR7-W<QJ6QG )(YX/Y5!IWQ"^(>
ML3F"P\2^)KV8+O,=O?W$C!>F<!NG(_.@#]B**_(N+7OBZDB-'J/C42 @J5FN
M\Y[=Z^\/VO?%&O\ A?\ 9S^W6.HW>D:O)+:13W%I*891N^^NY2",D<X^E 'T
M)17YQ_L5_$CQ9K'QZTG3=0\3:O?Z?<6]SYUK=WTLL3[869259B,@C(-?HY0
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M/C0#_KO=_P"-8?\ PM;QM_T..O\ _@SG_P#BJ /V2HK\B1KWQ:(R-1\:$?\
M7>[_ ,:^X/V$[_Q;??#G7?\ A*IM6G9-4(M6U=I&D"^4A8*9.=N?PR3[T ?2
MU%?D=X\^,'CMO'FNR#QGK\;1ZA,(_+U*9 @61MH4!@% P, =*_0SQW#XA\5?
MLJRRZ5JEY:^(9O#MO>K>6LK)/)(L22NH8<Y<*RG'7<: /9:*_);X7_'[Q?X-
M^(&@ZM>^*=:N].M[N,WEM<7\LD<L!8"12K,0?ESCC@@'M7ZSQR)-&DD;!XV
M964Y!!Z$4 .HHK\O/VE/CSXG\1?&?Q+_ &/XFU6QT:RN6L;2WLKZ2*(+%A&<
M*K ?,RLV>^1Z"@#]0Z*\C^"XU[PO^S7H]UK-_<ZAKB:1+J#3WTC2R#>'FC5B
MV2=JLBX/3;BOS2N_C#X^U:^DGF\9>()KF9LG;J4PR3V #<>P% '[$T5^2_\
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MY9?L]?%3QI=?&_P9;W'BW7+FWNM4A@GAGU&:1)8V<!E968A@?>OU-H ****
M"BBOR4^)GQH\=ZI\0/$,TGB[6HE6_G2.&"_ECCB02,%155@  .P% 'ZUT5^2
MUCJGQL2%+VSN_'RQ/'O2X@DO=K(1D$,#R".<UJ>#/VM/BMX!OT!\37FKPQ2?
MOK+7";H/@\J6?]XOX,#0!^JM%>;? 3XW:9\=O Z:W91?8KZ%_(OM/9][6\N,
M]<#*L.0<>HZ@UY-^WUX]\0>"_A_X?AT'5KO1VU"_=+B:RE:*1T6,G9N4@@$G
MD \X% 'U%17X_:+XS^)GB2XD@TC7?%FJSQKO>.RO+F9E7.,D*3@9(Y]ZV?\
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MZ?,0I^E>O?!']N_Q3X?UJUT_QY.NOZ%,ZQO?&-4N;0$XW_(H\Q1U((W>A[$
M_0VBHK6ZAO;:*XMY4G@F021R1L&5U(R"".H(K\S_ -JKXR>-F^.'B?3+?Q/J
MNGZ;IUS]GMK.RNW@C10B\X0C))R23D\^E 'Z:T5^:'[-O[5GB?P3\0=.M/%7
MB._UCPM?.MK=#5+IY_LN<!949R2H4XR!P5W<9P1^ERL&4$'(/((H 6BOB/\
MX*#>//$GAGQ-X3L='U[4M)M);.6:2&QNG@61]X 9MI&X@=,].?4UZC^PCXHU
MCQ9\%;JXUK5+S5[F#5YK>.:^G::18Q%"P7<Q)P"S8^M 'T71110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5QGQ%_YA_P#VT_\ 9:[.N,^(
MO_,/_P"VG_LM %WX?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR:]E_P"";]M&OP_\6W /[V34TC8?[*Q C_T(T ?7<<:0QK'&JHB@*JJ,  =
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M^@\PX_VE- 'A/[*OP_;XD_&K2DN$,]GIH?5KMFYRL6"N?7,AC!]B:\S\)_\
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M ->5K_Z*%?5G[!/_ ";Y:?\ 81NO_0A0!XC_ ,%(O^1V\'?]@Z;_ -&UU/\
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M/XS^)_B+XG:K;^+;[7[[1ETF1_\ B;"4QI-YL00J7'#8+\#J,^E 'VM1110
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MP5^NU !1110 5^,'CK_D=O$/_81N/_1K5^S]?C!XZ_Y';Q#_ -A&X_\ 1K4
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M]$P4 ?3]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&?
M$7_F'_\ ;3_V6NSKC/B+_P P_P#[:?\ LM %WX?_ /(&F_Z^&_\ 05KIJYGX
M?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /S(_;J\+RZ!^T%J=ZRL(-8M;>\B8CCB,1, ?K$3^->V_\$Z?B%:3
M>&?$'@N>94U"WNO[3MHV/,D3JB.%'^RR*3_UT%>K_M9?L^M\<O!,+Z6(T\3Z
M26EL3(P59E;&^%F[;L @G@,!T!)K\UH9?$GPM\7+(GV[PYXBTV7C(:&:%NAX
M/8@GV(/<&@#]G*:SJ@RQ"C(')QR3@#\Z_-RQ_P""@?Q1M=-%M+'H5[, !]LG
ML7$I]\)(J?\ CM<QI'Q.^)G[1'Q7\+VE[J-[J\D6I03QV5HGEV]LJR*3(40
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M3GN0U 'P/^U)_P G!^.?^PBW_H*U^@_[(?\ R;CX)_Z]Y?\ T?)7Y\?M2?\
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M  49_P"20^'_ /L.Q_\ I//7B'_!/'_DN6H_]@*X_P#1T% 'Z.4444 ?&_\
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M3\<5^=_P&^(#?#'XN>&?$)D,=K;W:QW7/'V>3Y)?KA6)^H% 'Z[7W_'C<?\
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MWK[EKX:_X*5?\?WP^_ZYWW\[>@ _X)J_\?WQ!_ZYV/\ .XK[EKX:_P"":O\
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M1>"+[:?*EM;F$-CC<KH2/_'Q7W?7C7[5'P1D^-_PU>QL-BZ_ITGVS3S(<!V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5QGQ%_YA_P#VT_\ 9:[.N,^(O_,/_P"VG_LM
M %WX?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=!X1_9W^&W@:Z6ZT;P=ID%TA#)<31FXD0CH5:0L5/N"*]%HH **** /.;_\
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MF2\EHC6K,3U),17)]SS7IM% 'CNE_L@_"#2)UF@\%6LCJVX"ZN;BX7/NLDC
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M]O+(?5FB92Q]R:J>%?V7_A9X+O4O-+\&6 N4.Y)+QI+LH>Q7SF?!'J*]2HH
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M** ,#Q9X!\-^/(((?$>@Z?K<<!+0B^MDE\LG&2I8<9P,XZXKF/\ AG/X7_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KC/B+_ ,P__MI_[+79UQGQ%_YA_P#VT_\ 9: +OP__ .0--_U\
M-_Z"M=-7,_#_ /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&?$7_ )A__;3_
M -EKLZXSXB_\P_\ [:?^RT 7?A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_
M -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ I&8*I9B  ,DGM2U0U[3WU;0]1L8Y/*DNK:2!9#_"64J#^&:
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MD]JUQYXRJHVX/M7((<=AT-?&_P#P46_Y+9HG_8O0?^E-S7NW_!/'_DANH_\
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MQ+?>,?A3X3US5)%EU'4--@N+B1$"!I&0%C@<#)[#B@#L:*** "BBB@ HHHH
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MPK97<&#;%_+%>NU\>_\ !-W_ )$GQC_V$8?_ $57V%0 4444 %%%% !1110
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MH N_#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !1110 4444
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M.QX'4 GHHSBO:?\ @I%XJN%7P9X<CD9;9_/OYX\\.PVI&?P!E_[ZK)_X)T^
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M!W4;R<=R!GC(/Z+^/O!>E^-/ >K^';^UB?3[JS> 1[!B+Y3L91V*G!&.A H
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M]^+GB'Q#X8MYK;2-2E2=([B,1OYAC7S6(!/WI [=?XJ_2O\ 9AU=];_9_P#
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MJUU97T8 E0J<E">Z-SE3QWZ@&O@W]EO_ ).#\#?]A%?_ $%J /U6\2>(M/\
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M* "BBB@ K\X_^"AW_)<M._[ 5O\ ^CIZ_1ROSC_X*'?\ERT[_L!6_P#Z.GH
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MLD"+/M)B<GS.-L@1OPKY?_97U=]%_:$\#SH2#)?BV./25&C/_H= 'ZRT444
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M-J-A+#;B>R0(L^TF)R?,XVR!&_"OE_\ 97U=]%_:$\#SH2#)?BV./25&C/\
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MW]NCPCI_A/X\7+Z= EM'JEC#J$L4:A5$K,Z,0!_>,>X^[$U]4_L#W$DW[/\
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M8?\ ]M/_ &6@"[\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444
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MC(P!^H<_D:L?\$W_ !=9V]UXO\,S3".]N!#?6T;,/WBKN23 ]1N3\#[5]/\
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MYK^![7X[?&KQQX>N;V7Q->Z=#?P7#W5UYEO91*LBLSC[L>0!G"@DXX!K]+Z
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M>^R)23G_ 'BH]Z^__A1\*=!^#?@^W\/:!"RVZ$R37$N#+<RGK(Y &3P!Z
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MT1*/+$(F8S* ,;0^-X ';- '>_MX>,;/Q7\=I;:RF$\>C6$6G2LI!7S0SR.
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M6<]A>1Q3E[>YC,<B[KB5ERI&1D$'Z$4 >7_\%&?^20^'_P#L.Q_^D\]>6?\
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MGNK $?2OS&^(W[/'Q%^"/B$SMIU]+;VTGF6FNZ0KM'@'(?<G,3>S8/!QD<T
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M^(/^P[)_Z3P5]6U\Q?\ !/\ \.ZKX=^$>L+JNFW6FO<:S)-"MW"T32)Y$(W
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M6<7<$X\PJS $1R,1PIY(QQ7M?_!//XA?V'\1M6\)W$FVVURU\Z!2?^7B'+8
M]XS(3_N"OL/]HCX?'XG?!OQ-H447G7SVQN+-0,L9XSYD8'NQ7;]&-?F;\/=)
M\:> ?B%H.LVGAG6C?:;?Q2BW6PE#OAANCQMS\PRN/>@#]5-<^)7A?PUXET_P
M_JVN6>FZQ?QF6UM;J3RS*N<<$\9)! &<G'%=+7QU^W/\ ?%OQ$UK1_%?AC3G
MUF.SL?L=U96^#.@5W=75.K@[R,+D\#@]ODVV^)?Q3^&L8TU?$'B?0(H08A93
MSSQ)'P>!&_"GZ 4 ?4G_  4<T;P]%H_A?5 EO%XIEN6AW( )9K4(22W<A7V
M9Z;C7F7_  3WANW^.=W)!N%O'HT_V@XXVF2+ S_O;3^%>4^'_ /Q)^/7B%9[
M:RUCQ+>SX#ZG?.[1JO\ M32': /3/T%?H7^R_P#LZ6_P#\+W NYXK_Q+J6UK
MZZA!\M N=L49(!VC))) ))Z<   ^<?\ @I%_R.W@[_L'3?\ HVNI_P"";'_(
M#\=_]?%G_P"@RU7_ ."@WP]\2^)M>\):GHVAZAJ]G%:S6\KV%L\_E/O# ,%!
MQD'@GK@U\MZ'X7^*?AE9ET?2/&&DK,09%L;:ZA#D9P6V@9QD]?6@#]<=5U:Q
MT+3Y[_4KRWT^Q@7=+<W4JQQH/5F8@ 5^8_[8'QTM/C3\1(%T:1I?#NC1-;6<
MK CSW8@RR@'D E5 ]D![XKEY/AG\8OB%)#'=^'O&&LA3B-]1@N6C0_[\GRCK
MZU[;\&_^"?\ KVKWUMJ'Q!F31M+4AVTNUF$EU+_LLRY5%/J"6[8!Y !Z!_P3
MO^'%QHOA'7O&-Y%Y8UB1+6RW#!,,1;>X]F<X_P"V5?)/[1'Q!_X6=\9/$VN1
MR>99M<FWLSG(\B+]VA'IN"[OJQK]*?C7<7/P_P#@-XD7PII<AGL]-^R6-GIT
M)9H5;$09%4=$5MWL$)K\\?V>_@CKWCCXN>'+.^T'4(=(ANTN;Z:XM72)88SO
M*LQ&!NV[1[M0!9M_V,?C)=6\4T?@UO+D4.N[4K-3@C(R#-D'V-/;]BSXS*I)
M\&G &>-3LS_[6K]3:* /Q>\'^);SP+XPTG7;0%+W2[R.Y5&^7+(P)4^QP0?J
M:_5#XR:+%\9?V?-=@T@"[75M*6]L!_ST8!9X@/<E5'XU\$?M0_!76_"/QH\1
M_P!FZ%?W&CZA<&^M)[:T=XB)?G= 0,?*Y9<=@!7V?^Q/JFM7OP(T^RUNPN[&
M?2[J:R@-Y"T;2PC#HP# 94;RF?\ 8QVH _-?P3XGG\$^,=$U^V7?/I=[#>*F
M<;BCAMI]CC'XU^P7@7QUHOQ(\,66OZ!>QWVGW2!E92-R-CE''\+#H0>E?'/[
M3G[$NJWOB"^\5?#VVCO(;QVGN]#5EC>*0\LT.2 RDY.S(()PN00!\MP2>/\
MX0WTWDMXB\'71P)=OGV3-@\;ONY'UXH _7[5M6LM!TVYU'4KN&QL+9#)-<W#
MA(XU'4DG@"OR=_:0^*<7QA^+FL^(+3<-+RMK8AQ@^1&,!B.VX[GQVW8K/N-6
M^)OQDEBM);KQ-XPW-F.W+SW2 ],A>5'3DX[5ST=I<>!/&4,/B#1#+/IMVAO-
M(OPT?F;6!:-\<@,._H<\T ?H[^P_\/IO _P-LKJ[B\J\UV=M396'S")@JQ ^
MQ1 P_P!^OH&O'_@W^U!X!^+5G:VNGZA%HVL%53^Q;]EBE#=-L7\,@]-O..H%
M>P4 %?F=^WM_R<'=_P#8.M?_ $$U^F-?GK^W-\,O%>K_ !J_M;3?#NJ:GIUU
MI\"I<V-I),FY=P925!PPQG![$4 >\_L!?\D!7_L*W/\ )*])_:.UG1]%^!_C
M236Y(EM)M,GMHTD(S),\96)5_P!K>5QZ8SVK\V_#]O\ &?PGI_V#0XO'>C6.
M\R?9M/6]@CW'JVU,#)P.:L3?#'XT_%*[A_M#0_&&NR+D1SZPEP47H#B2;"CH
M._:@#A? =O=7GCCP[!9$B\EU&W2 J,D.95"_KBOTO_;4_P"39?&7_;G_ .EL
M%>=?LL_L:W'PTUJW\7^,Y()M=@!-CIUNXDCM6*D%Y&QAG ) "Y ZY)QCU']K
M[1K_ ,0?LZ^+K'3+*XU"]D6U9+>UC,DC!;N%V(4#)PJD_0&@#X=_8B_Y.4\+
M_P#7.\_])9:^D?\ @HSHLMU\,O#>IHFY+/5?*D(_A$D38/TR@'XBO!_V*_!?
MB"R_:&\/WMSH>I6]G;Q71FN)K21(X]UO(J[F(P,D@#W-?H+\2OA_IOQ2\#ZM
MX8U8-]CU"+9YB?>B<$,DB^ZL%/OC!XH ^"O^"??BZST#XQ7VEW<PA.LZ<T%O
MN8 -,CJX7ZE0^/ICO7Z-DX&3P*_)WXF_LX_$'X,ZV[SZ5>7-E;R[[;6]+1WA
M.#E7W+S$W'1L$$<9ZU3N_CQ\5/%FF-H$OBO7-1MY5,3VL<C-)*K?*58J-S Y
MQ@D]: )_VH/&%IXZ^//B_5K"43V1N5MH95.5<0QI%N4]P2A(/<&OT'_9%\.S
M>&?V=_!UM<(4FGMY+Q@1@XFE>5#_ -\.M?'O[/O[%_B?QYKEGJ?C#3;CP]X7
MA<2217BF*YO #GRUC.&13W<@<'C/;]'[>WBM+>*"&-8H8E")&@P%4#  'H!0
M!^2_[3D3P_M >.U=2I.IR-@^AP0?R(K](OV:[F*Z^ ?@-XG#J-)@C)4Y^95V
ML/P((_"OD?\ ;@_9_P#$$/Q$N?&^AZ9=ZMI&K)&;O[+$9&M9U41X*J,A&"J0
MW3<6''&? _"'B[XF65L?"OAC5/$L$3/_ ,@K3)9U(9CDX1.1G]: /I;_ (*2
MZ+,NJ^"-6"YMWAN;5F'9E9& /U#'\C7%?L7?"'X??&1O$NF^++.2[U>S\JXM
M4CNY(2T)RKD!2,[6V9_WQ7V3\6/@M'\:/@[;^&-8G^SZQ%!#-#?-\YANT3!8
M^H.65O4,>^*_.?Q#\+?B=\ _%"W<FFZIH]Y:/F#5M-#M"PSC*RIP01_"<'!P
M1VH ^[_^&&?A!_T ;K_P93__ !=;7@W]D?X8>!/$MCKVE:%*NI6+^;;R3WDT
MJH^.&VLV"1VR.#S7PM;?M<?&S5HOL-KXKN[DL-NVWTVV,O7^\L6[K[U[?^Q_
MX4^+&J_%Q_%WC--?&EK830FXUR213*S%=J(DAR1QG(&T;?I0!G_\%)-&ECU[
MP3JP4F&:VN+4L.S(Z, ?J'/Y&I_^"</C*SM[SQ;X7GF$=[="&_M48@>8$#+(
M![C<AQZ9]*^G/V@O@S:_'+X=76@2RK::A&XNM/NW!(AG4$#=CG:P+*?8YZ@5
M^97BKX8>/_@SX@634=)U30[VTDWP:E:APF1_'%.G'3G(.1WQ0!^O-Y>0:?:S
M7-U/';6T*&22:9PB(H&2S$\  =S5'PSXHTKQEHMOJ^B7\.IZ9<%Q%=6[;D?:
MY1L'V92/PK\I/[>^+7QL2'2!?>)_%D#$;;42330D@X#,/N\8/S-TYYK](/V:
M?A[JGPM^"WAWP[K0C35+=9I)XXG#K&TDSR!-PX) 8 XXR#C/6@#\FK'_ (_K
M?_KHO\Q7[:5^.%G\,O%\>O06+>%M9%XLZH8/L$N_=GIC;7['T ?G'_P4._Y+
MEIW_ & K?_T=/7T7^P%_R0%?^PK<_P DKPO]O[PAKNJ_&+3+^RT74+RR;1H8
MA<V]J\D>\33$KN (R 0<=>1ZU] _L,:'J.@_ F&#4["YTZ:34;B5([J%HF9#
MM 8!@#@X//M0!\;_ +:G_)S7C+_MS_\ 2*"ON3]C?_DVOP7_ -<[G_TJFKXU
M_;-\$^(;O]HKQ1?6^A:E/972VC07$5I(\<H6TA1BK 8.&4@^XK[5_9+TF^T+
M]GGP?9:E9SV%Y'%.7M[F,QR+NN)67*D9&00?H10!Y?\ \%&?^20^'_\ L.Q_
M^D\]>6?\$X?^2B>*_P#L%+_Z.6O8O^"@7A_5/$'PCT9-+TV[U)[?68Y95M(&
ME,:>1,-S!0<#) STR1ZUYC_P3R\*ZUH_C;Q5>7^D7UC:-IR1+/<VSQH7\T':
M"P )P"<4 <1_P4#T673OCI#>LG[G4-*@E1^Q*L\9'U&T?F*]V_X)X^+K/4OA
M7JWA[SA_:.FZB\[0EAGR957:P'IN5Q^7K7H?[4G[/<?QZ\&P1V4L=IXDTMGE
ML)Y<A'# ;X7(Z!MJ\]BH[9K\[K[PQ\2/@+XC-U+9:UX3U*$-&+V$.B.IZA95
M^5U..Q(XH _5WQYXNLO /@W6?$.H2K%::=:O<,6/WB!\JCU+'  [DBOQU\/:
M+=>*O$FFZ3; R7FHW4=M'@9)>1PH_4UVFL^.OBA\<C!IMY?:[XM57#1V5O$\
MJ;P,!O+C7&X ]<9Y]Z^K_P!D7]D/4O!&N0>-O&\"VVIP*?[.TG<':%B,>=(0
M<;L$@+SC.3@@  'J?[9T*V_[+_BZ*,;41;)5'H!>0 5\6?L1?\G*>%_^N=Y_
MZ2RU]Q?M?:-?^(/V=?%UCIEE<:A>R+:LEO:QF21@MW"[$*!DX52?H#7QM^Q7
MX+\067[0WA^]N=#U*WL[>*Z,UQ-:2)''NMY%7<Q&!DD >YH ]X_X*,Z++=?#
M+PWJ:)N2SU7RI"/X1)$V#],H!^(KQ?\ X)]^+K/0/C%?:7=S"$ZSIS06^Y@
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M9Q:K_9VHNBYVH6W0N?0;F=<^KJ* /FGX]?&J[^-.J>'+NYW@Z9H]O9R[NCW
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7&?$7_ )A__;3_ -EKLZXSXB_\P_\ [:?^RT 7?A__ ,@:;_KX;_T%
M:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!\?:;>ZUX$\1Z?IS
MF/4+O3;F"V=3@K*T3*A_,BMZB@#\:O!'B&?X9_$71M9N=.,USHFH1SRV-P"C
M%HW!9#D?*V01TX/;BOO2'_@H=\-FL5EETWQ#'<;<M;K:Q,0?0-YH!^O%>K_$
M;]G/X>?%2Z>\\0>'()=18#-_:LUO.V. 69"-_''S9KS5?^"?_P +5G\PMKC)
MG/E&^7;]/N9Q^- 'Q/\ '_XO3_'WXG-KEOIC641ACL;*S4^9*44DKNP.69G;
M@#N!SC)_0G]DWX9ZA\*_@KI6F:M&UOJMU))?W5NW6%I,;4/N$5,CL<BMKX=_
MLY_#SX6W,=WX?\-V\.HH/EO[EFN)QG@E6<G9Q_=Q7I- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7&?$7_F'_\ ;3_V6NSKC/B+_P P_P#[:?\ LM %WX?_ /(&F_Z^
M&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XSXB_P#,/_[:
M?^RUV=<9\1?^8?\ ]M/_ &6@"[\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_
MZ"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M**AN;R"S0/<31P(3@-(X4$^G- $U%5[74+6]+"WN89RO7RG#8^N*L4 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5QGQ%_YA_P#VT_\ 9:[.N,^(O_,/
M_P"VG_LM %WX?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\E_VI/\ DX/QS_V$6_\ 05K]!_V0_P#D
MW'P3_P!>\O\ Z/DK\^/VI/\ DX/QS_V$6_\ 05I/#/[3WQ-\&^%;3PYHOBB3
M3]'M%*001V=N60%BQQ(8R_4GOWH ^DO^"DFM:<UGX*TG*/JRR7%UM!^:.$A5
MR?9F'_D,UPG_  3KTZYG^,6MWJ!A:V^BR)*PZ%GFAVJ?KM8_\!KQC1/ _P 1
MOCYXFDO+73]5\2ZC=./.U*X#&,=OGE;Y5 [#/08 K]&OV9_@#;? 7P2]G+-'
M>Z_J#+-J-Y&/E+ 86)"1G8F3@GDEF/&<  ^2?^"BW_);-$_[%Z#_ -*;FO(?
M!_Q1\=#P3'\./"<EY'!?7TEU)#I*.;J[=T1?+ROS; (_NKC.3G(Z>O?\%%O^
M2V:)_P!B]!_Z4W->N_\ !.WPAI,7PYUGQ,+.-M;FU*2Q:\89=84CB8(O]T;G
M)..O&>@H ^)/&'P^\6_#6^MO^$BT74-"N9OWD$ES&R;R,$E6Z$C(Z'(S7VK^
MPG^T!JOC>/4?!/B6_EU&_L8!=:?=7#%I7@!"O&S'EBI9""<G#'LHKNOV[-&M
M=2_9XU:ZGC#SZ?=VMQ;OCE&:58C_ ..R,*^3?V$'9?VA], ) :RN@?<>7G^8
M% 'V!^V5\3O$?PK^$L6H>&)?LE_>:C'8O>",.T$;1R,64'(#$H%!QQGUQ7Q3
MI?[.WQK^,K+K-WI.J7HEY%]K]V(F8'N!,V\COD#'Z5^G7B+6M*\.Z/<:GK5W
M;6.FV@\V6YNV"QQX/!R>^<8[YQBOG3Q3_P %!/AQHMQ)!I=KK'B!E) FM[=8
M86_&1@W_ ([0!\1_$#X3>/?@+JUA+K=G<:'<39:TOK.X!5BN,[9(VX8<<9!Z
M&OMW]B'X]ZM\5O#>JZ#XDNFOM:T7RWCO9/\ 67%N^0-Y[LI7!;N&7.3DGY\_
M:;_:RT3X]>!+'0[+P]>:9=6NH)>"XN)48;1'(A7 ]=X_*MG_ ()QL?\ A:'B
M89X_L?./^V\= 'M'_!0K4KO3?@GI)M+J:U,VO01R>3(4WKY%PVTXZC*J<>H'
MI7QGX+_:$\3^ ?AWXB\-Z1?W4%UK-Q$SZAYS%[>)58.L7/RL^5RPY 7CG!'V
M)_P46_Y(GHG_ &,,'_I-<U\W?L/_  YT;XB?&1CK< O+;1[%M1CM9 #'+*LD
M:+O!Z@%]V.Y49XR" <W\#? _C.P^,7P]UA] UNVM+C6[60:A+9S)'+'YJF4B
M0KAALW9YZ9KZ(_X*1:M>V$/P]AMKR>WBE;4'DCBE95=E%L%) /) 9L>FX^M?
M:=?$/_!2W_FG/_<2_P#;6@#P;PW^TAXVT?X6V_P_\.7-Y!<W5[)))?02-)=R
M+)M"P0XY3D$_+R2W&.<\/XV^&WC+P-]GO?%.@ZGI7VYBT=Q?Q,OF-U(W'^+N
M0>:^H/\ @G'X1TG4]8\7:_=V<=QJNF"VALYY!GR!*)?,*CLQV*,]<9'<U]!_
MMF:7;:G^SEXL-Q$LCVJP7$+$<HXGC&1[X+#Z,: /C7X7_MI>-/ASX"U7P_(Y
MUNY9572KZ_<R-8]0V<Y,BXQM4G ([CBO/O$?A#XG>.](N/'FMZ5KVL:<ZF5]
M7NHG=/+Z[AGI&/4#:*N_LP^%=+\;?'CPCH^LVJWNFS7$CRV[_=D\N&210WJ-
MR#([C(K]96M87M3;-#&;<IY9A*C9MQC;CIC'&* /RP_9J_:$UKX,^--/ADU"
M1_"=W<)'J-C,2T:1L<&5!_"RYW<=<8.:_5-B54D#<0. .]?BSXIL8M+\3:O9
MP#;!;WDT,8]%5R!^@K]E?#,SW'AS2I9#NDDM(F9O4E 30!^8^IZY\:OVH-<O
M8[>+6=6MO-9&L+4F"PMN>$;)6,$#C+G<<<DU7\5?L>_%3PAX?N=9O?#R2V=K
M&9IQ:7<4TD:#JQ16R0 ,G;GC\:^Z?B5^UG\-?A)?S:5=ZA)J.IP,1+I^C0B5
MHFSDAF)5 V2<@MGKD5Y/=?\ !1SPI(9(T\'ZM- PV_O)HE+ CG(R?YT >#_L
MK_M'>(OAUX^T;1;_ %2YOO"FH7"6<UG<R%TMM[!5ECR?DVD@D#@C/&<$?IPS
M!5))P!R2:_%;16'_  D%@T8*+]JC*\\CYQBOUH_:$UZ7PW\$/&^H0-LG32IH
MXV_NLZ[ 1[@MF@#X:_::_:XU_P"(GB2^T7POJ=QI/A&UD:%&LY#')?8.#([
MYV$CY5Z8P3ST\Z\/_LT_%#Q;H*:]IOA"_NM/F7S8YG>.-Y5/(94=@S ]00#G
M\:Q_@CX8MO&?Q>\'Z+>1B6RN]3@6XC;H\88,Z_BH(_&OV#50J@ 8 X % 'Q#
M^P?X[\:K\0M?\">([K47L;'3'N5L=4#^99RI-$FT;_F0$2-\O3@'%>I_M?\
M[2L_P5T6TT7P^T?_  E>J1M(DLBAA9P9*^;M/!8L"%!R/E8GI@_0B:?:QWTE
MXMM"MY(@C>X6,"1E'(4MU(&3Q7Y:?MB:_/K_ .T1XL:5LQV<D=G$N>%6.)1@
M?5MQ^I- %;P+\&_B=^TO?7FL6[3ZJD<FR;5]8NB(]YYV*S9)(!'"@X!'3(JG
MXL\$_$G]E[Q59R7$UUX?O)@9+6^T^XS#<!<;@&'#8R,JP[C(P1GV+X+_ +;V
MD_"+X:Z-X53P7/>/8H_FW4=\L8F=W9V;'EG^]CKV%<W^TI^UEIWQ]\%V&BQ>
M%I=(N;2_6\2[DNUE^41NC( $!&=X/7^$4 ?8'[*OQZ?XZ> 9+C45CB\1:7(M
MOJ"1#:LF1E)@.P8 \?WE;'&*^6?^"@^M:A;?&G2[>&^N8K==$A=8HY650QFF
MR0 <9.!^0K4_X)OZC)'X[\7V _U,VFQSM_O)*%'Z2-7/_P#!0[_DN6G?]@*W
M_P#1T] 'T9^P-J%UJ/P)D:[N9KEH]6N(T:9RY5=D9VC/09)./<UJ?MPZA=:;
M^SWJ\EI<S6LC75LC-"Y0E3*,@D=C6'_P3Y_Y(/<?]AFX_P#1<5:G[=W_ ";O
MJO\ U^VO_HT4 ?+_ .P?K6HS?'N""2_N9()-.N=\;S,5; !&1GG!JU^VEX!\
M?2?%OQ5X@;3-5N/"?E6[QWL89K6.(0QJ02.%Q(&R#CDY[Y.1^P3_ ,G!VG_8
M.NO_ $$5]K_M8?\ )N_CC_KR7_T:E 'Y8>&]'U7Q!K5KI^AVMS>ZK.Q$$%FI
M:5R 2=H'/0&OKK]B_P"&?Q*\*_&!K_Q!HVMZ7HXT^9)I-0#QQN25VKAOO'//
M'I7BG[(?_)QW@G_KXE_]$25^K5 'Y[_\%#M<U&U^,&AVD%_<PVHT**40QS,J
M;S<7 +8!QDA5&?85[C_P3_U*[U+X'WK7=U-=-'K4\:&:0N57RH3M&3P,DG'N
M:\!_X*+?\ELT3_L7H/\ TIN:]V_X)X_\D-U'_L.W'_HF"@"Y^V)^TO<_!K2K
M30/#KH/%.IQ&7[0ZAA9P9*^8 >"[$$+G(&UB>V?A3P_X0^(7Q\UZZDT^VU3Q
M;J2?-/<3S;A'N/&Z21@JYYP"1T/I73_M?Z]+KW[1'B]Y&REK-'9QKV58XE7'
MYAC]2:^Y_P!C'PO;>&?V>_#;PQJEQJ7FW]RXZN[R$*3]$5!^% 'P=;VWQ8_9
M?\26=Y):ZMX9D>52$+;K2[QR8VVDQR<#IR1UXXK]%_VC_'6L?#7X+>)?$6@A
M?[5M(XA"[H'$>^9(R^T\':')YR,@9XS7H5]I]KJ4(AO+:&[B#*XCGC#J&!R#
M@]P>0:-0FM;>QN)KYX8K.-"\TEP0(U0#)+$\  >M 'Y;:=\*?C7^T,PU>6RU
MG7+>3]XE[JUR(8"#WB\UE!'^X,5A_$K]GWX@_!2WMM4U_2FLK-Y?+BU"SN%E
M19.2 60Y0G!QG&>U?;_C+]O3X9>%[N6UL7U+Q)*AVF33;=1#GO\ /(RY'NH(
M/ZUX;\=OVUM ^+WPLUKPI!X7O[*XOO),5Q/.C+&R3))G YZ*1^- '9?L*_M#
M:[XMU:\\#>)]0FU62.V-UIU[=.7F 4@/$SGEAAMP)Y&UAG& /7_VU/\ DV7Q
ME_VY_P#I;!7QA^PRQ'[1V@X.,VUV#_WX>OL_]M3_ )-E\9?]N?\ Z6P4 ?%/
M[$7_ "<IX7_ZYWG_ *2RU]R_M2?&J7X'_#&75+&-9=:OIA8V&\ K'(RLQE8'
MJ%"DX[G:#P37PU^Q%_R<IX7_ .N=Y_Z2RU]B?ML?"O5/B=\(D;1+=KS4]&NU
MOUM8U+231;&214 ZM\P;'?80.2* /AWP;X#^(_[5/BS4)(;V36KZW02W5]JE
MT1% &)VKWQD@X51V/  KJ]0_9I^-WP0O(M;T6TNY)(F4_:O#=R9FX/ :-<.R
M^N5*XSFN&^"'QV\1? /Q'=7^C1P7,%TJQ7NGW:G9,%)V\C!5ERV"/4Y!Z5]U
M?!S]MKP3\4+ZVTG48Y?"FN3D)'!>N'MY7/14F '/LP7/ &2<4 ?0D98QH7 5
M\#<!V/>GT44 %%%% 'EG[4G_ ";YXY_[!S?^A+7YN?LY_P#)>/ 7_89MO_1@
MK](_VI/^3?/'/_8.;_T):_-S]G/_ )+QX"_[#-M_Z,% 'ZA_&FZFL?@[X[N;
M:62WN(=!OY(YHF*NC"WD(8$<@@C.:_+SX/\ QJU?X1^,E\10/-J4T=K/#';3
MSOY3.Z%5+C/S*K$-COMZCK7Z??'/_DB?Q!_[%[4/_2:2ORI^$6@67BKXJ>$-
M&U*(S:??ZM:VUQ&&*EXWE56&1R,@GI0!T^L:+\6_CVMUXLNM,U[Q/;*S'[4D
M#M F.JPJ!MP/1!QWK&^$_P 9/%'P7\21:EH-])%&&Q<Z?*28+A<C*NG3/'WA
MR.QK]>-/T^VTFQM[*RMX[2TMT$44$*!4C4# 50.  *_*;]K#1K70?VA_&UK9
MQB&!KM+C8HP-TL22O^;.Q_&@#]3/"OB2S\8>&=*UW3G+V.I6T=U"6&#L=0P!
M'8\\CUKX@_:__:SUI_%%_P""/!FH2Z78:>YM]0U&U8I-/,.'C1QRJ*?E.,$D
M'MU^C/V<]6;2/V6?#6I-\YL](FF^8\80R$#Z<5^7MC#/XE\0V\,LA:YU"Z5&
MD/4M(^"?S- ';^#_ (!_$GXI:;)KFB^&[[5K.1F)O9I4C$I!P2K2,-_/IGH?
M2O9_V0/%'Q \ _'K2OA]K;ZI8Z;>1W N-'U(/MBV022))&K?=RT8&Y>"#WXK
M[_T71[3P]H]CI=A"MO8V4"6T$2]$C10JC\@*EDT^UEO8KQ[:%[N)2D=PT8,B
M*>H#=0#@<4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XSXB_\
M,/\ ^VG_ ++79UQGQ%_YA_\ VT_]EH N_#__ ) TW_7PW_H*UTU<S\/_ /D#
M3?\ 7PW_ *"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH)_!U<?\!KZ4_8Q_9A\5?"GQ)?>+?%2PZ=/<6+64&F)())0&='+R%<J/N
MD\G.,<^E_M._LUVGQ\T*VFM;B/3?$^GJPL[N4'RY$/)BDQSMSR& )4YX.2*
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MAWP5>'=0!^F'Q0^-7@_X/Z>EUXGU>.TDD_U-G&/,N)>>JQCG'^T< >M>'?\
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M/B;HOQA\(:AJ'A"^LK&PU:WN;FXF9%1(XY59CG=SP#P,Y[4 ?I?7Y6?MD?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \>_:P\8:
MMX0^">LG0[*[O-4U+&FQ&SA:1H1(#OD.T' "!@#_ 'F6OG7]B/\ 9GO6UT>/
M/%VES6<-BV-)LKV$H\DW_/<JPSM7^'U8Y_A&?NNB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC/B+_
M ,P__MI_[+79UQGQ%_YA_P#VT_\ 9: +OP__ .0--_U\-_Z"M=-7,_#_ /Y
MTW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7&?$7_ )A__;3_ -EKLZXSXB_\P_\
M[:?^RT 7?A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO>/#?A72[KP[I4TMMOEDM(G=O,?DE 2>M &]_;6G_P#/_:_]_E_QH_MK3_\
MG_M?^_R_XU2_X0_2/^?3_P BO_C1_P (?I'_ #Z?^17_ ,: +O\ ;6G_ //_
M &O_ '^7_&C^VM/_ .?^U_[_ "_XU2_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_
M\: +O]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XU2_X0_2/^?3_R*_\
MC1_PA^D?\^G_ )%?_&@"[_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (U2_P"$
M/TC_ )]/_(K_ .-'_"'Z1_SZ?^17_P : +O]M:?_ ,_]K_W^7_&C^VM/_P"?
M^U_[_+_C5+_A#](_Y]/_ "*_^-'_  A^D?\ /I_Y%?\ QH N_P!M:?\ \_\
M:_\ ?Y?\:/[:T_\ Y_[7_O\ +_C5+_A#](_Y]/\ R*_^-'_"'Z1_SZ?^17_Q
MH N_VUI__/\ VO\ W^7_ !H_MK3_ /G_ +7_ +_+_C5+_A#](_Y]/_(K_P"-
M'_"'Z1_SZ?\ D5_\: +O]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C5+_ (0_
M2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !H N_VUI_\ S_VO_?Y?\:/[:T__ )_[
M7_O\O^-4O^$/TC_GT_\ (K_XT?\ "'Z1_P ^G_D5_P#&@"[_ &UI_P#S_P!K
M_P!_E_QH_MK3_P#G_M?^_P O^-4O^$/TC_GT_P#(K_XT?\(?I'_/I_Y%?_&@
M"[_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\ O\O^-4O^$/TC_GT_\BO_ (T?
M\(?I'_/I_P"17_QH N_VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"-4O\ A#](
M_P"?3_R*_P#C1_PA^D?\^G_D5_\ &@"[_;6G_P#/_:_]_E_QH_MK3_\ G_M?
M^_R_XU2_X0_2/^?3_P BO_C1_P (?I'_ #Z?^17_ ,: +O\ ;6G_ //_ &O_
M '^7_&C^VM/_ .?^U_[_ "_XU2_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\: +
MO]M:?_S_ -K_ -_E_P :/[:T_P#Y_P"U_P"_R_XU2_X0_2/^?3_R*_\ C1_P
MA^D?\^G_ )%?_&@"[_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (U2_P"$/TC_
M )]/_(K_ .-'_"'Z1_SZ?^17_P : +O]M:?_ ,_]K_W^7_&C^VM/_P"?^U_[
M_+_C5+_A#](_Y]/_ "*_^-'_  A^D?\ /I_Y%?\ QH N_P!M:?\ \_\ :_\
M?Y?\:/[:T_\ Y_[7_O\ +_C5+_A#](_Y]/\ R*_^-'_"'Z1_SZ?^17_QH N_
MVUI__/\ VO\ W^7_ !H_MK3_ /G_ +7_ +_+_C5+_A#](_Y]/_(K_P"-'_"'
MZ1_SZ?\ D5_\: +O]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C5+_ (0_2/\
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MT_\ Y_[7_O\ +_C5+_A#](_Y]/\ R*_^-'_"'Z1_SZ?^17_QH N_VUI__/\
MVO\ W^7_ !H_MK3_ /G_ +7_ +_+_C5+_A#](_Y]/_(K_P"-'_"'Z1_SZ?\
MD5_\: +O]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C5+_ (0_2/\ GT_\BO\
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MY]/_ "*_^-'_  A^D?\ /I_Y%?\ QH N_P!M:?\ \_\ :_\ ?Y?\:/[:T_\
MY_[7_O\ +_C5+_A#](_Y]/\ R*_^-'_"'Z1_SZ?^17_QH N_VUI__/\ VO\
MW^7_ !H_MK3_ /G_ +7_ +_+_C5+_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\
M: +O]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C5+_ (0_2/\ GT_\BO\ XT?\
M(?I'_/I_Y%?_ !H N_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-4O^$/TC_G
MT_\ (K_XT?\ "'Z1_P ^G_D5_P#&@"[_ &UI_P#S_P!K_P!_E_QH_MK3_P#G
M_M?^_P O^-4O^$/TC_GT_P#(K_XT?\(?I'_/I_Y%?_&@"[_;6G_\_P#:_P#?
MY?\ &C^VM/\ ^?\ M?\ O\O^-4O^$/TC_GT_\BO_ (T?\(?I'_/I_P"17_QH
M N_VUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"-4O\ A#](_P"?3_R*_P#C1_PA
M^D?\^G_D5_\ &@"[_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XU2_X0_2/^?3
M_P BO_C1_P (?I'_ #Z?^17_ ,: +O\ ;6G_ //_ &O_ '^7_&C^VM/_ .?^
MU_[_ "_XU2_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\: +O]M:?_S_ -K_ -_E
M_P :/[:T_P#Y_P"U_P"_R_XU2_X0_2/^?3_R*_\ C1_PA^D?\^G_ )%?_&@"
M[_;6G_\ /_:_]_E_QH_MK3_^?^U_[_+_ (U2_P"$/TC_ )]/_(K_ .-'_"'Z
M1_SZ?^17_P : +O]M:?_ ,_]K_W^7_&C^VM/_P"?^U_[_+_C5+_A#](_Y]/_
M "*_^-'_  A^D?\ /I_Y%?\ QH N_P!M:?\ \_\ :_\ ?Y?\:/[:T_\ Y_[7
M_O\ +_C5+_A#](_Y]/\ R*_^-'_"'Z1_SZ?^17_QH N_VUI__/\ VO\ W^7_
M !H_MK3_ /G_ +7_ +_+_C5+_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\: +O
M]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\ C5+_ (0_2/\ GT_\BO\ XT?\(?I'
M_/I_Y%?_ !H N_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-4O^$/TC_GT_\
M(K_XT?\ "'Z1_P ^G_D5_P#&@"[_ &UI_P#S_P!K_P!_E_QH_MK3_P#G_M?^
M_P O^-4O^$/TC_GT_P#(K_XT?\(?I'_/I_Y%?_&@"[_;6G_\_P#:_P#?Y?\
M&C^VM/\ ^?\ M?\ O\O^-4O^$/TC_GT_\BO_ (T?\(?I'_/I_P"17_QH N_V
MUI__ #_VO_?Y?\:/[:T__G_M?^_R_P"-4O\ A#](_P"?3_R*_P#C1_PA^D?\
M^G_D5_\ &@"[_;6G_P#/_:_]_E_QH_MK3_\ G_M?^_R_XU2_X0_2/^?3_P B
MO_C1_P (?I'_ #Z?^17_ ,: +O\ ;6G_ //_ &O_ '^7_&C^VM/_ .?^U_[_
M "_XU2_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\: +O]M:?_S_ -K_ -_E_P :
M/[:T_P#Y_P"U_P"_R_XU2_X0_2/^?3_R*_\ C1_PA^D?\^G_ )%?_&@"[_;6
MG_\ /_:_]_E_QH_MK3_^?^U_[_+_ (U2_P"$/TC_ )]/_(K_ .-'_"'Z1_SZ
M?^17_P : +O]M:?_ ,_]K_W^7_&C^VM/_P"?^U_[_+_C5+_A#](_Y]/_ "*_
M^-'_  A^D?\ /I_Y%?\ QH N_P!M:?\ \_\ :_\ ?Y?\:/[:T_\ Y_[7_O\
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M_P#Y_P"U_P"_R_XU2_X0_2/^?3_R*_\ C1_PA^D?\^G_ )%?_&@"[_;6G_\
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M !H N_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-4O^$/TC_GT_\ (K_XT?\
M"'Z1_P ^G_D5_P#&@"[_ &UI_P#S_P!K_P!_E_QH_MK3_P#G_M?^_P O^-4O
M^$/TC_GT_P#(K_XT?\(?I'_/I_Y%?_&@"[_;6G_\_P#:_P#?Y?\ &C^VM/\
M^?\ M?\ O\O^-4O^$/TC_GT_\BO_ (T?\(?I'_/I_P"17_QH N_VUI__ #_V
MO_?Y?\:/[:T__G_M?^_R_P"-4O\ A#](_P"?3_R*_P#C1_PA^D?\^G_D5_\
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M^7_&C^VM/_Y_[7_O\O\ C5+_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !H
MN_VUI_\ S_VO_?Y?\:/[:T__ )_[7_O\O^-4O^$/TC_GT_\ (K_XT?\ "'Z1
M_P ^G_D5_P#&@"[_ &UI_P#S_P!K_P!_E_QH_MK3_P#G_M?^_P O^-4O^$/T
MC_GT_P#(K_XT?\(?I'_/I_Y%?_&@"[_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\
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MM:?_ ,_]K_W^7_&C^VM/_P"?^U_[_+_C5+_A#](_Y]/_ "*_^-'_  A^D?\
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M_P#(K_XT?\(?I'_/I_Y%?_&@"[_;6G_\_P#:_P#?Y?\ &C^VM/\ ^?\ M?\
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M%?\ QH N_P!M:?\ \_\ :_\ ?Y?\:/[:T_\ Y_[7_O\ +_C5+_A#](_Y]/\
MR*_^-'_"'Z1_SZ?^17_QH N_VUI__/\ VO\ W^7_ !H_MK3_ /G_ +7_ +_+
M_C5+_A#](_Y]/_(K_P"-'_"'Z1_SZ?\ D5_\: +O]M:?_P _]K_W^7_&C^VM
M/_Y_[7_O\O\ C5+_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !H N_VUI_\
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MK_W^7_&C^VM/_P"?^U_[_+_C5+_A#](_Y]/_ "*_^-'_  A^D?\ /I_Y%?\
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M_E_QH_MK3_\ G_M?^_R_XU2_X0_2/^?3_P BO_C1_P (?I'_ #Z?^17_ ,:
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MH_MK3_\ G_M?^_R_XU2_X0_2/^?3_P BO_C1_P (?I'_ #Z?^17_ ,: +O\
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M/_(K_P"-'_"'Z1_SZ?\ D5_\: +O]M:?_P _]K_W^7_&C^VM/_Y_[7_O\O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC/B+_S#
M_P#MI_[+79UQGQ%_YA__ &T_]EH N_#_ /Y TW_7PW_H*UTU<S\/_P#D#3?]
M?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RI7TKX3_ .15
MT;_KRA_]%K7S57TKX3_Y%71O^O*'_P!%K0!K4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%L(I1##+- 9//8??VC<.%X&?4D=C7N7@']BG0=!U".]\1ZI)XA\L[ELTA\B
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M;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^5*^E?"?\
MR*NC?]>4/_HM:^:J^E?"?_(JZ-_UY0_^BUH UJ*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HKC/BQ\4--^$OA&?6[]3<2;A%;6BL%:XE/10>PP"2>P!Z\ _#GC/\
M:3\?^,-1EG&O76C6S-^[M-*E:W2,>FY3N;ZDG^E>O@LLK8U<\=(]V>;BL?2P
MKY9:OL?HM7S3^T!^U5!X9^T^'?!T\=UJ_,=QJ2X:.U/=4[,_OT7W/3YL'QW^
M(']AW>DOXKU&>SND\N7SY?,D*]P)&RXST.#R":XO3=-N]9OX+&QMI;N\N'$<
M4$*EG=CT  ZU]#@\CC1FZF)::6RZ?/\ R/%Q.;.I'DH)IO\ K09=75QJ-W+<
M7$LES<S.7DED8N[L3R23R237U)^S]^R@UY]F\1^.+5D@XDMM%D&&?N&F'8?[
M'4_Q>A[?]G_]EVT\!_9]?\41Q7WB+AX;7AX;(]CZ-(/7H#T_O5]"USYEG%[T
M<*].K_R_S^XVP.66M5Q"U[?YC(HTAC2.-%CC0!511@*!T 'I3Z**^//ICGO'
MW@72OB-X7O-"UB'S+6<?+(N-\+C[LB'LP/\ 4'@D5^<OQ,^&^J_"WQ7<Z)JB
M9*?/!<J,)<1$_*Z_U'8@BOT[K@/C1\(M.^,'A-].N-MOJ4&9+&]QDPR8Z'U1
ML $?0]0*]W*\Q>#GR3^!_AY_YGD9A@5BH<T?B7X^1\H?LR_'YOAMJRZ#K<[-
MX9O9.)&.?L4I/WQ_L'^(?CZY^[(Y$FC62-E=& 964Y!!Z$&ORN\3>&]1\(:[
M>:/JULUIJ%I(8Y8F]>Q![@C!!'!!!KZ9_91_:"^RM:^!_$=S^Y8B/2KR5ON'
MM Q]#_">WW?3'LYOERJQ^MT-^OGYGEY;C73?U>M\O+R/KJBBBOB3ZLJZIJ5K
MHVFW5_>SK;6=M&TTTTAPJ(HR2?P%?F_\:OBC=?%GQS=ZO)OCL(_W%C;L?]7"
M"<9']YOO'W..@%>Y_MD?&3S)!X#TF?Y5*RZI)&>IZI#^'#-_P$=B*^<? '@G
M4/B)XMT_0--3-Q=28:0C*Q(.6D;V R?TZFONLFP:P])XNMHVM/)=_G^1\CFF
M*=:HL-3UM^+/8_V2/@W_ ,)GXF/BC5(-VBZ3(/(1Q\MQ<C! ]PG#'W*CUK[B
MK%\&^$M/\"^&=/T+2XO*L[.(1KG[SGJSM_M,22?<UM5\OF&,EC:SJ=.GH?08
M/#+"TE#KU"BBBO-.X**** "BBB@ HHHH **** "BBB@ HHHH ^+/VT?AJ-#\
M4V?BVSBVVFK#R;K:.%N$'!_X&@_-&/>O,_@!\2F^&'Q)T_4)9"NF7)^R7R]O
M*<CYO^ D*WX$=Z^\_BIX"M_B5X#U70)]JR7$>ZWE8?ZJ9>8V^F0,^Q([U^9N
MH:?<:3?W-E=Q-!=6TK0RQ/U1U)# ^X(-??Y56CC<(\/4W6GRZ'QN8TI87$JO
M3ZZ_/J?JZ"& (.0:6O%_V5?B9_PGWPWALKJ7?JVB[;2?<<L\>/W3_BH*^Y0G
MO7M%?#UZ,L/5E2GNCZRC5C6IJI'9A1116!L%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV\<?+BN[HHI5*DZLN:I)M^8X0C37+!604445F6%%%% !1110 5Y7^U#'<2_
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M5N?895AYT:3<U:X4445\Z>V%%%% !1110 4444 %%%% !1110 4444 %%%%
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M=5TI_P##H^CPV(CB::J1"BBBN,Z@HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** /E2OI7PG_R*NC?]>4/_HM:^:J^E?"?_(JZ-_UY0_\
MHM: -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%<K\1?B5H7POT!]5URZ\I.5AMTYEN'Q]U%[GWZ#N15PA*I)0@K
MMDRE&$7*3LD;>N:[I_AG2;G4]5NXK&PMUWRSS-A5']3V '))P*^(/CU^T[J'
MQ(>?1=!,NF>&<E7/W9KSW?\ NI_L]^_H.,^,7QPUWXP:MOO7^QZ1"Q-KID3$
MQQ]MS'^-\?Q'U. !61\-?A?KWQ4UY=,T2VW!<&XNI,B&W4_Q.WYX Y..!7W6
M RNG@X_6,4US+[E_P?Z1\CC,PGBI>QPZT?WO_@&%X?\ #VI>*M8MM+TFSEO[
M^X;;'!",L??V ZDG@#DUN:I\)?&NCWCVMWX4UA)5Z[+.1U/N&4$$>X-??/PB
M^"N@_"#1_(T^/[5J<R@76I3*/-F/H/[J9Z*/QR>:] KEK<0<M1JE"\?,Z*63
M7@G4E:1\&_#/]D?Q;XVWW&M*WA2P"G:UY"6G=L<8BR"!ZEB/;-<_\2/V;/&O
MPY\VXEL/[7TM.?M^G R*H]77&Y/J1CW-?HE17#'/L2JG,TN7M_P=SK>3T.3E
M3=^Y^3D,TEO*DL3M'(AW*Z$@J1T(/:O;_AO^UQXP\%^5:ZLX\3Z:O&V\<BX4
M>TN"3_P,-^%?4/Q(_9M\%?$?S;B:P_LG57R?M^G 1LS>KKC:_N2,^XKY3^*7
M[*_BSX<V]UJ-OY>O:) K2/=VORR1( 26DC)R  ,DJ6 [D5[M/'8',HJG65GV
M?Z/_ (9GD3P>+P+YZ3NNZ_5'J_CC]MZQ_L.!?"6E3'59ES))J:@1VQ[@!6^<
M_B!TZ\BO)(OVMOB='>>>VN0219S]F:P@\OZ9"!O_ !ZO'**[Z65X2C'E5-/U
MU..IC\34=W-KTT/O?X"_M+67Q8F71M3METSQ(L9<+&?W%R!U,>3D$#DJ<\ D
M$\X]OK\JO#VNW?AC7+#5K"5H;RSF6>)U..5.<?0]#[&OU0M9Q=6T4RC"R('
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0<DZ=1I>:.N&=3Y??AJ?;NJ?MH?#[3[PP0QZQJ48./M%K:H$^O[QU;]*^?\
M]H;]HJ?XL7*:5I GL?#$!#^7+A9+J3^]( 3@#LN?<\X \2HKUL/E.&PTU4@K
MM=SS:V8UZ\'"3LGV.I^&_P .=7^*'BBWT32(LR/\TUPP/EV\8/+N?0?J2!WK
M]$_AM\.-(^%WA>WT72(L(OS3W##]Y<28Y=CZGT[# %<7^RWX<T'2/A'I&H:+
M"?/U*/S;VXDP9))E9D92?[JL&"CTYZDD^O5\EFV83Q-5T5I&+^]^9])EN#C0
MIJH]9/\ (****^?/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9Z_ <YCN+=(6''&&B"]_4&O*O'/CS6_B-KTVKZ[>-=W3\(O2.%,\(B_PJ/\
MZYR<FN>KU3]FWX=:3\3/B5'IFM>:UA!;/=M#$VWSBK( C'J%.[G'/&..M?02
MHX;!*6(C!*RZ(\95*^*<:+DW=]23X(_L^:S\7KU;I]^F>'(GQ-J#+S)CJD0/
MWF]^@[\\'[Q\%^"=&^'^@PZ1H=DEG9Q\G'+R-W=VZLQ]3_*M73]/MM*L8+.R
MMX[6T@01Q0PH%1%'0 #H*L5\!CLQJXZ6ND5LO\S[+!X&GA(Z:R[A1117DGHA
M1110 52US28->T6_TRY!-M>V\EM+C^ZZE3^AJ[133:=T)JZLS\NO'W@C4?AU
MXLU#0=33%Q:OA9 ,+,AY61?8CGVZ=17/5^G7Q!^%WAOXGZ:MGK^GK<^7_J;A
M#LFA/^PXY'TZ'N*\8N_V&_"K1S_9M>UB.0JWD^:8F56P=N["#(!QG&,^U?>X
M?/:$H+V]U+\#X^OE%:,W[+5'Q_X9ATZX\1Z7'J\S6VE-=1K=3*I8I%N&\X')
MXS7ZFV=S!>6D%Q:R1S6TJ*\4D1!1E(R"".H(K\N_&G@W5/ /B2\T36+<P7ML
MV#_==?X74]U(Y!KWO]E7]H+_ (1FZ@\'>(KG&D3OML+N5N+:0G_5L>R,>A_A
M)]#P\XPDL72C7HN_+T[I]4&68B.&J.E45K_GYGV?1117P!]B%%%% !1110 4
M444 %%%% !11575-2MM%TV[U"]E6"TM8FGFE;HB*"6)^@%-)MV0MM6?.O[:'
MQ,_L3PS:>$+*7;>:KB>[VGE;=6X7_@;C\D8=Z^1?!_A>\\:^*-,T+3UW7=].
ML*'&0N>K'V49)]@:T?B=XZN?B1XXU7Q!<[E%U*?)B8_ZJ(<1I^"@9]3D]Z^C
M?V)_AGMCO_&][%RVZRT_<.W_ "UD'XX0'V<5^B14<IP%W\7_ +<_\OR1\5)O
M,L99?#^B/IOPKX;L_!_AO3=$T]-EG8P+!'ZG Y8^Y.2?<FM6BBOSN4G)N3W9
M]JDHJR"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "N,^(O_ ##_
M /MI_P"RUV=<9\1?^8?_ -M/_9: +OP__P"0--_U\-_Z"M=-7,_#_P#Y TW_
M %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RI7TKX3_Y
M%71O^O*'_P!%K7S57TKX3_Y%71O^O*'_ -%K0!K4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %9/BGQ3IG@O0;O6-8NDL["U3<\C=_10.[$\
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M (/_ "/TFHHHK\\/M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\
MY^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W
M\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_
MB_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"
MU157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?V
MI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U
M+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/
MW!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@
M_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7
M_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_
MXT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U1
M57^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9
M_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/
M_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_
M '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/
M^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&
M@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT
M?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157
M^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\
M_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\
MY^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W
M\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_
MB_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"
MU157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?V
MI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U
M+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/
MW!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@
M_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7
M_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_
MXT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&@"U1
M57^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U157^U+/_G[@_P"_B_XT?VI9
M_P#/W!_W\7_&@"U157^U+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&@"U17B7[0/
M[1MM\*;6#3]'2#4_$%VA=0SYBMDZ!W ZDG.%R.A)/0'Y U3XZ?$'5[PW,WC#
M6(I"<[;6[>!/^^(R%_2O=P>45\7#VEU%/:_4\C$YE2P\N2UV?I917Q-\'?VN
MM=T'4[?3O&$YUG2)G5#?2 "XM0>-Q('SJ.I!Y]#V/UE-\4/!MNNZ7Q;H<2^K
MZE"HY^K5R8K+Z^$GR25[[-'3A\;1Q$>:+MZG3T5PEU\=OA[9Y\SQCI#8;;^Z
MNED_]!SQ[US/BC]JKX?:+HM]/8:[%JFH1Q.;>SBAE_?2 ?*N[9@ GN36$<)B
M)NT:;^YFLL31BKN:^\Z_XB?%SPM\+K6.37]26":7F*TB4R3R#U"#H/<X'O7F
M^G?MI?#Z^O!#-%K&GQYQ]HN+1"GUPCLWZ5\3>)/$>H>+M=O=8U2X:ZO[R0RR
MR,>Y[#T ' '8 "LROLZ.0T%"U5MR\CY>IG%9SO322/7?V@/CU>_%[6?LMH9+
M3PS:2$VMJ>&E/3S9!_>(Z#^$'U))Y;X4_"O5_BUXGCTK3$\J!</=WKJ3';1_
MWCZD]E[GVR1S_A;0SXG\2Z5HZW,5FU_=1VPN)ON1EV"[C[<U^CWPU\%^&_A;
MX8@T;2)H J_//<-(OF7$F.78YZ^W0# %:X[%4\JH*C06KV_S9GA,//,*KJU7
MIU_R-'P!X!TCX;>&;;1-&M_*MXAEY&QYDTF.9'/=C^G &  *Z.JO]J6?_/W!
M_P!_%_QH_M2S_P"?N#_OXO\ C7Y_*4JDG*3NV?9QBHI1BK)%JBJO]J6?_/W!
M_P!_%_QH_M2S_P"?N#_OXO\ C4%%JBJO]J6?_/W!_P!_%_QH_M2S_P"?N#_O
MXO\ C0!:HJK_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\
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M\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T
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MA?M]OMC&05VR$E@,=,.'&/0"OL.'\19SP[]5^OZ'S.<T=(UEZ/\ 0^T_V?\
MQQ_PG_PIT/49)/,O88_L=USSYL?RDGW8;6_X%7HM?&G[$OCZ/2M>UGPO>3K%
M!?1B\MO,; $J<.![LI!_[9U]@_VI9_\ /W!_W\7_ !KPLRP_U;%3@MMUZ/\
MJQZ^!K>WP\9/?9_(M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QKS#O+5%5
M?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_
M ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^
M?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\
M?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[
M^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:
M+5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_
M:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[
M4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]
MP?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G
M[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q
M?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+
M_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5
M%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:E
MG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L
M_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<
M'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_
M +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\
M: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C
M1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5
M?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_
M ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^
M?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\
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MY_:EG_S]P?\ ?Q?\:^9S''RQU6^T5LOU/?P.#CA*=OM/<M455_M2S_Y^X/\
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M?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M%
M&%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I
M/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_
M\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C
M?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_
MC1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 8
M7_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_
M\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_S
MP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_
MC6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-
M'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?
M\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_S
MP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!
MO^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-
M;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?
M\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_P
MA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!
MO^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_
M[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUN
MT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_P
MA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%
MZ3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_
M[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_O
MXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[1
M0!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%
MZ3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I
M/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_O
MXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C
M?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M%
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M '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\
MA"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;
M_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-
M_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_
M (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_
M&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">
M#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"
M_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\
M?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\
MG@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH
MPO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_
M '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_
M )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:*
M ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-
M_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])
M_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MV
MB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">
M#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O
M2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK
M=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\
MG@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$
M+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\
M:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$+TG_
M )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\
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M44 %%%% !1110 4444 %%%% !7&?$7_F'_\ ;3_V6NSKC/B+_P P_P#[:?\
MLM %WX?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /E2OI7PG_P BKHW_ %Y0_P#HM:^:J^E?"?\
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M[XZ;G8EF_$UT5%%92E*;YI.[+C%17+%604445)04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\(_MB>!_^
M$9^* U>&/99ZY"+C(''G)A9!_P"@-]7H_8[\<?\ ",_% Z1-)LL]<A-O@GCS
MDRT9_P#0U^KU]!_M;>!_^$M^$UU?0Q[[W19!?)@<^7]V4?3:=W_ *^#])U2X
MT/5;/4;-_*N[.9+B%_[KHP93^8%?H6!DLPRYT9;I<OW;?H?%XM/!XU5([;_Y
MGZMT5C^#_$EOXQ\+:5K=I_J+^V2X5<YV[ADJ?<'(_"MBOS^47%N+W1]G%J23
M04445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG_LM %WX?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@
MHHHH **** "BBB@ HHHH **** /E2OI7PG_R*NC?]>4/_HM:^:J^E?"?_(JZ
M-_UY0_\ HM: -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%.2VEK_G_7F;Y76]KAU%[QT_R"BBBO!/7"BBB@ HHHH **** "BBB@ HHHH
M**** "BH[BXBM())YY$AAC4N\DC!551R22>@KQ/Q'^V)\/M OI+6&34=9,;%
M6ETVW5H\CT9W3</<9%=%'#UL0[4HMF-6M3HJ]25CW"BO.?AS\?O!GQ0N?LFD
MZ@T&HXW"QOD\J5A_L\E6^BDFO1JBI2J49<E2-GYE4ZD*L>:#N@HHHK(T"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O,?CE\<--^#V@EB8[O7[I#]BL,]>WF/CH@/XD\#N1+\;?C9I?P=T#SI
M=MYK5RI%EI^[ES_??T0'OWZ#U'Y\>*O%6I^-->O-9UBZ:[O[I][R-T'HJCLH
M'  Z 5]'E>5O%/VM7X%^/_ /$S#,%AU[.G\7Y#?$OB74O&&N7>KZO=R7NH73
M[Y)I#^0 [ #@ < #%>\?L]_LN_\ "?:>=?\ %:W%IHLJ$6=M&WERW&1_K<]D
M';^\>>GWG_LT?LVOXPFMO%7BBV*Z"AWVEE*,&](Z,P_YYC_Q[Z=?M6-%C141
M0B*,!5& !Z"O4S3-%17U;#.S6[73R7]:'GY?E[J_O\1L]EW\V?.T/[#_ (,2
M[#OK&MR6X;/D^9$"1Z%O+KVOP3X!T'X=Z.NFZ!IT5A;<%RO+RM_>=CRQ^OX<
M5T%%?*5L9B,0N6K-M'T5+"T:+O3BDPHHHKC.D**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYG_ &HOV=+[QI??\)7X6MEG
MU01[;ZR4@/<!1A9$[%P!@CN ,<\'Z8HKKPN*J82JJM/<Y\10AB:;ISV/R@O+
M&YTVZDMKNWEM;B,[7AF0HZGT(/(KTKX/_L_^(OBIJ=O(+673_#ZNIN-2F4HI
M3J1%D?.V.F.!QDBOT.GL;:Z8--;Q3,!@-(@8X_&IZ^BJ\03E"U.%GWO?]#Q*
M>2PC.\YW7:Q2T;1[3P_I-GIEA MM96D2PPQ+T5%& *NT45\FVV[L^B225D%%
M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QGQ%_YA
M_P#VT_\ 9:[.N,^(O_,/_P"VG_LM %WX?_\ (&F_Z^&_]!6NFKF?A_\ \@:;
M_KX;_P!!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** /E2OI7PG_R
M*NC?]>4/_HM:^:J^E?"?_(JZ-_UY0_\ HM: -:BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *XSXB_\ ,/\ ^VG_ ++79UQGQ%_YA_\ VT_]EH N_#__
M ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110 4444
M %%%% !1110 4444 ?*E?2OA/_D5=&_Z\H?_ $6M?-5?2OA/_D5=&_Z\H?\
MT6M &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,FL+>3PW>MR)-//[DGWB/RX]EVU&'S^G/W<1"WIJON_X<JMD\X^]1E?UT?\
M7W'@'@7]L;QIX9\N'65@\36:\'[0/*G ]I%&#]65C7;>/OVW!>>'XH/".E36
M.J3*1-<Z@%9;<_\ 3-02'/NV /[I[<#XZ_9!\;^%?,GTQ(?$MDO.ZR.V<#WB
M;DGV4M7AO0X->A3P>78N2K4DG;M^J.*>*QN&7LZC:]?T9VUQ\;O']S>?:7\9
M:T),YVQWLB)_WPI"_I7O/P#_ &LM1O-:LO#GC22.Y2ZD$4&KD!'1SPJR@#!!
M.!NX(SSGJ/E"BNW$8##XBFX2@EYI;'+1QE:C/G4F_P!3]9J*Y3X4ZI<:W\,O
M"M_=L7NKC3+=Y7;JS&-<M^/7\:ZNORV<7"3B^A^@QESQ4EU"BBBH*"BBB@ H
MHK,\2^(+/PGX?U#6=0D\JRL8&GE;OA1G ]2>@'<D4TG)I+<3:BKL^8/VY/%V
MF31Z#X:2&.;5H7-])/\ Q01D%0@/^V>2/]A3W%?+WASPWJ?B[6+?2M'LY+_4
M+@D1P18RV 2>O   )R:M>./&%[X^\6:GK^H'_2;Z8R%0<B->BH/95  ^E?5G
M[%OPO.EZ+=^-+Z+%QJ -M8AARL*M\[_\"8 ?1/>OT;F648!7UDOS9\1RO,L8
M[:)_DCPW5OV8/B%H?A:?7+O1U$<'S26<4RRW 3!)?:F1@=QG(STX./,=.U&Z
MTB^@O;&XEM+N!Q)%/"Y5T8="".AK]7:^;_C]^RK;>+?M/B#PA%'9:V<R3Z>,
M)#=GN5[(Y_(GK@Y)\[!9XJLO9XI)7Z]/G_F=N*RETX\^';=NG7Y#_@#^U1:^
M,?LV@>+98['73B."^.$ANST /9)#^1[8.!7T;7Y0W^GW.E7L]G>6\EK=P.8Y
M89E*NC#@@@]#7TE\ ?VKI_#WV;P]XTGDNM+XCM]5;+2VXZ!9.[I[]1[CIEF.
M3;UL*OE_E_E]QI@<T_Y=8A_/_/\ S/LRBH;2\@O[6*YMIH[BWF4/'-$P9'4C
M(((X(-35\<?3A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;-GZ)A:<J5"$);I!1117$=04444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXD _\=KYQD"+(XC8L@)VL1@D=CBFU]I4R_"U9NI.FFV?+0QN(IQ4(SLD??\
M\%_VFM#^*UPFE74!T7Q"P)2T=]\<X R3&^!S@$[2 ?3/->SU^4>F:E=:+J5K
M?V4[VUY;2+-#-&<,CJ<@C\17Z?\ @/Q$WBWP5H6M.H234+&&Y=1T5F0%A^!)
MKXS-\OA@Y1J4OAET[,^HRW&RQ*<*GQ(W:***^=/;"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M***XCJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC/B+_S#
M_P#MI_[+79UQGQ%_YA__ &T_]EH N_#_ /Y TW_7PW_H*UTU<S\/_P#D#3?]
M?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RI7TKX3_ .15
MT;_KRA_]%K7S57TKX3_Y%71O^O*'_P!%K0!K4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\B_MB?&G[1,W@/1Y_W495]5EC/WFZK#GVX9
MO? [$5[7^T!\7X?A)X*DGA=&UR^W0Z?"W.&Q\TA']U 0?<E1WK\[KJZFOKJ6
MXGD>>XF<R22.2S.Q.22>Y)-?69)@/:2^LU%HMO7O\OS]#YW-<9R1]A!ZO?T_
MX)M> _!.H_$3Q78:#I:;KFZ?!D(.V)!RTC>RC)_3J:_2CP/X,T[X?^%K#0=+
MCV6EI'MW$#=(W5G;U9CDFO+_ -EWX+CX:^$_[6U.#;XBU5%>4,/FMH>JQ>QZ
M,WO@?PU[=7)G&/\ K57V4'[D?Q??_(Z,LP?U>G[2:]Y_@B&\LX-0M9K:ZACN
M+:92DD,JAD=2,$$'@@U\7_M"?LMS^$?M/B+PC#)=:'S)<Z>N6DM!U++W:/\
M5>^1R/M:BO.P>-JX*?/3VZKN=V*PM/%0Y9[]'V/RET?6+[P_J=MJ.FW4ME?6
M[B2*>%MK(P[@U]Q_ #]IBQ^)4<.B:\T6G^)U&U#]V*]QW3T?U3\1W Y#]H3]
ME--1^T^)/!-LL=WS)=:/&,++W+PCLWJG0]L'@_(F9K*YR/,@N(7]U=&!_,$&
MOMI0PN=4.9:27WK_ (!\I&6(RNK9ZI_<_P#@GZPT5\E_!O\ ;$@L=%;3?';7
M$UQ;)^XU*"/S'G _@D4?Q_[7?O@\GNM._;2^'U]>"":+6-/CSC[1<6B%/KA'
M9OTKXZIE>+IR<>1NW5'TU/,,-.*ESI7[GO5%4=%UO3_$6F0:CI=Y#?V,Z[HY
MX'#*P^H[^W:KU>6TT[,]!--704444AA1110!Q/QC^(T'PN^'^I:VY4W07R;.
M-O\ EI<,#L&/08+'V4U^:U[>3ZE>3W=U*T]S/(TLLKG+.[')8^Y)->X?M<?%
M+_A-O'IT.RF+:3H9:'Y3\LEQTD;\,!!_NMZU@_LT_"[_ (69\1K?[5%OT;2]
MMY>;AE7P?DB/^\W4?W5:OT'+:,<OP;Q%7=ZOTZ+^NY\9CJLL;B51I[+3_-GU
M-^RS\+?^%>_#N*]O(=FLZT%NI\CYHX\?NH_P!+$>KD=J]GHHKX6O6EB*LJL]
MV?6T:4:--4X[(****P-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HILD
MBQ1L[L$11EF8X 'J:^(_C=^V+K6L:K=:3X)G_LG28)&C_M.,!I[K'&Y21\B'
MMCYCP<C.*YZU>%!7D>MEV68C,ZCIT%MNWLC[>HK\P--^//Q%TJ^%U#XTUJ20
M'.VYO'GC_P"^')7]*^Q_V;?VDU^+RRZ+K,,-CXDM8O,!B.([M!PS*#]UAQE<
MGKD<9 YZ.-IUI<NS/5S'AS%9?2=:ZE%;VZ?+L>\4445Z!\H%%9GB3Q)IOA'0
M[O6-8NX['3K1-\T\F<*,X' Y))(  Y)( KY+\;?MX7ZZE-%X3T"T^Q(V$N=6
MWL\H]?+1EV_]]'^E<]6O3H_&SUL#E>+S%OZO"Z779'V/574M4L]%T^>^O[J&
MRLX%WRW%PX1$7U)/ KY#\*_M[7:1S+XE\,PS/Y;&.32I3&"^/E5E<M@$]6#'
M'H:\-^+/QT\4?&"_WZM=?9]-C;,&EVQ*P1^A(_C;_:;WQ@<5RU,?2C&\-6>[
MA>%L;4K<E?W(KKO]W_!L>Z_&S]M)YOM&C^ ,QQ\I)K<R?,?^N*'I_O,,^@'!
MKY.O;ZXU*\FNKN>2ZNIF+R33.7=V/4DGDFMKP/X!U[XC:TFE>'].EU"Z;EBH
MPD2_WG8\*/<_SK[>^"?[)>@_#G[/JNO>5X@\1+AU9US;6S?],U/WB#_$WH,!
M:\R,:V-E=[?@?9U*^6\-T?9P7OOI]I^KZ+\.R/FWX=?LD^-?B!H$VK,D.AP-
M%OLTU$,KW1[?*!E5(_B(YXP"#FLRX_93^*4%X;<>%I)3NVB2.[@*'WW;^GUK
M](:*]'^SZ5DKL^0_UNQRG*2C&SV5GI^*/S;^(?[,OC?X:^&8-<U*T@N;,Y^T
MBQD,K6G/'F<=#_>&0.Y'&?/_  KXLU;P3KEMK&B7LFGZA;G*31GMW4CHRGN#
MP:_6&:%+B)XI462-U*LCC(8'@@CN*^./VB/V17T_[3XD\"6K26O,EUHD8RT?
M<O".Z_['4=LC@<N(P3I^_2Z?>>[E7$D,8WAL>DF]GT=^C_K7\_8?@%^TII/Q
M>M(].OO+TOQ3&F9+/.([C Y>$GKZE3R/<#->TU^15G>7&FWD5S;326UU"X>.
M6)BKHP.001R"#7VQ^SO^UG;^*OLOAOQG/'::T<1VVIMA(KL]E?LDGOT;V. >
MC"XU3]RIOW/)SOAN6'OB<&KPZQZKT[K\4?3M%%%>L? A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <;\6OAK9?%;P3>
MZ'=[8YV'FVER1DP3 ':WTY(/J":_-K7=#O?#6LWNE:C UM?6<K0S1-_"P.#]
M1Z'N*_5>OF+]L+X,_P!L:9_PG&DP9O;) FI1H.981TE^J=#_ +/^[7T^2X[V
M-3ZO4?NRV\G_ ,$\#-<)[6'MH+5;^G_ -#]D/XR_\)5H/_"(:K/NU73(\VDC
MGF>W'&WW9.!_NX]":^C:_*[POXFU#P=X@L-:TN8P7]E*)8G[<=01W!&01W!-
M?I1\,_B!8?$WP;8:_IYVK.NV:#.6@E'#QGZ'IZ@@]ZG.L#]7J>W@O=E^#_X)
M65XOVT/93?O1_%'4U\7?MG?%#^W/$EMX/L9]UEI?[Z\V'A[AAPI_W%/YNP[5
M]1?%CX@6_P ,? >IZ_.%>6%-EM"Q_P!;,W"+],\GV!-?FAJ&H7&JW]S>W<K3
MW5S*TTLK]7=B2Q/N236V0X3VE1XB2TCMZ_\  ,LWQ/)!4([O?T.Y^!?PU?XI
M_$33])=6_LZ+_2;YU_AA4C(SV+$A1_O9[5^D4,*6\211(L<:*%5%& H'  'I
M7BO[*/PO_P"$#^'<>I7D'EZQK6VYEW#YHX<?ND_(EC[OCM7MM<.<8OZUB'&+
M]V.B_5G7EN&^KT>9[RU_R"BBBO"/7"BBB@ HHHH **** /SS_:6^%?\ PK'X
MA3FTA\O1-4W75EM&%3GYXA_ND\?[++6O^R?\5/\ A O'HTB^FV:-K96!RQ^6
M*?\ Y9O[ DE3_O GI7U;\??A>GQ4^'EYI\2*=5M?]*L'/7S5!^3/HPROU(/:
MOSDDCDMYF1U:*6-BK*P(96!Y!'8U^AX&K',\&Z-7=:/]'_74^+Q=.6 Q2JT]
MGJOU1^L=%>4_LW?%3_A:'P[MWNI?,UK3<6E]N/S.0/DE/^^HY_V@U>K5\%6I
M2H5)4I[H^OI5(UH*I'9A1116)J%%%% !1110 4444 %%%97B;Q1I/@[1YM4U
MJ_ATZPA^]-,V!GL .K$]@,DTXQ<G:*NQ-J*NRC\1]4N-#^'OB?4;0L+JTTRY
MGB9>H=8F*G\"!7Y>EBQ))R?6OH7XW?M8ZCXWBN]$\,(^E:#*K137#@?:+I",
M$?["$=AR1U(R17SS7Z)DV#J86E)U59R_K4^*S3%0Q%1*F[I!5C3[^?2]0MKV
MUD,5S;R+-%(O564@@_F*KUL>#I-*A\6:.^N>8='6[B:[\H9;R@PW<?2O>EI%
MNUSQXZM*]C]2+28W%K#*R[&D16*^F1G%35%:W4-]:PW-O*L]O,@DCDC.5=2,
M@@]P14M?CKW/TU!1112&%%%% !117/\ C[QK8?#SPCJ.OZDW^CV<>X1@X:5S
MPJ+[L2!^.:J,93DHQ5VR9244Y2V1\<?MI:-8:?\ %2"]MKM)+R_LHY+NV7[T
M3+\BL3T^95''7Y<]Q7@%;'B[Q3?^-O$NH:YJ<OFWM[*97/9>P4>P  'L!7O/
MP._90M_B)X-77_$%]?:8MT^;.&U" M$.-[;E/4YQ[#/<5^GQJ0RW"P6(EM9'
MP4H2QV(DZ,=]3YP2-I'5$4N[' 51DD^@KU/4/V7_ (E:?9171\-R7$;HKE;>
M>-Y$R,[2F[=D=\"OK_X:_LW^#/AC>)?V5K+J6J)]R]U%ED>,^J  *I]P,^]>
MI5X.)S]J:6'C=>9Z]#)KQ;KRU\C\L-<\(Z[X98KJ^C:AI9!Q_IEL\7_H0%9%
M?K(Z+(C(ZAE88*L,@CTKC/%'P8\%>+;>=+[PUIOGRHR?:H;98YE)'4.H!R.O
M6JI\0QVJT_N9-3)7_P NY_>C\SJ*Z'Q]X(U'X=>+-0T'4TQ<6KX60#"S(>5D
M7V(Y]NG45SU?71E&<5*+NF?-RBXMQDM4202+#/&[1K*JL&,;9PP!Z''K7ZL:
M5';PZ7:):0);6JPH(H8U"JB8&% '0 5^;GP9^&MW\5/'EAI$*'[&K":^FQQ%
M I&X_4_='N17Z6*H50 , < "OB^(:D7*G33U5[_.UCZG)8249S:T=A:***^0
M/I0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N,^(O_
M ##_ /MI_P"RUV=<9\1?^8?_ -M/_9: +OP__P"0--_U\-_Z"M=-7,_#_P#Y
M TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RI7TK
MX3_Y%71O^O*'_P!%K7S57TKX3_Y%71O^O*'_ -%K0!K4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !5#7=<LO#6CWFJZE.MM8V<3332MT50,_B?0
M=S5^OB_]K[XT_P#"0ZL?!6D3YTVPDSJ$B'B:<=(_]U._^U_NBO0P.$EC*RIK
M;J^R./%XF.%I.;WZ>IX]\7OB;>_%?QM=ZU=;HK;_ %5G:DY$$()VK]3DDGU)
M]J]3_9)^"W_"8Z__ ,)7JT&[1=+E_P!&CD'%Q<#D?54X)]3@=C7D?PO^'=_\
M4/&=CH-@"GFG?<7&,B"$$;W/TZ#U) [U^DWA?PUI_@_P_8:+I<(M["SB$42=
M_<D]R3DD]R37UN;8N."HK"T-&U]R_P""?-Y=AI8JJ\15U2_%FI1117P1]@%%
M%% !7S=^U=\$=!U'PSJ?C>V9-*U>R17N"J_N[P%@H# ='R1AN_0]B/I&O-OV
MCM N?$OP5\465FC27 @2X6- 26$4J2,,=^$/%>A@*TJ.)@XRM=I/TOJ<>,IQ
MJ4)J2OH[>I^<5%%%?JI^=GMO[*GQ3NO _P 0K3199"^C:Y*EK)$QXCF8XCD'
MH<D*?4'V%??-?DY%*\,B21NT<B$,K*<$$="#ZU[!X%_:L\>>#?+AN+]?$%BO
M'DZH"[@>TH(?/U)'M7R^:93/%3]M1M?JNY]!E^8QP\/95;VZ>1^@=%>!^!?V
MR/!OB7RX-:CN/#5XV 3./-MR?:11D?5E ]Z]PTG6+#7K%+S3;VWU"TD^[/:R
MK(C?0@XKXRMA:V'=JL6OZ[GU%+$4JZO3E<N5YI^T%\3U^%OPYO;Z"0+JUW_H
ME@N>1(P.7^B#+?4 =Z@^(7[2G@?X<ZA)I]]?3:AJ,?\ K+338Q*T9]&)(4'V
M)S7QY^T%\9/^%Q>+XKNTCGMM%LXA%9V]P '&<&1V ) )/'!Z*M>KEN6U:]6,
MJD6H;Z]?^'//QV.IT:<HTY7EMZ'F/SS2?Q22.?J6)_K7Z*_L\?"\?"[X<V=I
M<1[-7OL7=^2.5D8#$?\ P!<#Z[CWKY:_9+^%O_"=>/AK%[#OTC0RL[;A\LEQ
MG]TGO@@L?]T ]:^\Z]'/L9=K"PZ:O]%^IPY/AK)XB7HOU"BBBOCSZ8**** "
MBBB@ HHHH **** "BBB@ KC_ !M\7O!WPZD6+Q%K]KIT[+O%N=TDVWU\M 6Q
M[XKE?VE?B\_PC^'SW%D?^)WJ+&UL3@$1MC+2D'KM'3W*]LU^<^H:E=:O?3WM
M]<RWEW.Q>6XG<N[L>Y8\DUYN*QGL7R15V?99)P^\R@Z]:3C#96W9^FGA#X]>
M /'=\EEHOB:TN;R0[8[>97@DD/HJR*I8^PS7?5^0R.T;*RDJRG(93@@^M?=O
M['OQKN_B!H-WX;UNXDN]9TI!+%=2MN>>W)Q\Q/)920">X9>^:G#8WVTN2:LS
M?.>&U@*+Q&'DY16Z>Z\]/\CZ,HHHKU#X8**** "BBB@ HHHH **** "BBB@
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MP\7[-Z]7;RO^1U5%%%>@?)!1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'3T(![5^DOBCPY9>+_#VH:+J47FV5]"T,J]\$=1Z$'!![$"OS,\=^#;[X?\
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MZFIP>%EC*RI1^?DBL5B(X:DZDOZ9\_\ QB^)EU\5O'5]K4VZ.TSY-E;L?]5
MI.T?4\L?=C7K?['?PA_X2/Q WC+4X<Z;I<FRR1QQ+<XSO^B Y_WB/[IKPWP%
MX+O_ (A>+=.T#35S<7D@4R$96)!RSM[*,G\,5^EWA'PK8>"?#6G:'ID?E65E
M$(D]6[EC[DDD^Y-?89MBHX/#K"T=&U;T7_!_S/F<MP\L56>(JZI?B_\ @&Q1
M117P1]@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7&?$7_F'_\ ;3_V6NSKC/B+_P P_P#[:?\
MLM %WX?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /E2OI7PG_P BKHW_ %Y0_P#HM:^:J^E?"?\
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M),>9/(>KMCZ  =@ *ZNBBO G.523G-W;/9C&,(J,59(****@H**** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWCGXF>;!?:HVGZ8_']G:=F&(CT8YW/\ \")'M7F<,,EQ(L<2-)(QPJ("23Z
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MCYI45:C&+G'7:S^:Z_B9C,6)).2>II***X3Z@^]?V0_@SIOA'P;:>+IGAO\
M6]8@$D<R<K;0GI&I_O'^(^HQVR?H:O'OV2(KF'X!^&Q<!AN-PT0;KL,\F/ZG
MZ&O8:^MP\5&E&RMH?@.;5*E7'5G4E=J37R3L@HHHKH/("BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7DO[3_@&[^('PIO+?3XS/?Z?,NH0PKUDV*P91ZG8[8'<@"O6J
M*VHU94*D:L=T[F56FJT'3ELS\F:*^[OBE^R/X:\>7TNI:1<'PUJ4I+2B"$26
M\K'^(QY&TGU4@=\$UQ>@_L*V\-\CZSXJ>YM%()AL[3RW?U&]F;'Y&OT&&=8.
M4.:4K/M9GQDLJQ,9<L5==[G!_L<^ ;OQ!\2E\1-$1IFBHY:5NC3.A14'J0&+
M>V!ZBONBL?PGX0T?P/HL.DZ'8Q:?81<B.,<LQZLQ/+,<#D\\5L5\5F&,^NUW
M4M9;+T/JL'AOJM+DO=[L****\T[@HHHH **** "BBB@ HHHH **** /"_P!L
MGQ!/HOP>-M Q7^T[^*TD(_N;7D/YF,#\37P;7Z._M!_#B?XH?#._TNSP=2@=
M;RT5NCR(#\OU9691[D5^<LT,EO-)%*C12QL5='!#*0<$$'H:_0,AG!X9P6Z>
MI\;G$9*NI/9K097LO[)?B2ZT/XT:5:12,+74TEM;B,'A@(V=3CU#*/S/K7C5
M?2/[&/PSNM6\7R>,KB,QZ;I:O#;LP_UL[H5./948Y]V7WQZF8SA#"5'/:S^_
MI^)Y^!C*6)AR=_PZGVK1117Y6?H04444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN+2L[^3M;K^I^C=%%%?6GX$%%%% !1110 4444 %%%% !1110 4444 %%%%
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MP?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\
MOXW^- &G_:EG_P _<'_?Q?\ &C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?
M\(7I/_/!O^_C?XT :?\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^-<=XN;PGX)L
M/M6J,T9;/EP)(3+*1V5<_KT'<UY;+\:M!6XQ'X7G>#/WVORK?]\[2/UKS<1F
M.%PDN2M.S^;_ "(E.,=V?0?]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C7G_@
M?6O!_CR,K9"2"]49>SN)") /4<X8>X_'%=;_ ,(7I/\ SP;_ +^-_C792K4Z
M\%4I2NF4FGJC3_M2S_Y^X/\ OXO^-']J6?\ S]P?]_%_QK,_X0O2?^>#?]_&
M_P :/^$+TG_G@W_?QO\ &MAFG_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (UF
M?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG_P _<'_?Q?\ &C^U
M+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?\ :EG_ ,_<
M'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_:
MEG_S]P?]_%_QH_M2S_Y^X/\ OXO^-9G_  A>D_\ /!O^_C?XT?\ "%Z3_P \
M&_[^-_C0!I_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"-9G_"%Z3_ ,\&_P"_
MC?XT?\(7I/\ SP;_ +^-_C0!I_VI9_\ /W!_W\7_ !H_M2S_ .?N#_OXO^-9
MG_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_ &I9_P#/W!_W\7_&C^U+/_G[
M@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_VI9_\_<'_?Q?\:/[
M4L_^?N#_ +^+_C69_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XT :?]J6?
M_/W!_P!_%_QH_M2S_P"?N#_OXO\ C69_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&
M_P"_C?XT :?]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C69_PA>D_\\&_[^-_
MC1_PA>D_\\&_[^-_C0!I_P!J6?\ S]P?]_%_QH_M2S_Y^X/^_B_XUF?\(7I/
M_/!O^_C?XT?\(7I/_/!O^_C?XT :?]J6?_/W!_W\7_&C^U+/_G[@_P"_B_XU
MF?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^- &G_:EG_S]P?\ ?Q?\:/[4
ML_\ G[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG
M_P _<'_?Q?\ &C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C
M?XT :?\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z
M3_SP;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^-9G_  A>D_\ /!O^
M_C?XT?\ "%Z3_P \&_[^-_C0!I_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"-
M9G_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C0!I_VI9_\ /W!_W\7_ !H_
MM2S_ .?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_ &I9_P#/
MW!_W\7_&C^U+/_G[@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_
MVI9_\_<'_?Q?\:/[4L_^?N#_ +^+_C69_P (7I/_ #P;_OXW^-'_  A>D_\
M/!O^_C?XT :?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C69_PA>D_P#/!O\
MOXW^-'_"%Z3_ ,\&_P"_C?XT :?]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C
M69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_P!J6?\ S]P?]_%_QH_M2S_Y
M^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?]J6?_/W!_W\7_&C
M^U+/_G[@_P"_B_XUF?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^- &G_:E
MG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/
M!O\ OXW^- &G_:EG_P _<'_?Q?\ &C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C
M?XT?\(7I/_/!O^_C?XT :?\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z
M3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^
M-9G_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C0!I_VI9_\_<'_ '\7_&C^
MU+/_ )^X/^_B_P"-9G_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C0!I_VI
M9_\ /W!_W\7_ !H_M2S_ .?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_O
MXW^- &G_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C69_PA>D_\\&_[^-_C1_PA
M>D_\\&_[^-_C0!I_VI9_\_<'_?Q?\:/[4L_^?N#_ +^+_C69_P (7I/_ #P;
M_OXW^-'_  A>D_\ /!O^_C?XT :?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\
MC69_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XT :?]J6?_ #]P?]_%_P :
M/[4L_P#G[@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_P!J6?\
MS]P?]_%_QH_M2S_Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :
M?]J6?_/W!_W\7_&C^U+/_G[@_P"_B_XUF?\ "%Z3_P \&_[^-_C1_P (7I/_
M #P;_OXW^- &G_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7I/\ SP;_
M +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG_P _<'_?Q?\ &C^U+/\ Y^X/^_B_
MXUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?\ :EG_ ,_<'_?Q?\:/[4L_
M^?N#_OXO^-9G_"%Z3_SP;_OXW^->*_';XO>%?A7#+I>F0+JOB=EXM_-8Q6N1
MPTI!Z]P@Y/? QGHH4*F(FJ=)79C5K0H0<ZCLCL/VA/B9X<\*_#;7+"^U%&OM
M5L)[.UM;=@\KL\;*&P#PH)Y)X[<GBOSPJ_K>N7WB/4IM0U*Y>[NYCEI'/Z =
M@/0<"O1?A[^S;XS^)'AV?6M/MH;6S49MOMKF,W9SSY?'3_:. 3P#UQ^AX/#T
MLJH?O9[[OI?R/BL36J9A5_=QVV/*ZN:/I=QKFK6>G6B[[FZF6&-?]IB /YUZ
M3#^R[\3I;L6__",2(2VTR/=0!![[M_2OHWX'?LIV?@&1=8\1W"ZCKC(5CAMR
M1#:YZX/5FQQG@#)&#UJ\5FF'P]-RC-2?1)W)P^7UZTU&46EU;T/=K6\LK6UA
MA%Y"PC0)N,B\X&/6I/[4L_\ G[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_PA>D
M_P#/!O\ OXW^-?F)]Z:?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C69_PA>D
M_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XT :?]J6?_ #]P?]_%_P :/[4L_P#G
M[@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_P!J6?\ S]P?]_%_
MQH_M2S_Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?]J6?_/W
M!_W\7_&C^U+/_G[@_P"_B_XUF?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW
M^- &G_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_
MPA>D_P#/!O\ OXW^- &G_:EG_P _<'_?Q?\ &C^U+/\ Y^X/^_B_XUF?\(7I
M/_/!O^_C?XT?\(7I/_/!O^_C?XT :?\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO
M^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^
MX/\ OXO^-9G_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C0!I_VI9_\_<'_
M '\7_&C^U+/_ )^X/^_B_P"-9G_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-
M_C0!I_VI9_\ /W!_W\7_ !H_M2S_ .?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%
MZ3_SP;_OXW^- &G_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C69_PA>D_\\&_[
M^-_C1_PA>D_\\&_[^-_C0!I_VI9_\_<'_?Q?\:^"OVO/BY<^./']QX>M9BNA
MZ'(85C1OEFN!Q)(WK@Y4>F"?XC7W%_PA>D_\\&_[^-_C7YO_ !X\,3^$OB]X
MJL9XW17OY;F$MGYHI6,B$$]>&QGU!KR\PE)4TELV?<<)4J53&2G/XHK3[[-_
MUW.!HHHKYX_73O?A;\%_$/Q6OPFFQQV>G*V)M2O&V01^H!ZNW^RN?? YK[@^
M#_P'\$_"&&.XMI8-5UW;A]5NV7>#CD1KDB,=>G/J35+]FOX<PZ;\%O#G]IV\
MBWEQ&]TREBN%DD9DX_W"I_&O3O\ A"])_P">#?\ ?QO\:^DPN%A3BIM:L_&L
M\SK$XJM4PT)6IIM:=;=W^FQI_P!J6?\ S]P?]_%_QH_M2S_Y^X/^_B_XUF?\
M(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUZ)\>:?]J6?_/W!_P!_%_QH_M2S_P"?
MN#_OXO\ C69_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XT :?]J6?_ #]P
M?]_%_P :/[4L_P#G[@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I
M_P!J6?\ S]P?]_%_QH_M2S_Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O
M^_C?XT :?]J6?_/W!_W\7_&C^U+/_G[@_P"_B_XUF?\ "%Z3_P \&_[^-_C1
M_P (7I/_ #P;_OXW^- &G_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7
MI/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG_P _<'_?Q?\ &C^U+/\
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M^_C?XT?\(7I/_/!O^_C?XT :?]J6?_/W!_W\7_&C^U+/_G[@_P"_B_XUF?\
M"%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^- &G_:EG_S]P?\ ?Q?\:/[4L_\
MG[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG_P _
M<'_?Q?\ &C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT
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MP?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\
MOXW^- &G_:EG_P _<'_?Q?\ &C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?
M\(7I/_/!O^_C?XT :?\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z3_SP
M;_OXW^-'_"%Z3_SP;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^-9G_
M  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C0!I_VI9_\_<'_ '\7_&C^U+/_
M )^X/^_B_P"-9G_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C0!I_VI9_\
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M_&_QH_X0O2?^>#?]_&_QH T_[4L_^?N#_OXO^-']J6?_ #]P?]_%_P :S/\
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M_P!_&_QH T_[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:S/^$+TG_G@W_?QO\
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M])_YX-_W\;_&C_A"])_YX-_W\;_&@#3_ +4L_P#G[@_[^+_C1_:EG_S]P?\
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M:EG_ ,_<'_?Q?\:S/^$+TG_G@W_?QO\ &C_A"])_YX-_W\;_ !H T_[4L_\
MG[@_[^+_ (T?VI9_\_<'_?Q?\:S/^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\:
M-/\ M2S_ .?N#_OXO^-']J6?_/W!_P!_%_QK,_X0O2?^>#?]_&_QH_X0O2?^
M>#?]_&_QH T_[4L_^?N#_OXO^-']J6?_ #]P?]_%_P :S/\ A"])_P">#?\
M?QO\:/\ A"])_P">#?\ ?QO\: -/^U+/_G[@_P"_B_XT?VI9_P#/W!_W\7_&
MLS_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P : -/^U+/_ )^X/^_B_P"-']J6
M?_/W!_W\7_&LS_A"])_YX-_W\;_&C_A"])_YX-_W\;_&@#3_ +4L_P#G[@_[
M^+_C1_:EG_S]P?\ ?Q?\:S/^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\: -/^U+
M/_G[@_[^+_C1_:EG_P _<'_?Q?\ &LS_ (0O2?\ G@W_ '\;_&C_ (0O2?\
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M_G@W_?QO\:/^$+TG_G@W_?QO\: -Q6# $'(/((I:;&@CC5%X51@4Z@ HHHH
M**** "BBB@ HHHH **** "N,^(O_ ##_ /MI_P"RUV=<9\1?^8?_ -M/_9:
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M* /E2OI7PG_R*NC?]>4/_HM:^:J^E?"?_(JZ-_UY0_\ HM: -:BBB@ HHHH
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MAAAC&%1%& !^%7*[J> IPLY:O\#Y?&<58S$*5.DE"+ZK>WK?\D(JA5  P!P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?KFM%0_]G6,]WM/1O+C9L?CBORJUK6KWQ%J]YJ>HW#75]>2M--,_5V8Y)_\
MK5]\?M*_'OPSX*\+ZSX7+#5]<U*SEM'L8'&+=9$*[I6_AX;(7J>.@.:_/JO
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MG4+V40PQKW)[GT &23V )K]-?A#\,;#X2^![+0;+;)*H\V[N@,&XG(&YS[<
M =@!7BX>G+%574GM_6A^DYMC:>1X&.%PVDFK+R767K^OH=?;6T5G;Q6\$:PP
M1((XXXQA54#  '8 5+117T9^/!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>"-^P<^HK*$7.2@NIW8BM'#T9UY[13?W&+\._@MXP^*,RC0=(EEM-VU[^?\
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MHHKZDZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH_%N*%;,I:WT7RTV_7YA1117H'R84444 %%%% !1110 4444 %%%% !1110
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M1@JH@+,S'H !U-?1OPC_ &,=?\5^3J'BYY/#FEMAA:  WDH]-IXC_P"!9/\
ML]Z\>56OC'RQ6G];GZ#1P&6</P5:M*\^[W_[=7]>;/F^BONWQQ^Q#X0URU@_
MX1R[N/#=U#'L8MNN8YB/XF5F!#'U4@>U>9^)?V%=9T;PWJ5_8>(HM8U"WC\R
M'3X[,QF?'+*&+G#8Z#')XXJ)8*M'I<ZJ'$F6UDKU.5OHT_TNOQ."_9'73?\
MA>FAR:C=I:F-)C:K)TFG,914SV.&8CU*@=2*_1>OR)CDFL;I)(V>"XA<,K*2
MK(P/!'<$&OT1_9G^.4?Q<\)_9K^55\3::BI>)P//7HLZCWZ-CHWH"*[,OK12
M=)[GS?%F7U9...AK%*S\NS]-3V6BBBO;/S4**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OC#]MSXLW=QKD/@.QD:&RMD2YU JV#-(PW(A_V54AL=RP_NBOL^OSM_;!TT
MV/QYUN7S5D%Y#;3A5<,4_<HFUO0_)G![$>M>=CY.-'3JSZ_A:C3K9A>HK\J;
M7K=?YGBU%%%?-G[,>K_ O]GO6?C5?//'*NG>'[67R[K4&PS;L ^7&O\ $V".
MO !Y[ _??P\^&GA_X7:$NE>'[%;:+@RS-\TT[?WI&[G]!V KR/\ 8A\/W6D?
M".YO;E&C34]1DG@##&8U1$W?BRO^5?0M?2X.C&%-3MJS\8XBS*OB<5/#<W[N
M+M9?KW84445Z!\B%%%% !1110!GZ_H-CXHT6]TG4H%NK"\B:&:)OXE(P?H?0
M]CS7P%\5_P!D_P 8?#_4)9=)LKCQ-HC$M%<V,1>9%])(QR"/49'TZ5^AM%<M
M?#PQ"][<]S*\XQ&5R?LM8O=/^M&?EUX?^"?CSQ-?I:6/A/5?,8@&2XM7AC3)
MZL[@*/Q/:ON/]G3X 0_!;1;F:]FAOO$5^ +BXB4[(D'(B0GDC/).!DXXX%>Q
M45E0P<*,N;=G=F?$.)S&G[&RC#JEU]6%%%%=Y\J%%%% !1110!A^,_!>C_$#
MP_<Z+KEDE[83CE6X9&[.AZJP[$5^>WQV_9_UCX,ZMYGSZAX=N'Q:ZDJ]#U\N
M3'W7_1L9'<#]):X[XQ)"WPG\8F>UCO4CTBZE$,J!U++$S*2#Z$ ^V*XL3AXU
MHW>Z/I,ES:OE]90CK"3U7ZKL_P S\V/!7Q$\1_#J^GN_#FK3:7//&8I3'@JZ
M^ZL""1V.,CM6M%\=/B'#??:E\:ZX9<[MK7TC1_\ ?!.W'MBN&HKYI3FE9,_:
M)X:A4DYSIIM]6D?;7[.W[6A\77D?AWQK+:VFH>63;ZLS+#'<$<E9!PJMC)!&
M <8P#C/L6M?'WX=:!N%WXQTHLO5;:<7##VQ'N.?:OS#HKOACZD(\K5SY3$\*
MX.O6=6+<$^BM^';T/T!UK]M7X;Z9N^RS:GJY'3[)9E0?^_I2OG[]H;]J%/C!
MX?M=#TG3KK2M.2?S[AIY5+3X'R*57H 23U/('I7BNC^$==\18_LK1=1U//3[
M':22Y_[Y!KKQ^SO\1_[*NM1?PE?PVMM$T\IF"QN%49.$8AF..P!-3/$XBM%Q
MMIY(UP^3Y5EM6-1R]Y;<TEOZ:'G5%%%>>?7A2HK2,JJI9F. JC))]*^K?V2?
MV>-.\5:/=^*O%NE1WUA.?*TVVN-P#;3\\I (R,C:,^C>U?6F@^"] \+J%T;1
M-.TH 8_T.U2(_FH%>E1P,ZL5-NR9\7F'$]#!5I4(0<W'?6RO^/Y'YH^'_@OX
M[\4;3IOA/59XVZ3/;-%&?^!OA?UK1\?? #QM\,_#]OK.OZ6MM9S2^2QBG28Q
M,1D;]A(&><'.,C'<9_3:J]_86VJ6<UG>V\5W:3*4E@G0.CJ>H*G@BNS^SH<O
MQ:GSO^N&(]HG[-<O5:W^_P#X!^1E.CC:61412[L<*JC))/85]Z>)/V(O >M:
MB]U8W.J:*DA+&VM94>(9_NAU)'TS77?#']F?P3\+;Q-0LK2;4]50?)?:DRR/
M&?5% "J?<#/O7)'+ZKE9['T-3BS QI<T$W+M:WWO_AS\Y-1TV\T>\DM+^UFL
MKJ,X>"XC:-U/H5(R*V_!_P 2/%'@&X\[P_KEYI9SN,<,A,3G_:C.5;\0:_3S
MQ1X)T#QM9_9=>T>SU:$#"BZA#LG^ZW53[@BO ?'7[#/AG5_,G\,:G=:!.>1;
MS_Z3;_09(<?4LWTJYX&K3=Z;O^#.?#\4X+%1]GC(<M_^WH_Y_@<'X%_;LUK3
M_+@\5Z+!JL0X-W8'R)OJ4.58_3;75?$;]N73(='AC\%:?-<ZE.FYYM4BV1VW
M/3:&^=OH=HR.3R*\&^(7[,?CWX<V]S>7>F+J6EVZF22_TU_-1$ R69<!U ')
M)7 ]:\HK&6)Q--<DF>A3R7)\9)8BA%-=D]/FOTT/:(OVP?BE'?>>VNP2Q9S]
MF;3X/+^F0@;_ ,>KZ>_9]_:?L?B[,NB:I:II7B9(S($C/[BZ ^\8\G(8#DJ<
M\ D$\X_/FK6EZK>:'J%O?Z?=365[;MOBN+=RCHWJ".144L75IRNW='1CL@P6
M+HN%.FH2Z-*WWVW/UQHK\O\ _A?'Q$_Z'36O_ Q_\:/^%\?$3_H=-:_\#'_Q
MKTO[1A_*SX[_ %/Q/_/V/XGZ1>.O&FF_#WPKJ&OZM)Y=E9Q[RJXW2-T5%'=F
M) 'UKX)^(W[5_CKQQJ4K6&IS>&=,Z16>FRE' ]6E&&9OI@>@%>>^)?B5XK\9
M64=GKGB'4=5M8Y/-6&[N&= X! ;!/7!/YFN:KAQ&,E5TAHCZ;*>':.!3GB$I
MS]-$O*_7S/4O!O[2_P 1/!^HQ7"^([S5X%;,EIJTK7*2#TRQ++]5(K[/\!_M
M,>"?%O@RWUO4=9T_P]=9,=QI][=H)8W'7:#@NI!!! [^H(K\WJ*SHXNI1\UY
MG9F&08/,+.W))=4M_4_1#7?VPOAEHNY8M6N=6D7JEC9N?R9PJG\Z\\US]OG2
MH=PT;PG>77/#WUTD'X[5#_EFOCS3]*O=7N!!86=Q>S'I';Q-(WY 5WNA?LZ?
M$GQ%M-KX/U&)6Z->H+4?7]Z5K;ZYB*GP+[D>8N'LHPFN(E?_ !2M^5C!^)GQ
M$U+XI>,KWQ#J86.:XVJD",2D,:C"HN>W?W))[URU=U\3/@KXJ^$J:>_B*RCA
MBOE;RY()!*@8=48C@-C!QW'3.#CA:\^IS*3Y]SZ["RH2HQ^K-."T5MM- KT[
M2?VF/B9H=I;6UIXKN%@MHQ%$DL$,N% P =Z'/'KFO/-(TF\U[5+33=/MWNKZ
MZE6&&&,99W8X %?6=O\ L!K)IUN9O&;6]\44S*NG"2-6Q\P7]XI(ST/'TK:C
M3K3NZ7YV/-S+%Y=A^6./L[[77-^C/)K?]K[XJ0J0_B&*<GO)I]N,?]\QBM*#
M]M+XEP[-]SILVW&?,LE&[ZX(_3%=_<?L W2N!!XVAD3')DTPH<_02FLNZ_8)
M\11Q2-;^)],F< [%>&1-WU/.*Z_9XU=_O/#^M\.5.D/_  !K]#YU\7>+-2\<
M>([_ %S5Y_M.H7LGF2/C '8*!V4   =@!6/5K5-,NM%U*ZL+Z![6]M96AFAD
M&&1U."#]"*JUYCO?4^T@HQBE#;I;L=?\*/B)??"[QUINOV3L%A<)<Q#I- Q&
M]"/IR/0@'M7ZE1R++&KH=R,,@CN#7Y#5]+?"C]M37/#$=MIWBVU_M[38P(UN
MX $NXU' ST63 ]<'U8UZ>"Q$:-X3>C/BN),GK8_DKX:*<HW3[M=/NU/N6BN3
M^'_Q4\+_ !.L3<^'=6AO2H!EMB=D\7^_&>1]>A[$UUE>_&2DKQ9^35*<Z,G"
MI%IKHPHHHJC,**** "BBB@ HHHH **** "BBB@ HHK-\1^(+'PIH-_K&ISBV
ML+*%III&[*!T'J3T [D@4F[:LJ,7)J,5=L\F_:E^,X^%O@=K+3YMOB+5U:&U
MVGYH(^CS>V <+_M'/8U^>EO;S7UU'##&\]Q,X1(U!+.Q.  .Y)KJOBQ\2+[X
MJ^.-0\07NY%F;9;6Y.1!"OW$'T')]22>]>\?L6_!?^V-4;QWJT&;*Q<QZ;&X
MXDG'#2^X3H/]H^JU\Y4E+&5N6.WZ'['A*-+AS+75J_&]7YOHOE_FSZ#_ &>/
M@_%\(/ ,%I,BG7+[%QJ,PY_>8XC!_NH#CZ[CWKU&BBOH815.*C'9'Y%B*]3%
M595JKO*3NPHHHJSG"BBB@ HHHH **** "BBB@ HHHH *XSXB_P#,/_[:?^RU
MV=<9\1?^8?\ ]M/_ &6@"[\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=
M-0 4444 %%%% !1110 4444 %%%% !1110 4444 ?*E?2OA/_D5=&_Z\H?\
MT6M?-5?2OA/_ )%71O\ KRA_]%K0!K4444 %%%% !1110 5\Q?M ^+/[<\8#
M387W6NEJ8N#P93@N?PP%^JFOH/QEXCC\)^&=0U63!^SQ$HI_B<\(OXL17QA<
MW,MY<2W$SF2:5R[NW5F)R2?QKXSB3%\E..&CO+5^BV_'\CFK2TY3T/X#^$_^
M$B\;17<J;K33 +A\C@R?\LQ^?S?\!KZFKS_X(^$_^$9\#V\DJ;;S4/\ 2I<C
MD*1\B_\ ?.#]6->@5Z^383ZKA(IKWI:OY[?@:4X\L0HHHKW#4**** "BBB@
MJCKFD0:_H]YIUR,P7431-[9'4>XZ_A5ZBIE%23C+9@?#NL:7/H>K7>GW*[9[
M:5HG'N#C(]J^COV>_%G]M>$WTN9]USIC;!GJ8FR5_([A] *XG]H_PI]AUJTU
MZ%,17J^3.0.DJC@GZK_Z :X_X1^+/^$1\<64\C[+2Y/V:XR> K$88_1MI^@-
M?F>%D\HS-TY?#>WR>S_(X8_NYV/KJBBBOTX[@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KQ?]I#X\GX1Z1;6.E"&?Q)?@M$LHW+;Q#@RLO<D\*#P2"><
M8/J?B3Q1I'@_2Y-1UK4;?3;*/K-<.%!/H.Y/L.:_/'X^>/;3XD?%+5M:TV22
M73&$4-J95*G8D:@G!Z MN/XU[N48)8JOS5(^XON;['D9EBOJ]*T'[S_JYR7B
M/Q;K7BZ^DO-:U.ZU*X=BQ:XE+ $^@Z*/8  5U/P]^.GC'X:2/_9.JO-:LA0V
M5Z3- /0A2?E(ZY!'3G(XK@**_0I4:<X>SE%./8^+C5J1ESQD[G3^-?B5XF^(
M=UY_B#6+G4,'*0LVV&/_ '8QA1^ S63H/AW5/%&H)8Z1I]SJ5X_2&UB,C8]<
M#H/?I7O/[,/[/FA?%+2;W7O$$EU+:VMY]ECLH6\M)2$5B6<?-CYQPN/K7V+X
M:\):+X-T\6.B:9:Z7:CK';1A=Q]6/5C[G)KP,7FU'!-T*,+M?)(]G#Y;5Q25
M6K*R?S9\C?#W]BC6]6\NY\6Z@FB6QP39VI$UP1Z%ON)_X]]*]&\<?L7^%M4T
M.&+PS/-HNJ0+CSKB1IX[C_KH">#[K@>QKZ*HKYBIF^,G-3Y[6Z+;_@_,]^&6
MX:$'#EOYO?\ KT/AN']B;QVUV(Y+[18X=V#-]HD(QZ@>7FOHOX)_L[Z+\'T-
M[YK:KX@EC\N6^D7:J*<$K&O\(X')R3CL.*]9HJ,1FF*Q4/9SE9>0Z.7X?#RY
MXK7S"BBBO)/2"BBB@ I.O!Y%+10!\M?M _LHIJ?VGQ'X(MEBO.9+G1XQA9>Y
M:$=F_P!CH>V#P?D-UFLKEE99(+B%\%6!5T8'IZ@@U^L->'_'O]FG3OB?#-J^
MCB+3?%"KDOC;%>8_ADQT;T?\#D8Q];EN<.G:CB7=='V]?(^<QV6*=ZM!:]O\
MC@/V??VKQ-]F\.>.+H*_$=KK4IX/8+.?_9_^^O[U>U^(OVA/AWX6O7M-0\4V
MHN$;:Z6R27&T]P3&K8/UK\[->T'4/#&L76EZK:26.H6K[)8)1AE/]01@@C@@
M@BJ%>M6R7#8BI[6+:3Z*WX'FT\UQ%&'LVKM=S]0?!WQ(\,?$"*1_#VM6NIF,
M;GCB;$B#U9&PP'U%=+7Y4Z%KVH^&=5M]2TJ\FL+Z!MT<\#%6'M[@]P>#7Z._
M!CXDQ_%7P!8:X$$-WS!=Q+T2=<;L>QR&'LPKYO,LK>!2J0=XO[T>[@<P6+;A
M)6DCN:***\ ]@**** "BBB@ KP_]KWP?8^(OA3-J=S=1V=UHT@N+=Y.DFXA&
MB^K9&/=1VS7N%?$'[8/Q>'BKQ0/"NGSYTG1G/VAE/$MUT;\$&5^I;VKULKIS
MGB8SB[*.K?9+<\_'22HN%KN6B7=O8^>**IR7C$_)\HK=\+^/+SPDET]E96$E
M]*A6*_N(3)/:G^_%D[5;T;!(ZC! ->U7XMP%.3C!2E;JDK/[W?\  [L/X>YQ
M6A&I-PA?HV[K[DU^)TVB>.KOX3Z'JL&EN]KXIU:+[+-<8VO86N<E!W$KD*3_
M '0H_B/R^=6=G<:E>0VMK#)<W5Q(L<4,:EGD=C@* .I)--CCGU"Z6.-9+FYF
M<*JJ"[R.QX '4DDU]X?LQ_LUQ?#>SB\2>(H$F\47"9BA8 BP0CH/^FA!Y/;H
M.Y/YIB<17SC%2K5-/R2['[#2IX+A'+E1IZR_&3[^2_+U+O[-/[.,'PKTU-;U
MN..X\674>#T9;)#_ ,LT/=B/O,/H.,EO>:**]>G3C2BHQV/RS%XNMC:SKUG=
MO^K+R"BBBM#C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]659KO</F@3JD/M@'+?[1/H*]IKIP=#V,.:6[/%XBS3Z_B/94W^[AMYOJ_\
M+_@A1117H'R04444 %%%% !1110 4444 %%%% !1110 5QGQ%_YA_P#VT_\
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MIFO>RC%_6\)&3^):/Y?YHUIRYHA1117LFH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1163XK\4:?X
M+\.W^MZI-Y%C91&61NY]%'JQ. !W)%5&+DU&*U8FU%7>QK45^<GQ2^/WBKXH
M:A(;B]DTW2@2(=-LY"D:KVWD??;W/O@#I7$>'_%&K^%;Y+O1]3NM-N5(826T
MK)GZXZCV/%?50X?JRA><TI=K7_$^=GG5-3M&%UW_ . ?J/JFK66AV$U]J-W#
M8V<(W27%Q($1!ZDG@5\U?%+]M*PTWSK#P5:C4KD94ZG=J5@7W1.&?ZG ]C7S
M#XX^)WB?XCW23^(=7GU#R_\ 5PG"1)QC*QJ H/N!DU4\(>!]>\>ZH-/T#2[C
M4KGC<(E^6,'N['Y5'N2*[L+DE&@O:8J5[?)')B,UJUGR8=6_,3Q=XVUWQYJC
M:AKVIW&I7)^Z9F^5!Z(HX4>P J3PO\/_ !)XTCNI-"T2\U2.V4O*]O$65<#.
M,]"V.BCD]A7U1\+_ -BW3M+\F^\:W8U2Y'S?V;:,5@7V=^&?Z#:/J*^E-+TJ
MRT2QALM/M(;&SA&V.WMXPB(/0*.!1B<[HT%[/"QO;Y(*&4U:SY\0[7^\_*62
M-X9&CD1DD4E65A@@CJ"*VO!_@K6O'NM1:7H6GRW]X_58Q\J+_>=NBK[FOT'\
M<:;\+#J7F^+4\*PZ@W635'MXY6^I<@G\:Z3P;9^&+/21_P (K%I4>G-_%I(C
M\IB.Y*<$UA+B*#C:$/>]=#I60U(M3F_<[V_I%#X4_#VU^%_@?3M MG\YX5+W
M$^,>;,W+M],\#V KKJ**^/G.523G)W;/HH15.*C'9!117SC\?_VM(/ASJ5SX
M<\-6T>HZ_#A;BZGYM[9B,[< Y=P.HR /<Y%<]2K&E'FFST<'@J^/J^QP\;O\
MO-GT=17YV1?M@_%*.^\]M=@EBSG[,VGP>7],A W_ (]7T]^S[^T_8_%V9=$U
M2U32O$R1F0)&?W%T!]XQY.0P')4YX!()YQS4L92JRY5H_,]G&\.X[ TG6FE*
M*WL[V^](]UHHHKN/F HHHH **** "BBB@#\^_P!K;3[BR^.>MRS@^7=Q6\\)
M/=!"B<?\"1A^%>.U^B'Q^^!MO\9-"M_(FCL==L2QM;J12593UB?'.TG!SS@C
MIR0?B7Q%\%?'/A?4'M+WPOJ;,I($MM;/-$^.ZN@(-?H^5XZC6P\:;DE**M;T
M/A\PPE2G6E-*Z;O]YQ-?<'[$>G7%I\+=1N905ANM4D>$'N%CC4L/Q!'_  &O
MB>_T^ZTN[DM;VVFL[J/ >&XC*.N1D94C(X(_.OK?]D+XWP7-C!X"U=HX+F ,
M=,FP%$JDEFB/^V"20>XSW')G49U,&_9J^S?H&5RC#$KG=O\ ,^IZ***_.#[@
M**** "BBH[BXBL[>6>>18H8E+O(YPJJ!DDGL * /,_VAOBPOPI\ SW%O(HUN
M_P VU@G<,1\TF/1 <_4J.]?G%J4SRMN=V=W8LS,<DGU)KTWX\_%27XL>/KK4
M8V8:3;9MM/B;C$0/WR/5CEC]0.U<_I?PRU/Q%X!\0^+4>*VTS13&C-,=OGR.
MR@HAZ%@&!/U [U]7C,'+!Y)55[3DDW]ZT^Z_XG'D&,IU^(L-*HKP3:7K9I/_
M ,"L<)1117X^?U"?0'[$MCI]]\8I?MME'=30:=+/:R2#/DRAXQN ]=K,,]LU
M]]U\F_L.?"^[TVWU'QQ?1F%+V$V5@K#EX]X:23Z%D51_NM^/UE7TV!BXT5?J
M?BG$U>%;,9<CORI+Y]?Z[A1117>?*A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXI>&?[8TF 'Q1ID9,04<W4(Y,)]^I7WR/XLC\_HY)K&Z22-GM[B%PRLI*LC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9F_ *3^%>=2=IQ?F?78V/-A:L6[>Z]>VA^I=%%%?8G\[!1110 4444 %%%%
M!1110 4444 %%%% !1110 5QGQ%_YA__ &T_]EKLZXSXB_\ ,/\ ^VG_ ++0
M!=^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH ****
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MO$GBS6?&&H-?:WJ=UJET?^6ES(7VCT4=%'L,"KG@[X>^(_B!??9?#^D7.I2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117.^.O&EGX#T"74KI?-?.R&W5L-*YZ 'L.I)[ 5G4J0HP=2;LD)NRNSHJ*
M^1_$7QB\5>(+R24:I/IT)/R06+F)4'ID<G\35CPK\:_$WAR[1I[Z35K3^.WO
M'+DCV<_,#^GL:^77$F%=3E<7;O\ \ P]M&Y]845D^%O$MGXNT*UU2R;,,R\J
M?O(PZJ?<&M:OJ83C4BIQ=TSHW"BBO.?BS\64\ Q16=G$EUJ\Z%PKGY(5Z!F
MZY.<#V/XXXC$4\+3=6J[)$RDHJ[/1J*^.+WXF^*[^X,TGB#4$;.=L,[1+_WR
MN!^E=O\ #WX^:GI=[%:>()3J&GR,%-RPQ+#[Y ^8>N>??M7SU'B+"U*G)).*
M?5_J8JM%NQ](44V.19HUD1@Z, RLIR"#T(IU?5'0%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M117JGP@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M; [?LY!%SN_N^3C?^.,>^*^=?BA^V;K6O>;8^$+8Z%8M\OVV8![IQ[#E8_\
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M<*A7PG=#=TWS1)^>7&/QK1@_9.^*$S$/X=2 8SNDO[8CZ<2&O*^IY1'=Q_\
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MX N;JV7W4?ZQ1_>49]1QFO(K82IAWSTG=?B??X#/L)FD/JN.BE)]_A?IV?\
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M^;]NA QWRX&*Y\MQM7"5XN#T;U7<4).+T/M&BBBOU\]$**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR4YZ?)_F<-7 X>M+GG'4X3X6_!GPW\)-/:+1[8R7LJA;C4+C#3R]\9_A7/\
M",#@9R>:[NBBN&I4G5DYU'=LZX0C3BHP5D%%%%9EA1110 5\1?M<?M"?\)1>
MS>"O#MSG1[9\:A=1-Q=2J?\ 5J1U12.?5AZ $^B_M:?M"?\ "':?-X-\/7.-
M=NX\7MS$>;2%A]T'M(P_)3GJ01\2:=I]SJU_;V5E!)=7=Q(L4,,2[F=R<!0/
M4FO%QN)_Y=0^?^1^D\-Y,E;'XE?X4_\ TK_+[^QL> _ ^J_$;Q38Z#HT'G7E
MTV-QSLB0?>D<]E Y/Y#D@5^EGPM^&>E?"?PA:Z%I2;M@WW%RRX>XE(^:1OZ#
ML !VKDOV=?@7;?!OPMNN5CG\27RJU]<KSL[B%#_=7N?XCSZ >N5TX/#>QCS2
M^)GC<09R\PJ>PHO]W'\7W].WWA1117HGQX4444 %%%% !1110 4444 ?$_[<
M_@W1/#NM>&]4TS3(K&^U7[4;R:$;5F*>5M)4<;OG;)QDYYS7RY7Z,_M0?"*;
MXK_#TC3E+ZWI3M=V<8ZS<8>+ZL,$>ZK7YUW5K-8W$MO<0R6]Q$Q22*52KHP.
M""#R"/2OF<=3<*K=M&?M/#.+CB,!&FY7E"Z??>Z^5M/D1445]C_LQ?LP:;=>
M&9/$'CG11=3WQ'V*PO R^3$,_O&7(Y;/ /0 'OQST:,JTN6)[.8YC1RVC[:M
M\DMV?'%%?IU;_L_?#BV!">#-).?^>EN'_P#0LUHV_P '? 5KL\OP5X>5DQM;
M^RX"PQWSMSFN_P#LZ?62/DY<88;[-*7X'Y:45]Z_M&_LQVGCS0[>_P#!^FV&
MFZ]8Y'V>"-($NXSSL.  '!Z$\<D$]"/AG7-!U+PUJ,MAJMC<:=>Q'#P7,91A
M^![>]<5?#SH2M+;N?399FM#-*?/3=I+==5_P"A7V-^PY\0=%T_P_J?A:]U2*
MVU6XU W-K:SG;YJM&BG83P6RGW<Y[XKYB\)_"[Q9XXM;JZT'0+[4[>UC,DDL
M,?RX'92?O-_LKDGTKFI(Y;2X9'5X9HVVLK JR,#R".Q!I4:DJ$E4L5F&%HYI
M0GA'.STVLVGTNC]=Z\]^-WPITWXL>#9[*\>.TOK4-/97[_\ +!P.<G^X0,,/
MH>H%?*'P;_;$U[P3Y&F>*EE\1:*N%6X+9NX%]F/^L'LQS_M<8KZJUOQUI/Q*
M^#?BK4/"FI1:EYFDW2J(B?,CD,+X5D^\K>Q%?5X'%JI5C*E*TKGXMF^2XC+X
MR5>/-!]5L_\ )_TC\XG7:S+D-@XR.AIM%'2OV?979^-I-NR-CPGXDMO".N0Z
MM/9B^FM5:2UB?&P7 4^4[@_>56PQ7OC%<Q>7D^I7D]U<RO<7,\C22RR'+.['
M)8GN233;B;SI,]ATKWW]D3X+_P#"P/&'_"1:I;[]!T:0,%<?+<7/!1/<+PQ_
MX".]?AV=XYYMCK4O@CHOU?S_ "L?T_P[EM/A?*'7Q7\27O2[^4?E^;?0^B/V
M4_@Q_P *Q\$C4]2@V>(M8599PP^:"'JD7L?XF]SC^&O<J**Z*=-4XJ$>A^=8
MO%5,97E7JO67]6^04445H<@4444 %%%% !165>>+-#TVX\B[UG3[6;./+FND
M1OR)K0M[F*[A66"5)HFY62-@RGZ$5$9QD[)W8KDM%%<IXF^*'AKPGO6]U*-[
MA?\ EVM_WDF?0@=/QQ4U*M.C'FJ227F#:6YU,DBQHSNP5%&2QZ >M?*?Q3^*
M=[XVU2XM;6X>+0HWVPP+\OFX_C?UR>0#TX[UT?C3]HBYUJRN]/TG3EM+:XC:
M%I[EMTI5@0< <*<'U->.5\!G6;1Q"5##2]WKY^7H<E6IS:1"O5O@S\5KO0-6
MM='U.Y:;1YR(H_,.?L[$_*0?[N>".@SGZ^4TZ-7>150$N2 H7KGMBOF<+B:F
M$JJK2>J_'R,(R<7='W914=N'6",2',FT;OKCFI*_:CTPHHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"O<6%M=,&GMH9F P&D0,<>G-6***!W84444""BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KC/B+_S#_\ MI_[+79UQGQ%_P"8
M?_VT_P#9: +OP_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%%
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M 4444 %%%% !1110 4444 %%%% !7">//@;X(^)5S]JU_0H;F]P%^UPNT,Q
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M..$G3E9GUW14=O<17=O'/#(LL,BATD4Y#*1D$'TQ4E?IF^J.X**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "N,^(O_,/_ .VG_LM=G7&?
M$7_F'_\ ;3_V6@"[\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?*E?2OA/\ Y%71O^O*'_T6M?-5
M?2OA/_D5=&_Z\H?_ $6M &M7S?\ '[XA?VWJG_"/V,F;&R?-PRGB28<8^B]/
MKGT%>H_&+X@CP1X<,=M)C5KT&.WP>8Q_%)^&>/<CT-?*$DGWG=O=F8_J:^)X
M@S#E7U.F]7\7^1RUI_91E^)->B\.Z3+=R89_NQ1G^-ST'^?2O$F:75+J6YN'
M+O(Q9F[DFMKQCX@;Q1K!$3$64&5B]_5OQ_EBLU5"* . *^DX/X;^L+ZUBH^Y
M^;[>BZ^>A[^.S#_57 _5Z#_VNJKR?\D>B]7_ ,'HB%;-%/))K2TC1[W7-1M]
M/TVTFO;V=MD5O;H7=SUP /Q_*JE?2/[&/PSNM6\7R>,KB,QZ;I:O#;LP_P!;
M.Z%3CV5&.?=E]\?KSH83**$ZM"FH_J^BON?G-;,,?G=:$,75E/UV7=VV*'@G
M]C#QAK_ES:[<VOARU;DHY\^XQ_N*=H_%@?:O?_!/[)_@'PAY<MS8R>(+Q>?-
MU1@Z9]H@ F/]X'ZU[+17Q6(S7%XC1RLNRT_X)[]'+L/1U4;OSU_X!#:V<%C;
M);VT$=O;QC:D,2!44>@ X KS3Q%^S/\ #GQ-J#WMSX>2WN)"6<V<TD"L3WVJ
MP7/T%>HT5YU.M5HOFIR:?DSMG2IU%:<4T<CX&^$WA/X;JY\/:+!8S.NU[@EI
M)F'H78EL>P./:NNHHJ)U)U)<TW=^9481@N6*L@HHHJ"PHHHH **** .?\9^
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M_A/KOQ<\1+IFC0'RDPUU>./W5LG]YCW)YPO4_3)'JUO;I9V\<$:[8XU"*OH
M,"OA,TQ5:$5+K*^OIV^\^LX@S"&28:& R]\LGO;=+_-]]_P,Y/"FC1Q^6-+M
M2OJT2D_F>:L^#O@[X,\1^*$M-9GU#3+:Z7RH9+.5 L4I^Z6WJWRGIU'6KE%?
M-T,75HU%.]_)]3\SH9MCL/)SIUI7?FW^9=\;?L+^)M*\R;PUJUIKL(Y%O<#[
M-/\ 09)0_4LOTKP;Q9\/?$O@6X\G7]#O=*;.%>XA(C?_ '7^ZWX$U^AOP_\
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M47\EU-XLU*Q#,66#3;AK6-!_= 0C('N2?<U=3'4H?#J<V$X7Q^(;]HE!+O\
MI8_32BOS\^%G[7GC#P7J$<>O74OBC1F(62*[;-Q&.[))U)]FR#[=:^]-!URQ
M\3:+9:MILZW5A>1+-#,O1E(R/H?4=C6]#$0KKW=SR\SRC$97)*KK%[-;?\.7
MZ***ZCQ HHHH ***BNKJ&RMY;BXEC@@B4O)+*P544#)))X  [T!N2U\G_MR^
M/]#O/#.G>%+;44GUN'44O+BUA^811B*1?G(Z-EQA>N.3VK,^/7[8SS?:-!\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5QGQ%_YA__ &T_]EKLZXSXB_\ ,/\ ^VG_ ++0!=^'_P#R
M!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#Y4KZ*TG5;;0_ >GW]Y((;6WT^*21SV C'Z^U?.M7?BI\0O
M[4T71O#=C+FUM;6!KME/#RA!A/HO?W^E>;F&-C@:#JO?HN[(G+E5SCO''BZY
M\;>([G4[C*JYVPQ$Y$48^ZO]3[DUY-\2O$QMK<:1:M^_G&9B#]U/[OX_R^M=
M1XAUN+P_I<MY+R5XC3^^QZ"O+?#_ (?UGQYXDCL["UDU+6+Z3Y8XQZ]23T50
M.I/  KY/AS)ZN>8QUJS]R.LI?U_7W&N&K4\OIO,JZYFG:G'^:?\ \C'=^=EU
M*6BZ+=ZM?6VG:?;27E[<.(XH85+.['H *^O_  -^Q3I#>$A_PE=[=KKUQAS_
M &?*H2UX^YRI#GU/X#U/HGP)_9]TSX0Z>+NX\O4/$TZ8GO<?+$#UCBST'J>K
M>PP!ZY7[%BLT5.,<-@?=A'\?^!^9XE/"3Q-26*Q[YZD]7?\ K_@+H?/^@_L5
M^!]*ODN+V[U35T0@BVGF1(V_WMBAC^!%>[Z;IMIH]C!96%M#9V<"[(H($"(B
M^@ X%6:*\6MBJV(M[63=CT:6'I4/X<;!1117*= 4444 %%%% !1110 4444
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MJ6"2YU]T?^#_ ,._/HM0\;Z5X+\.+X1^'\#:;H\?$^HGBXNVZ%RW!&?7@]
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M7X*^,O@OXA!%T+Q#9W5PW2U=_*G_ ._;X8_@,5VE?D("1R.#7I/@G]HKX@>
M_+CT_P 0W%S:)P+/4/\ 2(L>@#Y*C_=(KU*>8]*D?N/B,5P>UKA:ORE_FO\
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M%9+0[5HK!1115C"BBB@ HHHH \L^/7@3_A)/#HU>UCW:AIJEF"CF2'JP_P"
M_>'_  +UKYLT_4+C2KZWO+60PW,#B2-UZA@<BON5E#*01D'@@U\E_%[P*?!'
MBJ18$VZ;>9FM3CA1GYD_X"3^1%?!<0X%PDL93^?KT?Z?<<E:/VD?2W@?Q9!X
MT\,VFJ085I%VS1@_ZN0?>7\^GL0:WZ^7O@5X\_X1;Q)_9UU)MT[4B(SN/$<O
M1&]@>A^H]*^H:^ERO'+'8=3?Q+1^O_!-Z<N:-PHHHKV#0**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T
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M7U7#F#JQG+$R5HVLO/\ JQT48N_,:5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\
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M:7\-_ VD0RQPV%C)YJE':XE\UB#Z%B<?ABO(OB1\%UT;S=0\.W*7UC]YK/S
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M\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\
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M\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\
MG[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%
M_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO
M^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +
M5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?
MVI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4
ML_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P
M?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#
M_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?
M\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_
M (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%
M5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_
M #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_
M^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'
M_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%(K!@"#D'D$4M
M !1110 4444 %%%% !1110 4444 %<9\1?\ F'_]M/\ V6NSKC/B+_S#_P#M
MI_[+0!=^'_\ R!IO^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH *^/?
MV;_^3R?C'_V]?^E25[3\8OA#XO\ B-K-C>>'?B;J7@>VM[?RI+2RMVD69]Q/
MF$B5.<$#H>E>0Z3^Q#XMT'Q!J&N:=\:=2LM8U#=]KOH-+999\L&.]A<Y.2 :
M /8_VI=#F\1?L^^-[2!#)(MA]IVKU(A=93^B&N=_8I\46_B/]GKP_#$ZFXTM
MIK&X0'E6$C,OYHZ'\:]-^'?A/4O"7@BRT/7M?F\77T(D6?5+R+:]P&=F 92S
M<!6"\D\#\*\#OOV,]9\(^)M0U7X7?$.^\%VM\VZ73#&SQKST!##<JY;:&4D?
MWN<T 87[;EPOC#XE_"CP-8E9]0GOC/-"O)1))(D0GT&%E)]ES4/[75R/!/[2
M'PB\970VZ;&\<$TIZ*L5QND_)9L_A7JOP9_9=L_ASXJN?&/B+7[OQKXSG! U
M.^4@0@C!V*68[L?+N)Z<  $Y[GXQ?!_0OC9X/ET#7%DC4.)K:\@P);:4 @.N
M>#P2"#P03T." #M_.3RO-WKY>W=OSQCKG/I7R#^R'+_PFO[07Q@\:VH\S2IK
MA[>WN!TD62=F3'K\D2D_4>M:$?[('Q%_L?\ X1F;XT:BWA+:(C:K;R;S%T\K
M!EX7  QNV^V*^@OA7\+=!^#W@^V\.^'X&CM8R9)9I2&EN)3C=(Y &6. /0
M# % '7T444 ,FB2>)XY%W(ZE64]P>HKX?U;2;O0=3N=.OHS%=VSF.12".1W'
MJ#U![@@U]QUY[\3/@_8>/LWL,OV#6538L^,QR@=!(OYC<.1GG< !7SN=9=/'
MTHNE\4=O.^YE4ASK0^4Z='&TKJB*SNQPJJ"22>@ '4UH'P[?K($\I6'&9%<;
M1^>#^E>]_"/X*V>CQZ?X@U65;Z_:-9[>!1^Y@+ %6YY=@.A( !/ ) :OB\/D
MF,K5%&<.5=6_ZU.:-&3>IUG@_P"'-CI/A72K6[MF2\CMT^T+YI.)2,N 0<8W
M$]*V/^$+TG_G@W_?QO\ &MVBOU.$5"*BMD=QA?\ "%Z3_P \&_[^-_C1_P (
M7I/_ #P;_OXW^-;M%6!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M%
M &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_
MC?XT?\(7I/\ SP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\
MOXW^-;M% &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_
M ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D
M_P#/!O\ OXW^-;M% &%_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XUNT4
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MP;_OXW^-'_"%Z3_SP;_OXW^-;M%>N:&%_P (7I/_ #P;_OXW^-'_  A>D_\
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MC?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C6[10!A?\(7I/\
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ML\$@(+1R(<@C@J1_(T4<;CLFG[&LKQ[/]'_7H"E*F[,^SO\ A"])_P">#?\
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M_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\
M?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&MVB@#"_P"$
M+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\ A"])_P">#?\ ?QO\
M:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;_&C_ (0O2?\ G@W_
M '\;_&MVB@#"_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QK=HH PO\
MA"])_P">#?\ ?QO\:/\ A"])_P">#?\ ?QO\:W:* ,+_ (0O2?\ G@W_ '\;
M_&C_ (0O2?\ G@W_ '\;_&MVB@#R[QU\"-)\1V[SZ8?[-U3J')+1R^SCM]1^
M1KYV\1>&M2\*ZD]CJEJ]K.O(W?=<?WE/0CW%?;58_BCPKIGB[3'L]4M5N8N2
MC#AT;U4]C_DU\QF624L7>I1]V?X/U_S,)TE+5;GR%H?BW4?#\4L5K(#%(I 2
M0%@A/\2C/!_3U%1OXJUB23S#J=UN]%E('Y#BLL]3QBDK\Z^M5U%04W9;*[.+
MF>USU/X?_%"PBF%IXHA,D!!*WT9;>IQP&5>H/3('USVTO$'QC\.P[DT;0[BY
M;H)KR8QK]=H))'XBO&JZ3P]\.?$?B@(^GZ3<20-TGD'EQD>H9L _A7LT<VS&
M4%0I-R?>UV:JI.UD)JWC[6-69OWXLXS_ ,L[7*#\R2WZUSS.TC%F8LQY))R3
M7MOA_P#9GNI-LFM:M' O4PV:EV^FYL '\#7I7A_X.>$_#VUH]+2\F7GSKT^:
M?K@_*/P%=,<GS'&OGQ$K?XG?\/\ ABO9SEN?(U%?5GCGX*Z'XR?[3$/[)U#H
M9[= 5?\ WDX!^HP:XFS_ &83]H4W6O@P]Q#;88_B6X_6L*V08VG/EA'F7>Z7
MYDNC)/0\V^&?@>3QYXFALF$BV,8\RZFCX*)Z D'DG@?CZ5[_ &7P'\'6:C=8
M27+?WIIW/Z @?I73^%/!^E>"].^QZ7;"%#@R2-S)*1W9N_\ (9XK;KZ[+LGH
MX6DO;Q4I^E[>2N=,*:BM3E[7X:>'+''V?3(H#ZQ\&G:C\.M"U6SEM;FU:2&0
M8(\QOS'/6NFHKW_9PY7#E5GT-;+8^=_$W[-NIVMQ+)HE[#=VO)6*Y)24>V0,
M-]>/I7C;*T;%6!5E."I&"#7W97RG\</"?_",^.+B:)-MGJ ^TQ8' 8GYU_[Z
MY^C"O@,[RFEA::KX=65]5Z[')5IJ*NCUOX0V>C>*O ]C-Y&VXMQ]FG57( 9>
M^/<$'\:[3_A"])_YX-_W\;_&O!/V>?%G]C>+)-*F?%MJ2[5ST$JY*_F-P^I%
M?3%?4Y1BEBL)&75:/Y?\ WIRYHF%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^
M_C?XUNT5[1J87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_
M[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUN
MT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_P
MA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%
MZ3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_
M[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_O
MXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[1
M0!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%
MZ3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I
M/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_O
MXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C
M?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M%
M&%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I
M/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_
M\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C
M?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_
MC1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 8
M7_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_
M\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_S
MP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_
MC6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-
M'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?
M\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_S
MP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!
MO^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-
M;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?
M\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_P
MA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!
MO^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_
M[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUN
MT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_P
MA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%
MZ3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_
M[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_O
MXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[1
M0!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%
MZ3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I
M/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_O
MXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C
M?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M%
M&%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I
M/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_
M\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C
M?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_
MC1_PA>D_\\&_[^-_C6[10 V-!'&J+PJC IU%% !1110 4444 %%%% !1110
M4444 %<9\1?^8?\ ]M/_ &6NSKC/B+_S#_\ MI_[+0!=^'__ "!IO^OAO_05
MKIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#Y4KZ5\)_\BKHW_7E#_Z+6OFJOI7PG_R*NC?]>4/_ *+6@#6HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^3OB]\/[CP7XDGFBB=M)NW,
ML$P7Y5)))C)[$<X]1CWK@J^Y[ZQMM3M);6[@CN;>0;7BE4,K#W!KB)/@7X+D
MG,O]E,N3DHMS(%_+=7P>,X=G.JYX:2L^CZ?F<DJ+O>)\W^!_!M[XXUZ#3[1&
M$98&>XVDK"G=C_0=S7V/8V46FV-O:0+M@MXUBC7T50 !^0JOHN@Z?X=LA::;
M9Q65N#G9$N,GU)[GW-7Z^@RO+(Y=!W=Y/=_HC:G3Y$%%%%>X:A1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBJMN36U^AG&DHNX4445](;A1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C'[2'A/[9I%GK
M\*9ELV\B<@?\LV/RD_1N/^!UX?X3\02^%?$>GZK#DM;2AF4?Q+T9?Q4D?C7V
M5K6DP:]I%YIURNZ"ZB:)_;(QD>XZ_A7Q7K.E3Z'JUYI]RNV>UE:)_J#C(]C7
MYUQ!AY8?$QQ=/3F_-''6CRRYD?;=G=Q:A:075NXD@F19(W'1E(R#^1J:O*?V
M>?%G]L^%)-*F?-SIK;5R>3$V2OY'</IBO5J^ZPF(CBJ$*T>J_P"'.J,N97"B
MBBNLH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ.(SS$JC17N]%^K_ *\D<4I.K*R,3PK\$_$/BS0UU2W^SVT,A_<K=.RM*O\
M>&%/'UZUT^@_LUZK-=J=8U"VMK4'YEM29)&'MD #Z\_2OH9$6-%1%"JHP%48
M 'I3J^II</8."CSWDUOKN;JC'J9WA_P_8^%])@TW3H?(M81PN<DD\DD]R36C
M117TD8QA%1BK)&X44450!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N,^(O\ S#_^
MVG_LM=G7&?$7_F'_ /;3_P!EH N_#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#
M?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% 'RI7TKX3_Y%71O^
MO*'_ -%K7S57TKX3_P"15T;_ *\H?_1:T :U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M><527/+E1[+^S_X"33="?7;Z!6N;\8@61<[(0>O/]X\_0#UKV!5"J%4 *!@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N,^(O_ ##_ /MI_P"RUV=<9\1?^8?_ -M/_9: +OP__P"0--_U\-_Z
M"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'RI7TKX3_Y%71O^O*'_P!%K7S57TKX3_Y%71O^O*'_ -%K0!K4444
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M*3L=O1117OFP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5QGQ%_YA_P#VT_\ 9:[.N,^(
MO_,/_P"VG_LM %WX?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /E2OI7PG_R*NC?]>4/_HM:^:J^
ME?"?_(JZ-_UY0_\ HM: -:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH CN+>*[MY()XUEAD4H\;C*LI&""/2OE?XN?"^
M7P)J?VFT5I-%N6_=/U\INOEL?Y'N/H:^K*Q_&%O87'A;51J< N;!+:226,]U
M52W!['C@]C7C9I@*>.HM2TDM4_ZZ&=2"DCY/\ ^.KWP#KB7UK^]@?Y+BV)PL
MJ>GL1V/;Z9%>KI^T];FXVOX>E6#/WUNP6Q_N[,?K7@=)7YOALSQ>$A[.C.R]
M$_S.&-24=$S[-\'^.]'\<6/VC3+C<ZC][;R?++%_O+_49'O70U\7^"?%5SX,
M\26FIV['$;;9D[21G[RG\/U K[/5@ZAE.5(R#7Z'E&9/,*3YU:4=_P#,[:<^
M=:BT445[QJ%%%)G')X% '%?%SQL/!/A&>6%]NH768+4=PQ'+_P# 1S]<>M?)
M*AI9  "[L< #DDFNU^+OC8^-O%TTL+[M.M<P6H[%0>7_ .!'GZ8]*W/@%X'_
M .$A\2'5KF/=8Z:0R[AP\W\(_#[WX+ZU^98ZM/-\>J-+X5HOU?\ 70X9/VD[
M(]J^%7@E? _A.WMI$ OY_P!_=-WWD?=SZ*./S/>NQHHK]'HTH4*<:4%HM#M2
MLK(****V&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !42VL*R>8(D$F<[@HS^=2T4@"BBBF 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y)\0O@':
M>);R74=&G33KZ5B\L4H)AD8]6XY4D]<9'M7"6?[-OB2:X5;B[T^WB_BD$CN?
MP&WG\Q7TM17@ULDP5>I[24;-]G9&3I1;N<IX!^'.F?#ZQ>*SW3W4P'GW4OWG
MQV _A')X_,FNKHHKV:5*%""ITU9(T225D%%%%:C"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH :Z+(C(ZAD88*L,@CTKSWQ5\"_#7B3?+;P'2+MO^6EF $)]X^GY8^M>B45S
M5\/1Q,>6M%21+BI;GR1\0?A-JOP^C2ZN)8;S3Y)/*2XB.#N() 93R#A3TR..
MM<17V1\1/""^./"=WIFX1SG$L#GHLB\C/L>0?8FOD#4=-NM)O9;.]@DMKF)M
MKQ2+A@:_,\YRY8&LG27N/;U['%4AR/38K5W?P2U1M,^)&E_O!'%<;X)-QP""
MAP/^^@M<)2\CVKQL/5="K"JOLM/[C).SN?=M%?+'@?XXZYX3\NVNV.KZ<O'E
M3L?,0?[+]?P.1]*^@/!WQ&T/QQ"#IUV!<@9>TF^65?P[CW&17ZK@<VPV.TB[
M2[/].YWQJ1D=/1117LFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7&?$7_F'_ /;3_P!EKLZX
MSXB_\P__ +:?^RT 7?A__P @:;_KX;_T%:Z:N9^'_P#R!IO^OAO_ $%:Z:@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^5*^E?"?_(JZ-_UY0_^BUKY
MJKZ5\)_\BKHW_7E#_P"BUH UJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"3>VHANP,)>6^$D7TSV8>QS7645S?4\-R.DJ:Y7TLA<L;6L?*7CCX*Z[X/\
M,N(D_M735Y^T6ZG<@_VTZCZC(]ZX*WN);69)H9'AE0[EDC8JRGU!'2ONJO//
M''P3T+Q=YEQ;H-)U)N?/MU&QS_MIT/U&#]:^0QW#K7[S!OY/]'_G]YS2H]8G
MFO@G]H?4-)5+77X6U2V48%S'@3K]>@;\<'W-4?$7[0WB34;R0Z68=)M<_(HC
M663'^T6!&?H!7%>,_!M_X%UHZ;J'EM)L$J21-E70D@,.XY!X/I6#7S]3,LPI
MQ^KSJ-<OW_?N8N<UHV>N>%?VBM;T^[1=<2/5+,\.T<:QS+[C&%/T(_$5]"Z-
MK%KK^EVVH6,HFM;A Z./3T/H1T(]17P]6]HOCSQ!X=L_LFFZK<6EMN+^5&W&
M3U//TKT,OSZKA[QQ+<X_B7"LX_$?:%%?&\GQ,\5S;MWB'4!NZ[;AE_+'2JDO
MC?Q', )-?U20#INO)#_[-7L/B:CTIO\  U]NNQZ[\9?C+>6.I3Z#H,X@\H;+
MJ\C^_O[HA[8[GKGCC'/ATM[<3W'GR3RR3YSYK.2WY]:BDD:61G=B[L<LS'))
M/<TVOC,9C:N-JNI4>G1=CFE)R=V>K_"WXTZCH>HVVG:U=->:3*VSSIR6DM\]
M#N/)7U!Z#IZ'Z65@R@@Y!Y!%?"5?57PO^)FAZQX>TK3Y-2CBU6&WCADAN#L9
MV50,J3PV<=CFOKL@S&4KX>O/TN_P.BC/HST2BBBON#J"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKPOXK?'2ZL-0N=&\/
M,L;0MY<U_P ,=PZJ@/''0D^^/6N'&8VC@:?M*S_S9$I**NSW2BOC5/B1XJCN
M//'B'4B^<X:Y8K_WR3C]*]H^$?QJE\37D6BZX(UOV4^1=KA1,1_"PZ!L9Z<'
M'3U\C"9]AL545)IQ;VN9QK1D['L5%%%?2FX4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?3!^M>9C<QP^ 2=9ZOHMR)34-SZ/HKYBT#]H;Q-IUTAU)H=6ML_.C1+$^/\
M99  #]0:^A?"?BJP\9:+#J>GNQADRK(_#QL.JL.Q_P 148+-,-CVXTG9KH]Q
M1J1GL;%%%%>L:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7&?$7_ )A__;3_ -EKLZXSXB_\P_\ [:?^RT 7?A__ ,@:;_KX;_T%
M:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /E2OI7PG_R*NC?]>4/_ *+6OFJOI7PG_P BKHW_ %Y0_P#HM: -:BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .+\9?"3P]XVF-S=0/:WI'-U:$([?[P((;\1GWKGM
M+_9S\-6-TLMS/?7ZJ01#+(JH?KM )_.O5:*\ZIEV$J3]I.FFR.2+=[$-G9P:
M?:QVUK#';V\8VI%$H55'H *FHHKT$DE9%A1113 **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN)\=_%K1/
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MXQO[GJ..XO?M*?'0_ WP5;W=E9+J?B#4Y_LFFV;Y*L^,EV Y*KQP.264<9R
M#URBODZ;PK^U(V@KXD'C321J(A^T?\(XMI$"!C=Y.?)VE^W+=?XN]>F_LP?'
MA_CKX'N+K4+2.P\0:7/]EU""($(6(RLB@DE0W(P>A5O:@#V2BBB@ HHHH ^5
M*^E?"?\ R*NC?]>4/_HM:^:J^E?"?_(JZ-_UY0_^BUH UJ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC#<K*<@@]"#3J_3#N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG_P _<'_?Q?\ &C^U+/\
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M^_C?XT?\(7I/_/!O^_C?XT :?]J6?_/W!_W\7_&C^U+/_G[@_P"_B_XUF?\
M"%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^- &G_:EG_S]P?\ ?Q?\:/[4L_\
MG[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG_P _
M<'_?Q?\ &C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT
M:?\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP
M;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^-9G_  A>D_\ /!O^_C?X
MT?\ "%Z3_P \&_[^-_C0!I_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"-9G_"
M%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C0!I_VI9_\ /W!_W\7_ !H_M2S_
M .?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_ &I9_P#/W!_W
M\7_&C^U+/_G[@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_VI9_
M\_<'_?Q?\:/[4L_^?N#_ +^+_C69_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^
M_C?XT :?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C69_PA>D_P#/!O\ OXW^
M-'_"%Z3_ ,\&_P"_C?XT :?]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C69_P
MA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_P!J6?\ S]P?]_%_QH_M2S_Y^X/^
M_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?]J6?_/W!_W\7_&C^U+/
M_G[@_P"_B_XUF?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^- &G_:EG_S]
MP?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\
MOXW^- &G_:EG_P _<'_?Q?\ &C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?
M\(7I/_/!O^_C?XT :?\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z3_SP
M;_OXW^-'_"%Z3_SP;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^-9G_
M  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C0!I_VI9_\_<'_ '\7_&C^U+/_
M )^X/^_B_P"-9G_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C0!I_VI9_\
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MVI9_\_<'_?Q?\:/[4L_^?N#_ +^+_C69_P (7I/_ #P;_OXW^-'_  A>D_\
M/!O^_C?XT :?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C69_PA>D_P#/!O\
MOXW^-'_"%Z3_ ,\&_P"_C?XT :?]J6?_ #]P?]_%_P :/[4L_P#G[@_[^+_C
M69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_P!J6?\ S]P?]_%_QH_M2S_Y
M^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?]J6?_/W!_W\7_&C
M^U+/_G[@_P"_B_XUF?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^- &G_:E
MG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/
M!O\ OXW^- &G_:EG_P _<'_?Q?\ &C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C
M?XT?\(7I/_/!O^_C?XT :?\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z
M3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^
M-9G_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C0!I_VI9_\_<'_ '\7_&C^
MU+/_ )^X/^_B_P"-9G_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C0!I_VI
M9_\ /W!_W\7_ !H_M2S_ .?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_O
MXW^- &G_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C69_PA>D_\\&_[^-_C1_PA
M>D_\\&_[^-_C0!I_VI9_\_<'_?Q?\:/[4L_^?N#_ +^+_C69_P (7I/_ #P;
M_OXW^-'_  A>D_\ /!O^_C?XT :?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\
MC69_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XT :?]J6?_ #]P?]_%_P :
M/[4L_P#G[@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_P!J6?\
MS]P?]_%_QH_M2S_Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :
M?]J6?_/W!_W\7_&C^U+/_G[@_P"_B_XUF?\ "%Z3_P \&_[^-_C1_P (7I/_
M #P;_OXW^- &G_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (UF?\(7I/\ SP;_
M +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG_P _<'_?Q?\ &C^U+/\ Y^X/^_B_
MXUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?\ :EG_ ,_<'_?Q?\:/[4L_
M^?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^- &G_:EG_S]P?]_%_Q
MH_M2S_Y^X/\ OXO^-9G_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C0!I_V
MI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"-9G_"%Z3_ ,\&_P"_C?XT?\(7I/\
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M (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG_P _<'_?Q?\
M&C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?\ :EG_
M ,_<'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-
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MO^_C?XUJ,T_[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:S/^$+TG_G@W_?QO\
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MR1T[;%];K35D\P36HDSG<&7/YU)_:EG_ ,_<'_?Q?\:S/^$+TG_G@W_?QO\
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M$+TG_G@W_?QO\: -/^U+/_G[@_[^+_C1_:EG_P _<'_?Q?\ &LS_ (0O2?\
MG@W_ '\;_&C_ (0O2?\ G@W_ '\;_&@#3_M2S_Y^X/\ OXO^-']J6?\ S]P?
M]_%_QK,_X0O2?^>#?]_&_P :/^$+TG_G@W_?QO\ &@#3_M2S_P"?N#_OXO\
MC1_:EG_S]P?]_%_QK,_X0O2?^>#?]_&_QH_X0O2?^>#?]_&_QH T_P"U+/\
MY^X/^_B_XT?VI9_\_<'_ '\7_&LS_A"])_YX-_W\;_&C_A"])_YX-_W\;_&@
M#3_M2S_Y^X/^_B_XU#>SZ9J-G-:W,UM/;S(8Y(WD4AE(P0>:I?\ "%Z3_P \
M&_[^-_C1_P (7I/_ #P;_OXW^-)I-68'B_BSX PF[>;P[K%F+=CG[+>38*>P
M<9R/KS[FL_2/V?;VXD;^T==TVSBYQY$GG,3CC@[1C\:]X_X0O2?^>#?]_&_Q
MH_X0O2?^>#?]_&_QKP)9#@93Y^7Y7T,?90O<^2?%?A&_\'ZDUI>A'7_EG<0M
MNCD'J#_0\BKO@7XAZMX"OO-L9/,M7.9K.0GRY!_0^X_4<5]0:A\.=!U2U>VN
MK,S1-U5I&X]QSP:\!^)?P7O_  6TE]8;]0T;J9,9D@'^V!V_VAQZXKY?'937
MRZ?UG"-N*^]?YK^F82IN'O1/>?!OQ*T3QIIXGMKE+>X4?O;6=PLD9_J/<?\
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M'S-]W  VY*@=NU?0?PP^&6A_"/P?:>'/#\#164)+O)*0TL\AQND<X&6.![
M    5UE% !1110 4444 ?*E?2OA/_D5=&_Z\H?\ T6M?-5?2OA/_ )%71O\
MKRA_]%K0!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"EQ;ZKI%KY.DR@12QH21%)V/)/##]1[BO)J^5Q6%J8.JZ-3=&$HN+LPKW_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 ?*E?2OA/_D5=&_Z\H?_ $6M?-5?2OA/_D5=&_Z\H?\ T6M
M&M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7F7Q4^#</CF4ZG83+::NJ!6WC]W.!TW8Y![9YX 'T]-HKFQ&&I
M8NFZ5971,HJ2LSY*D^"?C2.<Q?V*S\X#K/'M/OG=7IWPP^ [:#?V^KZ_)'+=
MPMOALXCN1&'1F;N1U '0@<FO9Z*\7#Y#A,/453636U_^&1G&C&+N%%%%?1FP
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<9\1?^8?\ ]M/_ &6NSKC/B+_S#_\ MI_[+0!=^'__ "!IO^OA
MO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#Y4KZ5\)_\BKHW_7E#_Z+6OFJOI7PG_R*NC?]>4/_ *+6@#6HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *XSXB_\ ,/\ ^VG_ ++79UQGQ%_YA_\
MVT_]EH N_#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?*E?2OA/_D5=&_Z\H?_ $6M?-5?2OA/
M_D5=&_Z\H?\ T6M &M1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QGQ%_P"8
M?_VT_P#9:[.N,^(O_,/_ .VG_LM %WX?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_
M *^&_P#05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y4KZ5\)_\
MBKHW_7E#_P"BUKYJKZ5\)_\ (JZ-_P!>4/\ Z+6@#6HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *XSXB_P#,/_[:?^RUV=<9\1?^8?\ ]M/_ &6@"[\/_P#D
M#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?*E?2OA/_D5=&_Z\H?\ T6M?-5?2OA/_ )%71O\ KRA_]%K0
M!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<9\1?^8?_P!M/_9:[.N,^(O_
M ##_ /MI_P"RT 7?A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^5*^E?"?_ "*NC?\ 7E#_ .BU
MKYJKZ5\)_P#(JZ-_UY0_^BUH UJ*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MN,^(O_,/_P"VG_LM=G7&?$7_ )A__;3_ -EH N_#_P#Y TW_ %\-_P"@K735
MS/P__P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M*E?2OA/_ )%71O\ KRA_]%K7S57TKX3_ .15T;_KRA_]%K0!K4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %<9\1?^8?_ -M/_9:[.N,^(O\ S#_^VG_LM %W
MX?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#Y4KZ5\)_P#(JZ-_UY0_^BUKYJKZ5\)_\BKHW_7E
M#_Z+6@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M&?$7_F'_ /;3_P!EKLZXSXB_\P__ +:?^RT 7?A__P @:;_KX;_T%:Z:N9^'
M_P#R!IO^OAO_ $%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^5*
M^E?"?_(JZ-_UY0_^BUKYJKZ5\)_\BKHW_7E#_P"BUH UJ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+^T'PZMK%TQGR@3%M+]L9Z_Q]Z]-_9@^/?\ PO;P3<7-[;1V7B'2Y1;ZC;Q
MA"2"4D4') ;#<$Y!5NV*]DKX]_9.C70OVF_C5HL(\NW^U32I&.@5+IPOY"2@
M#["HHHH **** /E2OI7PG_R*NC?]>4/_ *+6OFJO2])^,W]EZ5967]C^;]GA
M2'?]IQNVJ!G&SCI0![!17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K
M45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\
MV%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#8
M4 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y
M-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW
M_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^
MH)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@
MG_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\
M"]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +
MT_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>
M4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1
M_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% '
MJU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_
M -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\
MV% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?
M^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y
M-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3
M_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^
MH)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_
M  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\
M"]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM1
M7E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#8
M4?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0
M!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW
M_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_
M -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@
MG_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?
M^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +
MT_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3
M_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3
M_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_
M  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K
M45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\
MV%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#8
M4 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y
M-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW
M_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^
MH)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@
MG_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\
M"]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +
MT_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>
M4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1
M_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% '
MJU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_
M -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\
MV% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?
M^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y
M-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3
M_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^
MH)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_
M  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\
M"]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM1
M7E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#8
M4?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0
M!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW
M_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_
M -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@
MG_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?
M^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +
MT_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3
M_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3
M_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_
M  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K
M45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\
MV%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#8
M4 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y
M-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW
M_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^
MH)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@
MG_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\
M"]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +
MT_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>
M4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1
M_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% '
MJU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_
M -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\
MV% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?
M^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y
M-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3
M_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^
MH)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_
M  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\
M"]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM1
M7E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#8
M4?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0
M!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW
M_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_
M -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@
MG_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?
M^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +
MT_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3
M_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3
M_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_
M  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K
M45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\
MV%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#8
M4 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^H)_Y
M-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@G_DW
M_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\ "]/^
MH)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +T_Z@
MG_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>4_\
M"]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1_P +
MT_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% 'JU%>
M4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_ -A1
M_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\ V% '
MJU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?^3?_
M -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y-_\
MV% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3_J"?
M^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^H)_Y
M-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_  O3
M_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\ "]/^
MH)_Y-_\ V% 'JU%>4_\ "]/^H)_Y-_\ V%'_  O3_J"?^3?_ -A0!ZM17E/_
M  O3_J"?^3?_ -A1_P +T_Z@G_DW_P#84 >K45Y3_P +T_Z@G_DW_P#84?\
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M1?\ F'_]M/\ V6@"[\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU
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MLI=-T'3K28 306Z1OM.1D* : /)?^%*:Y_S]:?\ ]_)/_B*/^%*:Y_S]:?\
M]_)/_B*]KHH \4_X4IKG_/UI_P#W\D_^(H_X4IKG_/UI_P#W\D_^(KVNB@#Q
M3_A2FN?\_6G_ /?R3_XBC_A2FN?\_6G_ /?R3_XBO:Z* /%/^%*:Y_S]:?\
M]_)/_B*/^%*:Y_S]:?\ ]_)/_B*]KHH \4_X4IKG_/UI_P#W\D_^(H_X4IKG
M_/UI_P#W\D_^(KVNB@#Q3_A2FN?\_6G_ /?R3_XBC_A2FN?\_6G_ /?R3_XB
MO:Z* /%/^%*:Y_S]:?\ ]_)/_B*/^%*:Y_S]:?\ ]_)/_B*]KHH \4_X4IKG
M_/UI_P#W\D_^(H_X4IKG_/UI_P#W\D_^(KVNB@#Q3_A2FN?\_6G_ /?R3_XB
MC_A2FN?\_6G_ /?R3_XBO:Z* /%/^%*:Y_S]:?\ ]_)/_B*/^%*:Y_S]:?\
M]_)/_B*]KHH \4_X4IKG_/UI_P#W\D_^(H_X4IKG_/UI_P#W\D_^(KVNB@#Q
M3_A2FN?\_6G_ /?R3_XBC_A2FN?\_6G_ /?R3_XBO:Z* /%/^%*:Y_S]:?\
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MM/\ ^_DG_P 17M=% 'BG_"E-<_Y^M/\ ^_DG_P 11_PI37/^?K3_ /OY)_\
M$5[710!XI_PI37/^?K3_ /OY)_\ $4?\*4US_GZT_P#[^2?_ !%>UT4 >*?\
M*4US_GZT_P#[^2?_ !%'_"E-<_Y^M/\ ^_DG_P 17M=% 'BG_"E-<_Y^M/\
M^_DG_P 11_PI37/^?K3_ /OY)_\ $5[710!XI_PI37/^?K3_ /OY)_\ $4?\
M*4US_GZT_P#[^2?_ !%>UT4 >*?\*4US_GZT_P#[^2?_ !%'_"E-<_Y^M/\
M^_DG_P 17M=% 'BG_"E-<_Y^M/\ ^_DG_P 11_PI37/^?K3_ /OY)_\ $5[7
M10!XI_PI37/^?K3_ /OY)_\ $4?\*4US_GZT_P#[^2?_ !%>UT4 >*?\*4US
M_GZT_P#[^2?_ !%'_"E-<_Y^M/\ ^_DG_P 17M=% 'BG_"E-<_Y^M/\ ^_DG
M_P 11_PI37/^?K3_ /OY)_\ $5[710!XI_PI37/^?K3_ /OY)_\ $4?\*4US
M_GZT_P#[^2?_ !%>UT4 >*?\*4US_GZT_P#[^2?_ !%'_"E-<_Y^M/\ ^_DG
M_P 17M=% 'BG_"E-<_Y^M/\ ^_DG_P 11_PI37/^?K3_ /OY)_\ $5[710!X
MI_PI37/^?K3_ /OY)_\ $4?\*4US_GZT_P#[^2?_ !%>UT4 >*?\*4US_GZT
M_P#[^2?_ !%07WP?UG3[&XNI+FQ:."-I6"R/DA02<?)UXKW*J6M6LE]HU_;1
M &6:WDC3)P,E2!_.@#YAKOU^"NMLH(NM/P1G_6/_ /$55_X5#XB_YYV__?X5
M[I&I6-0>H&* /%O^%*:Y_P _6G_]_)/_ (BC_A2FN?\ /UI__?R3_P"(KVNB
M@#Q3_A2FN?\ /UI__?R3_P"(H_X4IKG_ #]:?_W\D_\ B*]KHH \4_X4IKG_
M #]:?_W\D_\ B*/^%*:Y_P _6G_]_)/_ (BO:Z* /%/^%*:Y_P _6G_]_)/_
M (BC_A2FN?\ /UI__?R3_P"(KVNB@#Q3_A2FN?\ /UI__?R3_P"(H_X4IKG_
M #]:?_W\D_\ B*]KHH \4_X4IKG_ #]:?_W\D_\ B*/^%*:Y_P _6G_]_)/_
M (BO:Z* /%/^%*:Y_P _6G_]_)/_ (BC_A2FN?\ /UI__?R3_P"(KVNB@#Q3
M_A2FN?\ /UI__?R3_P"(H_X4IKG_ #]:?_W\D_\ B*]KHH \4_X4IKG_ #]:
M?_W\D_\ B*/^%*:Y_P _6G_]_)/_ (BO:Z* /%/^%*:Y_P _6G_]_)/_ (BC
M_A2FN?\ /UI__?R3_P"(KVNB@#Q3_A2FN?\ /UI__?R3_P"(H_X4IKG_ #]:
M?_W\D_\ B*]KHH \4_X4IKG_ #]:?_W\D_\ B*/^%*:Y_P _6G_]_)/_ (BO
M:Z* /%/^%*:Y_P _6G_]_)/_ (BC_A2FN?\ /UI__?R3_P"(KVNB@#Q3_A2F
MN?\ /UI__?R3_P"(H_X4IKG_ #]:?_W\D_\ B*]KHH \4_X4IKG_ #]:?_W\
MD_\ B*/^%*:Y_P _6G_]_)/_ (BO:Z* /%/^%*:Y_P _6G_]_)/_ (BJ&N_"
MW5?#^DSZA<7%F\,(!98G<L<D#C*CU]:]ZK#\:Z3<:YX8OK&U"F>8*%#' X=3
MU^@H ^=[&S?4+ZWM8RJR3R+$I;H"Q &?;FNY_P"%*:Y_S]:?_P!_)/\ XBG:
M+\*]>L=9L+F6. 10W$<CXE!. P)_E7M- 'BG_"E-<_Y^M/\ ^_DG_P 11_PI
M37/^?K3_ /OY)_\ $5[710!XI_PI37/^?K3_ /OY)_\ $4?\*4US_GZT_P#[
M^2?_ !%>UT4 >*?\*4US_GZT_P#[^2?_ !%'_"E-<_Y^M/\ ^_DG_P 17M=%
M 'BG_"E-<_Y^M/\ ^_DG_P 11_PI37/^?K3_ /OY)_\ $5[710!XI_PI37/^
M?K3_ /OY)_\ $4?\*4US_GZT_P#[^2?_ !%>UT4 >*?\*4US_GZT_P#[^2?_
M !%'_"E-<_Y^M/\ ^_DG_P 17M=% 'BG_"E-<_Y^M/\ ^_DG_P 11_PI37/^
M?K3_ /OY)_\ $5[710!XI_PI37/^?K3_ /OY)_\ $4?\*4US_GZT_P#[^2?_
M !%>UT4 >*?\*4US_GZT_P#[^2?_ !%'_"E-<_Y^M/\ ^_DG_P 17M=% 'BG
M_"E-<_Y^M/\ ^_DG_P 11_PI37/^?K3_ /OY)_\ $5[710!XI_PI37/^?K3_
M /OY)_\ $4?\*4US_GZT_P#[^2?_ !%>UT4 >*?\*4US_GZT_P#[^2?_ !%'
M_"E-<_Y^M/\ ^_DG_P 17M=% 'BG_"E-<_Y^M/\ ^_DG_P 11_PI37/^?K3_
M /OY)_\ $5[710!XI_PI37/^?K3_ /OY)_\ $4?\*4US_GZT_P#[^2?_ !%>
MUT4 >*?\*4US_GZT_P#[^2?_ !%'_"E-<_Y^M/\ ^_DG_P 17M=% 'BG_"E-
M<_Y^M/\ ^_DG_P 15#7?A;JOA_29]0N+BS>&$ LL3N6.2!QE1Z^M>]5A^-=)
MN-<\,7UC:A3/,%"AC@<.IZ_04 ?.]C9OJ%];VL959)Y%B4MT!8@#/MS7<_\
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M*4US_GZT_P#[^2?_ !%'_"E-<_Y^M/\ ^_DG_P 17M=% 'BG_"E-<_Y^M/\
M^_DG_P 11_PI37/^?K3_ /OY)_\ $5[710!XI_PI37/^?K3_ /OY)_\ $4?\
M*4US_GZT_P#[^2?_ !%>UT4 >*?\*4US_GZT_P#[^2?_ !%'_"E-<_Y^M/\
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MEQ<>)KF.6>21%LV(5W) ^=.U>RUYK\-? FJ^%]<GNKY(EB>V:(;)-QW%E/\
M(&O2J "BBB@ HHHH **** "BBB@ HHHH *XSXB_\P_\ [:?^RUV=<9\1?^8?
M_P!M/_9: +OP_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7&?$7_F'_P#;3_V6NSKC/B+_ ,P__MI_[+0!=^'_ /R!IO\ KX;_
M -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "BBB@ J.>XBM8S)-(D48Z
MO(P4#\34E?,/_!0QV7X%V 5B VN6X8 ]1Y,YP?Q _*@#Z2BUBPFD6..^MI'8
MX"K*I)^@S5ROEK1?V$/AEX@\)Z5=-_;%I=75G%,\UO>C.YHP3@,C#J?2N(;7
M_&?[%/Q$T32=9UZ?Q-\,=7E*QR709Y+500&V]=C)N5BJG:XS@ ] #[<HID,R
M7$*2Q.LD4BAD=3D,",@@^E><ZU^TA\,?#^KMIE_XUTJ&]1S&\:RF01L."K,H
M*J0?4B@#TFBJ6C:UI_B+2[?4M+O;?4=/N%WPW5K()(Y%]0PX-5_$OBK1_!ND
MRZIKNIVNDZ?&0&N;R41H">@R>I/IU- &K17GWA+]H#X=>.M7&EZ'XNTZ]U%F
MVI;;S&\A]$#@;_\ @.:]!H *1F"J68@ #))[4M?+GQF\$?%7XN2>+DU?4X_!
M?P\TB.Y:VL[%P]SJZ1JQ5Y"#PC8S@D8R/D)^:@#Z:T_4K35K<7%E=0WD!) E
MMY ZY'49!Q5FOF?_ ()\_P#)![C_ +#-Q_Z+BKK/VPOB%K'PW^".I7^A326F
MH74\5BMW$</;J^=SJ>QPI4'J"P(YH ]8OO%6BZ;=K:WFL6%I=,<+#/<HCGZ*
M3GL?RK25UD564AE89# Y!'K7RU\+/V,_AKXD^&6BZKK<%YKVLZQ8Q7T^JF_E
M5A)*H=M@5@IP6Q\P8G'-97[&]_JGA/XL?$CX;QZI<:QX8T.1S9RS/N$#)-Y>
MT=@6!.0.,QDC'.0#Z\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5XC(?<^7N/N3TKYN^&/@]OVU/B+XF\7>,[R[?P=I-Q]DTO1[>5HT&>0,CIA
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M#4U>$_L1?\FU^%_^NEY_Z52U[M0 4444 %%%% !1110 4444 %%%% !1110
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MWP3\-?'#X_?%^W\4I=W"6.J7$L)M[@QG<UU*#D]^ * /ONWN8KJ,202I-&>
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M10 4444 %%%% !7S!_P4._Y(;IW_ &';?_T3/7T_7S!_P4._Y(;IW_8=M_\
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MF9@!D*V$QG/S$=.YXKN=6\ ^&->OGO-3\.:3J-XX :XN[&*61@!@ LRDG H
MR?AK\8_!_P 7K>^G\(ZPNK1V+(EQ_H\L)C+ E>)$4G.T\CT-:/Q(_P"2=^*/
M^P5=?^B6K0T/POHWAE)4T?2+'24F(,BV-LD(<CH3M SC)Z^M>>?%;XT> ]-\
M-^*]#NO%^CP:NEA<V[637B>:)#$P"%<_>R0,>M 'GO\ P3Y_Y(/<?]AFX_\
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MO#?PYM;*Y\2ZO!HUM>7'V6":YR$:3:S8+ 8484\M@>_(H ^8?B]_R?U\-O\
ML'P_^A757O\ @HA_R)/@O_L,_P#M,US^L>)-+^*W[>?@^Z\,7L6L6&E6 6XO
M+1A)#^[2=V(<<$9D1<CC)Q77?\%#-!O-0^$>CZI:Q/(FEZLDD[(/]6CQN@<^
MV\H/JPH ^IJ^1/V*_P#DKWQR_P"PJO\ Z475>L+^UI\,H_ $7B:;Q18EFMUE
M;2HIE:^\PCF+R,[MV[C)&WOG'->,?L&ZA-J_Q!^+]_<6<FGSW=W;W#VDP.^$
MO+<ML;('(SCH.E &=\?O!;?$?]M7PYX6.I7.E6NJZ,L-W-:-B1H%6XDDC!_V
MUC*\Y'S<@C@^C?'[]F/X=Z=\"_$4NC^&K/2;_1K"2]MKZW4B?,2[R'<G+A@"
M#N)ZYZ@5@>,/^4B/@;_L#2?^DUY7NO[0'_)#?'__ & KW_T2U ''?LJ>.#>?
MLR>']:UV\/EZ9:W,=Q=2Y.V&"20*3CD[8U4>ORTO_#:GP9_Z'+_REWO_ ,9K
M-_8BMXKO]FG18)XDF@EFO$DCD4,KJ9W!!!Z@CM7J_P#PJGP3_P!"=H'_ (*X
M/_B: .ATS4K;6--M+^SE$]G=1)/#* 0'1E#*W//((KY-_:3_ .3N_@M_UTA_
M]*37U#K_ (ET#P!H:7>L:A8Z#I,)2!)+F188E[*BYP.@X [#VKXV^/GQ1\(Z
M_P#M/?"?6M-\1Z;?:1I\D)N[V"X5HH,7!8[V!P..: /N.OB714\7?L=_%[Q;
M=/X3U'Q/X%\1S^='=:7'O:/#LT>< @,HD="K;=W4'BOK?PC\1O"WC[[5_P (
MWX@T[7#:[?/%C<+*8]V=NX \9P<?0UE?\+R^'JZAJ-A-XST2SO=/GDM[JWO+
MV.WDCD0D.-LA!."#R,B@#Y/_ &F/V@M8^*WP@U2QL?AQKFCZ LMO)<ZUK2>2
ML9$J[%C7&&);CAC@'IW'U%^SDLB? ?P$)?O?V/;$<8^4H"/TQ7SU^T?\3K?]
MI#6="^$_PYN!K/VB\2ZU/5(%W6\4: _Q=U7=N8CC(502217U[H6CVWAW1-/T
MJS4K:6-O':PJW4(BA5'Y 4 7J*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *^/?^"A7_-,_^PC/_P"T:^PJ^._^"ATBPQ_#:21@B+?W#,QZ
M #R<F@#[$KXT_P""D2Q1Z'X#G5BE['=W0B*\$+MC+$?B$KWS4OVG?A5I=JT\
MWCK1Y$7^&VG\YS]%0$G\J^;I-1OOVV/CIH%U8:7=6?PX\*R&22ZNDV^>VY6=
M?3=)LC7:"2%!8]<4 =G^W=X]NM*\+>$?" U :3;>)+HC4[I<YCMXS&&! ZKF
M3)'?9CN:;9^)/V4K/PF/#V_P_-:>5Y37$NG2M=,<8WF?R]X?D_,"",\8H_;T
M\+7:V'@CQS!8+J-GX;OS]O@8 AHW>)EW @C;NC*G_KH*]$\,^*O@)XJT.#5+
M0^!X89(Q(T-Y%:030^HD1P"I&#U],C(YH \U_8&\5F:W\>^$+:_?4]#T6_67
M2[EP?FAD:5<C/0'RE8# Y=JP/ ?AVR_:?_:F\<ZIXKA_M'P_X48V5EILA/E'
M;*R1EAGD'RY'([EAV&*^FOA;XD^'WB*+5O\ A 6TEX+698;Q])M1%&9-N5^9
M5 ?@GD9'7FOF#X9^+M/_ &</VJOB+HGBR9='T?Q',UY9WTN1" TK20Y..%VR
MR*6Z!EP>Y !]#W'[,_P\_P"$JT+Q%IN@0>']5T>Y6YADT=5MDD*_P2(HVLI[
M\ ^_)S5\3?M8?"KP?X@O]$U?Q4+74[&4P7$*V%U)L<=5W)$5./8FK>H?M+?#
MRW\2Z'H%AXAM_$&JZQ=QVD$.BNMTJ%SC?(ZG:JCC/.?8X-==??#CPEJEY-=W
MGA?1;NZF;?)//I\+N['NS%<D_6@"/X>_$SPU\5M"?6?"NIKJNFQSM;/,(9(M
MLBA6*E9%5NC*>G>N3_:D_P"3?/'/_8.;_P!"6O1-&T'3/#MH;72=.M-+MBYD
M,-G L*%B "VU0!G@<^U>$?M+?&;P)J7P<\;Z':>+M'NM8:T>W6RAO$:4R!@"
MH /)X/Y4 :_[%?\ R;+X-_[?/_2V>N8_;&^$_B?Q0WA'QOX,M&U#7O"USY_V
M.-0TDB!DD5U7JY5X_NCD[N.E1?L>?%KP7H_P,\&^';_Q3I5GKOF7,7]GSW2)
M-O>\F*+M)SE@RX]<BO=_%WQ'\,> 9M.C\2:Y9Z)_:#,EL]])Y<;E0"WSGY5Q
MN'4CK0!X/9?MFZI?VZ6D'PA\73>(2H5K%;=A$']"^W<%SCDI7$?L/S:C??&S
MXMW>HV2Z;>23,UW9HP=8)FN92T88=0IW#KSBO</B?^U7\/?AWX=NKR#Q'IVO
M:F(\VVG:7<I</*Y'R[BA(5>A))''3)P#S/[%OPVU?PGX(UCQ1XBA>#7O%MY_
M:$L<B[6$7S&,L.Q8R2-CL&% 'T31110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !117+>,?BAX4^'M]I=IXEUVTT274_-^RM>L8XY/+V;\N1M
M7&]?O$9SQWH ^9O#_P#RD<\3?]@Y/_2"WJ?]L+_DO7P+_P"PJG_I5;UF_"36
M++XD?MW^,/$V@3C4-$AT_'VR/_5MM@@@X/<%U;'J!FM3]NR.7PWXE^$_C8V\
MDNGZ-JK?:FC&<$20RHOU(BE_*@#ZYKY+_P""<?\ R2[Q-_V&3_Z(CKU'Q=^U
M?\.O#OA(:OIWB"S\1WMPH%EH^F3"2[GE;[J&,9:/GJ7 QZ$X!\P_X)SQM#\,
MO%$;J4==:*LK#!!$,>10!Q&J?#"U^+O[<GCCP_J=]<VVBBUAN[^VM7*&\CCA
MM<0L0>%+LC'_ '.,'!':?M>_L\^!_#_P1U#Q!X>\/6>AZIHCP/'-8IY9D1ID
MC97Q][A]V3DY7KR<K\.?^4@WQ%_[ P_]%V5>F?MD?\FU^-/^N=M_Z50T ;?P
M]^)MG9?L^^&_&GBG4/L]LFCV\]_>NC.=VU59MJ@DDMV [US\7[:'P:FD2-?&
M2[F(4;M-O%'/J3#@?4UL?L[Z;::O^SKX)L[ZUAO;2;285DM[B,21N.N"I&#7
M6+\*_!2L&7P?H((.01ID''_CM '4U\N?M@_$6Y\3"Q^#?A ?VCXI\031K>QQ
M'/V6W!#@.1]W=@,?1%)/#"NH_:H_:2C^"FCP:1I(2?QAJL>;038$5K&25\]R
MW'4$ 'C()/ YXS]G6Z^%GPGLKG7=>^(N@:UX^UC,NI:I)J*2%"QW&)&)SC/5
MOXB/0   ]FL_!47PK^ -QX<TUO._LG0[A%DQM\V7RG9WQVW.6;\:\F_X)WQJ
MOP/U0@8+:].3[_N+<?TKWW1?%7AOXGZ#?_V%K-GK6GN'M)YK&99 C,G*DCH<
M,#^-?(W[(/Q(T_X$Z_XR^&/CN^A\/W$.H?:+:XOF$4#R;0CY=L !E2)E)X(S
MSTR >K?MY1I)^SSJ#,,LE_:LOUWX_D37IOP'$B_!'P )L[_[!L<[NN/(3'Z8
MKYP_:\^*&E_&/_A&OA9X$O[?Q%J^I:E'+<36$@F@B50P53(N5/+%VP3M$9SB
MOK?PWHL7AKP[I>D0$M!I]K%:1L>ZQH%'Z"@#2HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ KX]_:?_ .3MO@I_U\6O_I8*^PJ^-/VL]4M-
M$_:D^#VH7]S'9V-K);S3W$S!4C1;O+,Q/0 #- 'V77QA^V-&L/[1WP=N+1B-
M3:XMUXX.!>(8^1_M,]>\ZY^U1\*M L9+J7QKIMT%4L(;&0W$CD#H%0'D^^!7
M@GPOM]8_:H_:,M?B==Z7/IG@CPZ%331<C!F="QC /0MYC&1B.%PJY/!H O?M
MK>-;2_\ B/X$^'VMZL=&\(W!34]9N$+9>+S&0*=N3@"-\<'E@>PJ[XD\0?LL
M:]X*N/#T-QX?TY3 T=O>6VFRK<P/C"R"41[R00I.2=V.<U3_ &P]*B\&_&;X
M<_$G5-+CU3PQ 5TW4HVB$H #NWS*00<K(Y&>I3''%>OV.O? 34-)74H9_ /V
M-D#EI%LT900#AE8!E;D?*0#[4 <3^P3XYOO$?P7O+'4IVN!H5\]K;R-R1;E%
M=5SWP6<#T&T=JX#]F3P?IO[3'C[QO\2O'-E'K2I=+:Z?I]T"\$*D$X*'@A4V
M* <C)8D9P:^J/AEKG@OQ-X;FNO XL&T3[1)"YT^U\B)I5 #<;5SQCY@,'UKY
M0_9-\?:5^S_XT\<?#;QO>PZ!*M_YMK>7K^7 Y4%3ES@*&01LK$@$>^,@'TII
M7[.O@3P[\0=-\8Z'HR:#JUDDJ>7IF(;:99$*$/$!MX#$C;MYQG.!6'J'[8WP
M?TN_N;.Y\8!+BWE:&55TV[8!E)!&1"0>1U!Q6[8_M%> ]:^(&D>#M%UJ+7]7
MU(2LKZ4RSV\*I&TA,DH.WD(0 I8Y(R #FNCF^%_@VXF>67PEH4LLC%G=]-A+
M,2<DD[>30!;\%^-=%^(?ANTU_P /7RZCI%WN\FX6-X]VUBK?*X###*1R!TJE
M\3/B-H_PI\&:AXDUN<16MJGR1Y >>0@[(D'=F/Y<D\ U-KFK^'_A3X)OM3GA
M@TC0=*A:=XK2$(B#.2$10!EF/0=2WO7Q=H?C[P[^TM\3/^$J^)GBC2_#W@O1
MIMND^%KN]16G;KOE7/0\;C_%]T< T >I?L;^ ]9U/4?$_P 7?%$)@U;Q7(QL
MX64@I;,^\L,\[6(0+_LQ@\AA6'XN9KK_ (**>#HYN8XM,81_06ETP_\ 'B:^
MA?#_ ,:_A[X@U*TTC1O%^B7M[,?+M[.UNT+-@9VJH/H.@]*^<OVLQ>?"K]H+
MX=?%86\TNBPA+&]>%=Q3:\F]?3+Q2OMR>2AH ^QJ^._V*XWC^-/QJ2-0MLM_
M@@=C]IN-H_+=7M7B3]J;X::#X+N/$,'BS2]3VPF2"PM;E6NIGQE8_*^^I)P#
MN "YYQ7G/[!O@G5-+\%>(O&.L1-#=>*[U;F-6!!>%-Y$F.P9I9,>H /0B@#Z
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKC_%7Q@\%
M^!]>BT;Q#XDL=%U&6V^V)'?2>4K1;F7(=OE)RK#;G/'2@#YT_9L_Y.[^-/\
MUTF_]*11\4O^4@'PX_[!2_RO*K_L@WR>,OV@_C!XLTX-+HMS.ZP7&T@.)+AF
M0\^JIG';(IO[3VH)\,_VK/AAX]U*-XM!^S+:3W2J6"%9)1(<#GY4G5L=\'%
M'TI\9/\ DD/CG_L!7W_I.]>2_L$_\F^6G_81NO\ T(5/\?/VDO T'PRUG2M#
MUFT\5ZUKEC-8VFGZ+.MRX,L;*7?9G8%#9P>3C '7$'[!/_)OEI_V$;K_ -"%
M 'B?P?\ A#IGQ>_::^+-KK\\\V@Z;KUU>S:3'(RQ7DPNIUC,F#R%#2>_S8S@
MD'I?VV/@[X:^&_A#P]XU\':3;>&M8L-5A@+Z:@A5E*.ZN5'&Y7C7!QD[CG/%
M:_[)W_)RWQW_ .PK<?\ I9/71_\ !0;_ )(/;_\ 89M__1<M 'LVM_%+0?!/
MP_L/%?BF_72M.FA@9YO*DDP\B@A0J*S'D]A7(:%^UU\)?$FM6&DZ=XM6>_OI
MTMK>)M/NXP\CL%5=S1!1DD#D@5W'AS1=.\0?#W0+35+"UU*T:PMF,%W"LL9(
MC7!VL",BI;3X:^$-/NH;JU\*Z);7,+B2*:'3H5=&!R&4A<@@\Y% '25\A_M1
M>)+OX[>/]%^"WA"07!CNEN]=OH_FCM0G&UB./D#%F'][8O7(KH/VL/VEYO =
MQ%X"\*W45IXKU%46?4[B18HM.B?@-O;@.1SG^$<]<5-\ M4^#?P/\+M:Q?$'
MP_J.O7Q$NIZM)>ION).N 2<A 2<#W)/)H ^A] T6U\-:%IVD6*>796%O':P)
MZ1HH51^0%<#^TQ_R0'QW_P!@J7^5=QX:\5:/XRTF/4]"U.UU;3Y&9%N;.42(
M2IP1D=P:\5_:.^,W@2]^$?CK0K?Q=H\^LM8S6PL8[Q&E,HX*!0>N01B@"S^Q
M%_R;7X7_ .NEY_Z52U[M7RY^QO\ %KP7H/P.\+:!J7BG2K#6O/N$^PW%VB2[
MGN9"@VD]2&&/J*^HZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "OCWQ!_P I'/#/_8.?_P!(+BOL*OBSXA>(]+\)?\%!- U;6K^WTO3;
M?3CYMU=2!(TW64ZKECTRS ?4B@#[3KXP^)02U_X*$>"Y+)L7$MM!]HQQR8IE
M8<?],P*]N\6?M;?"OPGI<UV?%=IJTJ)N2TTH_:)93V48^4'_ 'B!7D7[-?A?
M7?C)\;=8^-_B+3I-+TUD:'1+>7.6!3R@R\?,JQ;@6P S.2.AH Q?VEO&GA[Q
M;^TUH/@_QQJ_]F> M!MUNKV+,FVXG>/S K; 3R#&OJ 7P1NJS\9_$'[-OB[X
M7ZQIVB7&@:=K5O:/)IDVFZ8]O*)T4LB;EC&58_*0QQ\Q/4 U'\=K/3?A3^US
MHOC?Q9I5O?\ @S7K9;>XFN+<3QQR+$(B64J>5VQMT)*YQR*]SFUGX#0Z:;]K
MCX?_ &0#=YB_8FS[ #DGVZT <]^S?\5+RZ_93C\3ZLS7MSH-C>"1Y"=TJ6P=
MDR3U.Q5!/<C->=?L@_"/1?BQH^N?$OQY86_BC6]6U*58UU",2PQJN"Q$;97)
M8D#(.%4 8YKZ+M;7PY\2O@_?V?A(VB>'];TZZM+5K:W,$.)%>-B$V@@;MW;G
MK7SC^QC\9- ^'?AG6OA[XUU.U\,:SI.HS,@U298(V4X#IO;"AE=6X)Y##&<&
M@#W_ ,+_  +\#_"_QEJ'C/0;#^PII=/>UNK>W?;:>7O20R>7CY6'EC[I QGC
M)S7-']M3X,@X_P"$R_\ *7>__&:ZGPO\>?!/Q \=W/@[P_J*Z]>16+WEQ<6B
MB2T5%=$*&3.&)\P?=!&,Y(/%;G_"J?!/_0G:!_X*X/\ XF@#:\/Z]8>*M#L-
M8TNX%WIM]"MQ;SJI4/&PRIP0".#T(S7%?'?XS:7\$? -YKEZ\<NH.K1:=8L?
MFN9\?*,==HZL>P]R =+XD?$#0?@E\/;K7+^(6^EZ?&L4%G:(%+L?ECBC48 S
MT]  3T%?)7PL\5>%OC!X^/Q.^+GC#0K5K60IHGA:>]39:JIX=U)['D C+$;C
MQM% 'L7[&?PDU+P'X)U'Q+XB5E\2>*IEO;B.5<211?,45O1F+LY';< >17T-
M7'^&?C!X(\9ZHNF:%XKTG5M096=;6TNT>0J.I !YQ5WQ=\1_"W@$VH\2>(-.
MT0W6[R%OKA8C)MQNV@GG&1GZB@#YG\!?\I#/'?\ V"A_Z(M*^NZ^'/!?Q0\(
MV7[<7C+Q-/XCTV'P_<Z=Y<.I/<*()&\FV&%?."<JP_X":^S?#/BO1O&>E+J>
M@ZI::OI[,R"YLY5D3<#@C([CTH UJ*** "BBB@ HHHH **** "BBB@ HHHH
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M\6_!+X*^#[?0=$\<: QX>ZO9+V,2W4N.7?G\AT X]Z /?$18T5$4(BC 51@
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MTDJ1L.0RQNQ12#W !KK?#GP\\.^$=;UO6-'TJ*QU+6Y1/J%Q&S$W#@L=Q!)
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MK6;O5M6\(:;?:C=/YD]Q(AW2-C&3@]>*S_\ AEOX4?\ 0C:5_P!\-_C7J=%
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M:";.=JW$XBZY_P!6)-GZ5[!10!G:#X>TSPKI<&F:/I]MIFGP#$=M:1".-?P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KC/B+_ ,P__MI_[+79UQGQ%_YA_P#VT_\ 9: +OP__ .0--_U\-_Z"M=-7
M,_#_ /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7&?$7_ )A__;3_ -EKLZXS
MXB_\P_\ [:?^RT 7?A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *XSXB_\ ,/\ ^VG_ ++79UQGQ%_YA_\ VT_]EH N_#__
M ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45'<7$5G
M;RSSR+%#$I=Y'.%50,DD^@%?,?B']NC2K'4I8='\+W&JV:,56ZGO!;E\=POE
MOP?<@^U=F'PE?%-JC&]OZZG-6Q-+#I.K*USZ@HKY,_X;S_ZD;_RK_P#VBC_A
MO/\ ZD;_ ,J__P!HKM_L?'?\^_Q7^9R?VGA/Y_P?^1]9T5\F?\-Y_P#4C?\
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M<^@82'ZL: ,K6OBW^TG\.].GUOQ%X#T+4]%MQON5T]]TD2#DM\DS$#'4[6
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MC_Y)=XF_[#)_]$1UWG[:7Q"/@7X':G:VTA74M>==*@5?O;7!,IQZ>6&7ZN*
M/-O@_P#ML:[X\^,.FZ#K.CZ=IWA?6IYH--NHXI5GR"PB#,TA5B2 APH^9ATK
M[!KX@_:"^",_PV_9M^'6L:8AM]>\&R1374T8^96G8/(V>^V?9C/0$U]>_#OQ
ME;?$+P+H7B2TVB'4[2.XV*<[&(^=/JK;E_"@#QCXM_M)^(['XFK\-_AEX;M_
M$OBN-%ENYKYB+>V! 8J0&3.%*DL7 !8#D\53\/\ Q1^/7A7Q5HMGXY\ Z?J6
MAZE>0VCW^A$L]IYC!=[[7?Y5SD[E4<'YJ\T^(6K:U^RO^U)J_P 0+W1[C5O"
M/B6,Q/<0<E0^QF0,>!(KQ9"D@,O<=OJGX9_&CP=\7K$W'AC6H;V5%W2V;_N[
MB'_>C;D#/&X9![$T <-^UA\=]8^ _@W2=2T.QL;V^OK[[-_Q,%=HD0(S$[49
M23D#OZUQ,7Q1_:AM(&NKSX6>'[FV50^VTND\PCV NW)..P%97_!1[_DG?A3_
M +"K?^B6KZTL?^/&W_ZYK_(4 >%_!']K32/BCXBD\*:YI-QX0\8QED_LZ[;*
M2LN=RHQ"D. "2C ''0G!KWNOC7_@H!X93PW-X,^(VDC[%KMI?K:-=1#!<J#+
M"Q/JIC?'L<=A7UYH6J+KFAZ?J2+L2\MX[A5SG =0P'ZT >'?M5?M%:O\$X_#
M^G^&=/L]5\0:HTLI@O(Y)%2WC7EMJ.IR2>#G&$;BNW_9[^+/_"Z?A;I?B66.
M&WU!V>WO;>WR$BG1L$*"20"-K $GAAS7B/PY6/XY?MC>+_$\RK=Z!X0M3I5F
M'&Z,R'=$?8@DW+?BOUJE^R?<2?"'X[_$/X2W;LEH\S7VF+(>H7!&/4O"\;'_
M *Y&@#Z_GGCM89)IG6**-2[R.<*J@9))[#%?*UY^UAXU^*?BB^T3X+>#H=;M
MK/B;6-6)2+!) 8*70*#@E=S%CC[O!%=Y^VAXJN/"O[/?B%K29K>XU!HM/#J>
M=LCCS!^,8<?C6O\ LJ^"[7P3\!O"4%O$$FU"S34[E\89Y)U$F3]%*K]%% 'D
M&N?M!?'7X.0Q:I\0O .EWOATR*LUWI4F'BR<8++(X7VW* 2<9KZ4^'/Q"T;X
MI>$+#Q'H,YGT^[4X#C;)$X.&1QV8'_$9!!K9UC2;37])O=,OX5N+*\A>WGB8
M<.C JP_(U\C_ + %U-H.J?$WP;+,[Q:7?QR1*W]X-+%(V.Q/EQ_E0!]B5\]?
MM-_M >+/A/XK\&>'/"&E:7J&H^(':,'5%<KO,B1QJNV1,99N23CI7T+7QE^V
MMJEKH?QS^#NI7TPM[*SNDN)YF!(2-+J)F; YX )XH Z+7OC=^T/\.]/GUKQ3
M\,]#O-"M )+F72;@[TC&=QXGD8 #DMLP.]>\_"/XIZ1\8_ ]EXFT<21P3%HY
M;>;[\$J_>1L<''!R.H(->1_%3]LCX86_@36H-)UL>(-4NK26WMK"WMIAYCNI
M4;F9 H7)YR<XS@&M3]BOX;ZG\-_@K%%JQ5;O5KQ]3$*.'$2.D:(I()&2(PQQ
MTW8[4 ;_ ,.]:^*UY\7O%]GXJTBTM/ T/F_V/=P[-\F)5$71RQS'N+9 P0.G
M2O6Z^<?@?\5O%/BW]I#XI>&M5U5KO1-)>065H88U$.V8(,,%#'Y?4G/6M#]H
MSX^ZUX)\0:'X"\"6,.I^.M=&8C-@I:(20KE3P2<.?F.%"$D$4 >_45\K:[X$
M_:7\,:3<:_:?$;3M?OX(_-ET=+&(+*%Y*1YB )QGIL)]<UUWPT^,6O?M'_ W
M4;SPE?6GA7QU!(EK+)+&)H+>0.C%PK*V4>/<!D'!)'.W- '<^ _C=H'Q$\<>
M+/"NFV]_%J7AJ8P7<EU$BQ2,'9"8R')(RIZ@=J]"K\\/@GX5^+NI?&;XFVGA
MCQIIND^);6[==9U"XM(WCO)/.<%D4PL%&X,>%7K7V3JWC2]^#'P6DU[QUJ,6
MM:MI=IF[N+9!"MY.6PB( H W,57.T>N* /1J*^5O".G?'_XTZ';^+QXXL? =
MA?#[3INCP:>DW[HCY&=F7)##!Y+<'.!G%=-^S[\:O%.J>//$/PR^(L=K_P )
MAHJ":.^M%V)>Q?*2VT  '#HP( RK?=!4Y /H.BOGK]H[X]>(_"OB[0?AU\/K
M.&[\:ZV@<7$X#):1DD*0IX+?([$MPJKD@YXY^Z\'_M+^!$&N6OC+2O',BL)+
MG0Y+=(Q*.,B,E$QWX#)[ ]* )?VV/&_B'P?=_#9="UJ_T=;O5)%N!8W#1><H
M,6%?:1N7YFX/'-?4%?'7_!0J^:PA^&=XT1=H;^>4Q*>3@0G:#^&*W;O2?VE?
M'VBOXIM/$&F>"W93<6/A=;=&D"8RJRN\;?.1V8XR>0G( !]445XG^RC\<;_X
MV> [N;6X8X/$.DW/V.]\I-BR?*"LFW^$GY@0.,J<8! KS#XG_M!?$/PG^TYJ
M_A#PU;'Q"D]A#!IFBM&@B2X=(W,SN &VJ#(3\P&.I &0 ?7=%?'/Q(F_:*^"
MWA\^.[_QKIGB&RMY(VU'2(K1/*B1F P!Y:DH&(4LI5N0>F37T_\ #GQU:_$'
MX?:)XIA46UOJ%FMRZ.W$38^=2?\ 98,,^U '3T5\E:?\6OBG^TMXNUJV^&.I
M6?@_P9I,IMVUJY@6:6[;/! 93@D#<%4#:"-S9(%4_$/Q,^,'[+OB#19_'^L6
MOCGP/J$PM7O(8%CFMVY)Y"*V_:"P#;@P4C(/( .^_;B\6:UX-^"L=[H.K7FC
M7KZK!";FQG:&385D)7<I! )4?E7LW@.[FU#P/X=NKF5I[B;3K>221SEG8Q*2
M2?4DU\_?M]7<-_\ L^V-S;R+-;S:M:R1R(<JZF.4@@^A!KVOPSKUCX6^#^CZ
MQJ<XMM/L-#@N;B5OX42!6)]S@=.] '9T5\B>$/&/QN_:=6_UWPOK=G\.O!JS
M-;V@:W6>>X*]3N*DDCH2"JYX .#5C1_C-\2_@1\5-$\(_%B^LO$.@ZZPCLM?
MMXEB,39"\[57(#,H<,,@,&#$<$ ^LZ*\?_:>^-EU\$_ ,%[I5G'?:]J=TMC8
M13 E%<@DNP!!( &  >K#MFO*_&7A/]HSPCX"OO%S?$ZUNM1L;5KVZT>+3;<(
MB*I:0(QC*L54=-HS@X.<9 /K2BOE3X7^(/BUX\_9Y\2^+E\>1ZKJ5Y8&728X
M=,@AFM)X'8S1G$85BX38"0>H(Q7HW[)_Q<N_C#\(;/4M5N1=:[93R65_(%5-
M[J=ROM4 #*,G08R#0![+17SA\0OBKXJUC]JSPA\._"FJFQTVSC6]UT)#&_F+
MCS&C8LI('EA ",<S>P(^CZ /"_VLOCMKOP'\*:)J>@V6GWEQ?7QMY%U&.1T"
M",MP$=3G('?\*]PMY#-;Q2$8+*&./<5\D?\ !1[_ ))WX4_["K?^B6KVK]H'
MQ9JO@;X">(M<T2Z-CJEI9Q&"X"*Y0M)&I(# C.&/:@#U&BOC_P"'WBSX[?M$
M>#].N=#U>U\%Z-;6R0RZU=0*USJMRJ@2.JA"%0,#RH7GN>0O2? 'XR^.K/XO
M:U\*/B7/;ZCK-I"UQ9ZI!&J><H56V_*JAE*-N!V@C!#9/0 ^G**\0_:D^/5Y
M\&?#FF66@6L=_P"+==F-MI\,@W"/& 9-O\1RR*%X!+=\$'A8O#_[3'@G2U\4
M7'B?2_%L\:BXO/"YMT!=,99(W6-?G [(0"1QNX! +O[%OCWQ%XWO/B0-?UF\
MU<66I1QVPNY2XA4F7*KGH/E' ]*^G*^._P#@GC>'4(_B3=-&83/?V\IC)R4W
M><<?AFNZ^+7QF\9>(/BQ%\*OA:;2VUN&$7.JZY=H)4L$X. I4KD!DR2&Y<+@
M') !]%45\D^/-1^.?[..DQ>+M1\867Q"\-P3*-2L9[)8'C#L%#*RKN R0 0<
M D?*17I'QL\2>+/$_P #;3QI\+M:FL;F."/5A"EO'(UU;%-S)M=6^90=V!UV
MD<Y% 'MU%> >'OVLM$N_V<Y/B'>F(:G9I]CN-.5L%[_&%C4=E?AQUPI/]TUO
M_LP7/CS6_AV/$7C[57O;[6I/M=I9M;QQ"TMR/D&%4'YA\V#G V]\T >P4444
M %%%% !1110 4444 %%%% !1535M5MM#TVYO[R00VMNADD<]@/ZUXS>?M/6\
M=PRVOAZ2:$'Y7ENQ&Q^JA&Q^=<&*Q^&P=E7G:_J_R(E.,=SW&BO"/^&HO^I9
M_P#)_P#^U4?\-1?]2S_Y/_\ VJN'^W,O_P"?GX2_R)]K#N>[U#>7D&GVLMS=
M3);V\2[GED8*JCU)->'?\-1?]2S_ .3_ /\ :JX;XF?%N\^(D=K;BT_LVQA^
M<VZS>9YC_P!XG:.@Z#'<USXC/\'3IN5*7-+HK-?FB76BEH>MZE^T=X9L[EHK
M>WOKY5./.CC54/TW,#^@KI_!OQ2T#QQ(8;"X>*[ W?9;I0DA'J.2#^!-?']2
MVMU+97$5Q!(T,T3!TD0X*L#D$5\U2XCQ4:G-42<>VWW&*K2OJ?=-%>!6?[3T
MT5K"EQX?6>X5 ))5O-@=L<D+Y9QGTR:F_P"&HO\ J6?_ "?_ /M5?6+/,OM_
M$_"7^1T>UAW/=Z*\(_X:B_ZEG_R?_P#M5'_#47_4L_\ D_\ _:J?]N9?_P _
M/PE_D'M8=SW>BO'_  S^T=IVL:I!::AIDFEK,X19Q.)44G@;OE7 ]^:]@KT<
M-C*&,BY4)72_KJ7&2EL>1?M-_&NZ^"'P_@U+2K:VOM>OKR.SL;6Z5G1F.68E
M596("@C@CEEJI^RW\=KSXY^#=2N=9M+73_$&EWAMKNUM$=$"D91@KLQ&?F7!
M/5#7FOCYO^%U?MH>&/#"_OM%\$6_]I7@'*^?\LGT/S&V4CV:L[PF_P#PHO\
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M !Z_:&^'>GRZWXQ^%ND2:#;?/<MIEP-Z(.K$I/-M'^T5P.]5OVPO^2]? O\
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M5SG;L1LEHW=#G' 6@#WZ2-)HVCD571@596&00>H(KX__ &P/V</"?AKP+?\
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M/P[KGA7P7I^F^(]>?Q+K4?F/<ZDZ;/,9G9@ /100H]EZ#I0!U%%%% !1110
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MG2-D,;*1E%8@Y([>M<7;_#']J*XC^S7?Q2\/6UJ5"E[6U0R <=/]$4CCONH
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M_P#0$_\ )N#_ .+KZRHKS/\ 5K"?S2^]?Y&?L(GR;_PHWQO_ - 3_P FX/\
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M?_H"?^3<'_Q='_"C?&__ $!/_)N#_P"+KZRHI_ZM83^:7WK_ "#V$3Y?\/?
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MZ;XEA:=K?3[73[B7RR)F5E5F9$9=LGF2<>@'6J?P;_95\<?\*\T"^C^,&O\
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M4+MK226W8+(BR3P*2I((# '@D'FN^TO]@OX;6>H176H7?B#Q (R"(=3OU*$
MYP?+C0X_&MKX\_ G7?BE\3/AMXBTJ\TZWLO#=ZMS>1WDDBR.HFBDQ&%1@3B-
MNI7G'X>Z4 4])TBQT'3+;3M-M(;"PMD$<-M;H$CC4= JC@"OE?\ 8'_YJ?\
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M1/%>B2F6PO)-P0Y*G:S+EEPRJP8 X(/'- 'IGC^9+?P)XCDE=8XUTVY+.QP
M/*;DFO!O^"?/_)![C_L,W'_HN*J;? OXR_%:UCT;XG^-M/B\,0X:6ST-=LNH
M,IRHE81IA<X/?I]W."/1?V7/@_K/P1^&DGA[7+FQN[UK^6Z$FGR.\>UE0 9=
M%.?E/:@#RG]EM@/VGOCHI.&.H2D#_MZE_P 17K?[6'_)N_CC_KR7_P!&I7FW
MC+]GGXD^%?C)K?CWX5Z_I5K_ &XI^VV.J[N&;!; V,K LNX'Y2,XY&<^E^+O
MASXP\<?L\W_A'6M6T^^\8WUGY4^H;3%:M+Y@;^%,A0H"Y"<XSB@#F/@[#/<_
ML76<-J2MS)X<O$B([.5F _7%87_!/>XMI/@;>10LOGQ:S/YZ@\@F.(@D>ZX_
M*O8_@GX%O?AO\*?#OAC5);>YO=/MC#-):LS1,2[-\I902,'N!7A=U^S'\1/A
M/XVU;7/@WXGT_3M*U1_,N-%U53Y:_,2$4;&4JN3M/RL 2,GN ?5M?*ND_&#X
MH?M#^-/$5A\-+_2O"7A;0Y_L[ZO?6XN+BX8[@"JL&7!VE@,# QEB3BNZ^#OP
MJ^(^G^-I?&/Q)\9QZQJ'V-[.VTG3E*VD"NRL6^ZHW?(!POU8UPEG^SO\4O@[
MXX\0:C\*=>T,Z!KDWG2Z=K:N/(;+$8VJ<A=S8(()& 0<4 ><_$WPEXT\*_M)
M?!U?&?C-?&-Q<:K"]O*MBEJ(%%S'N4*O!R2/IBO8/V_?^2 M_P!A6V_D]8EQ
M^RMX^UKXE>"/'7B'QE9Z]KFGZG'=:E')OAMX;>-T9(K1%C.3Q(26V DCODGU
M']I[X2:O\:OA@WAS1+FRM+[[;#<B34'=(MJ;LC*(QSSZ4 :B_#_2/BE\"]'\
M-:Y$\FGWND6@9HFVR1L(T970]F! ([=B",BOGG6M!^,/['NAMJ>CZ_;^./AY
M8NHDT^_0K+:QE@!@9)1<D#*,1DY*8KWOQU\._&6H_"WP[H_A#Q2OAGQ+H_V9
MQ=J"T%QY<)C:)Q@YC);=RK<J,KZ>2^*?A'^T%\6M%/A?Q;XH\+Z7X=G9?ML^
MFQ.\TZJVX#;L&>0#C*=.>XH ^BOA[XTM/B-X(T7Q+8QO#;:G;+<+%(06C)^\
MI(ZD$$?A715QL5KHOP3^%/DI*UOHOAW3#B20@N5C0G)Z LQ'XDUXK^P7IGBC
M_A6^KZ]XBOKV[M]8O!)8K?3-(Q1 5>4;B<!F./?9GTH ^G*^1/'O_*0SP)_V
M"C_Z(NZ^NZ\+\3? G7=:_:G\-?$N"\TY-"TVR^SS6\DD@N6;RYU^50A4C,J]
M6'0\>H!A?M^_\D!;_L*VW\GKV[X;_P#)._"__8*M?_1*UP_[3WPDU?XU?#!O
M#FB7-E:7WVV&Y$FH.Z1;4W9&41CGGTKT;PGI,N@^%M&TR=D>>RLH;:1HR2I9
M$"DC(Z9% 'RS\"?E_;@^+:CA39S$@=,^=;\_J:A_9Z9;/]M+XO6]XZ_;IEN&
M@W'DQFXC; _X"4_ 5Z;\-_@3KO@W]HWQQX_O+S3Y='URW>*V@@DD-PC,\3?.
MI0*!^[;HQZBLWXX?LSZQXJ^(%C\0_AYK\7ACQI;JJ2M< B"XVJ5#,55CNVX0
M@JRLH (&.0#Z&HKYHT?X2?'+QQX@T>;X@^.M/L-!TV[ANVT_04P]VT;*P#D(
M@VDJ.I8#G"]*Z_\ :<^$_C7XL:!HMGX+\21^'Y[2Z::Y\VZFMUE7;\IW1*Q)
M4C(!&.<YXH ]HHJEHMK<6.C6%M=W!N[N&WCCFN#G,KA0&;\2"?QJ[0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7&?$7_ )A__;3_ -EKLZXSXB_\P_\ [:?^RT 7?A__ ,@:;_KX;_T%:Z:N
M9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB\D*TIP3N.2?-]NGO7L5% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %5=0TNSU:)(KZT@O(T=
M9%2XB60*P.0P!'!!Z&K5% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!Y5\=/V>]'^-]OID\^H7FA:_I3%[#
M5[$_O(22#@C(W#<%88(((X(R<\&W[._Q;U*U.GZC\=M0_LW;L)M=,"3NO3!D
M$@8$C/.3^-?2-% '"_!_X->'?@GX9;1_#\4K":3SKF\NF#3W$F,;G8 # '0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[_\ (2?X444 '_"8:O\ \_?_ )"3_"C_ (3#5_\ G[_\A)_A110 ?\)AJ_\
MS]_^0D_PH_X3#5_^?O\ \A)_A110 ?\ "8:O_P _?_D)/\*/^$PU?_G[_P#(
M2?X444 '_"8:O_S]_P#D)/\ "C_A,-7_ .?O_P A)_A110 ?\)AJ_P#S]_\
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M\*/^$PU?_G[_ /(2?X444 '_  F&K_\ /W_Y"3_"C_A,-7_Y^_\ R$G^%%%
M!_PF&K_\_?\ Y"3_  H_X3#5_P#G[_\ (2?X444 '_"8:O\ \_?_ )"3_"C_
M (3#5_\ G[_\A)_A110 ?\)AJ_\ S]_^0D_PH_X3#5_^?O\ \A)_A110 ?\
M"8:O_P _?_D)/\*/^$PU?_G[_P#(2?X444 '_"8:O_S]_P#D)/\ "C_A,-7_
M .?O_P A)_A110 ?\)AJ_P#S]_\ D)/\*/\ A,-7_P"?O_R$G^%%% !_PF&K
M_P#/W_Y"3_"C_A,-7_Y^_P#R$G^%%% !_P )AJ__ #]_^0D_PH_X3#5_^?O_
M ,A)_A110 ?\)AJ__/W_ .0D_P */^$PU?\ Y^__ "$G^%%% !_PF&K_ //W
M_P"0D_PH_P"$PU?_ )^__(2?X444 '_"8:O_ ,_?_D)/\*/^$PU?_G[_ /(2
M?X444 '_  F&K_\ /W_Y"3_"C_A,-7_Y^_\ R$G^%%% !_PF&K_\_?\ Y"3_
M  H_X3#5_P#G[_\ (2?X444 '_"8:O\ \_?_ )"3_"C_ (3#5_\ G[_\A)_A
M110 ?\)AJ_\ S]_^0D_PH_X3#5_^?O\ \A)_A110 ?\ "8:O_P _?_D)/\*/
M^$PU?_G[_P#(2?X444 '_"8:O_S]_P#D)/\ "C_A,-7_ .?O_P A)_A110 ?
M\)AJ_P#S]_\ D)/\*/\ A,-7_P"?O_R$G^%%% !_PF&K_P#/W_Y"3_"C_A,-
M7_Y^_P#R$G^%%% !_P )AJ__ #]_^0D_PH_X3#5_^?O_ ,A)_A110 ?\)AJ_
M_/W_ .0D_P */^$PU?\ Y^__ "$G^%%% !_PF&K_ //W_P"0D_PH_P"$PU?_
M )^__(2?X444 '_"8:O_ ,_?_D)/\*/^$PU?_G[_ /(2?X444 '_  F&K_\
M/W_Y"3_"C_A,-7_Y^_\ R$G^%%% !_PF&K_\_?\ Y"3_  H_X3#5_P#G[_\
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M^_\ R$G^%%% !_PF&K_\_?\ Y"3_  H_X3#5_P#G[_\ (2?X444 '_"8:O\
M\_?_ )"3_"C_ (3#5_\ G[_\A)_A110 ?\)AJ_\ S]_^0D_PH_X3#5_^?O\
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MX3#5_P#G[_\ (2?X444 '_"8:O\ \_?_ )"3_"C_ (3#5_\ G[_\A)_A110
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M_"8:O_S]_P#D)/\ "C_A,-7_ .?O_P A)_A110 ?\)AJ_P#S]_\ D)/\*/\
MA,-7_P"?O_R$G^%%% !_PF&K_P#/W_Y"3_"C_A,-7_Y^_P#R$G^%%% !_P )
MAJ__ #]_^0D_PH_X3#5_^?O_ ,A)_A110 ?\)AJ__/W_ .0D_P */^$PU?\
MY^__ "$G^%%% !_PF&K_ //W_P"0D_PH_P"$PU?_ )^__(2?X444 '_"8:O_
M ,_?_D)/\*/^$PU?_G[_ /(2?X444 '_  F&K_\ /W_Y"3_"C_A,-7_Y^_\
MR$G^%%% !_PF&K_\_?\ Y"3_  H_X3#5_P#G[_\ (2?X444 '_"8:O\ \_?_
M )"3_"C_ (3#5_\ G[_\A)_A110 ?\)AJ_\ S]_^0D_PH_X3#5_^?O\ \A)_
MA110 ?\ "8:O_P _?_D)/\*/^$PU?_G[_P#(2?X444 '_"8:O_S]_P#D)/\
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M_?\ Y"3_  H_X3#5_P#G[_\ (2?X444 '_"8:O\ \_?_ )"3_"C_ (3#5_\
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MC_A,-7_Y^_\ R$G^%%% !_PF&K_\_?\ Y"3_  H_X3#5_P#G[_\ (2?X444
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M /(2?X444 '_  F&K_\ /W_Y"3_"C_A,-7_Y^_\ R$G^%%% !_PF&K_\_?\
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@   J    'N" (   #/Y"D3    "7!(67,  &=8
M  !+^ 'D ^?!  !__TE$051XG.R=!U@4U_[W??[W?9.;Y,W5FQNC_Y2;)B:Q
M)B+8(F#%0A$005% K(C20:1WZ;WWMO3>R])[67IO"QACUU@P-LQ[V(WK2MU=
M=IC=Y?=YOH\/#%/7G?.9,^><F45_ 0    # <RS">P<      & _('@
MX$% \     # @X#@ 0   ( ' <$#      \"@@<     '@0$#P     \" @>
M     '@0$#P     \" @>     #@04#P     ,"#@. !    @ <!P0,
M#P*"!P     >! 0/     #P("!X     >! 0/     #P("!X     .!!0/
M    P(. X $   " !P'! P     / H('     !X$! \     / @('@    !X
M$! \     / @('@     X$% \     # @X#@ 0   ( ' <$#      \"@@<
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MM76=O7VT=9945!H8&J&Z.ZK!^P<&7KUZ-2\O#R.# &QA/MK@QVOPZ8$S*%E
M<A\(G@R"GT,6E."1W?7>V-W,TA+W_8&P-R>4E%:M7HV,'AH1R?)*D.#G7E]'
M)Y2WGQ]MG=W] Y>O&.[<M3LL(C(V/M[@RA4S,[,7+UY@)!%@[F K>"5'<T8$
MS]Z X!=@%H[@P>[<F*B8&%4U-4DIJ4-2TK)'Y([(R<L?.W;L^/$ILW+ERKD+
MGCYUC4W1<?'43BJ,1T96=H+@44(C(DZJJ+A[>B4D)3LZ.EE96?7W]V,D$6#N
M8"MX%5>K$PYF('@& X)G.0M$\#2["PD+@]VY)<%AX4CJ!\3$Q"0D5-4NVMC9
M.3@[4^/LZN9.Z>?K[N5%Z>'KZ>3JBJ:?/G>.C8)G+48FII,%7UU7;VYEK:.G
M'Q,7'Q028F%A$1L;BY%$@+F#K>"5G2VA!L]X0/ LI[J^X<S9<[PM^.[^ 3U]
M?:K=S:VL<-\?"",)#@V3/7*$:O<I6]9G" <*OG]HV-C,3&3'CJ#0L(2D)#4U
MM9,G3SYY\@0CCP!SA"/:X$'PU(#@60[/"Q[975=??P4?']B=BX(L>/B-W0])
M24<0HGL'R;CO%8-!@E_YPP\>WCX3IJ=G9:,:O)V#8UQ"HH>GEXV-#8E$PL@C
MP!S!7/!*CN8FIT#P# 4$SW)X6_#=??U@=Z[+!+L'AX5W]?7COE>,9SK!DUI:
MS2PL54Z//Y4K*CK:V-C8U=45(X\ <P1SP:NX6C$K>"5'BU_V[Z+UF9>ZK&Z8
M'@6"A\P0'A8\LKL.V)W;$A02BNQ^\(W=0\(CN,ON9(K@ERSY]W8AH1-*2LHJ
M*M0H*BLK*9\4$Y>0DI9![D],3K&TLC(P,!@9&<%()<!<P%SPRLZ6S I^D]2!
MM3NWG_*\JA;B+GCH '*\=DP "!XR0WA5\%UO["XL(F)A;8W[_D 824AX^!$Y
MN8/BXMQK=Q17=X_E__N_TXV@^^J__[VDKA$=&Q<2&FIM;9V<G(R12H"YP'%M
M\+M.*:S9\>N$@>]H5889!! \9+KPI.#![MR8D+!W[!X:$<F-=I\NW?T#MG;V
M_!LWKEF[=M?NW5$QL0E)R:JJJDI*2M#5C@/!2O#Q&6<6+_ZGKNR;Q\<R+'AJ
ME?UBJ(=9?@+Z]4IZ%*K0,U6)!\$OP/">X#M[^][:W<8&]_V!,!+>MCM]4M+3
MM75U'9Q=;.WM]Q\X</SX\::F)HQL K ,AH)7<10Q47G//"/HX_\DZ<0Q>H.=
M*OA3'K8FN7'H5TV"GX#$/A \9.;PF."1W;7U],#NW)7@L#"JW5%XV^XHM:1&
M+5W=U3]]<^8D?US\:1(IXO'C&QC9!& 9CA,\M0V>_OX\_\&]NO%!7-<&/S!$
M)A9[%Y;X=_:VDL=?&DO,R+:J(V4-C@Q/MP@(GN7PDN#I[6X)=N>2C(]WI[-[
M6&04#]N=FM+*JMB$Q)**DHKJU,HJI\)"M>IJJ^'ATF?/'F*D%8!9.$CP@H?V
MS_X4^FA_KA \LGM1:6!,_)FHF!-5M8G=_5TY^?91T0KQ29?J&W.G<SP(GN7P
MC. [>WJI=A?9L0/LSBT)"@U=:':GS_#UWQ\\?#0Z>F=@(!\YGD@\U]CH<_MV
MYXL73S'R"\ @^ M>/S%4B^!GFA>/!*\;'SR#N;<<%D>"UXD-U(D+0O-SK. I
M=@^(33A?41U;59N:1_3,(WH4E@21FHNR\^P2DC6F<SP(GN7PAN [Z.QN96N+
M^_Y &,FXW8\<H=D]/#*JNW\ ][V:Y]RZ<_?%RY>HY!\;>_7PX;7N[J324OWB
M8JV.CKC[]P=>O8(7TN #SH*GMJ_3,JO@Z6?6C/+E0,'3[%Y9$]=/'D"_9N=9
MA4=)5]<E(*GW4*KR%,?G# Y/=#P(GN7P@."1W;5T=<'NW)5W["Z]0.V.<NW&
MC4?O]J)'U?=;M]J:FP.+BM3;VH(P$@TP,W@*7G#26V(O!+N94CK/3\[EE/ )
M;?-K1+9-Z7@<!8]T7ECRUN[4B<7EH8DI>@W-!=1?9W \")[E<+O@P>[<F*"0
M=^T>15B8=J?F]KW[8V-C$T3PX,%@>SOAVK5RC$0#S R>@J=6W_420VAM\*??
M=)Z?'$V"+[H@H+7!;Y65F*X2/V^"_^BCC]0U-Z/:.34"@E\L6K1(75.$WNXH
M956$]&RKIK92VA2*XQU\ Z3%)'[0TMF*EA46^08M>UY5=?>>/2!X%L+5@F_O
M[GEK]ZM7<=\?"",)# D!N]/GMQLW'T^JQ \,9#0W>T%C/%YPEN!/N4\K>(TH
M7P%N$+RSJSV]W<GC_><+2BH([=TD^HG(\>F9YJ=.;S V%:8)7G3__O4__RP@
M*!B7F(C[Z<I=X5[!T]O=&NS.)4%V/TQG]PA"] *W.S7TE?BQL5?7KU<W-OK<
MN]>'D66 6>$LP5.:X:<>$;=91HR^%STG"!ZC<?#\&P5B$T#PS(5+!8_LKJFC
MP[=RY8Z=.\'NW)+ 8+#[U+E^\]:3I^.5=63W&S?J&QH\KU^OQ4@Q "/@+WCZ
MG'2U-LF9N@:O'NX]>7X0/(0:;A1\>U<WV)WK$@!U]^DS]-OUN_<?/'\^.C)2
M!G;G!/ 4/'*Y@+@HR[WH+X5YFA4D@N A9"X4?!N=W6WL['#?'P@C"7BW[HY*
M + [?3IZ>I-3(OS]SU16VMVYTXF17 #&@6%RK 0$SVGA+L&/VUU;>P4?']B=
MBS)N=UE9,;#[],DG)CLXRB4D:0P.5F%D%H I\!3\ID,')MQR9RKK=@MI$OQ
M\! R5PD>V5V#8O>=NW:!W;DE <'!8/=9TS/04U3F3X@Y4EOO/S8&#[?!'_S;
MX.D[V9WS=9KN$74<.$P.!,\YX1;!MW9V_6WWW;MM[.UQWQ\((_$/>L?N43&Q
M8/?I4D?*BXY33<_4(I,K,)(+P#B<)?BS/@[3"5XG-A#-L! $OU$ !,]TN$+P
M-+OOVKW;%NS.)?$/"I)Y8W<I:1FP^\SI(_>75H2$A$OG$YU&1^&M,SC#68*'
M87+P)#O6POF";^WHU-#2 KMS5_S>M3OZ=H'=9TUI1:ZCL[*;NTQ-311&?@$8
M!'_!TV>F6_31?H*2$U\WQY."7[-V;61T-.YG*7>%PP7?TM&I#G;GMHS;_?!A
ML#NSZ>KKR2L,"(^2+:]P'AV]BY%B $; 4/"+%_]35W:1N2(EZ8&330S#Y":D
MN;U#\I#49Y\ML[6S[^CIQ?U$Y:)PLN#I[7[5P0'W_8$P$K] L#OK:>VL3TFW
MBB0<;6F-P$@Q "-@)?AERY;)FNB<L#=%,5;Y>$K!3Z[$+_!A<B@V=O8;^/GE
MCRGDY!?@?I9R43A6\%2[\ZU<N6O/'K [M\0O,)#>[M%Q\6!W9E-=GQ86>3PS
MZ\J-&RT860:8%3P%/WF8W QOD].-#Q)\=_YUNX5Y;)@<2G%9^:DS9]:L7>OJ
MX=$_-,4[XR%3AC,%W]S>H:ZIR??##[OW[KWJZ(C[_D 8B6] H#2RNX0$S>X]
M X.X[Q77I7>PI[ T,#KN"*D17C:#&W@*?HJWR7E>G>YE,^KA7FA^WNYD1SDK
MR)<T-%;P\:%_*VMJ<3]+N24<*'AD]TN:FBN1W??LL0.[<TDFV#TF/@'LSG)(
M+66Q\;IQ\:>[N],Q$@TP,YPE^ 4^3(Z:^*3D@V)B_!LW!H>%XWZ*<DLX3?!@
M=VZ,;T  V)V-&1P>KJR)CXJ6+R^W>_3H=XQ< \P AH(_:GWEA(,94X*?AV%R
M H*"BR9!B(UEZHN+J> [>GIE9&67+EUZQ<BXL:45][.4*\)1@F]N:P>[<UU\
M>-KNJ,B:4.BI75*?A^UV=+=DY[G&QAUK;@YZ]0J>;3??8"AX>4N#MX+_NR]]
MP P][%!.>]J9Y&([3([RMO5W1IEOV;:-HP1/IO3Q$1(1$=VW+SXY&<="@8O"
M.8)O0G;7T%A):7>W=W+"_9.!,!(?_P!I&1D] X/CBHKC=D](Y"6[DRE%UN8M
M6S2UM:G9NFW;_ B>3'FV'2'V?&:VWO!P#4:Z :8#0\$?,=.CWJ(_;K=GE\KA
M*XH?3!"\3EP0_\$]+/>BGZ[!G@<$7]_4?.KT&3Z^E?:.3M!]EY%PB."1W2^"
MW;DM5+L?D9/_XHLOEBY=&AP6WD<>PGVOV!M49&T7$D)7,/,O^#YR?WEE1$*B
M/(GD^N>??V!D'&!*YJ,-'@G^P,43ADH?3A#\Y$K\/ R3FV?!HQ(?23HS-X_9
ML\+4W'S-VK6*RLH%Q<7X%@U<$4X0/,WN>\#NW!,??W]D]T-24E+2TJC46K1H
M46AX!.Y[Q?90:_!ZER]3'3^?@B>/#Q:M2\VP2DPZT]F9C)%Q@"G!5O!*CN8S
MU. G#Y.;X4EVDX?)K=\CK,7\,+GY%#PJ\964E5?P\1F9F#8TMS"UB3QBX1%Y
M>;Z5*UW<W6&\W*S!7?"-K6UO[>[LC/L' F$DWG[^4F_LGI:9M5U(F+<%C]1.
M=?P\"WYP9+BJ-CDZ]GAIB=FM6_">^/D#6\&?=+$ZX6 VG> G=[*[$.0ZW3AX
MG;@@MO2BGT_!Z^KK;T)GU=:MJ 1)S<A@:A.]@V0-3:UUZ]<;&AO7DAIQ+R X
M//@*?MSNZNI4NSM W9U+XNWG1[&[--7N \,C(CMV\+S@J8X7%A&93\&C]/1W
M%9<%)"8J-#7YL+&WW:L7CX=&2,&E*>8%R=8E>1%= R//7M'/,/9R]/KUYJCR
M=(N"),NB++_F]L['U*V//7]VM[FKQ*4062/-J::V\L[H&)K\^N631R-$4M[5
M C0]U:&RDGC]P;-WMCGV[,_;I(X25[0@6F=AEG]S9]]3M-&73YX,)E FTF)1
ME.G9<^N='9I?L!6\BILU$OS,G>SH!3_K+7KNZD6OH:7]Z_;MR\99[N3BVMG;
MQ]16(F-B^#=N1)7XH-!0W L(#@^.@F]L:55[:W>HNW-'QNTN+4UO=S21MP6/
M2R]Z^C0T%\4GJ&=DJ/?W%[%',Z]&?_N]*: HU:&\D-!4$5J1;EF<%]Y]_1%M
MAM?/[][MCBY.<R@O2>YJS6TI=BG*]&[LOO;J]<MG#SI[BJX69P<T-Q9V50>5
M9+C6D-J>OGSV]$YM4[9U<7902U-1=VU869I]17G)_>>T-;YX]J"M/<^J,-.'
MU%@ZT)[74NA$3'.N:>E[_H(B^&2;XGQ"6WUZ^W@R.EM*;CX:8\_1L@)GC8/G
ML;?)(<'OVK/GU^U"/_ZTZIB"0GYA$5-;01<$:A<OK5C!9VIFWM+1.<]G(W<%
M+\&_M;NH*-B=6^)%9_?TK&RJW<D\+7A.2/\0N;(V+B'I6%V=X^CHG3E+YO6+
MIW<;.PKL*\MR;CYY_=>+^P_Z4\HRO>I;>IZ]?C/'XZ&A*KO2@O"!.R__&GOZ
MY&8Y*<NYJKKZCZ?W[_?%E^7XM0\]&$.U_*<W;W3F]'0U__'DCX?]"<49'G7M
M0V.H,C_ZVU"%34ENR.#=-Y)^^?C)4&I)ADMUZ^!XQ?SUJQ>/!P=JPAIJ2N\\
MH0@^S:FJ=0A'I;\+_H*G1E)7[6?1';,.DY.^HK'AP&YN>9L<5?!GSY\7V;$3
M5<1] P*8;4WW\/+>NFV;[)$CF3FYN)^?G!Q<!$]Z8_>]HJ*.T.[.)?'RI;-[
M]EN[DT'PV*>MJR$[URXR4J&DQ&_NEAE[]>S!'[>''OSQ\.7KOUX_NWVGBU"<
M[=O8/?+J]9LY_KQUNRVD.-.GJ6MP],GM6^U195E>#1V#3Q__-E+K5EZ4,G+[
MYITATLBUP4=_4J0\]G3T1EE=EGU%1='M1Z.C-RH;<^W+2_+OT&[2OWKR9"2C
M-/5J:7'V;_<>OR/REPM1\$J.YB:GIA;\A2#7#?MWL]R+_J2+M4E.+(<+?L]>
M41-S"TDIJ15\?-JZ>C7U#4QMJ*JN7NFDRN+%BPT,C6"\W R9?\&36EK4+ET"
MNW-7O'Q]#[VQ>T9V#KW=R2#X>4EN?JRIR<ZPL%/-S=GL$\ZK)X]_*VG(MJLH
MR_K]$7V;]]CSAWT#%79_-XJG.%95EMU[ABX,NKH+K8FI#B7C;?.4]OO\F+X;
MC_\:K_4_N-\379Q,;42W+,X-Z;WU)_T*7SX9&:IRHC:Q$]-=JZMR!G^[A:XP
M_A8\_2WZANSNKJXG.#;!8R_XDRY6TPG>G-??)H<$CTI_4W,+5&DX*":V8>/&
MR!BFA\Z;65H*;MZ,7%*,V>'P0.99\ W-+1=H=G=QP?WP(8QD9KN30?#SDO;N
MCKP"W]1TA?IZ!W;<J/]KO)X^>J.FM>!J*3%VX.:3=_^":NWA91G.U14Y?1V%
M'14^)5G>C1U]#^]U=!68%V:X-[1V/G[Z^.%P04.V0T49\>XHJL%7-&3;EN1'
M=;27]S7&5679EY<5W!E]3;?6UV,O_G@P7-E5'5&9:3W>%R_-N:ZE[\\7DSK9
M)=N6%A7<P_/Y?9@+7L7-VN34OZ84_&89L=7"6UD>)O?+OIVT)GE<!(\*]R-R
M\BAR\D>/*B@<.WY\0C9OV2(LLL/$S+R@N.2 F!@J.W3T])O;VIG:5GIVMO3A
MP\@E[EY>N)^<')OY%/RXW2]>!+MS5SQ]?26EI/ZV>\X4=B>#X.<K;5VD@D*'
MK&SEQD;_.?>H?_W\Z9W&CL)QN_???/3ZG3\]&[W=T)KK6%5><F_\'CNJS?</
ME-J6%<;TC_3VE=B5%Z9<'Z^T__7JZ:T;C=ZE>>%]UZ[_5N=<G!O0<_,Y9=T/
M'G1'%F5ZDGIOOYYJXVB5?]XAM>9;%>>&#=YYM !OT?/PV^0^^NBCR1WR)_#M
M=]_IZE\NJ:CT"P@4V;%S[[Y]*>GI3&VK=Y",KA4^7;I42T>WMH&$^\G)F9DW
MP=/;W0GLSB7Q]/&1'!_L+H/LGIF3.Z7=R2#X>4Q#4WYB\KF4E/,U-7-Y],WK
M%W_>:^TN=2K.#>DD4^Z3_SW]Y:OGCT>?/!J]5=<\4? V9<28@=^O_][H@ZX)
MAAZ\^HO2F>Y:K5LI,1I-_ZW6<:+@,SP:>FY0USWV[/[M%E]4]2?UWARC;FGT
M^E"Y=7%.R, M$/PL@N>NM\DQ(G@:JU:O%A 4_&G5*E019_8QUU'1,:+[]_^Z
M?7M$% 'W,Y,S0Q4\\FY89!1V6VEH:J;:??QI-HXPWIT[XD&QN[0,Q>ZYT]J=
M#(*?QY16#ES2((E)IP:$>0X/-[)FF5<O'O63:[V(R;8E>2'-=91F;U)!?W_W
M_=O-G42[LL+X_I&!D3I78AKM%KUW<;I+=5W#X^=/1V]4DG+LRXN3N]M+*,/D
MW&H;.Y\^>_20G%:62G>+/L.Z-#^&<AU 87P0?&UCMF5AAD=]??% 5VE7=6!)
MFGUY1?7#/Q=6)SMTJNC*+GHS IZGALFI:VKM$17=?_ @LQ'<M.GL^?/,MJ:W
MM'>H7E#CXUMI:6W3T=V#^\DYG_'V\T-?I(T"7V3E6DPY ZDY3TMG*_VUU-IU
MR\*CI-.S#"?/W-16C/YTQ5B(\2LS>MY___T??OR1\B1:Z%7''?'P]I$\=(@1
MNY-!\/.2_J'AJ-C,GW]Q_??RPA\V1>PZZ)-?%,C2,^K'1A__7DK*H'^PC'E!
MBG-U=>G-6ZU=A=8E^6&]-QX_?SA KJ<\"2?)HC#=HZ&)=(_R0)N_7CU]\GM%
M<[X==7I]4^/]IV/4]O5[?1EU.=:4M5TM*\T<NO7P'6$CQ]\A=99Y%%'624QS
MJ:VOOO/DU8+J17_CX8/S[A(F*N^99P1]_)\DG;A9>MCM/:>T?H_P#,/D5 .<
M-XKOW7-6\6?1';@/DV,ML8F)QQ45?]FPP<??G]GQ<EX^OJ@&+RLGM]#&R]$$
M'Q.O4EP6-C!$IO_KX,A('2ES2L$GIJ@WM55,6-L<!8_X;-DRL#NWA-[N6;EY
M,]N=#(+'/IV]?<ZN;M^NV/')9];?K L7T_#>(A,D?\JEGN3)SI?)CCW]_49[
M?%U]PZ.7;%LG=X*GX"</DV,J. Z38_G+;6ALO&G39B,3T_K&)J:6+2FO0!<'
MBQ<O-C(Q65"/IJ<)'HF9$*M86.)'[_CQ%U55$3)R3.@7:6PI0#-/Z7BJX%,S
M]5G;F9[^@8KJ&MP_$P@C\?#VIMC],+)[=E[^K'8G@^ Q3GU3\Q4CX_]^>^!?
M__;Z]I>(4YZAJ+A6=HE=OS/DDJ%W9V<2F^0S_D";FHZJI.$'"UWO^ K>G&N'
MR;$<3Q^? V)BVX6$6'C5K)Z! =_*E:?/GEU0X^6H@M]WX$!W?R>QQ!<YGEC\
MUO%=?>VE%82RRN@)2Z&:?5-K:7R2>F+*)7K'(\&G9NA-N T X;VX>WM+,&EW
M,@@>RZ#26%;NPO]]3W[QI_X_[PW6B(RD%M>F>0E'3&/7_QKBX.,U-%2)D8\6
M+'@*?O(P.4V"GUE!XI3:UD\.VR3USC Y_@.[M6/P&2;'<D@MK7J7+_-OW&AC
M9]?:V<74LADY.<<5E;9LW>8?&(3[@<Q;:()'/U,<[T=QO"]5TFV==05%OJ26
M*=ZH.]GQ?>2!ZOJTG ('W \*@FG<O;QH=L_)+V#0[F00/#;I'QJ.3TH6W:^P
M_$O-Q4N#M\F%&&:^TPY[.27VP*7PK;O]HE.\[M\?Q$A)"Q/\V^#?Z47OZSAM
M+WHVO4T.]UC9V J+B"BKJ.02B4PMV-G;)W_L&"J 3IXZ5;-@QLO1"YY,<7SA
M&\?W#?95UZ=D9!M-5R-'CF]N*TM(5D^@.+ZCIYE8$EA+RL']H"#89=SNDI(L
MV)T,@L<@J-3R]/86V"SY^7]M/OD\3$)[ZC[4FE$$X>,!^P^[$DL\6>IP!TP-
M9PE^'MXFAWM01?STV;.??_ZYA94UL^/E(J-CI*1EQ,0E8N(3<#^0^<D$P9/_
M=KP_<GQ*NF%6KGU-_4SOX:4Y/B[Q;&Z!2WJ6:>]@+^X'!<$H;G.P.QD$S^XT
MM;6;65A^_=V^?WWB^O7:<$6'F8KWLS[1O^SU$]ZK[^>ES\X.=PL;SA(\MPR3
MFV/,+:U04:*MJUM65<74@@U-S6?/G5_!QV=SU6Z!/)I^LN#);QP?&2V?6^ P
M:X,ZU?'Q29<24RXUMU?B?D00C.+F^=;NN05$9NU.!L&S-655U<=/*+[WS\W_
M;TG0*J$H6J/[=!EOC#>)^NQ+3SF%J^V=&7?NW.GHZ,!(3PL'_ 5/S5&K*QOV
M[U)T,#/.B3U*3)(G)HD0D_2(28>)2=+$)'%BTH98M]6'1 \;:_,?W,.EP^1H
M"8V(D)63^V7#AH#@8&:7=7)U^^Z[[_>*[EL@X^6F%#Q*ST!W8VM9=U\'(RM!
MCN_L:6EH+L3]<" 8Q<W34YQF=R(K=B>#X-F4_J'AY+1TN6,JWWRO\?Z'D9ME
MPB<TND^7*^EQ$KJ1WZ[SDU92.R8O)"XN/@^.?SPZVM'7C_56\ )/P9_QLOME
MWR[DZ>W'9-;NW$[K12]',?I^8M(Y8M()BN,EB4D'B$GK*;WHA11DUNT61C\H
MV!H9945SH^ [>_N,S<P$-FTR-#:I;VIF:MF2BLISJA?6KEMG[^3<1Q["_5BP
MSG2"AT!H07:7F+/=R2!X=J2SI]?7/T!DE_R7WU@M619YX-),M^4G1R\Q1OA$
MZ,>+[25ESA@:&AX]>K2]O1TC25$!P;,"(T^R0S')B3M^U?AGT1VG/*[RB^V=
MM0U>V<5*4'*_I*Z:7F+H=/WM.5_P*"[N'DA:AZ2DDU+3F%JP=Y"LHZ>W@H_O
M_ 6U\JIJW \$ZX#@(3/'E6KWP^-VSR,6LFQW,@A^SFGMZ+2TL?ENQ8'%G[A_
MM2I2R3&$*;NC*-A&_^=+[W6[G-0\[#P(8=K:VJ*BHG?OWL7(4W^!X%F#D6?1
M3PA])SO]Y% M@I^ Q+XCIKJ&F02:X*=\?1PW"KZBIE936WO#!GY[1R=TS<O4
MLDDIJ1*'#O%OW.BW ,;+@> A,\35P^.MW0OG9'<R"'YNJ:JMT]#27KY<ZG_^
M$3#>Z!XU2Z/[E%&/(/"+!7ZU.NB(B?4E+P?'8#\='9W3IT]CYW@0/"NP)OA9
MGU[',X)'L;*UW2XDK'22E?%R"L=/?/KIIWJ7+S<TM^!^()AF.L%W=#>65!!H
M#[%I[:PE%ONW=2V4T8,0\AN[RU#LGE]8-$>[DT'PK*9_:#@]*_NHPMEERU7?
M_S!TLU3XY52&&MVGS%F?J)6;?'[8[*E@:Z'CY^(9$G#QXL4+%RX\>O0("U6!
MX%F!!<%3HQKHPG]PC[*+E4G.^'MC-2GU>"5'<^/L*9Y*R]6"3TA.43QY\O//
M/[>VO<KLTV>#P\(.BHL?ECV2F)**^X%@FBD%W][=D)YM$4&0S<PV[QWLZ^[O
M*BH+BHP^FIYERF"W.PBW!]E=G*UV)X/@60HJNT(C(M>O/_(__\?HTZ]"]ZD&
M&3'6I6Z&G/8D?+O>=^4FSZ-6)IJ>#LY^WN?.G;.QL7G^_#G;506"9P4D>'E+
M@Q,.9LP*7O#0^./J5 -<3/,2T*\Z\4&"DN,U>^V8 !X3/(J%E;6PB(B!H5%5
M73U3"Z**^SG5"XN7+-'1T^?M\7*3!=_6-6[WI#2MJMK4_$+?PM*@6E)F>I99
M37UZ0K)61K8Y.)[GX^).L;NL[+C=B]AC=S((GOET]/3:VMDO7R[V/_]P^VIU
MF((-<UWJILOEE-C=9R*6?><EJ7?AI(N5GK^[1W" JJJJG9T=VQT/@F<%)/BC
MUE?>"E[Q36^[M%GNL>]4.;9FQZ\3!(^<31LNSTN"]PL(E)8Y+"0L@BZ!F5T6
MU?O7K5^O<.)$;@%S=_BY*Q,$W]953[5[<WO5X,A(?6-.8HI.84EP96T2Y=FT
M)13'FX'C>3@N[NXTNQ<4%;/+[F00/).I;2"=/G/VGQ]N_=>__5=NCCSO'\$6
MNZ/(6R3\Z]/ C6+J1ZW%3MB=08[7\G)T\/8X>_8LVQT/@F<%^EOTQ^WV[+]X
M8H>2_!7%#V<5O$Y<D("XZ(2F]_/^SM,]PA;%,#WJ0I";DI/%1G%1]0AO+A)\
M8VNK@:'A1@$!$S/SIM8VII;-+RR2/W:,;^5*.T=''AXO1R]XBMW-D].TD=VI
M?VWO)F7FVF5D6[1UCM\"H3D>5>C!\3P99V1W"8F_[5Y<PD:[DT'PS"0K-T]T
MO_)[[ZLL61HJ*!FJ$Q?#+KNCG/(@?+W&YZM5]OO5Y(]9B1VW/8T\HN7MY.+G
MHZ*BXNCHR$;'@^!988+@=ZD<%E&48T3P*!->*C/#_7F=N$!)7;6?]^[8H2Q_
MU,J ZP2/XN#DO&__?NG#AYD=+X>DKJM_&57B]0VN5-<WX'X@&(4F^,EV)X\_
MTJZKL#2 _G6QU'?,)*9H07L\[P53NY-!\(RE?V@X)#QB_<]R[_W3Y+.O(W:?
M"9E[H_O4CE\[[O@#%^6/61]4M*?4X[V=S!WM#ATZ9&]OSR['@^!9@2IX]%]"
M$_S><TJ&2A\Q(GA:- E^J$(_7=U=V=EBBZP$VHI^4AAU3/PV>2FN$WPNL5!5
M[>*&#?S.KF[,/IH^.BY.<-.F[[[_WL??'_<#P2CT[X-/3M.AMSN9\CR[DO*0
MS!QS^HFT]\BA1?0-?EU$8=7JI>C7M,S+DS?1W%Z&_F1B)KQH1M:L68O[I[&0
MX^SF1K,[$0.[DT'P#*2CNP>55+_PRW[RJ>-GWT0>-@IEN]II.4UQ_/+O77_<
M:O79UV$;Q9R472PU/.R=?#TO7+C KGH\")X5W@K>P8S9&CPC4; UVGWZQ*4P
M+]/\!-I$;A0\BJ6-S:_;MRNKG$*R9VK!SMX^36V=%2OX# R-FMMYL[9*$WQJ
MAGY;UQ0W*GH'^]JZ&B=,1(YO:,J9+/CD-.WNOO8),X/@.3_OV+VD% N[DT'P
MLZ6FOD%'3^^[%3)+_N.[0B#\E$<X=G;_V_&>A"]_#/SD"\(J(?\ERR*V''91
M=##3]G%V#_(_?_X\6]KC0?"L0!6\DJ,YLYWL&(E&I,^O1Z61RR<\S(Y+!1\3
MGW!"40E5XMV]O)@=+^?K'[!7=-\Q!86TS$S<#P2+T 2?E6O!U(*-K42D[?2L
M*^AG0FPL5? 1A"-IF<9=[SJ>*OB4=)WI5I61G0."QS%.KFYB;^Q>B)G=R2#X
M&9-76"@A>?;]#U26+ WC/QBF28C"VN[T,4B-W7<A;,GRB&U'W%"]4<?7Q=[+
M75E9.3P\?(ZJ L&S LOCX!F)Z'EE=.E@E#6Q6P>7"AY5Q$W-S86$A8U-S6I)
M$RNC,Z>LJEI<0A*52EHZNCPY7HXM3[)#@D<KV;19H+8A@Q"KG)9I1'-\_]!
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M2CFA$_*E8F/9N2=\50T ]50224Y>/CHV=OKF+<2K*F$&!1[NH, +)P!X??T
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MARNLI6I1X&'- O#Z :?5Z,L"?V.FOZ&NX/JUWI5,!?"#EGUY:49U90Y'BQQ
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M*'KV& 5Z N#Q0ZV& 1XG=#0"RG*2^YN\\DE:[@[0I7W2XMOA%WCV(]!*=KP
MG]3;?LJL=?=>7$%)(U_U!6BF$]/2#AP\&!T;EY*:"JII=XS'_4>/X:B;GGWS
M5O<K4_7?OH*E>V"EH,##'11XX00 KZ_OKZ9&YQ%X <+[9C,]754K/4E!?BJX
MY_5KO?6U%&C<OO@ 3QIC!%=V24B<DY!HEI86S]WDDJ/D#1<V<),WU($FF"$X
M36YA&/SB5+VSKG;LJ]Z^MP4/->+ML%&*BST0JM:FUO%AX77%K#ER9&$!#V*;
MV/#%T0S_X(H;?!HV=''$V<45--Q!U69E;3,Q=0V.BNEWW7T7='\M5-V9*/#P
M!P5>. ' Z^KXJZHT" =X[M?@5P*>2DF%SN'9['A7Q[G)RYUB!3QAA.&5WRTA
M42(A82LM'2".P*^[:7+08KKLCP4M> AXT'"/I)>!LR6,<"Z$1Q8B\)'T9CF]
M.GEE7%US,U]5QO/Y%^&1D:!>4S^CT='5#4>MQ-)]\EJ#\'5GHL##'Q1XX61-
M@ <V5Y1EK+*+'CS)G5N#;2VE]^\,KW0.;U[=[.JHK*NAB!_PH 5/WK9M6VEI
MJ3@"O^ZFR7$!GON+OA=X_'!;0'DN^&[L^[)H-<"#&/JW;-V=D81OX7=I^NS<
M/ 5%Q=Q\"AQ5$M!]]'(Q@KHS4>#A#[K9C'#"._!<C&?M)L<+\!S3Y$"+G 7\
M_-Q5@'<CO8C+.5R^U$[)QS^\/R*>P!<6%HHC\ )/DUM-5C--CD?@P><#U_1D
M0W^,,RD!/"=IK)L[\#&M57H^K@;^&/ \)W5;5@F\?TG#<8TB [-T?O>7@R_S
MS!>3U^K?7G='2'<F"CS\08$73O@"?MGT,6BU-9228C*/7?1<@ =?CEYL+J02
M'S\<6^GE7GT[0Z^G4O)2P UQ W[KUJT%!07B"+S T^16D]5,D^,%>+_B3"UW
M!]ND2!]JNFU2A($?!GQZ.*G;O1+P0'?C8&],%AX_W$Y>=1<]](NEZ=*Y11)'
M3*^%:9(;OWGY^O7M>\-=C*CAD:RG<XA5_4);BQX%'@4>UJP2>.:W,U7GLIL;
MB_F=!Q\?%S0]Q5@*_,OYZ5I:7A&5^/HEYU!Y5A[<O9"1GL!N/ J\T(JH3)-#
MJ@7/^S0Y[L"#CPO&(=Z^A1FL*_'>%+)+6M(AQ=IE@2>.=%G'A[FE)Z<,MD)'
M5@\\B!.AX8!<KH=/Z=69ZXA71JS,O7@V>8W>Q8@8&"9?G6Z]]_ *:-D+\P10
MX.$."KQPLDK@QT9:JBMS[MT>YGTM^M)B\@_?W6EM+H$VF^$ _I?%5>XKSV43
M4Z-GIAC06K9+\VSV<G$A"8^+N#;9#>Z# B^T@LQ:](F,!I,0'VB+%RB1C16D
M,:&.HN=HP6LX6WOF$E::)L=E%#UTYQ :U3T3QW[.23T-3L1X*=G298&/[ZRU
MPT:%5%-91]8$^*3>=F6+UB_V)U!+:8A71AP!J-]_-#D^6=_3EXS 0C<H\' &
M!5XX60WPH F>EXL;Z*_[A?_-9BZ-M@8%NG,,LF,]Y*]_N7UQJ#$Q/C@RP@?<
M?_KJ,M*_>75S]&)S<E*8GX]S;$S !@8^OJM9YE3(-JD,"/A??OD%)F1Y*7 !
MOWOW;O"GL@"\UV(&WM&:-4U.3N_L5SIG$)DFM[2+7M/%ELLT.>XM>'Z!#ZLM
M]LPCLM]_38 G+RR!U[A;)B,XHNK.@X>(UT=+\_C9<RP.=TA&AE)8*+0718&'
M.RCPPHE@P(-&-KV>FHP-ZV/0('J7[@<OV#5X]OSXUWN/'XZ5EJ2SYL$OS4\_
M/F"^F&ZD%XD#\-NV;2LN+MZ8+7@ O!,A'EI(-=7O,P[@-](T.>A+J(O>OS2'
M]/M( NY=].:1@1R= 5OWD-<$^$AZLX(135X%6]LDBO44"OR&# J\<"+ -#EG
M)\O  +>*\DSV_6;8@0?H-M05%%&)H)'=TE0B,/!0P&<(+L"S9Z.N1<\.?$E)
MB3@"[XB/M8@*9/6'BP+PF&P\.*78]FK6_RX+O,_BQC9&XPS%"*(T :?7WV"V
MN.&- 3"[.%/7S]TJ+M2%G&09&_S>078<6:D%+ZOF#%[=)-0WL"(/V]?(RU/I
M>;=_+DE*Q-5#*\R+5! #?M<N(>P'CP*/ @]K! "^O#0=R,WQOTL'V56=RP''
MEP+/91X\"ORR$9<6O#,I<27@6=/D0,,7/]R.X#0Y 'S*4%MB3X-[9HHS*8&]
M!0]BX.?. ;S7XL8VYN,,!2SV(#Y1O^</X+W[FTPB A1-].3TM>0-M>V3HY)Z
MZ:M?Z 8"WBC0TR341\/9!GPVXCC)I?$M:CQVIL34.O?\A8N(5TD<01!X=)H<
M?-E(P"-8,K*RN9\AO\"_=S<YCFOPO ///2CPT#5X"H7R\\\_PX0L+P5&X%W3
MDSWS21#PRGK**XU3$ZFP3Y-;%GA6.+KHH3UF[''1T+9RP&#0YG9)2SJJWKPF
MP'ODI)(7-C"@VR5'Z?FZ!9;G$4>[5WHJ_'"7AE/;ENUQJ6GE(C)?CA44^ T9
M%'@4>!1X,0,^#<MJP8L^\&X9R=B^1O:1_!S +QL6\!$-I;9)$9'T,M9C8UHJ
MG4D)>X]7K 'PNK9Z>53G<8;I.,-[K-NBE7:XH5AMH-%KG(%;O&?R^:[HENY(
M.H,5H\#6/3)43[^*:S=N(EYOL@<IX#_[[+,S&AHVMG;.+JXKQ=7-W=W#0^"X
MNKM;6=L8&AF!UWKG:=V7?UI;>_L]>_;PN^R@:&8C 8](%SW&PQ,.X 7(&FXV
M ROP?D696_?LVG=<UH>:;A3@N77W3LN88,1U)R\91;]AN^C?N0;O]78XO8H^
MPM)_LJ5$0H+!$6_*\C\JWEOP(30J>*?L%QJXCZ+G#W@]1]V\8NC2@.<XP^M2
MCUI?K5Q/K=[%SI#%>VHX%4E(%$I(T"0DRG]/X__\J7WO@3A*237B]29[ /#Y
M!=2#APY!318[>P<AO"@ 7DI*RL34%-;F%_B=Q^)2/OCP0^D#!WA\R!XI*<1_
M(FL2%/A5AG?@A;F;W"HWFX$5>$PV_J,___F@PDDU6_.CZBJ?[Y T"?%!7'=Q
M!-XCU\@LPE//VQ7G]0GY?#7<WU_N.2#'4#*), KRTO=UT_5R =FVIW+UP$<W
MG[-/CH*K!?][%STKV+Y&J[A03'8JU%'O3*K=<SA-0D*-S0Z/SW8T[91.BXBI
M?C#[!/&JDQ6H!<\Z2Z$!OW/GSL#@X,Z>GHFK4W $J/#%WKUY%(JTM#0O]^_H
MZD:!%[6L"^ -] -.\PQ\0QTU*3%$7T^#F!J-30H%T3JK%A\7Q.6!?&TVTT0O
MNCG3SPOG< "_9><.11-]J.4FIZ]E%NZ'+"Y0Q&60'0#>MS # M[ SQ%0"H#?
M\FGUT@:TD/.5%ED;XPF$UO=Q@X#?>8"R_RO2LOEX,YWW:_"F8;ZQ;0N?8*!K
M\.Y9*<<T6N$ 'L0SE^A,?#LJT#6M7LFT8(>T-C@K\.59%UL _$F]QI.Z5:?.
MI#:TM2%>=;(" 7_PX*$\2@&UN'BM6L_O+7!/DQN;N (!?_CP$5[N/W/SEB@
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M(TO \\I 7UU=34YZ:I2 P.=D4;%SO\+)9K:,? &/WH.7#>##6JLUW>SLT^.
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MP ^32$X0>/X!P!\X<) 20\49^(\_+BHM@\!+)!!X"#S1(J? 4[EUD\,%>+T
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M[ !772TO1VG\1A*)G +/ZB9W2/DLD1O94;D!K^%JZY"9@+:WMTV.T0_T^,%
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MP<-6]!*/-*KHG\\_%@UX6$4OD<@/\)@O<IX:+GVL:PBLHB=:9!GX3S_]%'P
M-X"WW8@5I50HX*]X.Q]6N^B2GTSI:PIJ+%4RT 9E>G4GZZ,:RLZY&VP'-9:!
M+P$_&&BK.UH=U50!Z%)Z&X.:RDX;ZX&5VEY.)[35'#+BHWH;0ENKSIE=/:6K
MR?H2(%38[L%[E6=?LC>W3XN3K/&"-+(3)+ $+T@D#OS\\FQ/?VI]L^/$LT$^
M^Y$R\*^G7SR"P//91@: 9\7%S0T"3^3XU2 D4A^)]#^*BE(R5J!%BL";4H)
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MR&0,_MH_!0!_X-@16U_/$Q?.UD_<)V>G_O7C7;C_"IPY?47SJIL#B+6;26.
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M;HR:+ />/SV1J9;:WE:%+JW#6@2/%L?T9B'>M01X2T4A G@[NNBE )YS I8
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MJA<G+0W=9P /YP [@MQ@(7ZEZ6OA,8P ?,:%9KJX2LDX1VU/BW=DB"7 PUS
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M!4'5Q/8P'"<B0ZQ&\-CR5$P8#"@:#,@-(VXU@D<D1^8,01,E4V+)@+?I2D4
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M'DL!?/654[@[_/CZZ_Q\?",JH$QB%? ]CG[U@$>!J#^8S4@@ )[_/3$6#\L
M"8W<=.LR.T\T/#D>%.'[PJ!E^0,E*8!G":XMN N\)>1D5=!B>!@Q^ I$>2[,
M+[D*"G@DM:<(%8-5!+%IOGT%5ATS4'PC1/L"GOVBJW4!AQ V2"G<?8[>S,,V
MC3:E"_/!00'/\8L!#^!>$#S^5<>',[:N)C0LZS68>BR/+^#9+S!A69ZPE(3,
MYFK(5>O=JVP]+)QXEF<Y@(]5>PHAP#!Y<WM;6??!=Q<N66_ SWOP9?,'W6!(
MZNLKA$TN00^ZJ9T^E[S,>/"'7#_XYW^N6B?"2OQ;+\#_QW_\VW__]_]CGT.
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M.O;IU5"",.HE IXC%QR:'4"*M>A]U30G&?#<Q[-U<Q/Z>@^4-=0T(QP4BA3
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MBTQ3Q)HS]NI207I=[940X%G:F(!G(EURLC]HR)-%"5QG+]5C+?H0X$. #Y0
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M!ZP0V- <G2B72$.@Z/Y<.0T6(QTHBU%@^F@F[_B1"$W6RO;!^[^=VL;O>3-
MX3]*H0*V(C0I;GK8UKM778.-O>Z7?_>[WSW)@'_<M\GAOD%?T8>VR:T,\(]@
MD=VS+XVDT9LZX0!+_<(!E@XB=#@AMHVV,('?[\3F!0+\=W]P(CI+UWKW6@LJ
M QE;L!(J[\]EDZ$03SJ+HQ?I66T'F <O6/2U=(F9KJJA _O45!D95:SAUF5@
MX.UH16# 3^Y2)L)2:2?EF$07UM"S.!;,BPR6_^-9QV#G/.!E,3""VZEB5JH
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MM]1B #\R;@+GCJ#-Z Q" ;$!)P8NB%+  Z@P"+2V:87_H*.!N#\DY]F#8C&
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M8_+7(CX6QO.C+\<U!?B/.X3 PGBD3)>0#-O6??+%BR0XBF3 CDP<1\.&[:6
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M>!ZVFY$X+[_=O34I.4'30"]O>VFCFK-MT_)-&Y85KU^Q:4-NQ1:Z,W+Z%*6
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MTO:% 9X)$Y'" %\O#/!,F+1]88!GPD2D,,#7"P,\$R9M7QC@F3 1*0SP]<(
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M<N)RYEQ_DLQA_3K 7ZGDMBFF+-Y(&7D'^&]1+/    #0A, #  !0$ (/  !
M00@\    !2'P    %(3  P  4! "#P  0$$(/     4A\    !2$P ,  % 0
M @\  $!!"#P    %(?     4A, #  !0$ (/  ! 00@\    !2'P    %(3
M P  4! "#P  0$$(/     4A\    !2$P ,  % 0 @\  $!!"#P    %(?
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M>7."O:M0YNL^LAY2K\X.MGV;TN]AR4R>S)/CH$0YX[\^66<S9M=/[*XK^;?
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MCXM]=8\_+I;<D'8 >.+=!QX   !^A, #  !0$ (/  ! 00@\    !2'P
M%(3  P  4! "#P  0$$(/     4A\    !2$P ,  % 0 @\  $!!"#P    %
M(?     4A, #  !0$ (/  ! 00@\    !2'P    %(3  P  4! "#P  0$$(
M/     4A\    !2$P ,  % 0 @\  $!!"#P    %(?     4A, #  !0T/\!
4V,L S^$XH%X     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_1a.jpg
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MTS^ZPPUG2)_'4(TU'A-M9-R_>'4[%E+C&V!TP8]V8D29%J>RLA!$=9T9V U
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MDYIAVE&T#$Q6 0@-@55_2))J;OFCD,L&#AK<J5.78?UZOW'=E!]R)#/D0'+
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MAVY+98Q[U\/8,FF&]SF_@C=89CZ6@<2F-)<4#Y22ZDZA9#2:,0KW&'81BOA
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M.F9ELW?'(<O=]@<,P>=USPL==**<1L!"XD#*XO+9/$4@]2N2 UC%8':P.(Q
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MF%5&XXL&G.SMB/&['9U3R8%&ZGK0E5E1OB'9;:QA:,;;5S'Z@HR&T:"H/QV
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M#L96MB EHJ.C34Q,5-TN+"QLU:I5ZMNC3;/_LORSZY\P88+Z<!5O>?=W TC
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M)!+)\/ P&@K!2GL6;?.3+%;Z1ZO5:C0:=-G(P8,'MVW;9@I$5%E9N2SO_LL
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MM+RJ1A:'PV$TXE)3*R2]#]0V"I.S:K^'H!%M8WHQ_\>$+[/4C.4SM7*"+EM
M0WHC./GN-H(?="G=7(Z^V72QLQ-(Z"H[$X1N+Z"HAX1$3;V17T)H;FF1*&0"
MB1B3$NWC>N*2QTE_SZ_]/4]=<C\9&>*I4DO;VU5:G5*IDJ9E9]8W-Q7G8],C
M7+-C/7(3O?.3?4LQ@$G 3PHD9L)80E%4GA%8A@TH2?,K3/'&Q[NG19ROR IB
M-Y<IY1R]7C<Q-1P5%1 3X-18FLPCYTD81*#6.N+.-*22S4;[YHB78P[)?.X7
M@@<W#KFCH)M@Q'WI@1F:,,"K[UKSSAX)'UOLC19MC.W5GEA9!9(--BWL*[(4
MU?N.S/XK[Y'KWPY*<5_M#,J/]E\%$O3@')*^)2^#<C^TX_5I;7%"48\Y=N;V
M(=T>X\[;D+349BR?J963N95R-]$$$_#\T&W4/4)GB;Z%U\[=_M:4#&GVU *'
MS ,W("N_;UR[;L3GX?&YN54U1$ :+#;)R^68CYL#0)&O^TD?5P< ))E"VM[5
MT=;9KF[38O%Y%;6UE56$U+ +F=%NN#A/P*2"9)]2S"5"FG\9]G(9X%!& 'R0
M?KDTS;\$XUN0[)4=ZY86?HZ8$=#:4"@3MVK4HO')(0:SR>W<X>*T 'IENJ"I
M$*CE;K@!I>Z!-GX /?4VM.%EZ-VP1PH=9'X*F7E(H^S40[Z9:OW@=]].DW$^
MQT)K;Z%5?[A&SPO^XM_/VMG][^8S,8RN11RR52 MBZP"Z9%L/B 6HWK?YA%#
MOSP2;83N=C*2UO^_3U>!!#W0_IL/I2V_6969QATS&W@W[4-B$&)F-R0]P:OL
MYE9RW_H.!1) $1*@8>%!.1-O$#4_-;^(ND=H&*&9JQ/!@?ZA09<Q*7&5M34X
M/-;=^8C7Q>,^;B>\74]XN1P/]KL@D8NGKQF-5XV&&8.^OX]0545NIL0'G\>$
MNZ1'N6;&N&7'>>0D>.8G>Q>F^,PIX)!W?I)7;J)G=IP[)N)"2MC9,JP_C90C
MXE.5"CZ2<K#?Q_-L7*!30U$\IPX/U'(W(-&^^P30:W[0E S:X /9' '%,I @
MY/_-V"/PHH;W',(+^^XO:KBEHI8EI1:VPUME%TAN9IZ@#UUT9\N,^BJ0K(N-
M0(I&Q)2@C\NU$N#C$>27#22+^Y!^F.CBY&%Q!(;\!^A>)YLJ7IU#>J#]MQ6D
M[ ).M^FEVS<'" DXS;=F S"KJ^S,952O SJF;QN#2]TX6O:VC>N!ZL9[M":=
M@$O-6+<&'(_U:.!CY!24HUWJT6XU7':IKP#M5(UTJ(8[E$/MBJ$N>51\#+$H
M+RDNO(A07%2<[^=^*L#;*>32^5 _YV _YY#+KDP.LV^PK[.GNW>PK[VKL[2R
MALIHQ<1?SHSWPR4'X%,"<S%!!>EAQ9D19=E19;BH<EPTHE&$["A"5D1)9G@!
M-@07[T[,#*15XX2<1H6"U]8F&YL8K*PL]CA_L#CM<DLE!JCE;C! @;N@I%S(
M?C]47PE]LDR1&BS(I "S^8AG"?[RIL^]1^[='P9!+6S>O/E?__J7G659M#VK
M8DD>M>O>>><=T_$R1ONVWAA;Q&Z%@?3##99Y)I4:VFP4\!\[AQ0T)PN^Z;)\
MG(=M/@ZSEM[K_LFW[=CX-#)'JH;3[XE)!>E9C:J'_MN]>_/:]9MW?Y@9:2.3
MZH6Z@649N/M% FFR30K4V*4T="F-L*J,W:KI'C5:3NLU1KUF6J^=U5[==)\.
ME,9>N)SN;3/VM4WW@[(='!C[.Y"#]JE>H&U3>MW$@**WO\S1\:3KN=.!?FY9
M.5D55>41@1>B0]P2(CR3(KT2(KQ2$L)$"HU4I06E4*8"96TSLY'64E6212I(
MJB]):2A-)9>E4XA86E46LP;/(N6P:H'F,H&2<A@U.%I5=G-E9E5N=#4N% ")
MQZR7R[DJE7!HN*=_H/.BDWU\X)F&HEB@UCKBN@P*K85TA>#;!&6I()NCZ-L]
M.I &*-%'(LON0+=)D4?VQ&2Z/PBD#1LVF#^V'C5!W^.37[%],IG\^NNOHYU\
MZ- AT.>OO/(*>OK22R^A6%K&:-^_/"#=&RU-3D!2J40=6?L_KVSWYJ.>D.4Y
M)!-U%B3]$P0D(#<G!+0Z0G$QH8HB[AAY"#8S#=F@<S%)R<D83'Y#2U--5EJU
M<DE[#&:;L703*R\HD R=") ZE8!#L,) 4AM[--.H/@"D-L A6/O:T&- H&G
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M1]]Y'M3_S3O'<>SV17\AJT!"Q!1<E5.1@<DE418(KOI-3TUQ,>$!(3;*%G%
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MFS9Y?O6QQ\Z_'GKC?[:]>,3_?!"A(:&)X]_ \4[#_>7__EI4F"$0,:5RWN!
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MV72QL"J@H<77-9A^TN:GT$\*)."(K%FS9O?NW9;V,[F[NX/F.3@XH( QS<J
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MTAF@EWT<+WF>]KIX')>=(A*R^WH[>O4=4IDH-#(JM[BDA=XHDW*4<IY*P0=
M4L"[7#ER*4LFHHMY%"&WGL^LYC*(;%HIBU;*I!6WTHKI384MY+QJ0F)]!89)
M)5H#4E\S5,2&:I:Z,1;]^?T<'C?H&FC@%@ X=75U@5.T-%V<5]\TGP0\(5"3
MS6:#$E1#'8N'I\1-IDR608DNPS,%G9M7_SM$%FS/O!7;IA8".Z;ZH&' \P,7
MKURY@AXL^GE-[;$T>KG"L@HD2]5LO+CT]OP40+JK:L#C6\R_@=>JTM.%QON/
MEX<7,CS1&6-1( T-Z3O4,DEK,[NZG%J40RW$M9872:@-/5)>GY !M!^4@$S
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MC9D!SJ35F)52+)II_749RN)#UC]#\$1+DYU%#TD6(-UKLRFN?/#Z/**@!O)
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M+]^Z=6MP<#!XS@!KGC @@0<I\(\=_*\"]/'[S@  ?_])1$%4KVCLK//#'RU
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M<$C,D(OH@V1229G  )#4$WM(],RA^9""(4=7*/(Q\I"@@09]M5H]:;9S6H-
M&M=#>AQNXC4U-2M7KIS68\%<!!(X0'"8T^VVG"Z01CUJC'WL>(* =*M$2A[H
M.KI9JM44M'9#T(U,!OFN>2ANG^<A4=STPDOF=KQ;585IK'B\KF4&IHZ=8T!*
M2Y,/FG;(4M/D*5H9L-14:6JJ.#5%I-$(?(/LU^S^8.6O"[_];=%'*UY:_-Z+
MZW8OW6'[T=>K%VW>__ZZ7>^N^&;ARO\N<K3?Z6B[(P+F1:5BV%Q:5$10F-\I
M.A7+3^9PN PB/AZ#BB+@D!0RED"*1Z%A+#99)DYFP(/)X7X<2AP5Y4M"^@(@
M:502F80OX-&YB40>$T=%1[@Y69]PL$Y7\FJK3355 $C%>3DZF8 NX5&*"@R#
M0"H? A+ CUQ(59I;ZH"39&ZI V32R-G )CP9?T*9D9"G$.+80_]8#'EI9B_*
MKJT-PN/!<ZG9P/K!!%@SHLT$W U7K%@Q>87FHDI(D*\*NAM(PU\^/D!R=G:F
MT6C3VF4N @F#P8 CG>Y>%B"-+6LH.1S+,#QDPYB)D?KTT2C^M;\_WZY,H2#G
MX6C?><8L8(;\;&-!3D&AOK HK[#8 *RH!)BQN/2.!80Y_[3YG6]6O_'?-8L^
M_L_+[WR\X)O?W@ ?5_[ZQJ_;EGS\Y2O+5KYJ8_\+@10C5XH52G&R@"U(8@@Y
M-+37L3CO$U1L+#>1(I>+4K5J38I2*A.2R$@<(5*ID>6EIR4&>'KO^.VTW>^!
MGD>"3A\)\K0/]+0+\+ /]+ +<#\<&^).C@^V/[#-9M^N0D,F %)U16E.AH:4
M$!'N[X9"A!CUV8V-3<W-+>6F$@"D%+.'Q%") 9" ;Y2HDIH=([44@(H]D8=D
M5BMD?1 JS8:^WPH5&: USK,790<>NI<L^7N0B$'[ZBOH[H?Q-6O6/)G#L/:W
M0C7F!HK''$C+ER]O;Y_>%&IS$4C %R\N+I[N7A8@C2UK*#DE( T.KCJL>3JX
M*B\Y$1B+1^4E,SA\2D:>KJVGM__:U?*:RB*3L:N[L[6UH;VU#H7U_6GSN_]=
M^\:J[6__LO7M+W]^[<?-;ZW9]>ZJ+1]M^?W;%=^]]=]5;YTXO4-?D-'0TEC?
MTM#0UMS8WM+8UE*<KS?FI)LJ3-4-]36-#0VMS0UM+4WM;=6-M5EY&F.QH3P_
M+SG,)_"/M6?L=@$"A1S;'^BP.\#-)M#C<)"G'2 3(M"5&!O@<\HQR,^[N""W
MP)"5IA:S*?&XF$ /ET/.1P[I4E5-32W-+:WEY68/";!'*:8H162EA*:6):JE
MP)A#0+IW'Y)97=");5"(*_1Y&%0AA+[UA/IFL<E.(H%>?/%O&BU<"(UY_P.)
M1#XYK79_]4.E!5#!L%5 _7\^SDUVP$/=NG7K=/>:<T"Z?OTZJ-Y]]%9:@#2V
MK*'D<)3=\ 1](($;!:3!P56'-4\'5V5QJ<"8'!*+1TYDXU/3%=4-#;U]/55U
M584EN1<N=%WIZ[Q\OI''1JS9^=&FW9\=#_KV1/#7>XY^>MAS^2Z'3S;M^<K#
M=S^1%HU !LM422WM#>=[.SO/M_5<.'_QRH6+_1<O7.X#:XK*"W(*L_,KC WG
MZIIZF[HN]YR_W%M15UK=4%M;7,@-]/39OLKGR&YT\*G8H_O=UWWG8;75]^1A
M?P_[ (\C 9X.@:<=P3+ P\'?;$<"/1VB0T[A8@/.N-H=M-HCEXK-0&IN,9F*
M)0**0@2,)!<2Y$*22L(PT\B\!):HD4_L(?T%=>JA>")4<QX21D,94WH6GC$@
M 6W>_#>0;&S&[J+5:FW&6S\G]6<!].X_H"\W0M8[H7<70#^O@[8$G<\T/;8>
M$G@:B(F)F>Y><PY(!H-A_?KU][&C!4ACRQI*3B'*SA+V/2@4)G+0,/AH9$($
MEA!#)"/)5#25CJ,Q\0P6,9%#9G')%'(T-LPA(=@V(<PJ-GA/L.<VF/=V+Y?U
M<4%VN"@7 1DF949Q"2%".D(EP*5)J9DJ5K8F*3=5H->)]#HQ\$[D8H9&Q<G.
MDF;G*HS&].)B?5&QH:2TL% K3PH\%;1G?:"+%1UQ%G?"UFW5URX[?O-PWN_E
M:N/C9NMS\M#94X?]W.W,?!J 4] 9)WC@2> A>9]RVKUS&RN1.0BD<E.)F$]1
M"$D*(5$!@)1,4(II*C%=):$#(&EDB2F*B?N0AO4GU'L)FM+(03,*I)H:Z.67
MS31Z[35HO*:YNKJZ5:M63:E:C[\Z!= 6TL#X3']!-23(F@5QG&XB=8\MD#P]
M/:<57S>H.0<D</XC(B+N8T<+D,:6-92\5:7E2HHG?,"]=;DH3W^WYN6+L3A"
M[(#%$<D)>"*20$*1*&@R%4NAXRAT/)5!H"42Z2P2BXEF1AUC1C@P(QWIX4<8
MX4?HH7:,,+O!)0UVB!I\D!)\$"QI(;;4$%MRT$%2X$%RD"TE^# YY# I^! ^
MT!;K;QOG8XT,.0X_8Q-Y<F?\F;T)/E;\"#>6YQ'XH5TQ?L<%V CZZ:.^FW_R
MW+?>Y^3! $_[H#,.P5Y.P=Y'0WR<8;XNH7XGPOQ=(P)/QH5[$1-@06?=]N_=
MS:#3FEM:6EI;*RO*Y$*: G!(2%0*"8ID(D"1ZHY[9 92ZB1 >G1!#<-R<S,#
M*3AX>GO-15W60I_;0LI<J" 7BK.%K ,@ZU]N$+,'@31JV\<!2!X>'O<QKN"<
M ]+@'%WWL:,%2&/+&DK>>X"&8=WE(<DE0K%4,2\])!P^VFR$6#PQ'H>/ T8@
MQA.(*"(93:2@250LF8:E,7!,6CPKVH6-< ;&BCK*@CNQ(IW8D4ZL"(?$\"/
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M:Q5S9A\FPCW:QR[RY*X$G_U@I3C:0Q/IQ0KRY)!0:1RRP-\=L7\KPO40)B8
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M0GOOQYRUPOL?) ?;T4(=52B_+&28$A&L$[#R#;GY1KW9S(E<H\%L!D..(6_
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M"7*(0T-6C[@HD+#Y.@%G;""AG1JJA6"%"QA2ME/#'ZD'H.^W-J@+V.X$.P^
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MR<:7-+=\_NZ691]^^>DG[[[_R=)E*X]K:AGI&S@YN="H5!Z'A0*IK*ZN'EE
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M4M<08J80T40"%I_/@6%G;;EQ_>H5RS[3/GL\.BK\IK/#=YLWK%SV*8P52Y&
M0 KS=%*DQ>:F)2A2XYA!+AE.1BDVNBDV>EFNEN+X4$%L0+R3F9NQKH.Y:5Q4
M!(=)S$B)#/2T/K!WVYPYLV?,F+'TH_=_W/S5R4-[/6^Z1OIX1ME94N*B*BHJ
MZ^LQ('5 >]3>=:NVOA9=0T)N88YPB),AXF9!&O'9&2(>4<PG2@24IQZ(9CG
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MP>:RJ(0X'_V+=AI['33W>EW0"+YV/N*Z=H3N.<?#NW2VK@MV<RFMK(% :L:
MA-*HJ_MN4TNS5,2$U,F6,J$EPH DYI.DJ$/*EK*R)<QQ#D=/!? WF:1>=EAS
MU2)PJV],(/6"R#/@I9E@YWZPZ01PT@>KSH/JZ7A5Z4/0+ 3FVD#K O"G3OC=
MIU2:(*F -+F:$DDHKZ*2;!B%Q?*"0HE<SBXJE5=4YG1VME94%MVYU7"_MVV@
M'YJD@?I2&3W."2FTB[&G1-D@$(JRH4;9HH$\H$79(DS"61/#K3)#S-,#35+]
MC0E^1G@?@V0O/6:TFS ^D!/N1?-WI(=YDF,#4B.]0QQ-_ POTG&^DN0(LK]S
M@-,-+U_?1$(:A\<1"QD)D3Y&.IKGCNZ(#?=M:FYI;FVKJ*A,Q84;'MKK9V]=
M5E5;!_G3U@&!U#D*2#(11!$=@D<A94"?!.T1"B1D#0FAU#@.:7*%EGV?N )P
M8[89A:Q:9@+NW &>!]">JH,@7GNZ-5=5KJ^Y<BHH*+APX0+\\>-PN-\W IU.
MQ\Y37"[W]XTP6C*9#!N-0"#\OA&"@H+@V^WM[2LJGL.ZVLBW4RA^Y_VPW=S<
ML&FWQL;?<W6!:LIN<C4EDE!>A<52-% @*3A%I8KZQO+VCN;JFM+>NVV# ]TH
MD.[7E8B8<8Z,6#MF@A,CWHF9Z,Q,=&$ENL M(]Z9%F/'@/\;YT2+=:1&VY,C
MK%&?9)H68 *M$L'?F!WO+4^-DB2&\R+]1"E1 AK2?IN2%1\;[(;'>1/Q82FQ
M?CX>#FX>'I&Q"4PV4R)B)43Z&F) BO!%;GK4UE9564E-3+ ^I>ER_6I994U#
M<UM+6V<'!!)*HUMW>YI;6V1B5@YT0D@PY1*Z5/1H&0G:IAP9"V)ILH_W&%+N
M5GO#!6#]3I!9 7J:0,<]4$T%!S8!QO2ZW2IVQ94Z^' F6+$3?3#O";<B'$\Q
M,3&OOOKJ7_[R%^PL\W__]W___.<_T]+&ODO]+P1AMG#A0OC&EQ[KKW_]JXV-
MS;-F@NG:M6OP[2-#O?SRRV^__3;\".5'2$U-A5]AY!O!!Z^]]MKO ^W]^_?W
M[MT[^JO!?+[\\DOXNO*#^/KZ_N,?_Q@]R.NOO\[G/]ODJ@I(DZLID83R*B@2
MPT"!))8KD"F[^J;*UK:FFIKBGNZ6OGL=]WN[!OKOUA;S6!!%<?;T6'O()':2
M"SO9E97DRD* Y 1M$SW6@1YM3T5]4E:895J ,<%'/]7?" ,2*\Z+$Q.0Z64?
M:Z5'\'64\R@E18H<!5\B8>?FB@H*9-G90GQ*HKNW;VQBLD0FD8C8<3@?_<N:
M9X_LB,<%("V].SIJJJK$-)J/@9[E::W\HN+&UO:6]D<E=B- 4D@XD$80/] A
MR<4TM,J.C !)\BQ @C^YKHF_RJ<'N&P$'QT%>.F8[>D>@F8VL$Y%*P#[ <$%
MX NG9<UT,Q[L#D5KZQ^"LM!G+6I05U>'Y^O9LV?#GSW$TEMOO06?8CQH:&A0
M9@2X&SR]8N?].7/FP#,O?#QOWCRX7;ITZ3.=N.'.BQ<O'CEK__WO?W_CC3>P
MQW/GSE4R'WBBQ[ !\WGSS3>QM\,O")^>/GU:^62@*BLKY\^?CX$$'A,XR(P9
M,[ !O_CB"R6_&H/!&,GG_???Q]Z._05@966E?#(J($VNID02RJN@4(1$L3R_
M0 2!5% LJZDO:VMOKJ@LZ.IJ[.^_#6D$35)M$9>5X$S'G% \)),C>ITL,E^'
MSM3=&%E 0KQ1L'E:H"F"(C]#O(]^LI=>9H!%FK-AO*EVY/53:9XWBK)%+6W-
M-755(B:I4";L:&OMO-4ER\[%9Q"S*#2I7 J!%!/FJ7_IV/EC.Q.C@K#^0+75
M-;DB492SH]7)8R*!\!&01CNDMA:%% &20L+(D3$1("$T>K2&E"-GPZU2!T5?
M'Y1-_/WBT'N_AM) J"'2.-7"!Z0SQIG(JB8#<O5$I?>\U<T!:T\!DA#(.,#E
M)##G*/_6[[[[#O[:H95YY9571C" P4GY,\[(SJ,'@2=Q+R\O.-1GGWVF?#X?
M?_PQ?(N]O?U+H_2WO_WM]^4S:]:LT;G!KPF'VK)EBY+)0-Y "D)":VAHC,YG
MM-%1,A_L+2-P?0EU2&?/GH60L[2T5#(?; 'II:=HC!4F%9">BZ9$$LHK+U\(
M P%2/@JD4FEK>W-'5UM-;4GWG>;!@;N#@[T# SUUQ7Q>LAL[T1GZ)$@F=I(K
M#!9")@<&]$803M%V5!A1,&PAF3*#L64DHQ0? [R7'C7"D1OI2?6QQ=M>QSL:
MBU)CBP4,?E)$C)4>)=!-&!]$]+'%>3J%1T83J72Y0B;BTW%!K@:7-;2U=B=&
M![>@_8'J:FL+9?*L*)R'@2XE/?5GA_082$A1@YB)531 /X1.V5&1ZY!$T"I1
MQ7P*#*4.RB0""5D->@AN5P)2#+ S>$+KH-&2HS73TU7#H"P+&%YXUJ*&K*PL
M^$>ZDY,3Q, [[[QSXL0);V]O^'IP</ SG7 /'3J$[7SRY$EX$H<&9=6J51LV
M;/C7O_X5'1T-7[]X\:(RX\ $X,Y$(A&>K.';X2!P*#C@N7/GL/&UM+24&6<D
M^:BH*/@4?BDX\L*%"Y<L6>+N[@Z_,OSBRHRS:-$B"#!X-*!1@U\!#HCELWGS
M9FQ\F*KR^<#/E4@D\.UGSIQQ<W-;L&"!FIH:_(, LJJIJ4F9<51 FEQ-B224
MUR,@(=<A"179G.JZTK:.EEMW;K>WU_9T-]_O;>OOZ^Z[UU53P.(DN3 1_-A#
M_#!BD/HZ9KP3#&2R+M:1%F-/C;9'F(26VSU>0S).]3-(\=9C1#H+X_Q9(:Z<
MT)NL 'OR31/"C2LAEX[Z7]:DAWD+$T(S/6Y$N3L$!8>D99'R\G,P(!G_=/S2
M\3U),2%8P[JZFNHBN8Q')N-<G?#AP4UM'6T=CRY"@C2ZW=/;U(I4V6&7'"FD
M3(F0*N21((30-21JMHR1+1NOR@[3Y "I%X3J/EM7NND-I-^IF3-GOO;::R^_
M_/)''WVDJ:F)T0B34"A\"9VD@K@:>V(*A\-A<W30UHR\B#$)GG#AV7;^_/GP
M(Y3)!^X,/03<;MRX$:/1R'_IZ.C CX )C[T.!%.UM;7%YAOA5QAY'7XU^ 4_
M^. #./B,&3-@PN,F4U%1 1$"F0K?@A%Q=#Y'CAR!KT"HC+T.U-75M6?/'NS<
M/7(8,29I:VN_^>:;,!DX_A=??#%N/F!4E=W8^NT;54!Z+IH222BOGQU2@0@"
MJ::NO.M.5V_OG;O=K?U]=P;Z;@\.WA\:O%=3R.$D(D!BQCM""#$>>R,8T!MA
M]778K!TIW)(49D$,-<\,,DZ#-/*ZENSV$RW"49P8Q WWX..\N"$NI)NFR>:7
M@BX<\M8^1@GUE":%4WSL4CUM,N-P(@&OM*1 Q&=$A;A;7#_STZG]2;&AK9T=
MG7=N-];7E>5F%\-$J10.(;&E ^FIVGGG#D8C!$@M36(!729"0\R #DDFHL$M
M#(64GB-CYLK92AV4R0&2<L*Z?1?5O@BM@YY=\*]R>,+%5D1&O-&O=I@U:Q8\
M77[]]==,YA/^_H!GVQT[=D#W 'GSVXH#C$DCYB E)67L?. .(S4(OZ(1)O@1
M,)E77GE%75W]B8RLJJJ""(2#S)T[M^LW*Y>83QKQ$^,N_T#;A^6S9<N67]$(
M4TA("-SAU5=?O7#APA-'@ F_]]Y[<)^WWW[[5Q^',0G+!]I!Z,/&3@;3&/9(
MY9 F0%,B">4U J2"0@@D;GE5Z:WN6X.#_4.#O<-#<'M_>*AO>+@? 5*2*T01
M"YNL2W2!0*)%VU B+(@A)IF!ANG^!JG^!@1?_10?/;RG;KSKI2C[L^$W3H28
M:00:'TGU,1/&!W##/'@X+T[H_[-W'F!17.O_)\7D7DV,-XG_&!--3(Q)KC$F
MIJC8:V),C$:Q8(O=J&CLV%&:!E!$1 4!E=Y[;[O4[;T7D Z[+%::^,O\WYDC
MD[TT!Q:YY#Z\SV&>87;FS#NSN^>SW_>\<XYS@I-U\+'M5[<NO[QC;9JO.ROB
M9JJ'8Y+'659JK$HNUFH4^:"0O)QM#FWY??.RB"!OD$>&>W<KRDK5$K%66U1<
M7E5:45558R" = ]0=/=A'11<(3$R!5RZD)=-ANS8C#0>"[11AH#S/P&D9B&V
M;@T^C=#?>!S2)HR3T#+I5$O)H'3#48,""@F6;6F$$:D*("G0;A,G3DQ,3(3=
M/#T]MVS9$A04Y.'AX>3DA%X=/GQXNT(!)1>0'3E4_$'646TH=<*,2 0'?UQ<
M7, 3$$_@%6S9MV\?>G7LV+'MIC^ _^0EF^X/U$9VM@%[8F-C02."@-N[=R^\
MQ& PR,/'CQ_?UA_$)'B53.+HW!\JKG:4\M /I!ZQ/N$$=3-62#P>_79I4;5!
MU]S<^.A1'5H"EO[O<=-M64Y.Y'E:Z#D:GNW]1]RU(^&NNX.<=O@[;KUIM\GG
M]*]>)]=Y'E]S]:CEY<,K+AVPN+!WB=.N1>=V_&B_[0?;3=\%G#N0%^Q)\[Y
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MDYX<34P+BX!475Z-%!( 2:>KJ3%22#B0>&P\HP&A" 7K",&$1!(=!!.EFP)
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MF<EF9'#9-!Z;QF%F\3C9 AX>Q^O^G3(8_NI8,K*.^I ^^."#MH_6PQ;8?N#
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M[[[SUJB1[[PV^%7 $BH#!_[S[6'_;^2(=UX=//BS3]Y?_\M,6^OMV9GQ,IF
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M;;-SQ:K9X[__\KU-TSY;/?&CE9,^^OJC$>^]\\Z[PX=#&?G.N^\,&S;TC3<
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M"$@H\QZ-,HQ%*G**-)#$14LE9W$DYY/ZQQI(XI$ZR06PDO-&DI;T2^2R&ZI
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M,NC%^'Q2,1Q7#)"  <>/'U^Z=.F 4;)^G!9P'+X=\SDD2;&RLEJQ8H5T/22
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M-CF-@3\&X-G''W]\Y,@127LDO:5AV2.F$0AX;*=.G8+C.CHZ<MHCH_T)("E
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M,[%UZU;4YXJ95%Q<+&X<,"!/.^+!-! >CR>V!YHM*"B8,6/&WKU[7]D._ X
M2!PZ=&@ DTQ-3<6-PW/);@39+QG%+CZ.:,3A<,"YU-34?&4[% IEX<*%X#^!
M\R1ISZY=N\2-P_XKVY$A$T!2C(P+(^27CJX>4"!'>V=7<UMK0TMC8VMSFTC4
MWMDIPEE2WUCW/,7S2<!Y#?,?U<V./G3[4>/IMW>L]]RW^''7D<_/JA]\:*VK
M:WKCLN8/NXY^[NMK22G.*&42*CCDJE):52F]DD>M*,42XY7SJ,R\M#17ZU#C
MNVZ:%^VOG3;X;;^?B6Y>B%>&Q],4)W,LYMO!) 4/M$MV1(%V)@EVV$Q2@JU1
MG(U>JN<34DXRFT4A$?+34^(B0OV#_3T38T.+"U+)Q!P\VAO+H\IA4S @L2G
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MNRX[>1??ZU+B0.JR.CAB$A*\4PA0(,J!^ZPS+KCYGCY]&KW:7=2"6H#XJ5=
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M^U5Z%$HT($<'9.ZRD\/I^[GX7G=:M6H5&G=1P4=$QH\?CR9JJW0SF"\I^%]
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MJP@@*<EW7"F<D%[\9CX8G4FGU=:58U$1"X!$JVLHJ:"3:2Q.$Z^179N2\!R
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M -)C%940W-J+[W&Y1.8Z0GT1 20"2+*+T\AN:.*PV2RA4(B !&0"H5?S,R(
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MAJQ#T6&QF/I&;X"TUWC/WH#3IRJJRT&$5-G0 )A4T=A4];AE:HJKCF>!OF'
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M_&PY>6A'06'N#VM6+5GRA8RLO*SL+%E9>1D961EI:6DI($E)P"@H.H* I+A
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MEYT_3W;N', D*3E9*+5ACL+L-3_]B"53;1T.7 GQ.^WOQF22-5&J6)P649M
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M(-+(:)H.R>?4J>3TM/OIR7?B(X,NG'9VL3,R9I,I>!P1BR?A\=I$;2J%PF#
M$Y+TH,QOZ#&2R:$CKMQL;F5# SPA20RD<74D!I)8D]3T Y*@)=5%:\4N(V<?
M7Q_GO5@EG$MJR\0KV8F!-$G!J\3VMW=U#&?6P;-E^_N@1TH#O[<VUD,1$O(8
MJ:@*?HQT/^K<O3#ON//.X7Z6YUV-#YI1[ Z89F7$0<G?O(R2PK3BO.3\S+CT
MA+"8ZZ=M3&D;UJV1DY/[[-,9$C,E9*2ER=KXY'OQU77E]8TU3YX]?E11&GPA
MP,71TN&@^=$C=OXGO?S\/,Z>/7$[XGKLG8B;MZ[=BHZ(2XQ+3HH,\/>DTH@H
MM)H61AV#0V$)&!P1AR<12!0RA4X'0(*&[/0-V88F+ ,3*]L#D=&WJQKJJIH:
MQ4 :9T=B((DU24TW( E^B[?:YLY]+D#BHD'!<Z[[-JOXW\3%5?\Y@7@(?H;4
MAZQC#HZ \$C0/] K&'CQ1TM];4D]_!@)2?X&5O$(FHI469Y?49;[Z&'6@^(,
M7E%:V8.L1P^AQ?H>%*?Q\I(+,N]$^[E=<K+<IXM=NV:EG(SLS!DSI22@&4AR
M,I*''*QS\M+**DKJ&JJK:RM"KYYW=;%U<K2\<N5L83'W_OVX,Z>\;*U,M$E:
M%#K5Z_2YV'O)J:EQ/MZ'L7@4H!$:JX$> A(61\03R"1M&HW*8,) @HHUL U-
MS<SWG[\06%5?5]4H!M)X.Q(#2:Q):KH!J8/GR_+E=8QYY*/[FG!;(4HDG!B_
MD$(,"(& O>IL[^'SH5(- P/#2R4-]/>W/6^MJRENJ!\*DFJJ"JLK"LIX:>4/
MTLM*TDL*4PIR[F;<C\SE)H#P"%J* JJRFEZ2?Z\@,R[&U?X$5L-4>>M/JY;/
MF24K+RNI,%MZGH(,,$WU'=&1UXIYV0]*"QZ5\ZY>"3P" RDFYOK#A]E7+Y^U
MLC#68U,P&#66@?Z)"R&Q20DIR5%N;O9:& T46AUL082$(Z !D[ $+$$; 9(N
MG<5AZAF"\ @JM&I@Y.7M55%3 0.I1>@W4 PDL<1Z7],-2+U/PLWP(95OT[W[
M*D/P9N%/>B?3UX3;"E$BX<3XU2> !N5Z>OOY( Z"5D7J;.]H?_[B]^Z>SGYP
MIH\O@-37U?Z\KBJOH?YA/?(D"0Z2"E)"'Q;$5Y9E CZ%7_(UTS,Y;'\H)S,1
M*B/T@%O*RR@I2"GDQM^PWNN^=9/I9B6-7S8HK5^S;NWJ#>N^W[C^^TU*:S14
MMT;<OEQ8F)&?G\XKR;YXP=_QH+FS@\6]Y.C\O!1?;V<3(X8>BZR%4C79OS_P
MVLWH^-@[,6&.CE88G"8P-%83'K)#8_& 25B\-I%$I5(9#"BO@:V'%!!BZ1L[
M.CMQL],J 9">3E&6W8>NG&1'DVG^41V)@236)#7\<1A/IJ@( .GU8$=9B!Z.
MY7PF-#(J*OR\,UF-$U+6,8G$!A'Y!(F$$^,7LOQ$'SPT!UYV=G=W=G5"\X^@
M&&D @E$_M$9?5U='?55N4T-90T-I?=V#^MH'M=7%CXK3FILJGSRI+2Y(#W:S
M]#Q@Z>'BDLM-&EJ-HB2SI/!^8?;=N&.'K[)I#IHJO_R\1E%QSBQYZ3FS9>8J
MR,Y3D%VT8/;9,SX%^:DYN?<+"C/"0H.\CCJ</.Z6E97,S;AC;,0$L1&'I8U"
M*5O:.UR)B(Z.BPR_<='2T@R'U\+BM0"0M' H-&1:6E@TAH GD,G:.G2J+IO.
MAJ8B 1HQ]8PLK*QNW[Y1V= @CI#&V9$82&)-4A\U44$4@/0:2OU^QDL."_3U
M]0T,2^8]$U=J^.?5T]O;V=W5]V8A\^'BJKU]@H;J_.;&\L:F<L D*%2J*\E-
M"BW+3VYNK,A,B>6F1#K;V;F[N.5F)9>7PF6$'G ?%*45Y"1%'[8_IZ9LN6.K
MTG<K9\G+#2W-!]>R6[A P=_//2_G7G;VO=S<^S?#@GV/N02=\\W/OY^:$L%F
M43%H=3TV!8U6<SSJ<2L^\4Y\Y)7+9TQ,]7 $+6 8/$(C%!JKI8D&.U@\B42B
M4*FZ+ ;; *G\S> 8&)F8GCE[JJI1#*3Q=B0&DEB3U,=.LWO_':8>2$+O:VHZ
M&ELBX<2$!0_?]4+/DP;>_GD ]@&?&FL*FAH?-3=7-#65-X)0J?XA+^=N<494
M:4$B+R^E_$%660FW("<%;(>7['O(RRC,24HZ=>P*AWY 4_D_*Y9+24E_^ND,
MR#Z;\=EG,Q8MG._CY9*;G925E92=E1P;?3W W_-*2$!185I2P@TZG83!:G!8
M9 (1XWXB(#8E+3$Y)BC0C\W1(1#1")"P8(M#H=":&EH:($C"DX@D*HVF"]40
MTF'KTSD&$)G8>JY'7<NJ*OYQ($U20G?^0WZ*@226L#2>>=:C_K)-+9#$U;Y%
M0TCFPO#+_OZ!/BBE03#R G  1$C-=<4 10!(S4T0DP"<D)E)U>5YM95#BR1!
MB\G"1>V&:JT^X/+R4Y(\7:Z;Z=FPB"M7?"TA(0EH]!ED,\%VZ9>+/5SM<[B)
M7&Y29D9B-C<Y(2[\;OS-!R7<N)AK5"H!B]-D,<EL/:9?8'!L\KW[]^_X^WM2
M=4@D,@Y/PF @)FEI834UT1H:*'44&O )3]#6UJ8-C=HQ.%"$Q&#K'["S2\U(
MK9VJ9TA_!U'$0!)K.FH\OTXB *2!]OR@PZ'IO#^I[@^!N%+#U*JK5P!LF$D@
M&(*8U/>GW)(>?E]7%_]Q/0\"4E,%PB0(2S"3*M.C:LOSWE0!SZM\!"US#M5:
MA9E4RLO(SXQ/N7/YH*7^UU\NEI@)K0 K)3%DJU<N.V2W+R,U-CLK,3,](3LS
M*2LCD9N>D)YZY\*%DP02%D1"3"9YS_Z]9RY?BTE,N)\2[77L,%$;2]+&$;2Q
M."(:B]="8334-=74--0TM32Q!!P$)*H.39>MP]*GL_1 J,1@Z^W=;W']9MC4
M .F=X\(*;L1 $FLZ:IH 2= :9<&*$N:T$!'Y!(F$$^/7B/) @\C+@8&![IYN
M9!5S..6['TZTZV]I+H4"HZ8A&L%D G%2>75F;&UQ:O4#+I0+#F$)JBI4":^3
M5/$(6KBO.#_E?MQ5:W/V5U]^+B,M*2<C-4L.-EFIGW]<;;W?Z-JETRG)D=R,
M!,"DC-3XM)28N-@P'U]7' %-(>,9NN3]MK;^P9?#(V\FW D[<L0.A$?:%#S
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M&AH+%RZDT6A.3D[GSIT#0.)P.&M@-30T_.4[B($DEA U78 T\"324)7CY.W
M4K6,>L)_][0X0IH:P8SI .$,8O!Z2#![8 *U=W9T= T9=$%/9Q?$H<YN?M<;
M\'2UO?C]F*EV[*6 %__[G0]"I-[AF I@J \R.*(Z[G=LV;)ETE(R,M+2<K+
MI"@TTJWHF[[^/KI,,I.!,V 3#9AX?5V<'@/+8>!,]"E&'#*#BK&V,'9W=7 _
M8GOAC,?EX).G_3T#3GF=/.%^S,O%P=':T%B/2":HJ*O\LO.77W9N5U951:$Q
M6 *1H$TF4:B 210Z XZ0.% B.),C]!LH:D R-C;&X7  2^^?\O#P^/'''__R
M'<1 $DN(FB9 $K1&[:.&-P^^[GL:;C;JPZ2WA85\3P1>3QP]D/IS7T+Q>9(2
M"2?&KRY^#V0]R"A;=T<7--#6WM7>@1C,JFYP$H0[4,0#!3TP=2#8#(W:]?5=
M<;,XXV#V>^LS 503#\F&&$"6KD!V^@<&CA_W6KEJ^=RY\O/GSUJ@**^H*&]@
MQ+J3&',RP$^70=!GXLR-:7N,J"8&%$,.B</$,V@8BK8F$:^.12NC-':HJ?RR
M>^>6';]LV+Y-:<?6]3M_45)5WH)%[:02U0U81":#L%MEQ^9M6W>KJ*"TT#@"
MB:!- 4S2IE(I.G0XUXX#@B0&6U_H-U#4@+1Y\^;Z^OH/G1W/AT0,)+&$J.D#
M)"2IX0/9#0/-489O2J]&189?=!L]D/IS7T+S>Q(2"2?&K^Z>[FYHY T:@NN
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M0W=LW9":EA9R]+?MNW=NVKII]9K5\O/FR4Z=JJM'()/U2&0"2B/=EO (*(6
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MW\#N*B<G9_+DR79V=D>/'H7&$=I!> YW/C@XN+M-0)\""3L>W%-24H)'"-W
MVQT[=I!(I'9+.0!-QX\?;VEI"57 :N3DY#1UZM1^J%%4Y+XFV4%-BI0F"\,F
MV>%-&L0F^K:F@CK1-8+[[XD*6[H7/)\U:U9W=\$8 %+_2"*<P*_W[U^A]K+P
M_]D[#[ XKG-A^[E)G-B6D_AW["2.DWL5_[[7B8NL.+*O2V3)5B^H4(20A $5
M4*,7T;L0"VPO+'UI2UO*LO0N4$%"HO>V;&.7CNA-<\_,H)6L2'A!E)5]WN=[
MYAF69>>;@=V7[YPSY_2B8^VP$7<RI9#P,0[*@JEO4-Z/-=QA$[#B4]ZA_4GU
M#36IX32NMVFJS[D,;Y,XVZ.!IEKMC=65U=7;MN]\^R_KW_[+.V^\^=9KK[V.
MUT8OO[3N]76OOOW:;U]_]=>FYT[F9B;<O)YK>O'LAQ]\]-Y['WSPP0:+"V<*
M\S+Z^GKQFV='1T>$PH[*JKLW;UTO*LX+#F.[>+B L'6P-3YWQL!07^^8KJZN
M-MYP=_BPQL&#V%@[K$+"FNQV@4=<G6UOW;ZV[!?PL??5CQMU$!*"50\I*2FX
MD"HK*\%_[OC<WB^HGY 0;'E9D"$HF' A/:T=KZ"@P-_?7WE&^+B,E3XC/L<>
MT0C%AMC=1YI#$?U8).XL\O1UY_#7:6MK4YX1R!EDOJ@DE2^E_*-Z8GJ+/?=%
M'72Y6/A8RY[_$E"+)%1'+&T3H]U(0$@2>9]<II#(>U$A]0XH>@> EN2*/BE^
MV^Q\G83*2=X#OCNHZ,>TU#_88VIN]MY[__W1.W_RT-M*/KZ%H/OEY>]V<MBT
M39L^>^/-/[[^N]^_\<8??OO;UUY=]^HZS$8O_N*E%W_QJU=>?N7/?WK+[XIK
M17E!3=4U.UO+;=]NW[ES]\$#A]E,6GUMY=#0X/Q*%??Q&V,G!X;OB642068Z
MP=_'S=/9TM;B[(6S1B<-](Z!"DGSR!%-'1U-3:T#V#U)J)#V:\P/M-,_H1L5
MP;I;=7O9+^!C[ZMGK#^6Y4WRK$70@BS[!5S"I88\"]^;&BC.:V#]-ID;X2Z1
MT'AZV^Q6/<76CX;<(_]]ZB#56>QOT^6YK9 6?JF5R'\)J$42JB.2MH&0R(2*
M_N[N7E A27KZ>X!O^H<&>P=Z@7NZ>Z7X,(<'I9+\0?VDP*<&KZVKWK%[]Q_^
M\,;++[WT^;MO.6EL<C_T3\*)+T_O_N?ZM__PN]^]^<8;;_[FU[\%*@+QRDOK
M7OKERS__V2]_]K,7P<XAC3V9_ 21L$DN%S4W-_0H%%/8+ [ 0",C]\3B+JE4
M!,HCH*7IF=F1\<F!H1%Y3P\_(]W!V='*UMKFDHV-G=5IXY-'CQW1T3F,"ND(
M$-+!@X?V:VCLT3@ A+1G_X&]>_;M.G_NU-62[*K:N\M^ 1][7SWC1_:S_Q&O
MT-M@>=_)SY(#Y!GY_F1UJ3E!GB+=_2-;=_>?];A!<978$HM2GC"7G>HL]K<)
MA;2BJ$42JB.2M(,02SM[^A6R'FEWKPQX"$3_X&#?8)^B3]X-'NR1R.>%)%/T
MX4720R$5E11\NFGCKW^][L47?[G]P_^ZL&V#Q:Z/KAS]7./3___V[]_X_9MO
MOO:;W_QZW2N_>?755]>M U71+U]\Z>677GGEY75??_E%?D[6Q/@8NC+2_?OX
M DG*Q/ I[,;'QV0R24M+4T-#75M[N[RGKZ=_(#L_U\7#S=+&ZJ+Y10LKL_,7
MS^KIZ0 ;H:&KJ:5]$!W7<! 5TK[]J).T-#6\/9WN5-VJKJM:]@OXV/OJ682T
M],^8)7TB+"&WE7CE1>4 #[3<![J/C(@?#FIX^K#O9S[0$Y[YPH)W84,A+0MJ
MD83JB"0=(,1HA:20HN51'RB)^@;Z>@=[@9# #K"4O%<F[Y7@11(^IP/JI $%
MB+[!GN:6ADW__'C=*R_]XN<O_OQG+_[VY5_MWO 7+]W_W?KA?[[UYAM_?OO/
MP$FOO_[_?@.4]?*Z5U\!6GIUPX?O!_AZ=PG;9V=F\/5CYX4T.XL/JU.B;+*;
MG)KNELOKZJIOW[Z>Q(MS\W ULS0[;WK>Y+SQR=.&QXZC378Z1PYC8^T.X /M
ML+%V0$O[C,\8)L1'5M555M=7+_L%A$):-9;K^OS$^5Z!Q"/+_KY^ZLLMHUNW
MHG'$O?@ILWVKSJ)^FU!(*XU:)*$Z7>(.$.+N+GF?0B+K A52MT+:@TYMUZ=
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M@F)#V& ;$\Q6QEI?:0A$_1@N0[XZAJ25H+-]>Q]=N=F^H9#6"K5(0G4Z&AM
MM-;5-E57UM^MJ+UUL_)ZV>VK)>7%1:B*"@M /70M/P^=0R$GZWIN=EE61F%:
MLH#EEQOLFTEUNRN(NQ87>"TCI2PWNR@MY2K%*]+T6&[8%;;^WAB3H[<8/C>I
M'J5$UP*?2[E>5CGNEMDNYMDNIIF.YS- 7#H;:W28>FBSF<8.WPNGDEG^3 ]'
MIK-=J*=+I+]//(/,"V:F1@2G1H2D184+N%$9<3$"$/&QZ7&QN('PX7.@*L(+
MH_CP4""AZ&!V%)N%!R>0$1G(Q/?7^DI#(&K(+-*>B\[VK:V!.*>NW&S?4$AK
MA5HDH3H#"@46\@%%=[]<UM\MZY-)^V22'K&H6R@4M[=UU%;6E>3<2([*#2&E
M43R2?.PCG<TB'4RRF-X9%!=T7$-"\ U!8GE1 1!5.L$YTOI$0121K;^/?\GD
M)MT[W\,\W?YLFNV95.N3R98GD\R->.:&/#.#)%/]I(LGPH_M)>W:='KG9JJ#
M91Z'&7C9C6)O17>P#G1U"+OB$4TB)# I26Q:<@@S+2(X/2J,'Q6>%LU)B8I(
MYH3S.&&)G/!$K'4.J @OC**# H&!(IAT#HL! NR$,^@13'1_K:\T!*)^W)<C
MWH9(1@FB]P&R;A>2+UFAXT AK15JD83J#,CE( 85"A!@I[^[NT\FZY5*>\02
M>7M[77$.G^R2P_8M" W(#?(3T#V3"/8<Q[.,\T?X1.=,FFM9-+V<QRF.#[^1
M([B1DY$;%Y/@YU <2Z6?.I3O:7F+[IEF?3+66#?RE':XD6:$D6:XX>$P@T-8
M' PW.,#0^L;GFX^.??EQJ*=]0223ZGZ)8'4AP.8BQ=Z2Y3;O)"XM((Y!2F33
M>,$L7@B;%QJ4%!J4&!H4'\*."PWBAJ 1&\R."0J,9K,B@808M' Z%408G1I*
MHX1A.R#6^DI#(.H'NF)L$'*;CGQ!16I#8!_2\AYK=0ZT,&J1A.K@0L)5]-!&
M$HE"))*UM5879*3ZVV>SO/." _)#2 *:>Z*O79C]&<KI RG>%GR24Y3+V3@?
MVTAW\P0&@>/GSG"WY?I:E2;0@]PM"]@!9:&D%&<SSH7OPDST@HRTZ$?W4K1V
MT'5VLH[N#CRZFZVWBW)H\^4M?S_VV?O<*ZZ%,6R:^R4?,Q,_B[-$&U.J@S7;
MRR7<URLRX$HTV8]+)R4$TN)8-&X@/2Z(R64S8@,9L6QF#)L9'<B(!"41D_Y0
M131**)4<@@5P$HA@"FFMKS0$HG[T9R-?G$=L=B&$7"3ETLK=& N%M%:H11*J
MH_300Q6)Q7*1J+M+*&UOK2_-2_"Q3J=Z9@>!(HE8$.P')!3C<H%R^A#7V23.
MW33)Q[8R,[&80^-2O>/H/A&^S@G$2Z5QC% OZQ*:=PG-DV-NR#I[/,C4,,S:
M.,K9G.MI&^MI$^UAS?6PC7.WX[I:QSA<H%VZ* BE%"=Q&-Y. 786H#RB.%K1
MG.V"O-W"?+W"_2]SB%=BJ/ZQ#%(,DQS-($<S*6 ;Q:!$TM'@T,AA%!*0$.XA
M/("!@LA$$"'8/IL4L.1+-#X^_OGGGX/M,EYV"$0]F$1N<)' 3&2H&?$(7+D;
M8Z&0U@JU2$)UE"K"XX&-NF1=G9+VUH9KA0F7K=-(;CFL*WE!A)P@7P'5G>MF
M1C8^'&']7:2CL8#D7"7@%G.H1"M#<\W-GA<-DDCV5Z,I9/OSY73O<JI;B/X^
MDN86DN;79.VM5*UOJ-K?TK6W,72V,W5W!.KNH!_\E^_7[YW=O#'6USDSA$)V
MM278FI(NF5,<K!@>CL%7W,-\/<,)7D!(411"%-4OFD8$$4DC<J@!$=2 < HQ
M@DH*!]8A!023B2!"*"341D!%I  VR3\(>QS8*)#HO[3K SS$9#+-S<U/G3JU
MO%<>\N\\XVV/J\SSE>W: H6T5JA%$JH#2B)E/+214"@5=HC;6QJNEZ3XV:<2
M73*9E[,""=DL7P'%(\[3G'[^2- %[6B',VE^=A7)$=?C KD!KN[GCJ?'1J60
M'0HCB'07JUMT[UM4-[;>;@KF(9KVM^A69QOCR';FD1TLW9UL5$A?^7[]=Y/-
M_XB^[)@30B$Z6OJ8&_M;GB5:7:0Z6+,\'-G>+FQ0)Q&\.61?$%%4_Q@:*8J*
M.BF"ZA].\0\C!X22_(.)_L&D -Q&N)#81'\0\V8B^B]-2+B-Q&(QV %"<G)R
M6O;K#WF4A=_#:O(.5_)\9;NV0"&M%6J1A.K\NXUP(<F$'9*VUH:;9:ED=S[9
M34!SSV!X"VA>_  7KILY\X(>Q6A_A(UA\F6KTBCZK>3P=)J'C\69[$0NG^:<
M&T:@N=F""NDFR9FEMPM(B'YD.QX,W1T@F+H[42$=W479_]7ES7\_O743Q]LQ
M+Y3J:VOJ;78FP/(<R<:,ZF##=+4/]'0*]'8) 442R3<2#0(04@R#'$4G15#\
M0823 T*(?D%$?V CM-,(;"DDX"&6/R$PP _8:,E"4MI(^>7?_O:WYN8?^0IF
M:\OS]1'_?&6[MD AK15JD83J/%5(G1W2]M;&6]<SZ%Z95+<4?^<THBN?[)KB
MYQ#K9@J$1#B^(\+J1**G:5Z0SYVTZ!(.A>9BFY'(%3#=4NG.9%?;<JI7&<&>
M=6R7TD9H8$)2.HFX^W]=O_@?@RV?A7O9YX12W<W.>%TX%6!YGF1G076T83C;
ML3R<@GT]POR\T58[,B&2Y >$Q&52@9/0(@FMD/R!D())_J P4O8A 2$!&P$G
M 14%8>UU3'_"HB[+8S;"*2LK.W#@ .Q,6CF>KX_XYRO;A1@=1>KK5_0(4$AK
MA5HDH3K 0W@ &RG;Z[!MIZRCK?G.K4RVGX#LDNSOE$AP2O9S3+IB%^UR@7E1
MSUOW&X[%T017XPRRTUT^MS"<G,#PX\=Q\SG$.#][?T>KZQ3W @\+]K'=N($>
MVFA>3COH.MM]MG]B]>D[1S;_,\33+B.8[&!LX''6R-_R/-'.' B)ZF0+A!3N
MYQ41X!-))D13 Z*H ;%,2AR;'LNB1C/('!HIG()62"$D_S#:O)! A81*"!,2
MV*+E$;:O^C5YHHUP]/3TB$3B\EW^'SD_V,NR0OS(SFCE3F<>4/?;V*SH$99P
M%BMQXJMT/1\<:W4.M#!JD83JX.41KB*ED+! A=1:?2<[@IY"N)3%\$[PL8WW
MMN)Z6G <3.CG=3VTMX29ZG"=3J5>L:H4Q)5$4?E!Q/B@P+1@$MW9@F!O4>CO
MS+<[$WQL#_/H3A"HDW M'=F.=R:1M;YQ^?K#,QO7:WR^,=C=ENUQR<7$\/+%
M,WZHD,PH#C84)QNFAV.8GQ>HC=!1=G12#)W,#:3%!S& D[B!]&C&_[%WIL]M
M7.>:]Q]PDR^I^RE5\VFRU-1,I5R),_<FMF-;LK5:&[5Q$2GN!$'L^]KH;C0:
MC7U'H[$3)$%0W*E]M61)EBW)EBUK(261VNT[<SVY*==D&=VDYS2:1*B-!BD
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M??KT$[]<['UP*1_52ZA"LV#YN[?T[Z4"I,(VHZA_'D_459J*%E99-")_/?T
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MP^GIR8N?C#JA-,+?ZX%/QIV'2',:E43D+1[.=KSFO6#;!JIK&\7;>C+A^&2
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M*Q?.')\8RD0"01RVJ,1VM<2MD[MU"B^D\C/;3*#=+@*8I S)Y-H-A . 2>S
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M)F]]>>GT<"JM;P])&A+:SGY</N&!#_JQ?2[=@('K;-I MJV+\39&>)O2FD8
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M9"F2C,.0<AC)_'B]Z]V<OD8S0!JH+RFH[P.#[05E5RVJZVDE^,$5'"L'M>6
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MHDK *\/QGY&7!P->81)UZ1<@W0ODGYN,EG$O.YTV@/N& 6P> J8S$+# 5R%
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MY7%N:Z&'E$$RSR*:Y?O8'XX5WCH2>_MHY-$$0=6NX*9O(TL2Y#NVQ>[,2"I
M>8,A!\%/YNM/M-?AWNVIL:E1P4%^3!$5#X$D0/(&(322,,F!')J*QPX6^&%
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M]U&+N&$B;J14$*L(2$ G(<6'R!-^0T :N@_"*>#P:8!;!/ZR"9S0GG*/Y&(
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M.IC$#.*QU$)?+/@[3AF )&M002:]5R#]JM=-[U%@R 'B32#F&-@OQ::.OM;
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MPK[SEDR[?0AJL(!>R<+9'#Y:8_]K_R:C!M2'ABYO]AK2^TXHAD0:>PGHJ_]
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M:L 6D#*K C(5DD+LRL C<)*:X/JPR.8Z5'=S[7A_^]A Q]S$X.SDX/1(S_A
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MHW$@S2\:X7"?OS-?BBW%SU*C XD*HHE.K%?O9Z: D5>28!I-CA'P-6-#_3,
M2&0:D8$T/%!7F(*.]ZM(#L0D^C55Y$UW8S+]K$-LM /-U=UT$!E^-L@HS_P0
MU[P0I^P NQ1O\P1WXP@[+5]C.4R494VB/2[1O@6=4AYECHVRP,98%0;HEX6:
M%@<:)?K:E,1Z-B(3T%E1U06),)#R$DE)[5+P93EUZ)SZ\EP\)K\.4P",4 4[
M1L :X(CPXL:JDDY"]5!W,TR=H=[)T;[)X6[@$@WWM  : 2:-];<"4$UO#$CM
MD1#C#4C'#-(1@QAEH?;E-\:NQ4/:JK!O-!K^U_YS#T"4C):!1%XT,C:F+QIM
MKBWRC98U:$%RAZ5W'AU(FR*:Z,1Z19ZR R@BS]J9&>F?93W50JB?!7X2R4."
M_:31H8GAP59L?G&4=U: 8ZRK<65I[E1O14&D>ZHO8(]-K//K;'_GDB@OX"1E
M!SC%.)F$6NL%6VI'VAM$V.D5!)A5Q#J41]G49/J5AED7!9D@@TWSWNKGOS4H
M"C2)=-8OBO:HRHE 9<!3=I5Y\97YR=7(=+@J$BJKIC0+8(D$I$)@Y'4CX!L!
M&C77P'7Y!CL:1WI;21D9>F<GAJ9'^T;[VDA (H[VM4P,=H!# %?KOS!S4*0,
MY%U+>CY%86/L6H"T51MCP6!J9_?9!R!*1K- (B\:!05]_IY\N?8W?I8>_6O(
M7G;LI@-I4T03G5BO" UX8+75E66E2 \7N\N7.?B?/.QH(<Y-C@(#6"*3:7)D
MJ+$L&QWWMB(IL"S^#:&F;+JGLAU7--;=/-7?/C70,0V&_L'.R?Z.B;[6\=Z6
MT>XF8"-=A/_/WGE'M76E:]]S)S.3/^:N>[_,NID[WTRJ)Y/RI3MUXB1V;,=Q
M2^PX&+?@$IL88XP=FV9Z+S+5@.D=(20$HDJ 1)=H*@@0O8-H0JBB"NQO'PED
M;, V$(,<ZUW/TE(Y')TC6^>G9^]WO^_D4,?$0"NOCS/<V3#8SAIJ8_1S$)QT
M-=(Z6940.:WUE.;JHM:Z8D8IH9&:SZ[,XR /*2UU9$XMN9U1WE)?VM%0-=<Z
MMK&FKX7>T8"L3QIH8PQUL(4C/;+)896$IQ1/0"!-38Y ( F&NT6CO= >R85C
M$$BK<D@S@.8-C+U!12VHR !&>T#%TD-V]_\E^ B!!'_7PTNJGH\U00NB#T""
M^%EX&-I)(WTXL-^T=*/62[QJ -*C#[TXB)6&=@YI5BV?4<EF5%/DHH*K%A?'
MAP=G%%*H:3DBR"2%1#383*O.BJ5E)Y1E);>QZQ2CC9VUI)'6^M%.UDA'PV@G
MF]_'@1KI8/5SZ@=;Z7V<VM[&ZB&X03M]LJ=AHHL%Q>]K&N^H'^MD\+J9W-9J
M;FM-'YLZQ*GIH%,89=GLJKP&I- J"0*IC5[25%T$'5(KO;2-67%G82RGOIU%
MU8S=U8_WMTK&^R%O()#4TDF9B"?E<Z$]$HWUP>=E@E&9<%@N'%WED-VL"!1&
M@)]/@Y]O@,).<.^ZV ?/(2V<3/KUO_#P(GOLV(9?=.ZGZ&A].4+=3)MATF@=
M90#2QH9>',2*0ZW0:E8%F21';I6R&>74K$;3<@F4%DC]C34-Q.1N>LEH+Z>9
M5:WDM10E^&>&N. "'-"^MKGA[G7XR"K,+5*45U&T3VZX&^&6<[J?3:R3>7[8
MC9:\P);\H):\H/9R# /CQL1Y0Q6%7:U)=<&BKC00$]G%Z+KBC,:R' 89WU29
MUU">VUI+9I1D-U04M-26=K JH4GJ0-+MJ-!:04&/-=#&1#KR"<?5DDFU7*B4
M"^4BWM3DL&1B2#(^*!>/*80C"M&H:FIRQ:6#9H8!H12TU\YU&[IOEMW# .F1
M3"#!"ZL^IS/0Z<A%1Q]6F.IFV@R31NLK Y V-O3B(%8:L]-*1!H@Z029I ,2
M]$EJF40I%8^VLVJR8BNPMVE9\1P(I'%.65HH)3&P.,Z_, :5'^E5EQE9GAI4
MD1*4<\LY(_ &-L .YV^7X6^7&V+;DA?0513661C:74-H(P:W% 1!/I7'V$(@
M9?A?;B FL,GHVD(LBY+%)&<V5N1"(#54Y%?DII7G8IJHQ2UUB$G2"1GN8U,'
MVUF"D1Z%>$(M%ZF4(K5*K"E>A_2;D/&'E5+XO%"M$*KA2TKQRCZ4Z1X0B ;T
M?(!"S2MP<98=$H\H=^Z!@C_PX456GR^LT(7H23ZZ=J;-,&FT[EH#D A@N!4T
M="W9]F5U80#28Q+32J!ATAVK!!V28LXA:0?NU#*Q0BH8;F<U%V,Y9"RK(*6;
MPU;Q6_.C??#!+NDW[5-];'&!#C78\(KDP.P0I[PP5WA+"'+ ^%I%.UQ(][W2
MDAO05AC:3@SJK,I@X[P:,WP:\#[ET3;5*6ZXFU?000Z)@<X^]E?M+4TOG#IR
M[.">W5]\\N';K[[UKQ>#?9WHI7D-5:26^E*H=E9E*Z.BHX':SJ*.]' $HWW*
M*8%*+IY%R@6)I^4BA$:"$:68#VDTC32AD$ F3:NDJ_ED)(-@0**Y-PO&FT#'
MO0X)B8T"$KS"PNOL1E]QEI7^#-9I9]J\O R31NNOU0)IILC/!"F28K0=F,0#
MR:_#) .0'I.8'Z^[(PV0YN>0D"$[!$@2P7AW,W1(E.20XH2 [B:Z@M=4FAI2
MDAQ8'(\BQ?CEA+G5XFZ38WTI<7[0(>%NVF)0MMB;=AD!]JG>5\@Q]H10FP1O
MBV"7JW;G#E\XNN_HGFT[/GG[PS<WO__&/XV_V[/WJ\].&W]K;7[.U^%:M+\[
M+BZD.#.9499/+<3547):ZDI:ZLN@6AGE'.2VLJNQ9J2G13K!5<N$TTKIC$H&
M@:243LI%XQH@(;9)K91JF"2=5DZM\$.1 'PPL-P']EEJ[)$O,-FU.,L.B8T"
M$KR\ZL-HV)*"UWW]R;; 8L%++X']^T%4%()),S-]R;-X K1:($F89SX#%!X
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M#8AD"(KF'=+"=4BJ*9&4/\(BH<LPX44)_L0HGY+$0$IB0&&L7T&D=S:2VN!
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M^HG@A1T(BJ W*@\"?]V$M%KWSP?^YS3C<MRYN:)[AN:(#N"'Z/FDADW@TVN
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M2%H]_SQ(2%@3D X=0MBV<)_+;6SH37Y?O?67OZRQ8ZS#V;.M%,J&G\BZZ:&
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M*60BA8BGJ:G:+Q.,P"<5LDGU<@Y)S0*6W@"#!_1&$&$-K+(7OK:@8^SR\8B
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M%B+%28YEIUTJTMRXT4>/;E]]RNG7TWYV1RRV^#D?D19ERGA4*3='SLN3\0H
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MQPEH_6+H"L6H93XL&R6DU\-ZC/55'_6J473\VM&J8:-Y"0$*7*2*$*7$10+
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MMV@VMV'+=+!@D,PBW.RB/1V2 SQ3&10!.RB%#D#R3PL-SHA@9L>PD;11>ZI
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MZ%_?>4?U88>M+$< 27N"G_#H"3Z? $B0!KD@FJ5Y?O-76[9H_KC:Q=3Q6K
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M7#@4='8_P^(LAVP<[6X2Z6H>8'4CCNP0YF(9[6D7X6+)=C2-)]MS EVY09X
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M>$A4RZM7#^^U.'W\XC>':7(@&=-M;]/M;H>0S*(\[./)KAR*%X]&5CA)?@(
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MZU@?YY0@<C+5)Y'BE43U3F7X"UB4W)B0O%A63@PS(R((I(W:TSR&A/74K66
MOM<=2!I<M]6Z_?6 D[\'(+5MVS9G9J;[&@!);L\>#D@RPQQ/?_P#G:V&S&RQ
M;'(E4)H_H\>2E "2#Z?[ 9K>?;\\VHM$3AG$P6>RMSC$P3.BM'T%^;\HQLHO
ML<:&$>@.#DAHY[G;!&0:Z)T:'WMP;W2\O_/YI/ 7*$+"L(06<1AH;^UMKNL5
M54L\322N1A(70U"#JU%'-D?:*!9'!=7:7:VVN5)EK9=]_5CFY2/AW^ZO2@P1
MYR4+LQ.J,^(JTZ*KTJ/*P[U=/M_H_OE&MQWR678.9_>Q;2]ZWCIO>.*(Q873
M3K?U_<T,_$UNA)#,0YVLXGR<DP,\DH%&%._$ "\>S4_ I&9%,#(C&1F1##X[
M$*2-VM,PRTYIW @Q25I6AF;9:4F+?ZRH?]"L#R#-=YS0:R0+'9V9G_YT3A%E
MX[4 T@M[?*>S+,G?]*L/;Z9J95+#W+W!VG@O1U=J;')J2G)$@!O)@U70K#CS
M=$#6+BQ-BZ>XD,BI+XBU(GN]@:2D%WSJE:L?'*;OAI<P&N&QA/X$(/7+@53?
M(Q'6>IH5F)W+,3Z=87B<?^UK87*4K%F2YD5B?;.#?F0;Y>!6_R\_R;A\..+D
M_M)$AC KKBHMNH(?49K"KA:P(V]\Z[+](Z"1V^<;[?[Z%_NS>T.M+WC?UC,\
M?N3VN6]9[@[^)@8!I@9,>PNVLW4LV3DQP#V9ZLVADI,IWBG!_AGLX.S(D+0P
M6GH$G1L2 -)&[<WW'A*:X:WT8(4CF]]^V^#H4:7(;_#GA3U[_OK.._AN/?Q'
ML+#HFC^B^Z8#:?$764D:[*R&9"LOS")O:N6WL[IY+;Y($SHZI8</8^E?'R ]
MMV>/'C[2RJ0&N=V15<4'>3K:D1P]:!%I%=//#X^D4QSM[!Q<*?'5?[?O(=T=
MZL<$^,%VU/+I^?2'/AD>0DI.T@L@-?35"<N<#(K-SY>:7R@QNU!L>K:1%]G;
M6E\>X)1C<"SS^E?IEX_&?[L[X]+AR),':@51-9DQ%8+(LM2P$EZHB!OLLF.C
MZXZ-[@H@D3[;0#KS!=/JO)_%%<-O#AF=.<YRL:68&06:&S$=+.0>DJ]K,M5+
M'FDBT > !!Y2.IN6&4X7L(/2PH/Y[""0-FI/%4BHIPZ8I':E!A2@3PD\\!$X
M"*!2BNF'+>Z@- 0UWT<((,VMMB.U\EQ>;3FUD==BO@BT2M!W[R&]AD!:>5[S
MG'DVT%R16211Y_X\[FX02YJEJ[A4P^L*I,GA 0Q+^'T\JY[/=.B73?3)QGM[
M$(=@!]O'@"0/9-X"0*H6>1J+70W%S@:UCOI"Q^LMJ='2YKI:BGVMS84:J_-5
M9N<RKAS*O'PTZM1!KL.M;)9W8710*2^LB!.2039WV[/9?>\6]]U;@$PV6_],
M.OT%P^(\S=;0Z/AABROG@QTL*9:W@BQO@8?$<K1*\'?G!9-30_RY-#)'/H;D
MFQ%&S8JD940&9T6'9$;)I8W:4P42UE.GNI8=%J /#QCL3Z68?O@_%_D1 DBK
M6 PBK^6KI@;^BZZ^3D!Z,E%$/GOZ93M++IK01I=JX&B!  !2_DE$053=DZ;T
M(#M*^NIX0 L68TUR64W#(*1.RDRZ,R#ONP,@(29A.QB6T+P&\)#ZVAI[&T0M
M@78MON8-GL:U3C?*;2Z)HVG2QKITZRLIUX\F7SZ4<&%_Q+>[,BX=C3QUT'_O
MIYX[-@6=_4J8G2#)CA9S ^I3 FL3R56Q'N51;L)X<E6\=UFD2VFT5T8P*3V8
ME$TG)7J91[A:\*AN*32/3'9 3F1P;A0]*YR:&1:8%4;-C:87)K!R8D,*$L/R
M$^321NVI @D_PQM!"*WVC7>8,*(HD08#C&K V<5\A #2*A9CF5KB9]],(%V]
MRGG1*.;4 0G%ZYO#A3#'VW<M2PNM=;YIW[.C;37/K2R=>O7#'[R[WS:U\^'R
M^^P(("W35#FDRB=\/Y["2>K%@(1M\4 :E$^T:^IM_'_VSCRHJ2SM_\Y?4S4S
M55-3[SLS_7MKIMZJZ9JIF7Y[EFY7E%90UD81%Q85 94M0!)V$L@*V?<][&$-
M80F+R"*R8[NBH( *TJB@J."..\O]G9M "%M (2S=^=93MZXWY)Z3*S<?OL]Y
MSKG7Z@B(4L0!$*<"G2N"7"Y*J7?;FT\AW4[Y'BP^[E3HN2?+V;K<>W^6QS[1
M[AT,&[,XZZW)01X9X=ZY,8@\G'\.UC<[RB<[\D1:L$=Z;$ Q/^JDC)(G(.8+
M8]4BBI*%RZ1'Y_'CU")&A4)T)E-6G14/TRA3?B8[H5:5#(!4EY?66)C5H(;#
M&%?/\#PD (GPPX>MOOH*;*>-&P&NV'S]M<,WWTS+Q6G?<L#,;%KZ;B%O,0%I
M";OQF6$"DE()V=K^SWQ FN:0ULUP2RN2LAM[=Z]1CC S0\@;[RT"1N-MS?&*
M"4@&]6K@X;28U2U-2=SI 4G?).EF)L'38[MNW&^_VLP(N1H;"**9'-!,0ERD
MHJZG<"]%'S^//78VTJ,Q]$BICQ, DM+K@&C/#KKUEMB=FZB[-M&L-U*M-C)L
MS>"PV4K=M9FPXUNRY_?Q45Z*N'!I#"J!$)E$QJ3&8A5QF&PF2<F.S1<Q2A)X
MI8G"TB3X,4BG,Q*JE<GUN6FU>2#2M6&,JV<"TI)_8_[/; ]V6\XNF8#T^='1
M ?W[WU!3TQH$TL=G[6J"H[DC0=W^[.,</_-I;<WQB@9(K-2B"L.J.G_S_A)T
M8_&G6&;ID*-/HYE\FC&2-)ZX>Z[]IV9?.Z0$FZ2>[H>W;S[HN-HNP-Y@A\'!
M";_)#>]@A]QD!'<P@]OHJ&O4H%8RHA;E6N%S,.?8?I&C)=-V*\UZ"]5Z"QU
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MZ,NGAO;[5)<E6P$@F>(G$?,":95-C/UP3X5P2NF8+/?^V)'BA%#=^_Q%?$Q
M^DSIXV?<%>E9I9FSE.#0=TB:&@=M@8,V7S?8>T<+I(<W6KK%^&YA=*<0>TN(
M[11$W>1'=K#"VAFA[;20UCA4*]&_!G6XTL\93MDY6+#MOP,H8MAO!4&SA2L:
M*+LT#FG79MQWWP(@"8(/ R ),$A!%$J"A9D$'%(V)Q8&$A<&4H&0>5(NT(XA
M564DUJ@4#6IE?4$VV((PQM5;M])WOBE,L79CFBN:?F<9X6Z=Z[1C0]=2CNWU
MP$LR"M1J50+>V<8KY9IQGA@[>K^E2CF_\DZW]'Y^\[IN+/X4RRQ=ON[-TP%M
M3!M5FI;*TP))6]TP7N.@@1-<?3>1LM.,(=U^W'6S@8RL0+J=]#]0Z..4Z^60
M[6Z;X6J3=M JT6F[?(^YU&Z;]/MME?[.&>Y[>0X6=-MM5)M-=+LM $A4&QA(
M<1J31-JY$6O^#='+@1-\2(Y'\Z*"A!J3),(&)Q"BE!R*2D#+YL8I>< AL<H2
MQ16I<A"GTQ)J<Q3U!5F-A3GU^5GU1BO[UD\[Z"<?9FK6OP<7* .G-9*,<;GF
MO9@K_A5IBB4)W2_\NMGVIVDU  F"2[_O-U=FR]ELMCR[LOF^T59J&+W=F"N9
M7W)EXZU%]4#;C<6?8IGU]MG@7*%#E#ZK8"P-/!IZ_' \-/LZ,FE'DF FW>E^
M=/-Z,PU]A1QPB>!W">][">=](>9$4Y1G8X1'?9A[7<B1FB"7XN,.6B#Q]UC2
M;+;&[8++ZJBVF^.L-I%W;B);;@1!M-0 Z=AN%M(5!E)D("\2R<>@!)$H.2XB
MFQ,':)3))H-M@09(E:GR2D4\ %*-,E4+I 9@D@JRC7'UIMUOVNU</[G(AA;S
M]D]JR,"G^-GK/:3&0<?PT*7^E>[)Y^OMV[=/GQJWR$MW.TP[LIJ!M.1M+4]#
MAK4J.O%),@ D74SW3X./7D\PZ?54(&D3=QJ3U/WX1DL[']/!#F]GA5QGHML9
MZ'8Z^AHUZ!HEJ#4VH(7L?P7G4X=TJ?0[F.'NQ-]M"5!$WK4ISFHSU7I3W*X-
M $6Q.S>2+#<2+#=$FO^'[+6;$>0LQ2&YD8'<"*0@*I@?@9(#A\2C9W.I66PX
M<5<HTSQX0A%?E9E4G9T"'%)=7F93H7&+&DQ ^CGI-92"A+S04'KS2O=D56NM
M 6DY5_LV\/B)I=?:NXT7;H]TV3S@BE[KF23]W)T62/#J07>['W7=:.%ASY,0
M30 \V&/5$5Z5H>XG@]R*$2Z%OOOS3SBI//9D'[:K\#V8[N[$<["@6&TA 0+M
MVD3<"0?@$''G!G"$8+D^TOS?)$\'>N!!:0R2&Q$ @,2+0 $@R? 161QJ%H>2
MJ0%2D8QW,D%4EBJ#9\6JTH!#JLE):S1R48,)2#]7O81J*J'^Y?EB66-::T :
M?74^GIA1VSQ%78/#R[-2PXN:S(0E2=#-T@UCG-2HTI)&9X/T4:1OC";S=7#*
M#C9&$TR:91A)L^9W]Z-;'>>)@3]$'6N*]&J(\&@(.UH7<J0:=:@RP+G<?_\I
M7Z>28WOS#]E6^!Q(.[J7OWL[Q<H,;[D19[$19[D)#V?J-@![1++< ,B$V08[
M)  D&0Z@*( 3$<0-1X(01X>E,\E9;$H:@YC))H\#*44&[%%#7@;LD%3IVHH&
MXQ4UF(#T<Y+&(7EX:.( ].6?(8?#$+YRI7NUZK36@#3<KT9[J)>@B$"_K3E>
MF0FD@0H)35+1MH2M3W;#&"<UJN9R13--TF2-PX0] BC2[4P#$CR&U'&UC1MQ
MG1%\C1[<2D.W4I%7XX*NDOV;B;X78WS.8T_\$.%YVG]_I>]! "2NPW?DG9NC
MMZ\' 9B$M]A U#@D_,X-T1;?1IK]*_:X(Q/I(HM!:L:04, D<<*"^)'H5 H>
M "F=24IG$@O$[))X(7!(\ PD#9!JE6FUN1EU>9D@C''U3$#ZF6D,ZJ^#7/\-
M?>D*E19!#N901B/4.;C2O5IU6H- "G)@EZV00S(!24^SFJ&9!Z>4VPU,R=2!
M?5T5N&ZEAH&>KD<W6[L2R;<E,=UB.#J%T3?X4>WL\#966 L%U4P.O(3WJ4:Z
M:8'$=-A&V+D)LWT]YKMO 9-BMG\+C!&<P=NYD;!S0\2V;R@G'+GH0W(<2A@9
MQ(]"\C& 3$@1-E1!(^;PZ$HN1<FC%$JYA5)^N09((,:'D?(S:O,R:TU 6G!#
M)B#-HW=W(+8[Y'@,VFX#+6+NY$]8NMMA(96BJP-(_E]:'%BA)\::@*2G:7Y(
MOPI\UOIO>+K25"#I1H_TEPX:Z+G]L+.]-L;O5(!SB>]^]7''?"^'''?;+-==
M&<X[4_=;)NPQEWR_-6'/=@ DA;LCPWX;<>=&[(X-6$"C'1MB=JS'6ZPG:+)V
MX#@ $LW'B1]R! !)H 52%%* 08NCPQ1T8JZ F<.CY0KI&B#QRE/E@$:P/<I1
MP&3*33/JXR=,0/I9ZCUT3@K]U=($I%GU21,55@>03"F[U:%Y"QEF-TD 2-K'
M56CS=8_ZM0LWC,^-O7=G\,Z/_1W-;<S0%@JR)2[H"CG@,@EQD>!W/L;[!^SQ
MQG"/^E#W&J1;V0G'6G]GI>=^D=,N[EYKFL-W(!C?6]#LMM/A^(YN;\ZP-R=;
M;0% $D>X)Q*#!9$! @Q*'!,BC@Z5XB+2F>0< 2.'S\@3L@K$' "D"H5<BZ)J
M9>J9K-2ZO*RZ_&P0QKAZ)B#]S/0.JLF'FMJ@H<4LO/G3UZ=.LYMYAN4%TLA
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M!PHI/N!P0N!A/L9/C ]1 I!BB1D,HA((%$]*BR-J@,0@IL02TMD4<'/4GJF
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M(\Z_]>M]AF2X-7EL)24E@8&!4Q//$'-Q&3:*X;ZUM?%/Z+XYQB^#AAZX9;I
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MNX*/(',4[E]N+CUDO2I(G)&ML9RZK_H-)372H$GU]/3\^../%RQ80" 0 $A
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MIQ@?),0%)$;XR4EAFJ6^XPC@H)#R./3"Q(1" )*$6R+EER8+*U)%X.:HO<D
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MOJ\2XW8L;.^QD-UE <[%?D[EA[<>\]R9Z;I)NG4M;^-*UOIE7+L5_(?R:(4
MI-*&Y3R[I53KQ4G8?=GT %5\E)00+,:%2/"A8KRFRTZS9 ,V.(D4 0I)N]IW
M3'8"!112L8A5*N46B[FE28+29%'I$PFDFIJ:7V8[!C/8N)KOLK*R-JT=/GSX
M@P\^J*NK,T=(0#@0H*# D.P@ESU[]KS^^NLH@QQ7B;A<;G-S,^1"I5*!$%55
M5>90O9!F?GX^I"\2B2 OR!&#P?SI3W]"&>2,!=(/74K/W<J.QZ,8?NI0NNX6
MM]W5N^;^3[=NZ'9J1I.7@3.S0#)J8^+'*) >]]<- ]*-GLM7&VL[N1$=[-#V
MA. +<0$7*+[GB!XMN(-GP_<U!.\^Y;^KQM.Q8J_=40]'I;.]>(L5?],J+J#(
M?B6@"( DV+ 2@"3<M()OOPR )(O8JZ(!D/!B?" 02$X,ET:%"B(#>&&^PLB@
M9')D2C0NBQ$--,IF4H[P& "D$@D'@%0VG4;9F3;K,:^QMK;^93:L,X.A;.]Z
M>GKFSIW[\LLO XDW;-@P9\X<<Z^-O7[]^K???MO3TQ-$&$2X9,D2-)\:+Y!
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M;Y;LVZ"B>I;RL?FLJ+3H4'5<5&HT)HT2"9Y.Q263PI0T7&8<,8M!RF9% XW
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92!(A_3__9C#BB>W,N0    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034475936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 09, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AGIOS PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0662915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">88 Sidney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">649-8600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AGIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,557,785,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,194,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement for its 2024 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the end of the registrant&#8217;s fiscal year ended December&#160;31, 2023 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693036307376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034788736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 88,205<span></span>
</td>
<td class="nump">$ 139,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">688,723<span></span>
</td>
<td class="nump">643,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,810<span></span>
</td>
<td class="nump">2,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">19,076<span></span>
</td>
<td class="nump">8,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">35,021<span></span>
</td>
<td class="nump">38,955<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">833,835<span></span>
</td>
<td class="nump">832,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">29,435<span></span>
</td>
<td class="nump">313,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">54,409<span></span>
</td>
<td class="nump">65,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,382<span></span>
</td>
<td class="nump">22,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">4,057<span></span>
</td>
<td class="nump">3,956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">937,118<span></span>
</td>
<td class="nump">1,238,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,780<span></span>
</td>
<td class="nump">18,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">43,167<span></span>
</td>
<td class="nump">30,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">15,008<span></span>
</td>
<td class="nump">13,663<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">67,955<span></span>
</td>
<td class="nump">62,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">56,988<span></span>
</td>
<td class="nump">71,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,156<span></span>
</td>
<td class="nump">3,279<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">126,099<span></span>
</td>
<td class="nump">137,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingent liabilities (Note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value; 125,000,000 shares authorized; 72,161,489 shares issued and 55,945,078 outstanding at December 31, 2023 and 71,256,118 shares issued and 55,039,707 outstanding at December 31, 2022</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,436,523<span></span>
</td>
<td class="nump">2,386,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(12,535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(822,649)<span></span>
</td>
<td class="num">(470,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost (16,216,411 shares at December 31, 2023 and December 31, 2022)</a></td>
<td class="num">(802,486)<span></span>
</td>
<td class="num">(802,486)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">811,019<span></span>
</td>
<td class="nump">1,100,814<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 937,118<span></span>
</td>
<td class="nump">$ 1,238,718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034415632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">72,161,489<span></span>
</td>
<td class="nump">71,256,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">55,945,078<span></span>
</td>
<td class="nump">55,039,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">16,216,411<span></span>
</td>
<td class="nump">16,216,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035266288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 26,823<span></span>
</td>
<td class="nump">$ 14,240<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">2,881<span></span>
</td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">295,526<span></span>
</td>
<td class="nump">279,910<span></span>
</td>
<td class="nump">256,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">119,903<span></span>
</td>
<td class="nump">121,673<span></span>
</td>
<td class="nump">121,445<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">418,310<span></span>
</td>
<td class="nump">403,287<span></span>
</td>
<td class="nump">378,418<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(391,487)<span></span>
</td>
<td class="num">(389,047)<span></span>
</td>
<td class="num">(378,418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_GainLossOnSaleOfContingentPayments', window );">Gain on sale of contingent payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">127,853<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty income from gain on sale of oncology business</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,851<span></span>
</td>
<td class="nump">6,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">33,344<span></span>
</td>
<td class="nump">12,793<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">6,055<span></span>
</td>
<td class="nump">6,749<span></span>
</td>
<td class="nump">14,433<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">(352,088)<span></span>
</td>
<td class="num">(231,801)<span></span>
</td>
<td class="num">(356,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,961,225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (352,088)<span></span>
</td>
<td class="num">$ (231,801)<span></span>
</td>
<td class="nump">$ 1,604,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Net loss from continuing operations per share - basic (in usd per share)</a></td>
<td class="num">$ (6.33)<span></span>
</td>
<td class="num">$ (4.23)<span></span>
</td>
<td class="num">$ (5.90)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Net loss from continuing operations per share - diluted (in usd per share)</a></td>
<td class="num">(6.33)<span></span>
</td>
<td class="num">(4.23)<span></span>
</td>
<td class="num">(5.90)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Net income from discontinued operations per share - basic (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Net income from discontinued operations per share - diluted (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net (loss) income per share - basic (in usd per share)</a></td>
<td class="num">(6.33)<span></span>
</td>
<td class="num">(4.23)<span></span>
</td>
<td class="nump">26.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net (loss) income per share - diluted (in usd share)</a></td>
<td class="num">$ (6.33)<span></span>
</td>
<td class="num">$ (4.23)<span></span>
</td>
<td class="nump">$ 26.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share &#8211; basic (in shares)</a></td>
<td class="nump">55,651,487<span></span>
</td>
<td class="nump">54,789,435<span></span>
</td>
<td class="nump">60,447,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share &#8211; diluted (in shares)</a></td>
<td class="nump">55,651,487<span></span>
</td>
<td class="nump">54,789,435<span></span>
</td>
<td class="nump">60,447,346<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 26,823<span></span>
</td>
<td class="nump">$ 11,740<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Milestone revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GainLossOnSaleOfContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Sale Of Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GainLossOnSaleOfContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034437808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive (Loss) Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (352,088)<span></span>
</td>
<td class="num">$ (231,801)<span></span>
</td>
<td class="nump">$ 1,604,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">12,094<span></span>
</td>
<td class="num">(11,337)<span></span>
</td>
<td class="num">(1,303)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (339,994)<span></span>
</td>
<td class="num">$ (243,138)<span></span>
</td>
<td class="nump">$ 1,603,412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035407872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>&#160; Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,293,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 399,500<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 2,242,801<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="num">$ (1,843,475)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(1,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="nump">1,604,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,604,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">53,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,256,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">37,296<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">37,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,216,411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(802,486)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (802,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_StockholdersEquityDispositionOfBusiness', window );">Disposition of oncology business</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,550,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">1,291,975<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">2,334,348<span></span>
</td>
<td class="num">(1,198)<span></span>
</td>
<td class="num">(238,760)<span></span>
</td>
<td class="num">$ (802,486)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,216,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(11,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(231,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(231,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">49,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">$ 2,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">55,039,707<span></span>
</td>
<td class="nump">71,256,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,100,814<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">2,386,325<span></span>
</td>
<td class="num">(12,535)<span></span>
</td>
<td class="num">(470,561)<span></span>
</td>
<td class="num">$ (802,486)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="num">(16,216,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,216,411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">$ 12,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">(352,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(352,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 44,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP (in shares)</a></td>
<td class="nump">235,401<span></span>
</td>
<td class="nump">905,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued under stock incentive plan and ESPP</a></td>
<td class="nump">$ 5,433<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">55,945,078<span></span>
</td>
<td class="nump">72,161,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 811,019<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 2,436,523<span></span>
</td>
<td class="num">$ (441)<span></span>
</td>
<td class="num">$ (822,649)<span></span>
</td>
<td class="num">$ (802,486)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="num">(16,216,411)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,216,411)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_StockholdersEquityDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stockholders' Equity, Disposition Of Business</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_StockholdersEquityDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035315536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (352,088)<span></span>
</td>
<td class="num">$ (231,801)<span></span>
</td>
<td class="nump">$ 1,604,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Less: Net income from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,961,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss from continuing operations</a></td>
<td class="num">(352,088)<span></span>
</td>
<td class="num">(231,801)<span></span>
</td>
<td class="num">(356,510)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,623<span></span>
</td>
<td class="nump">8,564<span></span>
</td>
<td class="nump">9,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">44,766<span></span>
</td>
<td class="nump">49,296<span></span>
</td>
<td class="nump">53,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net (accretion of discount) amortization of premium on marketable securities</a></td>
<td class="num">(5,051)<span></span>
</td>
<td class="num">(1,198)<span></span>
</td>
<td class="nump">6,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_GainLossOnSaleOfContingentPayments', window );">Gain on sale of contingent payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(127,853)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="nump">553<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">10,720<span></span>
</td>
<td class="nump">9,995<span></span>
</td>
<td class="nump">9,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ExpenseAssociatedWithLicenseAgreement', window );">Expense associated with license agreement</a></td>
<td class="nump">17,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_RealizedGainOnInvestments', window );">Realized gain on investments</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(604)<span></span>
</td>
<td class="num">(2,206)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(10,584)<span></span>
</td>
<td class="num">(8,492)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Other receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">447<span></span>
</td>
<td class="num">(4,378)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="nump">3,833<span></span>
</td>
<td class="num">(176)<span></span>
</td>
<td class="num">(26,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(8,733)<span></span>
</td>
<td class="nump">3,436<span></span>
</td>
<td class="nump">1,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses</a></td>
<td class="nump">12,817<span></span>
</td>
<td class="num">(1,617)<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(13,663)<span></span>
</td>
<td class="num">(10,828)<span></span>
</td>
<td class="num">(7,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(2,123)<span></span>
</td>
<td class="nump">3,003<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities - continuing operations</a></td>
<td class="num">(296,062)<span></span>
</td>
<td class="num">(309,478)<span></span>
</td>
<td class="num">(314,086)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash used in operating activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(93,234)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(296,062)<span></span>
</td>
<td class="num">(309,478)<span></span>
</td>
<td class="num">(407,320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(417,930)<span></span>
</td>
<td class="num">(1,030,781)<span></span>
</td>
<td class="num">(1,378,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales of marketable securities</a></td>
<td class="nump">674,679<span></span>
</td>
<td class="nump">1,146,175<span></span>
</td>
<td class="nump">829,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ProceedsFromSaleOfContingentPayments', window );">Proceeds from sale of contingent payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">131,784<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_PaymentsAssociatedWithLicenseAgreement', window );">Payments associated with license agreement</a></td>
<td class="num">(17,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(999)<span></span>
</td>
<td class="num">(4,881)<span></span>
</td>
<td class="num">(5,741)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="nump">1,325<span></span>
</td>
<td class="nump">964<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities - continuing operations</a></td>
<td class="nump">239,575<span></span>
</td>
<td class="nump">243,261<span></span>
</td>
<td class="num">(554,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash provided by investing activities - discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,802,936<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">239,575<span></span>
</td>
<td class="nump">243,261<span></span>
</td>
<td class="nump">1,248,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on financing lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(331)<span></span>
</td>
<td class="num">(578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Purchase of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(802,486)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from stock option exercises and employee stock purchase plan</a></td>
<td class="nump">5,433<span></span>
</td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">37,296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">5,433<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
<td class="num">(765,768)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(51,054)<span></span>
</td>
<td class="num">(63,867)<span></span>
</td>
<td class="nump">75,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">139,259<span></span>
</td>
<td class="nump">203,126<span></span>
</td>
<td class="nump">127,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">88,205<span></span>
</td>
<td class="nump">139,259<span></span>
</td>
<td class="nump">203,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Additions to property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">1,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Net cash taxes paid</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Financing lease liabilities arising from obtaining financing lease assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 511<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ExpenseAssociatedWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense Associated With License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ExpenseAssociatedWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GainLossOnSaleOfContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Sale Of Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GainLossOnSaleOfContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PaymentsAssociatedWithLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Associated With License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PaymentsAssociatedWithLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProceedsFromSaleOfContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProceedsFromSaleOfContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_RealizedGainOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Realized Gain On Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_RealizedGainOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693040411440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text">Nature of Business<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">References to Agios</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Annual Report on Form 10-K, &#8220;the Company,&#8221; &#8220;Agios,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#8220;our board of directors&#8221; refers to the board of directors of Agios Pharmaceuticals, Inc. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company committed to transforming patients&#8217; lives through leadership in the field of cellular metabolism, with the goal of creating differentiated medicines for rare diseases, with a focus on classical hematology. With a history of focused study on cellular metabolism, we have a deep and mature understanding of this biology, which is involved in the healthy functioning of nearly every system in the body. Building on this expertise, these learnings can be rapidly applied to our clinical trials with the goal of developing medicines that can have a significant impact for patients. We accelerate the impact of our portfolio by cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for rare diseases.&#160;We are located in Cambridge, Massachusetts.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lead product candidate in our portfolio, PYRUKYND&#174; (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. In February 2022, the U.S. Food and Drug Administration, or FDA, approved PYRUKYND&#174; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In November 2022, we received marketing authorization from the European Commission for PYRUKYND&#174; for the treatment of PK deficiency in adult patients in the European Union, or EU. In December 2022, we received marketing authorization in Great Britain for PYRUKYND&#174; for the treatment of PK deficiency in adult patients under the European Commission Decision Reliance Procedure. In addition, we are currently evaluating PYRUKYND&#174; in clinical trials for the treatment of thalassemia, sickle cell disease, or SCD, and in pediatric patients with PK deficiency. We are also developing (i) AG-946, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndrome, or LR MDS, and hemolytic anemias, and (ii) AG-181, our phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the aforementioned development programs, in July 2023 we entered into a license agreement with Alnylam Pharmaceuticals, Inc., or Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the transmembrane serine protease 6, or TMPRSS6, gene and we intend to pursue development of a licensed product for the potential disease-modifying treatment of patients with polycythemia vera, or PV, a rare blood disorder.  </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks common to companies in our industry including, but not limited to, uncertainties relating to conducting preclinical and clinical research and development, the manufacture and supply of products for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for our products, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, potential litigation, potential product liability claims and potential government investigations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Alnylam License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2023, we entered into a license agreement with Alnylam under which we acquired the rights to develop and commercialize Alnylam&#8217;s novel preclinical siRNA targeting the TMPRSS6 gene, as a potential disease-modifying treatment for patients with PV. Because the acquired assets do not meet the definition of a business in accordance with ASC 805, Business Combinations, we will account for the agreement as an asset acquisition. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the license agreement, in the twelve months ended December 31, 2023, we made an up-front payment to Alnylam and recognized in-process research and development of $17.5&#160;million which was recorded in research and development expense within our Consolidated Statements of Operations and classified as investing activities within our Consolidated Statements of Cash Flows. We will also pay Alnylam for certain expenses associated with the development of TMPRSS6 and these will be recorded in our Consolidated Statements of Operations as incurred. Additionally, we are responsible to pay up to $130.0&#160;million in potential development and regulatory milestones, in addition to sales milestones as well as tiered royalties on annual net sales, if any, of licensed products, which may be subject to specified reductions and offsets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Sale of Oncology Business to Servier and Sale of Contingent Payments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO&#174;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $1.8&#160;billion in cash at the closing, subject to certain adjustments, and a payment of $200.0&#160;million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib&#8217;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through loss of exclusivity, and a royalty of 15% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#8217;s IDHIFA&#174; and the right to receive a $25.0&#160;million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier will conduct certain clinical development activities within the IDHIFA&#174; development program.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we sold our rights to future contingent payments associated with the royalty of 5% of U.S. net sales of TIBSOVO&#174; from the close of the transaction through the loss of exclusivity to entities affiliated with Sagard Healthcare Partners, or Sagard, and recognized income of $127.9&#160;million within the gain on sale of contingent payments line item in our Consolidated Statements of Operations for the year ended December&#160;31, 2022. We retain our rights to the potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded income from royalties of $9.9&#160;million and $6.6&#160;million on U.S. net sales of TIBSOVO&#174; by Servier in the royalty income from gain on sale of oncology business line item within the consolidated statements of operation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the years ended December&#160;31, 2022 and December&#160;31, 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Reclassifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2023, we had cash, cash equivalents and marketable securities of $806.4&#160;million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities to be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. If we are unable to raise additional funds through equity or debt financings, we may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 30, 2020, we entered into an at-the-market sales agreement, or the 2020 sales agreement, with Cowen &amp; Company LLC, or Cowen, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $250.0&#160;million through Cowen pursuant to a universal shelf registration statement on Form S-3 filed with the SEC on April 30, 2020. As of December&#160;31, 2022, $250.0&#160;million in common stock remained available for future issuance under the 2020 sales agreement. On February 15, 2023, we delivered written notice to Cowen that we were terminating the 2020 sales agreement, effective on February 22, 2023. As of the termination of the 2020 sales agreement, we had not sold any shares of our common stock under the 2020 sales agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693040495360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries, Agios Securities Corporation, Agios International Sarl (GmbH), Agios Germany GmbH, Agios Netherlands B.V., Agios Italy S.R.L., Agios France SARL, and Agios Limited. All intercompany transactions have been eliminated in consolidation. The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the recent COVID-19 pandemic, or other pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, PYRUKYND&#174;, by the FDA on February 17, 2022 for the treatment of hemolytic anemia in adults with PK deficiency in the United States, we began to capitalize inventories of PYRUKYND&#174;.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense PYRUKYND&#174; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contractual Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Government Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of manufacturing costs for sales of PYRUKYND&#174;. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#174; recorded during the twelve months ended December 31, 2023 and 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the twelve months ended December 31, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at&#160;December&#160;31, 2023 and 2022 consisted of investments in U.S. Treasuries, government securities and corporate debt securities. We determine the appropriate classification of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date. We classify our marketable securities as available-for-sale pursuant to ASC 320,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Marketable securities are recorded at fair value. Unrealized gains and losses are included as a component of accumulated other comprehensive (loss) income in the consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive (loss) income in the consolidated statements of comprehensive (loss) income, until realized. Realized gains and losses are included in investment income on a specific-identification basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;December&#160;31, 2023 and 2022, we held both current and non-current investments. Investments classified as current are those that: (i) have a maturity of less than one year, or (ii) have a maturity of <span style="-sec-ix-hidden:f-407">one</span> to two years but we intend to liquidate within the next twelve months. Investments classified as non-current are those that: (i)&#160;have a maturity of&#160;<span style="-sec-ix-hidden:f-409">one</span> to two years, and (ii)&#160;we do not intend to liquidate within the next&#160;one year, although these funds are available for use and therefore classified as available-for-sale.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review marketable securities for impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#8217;s carrying amount is not recoverable. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive (loss) income, net of taxes. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity of the impairment, collectability of the security, and any adverse conditions specifically related to the security, an industry, or geographic area.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and marketable securities at fair value. ASC&#160;820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1&#160;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2023 or 2022. Fair value information for these assets, including their classification in the fair value hierarchy is included in <a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Note 3</a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the valuation methods during the years ended December&#160;31, 2023 and 2022. We evaluate transfers between levels at the end of each reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other receivables, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values due to their short-term maturities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, and marketable securities. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of laboratory equipment, computer equipment and software, leasehold improvements, furniture and fixtures, and office equipment. Costs of major additions and betterment are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, and depreciated using the straight-line method over the estimated useful lives of the respective assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the lesser of the remaining lease term or the estimated useful life of the improvement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate our long-lived assets for potential impairment in accordance with ASC&#160;360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is assessed based on the undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. We did not recognize any impairment charges through December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. An arrangement is determined to contain a lease if the contract conveys the right to control the use of an identified property or equipment for a period of time in exchange for consideration. If we can benefit from the various underlying assets of a lease on their own or together with other resources that are readily available, or if the various underlying assets are neither highly dependent on nor highly interrelated with other underlying assets in the </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangement, they are considered to be a separate lease component. In the event multiple underlying assets are identified, the lease consideration is allocated to the various components based on each of the component&#8217;s relative fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the leasing arrangement. Operating lease assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, in determining the operating lease liabilities we use an estimate of our incremental borrowing rate. The incremental borrowing rate is determined using two alternative credit scoring models to estimate our credit rating, adjusted for collateralization. The calculation of the operating lease assets includes any lease payments made and excludes any lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, we record operating lease assets and lease liabilities in our consolidated balance sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Short-term leases, or leases that have a lease term of 12 months or less at commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any material short-term leases or financing leases as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs, including those accrued as of each balance sheet date, are expensed as incurred. These costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, fees paid to contract research organizations, or CROs, and other third parties in connection with clinical trials and preclinical development activities, fees paid to investigative sites in connection with clinical studies, the costs associated with the product manufacturing, development, and distribution of clinical supplies, the costs of laboratory equipment and facilities, and other external costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. Additionally, there may be instances in which payments made to our vendors will exceed the level of services provided, and result in a prepayment of the research and development expense. The capitalized amounts are expensed as the related goods are delivered or the services are performed. We estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation awards in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#160;&#8211;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 718. For stock-based awards granted to employees, non-employees and members of the board of directors for their services and for participation in our employee stock purchase plan, we estimate the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires us to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, we recognize stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. For awards subject to performance-based vesting conditions, we recognize stock-based compensation expense if the performance condition is considered probable of achievement using management&#8217;s best estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 740, which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. We determine our deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also account for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive (loss) income</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances, and currently consists of net loss and unrealized gains and losses on available-for-sale securities. Accumulated other comprehensive (loss) income consists entirely of unrealized gains and losses from available-for-sale securities as of December&#160;31, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (loss) income per share</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated by dividing net (loss) income by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by adjusting weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the dilutive net (loss) income per share calculation, stock options, restricted stock units, or RSUs, performance-based stock units, or PSUs, and market-based stock units, or MSUs, for which the performance and market vesting conditions, respectively, have been deemed probable, and employee stock purchase plan shares are considered to be common stock equivalents but are excluded from the calculation of diluted net (loss) income per share as their effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss from continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income (loss) from discontinued operations per share or net (loss) income per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and geographic information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker or decision-making group in making decisions on how to allocate resources and assess performance. Our chief operating decision maker is the chief executive officer. Our chief operating decision maker and we view our operations and manage our business as one operating segment.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the sale of our oncology business in the first quarter of 2021 in accordance with ASC 205, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Accounting Standards Update, or ASU, No. 2014-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We followed the held-for-sale criteria as defined in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 205. ASC 205 requires that a component of an entity that has been disposed of or is classified as held for sale and has operations and cash flows that can be clearly distinguished from the rest of the entity be reported as assets held for sale and discontinued operations. In the period a component of an entity has been disposed of or classified as held for sale, the results of operations for the periods presented are reclassified into separate line items in the consolidated statements of operations. Assets and liabilities are also reclassified into separate line items on the related consolidated balance sheets for the periods presented. The statements of cash flows for the periods presented are also reclassified to reflect the results of discontinued operations as separate line items. ASU 2014-08 requires that only a disposal of a component of an entity, or a group of components of an entity, that represents a strategic shift that has, or will have, a major effect on the reporting entity&#8217;s operations and financial results be reported in the financial statements as discontinued operations. ASU 2014-08 also provides guidance on the financial statement presentations and disclosures of discontinued operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the sale of our oncology business during the first quarter of 2021, in accordance with ASC 205, we have classified the results of the oncology business as discontinued operations in our consolidated statements of operations and cash flows for all periods presented, and refer to <a href="#i62bc41bff6df4446af4f8c46a1b0e260_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Note 15, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i62bc41bff6df4446af4f8c46a1b0e260_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">Discontinued Operations</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent events</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered events or transactions occurring after the balance sheet date, but prior to the issuance of the consolidated financial statements, for potential recognition or disclosure in our consolidated financial statements. All significant subsequent events have been properly disclosed in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693038111792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash equivalents and marketable securities measured at fair value and by level (as described in <a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Note</a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"> </a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">2,</a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">Su</a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">mmary of Significant Accounting Policies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on a recurring basis as of December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748,281&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level&#160;3 at any point during the year ended December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693154500816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2023 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(695)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,381&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,726)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,723&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,218&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,435&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,726)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2022 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652,339&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,491)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,860&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,930&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,143)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,874&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970,269&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,634)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,734&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material realized gains or losses on marketable securities for the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;December&#160;31, 2023 and 2022, we held&#160;151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of December&#160;31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at&#160;December&#160;31, 2023 and 2022 was $513.5 million and $868.2 million, respectively. There were&#160;no individual securities that were in a significant unrealized loss position as of&#160;December&#160;31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of&#160;December&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693037603216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">Inventory<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of commercial supply of PYRUKYND&#174;, consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034381344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of four years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease approximately 146,000 square feet at 88 Sidney Street, 43,000 square feet at 64 Sidney Street, and 13,000 square feet at 38 Sidney Street, Cambridge, Massachusetts. All leases, as amended, expire on February 29, 2028. At the end of the initial lease period, we have the option to extend the leases at all facilities for two consecutive five-year periods at the fair market rent at the time of the extension.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense and other information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,170&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,411&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any material short-term leases or financing leases as of December&#160;31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In arriving at the operating lease liabilities as of December&#160;31, 2023, we applied the weighted-average incremental borrowing rate of 5.7% from inception over a weighted-average remaining lease term of 4.2 years. In arriving at the operating lease liabilities as of December&#160;31, 2022, we applied the weighted-average incremental borrowing rate of 5.7% over a weighted-average remaining lease term of 5.2 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provided our landlord a security deposit of $2.9 million as security for our leases, which is included within other non-current assets on our consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a long-term sublease agreement for 13,000 square feet of the office space at 38 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through December 2024. In April 2022, we entered into a long-term sublease agreement for 27,000 square feet of the office space at 64 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through April 2025. At the end of the initial sublease periods, the subtenant has the option to extend the leases for one additional 6-month period. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, we entered into a long-term sublease agreement for 7,407 square feet of office space on the first floor of 64 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through April 2025. At the end of the initial sublease period, the subtenant has the option to extend the lease for <span style="-sec-ix-hidden:f-596">one</span> additional year, followed by a second extension option for <span style="-sec-ix-hidden:f-597">twenty-two</span> additional months. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded operating sublease income of $6.1&#160;million and $4.1&#160;million for the years ended December&#160;31, 2023 and December&#160;31, 2022, respectively, in other income, net in the consolidated statements of operations. We received a security deposit from our sublessee of approximately $1.2&#160;million which is recorded within other non-current assets on our consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the future minimum lease payments to be received under the long-term sublease agreements were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693037631296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following at December 31:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693040609680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue</a></td>
<td class="text">Product Revenue<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense PYRUKYND&#174; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, was as follows for the years ended December 31: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reserves for Variable Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize balances and activity in each of the product revenue allowance and reserve categories for the years ended December&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,899)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Component of accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets, which consisted of accounts receivable, net: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Deductions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,077)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1)  Additions to contract assets relate to amounts billed to Customers for product sales, and deductions to contract assets primarily relate to collection of receivables during the reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693036305536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Stock Incentive Plan and Inducement Grants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, our stockholders approved the 2023 Stock Incentive Plan, or the 2023 Plan. The 2023 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based share units, or PSUs, and other stock-based awards to employees, advisors, consultants and non-employee directors. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the adoption of the 2023 Plan, we ceased granting equity awards under the 2013 Stock Incentive Plan, or the 2013 Plan. Any outstanding equity awards that were previously granted under the 2013 Plan continue to be governed by their terms. Following adoption of the 2013 Plan, we ceased granting equity awards under the 2007 Stock Incentive Plan, or the 2007 Plan. There are no outstanding equity awards under the 2007 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the start of employment of our Chief Executive Officer and Chief Financial Officer in 2022, and our Chief Commercial Officer in 2023, our board of directors granted each of them equity awards in the form of stock options, RSUs and PSUs, which awards were made outside our equity incentive plans as inducements material to their respective entry into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 12,004,551, and we had 4,989,341 shares available for future issuance under the 2023 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock options</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity of all stock incentive plans for the year ended December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value (in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,772,564&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.81&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,401)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,160,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,681&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.94&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.36</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344,010&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.55&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.94&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.36</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted was $14.32, $15.64 and $31.20 during the years ended December&#160;31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $2.9 million, $0.3 million and $8.5 million during the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, the total unrecognized compensation expense related to unvested stock option awards was $27.8 million, which we expect to recognize over a weighted-average period of approximately 2.40 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon vesting, each RSU entitles the holder to receive a specified number of shares of our common stock. The following table presents RSU activity for the year ended December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,921&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(464,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.67&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was approximately $22.6 million of total unrecognized compensation expense related to RSUs, which we expect to be recognized over a weighted-average period of 1.75 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the achievement of the performance-based and service-based vesting criteria, each PSU entitles the holder to receive a specified number of shares of our common stock. The following table presents PSU activity for the year ended December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.66&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in unvested shares were 145,023 shares with performance-based vesting criteria that were considered probable of achievement at December&#160;31, 2023 and vested in January 2024. Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#8217;s best estimates. As of December&#160;31, 2023, there was no unrecognized compensation expense related to PSUs with performance-</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based vesting criteria that are considered probable of achievement that we expect to recognize. There is $5.9&#160;million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market-based stock units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued certain equity awards that contain market based vesting conditions, in which shares of stock are earned at vesting based on stock price performance. The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents MSU activity for the year ended December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was no remaining unrecognized compensation expense related to MSUs.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December&#160;31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December&#160;31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2023, 2022 and 2021, we recorded stock-based compensation expense for employee and non-employee stock options, RSUs, PSUs, and ESPP shares. Stock-based compensation expense by award type included within the consolidated statements of operations is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,163&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,731&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,985&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to equity-based awards were allocated as follows in the consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No related tax benefits were recognized for the years ended December&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option granted to employees and non-employees is estimated on the date of grant using the Black-Scholes option-pricing model. The following table summarizes the weighted average assumptions used in calculating the grant date fair value of the awards:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.30&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.72&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expected term</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the &#8220;simplified method&#8221; as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Based Payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to estimate the expected term of stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the stock options, taking into consideration multiple vesting tranches. We utilize this method due to the plain-vanilla nature of our share-based awards. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility has been determined using our historical volatilities for a period equal to the expected term of the option grant.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk-free rate</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate is based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term of the options being valued. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid, and do not anticipate paying, any cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the option-pricing model. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forfeitures</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for forfeitures as they occur and, therefore, do not estimate forfeitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693042133968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) per Share</a></td>
<td class="text">Net Income (Loss) per Share<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net income (loss) per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of December&#160;31, 2023 are not considered to be common stock equivalents.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is net loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss from continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income (loss) from discontinued operations per share or net income (loss) per share. Basic and diluted net income (loss) per share was the same for all periods presented.</span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,772,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,804,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,932,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,841,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693037518000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of loss from continuing operations before income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352,085)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,767)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356,665)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352,088)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,801)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356,510)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any provision for income taxes for the years ended December&#160;31, 2023, 2022 and 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the expected income tax benefit (expense) computed using the federal statutory income tax rate to our effective income tax rate is as follows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit computed at federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities for the years ended December&#160;31, 2023 and 2022 are as follows:</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible accruals and reserves, including inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 R&amp;D expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,767)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act (TCJA) requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. The Company capitalized research and experimental costs of $232.7 million and $261.4 million for the years ended December&#160;31, 2023 and December&#160;31, 2022, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $131.7 million, $502.4 million and $65.2 million, respectively. At December&#160;31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $25.5 million and $28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December&#160;31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $132.9 million. If not utilized, the orphan drug credits begin to expire in 2035.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As provided by Section&#160;382 of the Internal Revenue Code of 1986, or Section&#160;382, and similar state provisions, utilization of NOLs and tax credit carryforwards may be subject to substantial annual limitations due to ownership change limitations that have previously occurred or that could occur in the future. Ownership changes may limit the amount of NOLs and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section&#160;382, results from transactions that increase the ownership of five percent stockholders in the stock of a corporation by more than 50 percent in the aggregate over a three year period. We completed a review of our changes in ownership through December&#160;31, 2023 and determined that transactions have resulted in no ownership changes during the year ended December&#160;31, 2023, as defined by Section&#160;382. The impact of the historical ownership changes has been reflected in our deferred tax assets in the table above. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $379.7 million and $296.0 million as of December&#160;31, 2023 and December&#160;31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $83.7&#160;million for the year ended December&#160;31, 2023 and by $59.5&#160;million for the year ended December&#160;31, 2022 primarily due to the Section 174 R&amp;D expense capitalization.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our change in valuation allowance for the years ended December&#160;31, 2023 and, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">236,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) for the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the unremitted earnings of our foreign subsidiaries are not material. We have not provided for U.S. income taxes or foreign withholding taxes on these earnings as it is our current intention to permanently reinvest these earnings outside the U.S. The tax liability on these earnings is also not material. Events that could trigger a tax liability include, but are not limited to, distributions, reorganizations or restructurings and/or tax law changes.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. Our reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by us in our tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our unrecognized tax benefits activity for the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,578&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will recognize interest and penalties related to uncertain tax positions above the line as an expense to continuing operations. As of December&#160;31, 2023 and 2022, we had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized. If all of the Company&#8217;s unrecognized tax benefits as of December&#160;31, 2023 were to become recognizable in the future, we would record $28.6&#160;million of unrecognized tax benefits. The uncertain tax position does not impact our effective income tax rate due to the full valuation allowance.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation in the United States, Switzerland, Netherlands, Germany, Italy and France. The statute of limitations for assessment by the IRS and state tax authorities is open for tax years ending December&#160;31, 2023, 2022, 2021, and 2020, although carryforward attributes that were generated for tax years prior to 2020 may still be adjusted upon examination by the IRS or state tax authorities if they either have been, or will be, used in a future period. The statute of limitations for assessment in Switzerland remains open for tax years ending December&#160;31, 2023, 2022, 2021, 2020 and 2019. The Company&#8217;s subsidiaries in the Netherlands and Germany were incorporated in 2019 and have statute of limitations for 5 and 4 years, respectively, for assessment. The tax years that remain open in these jurisdictions are for the tax years ending December&#160;31, 2023, 2022, 2021, 2020 and 2019. The Company&#8217;s subsidiaries in Italy and France were incorporated in 2020 and have statute of limitations for 5 and 3 years, respectively, for assessment. The tax years that remain open in these jurisdictions are for the tax years ending December&#160;31, 2023, 2022, 2021 and 2020. There are currently no federal, state or foreign audits in progress.</span></div>As of December&#160;31, 2023 and 2022, we had an income tax receivable of $1.1&#160;million and $0.3&#160;million, respectively, recorded within prepaid expenses and other current assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034381344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">Property and Equipment, net<div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following at December 31:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2023, 2022 and 2021 was $6.6 million, $8.4 million and $8.8 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693042137488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 125,000,000 shares of our common stock. Holders of common stock are entitled to one vote per share. Additionally, holders of common stock are entitled to receive dividends, if and when declared by our board of directors, and to share ratably in our assets legally available for distribution to our shareholders in the event of liquidation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693153643984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchase Program<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Share Repurchase Program</a></td>
<td class="text">Share Repurchase Program<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $1.2&#160;billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1&#160;million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $344.5&#160;million, or $48.38 per share. This repurchase was completed on April 5, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $600.0&#160;million of shares of our common stock. As of December&#160;31, 2023, we repurchased approximately 9.1&#160;million shares of common stock for $458.0 million, or $50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December&#160;31, 2023, we repurchased 16.2 million shares of common stock for $802.5 million, or $49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December&#160;31, 2023 or December&#160;31, 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 5, 2021, we terminated our Rule 10b5-1 share repurchase plan and on October 13, 2021, we entered into a Rule 10b-18 repurchase plan that allows us to conduct open market repurchases over time up to our remaining authorization under the Repurchase Program. We have paused our share repurchases for the foreseeable future.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchased shares are held as treasury stock until they are retired or re-issued. Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Repurchases of our common stock are accounted for as of the settlement date. There were no retirements or re-issuances of treasury stock during the year ended December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693126273952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, we completed the sale of our oncology business to Servier. We determined the sale of the oncology business represented a strategic shift that had a major effect on our business and therefore met the criteria for classification as discontinued operations at March 31, 2021. Accordingly, the oncology business was reported as discontinued operations in accordance with ASC 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The results of operations from the oncology business were classified as discontinued operations in the consolidated statements of operations. We recognized a gain on the sale of the oncology business upon closing.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gain on the sale for the year ended December 31, 2021: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802,936&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: transaction and insurance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: net liabilities distributed, including working capital adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale, pre-tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-967">Gain on sale, net of tax</span></span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023 and December 31, 2022, there were no assets or liabilities classified as discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the financial results of the discontinued operations: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,409&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,821&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,412)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense for the sale of future revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on the sale of the oncology business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, pre-tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974,024&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,961,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 205-20, only expenses specifically identifiable and related to a business to be disposed may be presented in discontinued operations. As such, the research and development, marketing, selling and general and administrative expenses in discontinued operations include corporate costs incurred directly to solely support our oncology business.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also entered into a Transition Services Agreement with Servier, through which we provided transitional services related to discovery, clinical development, technical operations, commercial and general and administrative related activities through March 31, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The milestone payment for approval of vorasidenib and royalty payments related to vorasidenib and TIBSOVO&#174; represent contingent consideration. Contingent consideration has been accounted for as a gain contingency in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and will be recognized in earnings in the period when realizable. As described in <a href="#i62bc41bff6df4446af4f8c46a1b0e260_124" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Note 1, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i62bc41bff6df4446af4f8c46a1b0e260_124" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">Nature of Business</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, on October 27, 2022, we sold our rights to future contingent payments related to TIBSOVO&#174; royalties to entities affiliated with Sagard and recognized income of $127.9&#160;million within the gain on sale of contingent payments line item in our consolidated statements of operations for the year ended December 31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693030221056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingent Liabilities</a></td>
<td class="text">Commitments and Contingent Liabilities <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Commitments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to various agreements with contract manufacturing organizations that we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Under such agreements, we are obligated to make certain minimum payments, with the exact amounts in the event of termination to be based on the timing of the termination and the exact terms of the agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in disputes and legal proceedings in the ordinary course of business. These proceedings may include allegations of infringement of intellectual property, employment or other matters. We do not have any ongoing legal proceedings that, based on our estimates, could have a material effect on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034460144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Benefit Plan</a></td>
<td class="text">Defined Contribution Benefit Plan<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a 401(k) retirement plan, in which substantially all of our full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. We will make matching contributions equal to 100% of the employee&#8217;s contributions, subject to a maximum of 4% of eligible compensation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034473552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income</a></td>
<td class="num">$ (352,088)<span></span>
</td>
<td class="num">$ (231,801)<span></span>
</td>
<td class="nump">$ 1,604,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034437808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034801632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries, Agios Securities Corporation, Agios International Sarl (GmbH), Agios Germany GmbH, Agios Netherlands B.V., Agios Italy S.R.L., Agios France SARL, and Agios Limited. All intercompany transactions have been eliminated in consolidation. The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the recent COVID-19 pandemic, or other pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable, net</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable, net</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#8217;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, PYRUKYND&#174;, by the FDA on February 17, 2022 for the treatment of hemolytic anemia in adults with PK deficiency in the United States, we began to capitalize inventories of PYRUKYND&#174;.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from sales of PYRUKYND&#174; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#174; to pharmacies or dispense PYRUKYND&#174; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#174;.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance obligation related to the sale of PYRUKYND&#174; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contractual Adjustments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Government Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.</span></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Returns</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of sales</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of sales</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of manufacturing costs for sales of PYRUKYND&#174;. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#174; recorded during the twelve months ended December 31, 2023 and 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the twelve months ended December 31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at&#160;December&#160;31, 2023 and 2022 consisted of investments in U.S. Treasuries, government securities and corporate debt securities. We determine the appropriate classification of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date. We classify our marketable securities as available-for-sale pursuant to ASC 320,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Marketable securities are recorded at fair value. Unrealized gains and losses are included as a component of accumulated other comprehensive (loss) income in the consolidated balance sheets and statements of stockholders&#8217; equity and a component of total comprehensive (loss) income in the consolidated statements of comprehensive (loss) income, until realized. Realized gains and losses are included in investment income on a specific-identification basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;December&#160;31, 2023 and 2022, we held both current and non-current investments. Investments classified as current are those that: (i) have a maturity of less than one year, or (ii) have a maturity of <span style="-sec-ix-hidden:f-407">one</span> to two years but we intend to liquidate within the next twelve months. Investments classified as non-current are those that: (i)&#160;have a maturity of&#160;<span style="-sec-ix-hidden:f-409">one</span> to two years, and (ii)&#160;we do not intend to liquidate within the next&#160;one year, although these funds are available for use and therefore classified as available-for-sale.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review marketable securities for impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#8217;s carrying amount is not recoverable. Unrealized losses are evaluated for impairment under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive (loss) income, net of taxes. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity of the impairment, collectability of the security, and any adverse conditions specifically related to the security, an industry, or geographic area.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record cash equivalents and marketable securities at fair value. ASC&#160;820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1&#160;&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Unadjusted quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2023 or 2022. Fair value information for these assets, including their classification in the fair value hierarchy is included in <a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Note 3</a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">Fair Value Measurements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the valuation methods during the years ended December&#160;31, 2023 and 2022. We evaluate transfers between levels at the end of each reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other receivables, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values due to their short-term maturities.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of credit risk</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, and marketable securities. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of laboratory equipment, computer equipment and software, leasehold improvements, furniture and fixtures, and office equipment. Costs of major additions and betterment are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, and depreciated using the straight-line method over the estimated useful lives of the respective assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements are amortized over the lesser of the remaining lease term or the estimated useful life of the improvement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of long-lived assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate our long-lived assets for potential impairment in accordance with ASC&#160;360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is assessed based on the undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. We did not recognize any impairment charges through December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease at inception. An arrangement is determined to contain a lease if the contract conveys the right to control the use of an identified property or equipment for a period of time in exchange for consideration. If we can benefit from the various underlying assets of a lease on their own or together with other resources that are readily available, or if the various underlying assets are neither highly dependent on nor highly interrelated with other underlying assets in the </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangement, they are considered to be a separate lease component. In the event multiple underlying assets are identified, the lease consideration is allocated to the various components based on each of the component&#8217;s relative fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the leasing arrangement. Operating lease assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, in determining the operating lease liabilities we use an estimate of our incremental borrowing rate. The incremental borrowing rate is determined using two alternative credit scoring models to estimate our credit rating, adjusted for collateralization. The calculation of the operating lease assets includes any lease payments made and excludes any lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For operating leases, we record operating lease assets and lease liabilities in our consolidated balance sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Short-term leases, or leases that have a lease term of 12 months or less at commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not entered into any material short-term leases or financing leases as of December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs, including those accrued as of each balance sheet date, are expensed as incurred. These costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, fees paid to contract research organizations, or CROs, and other third parties in connection with clinical trials and preclinical development activities, fees paid to investigative sites in connection with clinical studies, the costs associated with the product manufacturing, development, and distribution of clinical supplies, the costs of laboratory equipment and facilities, and other external costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. Additionally, there may be instances in which payments made to our vendors will exceed the level of services provided, and result in a prepayment of the research and development expense. The capitalized amounts are expensed as the related goods are delivered or the services are performed. We estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for stock-based compensation awards in accordance with ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#160;&#8211;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 718. For stock-based awards granted to employees, non-employees and members of the board of directors for their services and for participation in our employee stock purchase plan, we estimate the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires us to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, we recognize stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. For awards subject to performance-based vesting conditions, we recognize stock-based compensation expense if the performance condition is considered probable of achievement using management&#8217;s best estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 740, which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. We determine our deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also account for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive (loss) income</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive (loss) income</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive (loss) income is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances, and currently consists of net loss and unrealized gains and losses on available-for-sale securities. Accumulated other comprehensive (loss) income consists entirely of unrealized gains and losses from available-for-sale securities as of December&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net (loss) income per share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (loss) income per share</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net (loss) income per share is calculated by dividing net (loss) income by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by adjusting weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the dilutive net (loss) income per share calculation, stock options, restricted stock units, or RSUs, performance-based stock units, or PSUs, and market-based stock units, or MSUs, for which the performance and market vesting conditions, respectively, have been deemed probable, and employee stock purchase plan shares are considered to be common stock equivalents but are excluded from the calculation of diluted net (loss) income per share as their effect would be anti-dilutive.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss from continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income (loss) from discontinued operations per share or net (loss) income per share.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and geographic information</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment and geographic information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker or decision-making group in making decisions on how to allocate resources and assess performance. Our chief operating decision maker is the chief executive officer. Our chief operating decision maker and we view our operations and manage our business as one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued operations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the sale of our oncology business in the first quarter of 2021 in accordance with ASC 205, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Accounting Standards Update, or ASU, No. 2014-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We followed the held-for-sale criteria as defined in ASC 360, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and ASC 205. ASC 205 requires that a component of an entity that has been disposed of or is classified as held for sale and has operations and cash flows that can be clearly distinguished from the rest of the entity be reported as assets held for sale and discontinued operations. In the period a component of an entity has been disposed of or classified as held for sale, the results of operations for the periods presented are reclassified into separate line items in the consolidated statements of operations. Assets and liabilities are also reclassified into separate line items on the related consolidated balance sheets for the periods presented. The statements of cash flows for the periods presented are also reclassified to reflect the results of discontinued operations as separate line items. ASU 2014-08 requires that only a disposal of a component of an entity, or a group of components of an entity, that represents a strategic shift that has, or will have, a major effect on the reporting entity&#8217;s operations and financial results be reported in the financial statements as discontinued operations. ASU 2014-08 also provides guidance on the financial statement presentations and disclosures of discontinued operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the sale of our oncology business during the first quarter of 2021, in accordance with ASC 205, we have classified the results of the oncology business as discontinued operations in our consolidated statements of operations and cash flows for all periods presented, and refer to <a href="#i62bc41bff6df4446af4f8c46a1b0e260_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Note 15, </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i62bc41bff6df4446af4f8c46a1b0e260_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">Discontinued Operations</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Treasury stock</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury stock</span></div>Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent accounting pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent accounting pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent events</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent events</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We considered events or transactions occurring after the balance sheet date, but prior to the issuance of the consolidated financial statements, for potential recognition or disclosure in our consolidated financial statements. All significant subsequent events have been properly disclosed in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org//705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693042096976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Estimated Useful Lives of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost, and depreciated using the straight-line method over the estimated useful lives of the respective assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693040595168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash equivalents and marketable securities measured at fair value and by level (as described in <a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">Note</a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"> </a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">2,</a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">Su</a><a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none">mmary of Significant Accounting Policies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) on a recurring basis as of December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748,281&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693042119776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2023 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(695)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,045&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(975)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689,381&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,726)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688,723&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,218&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,435&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,726)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities at December&#160;31, 2022 consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:49.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(811)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,289)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652,339&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,491)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643,860&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-current</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317,930&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,143)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,874&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total marketable securities</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970,269&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,634)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957,734&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693040591488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of commercial supply of PYRUKYND&#174;, consisted of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,076&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,492&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693038247280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Cost and Other Information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense and other information related to leases were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.531%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,170&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,411&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Undiscounted Minimum Rental Commitments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter, were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undiscounted minimum rental commitments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,037)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments to be Received</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the future minimum lease payments to be received under the long-term sublease agreements were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693040573024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following at December 31:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,167&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693038189840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Product Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net, was as follows for the years ended December 31: </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,823&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Product Revenue Allowance and Reserves</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize balances and activity in each of the product revenue allowance and reserve categories for the years ended December&#160;31, 2023 and December&#160;31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,079&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(938)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,003)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,958)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,899)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Government Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provisions relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(432)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments/returns relating to sales in the prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock', window );">Schedule of Revenue Related Reserves</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Component of accrued expenses </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock', window );">Schedule of Changes in Contract Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in our contract assets, which consisted of accounts receivable, net: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:74.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Additions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Deductions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,077)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,810&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1)  Additions to contract assets relate to amounts billed to Customers for product sales, and deductions to contract assets primarily relate to collection of receivables during the reporting period.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035203328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company's Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity of all stock incentive plans for the year ended December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value (in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,772,564&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.81&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235,401)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,160,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,681&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.94&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.36</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,344,010&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.55&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.02</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.94&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.36</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text">The following table presents RSU activity for the year ended December&#160;31, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,921&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.30&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(464,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346,701&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.67&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of PSU Activity</a></td>
<td class="text">The following table presents PSU activity for the year ended December&#160;31, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.66&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Market-based Stock Unit or MSU Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents MSU activity for the year ended December&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Stock&#160;Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date<br/>Fair&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested shares at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense by Award Type Included within the Condensed Consolidated Statements of Operations</a></td>
<td class="text">Stock-based compensation expense by award type included within the consolidated statements of operations is as follows:<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,163&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,731&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,985&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Expenses Related to Stock Options and Stock-based Awards</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to equity-based awards were allocated as follows in the consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,766&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,296&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Grant Date Fair Value Option Award Weighted Average Assumptions Used</a></td>
<td class="text">The following table summarizes the weighted average assumptions used in calculating the grant date fair value of the awards:<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.26&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.30&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.72&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693039929968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Excluded from Calculation of Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,772,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,798,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,346,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,804,118&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,932,511&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,841,614&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693036327184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Domestic and Foreign Components of Loss Before Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of loss from continuing operations before income taxes are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352,085)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,767)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356,665)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352,088)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231,801)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356,510)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Expected Income Tax Benefit (Expense) Computed Using Federal Statutory Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the expected income tax benefit (expense) computed using the federal statutory income tax rate to our effective income tax rate is as follows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit computed at federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General business credits and other credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Company's Deferred Tax Assets and Liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and liabilities for the years ended December&#160;31, 2023 and 2022 are as follows:<div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible accruals and reserves, including inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Section 174 R&amp;D expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,986)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,767)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(379,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295,993)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Changes in Valuation Allowance</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our change in valuation allowance for the years ended December&#160;31, 2023 and, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">236,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) for the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Rollforward</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our unrecognized tax benefits activity for the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases - current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits at the end of the year</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,578&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693037689248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following at December 31:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,182&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,229)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,070)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,382&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,987&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693037526592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the gain on the sale for the year ended December 31, 2021: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,802,936&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: transaction and insurance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: net liabilities distributed, including working capital adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale, pre-tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989,133&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-967">Gain on sale, net of tax</span></span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976,334&#160;</span></td><td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the financial results of the discontinued operations: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue &#8211; other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenue &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,409&#160;</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cost and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,821&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,412)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense for the sale of future revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,697)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on the sale of the oncology business</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,989,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, pre-tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,974,024&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,799)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,961,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031544992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_GainLossOnSaleOfContingentPayments', window );">Gain on sale of contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 127,853<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=agio_AtTheMarketOfferingMember', window );">At-the-market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction', window );">Maximum value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue', window );">Value of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member', window );">2010 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication', window );">Milestone payment for achievement of specified ex-U.S. commercial milestone event</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=agio_TIBSOVOMember', window );">TIBSOVO | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContingentGainOnDispositionOfBusinessRecognized', window );">Earn-out revenue for royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Agios Oncology Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,802,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Contingent milestone payment</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_GainLossOnSaleOfContingentPayments', window );">Gain on sale of contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Agios Oncology Business | TIBSOVO | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_GainContingencyRoyaltyPercentageOfNetSales', window );">Contingent royalty payment</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | Agios Oncology Business | vorasidenib | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_GainContingencyRoyaltyPercentageOfNetSales', window );">Contingent royalty payment</a></td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=agio_AlnylamPharmaceuticalsIncMember', window );">Alnylam Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_PaymentsForAssetAcquisition', window );">Payments for asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment', window );">Asset acquisition, contingent consideration, potential developmental and regulatory milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Contingent Consideration, Potential Developmental and Regulatory Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContingentGainOnDispositionOfBusinessRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Gain On Disposition Of Business Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContingentGainOnDispositionOfBusinessRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GainContingencyRoyaltyPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency Royalty Percentage Of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GainContingencyRoyaltyPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GainLossOnSaleOfContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Sale Of Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GainLossOnSaleOfContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PaymentsForAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Asset Acquisition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PaymentsForAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of potential milestone payment receivable for filing of new drug application.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfStockCommonStockReservedForFutureIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Common Stock Reserved For Future Issuance, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfStockCommonStockReservedForFutureIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value of Shares Issued in Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=agio_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=agio_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=agio_Agreement2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_TIBSOVOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_TIBSOVOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_VorasidenibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_VorasidenibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=agio_AlnylamPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=agio_AlnylamPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693036035952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod', window );">Investment maturity period, current</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod', window );">Minimum period to liquidate</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod', window );">Investment maturity period, current</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod', window );">Investment maturity period, non-current</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ScheduleOfSignificantAccountingPoliciesLineItems', window );"><strong>Schedule of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod', window );">Investment maturity period, current</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod', window );">Investment maturity period, non-current</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_AvailableForSaleSecuritiesCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities current maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_AvailableForSaleSecuritiesCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities non current maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities non current minimum liquidating period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ScheduleOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Significant Accounting Policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ScheduleOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031478864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031389312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 718,158<span></span>
</td>
<td class="nump">$ 957,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">718,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">748,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">35,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">257,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">425,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">30,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;1 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;1 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">30,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">718,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">718,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;2 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">35,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;2 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">257,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">425,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;2 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3 | Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693042112400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value of assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031319616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 718,599<span></span>
</td>
<td class="nump">$ 970,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,285<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,726)<span></span>
</td>
<td class="num">(12,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">718,158<span></span>
</td>
<td class="nump">957,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">689,381<span></span>
</td>
<td class="nump">652,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(1,726)<span></span>
</td>
<td class="num">(8,491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">688,723<span></span>
</td>
<td class="nump">643,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current: | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">30,876<span></span>
</td>
<td class="nump">68,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">30,820<span></span>
</td>
<td class="nump">67,367<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current: | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">247,460<span></span>
</td>
<td class="nump">220,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(695)<span></span>
</td>
<td class="num">(5,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">246,959<span></span>
</td>
<td class="nump">215,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember', window );">Current: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">411,045<span></span>
</td>
<td class="nump">363,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">874<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(975)<span></span>
</td>
<td class="num">(2,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">410,944<span></span>
</td>
<td class="nump">360,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">29,218<span></span>
</td>
<td class="nump">317,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">29,435<span></span>
</td>
<td class="nump">313,874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current: | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,802<span></span>
</td>
<td class="nump">17,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">4,832<span></span>
</td>
<td class="nump">17,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current: | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">9,986<span></span>
</td>
<td class="nump">117,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">10,061<span></span>
</td>
<td class="nump">115,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember', window );">Non-current: | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,430<span></span>
</td>
<td class="nump">183,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 14,542<span></span>
</td>
<td class="nump">$ 180,822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_CurrentAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=agio_NonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035298128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>security</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>security</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gain (loss) on marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Number of debt securities in an unrealized loss position for less than one year | security</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Aggregate fair value of debt securities in an unrealized loss position</a></td>
<td class="nump">$ 513,500,000<span></span>
</td>
<td class="nump">$ 868,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of unrealized loss position | security</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693041500112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">17,568<span></span>
</td>
<td class="nump">7,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,457<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 19,076<span></span>
</td>
<td class="nump">$ 8,492<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693036097984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>ft&#178; </div>
<div>extension</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>leaseTerm</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Standby letter of credit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Security deposit liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LeaseArrangementsAxis=agio_EightyEightSidneyStreetLeaseMember', window );">88 Sidney Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace', window );">Number of square feet of office space (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingLeaseNumberOfLeaseTerms', window );">Number of optional terms available at end of current lease term (in lease terms) | leaseTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term for extension of operating lease (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LeaseArrangementsAxis=agio_SixtyFourSidneyStreetLeaseMember', window );">64 Sidney Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace', window );">Number of square feet of office space (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingLeaseNumberOfLeaseTerms', window );">Number of optional terms available at end of current lease term (in lease terms) | leaseTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term for extension of operating lease (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased', window );">Area of premises subleased (in square feet)</a></td>
<td class="nump">7,407<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods', window );">Number of extension periods | extension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod', window );">Extension period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo', window );">Second extension period</a></td>
<td class="text">22 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LeaseArrangementsAxis=agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember', window );">38 Sidney Street Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace', window );">Number of square feet of office space (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingLeaseNumberOfLeaseTerms', window );">Number of optional terms available at end of current lease term (in lease terms) | leaseTerm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term for extension of operating lease (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased', window );">Area of premises subleased (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingLeaseNumberOfLeaseTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Lease Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingLeaseNumberOfLeaseTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Square Feet Of Office Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Extend, Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Extend, Extension Period Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Extend, Number Of Extension Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LesseeOperatingSubleaseAreaOfPremisesSubleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Area Of Premises Subleased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LesseeOperatingSubleaseAreaOfPremisesSubleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LeaseArrangementsAxis=agio_EightyEightSidneyStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LeaseArrangementsAxis=agio_EightyEightSidneyStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LeaseArrangementsAxis=agio_SixtyFourSidneyStreetLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LeaseArrangementsAxis=agio_SixtyFourSidneyStreetLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_LeaseArrangementsAxis=agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_LeaseArrangementsAxis=agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693038189840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Expense and Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 15,227<span></span>
</td>
<td class="nump">$ 15,227<span></span>
</td>
<td class="nump">$ 15,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 18,170<span></span>
</td>
<td class="nump">$ 17,035<span></span>
</td>
<td class="nump">$ 14,411<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035262160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Undiscounted Minimum Rental Commitments under Non-cancelable Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 17,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">19,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">20,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">20,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">3,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted minimum rental commitments</a></td>
<td class="nump">81,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="num">(9,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 71,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693030266320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Lease Payments to be Received under the Long-term Sublease Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 5,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2025</a></td>
<td class="nump">1,310<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total</a></td>
<td class="nump">$ 6,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693030174592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 23,232<span></span>
</td>
<td class="nump">$ 18,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development costs</a></td>
<td class="nump">15,463<span></span>
</td>
<td class="nump">8,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">3,115<span></span>
</td>
<td class="nump">2,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">1,357<span></span>
</td>
<td class="nump">1,385<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 43,167<span></span>
</td>
<td class="nump">$ 30,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031321488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Product Revenue, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 26,823<span></span>
</td>
<td class="nump">$ 14,240<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 26,823<span></span>
</td>
<td class="nump">$ 11,740<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031647408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractualAdjustmentsRollForward', window );"><strong>Contractual Adjustments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerContractualAdjustmentReserve', window );">Contractual adjustments, beginning balance</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_CurrentYearProvisionForContractualAdjustments', window );">Contractual adjustments, current provisions relating to sales in the current year</a></td>
<td class="nump">1,079<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_PriorYearProvisionForContractualAdjustments', window );">Contractual adjustments, adjustments relating to prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear', window );">Contractual adjustments, payments/returns relating to sales in the current year</a></td>
<td class="num">(938)<span></span>
</td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear', window );">Contractual adjustments, payments/returns relating to sales in the prior year</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerContractualAdjustmentReserve', window );">Contractual adjustments, ending balance</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_GovernmentRebatesRollForward', window );"><strong>Government Rebates</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserve', window );">Government rebates, beginning balance</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_CurrentYearProvisionsForRebateReserve', window );">Government rebates, current provisions relating to sales in the current year</a></td>
<td class="nump">2,086<span></span>
</td>
<td class="nump">912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_PriorYearProvisionsForRebateReserve', window );">Government rebates, adjustments relating to prior years</a></td>
<td class="num">(237)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear', window );">Government rebates, payments/returns relating to sales in the current year</a></td>
<td class="num">(1,003)<span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears', window );">Government rebates, payments/returns relating to sales in the prior years</a></td>
<td class="num">(335)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerRebateReserve', window );">Government rebates, ending balance</a></td>
<td class="nump">1,084<span></span>
</td>
<td class="nump">573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ProductReturnsRollForward', window );"><strong>Returns</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductReserve', window );">Returns, beginning balance</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ProvisionForRightToRecoverProductInCurrentYear', window );">Returns, current provisions relating to sales in the current year</a></td>
<td class="nump">2,182<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ProvisionForRightToRecoverProductInPriorYears', window );">Returns, adjustments relating to prior years</a></td>
<td class="num">(77)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries', window );">Returns, payments/returns relating to sales in the current year</a></td>
<td class="num">(1,958)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries', window );">Returns, payments/returns relating to sales in the prior years</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerRightToRecoverProductReserve', window );">Returns, ending balance</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerTotalAllowancesAndReserves', window );">Total revenue-related reserves</a></td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerCurrentYearReserveProvisions', window );">Total allowances and reserves, current provisions relating to sales in the current year</a></td>
<td class="nump">5,347<span></span>
</td>
<td class="nump">1,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerPriorYearsReserveProvisions', window );">Total allowances and reserves, adjustments relating to prior years</a></td>
<td class="num">(314)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerCurrentYearReserveRecoveries', window );">Total allowances and reserves, payments/returns relating to sales in the current year</a></td>
<td class="num">(3,899)<span></span>
</td>
<td class="num">(771)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerPriorYearsReserveRecoveries', window );">Total allowances and reserves, payments/returns relating to sales in the prior years</a></td>
<td class="num">$ (433)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerContractualAdjustmentReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerContractualAdjustmentReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerCurrentYearReserveProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerCurrentYearReserveProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerCurrentYearReserveRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerCurrentYearReserveRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerPriorYearsReserveProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerPriorYearsReserveProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerPriorYearsReserveRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerPriorYearsReserveRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerRightToRecoverProductReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerRightToRecoverProductReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerTotalAllowancesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerTotalAllowancesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractualAdjustmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractualAdjustmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CurrentYearProvisionForContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CurrentYearProvisionForContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_CurrentYearProvisionsForRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_CurrentYearProvisionsForRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GovernmentRebatesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GovernmentRebatesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PriorYearProvisionForContractualAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PriorYearProvisionForContractualAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PriorYearProvisionsForRebateReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PriorYearProvisionsForRebateReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProductReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProductReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProvisionForRightToRecoverProductInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProvisionForRightToRecoverProductInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ProvisionForRightToRecoverProductInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ProvisionForRightToRecoverProductInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034473552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Product Revenue - Schedule of Revenue-Related Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Reduction of accounts receivable</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerAllowanceAndReservesLiability', window );">Component of accrued expenses</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerTotalAllowancesAndReserves', window );">Total revenue-related reserves</a></td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="nump">$ 771<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAllowanceAndReservesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAllowanceAndReservesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerTotalAllowancesAndReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerTotalAllowancesAndReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035969120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Schedule of Changes in Contract Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractAssetsAndLiabilitiesHeadingRollForward', window );"><strong>Contract Assets and Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, beginning balance</a></td>
<td class="nump">$ 2,206<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerAssetRevenueRecognized', window );">Additions</a></td>
<td class="nump">31,855<span></span>
</td>
<td class="nump">13,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables', window );">Deductions</a></td>
<td class="num">(31,251)<span></span>
</td>
<td class="num">(11,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets, ending balance</a></td>
<td class="nump">$ 2,810<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractAssetsAndLiabilitiesHeadingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractAssetsAndLiabilitiesHeadingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ContractWithCustomerAssetRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ContractWithCustomerAssetRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693040443360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Product Revenue - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">$ 2,810<span></span>
</td>
<td class="nump">$ 2,206<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031678288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefits related to stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense excluding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense excluding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares', window );">Share-based compensation arrangement by share-based payment award, options, expected to vest, number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount', window );">Unrecognized compensation cost not expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember', window );">Market-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense excluding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember', window );">2007 Plan and 2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share based awards reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,004,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,989,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.32<span></span>
</td>
<td class="nump">$ 15.64<span></span>
</td>
<td class="nump">$ 31.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member', window );">2013 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,686,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized for issuance (in shares)</a></td>
<td class="nump">509,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under 2013 ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,832<span></span>
</td>
<td class="nump">104,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Opportunity to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,363,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Expected To Vest, Number of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_TwoThousandAndThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=agio_EmployeeStockPurchasePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035422528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Company's Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">5,772,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">886,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(235,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/expired (in shares)</a></td>
<td class="num">(1,160,277)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">5,263,681<span></span>
</td>
<td class="nump">5,772,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">3,344,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">5,263,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in usd per share)</a></td>
<td class="nump">$ 48.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">25.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="nump">12.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited/expired (in usd per share)</a></td>
<td class="nump">56.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in usd per share)</a></td>
<td class="nump">44.94<span></span>
</td>
<td class="nump">$ 48.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price, exercisable (in usd per share)</a></td>
<td class="nump">53.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in usd per share)</a></td>
<td class="nump">$ 44.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, outstanding (in years)</a></td>
<td class="text">6 years 4 months 9 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, exercisable (in years)</a></td>
<td class="text">5 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, vested and expected to vest (in years)</a></td>
<td class="text">6 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 5,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034640576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Unvested RSUs, Performance-Based Stock and Market-Based Stock Unit Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Stock&#160;Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">1,117,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">914,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(464,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(221,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">1,346,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 38.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">25.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">41.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">33.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 29.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Stock&#160;Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">430,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">125,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(92,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(101,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">362,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 35.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">25.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">30.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">46.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 30.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember', window );">Market-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of Stock&#160;Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares beginning of period (in shares) | shares</a></td>
<td class="nump">42,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested shares end of period (in shares) | shares</a></td>
<td class="nump">42,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested shares end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 41.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_MarketBasedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693030942880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included within the Condensed Consolidated Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 44,766<span></span>
</td>
<td class="nump">$ 49,296<span></span>
</td>
<td class="nump">$ 53,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">17,163<span></span>
</td>
<td class="nump">23,731<span></span>
</td>
<td class="nump">30,985<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">19,367<span></span>
</td>
<td class="nump">21,670<span></span>
</td>
<td class="nump">21,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">7,368<span></span>
</td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=agio_EmployeePurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 976<span></span>
</td>
<td class="nump">$ 1,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=agio_EmployeePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=agio_EmployeePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034689616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Expenses Related to Stock Options and Stock-based Awards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 44,766<span></span>
</td>
<td class="nump">$ 49,296<span></span>
</td>
<td class="nump">$ 53,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">17,064<span></span>
</td>
<td class="nump">20,988<span></span>
</td>
<td class="nump">24,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share based compensation expense</a></td>
<td class="nump">$ 27,702<span></span>
</td>
<td class="nump">$ 28,308<span></span>
</td>
<td class="nump">$ 28,981<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693041399760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Schedule of Grant Date Fair Value Option Award Weighted Average Assumptions Used (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">2.55%<span></span>
</td>
<td class="nump">0.72%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years 10 days<span></span>
</td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">54.26%<span></span>
</td>
<td class="nump">55.30%<span></span>
</td>
<td class="nump">61.72%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693032111792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">6,804,118<span></span>
</td>
<td class="nump">6,932,511<span></span>
</td>
<td class="nump">5,841,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">5,263,681<span></span>
</td>
<td class="nump">5,772,564<span></span>
</td>
<td class="nump">4,798,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">1,346,701<span></span>
</td>
<td class="nump">1,117,921<span></span>
</td>
<td class="nump">1,002,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember', window );">Performance-based stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">145,023<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember', window );">Employee Stock Purchase Plan shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total (in shares)</a></td>
<td class="nump">48,713<span></span>
</td>
<td class="nump">42,026<span></span>
</td>
<td class="nump">39,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_PerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=agio_EmployeePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034765936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (352,085)<span></span>
</td>
<td class="num">$ (231,767)<span></span>
</td>
<td class="num">$ (356,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss from continuing operations</a></td>
<td class="num">$ (352,088)<span></span>
</td>
<td class="num">$ (231,801)<span></span>
</td>
<td class="num">$ (356,510)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034689328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Expected Income Tax Benefit (Expense) Computed Using Federal Statutory Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit computed at federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(23.80%)<span></span>
</td>
<td class="num">(25.70%)<span></span>
</td>
<td class="num">(24.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments', window );">General business credits and other credits</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences and other adjustments</a></td>
<td class="num">(2.80%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock based compensation</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax credits adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693030147952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 64,066<span></span>
</td>
<td class="nump">$ 32,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">180,635<span></span>
</td>
<td class="nump">163,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Purchased intangible assets</a></td>
<td class="nump">14,155<span></span>
</td>
<td class="nump">11,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">20,954<span></span>
</td>
<td class="nump">26,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">16,780<span></span>
</td>
<td class="nump">21,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Non-deductible accruals and reserves, including inventory</a></td>
<td class="nump">5,134<span></span>
</td>
<td class="nump">3,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 174 R&amp;D expense</a></td>
<td class="nump">93,333<span></span>
</td>
<td class="nump">56,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">395,057<span></span>
</td>
<td class="nump">316,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(1,986)<span></span>
</td>
<td class="num">(3,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right of use asset</a></td>
<td class="num">(13,411)<span></span>
</td>
<td class="num">(16,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(379,660)<span></span>
</td>
<td class="num">(295,993)<span></span>
</td>
<td class="num">$ (236,478)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031413760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>audit</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>audit</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>audit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research and development costs</a></td>
<td class="nump">$ 232,700,000<span></span>
</td>
<td class="nump">$ 261,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_PercentageOfStockholdersOwnershipIncrease', window );">Percentage of stock owned resulting in an ownership change</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_PeriodOfChangeInStockholdersOwnership', window );">Aggregate period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 379,660,000<span></span>
</td>
<td class="nump">295,993,000<span></span>
</td>
<td class="nump">$ 236,478,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) for the current period</a></td>
<td class="nump">83,667,000<span></span>
</td>
<td class="nump">59,515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 28,578,000<span></span>
</td>
<td class="nump">$ 26,190,000<span></span>
</td>
<td class="nump">$ 24,220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_NumberOfStatesFederalOrForeignInAuditingProcess', window );">Number of federal, state or foreign audits in process | audit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income tax receivable</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=agio_FederalOrphanDrugTaxCreditMember', window );">Federal Orphan Drug Tax Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit</a></td>
<td class="nump">132,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">131,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit</a></td>
<td class="nump">25,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">502,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit</a></td>
<td class="nump">28,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 65,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod', window );">Capitalized research and development costs, amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod', window );">Capitalized research and development costs, amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Deferred Expense, Capitalized Research And Development Costs, Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_NumberOfStatesFederalOrForeignInAuditingProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of states, federal or foreign in auditing process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_NumberOfStatesFederalOrForeignInAuditingProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PercentageOfStockholdersOwnershipIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of stockholders ownership increase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PercentageOfStockholdersOwnershipIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_PeriodOfChangeInStockholdersOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of change in stockholders ownership .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_PeriodOfChangeInStockholdersOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=agio_FederalOrphanDrugTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=agio_FederalOrphanDrugTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693036272320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Changes in Valuation Allowance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DeferredTaxAssetsValuationAllowanceRollForward', window );"><strong>Deferred Tax Assets, Valuation Allowance [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the beginning of the year</a></td>
<td class="nump">$ 295,993<span></span>
</td>
<td class="nump">$ 236,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) for the current period</a></td>
<td class="nump">83,667<span></span>
</td>
<td class="nump">59,515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance at the end of the year</a></td>
<td class="nump">$ 379,660<span></span>
</td>
<td class="nump">$ 295,993<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_DeferredTaxAssetsValuationAllowanceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_DeferredTaxAssetsValuationAllowanceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034773232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at the beginning of the year</a></td>
<td class="nump">$ 26,190<span></span>
</td>
<td class="nump">$ 24,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases - current period tax positions</a></td>
<td class="nump">2,388<span></span>
</td>
<td class="nump">1,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits at the end of the year</a></td>
<td class="nump">$ 28,578<span></span>
</td>
<td class="nump">$ 26,190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035375136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, net - Summary of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 67,611<span></span>
</td>
<td class="nump">$ 73,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(52,229)<span></span>
</td>
<td class="num">(50,070)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">15,382<span></span>
</td>
<td class="nump">22,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">17,433<span></span>
</td>
<td class="nump">23,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">6,566<span></span>
</td>
<td class="nump">6,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">37,277<span></span>
</td>
<td class="nump">37,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">3,459<span></span>
</td>
<td class="nump">3,514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,268<span></span>
</td>
<td class="nump">2,248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 608<span></span>
</td>
<td class="nump">$ 657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=agio_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034497600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034414336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>vote </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_NumberOfVotesPerShare', window );">Number of votes per share | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Votes Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031533216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchase Program (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">33 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 02, 2021</div></th>
<th class="th"><div>Mar. 25, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramMember', window );">Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember', window );">BMS Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="nump">$ 344,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased (in usd per share)</a></td>
<td class="nump">$ 48.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramRule10b51RepurchaseMember', window );">Rule 10b5-1 Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 458,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramRule10b51RepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=agio_March252021RepurchaseProgramRule10b51RepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693035711744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Gain on Sale of Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Discontinued operation, gain (loss) on disposal, statement of income or comprehensive income [extensible enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Less: Net income from discontinued operations<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember', window );">Agios Oncology Business | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,802,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DiscontinuedOperationsTransactionAndInsuranceCosts', window );">Less: transaction and insurance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53,573)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DiscontinuedOperationsLiabilitiesDistributedNet', window );">Plus: net liabilities distributed, including working capital adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on sale, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,989,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,799)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on sale, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,976,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_DiscontinuedOperationsLiabilitiesDistributedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations, Liabilities Distributed, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_DiscontinuedOperationsLiabilitiesDistributedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_DiscontinuedOperationsTransactionAndInsuranceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discontinued Operations, Transaction And Insurance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_DiscontinuedOperationsTransactionAndInsuranceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from disposal of discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693030124432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_GainLossOnSaleOfContingentPayments', window );">Gain on sale of contingent payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 127,853,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember', window );">Agios Oncology Business | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal group. including discontinued operation, assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal group. including discontinued operation, liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_GainLossOnSaleOfContingentPayments', window );">Gain on sale of contingent payments</a></td>
<td class="nump">$ 127,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_GainLossOnSaleOfContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Sale Of Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_GainLossOnSaleOfContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693031465584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Financial Results of Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,961,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember', window );">Agios Oncology Business | Discontinued Operations, Disposed of by Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,551<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total cost and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,821<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">(Loss) income from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue', window );">Non-cash interest expense for the sale of future revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Gain on the sale of the oncology business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,989,133<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income from discontinued operations, pre-tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,974,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,799)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,961,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember', window );">Agios Oncology Business | Discontinued Operations, Disposed of by Sale | Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember', window );">Agios Oncology Business | Discontinued Operations, Disposed of by Sale | Collaboration revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember', window );">Agios Oncology Business | Discontinued Operations, Disposed of by Sale | Collaboration revenue &#8211; other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember', window );">Agios Oncology Business | Discontinued Operations, Disposed of by Sale | Royalty revenue &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Costs And Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Interest Expense, Non-Cash, Sale Of Future Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research And Development Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=agio_AgiosOncologyBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueRelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=agio_CollaborationRevenueOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693037606960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_agio_NumberOfLegalProceedingsThatHaveMaterialEffect', window );">Number of ongoing legal proceedings</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_agio_NumberOfLegalProceedingsThatHaveMaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Legal Proceedings that Have Material Effect</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">agio_NumberOfLegalProceedingsThatHaveMaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>agio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140693034460144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Benefit Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer's matching contribution percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employer's contribution percentage of eligible compensation</a></td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>100
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MF#=87EV?[PBZS>K-EU0(&F>;&X+A.2<O@/,K2L5A1WY!\3\.X_\ 4$L#!!0
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M-!K<T@V:MFFT!NK*%^I.(Y6]GQ;49\$X!]K?:XTGPQW0=>[T+U!+ P04
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M\O+D>)DVKOH8/.B'0Z2V%8G]D8T)=6R$INEHOY8FP!%KVIB$"$5#>+8=PKI
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MHK[<,*K1&P/]^YIKA=/<F!<#[8N@U;]02P,$%     @ &E1/6%JD6]P9 P
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M: -XO^)<O79T<5,7L\$?4$L#!!0    ( !I43U@Q&F',;08  "XA   8
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M*UE=&*J)%C/70L="FX;LAH6Y8X&T!N;[1 B]FM@?-+>VY ]02P,$%     @
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M;1+.UP5*:M[DU2M$\4M$+&+IE&.L9I* 3D\',+<%:V;FA[D;D( &3>F'4WE
M5@TAP2)(L!@(3! */0J%&H7R1I'&$#D<,)T3!FD0.);$WT(-<P.)8C6$$)OX
M%A;C0C4.6XX8$ZDQ4^S;U/:DP%@-[%LN]*)][$7;V(M/(Q=NP!GKC1UPD&!+
M2+ 0$BR"!(MM99(ZHQ'GJ!&G3:%G-,+O,(U*N!0X^>VKB^:&K;VI__6NR#+$
MEW:/2;G^6Z</!U(?D&!+2+ 0$BR"!(N!P 0IN4<IN<;IYGW.]9.E__#%QCW?
MW* 76;-J0<U&XB%)L^0V8U.^*9I62<90Q5;[DJ^CF'9)Z"HRGV)J46DB-S9G
MK$ @P<)![8\@2\9 8 +SWI%YS\C\KWPOW+&=MBM6':>>TB>\NNUAZ3:X,)8:
MRRHD6 @)%@WLCABHJ,"K?^35-_+:W@6FS19^C3BM.[XK25IG@'UJ7FMI]I7K
M<JAC^1+)QKIC21Y4,H0L&4&"Q4!@ L7!D>)@\)8,I56UYU3O<W[;?_J(+Q/S
MQ@9".[YD1'P/C\*;Z^O3E:-.!<:B8Q<"@3I4B.-Z6%J-+R&+AI!@$218# 0F
MR 5;O1%D?0W!:(T?2R&6>B1PI;FB"Q-V8Q+S9Y!L:0HP7]I84D'18B@TD=83
M?P\;:7W'=OMRM6EV L5=,]GW)']AJ)N!QXYU4+0E*%H(BA:!HL4=FKCD= EV
M[9-I4M1&[]IALVUW7AM:/:A&VM2WB.TKXQK2KEJ"HH6@:!$H6MRA.88.%HGN
M73=LMMV6:;4KJM;=;I@N^%H^*^X_H]M]Q2,KO7M/%;H]6U[3F^N.IGI R1"T
M9 2*%D.AB33WMB V^X*B#<_R]4!+$&OY!_4$L6IP>9;C6"Z5%WN@=4-0M @4
M+89"$]72&X38:!K-0U$?@S3A:%;L 0YDRWO1!9Y.99Y"M I&*+6I+6_P-(%3
MC ,I+-*%$>I[KO1_@EC3./,\VQMEV.R4R<;\?QV"D$;2 A1M"8H6@J)%H&@Q
MUIE^YA58[Z]A[W]TZ3&DD;4 15N"HH6@:!$H6@R%)DJJM_:PV=L#=.NQ:L#Q
MB9=23Y[M05T_4+1PX#5$H%5C*#11 [WWA\WFWR#?'JOV&[]?8N6?X0MSL='T
M@KIYH&C1T"Z)H<J*IVUZKXZ8O;KG^/=$M=+L0#7ES)7'DCVL: A:- )%BZ'0
M1*I[_XZ8_;NOY..;JXX^8J6:5'QW9_O2)+L$K1J"HD6@:#$4FJB:D_-XPP_D
M_4<SGZBN%'%]^1YA;L_H:4.U&M6:(6C-"!0MAD(3^>\-/V(V_)[K!!&M E1;
MSG$L&GB6O!#41'K-O_0P]N69 -)W"T'1(E"T& I-5$+O"1*S)VAV>?1\V\J(
MQ]BR?&S+=*N!BLM#5../4-^E1/9U-8%3KATJ'[O4Q=G\;N/*:S1-ZXPV#^F=
M,V)VSIYO\^C[6^=OR09#U^.@9^= T4)0M @4+1[4Q:(:>M./N/^CAT- /3]0
MM"4H6@B*%H&BQ5!HHJ1Z6Y"8S]T!>CA=)6$R)Y9\@F)A;M!HH8":?41SI$Z]
MA BT: R%)BJ@=_&(V<4;Y. 0C;=%'6+Y\JD\<['1[((:=*!HT= NB:'*BOSV
M#ATQ.W3/<G "92C;MN<J#@ZH74=42TQ3- 0M&H&BQ5!HXA-/O5E'O\K!NB\Y
M.%2UU@AU;,6]U<0%ED.5A;KY*L:.:E"T"!0MAD(3]= [>O2K.'I:#6!E1G!L
M*C].H8E2R%<-/ XDG<8,S1<VFE10PPT*322U-]SHF"=@AV\(J996U?YRG,!V
M+$^^L6LB/;ZKP;:O//D(>HP.%"T"18NAT$0EG#SA:K;>S(:+GF_U"5$?8PL'
M,MMJG">?F-;$$)NZ#J'R8-8\OVK;TL00Z:)\0EQ;:ENL#32X+;1WL*C9P7J^
MVZ+O;)W/I'=;S T;NY("10M!T2)0M'A0%Q_4,#OYZHKFNT]^2<K[-*]0QNYX
MKO7*XX(J#U\G<GA3%[OVVRQNB[HNMNW+#4OXW;,)X'^_*XKZZ4WS!1G'+W69
M_PM02P,$%     @ &E1/6$6<N*BE"0  >S   !@   !X;"]W;W)K<VAE971S
M+W-H965T."YX;6RMFVMOVS@6AO^*X!TL&F!<BQ?=LHF!UIK.%MAI@V9G]S,M
M,;:VLNB1Y*297[^D)%L6>40Y W]I+/GE,5]>#A^1ZMV+*+]76\YKY\<N+ZK[
MV;:N][>+195L^8Y5[\6>%_*;)U'N6"TOR\VBVI><I4VA7;[ KNLO=BPK9LN[
MYMY#N;P3ASK/"OY0.M5AMV/EZT>>BY?[&9H=;WS+-MM:W5@L[_9LPQ]Y_?O^
MH917BU.4--OQHLI$X93\Z7[V =W&-%(%&L5_,OY2G7UVE)6U$-_5Q>?T?N:J
M&O&<)[4*P>2?9[[B>:XBR7K\T06=G7Y3%3S_?(S^J3$OS:Q9Q5<B_V^6UMO[
M63AS4O[$#GG]3;S\DW>&/!4O$7G5_.N\M-H@F#G)H:K%KBLL:[#+BO8O^]$U
MQ%D!Y(\4P%T!K!>@(P5(5X!<6H!V!6C3,JV5IAUB5K/E72E>G%*I933UH6G,
MIK2TGQ6JWQ_K4GZ;R7+U<B6*2N19RFJ>.H^U_",[M:X<\>2L6+5U/LF!43ES
MY_?'V'GWTXWSDY,5SK^WXE"Q(JWN%K6L@XJT2+K?^]C^'A[Y/82=WT11;ROG
MER+EZ3# 0E;^Y  ?'7S$UH@Q3]X[!/WL8!<3H$*KRXMCH'A\>7%D<4-._4&:
M>&0DWM<]+UF=%9MV1F1UQL%6;J-0.(I*%K?5GB7\?B:S0<7+9SY;_OUOR'?_
M ;70-8/%5PHV:#UZ:CUJB[[\(A/ENUQ4U8T<IHG8<:CIVA!>$T*EQ>?EG'C8
M#<.[Q?-YJP Z3%#HHJ$N-G72#0V0=](-O'@G+Y[5R[]X5=TZRE%KQ7DJQ<Y)
MLRJ1\R<K#G*^BG:PR"D,^6S#^V?U<C6'DXK85*#(1QB/>/-/WOS)?E+=U'KJ
M#*E!;W?D&[6!>P[0@3T'QO,]Y,+N@I.[P#J'/Z3_DXF[S:.UD*NC-)AD.7>*
MHVUY5WU.5(8]5+(G95(5P,R_A5HAN.;4OV:P^$K!!HT>GAH]M ZIF,N@2<9:
MFBA2A^U$66=_-C>@9@R-SO=]M8 ,1I(I"CV?:L/(%$68CHRAZ&0GLMIYK$7R
M?:Z()I7S8R<QKVJM\1_J,YC8(J,>E :^KUD"5!&.-%5LJCSBN2%L"KD];;C3
M"9HE2<D;,Y(RFH1V*.J;08>I;V1_[K+#SI%7$DF_\YJMY1RJ>'(H1Y?%[N<'
M4]IS/6WBKR 90I&61V) YD<T&FF$,^1"UD;XE:GI7C@5DWZDT3;_;62^</;L
MM<D;H#<TF= !R1SA(/2([LP6:V@+][:P?<%2F>W=1IJ[4>YDQ^Z%M-AVI<IN
M]6LS,?D?AVRO7((FL3GP]-JO -&<&IUGBA >\=C3&;+BR_*+*.9-UNZS=<[E
M)+5-RR[DH")N@(V^,V51%'FZ*T#ED6#$5\]-R Y.O[35=UA5"95$9=9YR>JM
MDV=)>W]3<C[:9]0T&'BN8="4Z;AAE0RM]1B%[!SUC;,\^U,:VG33+BN>>;<\
M@VY,YIECG3  D>'%)AEZZ;$)^5:R6&V9S!.5A@M5Q25IJ*F59VR=Y>/H@*Q8
M]E9VN&JT^%K1ADW;,QNRTLGR0](L0Y7"-9X]J[7F9P5I8#,&YA"1R*^/$4"%
ML:NOM(!L;)ST+(3L,/19#O&B%N4K6'N35^;(]4*C_H NE*R@U]^4C=6_AQ]D
MIY^O]9:79ST!3U2348R4 R*1;L 4S2D)1E@']ZR#[:SS4/(]R]+CTM#.4-$X
MDPA3JN5>W2G4DG*\;J8R9!:;*$)"HB^,@&J. GW$02KLA]0?<=R##;:#S6D.
M28Q1W08: 1 E#$PGIHQ08C@Q52CTR8B/GF2PG62DCU(]7Q][#O0!X46( MT'
M@"K(UV4Q(//'NJ.'%6R'E:\:HYRM#J C$RWFB/B^T360S@WU-3*&=(&'1U@%
M]ZR"[:S2)H<I,R9)S#$RGN\ &7%=G98!U4B*PSV68#N6?+GD^=^97[XY@B%N
MB7S7Q[IG0$C<B 9&!T)"1-UP;&3V'(.G]W\N,?^&W2YL;N;HJ\&T) 8D\XA@
M0D<<]WB![7AQD6/0%T018+<"0KA; 2%U X+'QG2/'3BTXNGGAJPO\&2EE[=B
MZ%6CQ=>*-FS"GGRPG7P>#F6R98H6Y&/SQ=L>&$(8%$3$F * $+G$#4)];Q14
M2BK"&,'#A/1@1*; 2"2<I]WN[X[5G;,&A]2FR-O,$V"7)J!^$&G> 1U"5*[%
M^C,V( QQ%+HC28#T?$3L?#0T_L;M'S*]_0-($$&!3O:Q-=306\],Q,Y,#UW5
M_]H6 H$P"=A# '1Z"K=*AN;.#N7L)#68E9=O9A& @*+(&)> BH;&A(1D7D#'
M9F./4\2.4_"@M/L"-GP(]G1?IBHR]LX!T5AO]6A%+D0KV5//62H'XOK5>=<M
MO#?=_L]?!RUB8A$FD:>GD16DHP3[1L<"F.5Y%'DC3Z"DQRQR(6:=-\2(_3>@
M%IE&K6E)#$A0Z.*(C- EZ5F+7,A:4[9!<R8=P;T+Z,#>-74(TS 8VU\@/6T1
M.VU]R@I6)!<XNBIM735:?*UHPR;L:8M,T-9QT1*%\W1JSO9I6:SS;&.9!-.[
M3X!D3H@Q0 "5-S8Z: ]9= *RNB5+)?.ZE(X.Y:M3J5-%\)T($WET-].2&)#,
MY92F8P^,M"<G:B<G-:7WPX5*69&)JCL4Y662'??8^&Z?BU?..\W^V!+[G($G
MP=3$(8\:.U* "OO&*@VH2'!^O#IL@!ZOJ!VO)M:TIPMS 06.UP"KI@H3S^AM
M@-D"WPO\L;';XQ:=.&539INC#O6DW-A6_=I\4&#R+"%EA)(I1$G(]?3-;4CG
MD]#7-^8 7>#YT0BCT+,7E>S4M1HSY;#:6?--5A0-B<C)NY4CEY>92$&_$(I%
MV-,A$]!AER"L[ZA"\7! QQ9EVD,9M4.9U3!7.^.35DU."D/LZ@LS((-:) 9T
M6HL,G?;41>V'=(^'_3YOGG18WF!5+F3R;1)Q<3P^/J,1:;V?O77)BHHUK\3"
M)WCTJB=X5XT67RO:L-U[[*,3)WAIFC4-IUZO@A_25#IAVB%%^[+0!3O^U"0Y
MSQA\ .UY^@8<)/)'5_R>!ZG]T.^T1-3L!U?V,G@:F>=U2&8TW8CM5*^S 03R
MW5$?/911.Y1]TD#L;*??8656J6\:!!#KFF5-FM39;?P<K?MM;]S7:EH2 Q(/
MZ4_BB[.WLG>\W#1OMU=.,_K:UYM/=T]OT']HWAO7[G]$MW'['GP?IGTM_S=6
MRI6BDJZ?9$CW?2!K5+9ONK<7M=@W[WZO15V+7?-QRUG*2R60WS\)41\OU ^<
M_K_!\O]02P,$%     @ &E1/6&V5W=[0#P  7BD  !@   !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6RU6FMO&[<2_2N$FUNT@"Q+<NRDS0/P(VG2YF'828KB
MXGZ@=BF)S>YR2W(M*[_^GAF2^[!D)P'N!8)86BV'PYDS,V=F]^G:V,]NI907
M-V51N6=[*^_K7P\.7+92I71C4ZL*ORR,+:7'5[L\<+55,N=%97$PFTR.#TJI
MJ[WG3_G:A7W^U#2^T)6ZL,(U92GMYE059OUL;[J7+ESJY<K3A8/G3VNY5%?*
M?ZPO++X=M%)R7:K*:5,)JQ;/]DZFOYX^I/OYAD]:K5WOLZ"3S(WY3%]>Y\_V
M)J20*E3F28+$GVMUIHJ"!$&-?Z+,O79+6MC_G*2_Y+/C+'/IU)DI_M2Y7SW;
M>[PG<K603>$OS?J5BN<Y(GF9*1S_+];QWLF>R!KG31D70X-25^&OO(EV^)8%
ML[A@QGJ'C5C+<^GE\Z?6K(6ENR&-/O!1>364TQ4YY<I;_*JQSC]_)WUCE3 +
M<=HX_.;<TP,/N?3K019EG 89LSMD3&?BK:G\RHD75:[RH8 #*-1J-4M:G<[N
ME7BNLK$XG([$;#([O$?>87O*0Y9W>(>\]W8I*_U%$A!&XLQ4SA0ZEP$752XN
MK'*J\N$";/%25[+*M"S$%2XJ@- [\>^3N?,6,/K/+A,%!1[N5H!"ZU=7RTP]
MVZMI+WNM]I[_^,/T>/+DGN,];(_W\#[IW^C$[Y4A+M5"655ER@EOQ,E2&R<^
MK*QIEBN$M_ K[<1)534PTZ6JC?4"UJ-8$=/)_A\C\>,/CV>SR1._4C!Y6<MJ
M,^)+TR?I)Y9Y^^):W;[2=/>0M^)5T]C!9:=+74@KU V9F+*&&^%+IFHOUBN<
M1) F&9"J;CP2RC^-QGW"X*I=:Z=&E&24[<YZL9*(^TPU7F>R@+#7%6!)6VG
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M_8%O%!,6H-SIRW<GN%FU6.Q+[_)XJBE8B$*6-*+=O;3+$*L!NF!2)>(:?Y4
MLR='01=/4!7'?)X/;R\NKZ[P>:FJD-'75"C@)*[>=6-=,SPEZ9KLUU69;?_&
MD-@O#<C5AG4:>'P0#S4@EVT@@'(OCA81\(EPS\5P7E#2ATQCD1W:B &Y_1N5
MFU0EE#NV?X!*()=446/=TU6.IM52RLF*AIC-2,S1+%3&XSRE#OQSA/R3@>;
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MQ(?7IU?O/[T/C<UH,'[9!Q]?JNW!@$--M=*A#%9Z/B*2/WLT84OBX_'A<6@
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M\4$0W7<6VGWC7,FJ'S)IV>99]J?4.6#FI8 =0MXJ;PJC"/)>L^'0"_80E,,
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MXW!$NA_;^P>KEMVH/%46@W>W7.!+1VHG@/.94G;[X!P,WTY7_P%02P,$%
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MX7HMWNNB40>!0L):(N:S4W++^6,Y"DUZ4G;VQ.8K66^<+K8J$:\169E7R&?
MS!!WQG2EDU @)7 C40DBL],PB03]HC8.Y@\BNV(&6$,I<,0AVJ</516T[$P)
M)$M;&-FK6'<Q@YSN8&$ZJ"ZM?1_ ;?A1RKS/*55:V%N*O%=Y2_-!E/BYI"+M
M[+,>62FE=F!>]U%1MIO0KP?,J-Y!WM0/I4I=9QO.,02BUX ,D=A]%CH.J.)L
MC6,.!8L2!H#.:RYO2;X:#%#_0OSP*Y4W&@86_(_,EO23T4\JWCPJX=QZ['XA
MTD629:LG%U=(FJ_$3NJ"HR%KVY*[CWNIAK'6<;TR@YQIE'2=I*NI2%?)=+9
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M4=))J73#+6WU.C*M1EYX4",B%L?#J.&U#&83[UOJV41MK*@E+C683=-P_;Q
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M)>QUN.<PJ9E91P.0=HFFSOB'N::&?OKJ-WD6?$A!P7'\7:?;E&@0NE^NA=]
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M[<R*+Y=*P@!Z )_/#9A5>$,;M#^;NOH/4$L#!!0    ( !I43U@H<?!". ,
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M=@ZAP-HZ!$;;(]ZC$ Z(W/AQP Q.)IWB.7U$?^]CIUC6S."]$G_RQFX7015
M@RT;A/VL=A_P$,_4X=5*&+_";I3-R6(]&*NZ@S+Q'9?CSIX.>3A3J.*?**0'
MA=3[/1KR7KYEEBWG6NU .VE"<X0/U6N3<URZHGRQFFXYZ=GE2E-]M=T#DPV\
M^S'PGC)N0Y!HYY$E TXLJ@]@=R-8^A.P)(5/2MJM@7>RP>8E0$2>G=Q+C^[=
MI1<1WV(]@2P)(8W3[ )>=@HW\WC9OX0;PDHP:5]&#7_=KHW5]%#^?BWV$3E_
M'=DUS\STK,9%0-UA4#]BL/SUEZ2(?[O@=W[R.[^$_E_+]+_!X,4=OKRK%?6B
ML=B :L%N$5HEJ*FYW "S0*7";HV:RC6#-Q\E2:C!$(RY]M5S2PH/;*TTLTKO
MG]'A"I(RS+.,B#0+DRJ%>]7U@R6P9R'GD%&MW3&-4(33HJ U*6_@ :DKMTHT
MP+M>JT=TX@:R,DS+\KB]'[3D=B!5A]/R)T>34)A/;VB=)CG\WK:\QC.+:9@6
ME5OSBAR2]#2&<91P"61H0P &BKB"8EK"5V69<,>OI ^*,BR2!,HLC$GT@?1F
M-(_JH1L$<_ELD-Y,S9E'?S,ED^G--1%Q&)?Q]47LL324P6F84>(H@VEX4Y54
MCC-(?*(A;ES!M"_<'IDV@*Y)S^LVMEDX5LI9(2*!'3-P54P*&C]"$%H(5]4D
M/W)>C@ZJYVO*2X]^VHK]Y+7''YW-JP[UQD]E0^]KD'8<7:?3T^"_'>?=L_CX
M:WQB>L.E 8$MJ<:3<AJ 'B?QR%C5^^FW5I9FJ2>W]'FA=@)TWRIECXPS</H.
ME_\ 4$L#!!0    ( !I43UC._=*=JP(  /,%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;(V4WV_:,!#'_Y53)NT)D1!H5W6 !&VG[F%2U6KKP[0'
M)SZ(5<>F]@7*_OJ=G9 QJ65]"/C'?3_^7N*[Z<ZZ)U\A$KS4VOA94A%M+M/4
MEQ76P@_M!@WOK*RK!?'4K5._<2AD%-4ZS;/L/*V%,LE\&M?NW'QJ&]+*X)T#
MW]2U</LE:KN;):/DL'"OUA6%A70^W8@U/B!]W]PYGJ4]1:H:C5?6@,/5+%F,
M+I>3$!\#?BC<^:,QA$P*:Y_"Y*N<)5DPA!I+"@3!?UN\0JT#B&T\=\RD/S((
MC\<'^I>8.^=2"(]75C\J2=4LN4A XDHTFN[M[A:[?,X"K[3:QU_8M;$C#BX;
M3[;NQ.R@5J;]%R_=>S@27&1O"/).D$??[4'1Y;4@,9\ZNP,7HID6!C'5J&9S
MRH2/\D".=Q7K:'YEZYI?S@/9\FF:$A/#>EIVZF6KSM]0CW+X9@U5'FZ,1/DO
M(&4KO9_\X&>9GR1>8SF$\6@ >9:/3_#&?7[CR!N_P;MY;A3MX>>B\.3X"OQZ
M+<D6,7D=$<KBTF]$B;.$[[U'M\5D_O'#Z#S[?,+@I#<X.47_[P=XOQH>$83C
MIZ'*.O4;)9 %Y7V#,,K/!EF6A0=\Q5$>[ ILXZ!L"3X0AG!KM407-X\W(A<-
M*=(MU1J$K26$#;H6.(2%E"I4FM!Z/X#JG22')7)=@E1;)=%(/P"U F$D["HT
M7&"E9HF$8A_M%E8X&:!2L9*LX_@0S*1H QQ70:'WH$R,%]XC>="X#K9 ;(72
MO(_ _8P9?"E4T<3^$+)JNF0.YAE"%?O=LN-PJ%9\G:0(\</7OGUZ5(@UNG5L
M-YY?0&.HK<E^M>]HB[:0_X:W[?";<&ME@O,52[/AI[,$7-MBV@G932SKPA(W
MB3BLN"NC"P&\O[+\?;I).*#O\_,_4$L#!!0    ( !I43U@*-U=[M 0   D,
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;*U636_C-A#]*X0;].3(
MLFQGG30VD.P'NH=T@Z3M'HH>:&EL$9%(+4G%\?[ZOJ%D6XGC8%OT8DLDY\V;
MX<S37*Z-?7 YD1=/9:'=K)=[7UT,!B[-J90N,A5I["R-+:7'JUT-7&5)9L&H
M+ 9)')\-2JET;WX9UF[M_-+4OE":;JUP=5E*N[FFPJQGO6%ONW"G5KGGA<'\
MLI(KNB?_1W5K\3;8H62J).V4T<+2<M:[&EY<C_E\./"GHK7K/ N.9&', []\
MSF:]F E10:EG!(F_1WI/1<% H/&MQ>SM7+)A]WF+_BG$CE@6TM%[4WQ5F<]G
MO6E/9+24=>'OS/I7:N.9,%YJ"A=^Q;HYFTQZ(JV=-V5K# :ETLV_?&KST#&8
MQD<,DM8@";P;1X'E!^GE_-*:M;!\&FC\$$(-UB"G-%_*O;?85;#S\_M<6A)W
M5-4VS1&=N+5F965Y.?! YS.#M$6Z;I"2(TC#1-P8[7,G/NJ,LN<  ]#:<4NV
MW*Z3-Q$_4!J)T; ODC@9O8$WVL4Z"GBC(W@?O]7*;\1?5POG+<KA[]>";"#&
MKT-PBURX2J8TZZ$''-E'ZLU__FEX%O_R!L'QCN#X+?1_=1G_#4E\T>)&8DTD
MDY!79'=-0FIM:IU2)GPNO3 U2MU(FPFS%)FRZ"!CG9"USXU5WW%,HB%WV%6#
MW1?&POXUMWVQ;/<Z9L"N*^&-.!E&B5BHHN VQ2J[AWXX+W6F]$HX#L;Q3FK*
M$F?0%>E#M(^EK1'\*HTS6K<MOU8^/\H(89/V9!&-TF AN9F55JP2C<LN6;FR
M1! CWX!>W]PS\\Z!=]$0_=G$L"?,H71)BYR*3"PV(B7K(9D0PX53F9)6-08,
MS+F2$*P5?*ZD1X+WF59I2-S):#R.)EN'(?,GXVDTFHJ*;.,_$K_GRG4IKJ5C
M,E5!'D&#TA7P"M$60B0^U1;)LOW]5O*_Y/6N+D@,X\7D=/BL; H$B0/K7.$.
M85;*37>_+8ZS.([B76H1^_'L1N(JK$,XJ%P@$5OQ"*SVT*C?"D7[I*#J5&S$
M^:MW]^S>EB'#D^F>2I/T21R-)OND]T4-\6O;X'C8D?C,H7M9](7\0<K#,W3)
MC["<QLE!:9Q'X_,C+ ^N,!*_F>>P7#A[(EEMN2O9>$,2ND"L]X<1L.>7BTGH
MVB_0$U[L2A J!I\W&2H3U]I-WD$SALJ!.'"A;K&&HP[8D0(\'4X/"Y %3Q88
M3IRH'5<<"CVK4Z@@!A_4I'W :+2W0M(?.7683-H*9;J6> #BM&Q%4H9.>3O/
M7TGD$FI3R=JU<;^,U>V4$__XX)!<()9E[6ON\+M.?;0EP>9!9'!G'F.:J^VF
MO<9:>_0TL#:B<>(5)\DP_5/E7$T91..YS9X'F\@TQ7>"[XA9[8-+C?.B)$2>
MH9V1>B@<K^,>X*+91JWRDDSQ%6:W#7Y0J-18KJ #QMT 7Y?30U)-.[$G1]X7
MC69GJ"O60S!#>>!'FS9\WG:=%$A\!1N$YWEX4?3':CYZ;0H8=,:SDNPJ#*$L
MQ6#=3&J[U=V<>]6,=_OCS9",[]U*:2<*6L(TCMYAK+3-X-F\>%.%86]A/$;'
M\)AC5B?+!["_-,9O7]C!;OJ?_P-02P,$%     @ &E1/6'Y*P@C+!@  2!$
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MI;N F!U^^#U ^G25),:FJLST)CK@R%H$9XP-GAS6KK@RL391)A+)[W.ZNON
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M.I_]<I&I,#Q+@T#8I:=@B\0/2UJV_))#$ 4^KQ%I%,3!]-]@\P]02P,$%
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MX$97)1KK:R:*5]8,EEQI:['#7/\M0)@ O;_B7.TF)D'W_XG_ %!+ P04
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M-+Z]8@3;E?JD+#%8A\%RWF:551R<2E<EXF11GO+XD05J-TW6-JC",^*_,PY
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MR7R?!"G*,YMP<T]\C9G%W=UV<PQ;=K4<W%J-RY^:3M0F.:27<^F9JXLOTV2
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M.-\P;1 7-2)Y!3$F<".%*32\$QEF?P*$EE[+D>PX+LA!Q"M,^S"(>T B,CB
M-V@U#SS>X-^:KYA.N72R-7R_2+11MDQ^[!-=0P[W0[K6F>@U37$6V-[0J#88
MS(_>Q*?1^0'"PY;P\!#Z?%EW#,@<+JDNX-W/BFTH]P=%108W5#V@<0<&2TPK
MQ0RS>IKSS( :Z$AVK0!WSDTQL8(%U4SO$WR0TG[!]P5"+KEM=(=<$ZJ[G?VR
MA&2E('7\\2_^Y3-__<R_[/#/'?^-Y^\"DB?@N$$.QU3;'M2I8HEU9 (^2X-
M>K"LH,W9DJT$RUE*A8&+-)65,([?K>0L=1N=U#E1;4X2EQ.PT#;8%A^6":JV
M "=P?"W %++2EHH^@4^>2=R,I!D'<"\-Y?6!=06_A4'4B\G 3H[>C$E,SO^8
M-3_KX!?9:O[NW'=CLWRS+X\3^-)?]N%>^70ZO6W4J'<Z(G^;'^0&E7"W0/<P
M=DYD=-:+2/3"OI1J+16UR<\PV1LY)*/><'SZPJZ5[B^!G>]9/.[%H_$+^Y4L
MO5Y3G>3O,+K)/QN.>V0<P[Z>#3N7;(EJY9\2#;Z<ZONV76U?JXOZDGYVKY\Z
M>TXK)K2MX=R&1OVS40"J?CYJP\BUO[(3:>P#X*>%?7%1.0?[/Y>VS!O#;="^
MX?/?4$L#!!0    ( !I43UCG.4(V! 0  'P)   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;)U6;6_;-A#^*P>U*!R B\07451J&\A+VP58AZ!)N@_#
M/L@V;0N11)>DXG:_?D?)4=W"]H9]L<GCW7//\1Z*'&^-?7)KK3U\K:O&3:*U
M]YN+.';SM:X+=VXVNL&5I;%UX7%J5[';6%TLNJ"ZBEF2R+@NRB::CCO;G9V.
M3>NKLM%W%EQ;UX7]=J4KLYU$-'HQ?"I7:Q\,\72\*5;Z7OO'S9W%63R@+,I:
M-ZXT#5B]G$27].)*!/_.X7.IMVYO#*&2F3%/87*[F$1)(*0K/?<!H<"_9WVM
MJRH (8TO.\QH2!D"]\<OZ.^[VK&66>'TM:G^*!=^/8E4! N]+-K*?S+;7_6N
MGC3@S4WENE_8]KXI9IRWSIMZ%XSSNFSZ_^+K;A_V E1R)(#M EC'NT_4L;PI
M?#$=6[,%&[P1+0RZ4KMH)%<VH2GWWN)JB7%^^K&P3]H7LTK#O9ZWMO2E=C!Z
M"!9W-HX]Y@B>\7R'=]7CL2-XE,%'T_BU@W?-0B]^!(B1W,"0O3"\8B<1;_3\
M'#@EP!+&3^#QH6+>X?$C>+?-LW8>=>4=@1L]\U T"WCWI2W]M_T]^/-RYKQ%
MU?QU:!?Z'.)PCG"2+MRFF.M)A$?%:?NLH^F;5U0F;T]4((8*Q"GTZ3V>S$6+
M'3-+.-B_0X1/0AXFO(?MON]+X7'7YKJ>:3NT!>8&CZGS>A$X^;6&I:GPO)?-
MZ@)&MPV:3.MPG]T97-;&^O)O='UL\#-2_3Q\7Y06KEMKL4,7\'A^?PX/N.@P
M/V9_#3PA*I,X>/-*,<K>XFB4RK/="DO@@WG6M@D-WJ?-1$:$3(#F D8R3\_0
M(DF>YG!M[,;8PFL\S;,?8@2E)!$IJ QC\@QC!$U(+@0\&%]4+RQ!JIQP10&]
MI8(1)1E#0E(I''#XW32_S(_5(XA*&#(?JD$#9T=JR$FN)&3IX(QL$DE/5$ %
M$0A.\5@.,8*D@NTJV.,&+">,*F T&WS1)'BZ\ZT/RN$U9%21-,]Q1 E3:>C'
M;@?Z-9HJ^,]28O]/2M?&^7T1?<#KR.T;?C/.8<9.7)^+JM6G)":1=!8*X:$8
M16DH16:$R^R8NACJ(J& W4]Q$W)4%TV)1#4>[PV7G##)@<*($9YC$BZ#MOG/
MZDIQF>> /1PI(H*C%)PH%/-):5$4//83I4MS?A:FC.5'^-/@C"5GH7<R1?X4
M^2M4[PEM*4X2G@$>1BR !5Y4A2-X2%P<$^2H1(49!*$""7&*163B7]259PGN
M4E!7)[$1941R$1J2IQG)N(!#7]1X[T:LM5UU][Y#;;6-[R_'P3H\+2[[&_6[
M>_\N0>FN@I@JO<30Y#Q+([#]7=]/O-ET]^O,>+RMN^$:GT?:!@=<7QKC7R8A
MP?#@FOX#4$L#!!0    ( !I43UBYF\,DJ0(  *\%   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;(54:T_;,!3]*U<90B 5\NB3TD:B=&AH8JH*#*%I
M']SDMK%P[,QV"?S[72=MUFFE^^+XOH[/C7WNJ%3ZQ62(%MYR(<W8RZPMAKYO
MD@QS9LY5@9(B2Z5S9LG4*]\4&EE:%>7"CX*@Y^>,2R\>5;Z9CD=J;067.--@
MUGG.]/L$A2K'7NAM'7.^RJQS^/&H8"N\1_M8S#19?H.2\AREX4J"QN78NPJ'
MDX[+KQ*^<RS-SAY<)PNE7IQQFXZ]P!%"@8EU"(P^KWB-0C@@HO%K@^DU1[K"
MW?T6_:;JG7I9,(/72CSQU&9C;^!!BDNV%G:NRB^XZ:?K\!(E3+5"6>>V(P^2
MM;$JWQ03@YS+^LO>-O]AIV 0?% 0;0JBBG=]4,5RRBR+1UJ5H%TVH;E-U6I5
M3>2X=)=R;S5%.=79^%:^HK1*O\/) UL(-*<CWQ*NB_K)!F-28T0?8(01W"EI
M,P.?98KIWP ^$6I815M6D^@@XA23<VB'+8B"J'T K]UTV:[PVO_M<LI-(I19
M:X0?5PMC-3V+G_M:K@$[^P&=5(:F8 F./=*"0?V*7GS\*>P%EP?H=AJZG4/H
M\3U)+UT+!+6$AOH^D@=A]I-L\%I09CS)(%&D,&.-.RQ1>8XZX4R02HM"O#OG
M['G^^/7YVY3:ZW<N6]L"3%W09@A+)4C;7*Z&<'(KR:76ALG4G +=(^8+U,U=
M_N.)8,Y*>M 6-9UJX BZ(2W'GP91&%W"$TGZC,NS0JL$C8&PW^KV!D!K-X ;
M+CF]_!162J44:W6Z?;CH1/"@+'7 FTL_@O"B%?1[M!FT.A<1[+LC?T=$]!-6
MU:@PU.U:VEI/C;>91E>U"/^DUZ/LCND5EP8$+JDT..]W/=#U>*@-JXI*D@ME
M2>#5-J.)BMHE4'RIE-T:[H!F1L>_ 5!+ P04    "  :5$]8A27JCL@#  !B
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6R55FUOVS80_BL'-2A2
M0(U>;%EV:AM(TA4+L*!!DFX?AGV@I;-%5"0UDJJ3?[\C)2O)Y@K9%^DH\9Y[
M[NXY4<N]TM]-A6CA4=32K(+*VN8\BDQ1H6#F3#4HZ<U6:<$L+?4N,HU&5GHG
M44=I',\BP;@,UDO_[%:OEZJU-9=XJ\&T0C#]=(FUVJ^")#@\N..[RKH'T7K9
ML!W>H_W6W&I:10-*R05*PY4$C=M5<)&<7\[<?K_A=XY[\\(&E\E&J>]N<5VN
M@M@1PAH+ZQ 8W7[@%=:U R(:?_>8P1#2.;ZT#^A??.Z4RX89O%+U'[RTU2J8
M!U#BEK6UO5/[7['/)W-XA:J-O\*^VYOE 12ML4KTSL1 <-G=V6-?AQ<.\_@G
M#FGOD'K>72#/\C.S;+W4:@_:[28T9_A4O3>1X](UY=YJ>LO)SZY_0TK)P.D#
MV]1H/BPC2Z#N553T )<=0/H3@"2%&R5M9> 766+Y&B B-@.E]$#I,AU%_(S%
M&4R2$-(XG8S@3884)QYO,I[BGQ<;8S6IX*]C2780T^,0;C+.3<,*7 4D?8/Z
M!P;K]^^26?QIA.!T(#@=0U_?TZ25;8V@MN#)PI4R%I@LX:NM4,.U[*:/9'R,
M^RCZ<>X/%4*A1*,D2FM<X-H'QD>:=KJ[V,K'YL^Q:0AK9K$$J[KM!O:H:;.!
MK:IIO,TYG%Y+L)5J#2&8#[Z%[I*Z2P)?&]0$)7=]N(+R-' "21:F:?X?8P%7
MS%30,%Y2! U,J-;1Y;*H6Q(;&10,01!8JY&^%=:EHOX5I>9LPVMN.1%.YF&2
MQY#D83S)()F&TR2!D1YF0P^S-_?PFRRY*1Q5HGC#)1>M@#LBQVKJK!#<.J;F
M6"M'@QQOY85O'PT-B@WUZS X(;0O:8B>ANYH%,\TW#[RDTI^+)@LJ,7T)>C[
M&_JR(RLJ%\.56N*CA2U]2.$)F39>*%8Y2*<69%N+.GR++*:NR7F83+TTJ!6+
M,(MGSG:7,,D29^?.SK/,V7.8A--\ 0]#('C_;IXFZ:?7%1])=9Y0VR<T3^2,
M-&*G"UKG'^#!9S"FFQ/(DW"QF(UI939H9?9FK7QI+2EW4$DW_K?LJ>-+@[9!
MDDZ!5/'RF&!&(_U/P;C^;CL^AQIVA6A>\]$]GUXYSJU6<O>1BBKH=-]T3FRG
M$3NW-\DA"^-\WFLAG"1QWY03F(63^?QHW:,7YYY O?.GNP$OA.X(')X./Q 7
MW;GYO+W[^[AA>L>EH82WY!J?Y32)NCO1NX55C3]%-\K2F>S-BGZ"4+L-]'ZK
ME#TL7(#AMVK]#U!+ P04    "  :5$]8%DY^/*@"  #2!0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S-"YX;6Q]5%%OFS 0_BLG5DV=A H8DD99@I2TG=:'
M2E';;0_3'APX JK!S#9-^^]W-@G-JC0OYLZ^[_-W/NYF6ZF>=(EHX*46C9Y[
MI3'M- AT5F+-]85LL:&30JJ:&W+5)M"M0IX[4"T"%H;CH.95XZ4SM[=2Z4QV
M1E0-KA3HKJZY>EVBD-NY%WG[C?MJ4QJ[$:2SEF_P <V/=J7("P:6O*JQT95L
M0&$Q]Q;1=)G8>!?PL\*M/K#!9K*6\LDZM_G<"ZT@%)@9R\#I\XQ7*(0E(AE_
M=YS><*4%'MI[]F\N=\IES35>2?&KRDTY]R8>Y%CP3IA[N?V.NWQ&EB^30KL5
MMGUL''N0==K(>@<F!775]%_^LGN' \ D_ # =@#F=/<7.977W/!TIN06E(TF
M-FNX5!V:Q%6-+<J#471:$<ZDBRQ3'>9P\T)EUJCA_)&O!>HOL\ 0O0T*LAW5
MLJ=B'U!%#.YD8TH--TV.^?\$ >D:Q+&]N"4[R7B-V07$D0\L9/$)OGA(-G9\
M\0=\*_[JD@/>Y. RYT+#[\5:&T6_QY]C.?>,R7%&VS)3W?(,YQ[UA$;UC%[Z
M^5,T#K^>T)L,>I-3[.D#M6#>"019P/M"'=-ZDNVXUCTM[NN?26HX;6B++C4E
M0B$%=6[5;( ;H(I@O49%59G"^6U#$;+3])SZBRN27=B@-9.U9>6N_\Z Q3Z+
M&1G1Q(_"T1!FQ7"5E:XL.3[3I&BI[PWAM=$0C?QD',/$3]@;IE6R0&U' Q=0
M( F/_2@: ?.3^"U*4@(*(C\>7=IU,H)':0C WV=]!@GAQY=DQ"&%AW"L?,%!
MG]6H-FZ:V"?K&M.WW+ [#*Q%WZ=OX?VTN^-J4S4:!!8$#2\N1QZH?H+TCI&M
MZ]JU-#0#G%G2T$5E ^B\D-+L'7O!,,;3?U!+ P04    "  :5$]8&E!^DL$$
M  ! #@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R]5VUOVS80_BL'
MMR@<0(OU:MFI;<!)UZT?"@1)MGT8]H&6SK962?1(RD[VZW='R:J3.$KJ#P,$
MBJ_/W3W'.Y*3G53?]!K1P'V1EWK:6QNSN1@,=++&0NASN<&21I92%<)04ZT&
M>J-0I'91D0]\UQT."I&5O=G$]EVKV416)L]*O%:@JZ(0ZN$2<[F;]KS>ON,F
M6ZT-=PQFDXU8X2V:WS;7BEJ#%B7-"BQU)DM0N)SVYM[%9<SS[83?,]SI@SJP
M)0LIOW'C2SKMN:P0YI@81A#TV^(5YCD#D1K_-)B]5B0O/*SOT3];V\F6A=!X
M)?,_LM2LI[U1#U)<BBHW-W+W*S;V1(R7R%S;$G;UW(@D)I4VLF@64[O(ROHO
M[AL>#A:,W!<6^,T"W^I="[):?A)&S"9*[D#Q;$+CBC75KB;ELI*=<FL4C6:T
MSLRNE4RKQ, -;K&L$/IW8I&C/IL,#*'SG$'2(%W62/X+2)X/7V5IUAI^+E-,
M'P,,2*U6-W^OVZ7?B?@)DW,(/ =\UP\Z\(+6UL#B!2_@[6U<*EG %>FJ:$\0
MWV8-5Y9I5/#G?*%M_U_'&*CQP^/X'#\7>B,2G/8H0#2J+?9F']YY0_=CA_9A
MJWW8A3Z[I7A,JQQ!+N&)UXZIV@EV7-4]JJI1'2C1.+ 3&NA;RIP"F/\*S!KA
M 872@.QJ($=AL2#V N\"^E]*FB K+<I4GUG?<>%SX<$Q&? >_*$SHGGOP?.<
M.'2I\N'=R/?\C]#!7-0R%YW*',S9*E$F"*0N]5HJ]#%".V4<)_2.>*IYR\H5
M&!M93?K+_D7*)CE+UE:T34^9>8"L!!3)FI5EGC>/"0/Q2.%&%"3"X$JJ#%]U
M4!U-=O'37O^9\_9!4HD<YNG?%"24CXV&7^065<EUHFQ!LC7]3:5*#7?2T.3+
MVC00YKD4<NXPHB**K<,#+N/8HQA4BA')XFW&25^3>;DPECL)6C![66F-2YJY
M;"1XCAN/P7?<T9!*;^1#Y 1A_$CC0Z2-RHBCFI_]-NO[07P&_9B+P O/X%H\
MV)4#U1CV-EWZXV!$$*22&]C_..)VX(S&XQ\!/=2Q'[D,$414AHP6!H3=0;'E
M-1IR2:2$'%^!;UMA[/\?/O8. KB[=K+3PW$,8SIS>/]X3A3Z/^3NE_ZG>CT,
M?.LB\G&[HVA/G^KQU]0\);PZ$NFP3:3#-R?2?0*]87NP.W5VHKZ0.NT6:Y+>
M3ZH1T@Q3QES0[G2(NB2O.,$1A[)2D-#^D7F6VLE->@5[.=(."(7?DV]Z<*8]
M2WO/X^DYRS?(:9DOED2&2!)9U?LNP6S+B=Z&(,?!T*40*S:RY-U2SU45R<=[
MNEAKLL5S @J8V//@%:/W ?RJ/^/6G_&;_7FU%N6JWHWMU6BN-3%WS*.=N&\^
M#,&.,F_)=^F-'VL-A-6 +B'KC(Y$=F^FF9/CG-O;Q$G>O,155I:LV'[74,YT
M?'=XD*KF:9H9FZ'Z%-BT=!1%%%^./V+$9C?4@W2$.'[$%8\/)SI4Z$[\%'WD
MN:V48\X<'-SJZ6JZLF\7HHJMKB_X;6_[/)K7KX+OT^NWU5>AR#X-.2YIJ7L>
MTV5&U>^5NF'DQKX1%M+0/=A6U_3$0\43:'PII=DW6$#[:)S]!U!+ P04
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MYP)Y@=(,H/Z9$'K;, KZ>['+OP!02P,$%     @ &E1/6#<NWXY4 P  ] 8
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MNNZ3!<+L$0$9YA0_<*8-X=A!"-0_+U=<=SW JZF!C$1Z'#RFR]E3+SKLS/:
M[L#08.J3EX]^, $-;STB87>$J+4Z6OW!=($"S3.!Y]L-DS?H+KEE156'FZ&3
M3&8<N3<%$KZ$03R=UX-H&N/@ ZATJC','$HKTSP74&KHKX+@Z&XFFE(0B)MG
M",]S#OL35B;)!81<<S"V+\GROV$G*5WICFD+81JZWW"ZF#A_5?;5;7"YBQMD
MOX8_]FN$XV :N-_FO2ZN5R]2&M W\-XS&BBKI"NK9)"\6!Y,/OQJ@!#@&83
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M+9<=UO!KBYJY8!D8W;*E0',RBRR=XFRC:H=XT2.F+R F*7PFQ(V!GV2-]?<
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M^'1";[+N7^U^8E7K7\JELO3N^N&&/G10.P/:7REE]Q-WP/#IM/@74$L#!!0
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M*$RH?!_[2DLRQ'[:F!_7YJ,#YL,(W7*FEA)]8AED?Q/XVI?6H6CCT#AR,MY
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MA+V5*2KSEAD['$^;VR R)U.V$"QG&15(3K-,5@*96)")Y"QCH,E7<JF1F4#
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M@(\/[$UR5&\2*UJU6H"3'-6;Y'5OLO%.%G/6KJJ "#FR04G;VB[F";0^"?I
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M#NQ+NJB^)%:T:K6 ,%U4PG1/$Z8Y85=!0)@NLB7)+/T5<][6R]X'H7I J-[
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M;E]V6.H?# B3H-<7G*OWP/2P_I>5_0502P,$%     @ &E1/6)DK:MT!!P
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M%PV/+R) U3)DF-8R3*TR_"&W3*"//%WMA5 I$%VKQ8QLG=.LH*Y20,)\2%@
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MI^>8DVH:13,QLG*E<RX-%F(W++"W@K(!^'TAI=E,[ ^Z;IW\ 5!+ P04
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M@;Z!T"-=36=(=2HE5]2-9&BC'A\#+#P?KX4YA',1]T2#;5RHOF?J",)+--T
M5W(//<\*Z([3 %K9[+=<K=[*VV$"<)4 _'\7K%2$: T\+W=[M?,V_+UJ#_Q>
ML];&4,Y%K32);5SY#U:N$YAR9Z,])NSV_/I2;&[S7*9*;MAFO7&XAIU -6A0
MV;CG.W6J]U 8=B4Q;+/&:%_,3J!S&W2NUVMTP_<0'7:E.FRS[#@8<=!<X$[
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M%MG*Y1M&XJ2LE&<N\KS S>.T<*;C\MX]FX[I5F1I0>X9X-L\C]G++<GH?N)
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M),>-51\)JH*@F_)@?DZ%H'EYN29Q0IAZ03Y?4BI>"ZJ!YE/-]']02P,$%
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MMW4 /G[X!#X  ?80DY*A/&)SDPOVDH,9UDRO*Z;V"TRA#;Z2G,<,W(K!1&T
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M(=<C+_2V"W=\OC!VP4^'%9OC/9J'ZE;1S&]9<EY@J;DL0>%LY(W#JVQ@XUW
M=XYKO3,&J^11RB<[^9J/O, FA *GQC(P^EOA-0IAB2B-WPVGU[[2 G?'6_9/
M3CMI>60:KZ7XP7.S&'F7'N0X8TMA[N3Z"S9Z^I9O*H5VO[!N8@,/IDMM9-&
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M30#N+X30FXEY0?=_(OH+4$L#!!0    ( !I43U@H :HAK ,  )P,   9
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M9:D_'T"8 'V_X%SM!^8!W0?)_#M02P,$%     @ &E1/6$X8AV= !   WA
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MR]5V[DP<E-,UJ0MUPP^?: L4:7L9+V3SC0ZMK.>@K):*EZTR>%"RZOA+[MM
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M5\1Q,WT\47S7;"]77,%FM3G<4I)3H07@_IIS]7BB=ZS=OS06_P)02P,$%
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MCT2E6<[A1A)5%065+U-@8CUV>LYFX39?9MHLN/&HI$NX _U0WDB<N2U*FA?
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MX'F1FV/"G+AO;1,1]WFI*&$P$4B6>8[%RQ H7PT<W]D8IF21*6-PXWZ!%_
MZJF8"#US&Y24Y, DX0P)F ^<:_]J%!E_Z_"5P$INC9')9,;YLYG<I0/',X2
M0J(, M:_)8R 4@.D:?RL,9UF2Q.X/=Z@W]K<=2XS+&'$Z3>2JFS@]!R4PAR7
M5$WYZ@O4^70-7L*IM%^TJGT]!R6E5#RO@S6#G+#JC]>U#EL!?G0@(*@#@OV
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M4_%:17^]NP6O7KP&+P#-P9<=*X6*%7-7*I[ZU]RXX?2^YH2>X'1+XFO@PRN
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M,<JAH TW#W+_$3H_8\>72:[]&^W;W'&$4=9H(T4'M@H$J]HO?>K.X0@03LX
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M4V1,E=?Y<F)D5EQP5]+@=;D8;O %!,H:X/>UE&8WL0'J-U7P$U!+ P04
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
M  @ &E1/6*JT0,+\!0  @#0   \   !X;"]W;W)K8F]O:RYX;6S%FUU3VS@4
M0/^*)D]T9KLACC]HIS #9-EEAK89H+SN"%M)--A25I*!]-=74@B]#LZ=?;GA
M"2P[SK%DZ=PK*5^>M'FXU_J!/3>ULL>#A7/+S\.A+1>BX?9/O13*GYEITW#G
M#\U\:)=&\,HNA'!-/4P.#_-APZ4:G'S9W&MJAO! .U$ZJ94O# 5W4CS9W^?#
M(7N45M[+6KK5\2#^7XL!:Z22C?PIJN/!X8#9A7[Z1QOY4RO'ZYO2Z+H^'HS6
M)^Z$<;)\4WP3(&_YO8TECM]?<P]R/,@/_0UGTE@7KXCWYY[Q4?B+UT>MTQ>R
M=L),N!-_&]TNI9J'V_BG&(+'B/6P^;NNQ,_F_U2CGLUD*2:Z;!NAW+H>C:@#
MH+(+N;0#IG@CC@?G^E$8-N5S$1[*?\MEM7Y Y\E =9G/TI\PEU5DI.,Y;2OI
MV*5:?]B?!5@)@I708IW[8UW+RG][Q<YXS54I6&Q>"P#'".#XW0#9P90#R!2!
M3/<(>1,@P@<LTS/V?2D,@,P0R.S=(,]ULP20.0*9OQODC=,E@"P0R.+]:I+;
M!8 \0B"/:"&_<=<:$9C.6BN5L+!#?T*X/M%RW;1-P\TJMJB<*^D_QI5CIV6I
M6^4D'*T/L>'ZD!;S@DO#[GC="O95<.NK,K8QQ$-M0JR3K]P\"*_FV@^&HFR-
M=%)TX#"GC(BE<JD>_07:K" 0YI 1L42N? MVJP>3Q8C8%OY5-ZT?.?YZ]C?9
MXL+\,"(6A(\YJ[9T[%KXYFL[<1-FA!&Q$FX6W(B/9[X%*Q_/K=YT0TP$(V(3
M?!,AIBMU(]C!E;;V _.Z9Y$8(F(:&!%[X 7OEC]WWS1, 2-B!_@WS=>36S&N
M?#?XKY7+\($_F!(.AL78^)\0C_\^)&JTBD'' V3"!OV$>-"/[Y7OGLO6E O?
M'YBOQ[GA#>1#<PGB<7\B;>GS3*G"Z!8"W_4E$ ^S0$*>2C2-=.M0+;QXYY%U
M[H_9E>3W$!/30T*LAXF8^7!MC6?D?1LN8&="^6+'IC7$Q&R14-N"K]BC95-A
MXL=#6A;:O]8A5H*0F#L28G=<*BLK/R+?&E[YIF:GQG#?XML.23"'),0.00/B
M?Q.(B7DD(?8(CCF&F)A:$F*U[(C;V<%M")8[DQJ87L;$>NF-WS>0'R E)IPQ
ML7!> _E>,DPU8V+5K"/Z7BQTLHI8,=NA?2\@)I<QL5RV8OQ>/LPJ8V*K] 7[
MO9"85<;$5D&B_L *,3&QC(G% B/_WCK$=#(FU@F2 FS7(::3,;%.=H2T/3I)
M,9VDQ#IY.]G'#B;>+[+NM'B*R22ESE[0 "*%F)A94F*SX)@9Q,1,DQ*;9E><
M\Y'%!X"8Z,((L6]V8YY6E839?HII)R763G\XYNO2W[MJ8<Z58N))B<6S"S/6
MI=00$Q-/2BZ>U["Q;Q#"M),2:^<E;GRM,L7K'8NR*::=E%@[KY@O+V <VF-A
M#"WA@B*FG8Q8.[V8/U05I-DJV+LSS#P9L7EZ,2_:J,RO$C9ZAIDG(S;/V^2A
MI_=DF'0R8NEL9P_=&IU"3$PZV9Z3G YF9T8E0]?C][O>LE6;UQ 3DTY&+!T<
M\QQB8M+)B*7S%K,SQ$-,3$ 9]31:7X+[FQ5B8@+*J%?I^S$W+0\WBV "RHD%
MA&)V>GJ."2C?Q\+-3DPX=YIC LJI4Q\4$V9H.6:AG-A".";,T'+,0CFQA=!9
MHDFG"V$6RHDMU)DEZH[M$W\"8J+[PLA7<CJ8UZ+4JI2UC%<RF/KDF(7R?<ZY
M?8P;Z[3:; [K-CIFH7R/FP)ZDB&(B5DH)[;0=FTNPN*=95+%*04XR5%@%BJ(
M+;2%^4,9_W;.5=B$'0HA)F:A@MA"V)2K[_@0$[-006PA'/,48F(6*O:PFV"S
M0:0W4RLP^13$\MFU5>2%%&)B\BF(Y;-K>OWM+&:!R:<@EL]NS.U9S +=EDPL
MG]V8%U)QF%L4F'P*8OF@^W Z07N!R:>@7OK!]N%T,(\P^1Q%^0SCQ?;D2[6^
MZS?_%=:7E[PNIX:%/W%77I)F86?>K*WK<U_V75UI7FU^0+/Y\<_)+U!+ P04
M    "  :5$]8M,4*KF@"  !'+P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QSS=I+;J- %(7AK5@L(+ANW8?3BC/J2::M;  YY8=B&P2T.ME]6\[
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M^DZ]A_'S6(9;S]<:K_^=5(^7<\OM\M?EUTZ\7ZRN.-?W%</S7U!+ P04
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M<F]P<R]A<' N>&UL4$L! A0#%     @ &E1/6-:4HMOO    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ &E1/
M6)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    "  :5$]83HE2Z@\(  #O,   &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ &E1/
M6*,=!J,^ @  Q04  !@              ("!4Q   'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( !I43UC^X@1./08  !0:   8
M      " @<<2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M"  :5$]86J1;W!D#  #8"@  &               @($Z&0  >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ &E1/6#$:8<QM!@  +B$  !@
M             ("!B1P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( !I43UC*L</:$P,  ,$)   8              " @2PC  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  :5$]8\+_FX7,(  #@
M10  &               @(%U)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ &E1/6$6<N*BE"0  >S   !@              ("!'B\
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( !I43UAME=W>
MT \  %XI   8              " @?DX  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    "  :5$]8ZO]+>P4B  !_:P  &0
M@('_2   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !I4
M3UA5KIP=?P,  #8(   9              " @3MK  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ &E1/6/49X"1<!0  1PT  !D
M         ("!\6X  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    "  :5$]8QT0\Q)L"  "D!0  &0              @(&$=   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( !I43UC(81R>TP8  -D2
M   9              " @59W  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ &E1/6#KX\+.; @  S@4  !D              ("!8'X
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  :5$]8J^I5
M"VH&  #P$   &0              @($R@0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( !I43UAV-P-:50T  +@F   9
M  " @=.'  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
M&E1/6,R)YU)(!0  ; T  !D              ("!7Y4  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    "  :5$]8[CRY1@\-  !")0  &0
M            @('>F@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( !I43U@H<?!". ,  !H'   9              " @22H  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ &E1/6,[]TIVK @
M\P4  !D              ("!DZL  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    "  :5$]8"C=7>[0$   )#   &0              @(%U
MK@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( !I43UA^
M2L((RP8  $@1   9              " @6"S  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ &E1/6-85HO22 P  )P@  !D
M     ("!8KH  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !I43U@\E;-2I0(  ,T%   9              "
M@<OI  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ &E1/
M6.]H99E# P  SP<  !D              ("!I^P  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    "  :5$]8YSE"-@0$  !\"0  &0
M        @($A\   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( !I43UBYF\,DJ0(  *\%   9              " @5ST  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ &E1/6(4EZH[( P  8@D
M !D              ("!//<  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    "  :5$]8%DY^/*@"  #2!0  &0              @($[^P
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( !I43U@:4'Z2
MP00  $ .   9              " @1K^  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ &E1/6.^K!M*3!@  (Q,  !D
M ("!$@,! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  :
M5$]8-R[?CE0#  #T!@  &0              @('<"0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( !I43UCZT$T2,@8  * 0   9
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M970T,BYX;6Q02P$"% ,4    "  :5$]8-TS,;-("  "."P  &0
M    @(&Y)0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M !I43UB!A=$]3P<   -+   9              " @<(H 0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ &E1/6-V-Y!I& @  - 4  !D
M             ("!2# ! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    "  :5$]8$V8B#*$&  "4*P  &0              @('%,@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( !I43U@4S'(((P,
M  <)   9              " @9TY 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ &E1/6+\:ZZ1[ @  O@8  !D              ("!
M]SP! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  :5$]8
MF2MJW0$'  !M.P  &0              @(&I/P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( !I43UA2@]:MT0(  +D'   9
M      " @>%& 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ &E1/6&K7W=[8 @  ^ <  !D              ("!Z4D! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  :5$]8"7N^N% "   M!0
M&0              @('X3 $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( !I43U@H_+H2KP(  )D'   9              " @7]/ 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ &E1/6)\/ZGC)
M @  \0D  !D              ("!95(! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    "  :5$]8^U1KK)(%  !S(@  &0
M@(%E50$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !I4
M3UB^^8]6LP(   <(   9              " @2Y; 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ &E1/6 HNR1G8 @  PP<  !D
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M=#8Q+GAM;%!+ 0(4 Q0    ( !I43UA[G6 '*@0  +85   9
M  " @=QU 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @
M&E1/6'9V!U.  P  :@X  !D              ("!/7H! 'AL+W=O<FMS:&5E
M=',O<VAE970V,RYX;6Q02P$"% ,4    "  :5$]85Q^?FAP#  "1"0  &0
M            @('T?0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4
M Q0    ( !I43UAS_\.8^0,  /X4   9              " @4>! 0!X;"]W
M;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ &E1/6(F,L:GF @
M6P@  !D              ("!=X4! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX
M;6Q02P$"% ,4    "  :5$]8* &J(:P#  "<#   &0              @(&4
MB $ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( !I43UA.
M&(=G0 0  -X0   9              " @7>, 0!X;"]W;W)K<VAE971S+W-H
M965T-C@N>&UL4$L! A0#%     @ &E1/6$N&L[OB!@  4S   !D
M     ("![I ! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !I43UAI0N>!0 (  +L%   9              "
M@4JE 0!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ &E1/
M6"56,W?1!0  ?CH  !D              ("!P:<! 'AL+W=O<FMS:&5E=',O
M<VAE970W-2YX;6Q02P$"% ,4    "  :5$]8^5XXLA,$  !1#@  &0
M        @(')K0$ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0
M   ( !I43UAMQ?2M8 ,  %\-   9              " @1.R 0!X;"]W;W)K
M<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ &E1/6*+1GOR^!0  XB8
M !D              ("!JK4! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q0
M2P$"% ,4    "  :5$]8S+)%[0X"  ! !   &0              @(&?NP$
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( !I43UA5?0<^
M40(  %@%   9              " @>2] 0!X;"]W;W)K<VAE971S+W-H965T
M.# N>&UL4$L! A0#%     @ &E1/6%Y/.WQ) P  RA0   T
M ( !;, ! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  :5$]8EXJ[',     3
M @  "P              @ '@PP$ 7W)E;',O+G)E;'-02P$"% ,4    "  :
M5$]8JK1 POP%  " -   #P              @ ')Q $ >&PO=V]R:V)O;VLN
M>&UL4$L! A0#%     @ &E1/6+3%"JYH @  1R\  !H              ( !
M\LH! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ &E1/
M6"P!9SL; @  #BX  !,              ( !DLT! %M#;VYT96YT7U1Y<&5S
;72YX;6Q02P4&     %@ 6  ?&   WL\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>193</ContextCount>
  <ElementCount>401</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/NatureofBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Product Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenue</Role>
      <ShortName>Product Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Net Income (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/NetIncomeLossperShare</Role>
      <ShortName>Net Income (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Share Repurchase Program</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareRepurchaseProgram</Role>
      <ShortName>Share Repurchase Program</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CommitmentsandContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Defined Contribution Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/DefinedContributionBenefitPlan</Role>
      <ShortName>Defined Contribution Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://agios.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/MarketableSecurities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/Inventory</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/AccruedExpenses</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Product Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueTables</Role>
      <ShortName>Product Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/ProductRevenue</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/ShareBasedPayments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Net Income (Loss) per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/NetIncomeLossperShareTables</Role>
      <ShortName>Net Income (Loss) per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/NetIncomeLossperShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://agios.com/role/DiscontinuedOperations</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Nature of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/NatureofBusinessDetails</Role>
      <ShortName>Nature of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agios.com/role/NatureofBusiness</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agios.com/role/InventoryTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Leases - Schedule of Lease Expense and Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Lease Expense and Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Schedule of Undiscounted Minimum Rental Commitments under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Leases - Schedule of Future Minimum Lease Payments to be Received under the Long-term Sublease Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails</Role>
      <ShortName>Leases - Schedule of Future Minimum Lease Payments to be Received under the Long-term Sublease Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agios.com/role/AccruedExpensesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Product Revenue - Schedule of Product Revenue, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails</Role>
      <ShortName>Product Revenue - Schedule of Product Revenue, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails</Role>
      <ShortName>Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails</Role>
      <ShortName>Product Revenue - Schedule of Revenue-Related Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsDetails</Role>
      <ShortName>Product Revenue - Schedule of Changes in Contract Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Product Revenue - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ProductRevenueAdditionalInformationDetails</Role>
      <ShortName>Product Revenue - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Share-Based Payments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails</Role>
      <ShortName>Share-Based Payments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Share-Based Payments - Schedule of Company's Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Company's Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Share-Based Payments - Schedule of Unvested RSUs, Performance-Based Stock and Market-Based Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Unvested RSUs, Performance-Based Stock and Market-Based Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included within the Condensed Consolidated Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included within the Condensed Consolidated Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Share-Based Payments - Schedule of Expenses Related to Stock Options and Stock-based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Expenses Related to Stock Options and Stock-based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Share-Based Payments - Schedule of Grant Date Fair Value Option Award Weighted Average Assumptions Used (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails</Role>
      <ShortName>Share-Based Payments - Schedule of Grant Date Fair Value Option Award Weighted Average Assumptions Used (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Net Income (Loss) per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/NetIncomeLossperShareDetails</Role>
      <ShortName>Net Income (Loss) per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agios.com/role/NetIncomeLossperShareTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Income Taxes - Reconciliation of Expected Income Tax Benefit (Expense) Computed Using Federal Statutory Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Expected Income Tax Benefit (Expense) Computed Using Federal Statutory Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxesChangesinValuationAllowanceDetails</Role>
      <ShortName>Income Taxes - Changes in Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Income Taxes - Unrecognized Tax Benefits Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Property and Equipment, net - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment, net - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Property and Equipment, net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/PropertyandEquipmentnetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agios.com/role/CommonStock</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Share Repurchase Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/ShareRepurchaseProgramDetails</Role>
      <ShortName>Share Repurchase Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agios.com/role/ShareRepurchaseProgram</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Discontinued Operations - Summary of Gain on Sale of Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Gain on Sale of Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Discontinued Operations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails</Role>
      <ShortName>Discontinued Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Discontinued Operations - Financial Results of Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails</Role>
      <ShortName>Discontinued Operations - Financial Results of Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - Commitments and Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/CommitmentsandContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agios.com/role/CommitmentsandContingentLiabilities</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="agio-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - Defined Contribution Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://agios.com/role/DefinedContributionBenefitPlanDetails</Role>
      <ShortName>Defined Contribution Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://agios.com/role/DefinedContributionBenefitPlan</ParentRole>
      <Position>80</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="agio-20231231.htm">agio-20231231.htm</File>
    <File>agio-20231231.xsd</File>
    <File>agio-20231231_cal.xml</File>
    <File>agio-20231231_def.xml</File>
    <File>agio-20231231_lab.xml</File>
    <File>agio-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>agio-20231231_g1.jpg</File>
    <File>agio-20231231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="814">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>107
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "agio-20231231.htm": {
   "nsprefix": "agio",
   "nsuri": "http://agios.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "agio-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "agio-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "agio-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "agio-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "agio-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "agio-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 337,
   "keyCustom": 64,
   "axisStandard": 22,
   "axisCustom": 1,
   "memberStandard": 34,
   "memberCustom": 25,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2023": 1,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://agios.com/20231231": 4
   },
   "contextCount": 193,
   "entityCount": 1,
   "segmentCount": 63,
   "elementCount": 671,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 814,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://agios.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://agios.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://agios.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://agios.com/role/ConsolidatedStatementsofOperations",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive (Loss) Income",
     "shortName": "Consolidated Statements of Comprehensive (Loss) Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://agios.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://agios.com/role/NatureofBusiness",
     "longName": "0000009 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://agios.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://agios.com/role/FairValueMeasurements",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://agios.com/role/MarketableSecurities",
     "longName": "0000012 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://agios.com/role/Inventory",
     "longName": "0000013 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://agios.com/role/Leases",
     "longName": "0000014 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://agios.com/role/AccruedExpenses",
     "longName": "0000015 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://agios.com/role/ProductRevenue",
     "longName": "0000016 - Disclosure - Product Revenue",
     "shortName": "Product Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://agios.com/role/ShareBasedPayments",
     "longName": "0000017 - Disclosure - Share-Based Payments",
     "shortName": "Share-Based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://agios.com/role/NetIncomeLossperShare",
     "longName": "0000018 - Disclosure - Net Income (Loss) per Share",
     "shortName": "Net Income (Loss) per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://agios.com/role/IncomeTaxes",
     "longName": "0000019 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://agios.com/role/PropertyandEquipmentnet",
     "longName": "0000020 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://agios.com/role/CommonStock",
     "longName": "0000021 - Disclosure - Common Stock",
     "shortName": "Common Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://agios.com/role/ShareRepurchaseProgram",
     "longName": "0000022 - Disclosure - Share Repurchase Program",
     "shortName": "Share Repurchase Program",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TreasuryStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://agios.com/role/DiscontinuedOperations",
     "longName": "0000023 - Disclosure - Discontinued Operations",
     "shortName": "Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://agios.com/role/CommitmentsandContingentLiabilities",
     "longName": "0000024 - Disclosure - Commitments and Contingent Liabilities",
     "shortName": "Commitments and Contingent Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://agios.com/role/DefinedContributionBenefitPlan",
     "longName": "0000025 - Disclosure - Defined Contribution Benefit Plan",
     "shortName": "Defined Contribution Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R27": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://agios.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "agio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "agio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://agios.com/role/FairValueMeasurementsTables",
     "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://agios.com/role/MarketableSecuritiesTables",
     "longName": "9954474 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://agios.com/role/InventoryTables",
     "longName": "9954475 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://agios.com/role/LeasesTables",
     "longName": "9954476 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://agios.com/role/AccruedExpensesTables",
     "longName": "9954477 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://agios.com/role/ProductRevenueTables",
     "longName": "9954478 - Disclosure - Product Revenue (Tables)",
     "shortName": "Product Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://agios.com/role/ShareBasedPaymentsTables",
     "longName": "9954479 - Disclosure - Share-Based Payments (Tables)",
     "shortName": "Share-Based Payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://agios.com/role/NetIncomeLossperShareTables",
     "longName": "9954480 - Disclosure - Net Income (Loss) per Share (Tables)",
     "shortName": "Net Income (Loss) per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://agios.com/role/IncomeTaxesTables",
     "longName": "9954481 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://agios.com/role/PropertyandEquipmentnetTables",
     "longName": "9954482 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://agios.com/role/DiscontinuedOperationsTables",
     "longName": "9954483 - Disclosure - Discontinued Operations (Tables)",
     "shortName": "Discontinued Operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://agios.com/role/NatureofBusinessDetails",
     "longName": "9954484 - Disclosure - Nature of Business (Details)",
     "shortName": "Nature of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "agio:GainLossOnSaleOfContingentPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9954485 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "agio:AvailableForSaleSecuritiesCurrentMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "agio:AvailableForSaleSecuritiesCurrentMaturityPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:MarketableSecuritiesPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails",
     "longName": "9954486 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9954487 - Disclosure - Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Summary of Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-73",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "longName": "9954488 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-72",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-72",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails",
     "longName": "9954489 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)",
     "shortName": "Marketable Securities - Schedule of Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails",
     "longName": "9954490 - Disclosure - Marketable Securities - Additional Information (Details)",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://agios.com/role/InventoryDetails",
     "longName": "9954491 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://agios.com/role/LeasesAdditionalInformationDetails",
     "longName": "9954492 - Disclosure - Leases - Additional Information (Details)",
     "shortName": "Leases - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationRelatedtoLeasesDetails",
     "longName": "9954493 - Disclosure - Leases - Schedule of Lease Expense and Other Information Related to Leases (Details)",
     "shortName": "Leases - Schedule of Lease Expense and Other Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails",
     "longName": "9954494 - Disclosure - Leases - Schedule of Undiscounted Minimum Rental Commitments under Non-cancelable Leases (Details)",
     "shortName": "Leases - Schedule of Undiscounted Minimum Rental Commitments under Non-cancelable Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails",
     "longName": "9954495 - Disclosure - Leases - Schedule of Future Minimum Lease Payments to be Received under the Long-term Sublease Agreements (Details)",
     "shortName": "Leases - Schedule of Future Minimum Lease Payments to be Received under the Long-term Sublease Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://agios.com/role/AccruedExpensesDetails",
     "longName": "9954496 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails",
     "longName": "9954497 - Disclosure - Product Revenue - Schedule of Product Revenue, Net (Details)",
     "shortName": "Product Revenue - Schedule of Product Revenue, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R55": {
     "role": "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails",
     "longName": "9954498 - Disclosure - Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)",
     "shortName": "Product Revenue - Schedule of Product Revenue Allowance and Reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "agio:ContractWithCustomerContractualAdjustmentReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "agio:ContractWithCustomerContractualAdjustmentReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails",
     "longName": "9954499 - Disclosure - Product Revenue - Schedule of Revenue-Related Reserves (Details)",
     "shortName": "Product Revenue - Schedule of Revenue-Related Reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsDetails",
     "longName": "9954500 - Disclosure - Product Revenue - Schedule of Changes in Contract Assets (Details)",
     "shortName": "Product Revenue - Schedule of Changes in Contract Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "agio:ContractWithCustomerAssetRevenueRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://agios.com/role/ProductRevenueAdditionalInformationDetails",
     "longName": "9954501 - Disclosure - Product Revenue - Additional Information (Details)",
     "shortName": "Product Revenue - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
     "longName": "9954502 - Disclosure - Share-Based Payments - Additional Information (Details)",
     "shortName": "Share-Based Payments - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails",
     "longName": "9954503 - Disclosure - Share-Based Payments - Schedule of Company's Stock Option Activity (Details)",
     "shortName": "Share-Based Payments - Schedule of Company's Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails",
     "longName": "9954504 - Disclosure - Share-Based Payments - Schedule of Unvested RSUs, Performance-Based Stock and Market-Based Stock Unit Activity (Details)",
     "shortName": "Share-Based Payments - Schedule of Unvested RSUs, Performance-Based Stock and Market-Based Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails",
     "longName": "9954505 - Disclosure - Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included within the Condensed Consolidated Statements of Operations (Details)",
     "shortName": "Share-Based Payments - Schedule of Stock-Based Compensation Expense by Award Type Included within the Condensed Consolidated Statements of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails",
     "longName": "9954506 - Disclosure - Share-Based Payments - Schedule of Expenses Related to Stock Options and Stock-based Awards (Details)",
     "shortName": "Share-Based Payments - Schedule of Expenses Related to Stock Options and Stock-based Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://agios.com/role/ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails",
     "longName": "9954507 - Disclosure - Share-Based Payments - Schedule of Grant Date Fair Value Option Award Weighted Average Assumptions Used (Details)",
     "shortName": "Share-Based Payments - Schedule of Grant Date Fair Value Option Award Weighted Average Assumptions Used (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://agios.com/role/NetIncomeLossperShareDetails",
     "longName": "9954508 - Disclosure - Net Income (Loss) per Share (Details)",
     "shortName": "Net Income (Loss) per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails",
     "longName": "9954509 - Disclosure - Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Details)",
     "shortName": "Income Taxes - Schedule of Domestic and Foreign Components of Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails",
     "longName": "9954510 - Disclosure - Income Taxes - Reconciliation of Expected Income Tax Benefit (Expense) Computed Using Federal Statutory Income Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Expected Income Tax Benefit (Expense) Computed Using Federal Statutory Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954511 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9954512 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://agios.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
     "longName": "9954513 - Disclosure - Income Taxes - Changes in Valuation Allowance (Details)",
     "shortName": "Income Taxes - Changes in Valuation Allowance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://agios.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails",
     "longName": "9954514 - Disclosure - Income Taxes - Unrecognized Tax Benefits Rollforward (Details)",
     "shortName": "Income Taxes - Unrecognized Tax Benefits Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails",
     "longName": "9954515 - Disclosure - Property and Equipment, net - Summary of Property and Equipment (Details)",
     "shortName": "Property and Equipment, net - Summary of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://agios.com/role/PropertyandEquipmentnetAdditionalInformationDetails",
     "longName": "9954516 - Disclosure - Property and Equipment, net - Additional Information (Details)",
     "shortName": "Property and Equipment, net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://agios.com/role/CommonStockDetails",
     "longName": "9954517 - Disclosure - Common Stock (Details)",
     "shortName": "Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "agio:NumberOfVotesPerShare",
      "unitRef": "vote",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "agio:NumberOfVotesPerShare",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://agios.com/role/ShareRepurchaseProgramDetails",
     "longName": "9954518 - Disclosure - Share Repurchase Program (Details)",
     "shortName": "Share Repurchase Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-178",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails",
     "longName": "9954519 - Disclosure - Discontinued Operations - Summary of Gain on Sale of Discontinued Operations (Details)",
     "shortName": "Discontinued Operations - Summary of Gain on Sale of Discontinued Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-186",
      "name": "agio:DiscontinuedOperationsTransactionAndInsuranceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
     "longName": "9954520 - Disclosure - Discontinued Operations - Additional Information (Details)",
     "shortName": "Discontinued Operations - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "agio:GainLossOnSaleOfContingentPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-187",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
     "longName": "9954521 - Disclosure - Discontinued Operations - Financial Results of Discontinued Operations (Details)",
     "shortName": "Discontinued Operations - Financial Results of Discontinued Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-186",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://agios.com/role/CommitmentsandContingentLiabilitiesDetails",
     "longName": "9954522 - Disclosure - Commitments and Contingent Liabilities (Details)",
     "shortName": "Commitments and Contingent Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "agio:NumberOfLegalProceedingsThatHaveMaterialEffect",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "agio:NumberOfLegalProceedingsThatHaveMaterialEffect",
      "unitRef": "lawsuit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://agios.com/role/DefinedContributionBenefitPlanDetails",
     "longName": "9954523 - Disclosure - Defined Contribution Benefit Plan (Details)",
     "shortName": "Defined Contribution Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "agio-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://agios.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r707"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net (accretion of discount) amortization of premium on marketable securities",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://agios.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/AccruedExpensesDetails",
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "agio_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued research and development costs",
        "label": "Accrued Research And Development Costs Current",
        "documentation": "Accrued research and development costs current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r179",
      "r550"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax",
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r14",
      "r33",
      "r464",
      "r467",
      "r505",
      "r564",
      "r565",
      "r815",
      "r816",
      "r817",
      "r823",
      "r824",
      "r825"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r422",
      "r574",
      "r823",
      "r824",
      "r825",
      "r878",
      "r901"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r383"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r742",
      "r752",
      "r778"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r733",
      "r745",
      "r755",
      "r781"
     ]
    },
    "agio_AgiosOncologyBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "AgiosOncologyBusinessMember",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agios Oncology Business",
        "label": "Agios Oncology Business [Member]",
        "documentation": "Agios Oncology Business"
       }
      }
     },
     "auth_ref": []
    },
    "agio_Agreement2010Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "Agreement2010Member",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2010 Agreement",
        "label": "Agreement 2010 [Member]",
        "documentation": "Agreement 2010 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r746",
      "r756",
      "r773",
      "r782",
      "r786",
      "r794"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total stock-based compensation expense",
        "terseLabel": "Allocated share based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r427"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of accounts receivable",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r257",
      "r297"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "agio_AlnylamPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "AlnylamPharmaceuticalsIncMember",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alnylam Pharmaceuticals, Inc.",
        "label": "Alnylam Pharmaceuticals, Inc. [Member]",
        "documentation": "Alnylam Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "agio_AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, contingent consideration, potential developmental and regulatory milestone payment",
        "label": "Asset Acquisition, Contingent Consideration, Potential Developmental and Regulatory Milestone Payment",
        "documentation": "Asset Acquisition, Contingent Consideration, Potential Developmental and Regulatory Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r181",
      "r204",
      "r234",
      "r245",
      "r249",
      "r294",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r459",
      "r461",
      "r483",
      "r545",
      "r606",
      "r707",
      "r719",
      "r840",
      "r841",
      "r885"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r185",
      "r204",
      "r294",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r459",
      "r461",
      "r483",
      "r707",
      "r840",
      "r841",
      "r885"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal group. including discontinued operation, assets",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r78",
      "r92",
      "r128",
      "r171",
      "r172"
     ]
    },
    "agio_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market Offering",
        "label": "At-the-market Offering [Member]",
        "documentation": "At-the-market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://agios.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r725",
      "r738"
     ]
    },
    "agio_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://agios.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r725",
      "r738"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://agios.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r725",
      "r738"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r267"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r268"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r303",
      "r544"
     ]
    },
    "agio_AvailableForSaleSecuritiesCurrentMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "AvailableForSaleSecuritiesCurrentMaturityPeriod",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment maturity period, current",
        "label": "Available For Sale Securities Current Maturity Period",
        "documentation": "Available for sale securities current maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "agio_CashEquivalentsAndAvailableForSaleSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total marketable securities",
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r303",
      "r539",
      "r827"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r303"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r261",
      "r303"
     ]
    },
    "agio_AvailableForSaleSecuritiesNonCurrentMaturityPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "AvailableForSaleSecuritiesNonCurrentMaturityPeriod",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment maturity period, non-current",
        "label": "Available For Sale Securities Non Current Maturity Period",
        "documentation": "Available for sale securities non current maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "agio_AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum period to liquidate",
        "label": "Available For Sale Securities Non Current Minimum Liquidating Period",
        "documentation": "Available for sale securities non current minimum liquidating period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://agios.com/role/LeasesAdditionalInformationDetails",
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://agios.com/role/LeasesAdditionalInformationDetails",
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r69"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to property and equipment in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r176",
      "r672"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "agio_CashEquivalentsAndAvailableForSaleSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of the period",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r120",
      "r201"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r120"
     ]
    },
    "agio_CashEquivalentsAndAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cash equivalents and marketable securities",
        "label": "Cash Equivalents And Available For Sale Securities",
        "documentation": "Cash equivalents and available for sale securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashEquivalentsMember",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash Equivalents [Member]",
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash provided by investing activities - discontinued operations",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r120"
     ]
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash used in operating activities - discontinued operations",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r120"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Treasury Stock [Table]",
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r54",
      "r55"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "agio_CollaborationRevenueOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "CollaborationRevenueOtherMember",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration revenue \u2013 other",
        "label": "Collaboration Revenue, Other [Member]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_CollaborationRevenueRelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "CollaborationRevenueRelatedPartyMember",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaboration revenue \u2013 related party",
        "label": "Collaboration Revenue, Related Party [Member]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingent liabilities (Note 16)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r73",
      "r546",
      "r593"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://agios.com/role/CommitmentsandContingentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingent Liabilities",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r316",
      "r317",
      "r657",
      "r836"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r711",
      "r712",
      "r714",
      "r715",
      "r716",
      "r717",
      "r823",
      "r824",
      "r878",
      "r900",
      "r901"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://agios.com/role/CommonStockDetails",
      "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, authorized (in shares)",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r594"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, outstanding (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r98",
      "r594",
      "r612",
      "r901",
      "r902"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value; 125,000,000 shares authorized; 72,161,489 shares issued and 55,945,078 outstanding at December 31, 2023 and 71,256,118 shares issued and 55,039,707 outstanding at December 31, 2022",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r594"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r189",
      "r191",
      "r196",
      "r540",
      "r555"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "agio_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails",
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computer equipment and software",
        "terseLabel": "Computer equipment and software",
        "label": "Computer Equipment And Software [Member]",
        "documentation": "Computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of credit risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r160"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r677"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContingentGainOnDispositionOfBusinessRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContingentGainOnDispositionOfBusinessRecognized",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earn-out revenue for royalties",
        "label": "Contingent Gain On Disposition Of Business Recognized",
        "documentation": "Contingent Gain On Disposition Of Business Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractAssetsAndLiabilitiesHeadingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractAssetsAndLiabilitiesHeadingRollForward",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Assets and Liabilities [Roll Forward]",
        "label": "Contract Assets And Liabilities [Heading Roll Forward]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerAllowanceAndReservesLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerAllowanceAndReservesLiability",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component of accrued expenses",
        "label": "Contract With Customer, Allowance And Reserves, Liability",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Contract Assets",
        "label": "Contract With Customer, Asset And Liability, Product Revenue [Table Text Block]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ProductRevenueAdditionalInformationDetails",
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Contract assets, beginning balance",
        "periodEndLabel": "Contract assets, ending balance",
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r360"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r360"
     ]
    },
    "agio_ContractWithCustomerAssetProceedsFromCollectionOfReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerAssetProceedsFromCollectionOfReceivables",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deductions",
        "label": "Contract With Customer Asset Proceeds From Collection Of Receivables",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerAssetRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerAssetRevenueRecognized",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofChangesinContractAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract With Customer, Asset, Revenue Recognized",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerContractAdjustmentRecoveriesCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerContractAdjustmentRecoveriesCurrentYear",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contractual adjustments, payments/returns relating to sales in the current year",
        "label": "Contract With Customer, Contract Adjustment, Recoveries, Current Year",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerContractAdjustmentRecoveriesPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerContractAdjustmentRecoveriesPriorYear",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Contractual adjustments, payments/returns relating to sales in the prior year",
        "label": "Contract With Customer, Contract Adjustment, Recoveries, Prior Year",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerContractualAdjustmentReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerContractualAdjustmentReserve",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Contractual adjustments, beginning balance",
        "periodEndLabel": "Contractual adjustments, ending balance",
        "label": "Contract With Customer, Contractual Adjustment Reserve",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerCurrentYearReserveProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerCurrentYearReserveProvisions",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total allowances and reserves, current provisions relating to sales in the current year",
        "label": "Contract With Customer, Current Year Reserve Provisions",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerCurrentYearReserveRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerCurrentYearReserveRecoveries",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total allowances and reserves, payments/returns relating to sales in the current year",
        "label": "Contract With Customer, Current Year Reserve Recoveries",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerPriorYearsReserveProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerPriorYearsReserveProvisions",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total allowances and reserves, adjustments relating to prior years",
        "label": "Contract With Customer, Prior Years Reserve Provisions",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerPriorYearsReserveRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerPriorYearsReserveRecoveries",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total allowances and reserves, payments/returns relating to sales in the prior years",
        "label": "Contract With Customer, Prior Years Reserve Recoveries",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerRebateReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerRebateReserve",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Government rebates, beginning balance",
        "periodEndLabel": "Government rebates, ending balance",
        "label": "Contract With Customer, Rebate Reserve",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerRebateReserveRecoveriesInCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerRebateReserveRecoveriesInCurrentYear",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Government rebates, payments/returns relating to sales in the current year",
        "label": "Contract With Customer Rebate Reserve, Recoveries In Current Year",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerRebateReserveRecoveriesInPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerRebateReserveRecoveriesInPriorYears",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Government rebates, payments/returns relating to sales in the prior years",
        "label": "Contract With Customer Rebate Reserve, Recoveries In Prior Years",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerRightToRecoverProductCurrentYearRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerRightToRecoverProductCurrentYearRecoveries",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveRecoveries",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Returns, payments/returns relating to sales in the current year",
        "label": "Contract With Customer Right To Recover Product, Current Year Recoveries",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerRightToRecoverProductPriorYearRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerRightToRecoverProductPriorYearRecoveries",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveRecoveries",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Returns, payments/returns relating to sales in the prior years",
        "label": "Contract With Customer Right To Recover Product, Prior Year Recoveries",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerRightToRecoverProductReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerRightToRecoverProductReserve",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerTotalAllowancesAndReserves",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Returns, beginning balance",
        "periodEndLabel": "Returns, ending balance",
        "label": "Contract With Customer, Right To Recover Product, Reserve",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractWithCustomerTotalAllowancesAndReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractWithCustomerTotalAllowancesAndReserves",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails",
      "http://agios.com/role/ProductRevenueScheduleofRevenueRelatedReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenue-related reserves",
        "label": "Contract With Customer, Total Allowances And Reserves",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ContractualAdjustmentsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ContractualAdjustmentsRollForward",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual Adjustments",
        "label": "Contractual Adjustments [Roll Forward]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r699",
      "r899"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r538"
     ]
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "agio_CurrentAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "CurrentAssetMember",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Asset [Member]",
        "documentation": "Current asset."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "agio_CurrentYearProvisionForContractualAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "CurrentYearProvisionForContractualAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual adjustments, current provisions relating to sales in the current year",
        "label": "Current Year Provision For Contractual Adjustments",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_CurrentYearProvisionsForRebateReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "CurrentYearProvisionsForRebateReserve",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government rebates, current provisions relating to sales in the current year",
        "label": "Current Year Provisions For Rebate Reserve",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for credit losses",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r303",
      "r309",
      "r310"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of debt securities in an unrealized loss position for less than one year",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain (loss) on marketable securities",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate fair value of debt securities in an unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r305",
      "r686"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r306"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Section 174 R&amp;D expense",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r875"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred taxes",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agio_DeferredTaxAssetsOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "documentation": "Deferred Tax Assets, Operating Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r875"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r875"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r875"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible accruals and reserves, including inventory",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r875"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://agios.com/role/IncomeTaxesChangesinValuationAllowanceDetails",
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance",
        "terseLabel": "Valuation allowance",
        "periodStartLabel": "Valuation allowance at the beginning of the year",
        "periodEndLabel": "Valuation allowance at the end of the year",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "agio_DeferredTaxAssetsValuationAllowanceRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "DeferredTaxAssetsValuationAllowanceRollForward",
     "presentation": [
      "http://agios.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets, Valuation Allowance [Roll Forward]",
        "label": "Deferred Tax Assets, Valuation Allowance [Roll Forward]",
        "documentation": "Deferred Tax Assets, Valuation Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r875"
     ]
    },
    "agio_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs, amortization period",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research And Development Costs, Amortization Period",
        "documentation": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research And Development Costs, Amortization Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease right of use asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r875"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r875"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://agios.com/role/DefinedContributionBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer's matching contribution percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://agios.com/role/DefinedContributionBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer's contribution percentage of eligible compensation",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://agios.com/role/ShareBasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r385",
      "r416",
      "r417",
      "r419",
      "r703"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale, pre-tax",
        "verboseLabel": "Gain on the sale of the oncology business",
        "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81",
      "r83"
     ]
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain on sale, net of tax",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r81",
      "r83",
      "r94"
     ]
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operation, gain (loss) on disposal, statement of income or comprehensive income [extensible enumeration]",
        "label": "Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from disposal of discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from discontinued operations, pre-tax",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r89",
      "r109",
      "r896"
     ]
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 1.0
      },
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r82",
      "r83",
      "r89",
      "r94",
      "r434",
      "r451",
      "r455"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations, Disposed of by Sale",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "agio_DiscontinuedOperationsLiabilitiesDistributedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "DiscontinuedOperationsLiabilitiesDistributedNet",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plus: net liabilities distributed, including working capital adjustment",
        "label": "Discontinued Operations, Liabilities Distributed, Net",
        "documentation": "Discontinued Operations, Liabilities Distributed, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r21"
     ]
    },
    "agio_DiscontinuedOperationsTransactionAndInsuranceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "DiscontinuedOperationsTransactionAndInsuranceCosts",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: transaction and insurance costs",
        "label": "Discontinued Operations, Transaction And Insurance Costs",
        "documentation": "Discontinued Operations, Transaction And Insurance Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "agio_DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsAndExpensesAbstract",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost and expenses:",
        "label": "Disposal Group, Including Discontinued Operation, Costs And Expenses [Abstract]",
        "documentation": "Disposal Group, Including Discontinued Operation, Costs And Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r172"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "agio_DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Non-cash interest expense for the sale of future revenue",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense, Non-Cash, Sale Of Future Revenue",
        "documentation": "Disposal Group, Including Discontinued Operation, Interest Expense, Non-Cash, Sale Of Future Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost and expenses",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income from discontinued operations",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "agio_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Disposal Group, Including Discontinued Operation, Research And Development Expenses",
        "documentation": "Disposal Group, Including Discontinued Operation, Research And Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r172"
     ]
    },
    "agio_DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenuesAbstract",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Disposal Group, Including Discontinued Operation, Revenues [Abstract]",
        "documentation": "Disposal Group, Including Discontinued Operation, Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r126"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r701"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r725",
      "r738"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r725",
      "r738",
      "r774"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (loss) income per share - basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r221",
      "r223",
      "r226",
      "r227",
      "r228",
      "r232",
      "r472",
      "r473",
      "r541",
      "r556",
      "r681"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net (loss) income per share - diluted (in usd share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r223",
      "r226",
      "r227",
      "r228",
      "r232",
      "r472",
      "r473",
      "r541",
      "r556",
      "r681"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss) per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r229",
      "r230",
      "r231"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax benefit computed at federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r435",
      "r453"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r876"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences and other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r876"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r872"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r872",
      "r876"
     ]
    },
    "agio_EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments",
     "calculation": {
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesReconciliationofExpectedIncomeTaxBenefitExpenseComputedUsingFederalStatutoryIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General business credits and other credits",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Adjustments",
        "documentation": "Effective income tax rate reconciliation tax credits adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "agio_EightyEightSidneyStreetLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "EightyEightSidneyStreetLeaseMember",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "88 Sidney Street Lease",
        "label": "Eighty Eight Sidney Street Lease [Member]",
        "documentation": "Eighty Eight Sidney Street Lease"
       }
      }
     },
     "auth_ref": []
    },
    "agio_EmployeePurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "EmployeePurchasePlanMember",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "Employee Stock Purchase Plan shares",
        "label": "Employee Purchase Plan [Member]",
        "documentation": "Employee Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average period to recognize compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense excluding options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense related to options",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefits related to stock based compensation",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options",
        "terseLabel": "Stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "agio_EmployeeStockPurchasePlan2013Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "EmployeeStockPurchasePlan2013Member",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan 2013 [Member]",
        "documentation": "Employee Stock Purchase Plan 2013 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityClassOfTreasuryStockLineItems",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r169",
      "r193",
      "r194",
      "r195",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r219",
      "r233",
      "r295",
      "r296",
      "r347",
      "r420",
      "r421",
      "r422",
      "r448",
      "r449",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r505",
      "r564",
      "r565",
      "r566",
      "r574",
      "r632"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r730",
      "r742",
      "r752",
      "r778"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r739",
      "r749",
      "r775"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "agio_ExpenseAssociatedWithLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ExpenseAssociatedWithLicenseAgreement",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense associated with license agreement",
        "label": "Expense Associated With License Agreement",
        "documentation": "Expense Associated With License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r479"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r479"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Cash Equivalents and Marketable Securities Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r141"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Hierarchy [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r476",
      "r509",
      "r510",
      "r511",
      "r687",
      "r688",
      "r697",
      "r698",
      "r699"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r476",
      "r477",
      "r478",
      "r480"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://agios.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a01",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r365",
      "r370",
      "r476",
      "r509",
      "r697",
      "r698",
      "r699"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r365",
      "r370",
      "r476",
      "r510",
      "r687",
      "r688",
      "r697",
      "r698",
      "r699"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r476",
      "r511",
      "r687",
      "r688",
      "r697",
      "r698",
      "r699"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r509",
      "r510",
      "r511",
      "r687",
      "r688",
      "r697",
      "r698",
      "r699"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r480"
     ]
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of assets (liabilities)",
        "label": "Fair Value, Net Asset (Liability)",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": []
    },
    "agio_FederalOrphanDrugTaxCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "FederalOrphanDrugTaxCreditMember",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Orphan Drug Tax Credit",
        "label": "Federal Orphan Drug Tax Credit [Member]",
        "documentation": "Federal Orphan Drug Tax Credit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on financing lease obligations",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r499"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r307",
      "r308",
      "r332",
      "r345",
      "r469",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r554",
      "r686",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Income Tax",
        "label": "Foreign Tax Authority [Member]",
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r746",
      "r756",
      "r782"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r746",
      "r756",
      "r782"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r746",
      "r756",
      "r782"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r746",
      "r756",
      "r782"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r746",
      "r756",
      "r782"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails",
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Furniture and fixtures",
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "agio_GainContingencyRoyaltyPercentageOfNetSales": {
     "xbrltype": "pureItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "GainContingencyRoyaltyPercentageOfNetSales",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent royalty payment",
        "label": "Gain Contingency Royalty Percentage Of Net Sales",
        "documentation": "Gain Contingency Royalty Percentage Of Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainContingencyUnrecordedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainContingencyUnrecordedAmount",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent milestone payment",
        "label": "Gain Contingency, Unrecorded Amount",
        "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "agio_GainLossOnSaleOfContingentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "GainLossOnSaleOfContingentPayments",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows",
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of contingent payments",
        "negatedTerseLabel": "Gain on sale of contingent payments",
        "label": "Gain (Loss) On Sale Of Contingent Payments",
        "documentation": "Gain (Loss) On Sale Of Contingent Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss (gain) on disposal of property and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "agio_GovernmentRebatesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "GovernmentRebatesRollForward",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Rebates",
        "label": "Government Rebates [Roll Forward]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r724",
      "r725",
      "r738"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r130"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r112",
      "r122",
      "r212",
      "r213",
      "r214",
      "r215",
      "r225",
      "r228"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r452"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss from continuing operations",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r108",
      "r146",
      "r234",
      "r244",
      "r248",
      "r250",
      "r542",
      "r552",
      "r683"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/IncomeTaxesScheduleofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r452"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss from continuing operations per share - basic (in usd per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r145",
      "r147",
      "r197",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r223",
      "r226",
      "r227",
      "r473",
      "r541",
      "r897"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss from continuing operations per share - diluted (in usd per share)",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r197",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r223",
      "r226",
      "r227",
      "r228",
      "r473",
      "r541",
      "r897"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows",
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income from discontinued operations, net of tax",
        "terseLabel": "Less: Net income from discontinued operations",
        "totalLabel": "Net income from discontinued operations",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r83",
      "r89",
      "r94",
      "r139"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from discontinued operations per share - basic (in usd per share)",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r197",
      "r224",
      "r226",
      "r227",
      "r894",
      "r897"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income from discontinued operations per share - diluted (in usd per share)",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r224",
      "r226",
      "r227"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r701"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r19",
      "r20",
      "r78",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r93",
      "r95",
      "r96",
      "r129"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r617"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r617"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://agios.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r430",
      "r436",
      "r440",
      "r446",
      "r450",
      "r454",
      "r456",
      "r457",
      "r573"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r432",
      "r433",
      "r440",
      "r441",
      "r445",
      "r447",
      "r570"
     ]
    },
    "us-gaap_IncomeTaxReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReceivable",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivable",
        "label": "Income Taxes Receivable",
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "agio_IncomeTaxesDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "IncomeTaxesDisclosureLineItems",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes Disclosure [Line Items]",
        "label": "Income Taxes Disclosure [Line Items]",
        "documentation": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "agio_IncomeTaxesDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "IncomeTaxesDisclosureTable",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes Disclosure [Table]",
        "label": "Income Taxes Disclosure [Table]",
        "documentation": "Income Taxes Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net cash taxes paid",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r41"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r819"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current and non-current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r737",
      "r746",
      "r756",
      "r773",
      "r782",
      "r786",
      "r794"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r798"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r798"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r726",
      "r798"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://agios.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r674"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://agios.com/role/InventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets",
      "http://agios.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r673",
      "r707"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r175",
      "r183",
      "r311",
      "r312",
      "r313",
      "r537",
      "r678"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r676"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/InventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/InventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work-in-process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r675"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r578",
      "r579",
      "r581",
      "r583",
      "r638",
      "r640",
      "r642",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r712"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r578",
      "r579",
      "r581",
      "r583",
      "r638",
      "r640",
      "r642",
      "r645",
      "r646",
      "r647",
      "r648",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r712"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://agios.com/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r149",
      "r150",
      "r168",
      "r259",
      "r262",
      "r481",
      "r482"
     ]
    },
    "agio_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails",
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Laboratory equipment",
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "agio_LeaseArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "LeaseArrangementsAxis",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "documentation": "Lease Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "agio_LeaseArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "LeaseArrangementsDomain",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Arrangements [Domain]",
        "label": "Lease Arrangements [Domain]",
        "documentation": "Lease Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://agios.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Cost and Other Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r496"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://agios.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Undiscounted Minimum Rental Commitments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r883"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Undiscounted minimum rental commitments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "agio_LesseeOperatingLeaseNumberOfLeaseTerms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfLeaseTerms",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of optional terms available at end of current lease term (in lease terms)",
        "label": "Lessee, Operating Lease, Number Of Lease Terms",
        "documentation": "Lessee, Operating Lease, Number Of Lease Terms"
       }
      }
     },
     "auth_ref": []
    },
    "agio_LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace": {
     "xbrltype": "areaItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of square feet of office space (in square feet)",
        "label": "Lessee, Operating Lease, Number Of Square Feet Of Office Space",
        "documentation": "Lessee, Operating Lease, Number Of Square Feet Of Office Space"
       }
      }
     },
     "auth_ref": []
    },
    "agio_LesseeOperatingLeaseOptionToExtendExtensionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "LesseeOperatingLeaseOptionToExtendExtensionPeriod",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension period",
        "label": "Lessee, Operating Lease, Option To Extend, Extension Period",
        "documentation": "Lessee, Operating Lease, Option To Extend, Extension Period"
       }
      }
     },
     "auth_ref": []
    },
    "agio_LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo": {
     "xbrltype": "durationItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second extension period",
        "label": "Lessee, Operating Lease, Option To Extend, Extension Period Two",
        "documentation": "Lessee, Operating Lease, Option To Extend, Extension Period Two"
       }
      }
     },
     "auth_ref": []
    },
    "agio_LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of extension periods",
        "label": "Lessee, Operating Lease, Option To Extend, Number Of Extension Periods",
        "documentation": "Lessee, Operating Lease, Option To Extend, Number Of Extension Periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease terms",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term for extension of operating lease (in years)",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://agios.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "agio_LesseeOperatingSubleaseAreaOfPremisesSubleased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "LesseeOperatingSubleaseAreaOfPremisesSubleased",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Area of premises subleased (in square feet)",
        "label": "Lessee, Operating Sublease, Area Of Premises Subleased",
        "documentation": "Lessee, Operating Sublease, Area Of Premises Subleased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessor, Operating Lease, Payment to be Received",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "presentation": [
      "http://agios.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments to be Received",
        "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofFutureMinimumLeasePaymentstobeReceivedundertheLongtermSubleaseAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby letter of credit",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r204",
      "r294",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r460",
      "r461",
      "r462",
      "r483",
      "r592",
      "r682",
      "r719",
      "r840",
      "r885",
      "r886"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r144",
      "r548",
      "r707",
      "r821",
      "r833",
      "r879"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r174",
      "r204",
      "r294",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r460",
      "r461",
      "r462",
      "r483",
      "r707",
      "r840",
      "r885",
      "r886"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal group. including discontinued operation, liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r78",
      "r92",
      "r128",
      "r171",
      "r172"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "agio_March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BMS Repurchase",
        "label": "March 25 2021 Repurchase Program, Bristol-Myers Squibb Company Repurchase [Member]",
        "documentation": "March 25 2021 Repurchase Program, Bristol-Myers Squibb Company Repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "agio_March252021RepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "March252021RepurchaseProgramMember",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase Program",
        "label": "March 25 2021 Repurchase Program [Member]",
        "documentation": "March 25 2021 Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "agio_March252021RepurchaseProgramRule10b51RepurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "March252021RepurchaseProgramRule10b51RepurchaseMember",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Repurchase",
        "label": "March 25 2021 Repurchase Program , Rule 10b5-1 Repurchase [Member]",
        "documentation": "March 25 2021 Repurchase Program , Rule 10b5-1 Repurchase"
       }
      }
     },
     "auth_ref": []
    },
    "agio_MarketBasedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "MarketBasedStockUnitsMember",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market-based stock units",
        "label": "Market-Based Stock Units [Member]",
        "documentation": "Market-Based Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r380",
      "r536",
      "r563",
      "r584",
      "r585",
      "r639",
      "r641",
      "r643",
      "r644",
      "r649",
      "r667",
      "r668",
      "r685",
      "r689",
      "r702",
      "r709",
      "r842",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r380",
      "r536",
      "r563",
      "r584",
      "r585",
      "r639",
      "r641",
      "r643",
      "r644",
      "r649",
      "r667",
      "r668",
      "r685",
      "r689",
      "r702",
      "r709",
      "r842",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://agios.com/role/NatureofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r166"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities - continuing operations",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities - continuing operations",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r121",
      "r122"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows",
      "http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome",
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income",
        "terseLabel": "Net (loss) income",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r122",
      "r148",
      "r172",
      "r188",
      "r190",
      "r195",
      "r204",
      "r210",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r219",
      "r225",
      "r234",
      "r244",
      "r248",
      "r250",
      "r294",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r473",
      "r483",
      "r553",
      "r614",
      "r630",
      "r631",
      "r683",
      "r718",
      "r840"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "agio_NonCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "NonCurrentAssetsMember",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current:",
        "label": "Non Current Assets [Member]",
        "documentation": "Non current assets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r734",
      "r746",
      "r756",
      "r773",
      "r782"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonUsMember",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-US",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash investing and financing transactions:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agio_NumberOfLegalProceedingsThatHaveMaterialEffect": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "NumberOfLegalProceedingsThatHaveMaterialEffect",
     "presentation": [
      "http://agios.com/role/CommitmentsandContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of ongoing legal proceedings",
        "label": "Number Of Legal Proceedings That Have Material Effect",
        "documentation": "Number of Legal Proceedings that Have Material Effect"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "agio_NumberOfStatesFederalOrForeignInAuditingProcess": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "NumberOfStatesFederalOrForeignInAuditingProcess",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of federal, state or foreign audits in process",
        "label": "Number Of States Federal Or Foreign In Auditing Process",
        "documentation": "Number of states, federal or foreign in auditing process."
       }
      }
     },
     "auth_ref": []
    },
    "agio_NumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "NumberOfVotesPerShare",
     "presentation": [
      "http://agios.com/role/CommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per share",
        "label": "Number Of Votes Per Share",
        "documentation": "Number Of Votes Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails",
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Office equipment",
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r244",
      "r248",
      "r250",
      "r683"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r706"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/LeasesScheduleofUndiscountedMinimumRentalCommitmentsunderNoncancelableLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/LeasesScheduleofLeaseExpenseandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r499"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average incremental borrowing rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r706"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r706"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gain (loss) on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, Tax",
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r293"
     ]
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Other Depreciation and Amortization",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50",
      "r114"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Noncurrent Assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r732",
      "r744",
      "r754",
      "r780"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r747",
      "r757",
      "r783"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r735",
      "r747",
      "r757",
      "r783"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agio_PaymentsAssociatedWithLicenseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "PaymentsAssociatedWithLicenseAgreement",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments associated with license agreement",
        "label": "Payments Associated With License Agreement",
        "documentation": "Payments Associated With License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "agio_PaymentsForAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "PaymentsForAssetAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for asset acquisition",
        "label": "Payments For Asset Acquisition",
        "documentation": "Payments For Asset Acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfEquity",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of treasury stock",
        "label": "Payments for Repurchase of Equity",
        "documentation": "The cash outflow to reacquire common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r571"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r198",
      "r260"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://agios.com/role/DefinedContributionBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Benefit Plan",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r699"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "agio_PercentageOfStockholdersOwnershipIncrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "PercentageOfStockholdersOwnershipIncrease",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of stock owned resulting in an ownership change",
        "label": "Percentage Of Stockholders Ownership Increase",
        "documentation": "Percentage of stockholders ownership increase."
       }
      }
     },
     "auth_ref": []
    },
    "agio_PerformanceStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "PerformanceStockUnitMember",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareDetails",
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-based stock units",
        "verboseLabel": "Performance-based stock units",
        "label": "Performance Stock Unit [Member]",
        "documentation": "Performance Stock Unit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "agio_PeriodOfChangeInStockholdersOwnership": {
     "xbrltype": "durationItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "PeriodOfChangeInStockholdersOwnership",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate period",
        "label": "Period Of Change In Stockholders Ownership",
        "documentation": "Period of change in stockholders ownership ."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "agio_PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment for achievement of specified ex-U.S. commercial milestone event",
        "label": "Portion Of Potential Milestone Payment Receivable For Filing Of New Drug Application",
        "documentation": "Portion of potential milestone payment receivable for filing of new drug application."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in usd per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r334"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r594"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r334"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r594",
      "r612",
      "r901",
      "r902"
     ]
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and 2022",
        "label": "Preferred Stock, Value, Outstanding",
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r594"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "agio_PriorYearProvisionForContractualAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "PriorYearProvisionForContractualAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual adjustments, adjustments relating to prior years",
        "label": "Prior Year Provision For Contractual Adjustments",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_PriorYearProvisionsForRebateReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "PriorYearProvisionsForRebateReserve",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government rebates, adjustments relating to prior years",
        "label": "Prior Year Provisions For Rebate Reserve",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsSummaryofGainonSaleofDiscontinuedOperationsDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds",
        "label": "Proceeds from Divestiture of Businesses",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from stock option exercises and employee stock purchase plan",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r18"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturities and sales of marketable securities",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r199",
      "r828"
     ]
    },
    "agio_ProceedsFromSaleOfContingentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ProceedsFromSaleOfContingentPayments",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of contingent payments",
        "label": "Proceeds From Sale Of Contingent Payments",
        "documentation": "Proceeds From Sale Of Contingent Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equipment",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "documentation": "The cash inflow from sale of machinery and equipment."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue, net",
        "verboseLabel": "Product revenue, net",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/NatureofBusinessDetails",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and Services [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r538",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r670",
      "r690",
      "r708",
      "r803",
      "r837",
      "r838",
      "r843",
      "r898"
     ]
    },
    "agio_ProductReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ProductReturnsRollForward",
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returns",
        "label": "Product Returns [Roll Forward]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails",
      "http://agios.com/role/NatureofBusinessDetails",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products and Services [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r538",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r670",
      "r690",
      "r708",
      "r803",
      "r837",
      "r838",
      "r843",
      "r898"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails",
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r161",
      "r164",
      "r165"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r178",
      "r551"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails",
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets",
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r543",
      "r551",
      "r707"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r161",
      "r164",
      "r549"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails",
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful lives of property and equipment (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "agio_ProvisionForRightToRecoverProductInCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ProvisionForRightToRecoverProductInCurrentYear",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerCurrentYearReserveProvisions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returns, current provisions relating to sales in the current year",
        "label": "Provision For Right To Recover Product In Current Year",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "agio_ProvisionForRightToRecoverProductInPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ProvisionForRightToRecoverProductInPriorYears",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails": {
       "parentTag": "agio_ContractWithCustomerPriorYearsReserveProvisions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueAllowanceandReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returns, adjustments relating to prior years",
        "label": "Provision For Right To Recover Product In Prior Years",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r363",
      "r380",
      "r411",
      "r412",
      "r413",
      "r512",
      "r536",
      "r563",
      "r584",
      "r585",
      "r639",
      "r641",
      "r643",
      "r644",
      "r649",
      "r667",
      "r668",
      "r685",
      "r689",
      "r702",
      "r709",
      "r712",
      "r835",
      "r842",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r363",
      "r380",
      "r411",
      "r412",
      "r413",
      "r512",
      "r536",
      "r563",
      "r584",
      "r585",
      "r639",
      "r641",
      "r643",
      "r644",
      "r649",
      "r667",
      "r668",
      "r685",
      "r689",
      "r702",
      "r709",
      "r712",
      "r835",
      "r842",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892"
     ]
    },
    "agio_RealizedGainOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "RealizedGainOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized gain on investments",
        "label": "Realized Gain On Investments",
        "documentation": "Realized Gain On Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://agios.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r727",
      "r739",
      "r749",
      "r775"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r429",
      "r893"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchMember",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r728",
      "r740",
      "r750",
      "r776"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r729",
      "r741",
      "r751",
      "r777"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r736",
      "r748",
      "r758",
      "r784"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareDetails",
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "verboseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r133",
      "r547",
      "r567",
      "r568",
      "r572",
      "r595",
      "r707"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r219",
      "r295",
      "r296",
      "r420",
      "r421",
      "r422",
      "r448",
      "r449",
      "r463",
      "r465",
      "r466",
      "r468",
      "r471",
      "r564",
      "r566",
      "r574",
      "r901"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/ProductRevenueScheduleofProductRevenueNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r243",
      "r246",
      "r247",
      "r251",
      "r252",
      "r254",
      "r358",
      "r359",
      "r538"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://agios.com/role/ProductRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r361"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r669",
      "r679"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing lease liabilities arising from obtaining financing lease assets",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r706"
     ]
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyIncomeNonoperating",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty income from gain on sale of oncology business",
        "label": "Royalty Income, Nonoperating",
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/DiscontinuedOperationsFinancialResultsofDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone revenue",
        "verboseLabel": "Royalty revenue \u2013 related party",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "agio_SaleOfStockCommonStockReservedForFutureIssuanceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "SaleOfStockCommonStockReservedForFutureIssuanceValue",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of common stock reserved for future issuance",
        "label": "Sale of Stock, Common Stock Reserved For Future Issuance, Value",
        "documentation": "Sale of Stock, Common Stock Reserved For Future Issuance, Value"
       }
      }
     },
     "auth_ref": []
    },
    "agio_SaleOfStockMaximumValueOfSharesIssuedInTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "SaleOfStockMaximumValueOfSharesIssuedInTransaction",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum value of shares issued",
        "label": "Sale Of Stock, Maximum Value of Shares Issued in Transaction",
        "documentation": "Sale Of Stock, Maximum Value of Shares Issued in Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "agio_ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue Related Reserves",
        "label": "Schedule Of Accounts Notes Loans And Financing Receivable1 [Table Text Block]",
        "documentation": ""
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://agios.com/role/ProductRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Product Revenue Allowance and Reserves",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://agios.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://agios.com/role/NetIncomeLossperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Excluded from Calculation of Diluted Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://agios.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Marketable Securities",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense by Award Type Included within the Condensed Consolidated Statements of Operations",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://agios.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company's Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://agios.com/role/DiscontinuedOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r19",
      "r20",
      "r78",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r93",
      "r95",
      "r96",
      "r129"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://agios.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Expected Income Tax Benefit (Expense) Computed Using Federal Statutory Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expenses Related to Stock Options and Stock-based Awards",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://agios.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Domestic and Foreign Components of Loss Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://agios.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r104",
      "r105",
      "r106"
     ]
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of PSU Activity",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of RSU Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Market-based Stock Unit or MSU Activity",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "agio_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Useful Lives of Property and Equipment",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Life [Table Text Block]",
        "documentation": "Schedule of property plant and equipment estimated useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://agios.com/role/PropertyandEquipmentnetSummaryofPropertyandEquipmentDetails",
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r384",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r57"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Grant Date Fair Value Option Award Weighted Average Assumptions Used",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "agio_ScheduleOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ScheduleOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Accounting Policies [Line Items]",
        "label": "Schedule Of Significant Accounting Policies [Line Items]",
        "documentation": "Schedule Of Significant Accounting Policies."
       }
      }
     },
     "auth_ref": []
    },
    "agio_ScheduleOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ScheduleOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Significant Accounting Policies [Table]",
        "label": "Schedule Of Significant Accounting Policies [Table]",
        "documentation": "Schedule Of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://agios.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits Rollforward",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r873"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "us-gaap_SecurityDepositLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDepositLiability",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposit liability",
        "label": "Security Deposit Liability",
        "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r577",
      "r580",
      "r582",
      "r640",
      "r642",
      "r646",
      "r650",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r671",
      "r691",
      "r712",
      "r843",
      "r898"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment and geographic information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r252",
      "r684"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative expense",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "agio_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation arrangement by share-based payment award, options, expected to vest, number of shares (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Expected To Vest, Number of Shares",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Expected To Vest, Number of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested shares beginning of period (in shares)",
        "periodEndLabel": "Unvested shares end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Stock\u00a0Units",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested shares beginning of period (in usd per share)",
        "periodEndLabel": "Unvested shares end of period (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant\u00a0Date Fair\u00a0Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofExpensesRelatedtoStockOptionsandStockbasedAwardsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r382",
      "r384",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Opportunity to purchase common stock (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares authorized for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based awards reserved for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, exercisable (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r405"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value of options (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in usd per share)",
        "periodEndLabel": "Outstanding, ending balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r391"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofStockBasedCompensationExpensebyAwardTypeIncludedwithintheCondensedConsolidatedStatementsofOperationsDetails",
      "http://agios.com/role/ShareBasedPaymentsScheduleofUnvestedRSUsPerformanceBasedStockandMarketBasedStockUnitActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited/expired (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in usd per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r389",
      "r408",
      "r409",
      "r410",
      "r411",
      "r414",
      "r423",
      "r424",
      "r425",
      "r426"
     ]
    },
    "agio_ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost not expected to be recognized",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount",
        "documentation": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not Expected To Be Recognized, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofGrantDateFairValueOptionAwardWeightedAverageAssumptionsUsedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r410"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term, exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term, outstanding (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term, vested and expected to vest (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r406"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r202"
     ]
    },
    "agio_SixtyFourSidneyStreetLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "SixtyFourSidneyStreetLeaseMember",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "64 Sidney Street Lease",
        "label": "Sixty-Four Sidney Street Lease [Member]",
        "documentation": "Sixty-Four Sidney Street Lease"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r169",
      "r193",
      "r194",
      "r195",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r219",
      "r233",
      "r295",
      "r296",
      "r347",
      "r420",
      "r421",
      "r422",
      "r448",
      "r449",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r471",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r505",
      "r564",
      "r565",
      "r566",
      "r574",
      "r632"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r577",
      "r580",
      "r582",
      "r640",
      "r642",
      "r646",
      "r650",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r671",
      "r691",
      "r712",
      "r843",
      "r898"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r233",
      "r538",
      "r569",
      "r575",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r632",
      "r713"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations",
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r233",
      "r538",
      "r569",
      "r575",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r594",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r613",
      "r615",
      "r616",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r632",
      "r713"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r731",
      "r743",
      "r753",
      "r779"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued under 2013 ESPP (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r97",
      "r98",
      "r133"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://agios.com/role/ShareBasedPaymentsScheduleofCompanysStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under stock incentive plan and ESPP (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r97",
      "r98",
      "r133",
      "r395"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued under stock incentive plan and ESPP",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r133"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets",
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r101",
      "r102",
      "r124",
      "r596",
      "r612",
      "r633",
      "r634",
      "r707",
      "r719",
      "r821",
      "r833",
      "r879",
      "r901"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "agio_StockholdersEquityDispositionOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "StockholdersEquityDispositionOfBusiness",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Disposition of oncology business",
        "label": "Stockholders' Equity, Disposition Of Business",
        "documentation": "Stockholders' Equity, Disposition Of Business"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://agios.com/role/CommonStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r203",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r346",
      "r347",
      "r470",
      "r635",
      "r637",
      "r655"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r636"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r706"
     ]
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent events",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reporting subsequent events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "documentation": "Different names of stock transactions and the different attributes of each transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://agios.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "agio_TIBSOVOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "TIBSOVOMember",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TIBSOVO",
        "label": "TIBSOVO [Member]",
        "documentation": "TIBSOVO"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "agio_ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember",
     "presentation": [
      "http://agios.com/role/LeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "38 Sidney Street Lease",
        "label": "Thirty-Eight Sidney Street, Cambridge, Massachusetts Lease [Member]",
        "documentation": "Thirty-Eight Sidney Street, Cambridge, Massachusetts Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r152",
      "r153",
      "r255",
      "r256",
      "r258"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://agios.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r332",
      "r345",
      "r469",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r554",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r829",
      "r830",
      "r831",
      "r832"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r797"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchased (in usd per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "negatedPeriodStartLabel": "Treasury stock, beginning balance (in shares)",
        "negatedPeriodEndLabel": "Treasury stock, ending balance (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock (in shares)",
        "terseLabel": "Shares repurchased (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r98",
      "r133"
     ]
    },
    "us-gaap_TreasuryStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockTextBlock",
     "presentation": [
      "http://agios.com/role/ShareRepurchaseProgram"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program",
        "label": "Treasury Stock [Text Block]",
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://agios.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://agios.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock, at cost (16,216,411 shares at December 31, 2023 and December 31, 2022)",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r52",
      "r55"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://agios.com/role/ShareRepurchaseProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Repurchase of common stock",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r52",
      "r133"
     ]
    },
    "agio_TwoThousandAndThirteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "TwoThousandAndThirteenStockIncentivePlanMember",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Stock Incentive Plan",
        "label": "Two Thousand And Thirteen Stock Incentive Plan [Member]",
        "documentation": "Two thousand and thirteen stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "agio_TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember",
     "presentation": [
      "http://agios.com/role/ShareBasedPaymentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2007 Plan and 2013 Plan",
        "label": "Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan [Member]",
        "documentation": "Two Thousand Seven Stock Incentive Plan And Two Thousand Thirteen Stock Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government securities",
        "verboseLabel": "Government securities",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://agios.com/role/FairValueMeasurementsSummaryofCashEquivalentsandMarketableSecuritiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://agios.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasuries",
        "verboseLabel": "U.S. Treasuries",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r680",
      "r697",
      "r699",
      "r895"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://agios.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Unrecognized tax benefits at the beginning of the year",
        "periodEndLabel": "Unrecognized tax benefits at the end of the year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r438"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest and penalties related to uncertain tax positions",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/IncomeTaxesUnrecognizedTaxBenefitsRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increases - current period tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://agios.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49",
      "r158",
      "r159",
      "r162",
      "r163"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://agios.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://agios.com/role/IncomeTaxesChangesinValuationAllowanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) for the current period",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "agio_VorasidenibMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://agios.com/20231231",
     "localname": "VorasidenibMember",
     "presentation": [
      "http://agios.com/role/NatureofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "vorasidenib",
        "label": "Vorasidenib [Member]",
        "documentation": "Vorasidenib"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share \u2013 diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r228"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://agios.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share from continuing operations, net income per share from discontinued operations and net (loss) income per share \u2013 basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r228"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505-30/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//705/tableOfContent"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>108
<FILENAME>0001439222-24-000035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001439222-24-000035-xbrl.zip
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M*R,6=FKK*JCY)CSJ2:BMS^!!FW"2Q: (@F((-Y[XM_C7"NU!;=T(#]J#L\'
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MR_Z<79R?71QB6=P/_W$NCD^.+XZ_'AVOFA!_N&F3Y)59I/=A>J%E\17\[D,
M#,BP+_BY!)XV@0>0A7QPCNX!%6*>(ZEU(/H:I6UT.\W-,W(OH5&//-SAJI_.
M%RE)IX '$O,;18&'NKJ-<2H@.W(T1V?SD'Q4/MJMC 0RW@]06.8/<;:$9+G
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MD1/$[!(AQUGUG'!8\R>5WHT^(__<=]ER8"U'XEIJK)F'1!S%5+H"S2R4(8N
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M*_ECZ53UFM@G<M($-6[2-[>H" <N^WY4BE6J( (=>3_5,7^$4*,61I%2%9M
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MBVH@*W *8%Y<!5NYD6U<W3"8PC"F&.\@*ZC[7L=.+0?Q,,C<B#0(D-\!0A=
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M*4,^(95FRY^CY  BQ2--#&UB]4NVBD26QV(VC%JF7[/H4>X&.U&'*UG'I->
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MUKT*CH:^BT]C,(T\I%0WIA7$ 00/)U?P\>QT:EW3[5K-NTUT2$@"4.OI0O'
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M<P*?0AJ@4$.'&V#N?)%C6041]U7!;MYE6V0[-LS2)"@B[OXBH T?^Q*ZG:'
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M][BE&AHSSD??N&\<]=^$HQNO_^T#TN<S5^D%L4+,; 2OB5/$? *!]6.)B5J
M']S99V539FK9,N>QI,TH7=T4@.ED;= L8"2F"/:#*2+I>(=<6/P2Q1"ZQ-J0
M.D:*)354"$*-*P+";-1>%D+\*3">T1K.EO #JNSSKK48OQ>50J29N(([(N(R
M0<#H0%+E*E4*%OMILU=(0R<?FDR>A/#%+N$3N[I&?&,2_,-H/>'9 X>["/&:
MLZ?/G_^GFC8]G7=TK?BP"*7FS.=$L"0U<%"CTO0X@N $,# OTIXL_A80BU*Z
M0A[6YA>P-E>@8W"X$)FWT6PY$*/-*,CQWO(7SWGI H7WYL7;\SGE8MSJ0%ZJ
MK,IMO]5KT]*/4WQI]I.,I891XGMIQ<2NL0IKB&'QEA(RLD+6O'\3#KGFRDH6
M[W7ZYIQ;1*/CMNRE.8=O 'L<_V6O!G>!GQ,!8=UWJ6U\8.4EQGU8SY_Y7%^M
MR(U$7R(Q:3%%%K?MQ+6H,%B9TFLN,^>8*+?&XQ)FF2]9*Q)'\JEND+JRNBP@
M:E]6:VJ)G -64F[X;UN2I0-%%27%?X'0U\,J^4*L'NBU]CO.39GG-2*7>O[5
MD^^$;[=L >G04_H>S.2S.SF3SX[_B)E4)(-,I@$HS@G'\B)Y0A?%;C1YK IW
M$!FIB>=B]O63_YP]HD/B#_$_XAWYG- >O*=S"FO_]#CZ1&5\AWI]1)FQ([M;
M=,[P;%6XJ#N&TPB,8>V)/G  JFVITR+D]J6E]+2DQ$C9Y&\GC'@%BV1X?FP<
MNU/GNSO0[+X+B9]-XF\PI$QG>N=7_9VV7WRV21_)$;=:Q/GZJ>_(I6^3ZO;K
MBM/301E6VT 4&-R9N=></N>0A>U BHY2S$.BV9@/\\)A(W>AB(2B%$05ZYYU
M.$T 2;]U+_)8/W&NW''8:NHII3=-8,82^"FI.T!]E5I8I#P2T;I*]@N$MJ?]
M!5$41M,BI,G?]:N+&/V?26+1I-3I\ZDX47OJ->7/<P(L-IJ/D?.@9%8T@YI_
MHT+JG\F,S=ZQ L&9B5]'8_("AJB+ZTM^&Q^L:#^$E380"T,+1X(= :) *2P_
MLUO"\A'*C%*[OWMZ_(RDJC8;;Z\XV4OMS?&?#:B$F3Z:AJFOE!ZR 9K:*M.D
ME]&F(#5>]>(BI$RRSAM3,S,991_77$':'>GI4.2_&D+J4T:0F<4U^5A<7%!.
M&E54&]+X@F8W,PR]@3B9,/79?Y+=GJWC61'O1B^MZ M19KH6VDU:05).QC0F
M#36P(#][\OS9O=AA[\$.7A%GT0JK]Y2*+-%02:W<4=+22J!JH&."IJ5\'M<Q
M+-SL._H_&K@786D,Y,_FW-ZE,^QRQRWKP.2TGVD:>?Z/X\[@9?+TR9.G^JU;
M'IE:E0G<3U_]ZC^%\8EZ\<^+_=%I>_2_Z_[H^]IMZ2>(H<]/__?W/\WUN0*+
M@W37M6I=Z,X 0!5] _2&7\45R@N?PQL8%2_,<[JEZ+J@KL%VV<>#?<-<O_)[
M,3?Q.9>]2<P/AV%VC?(AS!ZKV\KJ+',J;L:,/H */:CPJP=0X0.H\*X:Z%LL
MG1VLOI@6(Z V>BY0@4D'I]K1KYY^8QPF7BDQGHV'79YDD'+K.'4P2FO9->*Z
M2SN0W8D?SV R"5##*BMS/IX_P4_C?SR]#X7X=_ WQ\?!V:FX3,F+M6# = X6
M,7"H^GAR4&MK]*3XZ 027O -ZD,R?5,AGA"W& :IR,?_W!3+J5(J=!Q>$67:
MQX+0$$)*,WK:]\7'V5DO</@_UXO6K8H_L).JA_TS!.9_F*?J,C^)Y J<B(4P
M$#)'CM?8"/KP*LIN#S[JJ=\2(E&/5NX/+9J&L(A(>5-?HZ+1?!,'58WG!+,B
M19),^)62"D2//OLQ.J%X(W(+XJ$J%?1W_8ZP2"*F$J\)^C70BU[TTN7><L=*
MZ)1^<?RV,ZE#^IHVE()GE$CE(C9WJ;/+Q%72 EH#?@4)V*MA'3YZH5X4\_1&
MY+#9#,3_]KU&-T[K7+I C7]^LA#/N5@1_N1>>PS?G_LJS.@BR;?)AVY5@L0(
MRX+>7#@9UK I995K L7U6U+TO&[C[UC1A=%I75%IM=8VACY;4CN3ZD<:VH05
MTI>BT B2]AHUDGK1\>POI6D.P)ZE8&9F"K8Z#)OR0^"V<-W"LIWZ*KXXX<0P
MC70=:]U2<.I]L'2T<=\W_78W.UW1D)M3#UQC5]<?E V.@+O)4N'$WY:,$X//
MGJ!9Q6"3>"@A,Z(B[Z&@IHM0 ?F%87>]:F(&(8/'A6#Z8RHZT!32GBWBHQ$1
MQYH0MR!-3W*,2B=I#XF=/7I0P:#+JG([!8N9'7@A#2LT!*TS'>5%WU (!;%I
MEAUU9>3Y)/W%?-BBQE*E0Z*1')?%'>,"IQ+R$=Z[&DK\4;?O93S'KVA,AG$>
M5>1*R>J#EZ<Q-@[L)BT)I8EG2+]V:#>BQ3J8/Q'U8CSZC!2*/ 3, 'X84@91
MVAF@:582N6[; 4F#G;!\85N$F!IIG2-Z&(''-=&<=)=!I%OYBL<SU;PEV&S^
M6O/QF[!,51.6TMO?A"/N50O?#MXC;8.=<=0(J6BH2=E"N/GI @ED*LVJ?E^D
M#G6Z@.,5./OIKZ]?'#W]TXGK6S L/-:^5>*L'*MH8EO!!)X4X+Y94:(EM:<7
MT-8(^7M=-Q\R,._)P0'H/!N@MC6_ 0Z'/1EK?V!P3NOIQ^R 'UZ?":<ZAJ(2
M^)RZ9A!KARHZNL0=D;]W9A\X!9]?4<:A$!(A+M=[X'M.0!Z]-.Y\]\/"'9V4
M( 0Q^9TZ!SZI,?T<-?H[]5XW8?C;3C#U#HLPM*O<FD*GWL+)!T$6 ZN#S0^\
M 2I8]<SE. U$?5]#LF<4+%@NC2#2T1Z#,&V910-EA3);R&F0LE2Y(C]=3X%8
M,._JL%(=C,ATUGO!Q3S:6!F%%[5(*4Y#B,^AGLR>I9!,$".3*BTIM%@ZK!VF
MQ# @:EGX2,<&[/S,<%%M4$;+^2#>UW)<4=C+SNFDXR)'F([TP-KGHN0(=?,G
MF<*K&%!?_#\CV-"3$_T&ZTT0L3V97A!5)PZ: R2FH'8G=-L69F>#DS-OTB@X
M9 )L/EY(FH>V=71I^*QI$G41.RMQW ?ER.]2=AV@'GD5Z^,Z*F08D0P=;@[)
M;=)XM9T497=D<FDTL*JTTPXX-TAFDY:@8W5($5M6#B9/9=%W4@*C5^=F&MHL
M296FD)>^IC)SG*(-&$P:PDS]TE="6?,ZSU^K@N:;=\FM<2.,<QV.4#Q?CF=_
M ](O?@_GE@:Q],TY+H'-)I*1I3@>X>-N0]L'C! [\XT)+]CL:C2',4T:$BS9
M^(\F9S#@TK4.0>BLKOW?SDD*Y$C&QSU:%*VP&MRML^@@!E[[*GD*?_CAG?DT
MU$B9"'ZS&1W"/9/S:8 5M']"2B_^5--J?WSRU>PU ]/Q;P'G82KQY[1;QI!E
M-/F<%56Q*GB:IXX#]CMT^R.\M\@7>Z@ 5P])N0J9Q^ \MCHU;.(P1! _FBLA
MEV_?G/*6THB8-:DM=$?7IYX8JY+;I$0;E3I5PZ*QHH3$]FPAZ0OKN*%E%^!.
MAT-["LOCQ!W_<R !GX;%F7T^/,)__*\?R2N6I?CHC&Y:K.)1_"K^1[F*D_6&
M^JWFN-L/Q787C]1&_ODF!@O+^-4?X]J[G+TH/M1=_/[[&(-$._K7Z&_7TF;W
M-T+.1,>D>LSCORLPP\+4);M!"\6E6^)VY+KE^WEGZK-.U>A@EVGC16VZA[<9
MC-25!40#G0PQ0L,1#G(>E6_[]QUHEZCX&J?_5TZ!6#LC98=8*I!PH5C%6*>E
MJONZ]7P?3CUK&M<3#R=;O "=<N[PB(%X#14BHIZ/*[19,$FS,N2:0^A1%MRA
MG9\I8Q@?C3/2;;7E%!C*-E==(B]OI#5UN>S>U!Z86(?R67V%?L_$1Y0*2:6C
M25CLN:A!P9H[S]F514@F#I\P-BS[ID'WJAN!S*G*\.@L<$,('V2UW(_8%4ON
MU3X')AH,4FC%#KRG4@U11U0\[%]3FTAY48*+@*$7 3[L1<T.0N(ZR!WA9WQJ
M<\8H&G+D(C@5^;I:;Y2^6 <PP1">X>!__38>^^8[(]O)0VLUG7CO[([/G]V'
M?4.+)KX[7KWT2;2QF_W"!"!:IEB U2ZNBG*C,*FL^4?HY^ ];CABS"]XRLI%
ME(AB/V[HUM.T4\@3)Y%;P5V/.V3%$-M5W26+&FW+?LL-V#<U4&BF2CLN\["^
MD_%(Y;:ANZC>;$+05A<@^*IDERK^-K7(VWL]6H2X"E!;0N'MV3>/YYKD3$'H
M$O+.'L>;Q7++8G<B^?36MND4AO8[EP-(4&4R58%MHSRP=,[H[3%Z^+-NFT?K
MLH&JMM0+GSU_?.++K&RC/@D*S64*5A^7SZ32AH]' _3UXW_C\UXWIXJBHZ1(
M"E<@]Q7K1H<=QUJ<\C!*6/;%7 U3CQSE^$6.K-YQ:@P!O1Z3\^3V4O^30 ;;
M+V0J'M!=A.[Z^@'=]8#NNJMNQSNA@63&J:$LU/@<==@:J7&39V]'&RFHZ&DI
M:6DY4'VVEK+4I%-*_)KAJ*W[9BG.;M8YGVN)K^J4H*$R(U.R2.<HZLGQAVWT
MKS=%DR)71W]_^&3F _,+,:J?)7'PYITPT>G<N5DC:O++^.4C4+"QMX6D.:*.
M_<BOL7XI\:SF(DG,;OS3KT<_X$ORM_\P'W_C.R0$Q]_]XUS0>I_X_3_Q\@K[
MNEK]&T_V^PS6QAUIDE/.Z%*PZQQMEZ<QM&:./PEVTF_<T4]C,!.J5G[Z]+FB
MV2E,+#TWG$I;C%DT;GD:,26SAB$/K5,>%6J]?]_ISA(ROK(JL4S+TSY*HQR4
MP85I=80WX>.29*ZZXB,F8QW#4(7%#?0R_-T7^R3/5<A!PU4I7@Q$5+A!%ULS
MD^Q+40W;*@71N2T^ F07;RWGC0(Z$XR"FD4DO]*Q!MUDS!5?)B &EI"+LSG^
MP9'(.1"5BJ:MQH*I=WP44[^@L+P=!W[3]Z<HC5X ]XYAIR,.CT$B)7IV]9*8
M8B2P!J-?QY#.KMQBK'[WU3PNM#C6M/O$(GY%DRGE?2Z1C,*^.5WH=\_<;[^0
MO72'G2X-)U-+F;/' OJ#MMSNLL@*=*XI9^"82:4,N##5M; L&@KSNR:(I A*
MR96D*$UG1HK+U,[3;Z1L1FD.&.6Z4J4O1MJY!^-$@K/(B0EX]JCVQ,#MXT^U
MUBZ%:L^WC'X=,2_)1J670/7:$'5XQH)K\XP:X;O^WBAI"1@=!YB*V<(#PAM&
M8VP;.E'U8+_37\J]#%Y\U137E","!!I8FR#P"3Y+J<(K8[$RDM41Y^TQWH8W
MM[PE%R?G+&Z :VV09J+L@QM^-]O,@<AF'A# /=]-0=EQY](YW_&#<"LZAN7W
M?#SWC6@@=X*$\RAR3X0[(\O,XI\ZD]Z%=RFR<?AP'S*UKP5A3CMD'K=DL_P0
MURH@[E;^+BX*X@2QDC_FMXTW[!1;/@UFDJRGU8Q M@,46WSZM-FU4I?EAFD]
M<?,WP/Q]A2BI:AGPP6=>W-U7JK"C>:M7Y9HDC*F/U_==G.GEL"'?]0OTW1 <
M:&ZH)&7P;;HRC"2-@0H[NRP 9$'\#%&+X*L0(YDMH2GG\931Q/%Y%?=%#0VD
MGGC88'4DVDMOSM@S44Z;F(,,5%]65_7FJC0B-@?R';4;D+56:\,=,O]H=/V?
MON 5?\H@#%%+8UXPUU>B.)6A< 8:I=M6NENH%D2#G?E2# ^:5,CVR#\CUYSF
M_$2(X*@7#?(WY/ZM$YAOP G-D.023'U6+QM3!"<$#=])0$P,&52:6(Z3XT6B
MR>X% )A!$S/.WR1.12 7:'&F]XY?C^L=50U7J(<O,- ;XK'H-Q](IW9YB3DX
M)HS-/D,!6+%RPNF? !H)+E0,.UR!>&WBCDA#FS#N\3DHKCM8266P]V4=_7FI
M2\9'7U!C-)F^6L<L9'IKQ2*ZN(=Y7UL YA+0BJ3C8 5\/^*P'<,M7M/K'*_?
M'NMU4:YD!=7+L *OPN"8C$[" =99>6&JU8F$JC*=+ZPO4KDB$+H,:V0'=?>8
MF>!.G::C).W39]&VO&54+KWHJ3@D1J8 !_!<QU+6XLN>5)OC@_Y<Q6&Z4R-P
MN]:$$'YZ,8FX^LE-U),HP^211H @'69;(@]A']*%W=;!20,<S]"]L[+4\),Q
MG)-*P815R;G&$Q\S_,".W(%B'41O(E!K0]S[G)IC-@V8XDG"$N69Z4A% 2**
M1K4MR66I@CE!+);R G62V@^C6U>$\]_$=145B&B"6+^BS0!,N4:!'TMVTT,F
M?<&I!U6D2#&%(!V=&(9IB+MQ]A9(PH62"\Q,H;(,P]'(-34'TF5X'K*4::;B
MU[.)BCY;EMN7G^.\LGE)8Z$"5-ASN^&>^]D)S'$VEXN@+36QBICIM-09D"34
MI%;&5XJ^:-G2@5.K)FI(DQ=L %3EA EU1+("IC1L-D?B"Y"#.!PR.C%-ZHR?
M;[0RAT-)BP"D,M:<X*1LZ.'SA(\T5! (M4R"*9F":^@&<G6(M@XM;J4$XX5.
M#OVI-->B"5 F__#/>?VU86J)^?<4, -?1EHPVGJS2G-\1XZ37ZE5>:9KY#VD
M6O20N>U=O[ACPF$.GQO2"H%:]H)$!F8@NT<O?WX\^[&>??W\F]\_>_+T*].(
M/_R;Z=9T,0(.:F)"'P1H'%SM!7?'7E&,_.1IO//O7YYQ3N>&9T7,1H!KH)_6
M>^N#++8;;<P;G0K,739RL D=-# -:95;$R7G59<U6+>%ID]\/$L)>?LX.JY@
M"^3(P![-OV'L>GA*=O2X3XG2-R1.\8:[/%BD6.S2RY\Q2W&T_:=S/I.0XUHX
M-QX(]05+>4@RQMD3/N$4KXL9<+9+'5'0(WEJH>$LO7;N^#LH%\P%.C0<9<0H
M&V6>4^,T>_E&3%H&4AN,ED(VYX>-J"Q#/S!)19N3;;>38GUQ._L[5"336D]:
M%SBM;]WE+HVL^;B -,ZJ7O;&1+9 QQ'M$+']A@=W:]T6CFO:DPU9!L^9[*(A
M5/:GI_)$BD44'=45H (36ZR-86^KJ2?W$%.7;AWV$3&<Q$_7-=)0T=U >>4U
M,I6X<%*6/7PVQQ<=+:MX59&)J<9;*CN!I[:^[_[B89[:U>T#E"J#4GWS *5Z
M@%+=#:.]))' IJ+B#5N<W.2HPO$&-.2(+P9[?^:N\(Z;UU:A6'$PE8 .GO!X
MVF(.+(\WH'SDQV#)O L+5&* 3+"*I=)]FH?D+IYL=9[[YM.$@\AD7KE&1NW;
M5&J?/*S]._^@O!Z *6\VB2TB3A./@CHHH/]/-SI\%-X:P7QQR^@6IUC;$D4A
MC;V"8"0<+GO#Q<I!.DA2%^REI[2'"KJE ]'F3D_&_:$9M&,1%\B77MD.7=X8
M0*\/?#-SBUF/D9YD>$+.;SBZB2*5=I9AK$?'*T9!>;TYR9IE?_C:'$744T]J
M*ICDN.<>/P'FX(\#\#9V 60Z1&8[)3=*2F98/ZHC!!]N2>X%L9YO4YNK=V5U
M)Q?[.1<*=<11*U%(Z""0H(F;'\HIS6.<$>=UN*9<E.)"UDZRQJNF.'L?G=H%
M3<#]3'6<JV2G9,^I8_?\[>LW+Q_/7B040QJ<NS$(GRPT]\U<@\UX!/75$IWU
ME71.(!T1K=.Z6!)7#IDR::'7<W1"N$UDE):*?:[7!(9MP.:4="1)JQ"99@"I
MBAV6./?V1>L 8\T'L4FJ;G5^N->=IF@^:^,#;PF'DW%[I H@ZU&X9Z:&>ZI6
MT</WU39T3@-:@CPQ?1 7BR<_"WKF[H/E>F-P1]SMG'*$T&G! +^RJJ+!E*Y-
MJM8$ST]$$4,C'9[F,!RGL@U.FW8;3_@C$21=E?T6DTP<,$ FE6U@:4R!EDA2
ME@ K*$:"(4-2K1@M'2QD4C;$.]XD#(&4/:7ZB'=OV&NQKM#IZ4;%A*_O4#^^
MUDDH*SJ/0?PEI#3TG'L=;<$?N<S_*@YA?:&( <N&K!N&4S@6'JXPYT:-G\/7
M9OT*T&ZMP!5T%9%U<_WF]#2;;RHT%+-5'6](1<51E'JL'>$,](A?Q9+"LF%0
M$<1K)>G6L*A=Z)OD5"0">9K$'_JXQ2>J>5CX9S^0.!/]1_:;4Z5=>6_;"47<
M'=I::=5@Q,6,9>O!=C>#71A5*:O56!T&!8!X0L09,<A->A8@'>X*R?JO/"K>
M6#7AU.<R[L:[WNQ16\7N<,TD%R=G6Q9]!;=K6:!U7&#59&N%G27MY'R!8MH4
MSC)&(I\0585B6XZ:41O^XJ#W.Y4/)0#)Y(.<)"_?_0TOUO5,YE5?B,J:,^3W
M84D<.J;2^:C! !-O(J,GN=2;ZV[P-A2WSE2TM/(F$HH9$=KK:*&!_?E+&9:7
M<6KC9)>,A_JQ;JZ+/3L,TP^-X&F[ZS<MK501^> H(RD3YRQ_YG#(-V1=B?.]
M*(EVX;+R0"K*/,/3UG-<3T2F\A4,ZKAD/$^L6>P-[:>_5"7I<-^++.>GN!_+
MH/Z7RWY0FMP8HJT)G&'$+5-*_R.N+*>M7#=_8)."H[XH'$7L(5T%[3$PA?'A
M#+8M>WC2U"MZ]FBD!S!- ][)F1?U<.Z^UXK.X:]*[-,P8;H:&K5G0A)( .&5
M%Y<5" B/YHVK4)]#R#K\X)@SB8T4S0H5WY&EH#4!G!1YO"6$B>+"19]97()8
M?LGAA)'D3HE\]S&IQB),CB0*08*8NB.1WHWVZ^>;G6U>,=H$0^FS=4,57(.U
M"^!=28)Q=,7I>_;TR6Q5[(G4[J,1N&[JY8?X?O4.E9:0H'6#")OFI2$_"?]9
M,T<A4:\H?:'5G&JNTHB]U-7'"%GZ!SQSK%"/N"7?\'AV.AVV;&EPD(-L6&M1
M,X/Q1\@*?5P&79N"JN1W&=LBK.-U'+U?\%"RBLR;A<M)7P!*;;BXF+52OTM?
ML>^[A>[6,V^H3YRB%&,=B-ZRS?CTZ_%LTCSRE-X/6?GWX"%%, !>[^O::)EC
M0$.YL:;N12+9VI,/X)H4PQ[/:4?O*':;[F"EZC56QA4MT OUH":N";NW!HFB
M0/:PWI?USGR\R>W[[6^?F =MO4^/@SY=;>_%M/_\.9LXCV<_.S'D Z= D:6F
MN7&+)5*V_2;Z/ $XT.P8'2%2;#?L#R "4Q\NY4'VH9-^W$0& #]V[Z]4*->B
M]/!CDY!K)H<WZT4@[+IUMPB*Q;WH\K)F1OLMN]O")]R*[X.ZPC+DGQ)I;BA6
MLD/-"\G-\  3\7_A23SLTW_&/GUS0]SZ>3?K:UG7-SS@/#DC.+Z9V2G?1K(A
ML_K;(SFAEJ+V<G"-/T9C2?0<B!^>/K3\XS@-(%Y7T>F6I3!*B3>IJW0^6W,9
M[% XW"J^%"E)[OJATAAARCK?L.*/6Z:,=55FE7&\],!FJQG/BGCEH (-%X0G
M8K^+PFY7LE3>NGEZTT-!O(^&#P_EX9W_;XG2^<,#2N<!I7-70X@42Q>+_Y^]
M-VURXTJ21?\*;.Z;>919%IM%2FJI]=Z8E4A*HC24>$FI9?=C D@44@0RT9G(
M*J)__3WN$7&67%!%M<2E&O-A6BP N9PE3BP>[O55X<8++5?SV,4 -8G@YST"
M7[R4B>842P-Z/,$1]&H*3S",A;4T/57V^=F%VS@"&'QZD8EZ"&"(2>&.]JIL
M7Y]9F]T\WP36]U#?J.4PFN>MA+J1O^/>')3]N=E85DW<P7*LL^?WNT$?3/'C
ML1$-1/T =R0\#FN)=2P!>C,<0, LV6UGE^HS= 4%!I5%-"(3Z]PH501,Y/NB
M;'=@U3?%NJC:1$'<^?5Y0*NS[C("IW7>Q6;RQF@^=Q[/+1ZQM02II86BO&1<
MY[T7DN,A,7[+_/8GY&2X5W[2;ZZ1BR?E^T%>&>GTX@J[3S)H7@&KS"^KVO9G
MP4YWYSTMBWFH9H('IUP59_LU28 KD2&3['3F'DB?Z#86(7E:<4"<JX)KN(N4
M3(F9H)RIX"6=<9)VS6?FNT1"US[AS/F>6!1:VG9+ S>]2H?2+865NXER&/11
M#8(HOZ>_L??$_9.\G+YPN<5O&0Y*-D=EDJK(H-MWAYG!X'C6W9X;K_5#[ 9@
M+8 UC6'1U:9U@9 PY>JG9NF^),)1Q@6BZ[=8SA+=HMR.=)65>&KWGI>ZW"7%
MJB,6O-BIZZWK#97"PO*/+]8G_[-='7KTZNJRUJ68-']HOYY4=<8OL]D47@E>
MFZ7=>KDL97UBG.[/'M]FAV,TI<ZVTOJIB*A+"[XVQU3$J.15U4GO8WGDM!25
MR; /%$-!@-[HF4MP#<U6F&CLY7HI31)!&0U7^DM<GHN&.V2"!>OJT8BCQ9;@
MI=!K$6LN&9ZQ\5:IHS@K/M9:D=]F%0I/F_X6O20(]'Q/))+EN(?40>NH)6LB
M:9UI.M47X21!/XYA^E@ZW-_2_W@9< 9/8"%>!-K[.X;-VVM#6U0@'<DI>NHH
M$0!"^Y%9'I9I3:).[.DN7[P&'B[!BK$@)%2$:'S"]Y0:Z0H6O]O1G$XTX%;$
M"4;;&84%?S$])N++[;H&"DO<;[UFQR\>L=DQ:<)\S";,OSY$$^:#3T42EZE4
MT'4)*SL-3%2I3X8GS:V.9'1BHS%(<%C>]$E_4-07:0,L;K2W*5"L&LPZFLU=
M O.S](DYA?K%NO'H*LX,JC,T"&Z>]>JS>_F\*9>7Q?*3$?=P!Y=HB0>()MJ]
M4=>H]%@Z=V>DN L_&LY@%MT9I39-7H6>.*X)/^Y>['CJC?S)H^FC9:9007^7
M$?="$V;235M[-(\^+0C9-U(<?+,KFR0K/7PA.4ZLE<*YA\D8F-<F:NL"+,U]
MQ=A=]/Q<UWNYRF9+&59Z-<Q*]G:7, ^@\JM$GC?[')Y_(:]&H%BUZ.^R$E&)
M1%]4.XT8UY#Z3)YO/'?O0Q1%_*?'&7$;Q8:#,%?^R1BBX-T:\Q3(6 QVA[)E
MURQ4RJT#PR-^[\^>7H%J;Z6VBP)3TN:@+&_JK;D1^/'QTQG*E^9<^T4U(V65
MM7GXQ(1?R'V[AG5IC!T OX+!URT!]Q=29BZ"\H@G%I&OHS\W6D^^%KX2XCN[
MFLQ:L9R<W6"PI62M>)N;C?> QR=+&" H=I*V!'PL!>RWQ>QS<D7_;' JO80G
MZ][]XWCSXQQBTQ8B;P-,?Q.R^223Q1FCEHG[VITM;F6)M3L6-L5A@.JZ^RM%
M7@84C0<UO]$P(8+[">WU>*IOJF]*A3]YX"]O93'[K4O'4XR'L/7<4;YA=+_L
M;W.PZAGP1@5ACW/X1/*>FPTI^-02EZ!@D<I)6U8J@SKU0A /THQ,%IBCV_*-
M:,8D;"53UU@H1R]-*)>(K(&Q=-=M\K##3K$<^9:%&^P,2T,V"\*YRP:F7,6L
ME=AX$,%FF@(A>2]G F=:Y)5@^8V[)2/YKI\PHFW$N"@=D Q/-P=;V,=740MA
M1C]8EGGK*NM<D,>X/[NH#OWILOYZENHCZG9!(K&D":<E@M(/G9N!.W-/(ST!
M;8[$N)\('GHD,V./AQOVRZ$>18#*H%*12^A^P_*9W:/_X!.A;5>!-6&QR;NV
M^.1NQITOF R#-_HJ8EAZ&OR)C^.MC_<8#M/3TWT 98A0?0Q$NQM$ZC4'5H:
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MZDA"9^!M]K4A=%N?)O;=[F92MU64ZZ@.O7!@+P*L[D-%3&:BF:3:1/R$F[U
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M+$Z]+0R) /@ )4O4,Q&XBAR*+EYS_Y[OQSHHD)@,[^!9$:;?N&RQ9/55MF2
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M963%+$;@(K$9O@L)C5_V[MW_R3(6DP_:UB3>+T#;](?SQ9KE2FGG0&5J52_
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MB,37J[@I@3(:XW'2QV=] $]3":X_<+0B?4@_8N-H9@HRE-MX?/MW4:H:P_I
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M]=I)8QTG =VEHEN:4Y9Y3R>CL#VN_[)>(*J0H^OC6V4_J3)R'-E:;#PT>8)
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MU3CXEIEVIJB\_:)&JT@E$$&941\<RA>%Z\[CD%QD]YLR"P@1NH:$V!S.='C
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M5<4 DFX"DQ#P]7M"^X:?[>N>*!##P3KY5'M5Q^1S7&JZS@T8/DVR9<(@^SW
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M:,W<9$8W))GQR=T?9:?1;H8]:0#C=0@B)*(DI">8DL0H6,\TD?@ZXA1,4%C
M!6$JX[S1FQ G;]&JM4=$54K/PM2H#R!CV@V/_H15 39M0R?K@XJ93L=#!HQ$
MNDEE9O@Q_>0BS!*LUFC:J(BR*W*9"T;+TS2-&@4:Z[E@374*DJ20P79U&O<R
M9AN(:/)8O,@9Y[N6?D/MX1 F<^KPX.6Y9K3[G=;_N/$J?;S9G0 V&N#E52V!
M;K@NQ!.?5I(32RY[0&4-^( O.N*4+L'^880XO+X6-Q0.M*Q'?AU,QH*P4@R0
M]AV&?RWJX)>NX 5" R&\*A,.'K@+EC6=C-HF8T=#O,GIXD79[OI.(Y.&6'(N
MBNZF*,:[2HA!XX$ET\<FB9:S@T>[:="<5W9GPQ4CFGH65Y,^@Q1+W?#18FHN
MRJ[)QSO7]:/F'49%_ G;TH/&AD$,Y@^*P^<#YEJ*?.C@09Y;K0O:U<K5*BS0
M[_,6F2@D&C@NY!SLIE["_U\M+L,JJ.D-:4-14U7+\%)ZK!RXD&H=UGN77M]"
M7'##Z7?HN5ZV35YLS(_Z,?][OG@7-OSNH42!MX;W;LJT9TUQKY;$;HOA')K?
MJW#L9$:5[RWJ/@RQ]9I#XGJMUF6#E\QD:GR(;V7G#&X_/_3_*PNSWQX+L\?"
M[.>?N;@'W=5+[S^\$?_A8:1I[IET>VFPU@C%%?@SX[3%OZ*,*_L#X Y<M*1[
MU:E\+YW,6E";D93<9ZXGK%V&(;7, 5_:7<K*+F4K&3CULBF:IW)%-NQQM,I2
MU'&<DVY,'\L02?1T2+ OV9T--W M_>Z0NFN+UO!&ZC8,$LO%ZC$D %^C6(N!
MD7,97A7G[+A$6 T'\L Z<XMADF<]TH:#!*294G8:NMUS$X/<DA*2>#UJ_V,]
MELG96S.1FCRJ;TN??]B<JVQ-M#-TAZJ^)L49)[O*HY'6"FAW$E2LZ: K4R=
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M"PFC,5RIFL!5D3?,C[FMI2&A<5G7IMP.$WT.,R"YR#5Y3KWHW8=WV>R% Y^
M8RV\T/!>S/++#HT^ $LE:Z3FL@\:R_DBSF1F/?AG2Y=9V@8?AYF[K1/2SWV"
M\&6]AGB'#7BG&P3%,$^F!^&$2AT2UVVWR-&7#I"3UU5Q TFW4@JO]53NM5-J
M!;V7_3)A_,3 >*X]$]RU>4LTP8-?^[<^Q-@@Z&#"O/;@N(1Q2\I8:1'7):S:
ML.5SP_%)B^+A:W/ISS<B!6^^DC:000$OK/M+9)\;]XZIA</5MMP:XYK*YQS^
M!?%&K.M-68>7_(O6<C W$UH14GY2IC5)"1IB1UN7)DS+>)'=7B0:DV8#=%UZ
M#F70F?_SS\G/^52<H.11;,8P9914<F8R20/.D835)'Q"7YS@ZAEJL7@0L[5$
MFMV] G'= RG2'B:938-()8+V5"H^=S@'4T.4&>6R$?=R;[*F8">FL:_X-F&R
M-&N0#>]P2XSNFZ"]*?/3=KKX ;23.76>9L+<0HU$S>&4)-W>LAF#5;4,EJ>G
M!.0V/-1%,#?MUC^Y+C0Y^W@=$LAK/V.UA!4&IJ!L@]M'5B#8+QN@44E1BK S
MCRLXEU5)9PCY[7%3W1GT]5D#CR8XC#!R]QNGC#MOFPY:/T7";OT/TJ8,*%/"
M2ML^7/83+G'2]G:\,J/1J'P[7X3[,\DD>TJ# 4OSSS+$^EBGBQ?!&28"6O8G
M1>7F'V-B.4!.>XB#2&MHXF@MJ%]OI9(,F%6^-PW5]T!V,0 3T41$A-%6+S<(
M2S9[E[L$8VI:+9GEZ6WCKLXF@&Q#3B6/=BF) V-'*CQ+L/=$29KU:&#N8&2X
MA186;I/?<,W N.P0&:A6"67'H^,6MEKNG,ZI3B 6);J)CE551]()K9S1GDI!
M<438D233_;,[ETMZF4X7KX)W66L5-XJM:&]5BEU@ R.F/:.4_J8@K(4>D(SE
MNL.XA260"?]ZF+%,5+[:0FDVZ,;B%0K,AISH!GE\-Z@ILAN!4FPZIP?Z:YA4
M8I2A+;(,H0C19"U#\*%G<CB\KNJ5N$"Z6+;AP50W(4:J[0=:MU;ZI\9/C'R^
MS"&6QC&R/*LS5WH(/[ &OCN29[Z-8.USAXXGL-(;J<P^3R%"K['0_QN)B>>F
MF;UX193/3?LPQNB>#KY+0S+[1^?+(;XAH>WZE9)/C%CH8XR4R <Y=KD!]OID
MB+WVP+YM'@DR5-V";9>_>I1SF:0%YXTO9(,'%7<.P1<!&TK.&<<=*MI<417+
M'C*+$)()N;84*H,NT;%X<6RGP!VU8QPW4]!L@C_(9C6])HA#1^S6>GV'+Z"R
M/;W"P[(.\YR@,\! H?#0+-&0E8@S(;<*723%3/D)N5995#)(4(RL<9>1XQ1V
MTG*?";O;XD-1[/#UL!(+9O.@#%Y^&7ZD"TAP@!WT+]&[SKG#C(%IEGR65!9<
MD>">L1<(]LY,J@ZQN$M@Z.)*'):H.JW2XS^\.'<.J%_4I-CIB%/&':-RA>]?
MG5OTGC=>[!J7X1:"3JXTX)QY#$OP'5*TZ&8>&4JQ%JT"YQV90\3JSK:'@1\0
M>-A^1Y/+85+B7'6@Z6D(^3 WZF1-U45O\ATP#JBM+^TJ)N>H0(-T/T45%19P
M!-N:K._3A;W_E("EI"=F1R'QUR[JODN>(.XLZ0&3R$Z)_> ERI72[X;_4E;^
MB[V0DQ6;@AKCI\9I+T128TOBXA)+KYH\0UT1B6F]@LDEY(E^0YM+:!1@^!D_
M447*5/2C,-EM0>+&*[T^].0_!I\XA:Q$K'=8ZTL'$<7J05<:9=;M-)V6,C5Z
M*NV7=/#NOCV0 WTXVS$IW82ML5>X=&3)LG(-$W!J] 1_Y-9>32<OFVF3:QS8
MJ6&?5,6A;I_]U-?GO!9*HV]YF4E@+(M0-:80%)O=3Q2; 55JP_SH36C:RVX;
MP<8-K4.1IL*7BIAHE.XE!Y.]!@;S*%&1X%F>'O$L1SS+0[6:[]D5S,R;XU-'
M*?MF7 NIF<92,F77@I5UG/K#F#'8O27YP\'F05(:!"DIZ;>ZI<%JT=.D39HL
MKR@I0+DQ'%MIF=\O?J+7:'_B"[PZ/S=@(SR/SDCAIR(J.;:9K&552&.\-K)P
MM(E#PX"<B07WG-*)<%O,9DX?$ >BV,%HK&IE_>.!H$B8#3:'@I[;:"V5\=D;
M9#I%JHYF\RRCSDIO.H!:Y_;:;&/=NG%J 9?SWIETH): %,3T@TP0*W31*$M[
M$$507#PR0F[/8[UX42@!H6 7A##2\M4Z#EC383!/9#1/8A>+R=O) V7I 3X\
MJ^,@#U:7',H:SE_L3>(;?*JN[9C'MA<*!&".MORV3@42-?S=AGB25@=X\MV,
M3+Q)N58I*J$3UI30*O/^K0XR^:-QZ;HX499@5]N2FQ^7H9IJ"H2+?JJ[[NT;
M8E)RM0'3?^S(4W\(PK(E6L[*RG->NVC*+7^>S00R?#F]8:-NK;I:7'WU/&JW
ME(@PABTQ4],"T JDF,A,*'K+3=\4ATW'O"U3DK(TVS;5IS/ZK3/=:A<2_M+'
M$"5(@WNF(V!-Q <"J# QX<VN;J/0R@9I4=H$'5%P;FFW,*MRV)'S1A0I'+5,
MV+TVWR1-H>$*]Z4)$BZ,(,4Z ]05-QNB3S='FJ!@$("(FPYR6VB)SY0M6JN+
MT(_1%M@I;7$C^T@8BZ>RQO6F1$;)VO!3H5G:KO4JT7.51'!1A0?6^H@;N/"J
M72_]5S&UQ4;!765,K6,Y$;;:G9.I<>8@<XC$F Q.O!K<^*\Q"T$RL?$"#X7K
MY>!6>5&V3;\3YN+HG44GT3*%DO'8U+J>B.,C6M1UG2088R)(X8H\.7Q&D7@"
M=(*;_E(_M\@TG$GQLI=4U--2-S])EA ,#+GL![UU"5#%.#HV*#*F1W>GE*ON
MEL29WE[UP6&I;RK[08<)P,Z4^L=$9C65YX3WC0/L*F=:E;[9H/JX;$3J,ZW:
M@Z[$/O.HQI>2<:")(+G0^+3TI'A0+2/7RV7?.'BH ]M*I4 08:ZG7U< I1_Y
M*':$569+^[G)3OL>[X;@FYFM]@K7T =21EAUBBJ?(BS;P5),$S23S\I6/;F,
MH]56)\K;,QF)Y7Y)SZ=E"#R<.N[Q*>FNV[ICT:N&Y:R\3KVL>L$_9'8IK+E.
M^CN)AJ;S4@#(*3)^FKE-8P50@,[$_$&E3P8=KVD+BP&KY"6FQH*9R4>CD0S%
MHW -RHH&<J3UZV4WA*M"#52D)Q/WW_$[B/_LD.%A5]8 /[LF!$>*++-L2?<T
M#M$""C4HQOY]>HC3Q3O1%^;'#T;G?->$*7OZY.DS9[Q>E)P97#Q'9[<66W^J
MX1%5\?-PO_=AJQF'DC44VQ/YV&"]V);K8D?YZ;JBM9^,C!IDPF$UY24/<33H
MX5F?AEEE,!!T4Q+(=MB[;,1X/+7@L2UR@HF%(5K5NP[D^93$S!=OOW_U#B!^
MX(,,ID)<4:U"^N4.R\[(I%;0-.^W%[0SUMI)[E+M"J=/+6,""(F%CT&M3@G\
MTN4RY4H^ACU$Z21>7N&USW>[PI?U?RC7P8M^3A1])29E4PJG.U@&9+ML=<W[
M9151Y+P#,^OW%[B7$==J<<SO)$:>;YP[+<NN)%Z.IHF[51Q+YH<*#J+&M'^4
M M5=WZT,!UR]44V1#5#QZ[5P16S*#X5(W(1C0WI/N<;L(&SJQ^;*4P+?]6.8
M5"H<Y49_E Q3DD=S+&YXX;.OL3J#63@3T@J61V]$C26GU@_:8-A"+\*AB2T1
MS<B[?D=8/!D%;82)AQ%"3SD)Q5Y@D'BCZ2Z<R-LXAB@$Q,Y"ZE'JSB8#EQ#
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MI$#G7,M)/\3<C+$+XN 6F1 8<68A6%XAU0P+F=[6@#Z" **_'0$0'@#QNR,
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M$NMAL5>K6I2U,I>()XH3:"5K0K[G]I<IYGLY1;60P2I\Z$C]B]$BW_-U!L+
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MYAN.N2C&R#8O(H\%RL("@("X-S5'6W"5/BR?#YP:\/@R3:)2O+KL.[AF4!2
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MGD4_IS8ZWB'-IB,$QI(9!;K975)TF;@V$L/.!;^Q$<&+221^!T=F!\AZ?HX
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M;D^&DG42J7EL:.O6B*#QN<V B:DH+&-K?A=9IL_*<B>MM;[H(4NFG=&+88$
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MPUI"]WT.9](W47,3^#X&M[&]^J)F\U,Z&K2JZCW0B@$A0A0GUPF&2^"(P@)
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M%YV[#HPM\1]MB^&Z!)=_.%W('LK8K-=%8P26GLC<"KP#6K,IA@>J[9<K1]
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M#1KC!T=C/+Y UZNKSZ=?OGKGY[=5U_W!?II!8#]^L&Q17]0E15;CW!03GS'
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MIM;SIW:<UD,C!S.)R8'![)28#+4AKD47ES"H[@K41/OVQ%U8%RSY-,J34OX
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M:90HV_ZO-<7$*4,[QS\GJ0Z(1/-6K"X3H05(U9#W?G2%56/#8"24(Y2W*\Q
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M<1V7A0/JKMHNRH9G9G;POD:Y)SF0+0_G%[?X_JT337PG\>7]F/7*$_UE&<&
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M_')[O33#.%-\V8K4)/^E=U2KJ?@CW) X_Z6%7WHBW478T,/73^?G5):KWS[
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M@9\^6*%W!:Q6+RNHZPP??X.Z]]V ,SM'KN>[5"*X2X_N:M48P$^_W[!I$J+
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M<5* IFLAA!<)]N!UR11[%?A,.3C$?A]QCFA1--JP-SL'+64RX* EN9:@%?>
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MRP-Z\A4R--V?<LOD>$XP&^(<OU:@=DL+H3TO^FQP;&\K>J'6[-A=;N&2,G@
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M1J@;H=YEH3[J^R<G)[LFU(WIN#VL>G>!=A^3:Q5Y91OQ]+?6R>!P>5#CF>)
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MO>I68V9KPF#+55CH0HZ#/$_#8<'(22X1*0.@Y<FP_!IF_Z+3/EI1?;O1&.P
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MV=E*VQF2%O/M"!LRN(<9CG!&[[^$LP!_#U$8X4/V /$L!&F*5H@M*F;;)DY
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M]MB/KA(X<+0![I[/:.+@S4(^H]FX8I5L-TIH_$P][L#8&Z0S_DA>:$J4WWV
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M/%_RK/3!(^D- ^43"0(2G*] Y#)_OC.4(K^<-D4>7RCL$AD@,J#=;DRQ/MJ
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M<T, BZ9X/G9^':3.&..!\\5V^62.#1!;=1NBG*FO(*PD!>)<!6(=\*U$(!P
MP@W5T4\D3G9&9ZA@_>(AG9RADCO-.Y@&I&3!5]A2&-Q:RS)5W1%E=U!N,Q]6
MGU;#18U:R]14TQ:E-,GE. ^S^9$%?U!NYU:3))F+QVA+X>"9/)JV<]1-' 0N
M66F[+,D=6<G5L$ZEZCBB5-\[]2U>.<"S'^ %[>)[\S'A73RLBSW=N08=[ R7
M7;W6<MP*JPB<Z*:W9,;=\<7NS&@ ,QJJL_O1BV-O"I^@*3JYS.'EWB8[.L+Z
M)V=6:!#%R$72"ZW8"]TZ/]0U:RW;49L-Z8B>(S=MYXANSTU6K>7J:K-Y(MLH
MPEL'.<"]N7JG8U_G3N94Y,N=N>[;Y'A. 2EOK_1L3*+4=S]B(7?+!.2B3<[H
M5,)%6$9$-=Q3;S94\/2TNGT>,;2*]L\V)<T92M'FT;.R8N."\C4<56M6526B
M+ ,?IDC?TJ%44*;OTIAQ\^A9669LX%:<JS:UG4M!'8 9SQXXWT;]OI]BA01^
M: *Y  8^@Z"5=]^CE"JZ\[ZZ5/FRNO$M\:]#/_C?6AICG\+9+B_C:6"/PWP2
M'N//C/&:\,I9CA,@Y;^L6.Y*AX:VE YG'X9]6GHD2#:&WEIM=?R7_,'9_5=X
M\;7>8-Q]C'5^B&F7@H>1'0)3E?]:)60/-'[JD9BN!&1WW[\N*)/.W\+8ZH'$
M]_%32E+:8:U4)T_=Q#YJ8_'45VN$98-UCC)8H];2ZIHVWR5@[@-E0&+E!=_U
M45DZOP3'D.RV#FP>R<TP[44QL$RG[)3,%?1?/+YRI-]U?%:M96!6G(;_;4!W
M/F:%C%^HEJ7_-O.[2Y+A[-RZ_AOM7/V'QM&":=FER;X-6]P/TR0%G -*JL38
MG(.PQ'9C<P]"M]++"2@_C-9SY^;\Z[,1\.8Q$T(I)%4^4X_VVS163%U5#,TP
MV47PBS&VZ6"B9/AWJ[XR!4Y@AJ(,DXY]O@9 ;P:WC(^"1.YD_/>@1?FJ8:.F
M)AH;'=1A$A!GH[L9A7L%V?P558+6YIX0]AY&*@2\+LQK1^S:K!Y;5S@XK/.R
M&[+>/^D7X;#U,P-L[1JJ[NBJU9C? EB L/8]C:7J?_U< (O;MMJT8*'<^7RL
MS;#AOGEPNU5R65Z083L+JWKMODJEI['#*C78*FEF4W6U^1.RZU9I%^"^4\[:
M\2*3%:+VPCK.8ZTY3-5$W7#43#0D^JDD-9X&@ZS!XZ48!-Z.>DD$#KF@>@\P
M8*0R"11LQ'GEAXI'!GY* IG+MG7EAS%-'X"D=^$M)VA!&$KN9.L:.!*&:IF.
M:AL['RR5@0T!66I=&8CJ6<I EC(;CFH:HK1BNYR:$#>>-^P/ W3;\P[E47\0
MTQX-$_^%*D&47%IQB'<[:> $Q@^_+2B?DM.9Y8;>%JE\%P+1Z3<@]?*V=#>=
M?P^3-.OK<=_]0=X6R9)9:UG6/'*9RV&1QW5.BLOFE/(AN:RD.F<Q)=5>T%;S
MX%QX0>BYH,8[M.M[_J6UYMJ+UGZD*8$W=;Z0. 1Z) 4R?^94+BT>=JW5, S5
ML>:CDIO+AT3.(G+5IEIZ#USE@-UW-=5V=K']8H'GD]TA_!%3D@SC4;Y'2%(@
M0Y(JRWEIN^!U_A[F=64.6/:@4I%K7:L^H::ZL6'NO*,:\)^E;[(IF.]0+=L(
MF0N\OS]6Y/UT%-N:,-/48K/P:FG]U02KJ!FJU9@_+2E]E]-FGC4!I=V91]<$
M8IX**HR=S?G(+;J1E*ON=&DGU-;HX>)1CR^,SJ5%20=1TG55T_=0X>EHQR9+
M#*6"DF.7QI1K]'L%3&FP0@J:IC;TG0]0'H M=SPBSQ\TV[7H_"I0!EOWKCH
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M D&G,J7;)AH-URFK^0H7[#JIUJ_M&"W%DJ?LGQ;&1K28-KO,HDW4,3.?,)*
M#!)ZG?_R,2\RZH?L>>RFC],Z!;7/K*>-,^9?9XJIV:R[FHNZ*8L39"_.U%8=
MQO=A_G/'J!N6N? KK:XO_'S9HW2M[IB+OUKVJ.6?V^:Y#VKUR]<$?$KN:^\'
M1#<VV]BY"Y6T%PWA$1U0<?3-HP@?<4N5Q6A 1V1_@0HA[Y5_4A(GRA<P$5,;
MJYM4%EI!%:X6CD.7Q7W6<?>XQ)S6%#4ZM:D;ESMU?6KJ>V\?)&[,]I&^T'"X
M8^/X+5N^R"?O[\F7<]+A(8XZ0R]58L[)K ?)3JVTSS-0>*81/W=UQ"]3;U_C
MJ(\.*S[Q'W[:NQTF,#T:?WGS@B&2Y29)*/R_LT5BO&Z#17'4QN[GYL3)<Y+R
M<J[RTCB^O#BUEJZKKK5SHV@I+U)>]BTOS3W+RZHB8;KN5E8E[#!ID,=O#W11
MO9 $[*MT @[#[WY 03Q#FKL,%W:BKHSZT[6CZK^&:%42Y<FZ2KE+/SX:;6*5
M"GM!D3S)8&? 8,8QU9=Q-D5>SR]+>1?37XHHYRA51]?:AEYQS$VTI-JRFP>2
M75>PJWE\?L6C+I9J5!;SDOQZQOQJ'16TF%7'G/:<M'R9^_;C5NX*?1O0,%G1
MJO14MJSEDR]S _\6BZA$724!333'Q7)GY5QW5M9X$<@5]]W?HJC#SNK0^,7W
M:/(4!1L6HR]8-&PSIC8:QRW\+/<;I514X*Q4*!8V'EYS*^M=+,5"BL71?*)-
MQ6*UZ^.<V';[&6W*/M*$DMCKL>,('?!P@VC09^?+Y-[LMF%83E&0A\\3>G[A
MWF)I8^$"AFK:JFW,U^*2&V5GP$MK8Z15,E,#F,EMJDU=[KJ>)3.M#6!6R4RX
M@6\[:M,5I6_)Y41NGF@ 'SZKRC,-:4P"9KQ)I^^'?I+&K#3"A?68J-!^9\3]
MC9,69.5FBK!;BHNI8?8UZ%[MC(XK2*;:V)#OB:MT; ZAJ\[N2EARE8A<M<:B
M[XFK#,Y5EK5S_Z@C^^/GES\5;;[_6*[,ZH7M]:\/:V% *Q.@#:OL%R0(^T;I
M#=6LS-,Z?N+);INTDAEWVWO8B1LMX$;-5(W&?!]ER8V2&\N'_'?B1KO6,MV&
M:NU>NG'OW%A!WO89=!_ %G=*-X[Z.?HH%C7;+8'['(J[E^K>,0<\EO2T&N>9
M3;H,EA8T!P2M"3!^@=HOW<=#A+X#)8920?+KY;'F' S9(V^ZP)N-IJI9DC<E
M;VX#2O;(FXWE $4HWKR<+(7?B!\JP"*8JHHIJ\@<, ,:ILJ C%C-59FP4#;8
M09[]Z!HIBT)R'V+CXOON[9BR#QEA2R3RF$W1#E[*#>9#!"JVXJ3UBMC"/3/#
M51NV*%O,DIT.$6FH7C%9NFB*Z7*2%1ZC$0G2D>(S0,;C",\S]CP*<33/(Z4]
M3. !R4[AA7.7FC5)/IS<'/Y^C\+QAE$9<3%$2\B5V\H'S3K<C(<VL.#8H@OL
M]QD= 9)LM'F^865L9-5:CNJ8.S=1E<<#2K+#'=:0ITF:6>^%19XEHMW4-N?4
MY!*1;: 5!>,[34O+!FZGF:II5=7*5?I(0G'4&E.]%Y;"2L&&ZC:EVWV6++7&
M;&_&4O-<X]9:#5.48TJ7XU_?IST:[VR?+P2QKN9\1LHBIT^)0&DUVD#4JMFB
M)-%*Y^>0AKEB7FHB+[F6*!Z0Y*5#6N1J><G66%$\RQ3ES,AALOO%MN* J91@
MG&?'][>'F.:_8\K=.6:S[B7A;I(ODA?XXPLPZ>/ZB8*<47[=#_)&DR]O:4R
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MB-CM5D)$=P$1N<"#)HVX&WX-:H[&>!4,AP@S%J47HU7Y9?UBNK76#]1U&-+
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M&[\!.-;WAWT%_NJ3^"?-COI1;QBO/NAPEGAWMZVHF<:B^0(40>Y]]W.V% G
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M-;W6,M6&*4^ZG@BK[3F\M!F/S;,1'F%T=]GQD?PC(O^4!JU[T5&XH>BH#4L
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MW$2RZG'B)J5YU90Q$LFKQXF1E.95J]:R-%<U%[27%(A7MXV'%$:DU>V58Q(
MUKA+RY,FFZ*8BFBR;6EW^>P=GUU1=K, S+RDPLHP]GH$2ZM$7:5/XI\TQ3-W
M2D*]82QSFW>*Z3V0$>LV\B.Z\?X<^C&]>2%^@.3]&L78I/MI3.3/M%VZKI9A
M@ZG07;5I5F J9/:I4(RU)HRW;\YB)V@U4U/=ABYYZ\QX:TT2U+YY"\^:8C5
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MOS!VK_ILJ,!,[@ LLU6GN;,;(>QQC%,!8+?+()="4J5-G_TP9 6YNDK:H\J
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MSR>C[AQ2.UTXLFB&9P,YUB*.@0_*[ MR!3 7*#,\C#",8]KY-$R_1^D_:?I
M_,XB_&!B*7M!@GX5!)BE!)RI!*Q)S]U%!+"A_8).#E(&1&$4*0,;)JAL*@,E
M?4P;BWTZNQ?Z//+>T,E!Q?'QI)2\442"?NG=GC.6]44S/!]97RWJ(-=1G_Y
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M_#&O;[E2;?W:CC^TQ%?&!7[,83@!2K#@ 7Q&._EJ,SJ OGJ.21\(#ISSUV'
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MN\+7'S)2>1^>XJM0J<5UCC<LSAU7[N_E-+/H0>)AIQOF\PU_%F>:XH'%U3I
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M<[:8QC&X"7CN6&"#IXB,=8(VH/37C=_'O+P2<)O1E/^R<:%R8K\I=ILPB"R
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M:__Y.P0ED[AS&,Y4E,GA4^$XD;4!5%U%C(RB^Z.$LPLJ&$5&@JRM_&*PM3"
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M#?^KR*;EZ^5A;EPOWKE.8]2UVLUL09X!IGU!TX?Y%9I6KP+3ZC9&@]Z@F47
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M(T3_ZP1$.TT5R;:V -A[60![,0CVA:K%R<WW/?+C8+VX-<9:$B_D[KX/2QB
MM>8[BQ8@484GK#&YL$XHP.BA@J+7 E;>LYN#;KLT!+>]&\%=!%9>[!>U&U1[
M]Z,TUKT>&.]7#&_/(-I?U=2M:H'Y+QHVO]N(O$S 4]"X?HTX/I3))IL]23O9
MZ'D6S:'TB5W$M.TSM 300'^M=M69]?%45V?1.TOKG=8[K7<;>K<E&EZBWME"
M[T[F,JYL5<T&C*&^_O);)YP;*P>&CG%[9PESC<),!G0)HK .*,M(2>CMZ<U3
MRG8.7M0KA D7<D*_.,^4\"VLF&WL3VA:_;+*+HJHP0MC]$KJ[*-%LZ"C=K1L
M=JC$K-7.\J%IV=2R68HS<[1L=A&;87:LDROU7T(VM\ <-T&-=03\$"0!(4X4
MAB7_)/(-QWN.R7[#N1]$-Y@.ETDQ\&MFKN=XDR2N;@?-Y4$L:&+N8H =S(M)
M9KDWE)=S'UF<#OOW=!92+'8K_HDS!@%81]M_DHE!7V@3/MQ8_8WU2?SO/(AC
MZ _L9APPYZ\;9P;#?>,LGISG$.4S*7P@9^+QW0%B@;?.__C$[6QV-A0MUXTI
M$JN2:+PA!"9^"X;C5&8LQCQ :_FW_1#F?F/TC:-&9P;R$*.Q_(]?G5'>CF_'
MY=86@?O1,YP@<!_14 C\PAXDYU8C0@@J9[5:N(SCI?B+V?0&3%@ RH%W+'ZC
M J,%YT% Y'%&@&R4,=XV>PAZA-#96?>SYQ3\(49RRP>"U(5XZ_L*;_[" K0N
MAYV/L,_J@.PU1MUF-LSV[\8L\)<X5<8Q9#Z\TW"RBY&'.RX..]XYSRS^V,J%
MR2 :)IX8:$0GYK)5Z!<"(S>-\@3&?F&!Z5U88 ;;!*94"<G@M<X@(4.<R38)
M.0GHE(5X?1+"]/RG$Q&+\!80U*!50Q#4[4YS"L>9D#O0#_ ;W.5Z24@ST 9D
M['0CCH'/+8*0,%F,<3%G,I>(- ]6SD ,G.CT0/A]JME%L!4CS\6L-ZIJT&_:
MK1)Y,7L:*W0@N.1U S% :SL:=Z$344?7JN\\_V0DY]V:?88G?GMBBT?&^Z$4
M#>X,+ H\6J71:50O6U4SN]'5W&_G5II_@KOS[<DOK"LV<4!T6V5Q0-2$M^O2
M&M'3A%TOHA'S@!U8W9?0B39ND9G7/JQ>=$PUTXF^/B5>0B<^^.N@L$IT2"7Z
MW;)RN?J8.$@E!OJ8>!&5<!^+GQ+=QJAM=OIE0>+T(7$ ^YZ*X>FCXMQZ<8O+
MG*\<.RG8![W2*-@O?%9<1]CN^V%A]E,.FA.B?%K50-4*'SU(X6:9K79;![@J
M(#$?";H41J_L3/KEI30E:<'>_T2F^EM"M1=6FT%C- 2MR2:I,]F@BA])(LMH
MGXE>^;(^'F5K=X$NCK1NIRS:=6>H3EJ9:ANI$FW4%NM4V H-&Z.^90Z')T?<
M2[4)EP0E#ZL$&?S!C%7@/[I8+(4$DPO'F\*;I]CS6G3Z!C$AG"^"3@IU<[=:
M@]W]W#^Q"'R)\&[VECI5WZVC,(+WPSX5.?+BWNW#5F-D-[,ABK@A?1C/"K$T
M-&.!K>&-=-U$\=B3&\V1OI*(BPB1(YI<"[9,Q /" Y#W"P6-N(S&S@)A.T8X
M9RS:@$]M%9!AM3&EM^L'& +BF"Q"^:7!Z\;"]QXX8#U<CS<X/7>SZ>6S'0X/
M9SN\%R^\#9AS-_L2L*4+>RD_G18E.AQ:AQ$=2A)5SF7+R6L+D1^:)%N<8$S@
M !4GH1&L/<()1G.P?P]SA2C##>@09O-V%;B+&'5YWOVP6I?;#QOTN7_T?F2Y
M-TO9#[7ZW5UTE&KM!=&<27^%3R/F.; 1<\&CNXN<<N=F*3:Z[(Y916D3[V@0
MW_SW- 1)HOA>ON$+GT)!*L5ANS'R/9;=.CR*\=]@E79#2BVKX,@W1IR+?ETB
MRB8>9*<QZFT>Y3?T';%S!Y,-5]R*_^D\Q\C^,YN,(ERH9=N,+G9FZ[2RU]Y-
MDY$R%SXO%)^Y 9QTLX6/SL&L4A:DN 'A.Y<4-]2!&_?GS=R=3IGW!I>K)Y24
M1#RIFH@H-@5F&!V;9^X2^O &97KDRP]Y41^)54&>GF^(7S7S/M*YPZF]JZQM
M/Q#N/\&[R#1QM5?["0ZFSUE%B[G3NYUIJ3$?Z>F%7><!V,'F-@B(\I]A\XN-
MN7W600^QNF7?H%$X42<X1)Y(IK>@]&E^V\I; A:NV 3K(A?/IJ'N!7PS3<-C
MD>+;3UX(X$83"7K[F'D"OM TN)0P>&#N;8LJC_!^07*#)A,?D*:(+_<Z=B^&
M\(Z/H."=7VU+KX5\8<UM<%2Y+>J^I52E[/M6X7(5/\BOM_[F_\Z^BJW:7;G2
M:V5ZA-2^<H7.Q37,FJF$FCB7Q/+@V3-."#,O8:%C:(=?47.VWT&O:5O%V'"W
MUJ58S>Y@-W&PKDO1=2G;ZU)T]KJ<G-PA]O_$<HU>RVZ,NF:K?W(G<IW,UM4:
M-=&9;T\^0JN*ZPKR?9EMJR9=UJ5' @-EVTF6-K]53G+\?-V'+Y\>/RU%>.3*
MO(H<^+%KHRW<AH4K;-DP[&RV!R5[ 2<;@W/DQ?,)J [L2=JQ=_0DI?G8EVU!
MVB_:@O1V0N"N$,0(5PW^,UBSZ:<8\7/K3>\P!)+X""E+%CY2F+[E(9&<P$,W
MTTT4/LNV+!7O,][SUCS[FY<>/K/[R9Q-UPMV-\M.:ENXI)<)E^3S,O&Y%(H'
M7RJ8(A98]#X**5[EAA%3 7X>[Q"<.RJ[V[;J%0#I=YK]?DD!$"3FZ);46:C;
MSG_)48,:Z*C,=?28T9V%JM)>!YYP(;]06F;L5 >FF8X73?&B*5Z.OAV\7ZX6
M_C.#6P U,DRX.\)-*WPMZ(/&MDV[77TN%]WQ0VOA"VEA[Z6U<,#;#+1.+O^_
MEAC]Y<_L@(7,"29S@FA,V2-;^"M"I^4VR-,A_'U'&"'QQ.)^%6M[ZTW?Q2N+
MG7..UJ A==#I]$XNV2PI<G^D>AS;TN#*96J+03ZO3%FMQFA@=NQ7QLER>=.[
M"OP9"T..TIRQ(WLD:986'OO%)?V26-$/[&@_Q;*0D\6RRG)37OA*<+21?1VB
MM,?K+5F4L-+&[)S>O*A>]#Z7-ZX$=M7NZ]%5RKA\V6S3L5K \2;=D_NM:J^U
M@J*TQZ"6+$H=$J5!W;W5EZ'@N)P=YOP;SD;.5G-N:,Z-RUT/2K ^W<:H U>#
M7LF=PU^:=>-EC=41&0BM\5KC2[C%E:#QO<:HW0+?]62L="5Y=M+XP1W,.Z^Q
MH>4@C=E+_F\1I&57(2UU&\S7TP:SXJQ5.Y"W@Z+(VZ_LD7EK]B'PE[@J:!]_
MN-'\+4S%AP=DT:E6/XNIM?I93.V7P)^N)Y$A7K 74IN';^7/S7E;;;N1_F#&
M _,8-7A<B14*^ KQXO80SC"J//[RSZ_?_]\_/[^#DZK?^<W@E"3NTD7,+&__
MB-_"\GO766")O!M&@3M>1[[H>1?_:35WX-B</$M6LR TL8$R@F;CXGT$X<I=
M#YO&MSD+$Q]@K7+(_K4&K5D\4^)YL<@9HGB3RSLT(Q@7KXZ;7YRZ ;P7GH._
M@ U'5>1]-P7S!?Y!S8<X%A(%TD@IHL85$[<(VI8@<+R'Y%?G#-9@/D&2$S5]
M6I^5\XQ+%<V=2/Z%:!$>L%NEAT^X@>WF%?7PSU_A3ZO ?222@1N//?B12W\+
MV!C^"2.9P.0?&#H/_ 62LE0,1' EX-QPK5?K 'X0LNQ>'\J05BG!_C8G3A9R
MT)![P!_#H+@R!QR#(B>.$IXCX"[(&'P_G+E\O95:"#:$!P]&,S6>YLQ+R2J\
M*7)<CR#E4> O)*!<:)?DL/,GDS5N? 1JM/)!5HB8PD66BNAYA6X7R.-Z!<.=
ML@6H1/ LQRM?= J1PCLW=!Y AOF*W,V$4=Q2 & -3N%+J(Y,?$D;..(#@?UP
MP@3!P4XF$L3_'\I]<^A"U**.H#MLVH.2(/M6LV<-JU9'4-5!V;8N;K@.A+\N
M;GB-4[?*K.N0E:/76$2>=S:?6&"KX[VEKLSUQ'O[N^.]>T(0[W\B]33R7X<A
M4KY-OSD_"T>"AV =>N; +KE=RHD6XF5S/X5'>7SN1]L";0OR;<'@XK; 1B9&
MR^QWSI,5TK9 VP)M"PZR!5N:&I1F"W8U*>S95FE-"B]K!VK<A86>^,:-X'63
M S)<6#\3/(H> /]P I=">6^12F0J*(3K&#H7<A[R!)#,"O%$$*8M%!>PPVG1
MD569_W4%N\LHEP/:X85"Y<2G@DN8-VX)#0931(9D2BX]RL6;)!>/UI7_+)!+
MC0. G\*7W7"N(O/A>B'(F"=",]>(&)SB0E+NQ4RD4>(,2<"B=>#Q[ AG-'8P
M"(P) Y&(P=?YLQGQ\ OJ8\$>36\1J11D/$ZD@/)2/*;,[\3O<CV>>#(F*JO%
M01#(0I_.3> +Q$:$I\3]4^P_E O"+&WXR8?=NO6F'UP/Y@[OYY19^=D V[Z.
M;,"W%,L/V2M,*RYAO/ 425K--PPE^1&)OV'_F8/IFU121^6&E/A(N42A-28@
M;0]^X++=V86#><[?O,841&?8'-J["9CK3V6D!W78H'HMG1>YA@CYV\1I?1N?
MUJ\T7_!'[*)\Y2[**UV(K]PO>Z6SS_+I7IP/[*)7^-]%^Y T$2-WA30UF"8E
M.HX#(R^$DSB.XM-(W/+S0C;MQJA7??XAS0*F%:ZB"L?=G!T:UFF,NOV2DZ1:
MQ;2*56O69U4Q?,\W_RN;X.U"P&QV:%P7VRMKC=,:IS7N2(VC^]NM2B3<>E.9
M*,K3MUYCU.]O:X]9'7TKB>R'WMNON$J(\EZ>O$':IG1BAN>Z9"9(?!<#^IHB
MZ,"^N!LZQ)<0NT]]D2O^P<^_C!5N3V7WD>.EU1]6A.-%TP5=4JQ"D*N-.T=!
M<1H@!UMKT-/B],K$*6F:<GWJCUY"X@K+%0*"36MP,J>\EJN:R55N'#(6)&&G
M8@M65++:+>QEVNY4A2^O)$K>6CB2";\EY4&N M</. 9$\_0>:8UA!8_Q&'=B
M,-NE8S U7>^Y)>J7DT0JA/'#O^V1K1RW,2L[R,[;SEK9#&9#B\PUBLQ>YU!)
M55X4J-W&*)"6G=<H.WD.8"PL.?Y?5GHZC5';ZEQ>?%Y3D%!V&/Y5@LAUB+!L
M;3D0K9&$:I#-C1D:^54\JS#=QFC8SO9U/EQA]#7[&B0HY=/%PG-2)*?=HX!S
M*YM"U=+URJ0KSQ%,A7:DP!66,4IJ#+O:@KUV&<M&"D^0J@&V*AH,LZFR%Y>J
MUQ0D/-R1?+UAPXOYD>HBEJ<OP\8HA\I;7]I?E_AL=2)W1GPZ+3"V.:V\M/2\
M,NG)<Q*5Y"0/\ZP(68U1YQ074$O0-4A0)E:X6VAL[#ISRN7TPK'"#583[&1P
M?6R(.TK>,CRB+[)@UX9E+G5MJFU\RFI$7D+!7 =[-W;+PLZ590G.'?,X>9P'
ME29H;=?:?F9M/PDYVZ%FFZU!-DVIM5]KO];^ZFM_L4)";%5FM\O",VMMU]JN
MM?T%M7U7$6/!@Y\2XIU^[4U!#K'IR42FFGIO[Z->+\M=)0>EJ?<T]=[U<:YI
MZCU-O:>I]XKD(:RB":/7>1UYK:0I[6-1./FIA(-+^#K],[51T!Q&6AVK->NS
MJN..6/]N_1MH_=/ZI_7O9/W;&6T_7!V'6AVU.FIU/%4=#PV'[U3&;JL^ROB:
M2GDUWU_YW"WM\@C_LGJ$P.=A50B-= 7<107G$&Z6KMT8#2W-K?;J!*8H:5]6
M<MJET&%KR:F;Y)R;EJ]+<,ANIRI&Z355W&I:OC,:W'/P\G6[FI=/B]2A+,Z[
M1:FG1>D5BU(AFK[#A:KTI*,6JMH(56'^OL/%JO1<FHX*:H*_"U:V%[YP^<<R
M_'6'6.:>O5QI?JQ7)D*'4?QEY*=']"P58,+2\G/1@_Q8#K^=YWJO/)IY+657
M8:5VT_AE!<C.;QJG>?HJX0_J..*+>X,)GK[#S7"[:M<K?6N_[&%_")/?X>+5
MT>*EQ>LHJK_#94PG1K2,'4P&>+A852Y)HMD"CZO2LS5;H.84J4IC]()L@;U^
M8]3+,B37C#5$$PA50JZULK^PLN_#Y/8&C5&W7Q:R4JNW5F^MWB^IWCOK$[/:
M/BP31ZVU76N[UO87U/9=Y8\97>^W\K-3-=/U'+H_,://:U@2=\+_&Q?6]=8.
M3?%@0L#>-D) OCCC  <@%FJ3:5#L>@<I_U9^Z.*;W_!DU".+F?Y0)!*_$N-H
MQ3]QQK!:ZVC[3S)432\OV3:.Z<.--4RO1O)_YT%,-?7 ;L8!<_ZZ<68PW#?.
MXLEY#G$SD_L"6R >WQV@.&V=_[X=W+X<LUDIRY$AJ8+EX&(#VNL')'-O0&58
M@-^"X3B5&8LQ#]#4_,WMV>-)QQK/9KWIK-/I])Q99S:8P#^M<8O9O=9_PRW_
M&[%@^C,#;0]GH7-&>3N^H6_2XEC]&YN;./@+F]Y&\M.V,HM"9[.]5A*6[WXR
M9]/U@MW-;B<3,$51^-F/6/C)AP4"D_?!]<#Z@4D!IX>YCSAFBT;^#1[X^\*?
M_!6;0'@P \.X0BT*UJR 7&VE"KV$YI'=-P+VR&!=;\C&L"G\-[?]AC,&Y\\T
M7&^R6$_A#ZYG^.L UYCL,'UY+(*3X9RQ*#0-)X!_7R]AQC".J>&$QLS'@R5\
ML]7@'6=):T&MVK>;@WZO'&Y.J]FSAB41AK8'G=(&9>]^N28,K0<WXMY&1#LF
M>$T<D;M3+*^;+_(KPS  GLQPF#OB$(7S0IZ7FC-2L_(4YJA?AS</CK-ZH^Z?
M'_S@G;\>1[/U0CIJL4LFH)1Y]U(;NT^=?"_5/%A:XZY%X[;$@4K3.+A_];(=
MDJNF<"55M55:%][ZRY7O894:/YGA4CHUV,\5\T)XR2NK6CMGXQ2E,XD@Z2?7
M&;L+-WHNRA+2)Y:0MEU6,%77B51)M(I&X?>(5E9ZNHU1WZJ*[)QX,[IN"-_N
M0-N11Z5.!9YM;:['"%VN,5B_K,9@)1N*%[JPG1D5H$V!-@650@7T2T$%7%K7
M#T %')YPS'7RPI!%L)3*L5/8*O(-MB4<!]G\9W]P<RUIR#D364(JMZ7$W@J=
M(XPN3^:.]\"+;T7RD=;4<' A0]-XFKN3.>4DW1"=JOS(M&EX+'IC[,M!5BCC
M.!PV!]UVX81CISD8#$IK!F@5:PNY*^%8K-?ASD'MSEWJA&,]$VTZX:@3CIG2
M-P9FT\-30>!,=(91YSN.SG=L]<<^LZCP[7;8&-FFW>I5/OU10LFVUC*M9?N[
MZQ17LYU5ZH/7UT[G8,6@Z\LEY(0O?/)_;V$&$375D=M1ZKAZ!.'>-[ <H#SN
M\DV[F7/7&CLAXX#J7ZR_;\"0=8(TPU%1-(N%FBZB&5@^]N A$+CH\3JP&B/P
MAP?=L@K$=6JT4D)5E/BD)*E"B%C;M =5Z?A2$L%>'<^-=Q)+^OH.COJ2&Q6C
MR3Q&Q[\$/JS.-/P0^,NW_F+!Z#UWLQB/5C@1.6C366+G8$,/9]34_%F5%+&C
MSI%SR!@BN2RSU<^V+7QQ&=-D6CO$Z[TW/2:<J(OP7VAMJFV<2BQW*#,8.>AB
M,')@G8S%OG11OB;@J(28:]VO3R)BT"LI$7%IW3^5D$.\_P:UZ8TUR$5Q\(]<
M;\J\Z,T-?NG%,_NVE*4\I@/"].SB06C3W=,PXJAKY&]B8CAS/<._.$L.A!F[
MX.5.\1,I;EB7'V!+=+R%<WY[TW"\*<BMNI?G/'H5N%C:OWA.O&2B7&@$W\28
MF]"8K@-"],P9?+SR Z+37\&*^=-FSF9F/LGB=78SJ. Z[6>DL#J#QFX(D&5?
M!AZ51\+1&"%+A3%L&H<ASZ2->>>&DX4?K@-V-\/J(.:%M*A?.?C\K1]&X?W<
M"=CO3LBFLOM!%GHVZ&>A9X-^%GI&S[JAAQGR:496@Y-;MD7,^=-SWFD7XV]Y
MT1VD)[YQ(WC=Y( ]1;R+<1_!0AL?/<2DN(_,^ )W$M+!CQ[H(,,E-/X('"),
M*94[XQ(@OX^>\5]KCQ'2QR0H7XC3G_N+*5HC9P6VZ!%MU)Q_)W=UX(=!_ W\
MI&E\2_XG6K1'=\JX><-O/N "HF%RU9/HQ8:_(BMG&B"?8>1$Z\@/GC?_QO\3
M!P<',)=2.L;@3P$+(Y!IQ!R*;STYP33O#^@IA#3TK_??X5_  M(9#P.Z&9/"
MA*@\B>]]H>^A*/@P![%4XKO\-6AXV7*U\)\96>[IHQOZ ?P;(B'7BPBEAAX
ML[N17S2F+LP#YADV]T(A:R!2'V+,*&RT,^6[AGN=$A'3>&+&A-'BD33@+]B_
MUF[T+!>3B(W$KZR]HF=)T;OUGD&2(Y >'E5(/S2:.Q&\.B PZZ/KKT,X-FD
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M:!*OJ#=0KU\,!?\B0/MN._\EUX/^[Y>!_K\R2+4&TK_&J6L@O032N^%?-[.
M87,\V";P&0SPWXY#]IR.&*Q1G,JC?JL[K^F=TGJ\?@!O _TDEO"1<.<^P,9]
M%/OV%;9-W7)O[-AI L^BTVR=@72_S$#597;WWP^P@"7A;+4&':A![0JJ$.*?
MFEVM0EJ%:J%"G0JJ4+LQ:C7[)\-2KU^%KAY@CI%ZZCLS=1_=*?.FQK/+%E,-
M)C_8L<S)GI2JU'*'WHD-XDI],('TL%,:@;3&"U=4'/=E\RHECUTMC]<NC_L2
M_)62QU[5Y/'J^^0HGP.\U*7QB^OQM/PAS##'3+ZR^G1H_@Y58;Q?6\9%M.4;
M++V54A.8S.3-=!W@7L3:T6^,NLWA<&LB[82MVA/%?@U;G4'/772O!XU1K]EJ
MZ[T^RU[G7_TOM==#VNONSKT^]O*[$UM9OU/JT4?4P<*-GD^Y%1^\*%?J$[Y<
M%$QNW#_4OFV)@PU:+3C=.DV[K"8A102_?K&P<UB!8R]1KUV;7C O4T"=+%"G
M;K-=5L-1K4Y:G:XN1U- G6SPT:P2TC2O0IT.XM*N:FT-/?&-&\'K)GO!W1L!
ME#2FM990ZQ\,4;X$W,50G-WZ+727JX4[<V&.2Q;-_2E];OV&E-RK@(63P!W#
MW\;/]*-[-ED';N0*\/7[GY,YJJ8!ZKITPQ MP'WDS&;&[60"BD$0XM_7BP6#
M?S,^^TVN3U:K;QIR-5]ZH_,7ALR*07;E_V_OVIH;-W+U7V%YSVXE5;16I.Z3
M4ZIRYI+U5C)VC2?9.H^TV+*X0Y,*+_8HO_X Z.9%XD6D1$F4W ^;]4ABLQL-
MH $T\$$1BL4_\ Q+YZ-2IKM(92?2L[58GCO/R8_W.\KO6'X O[=@@Y9+SS5F
M"W4M\_LZROR.QX/=9Y@XC[L-SBGEV#_R=T:_%;G>*.*H&4/#CF=QI @;"*+%
M*RPX9GZNX_T*>M=G3J+7>U?3@(F@YZ8#3@R<2YD7I#OFOHLEXH_2Q/:!HL8W
M_(7E *T0J=XR!22]\AS:@;6T4Z/ VF8+!GN#PH<'T5^,;Q"7-\4,&9(<W[*T
M#= :+X9CV;8!I M"CXCOAI[B(UW60/0[RGEHI)HZ]X]L%*#5R]M:V\*R\0UE
M >KUD0%OF@S9#)XS16D*[C5P1^!Z>/PGSZ#.Q>(Z0UF2!&!;!91#-U\[X(=I
MW= Y#V+6Y)4DCW<M?;?52]S*+][:HE U<ZD7]4R4-J+ .?Q"NN'WSD-'^>HQ
MPP^]E>(G!_2K%2P$K_B(6P2Z%'Z"(](W6[@&V1/9D8I]S M5-=%-IG\>J]MF
MVBW@!%,<!L>8LC0L4^4P\:[BN '\">Z$M<3M7QHK0KHTG)4R,_Q%G)$4-U\!
M/<-\QJBL:A[B*41CD27A,?Q6)3O2<!(66D]K2ID&EY/KTTTLB_[5%+_*%DD+
M"A:4$YX%F]44HD^N-V<6,LF%B)'!?1<Z;>?)XM C@JU=*>X,=&Q&'H2<Q39[
MZLE*I>W(6=M+A;4!5DS6HZ^F'Z$=5#YO?':!$EJW;B'M1\-S0&Q\L/5)I#,U
ML>/N(%,3"Y]E:V(_LT"Y=>#T8\H/O[J^_R.>B H-NDO)JGA'SIOU<ZV^!G4)
M&^( G2Q!)SNF$_D<:(!$)<$\$D"J'M5:]BD1)\CX5#22#\9MX <@.?@P.&Q1
MA3&W4E0R3. G&RX5RB':+ZXCW#!L* 9V"2./]X.%" YFO148)A%=O+[*;"-<
M"Q-?1V#0\SF<('C.%<TM]_EHJ1F['[\,8C..QN(.8D<!#:LL0V_I8F,U8:7%
M\RA;=US)[3KJI@O[Y>%W^.\]_)?,A-_P#YSDZ\*:+:*ITH'HS!C]!#CX&[PL
M<FQADTQ+# ;4PO,4YF.O5&Z'".^&841AZ;F/:$RH NU#ZRD?'^[O(SK35,66
MQ_&'(JJJ.$.P2]9G'AF[NTTX6!@!1S)!%;XQ:=3[0/1\$!.:.SY4>?YGXHAM
M#2/&D0P1%W)MA=MU^,\96P9))[_G91AP408ZFD)>F=#Q*78%PL5B ;O,\'15
MEB[B85C@ZA;*&3X;R0/X0MD9<60#GV0%9429>^YSI,7)Z8Y;"N8^'ZW(P[=Z
MA*4 #$-Q(3BWHE_!XN+)VJM$0E,^F;%<VI9 62"RD"(LIDCQ/)'%HM& ;O!&
MQ25Z(238D^M97%4(S0!RC>M&OG\"B]AF?J1(+(]<@^N,7@-"AZ (DN$ZRH.%
MDO6*CH:I&%6HR2,6,+?(#\4@(U9&@P9TW(PRC:,B*4"AB(L2599:E]!X- '3
M\N-S.3V%A)HPEQ)MV5'X44A.4X5#Y97;@YP%"M<I88W*88UZ&_21L$9O%=9H
M%YR=&Y"D2(DD=U,?O\_LT&1F!)8F3I^[>06_8IAINEOL"93:_),:7'5X>*48
M%JCP$"7SAPG*<8V:HW?3BI%T?Z(/Z32:T8;3K4CRGH5K _?X&S8P1IM,B_?_
M?60S P-*H&OA_<(<?E9>W= VN3E)1XZ3>U:=61?@86?2;PQRIS\I[VU[$LB=
M5DYJT"TG^CXX0-K@/"%A_J\,I+%.AG+5[/.B^N4M^<KMHUQ%"*5*"WY+1*L"
MOB2))F&;"IJTI4-8$JQI6PXF#Z]E<S#'Z9NV;@97?#^;^N89+T^JP8ZG+M2P
M_$W5ASUUN']CI/-N32KYN"H?3UK(QV/DX]%(5P=OO=^UY..*?#SHMI"/)U?3
MOCJ:C-7Q_D5;LCOMWGB5S \\B_)L>.0&>6HW"^@"P3&*Y$IKGUQIW:NIIO;Z
M0W74;4L#2 G+TCCGZ2WD/ TY3]-&ZD27G'>QG-=K(>?IR'G=K@Z<M[=-+*%_
MJC'.?9(+(XI&]C4<<BAPJ4+4;Z$0]4"(^@.5XLZ-F.-'=A[W=1'? M\-CLUW
MI4GN6G. EI+EVLIRPW:Q7'.8E0VQW,6'%J(&A J_7+D/O=D"[ 7EWL:Y$-?(
M.$.Y#(U::"X,KZ;]L3K2]K86I*O75K9KX36>-@*VT\%(;0KH2[)=Z]BNA;=N
MVOAJVINHX_VOW$X<7FBF67:KN\)_=0/#;B!W8Z\N\9<IFBT43$0_5<?=OJII
M9]Y0_KB2O.=%NA2.<B#'=DB'WD7IF/1T=: UG/0DI4-*1ZU<JA9*!X*<JN.^
MI@ZUAE.ICBT=E2 3-^$(ZH!"]'<"A3A%07$93H16%R>"(SM\-;Y_L/R9[?IA
M7DF7KF<!&W0]"Q4A8")@-)8!BZN$#<$'S7F57KL115S@QB?U,V&,)*N%_X/=
MFMTXYB?X'+8OOW/\6.]EJMFR_''ZZC13K(=*;^=\150?[3H<1V&^M<[XD2@4
MU>H&N(=4%F[XHO;-EU5B+2O(:N6D&JH2.ZDCOEE7DF\A_'"+A?5N"$.8E3H"
MG5O5C&QQ_Q:7+FNE!"TB(^$P6=JY;E#K8HW_<Z#%M]OW^Z'0^0M]LS1H>(VB
M ?.'O_)-;810X^Y>9(3=Q3;8AI'*_(@#JSE^O<1J!6^F-]#5[CC;>CQS4%UH
M\8R44BFEA='+EHCI  [<GJ:.AB,IIE),I9ANAE%;(J9#/$V'ZG#8ZM/TXO/L
M1*3NC>72M<46%=3/DX\1R,<>DB$3E5K)2@<TF$IX"?.0LG=5DIE:QTS[G>J'
M9*')U50;9(]JF<?6IL,\-XGM5-D'%^,I[$69=NN;MMA!'[\'G@$$M1S#6]T&
M[-G_[#H"[1IF_72+(7WP,^IZ&;UN%+/+IOGMZF6\G1PFJ3FDYFB]V7LPU:'Q
M..(X!Q!%J@ZI.J3J./O8Y<%4A\YCFP.M>[:JHR W=#,3M$I.Y[&;:6_K$6,"
MC; W#@&X8[?!I>>^6'[4TVDM62_"AE^505)3RQWZKRXZ">E:)Y.;N4N>Y4="
MDK=>$J[%CH!?&'9^L6R+^+H@R;)7)<GR#)KZW%#7E62Y4:>IN,-CLE_*(W/8
MW J4'_!+QV<_BG8V:]VLY@Q;>-FP#B,( ]=;I4>@1J2!2^UN643\S \L/Y7!
MN3N/O%OGD;VW1Z:0MB-;LY63.F2C@?/-RY/9F&]QZ3(;4]#B-GMVQB>F$>0<
ME=$1*%'NM]W85.@FG;FRJ6+NW02?^*X\1)NR]N/8';G6$U.P#UP/1T.[ 9-/
MLW]_K]+Y0R*/'U5&>B<1DH$4$BDDYR,D_9,(R5 *234AN?C$060:$253J>^B
M.X_M16%+OK&DPJ.;@K0%-X[YJPL42,6U<R5W=#75.I,V)/"T03QE*EK[C+9:
M[#R&@TBRLV3G]II7M=AY@NS<"G3*-K#SQ;=!>+\PG">\5U)>#%O M1AXFX2-
M$=Y8&X3B=(!J=E-!/D 5$>7;<.M\8'/F><R$']WX/@O\/Z)=N8DV)4]J^UU,
M$>HTD%IX]A(K(? ;9_--@^J$?(ZI<(-. _6TDL\EGV^SM$[(YSKP>;_30$'J
MV?/YQ8>O?F$.#U5A8A#S?64&_&(%/B7GN,&">=$G,HI5/XIE/%EN)8F%#]]S
M,M^8F,CTC,AZN;+9NYKV.[KTD*3#?\SXU0$8N7\U'4A&EHQ\W,C5 1AY@(S<
MBD8^;6#DBX]9W3/LVPG<H)@6\)''P(I.FTM&PBXR@G6L"-9G%]/-0_C9H\T^
M\JSW7&'%BWL9J9(>?,LC597Y>83\O ] CN1GR<^'CTA5YF>$Z,FYSWY[_'SQ
MD2?>T)0W/\=D>V )8I4W%F<ZH=%$W5]^Q@UXGZ+_Q^]@S_KPP,\\>PWL72Q>
MR976R=6TNU><^%*\'NF^M]F:VIO1!UW,&MP' $,RNF3TPYM9^S.Z)C5Z)?LK
MJAX'(K'B@M!S^95<K$1-E*U_6U7BD(?<LP[ ,[>^,_/Z+^:YN9I<OYK^XV]C
M7=-_.N/NC&TX"4Z''B:%[U05&7M+7T]*GY0^*7V[%9#L+7U]*7T->D'E\'?9
M5LDI "\Q=!^1M):N;^$/WGG,-G#/$P"MOZ^CL@DR=Y-'C$>@:A@4/Y*!VCD1
M3-NG:[V_#F>6_N_"B^:S-)[8]:/'C&_7QARF^\ZP7XV5CZHGC7]F.='P@W$'
MB5BT_FU(:<7DF,\;(4=>YVC.Z2#^+A?B=R!8S,-?P72,ULQ%67BHK/ZVO97W
M"+PD I=SYPHJ*9[D84SS=KRX#75^Q^M>C0UM%91DE&6^CA@))+5!M1,B();%
M(V(21Q*DCM$!>U["3GBKM2R:1Q:\,N;00S/#\U8(5FA0?WI\R* D=LJUL2WC
MT;*IT3T!#\XMQW!FEF'#BV'@ !]<AAXH$)&<@T/RD7PEQ#NG=8S+^,=UFYPG
M()69;'LL>DRF68!/.1ADN6$PR/8_?X"-MN9P2CC!1O-MQ&@THSW I920J1H^
M8X3,J&>;=._0>)U6TP!OGP6LXTCK:+I^T0B*_<E8-N&^# ! "?LHL0\_9(^.
M=PUXX'6=[',9N:&\'.[L3]K,&)\1S(C[WV!,V2X6AZ%-!G;$J^&9F>SFO>]R
MS[AI0=X2V^WGUVD^,"COL)8Q?.\BKL$V!._3/%.WA<!@>#4=]M7NL!68(,WT
M[I-R<JER,CR=G&";5%V==+/@!*UL37B^60#G=XX#NXD:[O+S^\+3WP]YX,7%
M@OL)\?AJJHV[ZK"W=X/1)K+@ZYO1;["HXI#'0T-<A2UKASUU-&X*KK8ES>3/
M0/7>A]YL014.EA,8SA-6OP@?^XV5.1Q2^_[BNN:K9=LWCGD;DYE_55=8AICH
MW5?;T^)9YEN?4@,WR5D:<):F#L:M0 IX4P8P59I=-U1I]C9,E1T,X.@S4=V9
M+D  \1&E!WY^A<)[MWYWR2&BE'75R:#?$K-&&LLG-I:/SH$]X,"AJO?V#DY*
MP[HF)]TE]Q(,MC+.<UA)L[JN3B=$I)+0)-(W2F-9U1:1/CJ?3?B>TIYN(4L5
M*.G#LA0UJ%*[_59@QYW D#XI=WQVG>L$R4,Q9C,OA-VGC#&/P: OV ?'<F9V
MB(N#OUZ8@SV5I+%]0&/[BZ \F#DW8D>BCVJ+U_!J.E"UGK2J+Y'5]K>JFV0U
MO+14)Y.]%;DTG^M&1!AG%6W45[[\PWA>_O1!$;WBI0'=F)Z^=>X]%Z$74$ ,
M;[8 F?G 7ICM+I\)?Z&FN(ROII.>VNNU)8(H;>E3JN:FN6L"Y_Y0'0S;<O-Q
ML1DD%Y S3% 1>44GLA_Z,>X[/=>O;6R-NF!L309J=[!WBMAAN]8>+2]<LF2#
M%Z4[L:0&+*D-5:W;5+[3X5CRXN$X/["E!SLE>O Y)A9+PM3^DIB<C6GO5#$H
MF&Y+6/#JWC:<  RWCW^&UDYFVTB_FFKJ9)R]@CHN9)MT!YKFJ^HJ^"!\U</8
MS&BX3[.[=L77VZMZ-R\SB1Y8V1WZ(EOPC07/#Z]_\0H*B'+C>=@I3_1VJ2DA
M>+794_O:/K"P,DC>1I;:2?4VP5(#NBWO]4_=>O$M&+R_,M]_UUC?Z3=BE-0-
M5>0U'*TI$T,P1$83=3C,II!($_>\N:ENE*$!;L)^.9.!.IGLTS/GQ(;MI0,1
M(_! .K;,JD,-'!B.L77I.-4KKQND3+LUT"&/LY2Y!TRZ%9(RI7?&EX!(N7-H
MO@DX5BGS4N9/<;6QN\Q/+D3F"T!@"T%?SP>Z\NN"*0B/\#X4>(G_=A]]Y686
M*#]\??_OFQ\5C_T96AZ\$,R0I;%B'OSE*C-C:04P_[]8^J:$40(L9F+0IYA/
MY5D8!S!LGEQE6D&(8Q'RJ'*+H&@.?/>%O3 G9,I[UV2*G\K,(L!&F!T';'QD
M0$*' #$1,#:&;E0$:J/647 Y6-1B.*O4',V2><U<GX-(_L_NQ^:@6GQDLSHG
MF5]^ @M6Y%2,H QCF1MWP;[OZ9ULV%H!]K&CNZU:JQVV=[4:%B!IG6RN;KS:
MFJ"?N5_I*G+0D@-UVZN.\A^F8%5LPOCP!I\)9HJX-D9?=4&Q; %5'7:+2@?V
M)>E-ZA;S'E[MFFM$!L4Q>V>&'I(G(:M^-1UL0IT*"EIS(F>11!$SO1J^ I_@
M:ZCRGY[XO?/0X5VB*Y!#:Q4Y>E=3K3EZN*!K+9/%1%G'D*T!:=V>8^2&5&B^
M6*G**U,6ADD@R&5P>JH"@O/Y[E?XPW@Q+)O0;N&P\;#:@BES!H>&8:NP-B/@
MYPX\";-PUG&7$29YN?3<[Z S I#6>KI.&^KEVFY?R*J4\J+[$ZU$5:MUY]X[
MVMP'H"&Z>IGBK7W,:,/^T::/J'J#3C;O/J'\NL*_"<JX&^;K$HLG?+NF#\Q$
M"=')P,&H!&XW9VOZ'>?L'$SNO9EZB\&2"[1S0V#AM4F+ <9!3@>]?1ACBP72
MY/3',/UQ3J?+(LZXG2N.&RAA8-'1HW+H=K'!9+*B#H,3 :QH/ KU;F\2P8N/
MJG- C@7"G"?CB9^O,U#)Z+DH ?-)N^*D7SCJ.0X+ X843!0U#F#$+XQ ^3.$
MPV.^BFVD:":NMUS (6)ZX5.*7[=)P;H Y(^QSO,)>SO TOOR^.AX3(*(4F!D
M9]MT1UQ2P!=IHI3SR.!"S +8SQ<+;>['E2**;@3KC'5J@P!4R7<$X4MM,AZ2
M5;#YI,J%Q8(Y&YX0&GJ3CYUR5$%U;GS!.&A4\!X(!4B RK.Q@HU0_/#QO]2S
MP<4_85QP\$DRP<NW%1O>QRTZ7S%#LDW<5P=<XH6U5&8+O/5>^PW)V,)XP;FQ
M%\L-?>3RF1!%DCD#>QF$MLD_CDSE>8A^<D>YVQB=SY->D6KG4&V%_%W  [#,
MB"G%PF!6N)3YW <+C;\;QR$Q%JI(#)U1?H[RQ!QNEL'0F]10L76"R>; &+D,
M0,.%-FH%SWU6 @]XC0N2F"^\W:.,(!*>>'18\-Q"LO(^KL  [NS;PK5-#$\(
M&M)GI%. PMY2-#W!68 '@ /"?/?I8GC[^=.:CR)ZRH)&OIL_I.83[^&M6$M>
MOZ9)%\VIK#:)%BC69#P]>>P)F9U\**-BIXYH?N#LW,W?T\[<.KESS/6%7EW@
M'^8DDP6G.UAXC/O4&;=H22^B$PJQAFP6(*,I* &@542[CHB?K333P*!N^+0H
M<\]-&,U[)GXB!EEC&1(USE'\6'2R HJ2Z^$)&<4$2D,"VQB81YRLYR5,(=)F
M"PM8SZ/3./ORA8$*GSE1=Q@^SZ(&)F+;>=\/XQ$VO:-<QK$@PHI$U)N']\JH
MWQ4V!&PAXSDIC/>LX2VP7K@.<I#]+?H-G"H.N(6/L(>XG^'2=80GCD$ @:U0
MTAZFHQ &CB(>XS,FA1';,-%+5 6HNLB?"4W;PZY*)O%Y3C[- <.+^Z4%)!;-
M1*<DDQ.%#1M;!>(138:='$T:KZ(D4E$Y  C\P&8&)J=&++NIE^#XM7Q^TMC6
M-S1FZ<!!BY#K+8H7"C&G4")^]8A'/Q['G(>9R?5+'DM%)R-)4#U#N7Q;LKNP
MN5'1";*;[3SI7TW'O1Q&XP3/"]MNC]K6IL&60,G!B8#ADTF.D[P;$70P,.%-
M'JCJR##%QTJ*W)/;$5KFAK,A.QIN=#0<R(Z&LJ-A64?#7FY'PWY\,5^UEU[X
M#'N\NIMG%5"V<=YDN-DBKT!Z3G_%S-OGD=E-M%YB>)2Z]\6^ !J[>0==O?L[
MK@[?%1K)LJ^>[*MWT'P=V5=/]M5K55^]DZ:E_9&CT+GWD\KF$7$3'DPZ1+G[
M96<URL3%PU5+3$JJ)=H&T'!0S) W(HC:X"T*(JVZCB#VM.-+(M[+]X9J?S1N
MO20>J7+TI'H[NLU2?H ]H[]^C%TUNN!T G$3],:J27</Q6;$Z#!1R)1,33 4
MJPYS,"XDGN(%<%?OI.PUZ>*E]D0=:&<"J%BQZD3#H.U!"D[;ZJHQ3-K>VTG;
MCWRM-QV;J$S;E3:7H[..#J\PZ6K%\ I-%*GMKBZ.6YJZPSQW+TZ52D J@1;%
M>29=_4!QGN,K@8):U52&WGE6JI:7&*%M$CH>>[8"S!L#*P5#RWZ4_A45"F%2
MKV5:AD>)\1ZCK!O,-O<LPZ:41<KFP4_CQ&7T:JEV;;W**!GTU0H6F$C)KS?I
M2T<D^,3S,'R1$D07GL(_MNBV&:4A<-%9!AK!ORG]![O&^,'F*)N58Y0=A!EM
M<?>OG%?#2ZD^97VI'U_H_C65@1P 8SU15NGZB+R5#>; A4%,,\I!QF0G5U5,
MRX=GX5N>>^TQUWLR')%90I3R8"U>. LH\Y+RE/\I:B1MXS7*C;R$A'=@(&.Y
MI&PO:@V$;A.RQ5-HF2)M*TIW5"AEADB8_B5R6PB_] (#V .IO\9W'>4N].(^
M0^DQ..?A_CQ&:8U&G)869\*_+AA,S>/Y\POW57D.9POX0A7;_LA[!,+?WQ@E
M2X=^E*"*7\^!)8@1/27*X_&+$]U<3&B+4ME2.0 P?<S\$5/"6NVE2Y) ]=A$
M!^;,4$1%GL#:.@7+BYEN<$V];(O9@IFAS>[FOSN8P?GDX$3A6(DZ)7Z!*7_B
M"?24(Y+)P9AT>V4Y&.?#N%N3-,(4A=+T]Z-2HU7-3(TMB1J[D4YF<LA,#IG)
M(3,Y9"9'T_[;[\7Z7^9SR'R.0_CY!499;=^^3TVJM4G#\;W6!/!D"H>4O=JR
MMRV%HRGAPU[%?577VR]\;R%K@[H4Q;5COG*]D:O!(2<BSUYF;NR:N5$@/5'2
M#'8L#&V,<WSRW.?W? MX@3;\^CZB?VUA&X*PJ;WQWAE2,IVCC2RW)9WC1#PW
MHO9+H[WU>ZMR/ X%*=YN%Z[1/ ^)/RSQAW?*\6C*\B0@+W70=+ZPQ!N7\B[E
MO85AGLEAPCPMP1H_^_R-"#(YWFQ*?\#, +H-7#+'L FO,'77&U^$K_NE' J)
M[!1\#R97P'HB9 N$)^>E^!2,YIBA\%1'*4LAB:\D8RC#G5D\A0RVW39WGQF:
MW]'J;QSS5I#E9C;S0F9NQ=OOQB*@=?<XB$\W:^UJZK@9H<U"^!A\Z(1O, NA
M%ML@;!,B^R$L*Z6T"\PP@<@5K97 &PW@56$,"T1Y:F4P^LDONPLOX[!7YC&>
M%$'Y'-$8 F8O!?Q'+/A*23D<6*I1]*B]].TPV3:=@%*S;7?7(6RPB6<1N7C^
M4OYN*:8+FXII)!&Z6N@IH)8Y!%,:(=5#/+P4Z@TB*.4A25Q*?I&W!E.).(T<
MBT2@K#N4E_6 D)B^JCR\6@'(G4W0&)\I]P?_AF]^H7RSE:K<!H:](MF +40Z
MT:X@IF88$"I*&M(2<SP0M<KW"<SXD6<ZW7YY2*'7$L1:&"Q<CP/08M8;R.E&
M-P?L!@'ZN2BACZMB[.J@1JJY"W_9>-?^M%C#M@3WE>>?1;"V)&@<ES(0"7S)
M>Y>>A?]V:43"TX0-!8YY!-*:N+OP!&')L>]&G#F56J?K%2V3E,5*8192.5$L
M!&#ZRE^A8D=;@OPS(J#-""ZQ.M'AZ=2V@HIX!N'9E\9$#4YH;;+62"-6>VO)
MDX+=4BQ%3PNNXEN 0LJ1-_F:<6B>>(:T*5GL@'[5YZO8A%Y;IT:2 \F73 S
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M/%HP/<<)J5CI&8/]\>$+[J<OI@FS^R]*)0;P0?3"P 55:L-A'*0:RE-(C,P
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MJ=)"<,L52K4@K3 =WT*.5:J:T6']4$H:_M@!Z&_R"&]"IOC33_\/4$L#!!0
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MS&99 K=&M*;Q<6=XQ-RR=?2/C9P(*LGY48'<ZHP%>)19<DY.M3A=KFI(1FG
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M];*Q?'LO_5 G8"..0;L!1^18/X([IB>PZND_7[7I3]'PK*V O-K^1500!&;
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M7M*,%7 IR8--/$(4J(!I7@M'%J%NWMGLO-0?@/3BK8:6*NLA0NX>>*NUM G
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M#N?:DLHI"XX[RY*4M/VV#MI^ -*S8DA+\3=,5NFVQQO8/DS.PVA^_AZGJ6Z
MIR2(WW%>)4(DYEY[)!,N1$TP5900T"2RZ(112J'326UT;&T^YK.@09]R;A@P
MN[3&)M-E-<3+\_#FJ?<!$PZ_K-HQ_#RD3SFMV/]Z.UV<OOK\>;3*BQPPFU%C
MCL#(O*<M3R,=CJ9S\Z+QY OP#<.YFD%Z/F0ZC)8:Q@9=+HG:J.%DO)3.E65V
MX1,,.'F-$F,M'J)"C8O(M: ]@ZQXUJQ6_8UZXRWG_K&>#SL:R[7ABW$'[PI.
M!7HROK,(ZZJUP7]C'DANBRY& >KJYDM?P.M,?Q@1,%E=_,T>46LXL.7 SX<0
M?4J\ASOY-V'VJ?Y_?83X0H)8/FM]_$2;WA\X/5N^2BQY+)%DD0,#CJ[4[LL!
MG$RU4:<N3H@BI6U=3'5S=,^"0#TKI6'A_F6-YZMY_Q:^#L\69UWU;_I65_!V
MV8#@W?C:_>2 (3,V)P4A1#*WLG,05&0@M=*>9Y7TS8?"=16VMQ[[63!D'W)O
M6+S_)MQKU:T_X RG7S!7DVE1??@*N^;G+KOKI,*9#038>^2U9IV$R 6=G$+6
M'F.F!'RPM/&C1W^65.E']NMK];>I=/UQ<79&4IF4CT,Z,&LAF/'\5>IB.&M?
MDPD9UT.<7>5ROQN7R?1L62WF\46Q&XRZ2_WLUI/>L=3VDDGI$^9%QZ;[0%UQ
M-B:9B:D%HLD.E(WD[3B7H3"R=@P&;MUF/NFV(^^V66TVV#)*0Y90R$ISP&VB
M795K0\N2)BN32,$*GI/<+/%MFU'[+GK=O[:_W:'Z$OBA"US7R/4/-3*L>W[G
MG(O(,4*2DIS I#T$QFH.F>,VFF+PYGW>H_(O+@?<=Q14S[J<["K3QHDV'8C5
MT_@F,!IF5UT;>O_Y5(\4_DWU[2"Y'A5I7):,D=V#H@;=84;PH6@PTI -I"3+
M=J-2?(=6X#U946WUMXW &NOM-Y(4.3X7A?I85 4M@^PB6:S9*W"*YL:\$LI)
MZYW?Z.7U <U],^A^<Z >+?9)"YDUKB.S\EHO0J2+8]ZG KIP!<I8,B(X'0FV
M]D/WI@AA; OE71_T"2KOT3)K'FZWMD7XF\5T2A;3;[7]S[![<!O6UF\VY!R1
M_$=CR7D5HH C<D',2JF@Z;^T84VH[0;>GX[W;#+WJ8#FD5UKL?X^&=\-EY7
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M83DFV9]<UN/:URWT7GEURX!KK:!CN9^^-K%K>\[/4_RO1:T,T-UYB!B<H!F
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M>SC'FL[)9E$+U]**%K41"Z/%')5/8+R,*NFL5&C>Y_[HF?K07?"Q$W4;I?9
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M+FG(/EIM518FMD[,/K9DD-8V>U.9[XD+%W68-D#VTI- MM+>Y@'_CQ']?I-
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M<3QNBM]7QQ%1J(=B:[M.]Z>O.$VUN,K%C/^8S&O0ZGPZ',^&:3G'X+.M]0Z
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M2V:^E^3:!4%K5D3B!_>*>X9)M YW.PS3'@JZ?:I$VT:!>PW'I4GIK#"#C]J
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M,/FSKC\#;AZ>;<9F7"J_ E%-%NG?3 2+2;Q'MB?B3@GP>%^XD[N\\&I\WP-
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M]1.C2Z6".5-YA\U":>4QJ9&4XL^R+R,$+%\TQN*P1_^JJV /4#0-OQUEH<S
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MB](B($6@KJ"P9X#'M>;IJI;-_FQKEH>GY=<WX!_O<,_."FE_)4/?"GH-&A[
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M@1\W3R*5CM!DR0<!-?95$="J2D3+648_A!6LBG[ZQWJQY:,)7"^,+$[=7/)
M&)?C( !;YPC<S!R9<'U(7'QB3UCP;NM7_DZ(*KV<X9>7%UB(-F>M.8.67!?R
M?=IJ KGA;.S[6W(4"7&$QC+*[)^@R;O]Y,<B'-&-<?A?I4C"4[P<2JQMAV@/
M_P0\)9[0;.ALCJ"W,TO.%T;HBSVU?8(5POBHA((E7)T"Y*,YZD*'5G3J<\S+
M)8?-[/CP*IJ2-G6CWLY1DHL[XB7T'N?%MEZ*KE(U:S@R'$%/3JG/HOA+0S4-
M$[1X3B0!NQ:\!7^[3_H?!-^M.B@(5+34 74@V]A]>N!.U@=+9J[!.>:0->&E
M1S<)V%62:_^&KMGVL,6SW0MFOZW-^O/D-3;*/1N9Z5=-O&!##Q!-=G9+C:5%
M7KS IKT6R[,/59_"N5071\_X>^HS2RX7OYPLT##"J0UR>W@!9*O5JUMR/)RG
MV("OY/>KKW(.#TXA++OPR-C"=DPAHEUZ3T>?80%>WS3ANFY".VYF*5A8L1H>
MH_E"JWD#7\/3]R!R-:/'-LH&'R42!F:3#*9#1<1^G;>T7(1T*W$V'KOT2^']
M4OS^-#W'/N: C^_M,='"FV192M-6J<K-1:OT;28V4=:0JR"@6@.GTR()\_&+
M0(]#OO<GK%F7/(N86@2DEXT*^Z2EMGWJ[ 9 L>#"MW9%:VXR95!7VWA<3F5D
M#IG]\"-UX!&'>+K3R4?UZD,K+!MZ+++369_9_U+U!O#!W2*V%^X(_0:W 9W\
MS%!FB:'QX#3H3E:!/P@@MJ)/![D>\QD-00)L'S$9V/$U'7#F:(TI_T96N2T:
M7:7)_38EJ,*%5MUN1/X$,<'4V&=SRGS^/,^;T-(9/KG;OG[/_B2='!P)U0ND
M"W!-T_)7N//#W.P;&ZD4Z,-'4C3=& B36T2Z((Q8N5;T=<:JKM.SR=,C1I!?
M#GMJ;TMYA5= H8U57EFY]&,*E@%R>K':,7I5]H@8?0&J($!#&>/!,W4):))=
MA\NWDMR>,K,E"QW."0TODD='KI))VL4_PFHTYRVD!W]N/$ IA#PB&+1AP01Z
MV*&S="84"=9(=$9E5G-2[\5^&ZP:^?/8UH7QXQW0<%IK0X3QYZ>-FC*P=>&M
MSL_J#Z*&WZE==*G0 SMP,<D^A?Z9H$X:L*GC;/)>XW/] O,=]'M^> ^0V<;+
M4LVMIBY$^"+E<=^*(/%Y)YF*4R<!]N&TE$(GL5KISE&IKM3H'RM0QD7RXJ+V
MT)@"3/$PPLC T:AU .#6KWK*7?<\-7TI#C<U2:D9B=I3^\6*4W(]Z@&'=">A
M&B*=OI%'!M^=[JP_XFA9PL\5FJ:=Y(JK#B"L;I7JG=251N5F?;EO]K^I(\W?
M=J3.WK'P8#QE_.LIU%6Y/B0P, A9S @ZL#4Y.62.MJ]/Y](\C--3"91LU([
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M_%+T>I8-SV?GK!,?\Q;(^/%<Y!5GI]OD(4YTME5\K6;/$3NK!FKNZQZDEN#
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MX\GOZ"S7+3S4CIR+#C=3%H(+VC,&W''6(\J12DD5&12@#KR%7EXMI0;\1Q3
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M!\@NCO-@:6N@K&@O7^.\ROYB+]TYM9[)8*UEF%3]]OK'IU?>;-5TOQ[RVXI
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MS&QQ,EN09BW[A%$ :Q^9$U]J@N-[5C2"9L8_P(M#RAB]=_FVGNDUT1<47+H
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MGFL[7S2?P2YUPH2R+P2$64./^2E,(MCP28VR]K A=S1CDDZVB5 WJ(B4(B+
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M2P-X?3(%BLP@4^UVC,'A"O%;(PD06T2B>RE.'9R#CTA0_DV.\1@U/'8>LKU
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M[ G^"<&H Y=N_#:!_]<="6#T&,X#S%*K^+;.Y,#<[E4Y3U8UZM<=/+<8$AY
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MUS 9+%&-L=-H-#U7<6":EA'=&MP=3QO.SIB1Q:S#^-2@P"*%RPB#4*V)W^G
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M7AC#PK3>9\D5O?;E/Z,8>(Y1=%W\_K6' R9'NF!((L,DSAHQK$8\A8?7*Y
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MSIAULP)BYHZK<G!^<+9>8L[,Y$1W+(RXNP"O#X/4[)/1,R#3T7@)$@ R$DO
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MLH$3Z9,L(4[%68T?AJSC,XE/A@X]WRT_<CL5*HS@C<\Y]YG^V_=/BEJ:+20
MO</;M+;[=F.C:^QM6=Z&_ G'H].+K]&$Q3 DO]:^CO_0(BUPQ3.VI<D!_Z%?
MW1C_,8Y-<#"47BH^FN+KXJL>QZ=]C;(H_P5/HFR-MU/[ WXTP\1**U$D#%G;
M 6/VKFPQS ^3!#'9W:\2;QP5MJMY','IZ5*A[,(3Y6[N/ ";20A>-GY:&# R
M*1T5(.#-JPBT,06,>CC1@>U&K[Y?-_0?S3B3V6)AL"05JOGAL0N/3;AEC*Z
MR]>S>^!7"9>%UBM#6GH$GM]#==2Q=M]8N?!Q.-8D[DWU2+USFZ(9):6S_!GJ
M>S<V4F5"S%<8)BE;B=<PTG%D_ZBG=98!P]M9ANA92M'9*=UK.U/>\$@39QUK
M'Y>YT*-R\W/GF=S/B;SZ?L H>9.2-45J]M&D^;1MQG57Y161\-KD^$97'R$7
M-_%^[IW!,?OSUG)Q7XI/:.N_97)^&M%U_P*E^1C;@$X0]H' ^\]7^$M /0VW
MLOFHB KT,CRXP=[7 QEX2;2;2EA+C2(/IK8E: $4;GJQ$??XDQ-$XN/4AGW^
M1:" ?5H\IV?X@QO(2!FQ\*<<IT3:^A2!$#YLT5MB'YRVD9OL"^9EFQ5Y"W8\
MEITMRB<T?.XJT8]:V[+4=$WAH%%;[IR#7RN]_X21 ER5=-?OD>=[$0!_9$DM
M[-7+:ZH:"C<6YD2>ZI</\!I>,TIXN$/)E4.92?QV."A?@(%'L,"8O@^$<5W]
MB#X(C8DM]\C1-,O&^F\-"3^]F@OE-Y7<TSLQ*1PYU,U)4U]^NC:]C/MVNG2[
M:&B3>.*^QW C0X[M9.Y2:"Y7RMN!'-O4CE?LL2E9*E5W42Z7]%<:,OF?JT?Q
M);U).B.KNJ.Y-SOP>FFQ9?KD Y;M)XDA@&/ZUA>])!#55HPO: \'^C6ZM[2Y
M^8X'[C^5Z<Y.SUZ!Q\XQ0/PQ(AL(DVCV*TG"G6G(QQCF[&(USV[[O)YGT:,O
M-U_ZC,'DBUD[S^9(3;DYK AV)&(X]MU&J^;":J12A4#H\N\Q:AV&IM4+'Z-6
M'10GD/;>?*(\@#NW!2(J1 5F9LZ:/_@8834P?#9+O]?ZQ.5CJ,DZRL";GQ4"
M-Q)?TGNWT)I]T+_:?7Q!@-8A%C"I9C:<?EKFC7S!(;0+2$^\B+]#R&JD1IKH
MM=8LJ'XM=G1RM_CTL3*A1^/;%0OUR9UCD,,\]06_Z.99_3<E[S2XSVJYB<24
MM4'#9T4QM9UR&SU]:LTT2 T6[>K1Y9&+\(G\J=N#DS2L;4ZUNURV6Y9"/4L1
MCYZV)\@/$B[#N)DG\V[5S25_YED*7XEI%G'I[G3+#(_OHI\3N&; T+/".$^[
MDL]% JS(R+0E >4,\%(86$03H[<N0G(K3#2LZH+ ERXUS+V2 G#,44E&P^V$
MCJ<.RV(\7JK""?)]E$(B+AQRY^^5-8/IOQLHRF!7D'KA*,>LAGAN]%S8VP9]
M+[6\6XP&N3J4%77)2QG?9 \CSU&)S!=N?+S5Q1Y[]QFM99Q@O_/)EBV7@0N^
MRPGJ;9P.6L&V;%12>F^%<AB5'K:@JA8*6GJ[S'N:1+W3## .&2MM<Y1VR1O(
MHH2OX/7GUM1MR66G/#_QGJ[-O%^6Q+QHY4,;]%P5N]G$B>6X@[6>-V%H3152
M5$W)F>*MTJR0\ %TKB3:A=AR;GDJL(W7B-EUA> OY'B+:R7WJ ZC-A_8QO3N
MY)CW?<RHV<Y$:G^2Z-?Q^KQ8.<_,VV0W99Z^6.DV@M9>I08I/;A>]%)&!HI\
M<CU1\__00>Y_R:1+"%TA^N>1 $TV.+H!/$Z+!(!\P[4U7'R7__OSX#X'[' _
MC7B8/4OS[K0 ],,T"3!0-7?0!S2K)P%@MO#M5(7YOTZ1^^7+\E]]D;]]SEU)
M1?MWY$UIT"Y*FK"KF10R>)P)-.X(79ETPBW'_<X+Y"T2SE](;',C 12'H7,2
M_K_+??!\]7DD[$\ :K^3_I\CL'7]\#<4^+=:QUG\MW@OF?U5/6G_S:XP_EM0
MMKB6/X<JV+J4T#]K%!4^R7KYP3:W_\A]U@3H=OSAR$3(UR]71\NK4<5Z4JN[
M4[U1/*Z=8J4YQTXJON 2 /_.4>NUR9F_.GR&_O4ZY%^'8$)HBTGIS(=UH][#
M6T%SA\1'GF;N*BK2VJD*ACSU'^*=A(R3C,)C7=58N\8B*X0<U0<F?J!#C_8.
M;_U5_'>]?ZNW_5K^ZL!1:V2Y??XA"?#[>%'\G?9_ X7N,PLM[0'<)9Q&;5)6
M2L^*1>27TS"71%BN/K.T/#1;DSQ^R1-@D.ZO3=)_C_B_FR!/6<S$9-K0J*+/
MYYDNZDQP[Z6D-YJ^%J) P^I]CDS0X \ N\W6OPJ0]^\A_8]1.(D)H\NI"7(]
MNWV%2*4S<EX+PUY,+E6X7!X.'S$&.3UN=%$ES;M/_RN']"8$OI^VF]U# MC"
M9?V9ABW<:'=(@$FG_CA10AY^[?O9-[4.4[  E[B>4C\="\K&/ZL=;>+XY!AA
M*TS!7_W[0BKD 1NWJN6D>C<GYC 0>D<H$/P#8/57,-A]_[>-K75W44(GB+Z8
M3EF_00NJ3#!.ZW!PB02HFLL0:%JB8O"-0UUP/I_^\@04QK5G " !_@P@0U/E
MY1\$@]EP! H&'<4VPI0ZKF]+<3[C+7\9B.]"'[T4'TX5"DS[543Y'^*^DZ&*
M9'57D!G8*9B<+Q(]32EU8KE3;6EL:BCJ(L^?8RK=8&-56/MF !CX<]%5F&^*
M_QE:_N!/DNR1U2+_YTI\C#-%0^IZ7JK+SSL[^Y  "@PND7^4*%_0\;ZM307%
MGZM D5S'.H4X'.#N T5)KVB_B[K(]NL;KA^UAE???3[QRQNU7RH=\?^7Y)=W
MH%-._?5E$9%ZB+E(9Q]VK4&.>K:=M'2]1S]?C&W.@>X_1P*<7FA]\Y1A7RM_
M9AY:>"^XVIWX@\.8W,_Q)QZ?^>]IZ/Q_5\7_ P 4+(G$J0 /CEN*3P*>14MM
MN2J #"M_O;7F:O0N= )%";GT58,RN8Z/DNTR4ADV].F263-0+L!C!?3'*R6S
M_M M5_65_^6:^@\#4+_&,^G"+AQSB6,&!U69Q[W<W3!]9=8?8,4U@6R<^L.M
M+;;1?QAU22_^]5OW7P+XI#QG ;$V7=GC4'U]BC*9!%!S^K1A&K^(/K%_M-RX
M\/-?JE]W_E\X (2LB>S74R[&855<ZN)@1)#XV#!Y"O"K?:1VH]T=R_5I_?D>
MC]?M?\!X\"'T'UNM_IN+W7]!#G@7>350+XC8"SQ;30*$#T/ 3F?M@)/<;23
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M]\*NC[XH>YI&6&KWV3:A2.)^8TI1W*4'P(MOC2OC+\D8'^S$A8!JM)\'G-L
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M^9\Z/4K]I@R?[@8=+R$!:I]^NJJX3A#LTR/>DX%O/B;;$>6FKV > :\ Z__
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MM1=QYXLEZ2W\8Z)R4*WJ5ZH_! 22':0&0S].>KXI9ZE7>QRON$)8=IZ#XW<
M,["LZDQR5%TLL:$./7.P\)*A-\XD\R9\ODXWO2V'O=<3%;A> B1+]N>J5O=C
MY:F_FU\#$QC9PIGWHYK,GB'RY6_$6U<G[%T3NOOP;GFB94+2FTL^O-$'K;.@
M-6!0(/LVB/4(#Z!!CW3BV!I35M,:7R9NS]4TER0P';R6-&)2NQ)"^LK/?Q(V
M[V\(1R<A3U=2-X,AVE8<VS :C\CJ$<JM[^E(DZ'LC*Z^3^I]5HDV=I(+H=12
M[2<E1*$P%GEQ+!!U&N34(O"]Y4H+$A8C9HN5HML/?MY@M.M20+B+<S/]O,CR
M+&B.Z!+]'48NW7.CC<B>Q2:KJT;UH/7I-FEX!,0% 9O#(%3"6^0A"O6HWI"-
MK( G[=.UE'-;XLD.+Z\N*NT*.7XC]R)MV<P2NURL%;(M2 $10%<48 U=*.U;
MF;4J5E)\W:714DT"=N1]9L\I%4^Z7>Z=*>7)]'%C6UP;@R(/R#1.!E ,X5 G
MD_VPAI88RV4*W/RSO,Y2D_F%@/=?'S=5F<08;GC>+=VH_!+=2&/+/6#)F8D'
M.(/G-KM!50$M058K3D#-:<_L0NN6B:SS%W5FXD/LDGG)AGG/7QA9YXH:&06'
MQ[TFYOUV0!$')A73CH)2M3JD(H_<80P^@6L=?K@P[I0%)7>ZQ5K837F%F W?
M+)X<2YU&X0'@@W<1,.PCE'@I1B5P&,:& ^TP4YQ<9CCQ4PF7%7%PY2J;.KFW
MK5^Y%'8^H2'KMI#Z[+:^!6J _=M3IM(K[CO[,3 &><'6/28'Y  BK#6871"M
ME(=B/36_&X^,)9F">ZK  [7$L?E^;S9K0)T@5GE>K-S%HI!P%6M[86(13A:H
M1^4.^>B!#F\W,B$7<1B_5JY,(AM/0'R?(MONE^B"TS"I?7KT6@>.$ \(CE0*
M6'5R5T,>OX:1Z MY?EI2<F)1G:N_2?BES8:J?D[JILEX,>0E.@?A,D>R"F^'
M12R3894*T 6&XU@]FS4Y]4V-.@9Q?6.GC)0AHXV(EP:)?=$7/FY 2F#;=R.C
M*P/F9&@$:O\D<O0]JJ"CE0S-T"E/TIAF*XI:B\GN+W?&%JTKBG"745,:76?L
MMS:(.WMQ2UMES845\A0=@Q%!IW2Q4XV+N80OTU9G?K0>=7:Z<C# 7?*AB4JT
M-M]9US;0=CW(2R2C+1%P=G:QRLE?/W_3I%3H4]#5PHZ&KR[/7LPW+8W)\_I(
M(Y18>?B'RKJPZ&I=DY6<H,Q,!>^'AQ^49JM[<J<Q-R"V$Y[ V>6N0&X4/(IW
M&B*',%/4K:U$Q?V R8K8SREE$6$<NN[;,5HJ<2NOCJ4Z'?!7I5'MX0'$.$YC
MK"'Z"<*%<?93-U%5@:+/%&KD)!SN;3I X,ED$U7%\I)\798\I"D.KER0?'4?
M+!?8$<C0C 3O9B/7M)K2QM6LOV;K#!4M,J1[BL)UR#L'9Z7W>Y3O]UXV&!TX
M5;GQQJOPSK_[=O/?[%L7%_Y=%CX Z&\WKFN&('^;A>_5S620L/@30W?; WZA
M)TFYDF4A4QG0I7/^SD'A3TS!6F5QS!UY!17#T!<CYW.@RDW<GD>V2CZ+2KY/
MZW89Q5D^FN7<7D7B/!UT:HL;@&%JQIW87U]\H)\R0!OI*T#CI"$\X&^K K<_
M_JI)//7!'3KKC@=X)>S6XP&-9CQC6\IC6RH_BT)P=H$$QT6LRR>F%[%J'N8N
M],>T6K6?SL4']\D"#\@"OPKXK\<5-NL-7!#M%\V.XO0Y62L:^68FL:93<98@
MEW#TL<Z *&<B'TVQ\Z3!2Y[BPH[;H4P^!6KPB:,AJC+',@(A=?@]P(QER3VP
M+-52-?'N/NKJ(1YP=0L/:&N$XJ3 &K@1NV]8X*@7Y34)WJ1<S:X"T' S_\L3
M[$[]<TG/_-GCI%5L!Y6.3L("'C"(]L<QS:\"STD*\ !"@=_?<,IIN8D'C#9
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M)#SJ(SJK 79RM\"A2*QBE%39G7;@9L(@1N<6X]V%E34Y"O4OCVL'\^7$I?
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MDFFAY YCH)54MSZHS3*U)-\UE-) HI6NT(F,N;1-T;"[V86C0TN]RGT>WQ3
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M:I\L-C_$9](QY0<!V:4M%MP;'%,=K!"&I\U0K<2]"[E8UFF:0,7HM<Y76-T
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M\H_<CRP3.DJ.EO^9_%;_WD,W@-7" Y+]5V&8RV9XP/>/9>_KH5'+!]J0)WB
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M"%IRP6RW@,]?)F!_8@W.V,!/ H9;A]B+S\8V$O2P.XF'%*?9N)]YO]/!?B*
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M@!B&+G$&XQ-X 8L&?S&CA4X!?^GZO>3(^/<B'&0]FEN-@W>6 WU:5PI>!=X
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M)GW$QAO:_:_\3LN:+-8M/PU][+P;:&HSU\(KVV]O+:#W]MB,O$$L58YI^(I
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M]:2+PIPK DJU<"-H._J&E;/XQ[EK.LJ[=\0#%3EG G2Y=;(O9D:T<6+?=A,
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M'?(*(F ?.<ULB!RVR-4!C3]4L:D<%W=J-FP,!T^H-@5?CKSS+;=?J!?],<B
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M-"GA<Z:.UMOK2;QJ:O:<OS2>_0C%KZ*Z/Y OD<SKY^X#L,V([=G[7<7V200
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M+GUK,JBVXYSG?QZU*-^U%H:KLZ%3GHMK?\:8&*S%-TU=''ZLTIU9?QAEG;L
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MT.#H^WHLZ%I&RJ8>O^VHGRVHH!KM$J RW+;U\@+W<N8D,G"O5)7>#>B^)7Y
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M#_J:-(N\?3,,^Z6#") =*&2#PRV*])FRFE+T'D)Q6%YNV,05)PKM6CPAVR
M0/5 G'N /*\'])4_],Q14O)(99T F*R0^+6K'>M# "@"<6GG^AR1^SMQ_D3\
MB?@O07!C;P^O8=$,&\B!_;TZ<#<$7[A7\8CZVP7RNW[#6,.T7_HCOYNU0Q1;
M<+@,.%G^UF=UK//KRT1(ZP&=]IF_]F]*E>_RWT/G_P3]"?H%N@CF]L598S^0
M<ZB=I3YXNO3F BDIQ\\*-4,/W%6W[[4^?3C1F*Z%.=AGZ7GVZWM+=(KM7_>E
M"RJV%] _]6BVZ=]\IYB+A/[XT]/Y$_(/"7%BMISE:?M&@NX=:;Y*?]BR+-7[
M$F1RD#]?3#*"3=VW/4O#<]61'I(]WJQ/9N66[H5\6Q:#_:8SK^UYH',K! #.
M'."K]<_Z-/XOQMW"^0_^@<JO><WP"8  6)G_$_.?@H'+[D0U?NTC]@<E_K)"
MORMF#_9>"GD+X2V^5^1@<G]V<2[I;O\4_==Z[T5$WM7U#47.T08;2FG25IG8
M.\)#?AM_T]*7/].?Z1\I$1%F_A]02P,$%     @ &U1/6&<IF#"QY@, R]@%
M !0   !A9VEO+3(P,C,Q,C,Q7V<R+FIP9^R\>3B4<=\^?$UHD)KL:T91E"0B
M91M+MB2T(&$4DH0VF3)F1/8M"86,+%&6R2[+3';:[$N498;LF;&,8;;?Y7Z>
M]WU_]_V\Q_/\WO>_YSFZ#E_'T<QY+=_E<W[.\_.]Q!GF3 ![SYI:F (0\#@+
M.0L G%' &.#:L6/[!SRXP1\>7AX>;FX>?BAT)Z\ OX# +OY=NW;O$=J[>X_@
MGEV[]HKM%106$145%8")2XB)2 B)B(IL7P3"!9[#S</'P\,GLGO7;I'_SP?G
M$R#(N_/RK@0NR %@AR"$2Q#":0'@  #A@?SC /[]@.P GW$GE)>/?Q<(J-P+
M[(!P<>W@YMI^:O#;(/![@%N01VB_FN%.8=MKT -W1=2?)+[AE3<J;12]T$-1
M.'']7@@?OYBXA*34P4.*2H>/:&B>U#IU6MOXC(FIF;G%V8N7+MO9.UQQ='/W
MN.%YT^O6_0?^#P-0CQZ'/@T+CXB,BGZ>]"(Y)?7EJ[3LG-R\M_D%[]Z7E5=4
M5E77?*QM:FYI;6OOZ/S<V]<_,#@T_&-DDD2>FOX],SLW3UU975NG;= WM[;[
M!0&X(/_7\?_:+T&P7SNXN;FXH=O]@NP(V 8(<O/L5]LI9&@+O797^(#Z$UX1
MH\0WI8U\\B<N4$2OW^OA%U/0F#Q(W>[:/WKV?]:QD/]?/?N_._;_]&L$$.""
M@)/')0@@ )8893Q\:9UQV-?7(\/R=_*FQ/U/IT]#,[V1;%$VC@/HE1"7\S@
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MTMF\0RX^*QI(B6826/GZAU&?^\C5,8M+3/MBQQ\C8Q*NU=7$E%,D@\+@]T4
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M'N N1T#>X3HU(AX[A3M)#Z 2VT?@<166D;K(8G/B[:<6/*W,LM8CJ4!ACIH
MKV)!%FQP7@F/0]R"C91U33S@R_'::_(>5?M;[4#SL7,G$S,3CO$J9-P)CEU7
M$'#GFM567CGQGW/5>^V("/8AE*Q@P;@7X2B%*9_WJT7\Y)=^P=5G.N0& /.I
M!_D*"P6]&'8?4Z^_>')H>8;J&^+ ET4,VCC2,'(ZX5OB;$OH4L;0[,Q3])4\
M^D*S]L.&'*?BWZ^P>],D[;O7N1^ZWN-=-!2!E)J@D1R 9P<=1TK@NY4IWO-
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MP<6N^\4!XJYQ@*9!:C5KCS8'8 O,< !2 1?M;#0S2FJC-5M=$RXER &<_W"
M-L($Z^DR\VH09<:9 SQ][^/XT,HFQFY@Q/29ZHNPD%>G1W'-"HQN:&^__51
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M\IO+[]TNWJC?A-=O$]T$C1H#U!2!<K<% [A)CXD(8/O?I-E+4L79H RA]7$
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M_/XS[_=T*L,)A2.G)(A%:2:71/PO]MXSJ,FV71N]D1*E&*K2HX*@ J)(E4!
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M[@JEGTQF /CM/A<__+:E:I^,PRO6[9,QU9-SH]ZAIUBW3F#O,0<9C%CKTZ7
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M\?,<S2PW^!%]N&_9,U2K$_4!U7VQ&1>)=F( @H\'V3I<T)D*,PJQU]R%&A@
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MGPK5-U+74@HR<:58-NS*AI0^[:7"<@@+H@'%GAXNPGKRGLGJBZ8@V72Y!Y'
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M+T)UT=H4RQB_T2L<^SGGIY"1F/LGP&L!\UW,^ G0/':;_87[<&V/Q_& #-N
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M^>+OLE#P(0B,2^D[8QEG%KW!G[E!Q3M1>;ST$37C#(J)KT'_6,U!PW;8WC?
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MB*OORA./7!<]=0[T.[92+QSS\.CN7<- Y>)B,@ T(9IW%Q/I'N4/ZF1_K5^
MEQ$#N20J&PDHX)5Q 9#;CA [MLC]VD<3D_"9MI1+M^MBQ5XU)DW]23\+\"=
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MZZVWZU\3%KTA#>&YGR@:8_C:\-V8I[C\-OT-C;MCO#5-!97WG/*%NR0^Z;:
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M^?P;_Q/_<#O[:[[TY_EB:C(8A_5#$'O:,#(AMA8!$84?_-FF(P\EI-4*QM&
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M:%=-_FRFZSI$G $V!Z"3QQY6V^1?D]5T/%?>&3#A1;ZT^\U69/2AIL&$U17
MS =EZ7BX#!I*2*WO&,NGIY7CCB/=7[;+ YIJ]@H'_ U5N L#GN*,!):ZR"?#
M.^7K#F/"*0H[BTZ?EB3O4@)-=O;:_249EU#3WN08W XZ'.HGQ^"OR%C4,]"Q
M0K0(J;X8=? (689X[L9N,'X&.*:SF*XGR5^-GI8M*&HHU!-\(_KK>=NMX(>
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M:E5\,QHE0;I.Z@,SP>DW7^ROFR3+&>_M5HX=E'N_65B!O-IG<1_\H<[M6 3
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MA@08O@W0KC-V@H_Y$4R(+:L1\$'* T(M,?T,6*XAWU=K)80<:@_EEZZG>Q3
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MQ_U$@O'L2V[Z:/:6!EJSL?+-+^(F22"Q#:X\,_ZA:[?L#-2.(5SAIQ/;EMN
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M0"J3 V$!PNTH5I^@\E[CI1:X45VG/X=#1<PU>A=U@="VH%*&.W=V$^).J<Z
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MW.I<H9,)IG I(<NX?-O9U47/0$7YENCYC6@3OUG.BF/@/6 8YUTR(&JB!71
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M4$'.)]_N[>'W8GO+;N.EL-LM04M-"Z[^GJO@G"$*W#BFMK5[%OAQFA7+\'%
M)7NFV550S##\F1/E9!'DX)K*:/GVU96#FJ)8'UI2DCMS'-MW=O&[QP$DYQ <
M^""$&.0^IJ#ABR HED?J#Q1-Y<2H&QDO5;BX--UN.?]X!R#'TG99PN(B! -$
M-T2;WP6>Q:5RQYQ_2&H6OT^D$K[W9'3$#Z0-!6'+&J>%<>^\9J?8C".?C!1L
MFF[!2\,QZ?EYL;M47<9,%A2RRXIWP"G@2IL@/LSV)CW:53"*\2CP^'R;C%#;
MU[3&X7;"^?K/Q#"X-9 1*H#E.0R%/BU>'9PTKOC,^O(A]^?S;BX[C%V1/P"
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M] @/7UHW'HOG$H0ZUE=UQB(;*[T185)@>ITW@>L:[]6=( 2SK$O9.E]UN\F
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M_&>%4!BN!*NBA=.<8]FOW9>YZDAO9BIT#A*LHTI5W,"=VL!91XE9#B,#[$!
M7+->G#/"W';DUTQM^4 6Q"W,V_%)=7UFVJI%/8UP8?@S[(#B^!*Z9*\8$6=:
MW[Y2 1W$WX,-ZWK:;"IQ8-RP4_:$=N=<45;Y)U-/RD!(U4-%I== #M(-^(NI
M53'T3S4?^<R=Q=W%76ZAR8MLHA)]LSL7B\2T!AWWDW#"KQVR:NM^.+/KWL]*
M&=L#7*[8DU6(D+1>>VEJ][H&>F)^6&>YLES.1Q=/S*[PO+GY,WL9E\EGFCP]
MOWY;:+QZN;6APQW3R3TZE%9VN/%U-,T:"XP0,;F!UG2XKAP(F\OF",)SZ&"]
M.6<.X,1X!P6J U]X*WVK+UJ4D\V"DXUK[%@R8/2K(N@G^/ZHDE6RQ=X;A#:"
M@.S=DFY8C*MX=G^TZB@L1#)0,D+2>/X>HY[:F7=]%*LZZ2&XW=4(G_;I<P/U
M7)X6N_=';NZ*V "%0\,Q/_"E-S<:R !=3VZC9;&6WL!C1-,,X^1*8OJKG-YS
M76$\+0\(1<BAMS="B/)%E//J32+R\U3O9[1_3#CE*B<(.SG'7/JRXJM73 %4
M&:(^=*EKG5WN!+TC<<*7O%@"S[W\U@,,ABFI=P'+Q-J7< [YH@&%OWOFDL9E
MHR)@K0(@*+P8_A&F5(TOE;MJ._)PW)SYO.&33\HKRHBN[6N>3GJ8P%JOC+61
M'KOOI@\MXWCW-Y2W+C2>?:-\OCZ!^!EN*U9:@7A'4'?%Q]U2%-PQQ >57_*E
MPZ3.> QR_G:*%RPYGJ(]/CI*M3 +=YL97H?6U446?3\9BYBUKIKL+$B&7971
M85EA14JY@^3@PS??0\0U".=@3@1[7(8[UJ9=QKLN:;XX\O"Z] 9\N.EBF_IA
MTC;0-<+/J)HT#F11Z*3RVTL@&0B)YG+;Y*Y](K%+P!O47PHM P&>?+JX8/04
MZ-[@$QDF_1>97$)7+YNJ'5#R[:U!MDI?LS8/>-:@I,MWS$GPJ!VY;(&1[\5#
M^U7H7DMBM!(M&=!D@[9$A^O3HD1C;NS0MW<[N]R^=WBQ&>B2,5*/+@"?QVGJ
M8,0"W8@TFJ%=964?U:KQO[W+JO"/-?@F1X:A]2_"XJ3+<@=SONTQ*X@W#>BN
M#YWXMEWMV?^!DJ5$]TZHSWWO(SRQ04_(5J+LFSMK4+)F[]F!.%:Z'N9#A 2.
M BM0SPS5&-R_^$HH^UE:*5C,2:#C"#G++00[ZX&H(PEZ4L^@C?SVS<_XYO.T
M^!0NOB#E62U)'[^ZA+\J/[KD^"UGTD[F4-K(69+)<*!<O(6H-_2I >]/ZTLR
M,)6=Y&H>FK+;68$Z6CXR?O8(H5.$5,I96[GI=V.!U10+'S="VQ#X9FCG2FOB
M887IF^5ISMT*GL1!DB U_C/?3Q]5J*+WOR2F6Y$%)XEI;E[4^$EB:LSV]Q8>
M_[EA% 7K2^-P@-'; FW*;+<4M+R#-N*6HZCW=I.]+S?C/NY1L?5G**BJ:B?6
M6AO8-X6Q+VU$S9,!57P?R\WPO72VF$DOU.*[.(V,R',O(^Y]N>1S9RR33EM'
M+RTV[W=6KCF$Z9"IJJS3W>/-DHEU;)5$B1QWFNDQW=SV!B3?L[FQV/XX%4%\
MY^/VX)-)I_TK)3UV"4*70:2N7$.;ERPP\XF;2X&DP'!J6M%RLY;!+Z$N-S1T
M&6P :U&BJ"4-#!->.--'='?<]<V7(92_[!JX?6">)['6\E:J:@XXYOJX>(CK
M!Y;N(\^P0U39@;RQ@M]\?YJS[/%S_.A HE*DY1Q1=$)[T.%624F55I19TS<]
MJF*B;R>"3K(GUR!]96YJNU;Q-5(D5SL]W\1TXM8F@QZ8V??>Z8[H/R>$NDC"
ML/[4ZS@]L;$B;E\CD^V<\2NF2N*7PCRU)UV\J)B7:IQ"+23A06F7W6>N/ C9
M'6_$QSK'[IK[\_I6B2\A)?9I[R\;(JM_UB5L.6YQVUDEJL1Y6$:W3\: 53\O
MEK199($_V*WU7KO3KDEC^P27-NOKE .;0D&KWCD1;KHZV*5:5=6;I &W&)3)
M@$BCOFD:+"D 2Z-B;G1_B*ON1+K&)6]ZFK$(KGD]V3\."R'4Y%K6I#);!<IE
M/LQJ3V MH<:M1LVP@%)\<&&A='JPY2DX?,ESS]6[#_[S,'X2%NL9,^_T3H'O
MA[T%_^!\%&SOMN9RAU(NYQ(PUDLG&.XP<W&U=E!MP)W#6J\_<\+A&HS/%3Y?
M@95RFV;#V:![F5_?E0ER9\--9/9/5,62 ;Y1Y3#W*QV8ST92=C)K&TA$@GY/
MB118A'\""Q_M6%&2)+P>(DG:Q\G(Q#G;C53>*56&T)2]^['X)68HF7_EKE'R
M*&(-5)K6HLC7+./=\SOA EZ<"G(AY^IDZ7)T7@(59;1$\N7]!6Y&;GI_>:/J
M#W' F)A+@V$^G-JWI*J/\G,\)A\=QQ\PEE:DF6#-?\4Y:WB<E4:S93^N>]2F
MU953N7&)#*@%BS9?BI?@UFT;Z.8Z][!?PYK/#\"AY4L&X,6@?#]PEK,R2?IA
MK87V&U5,MXL;/P"4GME,GFDYOLY5X94P;#O8](AV7:1^%RF4)8!^&MW/V7F2
M7"Q33?XWM\EY!Z\.I0I"UP<1,[+;HCS3VR060-2BNJX+)82#F+ZT^Y!92*C7
M'C[W1JJ<R-8+ETAVO_P,2O\+:Q>DCAO!MTDC:6>>#TM.(#AL.]F9#G*1^D$W
M#3W;.6W)@->7D=.<\VD%G;MBUB.L^?V;BXLKT"V;=P?!H]D59D>):67JFRQ.
MZ"D@B9X,8 "W.A6.M7Y!B+ZZ(#JG-U0R[QU1GY&V;62)-3OX@&GW)S!]!]NQ
M;L47K,ONB#@(;\VGO"_\Q#)L_"G?7]OWSE (82?]I]>"&Q\8-=WMXZ;083V<
MH3F.VJZVU$7^&!8K$G-<\@G-#SY)'C\MIHPM1/MJ2!WJ;.1@G$B,V^^155+\
MTNO'+?:MQM"1 Z(AZ*6G-1G@%SF'B",#K(DT][%,K9M7!\'P/8<>[BNEBWPI
M:OK2>V?]?3%4WD26(G8\$S_/A\#@-3+@@?LBLSLO]NH(2FSW1-K7\Q]__7MK
M:8@0T.N90#@F$E<ZT1KG[% R O)P+7\3+WB7#&@8LEDK\!E%[7="#3'LP*MU
MY_)M)<Y=??; =%KM9!*YBMVI(NZ=]PWF6!_H+@$_;5'+F/B7M0O+_W?MPGT-
MRH-7(#P&78+Q&%OHB/8([A(OX_G>L=$'@;8JV58N;(,S;@0" CY!=@(/?OM*
M[_AH?D^D2?)B%7CI'*C^Q#]G\@ID.^U$A>AA#YME142S=J7,&0H_XR-,YBD/
MM6%YTLO5]R$K91MBXA&"G)%[\-$H] (N5"8H/H^H8YT>(H3NS?W3$ZO_'1 H
M?5B2(5_\0"_ZUQO OM123<ZF &90O4ZZBE.HTDNY4;JO^RY\QCE#;-WL289^
MY6?T3'IU\MK]U+)HBYQL/>-Z1FSVAWG(-:^O:Y4U637)\F8=S-\4YH(,E%JH
M406+3$S=/-;/7F46I?3IJ3)R_<_]JR)+M$R+"-]<Y(>BBAX+\^(6Z5;JJ'HO
MNJEPJEPB@!LC.'?Q:?1[@PE>?5UM_;</VW$]6!\MG/*<S9!HY:2]A)7P:X\7
MV3$<.NF7+X*"](5V:ULM^(?J[!#3D+L_N\UGINJ/N!U3NZBL* &7&PS36B(_
MUE2UTC$^6_<N3XC6B6-SY[.J>TXH013O;VDHK@\BK=/&23K!INF0FDGA5*;R
MF/>O(RL[Z":!&Y2'D;-RG<"O<V^&2I/E"TWP4_!.(,M'Q!/Q@MP!G#<\Z6[D
M./C BS29.-$&XZG\G<+F-%B0!<;AGGO&OB,!O.G0"GOLQ,C'@<R;<P_354/X
MAP1O71+TNPW@^*!4S\<2EAN6MZ:S4 LT^-"L0J,3#0+=/K&[]^O_[J#])UV,
M <T%/\+ID%3-V4AUW\B ?@A8ZF_W]OO.5_SITOB?!894$5#G3((\9GBZJF#R
M@L@-=O[%1==#/:JW(**KW\6\,"LY_E;S4BL>AD6^=%DZ5)GNH$@]]?K;FG"4
MF:;'(D\ZIZF)H>J;/*40%Q]JPF'1*+J]U=P,/1K",^Q^_8Y9MOY IYF $Z<W
MG;XG3VW:<\ (3AU#TP)GOEG_8Y"5AHU-KVHSOO:]BV;[UJ@M=S)[3(3L/N.Q
MVODPEU]BVXL.CH2ZR*#684^"^I8E[./NHRTE&AP%B0?ZL'_/DK+WI=4UL .W
M0]5]FH6(!""_4H'0H-O,6'S;(9-M?&)@I(T30;]@X*%Z_]M+:;F,^U1-0/\:
MIL8I06/)&?%UW6J:@\+[<*3H7<!=07\=2BQO<;OUGL" ?5AUYD&5CL0S7C/3
MK =K;?WF/4!: A!C]/YMBE SJT-Y_J&U[=GH2!S;(M)T@S\="4K1&/)(JMU5
MZKH=QIA>P+AL<9N8!CTW7ZB\3_OD7N3F@/2JJ,@K3U:5M8D+EWP[>KQ%&)^N
M#:4?Y7;F+ @,?E"URT=(O,> &LB LP3Y&B9OW@^79!JNB"Z]333H/33IG&@'
MB@K5IH<8"&H75.=I5"W)WI<<%6;\=.+;$E[\M]U!"R.\;KNS6$,:0^CK^(LT
MTM.U9[$G@;9=F2!AD6O@KB4^:CKH6(Y?N;[T>XTWT/:9E3GS\X#]\U7?GHP-
M?U"KM".V&7S;%.CB&%1?Y&!<![(@;=*N0$6&MAQO5L3K8>8?MDV3&,46LUVN
MZU)U-7BL^' V=SLX\-7_>"CR+1KM=?DJ_Z>R.WL %\A^B$'NJ'^NUA0P>2CK
MKOY"8ME=\ ?Z22VL2I.&/=LF$#62)7W0DN>ZUPI+&>TF TJ7-Y:_>QKI@YD\
M\X;,P,*>@QO<<M&WFFFY W!F5!3>8<E^SF!=HT8;SSS/D#7)J2'#Y3$K8Z_^
MS,GAHA-? 5W=_/ ?&#B0'C8./M%\<VS8SYP"9:&.:870LDUVGJX(^'9%L\^G
MI3K\K%AK!B:H_6+N[YAG=C+TDDR5![-,;FL%7S_)G ?LJ+-PK,_ '7J!A1&A
M63@E?LMHR(!83E0#KZ2:X#M?&NDM7X:(?>PP+"9>%5U,S3@2J1.O,E?2\P(;
MX6:1#TXXOCD+1$$:D%<J+I3CS5;+>^X_^5A8(=NBIK)2<%'?M^K5 <(0T9F'
M[S[0Q.6X8RD;RE9K/@<ZZ*C<:1@LZ=:DH5PL\XZJ^)R*5UZ#+)<]SI8U]K$7
MFUI+4T%U[PJ\Y-O(*_3F7#[1G]VIN/^>>3JG,<%N*6.J&KPCD,(O[3+."-GJ
M:/ Z7@$Z+H^Q#J3(&22^OUX0W/,D-+E2+3),Z2;.J4$:VX.FM1[5-)%8+.B)
MA[JC H3A%,]F3I)2V\@@)=YZ34TZ!A3Q6\=3LR\+59,Z]RZ%?$TD[&"!P5(@
M)@@3:W:)CQ21L%F]E% *"^B[W/!&WM#*MT 6%L^'E.E9+-DI^YWGBH\R).B,
MV LMTHWMSJLN??,D48TXOJI5,M/*[I&(LZ(6[UO8]3N_N-=\^4O[\/Z.<9TP
MQMU<@ QHSEC!C'U$V^5%G82='[__KOS[QP&DIBULJ]% 3?-. ^6(GY(HL0@F
M9;'.R9W6F*CUJ_+8,&T'S#SAA,J^<;4PXOO/.U-EJ?[UKXLRT"E#,C/7%(Q<
M'=PY-LN/"X=*)A\T1JO:&?M?F WCG#02 Q<\7U&ANW_%?Q67EHS.ZZJP>Z23
MV^?)U&Z*;$;2FT%8I08G)N\WU+WXJ!$CQS^/^WP,4X3LY3201,NQR^_=?L):
M&"N1[Q_11SR247NRQ4R/,UJL\$$T E'1)Y/$.LKI*W@U:BWQDO:OP.OCSM>7
MA,?X%E]$:U_@\!Z-3;;::6W4CJX;14>JB[0)*R0+@MQ)-M.21G28PWGU]S#>
M)N188H&#IYIIT_RA$<WZ#O#G_K-([RVA6<$G*0(N/29':587V]*7 FI./F29
M\-_-N($M)+%^*%,.L?;9T&9Y[;--$U%NFNJ?#.Z6&_S8H! 1!<8Y7QUSY-2!
MV056&P-\3T2(8F<#YQ)2JOX&07E$B<<S>MEX1-3"A-MU4?G'E\U!!;6 8B#B
M28^/B:.9L%N28[]Z;$2[\"T-H<ZTMV*;JI@VU32;$"[K#RQ=21I#E>??9'TZ
MXSE+V0,%8S/FSV=A UII?9UK9C2K>(1?N[8(K/F:%U\$*?=1[ZZM* %QY@H.
M\^9LRM'8U]=TJQ_2-H=M=F[(Q_31Z0MMO!EW! *FK#RL1G-\HW:EL,/88/VW
M%BG:H[-,#?C>,,Y;4[>C)YHK'6DW46'7MVZI$-'R9,"%A0.J/3:-@==['.*C
MVH.;&>6EE6&JE^@O"?*S4SQ5 ,YQB#74<Y3U2_HX.UC:)QG @R,]+*>"%Q)1
MB)!?SCOM3^O[S<1&AXX+KE^6?6CFI3AV$BP64C^>%N[_LZ#.Y^ S;H@,N @5
M8+@+01"X3:->E4]^>\]_IUZ?CHH%0#F4.DMOUO?'TNRCQ.$$@WS6V^Y\I8IB
M9ECKH+E/.<8C;D1^F2F\^]";Y=4?(?&J6-X8M.QCE':N5=[]GZ]*?VA\A@EJ
MP<S667L./TH)[-,^VH*LCT^XQ3-=-A_#QQ@J2*##S1I1+7>S0^'2*?"+1]8?
MBITGZ?L")MD#P,8XG\F!G)^KWW;3)BP.B@='G^RKA>Q&^I$!UV_AJF=MW9EH
M./-?PWKAU&$4-U@FD1O%"]XN\D89HQW#68(2;DL%_7N?U]0*&.;*3KQ$J20U
M?UYB9:'-M]6JNX'?G#FR8LNM37(^S^G=6TBTD][XX&/?-<V+%4V:)5+O&@\7
M1??J5&CM=)$!7RFK^0 4G=S4A#W<%#9-']>,?N(JBC=G'8LM*>ZE1QQ.#$]4
M;_:Y%>J@*.<KEELW/38.LC7!M";5>)[<V:XIA7&JPX\KH/<^T3KRF,@YZ4*L
M:RO]:ASU\_)(.B]H]^>J2$7?L=T/VWMG(W]V%U]I>.*9K!9-B#\Z"5= 8$2;
M)@OHA8I3+XDB"R,S6Y2!#6WQ9YR!?$,50]9GE5;(@%2[U"*X=DX?Z3W.H[G&
MX_V>IB+7HPI-1:5AA1_?PMY0N?AJR'&G:G /@\_AQ!YAJ()$)+58Q\S&S1 <
M*#5%\]ZWBKU[#85=1V'MM^/N9B<JOT8:^N#8V=]\VN:K)9X)X4?<V//_>X78
M7_W;4,/=S4X,VFHT:N^T0=2I__/FAVL^6.@3?8&M#"ADL+1QSB%^4KIXYN'"
M6R[%4FY@%")1:(\,0,LT3PFA/3XXNHF8LVWL?,+V<)[]U*&TGLOU?7GM(L<Z
MF@Q@@77 %#!;6=S>!LFPF\53^-HD.WWI=H>.C0N@QY'>^%\YXAD;C*REB\[;
MP\";"<_M\4:&B36^D5<07L1HDJ#MB2K7R#=;W_V9?#=/A=W(\Y>>^'4RP&22
M\@=TZKS<?)11,[R$#&CA<&%9J*LH[VO*8!XYF#/)?-%_+_*MN$^R40PNH\D;
MZ5^14%[HV.2@=,RUJ\J_)B^>&I93PG+^IW=TL^6<\-U$6-CN35:<G%IM^$^=
MH5J?CT5?(VRY-;Y%J61&%5M9<=WPOQN@;[0<V8A ";4 +]I$])793W-:$Y=2
M),B _,[%=*=9I2FZ;"^@"U0!ES1'!H2PWAYR8QM.%CT[LKW30PF<<]O<7W%N
ME,(8;U167IQ:YR0#EL?PEWCOQ@F8V(FV&YQ(NVAO955&3>.1UPJ@[-[O]AYO
MQL;OU6;^^/'F8\;D'W/@_53L^-MZ*V(55"]+8W9*XI[6H^LC3'H1JQNZ6\Y7
M0@PFQ_!U-?.ROSU_"\7CVO&6D_9 VP$H=:&-0Y=2B3C:"+C723<)W.3T6LE)
M//)?6H.L!_/]B-,,#3:N[>:Z;F,Y%.W%6]\NU"78E.G,6%[9C>@MV94+M-+6
M=;.#P#*?&GF2 6>@T%2.JI'V#Q47A6W88KHCH;7PNI= 6:JA$+23\)8D/E>D
MZ&LT"BV-POSZP$'WC>H39'W.,$5S1P.DLI2E_087HYX'ZZIQ;_N&[6[N <@[
MU!TMOB#PWW3N'2H&AL,"C;K3BEM3PU!T'[?FPSA\':\*I%0+.3YEH%FAN2BQ
M7NY-?1R!5/R][O/8++RPJ_"8E(.R>DI,99$G:),!.2LGF8(G5?&??6'B?XQG
MB!9PL"E3$Y%BW]QEO4O;D,UMR2RH?4IUR_?X\H)!T]5<G@M"E8^SF%6[M#O9
MO)=J<W V&M5#^V8_"EZ+C$++?HT9 (<. "X:#8B/2HJPP9J@EJ TU;['-3:!
M+@:]4XF[4V1 3=K&X?:*;&\8F%UJ)HRU$C^*YXRBN0;)?M#2#G3X!0_'$M2'
M9BE,@+0PIO491JG%04E-A\8WCJ*9'8%3.EAYF"=E3,0YWQ%*H9R R)$[6JYB
MU?!&4M2.[*\FSUP?]KO]Q&T2Q8<30Z>SMQ <$2G_R?O;#(\/G&"_$E9R>$"9
MR^<G)U6=!^7!%D5Z'E3!&$:N&JR7_E9_LL6B?-8G  PEW,()?27<Z">$*X$J
M[%WYF4P_=RF,1WXEK=FD1[;S)>Y1+Q:VL%>P9M&T_UK)BK&X.!2;"67#]!ZH
M8YW"JR8ACZ89BJG?5BSPY+QM9PZ]\6[-./+U* C+=? :BVA.DT:;T6WZBLCA
M8<F70C*&1]EBUM04>V#!>L_N])8(YDAHQE<1.'Y7Q?0M+&K-5!_)71HPZXIN
MV63_Z"'T[48NQP7%_ D2&VF4\S8&' O)E\4J)=8YU+F(,OAH^NL0+LG,@74)
M#XE)4$8LL.='8C.>SP":5K7:H/9KNN@'BK00A@\YTD'';R#0O4'2AZ;AR'B$
M[2>AAX=OD<)1-\[&18N[ "BY<Y_+1UEL*KRE$@_),3$Y@&>0 8$V40J<8F>.
M5N6+UO?5\W'S!],EI.9W4)ZLQ^XF\>(:N=_I)SAGSSDEDVZXK7<@N$,/*G$I
M',NIJ(6KJLG$A((;.Z2$"R=ZC1/!GEZ[:N7YZ,[BT\']H?G<R)8A#U?(H,HV
MW ]97A'?&ARO-K09_QA[J^V9L,TATPWW.PL+5^0$71NXK_U6K$<*UBD63>$L
MGQ4/%_#8.@DOF:#=91>UG?<4Z4H0PS0FK</E3_B;.MXU*,U+8<?;SC/?C8H5
MX1)-*?"5-@F-X[TL)1,LPJ '5O)1_G<*G*GB88.)OFTY&(G6.V9G7CU,3_$G
M USD,CP(L1H$H=T\I*%[?K<(2+V^9BA1<O#;NX5J.S5=-8:XCJT[B82RD2WA
MK8K\HSW\V_+B:+1Z597UY,NP$L',PX:&W@K?=KJGCLFK$P^VX6"<Y4+9=Q[]
M:_5K,Z/3^D6U<YPISOE0?4Q*Q7=>ZV&124;2E5(A"1C@&LX =)D@CU4/K<O(
M\(3K#5E^_A2C_'J)*R!@=]X6@.U$E/S+D2WC33H?=C00Z]N72#<2Q43Y;QW%
M]>A,']56SUZ5I;QQ+<:B_D5$5F"&$-)K(U*>ZGVN1>;K\BV?/[:+OP"A?\[U
MJJ>5:?]IP,4?H"-FH9K]KZ#$V/+/QD29BUE3N!UDEB]\7HS%3HD"LSE246@N
M4AC[8V'?QK$CHY:S^=AH.:A-+#0QK8V.@>/1/JS'ZL*=<1.!KD86I9]C&(WM
M=V,48)THW5Q!TKB8.QB\H\ ^7<ZE/BZS+1&0GK+X(TQI9$R;TC+L&)9> Z(D
MR&'I6ASTA-TXQ"&C?'32TJU7MLQ[J4'@QZ/3CYS?/\O<B,)BP[*/7A9U(VE)
MHIY)<UI3OZ:!=0^OKCNA1):"7T685T]\\F*>]#K+"5D!4Y$F^Z4[ZO3F1E0(
M1J:/$X"'J[W P_&"'LL#IJ'Y@<V% 8(F1"EC42S-R9V&V\):R2%:5%MB4,A"
M9I[.KUX!HW8X!)5WYRDE [J'O^ ?&._S2)3#?X9@K(@)7WZ:NN#35EW'(D<Q
M0@\V#Q$XJLG_A[WWCFJJV_:&@X@H(H@TJ5%!4:I2I"81D28"(E($(4H7!*2W
MD" (2!<0$!2B@A0ID=X)'>F=T'NO"360]O&<^W[?^YQS[WGN&=][SCW/.X9_
MS#%VQEPS8^^UYUSS-]>:>\[)\_B]:0C7NJ9THWZ6\X2((^/(0O=GQH@6TCC&
M[OOJD!%O,HB<ZG$N[OW9&HV0\2N7]O@Q"V):C*=0G;/G'BUIA#WX^*@R03/D
MH,5J)S^0Z^+/NZ\89+J$@C(8%5OEW#A-;=:"W,!0."?28159$MRP <;6T7LW
M?[LH0U#._7[RB(P;1-\_!O#[0:2O&?A\YR3]=P+YV,:3D 11-HTL2/6ED],,
M[4B7+@!.4&BH84'FI>2@FE#Q^(Z=E=1:7;U6Z[X<\MC^&-P0H;S72WLEWQ;R
M$?N?W@2;5#W;WO2E757C6=O5GBEMB.";\0C<V#6Y(GR%V#]^D[30^&%A^ BI
MU0 P8">(X%T4^\!,*YQ!86=V]JX3Q\9";EK$6%JI/$)4Y%R\OKN4Q7^T!XNW
M_Z#-K-=KI"*V!;?NLRR3Z4G_#K(XCM._A@HM=5O\T],?WN-#L"W'JP^+I&Z&
MW9#&S:<?',P/K5Y'';O5(^Z 2,6\O- RK<?S&;16(>_-)>>NNG9W,X:C"]%O
MX1?&U3V*BZ&,$F8@%18*P&"Y (4%PH/SNUF7R*PX!]1TLA6/P3UT@G9-V&8[
MTZI\-G4#];(BZU&"DR/K^ 5%!75)\1NJD<KT.1G^IT'*L'Q<X3XD<FF#$^/7
M:Y:0D*!L55^:%1BE?<#(^^:5T,9-V0XA,?.P-4SJ'CD'EB<F%">P\6K*0V_9
M%4U' ;QD9/0,T_"L>HI;YLRMLIS4T[?S\3NE_L B&_'#):5Q-UL:6%+J=[EJ
M^]&848K"W ;3:#/S6M [Z17HV7>/WZF<3LM;L?!4UVPW\7ZZ\*3DJK*JIAS2
MV[-ROPH+#IG)W-H-"\:XG:G;?LFG$O(N<CL>>(G8NGYZL>8./A'GTXAD+884
MK7F\&>-CIGDC:WB) G#S0>Y':E<[Z>UJUP%';A^TL,4;'81DR#D$RN7T&-^I
M[78-?N?2RQ))C%V6D7K8\*S@0T7!5.7@T17+MTU6C_:=Q@K&%CVW_.!<^(!9
MJQ^2&R?J-M,NBG=,"=^\01: ^\$SN*FAMC N4@(,A,6T#KA=YJV>I6DX&Q)[
M<!-X9!%<1L8M1=[>1>ECNP-WD;0OSJ]XB[R1<POG6PABK>W. AFFS,\G#:(^
MM%BS.AD$0MPA87L4 -]4O641=O\]:05.!64BCZ;0DAMQ>PEO/T?9EQ2>&C%D
M4,#[Z>ZVL1S-9&^T;2-&?6HI .Q'V)7!>SI;U?VW,L>F70@_/**:SN+60A?:
M<$"#)A5MZ]1CFZN3DZ #3S'REQJAHK?1Z\ES47@ELLB(4>>U,1'+<V\2%1S-
MZ%77JF@H@-=)) "J=<TXZZ7#ES)_E5#/I^K<88.&W/[@(+1V#3>^0HS7$ZB,
MF1DC)[\L4,ONM>!60P<$ 0-]N!6#%S[9Y55 ^H^V%3J22B6O*N\.+"]_#3UD
M7OF[<?*?@.A)"--\;'.83[:MQUF[Y];,FI*Y1$%(XCI@/H8&YH@[N]^#$\W-
M;&5_\R5,J=_@[6)9X+4RQ/[;EU\I@,J /:EQ\OCDU8I\[%90D9J%1<F 0))/
MX*,[B.O7!L&IXLQ1>KR#N";?/.WXWBQE,R%1J_V:EK9%S]5W6>LO*HU=)JHD
M"!;' 9YJV<1W#6M4K<N'39$^-FZGH+=BB(=V;54N<YV.L[>K;Z/R)J4F^K%A
M?3*Z"E?$L)D4P-JG3TE+V8,0JZE@(^W&[A"=E21,TM!Y8]"8$K/]3F@!(-P[
M4+Z\1<$\LGCW0FI0W0TSOI,Y%7S->D*SGVS*I3T&8J>CU@]SB*;5QAE3Z9[.
M HVC 6+BYM_O,4XZP@/0"L J&/MT,M<,.8 A^LO(U>1/L$_.V](>[JL=OMK;
MN280[9*^G&>%!:610WTGF9KHK[,RJ=X!+ LVP4[)W\J.C*]0?HGN( CSGDJY
M(&<G.O.7,/OR;UCT<7'GM7,^RNA^4<7;F))M8XVHS8HXR)?L(EW-#-=K>3G=
M[2B@)Y\.WFVV4TEQH)^=#17XCE[XI]<3]N%(WPHWUFZ#%4PC,'"2"X],STU!
M9^1V)Y#39QA:OT#69>9]Y7AGJ\RV]KFPV:J0D>(-,UFZTMC%#XEZ/]PWZ^G]
MG#Z9@P</RF#[;SY75P^@J>?6%EA3I=>+55O(',%:93C>!%Z4A/$+33?.B0??
M#=.,@W9>M\Y)'7VT=J%92&-G*U"5*LI$L42?UWD?_ELZ$:H=S>DI_1C+&"(F
MJ6DV7N?S<A@RX49FUYU0F^<\0(\8[!]C[#=6JXRTGJ%+G/>V2NHW]6='[R(&
M\]?#O8$S CW8G7#^?-=4TS"TF-;*GF*\&5]0YLIC??32HB_R>,9J@6;_&;KJ
MN6G>'U/N=]@[.Z)_5L,PR>N;P]O0,V9P/UWU4@N18NLN=$EP8_>Z-OVHY]TV
MD]*D/('*42]C-P=V\JFY;16>M7DH+=YTI[GF>K^D",C#9$KKQY?FNTO90$L.
M@6'.7GSR7#8RA%=F$*;H4JX\D-$:$G64&<R4,?W9>F#^ )6*,$,$^9BC<=7K
M3TO61""O-B@ $0M@Y'F@->L1_V/G3S13311 *62;&(U[Y"C>_ 0&^0K^B$4%
MK1.!,]72]_K[+9/#SYZ$9U#'@^?GD<YV^J%".^7JK>6@D?VLZ]G'_O4&_1]Z
MRG]"Z_?_FJBVO_U-22O8X-_D2=SA'/BW;V'\WT6LL;-(EI64LST.>Q%F*\+K
M(KHN/R=(+ SKV@"&]&\XVK>2% #=<JEW2;8;3PK2CB/F29H" )(HX/=;81LX
M'.:.7\B$/<?\2+%$!N<^)84VIF@[BC]P<SF\+L/3NE= K/%<3?Y:BOBZHS#N
M("ZCYA$[P@J_#;,=!-_R?-LM2M#DG'A;T'_P*H"P$9GGDS)!6PFG@['_A6NL
M6(%1*Q'$8/"S4I#ZFCRO6J*F/AZ$#=;'HV<M^]=?E_YX$UR-MFR[$WR87U=_
M<'1"==G1G\B>1H1@%])#4HW/V@DY[7EQ599OMI23/[#N&1+=%$IB&F8PU8=>
M1Q1  Q(24*_-HX/)Q9(16!KL5("KXQF\>[=2_\LKP9K%3U69K[],65=?;8Q1
M/\A]^SQR\A:W6O[GY<R;M#/:7VM./7K_T=FC?)].4+"5AD7GD4X+'CW#& !S
MYUZ#\Q94)A^-Y\ ?4P 'N)M3N7 8T12KCO?!<3WM&;IQI;BTS*IX1US]=8U-
MEP\QC?XH )H^N #DJ:%:F>+(N?3A*<)JK<2FU=&KU+DB!59.^ZA\696/?R>&
ML<?2*ZQ^<"%7X"<%P"C1W'$3:IC1J>G3CH,H7$<]&8181H5XV\_5UO 2;,4F
M4H86KZGPI@J?)MZ16H724@#F/@L#&WM0[J*'QK5K5U;.5[3U17===8H[N\KR
M:><GJC [\?D+I>0![=X)I)@V]=LLL)9*M;8M*='U+)*!R(Q=J!Z5=.F(,6%Y
M[I_-'[Y" 43&02*\(ZYDZ@'HJ6I/Q*/%<W6&L@2CLAVWP-MQ4O>9_)=SCA7,
MS/9?HKGAE>_#HZ/# P(TE %P/7RL8@46_5:*Y]K^[<C5-@]_Y>>1CZ.17U9!
M$5:822B0 K *<PSM3W91*]>4;[2[J'(A:GR"AO#E)X<^M=\X%L#W!7A+FR!*
MU Q:KU6XQ9_AWLOO\9 %?#C5OP9-GY%X +Z2]#X]532K$DCSMGU-YZ-.F-VW
M8H5\IC2W>X\Z6J@>6\2N0#.FZ(MDB1+8K08CO1XAMQ<9BO1MB,!&\U=$!M49
M4U8LW[X&XLSJ/IP/Y]JKG6F$_FB?7JO4PA55L2V-.^\%>'6:5N";KS14(MD\
M:_;IBT<>&JC$+4M/V1ZM;\I61\<:!KWI,Z,9(Y5T6_7A<FVV$+T_X\,7 P]I
M%R%-433HAJFW29MO'K^USSOCEX(M[>2@ &H,X;*H;^CG% "W;Z'R4-4-A<28
M+D7?EVD["S5L=T !-)#]ON.HU$&,>N/C7=Q+)FSM"N8!K5/"6V1#!\>^CBD0
M"VP!8E$U@C;>:3%>[MIB(PZM,KP/D$+,ZVG',9X?9MF9 @@4+J$ ;*="*0#(
M /X8\?R8R^VC  *.4?)N4NAU5#=C\;]]0^*_R7<4FHD*=-CK-'J@?'Z,11#N
M-0]QESJ ?#Z90O/TLF#,P]!*B[;[3,ZQ!:K!\/%7*Q*>2G=B?!K#G@2MD-OM
MPXORQ5_?V ?DP,@\:W.<*_#+G@0]?-SLQVH7@P38#K?JA=B"TRT3$;3/((_4
M%6)-4PD0<L<VT>!'^9!;=EBRF!)'Y,@T'7_9.UZU\=/#LAPM J][,"LR;MRH
M4W%>]D>[JO5#SAVW1'HC*8 ,?4]-7U\""U&BHC]WCY'3M-E,XV=$<NB/A;E)
M^AC?LX+'D^^&YNVOA^1/O89)9:IZN3L6+T64\DMOB\6V//B:.;'+'V5[</&Y
MAF?,]6CS$!;!K_0TU'Z =:&ZCL*W!FG+/2.;W>;4\5H1ROJEFN^.KG^MN7=T
MYV\/L]L0-HS^;&AVHG3%N*KCK#S_M;:5,L;QQB5"1CZ9N3L3@I1+2?3XNLI^
MFWUHVVC26*U7DSZ5/ISA]!6T@= 2>C1@'\$+ZI_'@5\[4@"L/#D(M/^MSO7[
M<N95H7+>D9!*J$[LHFE=#LAZLQKIB*?M7C0$OJPNEMH2(5( TXF0 M3&<?1S
MAC47':"@[$(!,!LR.R ]A%R<_1#9YJ0]'D8<U:KLD2U:8&-3X$=%I*=%S.0L
M.T/,9<&?M?/G?<[;;46--,PU0EB+(.L36O?"FMAN18$\3ZS>:OF4BDF?EF-.
M>4/EU6R\_K&QUW1MPGUG5T"XQ>=>II[W[@[H^.E1[\%O_PKH+*+'E&:M]P6"
M[!4N6XJ.=1HP3VPHY%:4GJ4 J)T.^1CV=O6SLHQM*NPGO_@(UKVP8]:6S.UE
M4A36[J$C=OPW*.YKZZN4271QS,'SW^J42S1V.O$V1Q5&;A,K$B<9L=5+$3"=
M=!LC[\W*FN3G2N&!W?K@-G'M'U)'+C/0<R-X2(.W0TA&>KO\1;;3)"U:8=_6
M5O \I@.9#VD Y4_A)_=%C=WBD67N%$!\ 6/+:<;"T*/ZHNY;\-'2_,C>W^8:
MD<BA!1SIVR^8A/Z69;<C4/7?XHC_X\U:+"*LY@I^, <_"Z6'2?<)%_F*7N2+
M<61>#:5C?YZ<'W22VU5&578M=!O!0M3'[Q D5XWT4W&G=C1P"8%; MN6\6V2
M)N'.37KQ,HE0&S/I&[K^\D[[@3 DP<LSC(!0QZ(:-'G%2O$?C0;,RC4,#RW"
M:>\)]+N40N_!>FC[PV9-Y,E,T;.GR@UWH_))5>-HJN<C:*_]L4Y8]LQ6*) 3
M\2)7PP"-]_#-P'/5#>ER>3J@/C^Y6NY0QM], =P^S7^=RH,J7@&I1?J<T^T'
ML>CTT?"W>O[\Z]B*O]YTP>)UQL4SQ%7,NL^WNF_D+CBCX<,;*3<<^!W6NR5B
MM&=>X^D .^AC1,M3<YDHBV]YCIV:72D8X-(?E9QP;I.*,!F.TZ[X3E=X#NEF
M>%OBG8LIDJ!&] J85@VX7!TZZ,;CH_-^;*5$6 OSBLKZI;.>LS@M?T&D1/0L
M!8!]*,5I<M# X\T8<]3]\ ,?ZN1T_1S2[).O)F3_TV,,V@X2X'UUR*(H8J;\
M9JF@Q]-/N*UY/_A[*A\"[7Y664]"8\AL+IM0>M@&=0/"XJT:R\Z""X/T?AUL
M?\+T(^$F$0;A@5WV$"%]?4'FZ[,T]E49O7GW@N+8E8"VH-&&%_.L4NO%N*7U
MCE0E$@I^RV9_ZNJG]-FE=FY _8H:P)M1UN\SXX_E/]B23X4)98ZJSOCR&*VR
M6A:^.6\!"/CATW-JC]6 \*B;#)^F -!A9$F$[1,*H'L<>(!#-/N)Z.@ABH4I
M@*5-1@(>/:>Z_PU))-51  AVHLV)P5^"OP1_"?X2_"7X2_"7X/_=@K/0(L8-
M+GML^M YB*J:%.2\R1<W^L/0$3G:5W(Q+H$_E]5!5(?4C_$K.%J#*FD)SP;#
MT+LN)4,;T]J$67'V790'[7N#IH91$V40:F#[EFR<L$*YB#L\7@?*#.,AY15/
MT.J6]E<]EQUR#4E^.*4&*"NFC6A\O9.YJKC4LP]YHHE3JBM9JX"R+3N)9:\^
MS%Q:'6P-;5^;$6B]ZK/>VQ_<W-NHFB0ZF:&M_"H!RE/#.[+4@8M\-VR/KJAX
M MGEQFT][0Z%V**"1T7#?$%!E6Q9F:K,'WUDOB0<]%%MYVU\ *3,#S'5FUW;
MX'3<M"IH[ VM3")TH6<%FKK/PD2+(S41CPRO)7S(O:++O\WX,.#S@0SOWN*1
MQ\8W[-$15DG2J!G)Z[0?%G;OQEZ]O/0*E-DSMM$[.*QX;,+\<9E=-J&5ON!G
M2_DZ",!--0P0$J_IBE12O#MH[+P--DUW>M*UVZ>V-S5*/3>XU;1AO5X2I*%-
M/ZJFF9LU\PWT_^:$ A^I+]2P$(4&R2*>*2"A!]J"- T3DQ6Q/$6(27#:ONG2
M&+\+F:VG.X2H\<UFS87U(W1"]:7H-4)TPK/*J%*I(Q 64P?GPAO/O)6TOV)S
M M4-:E"KL?SM&'@)57KG)HU=9)-N6Z:@)!O*<<?*\X'"#EU>KD$&=%L21C7-
MPS=3&F1?I,DYU5;ZUG+^I5>L>J2%RT342NU% -WR*NKWBD(>**0 D&60K6,P
M' %'W+B?]BEM<V3?*314)[1 ^;O@WQ^L^(=<@-'7[Q3 []0U:D,#<D@(()/%
M\#TTOR1_2?Z2_"=(.D]=K+H O@R3PKC>>9UGY==JWZ(>NQ2U\XRV)XG8:2G8
M9'A>L8ZV&)[[5_^/5D#84 "TRM-3848=^I7G @F^-</-BB8%%PSI71N"+^Z>
MJ&D(QK&Y-*#UCLC!'4N2KA&6RQ2 T@9DA )H 1Z'H3=Z]CCX=\2>1ZU[/-U9
M;-F.\1VV=\2S>HO 7A NX(] 0J9#,#$ON2::7;/ML8Z75(*OIGT*WB$VDGT#
M2%G6% #D%>*W4S9.;*$P9#!?UW_,[?C_LWEK3I66-C1K^R)_%BOK_=63 D?C
M$3L'M"0B%(>ZN?6G<[:_!'\)_A+\]PFJ'16'VW0=E"R'BC_Y]A"PMW:':2UI
M(2JHR*=:5[=<0^.L84>AYN69QPB)88:T=T([Z+FH9HVM<%Y!NY(IQU2C^,CZ
M#F19XL(8J:16H/_U: 4%,&HW-T?4&!R[VVMEB6T*1_IJ@<<NS75 UAG<HQKW
M6Y*(M_ >")Q\D_LHZ&-NU0./\8G6>N-&1F%?[6?R,>#B@T334S*"CJQO^_0)
M_^N+GP_F5T.3&GH'X8[$R.Q]!)[/#>?3.);'IJ8@;U&'<C#P)S6J(:I\4AJ0
M=Q"*NQ-R&-7^C?67GR.'NB:E0J^;/16\?A' ^$"?W;\*,D,! #QMNY5ZYTO]
MNT9>25S9C$:'#!^8>0D<Z2_];@[M%EVX8?F#CD7Z[7L@(@.#S'UW@K;S'\QK
M56SOO_U=_N."X(>D;+3U5&$Q)E)!UIZ0?DU3O^LJ(:-JE=9QR]MWZRFL?09]
MP1;,A!'>BQ!<R!7;X+^@+'AT<-+CI,5YSTO1T*P+MFSBS3\/;F^&WVSKNW&2
MM[GF BF]AGZ$*(-)'=R5_6Q/_2C:WYC?KSBGK/6.1,P;BX"Q+QO(DM8=&B/(
M8U3VRF(E\$;BLV3IO5 H1$QB-2J0 @!62<UMT;3DF*[JRUT=EPD]FMR>,6-2
MC_R<SZ$T ,Q</><A!PS;%6-VX 079]A^@Q\,.\Q]!)JD818"C?KV-#K9'_H3
MM"N2VK9/3;$V,NCT5BOR"*YB2;*R<BZE%IH*BT[J6M(0@^NH"Z0DLARBOA/;
M.)0TT:$^RR-]PHOKM"@?Q/V.#,?ZG4VJK=!]R/_&$9AF3*H"2/5^^O*1MY2Y
M*5W:;<L_ A;/7OXM)LE>->7OVTT&+^ZODB>%[&R27EB(,\8]OJ ]?R-MK(!M
MM'!IZK\Y[=D6"R"*><U!65XDL:54YFUE&#Z<N^PR&%40'KM^SH:HA1OL;HSB
MMJVY5#[^=55WOK&%]%CI;3_VH<2JLP^F9RK?VL\^-^C+G*;R;*3*A'5&3C@5
M-=GHIP3^.K@;^E59]4:M"1%*<*$ Q%J!K-=VA"T3&H[X5L7H\ [==62N?E=-
MT.TGP[4_5%=?R9IO:JD?7"NV_8-(R..&K+1 )7CP*JO%'Z"S/@[;T.R_ C20
MWRGR';;,[^C_C5M2?Z_'5+:ARL]JSSLS7@HU^A>E"5$M(($UH!<0:IAXZ87/
M S!%GP^[G=<D=KH%-!L9[IY0T88#YC'L!%D8XY!P<24ZA )@,IST)!C2I/HK
M-G]DIG])C7^:QTZ]B6J?^![<Y#A,T,5'X6R76MP13**20O7/;[_+^[@DE9'
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M-.3]4^.P": U6UKL;_,9_N^O)/X?5(];+!<(@C'.\ICR6OWHWQ0UGX.(JW1
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MOKC00*_1JZ,"R"[2@5X;<U@_XH_Y+0QX=/&7-_\S4U7WG'6+IL!T5P)5"MN
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M5(<.1L>'W@'CY^VV?B0&<CO'?'/%(%:0/"%U@W5%J[:)1[%?5_8KM*+,S<T
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M[!T(;O2P^4X8W]OA@A/N^1?YW672,:./V['%5JM:2?9($7J'*Y\>\\GS^U(
M6.A^4@]9Z.FU.#>J7MC=VO=%'E/<T_2Q7-,N?EI]5+O=4NM[AZKIM@9&HM_L
M$);R8Z;&:H5*DM;TD1F7HAH-5B@ /^*]21&L?F"NW)O8A_E!"P.N^A8TP=/J
MJ/#.;?RS!<[W-1RNZ]V9[4X%C1ETR O2-E]##_O'_L\<'XJ#]+4&;$P4Z$47
M%F$B$2RFJA_X9)Z_#(Z2:EDJXDWSIC;N^:*@K'P_J=)*ZGM].(]Z-=-K@A:\
MIWU:7A9V:V;-#Z;ZZD-96?C2^JWH-0H =%K!F\%7:%9F+N5HA2_"HJPLL?Y[
MIO!F(Y;665UR;6PL0FO;IS(KK;PBN2.FDX_-VLQ9'=0JM0]=KR3((^J%'!UG
MMYB-*(#&5;T)<VO!'9LWOOL\:7REV"@X$AY'GW#.(P<Y.74(Y":5V$$+H,=O
M5D)I6G6],LW3ND%EIUG.)"\W=^JSF)T;9SM/DMMIB>9C@'KSB$%<.Q_O,;,5
MI'!50C/5$Z'9+^!0:#3Z%?+ _!5'2[&KI$$]IFFH4;W-V7MWV=>-&R1X2^>-
M.Z$^]'J>1-IO^&C1;2H(S(23FJD<A$E]FYK@+>RVB>#S->: 1+Q8!G/T*8B]
MV#<!:A3V;> [W%\)WW<:WZ 6&!]*9DW-DN8U$#!CN8(4-SHV^B?Q_Z,;0[_P
MXK^(OH]&?K%/6SF0QA1^*_Y69"_<K_8J,U3<$'F'!K2KF'^(QLW=*<=N-3.R
MCDWPW?CX,&GS]C.XYX+YE7<^V.&C@*>LWK0MP%!QF!%N8RB/N?5'"+S=DN/B
M<[H81<?]$+.6?IF-)S7G\)JS6V]ONTS@$4IE [G/$(+JT=$LMR5*A56T3J_T
M\PVA#5.E-1AI33*+XKJ[;/\?]KXSJLFV2S=65)HHB( 0!10U(@HB4B,@("!$
M1+H0D2[2I:>H2&\" @)2I$@GTGM"[[UW"+T%$B A)"0<WF_6S)DY9V;6F;6^
M;\WY,3_N?UG)L_+L?>WKNG=KG="-3"THV'06W^_=],U=*X>>W=M@-%K=$ME<
M2L"YS6'G1$!%7V0OS/GT[:[:+J)X#T\04(V)9V?U1DJ:PSJ4)P6,.HKA/TF7
M[-JX-N4%9*P$]1[.87ALP:Q$LG@H"V%SFW]NX7N$=QI*67L54?M4O#7T%U,O
M:Z>RK8KKQ.I:PTC,28SX\SWP*VO4?;(084.97/_;T[8<,CKW8FJM:RI9+^0(
M< F1]FL3DC6ZPI'5\W5:*J@;Z**9#E+29%D[]@W]^'\C@5V0;#5.5OB5>J_,
M !''_O'F[\%/1-L\G@%UKWL[>^NI0MGIXU!V#/8&X1D?6^$/<;](6&=JIG^E
M  ]R[H(3T9(W=Z 3C^(*>$VQI[%<L[QAFE5)7%N'T0IL]9($1QQ<C17,9'&+
MW3(#?)NM0JNRU7H31X#"(T##+/D9[!)=L#;8,KO@MG5C ;?T6X3\$> 4=6;!
M*@-6CA?"_DSFD./7M[$/^=@&F7!8-'G<D&[ALMYZ 3S3^YYVPX^]/) _\,J3
M?H6<VW4OGP!8U2@O]MFSZTUMB+.#J3+WTEA6A *2-6J]"O>TE&"JQ'\8&?O;
MX5B&7D6 /:!8YN#6K#<\.(O!!VNZ83(+$8T/CP QMEN>>V=3M4,X'R5&]"NR
MZEW6>I7&>4<N@(PD?267NA/,YIEQHS\:58K<R@9QC1:Z#YPPP!EGB<M[O+Z>
MH>QZK3V:SLXQFW2_QCX_[N_6@[HA.F&QV-GP4K!?TOU!(NV^0O$DN/?*<X,T
ML-=CDL#.')&#$HK%V<\V59U-R)VX9.> 2ZL*EG6K\@/^0K6KT?AH<7(WK.7N
MDZ&_UN(MMF@JSXO\1G8&WMPK+,IZ-;;U->PJXHDDQX;%L+#0V5Z?^<.[T7<]
M?K3JI"&,178/>XV/B<8T6/@?ZO@'R:0&LCBM-NW84.PRY!,5&AY4?;66C#DQ
M '%./ ;9(X ;^L=O=6X-GE;^>Q$5=]L:;WQ>/[=74'/_EH=:3IX4XO9RT\LP
M_H3,^YE+2+]#)216V*M5?U#H\3[I56#J-Z^P)O?3YFQ3ET![R5ADDS1K$!_C
MG]&\Y]JBFQ4^D@]>/*QE[=LCGN8CXK=Q7'@X_3)YG-[.@WS[7BFS$)$JA[!6
M);Y2!H^#9L6M2#;DIEE&F'79Z" 'GI35R3QFMM,P?<ETKX>5*DBY0/W0RLS4
MR53([FIC[%F02UF'%5RH^2,^S5TM>P3HHIU)C="7\GO%];Q-X%<&JC>\^,+M
M H=YB5"<W#6RB [AS!PK[T^ER'MSG3>P%^'ZGW'M.+VK'>G?^4O-.]3.=Q@)
M+(M,:L_[3[J"P*?'(#_LG%RS/LAPG:--6=&&I0.. #;>0?AMGR, RS+Y%^'4
MB[XHK\GG=+NI[)$GG+%R3?BT:5\7J>52]WGA=_NO,=^[O3W%>A_Y5S\4I%\;
MG406L3;LSAT!3I8'B/P:S['];*[1N!PVALSEFRR"3G'LH?IRU20U3RB#K\Q*
M#)&KM#QCQ.*-$,&_MD9T'6W*' T-F_X8&;44*EUBNLL?<H:O[H1VOQ+"M9+T
MM[2TZJA/6T;J)_!#]%V/L[M85%BI!LN6:#:[+RX==X])-;2>X@@_)U#JK$,Q
M)4AC&?SE[MF\FS0J;>YZ&NQ-?E!<GZR\!1Z7!(:+[[*&8][1U!OHP&%7. AJ
M_,:@R<KH<<G#3GZ1>R>8Y-^*>KF$C:/Z_AAT7^@+L94SP"WV!C=;N-JT=T36
M0)+V9+FWFPR;PV)-.1.]/47EF3Q;5MX!N'#M&] L/A8\Q0/2X/4X*+3V(_5)
MOGOX_.W/Z@A!*P*J,YAQ(_0^969GP+*\JCS"(LBZAXM74\>_XKK>FE[]=L#(
M$8"]YE2F;03.* 9Z:X?C& &TLWA:^Q8?D$S?_%3D#KL82=9;_KA8Y/]HD(Q1
M+#UVJ'G6W/^ .'X'6[-.5%&?CXC Q.9&PSA+D7=7].K<9N1VGK&>8OC2*K-R
MM05BR7E>CTM[? "*9WFC?"OIRC4B%Q'.<9#,V3(+;/0D91!BRBQZW$HW0X$T
MO.9L(\?>]N8*]>4;CQ5MGP;Z7;;[^?S HO7;)X4[6=RDPDXM"+)]<@HY-3K4
M;%Z*WYM^-A0YTWH6^"C-Y#VS0?&:U.U4-(RD\*_;>4#SY<UV0"SPF-*4NAKO
MJ@H<Z(XX+G0E$GXR[9VJ=ML7/$78/S;'#R(!7J5[D6NC,54<90M%,S,CDL]-
MZDJ"QN46@/(:M#\RZJYYA^;HP8R(T((HI@?R?)K]:/&(!+YTM-BL]1Z*#=4G
MVE7TU5HY7S];38VR44GX<0@WT(F6<BXRM(;+XEM) \-YQ',X&;O3[J1+%W_3
M>VY<ZP=NB[)&QXX!$+6@39!TFSCC\_OY&:JXWTJ1=\PD]5Z)7N6;\X%&$?<X
MZS$3'2M8E&\^3#;;NCMO?++:4X+1=:F=W7S%<B#] <.314>GB<K=>XD:=W\\
MWQ@^EAL25[ !,8E<^S<YYBBLN(1C2?5Z0@134F))%W"Q7;Y-N=IY"7QA#\ZP
MP/GY4.-SID>N>KSB@%"E_B(8S]"(B-YQ?> 1!.9]C%;I;^10R*Q_1+<R4X(1
M").D_#(\\QZ%U>]ML/;( D##]>&T@_WSGKX3!Y,,0R>25OAK6$0F)N<_NB=Y
MVWY3O>)"LOSCTTDQO^YPZ%7+) <):E*<  E2?^H4R\AR[4B7+\(="(,+NLEX
M[T9+[:*--U6ORAX+$L&[_30VI';=ELH**D"<IMC,W3V3F_.F=HDVY:?Z^]M.
MTQ'@.@. !0"X4+T X7X_>U%&R35_0^_6,FF.A!70ZK_HIC6&?*7A[;[92)5.
MYC%6G$>Q32*;P:>61T:TC@#  M97X)4?X/W^A11QXA,O=F>8=*X.=1K9CC2Q
MZAW)UQ/+RQZ<S#PH3J/%@*V@)3P0'H^DR7VS2VLQHJB9O<1ZW+0*LG8MN> .
MAT(6X"T+@+T43ZXQ?F&A]PIY<XS2]9COJN'[BT< _V,OJ0A+^:\4+/Z]S[^F
M^\:)_[K#$%!];!/TIX/(T4;D*LA8W 7,>@189):@P23H7TH'_U-*P= 1O8?Z
M>OQQG7[,1@>0=J5T5^?_2,\#;/^[<['_L!QO&Z9,J"6YY,7,J?X5VI %5"=&
M;#\AIS'9GJL6+\UF,DI]"H/Z8X6^I"=Q*H^*E"MF-DQA"W>?J^R_O AOUYK!
M2!<4_$97Q<Q[\GD'_FP7#%,7*Y043%J,@AI$OI5-1Q=K69<1MW<.::R)W4X_
M(T@7O6IIX+D$DU-XS33"Y68W;I:8A +[Y+,*+&/?G <DBD*2![-1 ^&GR&*:
M9"36EIE!/=PB(]W;_:+$\VF#R>$?B_$[QZ3$?:Z";(L%X^PTF='\PUHF+QN7
MR_QSFC>]Q+SGD,S>KLY65X\ ^3JDEXA%).?L85A(,0/1"S%@.X/\<J.FV.=E
M:?S$^M4MX=^O(A7O^JF\>B#/\(49!J4J(#I=R"HX.7Y\B*BQ-:S=);/ 4%U^
MJ&C?^@B@LQW11C4,VOWC,5%Q9W=P,F?+_=V?$L++I20:T&PG5F5$I :</?E>
MRFZH3&]D2S#(P\A6@&5N= H) -L$ P.U&E-MNZ\DS[ORO*2-H9RF98'#8+8I
M%D725]KW02TJ)%#F\H?"Z=V;(^%7&SJG:@2*O3(5)QE\=FY9%E6V[5ZO\*4-
M]W\^K#^+GGC9L/):,B82ZG4$^ 1+MPCH6!]?3YXZ LPEYSW2:T>>/0;_Y_<^
MZ@["W$8OOS$2VA*_+;#+YPC^H@1LI8\BR#))&__A5+B%' N/*F>G1?MIK;VA
M7:9'\QD]T=0DHI)6OVLMN,G0G#LLUI.9%K)1)3GGV-&X+DUURQU>*ADLECT]
MJ/?/A;TGF@[-R*$,#=O^E)BR)8T^Z*V>Q\=1.9:)I3Y<_DOKN ;"UF0&DFT"
M<7<%05QD0N\5579*%[:;;:F*;P%+6YM%R!HU7A^E[P3;2'%9([1WVIT&E \?
M7$16S93Z4!\=WC\"^,81N&=Q6@[]);7EL0E^.GC$\W!J]Q#2U1 CWVG=*E)?
MHV0\@QI,I5<G<X7EWK._J959-'@X3I38+,:7TSFV&RM0#C?&\S;D[3/;#M+"
M@57A^-.%? 4J[TE>MU&^*$/]H*)<V7%BB8URJ+BF]/5CRG#J[=\-Q1($@]D_
M;-6S*1O\F#NQ;CL/#ITMNU^:][[<$/+%BMX^\#8BC3X8<C9IXYK]*Y4V_S(Y
ML_JV'E!2J<=+O8@-BW%+ ;&LM3XC^YDVJE?08=T@0N90:0#E.R3W:"3]VS5<
M98WGPA$ ?2V:!MI$CI>3HJ#!G?>#\QJ9PP.%W^V>")B7+KDF=AOLZL_U)JGR
MFCF+UY,)UXS.8MDWK?X/#>!"ANM:1I.9G87;[%I*7@P=9SCBYB&7;-!L?5O$
MT'=;TKQ2_1+=,G$-(7..DH*1@%.1ST^BU0GE."RBZGN_!^1I"?72XTLKNC.]
MMXD[_;$.M#UDALLP2C.\I=?H5/3\[A4ZBC%CU!P>KN,J_*I7:7 %C:GRZ^@Y
M,RO<W/CU&?05Y"1:$8_"X=PBNM W\5UBX)@6R4?9+]ZBY70LG,=.$]^V\OG5
M2,SWMD+886\QL[G&\&2-T.*SL1_4ZH&_!,B3M-_[+0P<G=I M8<UXE;5OM@/
M=FI3T;2V@FK:+/Z#-ZJE=U)UF:H</L?4"KQSJUP4UDJO^+5&WV6BG*A'1:$<
M"L1![04%*Y'KZY8B@H.2[FZRJD*1MK9U]!.C: %;U0P/I&;LRRI[_:R&9Y@9
M-YG;^^ >] Q9B'IS%<R"Z,W9F-$+D'E6X6KU9M)(@B:FO1\ ;IKQ.6';%6)K
M9N%>/@=/5#MP8.XG.9I0UTC)N:L8EK:#<NSH9M0"-(#[]$2QH-0UYBO41T.*
MH&F^V=M<.@+D@)60DRRVH@LD;7+&&6PYWY5([6KK2.F*"T#X) 5NN^<7M(<L
M7C, %2^"1S:=?Z:G\<A&)R4'@1_3;]"[T!+'"/E#O%MM@#%!++DDF(LIWZ:7
MSXJ7==_OZ98*U^X1X *Y6!>O66F79QU;9$/QK>S0X,)-/U_M\/:I1XUP_5(/
M2+JC91XZE"L0XL?PY=P6:"%\0H"D! ?CY 3Q-W-5;;MB#07-A('.^+ ->JO6
MI,#GSH!Z*03M?K+GUM(;528SCP]>JK7)*HAPRN@N"?@)6O([BN U("M%[1PX
MU.:V5)>9EPYA,;GD18F6"7<4,QF$1NBZQW+;+>H]'E2U<V7T#]/_D9MVZIO\
MM2_,\$*J-'W$C7Z7*N)W:"7C%M_?Y#:18,I?+1M-%4RB\8S-\87<%X=,96-<
MVGO(]OK>\X[O\1M\N8-5AUI[.'8MDT+\C7_@I00##\$6FQ_;['!Z9M7=VRS1
M/\'&6?G%98!;^6 D:]8MS./2:9;]1L/NK>BLNI'1$><2L6>S#75S-)5?6R"B
M"?H=[0^:Z1BV;9+Q/VT>6)+:3[[72EG65U%%9/<= 8KI.+B<>AA)7 ZE12V:
M;#\"U,LPC9['F>)22HTHR+I'8'-P" 8?;0W&![POWAK^V+9K(Y!D57[-;M]\
M#ED=KF"[.G%8@,<$EK(R>'QI-!Q8?@ =5[L92'4:8IMB^Z;BJ('X#A,C?S8E
M2-27<=.3W/(VRJS%8KYH-;8@_#.SKN]G]_P!ZV7CYFK'$:ST\P8F(I.*XQK4
M_D.MH='FV3+W9E9<[R4C#[D6^(@A=!OUF(\/ZW\!.:5]4,TR3.1L#@^X<@1@
M@C%D;^SZ>IIJQ/05'@&,Q!R#]WJ%QBY#X[G]?CGES$[-3'<,3K_I&%0'$=W?
MJ5\^#@9EBE])T7S\ZL]Q&T< 0*=$TX[\R[!MI&(EF1,_3+]S^&QP+U:7WA-,
MNW4P2C9])2HV5GA#A3J.@Z:_;(@A"&KQMW+?UE&Z>H$!<&+-!$2]?2AR!/C*
MBIWRBE[D,RG,MZN,=3Q(\P=60=IBY+;#AG&EC3_?T4L#G(+WS5)I!J,Q6#1*
M)6Y;&/FWGJ_P?]/S=;A+RT ?2\V&0K*O9(E_9[^XQJBND3*'Y,$\<"NJE7JO
M%$45.GQ]_'N,K6G/T0F6H?G1GSN!,7>. $L)U).JVG2\4 ;<B+"/]8*])GMZ
M9C8%N1I!]W(99&'##(N]:4RH(9\)C.0QE_*,XS6\8_8N+^^<Q5O/TV[B%+ZS
M>2XR/&EZKFDT(''HF*9+OGVHEB^;E$M4V>#E6 (7NS=#R(9 %MS,.E3,<-#)
M!EYQV//TX"9X.VN%EC*\/HS7R5;S57V5M$JAZ @87DAW,U5BU[WUZ]_>L$7/
M.[#;R+'T+P^+YY(_;IQ#[ T^/NL-D"J4_=3^:(%3R#JW\'%J00>8C:@>RHK=
M#B3R*#2L#[ZH3+IE\FODUEWDR3,(DYA[JD)"(VA?\C15?UU.(FC[&;Y!+CJE
M(Y]]E(5AXOZW$#9Z ]N8L\HK4278+C35?$SJA^$K5YV?F'Q(4/?#ETVOU1*J
MY'4?40_V:A4F2".*'-TUP8]>B>A87/<Y"$(9\;%$J?DWQTMO))GVCVS=JM[Q
M,^I@DG#:0WD9*E6_(2SDJI' KX1O25SYT]%9F*[T#AW'U:RA93BM"+=E[J[)
ME:UI$PQ[WJ,S%/*%U5%)'1I6VSOX\IB]^/U3HN'-$2"\QM84O]L@%8;)EJ#(
M_O3^^A:;X=*02BV\CI#,";&0O-UL7&1QDWU).(+0BLM(T[<Y G!<KRVK5A41
MV4R+W!I'[+W \!?*REEHM4)C99L]SGSPJ&Z6H#\FW/]5\-[YH+R\*.X-R:1>
MY0_@Q.89[]ZZ[7&%V7DA'STHX0R1]*,<DO#$3N%D/XM$V9*LIM.FV)3>&B&;
MJ9SQ3$#,B$J]VJ76=X*KK7#(STN/(X;9U*NOG=&*A*2@M(? %D> 0$/X=SV5
M1N<WRJL%NC,>,\_:>@82RLW=ZU H.C>]F\Y$-O.()>D6K1NFPCNGE6)40B@I
M@+O)CF+;)ADF+$+@]S:F"Z[+7GNBMLU5.Z-MAW]&900*R!9!ZY3'OS*^.='C
M/A"0JT]UE1!%4O<"VM:Y]-_F,GV1!8405.K#SWB4S7Q$XT<25CI"DM_[C9O%
MJ?(J9C$(H QS8(J\.8/4.'%1O2/ _97]M%VIH%48?"Y4!3L:+,[,H/WBC2'Z
MRM,'Q3>6S*'O)$EK0WJR4&,N9:=7P556W1WWA5O47ZN>#F8B5"L7Y?PQX[%B
M.K'JM '-Y7[MAE]S"[0Y:628=YO?3_Q"UH^K+QF>GD'8P[C(MNX$[=88[F>W
M$2UYM] )UY1.1E30(--\BWIK[[)T $PGZDZB10+>*W4D/B+J87I&Y#)O?OUN
M];C$[4K0;=0WN>__W=U8_U.#_O=/(2H:C]ZK$4^;>5_U?</.S.JRQJ/\_M=,
M=*$^=W$$6H2&0C\ZAG;%7. 9F\LK&G^BI+X&>,0[#8#WM3%4Z%;0WH,GJF:@
MN[;VJ*(G!(\?6!O)6HI7DBS!>]YNNQG)8[RA9Y1:=BP7K=YK/KOXQ0TUM!@)
M5R6AM&F1"$9D@QGJ^+OU<N6KE0:6C@#*8?+-S76+<)TG0D-S;N*+2$8Z[^SA
M2T)BF,_;"YZ9\.86T>M?V8ZA*84HR$*D:&"1S#9T5CS-+SBC07CSWCS;LT1:
MNVR[I."^X.C(\EC%7%:>,#//7[/AOL!FC/UB[N8VZ0R+-,=_UU*"L9'^J9Y%
M C$\>_HCKTJC5'(H+NY1ODD[Q]8%U-;VB;<I#WB!@J;5>[(!%.6:25)8WWV8
M.EZO^8JN]<";<Y>P9D]53=FS!9C<L:P<JV]!:F&W6$1+)R #E)\>'4[9"N_5
M*-)>R3]?:RDA<A!NW@Z;V03-C;HCP,7\1P;F(FFVD1EY$0_G)7_,2S+\:K\
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M,4KTTX>&Y>3*N1\.@<^)WF_DLXQ0/.:M+ S[^LY@MHE<Z3KO.S3+^/[MQ>,
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M5AF3A!^;<_K?%RHGSD(J\Z5 7:ZW%CH6-]VSE.3,2X\I7_&]?RDM;P7;./B
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M(!PV&8,"!YI(5<Q^;W)!LRW3X(C:7_?D$)7M$MU:= ;E&"D'W9$6QVMT=\N
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M0L$!E[-!%3LN.+T]9.CI^/@KRSM9<6^O;$NA :YHKV^5-M-+ _'W5<I#9R[
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MUV7C[YD)'=@LAH\X?_@[$>$1S3V\0P.<D6* .9>)Y4I-1H64"K:.GH)]Y2[
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M&"W"15% J \)][G67KU;$VA](C.(-5)3B^^DS9YI:NDZ[@^>4.?F1YKL$2#
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MF[;"11W]5%A;?/6AKA?7:YS'NSD)JE*\4?>L+%;.3H_T:^>Q]^JHS+(%GBF
MF.MEIL3TC;M.Q(7>0?6(_\U_=Z.%R?/$354R__=Z^QMV*D8U!I*)/F]9KKNZ
M.^"?$7NCO2Z= ]ZPQ95)-5,?$;H=\HV7HZQO3@VW7GNXGL"<M%L@^ZO*!2)4
M:MTWOW])2C1KW28CO:]69/E53^^*X!S"[PA0]KDJ,\<NW6/E[,W#Q_G/5TAY
M\]\*I;F=K '6Y'B .^N<KX.)#HJ^@V"=$ME)9'/5L@Z.0!<O47_[_2!>_ Y:
MCEQ('&_$T:U?7=G3<,Q1K4X;N/MNH&*Y(AP/1@NI/ Y/%6R:H6+>CAV^JJ-/
M$=JFE;HR_W_[@P4V,_RZ/D5Q686![41R!VPXXO8L3FG/+(^"0-TI$,$C6C8O
M4(S[-1;\O>L,Z\5^=?UF^D!K+UX!-,9&-US]=.J^#CBL2KZC)/=Y4I:!9/12
M8^B=W/O_XOY7 W$D?&<SJ.[*8,W#7+6BGQTWYQ_N9]B'AM$&1 &^4*^ZB]0?
M,'%XH^,,AJQ44KGW)E$\XUD;S"0L[1-V@D] 80_X=+[90.]&]TC:^CS;VV)Y
MG>\D@R(89($D#\:FB@_";G@4ZQ#/9!]N;%H)ZP'C)):RZSJ^_C_,O6=<D^VW
M)AI?5&R "$@G2A$$!.E(26R @(" $'J4CA$0I9=$14!J! 0$E4B3)D1Z)W1$
MFO1>$GIH"24$TH9WS^PY___L.7M^9_8Y9\^'^\/S[7F>^UYK7=>ZU[K6B3UT
M#L81.K%M-%8>A.+V1S\,IP^N\BBN2_UJ%9$ *[8;54]BM#6;T2QD;D+Z"NX
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MH+&!C8DBM!H(KR$&\87%^+6,=NA_TAB(YRP@A@5[BYY6[;][!W\J4'S3F&+
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M14JO;)1E&EGA0VPJW#3/:6HO&44!D;NQ#Q/T\]<ZMO5-=_#)MQ(N("HZ'C$
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M#_W[LUT5=-F_@M,8J@SO"<0T82:V+<DCP;N=DFNSP(J4[MIA_@M3/]E2^!@
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MK'@GL>[XA_Q8^?]BIN7_W0K.A^J1C>A:MOST^@P&8  &58(,-G(P /$0;08
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M5D57L+'A(Z,_0UI^G;[LVB\E3+FY,A4_S$>S*-;!R;:@+E ?#XYVMZF]M U
MX#T>;:1ST%OC=(8RMJ0BN,*/6LQG@,;Q+L ),]$"J1;K*9]EN"7D%<$3ZW[0
M/B=@N>I;EU'! -@&>6<)G[ES^!GO#PB,GU+:#_[?['>%?-4_ 8(-CQ]1_;BP
M"UJ=9_U41@K%EOW!U)LN[Q"K3T<QJ@AR%!@;JB'" -QCK3AL90#:($./(?G[
M5L#?P2HDTG'H!*.P=)U?C2!:^ _%_K-X[G2>D0HIFO.,QOCSK?K2LH6$T&=O
M>6(6YI@:=7[YF9=93.M[>EU(/F"7TQ5.TJN]J7HE])?((,:V\!UQI6GN9+!>
M#<4<DW'O5=!K#"QLDO>]X G'*U74\TI=T!.\,/U[<[_)WXO.M_('Y(Y8K>_4
M@F77-XTF5$A^E24$ZNPU8GBTIX\?XHV30[ZUU"$[$^IF81POTE">DXEJM@YG
MHWT!"?D#38[=8[ Z!U1[:B%]"U(ME]Y^+^&$T#>7V0;Y&!#S1'?Z]XPO7BIC
MUX,N"'L9^>[!H^:6[[@XN.<V7:VHBIID'U1])(QL>KQG;%="<*\J5*B_@YU1
M:+=Z>.1<XG ZZZEJ6_+!&5XC3(G@^T5?](D1Q%,$TZR=QFA:>EENRW2T=_(M
MKI WCN) $WC%7@A7K)XB/OC9"IS[9ON3K9_[ J8:VUA$$Y29*C8C$_ED$,^J
M7)D5V&(=6[W*"G@4M,FDN3X@D5D>XW#*M5 DK2*P.K(V*7M)_.^KL,=/_%TZ
MC28<=,@E/C(5N38LW&TQ@ #25O@*$U./W;?Y$]7P*T0D((+$2Z38G<G&_%D(
M];W  +A]B E\L[1"0-?G%:M]TC,3ZQG-'<"JA@)#L_-:(/JPPO%#.'!<IQ5#
MB+SQ8W)SFRH*#L;+91Y>+3D(SAI!S-]&V8WLHMJ!$V,=B'.3EMOENWENY_]&
M2 D7-6T<O!&$*\S'$,GRP6]!O9\7?MR\PWNZ+/]-CI+K:E^].(?#S]V7!8>X
M(_! $4969 >L/^+IK;_JZ;U>L^%Y53VKNO)#IS#P4=,B9'#N/-B]UT5K1UK#
MQ856Y7P3,WFY26R0S=SNLA'5^RC1KI=H1+I/0"#KIWHEY; A3TMG?;X\:;[*
M 'C(,./JC(IA"^!HX&GJ/<(K\[?]MG',4:OJ5C/6NHVW1KRJW[3^I<)Z1C!H
M+$72A^"9)FO41 FTJ$>_M\]_C,1,K,DFTNL']HS:9*=*;GBFS36G24,^2#
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MI=!V[=81#[MZ[K?9F24#KS.;)!KQ*9CZLT"1]+NC].5IO_N'A$C[-: <SW,
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M77NE@3&/%O2E5*LH*S1.8W.DN0MD9@*;@=#=:]QGF#:IB9 X>^L9&TJNL:6
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M'Z*N>,^G&$R'YUE7[(B9NMT*OG'/NY*JN=J>N=O6TU)FKN/L[HD3]!(R'"8
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MOA!PO6B3(+&_7V(:0ZM?OSK#-RC'2;R!0[171:OR*'L7L9'?,]4&SW-FA/;
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M%N3??D\'SDS>-_T:)WID$]_@Q3'%+UN3OQDE_<B>Y0T-.^#ZVHK74V\HWE:
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MJ$(4D/Y%9N15S4^4.3[.'7N3 ZW-3.9QF%6Z[48WI]NZ%<_9"3>8L@.W!C*
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M/_;S[#QKKYV]WW>US[O?M98Z.OR\'KZSJ3P!%M'&N',5JUYBP<J88[4^.I:
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M^#['O=6$\XAN>,X4A=S9?6:K;;$[Y/,.'#[4! X(/9V0M^7&JO'MDMC.E$6
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MV_]NR:BKU<&6K3I#4%/6D\]3]K7)^6;&[B)R=1]:CUQK/(CLS^6;4"S46R0
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M-/K)NX>Q(I2UX28KY 6T9&/@GF6ZQ,XYVD%C0CVE('VTV.V LHQ-*3L[X?J
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MUM5OS1?EP[3SC*TVZ5L(A^M+AM5P0>-A^V,)O <<C6Z.["0!#+ML"+OZ923
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M#H47GMM-J&!]]?![NF=NBV?2>8DQ;'M^!C6#-%9GJA/PFASFY?&LH1,<S[?
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M#"^:C9J >P0?.<G7'PRR _.<43=\Q'3=+<6X773"-88O-D2HK9@<L'JC-T!
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M/][52!0]-.@DKG4]P3&W$"_Q3=NQM<T"X6VFC"-NN4Z7>Q5TX)@&'<>F=Z!
M[XD@VHW/-H/KAP=&MR3W%-)_I0"\/N.4VB;?9D??C50ONS KOM#P6&/DVHF
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MNZFUDO82Q9S06]1F.HH DN)LO35)?GXG;39%J2FLE;UY=\&Y?_*\\Z\%=)!
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MM-AB5L%K5P_')\'[$,*LT>7C^B ]EN-#,;05#8<&B=8+#]CRZ!F A#?RIU7
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M!CZR"(8UR=WY,3)G\T4IP9$1QI2]#5_6*!8;1/6< 5ADG,\ 5R5"*9(<.+=
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MO%N&UQM,N4[DE,=2J<?6J=GE&KW2>%OX27YU8],;[Z<SZ-_OA%L[>?#-8N*
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M7DRRN?$GC;4_+\_]:0$U_\N?%EC_*C62T_YGW!F1F+\&OGINB?+38:A8$%[
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M=:@Z9T'C<<QB=I-O"EEY;?(GA'NZE6"*CYHC(N\,4#'5D+L7P:5;][."S+%
MD&5LG:J&/7P7U.KKB:@V>,*C"\BE8]T7FS\#W)&[\C$::M<2=5GABEJ$K!?
M7>#<;5$=^^@U67YASY4(:=H?FZE#'4,[.%1UC](\@#?\1/1QW3/V!U<B6PP4
M>OB82WH!2Y^2B?F$$X_[N(Y'T>C-M2(;A)SSDL"T1=E:^#*2)ZTF!\OAXS9B
M=9FS]HA#U\86.O5M]R%UQ1ZH*244Y7.ET"Y]W?-_L?<>4%$M6;_X04!0$%1
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M,:#)SJ IN/;S[SI,*ZO:J15X9GR59 !76/.V3]&,6Q4LT%272]B*#QN,1>&
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M..:,I%OUF]WM$NEJ-C*ZA!MO1V1$/O_I)0^7+#Y-]%3@;RQHF8;94Z/D65S
M/A.]2QSC&'SD\A.TEPE*;RME[9G828[W[OQ74*.PF+?9L"Y#Y#7CW /4HM],
M?;M:^L0@<AMM :8Z\XR51;$XH!P'4,AA>&$A9S%D9O)9$#*! ][!L]C@.3A
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MCA"@V+S6!IMEK%!;2<L O'T'!75>Z3;L3O8PUK#S]"M^U_12R,E#V%]&.^&
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M%V-YG#&4_GX"DMU1'O4AP&&/5<P1(K$Z\Y7;EZ7(&76QH'!]?+#)J37S\)&
M!7.<UG<<T!;JI0QX\3*\X[->Z5QI8N]\3;Q_,1G"X-TQDC#3!(KTYD?+.>;T
MY*X(7%5PM%J*]OP"IU5/$U+NX.XFHO<Y[)4Z>>:Z;CSLJ7<66[XUIJ[WXCEL
M+BR .M'>BB-Z'9(>X>SYC1>O@YCHD11P+,M-;>FX!AE#K>M[QA]-'&A5A74E
M185_ZE7U<.8O@#RPF?D*:CH2HQ=/B7 B@5Q-)]HX3B]_,I&)O\@%<[$2:E<E
M$Z&K/2'': ]AO&:OZ$BC")O+W4<"M[3'EBM,^DNXZ+O(5.[X*E!+A+#AK]+]
M4=]&.D??<$K%]LH@SZ14I #E>^I(<4'@-?AL6-WV[H'MN$#IH.OI,\?J'*N)
M."#8F+X? S&=LZE],4Q^=49NV<#J!PZHC9*PDSSS+@5/=RSQOWS)LQ8)*(O)
MFH(8=\<-.Q?Q[2K?:FP-(>&E6 'N%F/NS'-2M"7P6$^#!E.'WBP[RU24ORQ<
M%&)>8\-_$;+(B>5PE5BMD:1H=G=E L5T#NDK-'(F;IE/,#, K\,D<F5>N K.
MCS1M!XND#HB!$;5@U4%Z44YIF@5/TN3<V1L-RV%[J63'9P$!\?*?C)75#9KW
M=E8LSW+3!F/Z<ZR\F?N=6ATRU^+<?9]LW2B_Q#7)P+#)RC 2[?GL-!$ZY^(Z
M/KS;S,0^^!F97)![VU* <S$HB?=&U,>%UY<CJU-$0I#@<>D#BWYO *T]@"!J
MFC+0Z"ME%-ABB=)?=F!?MC1[>8'8!$_CO91$DH]7GUJ/F///FF+YHL<^Q>T+
MA*HBT2I2ALN-.(!29=X^$$N#(NRVH1K.RIR8Z@YY\$4N7*]H,]IA$\*)\4:J
MM$#>,9&@8,&>YCEM<Y!+*RAE =A<@7ASI,O7Y#-[ZD=^I4.BL]82?\- M,OK
MT=B?#.KTTS.#*B(H-!MQ1=F8XN0:M*,4#<%6&4-7-4NW!O]0.A4MCV39_AZ_
M2<,F_ ?MU^4I8=U#(6B7>4'?DMX02+EVZ%RX1V^B0O7 H_8H134?);U%U:SR
M'ZE8UF$?B?'2^K+:J0./8(N)PYJL*Y&%["V>Y0CN49+OZS9W>M^6UMHTN4_:
M)-I$EKR[K;U984L>^:J)Z?0>[-MV:R]ER_RFQ1QKLX&_"T*<&SJZ?XFF>))@
M,>IC6)WJ.ZK>.XXI@WC[XE32AB,EVZ2K+G1Q!5[VF:L'ZU4&>3D$#JF'IBVO
MQJG/U&9O<T*CE;M+.%_E=KH#@P-?)OAAY"\&KCGF)X4D4Y0,59OK^CRU7QV=
M H/Q7=2=B!BQT%K.Q9@W^?73.X,WVNH>2C*&4_6@61%R 5@6W=J90*<)SA<T
MJ"6O.%5CL3VRH"7#V=-9$1T%24+S*=<\F:)Z _IDX\;I_2H#I=>AM\YF0$S*
M?B1*H]&]/,*3*-=2_VXU:V I21^#34YC>HW"TKT8.V)A-EI7YFV=LY"WJ5Z"
M42&MBV#D>.$X/43)^K41%PYXL%O]8BK=HFAYIA;P$B"3E;L=5_?D--!3#SZ^
MQB2*=BN U&60!]J]=?Y63;V#W)&Y?8]UZP4_>^VWZ=)U" ,U(J+((<,5.C<^
MMJI]V'5KT%/FS6PB/Z&D[DA,A9_;97<GXU3\@0'-XNC3#>VMB[7A+K7?VC-E
MC(4YDGS;,6M#GH(GPNB[*D&0LLAW&'&!/(="%8OTRGBUJMY/8A%Q_;P,T=Z[
M*>E)IC&0UW\XQ">T$5<<4-V5*1@4O$N]L[!C1EX4A$QB(B_5@T>!GX'16'0.
M#GBN6Y^TOS<(ONHI[#!_#\/*5/02R^+'+6'$)[BM1:P]*=?W <N'][-/K^XV
MZL:G.?$;ZSK#W"8#)1-:,_S=;<0^[_' [_!1&<@S#<6W364YG% 6Y4:%37R3
M8D;]("D]-,G,^^;/B^%4+1,82R3G2*"]IS0HY,W %[T?MA9U5HVMT3[D\3%#
M7V6!#F%$3$,]G1@YBFMNLX878<"HO7JU?;BO4L_/WV^"YF*K_#)C"^!<HB8#
M2+EYV6<9U+9,-6M_99V.LR#.VV?U5;72WTHL;#0?<"(Q>G1K:/.%GJ8WN[)K
M?#-X[.D$XK#95MH8%1G"KS1%<FB392D0N2CS\@:_#DO20K$=F(TH)2O#E?HL
MUK'C'N-51?9&>C-:EQ_@P67R#^(IXK5M,QJ$OEN.,E_4[K4&3A#%3MP4EL?W
M^YJRK<L$*!0.F2LKY<?J?(-[%3,*Y+P0\ O3;>G&99'9:R*.H4K=9A,*+!:F
M\T,*1$@X_@#T&02_QVS'-49G1$RZ\*F@H;6Z$7&7,,.W0GH<P,0I"7K2=EN9
MKN9E81A/?M;-2%6K(5361K%#/N;.Z1>QY\@0(W5;C::#G^(M7[J;CYZ(E<NJ
M)7&M+![YS'YEBCTP^F-)T;7G-;^5Q'2E;!&;M3IWW,[!O,O30J;/7-[C#@>5
M'38S4C1W.8J'"3Q:)*"@&16YD\LMX2,\ORH)>CUA+.6:4; <X41$F/:J ?24
MW?I(I07TU3LVW: N"SG37-466*-$U/MRP&CI!O/[C%AI^,D86-J(?",>=:*#
MCF4JG0/1VD:V5I'$QC]\:X70)N[N%)J.W"E[(&$^7P!X4<N8H6$M"=Q^>_&#
M^YOJ _(#?7Z)H1V/K2KV5%74O8CXNUR5YK>;>AFM0S-7O+D&[$N)3*+&CP*%
M69B_<?@89"&7?$2/V0K)6V<8:_"0VZH"3+=0VK L"!MA@=*G.ZKN=H\)"KU:
M )</VMQO,5:IZ&TENOB@4@_Q%\W)F3;"T@%VU08,.0="_*5G2@;:J/4%:L4(
M/C%IVIR='3_-$9L\MOT!55RLX_<4'O*^AW[$B:^$XFP+B#8H\9C(T[JK8-M8
MMA)(W(K0J;=[+23Q$ []+N&))QBP95N2V*,_8Z"K,K:]Q:7U_0,92:KJY9@1
MFH-4\AQK^JXN+XFI+:ZLB'$"6JL7KT+JU5VI=ETV0"AF?51O$Z.2RO#6XB!K
M'S=A";5&D<N#;Q<U7[!LC4OC;98X%^" =^!OS2":.F8CFQ0NE&R.X]R"_(@*
M\C3Q2*WA$;#1[9C<4X'$6_ <1?B(9RF.E/0X"\0H#]KR$P_.EN:OLX%"8G36
M9^O'.6:]ZC?RSOS [690D$@I-O'V3$'2\$!O#2^5%7647WNC &G0S06/D<DJ
MLIS3TL^KXQ%-H/'-M(I1:)![8-NZ)/7*'PC/[EUJZ)A5'P9%0!<44$2G_EO@
M/0W5BQD1GVUR#-YM;#VO#KKCV<Y"5LDH*Z,+CX/.)H-W'N_7G]!8X(!^&^MC
MZL=HW[G>ZZ[^6C_W>DS&#W7Z?TQ,R"=RX_UX,!-)>::?=.NX4''O9L5I]^VO
M6I\I@]<BK2/41)=I(X#CA*JJH="5-!V#[!\?;;&#7+Y'8@75Y<L#]GQXSB%S
M6W6":+*V1@$L6P5*._F&_ZMM!NIP;@J>:%HU[]VK4K,7K+=]O=E=Y1!FO IS
M7MY=>CL 3YL=#J@)8PIX/^<C)"YG#:S]T@,Y.=;#^OQ%%8/<G!NVW]L2'=E;
M/^UUW%1?K2J(*[+CNL_-N9TJ?J<LUDP#[2?C>K'VA&&U_IJG0X%K9%L=ZU I
MRM&)P^K8D^?HP9A!G"@SP4(2J==4VB!%CVMY,SE>^88+JJFA"N;/K[2]P7U5
M9<'(JOSZ]F0V*C]XM,&A[)D.\ZU 1TF0F[;6<DB)LL31R\+24!*;5J$;NT:W
MY:&S+$O%=7=<(>JH+-]](PKYX27DXNG:?:M<@QP>R>K!2L.KKU5YD+*".N_.
MC.,%#&^,3/2XRS 7OS!EW%!Z[>G!+L; H1@NQ.Y=@K<7\M6<@,&__<PZ/C[U
MQ>@4;*':_$KI5_DYP4V'UT*%/X42?^MGOAWM*KT82/+3<[IT?^J/:25U6Y/&
M:=D(@PG7!>/+-;G$&%[M]5ER_QD"##^J:?ZPY01*F3'5J+L6?[W1=HO4PM%(
MD4S%&T@EK]O<,JD*4R#(X;/PZ?OZ_"@DNNXQJGQ#CMOO_HL1['57F%X?1MHR
M4ZLD87VQDB1F,>]+#JD[,/%A3ZB#?Q7TS;ZM.C)\^E*5\G-U,,5*_WWJ$\J;
MGW09HS>QUYV_,F=JS@,^@/B/D 944&2-,!+;*MI[W<99G[,D3%VPYB/KQP:S
M *(XH0T.4 ,.H!<C0=U>WZBC1\G"<HUMN0\TWZ>WR*DS/Z/Q70\!-E>^U*RW
M@$KDFJ 7K?NM$MK"^"8,T#-=T5.&G7WE:1M$5L?SE'@K)=K.O@A.[A9]39&4
M\.SQM2K/IH=3>IW?9*?3;NXSMEGWI5[XMH'1^K)&76!ADZ]K. 6?+@]<9)+:
M5W4T!+6I^)?C +K[;\)O>:JYS6U>%C;:%_6X=M(U>)/PR3) GIC]O'T642.-
M&-D0GNV]XBD\S%]/8K26X%R9IJ^0+<TW8C"L<9V:W95>X?*K3EDR40=)$&3(
M2$[S6]\FM@_J0OB!MBW1@;VU<J]#",YX&NE]R[K^N@31:OSXX(ZQM8!CU_,[
M@Y7<#QX)%%,<)MH *J\OB0V[!(/-Q"D0K!%.D=?/XK4A3X6#=Z.CJWD/_:8[
M\0]-:5B2W/U2=]^K\.%MB;PH>EY@$!HN<C"-Q>\WT-.6P0Q&Z7#,PH*G\2,/
M5$Y3/0G=9I5E=QA%C3XQ5_8O?NRH),B-"#II[V+MJF9YP,+T\63\'UZ^@&J7
M"$,IBI6W2S[SE2:@IQ3B7F#( ^AWZ?J%P-69 \:S_N[C_4GTTYL0!T2Q-LT<
MD/WR'R6(! [X_FAS,QU-;\HR2B%7(+60Y%C1\H 9>]2!(70Q9CA-EZ"Q]+[<
MI[W;>BRB<"7L6@>EXU%$/C/@EQ?32FY]=(*(#S_S2FWM@^E ?I[45LYU)/U;
M=0/9Z[R/U<@)/;NO[<P)OM4(-%F^B== !$&=(+3S9B&C,]^OC4V*U^44KE8Y
MO1W(NW9;UA:_4VI?],(IPZ#$A1&P^381FGW@<64-$@MW6& WAD!6HY7Y=DR7
M;#>OL?-& \P,)E7V$S%SM6W!$@3Z=>$V-:ZOUT332$WOV&H+A)=%'K@P@\SY
M"Y!M;3#\NINN<D\'4T:^Z]O]+_;>,ZJI]]L6W@@:I 40I$H4$%2:]$Y I(D*
M%GH300$C(DH)$(B"]"8@8*-)[QVD]R92!*1#"KU)0@F1A.3F?]XO_W/.'>/]
M?;CC'>.^XWQ8GU)V]G[FFFO.9^^LE24J06C1.F:V% LV/8.O;;_L*\3+P@_L
M@Z<'>_A]DO#U6' P6:90*1_]2<3]P6VGYG=SHK"W31E-5^X;K@V>R<"6:D%G
MU0E#7SJM5S?(XA@)_8_3$LE6TY(!@^SPGU4%T.U,P:>M$408UB-,;;BI: ;.
M<<#GS:PRNJ@5_3RJB3<M>TB/:>D:G,7SK\6PEO!4YDDZTOU?<UR)(4KI?'BS
MN)Y6IEOZ?$[S-D*)G?+K9:Q P$@$#0D98>D7SX/!8>Y>$DU\2]^#]_5BW9^8
MZ[/07;O>O@1Z*3X:,F2%G]J1QTUAZB.E%2 <Q ]NQ[6-V8,O),N>3O/I2ENK
MS/@Q"+JTZ&#C9Y,P&6&.-5>QT5*O5O\\#&/6/._<E/SI(]W[TG>]K_<YQANP
M36DV[5J\4^7I^P]PJTD%BRIT9=+;CU/T@4>G?N9\90(&B#!\? <5X"G=S<?%
M5336^$A&>E+B)<7DVI.Q-^^_KMG39'4E&U*!1%]L/.FT'7(]I905W'FL'';_
MX:^#Z N7Q2[VURD-,+Y2.U?#LB1>7NJWUN,1*T0_CE#&MK!M]1QK\#=:VL[5
M)MF+?Q:5O<YH 0T09?$?!:73L*J%7 Z91TX_7:(">CWV@_@H5*>% ZOW-.*U
MI"G1$=TSGUAIUQR<ZSF,F_-9$O>YSHJ8([&3K7$.P:VL@WE;E"MC-0&$WRX?
M;!871$TJ<AXIG5TWU""9MY&YU/H>-A-M,NVL)<==";,? U;"U?67A96>>_&)
M.A]Y;FD+74(O&"_=#4%#.60Z.\HWH:SUC=.+]M:]THER=]?J[_0TAC'TO6>[
MRUT=GTT%'J<98R9:3S?5XA"IT#E2BIWKLR]ZVXFOPU30O6<?-?D[KZV*:T6B
M47$0%@^R2/[\AKW$:,V.M(27Y8Y+2]3"SOLKIY1B/W)=.R.[XZ")X/Y,0W)=
M7W2S&;K&"6/HSFMGKRLT[9*0K0<]FB\:5D\++:#?/OY'&SIE'KTHCF9EW.KD
MC[7NQF9^Q=J5OIE'G]<N\=\IF98\P^5H(O5VMS\3_#%(!CEP@E"B A4(Z#'W
M;WLJ$!R![$]"MY%8J,".O"VE$GM'!EN_LX8FE;/8]Y18NIG3O9"1XC4"_QGS
M?2SX4M]9KW])G'N*QD$* D.Z&*'X(NON/;'48M&D*O"A*[X1I#7W US,1!,^
MM!(=16.Z<L0KVM&*J,"&WF__3LID!DLVCL%>[$O/^<N?%YZX7[N:7-[<J1K=
M/[PS]WU (&!-<"HFJ*/QW6Q;-R3ZZ.C\*[?]A86Y><V<]MUWS?52E54@$95U
M-=,SOGV[I^N[D7,67>GGU9*'DV%%ZX.L\Y.QD?RG;2)%8R"$2;GF9<1\L(I6
M+)Y$<"+ZYB.8\5R-T+"2@R\G_)W&<[ M;V%$=U._K[@T[RDVK/]: ??;)?!?
MP_BW;=NLXI0D>XM&RBAD3Q>!I */)% GG!-T?4$_TE64,ZK%PP]+?7!__9^4
M_O3EN;^\$W96E.FNJKJ3F5";E Q9*;\CXUBP;2\U@ KTPI0)PO51NP2W7X_2
M13^??=IL))*@*U&8UL$@E!GW>Y,*X(H0YZC #9^WM)7X#B5^!M:]AF[-68Z[
MRVROG)M9N)G4=84!I&_Z8WZ_7[CUSDD.[8K^H3 CIPR1!SE3$VHT&>X%!ES=
M?$N>G5=C2SIKR&G\Z3QO:M6W-?I,-%O7;*L2\2_>H)/VOAU-7(;U.,(@#^7&
MCWC_I6E:FOM;",_I. *(/LZ5_H\:,57/A">H#\G3;.-%.3>!,$$[<(RL&7CG
M]K5D=U4;?#U%?R5AM-A]84)(8@O)2-;'U<>W_J;I=E2$PL[+V9W]GMC.'TX+
M:4UO-%Q $%TK!UQSJU!95L'TG25-SN$CDW3C@.* P>F=Y;B;HBISEQC0(?TT
M/"91 ;?X669+8BDNY&%E)=&SS/7XU*#'Y>':4O'$RH1KVY93O(]MXGC10FE]
M$P[5B?T9=&2&RR34-*';,_Y#ILA!#^*09$"^6W^2HYC&C(%V?7E;<O(-+UVK
M>?_T@@>7*QCO:[;0$+%TZ2&G$??AG]#L.;COS?&#8D4)-R>/"R77%FX(A][[
M2Z?-4_!/FJ<NH8A7+,CC4!+C"!6H@6U?(^Y2F"X(=T&ZW$0?1=0?L?ST!S2^
M?@9(G*T*M.5,D+RW'D2?9IF[[>M[0[B9O<E)T@#+V;)__R0_B-O-IU1C4>W7
MLAY%P(V\!M73-B(7KVXH"NS..2WEO?5VS%VP(JO@2L*,I,N2/-+GDM,"E8VJ
M%&?/7M)QFN*BFZ$L+&HVCC5+82",K-IN2HNBC2(/&FU7U>$_'=_2%ZW>3D ]
M5?_LGA$)?2(!/1L/]L"1)],M/DQQ;HS5C@LZ^64,+D*2]D\QCO!F$PYPM;/3
M<)&^ZY;2V2Z8IGT"D?<4OS+\D^\IQKE&N7Q*(].!"0NQ&"T>5:.B:*R+ACLF
MRHKH^G'GG-/=%#4 "GDU ^7D5#/!BB=OF\V?UN-WWTF5HQZ,'M@<IAHWO QR
M=7:S$-&DVTM^T[XR6Z$!PLS)S"()>?CA0NQW9 T"BM%7,K=^_NZOP?.2A!2^
M98BT@4B#X_3CUL]$&ZQ)^*)PM#D5>'>Z)C5X\DD8_N#+/:ZG=QH</CT$H=/U
M#>QAJ^ PFAFG B[@V6*L="1V(-7@%]E WMX*99S R"IAQ'97Q:ZJ/[?QC*W0
M,A (]B3)DS5HWU=\ W_^2Z8.YL3"H,'FH_.OW^Z)-]HZA*_,_@C @=O$%1%W
M2):(:SADA,S!'8>>&U,/*C]T>#)-VQE5]IG-)W"K$,1*-R$U]5V#2,YU_]/A
M$>YDG:(M'L]9';:H+:\"VR5$7/ZS@B6-M6GTE%T@;JG3.G=YRC>=Y]>+/WGN
M>R9:&<Q-E7]^6HB>N)Z"AK>=TU#$V]P(=.EL_+S9^/QU;?7/2XE255?,KYGK
MF:__\/<M,R'0TCX)@1\Y"?E"XPKK@SL".N,:ZJ[N7FEJX\9UTL[79]HKLAX#
M4K7:?.C7._8<)&/$4YQ8+NYU[_&%_.B:@%+'4J&%YUG-^A_Z>4]ET@^@*0_I
MRDG<5&"@BJA,04$/ZOQ7H<\]WE'$\;IP@UX*2XV[KCVN=B2#H#*AD'C1.<'.
MHC@93EE?_K.4JT<20ECC[.-Q\AVM%]KP=Y-=ROZFRB)=1KPBE8Z:/W[;$5=]
M-!AO&W6$Y$$8X/K>/!W/QHLUN'Q#NLI?KD89K?2N:$OM9R1[?O<6*07@FJD[
M7XH<YG)S((P(.^6(6Z$P[GI'=N0-DN_I8=6KM@;;4*7L0'PU=F$QV[G1?3E)
MWFXF&V0I!OMDK,_KS>3+UHQMZ<(B=RQP1QA4^(ORBWBAM/)GCS7FW&;M?MAJ
ME!D,?L^Z9)$EFM!W^RO]3TI/&VLM\BQ1Q!)O$)$%5]P]OXAT-1:,KGWG(!M3
ML6TY(.)4X:@-N?GK'W4A?[4H2\S"F(37S]KE1WK/W>&T,QDB2=A7QJEJM'S9
M6W:W]7!HUG_=YP_\_=)%!?821LXAIU6A!\&+^2<5;<LM".9_E47DAEG+4[+H
MI&2K:- "Y3I>Z2WMBAMZD0.KH(?N=8P7T4>G?U=NGH$](&S'.; 24S'0V-CF
MQ(UCI2+4,]?>ES??_X@^%+Z*O 8<K[8:TSC'D[:FTGCEDS 32D1<BT$/JA;9
M5<Y&-'QV[!LA238(>)EIY7KLW&G<L.+1&":;$I^>V]Z7I0+Z"45_Q== 69KO
M"10:V+D62["PWY1=-@5Q%"&NUQ*;2*_@2UW':8=#=5%2CDUM=;6OPO94,+7=
MDCH8XRI9*O Z1I!C-FBJK7KD+1F*,S#%@\*;-5VR-C^+M..''J=;)? [QR;C
MC[X'SJBJVC=_+>_*^&NHW.U H@>?\#RQ_T1R_M<]BW%*PQQRXZ$"73WN".N>
MEKI-PK3QP_--29I5KH1]U&*C?-J<F55=@6CBPIM=6[)#77A'88[A5*]Q0\2]
MICO-]T8*KZ,#[SP/&CYVSRLGJ1'%AH\G!>:,:CZ:&P=$="=\WPK.>31EV<9$
MYBKA0T R@]ET^)T%D4LU=!-3@QEUX&Z;C'/,D) @=LBLUE4\PZ_2;4_!DY1Y
M=K0JQ->''G+SO@F+1,%)$=3M"H7)%>?&;VA$=BSJ^Z*CQ&!>F6@Q\FK>FP&
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MH Q:SV?BGK9@7YP6']P":_95:5%\M.3P8Y9H]XMS:_$B(%B,W-HT02BY'QY
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M3%Q: 9UK^=<@%80/'H:X6T$TPW4N_B:;>?(/^14N.&97W6=><F-P%N--!+,
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M[=&LP$_^H).5EN;^K2^9U<<?=+B%0%/+AOQ$BW_))+/^Z-!,KSTWK.BW887
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M![Z6(_YDHBMD$,N]2[1OZ'_GF? (%H2'B00!&?N)^/G;IWFH;J]"IMGF1OW
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M!T0QKCXQKV!-2XEP_K6SKK>6M ;=LIA?B:UW?]KQ FWQM6];8CSE#^4A)^C
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MA"!V0P(]+XQ0Y"/$8JPR317[6]KTC6/0(@4M5-!@59NTJA2/3V8+Q-D^:6_
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M%P:_,2Q3@-"K_(L,("GEM6-.A48L^[\*?9I5-S+29(5)&O' =6'B1I%02&$
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M-'6\D(3J9LWI_I9FY^Q@@@ZGQO*N0*^"_6.6-,N:H $+O$#J1A>\9&^*E:1
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M;#I%LYKI8)(\RU.[@RH):\'N;]9,!9GK,F.JE-.I[N8MZ*0H_(NR3JKOZ3L
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M%SGK=/8J<C%+ C''2>)1B+CK0.RP!(:!F.\1Q]A3NYVWC'-IRJ.1%."=J!>
M;(65/^ZDO0 /O;R #@5N/)G*K<C@OI<9/+1":Z01LOB%C*NV!8V[9279#OGE
M<,AW<H*W^T.^%16\>S'D.VG!5MQ^L[",(=?(.+6,H9\I4]7K?@)ZZ:[L#\QH
MFBR+W<^77LL^AWMIN6;H;J)?T:YPV=M-64H5$02(HRA",'(]L57P_ 2F8M)
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MR^(QJT3+HJTOLHC43?&%D>*1E>)?Z(;4'_,N#?)_,URN@H1QEX0.#'T:RE+
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M32BDJ1LF&'&.?*W,@R-]+6T5:K"U5PVNWJHS1JC:$F&()LOZ?%=HY@*T0"]
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M;,'IF6,3^%<SNNRR:ED%]>!!@UYZ"73XP5" 72+&"_#E!/G:5M=T_@S95A,
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MIIK"JQ--W38/3'[;1.%]RG J#.[ZZ;,0K:W;OO(]&L>.)ZO0.%C\P1#$4>)
M[%(W\!W/X1QIV:RG>ER:JMD"!NOF!G'=06Z,EYS5\B*E@PX>BE+_-./T&"A:
MD":9M6T*;DGMPG&W<"_ #K!!4TZ5&U,VV<G^YC6N5,5_824IOSBA#-97<L?H
M9LVN^-'""^^K.KN73A:_5XQOUI\RSIKXX%VJ2#]%CLL< AV2"/WD12&,G3B
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M7UB]*?/J2[%>?RA*:6"M?)DUT7$=Z$?RKMVG!"91*C,PI Y-?2<FH5:Y)=N
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MGYGH$4;N&-VLQ;;MS(H%-_(*:<6)$Z(T9-#WO 0B&4^3D-2!<90FA/$T"OU
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ME7I.H^^EK2 -T.G9YW185[/1+7%I>5G86ML_];A_%ALFT+([\"54X%G;UI[
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MD39"[?8/7-;E#M:OGU=2SCHSJJKSH.\?\>I;7?NI^GNMR.=5F\I%4>#C+ Q
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M01@2DH59Q'C(%B^\),6$V/;[^U.C.VQ\'2(V=N#%3LB&\=-38EXNHF$$ED'
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M;LIJN$+1D>&R%F-2RW8M6(>F[^KVKB1[_X[_^"+-;IGC95-2J$WUJA9!QD3
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MZ6U5'?VHL<F*HI]3HU\+_>PS]N1TA9SQJPUG[76,] T/:[C&8:JB12) &.0
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M21RC,,X0XT;QFI9RS,U<JB!;O'K]M\KKU*A+43:*U*?J/55LBY&;C92>G9P
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M:KU2K+UXR7];E1PO\__A3%74N"NJ7$G2V+UOHOMWM1 <A3%- I"1B,OU(^:
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M?M[Q\LYCY(T#XV<;#3]I!+S#L/>WBG6_'.#N-*K=)I5Z@?PH1%BD(,O"#,!
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MWS=+'O@D#F[+\I85SVO./BWQ@ZXO=+Z%N=D_*2E0HGI*5A#LY>*V8NL[10/
M77:)W& VLAG4@,O[7<GLR#.Z#(J57S30[&1>T675^CZ1QM/7E(OX(<U_D\B+
ME^ID^L<CYVJ_=<M8'8J E[L-5_7N=8_6N!KF-:[J2G<+&'(6PH""U(\1@(A
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MJ.@9G'&P'MD 29A5^,1]&^8?#<P[X<%-/\S&1LD<,4M&RJ#C28V6.2#'1FQ
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M%OM=XB#F<>(&T,4\@"B* A@3C\ @BFE,TM3W$#9+9^_HS61R3).:_JX5*[L
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MF,:0H,B'(8T3AEPOP4XR99*DIMQS6X1VI0J>I70+P/=JC%\-P]*GH+<RS7"
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M.0&'A(8,NI'#$B=*4I9J44H8]#DWQ[&1%#Q(44W3A_HAUG,L+0,WLN7?2;L
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M.XL[&7DG9. 'H,,NT0$->$"Y;&P50*!": :JATX]<R5*,U#C!"J@@$$*:*C
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MLS:U\)!6/2Q61GSM7]/DU.J<;#JK%&!7UD28'H8[LX%=J5.#.2OL^Z\ _:2
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M5_]%@F&..8\XI1<V.+67IH<M].74L^]J.F O.8=YM-B$>IB;:_)PO^H2?-&
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MV0628E36<^<%U$@B[%^]'S::ST%6$&T3$'D_QT]#<4R_PUN_]ENV)L(:HSP
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MU\=. U]A/8U^=I?\$YN W?WD@3J"/4+^2[8'XUYKY]&.E7>]I=>O)9;%1!1
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MLV9-[;.4UH!9/<#9N^G<S^-^04905%J7B3'2X\%!.4'O.Q$>%/I *C.E^<O
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M\RA!XUJ6:KAX4$1830G-F91?_?*?L"XO_G?:(1QA4?9^SFD&Y6G2*MF3G2E
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M/5-I::&EQ%WD.<G"R2@8>NN\=CE;70[&M4FU<'??0(VHY>8,VL?E(EW&]2=
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M0]JTV7U@H'T.VEA+0I2F"-(0J[@@N)DP9J'=H)?:>8<CZ.R'Q!\M-S^XQAI
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MW<WZW6)Y_Y'!Q+B@O!***-XU50]HQSUU*")GK*< ,?6KQ'ADD0;/L",5N1A
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M>)-BF VL!# F2U)LR<$S3T:C5,BB4-GIHW?CV(..<<%] *R:)9<WDG$'./]
MAM]B6OV'*ZMN26;@[[AN;8 8'%JTH)4A!Z<8I)O(,Y V6).+XSZU'O;PY(8Z
M?^T?'"_SH80W]D#"&U['%2D;,CQ=0+P.4C0QDX;G=?Z1L\"$YO2C(O+=J.0C
MXP0?7Z/S]^ICP:JE),8&U$/NZG)#AQ&^R)K6YA/+M<8G@T?C('OELO%!&9ZV
M0M03BW3^?GI42+6210?7Y=Y1N[=74TE4YIYLEMKQ5"@@5P_!2Z8@*Q<RF3-*
MIT%>60[:]<@G9!?^S)%E?\IH?W:2\M6<V9O](S.B\=HY<(4ENE]8 )=S FF,
M-#DR'67KF23'I;!S\[4Q?ENIS_!@^F>HVJ9='8\Y!ZT-Y&@"J-JOU;O 0><8
MLPY6Q=A-,[9=B3M1!3L"PH^OC'O [72:1.W-GMMM?"8:)0^2">"\U.Q<F\!K
MQ0%=,A@D-Z7]G(,CT=:Y4_U/T,4#P+:W*G['19QW?RE>9$]<<:80"Z*7%FRL
MB1PN68@\:Y V"6\5V3RRFUK?'6GK/!#Q3U## \!VVB,<GN7,ICO/#>:0=Q%<
MR1&L8@:4C1I<$+69,F<8Z?NDNLGEWIV\$\WN?DG*>!CD7K@^WC7>(T,??<I@
M,R?6&*S&.W<09,[",9Z".QUMW,=7["]!_"7IXB%P._6V3]LSYTY!V-JH_YD.
MDZM)XS<%'5C(L6@/!CT#Y7VBP\QI",DQ8:02S+5^L>^,!2?J=YY,D'4P./XS
MHK#/LF\2;':^-E./ 2VHD 4$- :"M5);XEH*W;3 :4CWBX_=#J<X'1X".Z'X
M'Q?W?9Y]GHGBL1A@P6A0*A>(#@WH4'P2,=>KX&0.@1V)/]$;_!]U$@R)YQ=M
M"-P.!C[/.%TP12P!"D;RB0(SX&1T$#79B%)H%%&>S$&P(_$O/G;] @Z"(?'\
MH@^"&YWIG^>:*T$FZ178]9ATX3D94DD#<XYE[13/KIN*\::4O_B(^0LX @9#
M\HO6_QU\*299"(%;X%D54-9K\"4B!"?(;$)C)<LGH_V-(P*G'*%_ ;H_$(J;
M1O>/T7MB7=APC\.U-\=LB?''55G%;[-T=IXQ_S5=?9G.B)FOY[-<_X;^W6PY
M/YOFL"[GHJ_K%>;E/9&T_K#E0/TICKGUX7I8C": /OI<"*M,UMZ!-XK,:E8B
M!(T6')G:,96HBFQ=5?)2^EPP.GDT,@\1XSHM#B$ZQL$DA1YSB$3YOWTN!NAS
ML0MFA^MSL8OX.S!(;Y>_!^6,MX4#6E/?]3D'+WB!K%@.PNL87.OV-B^RS\5.
M('BRS\4N$ND 3H-4BD:T+%I'ZLRY!R49_1^3F<R]X 7]CQ"E-2J'H*.G/A<[
MP>H8?2YVD7$'.']#5O+\!U[4M%_X+IL*9*>3$!8S9%O(KQ+:063< +=:6RUS
MT;QU@/W1S73^!CXX3N9#"*V+4H:G6W7D'!0IMJ3[!I%\^^3))G(.I(BHF5.!
M5+^[/BNGU1#C$!RV$][8;3&>Z.ZA4L"H$P<F1095O(>@C('$L^-*,TE&T#'Z
MK)Q64XQ]8-52$J,>;FM"+@_I/\X7Z0MQKC+HL@-19KF4%""A#J!LDN"20!!<
M%7+\R+V+9BM(/;Y&Y^]#1X54(TET8*TUR*(-Y+1):<A,EL&M6V="E#&"*T+*
MZ*Q!W\W$ZK<OK<W*(>[TD67? =I?G:W_AJR+!TG?Q+ GY.AYR0*#+'*MI,\%
M@M2:K-\H2]&DP2ZVCO5LM;/.O9;&>+D;_6DOO(9W^C&>OC8D+C=1W]7\AKNV
M#+,+FWD= 5ZS?:AGK'VW,=R35!/&]/&\I$74+G$.@2P34(J,B. 8 T13HM'6
M:]GZ-GTISTO&%4/6NX/"@J7#Q54F\@S2DC67O$!FFU=D_?N\M"-F!VRCOH/X
M.[!%?IO1T897S]]OZS^H]-88-.,I&BD=:.0%%)/DF!CMP >78T!A6&G=OOJ)
M[;R4IZ>= #(?1EK] F_C$W.K$W/*0M"2DT,1%81B/"05I(DEV5A:-VAY<D/C
M@J^9V+>#TQXRZ !0'T@FM($OKV;Y9_R.9_-OE::-37;9T3@GH6V.0/HG:U5*
M I^] W31.PQ1\^8C3K;85I?@V@<$]\/H3272 <@^XAG]ZO.O.,-%."/"7N6O
MT]FT6B"KZ7>\]  VQ EN4.LL 8M5M?LL0K!<@\U).Z&]3J6U![_3!L<-/PT'
MO.&DU ,$#X]_,,TRLQ8A:^$N>C3&' HD#!Q=T8R);JI+7ERL]!#[[\BR[P#M
M6X;;8DC9&Q% DY,'*J&M52:,;A7R_G),6N;63O<_)%:Z$U[VBY7N(KR3&E!Y
MORCB(ABX9O&= HI7R^7YUXM0X9_T80,%31OL:+CX:6MV]1%*+25*C:0[.>CZ
MV) 5N!@SE*QMT2$H;-YK=.10ZKZ'SI78;PCWPW3YGU\66&?:(J%M]8$(F"3K
M9,FUB%AEND*S)HLMA B\*.^+29EA<[MZ:*)..O2Z"\:;V32#P*4#DZ<I0RZG
M1?\\_3[-=!JN&1*#CBR)3%YVSJ!\T>!E]A \,X$E5,)V,Q)@6Z+&=0]>BOX<
M#)=>]"<^SY"X"T,^X>(KG["2F8DI0S#(02&7$+(C8]@H=%H+D?(@A=F#4#-N
M=N;8&C,^0'I1E=9GQW_-28+3L^GJQ_KT*)XE:W4D:*,AEAA/IT<T='I$;@7:
M0+[?*5PVM\D:-P]U;.7I"#+=!03>X>HBLOUVOEQ^P\6:&P>X\T]^WF'.^/9;
M;>1*OPF+V73V>?G'9JTK1'*N3 I6@Y3T17''P)7$(7GCD1EM0_-4@\?VTBZ3
MZ-5L-<W3L_/ZYO 1T_EBNIHB8?ZB(<$OI-55A<XO1/:^W-W01;BX9%0Y6 M.
MUND1246(=1*KX_0#G8MPJGD_N*84C.O8-D'<X]E"1Q=Q!T;#@33_]./A#UAG
M,X@BN%7<0"KU<40R1O83UFRNY(+ST8OF>1\#DM-+RM+Q47KW(: 3R'2K/3?*
M@;PCWDIN(6LOR?@)@C@NJBW$O>*>81*M:T.?V]/(A?&]@&<K4.\IR0Z0^7CU
M-3&!? 3,X*,F>[RH K'F2AAM3 Q%1L9:CX7IM&2^K<RW+G_?10 =(.GI^FF3
ML;@@ TA=VP I15<*%QZ*%L98$9@;(@FOU^+W01'53A#CUQT_54#-"HM>.6*,
M)4(R!HB&)^"8LY'2>Q7OO >>6"G[("!IR=6Q^QP\40K-A+#,T^9+J"%9$STY
M>F3&)L:E2"8*5?16X.BU*'TX<#3B:A<-60ZT(M]>%X]ZFU3Q#H3R'I0(I!92
MT%TL; E%!,%YZS>@5GOO)87RU/W1_<#0@6%V(-VOOL[/9ZM)-"5%9 :"](7L
M!G*?HLD"3!#980[<-.\]VF3C/;H.0V.N+?#W $!W[S,7+QZ?PM]X(_60;DHR
ME:<IS/(O\P5./\\J'^8S7'<$KL\C/R'927CC'Q_PI--Z"X>] @W*D$8/1U?+
M7+]\7K>5U2&J2">_<@Z!P%C Z5) AAA]"M;?:V35J%;PP>VTJ8NL#+[01E+8
MV3GIX'57ZON,W\AJ@EZ231?KNVZD*[%("3&B ,U=CHS%Z&SKNHX#MMM#V=OA
MB'JXIG)X^75@3>Q!ZN8LF3CMB;^NC@%)M3]5S.#(GX"$/";C112L=0;O_KOM
MH4RN"Z#N([W3Q.F;OXG!)-GI+"Q^K,VN=W/Z[6Q%6Z-E/E_F%T\,MRF9$H G
M84$QIB$Z^M8HFXQ(T;#F39H&)&?<*%='2!]$_ONKPGP5SH8UA3\@49>F9]/U
MIUWT,DKK06^;/_D)9UBFE]7;%UX"YC^7Q(Q?,-<ZVUK)>TZ:^./JW]1DKC9F
M\N#;:V9"'Y>1QS"O!9,E9PG>UP83PC@(*@801A:?M.-"#6-4#F)>ORF%Q$'>
M[RW>WA;:J]63@IB8H)+(AD'A=;:IC!H\^<- GQR8(?6WIG622H-M=VQN[X"P
M>V^F1Y9G!^;,-B2ONRJ\FN7:5.'LQNDT02.=-)R!U"'3/6IK(_4BP'G/I";?
MPYO6HQH.V6_'IO? H&TBP1-!Z^LO-7G\M]G/FRW2'[U:+G&UK/GB%](^.YO_
M51\I)XX9H1.I:%*A\ET8B,*221B,<-:5VLAS! #O0$+'1O; F!Y*SJ._/F]!
M._WP-6UKNEJ^RO_G?+E:5V1,'-$2N#;@URD8=<)%P*A 8(Z969'LW>/XL<?I
M?;<P[MMU:S0>41PG<K:^J^,.\SG]63R[['PT(4(T"O*AF2ID\3A.K#4R0]0A
M*6688+FU3;_O7L<="COF:7FPY$X$H8\UATFX7%[[RW_@(I' )H9[LM7K* /&
M.2AE"SA5,ET32K+$C#6B]6M/<R*VPK1YB9@>3M;=@OVA>.-$)V.L(F\S645&
M?+*>+AJI(*+4401;,F]>[[;U[K:"IWT9\#Q8.CT'=6\^V=^SN0/YEM,0:]7M
MM%4VPQX+-@N\'DKL$4*I+# LSA<0#E.%KZ9[FWP:#-$D(2T3>IBNQH.$4N\Q
M^1VNWI?[KMQUV;FD8URA@!23)4?.U7H&E:"4Z)35V:34NDG?KGOL-TBZ"W;N
M'GV#2JJ#B_<>?9NS?/:Y/OJ]#HO%CS)?K&=N3))Q1DO.@)F"H#1+=+9G#YH;
MSPW=(T*T3M_=87LC=P$;%"?/@;*1T'K$XU6TX399)@?K3-9@.'JR,W2NC]ID
M<2AIC I"%=.ZKF[+K8W<36M4'#805H\8_'4^SW]-SVH[[-](EK//-:QP\:N)
MHLTG(QQXC0&4JZ-3D.X:'QP&FTC5N!T:B$_L;^1.5:.BL978>H1DM70V/[N1
M#G'54VB6-_& Y<-A@]KF:!*8SP0N!LD7!\K6Z9E"&W >T5@7E6N>_3L$'2/W
MDQK[P#TJ#,9^+GK"\D$B[M)1_3%1SDBZ=0R1PB1=.3& RSP#"D:JGRR3)6SU
M.K3MBN,&VX^"PN$D<!HG;!W*LOB.RSH5(Z7%>3A;7OYHPI0W@OL,(4A-2B0Y
MN,@Y"!Y*B#9EKUNWZCMLQ^,&TGL[-5N)MD<@_S;[8S&OKP0/#Q6:).Z8=L&"
M\<K7J1H>0C8%T"E,PG$,N7F7]1WW.&Y8?5RPMA1?C_#\=3%?+B?)<I=K7()L
M[_I>E140VSB@$@Y-5DDTG_?T\$ZV@II[F5#;713-GG": .K&.P7I#-DEJQ^U
M[\**-.;-_SV?7N@+6F%"??R/.I"^&(40B]#@M$E*8%2V>9^\';?8;^9FHTAZ
M<SGM#D-_ <,9?@X7':C;'V\WJ*RF,5G(-R==3;3T-GEFP(A0._4RLH]KCQAB
MJ#>&DWWL6J<3;[VY?O,LVR/P4-D<BKUA;M4'TD(3RB*DE& QT;E.UP3X) *4
M*&UDWCF5!P_W[)G2.TH29=-GPP/ET2?(;F@1V2F3+)1SIO;6$XF!XCJ!$U8#
MF:!2*\D$MV%H@-W>4K\9D$W!=8 <>L[!>97SM'Y.+>)8=UJKW[3)MGGRHYOE
MU6Q/P!$R:%#'K!C94R;I"(KY"(1! =XKIIRB+Z5UZZ$!,FC6,<B;#2"N/OFB
MM94+3-09#,"S+*!D$!"M*Y74[$UB7KC\'$Z>6:/?1)==1'PKJ-N(H2.&%Y:+
MU>1J'O*O./^\"-^^3%,X6_<J3LX6EH4G1S:1+X'%@TN"CD7EF6=9"U6V2I^B
M56[@GKZ[QOR3&Q@',DU%.V_-Y['!@I_ODK#I^1@B7926(7BR]D&%*"'*VB_!
MD[EFO"O<;G50/@>6QS8P#E@:"G;>FLLC0B75KFV+'Y,_/TZBS(X3K6"=E:"B
M9#46D<'R((1/RB3UU.B_):;_Y_/\^__:?.(%-#;?7"/C>KT18=!&:/.#.-A!
MJ/K=?/;G]:1[9PHR#3D[5@=A,@C&!!"R6NK,"AY:^S8WEA\G(M@>"X=RM@-0
M7-VGK\Y77^:+Z>K'^H#4S'CO,! W<@!E,-8.CP)DIN.1!>VE;#UZXN&=C .5
M(4R-AASO$C<;/3+6:!T-@N2NAH'H?G4Z21!8:V95YJ1.@R.GAV$E+>3\+'3V
M8'H'X+EL<_CZXB[=G)PAQT)ZA9!=(7<O9EY??A.(:%C4.?)4FN?C/[21WF"S
MCXSOAM@.9G@'J+G5!^7_.U],EWF:;HQ&"<XB,U@[SS-'A[(+X+R2@"5P:WCP
MUC>?!?_TECIY^6R)I)9"Z !35QV-;^H%[5SZ@&0 \I+JT%$-4>D$H? BDV;!
M-[_"'MI')Z^6+=%S,+L[@,R#12$7(\0$9U(PLO53K4FNG9F\8:4Z$VB$2RQB
MZR*>1S<S#GB&M)O;\+U7 -T8TL*2LLI' =QJ142DN"[C &&T\)$T+V!KW^N9
M+8UK$342_#9PVE,*'8#J,IOR\AH. I,J@33+,J#_81"X2Q!=]E88@ZYY-L[M
M'70(F7V%>W^2VKZ<'KO<9-/\\OWBVY<P^WEQ_OF*3QMB--EK.G@'-@5-"J4+
M^$A:%9B,,C.4TFSWW/C<2N-:QD/ HSV#.SA5?@IGZWEP7Q!7U>)?"ZB>O%Q[
MSF7@8)(7H&K21]3(R29DDJ/5PHG676L>V\LX&5=#6CI-N-XI>C8:QC-+TNKJ
M' 9R$Z/($'UT$+**2J(*+K6^GQ[?S;AW51MI;P&A/5C? 8C^6."W,+TL;*H5
M3>]77W#Q^GQ1F7N1,'9YN#*5/#?$*^$S>:9<U_==!N1>"DXD"]N\J<[VN^L/
M9/O@87X4X8QM)SUXKK^]&KOF5,:8C2-GHU;0E<(AHB-#@0LFC1>:F>V&S#Z]
MSCC9GD-<;*V9VL&Q]'#R_=WB]?!MN@IGT__!_'"U6RU8IX.>HRANK7PY$L'!
M@U<J@ZCIU+RFZ\?6#G_#[?>6#+8GI+8JKAA>OF,??0WI?O5UOEA-_V<-A3]P
M,9WGB4N))Q4R,*\Y'1XVDK,<ZJ36$'36@KE2MCHY!]UF;SD'AR&Z,[%V<'8_
MT5XL%C3:6@XNFSK/C*P49UR&3 82.F*U]ZV??@YL 7?$&'Z;D[41]SO T<.!
MZ8O!N*%DYH05X N/=3">AV!JD#JB5E(G^G5K7^2)[?06(VF#I%;\'_O.W32Y
M#I_Q??FXFJ?_?)F?D426[_^:T=<OTV_$PT7M1C.1R6HFM :AT1"WF(6:3 0E
MFR*899ZI[=H ;;UD;TY(@[MP&'9W "*ZBM^7R\DJ#U(VB4ZE1#<RA&CIA-58
M^RL4^K^$2G/&O69Z6P ]O]PX37F&!D]C-G=PD6U3WAN85B6' "DRI&.4J'&)
M![#!,^<ML5,,WM%DSW+KYIUTCNA\-I%'!Q"[3\%=(B\U:G.!Q\1$)!K!*K-6
M' $N$)':I2(XJ^9@:P-JUSV.TUMG:/ -*JD.D/CG;(%I_GE6W=Q/5X-&EE<<
M_0-GX:QZQQ=]5M?#?==-U#!/&//<QR!!*4Y?:H?5R)@ [DUDV6@?9.N^]0=L
M=RM\^E/#Y['DUR]4)TH(="(A&+GN15D8N#H)*@81BXE<&=.Z>NN1K6P7_&4O
M!&,[,7YLA^#=>7UWJRY.6.'R*C-EDX)+I_=Y[>8P^[QIQS?AW @EI8%DA0<E
MDZDI30@A6*(,-4J1MG(-=EQX.PB=S /"X+SOX%RZGIN$":??U^^"EK& RB:0
M/!?BE0P0-5>@:R$L,BU3\XS#![:Q'9A.)G;?BN'-,#/$:*JU-;F<SAXR/)N,
MHGI^@7:CIW8DY@B-<IP+RHD:2O<I@?(!"7<^ ;=9!3)[O-&#%60V;I2SA5_\
M87YV]LM%)'CBN=*9" 1I,(-B(1'E(H'7 F4J\7Z1^[9-TY]<MY/ZP0.A\'27
M]':,[^ ZVR;<$J4QQ6H-09A4>Q$9<":0IYM*T:Q(E6)K+6H5_AK&=!H2$GN$
MPW:1S]Z0^[8._I)1MUB-$Q13W&G+=8!2:B8=\QJBTP8,.;911L64;5UA-DA0
M;!@#[(B0'%1R)W(D%DDF:XX%DO01%'(.P=1&;59ZJ<B?B<U[R+0Z$H=)FNCL
M2-Q%/@<>B6]F>5@GX9& 3&7GYMV_C:^P_3K-7(8]23O&D-I2Z(@*%K(-!)O$
M,@2E)<@2<G$9BQ6M9\$-.*3V]OCQ]^41OK_Y.YV=Y]I!>WUP+__ !7%_1C_X
M-'_S=_A*_GQ>.^*K\\5L>5.?G<P<R2D'#'4LH,\>HK#DY=O,,I-<R>;SZ(>F
MJ5]79A=LWJ_@[ @)'5SVCT6[3:GO(99L%ED,**481.:(C(19ZCKQ2K9NL7O0
M,\-0..P++UL^5>PBO&X<HL??]M8)675FT/E9#9S_0D+:5!E=9.34A[_Y<MV>
M>CF13&-0+ $G;Q!4R06BM/1_6>3"DT,N6D\O:[/S<<NB3Q'G0T*CXZ.9.\9]
MX&3;!UOK2D*=1A@XY"138B73]=@Z.^:0HWFP+D6G"-F=A->E8W8YY2C<&' T
MP]7'\Z]?P^+'O#ST^P/\LT.6.\Q-:T9H(V_MT?%25W8QX8HQYA0D96I+G*3(
M+F9U*(MQJ#)REELW47QV4P<W_DM?,)^?X?ORZ%(7M:E66L$,UG=S\@<463BU
MT,Y CD9@+DIQW3H\NNW>QK5@V^+F7D_ (>33P>7[*#4__?A$'W'1I$$%DZ43
M4#= 9WDRX.M88')+G6+(K?#J6/IVO:UQT38,'NZU'F@KG)[Q5@G:=&M H8E#
MWD*2I=HCFE@6,@.657'.&D\D'PMOU]OJ]'3;%PK;0FU/N8R=&4B?,%_4/_AQ
M1<FF24=!*[(FGZ@PC.03^3I\%V5M]5DDD2<M\N>LM:>7Z!0I^TIRWIRM8X/C
M]?SKMW/ZK&L3898_SLN*O"'<D..L2R[*")XK.K85,@C.2<C!"9-$U,[8K5#R
M_%KC!D0&A4MC1G=P?]71HUAKX7[[^FTQ_WXQ?'1#BO6!<2X\T*XM*![7[]_D
M3'N> Q%F;&Y];SVQG7&#%D/!JK4<.H#4+^>+V715'WYF^9?IW_7_+BF1UM8N
M4N2QI#I061,Y0:Y;JQB>>#:!I]8M"!_?S;AC7X<&5",I=("G]Z5,$]Z]GV5Q
M)6F5($2E005IP0M;NW+&K",RNIY;'TX/;F3<^:Y#H^APWG< H-?SV7*U.%^/
M//AM1BS[3%*Z5 8G8[">)^#H7*5%0;#<@0P.L2;K([9.F'AJ/^.4WQ\+3LTD
MT0&J'N75V^OR$;JJM6$1@JI%(\[2G<TU I,Z>U6TT[E]<\OG=C6N>3YNG&D_
MT?0,ME\7\^5RHJUE)=,)3)N7M0F3H1L]14@\"*8"+UP?+<*TWE&G(8,]Y;\M
MO'871@?0>I72^=?SL[#"_#/2)M)T,R/\VQFN!3;+M]K'/4;\)%MGL=1)[\:S
MVC)6UN<(!M88%;T((H?6-VFKO7<:LF@#UU$$O#NP_06P9_BY[G384_,=KB;&
MIZ(<Z25J31=,< $"NOJM$%P8[E3S9B5/[:?3\,; )^:N@MC_O)ROPMGQTBI>
MY;Q.7@IGO\W*?/%UHW&MTRF>7&:0-(KM"3M:^D3F/ 7O!+#B:H,0Y<$G&\&S
M(B77W@?YU%#L+M,G;A[4DZP]2L.J)Q0MJ#JN.A9#CK>W)I%EH<CU:EZT<[U^
MI[;<7O*_7Y.S)Y_W/HB^XR+.!ZG/?SW_^G5^T=SN@)/F@4\Y["!Y;EN-SHF*
MB]6/*U"4VJY/I@19U*$]WC (V7,2K<Y.&R[*W5?1@W7F]@X.#UI=L>WC%]*4
MY6:FX_]@K@FQ6J$GW]C6 &Y(]8W)T+<Q*-2.%:M:FRY/;&?<\^$ N=^/3K5A
M^=C/P9>=;/YKOL*:-KLF9I)T#<]Q8H5(=$P&7R<'8^U"8E,.G#O/M\L3>/#C
MQ_6@&H"@$>>ZZ]JR)N$#?CM?I"]AB>N8:_AZP 7Q] <>=E?LL-EAK@TBDB=E
M2Q6PKHVG#<3L+;FX-H9DN4?1NCZZ\;5Q%I;+]^53+; X7_Q8'V:;(3 B>^8Y
M VZ4J=5W@LRD&,%81)>X<=:V[H/XZ&:ZNC)VD?F]*Z,)NSN( CZL>>LT/!8D
ME[4/.TNJIAF3DQZ3E1"ED(SEZ*QKGJ']Z&[&14XC<=_-Q6[#^VY1M'DX+-:;
MXK(%@?7AL# -CJE$I)E@4&9E5>M:ZZ?V,W*^=2.9;P6E/00PM@W[.RW]16B2
M*+]'SN:]V.N<8JZ3Y]EZ2$0*X#F=X,0ACD42S\IVS2^?7ZM'K.PCU/EP'.X9
M,#\MILO5_.SW'[341[K\8ZR)G&'VX_HO-Q1SEKES 4$[5%"3S,&'Y$#DPJ0D
MUT]*=3"FMM[.R$_U1X?=,'+J&9D?SL^0LZCY/0J3KE/*C0)I%#%8D0\;A0T@
MK6<9DR!75!R,Q$>7'_<UZOC(:R.'#BRP"]_F(3OU^B4/G;/)8 $K/1WKW&7P
M2/Z/1)%X1 R\>8^@+;8U[F$WC&7?6AH= &R]^_N&ZU6D]*):GT^4$1YC]."4
M935H5N?"Y0"FMG4TI5BN6L^>V7)K/00?&D+BK@<P@'PZ@-TM3FVB\XE823N9
MV()U0AP#PW)] #018K09E)2A\!#J+*?&4'MB.SU$PH>#5RLY] :IVHL1+RFI
M,U-_1]*8/-$!%>.&0\;:2Z0X 9%[1=]ZYPNS*)JW)=IF7^/:9T<%60O)](:V
M2W)>?<=%^(R5JJO7)EJ<SM^0@"M-C$-IR>#T$LBR35Q*<G5*ZW#KMGL;MV+J
MJ*AK):'NW@-K7\;Y;#6=G6/>C/6=SY97W7%^)1=K/OL8SG!>'O[3 YX.FZU]
MV"OC,"QH]"#Y\(IUIO=T^6V^#&>_+N;GWY97KU>2*4S:,:#_QIJ6F2#F7#MK
M2L$Q&$=N:NODL-VVV&9RS7HLS[I!1#BKK9(_?D&L^6#7"8G7'4>7/_VXO17Z
MB(M>8@]O_<+1DZED):P#M!EK]T4)WB9&9X<M*2@7@FO-R2.1-J[',R2B'QZZ
MTQ=6.C ^AF?+^N4JD4<I41;@VJ^[HROPW%CP3FMC2W:IM$Y4/0YE/?14[@S4
M1U>\G1'6@=[M1."[\/6JQM86ZS5'D+:.9XV:@2LF@4M"LR"SRWJ 2WV?K;YT
MS=@==7<SS(\ @;%?N%Y5^_H]R>)L_OG'3^=+<L>NJKJU4*B33T!>NB!G213B
M'=-@M$DA)ZD<B\_Y#<\M,KI],[R$YP.PN[<#<NW:3\LT78BN:EYV3I(3[R$:
M1U<2-QI"B*5V]B6/VTA55.NDQ6>V-&YX]Q1,@98R[1NB&T46M'.>3 06M0>5
M"];^Y!%"MI'0932I^?% VL.]W!0"V\-K#WGT ;"'8DQK,NDGY:<?-19U>;X'
M(RT*!DD)<HX#'>W$,P/,H:\EN,J;YK6 .^RO6]CM XW[P!M&3AU@</A[Y3I&
M;XR3.9'=D^L$(.40P9>4(0<>E-0.M6F=!WQ$\L9]F3L%^Z!7K'6@ANO9\IB7
M=1[*S]/ON%RM6_C1V;*Q\G$Y\4)D;TJ!P.@<4\8%\)@M8,PQ:[HXDVV=O;7%
MMEYZ'&!/2-WO@]%4OF,[_H\<$8LP6X:TZ2WSVXSX7<51WU K>5DCYP)"DK7+
MF\K@>,[ &)=)!%^<WJX,=?>U7[KK=AA&CR'00[L"?1H2MF^G(4[/2 I8C;K5
M8AK/:<G:H89KKJ4@132U]ZY2A4BDVP\2XX$;AMFA/ "SCR[\TFV)P0#;1I0=
M& 0/DE<3%-[.EYM;Y(+?[Q].5?@)RWR!5T,Y)RI)S-)QHK>FZ%FO(!BNH3CF
MHXB9;+>CN(_[DS!N#E+O.M$#;GI5&Z+C32F85H_0/)'>6-2UL8,J]8L1X&(@
MQ]V(HGWFW*>CI-(\M]%Q6TZ?M HTQ<#XULQ6ZOY^]HRRT[WXOE0M3U%Y]'5B
M10K5JR\*'#,&8@HI"6]":MY&MLW.Q^V:?=(:,2Q*FO5K'%PWKL3WOES(\_VB
M%I\N\ O.EN2J7_SP34WR7$[C&;Z9G7^]/#2\2[FL$P(T\4'%M'[)K;4TQ:.1
M@OC4>NCV\%1MI5/V7YWJ"ETGDF[>NCWJ'JL,D4)^].:HNZ;6<EF06<. V4)F
MO'>2#G$K0!>5C74Y*VS=*G7'+?;_D+493\"#%<0Q0)]K)SB)$*TES50JF!2%
M*\TG&?V;+'X@HL=*%M\%*QTXST=*JN0N:U$B@Q2"J&,2<ATG%,';''DRRBC7
M.K7KWV3QD4 ]3K+X+@CK0._VS2,U1%B,F4&QM3VI$41F;7F:O&-%J.AUE.TO
M]7^3Q5N@KE&R^"X0&/O-^*GL93I3<J!K&S2WOO(N0)0Z #>A%(S6%!6>\P5>
M9K+X3A+>-EE\%W;W=D ^D%4:%:H2HP0NN:JC=QW$E 1(P8O//$G7?"3D,UMZ
MZ1D'AYL"+67:-T0WBNR"9HS5'O)8Z'J0BA0YUZ=H:QSM2 7-6_?N?W93'1V)
MAT)@YV3Q7>31!\"V3T+&:-2Z;9TN*9!BE@P^HJWM/(TQ61J7CA*7/M%D\9V@
M<4BR^"YRZ@"#QXS-2RU]<&3HN&0YR2 A!"WJB!Y#FN]]4*FU<_-OLGA']D&O
M6.M #5\ME[A:KE]KKZE]FMA)RDHYF3*(R R1Z"4068XHSM9QYH3TS6=T[K[-
MEQXGV!-R=^=Z#BS_#B!^(X]S-SK1!+I/<R9_-I'-6,>5>ZS9"I%K731GPK1.
MY=IWKR_=1VP#]J,@8>S0V'7>0#4.WY?7:W(^DUS^"#^J>):38!-B\ @NJU![
MSS$(/'DH3"-/+OJ0GGTMWW*MEVZ<' ;,(01V(MD;OTQG)(MI./N RW,Z$X_6
M*7#7A8?(\3B(^)'2/A(*Q2-*0+KA"8,A$1IU A2&24/N9?9'R>M\ 6D?R4<M
M7;U#+&FSR[78*7JPPB5?E# %6W/RW[2/ Q$]6MK'#ECIP-8^TO,HTR)F80P!
MW3-0O-ICHD1(S"%W=%LRTWHP[[]I'R.!>IRTCUT0UH'>[?LB3+ZZ)M=&0?!N
M+0D.]"T=@;$4YY62<MC7SG_3/O9'7:.TCUT@,+9O^V0>0I("!7*0)1 =-6_&
M)X50DI8F,!>C\5LYM2\N[6,G"6^=]K$#NWL[(!]J)A8"<2%)\%YX4(F^1.<4
MN* +%JX*$T=\4?\'I7T<8 JTE&G?$-TH<A#9BQ@+2)GJ*$V+$"-FR%RI'(PW
MG U0>7'*:1\[06#GM(]=Y-$'P+9/)S#*FJ"8!:X8DF+*0-='*! -#RP7)Y$/
MD!#\8M(^=H+&(6D?N\AI1 PN%ZO:N"J?I]7[Q4=<?)\F7&NH=+J4J"-XF2-I
M:+ 00C$@C?#:2#(DTE:-_&B!&QBC[Z[Q]=C:+_UM8O\;MHFT^D!;C?]M*%AN
M=#/9&!!U?9])F4Q7ZR&XA&"M"TSXF(BN=I"[OX%QSJXV,KT/D ,9W,&]^/^W
M=VW+;>-(]'W_A;N\BWS9*L>),ZE*;)6M2=4\N4 0E+FA" ])>:*_7X"B9%UX
M 4E0#2=^F4KB<:-Q3J.!;C0;U40JAQI&EL=? -.8"W<X'"QN,GU/,ZW(LF:N
MY\Y\V?6.1PJ 6\=80L_;%0Y$=[!IO) LH#+R#=<T8?]$M_[TGKP0YF#O2<+[
MKLQ15FRJ2=FZ-^.]J+5PYF#-MK'-8F',7:RISZQ98#FG%SH-J0>Q\6 B0_D6
M,A7$:MK-7?%$LFHVOA\1MA&[FNDXKF:[3L0C$EVS&521:1#3/^V@UL-@#@:"
M.>%<T%*&@@IJ(CO/>$\W*-E;>. 9+M%]6],=PI0V">_5P?9B; ;((_:,10]"
MIY(>^\Z1 C ]\:;;=X:CJX1Q7+)T:69Y@<\6B>9@MC/;!EL^@>7ZFA-8!M9M
M*T1(=O)3M?KX-]SL\2W<J0ZS->CKIAXEHM5^]%I<$A&D(S8=S35F1+,=_CY$
M9#I:0)B6#K'M"(5"6_P()7[U.].!5D4!*%8@S.T_U4?7QGIDA9ZF&ZZGV59@
M:$&(/0VSN(VXV/1\0W:#HOY:PECY9:VG[6I"/I5OR.^6[>.9._GT\YFD^0&\
MB!C6+ J1YLQLYA%,AK%OX4 +3=TQ=,_SHT#XB8"QROSJ5[F7]<-2*'];_KB<
M\EWTF=(P?Z!)^*C;MA7Y;J"1D)>NVC[_(" RV&KV]2#R9Z9E3_JV:S]UWX:'
MEF-7PSWU*)+?D,N^9_0S19]X83;;G!+ZS-W2#O5'8@<N<5VD!3,+\8V*OPKE
MAAHAB+AZZ(86BN0?G-M4@G'?H.8+R.G;\LR?2<K^E)0;Z2I.^3LA[-]?2#5U
M%I:;AA.PPY;NE*TE=:)Y,V1H:.8AT]6]P-(G>"M#DO8PZ>.WYK=EFL#;,O[J
M#^ER-U4K<) ?F+SY%T^\$]Y@S+0"S;)\.S!,Q_## ,[:3]6%20R^-?,>1;(:
MK?M[3W4;,O&/<A^1;D1VR.(8K)>-TPV+H^RSO[+#1FCB )_&D2 F_:KQKU[5
M-"[8!+ *P#70U]=\2=D^0O+=P>V6>1^4/VT_2[]9\U<F=^DD8@5!%*&9YGDZ
M.]&9+$#Q;,?2#-W2/<,P" FDI[>%M?O5;WPNFV^9QBC&OGNDY,MX,\MQ/)<W
M/\46B]@-'&F>Y9L:TK'O$,]D>W(D?[.0.87?YUFPD;L'F-TH49W0X"AV^V,%
M@<#$#=MA^ZBA\6\QV%F28,W3V69JNM',,DW#-H,)+IADJ/[[O!8F?:%,;"=J
MQ!SG<^I\-I"$-O)]3-C:#YD7B'Q/0Y9G:[X;>9:+2*2;$X0:_17]?1[UDF[Z
M4FU G:<C!59TOGOZ[ZK8/J7,JY86])X\TZS,+K!?*#:/;F1'KAOXFLZ+EVS?
M98%5:+&_6KKC6>8,X6B:!UTD*"^T+KS??5W V(JT34%65[1KNEK%1=G>#:7A
M:\^WPU?'A[<^ZR%]7'^SH=.0U,3L8/BK@^'Q]LWVRL[W&5,'F<PV9H86N/RI
M"C.T-#1#H>:AF6X8D6&&TA\N[Z7@J#3/[9H7.M]%7YES3^89Q83PI9POGE#Q
M!WHAWYACR&*4;/>?1PLAY#FFKKEXQDY4GA=JR D-C3C1+&3G*Y\X8CT@^XT+
M6Y(XG;D<)5<FI$*][HXD8MM"B67IJLO#>\K^L9BS#6A,]T8AP2.[,_977I[C
MXMFTK>6GX3TIXJS<MVOL4#=(@#PST)!A&"SX"4P->;JI$3=R'=]R$#--^6Y+
M5+W1L=(Y!QS\3\Q&Z(9D;*VP19TNCWY.,DSX,[CE#Q\]VS61RS=^7B)CAQ;O
M=&.R]>/-=((#[)JZ["]G1BL-[@<GL;ZS&.BBW*IP>5X_X6_H9[Q:KZ[2=(V2
MPQ_F;+H5&J2:^:/%M@'/<HAFV3X[7&,<:KZ-;,VR+';H-O0 >T(=$<:;<Q^U
M86M<@0UZ,G[AM_M2=D[POY?TY3\$AUOQ5_^@+%S$JRI6W"+<O<L?&>JAT*V-
M\B<%=J99/T+/[7ZP\I)V^8<G9KT?4,XMYL! LPRQ8V=Y#/VP>?U_JG;?I7I;
M'=DPS)JYA1TT0I2[]"=1<>R'L80MU1@7)'PH*/[Q9QH7^?W#G]5WJG+GWSX6
MZ$7RE-9S]K6L".2#O5$RNHB!.<^(9JLRI;53L,X>&H+4EE\'O?"\!,6"^ &2
M^PUE/TA13O'5^GJPV_;[H-=T%Z-7 $% ?O<GH'6&GYB.Y9%)G-Z67P>]B;H8
MN]WXP9#+3E2/VZFLRI/4_H)@\*FO6:($%;^ESS$7NF"GNP_LAS^DJ'DN%22T
M[^1B9U%"B "&TD?ZD>*)AI+Y.I$)$K<.8ZL>#46XFK-ABVR5AC<)6DIAZE@B
M2%GS()YJD5"$);[BK],\S.31="(2)&0:[/W.L5"$J#_H/Z_ZR?6 #:)! J%!
MQ+5C TS@?D^-5R2\H1D_&WY'R>CEUB87),CI19T *BHLO/PZH3E9T+VZ9>6)
MO-77(1\DG.F_!,504I;/B6B$*?^2Q)XBI'U)P_@E#M<H*1MTCR'J1!1L4-:.
M.>T" 'HI)<FK7K6)N;Z+J$X@&$,-F%,Q !2X=7Y-)[4OFD$OKQ_)A@V6A591
M*RC2R;ITY4;]K$ZF/FEB$M[<=^G0,M-]]\SG-LG58/,XH+4.E[P6[(1: 7,H
M=;MZ9L/C>-N,)EX^%?G#U?W#)&;1/1[H%_B7- ]AZ*$/,'6[!]O1^0SE1P,[
MP2)FX$^V60Z.!TYP48&Z/],P2S;+!X+76?E-P=6J&,];K52AW5V'9ZT-$A4H
M^_0SP_,LQA+6UZLH(7(4N%H[F[P*C'QF.T#Q$17D!L79=Y2L)5!3(U.((P4N
MU)KA ";K>&5OOOTH2E.Z?DJ7<SS.[76(%J(.]HY-#!Q5RV8_967B>Z*2V7/I
M4LIE.Y0>62K+2;TGF+Z0;',7G8UU9@R#[%YH@!%+MI*Z&V9\EKE6(%B"K \_
MAXNU#19@)\OK7:LOI?D>,#K;7"</C*]6W*D0"+_U/< DIQ-14MYO -YO 'IQ
M<TO36T)ED'(L">[&K UKVC%QA?85PD2NXK3$C/M7:1O,F6 PIS;T9" "$[3+
M6RZ+:E*CLTW'HL J&8>R50\%,#\[A5*4;/(XEU.DTR@4K*IQY-F[$1Y@]AZ*
M'_,,WV6+//N4%_$*;:^6Y)5["PT 5O(XE-4^L $S?+<NF(]/>>,3B:ZT62I8
M#>10+CL!4F<#O*7%7V2_4Q-9]<@B X"51$K8+#MA V;XA@FE*=G-5,:%:(-(
ML-+(H2RV0Z,6;Q_79$&K[MQLGFE$,UP>K<<ZVS[C@%UV2V)8!$0%:?\>TV3[
M2D'T!UV1:[I.BVSS%?TS!?>M@\%=G,NT !$\%30#-N._URB)HQA7VB_0SZJ5
MV>ABB4$#PEW5RS0'45S5,@GFQA*45@I_63WSMD=L F5#SHV<L]NP$>%J R09
M13]DU8G 9![Q6L3"%1!(",+4/.O5*"@YCCX5*T2B4KFN;HP4NA6@)&=QX3WY
M>QUG>[\BQRGW&$:(9*527_TQ5+4*:/XR5070L60IU3\MRDJH_)FCS??\H#>5
M[,(?$?DCUC4#9WRMSUX(V(5K#Q8.5^3I[*$OA'X2O.8/KUXS-[&DV69TZ4B]
M1#B:3O&F@I.'3B0GR:EZ,9%41-(L&*[ZJI4*V@\78.KFA$K@Z54*9$U)-]:T
M9>+P13Y,I5LI=)S*@ONHMR<I#2"\URI><J=YKT]\KT_LQTWXOP4MX_&QR^-8
M$E@95=OJJ)TL- %)LE=+SM(X%0>WK=?"347F#MTFC*#R58*Q:^)0#EB16MN*
MJ)DH]*&VTE9.TNU<&MRV/2Z.5^W^XIH^D(3PGO25#8V^NJB7"+>1#..K%1?H
M.(6I$NX/]7=1%&,F]R:5L]:ZI<.YP&%<"N,%[3,)R<I'0K_D^5HBHVURP:IS
MA_K1;HR@/>H3;P(3[A65Q6*;7+"ZW*'>M1LC\+5(%_Q56AGWP*>RP,IM!Z^Y
M6BS@&;K"!8O$D\T<Q:$DHNI$@A76#N>K!1GH0)E'BDQ#KI4LU]@D$ZQ>=B!Q
M'=A 'SMWF>&KEZ4TW]@H%*[4=>@ILP,>A=@K-3OP$#))K),-5Z<J@<L6L%1P
MI7M5I3O41LEP%:9C_&H74-"5%7^OXV+#>V1MH63AS:KL!?HQCI@RA,U6%KL]
MAX(K.!U(]S HH</&$S?S/2\WD;*+Z!--&,KWA:Q(LM]0<+6J@W-W0Z!4CO];
M4GQ),5U)RJ$+#0!7LBJ-ZV;8E&/X+,D\%=,M PDQKE3N: ",P,S7N!\^\RKY
M)8=TT3&$^%8I^]03/.46^5WQ1+*)UW?]&$)4JY2XZ@D>]*I&P3I!V=<X+R1>
M=3=+%:)3I716)T#0!)Y[EK&9D :10M4**B6SVJ$!S_SOG+]\ KMD"S&I4BI+
M$"P%WAC9']R_TESV"TO'LH5(5"6!U0H/^&GGY.0]=OG5"A2B2Z4$5!LLT)\Z
M\P,5GY$DPNKD"?&E4L*H!1054OQ2VF,>"A(B2*4L3QT,X(<0.KI4<B=#B ^5
M<C GDU>CS'LT'7WK54V5TB0*EJG2]#,[N%2*?20YSN+R&D92G6JW>"$254J
MB$,&OB^%,=<+);9NOKS.3M;U<Y=T(695RH4( Z9J0XTO:1XS6!<9*INI'CQU
M>*SYR.X:+<-(:;4A.@T)?3?.ACHSD('?KS:*'9,+VXO[P)LSC>^X42L0\./.
M+BZ.LE\M8$#G+/>JC?ZJ[404&#>M:->RHM!W;E=)4N-+Y'P!VBQ8 :Y:/@;M
M!.2]F0#4&GIO+/#>6*!?;%UDR8)DJ_PN6F0ALR\Y)_P6L6!KJ-\9H1L8\),"
MUTI&,])C26!?\O8]P]5,7Q5*%G$Q^GA]) KLD]R!I!P! -TX=)T00P\<@Y]J
M0OI<D/ F0<M1]#3)!/O<MA]/'9# )Q:GX*Q%+-CWM?UHZP9&"0=8ZB7CO;X:
M<6#?U@YQA'5 *.0,%]DJ+>3ZP@.18%_5#G>%YX"HY0DE$=8L%>R#VE%^4#G:
M=@&#O)=+ZR7"?4,[Q!LVX*$$5Q_76:F8!)+VHN"^BAW"SBD"2M#R0/ ZBXN8
MY%?+Y=4+BI/1!;PM<N&^>QU"6"LV;^.6<4Z3&+,)S#.*)[QE/!IF@EO&YFE(
MOV4\'.K,1B1<-];+'Y6+K\2'AZ)EA73=TA6YD6SE[3B!+X@7^!U+G9ZWM*A4
ME9-&%A]%D:SR2)Y;\)O>HU<_X/\)4$[^^Z__ U!+ P04    "  ;5$]8%2&_
MX 0#  "+%   %0   &%G:6\M97@R,3%X,3(S,3(S+FAT;>58;6_3,!#^SJ\P
M10B02)JD[<JRKM+>&$5C2,M@'Y$37QMKCAW9;KOLU^,XR=;1O3$A8&T_5''M
M.]_S/'>N<X-49VPX2 &3X8O!2\=!^R*99L U2B1@#01-%>43=$9 G2/'J5?M
MB;R0=))J%'A!%YT)>4YGN)K75#,8-GX&[6H\:-M-!K$@Q7! Z Q1LMVB7@R^
M%WO$2X*@&W02W/&3/B0)WHPWQO"A_\-O&5.SO+)1NF"PW<HH=U(H]P^[@=OO
MY7IK3HE.0]_S7K?LTN%@++@V^TEC7SU6;I:<:;C0#F9TPD,+J569-M.)8$*&
MKSS[V2IGG#'.*"O"-Z<T X6.88Y.1(;YF_<*<^4HD'1<+53T$DQ,)CP[G%<A
M]XT?1CDT$/R@#/K@(J4Q-83ZKG\SXD7@6$X,=BUR8V7<+L2>&+)!_J/@HV^[
MT6A_M',R.HB:X#6.&32!Q$(2D(Z)A^%<0=@\;!&J<H:+D'+KU1IMU3!CH;7(
MPE+>&4A-$\QJL!9W-5TKO[GI]C;\4GQM%->DV;C."]?F15N3Y;GNAMOOWSWM
MN?X3YWJ=[I,L[PNVY[G!YL:CW+8M$149AFZ58[[=ZK0:@QP38BH[#/(+Y-],
M)0;C)<8KLO]^>MF"/N#F$"FNJJ)&?@\HKX34>M32YX _TN8H1D(BH5.0Z/-4
M4D5HHJG@2(S1B"="YD+BZ@>)OLH)YO32CF^P]D!.U%5JCY?<H!2,$M3 ^S\)
MZ]Y*V,Z$"H4B2 Q3FAJ_>]<$_=DT6AG*OF"E<)).%6BM?B=IGA/(*B^.:$;-
MU68=SI/;:=@%F4T)7D&5_=Z5RJ/R/L1MR6.&(BP9>GN8Q9_>K:_NT9SJ2Y ,
M<[+:VA]#^4=9XE1HU_WNKJ_DIRDLLK':LA^:<PWS I5EOKZ2URRLMM0CC5F!
M(O?$/5KCZK8LK+;0'R7F":!HY^1H?76N2%@6NFW[)0N-HCO;7@M-I%\Z9[E0
MM+PDA1*8N2W-8*F7=OVN8_LQWK4)CLT+SU0OFSS0?JN_JV9@VS8A?P)02P,$
M%     @ &U1/6"@^0Y0, P  G @  !4   !A9VEO+65X,C,Q>#$R,S$R,RYH
M=&W%5NMOTS 0_\Y?<0SQDIHN[RY=F01=-U6,KFJ']A&YSJ6Q2.S(=EO*7X^=
MQ]@T"A(2+!^BN]SY[G[W<D:Y+HNS48XD/7LV>NXX<"[HID2N@4HD&E/8*,;7
M<)NB^@J.TVJ-1;67;)UK\%T_A%LAO[(M:>2:Z0+/.CNCXX8?'==.1BN1[L]&
M*=L"2]\=L8 @B3!"FJRB,/+]$QJM$NK'7N+2)(N2+Z%[9,X:_>:0TOL"WQV5
MC#LYV@"& [_2ISN6ZGSHN>[+HP=Z&K]IAQ1LS8=UN$::":Y-&-)8;<A'Q@\<
MZL14%$(.7[CU<VHE3D9*5NR'KV]8B0IFN(.%* E_W5.$*T>A9%FCJ-AW-&&:
MB&MVUT(P=@K&L8/4X)A\R]F*F0P'?>]AK(_30>3:9&0EM!;ET ^-_?:3%E7#
MWP-%35E0/A&J\?5L.9G=P/4%3&?GD_G$O R[F%Q.ES>3Q>0<YI\_7$W'\'X\
MOOX\NYG.+N%BNOATL%H/L<?5OR]7^$M@MP@Y2ESM@0JN[ 1I 3I'8)P*60E)
M-!,<C%QB9A0YM:):8X%KIG2KL-1F[.SD*##<A9!E!_TIR@7_Q_FO4[IT3N#-
M3*@^!$'@^ .S%J)>0\=)$GD=[2=1W-%Q/+C3&<1^V-!@#GCN22N(@C#IZ"".
M_*"E_22.DXX.W*!SX,6>VSEPDT'4.7"]0=)^]Y+@Q/5[0'C:\J[G>F]KWM80
MEDY@L?3OP@^3MR R>+]F0L$\)[(D%#>:45*H'DPY[5NQV$C3+Z9[-*3U.K[
ME=P0N0>;BGKY2BQ,YY@=W?9;QCCAE)'"E.NNE6P<5HA9AE2S+7)4RCI@=A=P
MHVRZ5DM1@-BBO&>C<6[,]V"7,YH#J2HD4C6]RU2#SG.=C_T_C:C=19[_9 /Z
MZD4X.%7U&^:24=R9[,A<;!2.A:C08+JZFMN;X8-06O >?")*$9H;!:V5%3Q*
M_D'(]R^G2BAF1WO85&J+!Z^K=HFY/X^0E1+%1A\^\O>7U24*4Q9BDOIW^?0>
M@?_=Y7I0]N#=_!T<UW\E/P!02P,$%     @ &U1/6#T*X(G.7   S? " !<
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MOB,3]H&D2A=1"B9[2K031?W5='D_B8>E9Y)RKQ4;YU.AESJ>#W07>$!AA<D
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M]Z"]M[T/LK (J.I7HE,U 0G:QWRR35K>_&EYRI-%6G/%E651%]*2:]RG6NG
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M]5$DM?:W"G]N0U\&8^-[IK<\GH4BMTZS@68IP6F@#P,2E+S3%>LF5NF..G>
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M+Y$O+1SM>0Z#@)J&F 35=PHD0%/ 0KC5IQ(<#/GY;0 S4PU3D"16)?:10Y2
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MP-QTK658R#^N4O$)5K"FC+<:M>[&X[DU57;J_IYXRK5#V_)?EYQ&T[")/=V
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M78-ND63.R3;"D$?H9>^F?RRG3'O0RJ*0W.M7Q\]L"SVH86@;? 9'_(( *>E
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M7M$O/Q^WWUR?_WIY<O/YJGOMG'SZU#VY<CY>.N\^7EQ\_()%8)].?NUN-Z-
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MA/:;9>-OT3UP4N"'EPQ#Q'LH9?OB$4"7*9@9F;(X8!XR(8,0^ .Z4<G)AL\
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M6GT\)")R6NV=+42)0N<QD@"M*M-./;4W$*1MEKVQ=L@>K"=0%&$GS]25")@
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M?W"TL[/=WIW.Q?[2BX,)_#/(AN'?_S]02P,$%     @ &U1/6(ISD\;B#@
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M_%%QG>##MQ*-D-*F!13I\=?@PZT1IGB;A.FD)4N@Y6"PKD#7T5IMBT!Q='3
M$411"JR]OD-08- CO;L'#$'&ZV,*5AA,#[<$'BQP >98H^4DMRXT.0>$,=Z_
MILIA$F]]T9- -(C6\TYT?^1&)"TI_HHLP1;(6K)-LM8R7.\ :13"(:W1#'1Z
M8;^W1_Q(2')$*6B5'I,1#PE!-J]%+"3**7TC[F,ADJ=3(F\ZD^!X'<R<<)#T
M2(BBH3_AR5/(TN1$ ,C)8;4)BVB(<NC(H^O$$P,/C^"_Q&\0ZZL2D>(8K3."
M'-0R?@^;/>624BS.F(<F!!%!_< %#?Y5RZ:&;'\D)CQ+>^PGF/CX.BJ^'08!
MZ(CQ"2BT(K Q =0Z41GB'\ XI2XP X.@N[U57Y)!#! 0^YHR^@WC#%@VX,N)
M0) 94[@#?^,R\^B/_!60(FB&;PH1*6+=AR'T$_F:R2R#S6JV 8$@AYTD,P:$
M)48AP=ZW7:Y+S%2?5O-4G=2:&\S**1EH3'/AM$=/+]00S!J%,24L+.< P^'_
M$)ZXQ'N-;9%R);W!E]RN7#["W*E6"$\=;&[3@]-TJ;R=1!%BFRQ[B"*6?/+6
M6/+-;=C>Q497OPIF*W<X!I%4@CE#EUYP>>ECWAWLIP=!YB9,,>^DOJ3;HR]'
MO?YAH# _U>F9ZSK:_P7,&03+9FMTA[(ZN>?*F5S,# 50PEE;2B,Y45JLFY"/
M6Y'N,:PT;H9+4E:8?9TT5H=>BYYC%6^:(!)$#1DX4I\>Y-HZ!TT>H9ZU#_B
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M#K\NX_32_8;G2_KMT/\!4$L#!!0    ( !M43UA[',%0@ <  &TE   8
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M,C R,S$R,S%?9S(N:G!G4$L! A0#%     @ &U1/6 \GJ%<D-@$ LAD- !4
M             ( ! ?4) &%G:6\M,C R,S$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( !M43U@<?;! 8*X  )TN"  5              "  5@K"P!A9VEO+3(P
M,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    "  ;5$]8%2&_X 0#  "+%   %0
M            @ 'KV0L 86=I;RUE>#(Q,7@Q,C,Q,C,N:'1M4$L! A0#%
M  @ &U1/6"@^0Y0, P  G @  !4              ( !(MT+ &%G:6\M97@R
M,S%X,3(S,3(S+FAT;5!+ 0(4 Q0    ( !M43U@]"N")SEP  ,WP @ 7
M          "  6'@"P!E>&AI8FET+3$P,C%X,3(S,3(S+FAT;5!+ 0(4 Q0
M   ( !M43UB*<Y/&X@X  $)4   6              "  60]# !E>&AI8FET
M+3DW,7@Q,C,Q,C,N:'1M4$L! A0#%     @ &U1/6'L<P5" !P  ;24  !@
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M &5X:&EB:70S,BTR>#$R>#,Q>#(S+FAT;5!+!08     $  0 #4$  !090P
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>agio-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:agio="http://agios.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="agio-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2024-02-09</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">agio:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:VorasidenibMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">agio:Agreement2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:TIBSOVOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agio:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">agio:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agio:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agio:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:CurrentAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">agio:NonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:EightyEightSidneyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:EightyEightSidneyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:ThirtyEightSidneyStreetCambridgeMassachusettsLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="agio:LeaseArrangementsAxis">agio:SixtyFourSidneyStreetLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandSevenStockIncentivePlanAndTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:TwoThousandAndThirteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:MarketBasedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">agio:EmployeeStockPurchasePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:PerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">agio:EmployeePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">agio:FederalOrphanDrugTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agio:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">agio:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramBristolMyersSquibbCompanyRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-05</startDate>
            <endDate>2021-04-05</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramRule10b51RepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramRule10b51RepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-02</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">agio:March252021RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueRelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">agio:CollaborationRevenueOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439222</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">agio:AgiosOncologyBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>agio:segment</measure>
    </unit>
    <unit id="security">
        <measure>agio:security</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="leaseterm">
        <measure>agio:leaseTerm</measure>
    </unit>
    <unit id="extension">
        <measure>agio:extension</measure>
    </unit>
    <unit id="audit">
        <measure>agio:audit</measure>
    </unit>
    <unit id="vote">
        <measure>agio:vote</measure>
    </unit>
    <unit id="lawsuit">
        <measure>agio:lawsuit</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-32">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-33">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-34">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0001439222</dei:EntityCentralIndexKey>
    <agio:AvailableForSaleSecuritiesCurrentMaturityPeriod contextRef="c-60" id="f-407">P1Y</agio:AvailableForSaleSecuritiesCurrentMaturityPeriod>
    <agio:AvailableForSaleSecuritiesNonCurrentMaturityPeriod contextRef="c-60" id="f-409">P1Y</agio:AvailableForSaleSecuritiesNonCurrentMaturityPeriod>
    <agio:LesseeOperatingLeaseOptionToExtendExtensionPeriod contextRef="c-113" id="f-596">P1Y</agio:LesseeOperatingLeaseOptionToExtendExtensionPeriod>
    <agio:LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo contextRef="c-113" id="f-597">P22M</agio:LesseeOperatingLeaseOptionToExtendExtensionPeriodTwo>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-14" id="f-967">http://fasb.org/us-gaap/2023#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</us-gaap:DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-36014</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">AGIOS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">26-0662915</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">88 Sidney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">649-8600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">AGIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-29" unitRef="usd">1557785326</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">56194847</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">Portions of the registrant&#x2019;s definitive proxy statement for its 2024 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120 days of the end of the registrant&#x2019;s fiscal year ended December&#160;31, 2023 are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-36">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-37">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-38">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-39">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-40">238</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-41">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-42">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">88205000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-44" unitRef="usd">139259000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">688723000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-46" unitRef="usd">643860000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">2810000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-6" decimals="-3" id="f-48" unitRef="usd">2206000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">19076000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-6" decimals="-3" id="f-50" unitRef="usd">8492000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">35021000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-52" unitRef="usd">38955000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">833835000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-54" unitRef="usd">832772000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">29435000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-6" decimals="-3" id="f-56" unitRef="usd">313874000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">54409000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-58" unitRef="usd">65129000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">15382000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-60" unitRef="usd">22987000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">4057000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">3956000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">937118000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-64" unitRef="usd">1238718000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">9780000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">18616000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">43167000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-68" unitRef="usd">30350000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">15008000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-70" unitRef="usd">13663000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">67955000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">62629000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">56988000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-74" unitRef="usd">71996000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">1156000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-76" unitRef="usd">3279000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">126099000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-78" unitRef="usd">137904000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-79" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-80" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-82"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-83" unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-84" unitRef="shares">25000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-85" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-86" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-87" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-88" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding contextRef="c-6" decimals="-3" id="f-90" unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-91"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-92"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-93" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-94" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-95" unitRef="shares">72161489</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-96" unitRef="shares">55945078</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="INF" id="f-97" unitRef="shares">71256118</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-98" unitRef="shares">55039707</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">72000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-6" decimals="-3" id="f-100" unitRef="usd">71000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">2436523000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-6" decimals="-3" id="f-102" unitRef="usd">2386325000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">-441000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-104" unitRef="usd">-12535000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">-822649000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-106" unitRef="usd">-470561000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares contextRef="c-6" decimals="INF" id="f-107" unitRef="shares">16216411</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="INF" id="f-108" unitRef="shares">16216411</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">802486000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-6" decimals="-3" id="f-110" unitRef="usd">802486000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">811019000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-112" unitRef="usd">1100814000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">937118000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-114" unitRef="usd">1238718000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-115" unitRef="usd">26823000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-116" unitRef="usd">11740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-117" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-118" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-119" unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-120" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-121" unitRef="usd">26823000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-122" unitRef="usd">14240000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-123" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">2881000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-3" id="f-125" unitRef="usd">1704000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-14" decimals="-3" id="f-126" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">295526000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-13" decimals="-3" id="f-128" unitRef="usd">279910000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-129" unitRef="usd">256973000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">119903000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-131" unitRef="usd">121673000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-132" unitRef="usd">121445000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">418310000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-13" decimals="-3" id="f-134" unitRef="usd">403287000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-14" decimals="-3" id="f-135" unitRef="usd">378418000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">-391487000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-137" unitRef="usd">-389047000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-138" unitRef="usd">-378418000</us-gaap:OperatingIncomeLoss>
    <agio:GainLossOnSaleOfContingentPayments contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">0</agio:GainLossOnSaleOfContingentPayments>
    <agio:GainLossOnSaleOfContingentPayments contextRef="c-13" decimals="-3" id="f-140" unitRef="usd">127853000</agio:GainLossOnSaleOfContingentPayments>
    <agio:GainLossOnSaleOfContingentPayments contextRef="c-14" decimals="-3" id="f-141" unitRef="usd">0</agio:GainLossOnSaleOfContingentPayments>
    <us-gaap:RoyaltyIncomeNonoperating contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">0</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating contextRef="c-13" decimals="-3" id="f-143" unitRef="usd">9851000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating contextRef="c-14" decimals="-3" id="f-144" unitRef="usd">6639000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">33344000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-13" decimals="-3" id="f-146" unitRef="usd">12793000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-14" decimals="-3" id="f-147" unitRef="usd">836000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">6055000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-149" unitRef="usd">6749000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-150" unitRef="usd">14433000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">-352088000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-152" unitRef="usd">-231801000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-153" unitRef="usd">-356510000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-13" decimals="-3" id="f-155" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-14" decimals="-3" id="f-156" unitRef="usd">1961225000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">-352088000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-158" unitRef="usd">-231801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-159" unitRef="usd">1604715000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">-6.33</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-161"
      unitRef="usdPerShare">-6.33</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-13"
      decimals="2"
      id="f-162"
      unitRef="usdPerShare">-4.23</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-13"
      decimals="2"
      id="f-163"
      unitRef="usdPerShare">-4.23</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-14"
      decimals="2"
      id="f-164"
      unitRef="usdPerShare">-5.90</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-14"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">-5.90</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-166"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-167"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-13"
      decimals="2"
      id="f-168"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-13"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-14"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">32.45</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-14"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">32.45</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">-6.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">-6.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">-4.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">-4.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">26.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-177"
      unitRef="usdPerShare">26.55</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-178" unitRef="shares">55651487</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-179" unitRef="shares">55651487</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="0" id="f-180" unitRef="shares">54789435</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="0" id="f-181" unitRef="shares">54789435</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="0" id="f-182" unitRef="shares">60447346</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="0" id="f-183" unitRef="shares">60447346</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">-352088000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-185" unitRef="usd">-231801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-186" unitRef="usd">1604715000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">12094000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="-3" id="f-188" unitRef="usd">-11337000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-14" decimals="-3" id="f-189" unitRef="usd">-1303000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">-339994000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-191" unitRef="usd">-243138000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-3" id="f-192" unitRef="usd">1603412000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-15"
      decimals="INF"
      id="f-193"
      unitRef="shares">69293920</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-194" unitRef="usd">69000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-195" unitRef="usd">2242801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-196" unitRef="usd">105000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-197" unitRef="usd">-1843475000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-19"
      decimals="INF"
      id="f-198"
      unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-199" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-200" unitRef="usd">399500000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax contextRef="c-21" decimals="-3" id="f-201" unitRef="usd">1303000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax contextRef="c-14" decimals="-3" id="f-202" unitRef="usd">1303000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-203" unitRef="usd">1604715000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-204" unitRef="usd">1604715000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-205" unitRef="usd">53508000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-206" unitRef="usd">53508000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-24"
      decimals="INF"
      id="f-207"
      unitRef="shares">1256711</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-24" decimals="-3" id="f-208" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-23" decimals="-3" id="f-209" unitRef="usd">37294000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-210" unitRef="usd">37296000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-25"
      decimals="INF"
      id="f-211"
      unitRef="shares">16216411</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-25" decimals="-3" id="f-212" unitRef="usd">802486000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-14" decimals="-3" id="f-213" unitRef="usd">802486000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <agio:StockholdersEquityDispositionOfBusiness contextRef="c-23" decimals="-3" id="f-214" unitRef="usd">-745000</agio:StockholdersEquityDispositionOfBusiness>
    <agio:StockholdersEquityDispositionOfBusiness contextRef="c-14" decimals="-3" id="f-215" unitRef="usd">-745000</agio:StockholdersEquityDispositionOfBusiness>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-216"
      unitRef="shares">70550631</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-217" unitRef="usd">71000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-218" unitRef="usd">2334348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-219" unitRef="usd">-1198000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-220" unitRef="usd">-238760000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-30"
      decimals="INF"
      id="f-221"
      unitRef="shares">16216411</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-222" unitRef="usd">-802486000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-223" unitRef="usd">1291975000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax contextRef="c-32" decimals="-3" id="f-224" unitRef="usd">11337000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax contextRef="c-13" decimals="-3" id="f-225" unitRef="usd">11337000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax>
    <us-gaap:NetIncomeLoss contextRef="c-33" decimals="-3" id="f-226" unitRef="usd">-231801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-227" unitRef="usd">-231801000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-228" unitRef="usd">49296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-229" unitRef="usd">49296000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-35"
      decimals="INF"
      id="f-230"
      unitRef="shares">705487</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-34" decimals="-3" id="f-231" unitRef="usd">2681000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-232" unitRef="usd">2681000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-36"
      decimals="INF"
      id="f-233"
      unitRef="shares">71256118</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-234" unitRef="usd">71000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-235" unitRef="usd">2386325000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-236" unitRef="usd">-12535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-237" unitRef="usd">-470561000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-40"
      decimals="INF"
      id="f-238"
      unitRef="shares">16216411</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-239" unitRef="usd">-802486000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-240" unitRef="usd">1100814000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax contextRef="c-41" decimals="-3" id="f-241" unitRef="usd">-12094000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax contextRef="c-1" decimals="-3" id="f-242" unitRef="usd">-12094000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax>
    <us-gaap:NetIncomeLoss contextRef="c-42" decimals="-3" id="f-243" unitRef="usd">-352088000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-244" unitRef="usd">-352088000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="-3" id="f-245" unitRef="usd">44766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">44766000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-44"
      decimals="INF"
      id="f-247"
      unitRef="shares">905371</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-44" decimals="-3" id="f-248" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-43" decimals="-3" id="f-249" unitRef="usd">5432000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-250" unitRef="usd">5433000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-45"
      decimals="INF"
      id="f-251"
      unitRef="shares">72161489</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-252" unitRef="usd">72000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-253" unitRef="usd">2436523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-254" unitRef="usd">-441000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-255" unitRef="usd">-822649000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-49"
      decimals="INF"
      id="f-256"
      unitRef="shares">16216411</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-257" unitRef="usd">-802486000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-258" unitRef="usd">811019000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">-352088000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-260" unitRef="usd">-231801000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-261" unitRef="usd">1604715000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-1" decimals="-3" id="f-262" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-13" decimals="-3" id="f-263" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-14" decimals="-3" id="f-264" unitRef="usd">1961225000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">-352088000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-13" decimals="-3" id="f-266" unitRef="usd">-231801000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-14" decimals="-3" id="f-267" unitRef="usd">-356510000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-268" unitRef="usd">6623000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-13" decimals="-3" id="f-269" unitRef="usd">8564000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-14" decimals="-3" id="f-270" unitRef="usd">9240000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-271" unitRef="usd">44766000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-3" id="f-272" unitRef="usd">49296000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-14" decimals="-3" id="f-273" unitRef="usd">53508000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-274" unitRef="usd">5051000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-13" decimals="-3" id="f-275" unitRef="usd">1198000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-14" decimals="-3" id="f-276" unitRef="usd">-6949000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <agio:GainLossOnSaleOfContingentPayments contextRef="c-1" decimals="-3" id="f-277" unitRef="usd">0</agio:GainLossOnSaleOfContingentPayments>
    <agio:GainLossOnSaleOfContingentPayments contextRef="c-13" decimals="-3" id="f-278" unitRef="usd">127853000</agio:GainLossOnSaleOfContingentPayments>
    <agio:GainLossOnSaleOfContingentPayments contextRef="c-14" decimals="-3" id="f-279" unitRef="usd">0</agio:GainLossOnSaleOfContingentPayments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-3" id="f-280" unitRef="usd">-553000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-13" decimals="-3" id="f-281" unitRef="usd">48000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-14" decimals="-3" id="f-282" unitRef="usd">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">10720000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-13" decimals="-3" id="f-284" unitRef="usd">9995000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-14" decimals="-3" id="f-285" unitRef="usd">9537000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <agio:ExpenseAssociatedWithLicenseAgreement contextRef="c-1" decimals="-3" id="f-286" unitRef="usd">17500000</agio:ExpenseAssociatedWithLicenseAgreement>
    <agio:ExpenseAssociatedWithLicenseAgreement contextRef="c-13" decimals="-3" id="f-287" unitRef="usd">0</agio:ExpenseAssociatedWithLicenseAgreement>
    <agio:ExpenseAssociatedWithLicenseAgreement contextRef="c-14" decimals="-3" id="f-288" unitRef="usd">0</agio:ExpenseAssociatedWithLicenseAgreement>
    <agio:RealizedGainOnInvestments contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">28000</agio:RealizedGainOnInvestments>
    <agio:RealizedGainOnInvestments contextRef="c-13" decimals="-3" id="f-290" unitRef="usd">0</agio:RealizedGainOnInvestments>
    <agio:RealizedGainOnInvestments contextRef="c-14" decimals="-3" id="f-291" unitRef="usd">0</agio:RealizedGainOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-292" unitRef="usd">604000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="-3" id="f-293" unitRef="usd">2206000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-14" decimals="-3" id="f-294" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">10584000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-13" decimals="-3" id="f-296" unitRef="usd">8492000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-14" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-13" decimals="-3" id="f-299" unitRef="usd">-447000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-14" decimals="-3" id="f-300" unitRef="usd">4378000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">-3833000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="-3" id="f-302" unitRef="usd">176000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-14" decimals="-3" id="f-303" unitRef="usd">26846000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">-8733000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-13" decimals="-3" id="f-305" unitRef="usd">3436000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-14" decimals="-3" id="f-306" unitRef="usd">1863000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">12817000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-13" decimals="-3" id="f-308" unitRef="usd">-1617000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c-14" decimals="-3" id="f-309" unitRef="usd">66000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">-13663000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-13" decimals="-3" id="f-311" unitRef="usd">-10828000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-14" decimals="-3" id="f-312" unitRef="usd">-7527000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">-2123000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-13" decimals="-3" id="f-314" unitRef="usd">3003000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-14" decimals="-3" id="f-315" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c-1" decimals="-3" id="f-316" unitRef="usd">-296062000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c-13" decimals="-3" id="f-317" unitRef="usd">-309478000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="c-14" decimals="-3" id="f-318" unitRef="usd">-314086000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-13" decimals="-3" id="f-320" unitRef="usd">0</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations contextRef="c-14" decimals="-3" id="f-321" unitRef="usd">-93234000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">-296062000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-3" id="f-323" unitRef="usd">-309478000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-14" decimals="-3" id="f-324" unitRef="usd">-407320000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">417930000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-13" decimals="-3" id="f-326" unitRef="usd">1030781000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-14" decimals="-3" id="f-327" unitRef="usd">1378221000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-1" decimals="-3" id="f-328" unitRef="usd">674679000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-13" decimals="-3" id="f-329" unitRef="usd">1146175000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="c-14" decimals="-3" id="f-330" unitRef="usd">829804000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <agio:ProceedsFromSaleOfContingentPayments contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">0</agio:ProceedsFromSaleOfContingentPayments>
    <agio:ProceedsFromSaleOfContingentPayments contextRef="c-13" decimals="-3" id="f-332" unitRef="usd">131784000</agio:ProceedsFromSaleOfContingentPayments>
    <agio:ProceedsFromSaleOfContingentPayments contextRef="c-14" decimals="-3" id="f-333" unitRef="usd">0</agio:ProceedsFromSaleOfContingentPayments>
    <agio:PaymentsAssociatedWithLicenseAgreement contextRef="c-1" decimals="-3" id="f-334" unitRef="usd">17500000</agio:PaymentsAssociatedWithLicenseAgreement>
    <agio:PaymentsAssociatedWithLicenseAgreement contextRef="c-13" decimals="-3" id="f-335" unitRef="usd">0</agio:PaymentsAssociatedWithLicenseAgreement>
    <agio:PaymentsAssociatedWithLicenseAgreement contextRef="c-14" decimals="-3" id="f-336" unitRef="usd">0</agio:PaymentsAssociatedWithLicenseAgreement>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-337" unitRef="usd">999000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-338" unitRef="usd">4881000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-339" unitRef="usd">5741000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-1" decimals="-3" id="f-340" unitRef="usd">1325000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-13" decimals="-3" id="f-341" unitRef="usd">964000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment contextRef="c-14" decimals="-3" id="f-342" unitRef="usd">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c-1" decimals="-3" id="f-343" unitRef="usd">239575000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c-13" decimals="-3" id="f-344" unitRef="usd">243261000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="c-14" decimals="-3" id="f-345" unitRef="usd">-554158000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-13" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations contextRef="c-14" decimals="-3" id="f-348" unitRef="usd">1802936000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">239575000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-3" id="f-350" unitRef="usd">243261000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-14" decimals="-3" id="f-351" unitRef="usd">1248778000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-13" decimals="-3" id="f-353" unitRef="usd">331000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-14" decimals="-3" id="f-354" unitRef="usd">578000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsForRepurchaseOfEquity contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity contextRef="c-13" decimals="-3" id="f-356" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity contextRef="c-14" decimals="-3" id="f-357" unitRef="usd">802486000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">5433000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-13" decimals="-3" id="f-359" unitRef="usd">2681000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-14" decimals="-3" id="f-360" unitRef="usd">37296000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-361" unitRef="usd">5433000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-3" id="f-362" unitRef="usd">2350000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-14" decimals="-3" id="f-363" unitRef="usd">-765768000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">-51054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-3" id="f-365" unitRef="usd">-63867000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-14" decimals="-3" id="f-366" unitRef="usd">75690000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-367" unitRef="usd">139259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-368" unitRef="usd">203126000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-20" decimals="-3" id="f-369" unitRef="usd">127436000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-370" unitRef="usd">88205000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-371" unitRef="usd">139259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-372" unitRef="usd">203126000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-373" unitRef="usd">55000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-13" decimals="-3" id="f-374" unitRef="usd">158000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-14" decimals="-3" id="f-375" unitRef="usd">1678000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">1569000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-13" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-14" decimals="-3" id="f-378" unitRef="usd">16078000</us-gaap:IncomeTaxesPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-1" decimals="-3" id="f-379" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-13" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-14" decimals="-3" id="f-381" unitRef="usd">511000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-382">Nature of Business&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;References to Agios&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout this Annual Report on Form 10-K, &#x201c;the Company,&#x201d; &#x201c;Agios,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our,&#x201d; and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and &#x201c;our board of directors&#x201d; refers to the board of directors of Agios Pharmaceuticals, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biopharmaceutical company committed to transforming patients&#x2019; lives through leadership in the field of cellular metabolism, with the goal of creating differentiated medicines for rare diseases, with a focus on classical hematology. With a history of focused study on cellular metabolism, we have a deep and mature understanding of this biology, which is involved in the healthy functioning of nearly every system in the body. Building on this expertise, these learnings can be rapidly applied to our clinical trials with the goal of developing medicines that can have a significant impact for patients. We accelerate the impact of our portfolio by cultivating connections with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver potential therapies for rare diseases.&#160;We are located in Cambridge, Massachusetts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lead product candidate in our portfolio, PYRUKYND&#xae; (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. In February 2022, the U.S. Food and Drug Administration, or FDA, approved PYRUKYND&#xae; for the treatment of hemolytic anemia in adults with PK deficiency in the United States. In November 2022, we received marketing authorization from the European Commission for PYRUKYND&#xae; for the treatment of PK deficiency in adult patients in the European Union, or EU. In December 2022, we received marketing authorization in Great Britain for PYRUKYND&#xae; for the treatment of PK deficiency in adult patients under the European Commission Decision Reliance Procedure. In addition, we are currently evaluating PYRUKYND&#xae; in clinical trials for the treatment of thalassemia, sickle cell disease, or SCD, and in pediatric patients with PK deficiency. We are also developing (i) AG-946, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndrome, or LR MDS, and hemolytic anemias, and (ii) AG-181, our phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the aforementioned development programs, in July 2023 we entered into a license agreement with Alnylam Pharmaceuticals, Inc., or Alnylam for the development and commercialization of products containing or comprised of an siRNA preclinical development candidate discovered by Alnylam and targeting the transmembrane serine protease 6, or TMPRSS6, gene and we intend to pursue development of a licensed product for the potential disease-modifying treatment of patients with polycythemia vera, or PV, a rare blood disorder.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to risks common to companies in our industry including, but not limited to, uncertainties relating to conducting preclinical and clinical research and development, the manufacture and supply of products for clinical and commercial use, obtaining and maintaining regulatory approvals and pricing and reimbursement for our products, market acceptance, managing global growth and operating expenses, availability of additional capital, competition, obtaining and enforcing patents, stock price volatility, dependence on collaborative relationships and third-party service providers, dependence on key personnel, potential litigation, potential product liability claims and potential government investigations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Alnylam License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 28, 2023, we entered into a license agreement with Alnylam under which we acquired the rights to develop and commercialize Alnylam&#x2019;s novel preclinical siRNA targeting the TMPRSS6 gene, as a potential disease-modifying treatment for patients with PV. Because the acquired assets do not meet the definition of a business in accordance with ASC 805, Business Combinations, we will account for the agreement as an asset acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the license agreement, in the twelve months ended December 31, 2023, we made an up-front payment to Alnylam and recognized in-process research and development of $17.5&#160;million which was recorded in research and development expense within our Consolidated Statements of Operations and classified as investing activities within our Consolidated Statements of Cash Flows. We will also pay Alnylam for certain expenses associated with the development of TMPRSS6 and these will be recorded in our Consolidated Statements of Operations as incurred. Additionally, we are responsible to pay up to $130.0&#160;million in potential development and regulatory milestones, in addition to sales milestones as well as tiered royalties on annual net sales, if any, of licensed products, which may be subject to specified reductions and offsets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Sale of Oncology Business to Servier and Sale of Contingent Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO&#xae;, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $1.8&#160;billion in cash at the closing, subject to certain adjustments, and a payment of $200.0&#160;million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib&#x2019;s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5% of U.S. net sales of TIBSOVO&#xae; from the close of the transaction through loss of exclusivity, and a royalty of 15% of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb&#x2019;s IDHIFA&#xae; and the right to receive a $25.0&#160;million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier will conduct certain clinical development activities within the IDHIFA&#xae; development program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we sold our rights to future contingent payments associated with the royalty of 5% of U.S. net sales of TIBSOVO&#xae; from the close of the transaction through the loss of exclusivity to entities affiliated with Sagard Healthcare Partners, or Sagard, and recognized income of $127.9&#160;million within the gain on sale of contingent payments line item in our Consolidated Statements of Operations for the year ended December&#160;31, 2022. We retain our rights to the potential milestone payment and royalties from Servier if a new drug application for vorasidenib is approved by the FDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded income from royalties of $9.9&#160;million and $6.6&#160;million on U.S. net sales of TIBSOVO&#xae; by Servier in the royalty income from gain on sale of oncology business line item within the consolidated statements of operation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the years ended December&#160;31, 2022 and December&#160;31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts in prior periods have been reclassified to reflect the impact of the discontinued operations treatment of the oncology business in order to conform to the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2023, we had cash, cash equivalents and marketable securities of $806.4&#160;million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities to be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. If we are unable to raise additional funds through equity or debt financings, we may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 30, 2020, we entered into an at-the-market sales agreement, or the 2020 sales agreement, with Cowen &amp;amp; Company LLC, or Cowen, pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $250.0&#160;million through Cowen pursuant to a universal shelf registration statement on Form S-3 filed with the SEC on April 30, 2020. As of December&#160;31, 2022, $250.0&#160;million in common stock remained available for future issuance under the 2020 sales agreement. On February 15, 2023, we delivered written notice to Cowen that we were terminating the 2020 sales agreement, effective on February 22, 2023. As of the termination of the 2020 sales agreement, we had not sold any shares of our common stock under the 2020 sales agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <agio:PaymentsForAssetAcquisition contextRef="c-50" decimals="-5" id="f-383" unitRef="usd">17500000</agio:PaymentsForAssetAcquisition>
    <agio:AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment contextRef="c-50" decimals="-5" id="f-384" unitRef="usd">130000000</agio:AssetAcquisitionContingentConsiderationPotentialDevelopmentalAndRegulatoryMilestonePayment>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-51" decimals="-8" id="f-385" unitRef="usd">1800000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:GainContingencyUnrecordedAmount contextRef="c-52" decimals="-5" id="f-386" unitRef="usd">200000000</us-gaap:GainContingencyUnrecordedAmount>
    <agio:GainContingencyRoyaltyPercentageOfNetSales contextRef="c-53" decimals="2" id="f-387" unitRef="number">0.05</agio:GainContingencyRoyaltyPercentageOfNetSales>
    <agio:GainContingencyRoyaltyPercentageOfNetSales contextRef="c-54" decimals="2" id="f-388" unitRef="number">0.15</agio:GainContingencyRoyaltyPercentageOfNetSales>
    <agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication contextRef="c-55" decimals="-5" id="f-389" unitRef="usd">25000000</agio:PortionOfPotentialMilestonePaymentReceivableForFilingOfNewDrugApplication>
    <agio:GainContingencyRoyaltyPercentageOfNetSales contextRef="c-53" decimals="2" id="f-390" unitRef="number">0.05</agio:GainContingencyRoyaltyPercentageOfNetSales>
    <agio:GainLossOnSaleOfContingentPayments contextRef="c-13" decimals="-5" id="f-391" unitRef="usd">127900000</agio:GainLossOnSaleOfContingentPayments>
    <agio:ContingentGainOnDispositionOfBusinessRecognized contextRef="c-56" decimals="-5" id="f-392" unitRef="usd">9900000</agio:ContingentGainOnDispositionOfBusinessRecognized>
    <agio:ContingentGainOnDispositionOfBusinessRecognized contextRef="c-57" decimals="-5" id="f-393" unitRef="usd">6600000</agio:ContingentGainOnDispositionOfBusinessRecognized>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="c-5" decimals="-5" id="f-394" unitRef="usd">806400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <agio:SaleOfStockMaximumValueOfSharesIssuedInTransaction contextRef="c-58" decimals="-5" id="f-395" unitRef="usd">250000000</agio:SaleOfStockMaximumValueOfSharesIssuedInTransaction>
    <agio:SaleOfStockCommonStockReservedForFutureIssuanceValue contextRef="c-59" decimals="-5" id="f-396" unitRef="usd">250000000</agio:SaleOfStockCommonStockReservedForFutureIssuanceValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-397">Summary of Significant Accounting Policies &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries, Agios Securities Corporation, Agios International Sarl (GmbH), Agios Germany GmbH, Agios Netherlands B.V., Agios Italy S.R.L., Agios France SARL, and Agios Limited. All intercompany transactions have been eliminated in consolidation. The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which the recent COVID-19 pandemic, or other pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#x2019;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, PYRUKYND&#xae;, by the FDA on February 17, 2022 for the treatment of hemolytic anemia in adults with PK deficiency in the United States, we began to capitalize inventories of PYRUKYND&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Accounting Standards Codification 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate product revenue from sales of PYRUKYND&#xae; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#xae; to pharmacies or dispense PYRUKYND&#xae; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation related to the sale of PYRUKYND&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Contractual Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Government Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of manufacturing costs for sales of PYRUKYND&#xae;. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#xae; recorded during the twelve months ended December 31, 2023 and 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the twelve months ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at&#160;December&#160;31, 2023 and 2022 consisted of investments in U.S. Treasuries, government securities and corporate debt securities. We determine the appropriate classification of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date. We classify our marketable securities as available-for-sale pursuant to ASC 320,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Marketable securities are recorded at fair value. Unrealized gains and losses are included as a component of accumulated other comprehensive (loss) income in the consolidated balance sheets and statements of stockholders&#x2019; equity and a component of total comprehensive (loss) income in the consolidated statements of comprehensive (loss) income, until realized. Realized gains and losses are included in investment income on a specific-identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At&#160;December&#160;31, 2023 and 2022, we held both current and non-current investments. Investments classified as current are those that: (i) have a maturity of less than one year, or (ii) have a maturity of &lt;span style="-sec-ix-hidden:f-407"&gt;one&lt;/span&gt; to two years but we intend to liquidate within the next twelve months. Investments classified as non-current are those that: (i)&#160;have a maturity of&#160;&lt;span style="-sec-ix-hidden:f-409"&gt;one&lt;/span&gt; to two years, and (ii)&#160;we do not intend to liquidate within the next&#160;one year, although these funds are available for use and therefore classified as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review marketable securities for impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#x2019;s carrying amount is not recoverable. Unrealized losses are evaluated for impairment under ASC 326, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive (loss) income, net of taxes. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity of the impairment, collectability of the security, and any adverse conditions specifically related to the security, an industry, or geographic area.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents and marketable securities at fair value. ASC&#160;820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&#160;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2023 or 2022. Fair value information for these assets, including their classification in the fair value hierarchy is included in &lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;Note 3&lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;, &lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none"&gt;Fair Value Measurements&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the valuation methods during the years ended December&#160;31, 2023 and 2022. We evaluate transfers between levels at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of other receivables, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of credit risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, and marketable securities. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of laboratory equipment, computer equipment and software, leasehold improvements, furniture and fixtures, and office equipment. Costs of major additions and betterment are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost, and depreciated using the straight-line method over the estimated useful lives of the respective assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are amortized over the lesser of the remaining lease term or the estimated useful life of the improvement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically evaluate our long-lived assets for potential impairment in accordance with ASC&#160;360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is assessed based on the undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. We did not recognize any impairment charges through December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. An arrangement is determined to contain a lease if the contract conveys the right to control the use of an identified property or equipment for a period of time in exchange for consideration. If we can benefit from the various underlying assets of a lease on their own or together with other resources that are readily available, or if the various underlying assets are neither highly dependent on nor highly interrelated with other underlying assets in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;arrangement, they are considered to be a separate lease component. In the event multiple underlying assets are identified, the lease consideration is allocated to the various components based on each of the component&#x2019;s relative fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the leasing arrangement. Operating lease assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, in determining the operating lease liabilities we use an estimate of our incremental borrowing rate. The incremental borrowing rate is determined using two alternative credit scoring models to estimate our credit rating, adjusted for collateralization. The calculation of the operating lease assets includes any lease payments made and excludes any lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For operating leases, we record operating lease assets and lease liabilities in our consolidated balance sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Short-term leases, or leases that have a lease term of 12 months or less at commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not entered into any material short-term leases or financing leases as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs, including those accrued as of each balance sheet date, are expensed as incurred. These costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, fees paid to contract research organizations, or CROs, and other third parties in connection with clinical trials and preclinical development activities, fees paid to investigative sites in connection with clinical studies, the costs associated with the product manufacturing, development, and distribution of clinical supplies, the costs of laboratory equipment and facilities, and other external costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. Additionally, there may be instances in which payments made to our vendors will exceed the level of services provided, and result in a prepayment of the research and development expense. The capitalized amounts are expensed as the related goods are delivered or the services are performed. We estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based compensation awards in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#160;&#x2013;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 718. For stock-based awards granted to employees, non-employees and members of the board of directors for their services and for participation in our employee stock purchase plan, we estimate the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires us to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, we recognize stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. For awards subject to performance-based vesting conditions, we recognize stock-based compensation expense if the performance condition is considered probable of achievement using management&#x2019;s best estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 740, which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. We determine our deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also account for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive (loss) income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive (loss) income is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances, and currently consists of net loss and unrealized gains and losses on available-for-sale securities. Accumulated other comprehensive (loss) income consists entirely of unrealized gains and losses from available-for-sale securities as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net (loss) income per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net (loss) income per share is calculated by dividing net (loss) income by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by adjusting weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the dilutive net (loss) income per share calculation, stock options, restricted stock units, or RSUs, performance-based stock units, or PSUs, and market-based stock units, or MSUs, for which the performance and market vesting conditions, respectively, have been deemed probable, and employee stock purchase plan shares are considered to be common stock equivalents but are excluded from the calculation of diluted net (loss) income per share as their effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss from continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income (loss) from discontinued operations per share or net (loss) income per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and geographic information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker or decision-making group in making decisions on how to allocate resources and assess performance. Our chief operating decision maker is the chief executive officer. Our chief operating decision maker and we view our operations and manage our business as one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the sale of our oncology business in the first quarter of 2021 in accordance with ASC 205, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Accounting Standards Update, or ASU, No. 2014-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We followed the held-for-sale criteria as defined in ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ASC 205. ASC 205 requires that a component of an entity that has been disposed of or is classified as held for sale and has operations and cash flows that can be clearly distinguished from the rest of the entity be reported as assets held for sale and discontinued operations. In the period a component of an entity has been disposed of or classified as held for sale, the results of operations for the periods presented are reclassified into separate line items in the consolidated statements of operations. Assets and liabilities are also reclassified into separate line items on the related consolidated balance sheets for the periods presented. The statements of cash flows for the periods presented are also reclassified to reflect the results of discontinued operations as separate line items. ASU 2014-08 requires that only a disposal of a component of an entity, or a group of components of an entity, that represents a strategic shift that has, or will have, a major effect on the reporting entity&#x2019;s operations and financial results be reported in the financial statements as discontinued operations. ASU 2014-08 also provides guidance on the financial statement presentations and disclosures of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the sale of our oncology business during the first quarter of 2021, in accordance with ASC 205, we have classified the results of the oncology business as discontinued operations in our consolidated statements of operations and cash flows for all periods presented, and refer to &lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;Note 15, &lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none"&gt;Discontinued Operations&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Subsequent events&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We considered events or transactions occurring after the balance sheet date, but prior to the issuance of the consolidated financial statements, for potential recognition or disclosure in our consolidated financial statements. All significant subsequent events have been properly disclosed in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-398">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include our accounts and the accounts of our wholly owned subsidiaries, Agios Securities Corporation, Agios International Sarl (GmbH), Agios Germany GmbH, Agios Netherlands B.V., Agios Italy S.R.L., Agios France SARL, and Agios Limited. All intercompany transactions have been eliminated in consolidation. The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-399">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which the recent COVID-19 pandemic, or other pandemics or public health emergencies, may in the future directly or indirectly impact our business, results of operations and financial condition, including expenses, reserves and allowances, clinical trials, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-400">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. Cash equivalents are stated at fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-401">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our trade accounts receivable arise from product sales and represent amounts due from specialty distributors and specialty pharmacy providers in the U.S. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We reserve against these receivables for estimated losses that may arise from a customer&#x2019;s inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-402">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. Prior to the regulatory approval of our product candidates, we incur expenses for the manufacture of drug product that could potentially be available to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, we record all such costs as research and development expenses. Upon approval of our wholly owned product, PYRUKYND&#xae;, by the FDA on February 17, 2022 for the treatment of hemolytic anemia in adults with PK deficiency in the United States, we began to capitalize inventories of PYRUKYND&#xae;.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-403">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Accounting Standards Codification 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 606, revenue is recognized when the customer obtains control of promised goods or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that have been determined to be within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy a performance obligation. We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or services we transfer to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once the contract is determined to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are performance obligations, and assess whether each promised good or service is distinct. We will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate product revenue from sales of PYRUKYND&#xae; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#xae; to pharmacies or dispense PYRUKYND&#xae; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation related to the sale of PYRUKYND&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Contractual Adjustments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. We generally provide Customers with discounts, including prompt pay discounts, and allowances that are explicitly stated in the contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, we receive sales order management, data and distribution services from certain Customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Chargebacks and discounts represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to Customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are estimated using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated channel mix and are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Government Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. Government rebates include Medicare, TriCare, and Medicaid rebates, which we estimate using the expected value method, based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Returns&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. We estimate the amount of product sales that may be returned by Customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized. We currently estimate product return liabilities using the expected value method, based on available industry data, including our visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="c-1" id="f-404">&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of manufacturing costs for sales of PYRUKYND&#xae;. Based on our policy to expense costs associated with the manufacturing of our products prior to regulatory approval, certain of the manufacturing costs associated with product shipments of PYRUKYND&#xae; recorded during the twelve months ended December 31, 2023 and 2022 were expensed prior to February 17, 2022 and, therefore, are not included in costs of sales during the twelve months ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-405">&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at&#160;December&#160;31, 2023 and 2022 consisted of investments in U.S. Treasuries, government securities and corporate debt securities. We determine the appropriate classification of the securities at the time they are acquired and evaluate the appropriateness of such classifications at each balance sheet date. We classify our marketable securities as available-for-sale pursuant to ASC 320,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Debt and Equity Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Marketable securities are recorded at fair value. Unrealized gains and losses are included as a component of accumulated other comprehensive (loss) income in the consolidated balance sheets and statements of stockholders&#x2019; equity and a component of total comprehensive (loss) income in the consolidated statements of comprehensive (loss) income, until realized. Realized gains and losses are included in investment income on a specific-identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At&#160;December&#160;31, 2023 and 2022, we held both current and non-current investments. Investments classified as current are those that: (i) have a maturity of less than one year, or (ii) have a maturity of &lt;span style="-sec-ix-hidden:f-407"&gt;one&lt;/span&gt; to two years but we intend to liquidate within the next twelve months. Investments classified as non-current are those that: (i)&#160;have a maturity of&#160;&lt;span style="-sec-ix-hidden:f-409"&gt;one&lt;/span&gt; to two years, and (ii)&#160;we do not intend to liquidate within the next&#160;one year, although these funds are available for use and therefore classified as available-for-sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We review marketable securities for impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#x2019;s carrying amount is not recoverable. Unrealized losses are evaluated for impairment under ASC 326, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine if the impairment is credit-related or noncredit-related. Credit-related impairment is recognized as an allowance on the balance sheet with a corresponding adjustment to earnings, and noncredit-related impairment is recognized in other comprehensive (loss) income, net of taxes. Evidence considered in this assessment includes reasons for the impairment, compliance with our investment policy, the severity of the impairment, collectability of the security, and any adverse conditions specifically related to the security, an industry, or geographic area.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <agio:AvailableForSaleSecuritiesCurrentMaturityPeriod contextRef="c-1" id="f-406">P1Y</agio:AvailableForSaleSecuritiesCurrentMaturityPeriod>
    <agio:AvailableForSaleSecuritiesCurrentMaturityPeriod contextRef="c-61" id="f-408">P2Y</agio:AvailableForSaleSecuritiesCurrentMaturityPeriod>
    <agio:AvailableForSaleSecuritiesNonCurrentMaturityPeriod contextRef="c-61" id="f-410">P2Y</agio:AvailableForSaleSecuritiesNonCurrentMaturityPeriod>
    <agio:AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod contextRef="c-1" id="f-411">P1Y</agio:AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-412">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record cash equivalents and marketable securities at fair value. ASC&#160;820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The hierarchy consists of three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&#160;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets, which include cash equivalents and marketable securities, have been initially valued at the transaction price, and subsequently revalued at the end of each reporting period, utilizing third-party pricing services or other observable market data. The pricing services utilize industry standard valuation models, including both income and market based approaches, and observable market inputs to determine value. After completing our validation procedures, we did not adjust or override any fair value measurements provided by the pricing services as of December&#160;31, 2023 or 2022. Fair value information for these assets, including their classification in the fair value hierarchy is included in &lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;Note 3&lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;, &lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_130" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none"&gt;Fair Value Measurements&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the valuation methods during the years ended December&#160;31, 2023 and 2022. We evaluate transfers between levels at the end of each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of other receivables, prepaid expenses and other current assets, accounts payable, and accrued expenses approximate their fair values due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-413">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of credit risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments which potentially subject us to credit risk consist primarily of cash, cash equivalents, and marketable securities. We hold these investments in highly rated financial institutions, and, by policy, limit the amounts of credit exposure to any one financial institution. These amounts at times may exceed federally insured limits. We have not experienced any credit losses in such accounts and do not believe we are exposed to any significant credit risk on these funds. We have no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts, or other hedging arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-414">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of laboratory equipment, computer equipment and software, leasehold improvements, furniture and fixtures, and office equipment. Costs of major additions and betterment are capitalized; maintenance and repairs, which do not improve or extend the life of the respective assets, are charged to expense as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost, and depreciated using the straight-line method over the estimated useful lives of the respective assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements are amortized over the lesser of the remaining lease term or the estimated useful life of the improvement.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <agio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="c-1" id="f-415">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost, and depreciated using the straight-line method over the estimated useful lives of the respective assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.182%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-62" id="f-416">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-63" id="f-417">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-64" id="f-418">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-65" id="f-419">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically evaluate our long-lived assets for potential impairment in accordance with ASC&#160;360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Potential impairment is assessed when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is assessed based on the undiscounted expected future cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market trends and product development cycles. If impairments are identified, assets are written down to their estimated fair value. We did not recognize any impairment charges through December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-421">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease at inception. An arrangement is determined to contain a lease if the contract conveys the right to control the use of an identified property or equipment for a period of time in exchange for consideration. If we can benefit from the various underlying assets of a lease on their own or together with other resources that are readily available, or if the various underlying assets are neither highly dependent on nor highly interrelated with other underlying assets in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;arrangement, they are considered to be a separate lease component. In the event multiple underlying assets are identified, the lease consideration is allocated to the various components based on each of the component&#x2019;s relative fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the leasing arrangement. Operating lease assets and operating lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, in determining the operating lease liabilities we use an estimate of our incremental borrowing rate. The incremental borrowing rate is determined using two alternative credit scoring models to estimate our credit rating, adjusted for collateralization. The calculation of the operating lease assets includes any lease payments made and excludes any lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For operating leases, we record operating lease assets and lease liabilities in our consolidated balance sheets. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Short-term leases, or leases that have a lease term of 12 months or less at commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not entered into any material short-term leases or financing leases as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-422">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs, including those accrued as of each balance sheet date, are expensed as incurred. These costs include salaries and personnel-related costs, consulting fees, fees paid for contract research services, fees paid to contract research organizations, or CROs, and other third parties in connection with clinical trials and preclinical development activities, fees paid to investigative sites in connection with clinical studies, the costs associated with the product manufacturing, development, and distribution of clinical supplies, the costs of laboratory equipment and facilities, and other external costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. Additionally, there may be instances in which payments made to our vendors will exceed the level of services provided, and result in a prepayment of the research and development expense. The capitalized amounts are expensed as the related goods are delivered or the services are performed. We estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-423">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for stock-based compensation awards in accordance with ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#160;&#x2013;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 718. For stock-based awards granted to employees, non-employees and members of the board of directors for their services and for participation in our employee stock purchase plan, we estimate the grant date fair value of each option award using the Black-Scholes option-pricing model. The use of the Black-Scholes option-pricing model requires us to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates and expected dividend yields of the common stock. For awards subject to service-based vesting conditions, we recognize stock-based compensation expense equal to the grant date fair value of stock options on a straight-line basis over the requisite service period. For awards subject to performance-based vesting conditions, we recognize stock-based compensation expense if the performance condition is considered probable of achievement using management&#x2019;s best estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-424">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, or ASC 740, which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. We determine our deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also account for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-425">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive (loss) income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive (loss) income is defined as the change in equity of a business enterprise during a period from transactions, and other events and circumstances, and currently consists of net loss and unrealized gains and losses on available-for-sale securities. Accumulated other comprehensive (loss) income consists entirely of unrealized gains and losses from available-for-sale securities as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-426">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net (loss) income per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net (loss) income per share is calculated by dividing net (loss) income by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net (loss) income per share is calculated by adjusting weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the dilutive net (loss) income per share calculation, stock options, restricted stock units, or RSUs, performance-based stock units, or PSUs, and market-based stock units, or MSUs, for which the performance and market vesting conditions, respectively, have been deemed probable, and employee stock purchase plan shares are considered to be common stock equivalents but are excluded from the calculation of diluted net (loss) income per share as their effect would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss from continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income (loss) from discontinued operations per share or net (loss) income per share.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-427">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment and geographic information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker or decision-making group in making decisions on how to allocate resources and assess performance. Our chief operating decision maker is the chief executive officer. Our chief operating decision maker and we view our operations and manage our business as one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-428"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="c-1" id="f-429">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the sale of our oncology business in the first quarter of 2021 in accordance with ASC 205, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Accounting Standards Update, or ASU, No. 2014-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reporting of Discontinued Operations and Disclosures of Disposals of Components of an Entity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We followed the held-for-sale criteria as defined in ASC 360, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and ASC 205. ASC 205 requires that a component of an entity that has been disposed of or is classified as held for sale and has operations and cash flows that can be clearly distinguished from the rest of the entity be reported as assets held for sale and discontinued operations. In the period a component of an entity has been disposed of or classified as held for sale, the results of operations for the periods presented are reclassified into separate line items in the consolidated statements of operations. Assets and liabilities are also reclassified into separate line items on the related consolidated balance sheets for the periods presented. The statements of cash flows for the periods presented are also reclassified to reflect the results of discontinued operations as separate line items. ASU 2014-08 requires that only a disposal of a component of an entity, or a group of components of an entity, that represents a strategic shift that has, or will have, a major effect on the reporting entity&#x2019;s operations and financial results be reported in the financial statements as discontinued operations. ASU 2014-08 also provides guidance on the financial statement presentations and disclosures of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the sale of our oncology business during the first quarter of 2021, in accordance with ASC 205, we have classified the results of the oncology business as discontinued operations in our consolidated statements of operations and cash flows for all periods presented, and refer to &lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;Note 15, &lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_166" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none"&gt;Discontinued Operations&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. All amounts included in the notes to the consolidated financial statements relate to continuing operations unless otherwise noted.&lt;/span&gt;&lt;/div&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-430">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury stock&lt;/span&gt;&lt;/div&gt;Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-431">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting standards that have been issued by the Financial Accounting Standards Board or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="c-1" id="f-432">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Subsequent events&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We considered events or transactions occurring after the balance sheet date, but prior to the issuance of the consolidated financial statements, for potential recognition or disclosure in our consolidated financial statements. All significant subsequent events have been properly disclosed in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-433">Fair Value Measurements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash equivalents and marketable securities measured at fair value and by level (as described in &lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;Note&lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt; &lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;2,&lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt; &lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none"&gt;Su&lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none"&gt;mmary of Significant Accounting Policies&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) on a recurring basis as of December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level&#160;3 at any point during the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-434">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our cash equivalents and marketable securities measured at fair value and by level (as described in &lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;Note&lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt; &lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;2,&lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt; &lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none"&gt;Su&lt;/a&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_127" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none"&gt;mmary of Significant Accounting Policies&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) on a recurring basis as of December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-435" unitRef="usd">30123000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-436" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-438" unitRef="usd">30123000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-70" decimals="-3" id="f-439" unitRef="usd">30123000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-71" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-72" decimals="-3" id="f-441" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-442" unitRef="usd">30123000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-74" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-75" decimals="-3" id="f-444" unitRef="usd">35652000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-76" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-77" decimals="-3" id="f-446" unitRef="usd">35652000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-78" decimals="-3" id="f-447" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-79" decimals="-3" id="f-448" unitRef="usd">257020000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-80" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-81" decimals="-3" id="f-450" unitRef="usd">257020000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-82" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-83" decimals="-3" id="f-452" unitRef="usd">425486000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-84" decimals="-3" id="f-453" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-85" decimals="-3" id="f-454" unitRef="usd">425486000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-70" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-71" decimals="-3" id="f-456" unitRef="usd">718158000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-72" decimals="-3" id="f-457" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-73" decimals="-3" id="f-458" unitRef="usd">718158000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities contextRef="c-70" decimals="-3" id="f-459" unitRef="usd">30123000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities contextRef="c-71" decimals="-3" id="f-460" unitRef="usd">718158000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities contextRef="c-72" decimals="-3" id="f-461" unitRef="usd">0</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <agio:CashEquivalentsAndAvailableForSaleSecurities contextRef="c-73" decimals="-3" id="f-462" unitRef="usd">748281000</agio:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:FairValueNetAssetLiability contextRef="c-72" decimals="INF" id="f-463" unitRef="usd">0</us-gaap:FairValueNetAssetLiability>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-464">Marketable Securities&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at December&#160;31, 2023 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at December&#160;31, 2022 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no material realized gains or losses on marketable securities for the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At&#160;December&#160;31, 2023 and 2022, we held&#160;151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did not record an allowance for credit losses as of December&#160;31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at&#160;December&#160;31, 2023 and 2022 was $513.5 million and $868.2 million, respectively. There were&#160;no individual securities that were in a significant unrealized loss position as of&#160;December&#160;31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of&#160;December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-465">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at December&#160;31, 2023 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities at December&#160;31, 2022 consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.707%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.650%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(811)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,289)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-86" decimals="-3" id="f-466" unitRef="usd">30876000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-86" decimals="-3" id="f-467" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-86" decimals="-3" id="f-468" unitRef="usd">56000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-86" decimals="-3" id="f-469" unitRef="usd">30820000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-87" decimals="-3" id="f-470" unitRef="usd">247460000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-87" decimals="-3" id="f-471" unitRef="usd">194000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-87" decimals="-3" id="f-472" unitRef="usd">695000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-87" decimals="-3" id="f-473" unitRef="usd">246959000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-88" decimals="-3" id="f-474" unitRef="usd">411045000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-88" decimals="-3" id="f-475" unitRef="usd">874000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-88" decimals="-3" id="f-476" unitRef="usd">975000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-88" decimals="-3" id="f-477" unitRef="usd">410944000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-89" decimals="-3" id="f-478" unitRef="usd">689381000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-89" decimals="-3" id="f-479" unitRef="usd">1068000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-89" decimals="-3" id="f-480" unitRef="usd">1726000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="-3" id="f-481" unitRef="usd">688723000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-90" decimals="-3" id="f-482" unitRef="usd">4802000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-90" decimals="-3" id="f-483" unitRef="usd">30000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-90" decimals="-3" id="f-484" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="-3" id="f-485" unitRef="usd">4832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-91" decimals="-3" id="f-486" unitRef="usd">9986000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-91" decimals="-3" id="f-487" unitRef="usd">75000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-91" decimals="-3" id="f-488" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-91" decimals="-3" id="f-489" unitRef="usd">10061000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-92" decimals="-3" id="f-490" unitRef="usd">14430000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-92" decimals="-3" id="f-491" unitRef="usd">112000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-92" decimals="-3" id="f-492" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="-3" id="f-493" unitRef="usd">14542000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-93" decimals="-3" id="f-494" unitRef="usd">29218000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-93" decimals="-3" id="f-495" unitRef="usd">217000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-93" decimals="-3" id="f-496" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-93" decimals="-3" id="f-497" unitRef="usd">29435000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="-3" id="f-498" unitRef="usd">718599000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="-3" id="f-499" unitRef="usd">1285000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="-3" id="f-500" unitRef="usd">1726000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-3" id="f-501" unitRef="usd">718158000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-94" decimals="-3" id="f-502" unitRef="usd">68175000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-94" decimals="-3" id="f-503" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-94" decimals="-3" id="f-504" unitRef="usd">811000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-94" decimals="-3" id="f-505" unitRef="usd">67367000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-95" decimals="-3" id="f-506" unitRef="usd">220901000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-95" decimals="-3" id="f-507" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-95" decimals="-3" id="f-508" unitRef="usd">5289000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-95" decimals="-3" id="f-509" unitRef="usd">215620000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-96" decimals="-3" id="f-510" unitRef="usd">363263000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-96" decimals="-3" id="f-511" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-96" decimals="-3" id="f-512" unitRef="usd">2391000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-96" decimals="-3" id="f-513" unitRef="usd">360873000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-97" decimals="-3" id="f-514" unitRef="usd">652339000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-97" decimals="-3" id="f-515" unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-97" decimals="-3" id="f-516" unitRef="usd">8491000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-97" decimals="-3" id="f-517" unitRef="usd">643860000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-98" decimals="-3" id="f-518" unitRef="usd">17418000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-98" decimals="-3" id="f-519" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-98" decimals="-3" id="f-520" unitRef="usd">193000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-98" decimals="-3" id="f-521" unitRef="usd">17229000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-99" decimals="-3" id="f-522" unitRef="usd">117475000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-99" decimals="-3" id="f-523" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-99" decimals="-3" id="f-524" unitRef="usd">1659000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-99" decimals="-3" id="f-525" unitRef="usd">115823000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-100" decimals="-3" id="f-526" unitRef="usd">183037000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-100" decimals="-3" id="f-527" unitRef="usd">76000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-100" decimals="-3" id="f-528" unitRef="usd">2291000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-100" decimals="-3" id="f-529" unitRef="usd">180822000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-101" decimals="-3" id="f-530" unitRef="usd">317930000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-101" decimals="-3" id="f-531" unitRef="usd">87000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-101" decimals="-3" id="f-532" unitRef="usd">4143000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-101" decimals="-3" id="f-533" unitRef="usd">313874000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-6" decimals="-3" id="f-534" unitRef="usd">970269000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-6" decimals="-3" id="f-535" unitRef="usd">99000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-6" decimals="-3" id="f-536" unitRef="usd">12634000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-6" decimals="-3" id="f-537" unitRef="usd">957734000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-13" decimals="INF" id="f-538" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-1" decimals="INF" id="f-539" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-5"
      decimals="INF"
      id="f-540"
      unitRef="security">151</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="c-6"
      decimals="INF"
      id="f-541"
      unitRef="security">259</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-6" decimals="INF" id="f-542" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss contextRef="c-5" decimals="INF" id="f-543" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-5" decimals="-5" id="f-544" unitRef="usd">513500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-6" decimals="-5" id="f-545" unitRef="usd">868200000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-5"
      decimals="INF"
      id="f-546"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-6"
      decimals="INF"
      id="f-547"
      unitRef="security">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-548">Inventory&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which consists of commercial supply of PYRUKYND&#xae;, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-549">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which consists of commercial supply of PYRUKYND&#xae;, consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-5" decimals="-3" id="f-550" unitRef="usd">51000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-6" decimals="-3" id="f-551" unitRef="usd">0</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-5" decimals="-3" id="f-552" unitRef="usd">17568000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-6" decimals="-3" id="f-553" unitRef="usd">7550000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-5" decimals="-3" id="f-554" unitRef="usd">1457000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-6" decimals="-3" id="f-555" unitRef="usd">942000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-556" unitRef="usd">19076000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-6" decimals="-3" id="f-557" unitRef="usd">8492000</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-558">Leases&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our building leases are comprised of office and laboratory space under non-cancelable operating leases. These lease agreements have remaining lease terms of four years and contain various clauses for renewal at our option. The renewal options were not included in the calculation of the operating lease assets and the operating lease liabilities as the renewal options are not reasonably certain of being exercised. The lease agreements do not contain residual value guarantees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently lease approximately 146,000 square feet at 88 Sidney Street, 43,000 square feet at 64 Sidney Street, and 13,000 square feet at 38 Sidney Street, Cambridge, Massachusetts. All leases, as amended, expire on February 29, 2028. At the end of the initial lease period, we have the option to extend the leases at all facilities for two consecutive five-year periods at the fair market rent at the time of the extension.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense and other information related to leases were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not entered into any material short-term leases or financing leases as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In arriving at the operating lease liabilities as of December&#160;31, 2023, we applied the weighted-average incremental borrowing rate of 5.7% from inception over a weighted-average remaining lease term of 4.2 years. In arriving at the operating lease liabilities as of December&#160;31, 2022, we applied the weighted-average incremental borrowing rate of 5.7% over a weighted-average remaining lease term of 5.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter, were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provided our landlord a security deposit of $2.9 million as security for our leases, which is included within other non-current assets on our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we entered into a long-term sublease agreement for 13,000 square feet of the office space at 38 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through December 2024. In April 2022, we entered into a long-term sublease agreement for 27,000 square feet of the office space at 64 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through April 2025. At the end of the initial sublease periods, the subtenant has the option to extend the leases for one additional 6-month period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, we entered into a long-term sublease agreement for 7,407 square feet of office space on the first floor of 64 Sidney Street, Cambridge, Massachusetts, with the term of the lease running through April 2025. At the end of the initial sublease period, the subtenant has the option to extend the lease for &lt;span style="-sec-ix-hidden:f-596"&gt;one&lt;/span&gt; additional year, followed by a second extension option for &lt;span style="-sec-ix-hidden:f-597"&gt;twenty-two&lt;/span&gt; additional months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recorded operating sublease income of $6.1&#160;million and $4.1&#160;million for the years ended December&#160;31, 2023 and December&#160;31, 2022, respectively, in other income, net in the consolidated statements of operations. We received a security deposit from our sublessee of approximately $1.2&#160;million which is recorded within other non-current assets on our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the future minimum lease payments to be received under the long-term sublease agreements were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.217%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-5" id="f-559">P4Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <agio:LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace contextRef="c-102" decimals="-3" id="f-560" unitRef="sqft">146000</agio:LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace>
    <agio:LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace contextRef="c-103" decimals="-3" id="f-561" unitRef="sqft">43000</agio:LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace>
    <agio:LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace contextRef="c-104" decimals="-3" id="f-562" unitRef="sqft">13000</agio:LesseeOperatingLeaseNumberOfSquareFeetOfOfficeSpace>
    <agio:LesseeOperatingLeaseNumberOfLeaseTerms
      contextRef="c-102"
      decimals="INF"
      id="f-563"
      unitRef="leaseterm">2</agio:LesseeOperatingLeaseNumberOfLeaseTerms>
    <agio:LesseeOperatingLeaseNumberOfLeaseTerms
      contextRef="c-103"
      decimals="INF"
      id="f-564"
      unitRef="leaseterm">2</agio:LesseeOperatingLeaseNumberOfLeaseTerms>
    <agio:LesseeOperatingLeaseNumberOfLeaseTerms
      contextRef="c-104"
      decimals="INF"
      id="f-565"
      unitRef="leaseterm">2</agio:LesseeOperatingLeaseNumberOfLeaseTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-105" id="f-566">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-106" id="f-567">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-107" id="f-568">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-569">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense and other information related to leases were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.853%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-570" unitRef="usd">15227000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-3" id="f-571" unitRef="usd">15227000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-14" decimals="-3" id="f-572" unitRef="usd">15229000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-573" unitRef="usd">18170000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-13" decimals="-3" id="f-574" unitRef="usd">17035000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-14" decimals="-3" id="f-575" unitRef="usd">14411000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-576" unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-577">P4Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-578" unitRef="number">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-579">P5Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-580">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, undiscounted minimum rental commitments under non-cancelable leases, for each of the next five years and total thereafter, were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.596%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undiscounted minimum rental commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-581" unitRef="usd">17142000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-582" unitRef="usd">19506000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-583" unitRef="usd">20151000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-584" unitRef="usd">20755000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-5" decimals="-3" id="f-585" unitRef="usd">3479000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-5" decimals="-3" id="f-586" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-587" unitRef="usd">81033000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-588" unitRef="usd">9037000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-589" unitRef="usd">71996000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-108" decimals="-5" id="f-590" unitRef="usd">2900000</us-gaap:LettersOfCreditOutstandingAmount>
    <agio:LesseeOperatingSubleaseAreaOfPremisesSubleased contextRef="c-109" decimals="-3" id="f-591" unitRef="sqft">13000</agio:LesseeOperatingSubleaseAreaOfPremisesSubleased>
    <agio:LesseeOperatingSubleaseAreaOfPremisesSubleased contextRef="c-110" decimals="-3" id="f-592" unitRef="sqft">27000</agio:LesseeOperatingSubleaseAreaOfPremisesSubleased>
    <agio:LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods
      contextRef="c-111"
      decimals="INF"
      id="f-593"
      unitRef="extension">1</agio:LesseeOperatingLeaseOptionToExtendNumberOfExtensionPeriods>
    <agio:LesseeOperatingLeaseOptionToExtendExtensionPeriod contextRef="c-111" id="f-594">P6M</agio:LesseeOperatingLeaseOptionToExtendExtensionPeriod>
    <agio:LesseeOperatingSubleaseAreaOfPremisesSubleased contextRef="c-112" decimals="INF" id="f-595" unitRef="sqft">7407</agio:LesseeOperatingSubleaseAreaOfPremisesSubleased>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-5" id="f-598" unitRef="usd">6100000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-13" decimals="-5" id="f-599" unitRef="usd">4100000</us-gaap:SubleaseIncome>
    <us-gaap:SecurityDepositLiability contextRef="c-108" decimals="-5" id="f-600" unitRef="usd">1200000</us-gaap:SecurityDepositLiability>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock contextRef="c-1" id="f-601">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the future minimum lease payments to be received under the long-term sublease agreements were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.217%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.583%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths contextRef="c-5" decimals="-3" id="f-602" unitRef="usd">5078000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears contextRef="c-5" decimals="-3" id="f-603" unitRef="usd">1310000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-5" decimals="-3" id="f-604" unitRef="usd">6388000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="c-1" id="f-605">Accrued Expenses&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following at December 31:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-606">&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of the following at December 31:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-607" unitRef="usd">23232000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-608" unitRef="usd">18105000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <agio:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-5" decimals="-3" id="f-609" unitRef="usd">15463000</agio:AccruedResearchAndDevelopmentCostsCurrent>
    <agio:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-6" decimals="-3" id="f-610" unitRef="usd">8425000</agio:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-611" unitRef="usd">3115000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-3" id="f-612" unitRef="usd">2435000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-613" unitRef="usd">1357000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-614" unitRef="usd">1385000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-615" unitRef="usd">43167000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-616" unitRef="usd">30350000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-617">Product Revenue&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generate product revenue from sales of PYRUKYND&#xae; to a limited number of specialty distributors and specialty pharmacy providers, or collectively, the Customers. These Customers subsequently resell PYRUKYND&#xae; to pharmacies or dispense PYRUKYND&#xae; directly to patients. In addition to distribution agreements with Customers, we enter into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of PYRUKYND&#xae;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance obligation related to the sale of PYRUKYND&#xae; is satisfied and revenue is recognized when the Customer obtains control of the product, which occurs at a point in time, typically upon delivery to the Customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue, net, was as follows for the years ended December 31: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the net sales price, or transaction price, which includes estimates of variable consideration for which reserves are established and result from contractual adjustments, government rebates, returns and other allowances that are offered within the contracts with our Customers, healthcare providers, payors and other indirect customers relating to the sale of our products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize balances and activity in each of the product revenue allowance and reserve categories for the years ended December&#160;31, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Component of accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in our contract assets, which consisted of accounts receivable, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Additions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Deductions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)  Additions to contract assets relate to amounts billed to Customers for product sales, and deductions to contract assets primarily relate to collection of receivables during the reporting period.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-618">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue, net, was as follows for the years ended December 31: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-619" unitRef="usd">26823000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-620" unitRef="usd">11740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-621" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-622">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize balances and activity in each of the product revenue allowance and reserve categories for the years ended December&#160;31, 2023 and December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(314)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,899)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Government Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments/returns relating to sales in the prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <agio:ContractWithCustomerContractualAdjustmentReserve contextRef="c-6" decimals="-3" id="f-623" unitRef="usd">65000</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve contextRef="c-6" decimals="-3" id="f-624" unitRef="usd">573000</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve contextRef="c-6" decimals="-3" id="f-625" unitRef="usd">133000</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves contextRef="c-6" decimals="-3" id="f-626" unitRef="usd">771000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:CurrentYearProvisionForContractualAdjustments contextRef="c-1" decimals="-3" id="f-627" unitRef="usd">1079000</agio:CurrentYearProvisionForContractualAdjustments>
    <agio:CurrentYearProvisionsForRebateReserve contextRef="c-1" decimals="-3" id="f-628" unitRef="usd">2086000</agio:CurrentYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInCurrentYear contextRef="c-1" decimals="-3" id="f-629" unitRef="usd">2182000</agio:ProvisionForRightToRecoverProductInCurrentYear>
    <agio:ContractWithCustomerCurrentYearReserveProvisions contextRef="c-1" decimals="-3" id="f-630" unitRef="usd">5347000</agio:ContractWithCustomerCurrentYearReserveProvisions>
    <agio:PriorYearProvisionForContractualAdjustments contextRef="c-1" decimals="-3" id="f-631" unitRef="usd">0</agio:PriorYearProvisionForContractualAdjustments>
    <agio:PriorYearProvisionsForRebateReserve contextRef="c-1" decimals="-3" id="f-632" unitRef="usd">-237000</agio:PriorYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInPriorYears contextRef="c-1" decimals="-3" id="f-633" unitRef="usd">-77000</agio:ProvisionForRightToRecoverProductInPriorYears>
    <agio:ContractWithCustomerPriorYearsReserveProvisions contextRef="c-1" decimals="-3" id="f-634" unitRef="usd">-314000</agio:ContractWithCustomerPriorYearsReserveProvisions>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear contextRef="c-1" decimals="-3" id="f-635" unitRef="usd">938000</agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear contextRef="c-1" decimals="-3" id="f-636" unitRef="usd">1003000</agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear>
    <agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries contextRef="c-1" decimals="-3" id="f-637" unitRef="usd">1958000</agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries>
    <agio:ContractWithCustomerCurrentYearReserveRecoveries contextRef="c-1" decimals="-3" id="f-638" unitRef="usd">3899000</agio:ContractWithCustomerCurrentYearReserveRecoveries>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear contextRef="c-1" decimals="-3" id="f-639" unitRef="usd">50000</agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears contextRef="c-1" decimals="-3" id="f-640" unitRef="usd">335000</agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears>
    <agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries contextRef="c-1" decimals="-3" id="f-641" unitRef="usd">48000</agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries>
    <agio:ContractWithCustomerPriorYearsReserveRecoveries contextRef="c-1" decimals="-3" id="f-642" unitRef="usd">433000</agio:ContractWithCustomerPriorYearsReserveRecoveries>
    <agio:ContractWithCustomerContractualAdjustmentReserve contextRef="c-5" decimals="-3" id="f-643" unitRef="usd">156000</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve contextRef="c-5" decimals="-3" id="f-644" unitRef="usd">1084000</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve contextRef="c-5" decimals="-3" id="f-645" unitRef="usd">232000</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves contextRef="c-5" decimals="-3" id="f-646" unitRef="usd">1472000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ContractWithCustomerContractualAdjustmentReserve contextRef="c-31" decimals="-3" id="f-647" unitRef="usd">0</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve contextRef="c-31" decimals="-3" id="f-648" unitRef="usd">0</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve contextRef="c-31" decimals="-3" id="f-649" unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves contextRef="c-31" decimals="-3" id="f-650" unitRef="usd">0</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:CurrentYearProvisionForContractualAdjustments contextRef="c-13" decimals="-3" id="f-651" unitRef="usd">497000</agio:CurrentYearProvisionForContractualAdjustments>
    <agio:CurrentYearProvisionsForRebateReserve contextRef="c-13" decimals="-3" id="f-652" unitRef="usd">912000</agio:CurrentYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInCurrentYear contextRef="c-13" decimals="-3" id="f-653" unitRef="usd">133000</agio:ProvisionForRightToRecoverProductInCurrentYear>
    <agio:ContractWithCustomerCurrentYearReserveProvisions contextRef="c-13" decimals="-3" id="f-654" unitRef="usd">1542000</agio:ContractWithCustomerCurrentYearReserveProvisions>
    <agio:PriorYearProvisionForContractualAdjustments contextRef="c-13" decimals="-3" id="f-655" unitRef="usd">0</agio:PriorYearProvisionForContractualAdjustments>
    <agio:PriorYearProvisionsForRebateReserve contextRef="c-13" decimals="-3" id="f-656" unitRef="usd">0</agio:PriorYearProvisionsForRebateReserve>
    <agio:ProvisionForRightToRecoverProductInPriorYears contextRef="c-13" decimals="-3" id="f-657" unitRef="usd">0</agio:ProvisionForRightToRecoverProductInPriorYears>
    <agio:ContractWithCustomerPriorYearsReserveProvisions contextRef="c-13" decimals="-3" id="f-658" unitRef="usd">0</agio:ContractWithCustomerPriorYearsReserveProvisions>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear contextRef="c-13" decimals="-3" id="f-659" unitRef="usd">432000</agio:ContractWithCustomerContractAdjustmentRecoveriesCurrentYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear contextRef="c-13" decimals="-3" id="f-660" unitRef="usd">339000</agio:ContractWithCustomerRebateReserveRecoveriesInCurrentYear>
    <agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries contextRef="c-13" decimals="-3" id="f-661" unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductCurrentYearRecoveries>
    <agio:ContractWithCustomerCurrentYearReserveRecoveries contextRef="c-13" decimals="-3" id="f-662" unitRef="usd">771000</agio:ContractWithCustomerCurrentYearReserveRecoveries>
    <agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear contextRef="c-13" decimals="-3" id="f-663" unitRef="usd">0</agio:ContractWithCustomerContractAdjustmentRecoveriesPriorYear>
    <agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears contextRef="c-13" decimals="-3" id="f-664" unitRef="usd">0</agio:ContractWithCustomerRebateReserveRecoveriesInPriorYears>
    <agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries contextRef="c-13" decimals="-3" id="f-665" unitRef="usd">0</agio:ContractWithCustomerRightToRecoverProductPriorYearRecoveries>
    <agio:ContractWithCustomerPriorYearsReserveRecoveries contextRef="c-13" decimals="-3" id="f-666" unitRef="usd">0</agio:ContractWithCustomerPriorYearsReserveRecoveries>
    <agio:ContractWithCustomerContractualAdjustmentReserve contextRef="c-6" decimals="-3" id="f-667" unitRef="usd">65000</agio:ContractWithCustomerContractualAdjustmentReserve>
    <agio:ContractWithCustomerRebateReserve contextRef="c-6" decimals="-3" id="f-668" unitRef="usd">573000</agio:ContractWithCustomerRebateReserve>
    <agio:ContractWithCustomerRightToRecoverProductReserve contextRef="c-6" decimals="-3" id="f-669" unitRef="usd">133000</agio:ContractWithCustomerRightToRecoverProductReserve>
    <agio:ContractWithCustomerTotalAllowancesAndReserves contextRef="c-6" decimals="-3" id="f-670" unitRef="usd">771000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock contextRef="c-1" id="f-671">&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenue-related reserves above, included in our consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Component of accrued expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</agio:ScheduleOfAccountsNotesLoansAndFinancingReceivable1TableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-3" id="f-672" unitRef="usd">151000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-6" decimals="-3" id="f-673" unitRef="usd">60000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <agio:ContractWithCustomerAllowanceAndReservesLiability contextRef="c-5" decimals="-3" id="f-674" unitRef="usd">1321000</agio:ContractWithCustomerAllowanceAndReservesLiability>
    <agio:ContractWithCustomerAllowanceAndReservesLiability contextRef="c-6" decimals="-3" id="f-675" unitRef="usd">711000</agio:ContractWithCustomerAllowanceAndReservesLiability>
    <agio:ContractWithCustomerTotalAllowancesAndReserves contextRef="c-5" decimals="-3" id="f-676" unitRef="usd">1472000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ContractWithCustomerTotalAllowancesAndReserves contextRef="c-6" decimals="-3" id="f-677" unitRef="usd">771000</agio:ContractWithCustomerTotalAllowancesAndReserves>
    <agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock contextRef="c-1" id="f-678">&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in our contract assets, which consisted of accounts receivable, net: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Additions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Deductions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)  Additions to contract assets relate to amounts billed to Customers for product sales, and deductions to contract assets primarily relate to collection of receivables during the reporting period.</agio:ContractWithCustomerAssetAndLiabilityProductRevenueTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-6" decimals="-3" id="f-679" unitRef="usd">2206000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-31" decimals="-3" id="f-680" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <agio:ContractWithCustomerAssetRevenueRecognized contextRef="c-1" decimals="-3" id="f-681" unitRef="usd">31855000</agio:ContractWithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetRevenueRecognized contextRef="c-13" decimals="-3" id="f-682" unitRef="usd">13283000</agio:ContractWithCustomerAssetRevenueRecognized>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables contextRef="c-1" decimals="-3" id="f-683" unitRef="usd">31251000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables contextRef="c-13" decimals="-3" id="f-684" unitRef="usd">11077000</agio:ContractWithCustomerAssetProceedsFromCollectionOfReceivables>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-5" decimals="-3" id="f-685" unitRef="usd">2810000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-6" decimals="-3" id="f-686" unitRef="usd">2206000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-687">Share-Based Payments &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2023 Stock Incentive Plan and Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, our stockholders approved the 2023 Stock Incentive Plan, or the 2023 Plan. The 2023 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, or RSUs, performance-based share units, or PSUs, and other stock-based awards to employees, advisors, consultants and non-employee directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the adoption of the 2023 Plan, we ceased granting equity awards under the 2013 Stock Incentive Plan, or the 2013 Plan. Any outstanding equity awards that were previously granted under the 2013 Plan continue to be governed by their terms. Following adoption of the 2013 Plan, we ceased granting equity awards under the 2007 Stock Incentive Plan, or the 2007 Plan. There are no outstanding equity awards under the 2007 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the start of employment of our Chief Executive Officer and Chief Financial Officer in 2022, and our Chief Commercial Officer in 2023, our board of directors granted each of them equity awards in the form of stock options, RSUs and PSUs, which awards were made outside our equity incentive plans as inducements material to their respective entry into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 12,004,551, and we had 4,989,341 shares available for future issuance under the 2023 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity of all stock incentive plans for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.851%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value (in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,772,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,160,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,344,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted was $14.32, $15.64 and $31.20 during the years ended December&#160;31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $2.9 million, $0.3 million and $8.5 million during the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, the total unrecognized compensation expense related to unvested stock option awards was $27.8 million, which we expect to recognize over a weighted-average period of approximately 2.40 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon vesting, each RSU entitles the holder to receive a specified number of shares of our common stock. The following table presents RSU activity for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(464,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was approximately $22.6 million of total unrecognized compensation expense related to RSUs, which we expect to be recognized over a weighted-average period of 1.75 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the achievement of the performance-based and service-based vesting criteria, each PSU entitles the holder to receive a specified number of shares of our common stock. The following table presents PSU activity for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in unvested shares were 145,023 shares with performance-based vesting criteria that were considered probable of achievement at December&#160;31, 2023 and vested in January 2024. Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management&#x2019;s best estimates. As of December&#160;31, 2023, there was no unrecognized compensation expense related to PSUs with performance-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based vesting criteria that are considered probable of achievement that we expect to recognize. There is $5.9&#160;million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Market-based stock units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have issued certain equity awards that contain market based vesting conditions, in which shares of stock are earned at vesting based on stock price performance. The fair value of MSUs are estimated using a Monte Carlo simulation model. Assumptions and estimates utilized in the model include the risk-free interest rate, dividend yield, expected stock volatility and the estimated period to achievement of the market condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents MSU activity for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was no remaining unrecognized compensation expense related to MSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December&#160;31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December&#160;31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2023, 2022 and 2021, we recorded stock-based compensation expense for employee and non-employee stock options, RSUs, PSUs, and ESPP shares. Stock-based compensation expense by award type included within the consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses related to equity-based awards were allocated as follows in the consolidated statements of operations:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No related tax benefits were recognized for the years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option granted to employees and non-employees is estimated on the date of grant using the Black-Scholes option-pricing model. The following table summarizes the weighted average assumptions used in calculating the grant date fair value of the awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the &#x201c;simplified method&#x201d; as prescribed by the Securities and Exchange Commission Staff Accounting Bulletin No.&#160;107, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Based Payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to estimate the expected term of stock option grants. Under this approach, the weighted-average expected life is presumed to be the average of the contractual term of ten years and the weighted-average vesting term of the stock options, taking into consideration multiple vesting tranches. We utilize this method due to the plain-vanilla nature of our share-based awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected volatility has been determined using our historical volatilities for a period equal to the expected term of the option grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risk-free rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate is based on the yield curve of U.S. Treasury securities with periods commensurate with the expected term of the options being valued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have never paid, and do not anticipate paying, any cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the option-pricing model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Forfeitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for forfeitures as they occur and, therefore, do not estimate forfeitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-114"
      decimals="INF"
      id="f-688"
      unitRef="shares">12004551</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-115"
      decimals="INF"
      id="f-689"
      unitRef="shares">4989341</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-690">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock option activity of all stock incentive plans for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.851%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Value (in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,772,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,160,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,344,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.36&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="INF" id="f-691" unitRef="shares">5772564</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-692"
      unitRef="usdPerShare">48.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-13" id="f-693">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-694" unitRef="usd">5362000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-695" unitRef="shares">886795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-696"
      unitRef="usdPerShare">25.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-697" unitRef="shares">235401</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-698"
      unitRef="usdPerShare">12.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-699" unitRef="shares">1160277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-700"
      unitRef="usdPerShare">56.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="INF" id="f-701" unitRef="shares">5263681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-702"
      unitRef="usdPerShare">44.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-703">P6Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-704" unitRef="usd">423000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-5" decimals="INF" id="f-705" unitRef="shares">3344010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-706"
      unitRef="usdPerShare">53.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-707">P5Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-3" id="f-708" unitRef="usd">398000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-5" decimals="INF" id="f-709" unitRef="shares">5263681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-710"
      unitRef="usdPerShare">44.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-711">P6Y4M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-5" decimals="-3" id="f-712" unitRef="usd">423000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-116"
      decimals="2"
      id="f-713"
      unitRef="usdPerShare">14.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-117"
      decimals="2"
      id="f-714"
      unitRef="usdPerShare">15.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-118"
      decimals="2"
      id="f-715"
      unitRef="usdPerShare">31.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-116" decimals="-5" id="f-716" unitRef="usd">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-117" decimals="-5" id="f-717" unitRef="usd">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-118" decimals="-5" id="f-718" unitRef="usd">8500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-115" decimals="-5" id="f-719" unitRef="usd">27800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-116" id="f-720">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-721">The following table presents RSU activity for the year ended December&#160;31, 2023:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;914,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(464,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-119"
      decimals="INF"
      id="f-722"
      unitRef="shares">1117921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-119"
      decimals="2"
      id="f-723"
      unitRef="usdPerShare">38.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-120"
      decimals="INF"
      id="f-724"
      unitRef="shares">914943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-120"
      decimals="2"
      id="f-725"
      unitRef="usdPerShare">25.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-120"
      decimals="INF"
      id="f-726"
      unitRef="shares">464881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-120"
      decimals="2"
      id="f-727"
      unitRef="usdPerShare">41.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-120"
      decimals="INF"
      id="f-728"
      unitRef="shares">221282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-120"
      decimals="2"
      id="f-729"
      unitRef="usdPerShare">33.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-121"
      decimals="INF"
      id="f-730"
      unitRef="shares">1346701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-121"
      decimals="2"
      id="f-731"
      unitRef="usdPerShare">29.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-121" decimals="-5" id="f-732" unitRef="usd">22600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-120" id="f-733">P1Y9M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock contextRef="c-1" id="f-734">The following table presents PSU activity for the year ended December&#160;31, 2023:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,750)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-122"
      decimals="INF"
      id="f-735"
      unitRef="shares">430243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-122"
      decimals="2"
      id="f-736"
      unitRef="usdPerShare">35.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-123"
      decimals="INF"
      id="f-737"
      unitRef="shares">125897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-738"
      unitRef="usdPerShare">25.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-123"
      decimals="INF"
      id="f-739"
      unitRef="shares">92257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-740"
      unitRef="usdPerShare">30.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-123"
      decimals="INF"
      id="f-741"
      unitRef="shares">101750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-123"
      decimals="2"
      id="f-742"
      unitRef="usdPerShare">46.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-124"
      decimals="INF"
      id="f-743"
      unitRef="shares">362133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-124"
      decimals="2"
      id="f-744"
      unitRef="usdPerShare">30.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <agio:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares
      contextRef="c-124"
      decimals="INF"
      id="f-745"
      unitRef="shares">145023</agio:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-124" decimals="INF" id="f-746" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <agio:ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount contextRef="c-124" decimals="-5" id="f-747" unitRef="usd">5900000</agio:ShareBasedPaymentArrangementNonvestedAwardExcludingOptionCostNotExpectedToBeRecognizedAmount>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="c-1" id="f-748">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents MSU activity for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Stock&#160;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested shares at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-125"
      decimals="INF"
      id="f-749"
      unitRef="shares">42695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-125"
      decimals="2"
      id="f-750"
      unitRef="usdPerShare">41.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-126"
      decimals="INF"
      id="f-751"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-126"
      decimals="2"
      id="f-752"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-127"
      decimals="INF"
      id="f-753"
      unitRef="shares">42695</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-127"
      decimals="2"
      id="f-754"
      unitRef="usdPerShare">41.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-127" decimals="INF" id="f-755" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-128"
      decimals="INF"
      id="f-756"
      unitRef="shares">509091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-129"
      decimals="INF"
      id="f-757"
      unitRef="shares">112832</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-130"
      decimals="INF"
      id="f-758"
      unitRef="shares">104867</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="c-129"
      decimals="INF"
      id="f-759"
      unitRef="shares">2363636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-131"
      decimals="INF"
      id="f-760"
      unitRef="shares">1686039</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-761">Stock-based compensation expense by award type included within the consolidated statements of operations is as follows:&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-3" id="f-762" unitRef="usd">17163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-133" decimals="-3" id="f-763" unitRef="usd">23731000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-134" decimals="-3" id="f-764" unitRef="usd">30985000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-120" decimals="-3" id="f-765" unitRef="usd">19367000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-135" decimals="-3" id="f-766" unitRef="usd">21670000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-136" decimals="-3" id="f-767" unitRef="usd">21510000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-123" decimals="-3" id="f-768" unitRef="usd">7368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-137" decimals="-3" id="f-769" unitRef="usd">2919000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-138" decimals="-3" id="f-770" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-139" decimals="-3" id="f-771" unitRef="usd">868000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-140" decimals="-3" id="f-772" unitRef="usd">976000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-141" decimals="-3" id="f-773" unitRef="usd">1013000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-774" unitRef="usd">44766000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-775" unitRef="usd">49296000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-3" id="f-776" unitRef="usd">53508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-777">&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses related to equity-based awards were allocated as follows in the consolidated statements of operations:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-142" decimals="-3" id="f-778" unitRef="usd">17064000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-143" decimals="-3" id="f-779" unitRef="usd">20988000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-144" decimals="-3" id="f-780" unitRef="usd">24527000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-145" decimals="-3" id="f-781" unitRef="usd">27702000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-146" decimals="-3" id="f-782" unitRef="usd">28308000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-147" decimals="-3" id="f-783" unitRef="usd">28981000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-784" unitRef="usd">44766000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-785" unitRef="usd">49296000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-14" decimals="-3" id="f-786" unitRef="usd">53508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-14" decimals="INF" id="f-787" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="INF" id="f-788" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-13" decimals="INF" id="f-789" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-790">The following table summarizes the weighted average assumptions used in calculating the grant date fair value of the awards:&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.207%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="4" id="f-791" unitRef="number">0.0405</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-13" decimals="4" id="f-792" unitRef="number">0.0255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-14" decimals="4" id="f-793" unitRef="number">0.0072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-794" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-13"
      decimals="INF"
      id="f-795"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-14"
      decimals="INF"
      id="f-796"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-797">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-13" id="f-798">P6Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-14" id="f-799">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="4" id="f-800" unitRef="number">0.5426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-13" decimals="4" id="f-801" unitRef="number">0.5530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-14" decimals="4" id="f-802" unitRef="number">0.6172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-1" id="f-803">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-804" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-805">Net Income (Loss) per Share&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury stock method. For purposes of the dilutive net income (loss) per share calculation, stock options, RSUs, PSUs and MSUs for which the performance and market vesting conditions, respectively, have been deemed probable, and 2013 ESPP shares are considered to be common stock equivalents, while PSUs and MSUs with performance and market vesting conditions, respectively, that were not deemed probable as of December&#160;31, 2023 are not considered to be common stock equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize the control number concept in the computation of diluted earnings per share to determine whether potential common stock equivalents are dilutive. The control number used is net loss from continuing operations. The control number concept requires that the same number of potentially dilutive securities applied in computing diluted earnings per share from continuing operations be applied to all other categories of income or loss, regardless of their anti-dilutive effect on such categories. Since we had a net loss from continuing operations for all periods presented, no dilutive effect has been recognized in the calculation of income (loss) from discontinued operations per share or net income (loss) per share. Basic and diluted net income (loss) per share was the same for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,772,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,804,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,932,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,841,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-806">&lt;div style="margin-bottom:9pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,263,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,772,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,798,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,346,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee Stock Purchase Plan shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,804,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,932,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,841,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-148" decimals="0" id="f-807" unitRef="shares">5263681</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-149" decimals="0" id="f-808" unitRef="shares">5772564</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-150" decimals="0" id="f-809" unitRef="shares">4798826</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-151" decimals="0" id="f-810" unitRef="shares">1346701</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-152" decimals="0" id="f-811" unitRef="shares">1117921</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-153" decimals="0" id="f-812" unitRef="shares">1002924</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-154" decimals="0" id="f-813" unitRef="shares">145023</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-155" decimals="0" id="f-814" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-156" decimals="0" id="f-815" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-157" decimals="0" id="f-816" unitRef="shares">48713</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-158" decimals="0" id="f-817" unitRef="shares">42026</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-159" decimals="0" id="f-818" unitRef="shares">39864</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-819" unitRef="shares">6804118</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-13" decimals="0" id="f-820" unitRef="shares">6932511</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-14" decimals="0" id="f-821" unitRef="shares">5841614</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-822">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of loss from continuing operations before income taxes are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not have any provision for income taxes for the years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the expected income tax benefit (expense) computed using the federal statutory income tax rate to our effective income tax rate is as follows for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities for the years ended December&#160;31, 2023 and 2022 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible accruals and reserves, including inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act (TCJA) requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. The Company capitalized research and experimental costs of $232.7 million and $261.4 million for the years ended December&#160;31, 2023 and December&#160;31, 2022, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $131.7 million, $502.4 million and $65.2 million, respectively. At December&#160;31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $25.5 million and $28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December&#160;31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $132.9 million. If not utilized, the orphan drug credits begin to expire in 2035.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As provided by Section&#160;382 of the Internal Revenue Code of 1986, or Section&#160;382, and similar state provisions, utilization of NOLs and tax credit carryforwards may be subject to substantial annual limitations due to ownership change limitations that have previously occurred or that could occur in the future. Ownership changes may limit the amount of NOLs and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section&#160;382, results from transactions that increase the ownership of five percent stockholders in the stock of a corporation by more than 50 percent in the aggregate over a three year period. We completed a review of our changes in ownership through December&#160;31, 2023 and determined that transactions have resulted in no ownership changes during the year ended December&#160;31, 2023, as defined by Section&#160;382. The impact of the historical ownership changes has been reflected in our deferred tax assets in the table above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $379.7 million and $296.0 million as of December&#160;31, 2023 and December&#160;31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $83.7&#160;million for the year ended December&#160;31, 2023 and by $59.5&#160;million for the year ended December&#160;31, 2022 primarily due to the Section 174 R&amp;amp;D expense capitalization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our change in valuation allowance for the years ended December&#160;31, 2023 and, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;236,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) for the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the unremitted earnings of our foreign subsidiaries are not material. We have not provided for U.S. income taxes or foreign withholding taxes on these earnings as it is our current intention to permanently reinvest these earnings outside the U.S. The tax liability on these earnings is also not material. Events that could trigger a tax liability include, but are not limited to, distributions, reorganizations or restructurings and/or tax law changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the accounting guidance in ASC 740 related to accounting for uncertainty in income taxes. Our reserves related to taxes are based on a determination of whether, and how much of, a tax benefit taken by us in our tax filings or positions is more likely than not to be realized following resolution of any potential contingencies present related to the tax benefit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our unrecognized tax benefits activity for the years ended December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - current period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will recognize interest and penalties related to uncertain tax positions above the line as an expense to continuing operations. As of December&#160;31, 2023 and 2022, we had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized. If all of the Company&#x2019;s unrecognized tax benefits as of December&#160;31, 2023 were to become recognizable in the future, we would record $28.6&#160;million of unrecognized tax benefits. The uncertain tax position does not impact our effective income tax rate due to the full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to taxation in the United States, Switzerland, Netherlands, Germany, Italy and France. The statute of limitations for assessment by the IRS and state tax authorities is open for tax years ending December&#160;31, 2023, 2022, 2021, and 2020, although carryforward attributes that were generated for tax years prior to 2020 may still be adjusted upon examination by the IRS or state tax authorities if they either have been, or will be, used in a future period. The statute of limitations for assessment in Switzerland remains open for tax years ending December&#160;31, 2023, 2022, 2021, 2020 and 2019. The Company&#x2019;s subsidiaries in the Netherlands and Germany were incorporated in 2019 and have statute of limitations for 5 and 4 years, respectively, for assessment. The tax years that remain open in these jurisdictions are for the tax years ending December&#160;31, 2023, 2022, 2021, 2020 and 2019. The Company&#x2019;s subsidiaries in Italy and France were incorporated in 2020 and have statute of limitations for 5 and 3 years, respectively, for assessment. The tax years that remain open in these jurisdictions are for the tax years ending December&#160;31, 2023, 2022, 2021 and 2020. There are currently no federal, state or foreign audits in progress.&lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2023 and 2022, we had an income tax receivable of $1.1&#160;million and $0.3&#160;million, respectively, recorded within prepaid expenses and other current assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-823">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of loss from continuing operations before income taxes are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352,085)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(231,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-824" unitRef="usd">-352085000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-3" id="f-825" unitRef="usd">-231767000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-14" decimals="-3" id="f-826" unitRef="usd">-356665000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-827" unitRef="usd">-3000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-3" id="f-828" unitRef="usd">-34000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-14" decimals="-3" id="f-829" unitRef="usd">155000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-830" unitRef="usd">-352088000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-831" unitRef="usd">-231801000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-832" unitRef="usd">-356510000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-833">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the expected income tax benefit (expense) computed using the federal statutory income tax rate to our effective income tax rate is as follows for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit computed at federal statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General business credits and other credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-834" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="3" id="f-835" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-14" decimals="3" id="f-836" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-837" unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="3" id="f-838" unitRef="number">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-14" decimals="3" id="f-839" unitRef="number">0.026</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-840" unitRef="number">-0.238</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="3" id="f-841" unitRef="number">-0.257</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="3" id="f-842" unitRef="number">-0.245</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <agio:EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments contextRef="c-1" decimals="3" id="f-843" unitRef="number">0.042</agio:EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments>
    <agio:EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments contextRef="c-13" decimals="3" id="f-844" unitRef="number">0.052</agio:EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments>
    <agio:EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments contextRef="c-14" decimals="3" id="f-845" unitRef="number">0.053</agio:EffectiveIncomeTaxRateReconciliationTaxCreditsAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-846" unitRef="number">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-13" decimals="3" id="f-847" unitRef="number">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-14" decimals="3" id="f-848" unitRef="number">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-1" decimals="3" id="f-849" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-13" decimals="3" id="f-850" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-14" decimals="3" id="f-851" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-852" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-13" decimals="3" id="f-853" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-14" decimals="3" id="f-854" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-855">Significant components of our deferred tax assets and liabilities for the years ended December&#160;31, 2023 and 2022 are as follows:&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible accruals and reserves, including inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Section 174 R&amp;amp;D expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(379,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295,993)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-856" unitRef="usd">64066000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-857" unitRef="usd">32907000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-858" unitRef="usd">180635000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-6" decimals="-3" id="f-859" unitRef="usd">163780000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-5" decimals="-3" id="f-860" unitRef="usd">14155000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-6" decimals="-3" id="f-861" unitRef="usd">11583000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-862" unitRef="usd">20954000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-863" unitRef="usd">26236000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <agio:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-864" unitRef="usd">16780000</agio:DeferredTaxAssetsOperatingLeaseLiability>
    <agio:DeferredTaxAssetsOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-865" unitRef="usd">21042000</agio:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="c-5" decimals="-3" id="f-866" unitRef="usd">5134000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves contextRef="c-6" decimals="-3" id="f-867" unitRef="usd">3992000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-868" unitRef="usd">93333000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-869" unitRef="usd">56565000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-870" unitRef="usd">395057000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-871" unitRef="usd">316105000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-872" unitRef="usd">1986000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-873" unitRef="usd">3767000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-874" unitRef="usd">13411000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-6" decimals="-3" id="f-875" unitRef="usd">16345000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-876" unitRef="usd">379660000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-877" unitRef="usd">295993000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-878" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-3" id="f-879" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-5" decimals="-5" id="f-880" unitRef="usd">232700000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c-6" decimals="-5" id="f-881" unitRef="usd">261400000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <agio:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod contextRef="c-160" id="f-882">P5Y</agio:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod>
    <agio:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod contextRef="c-161" id="f-883">P15Y</agio:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCostsAmortizationPeriod>
    <us-gaap:OperatingLossCarryforwards contextRef="c-162" decimals="-5" id="f-884" unitRef="usd">131700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-163" decimals="-5" id="f-885" unitRef="usd">502400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-164" decimals="-5" id="f-886" unitRef="usd">65200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-165" decimals="-5" id="f-887" unitRef="usd">25500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-166" decimals="-5" id="f-888" unitRef="usd">28100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-167" decimals="-5" id="f-889" unitRef="usd">132900000</us-gaap:TaxCreditCarryforwardAmount>
    <agio:PercentageOfStockholdersOwnershipIncrease contextRef="c-1" decimals="INF" id="f-890" unitRef="number">0.50</agio:PercentageOfStockholdersOwnershipIncrease>
    <agio:PeriodOfChangeInStockholdersOwnership contextRef="c-1" id="f-891">P3Y</agio:PeriodOfChangeInStockholdersOwnership>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-5" id="f-892" unitRef="usd">379700000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-5" id="f-893" unitRef="usd">296000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-5" id="f-894" unitRef="usd">83700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-13" decimals="-5" id="f-895" unitRef="usd">59500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-896">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our change in valuation allowance for the years ended December&#160;31, 2023 and, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;236,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) for the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-897" unitRef="usd">295993000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-31" decimals="-3" id="f-898" unitRef="usd">236478000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-3" id="f-899" unitRef="usd">83667000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-13" decimals="-3" id="f-900" unitRef="usd">59515000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-901" unitRef="usd">379660000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-902" unitRef="usd">295993000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-903">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our unrecognized tax benefits activity for the years ended December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross increases - current period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits at the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-904" unitRef="usd">26190000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-31" decimals="-3" id="f-905" unitRef="usd">24220000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-906" unitRef="usd">2388000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-907" unitRef="usd">1970000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-908" unitRef="usd">28578000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-909" unitRef="usd">26190000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-6" decimals="INF" id="f-910" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-5" decimals="INF" id="f-911" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-5" id="f-912" unitRef="usd">28600000</us-gaap:UnrecognizedTaxBenefits>
    <agio:NumberOfStatesFederalOrForeignInAuditingProcess contextRef="c-13" decimals="INF" id="f-913" unitRef="audit">0</agio:NumberOfStatesFederalOrForeignInAuditingProcess>
    <agio:NumberOfStatesFederalOrForeignInAuditingProcess contextRef="c-14" decimals="INF" id="f-914" unitRef="audit">0</agio:NumberOfStatesFederalOrForeignInAuditingProcess>
    <agio:NumberOfStatesFederalOrForeignInAuditingProcess contextRef="c-1" decimals="INF" id="f-915" unitRef="audit">0</agio:NumberOfStatesFederalOrForeignInAuditingProcess>
    <us-gaap:IncomeTaxReceivable contextRef="c-168" decimals="-5" id="f-916" unitRef="usd">1100000</us-gaap:IncomeTaxReceivable>
    <us-gaap:IncomeTaxReceivable contextRef="c-169" decimals="-5" id="f-917" unitRef="usd">300000</us-gaap:IncomeTaxReceivable>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-918">Property and Equipment, net&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following at December 31:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2023, 2022 and 2021 was $6.6 million, $8.4 million and $8.8 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-919">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consisted of the following at December 31:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,229)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,070)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-62" decimals="-3" id="f-920" unitRef="usd">17433000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-170" decimals="-3" id="f-921" unitRef="usd">23182000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-63" decimals="-3" id="f-922" unitRef="usd">6566000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-171" decimals="-3" id="f-923" unitRef="usd">6179000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-172" decimals="-3" id="f-924" unitRef="usd">37277000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-173" decimals="-3" id="f-925" unitRef="usd">37277000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-64" decimals="-3" id="f-926" unitRef="usd">3459000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-174" decimals="-3" id="f-927" unitRef="usd">3514000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-65" decimals="-3" id="f-928" unitRef="usd">2268000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-175" decimals="-3" id="f-929" unitRef="usd">2248000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-176" decimals="-3" id="f-930" unitRef="usd">608000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-177" decimals="-3" id="f-931" unitRef="usd">657000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-932" unitRef="usd">67611000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="-3" id="f-933" unitRef="usd">73057000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-934" unitRef="usd">52229000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-935" unitRef="usd">50070000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-936" unitRef="usd">15382000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-937" unitRef="usd">22987000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-938" unitRef="usd">6600000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-5" id="f-939" unitRef="usd">8400000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-14" decimals="-5" id="f-940" unitRef="usd">8800000</us-gaap:Depreciation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-941">Common Stock&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are authorized to issue 125,000,000 shares of our common stock. Holders of common stock are entitled to one vote per share. Additionally, holders of common stock are entitled to receive dividends, if and when declared by our board of directors, and to share ratably in our assets legally available for distribution to our shareholders in the event of liquidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-942" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-943" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <agio:NumberOfVotesPerShare contextRef="c-6" decimals="INF" id="f-944" unitRef="vote">1</agio:NumberOfVotesPerShare>
    <agio:NumberOfVotesPerShare contextRef="c-5" decimals="INF" id="f-945" unitRef="vote">1</agio:NumberOfVotesPerShare>
    <us-gaap:TreasuryStockTextBlock contextRef="c-1" id="f-946">Share Repurchase Program&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $1.2&#160;billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1&#160;million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $344.5&#160;million, or $48.38 per share. This repurchase was completed on April 5, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $600.0&#160;million of shares of our common stock. As of December&#160;31, 2023, we repurchased approximately 9.1&#160;million shares of common stock for $458.0 million, or $50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December&#160;31, 2023, we repurchased 16.2 million shares of common stock for $802.5 million, or $49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December&#160;31, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 5, 2021, we terminated our Rule 10b5-1 share repurchase plan and on October 13, 2021, we entered into a Rule 10b-18 repurchase plan that allows us to conduct open market repurchases over time up to our remaining authorization under the Repurchase Program. We have paused our share repurchases for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Repurchased shares are held as treasury stock until they are retired or re-issued. Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Repurchases of our common stock are accounted for as of the settlement date. There were no retirements or re-issuances of treasury stock during the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-178" decimals="-8" id="f-947" unitRef="usd">1200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-179"
      decimals="-5"
      id="f-948"
      unitRef="shares">7100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-180" decimals="-5" id="f-949" unitRef="usd">344500000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-180"
      decimals="2"
      id="f-950"
      unitRef="usdPerShare">48.38</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-181" decimals="-5" id="f-951" unitRef="usd">600000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-182"
      decimals="-5"
      id="f-952"
      unitRef="shares">9100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-182" decimals="-5" id="f-953" unitRef="usd">458000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-182"
      decimals="2"
      id="f-954"
      unitRef="usdPerShare">50.35</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-183"
      decimals="-5"
      id="f-955"
      unitRef="shares">16200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-183" decimals="-5" id="f-956" unitRef="usd">802500000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-183"
      decimals="2"
      id="f-957"
      unitRef="usdPerShare">49.49</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-184"
      decimals="INF"
      id="f-958"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-185"
      decimals="INF"
      id="f-959"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-960">Discontinued Operations&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, we completed the sale of our oncology business to Servier. We determined the sale of the oncology business represented a strategic shift that had a major effect on our business and therefore met the criteria for classification as discontinued operations at March 31, 2021. Accordingly, the oncology business was reported as discontinued operations in accordance with ASC 205-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The results of operations from the oncology business were classified as discontinued operations in the consolidated statements of operations. We recognized a gain on the sale of the oncology business upon closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the gain on the sale for the year ended December 31, 2021: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash proceeds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,802,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: transaction and insurance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: net liabilities distributed, including working capital adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale, pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-967"&gt;Gain on sale, net of tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023 and December 31, 2022, there were no assets or liabilities classified as discontinued operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the financial results of the discontinued operations: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue &#x2013; other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenue &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense for the sale of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on the sale of the oncology business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,961,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 205-20, only expenses specifically identifiable and related to a business to be disposed may be presented in discontinued operations. As such, the research and development, marketing, selling and general and administrative expenses in discontinued operations include corporate costs incurred directly to solely support our oncology business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also entered into a Transition Services Agreement with Servier, through which we provided transitional services related to discovery, clinical development, technical operations, commercial and general and administrative related activities through March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The milestone payment for approval of vorasidenib and royalty payments related to vorasidenib and TIBSOVO&#xae; represent contingent consideration. Contingent consideration has been accounted for as a gain contingency in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and will be recognized in earnings in the period when realizable. As described in &lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_124" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none"&gt;Note 1, &lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&lt;a href="#i62bc41bff6df4446af4f8c46a1b0e260_124" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:none"&gt;Nature of Business&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, on October 27, 2022, we sold our rights to future contingent payments related to TIBSOVO&#xae; royalties to entities affiliated with Sagard and recognized income of $127.9&#160;million within the gain on sale of contingent payments line item in our consolidated statements of operations for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-961">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the gain on the sale for the year ended December 31, 2021: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.620%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash proceeds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,802,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: transaction and insurance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: net liabilities distributed, including working capital adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale, pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-967"&gt;Gain on sale, net of tax&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the financial results of the discontinued operations: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.351%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue &#x2013; other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenue &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cost and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash interest expense for the sale of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,697)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on the sale of the oncology business&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,989,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, pre-tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,974,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income from discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,961,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-186" decimals="-3" id="f-962" unitRef="usd">1802936000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <agio:DiscontinuedOperationsTransactionAndInsuranceCosts contextRef="c-186" decimals="-3" id="f-963" unitRef="usd">53573000</agio:DiscontinuedOperationsTransactionAndInsuranceCosts>
    <agio:DiscontinuedOperationsLiabilitiesDistributedNet contextRef="c-186" decimals="-3" id="f-964" unitRef="usd">239770000</agio:DiscontinuedOperationsLiabilitiesDistributedNet>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-186" decimals="-3" id="f-965" unitRef="usd">1989133000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-186" decimals="-3" id="f-966" unitRef="usd">12799000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax contextRef="c-186" decimals="-3" id="f-968" unitRef="usd">1976334000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-187" decimals="INF" id="f-969" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-187" decimals="INF" id="f-970" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-188" decimals="INF" id="f-971" unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-188" decimals="INF" id="f-972" unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-189" decimals="-3" id="f-973" unitRef="usd">36909000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-190" decimals="-3" id="f-974" unitRef="usd">1350000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-191" decimals="-3" id="f-975" unitRef="usd">491000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-192" decimals="-3" id="f-976" unitRef="usd">2659000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-186" decimals="-3" id="f-977" unitRef="usd">41409000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold contextRef="c-186" decimals="-3" id="f-978" unitRef="usd">706000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <agio:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses contextRef="c-186" decimals="-3" id="f-979" unitRef="usd">41564000</agio:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c-186" decimals="-3" id="f-980" unitRef="usd">8551000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="c-186" decimals="-3" id="f-981" unitRef="usd">50821000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c-186" decimals="-3" id="f-982" unitRef="usd">-9412000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <agio:DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue contextRef="c-186" decimals="-3" id="f-983" unitRef="usd">5697000</agio:DisposalGroupIncludingDiscontinuedOperationInterestExpenseNonCashSaleOfFutureRevenue>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-186" decimals="-3" id="f-984" unitRef="usd">1989133000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-186" decimals="-3" id="f-985" unitRef="usd">1974024000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-186" decimals="-3" id="f-986" unitRef="usd">12799000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-186" decimals="-3" id="f-987" unitRef="usd">1961225000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <agio:GainLossOnSaleOfContingentPayments contextRef="c-193" decimals="-5" id="f-988" unitRef="usd">127900000</agio:GainLossOnSaleOfContingentPayments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-989">Commitments and Contingent Liabilities &lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Manufacturing Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are party to various agreements with contract manufacturing organizations that we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Under such agreements, we are obligated to make certain minimum payments, with the exact amounts in the event of termination to be based on the timing of the termination and the exact terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may be involved in disputes and legal proceedings in the ordinary course of business. These proceedings may include allegations of infringement of intellectual property, employment or other matters. We do not have any ongoing legal proceedings that, based on our estimates, could have a material effect on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <agio:NumberOfLegalProceedingsThatHaveMaterialEffect
      contextRef="c-5"
      decimals="INF"
      id="f-990"
      unitRef="lawsuit">0</agio:NumberOfLegalProceedingsThatHaveMaterialEffect>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-991">Defined Contribution Benefit Plan&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor a 401(k) retirement plan, in which substantially all of our full-time employees are eligible to participate. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. We will make matching contributions equal to 100% of the employee&#x2019;s contributions, subject to a maximum of 4% of eligible compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="c-1" decimals="INF" id="f-992" unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="c-1" decimals="INF" id="f-993" unitRef="number">0.04</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
